,pubmed_id,title,abstract,keywords,journal,publication_date,authors,methods,conclusions,results,copyrights,doi,xml
0,"38246956
29754747
7920638
30334074
29985474
22784036
23477989
15379294
16981857
27443609
31097468
33560670
29275859
22018233
28930663
11704183
23460719
26285177
9037091
34854884
9343467
19595937
28874832
16906128
11796757
30627643
25991443
18045930
15081593
12515896
12700177
36307876
35440664
30291623
35618840
34127866
29892276
36721148
36755206
37315112
3828426",Early modulation of the gut microbiome by female sex hormones alters amyloid pathology and microglial function.,"It is well-established that women are disproportionately affected by Alzheimer's disease. The mechanisms underlying this sex-specific disparity are not fully understood, but several factors that are often associated-including interactions of sex hormones, genetic factors, and the gut microbiome-likely contribute to the disease's etiology. Here, we have examined the role of sex hormones and the gut microbiome in mediating Aβ amyloidosis and neuroinflammation in APPPS1-21 mice. We report that postnatal gut microbiome perturbation in female APPPS1-21 mice leads to an elevation in levels of circulating estradiol. Early stage ovariectomy (OVX) leads to a reduction of plasma estradiol that is correlated with a significant alteration of gut microbiome composition and reduction in Aβ pathology. On the other hand, supplementation of OVX-treated animals with estradiol restores Aβ burden and influences gut microbiome composition. The reduction of Aβ pathology with OVX is paralleled by diminished levels of plaque-associated microglia that acquire a neurodegenerative phenotype (MGnD-type) while estradiol supplementation of OVX-treated animals leads to a restoration of activated microglia around plaques. In summary, our investigation elucidates the complex interplay between sex-specific hormonal modulations, gut microbiome dynamics, metabolic perturbations, and microglial functionality in the pathogenesis of Alzheimer's disease.",[],Scientific reports,2024-01-22,"[{'lastname': 'Saha', 'firstname': 'Piyali', 'initials': 'P', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Weigle', 'firstname': 'Ian Q', 'initials': 'IQ', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Slimmon', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'School of Biomedical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.'}, {'lastname': 'Poli', 'firstname': 'Pedro Blauth', 'initials': 'PB', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Patel', 'firstname': 'Priyam', 'initials': 'P', 'affiliation': 'Center for Genetic Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Zhang', 'firstname': 'Xiaoqiong', 'initials': 'X', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Cao', 'firstname': 'Yajun', 'initials': 'Y', 'affiliation': 'Genomic Facility, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Michalkiewicz', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Department of Physiology and Biophysics, The University of Illinois, Chicago, IL, USA.'}, {'lastname': 'Gomm', 'firstname': 'Ashley', 'initials': 'A', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Zhang', 'firstname': 'Can', 'initials': 'C', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Tanzi', 'firstname': 'Rudolph E', 'initials': 'RE', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Dylla', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'Duchossois Family Institute, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Al-Hendy', 'firstname': 'Ayman', 'initials': 'A', 'affiliation': 'Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Sisodia', 'firstname': 'Sangram S', 'initials': 'SS', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA. ssisodia@bsd.uchicago.edu.'}]",,,,© 2024. The Author(s).,"10.1038/s41598-024-52246-6
10.1016/j.neurobiolaging.2018.04.004
10.1038/ng0694-180
10.1007/s00401-018-1920-1
10.1038/s41582-018-0032-9
10.1056/NEJMoa1202753
10.1016/S1474-4422(13)70044-9
10.3949/ccjm.71.Suppl_2.S4
10.1111/j.1528-1167.2006.00672.x
10.1038/srep30028
10.1084/jem.20182386
10.1097/WCO.0000000000000911
10.1016/j.cell.2017.11.042
10.1016/j.chom.2011.10.003
10.1016/j.immuni.2017.08.008
10.1210/er.2012-1055
10.1016/j.lfs.2015.08.004
10.1073/pnas.94.4.1550
10.1084/jem.20200895
10.1001/jama.1997.03550160069041
10.1016/j.jalz.2007.04.381
10.1038/s41598-017-11047-w
10.1038/sj.embor.7400784
10.1046/j.0022-3042.2001.00690.x
10.1038/nrn3880
10.1523/JNEUROSCI.2718-07.2007
10.1016/j.expneurol.2004.01.015
10.3233/JAD-2002-4601
10.1210/er.2001-0016
10.1186/s13293-022-00466-8
10.1038/s41467-022-29903-3
10.1002/cne.24551
10.1038/s41386-022-01349-7
10.1038/s41684-021-00777-0
10.3389/fmicb.2018.01085
10.1186/s13024-023-00595-7
10.30802/AALAS-JAALAS-22-000068
10.1126/scitranslmed.abo2984
10.1095/biolreprod35.5.1088",<Element 'PubmedArticle' at 0x7f05dc381090>
1,38191034,Nanotechnology in the diagnostic and therapy for Alzheimer's disease.,"Alzheimer's disease (AD) is a neurodegenerative disorder primarily characterized by β-amyloid plaque, intraneuronal tangles, significant neuronal loss and cognitive deficit. Treatment in the early stages of the disease is crucial for preventing or perhaps reversing the neurodegeneration in the AD cases. However, none of the current diagnostic procedures are capable of early diagnosis of AD. Further, the available treatments merely provide symptomatic alleviation in AD and do not address the underlying illness. Therefore, there is no permanent cure for AD currently. Better therapeutic outcomes need the optimum drug concentration in the central nervous system (CNS) by traversing blood-brain-barrier (BBB). Nanotechnology offers enormous promise to transform the treatment and diagnostics of neurodegenerative diseases. Nanotechnology based diagnostic tools, drug delivery systems and theragnostic are capable of highly sensitive molecular detection, effective drug targeting and their combination. Significant work has been done in this area over the last decade and prospective results have been obtained in AD therapy. This review explores the various applications of nanotechnology in addressing the varied facets of AD, ranging from early detection to therapeutic interventions. This review also looks at how nanotechnology can help with the development of disease-modifying medicines, such as the delivery of anti-amyloid, anti-tau, cholinesterase inhibitors, antioxidants and hormonal drugs. In conclusion, this paper discusses the role of nanotechnology in the early detection of AD, effective drug targeting to the CNS and theragnostic applications in the management of AD.","[""Alzheimer's disease"", 'Amyloid plaques', 'Nano-diagnostics', 'Nanomedicine', 'Nanoparticles', 'Nanotechnology', 'Nanotherapeutics', 'Quantum dots', 'Theragnostic']",Biochimica et biophysica acta. General subjects,2024-01-09,"[{'lastname': 'Panghal', 'firstname': 'Archna', 'initials': 'A', 'affiliation': 'National Institute of Pharmaceutical Education and Research, SAS Nagar, Mohali, Panjab 160012, India.'}, {'lastname': 'Flora', 'firstname': 'S J S', 'initials': 'SJS', 'affiliation': 'National Institute of Pharmaceutical Education and Research, SAS Nagar, Mohali, Panjab 160012, India; Institute of Pharmaceutical Sciences, Era Medical University, Safarajganj, Lucknow 226003, U.P., India. Electronic address: sjsflora@hotmail.com.'}]",,,,Copyright © 2024 Elsevier B.V. All rights reserved.,10.1016/j.bbagen.2024.130559,<Element 'PubmedArticle' at 0x7f05dc855720>
2,38185192,GLP-1 derivatives with functional sequences transit and migrate through trigeminal neurons.,"Patients with dementia are increasing with the aging of the population, and dementia has become a disease with high unmet medical needs. Glucagon-like peptide-1 (GLP-1), a neuropeptide, has been reported to improve learning and memory following intracerebroventricular administration. We focused on intranasal administration, which can deliver drugs noninvasively and efficiently to the brain. Although much of the human nasal mucosa is occupied by respiratory epithelium, many capillaries are present in the paracellular route of respiratory epithelium. Therefore, to incorporate GLP-1 into cells, we created a GLP-1 derivative by adding cell-penetrating peptides (CPP) and penetration accelerating sequences (PAS) to GLP-1. We investigated in vitro and in vivo function of PAS-CPP-GLP-1 to enable the translocation of GLP-1 directly from nose to brain. PAS-CPP-GLP-1 enhanced cellular uptake by macropinocytosis with CPP, efficiently escaped from the endosomes due to PAS, and exited the cells. PAS-CPP-GLP-1 also transited trigeminal nerve cells through axon transport and migrated to the adjacent trigeminal nerve cell. Moreover, PAS-CPP-GLP-1 showed significant improvement in learning memory in mice within 20 min of intranasal administration. These results suggested CPP and PAS may be important for the efficient transfer of GLP-1 to the site of action in the brain following intranasal administration.","['Cell-penetrating peptide', 'Glucagon-like peptide-1', 'Intracellular dynamics', 'Learning and memory', 'Nose-to-brain system', 'Penetration accelerating sequence']",European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,2024-01-08,"[{'lastname': 'Akita', 'firstname': 'Tomomi', 'initials': 'T', 'affiliation': 'Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.'}, {'lastname': 'Shimamura', 'firstname': 'Mizuki', 'initials': 'M', 'affiliation': 'Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.'}, {'lastname': 'Tezuka', 'firstname': 'Ayano', 'initials': 'A', 'affiliation': 'Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.'}, {'lastname': 'Takagi', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.'}, {'lastname': 'Yamashita', 'firstname': 'Chikamasa', 'initials': 'C', 'affiliation': 'Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan. Electronic address: chikamasa_yamashita@rs.tus.ac.jp.'}]",,,,Copyright © 2024 Elsevier B.V. All rights reserved.,10.1016/j.ejpb.2024.114176,<Element 'PubmedArticle' at 0x7f05dc8b05e0>
3,38181530,"Neuroprotective potentials of Lead phytochemicals against Alzheimer's disease with focus on oxidative stress-mediated signaling pathways: Pharmacokinetic challenges, target specificity, clinical trials and future perspectives.","Alzheimer's diseases (AD) and dementia are among the highly prevalent neurological disorders characterized by deposition of beta amyloid (Aβ) plaques, dense deposits of highly phosphorylated tau proteins, insufficiency of acetylcholine (ACh) and imbalance in glutamatergic system. Patients typically experience cognitive, behavioral alterations and are unable to perform their routine activities. Evidence also suggests that inflammatory processes including excessive microglia activation, high expression of inflammatory cytokines and release of free radicals. Thus, targeting inflammatory pathways beside other targets might be the key factors to control- disease symptoms and progression.
This review is aimed to highlight the mechanisms and pathways involved in the neuroprotective potentials of lead phytochemicals. Further to provide updates regarding challenges associated with their use and their progress into clinical trials as potential lead compounds.
Most recent scientific literature on pre-clinical and clinical data published in quality journals especially on the lead phytochemicals including curcumin, catechins, quercetin, resveratrol, genistein and apigenin was collected using SciFinder, PubMed, Google Scholar, Web of Science, JSTOR, EBSCO, Scopus and other related web sources.
Literature review indicated that the drug discovery against AD is insufficient and only few drugs are clinically approved which have limited efficacy. Among the therapeutic options, natural products have got tremendous attraction owing to their molecular diversity, their safety and efficacy. Research suggest that natural products can delay the disease onset, reduce its progression and regenerate the damage via their anti-amyloid, anti-inflammatory and antioxidant potentials. These agents regulate the pathways involved in the release of neurotrophins which are implicated in neuronal survival and function. Highly potential lead phytochemicals including curcumin, catechins, quercetin, resveratrol, genistein and apigenin regulate neuroprotective signaling pathways implicated in neurotrophins-mediated activation of tropomyosin receptor kinase (Trk) and p75 neurotrophins receptor (p75NTR) family receptors.
Phytochemicals especially phenolic compounds were identified as highly potential molecules which ameliorate oxidative stress induced neurodegeneration, reduce Aβ load and inhibit vital enzymes. Yet their clinical efficacy and bioavailability are the major challenges which need further interventions for more effective therapeutic outcomes.","['Clinical trials', 'Neuro-degenerative disorders', 'Neurotrophins', 'Phytochemicals', 'Pro-inflammatory cytokines', 'Signaling pathways']",Phytomedicine : international journal of phytotherapy and phytopharmacology,2024-01-06,"[{'lastname': 'Ayaz', 'firstname': 'Muhammad', 'initials': 'M', 'affiliation': 'Department of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18000 Dir (L), KP, Pakistan. Electronic address: ayazuop@gmail.com.'}, {'lastname': 'Mosa', 'firstname': 'Osama F', 'initials': 'OF', 'affiliation': 'Public health Department, Health Sciences College at Lieth, Umm Al Qura University, Makkah, KSA.'}, {'lastname': 'Nawaz', 'firstname': 'Asif', 'initials': 'A', 'affiliation': 'Department of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18000 Dir (L), KP, Pakistan.'}, {'lastname': 'Hamdoon', 'firstname': 'Alashary Adam Eisa', 'initials': 'AAE', 'affiliation': 'Public health Department, Health Sciences College at Lieth, Umm Al Qura University, Makkah, KSA; University of Khartoum, Faculty of Public and Environmental Health, Sudan.'}, {'lastname': 'Elkhalifa', 'firstname': 'Modawy Elnour Modawy', 'initials': 'MEM', 'affiliation': 'Public health Department, Health Sciences College at Lieth, Umm Al Qura University, Makkah, KSA; University of Khartoum, Faculty of Public and Environmental Health, Sudan.'}, {'lastname': 'Sadiq', 'firstname': 'Abdul', 'initials': 'A', 'affiliation': 'Department of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18000 Dir (L), KP, Pakistan.'}, {'lastname': 'Ullah', 'firstname': 'Farhat', 'initials': 'F', 'affiliation': 'Department of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18000 Dir (L), KP, Pakistan.'}, {'lastname': 'Ahmed', 'firstname': 'Alshebli', 'initials': 'A', 'affiliation': 'Public health Department, Health Sciences College at Lieth, Umm Al Qura University, Makkah, KSA; University of Khartoum, Faculty of Public and Environmental Health, Sudan.'}, {'lastname': 'Kabra', 'firstname': 'Atul', 'initials': 'A', 'affiliation': 'University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, India.'}, {'lastname': 'Khan', 'firstname': 'Haroon', 'initials': 'H', 'affiliation': 'Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan.'}, {'lastname': 'Murthy', 'firstname': 'H C Ananda', 'initials': 'HCA', 'affiliation': 'Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University, P O Box 1888, Adama, Ethiopia; Department of Prosthodontics, Saveetha Dental College & Hospital, Saveetha Institute of Medical and technical science (SIMATS), Saveetha University, Chennai-600077, Tamil Nadu, India.'}]",,,"Literature review indicated that the drug discovery against AD is insufficient and only few drugs are clinically approved which have limited efficacy. Among the therapeutic options, natural products have got tremendous attraction owing to their molecular diversity, their safety and efficacy. Research suggest that natural products can delay the disease onset, reduce its progression and regenerate the damage via their anti-amyloid, anti-inflammatory and antioxidant potentials. These agents regulate the pathways involved in the release of neurotrophins which are implicated in neuronal survival and function. Highly potential lead phytochemicals including curcumin, catechins, quercetin, resveratrol, genistein and apigenin regulate neuroprotective signaling pathways implicated in neurotrophins-mediated activation of tropomyosin receptor kinase (Trk) and p75 neurotrophins receptor (p75NTR) family receptors.",Copyright © 2023 Elsevier GmbH. All rights reserved.,10.1016/j.phymed.2023.155272,<Element 'PubmedArticle' at 0x7f05dc90bdb0>
4,"38142584
36408740
34605674
33755127
34775186
37061017
35304113
30290832
33460635
36722980
28953238
33790462
28329261
36566737
29905797
16103423
35138681
22470931
12631430
24583674
29420965
23500398
29695315
31480420
30669300
19164703
32371009
30937979
23821397
10557325
15320828
7714806
23868934
15359489
28337251
9808606
12431443
16627383
30384259
20840865
32823544
28903579
24348350
32371009
31769799
31769799
31859340
28088338
31248544
27460892
29482991
32422434
28611191
32783534
34279611
33296779
36011669
37182833
37073726
37073733
37738461
36607286
27380755
30804165
29350061
34609502
29470452
28953453
27667192
27343184
34612059
34487721
21266374
29518662
35358546
30136675
25838021
37265507
19116496
22491084
24906068
19017691
20881600
24103537
35031374
28280950
32442789
30622064
30357335
36967400
33766056
32278155
31783239
37545808
21353301
23760528
34432723
1985444
20356818
35809585
29505969
33245107
37329756
28934721
28338949
29045908
33778334
31084449
32146894
34855467
23229017
36402187
26492400
29161230
30347370
31801799
36334460
32738937
16140637
35635962
32560306
32854453
29909174
30206085
31137595
26863687
34497091
33555809
31964412
29122366
29194408
24338235
28516298
36764429
34467460
28813586
28770538
26113038
26305219
35395236
8719596
16299704
16446561
11119634
24366410
32873002
15242844
35181171
22885407
27518135
19906956
30921644
21940438
23827090
15474168
12239260
36188462
33000672
18440718
25339938
25642690
22750224
27441392
34261495
33126026
33069327
28599022
26003939
34501923
26516622
31261828
37156356
37390771
12537836
22440225
28579842
36266164
29213140
34869603
16987039
28441057
32231263
28684621
28110218
22928487
11444502
10900169
26660451
9231817
19139972
31922930
10793197
34183223
34304945
26356376
24231419
27174896
7466404
6543864
7702540
32088192
32974180
30383236
30273797
7200873
3264136
12537837
20049122
28442544
29233481
32069756
12689468
11485215
27436863
14164470
14164473
5722800
31138406
18335099
21885382
18270210
27195894
32034913
32306084
31664594
11723017
28934719
25145323
32914847
31583936
34304945
19006047
1537714
1473299
11725006
35174211
37567316
32345536
36702626
9554432
4301849
11939505
21726571
33229555
29936225
11070333
11139006
16519909
12975524
15705773
15142987
28680154
34656633
32763645
28579229
30935305
30356756
32098382
22737128
28062563
26251361
29228900
19908146
30978359
24161514
16481110
19225220
30784814
21783581
28161157
28012927
33929610
34547993
31611768
28941872
31814877
15936421
29414890
27816007
31717834
33755127
32805247
17317241
32563308
23761983
34965303
30568267
34627796
35046099
36502895
19444258
17430213
25424573
25364077
21300732
26058943
21868506
23897221
27475725
26616531
22746161
30760925
21682397
27036284
34501721
30530085
22225031
29981033
33542290
27989756
30443019
22968153
23000955
29933742
33407614
27811997
28525342
31217930
37180445
34783872
30258412
33679706
25898780
24583676
33670865
33246065
36312027
30279527
25972177
31066107
23966690
35197842
14568884
14581381
33541847
12531868
22117137
37839355
12952971
18483407
19934023
22657349
21930693
23573415
12697739
21528437
12364355
16293794
11914250
23899412
23886424
33916471
34274810
37567316
22431579
10720482
22483692
30687454
12885792
14517226
12600921
28797292
30004243
30621955
20448215
24053613
24228094
19242638
16100048
12676600
31833063
10737412
37047436
37371593
7925950
29431026
33155668
19270454
21989948
9188956
30716302
23670301
33476795
37047416
27157635
33119054
37548932
29051737
26990284
31165272
17367510
17988655
24815185
20122895
36719770
31510846
10874031
24499461
20116425
33122809
18155177
18193017
31172476
17015830
23051008
28890317
29739855
29037049
12426202
33823245
1688694
10758236
29496266
29567392
36918556
17296874
17761297
9107302
12748170
18976629
26034893
33102447
22731669
34118047
26839313
21115844
15129734
24080119
22978713
27418630
20406350
16256084
25913553
35857401
3997680
16785328
20008675
21906672
8621776
16224052
28209543
28558479
28108279
31341533
32484729
28575405
33921821
32208177
32326776
33529949
21875910
28986948
29433422
36907540
31795714
29084230
33733673
24194529
31189380
35915324
36649457
30982669
33462618
37269269
29309706
11034938
29856365
26858430
35948413
30796369
34058652
24855952
26810072
35088601
27194331
20587160
34836742
31795664
34217678
25999309
22960578
23746849
19833968
23887727
22750052
15298678
20832105
30635659
17895391
24856209
18662547
18662546
26332969
29198727
20603647
31578516
26079210
28332701
28816061
25962978
27914298
34280920
32201268
28562070
32723695
19711202
33402608
31509369
37165157
30206078
34144479
34167845
30167570
34600028
35697921
26771008
32131026
35760871
35190722
28212522
26415143
32035921
28807817
19560987
22260866
8384150
30934586
23541987
21861450
31202785
16298907
26964509
31672919
33744200
28229915
31563634
32466448
34166769
29507103
29363060
12892994
27815191
20919990
22892029
37295280
33238128
18089952
37371918
28577489
35613665
26776972
37185661
31805502
29063418
35154590
6150890
27836585
25599753
26657417
25880434
35273964
30380665
32769796
23297662
28570388
23032870
23891906
12578963
24317383
23490070
23320850
27872049
28230726
28437655
37165157
23681765
34792619
34414346
35169663
30095351
34552080
26722641
21273555
36764624
31974245
24659601
37690630
26780956
15579411
17963121",Health position paper and redox perspectives - Disease burden by transportation noise.,"Transportation noise is a ubiquitous urban exposure. In 2018, the World Health Organization concluded that chronic exposure to road traffic noise is a risk factor for ischemic heart disease. In contrast, they concluded that the quality of evidence for a link to other diseases was very low to moderate. Since then, several studies on the impact of noise on various diseases have been published. Also, studies investigating the mechanistic pathways underlying noise-induced health effects are emerging. We review the current evidence regarding effects of noise on health and the related disease-mechanisms. Several high-quality cohort studies consistently found road traffic noise to be associated with a higher risk of ischemic heart disease, heart failure, diabetes, and all-cause mortality. Furthermore, recent studies have indicated that road traffic and railway noise may increase the risk of diseases not commonly investigated in an environmental noise context, including breast cancer, dementia, and tinnitus. The harmful effects of noise are related to activation of a physiological stress response and nighttime sleep disturbance. Oxidative stress and inflammation downstream of stress hormone signaling and dysregulated circadian rhythms are identified as major disease-relevant pathomechanistic drivers. We discuss the role of reactive oxygen species and present results from antioxidant interventions. Lastly, we provide an overview of oxidative stress markers and adverse redox processes reported for noise-exposed animals and humans. This position paper summarizes all available epidemiological, clinical, and preclinical evidence of transportation noise as an important environmental risk factor for public health and discusses its implications on the population level.","['Adverse redox signaling', 'Environmental risk factors', 'Non-communicable diseases', 'Oxidative stress and inflammation', 'Stress hormones', 'Transportation noise']",Redox biology,2023-12-25,"[{'lastname': 'Sørensen', 'firstname': 'Mette', 'initials': 'M', 'affiliation': 'Work, Environment and Cancer, Danish Cancer Institute, Copenhagen, Denmark; Department of Natural Science and Environment, Roskilde University, Denmark. Electronic address: mettes@cancer.dk.'}, {'lastname': 'Pershagen', 'firstname': 'Göran', 'initials': 'G', 'affiliation': 'Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Thacher', 'firstname': 'Jesse Daniel', 'initials': 'JD', 'affiliation': 'Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden.'}, {'lastname': 'Lanki', 'firstname': 'Timo', 'initials': 'T', 'affiliation': 'Department of Health Security, Finnish Institute for Health and Welfare, Kuopio, Finland; School of Medicine, University of Eastern Finland, Kuopio, Finland; Department of Environmental and Biological Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Wicki', 'firstname': 'Benedikt', 'initials': 'B', 'affiliation': 'Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.'}, {'lastname': 'Röösli', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.'}, {'lastname': 'Vienneau', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': 'Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.'}, {'lastname': 'Cantuaria', 'firstname': 'Manuella Lech', 'initials': 'ML', 'affiliation': 'Work, Environment and Cancer, Danish Cancer Institute, Copenhagen, Denmark; Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital & University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Schmidt', 'firstname': 'Jesper Hvass', 'initials': 'JH', 'affiliation': 'Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital & University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Aasvang', 'firstname': 'Gunn Marit', 'initials': 'GM', 'affiliation': 'Department of Air Quality and Noise, Norwegian Institute of Public Health, Oslo, Norway.'}, {'lastname': 'Al-Kindi', 'firstname': 'Sadeer', 'initials': 'S', 'affiliation': 'Department of Medicine, University Hospitals, Harrington Heart & Vascular Institute, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH, 44106, USA.'}, {'lastname': 'Osborne', 'firstname': 'Michael T', 'initials': 'MT', 'affiliation': 'Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA, USA; Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.'}, {'lastname': 'Wenzel', 'firstname': 'Philip', 'initials': 'P', 'affiliation': 'Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.'}, {'lastname': 'Sastre', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Department of Physiology, Faculty of Pharmacy, University of Valencia, Spain.'}, {'lastname': 'Fleming', 'firstname': 'Ingrid', 'initials': 'I', 'affiliation': 'Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt Am Main, Germany; German Center of Cardiovascular Research (DZHK), Partner Site RheinMain, Frankfurt, Germany.'}, {'lastname': 'Schulz', 'firstname': 'Rainer', 'initials': 'R', 'affiliation': 'Institute of Physiology, Faculty of Medicine, Justus-Liebig University, Gießen, 35392, Gießen, Germany.'}, {'lastname': 'Hahad', 'firstname': 'Omar', 'initials': 'O', 'affiliation': 'Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.'}, {'lastname': 'Kuntic', 'firstname': 'Marin', 'initials': 'M', 'affiliation': 'Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.'}, {'lastname': 'Zielonka', 'firstname': 'Jacek', 'initials': 'J', 'affiliation': 'Department of Biophysics, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'lastname': 'Sies', 'firstname': 'Helmut', 'initials': 'H', 'affiliation': 'Institute for Biochemistry and Molecular Biology I, Faculty of Medicine, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.'}, {'lastname': 'Grune', 'firstname': 'Tilman', 'initials': 'T', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.'}, {'lastname': 'Frenis', 'firstname': 'Katie', 'initials': 'K', 'affiliation': ""Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; Stem Cell Program, Boston Children's Hospital, Boston, MA, USA.""}, {'lastname': 'Münzel', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.'}, {'lastname': 'Daiber', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Department of Cardiology, Cardiology I, University Medical Center Mainz, Mainz, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany. Electronic address: daiber@uni-mainz.de.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,"10.1016/j.redox.2023.102995
10.1002/dmrr.3595
10.1289/EHP8949
10.1093/ije/dyab024
10.1016/j.envint.2021.106974
10.1016/j.envpol.2023.121642
10.1016/j.envres.2022.113106
10.1186/s13058-018-1047-2
10.1016/j.envres.2021.110739
10.1289/EHP11248
10.3390/ijerph14101139
10.1038/s41569-021-00532-5
10.1093/eurheartj/ehx081
10.1016/j.redox.2022.102580
10.1093/eurheartj/ehy333
10.1158/1055-9965.EPI-05-0456
10.1111/joim.13467
10.1016/j.amjcard.2011.10.038
10.4103/1463-1741.127847
10.1016/j.jacc.2017.12.015
10.1016/j.scitotenv.2013.02.034
10.1016/j.ijcard.2018.03.126
10.3390/ijerph16020269
10.1164/rccm.200808-1344OC
10.1016/j.redox.2020.101506
10.1002/biof.1506
10.1093/eurheartj/eht269
10.1073/pnas.96.23.13357
10.1161/ATVBAHA.113.301624
10.1016/j.ejphar.2004.06.028
10.1155/2017/4353462
10.1161/01.cir.98.19.2065
10.1006/jmcc.2002.2076
10.1016/j.redox.2018.09.025
10.1016/j.freeradbiomed.2010.09.006
10.3390/antiox9080743
10.1089/ars.2017.7312
10.3389/fnint.2013.00086
10.1016/j.redox.2020.101506
10.1093/eurheartj/ehz820
10.1093/eurheartj/ehz820
10.1093/eurheartj/ehz867
10.1016/S0140-6736(16)31714-7
10.1016/j.jacc.2019.04.042
10.1093/eurheartj/ehw269
10.1016/j.ijheh.2018.02.005
10.1016/j.scitotenv.2020.139226
10.1136/oemed-2016-104180
10.1289/EHP5809
10.1093/ije/dyab068
10.1016/j.ijheh.2020.113666
10.3390/ijerph191610034
10.1016/j.envres.2023.116075
10.1161/HYPERTENSIONAHA.122.18732
10.1161/HYPERTENSIONAHA.123.20617
10.1093/eurjpc/zwad306
10.1289/EHP10745
10.3238/arztebl.2016.0407
10.1136/oemed-2018-105333
10.1089/ars.2017.7118
10.1093/cvr/cvab316
10.3390/ijerph15020379
10.1289/EHP1272
10.1016/j.ijheh.2016.09.012
10.1136/oemed-2015-103531
10.1161/JAHA.121.021436
10.1016/S1474-4422(21)00252-0
10.1093/eurheartj/ehq466
10.1016/j.envint.2018.02.048
10.1016/j.envres.2022.113129
10.4103/nah.NAH_7_18
10.3238/arztebl.2015.0195
10.1016/j.lanepe.2023.100655
10.1097/EDE.0b013e31819463bd
10.1093/aje/kwr424
10.1016/j.envres.2014.05.011
10.1136/oem.2008.042358
10.1016/j.scitotenv.2022.153057
10.1007/s10654-017-0234-2
10.1016/j.envres.2020.109633
10.1016/j.envint.2018.12.015
10.1093/eurheartj/ehy650
10.1186/s12940-023-00983-y
10.1186/s12940-021-00720-3
10.1016/j.envres.2020.109446
10.1016/j.envint.2019.105341
10.1097/EE9.0000000000000259
10.1016/S0140-6736(10)62296-9
10.1093/ije/dyt092
10.1097/ede.0000000000001410
10.1093/oxfordjournals.aje.a115853
10.1016/s2542-5196(22)00138-3
10.1016/j.envint.2018.02.030
10.1093/eurheartj/ehaa957
10.1016/j.envint.2023.108016
10.1289/EHP1279
10.1093/ije/dyx020
10.1016/j.envres.2017.10.008
10.1097/ee9.0000000000000037
10.1289/EHP4389
10.1161/JAHA.119.013021
10.1289/EHP9146
10.1289/ehp.1205503
10.1016/j.envres.2022.114795
10.1016/j.envres.2015.10.007
10.1289/EHP1910
10.1016/j.envint.2018.09.057
10.1136/oemed-2019-105843
10.1016/j.envint.2022.107570
10.1016/S0140-6736(20)30367-6
10.1289/ehp.7567
10.1016/j.envint.2022.107306
10.3390/ijms21124306
10.3390/ijerph17176175
10.1016/j.envres.2018.06.008
10.1136/bmjopen-2018-022404
10.3390/ijerph16101790
10.1289/ehp.1509824
10.1136/bmj.n1954
10.1097/EDE.0000000000001249
10.1186/s12940-020-0565-4
10.1016/j.envpol.2017.10.093
10.3390/ijerph14121492
10.1002/ijc.28592
10.1007/s10552-017-0904-0
10.1016/j.envres.2023.115454
10.1007/s10552-021-01492-4
10.5271/sjweh.3665
10.1007/s40572-017-0155-y
10.1016/j.envres.2015.06.016
10.1371/journal.pone.0135407
10.1016/j.envres.2022.113180
10.1007/BF02114761
10.1002/ajim.20223
10.1097/01.aud.0000191942.36672.f3
10.1136/oem.58.1.46
10.1097/AUD.0b013e3182a143ec
10.1121/10.0001789
10.1093/annhyg/meh041
10.1016/j.heares.2022.108459
10.1097/AUD.0b013e31825f9d89
10.1097/MAO.0000000000001071
10.1523/JNEUROSCI.2845-09.2009
10.1016/j.heares.2019.02.016
10.1523/JNEUROSCI.2156-11.2011
10.1016/S0140-6736(13)60142-7
10.1016/j.tins.2004.08.010
10.1056/NEJMra013395
10.3389/fnins.2022.1000304
10.1080/14992027.2020.1827306
10.1016/j.neuroscience.2008.02.077
10.3389/fneur.2014.00196
10.3390/ijerph120201612
10.1016/j.smrv.2012.04.003
10.1001/jamaoto.2016.1700
10.1186/s12940-021-00769-0
10.1016/j.ijheh.2020.113652
10.1016/S0140-6736(20)30752-2
10.5271/sjweh.3653
10.1016/j.ijheh.2015.05.003
10.3390/ijerph18179337
10.1016/j.jth.2015.06.005
10.3390/ijerph16132304
10.1016/j.envres.2023.116077
10.1016/j.envint.2023.107966
10.1016/j.heares.2012.02.009
10.2147/NSS.S134864
10.1016/j.tem.2022.08.002
10.1038/nrcardio.2017.189
10.3389/fmolb.2021.784910
10.1089/ars.2006.8.1865
10.1146/annurev-biochem-061516-045037
10.1038/s41580-020-0230-3
10.1161/CIRCRESAHA.117.311182
10.1016/j.redox.2016.12.035
10.3109/10715762.2012.724532
10.1006/jmcc.2000.1178
10.1111/bph.13403
10.1007/s11010-008-0023-z
10.1146/annurev-publhealth-081519-062400
10.1016/s0006-8993(00)02172-7
10.1016/j.psyneuen.2021.105331
10.1016/j.psyneuen.2021.105347
10.4103/1463-1741.165063
10.4103/1463-1741.121236
10.4149/gpb_2016003
10.1007/BF00794951
10.1016/j.yexmp.2020.104409
10.3389/fonc.2020.01492
10.1210/jc.2018-01456
10.1016/j.psyneuen.2018.09.024
10.1080/00039896.1988.9935859
10.1289/ehp.0900933
10.1136/oemed-2016-104208
10.1016/j.ijheh.2017.11.003
10.1016/j.envres.2019.109086
10.1016/s0160-4120(01)00030-7
10.1093/eurheartj/ehw314
10.1016/j.mrgentox.2019.04.006
10.1289/ehp.10775
10.1093/eurheartj/ehn013
10.1371/journal.pone.0155357
10.1093/eurpub/ckaa015
10.1007/s00392-020-01645-6
10.1007/s00395-019-0753-y
10.1161/hc4601.099485
10.1289/EHP1136
10.1007/s00392-014-0751-x
10.1093/cvr/cvaa204
10.1161/JAHA.119.012509
10.1016/j.psyneuen.2021.105347
10.1055/s-0028-1100941
10.3389/fmolb.2021.814921
10.1016/j.scitotenv.2023.166106
10.1016/j.redox.2020.101515
10.1093/cvr/cvad021
10.1001/archpsyc.55.4.362
10.1038/220911a0
10.1089/089771502753594945
10.1016/j.physbeh.2011.06.018
10.1073/pnas.2017841117
10.1016/j.expneurol.2018.06.011
10.1016/s0306-4530(00)00035-4
10.1097/00006842-200011000-00016
10.1016/j.physbeh.2006.01.014
10.1073/pnas.1934666100
10.1210/en.2004-1603
10.1210/en.2004-0305
10.1038/s41598-017-04943-8
10.1016/j.envres.2021.112221
10.1016/j.envint.2020.106014
10.1016/j.ijheh.2017.05.010
10.1146/annurev-publhealth-040218-044058
10.3389/fncel.2018.00338
10.3390/ijms21041505
10.3389/fphys.2012.00189
10.1101/cshperspect.a028035
10.1038/srep12943
10.1186/s12199-017-0686-8
10.1007/s11065-009-9118-x
10.1016/j.neubiorev.2019.04.001
10.1016/j.physbeh.2013.10.006
10.1016/j.neulet.2006.01.037
10.1539/joh.l8084
10.1016/j.neurobiolaging.2019.01.019
10.1016/j.etap.2004.12.059
10.1016/j.jaim.2016.10.004
10.1016/j.biopha.2016.12.054
10.1007/s00395-021-00869-5
10.2174/0929867328666210921161711
10.3389/fnins.2019.01036
10.1016/j.neulet.2017.09.040
10.1155/2019/4623109
10.1016/S0140-6736(05)66660-3
10.3390/ijerph15020285
10.1016/j.envres.2016.10.017
10.3390/ijerph16214134
10.1093/ije/dyab024
10.1016/j.envres.2020.110013
10.1016/j.smrv.2006.09.001
10.1016/S2215-0366(20)30136-X
10.2147/NSS.S34842
10.1093/sleep/zsab302
10.1038/s41366-018-0293-9
10.1016/j.envres.2021.112195
10.1136/oemed-2021-107921
10.1016/j.envres.2022.115037
10.1038/nrendo.2009.23
10.1161/JAHA.114.001143
10.5665/sleep.4178
10.1093/eurheartj/ehr007
10.3892/mmr.2015.3894
10.1164/rccm.201107-1173OC
10.1038/ijo.2013.139
10.1016/j.freeradbiomed.2016.07.027
10.1016/j.brainresbull.2015.11.017
10.1089/ars.2012.4720
10.1038/s41586-019-0948-2
10.1121/1.3543957
10.1260/0263-0923.31.4.239
10.1121/1.4942390
10.3390/ijerph18179133
10.1016/j.envres.2018.11.032
10.1121/1.3653984
10.17269/s41997-018-0040-y
10.1038/s41598-021-82203-6
10.1016/j.freeradbiomed.2016.10.495
10.1038/s41575-018-0079-5
10.1038/nrn3346
10.1038/nrmicro2876
10.1186/s12974-018-1223-4
10.1186/s12974-020-02053-3
10.1038/srep36693
10.1515/pjvs-2017-0020
10.22038/ijbms.2019.33956.8078
10.3389/fcimb.2023.1067367
10.1007/s00248-021-01924-3
10.3389/fmicb.2018.02013
10.3389/fimmu.2020.619189
10.1016/j.mrfmmm.2015.03.009
10.4103/1463-1741.127849
10.3390/ijms22052419
10.1016/j.neuroscience.2020.11.019
10.3389/fnins.2022.1001686
10.1038/s41598-018-32948-4
10.1523/JNEUROSCI.5138-14.2015
10.1002/jnr.24439
10.1523/JNEUROSCI.1783-13.2013
10.3389/fnagi.2022.803973
10.1016/j.redox.2021.101875
10.1089/ars.2011.4414
10.1016/j.redox.2023.102894
10.1074/jbc.M302836200
10.1161/CIRCRESAHA.108.172072
10.1089/ars.2012.4609
10.1074/jbc.M111.243469
10.1155/2013/793630
10.1172/JCI14172
10.1007/s00395-011-0179-7
10.1161/01.ATV.0000196651.64776.51
10.1016/j.heares.2013.07.012
10.3766/jaaa.24.6.3
10.3390/cells10040810
10.1016/j.redox.2021.102063
10.1016/j.scitotenv.2023.166106
10.1161/HYPERTENSIONAHA.111.183368
10.1016/j.lfs.2012.03.024
10.1155/2018/7845629
10.1161/01.HYP.0000084853.47326
10.1161/01.HYP.0000095980.43859.59
10.1186/s12906-017-1902-1
10.1152/ajpheart.00124.2018
10.1016/j.jacc.2018.09.086
10.1089/ars.2012.4918
10.1007/s00395-009-0007-5
10.1161/01.RES.0000181171.65293.65
10.1289/ehp.5847
10.1111/bph.14949
10.1016/s0024-3205(00)00422-7
10.3390/ijms24076459
10.3390/biom13061013
10.1016/0014-5793(94)00922-8
10.1080/14728222.2018.1439922
10.1007/s11239-020-02331-0
10.1159/000205962
10.2119/molmed.2011.00225
10.1111/j.1398-9995.1997.tb04813.x
10.1016/j.yexcr.2019.01.022
10.1161/HYPERTENSIONAHA.113.01314
10.1016/j.freeradbiomed.2021.01.020
10.3390/ijms24076443
10.1038/srep25450
10.1093/cvr/cvaa310
10.14336/AD.2023.0715
10.3389/fphys.2017.00733
10.1111/bph.13478
10.1007/s00395-019-0738-x
10.1111/j.1582-4934.2007.00009.x
10.1016/j.brainres.2007.09.073
10.1016/j.cellsig.2014.05.002
10.1089/ars.2023.0006
10.1369/0022155419876644
10.1074/jbc.M003198200
10.1042/BJ20131262
10.1016/j.freeradbiomed.2010.01.028
10.1038/s41598-020-75373-2
10.1016/j.freeradbiomed.2007.11.013
10.1038/nprot.2007.473
10.1007/978-1-4939-9424-3_14
10.1073/pnas.0601945103
10.1016/j.freeradbiomed.2012.09.018
10.1016/j.chembiol.2017.08.003
10.1074/jbc.RA118.003044
10.1089/ars.2017.7398
10.1161/01.atv.0000034022.11764.ec
10.1016/j.freeradbiomed.2021.03.041
10.1023/A:1015363220266
10.1016/0003-9861(90)90020-y
10.1016/s0022-1759(00)00156-3
10.1016/j.acthis.2018.02.005
10.1016/j.freeradbiomed.2018.03.032
10.1038/s41467-023-37121-8
10.1016/j.freeradbiomed.2007.06.026
10.1016/S0022-1759(96)00244-X
10.1074/jbc.M300054200
10.1016/j.abb.2008.10.014
10.1146/annurev-biochem-060614-034018
10.3389/fchem.2020.580899
10.1007/978-1-0716-1262-0_20
10.1074/jbc.M115.702787
10.1073/pnas.1012864107
10.1016/j.dyepig.2020.108693
10.1016/j.freeradbiomed.2013.09.017
10.1089/ars.2012.4886
10.1161/RES.0000000000000110
10.1111/j.1365-2826.2010.02007.x
10.1016/j.brainres.2005.09.031
10.4103/1463-1741.155838
10.1289/EHP10197
10.1016/0378-5955(85)90128-5
10.1161/01.HYP.0000231307.69761.2e
10.1161/HYPERTENSIONAHA.109.142646
10.1016/j.freeradbiomed.2011.08.014
10.1172/JCI118623
10.1016/j.psyneuen.2017.01.035
10.1089/ars.2017.7186
10.1016/j.freeradbiomed.2017.01.027
10.1155/2019/7092151
10.1289/EHP6174
10.1093/eurheartj/ehx263
10.3390/antiox10040625
10.1016/j.brainresbull.2020.03.004
10.1080/10715762.2020.1754410
10.1016/j.chemosphere.2021.129739
10.1161/CIRCULATIONAHA.111.034470
10.1113/EP086434
10.1186/s12199-018-0694-3
10.1016/j.clim.2023.109287
10.1121/1.5132545
10.1371/journal.pone.0187084
10.1093/eurheartj/ehab121
10.1093/eurheartj/eht426
10.1177/2047487319854818
10.1007/s12350-022-03003-7
10.1161/CIRCIMAGING.122.014544
10.1016/j.jcmg.2018.10.038
10.1093/eurheartj/ehaa1095
10.1016/j.jcmg.2023.04.004
10.1093/eurheartj/ehx775
10.1161/01.cir.102.16.1912
10.1172/JCI80590
10.1073/pnas.1516953113
10.1136/oemed-2022-108347
10.1038/s41569-019-0167-4
10.1016/j.jpsychires.2021.05.045
10.1016/j.cell.2014.03.057
10.14348/molcells.2016.2323
10.1089/ars.2021.0272
10.1523/JNEUROSCI.3616-15.2016
10.1016/j.heares.2021.108395
10.1121/1.5132290
10.1016/j.bjorl.2021.05.010
10.1016/j.febslet.2015.05.024
10.1016/j.freeradbiomed.2012.08.568
10.1016/j.cell.2013.05.011
10.1126/science.1172156
10.1038/emm.2013.65
10.1016/j.mce.2012.06.017
10.1111/j.1356-9597.2004.00758.x
10.1016/j.cell.2010.08.016
10.1038/s41580-018-0096-9
10.1073/pnas.0701599104
10.1016/j.cub.2014.04.018
10.1016/j.cell.2008.07.002
10.1016/j.cell.2008.06.050
10.1111/dom.12519
10.1016/j.freeradbiomed.2017.11.023
10.1038/nrcardio.2010.104
10.1038/s41569-019-0265-3
10.1016/j.redox.2015.05.008
10.1111/bph.13792
10.1089/ars.2017.7276
10.1038/nrcardio.2015.71
10.1016/j.envres.2016.11.017
10.1159/000514143
10.1016/j.neuroscience.2020.03.023
10.1089/ars.2017.7175
10.1016/j.redox.2020.101580
10.1007/s12031-009-9252-1
10.4103/nah.NAH_17_20
10.18388/abp.2019_2853
10.1038/s41569-023-00873-3
10.1136/bmjopen-2017-021311
10.1016/j.envint.2021.106683
10.1016/j.mam.2021.100986
10.3945/cdn.117.001826
10.1016/j.ygeno.2021.09.018
10.1007/s43032-022-00999-8
10.7874/jao.2015.19.3.111
10.1016/j.freeradbiomed.2020.02.026
10.1038/s42255-022-00591-z
10.1038/s41580-022-00456-z
10.1016/j.redox.2017.02.001
10.1089/ars.2015.6317
10.1016/j.redox.2020.101442
10.1016/j.freeradbiomed.2017.08.008
10.1016/j.jchromb.2009.06.016
10.1016/j.nutres.2011.11.005
10.1016/0891-5849(93)90508-r
10.3390/antiox8030072
10.1016/j.bbagen.2013.03.020
10.1021/cr200084z
10.1016/j.freeradbiomed.2019.06.006
10.1080/13547500500216546
10.1016/j.freeradbiomed.2016.03.001
10.1074/jbc.REV119.006217
10.1016/j.redox.2021.101901
10.1016/j.freeradbiomed.2017.02.010
10.1016/j.freeradbiomed.2019.09.030
10.1016/j.freeradbiomed.2021.06.014
10.1124/pr.117.014753
10.1007/s11010-018-3293-0
10.1016/s0098-2997(03)00011-6
10.1016/j.freeradbiomed.2016.10.497
10.1042/BJ20100878
10.1042/BJ20120298
10.1016/j.heares.2023.108821
10.1016/j.celrep.2020.108431
10.1097/MCO.0b013e3282f0c97c
10.3390/antiox12061188
10.1016/j.redox.2017.05.007
10.1016/j.freeradbiomed.2022.05.016
10.1038/srep19329
10.1093/eurjpc/zwad075
10.1016/j.redox.2019.101393
10.1016/j.smhs.2023.09.001
10.1007/s11892-017-0951-7
10.32598/bcn.2021.2026.1
10.1016/j.bbr.2016.10.046
10.4103/1463-1741.149565
10.1016/j.phrs.2015.11.022
10.1371/journal.pgen.1005094
10.3389/fcell.2022.832314
10.3390/ijerph15112400
10.1097/JOM.0000000000001978
10.1146/annurev-publhealth-031912-114452
10.1097/EDE.0000000000000666
10.5271/sjweh.3324
10.1016/j.neubiorev.2013.07.004
10.1073/pnas.0438019100
10.3390/ijerph10126662
10.1016/j.psyneuen.2013.02.004
10.1089/ars.2012.4569
10.1161/CIRCRESAHA.116.309491
10.3390/jcm6020022
10.1016/j.redox.2017.04.017
10.1038/s41569-023-00873-3
10.1002/em.21777
10.1007/s00125-021-05618-w
10.1097/EE9.0000000000000162
10.1097/EE9.0000000000000184
10.1146/annurev-pharmtox-010818-021315
10.1038/s41467-021-25840-9
10.1016/j.toxrep.2015.11.009
10.1161/CIRCRESAHA.110.237560
10.1016/j.freeradbiomed.2023.02.007
10.1126/science.aay3164
10.1289/ehp.1308015
10.1016/j.envres.2023.117108
10.4103/1463-1741.174364
10.1289/ehp.7249
10.1080/10715760701687117",<Element 'PubmedArticle' at 0x7f05dc938ea0>
5,"38116383
36644587
34190962
36724109
35032505
34352138
36191643
23253178
23563222
33387701
37132201
26330638
30085612
37004608
37032920
36889197
36239744
36880807
36738337
36869373
36915226
36833872
30691372
30552910
32730861
37131982
26514657
28889048
24446553
36637712
27609245
33406713
319772
9014137
37717999
32073124
29981391
33266110
35688208
25196185
23958466
32722286
26039154
9295207
24215796
17651807
24044974
15171722
31767256
26223009
24172649
23669456
24121112
19272715
26272051
34071053
32435663
32980990
28278440
9659856
34714413
30906252
21439354
16934764
24776841
33578758
29727810
30529908
11744070
7729823
8393520
1330306
17159334
26105109
31525393
36909842
34962690
32440589
15261843
31818365
26681259
32669383
23438839
21994747
26965674
9924747
11358277
22386322
31866547
19082489
32976892
22737266
31483961
31476884
36608082
34594247
30177236
34287271
31642037
31514247
34462985
35869362
28619476
34267503
31323375
33224470
37875578
36811520
28993837
29570866
30704685
31513776
32756865
21514366
26970579
32636474
24917198
29045302
25410258
16319920
0
10227077",Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.,"With each passing year, the number of people suffering from mental disorders grows at a disturbing speed. Neuroactive steroids are a new promising group of drugs with the potential for use in many diseases like postpartum depression, postnatal psychosis, major depression, insomnia, bipolar disorder, and Parkinson's tremor, due to their ability to modulate the activity of GABA","['GABA', 'SAGE-217', 'allopregnanolone', 'brexanolone', 'depression', 'neurosteroid', 'pregnenolone', 'zuranolone']",Frontiers in psychiatry,2023-12-20,"[{'lastname': 'Marecki', 'firstname': 'Rafał', 'initials': 'R', 'affiliation': 'Department of Psychiatry, Medical University of Białystok, Białystok, Poland.'}, {'lastname': 'Kałuska', 'firstname': 'Joanna', 'initials': 'J', 'affiliation': 'Department of Psychiatry, Medical University of Białystok, Białystok, Poland.'}, {'lastname': 'Kolanek', 'firstname': 'Agata', 'initials': 'A', 'affiliation': 'Department of Psychiatry, Medical University of Białystok, Białystok, Poland.'}, {'lastname': 'Hakało', 'firstname': 'Dominika', 'initials': 'D', 'affiliation': 'Department of Psychiatry, Medical University of Białystok, Białystok, Poland.'}, {'lastname': 'Waszkiewicz', 'firstname': 'Napoleon', 'initials': 'N', 'affiliation': 'Department of Psychiatry, Medical University of Białystok, Białystok, Poland.'}]",,,,"Copyright © 2023 Marecki, Kałuska, Kolanek, Hakało and Waszkiewicz.","10.3389/fpsyt.2023.1298359
10.9740/MHC.2022.12.342
10.1001/jamapsychiatry.2021.1559
10.4088/JCP.22m14475
10.1016/j.jad.2022.01.059
10.1002/hup.2806
10.1016/j.jad.2022.09.143
10.1186/1744-9081-8-61
10.1016/j.yfrne.2013.03.001
10.1016/J.JNS.2020.117277
10.1176/appi.ajp.20220459
10.4103/0019-5545.161481
10.1007/s12035-023-03313-y
10.3389/fpsyt.2023.1133386
10.1016/j.jpsychires.2023.02.036
10.1007/s00127-022-02372-1
10.1080/17482631.2023.2187333
10.1007/s00737-023-01295-3
10.1186/s40359-023-01105-6
10.1002/npr2.12326
10.3390/ijerph20043178
10.1146/annurev-med-041217-011106
10.1016/j.yfrne.2018.12.001
10.1016/j.yfrne.2020.100856
10.1002/CL2.1074
10.1176/appi.ajp.2015.15010124
10.1016/j.jad.2017.08.054
10.1016/j.jad.2013.09.034
10.1007/s11920-022-01406-4
10.1176/appi.ajp.2016.16040454
10.3390/BRAINSCI11010047
10.1001/archpsyc.1977.01770130100011
10.1016/S0028-3908(96)00066-4
10.1016/bs.vh.2022.12.002
10.1093/ajhp/zxz333
10.1016/j.pneurobio.2018.06.007
10.3390/ijms21239114
10.1016/j.jbc.2022.102110
10.1016/j.jsbmb.2014.09.001
10.1016/j.pneurobio.2013.07.006
10.1210/en.2014-1913
10.1016/S0006-8993(97)00455-1
10.1016/j.pneurobio.2013.09.003
10.1016/j.pharmthera.2007.04.011
10.1016/J.PNPBP.2013.09.005
10.1677/jme.0.0320921
10.1016/j.encep.2019.09.007
10.1016/j.jsbmb.2015.07.012
10.1016/j.pneurobio.2013.09.004
10.1016/j.jsbmb.2013.04.002
10.1016/j.pneurobio.2013.09.005
10.1016/j.psyneuen.2009.02.003
10.1038/npp.2015.246
10.3390/ijms22115495
10.1016/J.YNSTR.2020.100212
10.1007/s40261-020-00966-8
10.1016/j.psyneuen.2017.02.012
10.1176/ajp.155.7.910
10.1007/s00737-021-01186-5
10.3389/fncel.2019.00083
10.1016/j.neuroscience.2011.03.025
10.1016/j.biopsych.2006.03.026
10.1159/000358838
10.3390/IJMS22041758
10.1016/j.psyneuen.2018.04.024
10.1016/j.psyneuen.2018.11.027
10.1016/S0165-0173(01)00109-6
10.1006/hbeh.1994.1052
10.1097/00002826-199210000-00002
10.1159/000097879
10.1007/s00213-015-3991-1
10.1016/j.yfrne.2019.100789
10.1016/j.coemr.2022.100359
10.1111/jne.13062
10.1177/2470547018818555
10.1016/j.beem.2004.02.006
10.5483/BMBRep.2020.53.1.279
10.1111/JNE.12351
10.1194/jlr.RA119000479
10.1038/nrendo.2013.31
10.3390/v3050586
10.1038/nrneurol.2016.27
10.1016/S0306-4530(98)00071-7
10.1023/A:1007668213330
10.1016/j.mehy.2012.02.008
10.1016/j.steroids.2019.108556
10.3892/ijo_00000140
10.1016/j.neuropharm.2020.108333
10.1177/1947601912440575
10.1056/NEJMoa1815981
10.1017/9781108921275.017
10.1177/1060028019873320
10.1097/HRP.0000000000000354
10.3389/fpsyt.2021.699740
10.1016/S0140-6736(18)31551-4
10.3390/diseases9030052
10.1007/s40263-019-00672-w
10.1002/phar.2331
10.1111/jne.13019
10.1007/s40262-022-01155-w
10.1016/S0140-6736(17)31264-3
10.2147/DDDT.S240856
10.1016/j.psychres.2019.07.006
10.1177/2045125320968658
10.1038/s41386-023-01751-9
10.4088/JCP.22M14445
10.1007/164_2017_56
10.1002/mds.27372
10.1016/j.mcna.2018.10.014
10.1016/j.yfrne.2019.100788
10.1042/EBC20200043
10.1016/j.neuroscience.2011.04.010
10.1016/j.bbr.2016.03.019
10.1038/s41380-020-0831-4
10.1038/npp.2014.138
10.1097/JCP.0000000000000793
10.1027/0227-5910/a000280
10.1038/sj.npp.1300952
10.1001/jama.1943.02840030028007
10.1007/s002130050916",<Element 'PubmedArticle' at 0x7f05dd4089a0>
6,"38113227
15986431
28861666
30072062
33266110
16703453
20091865
22287638
23800670
30761745
29277854
34830286
25335165
24138870
32705456
33536184
35621369
34935947
21775350
26604824
21775349
21775362
24474847
15460170
15550597
34247270
37309803
21520030
20722711
15252064
34187864
23702884
18182668",Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study.,"Use of estrogen-containing menopausal hormone therapy has been shown to influence the risk of central nervous system (CNS) tumors. However, it is unknown how the progestin-component affects the risk and whether continuous versus cyclic treatment regimens influence the risk differently.
Nested case-control studies within a nationwide cohort of Danish women followed for 19 years from 2000 to 2018. The cohort comprised 789,901 women aged 50 to 60 years during follow-up, without prior CNS tumor diagnosis, cancer, or contraindication for treatment with menopausal hormone therapy. Information on cumulative exposure to female hormonal drugs was based on filled prescriptions. Statistical analysis included educational level, use of antihistamines, and use of anti-asthma drugs as covariates. During follow-up, 1,595 women were diagnosed with meningioma and 1,167 with glioma. The median (first-third quartile) follow-up time of individuals in the full cohort was 10.8 years (5.0 years to 17.5 years). Compared to never-use, exposure to estrogen-progestin or progestin-only were both associated with increased risk of meningioma, hazard ratio (HR) 1.21; (95% confidence interval (CI) [1.06, 1.37] p = 0.005) and HR 1.28; (95% CI [1.05, 1.54] p = 0.012), respectively. Corresponding HRs for glioma were HR 1.00; (95% CI [0.86, 1.16] p = 0.982) and HR 1.20; (95% CI [0.95, 1.51] p = 0.117). Continuous estrogen-progestin exhibited higher HR of meningioma 1.34; (95% CI [1.08, 1.66] p = 0.008) than cyclic treatment 1.13; (95% CI [0.94, 1.34] p = 0.185). Previous use of estrogen-progestin 5 to 10 years prior to diagnosis yielded the strongest association with meningioma, HR 1.26; (95% CI [1.01, 1.57] p = 0.044), whereas current/recent use of progestin-only yielded the highest HRs for both meningioma 1.64; (95% CI [0.90, 2.98] p = 0.104) and glioma 1.83; (95% CI [0.98, 3.41] p = 0.057). Being an observational study, residual confounding could occur.
Use of continuous, but not cyclic estrogen-progestin was associated with increased meningioma risk. There was no evidence of increased glioma risk with estrogen-progestin use. Use of progestin-only was associated with increased risk of meningioma and potentially glioma. Further studies are warranted to evaluate our findings and investigate the influence of long-term progestin-only regimens on CNS tumor risk.",[],PLoS medicine,2023-12-19,"[{'lastname': 'Pourhadi', 'firstname': 'Nelsan', 'initials': 'N', 'affiliation': 'Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.\nCancer Surveillance and Pharmacoepidemiology, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.'}, {'lastname': 'Meaidi', 'firstname': 'Amani', 'initials': 'A', 'affiliation': 'Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.'}, {'lastname': 'Friis', 'firstname': 'Søren', 'initials': 'S', 'affiliation': 'Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.'}, {'lastname': 'Torp-Pedersen', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Public Health, University of Copenhagen, Copenhagen, Denmark.\nDepartment of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.'}, {'lastname': 'Mørch', 'firstname': 'Lina S', 'initials': 'LS', 'affiliation': 'Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.'}]",,,,"Copyright: © 2023 Pourhadi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","10.1371/journal.pmed.1004321
10.1002/ijc.21255
10.1007/s11060-017-2607-5
10.1016/j.ncl.2018.04.001
10.3390/ijms21239114
10.1007/s11060-006-9146-9
10.1002/ijc.25184
10.1093/aje/kwr335
10.1016/j.ejca.2013.05.026
10.1111/ajco.13138
10.1007/s11060-017-2725-0
10.3390/ijms222212404
10.1002/ijc.29274
10.1016/j.canep.2013.09.017
10.1007/s11060-020-03576-8
10.1136/bmj.n37
10.1111/ene.15423
10.1210/endocr/bqab259
10.1177/1403494810393562
10.2147/CLEP.S91125
10.1177/1403494810394717
10.1177/1403494810394715
10.2147/IJWH.S38342
10.1592/phco.24.13.1105.38083
10.1136/oem.2004.014472
10.1007/s00228-021-03188-9
10.1111/ene.15914
10.1002/ijc.25858
10.1111/j.1468-1331.2010.03187.x
10.1136/jech.2003.008466
10.1136/jnnp-2021-326138
10.1007/s10552-013-0228-7
10.1200/JCO.2007.14.2133",<Element 'PubmedArticle' at 0x7f05dd6f0400>
7,38103230,Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain.,"The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity. Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in many tissues, including different brain regions. Glucagon-like peptide 1 activates several signaling pathways related to neuroprotection, like the support of cell growth/survival, enhancement promotion of synapse formation, autophagy, and inhibition of the secretion of proinflammatory cytokines, microglial activation, and apoptosis during neural morphogenesis. The glial cells, including astrocytes and microglia, maintain metabolic homeostasis and defense against pathogens in the central nervous system. After brain insult, microglia are the first cells to respond, followed by reactive astrocytosis. These activated cells produce proinflammatory mediators like cytokines or chemokines to react to the insult. Furthermore, under these circumstances, microglia can become chronically inflammatory by losing their homeostatic molecular signature and, consequently, their functions during many diseases. Several processes promote the development of neurological disorders and influence their pathological evolution: like the formation of protein aggregates, the accumulation of abnormally modified cellular constituents, the formation and release by injured neurons or synapses of molecules that can dampen neural function, and, of critical importance, the dysregulation of inflammatory control mechanisms. The glucagon-like peptide 1 receptor agonist emerges as a critical tool in treating brain-related inflammatory pathologies, restoring brain cell homeostasis under inflammatory conditions, modulating microglia activity, and decreasing the inflammatory response. This review summarizes recent advances linked to the anti-inflammatory properties of glucagon-like peptide 1 receptor activation in the brain related to multiple sclerosis, Alzheimer's disease, Parkinson's disease, vascular dementia, or chronic migraine.",[],Neural regeneration research,2023-12-17,"[{'lastname': 'Diz-Chaves', 'firstname': 'Yolanda', 'initials': 'Y', 'affiliation': 'Biomedical Research Centre (CINBIO), Laboratory of Endocrinology, University of Vigo, Galicia Sur Health Research Institute, Vigo, Spain.'}, {'lastname': 'Maastor', 'firstname': 'Zainab', 'initials': 'Z', 'affiliation': 'Biomedical Research Centre (CINBIO), Laboratory of Endocrinology, University of Vigo, Galicia Sur Health Research Institute, Vigo, Spain.'}, {'lastname': 'Spuch', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Translational Neuroscience Research Group, Galicia Sur Health Research Institute, CIBERSAM, Hospital Álvaro Cunqueiro, Sala Investigación, Estrada Clara Campoamor, Vigo, Spain.'}, {'lastname': 'Lamas', 'firstname': 'José Antonio', 'initials': 'JA', 'affiliation': 'Biomedical Research Centre (CINBIO), Laboratory of Neuroscience, University of Vigo, Galicia Sur Health Research Institute, Vigo, Spain.'}, {'lastname': 'González-Matías', 'firstname': 'Lucas C', 'initials': 'LC', 'affiliation': 'Biomedical Research Centre (CINBIO), Laboratory of Endocrinology, University of Vigo, Galicia Sur Health Research Institute, Vigo, Spain.'}, {'lastname': 'Mallo', 'firstname': 'Federico', 'initials': 'F', 'affiliation': 'Biomedical Research Centre (CINBIO), Laboratory of Endocrinology, University of Vigo, Galicia Sur Health Research Institute, Vigo, Spain.'}]",,,,Copyright © 2024 Copyright: © 2024 Neural Regeneration Research.,10.4103/1673-5374.389626,<Element 'PubmedArticle' at 0x7f05dd835310>
8,"38063284
29079522
33109997
20034703
24684956
32504632
25750611
32910516
26007613
12017547
16476744
9931268
32767637
31615888
21477602
31987814
9931269
24064221
30928686
27543884
35696793
21961711
21182120
22344196
21185655
27991897
36414622
35356299
29628218
27183047
33525512
27643430
29393299
34108509
30540774
32104920
32722686
19702455
15345733
37120339
17761551
34762113
34732544
29615896
27377060
10101041
18501637
24948804
31333434
35102101
12410009
24530839
30326011",Previous pregnancies might mitigate cortical brain differences associated with surgical menopause.,"Surgical menopause causes a sharp drop in estrogen levels in middle-aged women, thus preventing the gradual physiological adaptation that is characteristic of the perimenopause. Previous studies suggest that surgical menopause might increase the risk of dementia later in life. In addition, the transition to motherhood entails long-lasting endocrine and neuronal adaptations. We compared differences in whole-brain cortical volume between women who reached menopause by surgery and a group of women who reached spontaneous non-surgical menopause and determined whether these cortical differences were influenced by previous childbearing. Using surface-based neuroimaging techniques, we investigated cortical volume differences in 201 middle-aged women (134 women who experienced non-surgical menopause, 78 of whom were parous women; and 67 women who experienced surgical menopause, 39 of whom were parous women). We found significant atrophy in the frontal and temporal regions in women who experienced surgical menopause. Nulliparous women with surgical menopause showed significant lower cortical volume in the left temporal gyrus extending to the medial temporal lobe cortex, as well as in the precuneus bilaterally compared to parous women with surgical menopause; whereas our results revealed no significant differences between parous women with surgical menopause and both parous and nulliparous women who reached a non-surgical menopause. Furthermore, in the surgical menopause group, we found a negative correlation between cortical volume and age at first pregnancy in the temporal lobe. Our study suggests that the long-term brain remodeling of parity may mitigate the neural impact of the sudden drop in estrogen levels that characterizes surgical menopause.","['cortical atrophy', 'menopause', 'neuroimaging', 'oophorectomy', 'parity']",Human brain mapping,2023-12-08,"[{'lastname': 'Fernández-Pena', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain.\nInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.\nCIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Navas-Sánchez', 'firstname': 'Francisco J', 'initials': 'FJ', 'affiliation': 'Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.'}, {'lastname': 'de Blas', 'firstname': 'Daniel Martín', 'initials': 'DM', 'affiliation': 'Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain.\nInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.\nCIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Marcos-Vidal', 'firstname': 'Luis', 'initials': 'L', 'affiliation': 'Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain.\nInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.\nCIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Desco', 'firstname': 'Manuel', 'initials': 'M', 'affiliation': 'Departamento de Bioingeniería, Universidad Carlos III de Madrid, Madrid, Spain.\nInstituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.\nCIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.\nCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.'}, {'lastname': 'Carmona', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': 'Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.\nCIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.'}]",,,,© 2023 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.,"10.1002/hbm.26538
10.1038/nrendo.2015.82
10.1002/hbm.25152
10.1073/pnas.1910666116
10.1002/jmri.22328
10.3389/fnagi.2022.831807
10.1038/nrendo.2017.180
10.1371/journal.pone.0207885
10.1371/journal.pone.0236031
10.2217/WHE.09.42
10.3389/fnagi.2018.00074
10.1186/s12884-016-0937-5
10.3389/fnhum.2019.00224
10.1001/jamaneurol.2018.3057",<Element 'PubmedArticle' at 0x7f05dd8a5f90>
9,38059664,"Hormone profiles of the African pygmy mouse Mus minutoides, a species with XY female sex reversal.","In mammals, most sex differences in phenotype are controlled by gonadal hormones, but recent work on transgenic mice has shown that sex chromosomes can have a direct influence on sex-specific behaviors. In this study, we take advantage of the naturally occurring sex reversal in a mouse species, Mus minutoides, to investigate for the first time the relationship between sex chromosomes, hormones, and behaviors in a wild species. In this model, a feminizing variant of the X chromosome, named X*, produces three types of females with different sex chromosome complements (XX, XX*, and X*Y), associated with alternative behavioral phenotypes, while all males are XY. We thus compared the levels of three major circulating steroid hormones (testosterone, corticosterone, and estradiol) in the four sex genotypes to disentangle the influence of sex chromosomes and sex hormones on behavior. First, we did not find any difference in testosterone levels in the three female genotypes, although X*Y females are notoriously more aggressive. Second, in agreement with their lower anxiety-related behaviors, X*Y females and XY males display lower baseline corticosterone concentration than XX and XX* females. Instead of a direct hormonal influence, this result rather suggests that sex chromosomes may have an impact on the baseline corticosterone level, which in turn may influence behaviors. Third, estradiol concentrations do not explain the enhanced reproductive performance and maternal care behavior of the X*Y females compared to the XX and XX* females. Overall, this study highlights that most of the behaviors varying along with sex chromosome complement of this species are more likely driven by genetic factors rather than steroid hormone concentrations.","['African pygmy mouse', 'behavior', 'sex chromosomes', 'sex-reversed females', 'steroid hormones']","Journal of experimental zoology. Part A, Ecological and integrative physiology",2023-12-07,"[{'lastname': 'Veyrunes', 'firstname': 'Frederic', 'initials': 'F', 'affiliation': ""ISEM, Institut des Sciences de l'Evolution de Montpellier UMR 5554, CNRS, Université Montpellier, IRD, Montpellier, France.""}, {'lastname': 'Perez', 'firstname': 'Julie', 'initials': 'J', 'affiliation': ""ISEM, Institut des Sciences de l'Evolution de Montpellier UMR 5554, CNRS, Université Montpellier, IRD, Montpellier, France.""}, {'lastname': 'Heitzmann', 'firstname': 'Louise D', 'initials': 'LD', 'affiliation': ""ISEM, Institut des Sciences de l'Evolution de Montpellier UMR 5554, CNRS, Université Montpellier, IRD, Montpellier, France.""}, {'lastname': 'Saunders', 'firstname': 'Paul A', 'initials': 'PA', 'affiliation': ""ISEM, Institut des Sciences de l'Evolution de Montpellier UMR 5554, CNRS, Université Montpellier, IRD, Montpellier, France.""}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': 'MMDN, Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Université Montpellier, EPHE-PSL, INSERM U1198, Montpellier, France.\nDepartment of Psychiatry and Neurosciences, CR-CHUQ, Faculty of Medicine, Laval University, Québec City, Canada.\nCNRS, Paris, France.'}]",,,,© 2023 The Authors. Journal of Experimental Zoology Part A: Ecological and Integrative Physiology published by Wiley Periodicals LLC.,10.1002/jez.2767,<Element 'PubmedArticle' at 0x7f05deaa1c20>
10,"38035277
19184666
32920880
22401743
25009471
31638686
24130779
34211387
7499560
26525152
30010124
33350452
22492304
20300040
27252160
19121391
10085356
33766745
34472455
33731156
14985348
32311609
15261846
29237809
35381014
17974126
33973274
14692890
18039070
15608005
25792098
27335395
25128029
8713135
28963121
33554914
21880379
27163830
23163235
33889084
14568026
29151590
37023830
37396803
30042661
16422148
32817249
21078303
35264008
34589766
35563362
27078860
3344537
30941031
14998904
33097048
32417786
16000616
16049335
36834617
36206386
21913092
30212304
28855400
30540774
29250747
33155924
32778793
18202172
32074468
24275289
26130062
21969914
29222909
33556248
26174330
37074915
31296239
18706995
36624497
21745355
27805868
11500035
35398231
37459141
25510382
36746627
27395435
25999809
29171994
36240091
8063952
21956752
14692704
12836175
24371084
24926825
21211517
32535839
34349624
21280086
21277946
21224009
18348702
12612547
17331655
24037035
25420705
29782911",Hippocampal glial inflammatory markers are differentially altered in a novel mouse model of perimenopausal cerebral amyloid angiopathy.,"Dementia is often characterized by age-dependent cerebrovascular pathology, neuroinflammation, and cognitive deficits with notable sex differences in risk, disease onset, progression and severity. Women bear a disproportionate burden of dementia, and the onset of menopause (i.e., perimenopause) may be a critical period conferring increased susceptibility. However, the contribution of early ovarian decline to the neuroinflammatory processes associated with cerebrovascular dementia risks, particularly at the initial stages of pathology that may be more amenable to proactive intervention, is unknown. To better understand the influence of early ovarian failure on dementia-associated neuroinflammation we developed a model of perimenopausal cerebral amyloid angiopathy (CAA), an important contributor to dementia. For this, accelerated ovarian failure (AOF) was induced by 4-vinylcyclohexene diepoxide (VCD) treatment to isolate early-stage ovarian failure comparable to human perimenopause (termed ""peri-AOF"") in transgenic SWDI mice expressing human vasculotropic mutant amyloid beta (Aβ) precursor protein, that were also tested at an early stage of amyloidosis. We found that peri-AOF SWDI mice showed increased astrocyte activation accompanied by elevated Aβ in select regions of the hippocampus, a brain system involved in learning and memory that is severely impacted during dementia. However, although SWDI mice showed signs of increased hippocampal microglial activation and impaired cognitive function, this was not further affected by peri-AOF. In sum, these results suggest that elevated dysfunction of key elements of the neurovascular unit in select hippocampal regions characterizes the brain pathology of mice at early stages of both CAA and AOF. However, neurovascular unit pathology may not yet have passed a threshold that leads to further behavioral compromise at these early periods of cerebral amyloidosis and ovarian failure. These results are consistent with the hypothesis that the hormonal dysregulation associated with perimenopause onset represents a stage of emerging vulnerability to dementia-associated neuropathology, thus providing a selective window of opportunity for therapeutic intervention prior to the development of advanced pathology that has proven difficult to repair or reverse.","['aging model', 'amyloid beta', 'astrocytes', 'blood vessel', 'microglia', 'subiculum']",Frontiers in aging neuroscience,2023-11-30,"[{'lastname': 'Platholi', 'firstname': 'Jimcy', 'initials': 'J', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.\nAnesthesiology Department, Weill Cornell Medicine, New York, NY, United States.'}, {'lastname': 'Marongiu', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': ""Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.\nNeurological Surgery Department, Weill Cornell Medicine, New York, NY, United States.\nGenetic Medicine Department, Weill Cornell Medicine, New York, NY, United States.\nAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, United States.""}, {'lastname': 'Park', 'firstname': 'Laibaik', 'initials': 'L', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.'}, {'lastname': 'Yu', 'firstname': 'Fangmin', 'initials': 'F', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.'}, {'lastname': 'Sommer', 'firstname': 'Garrett', 'initials': 'G', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.'}, {'lastname': 'Weinberger', 'firstname': 'Rena', 'initials': 'R', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.'}, {'lastname': 'Tower', 'firstname': 'William', 'initials': 'W', 'affiliation': 'Neurological Surgery Department, Weill Cornell Medicine, New York, NY, United States.'}, {'lastname': 'Milner', 'firstname': 'Teresa A', 'initials': 'TA', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.\nHarold and Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, United States.'}, {'lastname': 'Glass', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': 'Weill Cornell Medicine, Feil Family Brain and Mind Research Institute, New York, NY, United States.'}]",,,,"Copyright © 2023 Platholi, Marongiu, Park, Yu, Sommer, Weinberger, Tower, Milner and Glass.","10.3389/fnagi.2023.1280218
10.1007/s00401-009-0485-4
10.1111/ejn.14969
10.1016/j.yhbeh.2012.02.021
10.3389/fnana.2014.00053
10.1001/jama.2019.4782
10.1371/journal.pone.0076526
10.3389/fnagi.2021.653334
10.1002/cne.903600111
10.1101/cshperspect.a021733
10.3233/JAD-180141
10.1093/cercor/bhaa359
10.1210/en.2011-1925
10.1097/gme.0b013e3181cc49e9
10.1152/physiol.00057.2014
10.1016/j.nbd.2008.11.017
10.1152/jn.1999.81.3.1296
10.1016/j.mad.2021.111473
10.4103/1673-5374.322423
10.1186/s12974-021-02117-y
10.1074/jbc.M312946200
10.1016/j.neurobiolaging.2020.03.006
10.1016/j.beem.2004.02.001
10.1098/rsob.170228
10.1371/journal.pmed.1003955
10.1002/glia.24017
10.1046/j.1351-5101.2003.00707.x
10.1586/14737175.7.11s.S7
10.1136/jnnp.2003.024927
10.1016/S1474-4422(15)70016-5
10.1523/JNEUROSCI.3951-13.2016
10.1007/s12035-014-8853-z
10.1006/bbrc.1996.1112
10.1042/CS20170033
10.3233/JAD-201410
10.1016/j.tins.2011.07.007
10.3233/JAD-160258
10.1111/nan.12003
10.3389/fnagi.2021.651973
10.1016/S0306-4522(03)00245-8
10.1038/nri.2017.125
10.1016/j.nbd.2023.106114
10.1016/j.eclinm.2023.102033
10.3389/fncel.2018.00193
10.1523/JNEUROSCI.0115-20.2020
10.1016/j.brainres.2010.11.030
10.1161/STROKEAHA.121.035836
10.1016/j.bbih.2021.100260
10.3390/ijms23094972
10.1159/000446073
10.1161/01.STR.19.2.205
10.3389/fnagi.2019.00059
10.1095/biolreprod.103.016113
10.1186/s12974-020-01998-9
10.3233/JAD-200238
10.1523/JNEUROSCI.1306-05.2005
10.1016/S0002-9440(10)62993-8
10.3390/ijms24043205
10.1101/lm.053507.121
10.1212/WNL.0000000000004425
10.1371/journal.pone.0207885
10.1007/s00441-017-2745-2
10.2174/1573403X16666201106141811
10.1038/s41593-020-0686-7
10.1073/pnas.0711568105
10.1089/jwh.2019.7826
10.1016/j.jchemneu.2013.10.004
10.1016/j.neurobiolaging.2015.05.023
10.4061/2011/251517
10.1111/jnc.14273
10.1146/annurev-immunol-093019-110159
10.1038/jcbfm.2015.164
10.1016/j.celrep.2023.112397
10.1186/s12974-019-1534-0
10.1016/j.reprotox.2008.07.005
10.1186/s13195-022-01121-5
10.1186/2042-6410-2-7
10.1210/en.2016-1516
10.1006/bbrc.2001.5388
10.1016/j.bbr.2022.113882
10.1001/jama.2023.13239
10.1016/j.jalz.2014.10.008
10.1523/JNEUROSCI.1333-22.2023
10.1016/j.bbi.2016.07.003
10.3389/fnins.2015.00160
10.3233/JAD-170344
10.1212/WNL.0000000000200960
10.1002/cne.903440108
10.1002/hipo.20974
10.1093/jnen/62.12.1287
10.1002/cne.10753
10.1161/ATVBAHA.113.302440
10.1210/en.2014-1190
10.1016/j.brainres.2010.12.064
10.1007/s00429-020-02095-6
10.3389/fncel.2021.695479
10.1002/ana.22239
10.1016/j.neuroscience.2011.01.034
10.1016/j.nlm.2011.01.002
10.1359/jbmr.080309
10.1038/nm838
10.1016/j.neuroscience.2007.01.043
10.3233/JAD-130758
10.1002/cne.23712
10.1016/j.bbi.2018.05.013",<Element 'PubmedArticle' at 0x7f05debddae0>
11,"38025979
24418058
26836168
32560743
30715078
35768637
24623176
32859588
34227023
35356299
31333434
36624497
34323137
35710453
36240091
37380188
25500343
18827120
29937152
21961824
32999626
33752880
32041390
36170998
17551351
36126748
33224053
25222701
29522764
27680324
30453902
36274762
25034198
35381014
36760712
32856754
24064221
22994984
34732544
23189030
32112728
32396982
28315609
30881301
27217764
19470968
37758482
32573980
33925655
37357283
34865028
25913700
36845663
31921966
31122239
37158951
32738937
3280486
31000129
36038209
20207237
33416284
35871816",Hormonal contraception and risk for cognitive impairment or Alzheimer's disease and related dementias in young women: a scoping review of the evidence.,"Women are significantly more likely to develop Alzheimer's disease and related dementias (ADRD) than men. Suggestions to explain the sex differences in dementia incidence have included the influence of sex hormones with little attention paid to date as to the effect of hormonal contraception on brain health. The aim of this scoping review is to evaluate the current evidence base for associations between hormonal contraceptive use by women and non-binary people in early adulthood and brain health outcomes.
A literature search was conducted using EMBASE, Medline and Google Scholar, using the keywords ""hormonal contraception"" OR ""contraception"" OR ""contraceptive"" AND ""Alzheimer*"" OR ""Brain Health"" OR ""Dementia"".
Eleven papers were identified for inclusion in the narrative synthesis. Studies recruited participants from the UK, USA, China, South Korea and Indonesia. Studies included data from women who were post-menopausal with retrospective data collection, with only one study contemporaneously collecting data from participants during the period of hormonal contraceptive use. Studies reported associations between hormonal contraceptive use and a lower risk of ADRD, particularly Alzheimer's disease (AD), better cognition and larger grey matter volume. Some studies reported stronger associations with longer duration of hormonal contraceptive use, however, results were inconsistent. Four studies reported no significant associations between hormonal contraceptive use and measures of brain health, including brain age on MRI scans and risk of AD diagnosis.
Further research is needed on young adults taking hormonal contraceptives, on different types of hormonal contraceptives (other than oral) and to explore intersections between sex, gender, race and ethnicity.
https://doi.org/10.17605/OSF.IO/MVX63, identifier: OSF.io: 10.17605/OSF.IO/MVX63.","['Alzheimer’s disease', 'brain health', 'hormonal contraception', 'oral contraception', 'scoping review']",Frontiers in global women's health,2023-11-29,"[{'lastname': 'Gregory', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Booi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Memory and Aging Center, Global Brain Health Institute, Trinity College, Dublin, Ireland.\nCentre for Dementia Research, School of Health, Leeds Beckett University, Leeds, United Kingdom.'}, {'lastname': 'Jenkins', 'firstname': 'Natalie', 'initials': 'N', 'affiliation': 'Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.\nSchool of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.'}, {'lastname': 'Bridgeman', 'firstname': 'Katie', 'initials': 'K', 'affiliation': 'Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Muniz-Terrera', 'firstname': 'Graciela', 'initials': 'G', 'affiliation': 'Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.\nOhio University Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, United States.'}, {'lastname': 'Farina', 'firstname': 'Francesca R', 'initials': 'FR', 'affiliation': 'Memory and Aging Center, Global Brain Health Institute, Trinity College, Dublin, Ireland.\nDepartment of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.'}]",,,"Eleven papers were identified for inclusion in the narrative synthesis. Studies recruited participants from the UK, USA, China, South Korea and Indonesia. Studies included data from women who were post-menopausal with retrospective data collection, with only one study contemporaneously collecting data from participants during the period of hormonal contraceptive use. Studies reported associations between hormonal contraceptive use and a lower risk of ADRD, particularly Alzheimer's disease (AD), better cognition and larger grey matter volume. Some studies reported stronger associations with longer duration of hormonal contraceptive use, however, results were inconsistent. Four studies reported no significant associations between hormonal contraceptive use and measures of brain health, including brain age on MRI scans and risk of AD diagnosis.","© 2023 Gregory, Booi, Jenkins, Bridgeman, Muniz-Terrera and Farina.","10.3389/fgwh.2023.1289096
10.1016/j.jalz.2013.10.005
10.3233/JAD-150780
10.1186/s13293-020-00310-x
10.1001/jamaneurol.2018.4693
10.1038/s41380-022-01675-8
10.1002/ana.24135
10.1242/dmm.045211
10.1007/s11910-021-01133-y
10.3389/fnagi.2022.831807
10.3389/fnhum.2019.00224
10.1186/s13195-022-01121-5
10.1080/13697137.2021.1951203
10.1186/s13195-022-01026-3
10.1212/WNL.0000000000200960
10.1136/bmj.p1404
10.1097/AOG.0b013e3181875ec5
10.1016/j.fertnstert.2018.03.012
10.1016/j.ajog.2011.06.056
10.1080/15532739.2019.1631929
10.1016/j.fertnstert.2021.02.007
10.4274/jcrpe.galenos.2019.2019.S0003
10.1136/bmj.o2311
10.1097/YCO.0b013e32816ebc8c
10.1016/j.yfrne.2022.101036
10.3389/fpsyg.2020.556577
10.1016/j.psyneuen.2014.07.025
10.1016/j.yhbeh.2018.03.004.
10.1001/jamapsychiatry.2016.2387
10.1186/s12874-018-0611-x
10.4300/JGME-D-22-00621.1
10.1016/j.jclinepi.2014.03.013
10.1371/journal.pmed.1003955
10.3389/fnagi.2022.1014605
10.1002/hbm.25180
10.1016/j.psyneuen.2013.08.005
10.1089/jwh.2012.3522
10.1212/WNL.0000000000012941
10.2147/NDT.S36622
10.33879/AMH.113.2019.08020
10.1016/j.ajog.2020.02.032
10.1111/ene.14315
10.1016/j.psyneuen.2017.02.025
10.3389/fnagi.2019.00043
10.2147/JMDH.S104807
10.3389/frdem.2023.1098693
10.1212/WNL.0b013e3181a71193
10.1212/WNL.0000000000207845
10.1002/alz.12118
10.3390/diagnostics11050788
10.14283/jpad.2023.43
10.1093/geronb/gbab226
10.1016/j.neuroimage.2015.04.036
10.3389/fnagi.2023.1107372
10.1016/j.trci.2019.09.018
10.1186/s12889-019-6911-1
10.1186/s40900-023-00434-5
10.1016/S0140-6736(20)30367-6
10.1016/S2214-109X(19)30074-9
10.1016/bs.irn.2022.07.004
10.1016/j.ajog.2009.08.022
10.1097/AOG.0000000000004224
10.1016/S0140-6736(22)00936-9",<Element 'PubmedArticle' at 0x7f05dee9d540>
12,"38010200
21436401
33686181
32428501
34572087
31420552
34017238
35882862
15288712
32075509
23273601
30927700
8329192
4748425
34936461
29950970
21632750
22869320
21035308
36473871
2360787
30833547
30686981
10936180
26813123
31551756
20035364
31160730
16802347
26290229
26216852
15033922
12086937
30263000
27416781
31024073
27034026
33621703
35484130
21683721
15755733
20724638
11846609
27207919
35230639
22749857
35778755
25186765
25164819
26404616
35196169
32365859
30733432
29874566
19887566
34779769
32940941
36241425
18479783
25231068
25030513
11287630
11147790
36869288
20126541
32578146
9671656
28776086
21433241
16340083
31534057
35331736
2325814
34576151
17316461
35360151
26967226
31417349
15750215
15731448
26529666
19943139
10389839
24298137
24640977
22476197
34804173
30718702
1789684
31723029
33337559
31987911
25645581
31277657
28688899
20957377
32230718
26340637
24591653
35141048
31693892
25576061
29967007
33292257
11788580
35954198
23816567
18952604
33707434
21214928",Influence of metabolic stress and metformin on synaptic protein profile in SH-SY5Y-derived neurons.,"Insulin resistance (IR) is associated with reductions in neuronal proteins often observed with Alzheimer's disease (AD), however, the mechanisms through which IR promotes neurodegeneration/AD pathogenesis are poorly understood. Metformin (MET), a potent activator of the metabolic regulator AMPK is used to treat IR but its effectiveness for AD is unclear. We have previously shown that chronic AMPK activation impairs neurite growth and protein synthesis in SH-SY5Y neurons, however, AMPK activation in IR was not explored. Therefore, we examined the effects of MET-driven AMPK activation with and without IR. Retinoic acid-differentiated SH-SY5Y neurons were treated with: (1) Ctl: 24 h vehicle followed by 24 h Vehicle; (2) HI: 100 nM insulin (24 h HI followed by 24 h HI); or (3) MET: 24 h vehicle followed by 24 h 2 mM metformin; (4) HI/MET: 24 h 100 nM insulin followed by 24 h 100 nM INS+2 mM MET. INS and INS/MET groups saw impairments in markers of insulin signaling (Akt S473, mTOR S2448, p70s6k T389, and IRS-1S636) demonstrating IR was not recovered with MET treatment. All treatment groups showed reductions in neuronal markers (post-synaptic marker HOMER1 mRNA content and synapse marker synaptophysin protein content). INS and MET treatments showed a reduction in the content of the mature neuronal marker NeuN that was prevented by INS/MET. Similarly, increases in cell size/area, neurite length/area observed with INS and MET, were prevented with INS/MET. These findings indicate that IR and MET impair neuronal markers through distinct pathways and suggest that MET is ineffective in treating IR-driven impairments in neurons.","['AMPK', ""Alzheimer's disease"", 'insulin-resistance', 'metformin', 'neuronal health']",Physiological reports,2023-11-27,"[{'lastname': 'Yang', 'firstname': 'Alex J T', 'initials': 'AJT', 'affiliation': 'Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada.'}, {'lastname': 'Mohammad', 'firstname': 'Ahmad', 'initials': 'A', 'affiliation': 'Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada.'}, {'lastname': 'Finch', 'firstname': 'Michael S', 'initials': 'MS', 'affiliation': 'Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada.'}, {'lastname': 'Tsiani', 'firstname': 'Evangelia', 'initials': 'E', 'affiliation': 'Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada.'}, {'lastname': 'Spencer', 'firstname': 'Gaynor', 'initials': 'G', 'affiliation': 'Department of Biological Sciences, Brock University, St Catharines, Ontario, Canada.\nCentre for Neuroscience, Brock University, St. Catharines, Ontario, Canada.'}, {'lastname': 'Necakov', 'firstname': 'Aleksandar', 'initials': 'A', 'affiliation': 'Department of Biological Sciences, Brock University, St Catharines, Ontario, Canada.\nCentre for Neuroscience, Brock University, St. Catharines, Ontario, Canada.'}, {'lastname': 'MacPherson', 'firstname': 'Rebecca E K', 'initials': 'REK', 'affiliation': 'Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St Catharines, Ontario, Canada.\nCentre for Neuroscience, Brock University, St. Catharines, Ontario, Canada.'}]",,,,© 2023 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.,10.14814/phy2.15852,<Element 'PubmedArticle' at 0x7f05df0c4b30>
13,38007653,Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease.,"Alzheimer's disease (AD) affects more women than men, with women throughout the menopausal transition potentially being the most under researched and at-risk group. Sleep disruptions, which are an established risk factor for AD, increase in prevalence with normal aging and are exacerbated in women during menopause. Sex differences showing more disrupted sleep patterns and increased AD pathology in women and female animal models have been established in literature, with much emphasis placed on loss of circulating gonadal hormones with age. Interestingly, increases in gonadotropins such as follicle stimulating hormone are emerging to be a major contributor to AD pathogenesis and may also play a role in sleep disruption, perhaps in combination with other lesser studied hormones. Several sleep influencing regions of the brain appear to be affected early in AD progression and some may exhibit sexual dimorphisms that may contribute to increased sleep disruptions in women with age. Additionally, some of the most common sleep disorders, as well as multiple health conditions that impair sleep quality, are more prevalent and more severe in women. These conditions are often comorbid with AD and have bi-directional relationships that contribute synergistically to cognitive decline and neuropathology. The association during aging of increased sleep disruption and sleep disorders, dramatic hormonal changes during and after menopause, and increased AD pathology may be interacting and contributing factors that lead to the increased number of women living with AD.","['Alzheimer’s disease', 'hormones', 'menopause', 'sex differences', 'sleep', 'women']",Journal of Alzheimer's disease : JAD,2023-11-26,"[{'lastname': 'Johnson', 'firstname': 'Carrie E', 'initials': 'CE', 'affiliation': 'University of Kentucky, College of Medicine, Department of Molecular and Cellular Biochemistry, Lexington, KY, USA.'}, {'lastname': 'Duncan', 'firstname': 'Marilyn J', 'initials': 'MJ', 'affiliation': 'University of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY, USA.'}, {'lastname': 'Murphy', 'firstname': 'M Paul', 'initials': 'MP', 'affiliation': 'University of Kentucky, College of Medicine, Department of Molecular and Cellular Biochemistry, Lexington, KY, USA.\nUniversity of Kentucky, Sanders-Brown Center on Aging, Lexington, KY, USA.'}]",,,,,10.3233/JAD-230527,<Element 'PubmedArticle' at 0x7f05df5d6a40>
14,37992797,Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain.,"In the early stages of sporadic Alzheimer's disease (SAD), there is a strong correlation between memory impairment and cortical levels of soluble amyloid-β peptide oligomers (Aβ). It has become clear that Aβ disrupt glutamatergic synaptic function, which can in turn lead to the characteristic cognitive deficits of SAD, but the actual pathways are still not well understood. This opinion article describes the pathogenic mechanisms underlying cerebral amyloidosis. These mechanisms are dependent on the amyloid precursor protein and concern the synthesis of Aβ peptides with competition between the non-amyloidogenic pathway and the amyloidogenic pathway (i.e. a competition between the ADAM10 and BACE1 enzymes), on the one hand, and the various processes of Aβ residue clearance, on the other hand. This clearance mobilizes both endopeptidases (NEP, and IDE) and removal transporters across the blood-brain barrier (LRP1, ABCB1, and RAGE). Lipidated ApoE also plays a major role in all processes. The disturbance of these pathways induces an accumulation of Aβ. The description of the mechanisms reveals two key molecules in particular: (i) free estradiol, which has genomic and non-genomic action, and (ii) free DHA as a preferential ligand of PPARα-RXRα and PPARɣ-RXRα heterodimers. DHA and free estradiol are also self-regulating, and act in synergy. When a certain level of chronic DHA and free estradiol deficiency is reached, a permanent imbalance is established in the central nervous system. The consequences of these deficits are revealed in particular by the presence of Aβ peptide deposits, as well as other markers of the etiology of SAD.","['ADAM10', 'Amyloid β-peptide', 'BACE1', 'Clearance', 'DHA', 'Estradiol', 'IDE', 'NEP']",Brain research,2023-11-23,"[{'lastname': 'Majou', 'firstname': 'Didier', 'initials': 'D', 'affiliation': 'ACTIA, 149, rue de Bercy, 75595 Paris Cedex 12, France. Electronic address: d.majou@actia-asso.eu.'}, {'lastname': 'Dermenghem', 'firstname': 'Anne-Lise', 'initials': 'AL', 'affiliation': 'ACTIA, 149, rue de Bercy, 75595 Paris Cedex 12, France.'}]",,,,Copyright © 2023. Published by Elsevier B.V.,10.1016/j.brainres.2023.148681,<Element 'PubmedArticle' at 0x7f05df658bd0>
15,37985011,Alzheimer's disease-related brain insulin resistance and the prospective therapeutic impact of metformin.,"Besides COVID-19, two of the most critical outbreaks of our day are insulin resistance, type 2 diabetes mellitus (T2DM), and Alzheimer's disease (AD). Each disease's pathophysiology is well established. Furthermore, a substantial overlap between them has coexisted. Uncertainty remains on whether T2DM and AD are parallel illnesses with the same origin or separate illnesses linked through violent pathways. The current study was aimed at testing whether the insulin resistance in the brain results in AD symptoms or not. Insulin resistance was induced in the brains of rats using a single intracerebroventricular streptozotocin (STZ) dose. We then measured glucose, insulin receptor substrate 2 (IRS-2), amyloid β (Aβ) deposition, and tau phosphorylation in the brain to look for signs of insulin resistance and AD. The results of this study indicated that a single dose of STZ was able to induce insulin resistance in the brain and significantly decline IRS-2. This resistance was accompanied by obvious memory loss, Aβ deposition, and tau phosphorylation, further visible diminishing in neurotransmitters such as dopamine and acetylcholine. Furthermore, oxidative stress was increased due to the antioxidant system being compromised. Interestingly, the pancreas injury and peripheral insulin resistance coexisted with brain insulin resistance. Indeed, the antidiabetic metformin was able to enhance all these drastic effects. In conclusion, brain insulin resistance could lead to AD and vice versa. These are highly linked syndromes that could influence peripheral organs. Further studies are required to stabilize this putative pathobiology relationship between them.","['Alzheimer disease', 'amyloid β', 'brain insulin resistance', 'insulin receptor substrate 2', 'metformin']",Journal of neuroendocrinology,2023-11-21,"[{'lastname': 'Abosharaf', 'firstname': 'Hamed A', 'initials': 'HA', 'affiliation': 'Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.'}, {'lastname': 'Elsonbaty', 'firstname': 'Yasmin', 'initials': 'Y', 'affiliation': 'Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.'}, {'lastname': 'Tousson', 'firstname': 'Ehab', 'initials': 'E', 'affiliation': 'Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt.'}, {'lastname': 'M Mohamed', 'firstname': 'Tarek', 'initials': 'T', 'affiliation': 'Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.'}]",,,,© 2023 British Society for Neuroendocrinology.,10.1111/jne.13356,<Element 'PubmedArticle' at 0x7f05df64d8b0>
16,"37974165
5322983
18305538
30602725
29626653
29028540
31704179
33812000
23185029
29744576
34693284
25155018
18565828
16862116
16862115
28435163
28835281
34453183
28778989
36207292
34450028
28966121
23764284
29924488
23371551
34079125
28199306
29256494
28728022
35799292
33028409
31539493
33201688
35815987
12376573
29036611
21368173
20147306
35793413
34587451
31882993
30476243
28237098
22930834
32553155
31768005
33510479
29074583
34477805
16450005
20381137
22335796
27114033
24619111
33556866
29449567
32238265
34259807
30643292
35767949
16239184
9548376
35786165
29914620
32001091
34344440
35120524
30180904
26299959
28073925
29695488
34433069",Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons.,"Progranulin (PGRN) is a lysosomal glycoprotein implicated in various neurodegenerative diseases, including frontotemporal dementia and neuronal ceroid lipofuscinosis. Over 70 mutations discovered in the GRN gene all result in reduced expression of the PGRN protein. Genetic and functional studies point toward a regulatory role for PGRN in lysosome functions. However, the detailed molecular function of PGRN within lysosomes and the impact of PGRN deficiency on lysosomes remain unclear.
We developed multifaceted proteomic techniques to characterize the dynamic lysosomal biology in living human neurons and fixed mouse brain tissues. Using lysosome proximity labeling and immuno-purification of intact lysosomes, we characterized lysosome compositions and interactome in both human induced pluripotent stem cell (iPSC)-derived glutamatergic neurons (i
Leveraging the multi-modal proteomics and live-cell imaging techniques, we comprehensively characterized how PGRN deficiency changes the molecular and functional landscape of neuronal lysosomes. We found that PGRN loss impairs the lysosome's degradative capacity with increased levels of v-ATPase subunits on the lysosome membrane, increased hydrolases within the lysosome, altered protein regulations related to lysosomal transport, and elevated lysosomal pH. Consistent with impairments in lysosomal function, GRN-null i
This study suggested PGRN as a critical regulator of lysosomal pH and degradative capacity, which influences global proteostasis in neurons. Beyond the study of progranulin deficiency, these newly developed proteomic methods in neurons and brain tissues provided useful tools and data resources for the field to study the highly dynamic neuronal lysosome biology.","['Frontotemporal dementia', 'Half-life', 'Lysosome', 'Neuron', 'PGRN', 'Progranulin', 'Proteomics', 'Turnover', 'dSILAC', 'iPSC']",Molecular neurodegeneration,2023-11-17,"[{'lastname': 'Hasan', 'firstname': 'Saadia', 'initials': 'S', 'affiliation': 'National Institute of Neurological, Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.\nDepartment of Neurodegenerative Disease, UK Dementia Research Institute, Institute of Neurology, University College London, London, UK.\nAugusta University, University of Georgia Medical Partnership, Athens, GA, USA.'}, {'lastname': 'Fernandopulle', 'firstname': 'Michael S', 'initials': 'MS', 'affiliation': 'National Institute of Neurological, Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.\nCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.\nMedical Scientist Training Program, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Humble', 'firstname': 'Stewart W', 'initials': 'SW', 'affiliation': ""National Institute of Neurological, Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.\nDepartment of Physiology, Anatomy and Genetics, Oxford Parkinson's Disease Centre, Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford, OX1 3QU, UK.""}, {'lastname': 'Frankenfield', 'firstname': 'Ashley M', 'initials': 'AM', 'affiliation': 'Department of Chemistry, George Washington University, Washington, DC, USA.'}, {'lastname': 'Li', 'firstname': 'Haorong', 'initials': 'H', 'affiliation': 'Department of Chemistry, George Washington University, Washington, DC, USA.'}, {'lastname': 'Prestil', 'firstname': 'Ryan', 'initials': 'R', 'affiliation': 'Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Johnson', 'firstname': 'Kory R', 'initials': 'KR', 'affiliation': 'National Institute of Neurological, Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'lastname': 'Ryan', 'firstname': 'Brent J', 'initials': 'BJ', 'affiliation': ""Department of Physiology, Anatomy and Genetics, Oxford Parkinson's Disease Centre, Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford, OX1 3QU, UK.""}, {'lastname': 'Wade-Martins', 'firstname': 'Richard', 'initials': 'R', 'affiliation': ""Department of Physiology, Anatomy and Genetics, Oxford Parkinson's Disease Centre, Kavli Institute for Nanoscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford, OX1 3QU, UK.""}, {'lastname': 'Ward', 'firstname': 'Michael E', 'initials': 'ME', 'affiliation': 'National Institute of Neurological, Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA. wardme@nih.gov.'}, {'lastname': 'Hao', 'firstname': 'Ling', 'initials': 'L', 'affiliation': 'Department of Chemistry, George Washington University, Washington, DC, USA. linghao@gwu.edu.'}]",,"This study suggested PGRN as a critical regulator of lysosomal pH and degradative capacity, which influences global proteostasis in neurons. Beyond the study of progranulin deficiency, these newly developed proteomic methods in neurons and brain tissues provided useful tools and data resources for the field to study the highly dynamic neuronal lysosome biology.","Leveraging the multi-modal proteomics and live-cell imaging techniques, we comprehensively characterized how PGRN deficiency changes the molecular and functional landscape of neuronal lysosomes. We found that PGRN loss impairs the lysosome's degradative capacity with increased levels of v-ATPase subunits on the lysosome membrane, increased hydrolases within the lysosome, altered protein regulations related to lysosomal transport, and elevated lysosomal pH. Consistent with impairments in lysosomal function, GRN-null i",© 2023. The Author(s).,"10.1186/s13024-023-00673-w
10.1146/annurev.ph.28.030166.002251
10.1038/nature06639
10.1038/s41556-018-0244-7
10.1016/j.neulet.2018.04.005
10.1016/j.conb.2017.09.005
10.1016/j.tins.2019.10.002
10.1016/j.nbd.2021.105360
10.1083/jcb.201208152
10.1007/s00401-018-1861-8
10.1093/braincomms/fcab095
10.1084/jem.20140214
10.1212/01.wnl.0000319688.89790.7a
10.1038/nature05017
10.1038/nrn.2017.36
10.1186/s13024-017-0205-9
10.1007/s00109-021-02127-6
10.1084/jem.20160999
10.1038/s41467-022-33500-9
10.1016/j.cell.2021.08.002
10.1016/j.stemcr.2017.08.019
10.1016/j.neuron.2013.05.029
10.1002/cpcb.51
10.1126/science.1230593
10.1038/s41586-021-03592-2
10.1038/nature21423
10.1038/nmeth.4533
10.1016/j.neuron.2017.06.026
10.1186/s40478-022-01387-8
10.1186/s40478-020-01037-x
10.1016/j.cell.2019.08.050
10.1021/acs.analchem.0c03107
10.1074/mcp.M200046-MCP200
10.1093/hmg/ddx364
10.1073/pnas.1100650108
10.1093/bioinformatics/btq054
10.1021/acs.jproteome.2c00145
10.1021/acs.analchem.1c02309
10.1093/bioinformatics/btz931
10.1093/nar/gky1131
10.1016/bs.mie.2016.09.073
10.1038/nmeth.2089
10.1016/j.celrep.2020.107775
10.1038/s41580-019-0185-4
10.1038/s41593-020-00785-2
10.1126/science.aan6298
10.1039/D1MO00205H
10.1038/ncb0206-107
10.1016/j.cell.2010.02.024
10.1146/annurev-physiol-012110-142317
10.1016/j.cell.2016.04.001
10.1074/mcp.R120.002190
10.1038/s41467-018-03106-1
10.7554/eLife.52939
10.1083/jcb.202005193
10.1038/s41593-018-0300-4
10.1016/j.celrep.2022.111001
10.1016/S1474-4422(05)70223-4
10.1016/S0171-9335(98)80061-7
10.1080/15548627.2022.2095834
10.7554/eLife.34202
10.1016/j.tibs.2019.12.007
10.1186/s13024-021-00472-1
10.1186/s13024-021-00513-9
10.1186/s13024-018-0281-5
10.1016/j.celrep.2015.07.050
10.1083/jcb.201711083
10.1016/j.celrep.2021.109581",<Element 'PubmedArticle' at 0x7f05df7dbd10>
17,37871560,SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model.,"Alzheimer's disease (AD) and type 2 diabetes mellitus (T2D) share common features, including insulin resistance. Brain insulin resistance has been implicated as a key factor in the pathogenesis of AD. Recent studies have demonstrated that anti-diabetic drugs sodium-glucose cotransporter-2 inhibitor (SGLT2-i) and dipeptidyl peptidase-4 inhibitor (DPP4-i) improve insulin sensitivity and provide neuroprotection. However, the effects of these two inhibitors on the brain metabolism and insulin resistance remain uninvestigated. We developed a T2D-AD mouse model using a high-fat diet (HFD) for 19 weeks along with a single dose of streptozotocin (100 mg/kg, intraperitoneally) at the fourth week of HFD initiation. Subsequently, the animals were treated with SGLT2-i (empagliflozin, 25 mg/kg/day orally [p.o.]) and DPP4-i (sitagliptin, 100 mg/kg/day p.o.) for 7 weeks. Subsequently, behavioral tests were performed, and the expression of insulin signaling, AD-related, and other signaling pathway proteins in the brain were examined. T2D-AD mice not only showed increased blood glucose levels and body weight but also insulin resistance. SGLT2-i and DPP4-i effectively ameliorated insulin sensitivity and reduced body weight in these mice. Furthermore, SGLT2-i and DPP4-i significantly improved hippocampal-dependent learning, memory, and cognitive functions in the T2D-AD mouse model. Interestingly, SGLT2-i and DPP4-i reduced the hyperphosphorylated tau (pTau) levels and amyloid β (Aβ) accumulation and enhanced brain insulin signaling. SGLT2-i reduced pTau accumulation through the angiotensin converting enzyme-2/angiotensin (1-7)/ mitochondrial assembly receptor axis, whereas DPP4-i reduced Aβ accumulation by increasing insulin-degrading enzyme levels. These findings suggest that SGLT2-i and DPP4-i prevent AD-like pathology and cognitive dysfunction in T2D mice potentially through affecting brain insulin signaling via different mechanisms.","['Alzheimer’s disease', 'Amyloid β', 'Dipeptidyl peptidase-4 inhibitor', 'Hyperphosphorylated tau', 'Sodium–glucose cotransporter-2 inhibitor', 'Type 2 diabetes mellitus']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2023-10-24,"[{'lastname': 'Sim', 'firstname': 'A Young', 'initials': 'AY', 'affiliation': 'Department of Anatomy, Yonsei University College of Medicine, Seoul, Republic of Korea; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: ayoung2kr@gmail.com.'}, {'lastname': 'Choi', 'firstname': 'Da Hyun', 'initials': 'DH', 'affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Systems Biology, Glycosylation Network Research Center, Yonsei University, Seoul, Republic of Korea; Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Republic of Korea. Electronic address: cdh080330@gmail.com.'}, {'lastname': 'Kim', 'firstname': 'Jong Youl', 'initials': 'JY', 'affiliation': 'Department of Anatomy, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jongyoul74@gmail.com.'}, {'lastname': 'Kim', 'firstname': 'Eun Ran', 'initials': 'ER', 'affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Goh', 'firstname': 'A-Ra', 'initials': 'AR', 'affiliation': 'Department of Anatomy, Yonsei University College of Medicine, Seoul, Republic of Korea; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: karara7676@gmail.com.'}, {'lastname': 'Lee', 'firstname': 'Yong-Ho', 'initials': 'YH', 'affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Systems Biology, Glycosylation Network Research Center, Yonsei University, Seoul, Republic of Korea; Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Republic of Korea. Electronic address: yholee@yuhs.ac.'}, {'lastname': 'Lee', 'firstname': 'Jong Eun', 'initials': 'JE', 'affiliation': 'Department of Anatomy, Yonsei University College of Medicine, Seoul, Republic of Korea; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: jelee@yuhs.ac.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.,10.1016/j.biopha.2023.115755,<Element 'PubmedArticle' at 0x7f05df18be50>
18,37866336,"The location, physiology, pathology of hippocampus Melatonin MT","Melatonin, a neurohormone secreted by the pineal gland and regulated by the suprachiasmatic nucleus (SCN) of the hypothalamus, is synthesized and directly released into the cerebrospinal fluid (CSF) of the third ventricle (3rdv), where it undergoes rapid absorption by surrounding tissues to exert its physiological function. The hippocampus, a vital structure in the limbic system adjacent to the ventricles, plays a pivotal role in emotional response and memory formation. Melatonin MT","['Hippocampus', 'LTP', 'MT(2) receptor', 'Melatonin', 'Selective ligands']",European journal of medicinal chemistry,2023-10-23,"[{'lastname': 'Feng', 'firstname': 'Yueqin', 'initials': 'Y', 'affiliation': 'Department of Ultrasound, the First Affiliated Hospital of China Medical University, Shenyang, PR China.'}, {'lastname': 'Jiang', 'firstname': 'Xiaowen', 'initials': 'X', 'affiliation': 'School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, PR China.'}, {'lastname': 'Liu', 'firstname': 'Wenwu', 'initials': 'W', 'affiliation': 'School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China.'}, {'lastname': 'Lu', 'firstname': 'Hongyuan', 'initials': 'H', 'affiliation': 'Department of Clinical Pharmacology, China Medical University, Shenyang, PR China. Electronic address: hylu@cmu.edu.cn.'}]",,,,Copyright © 2023 Elsevier Masson SAS. All rights reserved.,10.1016/j.ejmech.2023.115888,<Element 'PubmedArticle' at 0x7f05df8e04a0>
19,37827260,Molecular mechanisms underlying major depressive disorder and post-stroke affective disorders.,"Two of the most common and incapacitating mental health disorders around the world are major depressive disorder (MDD) and post-stroke depression (PSD). MDD is thought to result from abnormal connectivity between the monoaminergic, glutamatergic, GABAergic, and/or cholinergic pathways. Additional factors include the roles of hormonal, immune, ageing, as well as the influence of cellular, molecular, and epigenetics in the development of mood disorders. This complexity of factors has been anticipated by the Swiss psychiatrists Paul Kielholz and Jules Angst who introduced a multimodal treatment of MDD. Depression is the predominant mood disorder, impacting around one-third of individuals who have experienced a stroke. MDD and PSD share common underlying biological mechanisms related to the disruption of monoaminergic pathways. The major contributor to PSD is the stroke lesion location, which can involve the disruption of the serotoninergic, dopaminergic, glutamatergic, GABAergic, or cholinergic pathways. Additionally, various other disorders such as mania, bipolar disorder, anxiety disorder, and apathy might occur post-stroke, although their prevalence is considerably lower. However, there are differences in the onset of MDD among mood disorders. Some mood disorders develop gradually and can persist for a lifetime, potentially culminating in suicide. In contrast, PSD has a rapid onset because of the severe disruption of neural pathways essential for mood behavior caused by the lesion. However, PSD might also spontaneously resolve several months after a stroke, though it is associated with higher mortality. This review also provides a brief overview of the treatments currently available in medical practice.","['Affective disorders', 'Ageing', 'Biological mechanisms', 'Epigenetic', 'Major depression', 'Post-stroke depression', 'Treatments']",Journal of affective disorders,2023-10-13,"[{'lastname': 'Colita', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Doctoral School, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.'}, {'lastname': 'Burdusel', 'firstname': 'Daiana', 'initials': 'D', 'affiliation': 'Department of Psychiatry, University of Medicine and Pharmacy, 200349 Craiova, Romania; Chair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.'}, {'lastname': 'Glavan', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Psychiatry, University of Medicine and Pharmacy, 200349 Craiova, Romania; Chair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.'}, {'lastname': 'Hermann', 'firstname': 'Dirk M', 'initials': 'DM', 'affiliation': 'Chair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.'}, {'lastname': 'Colită', 'firstname': 'Cezar-Ivan', 'initials': 'CI', 'affiliation': 'Doctoral School, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.'}, {'lastname': 'Colita', 'firstname': 'Eugen', 'initials': 'E', 'affiliation': 'Doctoral School, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.'}, {'lastname': 'Udristoiu', 'firstname': 'Ion', 'initials': 'I', 'affiliation': 'Department of Psychiatry, University of Medicine and Pharmacy, 200349 Craiova, Romania. Electronic address: ion.udristoiu@gmail.com.'}, {'lastname': 'Popa-Wagner', 'firstname': 'Aurel', 'initials': 'A', 'affiliation': 'Chair of Vascular Neurology, Dementia and Ageing, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany. Electronic address: aurel.popa-wagner@geriatrics-healthyageing.com.'}]",,,,Copyright © 2023. Published by Elsevier B.V.,10.1016/j.jad.2023.10.037,<Element 'PubmedArticle' at 0x7f05df8f2b80>
20,"37788276
31375134
28899446
33219130
14749724
33543942
12438432
29991131
33100197
22529971
22217452
30853341
23360216
26049556
22074294
20536467
30063850
10338310
23045978
22324420
1627460
20627173
23073962
27450729
25613458
28647411
17976961
16407119
32502508
20627173
29080524
33679375
28819546
32231263
35782387
11942415
12707936
27942867
31612500
31877278
28713158
31450506
31754613
29089887
19699263
23983897
17244475
21106936
14517430
20554859
27114850
20833817
20079433
12566928
19843174",Antioxioxidant and antiapoptotic effects of Thymosin β4 in Aβ-induced SH-SY5Y cells via the 5-HTR1A/ERK axis.,"Alzheimer's disease (AD) is a common amnestic cognitive impairment characterised by β-amyloid (Aβ) plaques deposit in the brain of the elderly. AD is a yet incurable disease due to its unknown exact pathogenesis and unavailability of effective remedies in clinical application. Thymosin β4 (Tβ4) is a housekeeping protein that plays important role in cell proliferation, migration and differentiation. It has the ability to protect and repair neurons however it is still unclear involvement in AD. Therefore, the aim of this study is to elucidate the role and mechanism of Tβ4 in mediating the improvement of AD. AD-like cell model was constructed in neuroblastoma cell line SH-SY5Y treated with Aβ. Overexpression of Tβ4 were done using lentivirus infection and downregulation through siRNA transfection. We performed western blot and flow cytometry to study the apoptosis and standard kits to measure the oxidative stress-associated biomarkers. There is significant increased in viability and decreased apoptosis in Tβ4 overexpression group compared to control. Furthermore, overexpression of Tβ4 suppressed the expression of pro-apoptotic markers such as Caspase-3, Caspase-8, and Bax meanwhile upregulated the expression of anti-apoptotic gene Bcl-2. Tβ4 alleviated oxidative damage by reducing MDA, LDH and ROS and increasing SOD and GSH-PX in Aβ-treated SH-SY5Y cells. We found that Tβ4 inhibit ERK/p38 MAPK pathway and intensify the expression of 5-HTR1A. Additionally, we showed that upregulation of 5-HTR1A dampened the Tβ4 to activate ERK signalling. In conclusion, our study revealed the neuroprotective role of Tβ4 in AD which may open up new therapeutic applications in AD treatment.",[],PloS one,2023-10-03,"[{'lastname': 'Zhang', 'firstname': 'Gui-Hong', 'initials': 'GH', 'affiliation': ""School of Medicine, Xi'an International University, Xi'an, Shaanxi, China.\nFaculty of Medicine and Health Sciences, Department of Biomedical Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.""}, {'lastname': 'Chin', 'firstname': 'Kai Ling', 'initials': 'KL', 'affiliation': 'Faculty of Medicine and Health Sciences, Department of Biomedical Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.'}, {'lastname': 'Yan', 'firstname': 'Shi-Yan', 'initials': 'SY', 'affiliation': 'International Innovation Institute of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, Beijing, Hebei, China.'}, {'lastname': 'Pare', 'firstname': 'Rahmawati', 'initials': 'R', 'affiliation': 'Faculty of Medicine and Health Sciences, Department of Biomedical Science, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.'}]",,,,"Copyright: © 2023 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","10.1371/journal.pone.0287817
10.1017/S1041610217001880
10.1074/jbc.REV120.008207
10.1021/acs.chemrev.0c01122
10.3233/JAD-180183
10.2174/1381612826666201023144836
10.1371/journal.pone.0035035
10.1016/j.tins.2011.11.004
10.1016/j.pnpbp.2019.02.013
10.1089/neu.2012.2689
10.1016/j.npep.2015.05.002
10.1111/j.1749-6632.2012.06651.x
10.1007/BF02919408
10.1016/j.neuropharm.2017.06.021
10.1016/j.pscychresns.2007.07.003
10.1073/pnas.0510237103
10.1016/j.neulet.2020.135118
10.1016/j.neuroscience.2010.05.017
10.1016/j.redox.2017.10.014
10.3389/fnagi.2021.617588
10.1155/2017/8416763
10.3389/fnmol.2022.931704
10.1038/sj.cr.7290105
10.1002/ajmg.b.10068
10.1016/j.ejphar.2019.172891
10.1038/aps.2017.28
10.1016/j.neulet.2009.08.037
10.1155/2013/316523
10.5483/bmbrep.2007.40.1.001
10.14336/AD.2015.0929
10.1016/j.bbadis.2009.12.009
10.1159/000067426
10.1111/j.1742-4658.2009.07366.x",<Element 'PubmedArticle' at 0x7f05df2d98b0>
21,"37759830
31010420
29653606
21514250
23390181
27870425
14745052
11982672
26644522
20934413
17846406
22962256
19427328
23689636
22115850
36449103
25827959
29486372
30802710
19819951
24523714
35945232
21896736
15113628
21930921
25284473
20737609
32998030
23258636
25514102
28413602
23017880
31028478
24236143
31418510
33889090
29499227
23575643
22674640
20364887
33168880
28370849
1202204
12034782
16257514
32781308
24968011
30496104
25658103
31379616
23599941
24931304
16217697
32123386
29076399
8748926
27371494
35973034
36909947
25079805
26402007
17695343
21547078
22743772
11187541
30951538
32942249
33517845
29164314
11578676
17707515
25251617
33759810
16603029
19263413
18988284
32057822
32014464
30686833
19958785
8917147
15802685
12060178",Digit Ratio (2D:4D) Is Not Associated with Alzheimer's Disease in the Elderly.,"The development of Alzheimer's disease (AD) is influenced by sex hormones-estrogens and androgens in particular. However, the impact of prenatal sex hormone exposure is less clear; very few investigations have examined the relationship between the second-to-fourth digit length ratio (2D:4D), a putative proxy for the ratio of prenatal estrogens to androgens, and AD, with inconsistent results among the few that have. Therefore, we aimed to investigate this relationship using methodologically robust metrics. In a 2 (sex) × 4 (group) MANOVA incorporating 108 participants (30 AD patients, 19 patients with tauopathy but no amyloidopathy, 31 clinical and 28 healthy age- and education-matched controls), the effects of sex and group on the dependent variables right and left 2D:4D were examined. We also explored the association between 2D:4D and the severity of AD symptoms assessed via neuropsychological examination. We did not find any significant differences in the right- and left-hand 2D:4D between patients with AD and the other groups; no significant associations between 2D:4D and neuropsychological task performances were found in the dementia groups. The 2D:4D of healthy women was significantly lower than that of depressed women without AD, i.e., clinical controls, but not significantly different from depressed female patients with AD. This investigation does not support the role of 2D:4D in the development or severity of AD in general, but suggests a potential role of 2D:4D for depression in women. Future studies are warranted to clarify whether 2D:4D can distinguish between early- and late-onset depression in women.","['Alzheimer’s disease', 'dementia', 'digit ratio', 'fetal development', 'finger length ratio']",Brain sciences,2023-09-28,"[{'lastname': 'Siegmann', 'firstname': 'Eva-Maria', 'initials': 'EM', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}, {'lastname': 'Olm', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}, {'lastname': 'Lenz', 'firstname': 'Bernd', 'initials': 'B', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.\nDepartment of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, Heidelberg University, 68159 Mannheim, Germany.'}, {'lastname': 'Mühle', 'firstname': 'Christiane', 'initials': 'C', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}, {'lastname': 'Oberstein', 'firstname': 'Timo Jan', 'initials': 'TJ', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}, {'lastname': 'Maler', 'firstname': 'Juan Manuel', 'initials': 'JM', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}, {'lastname': 'Kornhuber', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany.'}]",,,,,"10.3390/brainsci13091229
10.1186/s13195-019-0485-0
10.1016/j.jalz.2018.02.018
10.1016/j.jalz.2011.03.005
10.1212/WNL.0b013e31828726f5
10.1002/jnr.23827
10.1212/WNL.62.2.188
10.1046/j.1532-5415.2002.50166.x
10.1200/JCO.2015.63.6266
10.1016/j.brainres.2010.10.009
10.1212/01.wnl.0000279584.03800.3d
10.1210/en.2012-1464
10.1016/j.yfrne.2009.04.015
10.1093/cercor/bht125
10.1016/j.pneurobio.2011.11.001
10.1007/s00406-022-01515-4
10.1016/j.psyneuen.2015.03.004
10.1016/j.earlhumdev.2018.02.012
10.1016/j.psyneuen.2019.02.014
10.1210/en.2009-0774
10.3389/fendo.2014.00009/full
10.3389/fendo.2014.00009
10.1038/s41598-022-17247-3
10.1073/pnas.1108312108
10.1016/j.earlhumdev.2003.12.002
10.1073/pnas.1113312108
10.1002/ajhb.22639
10.1002/ajhb.21054
10.1016/j.yhbeh.2020.104867
10.1111/j.2047-2927.2012.00013.x
10.1210/jc.2014-2834
10.1186/s13293-017-0132-z
10.1016/j.earlhumdev.2012.08.009
10.1007/s00702-019-02002-2
10.1007/s00702-019-02002-2
10.1371/journal.pone.0079539
10.1024/0939-5911/a000736
10.1111/adb.12815
10.3389/fpsyt.2021.517411/full
10.3389/fpsyt.2021.517411
10.1016/j.pnpbp.2018.02.012
10.1007/s10803-013-1819-6
10.1002/aur.1230
10.1037/a0018764
10.1038/s41598-020-72486-6
10.1080/20445911.2017.1279166
10.1002/ajhb.23003
10.1016/0022-3956(75)90026-6
10.1212/WNL.58.10.1476
10.1016/j.pscychresns.2004.05.010
10.1016/j.earlhumdev.2020.105152
10.1097/WNN.0000000000000024
10.1016/S0140-6736(18)32279-7
10.1371/journal.pone.0116820
10.1016/j.paid.2004.12.017
10.3389/fpsyt.2019.00483
10.1016/j.paid.2014.06.039
10.1001/jamaneurol.2013.603
10.1016/j.maturitas.2014.05.009
10.1055/s-2004-830249
10.1038/s41591-020-0762-2
10.1080/15622975.2017.1375556
10.1007/BF02815140
10.1212/WNL.0000000000002923
10.1093/brain/awac297
10.3389/fnagi.2023.1121500/full
10.3389/fnagi.2023.1121500
10.3233/JAD-140771
10.3233/JAD-150342
10.3758/bf03193146
10.3758/BF03193146
10.1371/journal.pone.0019332
10.1038/nmeth.2019
10.1093/biomet/24.3-4.471
10.1371/journal.pone.0213490
10.1177/1474704916632536
10.1016/j.earlhumdev.2020.105159
10.1080/1357650X.2020.1862141
10.1002/alz.042328
10.1007/s00702-017-1815-7
10.1007/s00702-017-1815-7
10.34172/ijbsm.2021.18
10.1016/S0165-0327(00)00317-7
10.1016/j.jad.2007.06.005
10.1056/NEJMcp1402180
10.22365/jpsych.2021.009
10.1111/j.1600-0447.2006.00770.x
10.1002/ajhb.20892
10.1002/ajhb.20843
10.1016/j.yhbeh.2020.104710
10.1016/j.yhbeh.2020.104686
10.1055/a-0677-2630
10.1016/j.physbeh.2009.11.015
10.1192/bjp.186.4.297
10.1046/j.1440-1614.2002.01035.x",<Element 'PubmedArticle' at 0x7f05df3a9180>
22,"37664737
28350794
34998485
33706960
33008519
36206395
18513207
28179809
34116197
33775739
36528281
22319659
34453737
31036290
27870427
26109339
11113299
12773955
11978836
34623401
22612612
29907423
34588168
34513605
36403287
32111534
31027548
27716751
32112728
35381014
22994984
33224053
12771112
15608005
30842086
28274328
28202700
32057896
11255426
15804727
31453973
32210745
24277815
32149891
24898656
22269187
30923235
25299675
19473181
28078219
34247950",Ageing perspective on cognitive outcomes from reproductive hormone adjustments.,"In addition to primary reproductive functions, gonadal hormones play an important role in an array of neural mechanisms across the human lifespan. The ageing-related decline in their activity has been linked to the deterioration of cognitive functions in otherwise healthy women, associated with menopause transition, contributing to higher incidents of post-menopause dementia. Given the growing utility of gonadal steroids for birth control, as well as for compensatory treatment of menopause and oophorectomy symptoms, and adjuvant transgender therapy, their long-term effects on neural mechanisms warrant comprehensive assessment. In this article, we present an ageing perspective on the cognitive outcomes from contraceptive and replacement therapeutic use of gonadal hormones and discuss their effects on the risk of developing Alzheimer's and Parkinson's dementia. Despite rising data supporting the ameliorative effects of reproductive hormones on cognitive facilities, their impact varies depending on study design and type of intervention, thus, implying dynamic neuro-endocrine interactions with complex compensatory mechanisms. Elucidating differential effects of reproductive hormone adjustments on cognition with underlying mechanisms is expected not only to shed light on important aspects of brain ageing and dementia but to facilitate their use in personalized medicine with improved safety margins and therapeutic outcomes.","['Cognitive decline', 'Contraception', 'Gender transition', 'Healthy ageing', 'Hormone replacement therapy', 'Neuroprotection', 'Oestrogen', 'Transgender']",Heliyon,2023-09-04,"[{'lastname': 'Zhang', 'firstname': 'Grace', 'initials': 'G', 'affiliation': ""Faculty of Health Sciences, Queen's University, Kingston, Ontario, K7L 3N6, Canada.\nBader College, Herstmonceux Castle, Hailsham, BN27 1RN, United Kingdom.""}, {'lastname': 'Devo', 'firstname': 'Perry', 'initials': 'P', 'affiliation': 'Faculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, United Kingdom.'}, {'lastname': ""O'Leary"", 'firstname': 'Valerie B', 'initials': 'VB', 'affiliation': 'Department of Medical Genetics, Third Faculty of Medicine, Charles University, Ruská 87, 10000 Prague, Czech Republic.'}, {'lastname': 'Ovsepian', 'firstname': 'Saak V', 'initials': 'SV', 'affiliation': 'Faculty of Engineering and Science, University of Greenwich London, Chatham Maritime, Kent, ME4 4TB, United Kingdom.'}]",,,,Crown Copyright © 2023 Published by Elsevier Ltd.,"10.1016/j.heliyon.2023.e19050
10.1016/j.drudis.2022.103467",<Element 'PubmedArticle' at 0x7f05df6529a0>
23,37657738,GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.,"Glucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor agonist has a peripheral and a central action, including stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake. Through their mechanism, their use in the treatment of type 2 diabetes has been extended to the management of obesity, and numerous trials are being conducted to assess their cardiovascular effect. Type 2 diabetes appears to share common pathophysiological mechanisms with the development of cognitive disorders, such as Alzheimer's and Parkinson's disease, related to insulin resistance. In this review, we aim to examine the pathological features between type 2 diabetes and dementia, GLP-1 central effects, and analyze the relevant literature about the effect of GLP-1 analogs on cognitive function of patients with type 2 diabetes but also without. Results tends to show an improvement in some brain markers (e.g. hippocampal connections, cerebral glucose metabolism, hippocampal activation on functional magnetic resonance imaging), but without being able to demonstrate a strong correlation to cognitive scores. Some epidemiological studies suggest that GLP-1 receptor agonists may offer a protective effect, by delaying progression to dementia when diabetic patients are treated with GLP-1 receptor agonists. Ongoing trials are in progress and may provide disease-modifying care for Alzheimer's disease and Parkinson's disease patients in the future.","['Cognitive dysfunction', 'Dementia', 'Glucagon-like-peptide 1', 'Glucagon-like-peptide 1 receptor agonist', 'Insulin resistance', 'Type 2 diabetes']",Diabetes & metabolism,2023-09-02,"[{'lastname': 'Monney', 'firstname': 'Marine', 'initials': 'M', 'affiliation': 'Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva 1211, Switzerland. Electronic address: marine.monney@hcuge.ch.'}, {'lastname': 'Jornayvaz', 'firstname': 'François R', 'initials': 'FR', 'affiliation': 'Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medical Specialties, Geneva University Hospitals, Geneva 1211, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland; Department of Cell Physiology and Metabolism, Centre Medical Universitaire (CMU), Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland.'}, {'lastname': 'Gariani', 'firstname': 'Karim', 'initials': 'K', 'affiliation': 'Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medical Specialties, Geneva University Hospitals, Geneva 1211, Switzerland; Diabetes Center, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.,10.1016/j.diabet.2023.101470,<Element 'PubmedArticle' at 0x7f05df7caa40>
24,37619647,Parvalbumin as a sex-specific target in Alzheimer's disease research - A mini-review.,"Alzheimer's disease (AD) is the most common form of dementia, and both the incidence of this disease and its associated cognitive decline disproportionally effect women. While the etiology of AD is unknown, recent work has demonstrated that the balance of excitatory and inhibitory activity across the brain may serve as a strong predictor of cognitive impairments in AD. Across the cortex, the most prominent source of inhibitory signalling is from a class of parvalbumin-expressing interneurons (PV","['Aging', 'Alzheimer’s disease', 'Parvalbumin', 'Sex differences']",Neuroscience and biobehavioral reviews,2023-08-25,"[{'lastname': 'Terstege', 'firstname': 'Dylan J', 'initials': 'DJ', 'affiliation': 'Department of Cell Biology and Anatomy, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada.'}, {'lastname': 'Epp', 'firstname': 'Jonathan R', 'initials': 'JR', 'affiliation': 'Department of Cell Biology and Anatomy, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. Electronic address: Jonathan.epp1@ucalgary.ca.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.neubiorev.2023.105370,<Element 'PubmedArticle' at 0x7f05df7c3a40>
25,37598068,The impact of chromosomal sex on cardiometabolic health and disease.,"Many aspects of metabolism are sex-biased, from gene expression in metabolic tissues to the prevalence and presentation of cardiometabolic diseases. The influence of hormones produced by male and female gonads has been widely documented, but recent studies have begun to elucidate the impact of genetic sex (XX or XY chromosomes) on cellular and organismal metabolism. XX and XY cells have differential gene dosage conferred by specific genes that escape X chromosome inactivation or the presence of Y chromosome genes that are absent from XX cells. Studies in mouse models that dissociate chromosomal and gonadal sex have uncovered mechanisms for sex-biased epigenetic, transcriptional, and post-transcriptional regulation of gene expression in conditions such as obesity, atherosclerosis, pulmonary hypertension, autoimmune disease, and Alzheimer's disease.","['X chromosome inactivation escape', 'four core genotypes mouse model', 'gene regulation', 'gonadal sex', 'sex chromosomes']",Trends in endocrinology and metabolism: TEM,2023-08-20,"[{'lastname': 'Wiese', 'firstname': 'Carrie B', 'initials': 'CB', 'affiliation': 'Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.'}, {'lastname': 'Avetisyan', 'firstname': 'Rozeta', 'initials': 'R', 'affiliation': 'Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.'}, {'lastname': 'Reue', 'firstname': 'Karen', 'initials': 'K', 'affiliation': 'Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: reuek@ucla.edu.'}]",,,,Copyright © 2023 Elsevier Ltd. All rights reserved.,10.1016/j.tem.2023.07.003,<Element 'PubmedArticle' at 0x7f05df7becc0>
26,"37528055
27036079
24244562
21374718
23900711
29653607
19021630
35697880
25707479
31039256
17469117
32759188
26260327
36617779
30792090
30775996
22578327
25367383
24899141
25188341
24770881
20197700
30093249
26139635
31924160
32797255
36512061
22101365
16906426
12084879
2011243
33568819
31675358
17701901
25722852
18723524
29970152
28131462
28731440
25529636
36119389
35366087
35971593
12446984
20949309
11790212
22064377
23571587
27231719
26092349
28078323
9382479
33781362","LATE-NC risk alleles (in TMEM106B, GRN, and ABCC9 genes) among persons with African ancestry.","Limbic-predominant age-related TDP-43 encephalopathy (LATE) affects approximately one-third of older individuals and is associated with cognitive impairment. However, there is a highly incomplete understanding of the genetic determinants of LATE neuropathologic changes (LATE-NC) in diverse populations. The defining neuropathologic feature of LATE-NC is TDP-43 proteinopathy, often with comorbid hippocampal sclerosis (HS). In terms of genetic risk factors, LATE-NC and/or HS are associated with single nucleotide variants (SNVs) in 3 genes-TMEM106B (rs1990622), GRN (rs5848), and ABCC9 (rs1914361 and rs701478). We evaluated these 3 genes in convenience samples of individuals of African ancestry. The allele frequencies of the LATE-associated alleles were significantly different between persons of primarily African (versus European) ancestry: In persons of African ancestry, the risk-associated alleles for TMEM106B and ABCC9 were less frequent, whereas the risk allele in GRN was more frequent. We performed an exploratory analysis of data from African-American subjects processed by the Alzheimer's Disease Genomics Consortium, with a subset of African-American participants (n = 166) having corroborating neuropathologic data through the National Alzheimer's Coordinating Center (NACC). In this limited-size sample, the ABCC9/rs1914361 SNV was associated with HS pathology. More work is required concerning the genetic factors influencing non-Alzheimer disease pathology such as LATE-NC in diverse cohorts.","['\n          KCNMB2\n        ', 'Dementia', 'Diversity', 'Epidemiology', 'FTLD', 'Genome-Wide Association Studies (GWAS)', 'KATP']",Journal of neuropathology and experimental neurology,2023-08-02,"[{'lastname': 'Katsumata', 'firstname': 'Yuriko', 'initials': 'Y', 'affiliation': 'University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, USA.\nUniversity of Kentucky Department of Biostatistics, Lexington, Kentucky, USA.'}, {'lastname': 'Fardo', 'firstname': 'David W', 'initials': 'DW', 'affiliation': 'University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, USA.\nUniversity of Kentucky Department of Biostatistics, Lexington, Kentucky, USA.'}, {'lastname': 'Shade', 'firstname': 'Lincoln M P', 'initials': 'LMP', 'affiliation': 'University of Kentucky Department of Biostatistics, Lexington, Kentucky, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Nelson', 'firstname': 'Peter T', 'initials': 'PT', 'affiliation': 'University of Kentucky Sanders-Brown Center on Aging, Lexington, Kentucky, USA.\nUniversity of Kentucky Department of Pathology and Laboratory Medicine, Lexington, Kentucky, USA.'}]",,,,"© The Author(s) 2023. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.",10.1093/jnen/nlad059,<Element 'PubmedArticle' at 0x7f05df791130>
27,"37509151
36047605
34998485
35931410
28751861
10854354
9008508
37010830
24898656
24336141
21865747
29754747
22554955
30715078
26295370
24239930
17490623
26490364
30822454
28948468
27250720
28855400
22156442
17889406
17132983
15944651
36408108
33260715
28208064
22926141
9030703
15024130
20096765
34440676
33166649
29982985
32507541
17113982
15337246
36240091
21280086
20965156
15608005
36834617
37124925
36967089
36871845
36806512
19703392
9774109
18757748
15189344
29650645
29254089
20346371
18988731
37201560
20144586
8031826
20037155
14729675
26417093
25168729
32929284
11509182
11815616
23356252
12614671
22185089
21237293
18256777
15734603
11063905
12475720
22472608
22239089
12124396
15932948
30536184
28332151
27672379
20640154
20091232
29788201
19010568
23639789
19154338
23036890
22451324
22642937
18365858
34058569
31278797
34058440
27688871
35742897
24586428
21346783
27095058
23159929
23067392
27265389
35572126
36536457
30565287
19897719
7704571
36278346
36508924
17116346
28553339
22067260
25052429
7058341
15854764
6822833
7161627
719462
26122294
10022763
18025470
21496024
26346601
23648513",Repurposing of Tibolone in Alzheimer's Disease.,"Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully understood, but some risk factors, such as age, genetics, and hormones, may play a crucial role. Studies show that postmenopausal women have a higher risk of developing AD, possibly due to the decrease in hormone levels, especially oestrogen, which may be directly related to a reduction in the activity of oestrogen receptors, especially beta (ERβ), which favours a more hostile cellular environment, leading to mitochondrial dysfunction, mainly affecting key processes related to transport, metabolism, and oxidative phosphorylation. Given the influence of hormones on biological processes at the mitochondrial level, hormone therapies are of clinical interest to reduce the risk or delay the onset of symptoms associated with AD. One drug with such potential is tibolone, which is used in clinics to treat menopause-related symptoms. It can reduce amyloid burden and have benefits on mitochondrial integrity and dynamics. Many of its protective effects are mediated through steroid receptors and may also be related to neuroglobin, whose elevated levels have been shown to protect against neurological diseases. Its importance has increased exponentially due to its implication in the pathogenesis of AD. In this review, we discuss recent advances in tibolone, focusing on its mitochondrial-protective effects, and highlight how valuable this compound could be as a therapeutic alternative to mitigate the molecular pathways characteristic of AD.","['Alzheimer’s disease', 'mitochondria', 'neuroglobin', 'oestrogen receptors', 'tibolone']",Biomolecules,2023-07-29,"[{'lastname': 'Barreto', 'firstname': 'George E', 'initials': 'GE', 'affiliation': 'Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland.'}]",,,,,"10.3390/biom13071115
10.13140/RG.2.2.16880.81923
10.1002/alz.12774
10.1016/S2468-2667(21)00249-8
10.1016/j.arr.2022.101703
10.3389/fnagi.2017.00221
10.1212/WNL.48.1.132
10.1001/jamaneurol.2023.0455
10.3233/JAD-140336
10.1212/WNL.0000000000000033
10.1159/000330472
10.1016/j.neurobiolaging.2018.04.004
10.1016/j.yhbeh.2012.04.006
10.1001/jamaneurol.2018.4693
10.1210/en.2015-1514
10.1016/j.brainres.2013.11.010
10.1016/j.brainres.2007.04.016
10.1111/jnc.13404
10.1016/j.mce.2019.02.017
10.1007/s12035-017-0777-y
10.1016/j.mce.2016.05.024
10.1212/WNL.0000000000004425
10.1159/000334522
10.1016/j.neurobiolaging.2007.08.003
10.1097/01.wad.0000213861.12484.33
10.1038/sj.ejhg.5201447
10.3389/fnagi.2022.1013943
10.3390/cells9122552
10.1016/j.neurobiolaging.2016.12.029
10.1093/hmg/dds360
10.1016/S0169-328X(96)00191-X
10.1073/pnas.0306948101
10.1016/j.exger.2010.01.015
10.3390/cells10081907
10.1016/j.freeradbiomed.2020.11.002
10.1007/s12035-018-1203-9
10.1016/j.tem.2020.04.007
10.1016/j.jsbmb.2006.09.037
10.1016/j.maturitas.2004.02.012
10.1212/WNL.0000000000200960
10.1002/ana.22239
10.1016/j.brainres.2010.10.031
10.1136/jnnp.2003.024927
10.3390/ijms24043205
10.1007/s12551-023-01057-6
10.1016/j.arr.2023.101918
10.1016/j.drudis.2023.103547
10.3233/JAD-221286
10.1016/j.cell.2009.08.005
10.1038/26780
10.1073/pnas.0806192105
10.1111/j.1471-4159.2004.02438.x
10.1126/science.aan4146
10.3233/JAD-170613
10.1016/j.mam.2010.03.002
10.1073/pnas.0809634105
10.1016/j.bbamem.2023.184175
10.1016/j.bbabio.2010.02.004
10.1016/0304-4157(94)90004-3
10.1074/jbc.M109.082990
10.1074/jbc.M310593200
10.1073/pnas.1510574112
10.1016/j.neuroscience.2014.07.079
10.1038/s41594-020-0503-8
10.1016/S0092-8674(01)00452-4
10.1074/jbc.M111210200
10.1042/BST20110773
10.1016/S0306-4522(02)00747-9
10.3109/00207454.2011.649867
10.1016/j.jprot.2010.12.012
10.1007/s00198-007-0545-3
10.1016/j.maturitas.2004.06.001
10.1016/S0378-5122(00)00147-X
10.1016/S0039-128X(02)00112-5
10.1038/jcbfm.2012.21
10.1042/BJ20111856
10.1073/pnas.122347199
10.1073/pnas.0408766102
10.1007/s12035-018-1442-9
10.1007/s12035-017-0481-y
10.3389/fneur.2016.00146
10.3390/ijms11062306
10.1007/s10495-009-0436-5
10.1093/hmg/ddy102
10.1016/j.neurobiolaging.2008.10.003
10.1016/j.nbd.2013.04.015
10.1111/j.1471-4159.2008.05846.x
10.1016/j.bbamcr.2012.09.009
10.3233/JAD-2012-120283
10.3109/13697137.2012.668251
10.1080/13697130801954484
10.1016/j.cyto.2021.155582
10.1111/jne.12768
10.1016/j.biopha.2021.111769
10.1186/s13293-016-0104-8
10.3390/ijms23126454
10.1371/journal.pone.0088887
10.1038/nrc3025
10.1016/j.arr.2016.04.004
10.1038/ncb2621
10.1111/tra.12021
10.1038/ncomms11390
10.3389/fnagi.2022.835288
10.1186/s13024-022-00589-x
10.1002/ana.25399
10.1073/pnas.0905529106
10.1016/S0960-9822(00)00246-3
10.3233/JAD-220434
10.1016/j.intimp.2022.109504
10.1016/j.neuint.2006.10.002
10.4103/1673-5374.205098
10.1016/j.yhbeh.2011.10.005
10.1007/s11064-014-1385-0
10.1126/science.7058341
10.1016/j.neulet.2005.01.031
10.1111/j.1471-4159.1983.tb11311.x
10.1016/0022-510X(82)90045-4
10.1136/bmj.2.6150.1457
10.1016/j.yhbeh.2015.06.010
10.1016/S0303-7207(98)00197-X
10.1073/pnas.0706167104
10.1111/j.1471-4159.2011.07275.x
10.1007/s12031-015-0645-z
10.3233/JAD-130323",<Element 'PubmedArticle' at 0x7f05dc6a0450>
28,37479008,Evidence of disturbed insulin signaling in animal models of Alzheimer's disease.,"Since glucose reuptake by neurons is mostly independent of insulin, it has been an intriguing question whether insulin has or not any roles in the brain. Consequently, the identification of insulin receptors in the central nervous system has fueled investigations of insulin functions in the brain. It is also already known that insulin can influence glucose reuptake by neurons, mostly during activities that have the highest energy demand. The identification of high density of insulin receptors in the hippocampus also suggests that insulin may present important roles related to memory. In this context, studies have reported worse performance in cognitive tests among diabetic patients. In addition, alterations in the regulation of central insulin pathways have been observed in the brains of Alzheimer's disease (AD) patients. In fact, some authors have proposed AD as a third type of diabetes and recently, our group proposed insulin resistance as a common link between different AD hypotheses. Therefore, in the present narrative review, we intend to revise and gather the evidence of disturbed insulin signaling in experimental animal models of AD.","['AD animal models', 'Alzheimer’s Disease', 'Biomarkers', 'Insulin resistance', 'Memory', 'Metabolism']",Neuroscience and biobehavioral reviews,2023-07-22,"[{'lastname': 'Alves', 'firstname': 'Suélen Santos', 'initials': 'SS', 'affiliation': 'Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil.'}, {'lastname': 'Servilha-Menezes', 'firstname': 'Gabriel', 'initials': 'G', 'affiliation': 'Department of Physiology, Ribeirão Preto Medical School - University of São Paulo (FMRP-USP), Brazil.'}, {'lastname': 'Rossi', 'firstname': 'Leticia', 'initials': 'L', 'affiliation': 'Department of Physiology, Ribeirão Preto Medical School - University of São Paulo (FMRP-USP), Brazil.'}, {'lastname': 'da Silva Junior', 'firstname': 'Rui Milton Patrício', 'initials': 'RMP', 'affiliation': 'Department of Physiology, Ribeirão Preto Medical School - University of São Paulo (FMRP-USP), Brazil; Institute of Neuroscience of Castilla y León, University of Salamanca, Salamanca, Spain.'}, {'lastname': 'Garcia-Cairasco', 'firstname': 'Norberto', 'initials': 'N', 'affiliation': 'Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil; Department of Physiology, Ribeirão Preto Medical School - University of São Paulo (FMRP-USP), Brazil. Electronic address: ngcairas@usp.br.'}]",,,,Copyright © 2023. Published by Elsevier Ltd.,10.1016/j.neubiorev.2023.105326,<Element 'PubmedArticle' at 0x7f05de24d8b0>
29,37394097,Association between insulin and Nrf2 signalling pathway in Alzheimer's disease: A molecular landscape.,"Insulin, a well-known hormone, has been implicated as a regulator of blood glucose levels for almost a century now. Over the past few decades, the non-glycemic actions of insulin i.e. neuronal growth and proliferation have been extensively studied. In 2005, Dr. Suzanne de La Monte and her team reported that insulin might be involved in the pathogenesis of Alzheimer's Disease (AD) and thus coined a term ""Type-3 diabetes"" This hypothesis was supported by several subsequent studies. The nuclear factor erythroid 2- related factor 2 (Nrf2) triggers a cascade of events under the regulation of distinct mechanisms including protein stability, phosphorylation and nuclear cytoplasmic shuttling, finally leading to the protection against oxidative damage. The Nrf2 pathway has been investigated extensively in relevance to neurodegenerative disorders, particularly AD. Many studies have indicated a strong correlation between insulin and Nrf2 signalling pathways both in the periphery and the brainbut merely few of them have focused on elucidating their inter-connective role in AD. The present review emphasizes key molecular pathways that correlate the role of insulin with Nrf2 during AD. The review has also identified key unexplored areas that could be investigated in future to further establish the insulin and Nrf2 influence in AD.","[""Alzheimer's disease"", 'Heme oxygenase-1', 'Insulin signalling', 'Nuclear factor erythroid 2-related factor 2', 'PI3K-AKT pathway']",Life sciences,2023-07-03,"[{'lastname': 'Rahman', 'firstname': 'Syed Obaidur', 'initials': 'SO', 'affiliation': 'Pharmaceutical Medicine, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Khan', 'firstname': 'Tahira', 'initials': 'T', 'affiliation': 'Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Iqubal', 'firstname': 'Ashif', 'initials': 'A', 'affiliation': 'Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Agarwal', 'firstname': 'Shivani', 'initials': 'S', 'affiliation': 'Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Akhtar', 'firstname': 'Mohd', 'initials': 'M', 'affiliation': 'Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Parvez', 'firstname': 'Suhel', 'initials': 'S', 'affiliation': 'Neurobehavioral Pharmacology Laboratory, Department of Medical Elementology and Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.'}, {'lastname': 'Shah', 'firstname': 'Zahoor Ahmad', 'initials': 'ZA', 'affiliation': 'Department of Medicinal and Biological Chemistry, University of Toledo, 3000 Arlington Avenue, Toledo, OH 43614, USA.'}, {'lastname': 'Najmi', 'firstname': 'Abul Kalam', 'initials': 'AK', 'affiliation': 'Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address: aknajmi@jamiahamdard.ac.in.'}]",,,,Copyright © 2023. Published by Elsevier Inc.,10.1016/j.lfs.2023.121899,<Element 'PubmedArticle' at 0x7f05de237f90>
30,"37375800
36836457
35346089
28329228
35743692
31873866
35365525
17039630
35043198
21852955
25651185
23684841
28650954
27197214
22434084
30156571
34015416
15692275
2395805
12608462
14744256
19385708
20417416
19279650
32250385
32422233
32276929
32600476
33179220
32977363
33135263
32765279
32788835
33283178
32445440
36768959
33225306
32383183
23835249
37109111
32535032
32282022
34836187
35157542
28992436
34454035
33378609
33301246
33545094
33335323
33630816
33923530
34835253
33838206
33641264
34405381
28444290
31504418
18065424
18078008
25980844
21474685
18658047
6813411
24206025
25240453
35721098
29402296
28863328
25579834
25911079
14512885
35029178
35893318
35083771
15650343
21859459
18456027
18230903
18775919
23115066
25931040
26136131
27713605
12457784
32050497
26132393
23448151
30061888
29899295
28002731
27812716
29353098
27184174
20228404
25149070
32501203
31451872
28843891
27159875
28779681
24857340
30072404
35334606
32048185
32908086
32100113
31902326
30571494
28815568
34497589
35330453
16531507
17329619
20129687
18174521
14749281
23328000","Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review.","Pharmacological responses vary by sex in several illnesses. This narrative review summarizes sex variations in pharmaceutical response in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus. Infection with SARS-CoV-2 is more severe and deadly in men than women. This may be attributed to immunological responses, genetics, and hormones. Some research shows that men may respond better to genomic vaccinations and females to antiviral medications such as remdesivir (Moderna and Pfizer-BioNTech). In dyslipidemia, women tend to have greater HDL-C and lower LDL-C than men. Some studies show that females may need lower statin dosages than men to obtain equal LDL-C reductions. Ezetimibe co-administered with a statin significantly improved lipid profile indicators in men compared to women. Statins reduce dementia risk. Atorvastatin decreased dementia risk in males (adjusted HR 0.92, 95% CI 0.88-0.97), whereas lovastatin lowered dementia risk in women (HR 0.74, 95% CI 0.58-0.95). In diabetes mellitus, evidence suggests that females may have a higher risk of developing certain complications such as diabetic retinopathy and neuropathy, despite having lower rates of cardiovascular disease than males. This could be the result of differences in hormonal influences and genetic factors. Some research shows females may respond better to oral hypoglycemic medications such as metformin. In conclusion, sex-related differences in pharmacological response have been observed in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus. Further research is needed to better understand these differences and to develop personalized treatment strategies for males and females with these conditions.","['COVID-19', 'adverse drug reactions', 'antidiabetic drugs', 'differences in pharmacological response', 'lipid-lowering agents', 'pharmacodynamics']","Pharmaceuticals (Basel, Switzerland)",2023-06-28,"[{'lastname': 'Lombrea', 'firstname': 'Adelina', 'initials': 'A', 'affiliation': 'Doctoral School, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nResearch Center for Pharmaco-Toxicological Evaluation, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Romanescu', 'firstname': 'Mirabela', 'initials': 'M', 'affiliation': 'Doctoral School, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Jianu', 'firstname': 'Narcisa', 'initials': 'N', 'affiliation': 'Doctoral School, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Andor', 'firstname': 'Minodora', 'initials': 'M', 'affiliation': 'Faculty of Medicine, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nMultidisciplinary Heart Research Center, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 340001 Timisoara, Romania.'}, {'lastname': 'Suciu', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Research Center for Pharmaco-Toxicological Evaluation, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nFaculty of Pharmacy, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Man', 'firstname': 'Dana Emilia', 'initials': 'DE', 'affiliation': 'Faculty of Medicine, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Danciu', 'firstname': 'Corina', 'initials': 'C', 'affiliation': 'Research Center for Pharmaco-Toxicological Evaluation, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nFaculty of Pharmacy, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Dehelean', 'firstname': 'Cristina Adriana', 'initials': 'CA', 'affiliation': 'Research Center for Pharmaco-Toxicological Evaluation, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nFaculty of Pharmacy, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.'}, {'lastname': 'Buda', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Research Center for Pharmaco-Toxicological Evaluation, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nFaculty of Pharmacy, ""Victor Babeş"" University of Medicine and Pharmacy, 2 Eftimie Murgu Street, 300041 Timisoara, Romania.\nIneu City Hospital, 2 Republicii Street, 315300 Ineu, Romania.'}]",,,,,"10.3390/ph16060853
10.3390/jpm13020223
10.1186/s12879-022-07284-8
10.1093/ehjcvp/pvw042
10.3390/jpm12060907
10.1007/s12325-019-01201-3
10.1136/bmjopen-2021-054513
10.13140/RG.2.2.12655.97443
10.1111/j.1467-8519.2006.00485.x
10.1093/inthealth/ihab093
10.1371/journal.pgen.1002215
10.1016/j.cmet.2015.01.002
10.1016/j.bbadis.2013.05.006
10.1038/ncomms15475
10.1101/gr.197897.115
10.1210/en.2011-2134
10.1097/MOL.0000000000000536
10.1016/j.addr.2021.05.014
10.1089/jwh.2005.14.30
10.1023/A:1015827908309
10.1080/00365520310000410
10.1146/annurev.pharmtox.44.101802.121453
10.2165/00003088-200948030-00001
10.1016/S1473-3099(10)70049-9
10.1038/gene.2009.12
10.1001/jama.2020.5394
10.1016/j.metabol.2020.154262
10.1158/2159-8290.CD-20-0451
10.1017/S1049023X20000837
10.1007/s12020-020-02536-6
10.1111/jdv.16953
10.1111/jdv.17021
10.3389/fphar.2020.01085
10.1016/j.jsps.2020.06.022
10.1016/j.eclinm.2020.100652
10.1056/NEJMoa2007764
10.3390/ijms24032638
10.1097/CCE.0000000000000280
10.1002/jmv.25989
10.1016/j.tmrv.2013.05.004
10.3390/jcm12082775
10.1016/j.jsbmb.2020.105719
10.1001/jama.2020.6019
10.3390/nu13113932
10.1080/14760584.2022.2042257
10.1146/annurev-cellbio-100616-060718
10.1016/j.phrs.2021.105848
10.1056/NEJMoa2035389
10.1056/NEJMoa2034577
10.1016/S0140-6736(21)00234-8
10.1038/s41591-020-01194-5
10.15585/mmwr.mm7008e3
10.3390/vaccines9040393
10.3390/vaccines9111322
10.1016/j.jaad.2021.03.092
10.1111/ajt.16516
10.1007/s40266-021-00886-y
10.1093/eurheartj/ehx144
10.1093/eurheartj/ehz455
10.1093/eurheartj/ehm565
10.1016/j.atherosclerosis.2015.04.806
10.1210/jc.2010-2061
10.1161/ATVBAHA.108.163931
10.1016/S0022-2275(20)38087-1
10.1089/jwh.2012.3972
10.1016/j.jcmg.2014.04.019
10.3389/fmed.2022.887741
10.1186/s12944-018-0667-y
10.1016/j.atherosclerosis.2017.08.014
10.1016/S0140-6736(14)61368-4
10.1016/j.jacl.2014.12.003
10.1002/hep.1840380424
10.1097/MD.0000000000028394
10.3390/geriatrics7040071
10.1111/bcp.15245
10.1089/jwh.2004.13.1101
10.1186/1476-511X-10-146
10.1016/j.amjmed.2008.01.032
10.1093/eurheartj/ehn387
10.5603/EP.2015.0017
10.5603/EP.2015.0029
10.1016/S0140-6736(02)11600-X
10.3390/biomedicines8020030
10.1371/journal.pone.0124451
10.1186/1741-7015-11-57
10.3389/fimmu.2018.01616
10.3390/nu10060764
10.1016/j.immuni.2016.11.008
10.1016/j.autrev.2017.10.013
10.1016/j.amjcard.2016.04.004
10.1007/s00125-014-3344-3
10.1007/s00125-019-4939-5
10.1016/j.physbeh.2017.08.016
10.1210/er.2015-1137
10.1016/j.diabres.2017.07.012
10.1586/17512433.2014.922866
10.2337/dc18-0344
10.3390/medicina58030430
10.1007/s40264-020-00913-8
10.1507/endocrj.EJ20-0006
10.1007/s00384-020-03539-5
10.1161/JAHA.119.012940
10.1161/JAHA.118.008959
10.1111/eci.12817
10.3389/fendo.2021.721135
10.3390/jpm12030454
10.1152/ajpendo.00572.2004
10.2337/db06-1506
10.1016/j.diabres.2010.01.013
10.2337/db07-0990
10.2337/diabetes.53.2007.S152
10.1016/j.regpep.2012.12.005",<Element 'PubmedArticle' at 0x7f05de22a9a0>
31,"37253999
30820047
30535378
33619569",The influence of growth and sex hormones on risk of alzheimer's disease: a mendelian randomization study.,"Alzheimer's disease is more prevalent in women, possibly due to sex or growth hormones but existing evidence is inconclusive. We investigated whether genetically predicted sex and growth hormones are associated with risk of Alzheimer's disease. Genetic variants strongly and independently predicting insulin-like growth factor 1 (IGF-1), testosterone and sex hormone-binding globulin (SHBG) were obtained from large, published genome wide associations studies (GWAS) and applied to GWAS of Alzheimer's disease based on clinical diagnosis (cases = 21,982, control = 41,944) from the International Genomics of Alzheimer's Project and the UK Biobank parental (maternal cases = 27,696; paternal cases = 14,338) and siblings' diagnosis (cases = 2,171) as proxy cases. Published GWAS summary statistics were used in our analyses. Estimates were obtained from inverse variance weighting with sensitivity analysis (i.e., MR-Egger, weighted median and MR-PRESSO). Multivariable analyses adjusted for pleiotropic effects and possible sources of selection bias were also performed. Genetically predicted higher total testosterone may reduce the risk of paternal Alzheimer's disease (odds ratio (OR) 0.86, 95% confidence interval (CI) 0.76 to 0.97, per SD increase in testosterone) and in meta-analysis for women (OR 0.92, 95% CI 0.87, 0.98) with directionally similar results from other analyses. SHBG were not associated with Alzheimer's disease. IGF-1 in women was inversely associated with risk of clinical Alzheimer's disease in sensitivity analysis but not in the main analysis. These results suggest genetically predicted higher total testosterone may lower risk of Alzheimer's disease. The role of testosterone and the immune system in Alzheimer's disease could be further investigated.","['Alzheimer’s disease', 'IGF-1', 'Mendelian randomization', 'SHBG', 'Testosterone']",European journal of epidemiology,2023-05-31,"[{'lastname': 'Yeung', 'firstname': 'Chris Ho Ching', 'initials': 'CHC', 'affiliation': 'School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. ho.ching.yeung@uth.tmc.edu.\nDepartment of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA. ho.ching.yeung@uth.tmc.edu.'}, {'lastname': 'Au Yeung', 'firstname': 'Shiu Lun', 'initials': 'SL', 'affiliation': 'School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Kwok', 'firstname': 'Man Ki', 'initials': 'MK', 'affiliation': 'School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Zhao', 'firstname': 'Jie V', 'initials': 'JV', 'affiliation': 'School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.'}, {'lastname': 'Schooling', 'firstname': 'C Mary', 'initials': 'CM', 'affiliation': 'School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.\nGraduate School of Public Health and Health Policy, City University of New York, New York, USA.'}]",,,,© 2023. Springer Nature B.V.,"10.1007/s10654-023-01015-2
10.1016/j.jalz.2016.08.004
10.1177/0891988720933351
10.1016/j.neurobiolaging.2008.10.001
10.1038/nm1202-793
10.1038/s41588-019-0358-2
10.1016/j.jsbmb.2019.04.008
10.1385/JMN:23:3:189
10.1097/NMD.0000000000000859
10.1136/bmj.322.7300.1447
10.1093/ije/dyy262
10.1002/gepi.21998
10.1007/s12035-015-9315-y
10.1001/archneur.63.2.nct50002
10.1080/tam.6.1.13.17
10.1016/j.jagp.2019.05.008
10.1016/j.ijcard.2018.05.051
10.1016/j.autrev.2011.09.005
10.1136/jech-2016-207809
10.1016/j.jsbmb.2010.02.007
10.1111/brv.12243
10.1002/ajpa.23054
10.1016/j.molmed.2019.05.001
10.1371/journal.pmed.0040352
10.1016/j.neuron.2019.01.056
10.1093/ije/dyaa266",<Element 'PubmedArticle' at 0x7f05dca115e0>
32,37146892,Association between behavioural risks and Alzheimer's disease: Elucidated with an integrated analysis of gene expression patterns and molecular mechanisms.,"Alzheimer's disease (AD) remains a global health challenge. Previous studies have reported linkages between AD and multiple behavioural risk exposures, however, the underlying biological mechanisms and crucial genes of gene expression patterns driven by behavioural risks on the onset or progression of AD remains ambiguous. In this study, we performed an integrated analysis on the influence of behavioural risks including smoking, excessive alcohol consumption, physical inactivity, and non-healthy dietary pattern on AD with a comprehensive strategy. Our results demonstrated that multiple behavioural risk exposures could independently or collectively influence diverse hierarchical levels of gene expression patterns through multiple biological mechanisms such as Wnt, mitogen-activated protein kinase (MAPK), AMP-activated protein kinase (AMPK), nuclear factor (NF)-κB, phosphatidylinositol 3-kinase (PI3K)-Akt, and insulin (INS) signalling pathways-mediated pathological processes, thereby prodromally or intermediately impacting AD. Our study provided insights into understanding the association of behavioural risk exposures with AD and informative support for further studies.","[""Alzheimer's disease"", 'Behavior', 'Behavioural risk', 'Dementia', 'Gene expression', 'Mechanisms']",Neuroscience and biobehavioral reviews,2023-05-06,"[{'lastname': 'Li', 'firstname': 'Dun', 'initials': 'D', 'affiliation': 'School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.'}, {'lastname': 'Yang', 'firstname': 'Hongxi', 'initials': 'H', 'affiliation': 'School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.'}, {'lastname': 'Lyu', 'firstname': 'Mingqian', 'initials': 'M', 'affiliation': 'Department of Computer Science, RWTH Aachen University, Aachen 52062, Germany.'}, {'lastname': 'Zhou', 'firstname': 'Lihui', 'initials': 'L', 'affiliation': 'School of Public Health, Tianjin Medical University, Tianjin 300070, China.'}, {'lastname': 'Zhang', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin 300052, China.'}, {'lastname': 'Kang', 'firstname': 'Chunsheng', 'initials': 'C', 'affiliation': 'Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neurotrauma Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin 300052, China.'}, {'lastname': 'Wang', 'firstname': 'Ju', 'initials': 'J', 'affiliation': 'School of Biomedical Engineering, Tianjin Medical University, Tianjin 300070, China.'}, {'lastname': 'Wang', 'firstname': 'Yaogang', 'initials': 'Y', 'affiliation': 'School of Integrative Medicine, Public Health Science and Engineering College, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; School of Public Health, Tianjin Medical University, Tianjin 300070, China; National Institute of Health Data Science at Peking University, Peking University, Beijing 100191, China. Electronic address: YaogangWANG@tmu.edu.cn.'}]",,,,Copyright © 2023 Elsevier Ltd. All rights reserved.,10.1016/j.neubiorev.2023.105207,<Element 'PubmedArticle' at 0x7f05dc9f0950>
33,37137431,Sleep deprivation modulates APOE and LDL receptor-related protein 1 through thyroid hormone T4 and impairs Aβ clearance in hippocampus of rats.,"Alzheimer's disease is the most common form of dementia. One of its pathological hallmarks is Aβ accumulation, which is influenced by APOE genotype and expression, as well as by sleep homeostasis. However, conflicting mechanisms for APOE roles in Aβ clearance have been reported, and the relationship between APOE and sleep also remains unclear. In this study, we aimed to investigate how hormonal alteration caused by sleep deprivation affects APOE and its receptors in rats, and to evaluate the role of different cell types in Aβ clearance. Paradoxical sleep deprivation for 96 h increased Aβ level in hippocampus with concomitant reduction of APOE and LRP1 at the time point within the resting period. Sleep deprivation also significantly reduced T4 levels in both active and resting times. To evaluate the effect of T4 variation, C6 glial cells and primary brain endothelial cells were treated with T4. High T4 level (300 ng/mL) increased APOE, but reduced LRP1 and LDL-R in C6 cells, while in primary endothelial cells, LDL-R levels were increased. Treatment of C6 cells with exogenous APOE reduced LRP1 and Aβ uptake. These results suggest that T4 modulates LRP1 and LDL-R in both cell types, but in the opposite manner, thus, sleep deprivation might modify the ratio of the receptors in blood-brain barrier and glial cells by altering T4 levels. Considering that LRP1 and LDL-R are important for Aβ clearance, sleep deprivation might also affect the degree of participation of glia in Aβ clearance, and consequently, turnover of Aβ in the brain.","['Amyloid-beta', 'Apolipoprotein E', 'Interleukin-6', 'LRP1', 'Sleep deprivation', 'Thyroxine']",Biochimica et biophysica acta. Molecular basis of disease,2023-05-04,"[{'lastname': 'da Luz', 'firstname': 'Marcio Henrique Mello', 'initials': 'MHM', 'affiliation': 'Department of Biochemistry, Universidade Federal de São Paulo, Brazil. Electronic address: mhmluz@unifesp.br.'}, {'lastname': 'Pino', 'firstname': 'Jessica Monteiro Volejnik', 'initials': 'JMV', 'affiliation': 'Department of Biochemistry, Universidade Federal de São Paulo, Brazil.'}, {'lastname': 'Mônico-Neto', 'firstname': 'Marcos', 'initials': 'M', 'affiliation': 'Post Graduate Program of Interdisciplinary Health Sciences, Universidade Federal de São Paulo, Santos, Brazil.'}, {'lastname': 'de Amorim', 'firstname': 'Priscila Nicolicht', 'initials': 'PN', 'affiliation': 'Department of Biochemistry, Universidade Federal de São Paulo, Brazil.'}, {'lastname': 'Antunes', 'firstname': 'Hanna Karen Moreira', 'initials': 'HKM', 'affiliation': 'Department of Psychobiology, Universidade Federal de São Paulo, Brazil. Electronic address: hanna.karen@unifesp.br.'}, {'lastname': 'Porcionatto', 'firstname': 'Marimelia Aparecida', 'initials': 'MA', 'affiliation': 'Department of Biochemistry, Universidade Federal de São Paulo, Brazil. Electronic address: marimelia.porcionatto@unifesp.br.'}, {'lastname': 'Lee', 'firstname': 'Kil Sun', 'initials': 'KS', 'affiliation': 'Department of Biochemistry, Universidade Federal de São Paulo, Brazil. Electronic address: kslee@unifesp.br.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2023.166729,<Element 'PubmedArticle' at 0x7f05dc9e5e00>
34,37125547,Insulin Resistance and Impaired Branched-Chain Amino Acid Metabolism in Alzheimer's Disease.,"The pathogenesis of Alzheimer's disease (AD) is complicated and involves multiple contributing factors. Mounting evidence supports the concept that AD is an age-related metabolic neurodegenerative disease mediated in part by brain insulin resistance, and sharing similar metabolic dysfunctions and brain pathological characteristics that occur in type 2 diabetes mellitus (T2DM) and other insulin resistance disorders. Brain insulin signal pathway is a major regulator of branched-chain amino acid (BCAA) metabolism. In the past several years, impaired BCAA metabolism has been described in several insulin resistant states such as obesity, T2DM and cardiovascular disease. Disrupted BCAA metabolism leading to elevation in circulating BCAAs and related metabolites is an early metabolic phenotype of insulin resistance and correlated with future onset of T2DM. Brain is a major site for BCAA metabolism. BCAAs play pivotal roles in normal brain function, especially in signal transduction, nitrogen homeostasis, and neurotransmitter cycling. Evidence from animal models and patients support the involvement of BCAA dysmetabolism in neurodegenerative diseases including Huntington's disease, Parkinson's disease, and maple syrup urine disease. More recently, growing studies have revealed altered BCAA metabolism in AD, but the relationship between them is poorly understood. This review is focused on the recent findings regarding BCAA metabolism and its role in AD. Moreover, we will explore how impaired BCAA metabolism influences brain function and participates in the pathogenesis of AD.","['Alzheimer’s disease', 'branched-chain amino acids', 'insulin resistance', 'metabolic neurodegenerative disease', 'metabolism']",Journal of Alzheimer's disease : JAD,2023-05-01,"[{'lastname': 'Liu', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'Department of Public Health and Preventive Medicine, School of Medicine, Jianghan University, Wuhan, Hubei, China.'}, {'lastname': 'Zhang', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'Department of Chinese Medicine, School of Medicine, Jianghan University, Wuhan, Hubei, China.'}, {'lastname': 'You', 'firstname': 'Hao', 'initials': 'H', 'affiliation': 'Department of Public Health and Preventive Medicine, School of Medicine, Jianghan University, Wuhan, Hubei, China.'}]",,,,,10.3233/JAD-221147,<Element 'PubmedArticle' at 0x7f05df15c220>
35,"37093889
33717092
32463598
24312902
33888706
34010064
23715323
27135365
30204156
19114008
22751426
34276057
35213535
30020411
31856181
33974632
28881986
27487303
0
29719227
25904405
24205186
35428049
31001320
34447416
23383947
34282354
20215462
28679235
36000859
31076572
30204156
25583121
29892006
32913098
6990179
31512725
15481327
32908223
23271574
24391596
27226307
19004004
29773801
32930093
34408653
29773671
16930429
20585360
33628198
27773998
18436706
31346329
25405189
29490708
28827321
32184914
25374890
25426780
31824945
30404002
30759402
31819264
33853780
35863345
34108219",MultiCens: Multilayer network centrality measures to uncover molecular mediators of tissue-tissue communication.,"With the evolution of multicellularity, communication among cells in different tissues and organs became pivotal to life. Molecular basis of such communication has long been studied, but genome-wide screens for genes and other biomolecules mediating tissue-tissue signaling are lacking. To systematically identify inter-tissue mediators, we present a novel computational approach MultiCens (Multilayer/Multi-tissue network Centrality measures). Unlike single-layer network methods, MultiCens can distinguish within- vs. across-layer connectivity to quantify the ""influence"" of any gene in a tissue on a query set of genes of interest in another tissue. MultiCens enjoys theoretical guarantees on convergence and decomposability, and performs well on synthetic benchmarks. On human multi-tissue datasets, MultiCens predicts known and novel genes linked to hormones. MultiCens further reveals shifts in gene network architecture among four brain regions in Alzheimer's disease. MultiCens-prioritized hypotheses from these two diverse applications, and potential future ones like ""Multi-tissue-expanded Gene Ontology"" analysis, can enable whole-body yet molecular-level systems investigations in humans.",[],PLoS computational biology,2023-04-24,"[{'lastname': 'Kumar', 'firstname': 'Tarun', 'initials': 'T', 'affiliation': 'Department of Computer Science and Engineering, Indian Institute of Technology (IIT) Madras, Chennai, India.\nThe Centre for Integrative Biology and Systems medicinE (IBSE), IIT Madras, Chennai, India.\nRobert Bosch Center for Data Science and Artificial Intelligence (RBCDSAI), IIT Madras, Chennai, India.'}, {'lastname': 'Sethuraman', 'firstname': 'Ramanathan', 'initials': 'R', 'affiliation': 'Intel Corporation, Bangalore, India.'}, {'lastname': 'Mitra', 'firstname': 'Sanga', 'initials': 'S', 'affiliation': 'Department of Computer Science and Engineering, Indian Institute of Technology (IIT) Madras, Chennai, India.'}, {'lastname': 'Ravindran', 'firstname': 'Balaraman', 'initials': 'B', 'affiliation': 'Department of Computer Science and Engineering, Indian Institute of Technology (IIT) Madras, Chennai, India.\nThe Centre for Integrative Biology and Systems medicinE (IBSE), IIT Madras, Chennai, India.\nRobert Bosch Center for Data Science and Artificial Intelligence (RBCDSAI), IIT Madras, Chennai, India.'}, {'lastname': 'Narayanan', 'firstname': 'Manikandan', 'initials': 'M', 'affiliation': 'Department of Computer Science and Engineering, Indian Institute of Technology (IIT) Madras, Chennai, India.\nThe Centre for Integrative Biology and Systems medicinE (IBSE), IIT Madras, Chennai, India.\nRobert Bosch Center for Data Science and Artificial Intelligence (RBCDSAI), IIT Madras, Chennai, India.\nMultiscale Digital Neuroanatomy (MDN), IIT Madras, Chennai, India.'}]",,,,"Copyright: © 2023 Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","10.1371/journal.pcbi.1011022
10.3389/fimmu.2021.608680
10.15252/msb.20198982
10.3389/fcimb.2013.00082
10.1038/s41467-021-22599-x
10.1152/ajplung.00209.2021
10.1038/ng.2653
10.1016/j.cels.2016.02.002
10.1038/sdata.2018.185
10.1186/1471-2105-9-559
10.1038/nrg3253
10.1038/s41431-021-00930-w
10.1371/journal.pcbi.1009903
10.1093/bioinformatics/bty637
10.1371/journal.pcbi.1007434
10.1371/journal.pcbi.1009002
10.1093/bioinformatics/btx252
10.1371/journal.pbio.1002527
10.1186/s41044-020-00046-0
10.1016/j.cmet.2018.03.015
10.1038/ncomms7868
10.1371/journal.pone.0078293
10.1007/s41109-021-00429-9
10.1103/PhysRevE.105.034305
10.3389/fgene.2019.00266
10.3389/fgene.2021.720327
10.1038/s42005-022-00937-9
10.1103/PhysRevLett.110.028701
10.1007/s41745-019-0103-y
10.1093/bioinformatics/btq108
10.1007/s41109-020-00277-z
10.1016/j.omega.2021.102520
10.1016/j.neucom.2020.10.040
10.1038/s41597-019-0055-0
10.1038/sdata.2018.185
10.1093/bioinformatics/btv015
10.1038/s41598-018-27293-5
10.1126/science.aaz1776
10.1016/0026-0495(80)90170-5
10.1210/endrev/bnz001
10.1023/B:DDAS.0000042254.35986.57
10.1038/s41568-020-0295-5
10.1007/s11892-012-0356-6
10.3389/fphys.2013.00379
10.1073/pnas.1600561113
10.1002/ijc.24063
10.1038/s41467-018-04353-y
10.7554/eLife.58941
10.3389/fphar.2021.701390
10.1042/CS20180041
10.1111/j.1460-9568.2006.05002.x
10.1155/2010/876514
10.3389/fendo.2020.610213
10.4137/CMED.S38201
10.1210/er.2007-0036
10.1186/s41065-019-0101-0
10.12998/wjcc.v2.i11.661
10.1186/s40478-018-0524-2
10.1073/pnas.1707039114
10.1155/2020/2786139
10.1155/2014/796869
10.1210/er.2014-1034
10.3389/fcell.2019.00288
10.1016/j.celrep.2018.10.047
10.1016/j.celrep.2019.01.063
10.1038/s41592-019-0667-5
10.1126/sciadv.abf1356
10.1016/j.cels.2022.06.005
10.1126/sciadv.abg6677",<Element 'PubmedArticle' at 0x7f05df16aae0>
36,37084561,Molecular insights into the pathogenic impact of vitamin D deficiency in neurological disorders.,"Neurological disorders are the major cause of disability, leading to a decrease in quality of life by impairing cognitive, sensorimotor, and motor functioning. Several factors have been proposed in the pathogenesis of neurobehavioral changes, including nutritional, environmental, and genetic predisposition. Vitamin D (VD) is an environmental and nutritional factor that is widely distributed in the central nervous system's subcortical grey matter, neurons of the substantia nigra, hippocampus, thalamus, and hypothalamus. It is implicated in the regulation of several brain functions by preserving neuronal structures. It is a hormone rather than a nutritional vitamin that exerts a regulatory role in the pathophysiology of several neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. A growing body of epidemiological evidence suggests that VD is critical in neuronal development and shows neuroprotective effects by influencing the production and release of neurotrophins, antioxidants, immunomodulatory, regulation of intracellular calcium balance, and direct effect on the growth and differentiation of nerve cells. This review provides up-to-date and comprehensive information on vitamin D deficiency, risk factors, and clinical and preclinical evidence on its relationship with neurological disorders. Furthermore, this review provides mechanistic insight into the implications of vitamin D and its deficiency on the pathogenesis of neurological disorders. Thus, an understanding of the crucial role of vitamin D in the neurobiology of neurodegenerative disorders can assist in the better management of vitamin D-deficient individuals.","['Alzheimer’s disease', 'Epilepsy', 'Multiple Sclerosis', 'Neurological disorders', 'Parkinson’s disease', 'Pathophysiology', 'Risk factor', 'Vitamin D deficiency']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2023-04-22,"[{'lastname': 'Anwar', 'firstname': 'Md Jamir', 'initials': 'MJ', 'affiliation': 'Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Unaizah 51911, Saudi Arabia.'}, {'lastname': 'Alenezi', 'firstname': 'Sattam Khulaif', 'initials': 'SK', 'affiliation': 'Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Unaizah 51911, Saudi Arabia. Electronic address: sk.alenezi@qu.edu.sa.'}, {'lastname': 'Alhowail', 'firstname': 'Ahmad Hamad', 'initials': 'AH', 'affiliation': 'Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim, Buraydah 51452, Saudi Arabia.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.,10.1016/j.biopha.2023.114718,<Element 'PubmedArticle' at 0x7f05dc8d7450>
37,"37076875
22820012
31213970
27852778
9443474
20697751
33433042
6337049
31647782
33826918
36644126
9392846
8408635
8918685
8801538
9396070
24370925
10447096
28601906
18403490
30044494
29584446
35420782
36280236
35175106
32568367
30500332
18782558
8246142
9031222
28222522
5950056
22476197
17848936
15504987
18230654
35715625
7705198
1100460
16936707
32399074
34545146
32004344
9219216
33766485
21263116
27122366
19724283
20725515",Central nervous system insulin signaling can influence the rate of insulin influx into brain.,"Insulin transport across the blood-brain barrier (BBB) is a highly regulated, saturable process, known to be affected by many peripheral substrates including insulin itself and triglycerides. This is in contrast to insulin leakage into peripheral tissues. Whether the central nervous system (CNS) can control the rate of insulin uptake by brain remains to be determined. Insulin BBB interactions are impaired in Alzheimer's disease (AD) and CNS insulin resistance is widely prevalent in AD. Therefore, if CNS insulin controls the rate of insulin transport across the BBB, then the defective transport of insulin seen in AD could be one manifestation of the resistance to CNS insulin observed in AD.
We investigated whether enhancing CNS insulin levels or induction of CNS insulin resistance using an inhibitor of the insulin receptor altered the blood-to-brain transport of radioactively labeled insulin in young, healthy mice.
We found that insulin injected directly into the brain decreased insulin transport across the BBB for whole brain and the olfactory bulb in male mice, whereas insulin receptor blockade decreased transport in female mice for whole brain and hypothalamus. Intranasal insulin, currently being investigated as a treatment in AD patients, decreased transport across the BBB of the hypothalamus.
These results suggest CNS insulin can control the rate of insulin brain uptake, connecting CNS insulin resistance to the rate of insulin transport across the BBB.","['Alzheimer’s disease', 'Blood-brain barrier', 'Insulin receptor', 'Insulin resistance']",Fluids and barriers of the CNS,2023-04-20,"[{'lastname': 'Nguyen', 'firstname': 'Van', 'initials': 'V', 'affiliation': 'School of Medicine, University of Washington, Seattle, WA, 98195, USA.'}, {'lastname': 'Thomas', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.'}, {'lastname': 'Pemberton', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.\nUniversity of Washington, Seattle, WA, 98195, USA.'}, {'lastname': 'Babin', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.'}, {'lastname': 'Noonan', 'firstname': 'Cassidy', 'initials': 'C', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.\nUniversity of Washington, Seattle, WA, 98195, USA.'}, {'lastname': 'Weaver', 'firstname': 'Riley', 'initials': 'R', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.'}, {'lastname': 'Banks', 'firstname': 'William A', 'initials': 'WA', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA.\nDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, 98195, USA.'}, {'lastname': 'Rhea', 'firstname': 'Elizabeth M', 'initials': 'EM', 'affiliation': 'Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, 98108, USA. meredime@uw.edu.\nDepartment of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington, Seattle, WA, 98195, USA. meredime@uw.edu.'}]",,,"We found that insulin injected directly into the brain decreased insulin transport across the BBB for whole brain and the olfactory bulb in male mice, whereas insulin receptor blockade decreased transport in female mice for whole brain and hypothalamus. Intranasal insulin, currently being investigated as a treatment in AD patients, decreased transport across the BBB of the hypothalamus.",© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.,"10.1186/s12987-023-00431-6
10.1016/j.pharmthera.2012.07.006
10.3389/fnins.2019.00521
10.1523/JNEUROSCI.2119-16.2016
10.1212/WNL.50.1.164
10.1007/s00702-010-0456-x
10.1111/jne.12929
10.1210/endo-112-3-898
10.1016/j.cmet.2021.03.020
10.1016/S0196-9781(97)00231-3
10.1172/JCI116773
10.1006/hbeh.1996.0034
10.1016/0196-9781(96)00025-3
10.1016/S0196-9781(97)00198-8
10.1007/s00592-013-0546-y
10.1016/S0196-9781(99)00045-5
10.1007/s00125-017-4285-4
10.1210/en.2008-0008
10.1113/JP276149
10.1152/ajpendo.00350.2016
10.1021/acs.bioconjchem.2c00126
10.1016/j.expneurol.2018.11.007
10.1016/j.bbrc.2008.08.151
10.3233/JAD-161095
10.1111/j.1471-4159.1966.tb09873.x
10.1172/JCI59903
10.1038/sj.ijo.0803722
10.2337/diabetes.53.11.3024
10.1210/jc.2007-2606
10.1038/s41366-022-01167-3
10.1016/0168-8227(94)90144-9
10.2337/diab.24.10.910
10.1038/sj.npp.1301193
10.1007/s11571-020-09571-z
10.1038/s41598-021-98061-1
10.1371/journal.pone.0228455
10.3109/10739689709146787
10.1016/j.metabol.2021.154766
10.1161/HYPERTENSIONAHA.110.160671
10.1152/ajpregu.00054.2016
10.1038/jcbfm.2009.177",<Element 'PubmedArticle' at 0x7f05dc8d4d60>
38,"37029828
32798480
22430227
8103166
33664071
21042579
25173690
35153648
11683554
16533523
15128277
25880521
30227888
27401522
30013920
20837515
21247885
28119581
30974821
26814847
35538422
34371238
23874573
26501691
16917193
29888312
27919275
26336076
2039382
8829739
11416775
8290099
3941254
6881929
6214576
3383025
10732803
3973334
7629473
2285263
6219416
10668705
2910259
2774509
11416089
3531918
8498809
6807386
3614653
1513459
30020924
18425990
25551457
1863706
1780406
1771206
28204514
2611596
16021850
31631460
34002295
8643753
34227095
8778999
18583392
28759663
21297428
31058684
16352909
25466513
28443508
29164314
24968011
32781308
15901628
21470263
27693973
22922820
33221303
29530279
27044700
18395201
19949032
2370502
28370849
30571751
30134873
25956369
25461896
17239180",Do prenatal factors shape the risk for dementia?: A systematic review of the epidemiological evidence for the prenatal origins of dementia.,"Prenatal factors such as maternal stress, infection and nutrition affect fetal brain development and may also influence later risk for dementia. The purpose of this systematic review was to provide an overview of all studies which investigated the association between prenatal factors and later risk for dementia.
We systematically searched MEDLINE and Embase for original human studies reporting on associations between prenatal factors and dementia from inception to 23 November 2022. Prenatal factors could be any factor assessed during pregnancy, at birth or postnatally, provided they were indicative of a prenatal exposure. Risk of bias was assessed using the Newcastle Ottawa Scale. We followed PRISMA guidelines for reporting.
A total of 68 studies met eligibility criteria (including millions of individuals), assessing maternal age (N = 30), paternal age (N = 22), birth order (N = 15), season of birth (N = 16), place of birth (N = 13), prenatal influenza pandemic (N = 1) or Chinese famine exposure (N = 1), birth characteristics (N = 3) and prenatal hormone exposure (N = 4). We observed consistent results for birth in a generally less optimal environment (e.g. high infant mortality area) being associated with higher dementia risk. Lower and higher birth weight and prenatal famine exposure were associated with higher dementia risk. The studies on season of birth, digit ratio, prenatal influenza pandemic exposure, parental age and birth order showed inconsistent results and were hampered by relatively high risk of bias.
Our findings suggest that some prenatal factors, especially those related to a suboptimal prenatal environment, are associated with an increased dementia risk. As these associations may be confounded by factors such as parental socioeconomic status, more research is needed to examine the potential causal role of the prenatal environment in dementia.","['Alzheimer’s disease', 'Dementia', 'Developmental programming', 'Prenatal', 'Systematic review']",Social psychiatry and psychiatric epidemiology,2023-04-09,"[{'lastname': 'Wiegersma', 'firstname': 'Aline Marileen', 'initials': 'AM', 'affiliation': 'Epidemiology and Data Science, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. a.m.wiegersma@amsterdamumc.nl.\nAmsterdam Public Health Research Institute, Aging & Later Life, Health Behaviors & Chronic Diseases, Amsterdam, The Netherlands. a.m.wiegersma@amsterdamumc.nl.\nAmsterdam Reproduction and Development, Amsterdam, The Netherlands. a.m.wiegersma@amsterdamumc.nl.'}, {'lastname': 'Boots', 'firstname': 'Amber', 'initials': 'A', 'affiliation': 'Epidemiology and Data Science, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.\nAmsterdam Public Health Research Institute, Aging & Later Life, Health Behaviors & Chronic Diseases, Amsterdam, The Netherlands.\nAmsterdam Reproduction and Development, Amsterdam, The Netherlands.'}, {'lastname': 'Langendam', 'firstname': 'Miranda W', 'initials': 'MW', 'affiliation': 'Epidemiology and Data Science, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.\nAmsterdam Public Health Research Institute, Methodology, Amsterdam, The Netherlands.'}, {'lastname': 'Limpens', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'Medical Library, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.'}, {'lastname': 'Shenkin', 'firstname': 'Susan D', 'initials': 'SD', 'affiliation': 'Geriatric Medicine, Usher Institute, University of Edinburgh, Edinburgh, Scotland, UK.'}, {'lastname': 'Korosi', 'firstname': 'Aniko', 'initials': 'A', 'affiliation': 'Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.'}, {'lastname': 'Roseboom', 'firstname': 'Tessa J', 'initials': 'TJ', 'affiliation': 'Epidemiology and Data Science, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.\nObstetrics and Gynaecology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.\nAmsterdam Public Health Research Institute, Aging & Later Life, Health Behaviors & Chronic Diseases, Amsterdam, The Netherlands.\nAmsterdam Reproduction and Development, Amsterdam, The Netherlands.'}, {'lastname': 'de Rooij', 'firstname': 'Susanne R', 'initials': 'SR', 'affiliation': 'Epidemiology and Data Science, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.\nAmsterdam Public Health Research Institute, Aging & Later Life, Health Behaviors & Chronic Diseases, Amsterdam, The Netherlands.\nAmsterdam Reproduction and Development, Amsterdam, The Netherlands.'}]",,"Our findings suggest that some prenatal factors, especially those related to a suboptimal prenatal environment, are associated with an increased dementia risk. As these associations may be confounded by factors such as parental socioeconomic status, more research is needed to examine the potential causal role of the prenatal environment in dementia.","A total of 68 studies met eligibility criteria (including millions of individuals), assessing maternal age (N = 30), paternal age (N = 22), birth order (N = 15), season of birth (N = 16), place of birth (N = 13), prenatal influenza pandemic (N = 1) or Chinese famine exposure (N = 1), birth characteristics (N = 3) and prenatal hormone exposure (N = 4). We observed consistent results for birth in a generally less optimal environment (e.g. high infant mortality area) being associated with higher dementia risk. Lower and higher birth weight and prenatal famine exposure were associated with higher dementia risk. The studies on season of birth, digit ratio, prenatal influenza pandemic exposure, parental age and birth order showed inconsistent results and were hampered by relatively high risk of bias.",© 2023. The Author(s).,"10.1007/s00127-023-02471-7
10.1016/S0140-6736(20)30367-6
10.3233/JAD-132225
10.1001/jama.2019.9879
10.1007/s11154-012-9210-z
10.1001/jama.2008.886
10.1016/0140-6736(93)91224-A
10.1136/bmjopen-2020-042078
10.1371/journal.pone.0013582
10.1007/s11892-014-0536-7
10.3389/ijph.2021.603859
10.1079/phn2001145
10.1016/j.placenta.2006.01.014
10.1677/joe.0.1810291
10.1002/cphy.c140036
10.1186/s13195-018-0422-7
10.1093/brain/aww132
10.1016/j.neuroimage.2017.10.047
10.1073/pnas.1009459107
10.1093/ije/dyq261
10.3389/fnbeh.2016.00146
10.3390/jcm8040484
10.1038/srep13792
10.1186/S12877-022-02820-2
10.1016/j.nicl.2021.102776
10.1371/journal.pone.0054707
10.1016/j.intell.2017.02.001
10.1159/000439568
10.1097/01.wad.0000201854.62116.d7
10.1016/J.YNSTR.2018.02.003
10.1186/s13643-016-0384-4
10.1371/journal.pone.0136065
10.1001/archneur.1991.00530180051017
10.1192/bjp.167.6.732
10.1097/00001648-200107000-00007
10.1212/WNL.44.1.97
10.1017/S1041610200006566
10.1017/S104161029700447X
10.1093/geronj/41.1.40
10.1212/wnl.44.11.2073
10.1002/ana.410140503
10.1002/ana.410130618
10.1111/j.1532-5415.1982.tb05065.x
10.1017/S0317167100027505
10.1007/s100480050041
10.1159/000106991
10.1111/j.1532-5415.1985.tb04886.x
10.1136/jech.49.3.253
10.1002/ana.410280607
10.1192/bjp.157.2.273
10.1016/0165-1781(82)90071-3
10.1212/WNL.54.2.415
10.1001/archneur.1989.00520370040016
10.1002/ana.410250402
10.1093/ije/30.3.590
10.1089/whr.2021.0007
10.1212/WNL.36.7.922
10.1002/ana.410330306
10.1192/bjp.140.3.249
10.1212/WNL.37.8.1295
10.1212/WNL.42.8.1481
10.1371/journal.pmed.1002609
10.1371/journal.pone.0114679
10.1371/journal.pone.0114679
10.1017/S1041610291000510
10.1017/S003329170002047X
10.1016/S0924-9338(01)00557-0
10.1016/0165-1781(91)90004-9
10.1093/ije/dyw314
10.1192/bjp.155.5.662
10.3961/jpmph.16.018
10.1007/s11577-015-0328-3
10.1002/ajhb.23319
10.1007/s10654-021-00755-3
10.1017/S003329170003378X
10.1111/acps.13313
10.1016/0277-9536(95)00185-9
10.1002/gps.930080503
10.1093/ije/dyn125
10.1001/jamaneurol.2017.1553
10.1097/WAD.0b013e31820905e7
10.1016/j.ssmph.2021.100841
10.1097/WAD.0000000000000270
10.1136/jech.45.4.307
10.1007/BF01257128
10.1159/000085307
10.1016/j.archger.2014.11.006
10.1111/irv.12542
10.2174/1567205014666170425112331
10.1007/s00702-017-1815-7
10.1097/WNN.0000000000000024
10.1016/j.earlhumdev.2020.105152
10.1002/dad2.12049
10.1016/j.jjie.2018.07.001
10.1093/aje/kwi137
10.3386/w25147
10.1377/hlthaff.2021.00139
10.1111/j.1365-3016.2011.01192.x
10.1016/j.socscimed.2016.02.014
10.1289/ehp.1204918
10.1289/EHP4709
10.1016/j.envres.2020.110446
10.1016/j.biopsych.2018.01.016
10.1016/j.acap.2016.01.014
10.1016/j.ejphar.2008.02.049
10.1212/WNL.0b013e3181c47cad
10.1136/jech.44.2.139
10.1002/ajhb.23003
10.1371/journal.pone.0191002
10.1186/s12884-018-1984-x
10.1016/j.fertnstert.2015.04.015
10.3233/JAD-210289
10.1098/rspb.2012.1363
10.1016/j.jhealeco.2014.10.002
10.1111/j.1365-3016.2007.00783.x",<Element 'PubmedArticle' at 0x7f05dc8a53b0>
39,"37010830
32799367
30715078
15939846
31915896
30219939
25225714
21865747
20689282
24336141
1826173
9344402
24084921
15213207
12771113
12771112
15608005
27028912
21280086
36240091
23100399
16607096
15516400
35797481
28703650
31940155
35471588
29322089
21784354
22344196
24269021
11771995
26059712
35856240
29777006
31673596
24886908
24771324
31453973
18212285
25443857
31416275
32580974
34588168
26962899
30842086
35394117
30824901
30824902
33687445
27721640
22888911
14662210
10940145
27716751
6859020
17573335
31738818",Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography.,"Postmenopausal females represent around 70% of all individuals with Alzheimer disease. Previous literature shows elevated levels of tau in cognitively unimpaired postmenopausal females compared with age-matched males, particularly in the setting of high β-amyloid (Aβ). The biological mechanisms associated with higher tau deposition in female individuals remain elusive.
To examine the extent to which sex, age at menopause, and hormone therapy (HT) use are associated with regional tau at a given level of Aβ, both measured with positron emission tomography (PET).
This cross-sectional study included participants enrolled in the Wisconsin Registry for Alzheimer Prevention. Cognitively unimpaired males and females with at least 1 18F-MK-6240 and 11C-Pittsburgh compound B PET scan were analyzed. Data were collected between November 2006 and May 2021.
Premature menopause (menopause at younger than 40 years), early menopause (menopause at age 40-45 years), and regular menopause (menopause at older than 45 years) and HT user (current/past use) and HT nonuser (no current/past use). Exposures were self-reported.
Seven tau PET regions that show sex differences across temporal, parietal, and occipital lobes. Primary analyses examined the interaction of sex, age at menopause or HT, and Aβ PET on regional tau PET in a series of linear regressions. Secondary analyses investigated the influence of HT timing in association with age at menopause on regional tau PET.
Of 292 cognitively unimpaired individuals, there were 193 females (66.1%) and 99 males (33.9%). The mean (range) age at tau scan was 67 (49-80) years, 52 (19%) had abnormal Aβ, and 106 (36.3%) were APOEε4 carriers. There were 98 female HT users (52.2%) (past/current). Female sex (standardized β = -0.41; 95% CI, -0.97 to -0.32; P < .001), earlier age at menopause (standardized β = -0.38; 95% CI, -0.14 to -0.09; P < .001), and HT use (standardized β = 0.31; 95% CI, 0.40-1.20; P = .008) were associated with higher regional tau PET in individuals with elevated Aβ compared with male sex, later age at menopause, and HT nonuse. Affected regions included medial and lateral regions of the temporal and occipital lobes. Late initiation of HT (>5 years following age at menopause) was associated with higher tau PET compared with early initiation (β = 0.49; 95% CI, 0.27-0.43; P = .001).
In this study, females exhibited higher tau compared with age-matched males, particularly in the setting of elevated Aβ. In females, earlier age at menopause and late initiation of HT were associated with increased tau vulnerability especially when neocortical Aβ elevated. These observational findings suggest that subgroups of female individuals may be at higher risk of pathological burden.",[],JAMA neurology,2023-04-04,"[{'lastname': 'Coughlan', 'firstname': 'Gillian T', 'initials': 'GT', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'lastname': 'Betthauser', 'firstname': 'Tobey J', 'initials': 'TJ', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.\nDepartment of Medicine, University of Wisconsin-Madison, Madison.""}, {'lastname': 'Boyle', 'firstname': 'Rory', 'initials': 'R', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'lastname': 'Koscik', 'firstname': 'Rebecca L', 'initials': 'RL', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.\nDepartment of Medicine, University of Wisconsin-Madison, Madison.""}, {'lastname': 'Klinger', 'firstname': 'Hannah M', 'initials': 'HM', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'lastname': 'Chibnik', 'firstname': 'Lori B', 'initials': 'LB', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Jonaitis', 'firstname': 'Erin M', 'initials': 'EM', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.\nDepartment of Medicine, University of Wisconsin-Madison, Madison.""}, {'lastname': 'Yau', 'firstname': 'Wai-Ying Wendy', 'initials': 'WW', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'lastname': 'Wenzel', 'firstname': 'Allen', 'initials': 'A', 'affiliation': 'Department of Medicine, University of Wisconsin-Madison, Madison.'}, {'lastname': 'Christian', 'firstname': 'Bradley T', 'initials': 'BT', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.""}, {'lastname': 'Gleason', 'firstname': 'Carey E', 'initials': 'CE', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.""}, {'lastname': 'Saelzler', 'firstname': 'Ursula G', 'initials': 'UG', 'affiliation': 'Department of Psychiatry, University of California, San Diego, San Diego.'}, {'lastname': 'Properzi', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': 'Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.'}, {'lastname': 'Schultz', 'firstname': 'Aaron P', 'initials': 'AP', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'lastname': 'Hanseeuw', 'firstname': 'Bernard J', 'initials': 'BJ', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.\nDepartment of Neurology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.\nGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.\nInstitute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.""}, {'lastname': 'Manson', 'firstname': 'JoAnn E', 'initials': 'JE', 'affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard T.H. Chan School of Public Health, Boston, Massachusetts.""}, {'lastname': 'Rentz', 'firstname': 'Dorene M', 'initials': 'DM', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'lastname': 'Johnson', 'firstname': 'Keith A', 'initials': 'KA', 'affiliation': ""Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.\nGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.""}, {'lastname': 'Sperling', 'firstname': 'Reisa', 'initials': 'R', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'lastname': 'Johnson', 'firstname': 'Sterling C', 'initials': 'SC', 'affiliation': ""Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, School of Medicine and Public Health, Madison.\nDepartment of Medicine, University of Wisconsin-Madison, Madison.""}, {'lastname': 'Buckley', 'firstname': 'Rachel F', 'initials': 'RF', 'affiliation': ""Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.\nCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts.\nMelbourne School of Psychological Sciences, University of Melbourne, Melbourne, Victoria, Australia.""}]",,,"Of 292 cognitively unimpaired individuals, there were 193 females (66.1%) and 99 males (33.9%). The mean (range) age at tau scan was 67 (49-80) years, 52 (19%) had abnormal Aβ, and 106 (36.3%) were APOEε4 carriers. There were 98 female HT users (52.2%) (past/current). Female sex (standardized β = -0.41; 95% CI, -0.97 to -0.32; P < .001), earlier age at menopause (standardized β = -0.38; 95% CI, -0.14 to -0.09; P < .001), and HT use (standardized β = 0.31; 95% CI, 0.40-1.20; P = .008) were associated with higher regional tau PET in individuals with elevated Aβ compared with male sex, later age at menopause, and HT nonuse. Affected regions included medial and lateral regions of the temporal and occipital lobes. Late initiation of HT (>5 years following age at menopause) was associated with higher tau PET compared with early initiation (β = 0.49; 95% CI, 0.27-0.43; P = .001).",,"10.1001/jamaneurol.2023.0455
10.1002/ana.25878
10.1001/jamaneurol.2018.4693
10.1001/archpsyc.62.6.685
10.1007/s00259-019-04669-x
10.1007/s00401-018-1908-x
10.1097/GME.0000000000000319
10.1159/000330472
10.1159/000314681
10.1212/WNL.0000000000000033
10.1016/0091-7435(91)90006-p
10.1016/S0002-9343(97)00261-1
10.1001/jama.2013.278040
10.1001/jama.291.24.2959
10.1001/jama.289.20.2663
10.1001/jama.289.20.2651
10.1136/jnnp.2003.024927
10.1056/NEJMoa1505241
10.1002/ana.22239
10.1212/WNL.0000000000200960
10.1212/WNL.0b013e318271f823
10.1097/01.gme.0000191204.38664.61
10.1097/01.AOG.0000143826.38439.af
10.1097/GME.0000000000002028
10.4158/EP171828.PS
10.1002/ana.26382
10.1016/j.dadm.2017.11.007
10.1016/j.jalz.2010.11.012
10.1210/jc.2011-3362
10.1016/j.neurobiolaging.2013.09.028
10.1006/nimg.2001.0978
10.1016/j.neurobiolaging.2015.05.004
10.1093/brain/awac213
10.2967/jnumed.118.209650
10.1016/j.dadm.2018.11.006
10.1001/jamaneurol.2014.803
10.1111/j.2517-6161.1995.tb02031.x
10.1093/ije/dyu094
10.1097/GME.0000000000001326
10.1161/CIRCULATIONAHA.107.699579
10.1509/jmr.12.0420
10.1016/j.jalz.2014.07.003
10.3390/medicina55080482
10.1212/WNL.0000000000009781
10.1136/bmj.n2182
10.1056/NEJMp1514242
10.1136/bmj.l665
10.1002/alz.12662
10.1093/aje/kwz048
10.1093/aje/kwz047
10.1001/jamanetworkopen.2021.1001
10.4103/0976-7800.191012
10.3109/13697137.2012.696288
10.1016/j.obstetgynecol.2003.09.024
10.1046/j.1525-1497.2000.03499.x
10.1038/nrendo.2016.164
10.1093/oxfordjournals.aje.a113598
10.1093/aje/kwm116
10.1001/jama.2019.19191",<Element 'PubmedArticle' at 0x7f05dcae3540>
40,"36918783
26568120
28611660
34759373
35008933
22028968
30792350
28052921
17245414
11779462
25385339
35000606
23797088
36574855
34596047
30784558
34595127
30911133
35269386
7624138
12152783
12684440
20584423
34219712
19619927
15923260
17404835
17514197
25590687
20472889
20436277
17095196
21630160
20157524
8395408
25203735
25369242
34225974
33610813
32921425
28294066
30756405
33871799
15582288
36018154
19605939
24112071
34573143
21451205
35721030
28503116
10852441
29251845
35176989
35126722
33622399
31379746
26784870
27645169
32784556
32502393
19421166
32781737
33957167
35167824
19224887
29933646
13158575
14653994
23969329
25228643
22217096
34949832
32415999
16840546
31728887
31800167
29892224
30689226
31879834
28671110
30614107
26252151
21454296
26727258
34795773
34333153
29981776
34384302
31824299
30943316
29562506
31715192
31833091
31855161
25774133
34819005
25247581
17482541
18419307
12214061
21840306
28100031
19048107
12360586
28087763
26439128
24268780
9765203
27870848
28324298
14556704
12593979
9988216
11179874
17453017
19447088
23861057
12639981
15019174
9176387
14593698
12600719
20497605
15936057
17055782
34336099
34924393
9116237
9869328
35163135
22856547
10383401
22833568
24244372
19196437
24027266
26109945
21762680
25917367
25153701
12028822
12895507
18550843
18533137
26292069
10604467
26317805
15592431
36152679
20392944
21415596
26601962
16499562
17401652
17439556
15978052
23470834
10830966
23688838
21108658
18395440
25116835
25556849
27073990
24119401
17135279
18366763
11939591
25259610
16554754
19801542
20181888
35180113
29394901
15108800
15936508
19946466
9525997
23983601
23861893
31370106
28439991
9125193
17399897
18184373
25454643
25628964
19076455
22411259
28507478
18356527
18498087
11124427
21931181
27832629
17314399
26334640
16507903
16461276
17141486
15298664
23857055
19291319
25491598
26123100
29352484
22810102
25625488
33923672
33926537
20387301
18410586
27216337
26639408
21073519
28018215
14557245
10722740
11696557
22805479
32579500
15136759
19595878
15953822
23613819
22306812
16242812
12887656
28052641
12464348
24171672
10809662
23312803
26272235
27500468
16098097
24810171
29765834
22068613
23471746
23900682
22642576
24987325
24611040
24578681
19943348
24137328
25705693
11731235
18818287
12857869
19458225
25251028
17850928
26366944
21948688
33396426
25975679
17319972
16217123
22005580
27649385
27987529
29654697
11018017
6206131
9083562
21718363
28275319
25030435
34561612
30108467
35858673
32681810
36049659
18274263
34990120
30881340
27579149
34309908
33410930
33935759
29578489
24218292
18848476
16262649
25937398
30837464
35813507
29495460
23294620
29904334
35316766
29710710
29318587
34297074
32888482
33023629
23691095
10709969
27620814
20461523
24286859
18343081
36431847
24969726
29926372
19437554
22198054
2155058
8691990
23789008
12941059
23114457
29749262","Melatonin as a Harmonizing Factor of Circadian Rhythms, Neuronal Cell Cycle and Neurogenesis: Additional Arguments for Its Therapeutic Use in Alzheimer's Disease.","The synthesis and release of melatonin in the brain harmonize various physiological functions. The apparent decline in melatonin levels with advanced aging is an aperture to the neurodegenerative processes. It has been indicated that down regulation of melatonin leads to alterations of circadian rhythm components, which further causes a desynchronization of several genes and results in an increased susceptibility to develop neurodegenerative diseases. Additionally, as circadian rhythms and memory are intertwined, such rhythmic disturbances influence memory formation and recall. Besides, cell cycle events exhibit a remarkable oscillatory system, which is downstream of the circadian phenomena. The linkage between the molecular machinery of the cell cycle and complex fundamental regulatory proteins emphasizes the conjectural regulatory role of cell cycle components in neurodegenerative disorders such as Alzheimer's disease. Among the mechanisms intervening long before the signs of the disease appear, the disturbances of the circadian cycle, as well as the alteration of the machinery of the cell cycle and impaired neurogenesis, must hold our interest. Therefore, in the present review, we propose to discuss the underlying mechanisms of action of melatonin in regulating the circadian rhythm, cell cycle components and adult neurogenesis in the context of AD pathogenesis with the view that it might further assist to identify new therapeutic targets.","['Alzheimer’s disease', 'Melatonin', 'cell cycle', 'circadian rhythm', 'neurogenesis', 'therapeutic']",Current neuropharmacology,2023-03-16,"[{'lastname': 'Shukla', 'firstname': 'Mayuri', 'initials': 'M', 'affiliation': 'Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand.\nPresent Address: Chulabhorn Graduate Institute, Chulabhorn Royal Academy, 10210, Bangkok, Thailand.'}, {'lastname': 'Vincent', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': ""Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand.\nInstitute of Molecular and Cellular Pharmacology, Laboratory of Excellence DistALZ, Université Côte d'Azur, INSERM, CNRS, Sophia-Antipolis, 06560, Valbonne, France.""}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.","10.2174/1570159X21666230314142505
10.1016/j.jsmc.2015.08.002
10.3389/fnagi.2017.00170
10.1038/s41582-021-00577-7
10.3390/ijms23010504
10.4061/2011/383091
10.1073/pnas.1812405116
10.1093/cercor/bhw406
10.1038/nrm2106
10.1016/S0092-8674(01)00610-9
10.1038/nrneurol.2014.206
10.1186/s13024-021-00504-w
10.1016/j.conb.2013.05.004
10.1016/j.exger.2022.112076
10.1172/JCI148288
10.1016/S1474-4422(18)30461-7
10.3389/fcimb.2021.696554
10.1038/s41591-019-0375-9
10.3390/cells11050764
10.1093/jnen/61.8.678
10.1523/JNEUROSCI.23-07-02557.2003
10.1017/S146239941000150X
10.3233/JAD-210091
10.1016/j.pneurobio.2009.01.007
10.1073/pnas.0500989102
10.1007/s11064-007-9312-2
10.1038/nrn2097
10.1080/15384101.2015.1004937
10.2353/ajpath.2010.090955
10.4161/cc.9.10.11582
10.1016/j.bbadis.2006.09.010
10.1007/978-3-642-19065-0_23
10.18632/aging.100045
10.1007/BF01923947
10.1371/journal.pone.0106819
10.1111/jpi.12189
10.1016/B978-0-12-819975-6.00022-4
10.1016/j.arr.2021.101304
10.1016/j.neurol.2020.06.009
10.2174/1570159X15666170313123454
10.1111/nyas.14005
10.32794/mr11250059
10.1007/s11064-021-03325-x
10.1016/j.exger.2004.04.012
10.4103/1673-5374.350189
10.1016/S1734-1140(09)70081-7
10.1111/jpi.12090
10.3390/brainsci11091121
10.3389/fnagi.2022.888292
10.2174/1570159X14666161228122115
10.1210/jcem.85.6.6660
10.1002/bdr2.1171
10.2174/1570159X20666220217152617
10.3892/etm.2022.11142
10.1186/s13195-021-00788-6
10.3389/fendo.2019.00480
10.3390/antiox3020245
10.1002/gps.4571
10.3390/biom10081158
10.1016/j.cell.2020.04.049
10.1038/npp.2009.46
10.3390/ijms21165645
10.1016/j.neubiorev.2021.04.034
10.1016/j.yfrne.2022.100986
10.1177/1073858408327808
10.3390/medsci6030052
10.1152/ajplegacy.1954.177.3.361
10.1016/j.cub.2003.10.022
10.1016/j.ceb.2013.07.013
10.1101/gad.249417.114
10.3109/07420528.2011.635237
10.1038/s41590-021-01083-0
10.1111/jpi.12669
10.1210/en.2006-0628
10.1007/s11011-019-00509-x
10.1111/acel.13078
10.3389/fphar.2018.00556
10.1111/ejn.14358
10.1007/s11011-019-00531-z
10.3233/JAD-160942
10.1111/ejn.14334
10.18632/oncotarget.4036
10.1177/0748730410395732
10.1371/journal.pone.0146200
10.12779/dnd.2021.20.4.99
10.1016/j.nbd.2021.105454
10.1016/j.phrs.2018.06.011
10.1080/07420528.2021.1966025
10.3389/fnagi.2019.00320
10.1111/jpi.12578
10.3233/JAD-170900
10.1016/j.bbagen.2019.129467
10.1002/jnr.24572
10.5664/jcsm.8078
10.3389/fphar.2015.00029
10.2174/1567205018666211124104710
10.3390/ijms150916848
10.1016/j.cell.2007.04.015
10.1101/sqb.2007.72.050
10.3233/JAD-2001-3205
10.1016/j.ydbio.2011.07.038
10.1002/hipo.22706
10.1371/journal.pone.0003835
10.1002/neu.10095
10.1523/JNEUROSCI.3222-16.2017
10.1371/journal.pone.0139655
10.1016/j.celrep.2013.10.037
10.1101/gad.12.19.3008
10.1371/journal.pgen.1006445
10.1007/s11910-017-0745-y
10.1016/S0896-6273(03)00632-9
10.1016/S0959-4388(03)00005-9
10.1016/S0092-8674(00)80561-9
10.1016/S0959-4388(00)00175-6
10.1038/nrn2124
10.1016/j.neuron.2009.03.029
10.1242/dev.091744
10.1172/JCI200318182
10.1016/j.pneurobio.2003.12.005
10.1016/S0197-4580(02)00132-X
10.1186/alzrt37
10.1016/j.mad.2005.03.024
10.1016/j.molmed.2006.10.002
10.1155/2021/5552623
10.3233/JAD-215349
10.1097/00001756-199611250-00050
10.1007/s007020050104
10.3390/ijms23031211
10.1111/j.1600-079X.2012.01026.x
10.1074/jbc.274.27.19011
10.1091/mbc.e12-02-0125
10.1371/journal.pone.0078842
10.1111/j.1600-079X.2008.00656.x
10.1523/JNEUROSCI.1327-13.2013
10.4103/1673-5374.156967
10.1016/j.bcp.2011.06.040
10.1038/mp.2015.49
10.1371/journal.pone.0102136
10.1162/153840902753658329
10.1016/S0306-4522(03)00342-7
10.1073/pnas.0711355105
10.1016/j.brainres.2008.04.050
10.1080/15548627.2015.1082020
10.1038/45159
10.1371/journal.pone.0136950
10.1038/sj.emboj.7600441
10.1016/j.lfs.2022.120986
10.1523/JNEUROSCI.5628-09.2010
10.4161/cc.10.8.15328
10.2174/1381612822666151124235028
10.1111/j.1600-079X.2005.00308.x
10.1007/s11064-007-9308-y
10.1111/j.1600-079X.2007.00433.x
10.1111/j.1600-079X.2004.00206.x
10.1016/j.bone.2013.02.021
10.1038/35012636
10.1016/j.jsbmb.2013.04.008
10.1111/jpi.12023
10.1016/j.jsbmb.2008.02.009
10.1038/tp.2014.61
10.1111/jnc.13018
10.4155/fmc-2016-0013
10.1016/j.molcel.2013.09.009
10.1093/hmg/ddl437
10.1186/1471-2199-9-30
10.1093/jnen/61.4.358
10.1371/journal.pone.0108602
10.1038/nature04678
10.1074/jbc.M109.042234
10.4049/jimmunol.0902961
10.3233/JAD-215144
10.1186/s13041-018-0350-2
10.1016/j.gde.2003.11.002
10.1016/j.neulet.2005.04.019
10.18632/aging.100044
10.1523/JNEUROSCI.18-08-02801.1998
10.7150/ijms.5645
10.1371/journal.pone.0068361
10.1111/jpi.12603
10.1111/jpi.12416
10.1006/bbrc.1997.6301
10.1016/j.neulet.2007.03.026
10.1111/j.1601-183X.2007.00377.x
10.1016/j.jns.2014.10.009
10.1196/annals.1427.024
10.1007/s11357-012-9397-7
10.17179/excli2016-852
10.1126/science.1152337
10.1002/dneu.20637
10.1016/S0197-4580(00)00218-9
10.18632/aging.100382
10.1159/000447922
10.1091/mbc.e06-10-0908
10.1371/journal.pone.0137193
10.2353/ajpath.2006.050540
10.1016/j.cub.2005.12.042
10.1016/j.bbadis.2006.10.007
10.1111/j.1600-079X.2004.00136.x
10.3390/ijms140714575
10.1186/1750-1326-4-14
10.1111/jpi.12200
10.1111/jpi.12260
10.1111/jpi.12470
10.3233/JAD-2012-121129
10.1371/journal.pone.0114050
10.1016/j.radmp.2021.01.003
10.3390/antiox10040615
10.1186/s13287-021-02322-9
10.2217/bmm.09.86
10.1111/j.1600-079X.2007.00539.x
10.2500/ajra.2016.30.4313
10.1111/jpi.12300
10.1111/j.1600-079X.2010.00820.x
10.3389/fnagi.2016.00303
10.1083/jcb.200304003
10.1074/jbc.275.12.8929
10.1083/jcb.200104035
10.1111/j.1582-4934.2012.01604.x
10.2174/1567205017666200624201356
10.4161/cc.3.6.901
10.1016/j.jalz.2006.03.001
10.1385/MN:31:1-3:205
10.1371/journal.pone.0061246
10.1016/j.bbadis.2012.01.009
10.1016/j.neurobiolaging.2005.08.013
10.1034/j.1600-079X.2003.00065.x
10.4103/2231-0738.132671
10.4077/CJP.2017.BAF435
10.1016/S1383-5742(02)00046-7
10.3109/01480545.2013.838777
10.1101/gad.14.9.1021
10.1016/j.neurobiolaging.2012.12.005
10.1111/jpi.12267
10.1111/jpi.12360
10.1111/j.1600-079X.2005.00234.x
10.1016/j.freeradbiomed.2014.04.031
10.3233/BPL-150013
10.1007/s00018-011-0880-6
10.1007/s12035-013-8422-x
10.1007/s12015-013-9460-5
10.1042/BJ20112040
10.3389/fnins.2014.00162
10.3389/fnins.2014.00032
10.3389/fnins.2014.00039
10.1002/ar.20980
10.3892/ol.2013.1413
10.1155/2015/854359
10.1016/S0925-4773(01)00527-5
10.1210/en.2008-0882
10.1091/mbc.e03-01-0865
10.1523/JNEUROSCI.0421-09.2009
10.1111/jpi.12182
10.1016/j.neurobiolaging.2007.07.016
10.1016/j.neulet.2015.09.011
10.1002/stem.747
10.3390/cells10010054
10.1111/jpi.12250
10.1186/1750-2187-2-2
10.1385/ENDO:27:2:101
10.1016/j.neulet.2011.10.004
10.1002/mrd.22739
10.1111/jpi.12383
10.1111/jpi.12496
10.1101/gad.836800
10.4049/jimmunol.133.4.1710
10.1007/s004010050617
10.1111/j.1600-079X.2011.00912.x
10.17179/excli2016-606
10.4149/neo_2014_064
10.1038/s41380-021-01303-x
10.17179/excli2017-654
10.1016/j.physbeh.2022.113919
10.1002/npr2.12125
10.1016/j.bbr.2022.114083
10.1093/sleep/31.2.167
10.1021/acschemneuro.1c00465
10.3389/fendo.2019.00087
10.1155/2016/2136902
10.1111/jpi.12759
10.1007/s00415-020-10353-0
10.3389/fphar.2021.650597
10.3233/JAD-171164
10.1007/7854_2013_251
10.1016/j.smrv.2008.07.004
10.1111/j.1460-9568.2005.04376.x
10.1016/j.neuroscience.2015.04.053
10.1038/s41467-019-08806-w
10.3389/fncel.2022.836885
10.3390/molecules23030530
10.1186/1471-2121-14-1
10.3389/fnins.2018.00330
10.1016/j.bbrc.2022.03.025
10.3233/JAD-171169
10.1111/bph.14116
10.1001/jamanetworkopen.2021.17573
10.1016/j.cub.2020.08.017
10.1186/s12974-020-01960-9
10.1371/journal.pone.0063773
10.1034/j.1600-079X.2001.280203.x
10.1016/j.neuint.2016.09.006
10.1007/s00381-010-1147-5
10.1016/j.neuropharm.2013.11.009
10.1016/j.ijdevneu.2008.02.001
10.3390/molecules27227742
10.1017/S1461145714000844
10.1007/s40263-018-0535-3
10.1002/jnr.22125
10.1016/j.bbr.2011.12.013
10.1016/0304-3835(90)90146-O
10.1016/0024-3205(96)00249-4
10.1046/j.1365-2869.2003.00360.x
10.1007/s00228-012-1424-1
10.1177/1060028018776608",<Element 'PubmedArticle' at 0x7f05dca66900>
41,"36897751
35289055
15537512
28978656
10884442
23242312
22395208
28974571
30118343
30721555
32767848
23417608
17600562
28529128
9403576
12053012
20921429
15626687
1977331
27496877
26968546
25910805
8500863
30535688
221551
24236177
27696155
36149767
36240435
32939871
22556255
35943101
25287860
17090684
17142339
28859530
25005230
10512927
26056343
29462784
19661060
19246694
16214843
31738403
32337692
29873596
24804145
26133668
17400711
1451262
31271793
15851723
22447734
20408259
28963120
28588075
32216612
31886721
15178697
7298125
11901215
32493776
8554711
16647766
34724971
17562087
9445346
1997500
12527389
17982007
28957666
11566935
24760441
15798185
27196727
29924994
19056393
22747981
25660297
16439707
15499027
32008372
25994604
15890798
25767191
23316164
25854990
14530222
25164079
18711010
15158151
11230360
23608648
17116756
24855104
12384478
30102356
9435644
28661206
32860555
25659489",Female mice are protected from impaired parenchymal arteriolar TRPV4 function and impaired cognition in hypertension.,"Hypertension is a leading modifiable risk factor for cerebral small vessel disease. Our laboratory has shown that endothelium-dependent dilation in cerebral parenchymal arterioles (PAs) is dependent on transient receptor potential vanilloid 4 (TRPV4) activation, and this pathway is impaired in hypertension. This impaired dilation is associated with cognitive deficits and neuroinflammation. Epidemiological evidence suggests that women with midlife hypertension have an increased dementia risk that does not exist in age-matched men, though the mechanisms responsible for this are unclear. This study aimed to determine the sex differences in young, hypertensive mice to serve as a foundation for future determination of sex differences at midlife. We tested the hypothesis that young hypertensive female mice would be protected from the impaired TRPV4-mediated PA dilation and cognitive dysfunction observed in male mice. Angiotensin II (ANG II)-filled osmotic minipumps (800 ng/kg/min, 4 wk) were implanted in 16- to 19-wk-old male C56BL/6 mice. Age-matched female mice received either 800 ng/kg/min or 1,200 ng/kg/min ANG II. Sham-operated mice served as controls. Systolic blood pressure was elevated in ANG II-treated male mice and in 1,200 ng ANG II-treated female mice versus sex-matched shams. PA dilation in response to the TRPV4 agonist GSK1016790A (10","['TRPV4', 'endothelium', 'hypertension', 'microcirculation', 'sex']",American journal of physiology. Heart and circulatory physiology,2023-03-11,"[{'lastname': 'Chambers', 'firstname': 'Laura C', 'initials': 'LC', 'affiliation': 'Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States.'}, {'lastname': 'Yen', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States.'}, {'lastname': 'Jackson', 'firstname': 'William F', 'initials': 'WF', 'affiliation': 'Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States.'}, {'lastname': 'Dorrance', 'firstname': 'Anne M', 'initials': 'AM', 'affiliation': 'Department of Pharmacology and Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States.\nDepartment of Pharmacology and Toxicology, College of Human Medicine, Michigan State University, East Lansing, Michigan, United States.\nDepartment of Pharmacology and Toxicology, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States.'}]",,,,,"10.1152/ajpheart.00481.2022
10.1002/alz.12638
10.1016/j.jns.2004.09.004
10.1212/WNL.0000000000004602
10.1161/01.str.31.7.1487
10.1038/nn.3278
10.1038/jcbfm.2012.25
10.1161/HYPERTENSIONAHA.117.09598
10.1152/ajpheart.00207.2018
10.1111/micc.12535
10.1111/micc.12653
10.1007/s00424-013-1247-7
10.1111/j.1440-1681.2007.04683.x
10.1016/j.jsbmb.2017.05.006
10.1161/01.hyp.30.6.1517
10.1161/01.str.0000016325.54374.93
10.1161/HYPERTENSIONAHA.110.158071
10.1152/ajpheart.00969.2004
10.1213/00000539-199011000-00001
10.1152/ajpheart.00197.2016
10.1152/ajpheart.00890.2015
10.1152/ajpheart.00168.2015
10.1161/01.hyp.21.6.816
10.1007/978-1-4939-8994-2_10
10.1037/h0077579
10.1371/journal.pone.0080355
10.1007/s00429-016-1316-8
10.1152/ajpheart.00276.2022
10.1152/ajpheart.00369.2022
10.1096/fj.202000085R
10.1126/science.1216283
10.1097/HJH.0000000000003208
10.1152/physrev.00041.2013
10.1073/pnas.0602841103
10.1152/ajpheart.01011.2005
10.1080/10253890.2017.1369523
10.1126/scisignal.2005052
10.1161/01.str.30.10.2186
10.1161/HYPERTENSIONAHA.115.05303
10.1074/jbc.M117.811075
10.1074/jbc.M109.028803
10.1161/STROKEAHA.108.535435
10.1152/ajpheart.00752.2005
10.1093/cvr/cvz314
10.1007/s11596-020-2171-7
10.1152/physrev.00038.2017
10.1155/2014/689360
10.1016/j.vph.2015.06.013
10.1152/ajpheart.00165.2007
10.1161/01.cir.86.6.1909
10.1016/j.pharmthera.2019.06.009
10.1212/01.WNL.0000158283.28251.3C
10.1002/ana.23554
10.1097/hjh.0b013e328335c34f
10.1042/CS20160727
10.1161/CIRCULATIONAHA.117.027448
10.1152/ajpheart.00722.2019
10.1152/ajpheart.00582.2019
10.1124/jpet.104.069856
10.1161/01.hyp.3.6.718
10.1124/mol.61.4.768
10.1074/jbc.RA120.014325
10.1037//0735-7044.109.5.859
10.1016/j.bbr.2006.03.033
10.1186/s12993-021-00184-y
10.1007/s10071-007-0096-1
10.1161/01.str.29.1.159
10.1038/jcbfm.1991.61
10.1016/s0304-3940(02)01179-5
10.1152/ajpheart.01137.2007
10.1016/j.neuron.2017.07.030
10.1161/hy09t1.096249
10.1007/s11906-014-0431-2
10.1128/MCB.25.8.2957-2968.2005
10.1210/er.2016-1007
10.1016/j.celrep.2018.05.048
10.1016/j.yhbeh.2008.10.016
10.1186/1742-2094-9-157
10.1111/micc.12193
10.1161/01.ATV.0000205849.22807.6e
10.1161/01.RES.0000148637.85595.c5
10.1161/CIRCULATIONAHA.119.043385
10.1038/hr.2015.65
10.1113/expphysiol.2005.030080
10.1177/1535370215576312
10.3389/fphys.2012.00484
10.1038/hr.2015.55
10.1038/sj.bjp.0705484
10.1152/ajprenal.00288.2014
10.1161/HYPERTENSIONAHA.108.114058
10.1016/j.cardiores.2004.01.020
10.1161/01.hyp.37.2.703
10.1161/HYPERTENSIONAHA.111.00627
10.1161/01.HYP.0000251865.35728.2f
10.1095/biolreprod.114.118968
10.1152/ajpheart.01054.2001
10.1093/biolre/ioy179
10.1152/ajpregu.1997.273.6.R1908
10.1177/1535370217718808
10.1007/s10286-020-00720-2
10.1152/ajpheart.00897.2014",<Element 'PubmedArticle' at 0x7f05dd15b900>
42,36878045,Thymosin beta 4 prevents systemic lipopolysaccharide-induced plaque load in middle-age APP/PS1 mice.,"Lipopolysaccharide (LPS) produced by the gut during systemic infections and inflammation is thought to contribute to Alzheimer's disease (AD) progression. Since thymosin beta 4 (Tβ4) effectively reduces LPS-induced inflammation in sepsis, we tested its potential to alleviate the impact of LPS in the brain of the APPswePS1dE9 mouse model of AD (APP/PS1) and wildtype (WT) mice. 12.5-month-old male APP/PS1 mice (n = 30) and their WT littermates (n = 29) were tested for baseline food burrowing performance, spatial working memory and exploratory drive in the spontaneous alternation and open-field tests, prior to being challenged with LPS (100ug/kg, i.v.) or its vehicle phosphate buffered saline (PBS). Tβ4 (5 mg/kg, i.v.) or PBS, was administered immediately following and at 2 and 4 h after the PBS or LPS challenge, and then once daily for 6 days (n = 7-8). LPS-induced sickness was assessed though monitoring of changes in body weight and behaviour over a 7-day period. Brains were collected for the determination of amyloid plaque load and reactive gliosis in the hippocampus and cortex. Treatment with Tβ4 alleviated sickness symptoms to a greater extent in APP/PS1 than in WT mice by limiting LPS-induced weight loss and inhibition of food burrowing behaviour. It prevented LPS-induced amyloid burden in APP/PS1 mice but increased astrocytic and microglial proliferation in the hippocampus of LPS-treated WT mice. These data show that Tβ4 can alleviate the adverse effects of systemic LPS in the brain by preventing exacerbation of amyloid deposition in AD mice and by inducing reactive microgliosis in aging WT mice.","['Alzheimer’s disease', 'Amyloid load', 'Gliosis', 'LPS-induced sickness', 'Lipopolysaccharide', 'Thymosin beta 4']",International immunopharmacology,2023-03-07,"[{'lastname': 'Othman', 'firstname': 'Othman', 'initials': 'O', 'affiliation': 'School of Life Sciences, Division of Physiology, Pharmacology & Neuroscience, University of Nottingham Medical School, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom.'}, {'lastname': 'Marshall', 'firstname': 'Hayley', 'initials': 'H', 'affiliation': 'School of Life Sciences, Division of Physiology, Pharmacology & Neuroscience, University of Nottingham Medical School, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom.'}, {'lastname': 'Masterson', 'firstname': 'Mitchell', 'initials': 'M', 'affiliation': 'School of Life Sciences, Division of Physiology, Pharmacology & Neuroscience, University of Nottingham Medical School, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom.'}, {'lastname': 'Winlow', 'firstname': 'Poppy', 'initials': 'P', 'affiliation': 'School of Life Sciences, Division of Physiology, Pharmacology & Neuroscience, University of Nottingham Medical School, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom.'}, {'lastname': 'Gibson', 'firstname': 'Graham', 'initials': 'G', 'affiliation': 'Nottingham University Hospitals NHS Trust, Department of Histopathology, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom.'}, {'lastname': 'Ding', 'firstname': 'Yuchun', 'initials': 'Y', 'affiliation': 'School of Computer Sciences, University of Nottingham, Jubilee Campus, Wollaton Road, Nottingham NG8 1BB, United Kingdom.'}, {'lastname': 'Pardon', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': 'School of Life Sciences, Division of Physiology, Pharmacology & Neuroscience, University of Nottingham Medical School, Queens Medical Centre, Nottingham NG7 2UH, United Kingdom. Electronic address: marie.pardon@nottingham.ac.uk.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.intimp.2023.109951,<Element 'PubmedArticle' at 0x7f05deaa8ef0>
43,"36835187
3088567
4065091
21045163
30820070
31072403
25173806
7920638
33148290
8346443
35232622
22372522
24622366
24117198
23794448
24440525
28696548
27354094
36596993
28059785
24614496
24520345
31947546
31206565
32131431
1833120
24589570
25188736
27476881
36008818
30700991
25737044
36077227
21772670
24618582
24163429
36348357
31287614
15820240
25700985
1759558",Plasma IAPP-Autoantibody Levels in Alzheimer's Disease Patients Are Affected by ,"Pancreas-derived islet amyloid polypeptide (IAPP) crosses the blood-brain barrier and co-deposits with amyloid beta (Aβ) in brains of type 2 diabetes (T2D) and Alzheimer's disease (AD) patients. Depositions might be related to the circulating IAPP levels, but it warrants further investigation. Autoantibodies recognizing toxic IAPP oligomers (IAPP","['AD', 'APOE4', 'IgA', 'IgG', 'IgM', 'T2D', 'amylin', 'amyloid beta', 'autoantibodies', 'cognition']",International journal of molecular sciences,2023-02-26,"[{'lastname': 'Pocevičiūtė', 'firstname': 'Dovilė', 'initials': 'D', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden.'}, {'lastname': 'Roth', 'firstname': 'Bodil', 'initials': 'B', 'affiliation': 'Department of Internal Medicine, Lund University, Skåne University Hospital, 214 28 Malmö, Sweden.'}, {'lastname': 'Schultz', 'firstname': 'Nina', 'initials': 'N', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, 223 62 Lund, Sweden.'}, {'lastname': 'Nuñez-Diaz', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden.'}, {'lastname': 'Janelidze', 'firstname': 'Shorena', 'initials': 'S', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, 223 62 Lund, Sweden.'}, {'lastname': 'The Netherlands Brain Bank', 'firstname': None, 'initials': None, 'affiliation': 'Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands.'}, {'lastname': 'Olofsson', 'firstname': 'Anders', 'initials': 'A', 'affiliation': 'Department of Medical Biochemistry and Biophysics, Umeå University, 901 87 Umeå, Sweden.'}, {'lastname': 'Hansson', 'firstname': 'Oskar', 'initials': 'O', 'affiliation': 'Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, 223 62 Lund, Sweden.\nMemory Clinic, Skåne University Hospital, 212 24 Malmö, Sweden.'}, {'lastname': 'Wennström', 'firstname': 'Malin', 'initials': 'M', 'affiliation': 'Cognitive Disorder Research Unit, Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden.'}]",,,,,"10.3390/ijms24043776
10.1073/pnas.83.13.4913
10.1002/j.1460-2075.1985.tb04000.x
10.1177/0891988710383571
10.1186/s12929-019-0524-y
10.1016/j.nbd.2014.08.025
10.1038/ng0694-180
10.1186/s13024-020-00413-4
10.1126/science.8346443
10.1016/j.smim.2022.101594
10.1111/j.1445-5994.2012.02758.x
10.1016/S2213-8587(13)70048-2
10.1586/14789450.2013.841549
10.1002/ana.23956
10.1016/j.bbadis.2014.01.002
10.1002/ana.24992
10.1177/0271678X16657093
10.1038/s42003-022-04398-2
10.3233/JAD-160800
10.1038/mp.2014.17
10.1371/journal.pone.0088063
10.3390/biom10010134
10.1371/journal.pone.0218561
10.3390/vaccines8010116
10.1111/j.1464-5491.1991.tb01675.x
10.1038/srep04267
10.1089/dna.2014.2639
10.7555/jbr.30.20150131
10.1186/s13195-022-01062-z
10.1186/s12979-018-0142-7
10.3233/JAD-142184
10.3390/ijms23179829
10.1155/2011/949072
10.1371/journal.pone.0090857
10.1136/jnnp-2013-306485
10.1186/s13024-022-00574-4
10.1111/febs.14988
10.1016/j.biopsych.2004.12.008
10.1016/j.ajpath.2014.11.016
10.1007/BF00308809",<Element 'PubmedArticle' at 0x7f05dea96270>
44,"36820164
17634462
28516265
28516265
8092101
23220549
19307517
25038903
30150419
29657326
22544696
21133662
28062563
19545951
6977846
29346788
22796576
24529992
27176073
24729696
29080638
22503810
15589699
29067566
29435763
21870057
9790574
8089147
30627846
12609940
9278463
15040824
15113819
23857223
19948723
15985530
19748465
10679076
10812248
17641030
29018141
17293106
17295352
2542952
9452309
26049634
9482214
10428085
27377727
28360616
31524100
11893522
25267625
6288172
9011759
16521124
34070202
11297596
17846391
26827961
34183042
25813397
27578035
30112972
19585947
29974395
21371747
26529297
22229116
28168427
31722673
29447107
29318446
24849345
29257109
35822270
27031473
19433889
34953963
22306846
31982424
21408608
16780945
11150325
25998734
24934545
33159979
21982773
16777406
34680401
23626767
12759183
32576618
10349507
28400134
34734656
23254192
30672512
30672512
32536905
27090608
28594127
27987058
33198348
34393753
19998477
27450565
20884326
30246874
28931491
29209434
26250739
21478203
28619429
17179460
31686407
29736427
28196884
32226379
26402698
32188044
30626090
25773147
31302671
12660385
21369414
26170481
20091409
19661625
20850134
2396937
19539236
26036976
30103977
35025861
10699453
19940273
28984598
34324883
32857616
28825325
28509078
31084577
25815722
33572397
34421513
30065237
22638071
28611659
31296588
21694461
29357799
28552878
33164936
23176129
34853363
9886454
31278117
30256811
23485413
9251086
23202962
21542721
22354743
23767916
23665342
28566173
27597724
22362918
31454777
29243005
31594857
28374837
25344375
32679784
34761480
31538442
30358476
22232355
17145139",Vitamin D and neurodegenerative diseases.,"Neurodegenerative diseases, featured by progressive loss of structure or function of neurons, are considered incurable at present. Movement disorders like tremor and postural instability, cognitive or behavioral disorders such as memory impairment are the most common symptoms of them and the growing patient population of neurodegenerative diseases poses a serious threat to public health and a burden on economic development. Hence, it is vital to prevent the occurrence of the diseases and delay their progress. Vitamin D can be transformed into a hormone ","['AD, Alzheimer’s disease', 'Alzheimer’s disease', 'MS, multiple sclerosis', 'Multiple sclerosis', 'Neurodegenerative disease', 'PD, Parkinson’s disease', 'Parkinson’s disease', 'SVD, small vessel disease', 'VDBP, vitamin D binding protein', 'VDR, vitamin D receptors', 'VaD, vascular dementia', 'Vitamin D']",Heliyon,2023-02-24,"[{'lastname': 'Wang', 'firstname': 'Weixia', 'initials': 'W', 'affiliation': 'Department of Neurobiology, School of Basic Medical Sciences of Tongji Medical College of Huazhong University of Science and Technology, 430030, Wuhan, China.'}, {'lastname': 'Li', 'firstname': 'Yijin', 'initials': 'Y', 'affiliation': 'Department of Neurobiology, School of Basic Medical Sciences of Tongji Medical College of Huazhong University of Science and Technology, 430030, Wuhan, China.'}, {'lastname': 'Meng', 'firstname': 'Xianfang', 'initials': 'X', 'affiliation': 'Department of Neurobiology, School of Basic Medical Sciences of Tongji Medical College of Huazhong University of Science and Technology, 430030, Wuhan, China.'}]",,,,© 2023 Published by Elsevier Ltd.,"10.1016/j.heliyon.2023.e12877
10.3390/biomedicines9020172",<Element 'PubmedArticle' at 0x7f05df58f3b0>
45,"36820052
32157811
10369305
27570871
22784036
23007870
8748926
25659881
17538054
32892066
25602865
27124099
32056347
18789389
23983028
21756430
19822172
21129851
24011541
35079029
32758482
30291317
32738937
19414615
31073376
8379800
31503006
29907423
27130306
31526019
31249398
14690807
30881301
11515736
9343003
21514248
15324367
0
31430566","Longitudinal study of Alzheimer's disease biomarkers, allostatic load, and cognition among memory clinic patients.","Allostatic load (AL) is defined as the cumulative dysregulation of neuroendocrine, immunological, metabolic, and cardiovascular systems that increases the susceptibility to stress-related health problems. Several dementia and Alzheimer's disease (AD) risk factors have been identified, yet little is known about the role of AL and its associations with AD biomarkers (e.g., beta-amyloid (Aβ) or tau) and cognitive function among memory clinic patients. Hence, this study aims to assess the association between AL and AD biomarkers, cognitive performance, and cognitive decline after 3-years of follow-up.
Data from 188 memory clinic patients were derived from the Cortisol and Stress in AD (Co-STAR) study in Sweden. Participants underwent baseline assessments including blood tests for AL measures (including cortisol, thyroid stimulating hormone, cobalamin, homocysteine, leukocytes, glycated hemoglobin, albumin, high-density and low-density lipoprotein cholesterol, triglycerides, and creatinine), cerebrospinal fluid (CSF) sampling for AD biomarkers and neuropsychological tests including five cognitive domains. Linear regressions were conducted, adjusting for age, sex, and education.
Higher AL was associated with lower CSF Aβ1-42 levels (
This study showed that higher AL was associated with increased brain amyloid accumulation. This suggests that AL may play a role in AD/dementia pathophysiology. Potential sex-related differences should be assessed in further larger studies.","['AD biomarkers', 'Allostatic load', 'Chronic stress', 'Cognition', 'Memory clinic']","Brain, behavior, & immunity - health",2023-02-24,"[{'lastname': 'Adedeji', 'firstname': 'Dickson O', 'initials': 'DO', 'affiliation': 'Psychiatric Clinic, Vrinnevi Hospital, Norrköping, Sweden.\nDivision of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Holleman', 'firstname': 'Jasper', 'initials': 'J', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Juster', 'firstname': 'Robert-Paul', 'initials': 'RP', 'affiliation': 'Department of Psychiatry and Addiction, University of Montreal, Canada.'}, {'lastname': 'Udeh-Momoh', 'firstname': 'Chinedu T', 'initials': 'CT', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nAgeing Epidemiology Research Unit (AGE), School of Public Health, Faculty of Medicine, Imperial College London, UK.'}, {'lastname': 'Kåreholt', 'firstname': 'Ingemar', 'initials': 'I', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nInstitute of Gerontology, School of Health and Welfare, Aging Research Network - Jönköping (ARN-J), Jönköping University, Jönköping, Sweden.\nAging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.'}, {'lastname': 'Hagman', 'firstname': 'Göran', 'initials': 'G', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nTheme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Aspö', 'firstname': 'Malin', 'initials': 'M', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nTheme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Adagunodo', 'firstname': 'Sofia', 'initials': 'S', 'affiliation': 'Memory Clinic Zentralschweiz, Luzerner Psychiatrie, Lucerne, Switzerland.'}, {'lastname': 'Håkansson', 'firstname': 'Krister', 'initials': 'K', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Kivipelto', 'firstname': 'Miia', 'initials': 'M', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nAgeing Epidemiology Research Unit (AGE), School of Public Health, Faculty of Medicine, Imperial College London, UK.\nTheme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.\nInstitute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Solomon', 'firstname': 'Alina', 'initials': 'A', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nAgeing Epidemiology Research Unit (AGE), School of Public Health, Faculty of Medicine, Imperial College London, UK.\nTheme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.\nInstitute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Sindi', 'firstname': 'Shireen', 'initials': 'S', 'affiliation': 'Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.\nAgeing Epidemiology Research Unit (AGE), School of Public Health, Faculty of Medicine, Imperial College London, UK.'}]",,This study showed that higher AL was associated with increased brain amyloid accumulation. This suggests that AL may play a role in AD/dementia pathophysiology. Potential sex-related differences should be assessed in further larger studies.,Higher AL was associated with lower CSF Aβ1-42 levels (,© 2023 Published by Elsevier Inc.,"10.1016/j.bbih.2023.100592
10.1002/alz.12068
10.1001/archneur.56.6.673
10.1056/NEJMoa1202753
10.1177/1099800412455688
10.1007/bf02815140
10.1016/j.neurobiolaging.2014.12.020
10.2105/ajph.2006.091892
10.1016/j.psyneuen.2020.104849
10.2105/ajph.2014.302285
10.1037/pas0000319
10.1111/ene.14174
10.1016/j.neuroimage.2008.07.053
10.1093/brain/awt206
10.1177/0829573513493982
10.17340/jkna.2019.1.1
10.1017/s0954579411000289
10.1016/j.neubiorev.2009.10.002
10.1016/j.psyneuen.2010.11.001
10.1016/j.neurobiolaging.2013.07.028
10.1038/s41598-022-05165-3
10.1016/j.yfrne.2020.100858
10.1038/s41582-018-0070-3
10.1016/S0140-6736(20)30367-6
10.1097/PSY.0b013e3181a4fea8
10.1590/1980-57642018dn13-010002
10.1001/archinte.1993.00410180039004
10.18632/aging.102243
10.1016/j.jalz.2018.04.008
10.1016/j.nrl.2016.02.016
10.1177/0022146519867924
10.1038/s41574-019-0228-0
10.1207/s15324826an1004_8
10.3389/fnagi.2019.00043
10.1037/0278-6133.20.4.243
10.1016/j.jalz.2011.03.003
10.1111/j.1365-2796.2004.01380.x
10.1016/j.arr.2019.100944",<Element 'PubmedArticle' at 0x7f05df7eebd0>
46,"36759538
4347575
4682131
8622767
23230430
7905265
23872332
18243519
11227737
15104567
9221784
11011067
29192843
19595735
18359553
6108540
6107862
20164562
16271420
2569349
32232904
32469963
2858057
2858056
17987251
19733630
15778722
10655101
20937084
19073193
22509294
28650319
32915532
17911027
19541956
24782311
24728269
11430867
11846609
18206294
28832675
31494281
17761762
33711010
15530403
11375493
19559700
15190254
33391505
25613900
27901064
25830706
34737456",Somatostatin slows Aβ plaque deposition in aged APP,The neuroendocrine peptide somatostatin (SST) has long been thought of as influencing the deposition of the amyloid β peptide (Aβ) in Alzheimer's disease (AD). Missing have been in vivo data in a relevant Aβ amyloidosis model. Here we crossed App,[],Scientific reports,2023-02-10,"[{'lastname': 'Williams', 'firstname': 'Declan', 'initials': 'D', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Yan', 'firstname': 'Bei Qi', 'initials': 'BQ', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.\nDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Wang', 'firstname': 'Hansen', 'initials': 'H', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Negm', 'firstname': 'Logine', 'initials': 'L', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Sackmann', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Verkuyl', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.\nDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Rezai-Stevens', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Eid', 'firstname': 'Shehab', 'initials': 'S', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.\nDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Vediya', 'firstname': 'Nimit', 'initials': 'N', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Sato', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Watts', 'firstname': 'Joel C', 'initials': 'JC', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.\nDepartment of Biochemistry, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Wille', 'firstname': 'Holger', 'initials': 'H', 'affiliation': 'Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, AB, Canada.\nDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada.'}, {'lastname': 'Schmitt-Ulms', 'firstname': 'Gerold', 'initials': 'G', 'affiliation': 'Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada. g.schmittulms@utoronto.ca.\nDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. g.schmittulms@utoronto.ca.\nTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Rm 6KD447, 60 Leonard Ave, Toronto, ON, M5T 0S8, Canada. g.schmittulms@utoronto.ca.'}]",,,,© 2023. The Author(s).,10.1038/s41598-023-29559-z,<Element 'PubmedArticle' at 0x7f05df5d3ef0>
47,36759181,Baseline Computerized Neurocognitive Testing and Oculomotor Measures are not Altered by Hormonal Contraceptive Use.,"Neurocognitive testing and oculomotor assessment have been an integral component to provide objective measures for sport-related concussion (SRC) detection and management. Hormonal contraceptive (HC) use is common among collegiate female athletes and may modify baseline SRC performance. The purpose was to examine the effects of HC use on baseline computerized neurocognitive testing (CNT) and oculomotor testing in college-aged individuals.
A total of 63 participants (22 HC using females, 22 non-HC using females, 19 males) completed a baseline SRC battery consisting of CNT, near point of convergence (NPC), and the King-Devick (KD) test. CNT measures were composite scores of verbal and visual memory, visual motor processing speed and reaction time, impulse control, and cognitive efficiency index (CEI). NPC was measured as the average convergence distance across three trials. KD time was recorded as total time for each of the two trials and best trial marked as baseline.
There were no group differences between HC, non-HC, and male control groups on all baseline CNT composite scores (p = .13-.98), impulse control (p = .47), and CEI (p = .49). NPC distance was similar between groups (p = .41), as well as KD time by trial (Trial 1 p = .65; 2 p = .48) and best time (p = .49).
HC use does not appear to influence baseline SRC measures of neurocognition and oculomotor assessment. Clinicians should continue to consider the effects of modifying factors at baseline and post-concussion. Additional research is needed to better understand sex hormone levels and SRC performance measures.","['Athletes', 'Birth control', 'Cognition', 'Concussion', 'Hormones', 'Vision']",Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists,2023-02-10,"[{'lastname': 'Moran', 'firstname': 'Ryan N', 'initials': 'RN', 'affiliation': 'Department of Health Science, Athletic Training Research Laboratory, The University of Alabama, Tuscaloosa, AL, USA.'}, {'lastname': 'Guin', 'firstname': 'J Russell', 'initials': 'JR', 'affiliation': 'Department of Health Science, Athletic Training Research Laboratory, The University of Alabama, Tuscaloosa, AL, USA.'}, {'lastname': 'Gardner', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Department of Physical Medicine and Rehabilitation, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'lastname': 'Simer', 'firstname': 'Josh', 'initials': 'J', 'affiliation': 'Department of Health Science, Athletic Training Research Laboratory, The University of Alabama, Tuscaloosa, AL, USA.'}]","A total of 63 participants (22 HC using females, 22 non-HC using females, 19 males) completed a baseline SRC battery consisting of CNT, near point of convergence (NPC), and the King-Devick (KD) test. CNT measures were composite scores of verbal and visual memory, visual motor processing speed and reaction time, impulse control, and cognitive efficiency index (CEI). NPC was measured as the average convergence distance across three trials. KD time was recorded as total time for each of the two trials and best trial marked as baseline.",,"There were no group differences between HC, non-HC, and male control groups on all baseline CNT composite scores (p = .13-.98), impulse control (p = .47), and CEI (p = .49). NPC distance was similar between groups (p = .41), as well as KD time by trial (Trial 1 p = .65; 2 p = .48) and best time (p = .49).","© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",10.1093/arclin/acad015,<Element 'PubmedArticle' at 0x7f05df5cb680>
48,36736846,The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury.,"Spinal cord injury (SCI) occurs when the spinal cord is damaged from either a traumatic event or disease. SCI is characterised by multiple injury phases that affect the transmission of sensory and motor signals and lead to temporary or long-term functional deficits. There are few treatments for SCI. Estrogens and estrogenic compounds, however, may effectively mitigate the effects of SCI and therefore represent viable treatment options. This review systematically examines the pre-clinical literature on estrogen and estrogenic compound neuroprotection after SCI. Several estrogens were examined by the included studies: estrogen, estradiol benzoate, Premarin, isopsoralen, genistein, and selective estrogen receptor modulators. Across these pharmacotherapies, we find significant evidence that estrogens indeed offer protection against myriad pathophysiological effects of SCI and lead to improvements in functional outcomes, including locomotion. A STRING functional network analysis of proteins modulated by estrogen after SCI demonstrated that estrogen simultaneously upregulates known neuroprotective pathways, such as HIF-1, and downregulates pro-inflammatory pathways, including IL-17. These findings highlight the strong therapeutic potential of estrogen and estrogenic compounds after SCI.","['Estrogen', 'Estrogenic compounds', 'Neuroprotection', 'Spinal cord injury']",Neuroscience and biobehavioral reviews,2023-02-04,"[{'lastname': 'Shvetcov', 'firstname': 'Artur', 'initials': 'A', 'affiliation': 'Black Dog Institute, Sydney, Australia; School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia.'}, {'lastname': 'Ruitenberg', 'firstname': 'Marc J', 'initials': 'MJ', 'affiliation': 'School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Australia.'}, {'lastname': 'Delerue', 'firstname': 'Fabien', 'initials': 'F', 'affiliation': 'Dementia Research Centre, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.'}, {'lastname': 'Gold', 'firstname': 'Wendy A', 'initials': 'WA', 'affiliation': ""School of Medical Sciences, Faculty of Medicine Health, The University of Sydney, Sydney, Australia; Molecular Neurobiology Research Laboratory, Kids Research, Children's Hospital at Westmead and the Children's Medical Research Institute, Westmead, Australia; Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, Australia.""}, {'lastname': 'Brown', 'firstname': 'David A', 'initials': 'DA', 'affiliation': 'Neuroinflammation Research Group, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia; Department of Immunopathology, Institute for Clinical Pathology and Medical Research-New South Wales Health Pathology, Westmead Hospital, Sydney, Australia; Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'lastname': 'Finney', 'firstname': 'Caitlin A', 'initials': 'CA', 'affiliation': 'School of Medical Sciences, Faculty of Medicine Health, The University of Sydney, Sydney, Australia; Neuroinflammation Research Group, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia. Electronic address: caitlin.finney@wimr.org.au.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.neubiorev.2023.105074,<Element 'PubmedArticle' at 0x7f05df5be2c0>
49,"36716780
27733283
29256397
23895362
19427328
17192562
22701110
24477111
17640948
34255042
11085689
17895444
32614391
11971659
10680789
17090633
36366914
31408149
24113028
28329340
3611032
18313558
31408149
26918290
10726605
14590600
14588937
16029111
29111960
25475395
22607736
24277815
34790110
19702939
20060437
28883857
27346998
23996907
14641001
9724073
33139661
15687322
32699184
19022535
28898980
34969617
29111960","Sex hormones, SHBG and cognitive performance among older Australian women: an observational study.","This study aims to explore the associations between sex hormones and cognitive performance in older women.
Associations between sex hormones, sex hormone binding globulin (SHBG) and cognitive performance were examined in women aged at least 70 years, without dementia and not using medications that influence sex hormones. Linear and generalized linear regression models included age, body mass index, education, smoking, alcohol, living circumstances, diabetes, hypertension, depression and impaired renal function.
The included 5511 women had a median (interquartile range) age of 73.9 (71.6-77.6) years. No associations were found for estrone, estradiol, testosterone or dehydroepiandrosterone and cognitive performance. SHBG concentrations above quartile 1 (Q1) were significantly inversely associated with processing speed (Q2, 
Sex hormones were not associated with cognitive performance. The finding that low SHBG is associated with better processing speed warrants further investigation. The null findings for the sex hormones establish a firm baseline to confidently explore the association between sex hormones and longitudinal cognitive performance in this population.
International Standard Randomized Controlled Trial Number Register (ISRCTN83772183) and ClinicalTrials.gov (NCT01038583).","['Postmenopause', 'cognitive function', 'cognitive performance', 'dementia', 'estrogen', 'sex hormone binding globulin']",Climacteric : the journal of the International Menopause Society,2023-01-31,"[{'lastname': 'Sultana', 'firstname': 'F', 'initials': 'F', 'affiliation': ""Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.\nEnvironmental Interventions Unit, Infectious Diseases Division, Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka, Bangladesh.""}, {'lastname': 'Davis', 'firstname': 'S R', 'initials': 'SR', 'affiliation': ""Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.\nDepartment of Endocrinology and Diabetes, Alfred Health, Melbourne, Vic 3004, Australia.""}, {'lastname': 'Murray', 'firstname': 'A M', 'initials': 'AM', 'affiliation': 'Berman Center for Outcomes and Clinical Research, Hennepin-Health Research Institute and Division of Geriatrics, Department of Medicine, Hennepin Healthcare, Minneapolis, MN, USA.'}, {'lastname': 'Woods', 'firstname': 'R L', 'initials': 'RL', 'affiliation': 'Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'lastname': 'McNeil', 'firstname': 'J J', 'initials': 'JJ', 'affiliation': 'Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}, {'lastname': 'Islam', 'firstname': 'R M', 'initials': 'RM', 'affiliation': ""Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.""}]",,,"The included 5511 women had a median (interquartile range) age of 73.9 (71.6-77.6) years. No associations were found for estrone, estradiol, testosterone or dehydroepiandrosterone and cognitive performance. SHBG concentrations above quartile 1 (Q1) were significantly inversely associated with processing speed (Q2, ",,"10.1080/13697137.2023.2166824
10.1016/s0140-6736(17)33304-4",<Element 'PubmedArticle' at 0x7f05df5b2f40>
50,"36697895
19211488
21775213
10573435
26045020
29784147
35080734
23666019
8295288
24924665
10867777
27153869
23962667
26505985
15737222
9743505
9187066
26270318
25069991
27028912
26682695
23042370
27951525
24898655
11113299
11731710
12826744
34443985
34969617
28912076
16216938
29643079
9921852
11255426
18254016
7978718
32738937
17478968
8629615
23460719
28592453
6610841
15947175
26874358
31453973
22064958
25030513
12145368
33399323
19585947
24367955
15583070
12413378
23262943
7905101
23419980
33506261
15213206
29039993
4047106
1870648
23079557
31732015
30222945
28800328
27523477
28617071
21873835",Sex Differences in Dementia.,"BackgroundWomen in many cohorts have a higher risk for Alzheimer's disease (AD), the most common form of dementia. Sex is a biological construct whereby differences in disease manifestation and prevalence are rooted in genetic differences between XX and XY combinations of chromosomes. This chapter focuses specifically on sex-driven differences in dementia, as opposed to differences driven by gender - a social construct referring to the societal norms that influence people's roles, relationships, and positional power throughout their lifetime.MethodsUsing a narrative review, this chapter explored the characteristics and risk factors for the dementias, alongside a discussion of sex differences including loss of sex steroid hormones in middle-aged women, differences in the prevalence of cardiovascular diseases and engagement in lifestyle protective factors for dementia.ResultsThe sex difference in AD prevalence may exist because of systematic and historic differences in risk and protective factors for dementia, including level of education obtained and socioeconomic status differences, which can impact on health and dementia risk.Levels of sex steroids decline significantly after menopause in women, whereas this is more gradual in men with age. Animal and cell culture studies show strong biological plausibility for sex steroids to protect the ageing brain against dementia. Sex steroid hormone replacement therapy has in some observational studies shown to protect against AD, but treatment studies in humans have mainly shown disappointing results. Cardiovascular disease (CVD) shares midlife medical risk (e.g. hypertension, hyperlipidaemia, obesity etc.) factors with AD and other forms of dementia, but also with related lifestyle risk - and protective factors (e.g. exercise, not smoking etc.). Men tend to die earlier of CVD, so fewer survive to develop AD at an older age. Those who do survive may have healthier lifestyles and fewer risk factors for both CVD and AD. An earlier age at menopause also confers great risk for both without hormone treatment.DiscussionIt could be the case that the decline in sex steroids around the menopause make women more susceptible to lifestyle-related risk factors associated with dementia and CVD, but this remains to be further investigated. Combining hormone treatment with lifestyle changes in midlife (e.g. exercise) could be an important preventative treatment for dementia and CVD in later life, but this also requires further research.","['Age', 'Cardiovascular', 'Dementia', 'Risk/protective factors', 'Sex', 'Sex steroids']",Current topics in behavioral neurosciences,2023-01-26,"[{'lastname': 'Hogervorst', 'firstname': 'Eef', 'initials': 'E', 'affiliation': 'National Centre for Sports and Exercise Medicine (NCSEM), School of Sports Exercise and Health Sciences (SSEHS), Loughborough University, Loughborough, UK. e.hogervorst@lboro.ac.uk.'}, {'lastname': 'Temple', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'National Centre for Sports and Exercise Medicine (NCSEM), School of Sports Exercise and Health Sciences (SSEHS), Loughborough University, Loughborough, UK.'}, {'lastname': ""O'Donnell"", 'firstname': 'Emma', 'initials': 'E', 'affiliation': 'National Centre for Sports and Exercise Medicine (NCSEM), School of Sports Exercise and Health Sciences (SSEHS), Loughborough University, Loughborough, UK.'}]",,,,"© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.","10.1007/7854_2022_408
10.1161/STROKEAHA.108.540781
10.1016/S1474-4422(11)70072-2
10.1111/j.1532-5415.1999.tb07427.x
10.1093/geront/gnw031
10.1016/j.jalz.2015.05.016
10.1016/S0140-6736(18)30843-2
10.1007/s12975-021-00983-5
10.1196/annals.1347.005
10.1136/bjsports-2012-091974
10.1001/jama.1994.03510280051032
10.1016/j.jalz.2014.04.009
10.1001/archneur.57.6.808
10.1016/j.cobeha.2015.01.005
10.1136/bjsports-2015-095551
10.1017/S1041610213001385
10.1159/000441106
10.1111/j.1365-2648.2004.03331.x
10.1161/01.CIR.98.12.1158
10.1056/nejm199706193362501
10.1016/j.tcm.2015.01.008
10.7326/M14-0353
10.1056/nejmoa1505241
10.3233/JAD-150817
10.4172/2161-0460.1000e117
10.1177/1754045312473873
10.3233/JAD-140909
10.4172/2161-0460.1000e128
10.1016/S0306-4522(00)00410-3
10.1159/000048628
10.1159/000071006
10.2217/ahe.12.56
10.4324/9781351122719-4
10.3390/ijerph18168235
10.1016/j.bpobgyn.2021.10.009
10.1016/j.arr.2017.09.003
10.4062/biomolther.2018.159
10.1001/archneur.62.10.1556
10.1212/WNL.0000000000005486
10.1136/bmj.k1675
10.1212/wnl.52.1.78
10.1001/jama.285.11.1489
10.1002/14651858.CD003122.pub2
10.7326/0003-4819-121-12-199412150-00005
10.1016/S0140-6736(20)30367-6
10.1159/000102141
10.1093/oxfordjournals.aje.a008678
10.1210/er.2012-1055
10.1080/13607863.2017.1423031
10.1212/WNL.0000000000004058
10.1212/WNL.34.7.939
10.1126/science.1112062
10.1093/humrep/dew014
10.1097/GME.0000000000001326
10.1161/CIRCULATIONAHA.110.968792
10.1016/S1474-4422(14)70136-X
10.1002/trc2.12202
10.1093/gerona/57.8.M532
10.1097/GME.0000000000001729
10.31887/dcns.2009.11.2/cqiu
10.5014/ajot.2014.009035
10.1161/01.HYP.0000151825.36598.36
10.1001/jama.288.17.2170
10.1001/jama.288.3.321
10.1097/AOG.0b013e31827a08c8
10.1016/S0140-6736(94)91117-7
10.1152/ajpregu.1999.276.2.r474
10.1089/jwh.2014.4746
10.1016/j.jamda.2013.01.014
10.1210/clinem/dgab042
10.1001/jama.291.24.2947
10.1080/13607863.2017.1390731
10.1056/nejm198510243131703
10.1056/NEJM199109123251102
10.1016/S1474-4422(12)70191-6
10.1016/j.neurobiolaging.2019.03.022
10.1016/j.jalz.2018.07.219
10.1093/humrep/dew027
10.3233/JAD-170014
10.1093/eurheartj/ehw334
10.1177/0271678X17714655
10.1136/bmj.n2182
10.1097/JGP.0b013e3181ff678a",<Element 'PubmedArticle' at 0x7f05dc808090>
51,36657564,Metformin Adherence Reduces the Risk of Dementia in Patients With Diabetes: A Population-based Cohort Study.,"Metformin is widely used as the first-line drug for type 2 diabetes mellitus and has numerous benefits apart from lowering blood glucose. However, metformin-retained regimen is challenged by newly launching, powerful glucose-lowering antiglycemic agents. This population-based cohort study examined the association between metformin adherence and the risk of dementia and Parkinson's disease (PD).
Diabetic patients with metformin-included combination antiglycemic therapy were identified from the National Health Insurance Research Database and categorized into metformin-adherent and -nonadherent groups according to the medical record of the first year prescription. Patients contraindicated with metformin, severe diabetic complications, and poor drug compliance were excluded. The study outcome was the diagnosis of dementia or PD.
A total of 31 384 matched pairs were included after using propensity score matching and both groups were followed up for an average of 5 years. Metformin adherence was associated with a significantly lower risk of dementia (adjusted hazard risk ratio = 0.72, P < .001) but not PD (adjusted hazard risk ratio = 0.97, P = .825). Subgroup analysis revealed that the risk of dementia was significantly reduced in metformin-adherent patients, both male and female, aged >65 or ≤ 65 years, and with or without concurrent insulin treatment. This effect was not influenced by concurrent insulin treatment, which may eliminate the bias caused by the severity of diabetes mellitus.
Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence.","['Parkinson’s disease', 'dementia', 'diabetes', 'metformin']",Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,2023-01-20,"[{'lastname': 'Chen', 'firstname': 'Po-Chih', 'initials': 'PC', 'affiliation': 'Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.'}, {'lastname': 'Hong', 'firstname': 'Chien-Tai', 'initials': 'CT', 'affiliation': 'Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.'}, {'lastname': 'Chen', 'firstname': 'Wan-Ting', 'initials': 'WT', 'affiliation': 'Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taipei City, Taiwan.'}, {'lastname': 'Chan', 'firstname': 'Lung', 'initials': 'L', 'affiliation': 'Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan. Electronic address: cjustinmd@tmu.edu.tw.'}, {'lastname': 'Chien', 'firstname': 'Li-Nien', 'initials': 'LN', 'affiliation': 'Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taipei City, Taiwan; Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan; School of Health Care Administration, College of Management, Taipei Medical University, Taipei City, Taiwan; Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: linien.chien@nycu.edu.tw.'}]",,"Despite the launching of numerous new oral antiglycemic agents, metformin may provide further benefit on lowering risk of dementia beyond conventional glycemic control according to the real-world evidence.","A total of 31 384 matched pairs were included after using propensity score matching and both groups were followed up for an average of 5 years. Metformin adherence was associated with a significantly lower risk of dementia (adjusted hazard risk ratio = 0.72, P < .001) but not PD (adjusted hazard risk ratio = 0.97, P = .825). Subgroup analysis revealed that the risk of dementia was significantly reduced in metformin-adherent patients, both male and female, aged >65 or ≤ 65 years, and with or without concurrent insulin treatment. This effect was not influenced by concurrent insulin treatment, which may eliminate the bias caused by the severity of diabetes mellitus.",Copyright © 2023. Published by Elsevier Inc.,10.1016/j.eprac.2023.01.007,<Element 'PubmedArticle' at 0x7f05dcc4e2c0>
52,36649137,[The role of steroid hormones in the neurodegenerative diseases].,"An increasing number of elders in a general population and longer life expectancy have a negative outcome in the growth of dissemination of neurodegenerative diseases (NDs). The NDs like Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) show sex-dependent prevalence. It is considered that sex steroids could influence on the NDs occurrence. Epidemiological studies indicate that women suffer more frequently from AD, whereas men from PD and ALS. Research suggest neuroprotective effects of estrogens and confirm that factors reducing their level may have a contribution to a higher morbidity rate to NDs. Adverse effects of androgens on NDs have been noticed, however some data suggest their beneficial actions. Therefore, the understanding of the potential role of sex steroids and their receptors in the pathogenesis and course of NDs would contribute to broadening the knowledge of molecular mechanisms leading to NDs. Moreover effective prevention and treatment could be assessed in the future.
Wraz ze wzrostem średniej długości życia i starzeniem się ludzkiej populacji, zwiększa się odsetek osób cierpiących na choroby neurodegeneracyjne (NDs). W przypadku choroby Alzheimera (AD), choroby Parkinsona (PD) i stwardnienia zanikowego bocznego (ALS), zaobserwowano wyraźną dysproporcję w zachorowalności w zależności od płci. Uważa się, że może to mieć związek z wpływem steroidów płciowych na ryzyko wystąpienia tych chorób. Dane epidemiologiczne pokazują, że na AD częściej cierpią kobiety, natomiast PD i ALS są bardziej rozpowszechnione u mężczyzn. Liczne badania wskazują na neuroprotekcyjne działanie estrogenów i potwierdzają, że czynniki redukujące ich poziom zwiększają ryzyko zachorowania na NDs. Odwrotne efekty zaobserwowano dla androgenów, chociaż dowiedziono także korzystnego wpływu tych hormonów. Zrozumienie potencjalnej roli steroidów płciowych i ich receptorów w patogenezie i przebiegu NDs może przyczynić się do lepszego poznania molekularnych mechanizmów leżących u podłoża tych schorzeń, a tym samym do opracowania skuteczniejszych sposobów prewencji i leczenia.",[],Postepy biochemii,2023-01-18,"[{'lastname': 'Sadowska', 'firstname': 'Aleksandra', 'initials': 'A', 'affiliation': 'Zakład Endokrynologii, Instytut Zoologii i Badań Biomedycznych, Wydział Biologii, Uniwersytet Jagielloński w Krakowie. aleksa.sadowska@student.uj.edu.pl.'}, {'lastname': 'Grzesiak', 'firstname': 'Małgorzata', 'initials': 'M', 'affiliation': 'Uniwersytet Jagielloński w Krakowie. m.e.grzesiak@uj.edu.pl.'}]",,,,,10.18388/pb.2021_468,<Element 'PubmedArticle' at 0x7f05dcc36770>
53,36626931,The Correlation between Diabetes Mellitus and Neurodegenerative Diseases.,"Today there is no longer any doubt that diabetes mellitus is associated with cognitive impairment and neurodegenerative diseases. The two most common forms of diabetes mellitus are type 1 and type 2. Type 1 diabetes mellitus is characterized by an absolute insulin deficiency that is associated with a large number of metabolic changes. This type of diabetes requires insulin therapy. Without insulin, this disease is fatal. The far more common form of diabetes mellitus nowadays is type 2 diabetes mellitus. It is characterized by insulin resistance. For a number of years drugs have been available that can be used to treat this form of diabetes in a multimodal manner. These therapy options can not only improve metabolic control, but also prevent cardiovascular events. Different cognitive alterations associated with diabetes mellitus can be distinguished. On the one hand, the change in glucose homeostasis itself leads to cognitive alterations, i.e. blood sugar levels that are too high or acutely too low are regularly associated with significant impairments in mental performance, including loss of consciousness. But not only the momentary blood sugar levels, but also long-term changes in glucose metabolism might lead to neurodegeneration and even dementia in a way that has not yet been fully understood. Insulin or insulin-like molecules have important effects in the central nervous system. In the last decades, it has been shown that insulin receptors themselves are expressed in many regions of the brain and e.g. regulate food intake and memory formation in humans and in animal models. In the animal model, disturbances in insulin signal transduction influence the development of pathologies typical of Alzheimer's disease (AD). In humans, central insulin resistance is at least part of the formal pathogenesis of AD. Vascular changes (macroangiopathy) in patients with diabetes mellitus often lead to cerebral insults, microangiopathies and vascular dementia.
Es besteht heute kein Zweifel mehr, dass der Diabetes mellitus mit kognitiven Leistungseinschränkungen und neurodegenerativen Erkrankungen assoziiert ist. Die beiden häufigsten Formen des Diabetes mellitus sind der Diabetes mellitus Typ 1 und 2. Der Diabetes mellitus Typ 1 ist gekennzeichnet durch einen absoluten Insulinmangel, der mit einer Vielzahl von Stoffwechselveränderungen assoziiert ist. Diese Diabetesform bedarf zwingend einer Insulintherapie. Ohne Insulin verläuft diese Erkrankung tödlich. Die heutzutage weit häufigere Form ist der Diabetes mellitus Typ 2. Dieser ist gekennzeichnet durch eine Insulinresistenz. Seit mittlerweile einigen Jahren stehen Medikamente zur Verfügung, mit der diese Form des Diabetes multimodal behandelbar ist. Diese Therapieoptionen können nicht nur die Stoffwechseleinstellung verbessern, sondern auch kardiovaskuläre Ereignisse verhindern. Es können verschiedene kognitive Einschränkungen, die mit dem Diabetes mellitus assoziiert sind, unterschieden werden. Zum einen führt die Veränderung der Glukosehomöostase an sich zu kognitiven Einschränkungen, d. h., zu hohe oder akut zu niedrige Blutzuckerspiegel gehen z. T. mit erheblichen Störungen der geistigen Leistungsfähigkeit bis hin zur Bewusstlosigkeit einher. Aber nicht nur die Blutzuckerspiegel, auch langfristige Veränderungen des Stoffwechsels führen letztendlich auf noch nicht ganz geklärte Weise zu Neurodegenerationen bis hin zur Demenz. Insulin oder insulinähnliche Moleküle haben eine bedeutende Wirkung im zentralen Nervensystem. In den letzten Jahrzehnten konnte gezeigt werden, dass Insulinrezeptoren selbst in vielen Regionen des Gehirns exprimiert werden und z. B. die Nahrungsaufnahme und Gedächtnisleistung im Menschen und im Tiermodell regulieren. Im Tiermodell beeinflussen Störungen der Insulinsignaltransduktion die Ausprägung von z. B. für den Morbus Alzheimer (AD) typischen Pathologien. Beim Menschen gehört eine zentrale Insulinresistenz zumindest zur formalen Pathogenese des AD. Gefäßveränderungen (Makroangiopathie) bei Patienten mit Diabetes mellitus führen nicht selten zu zerebralen Insulten, Mikroangiopathien und vaskulärer Demenz.",[],Klinische Monatsblatter fur Augenheilkunde,2023-01-11,"[{'lastname': 'Schubert', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Innere Medizin, St.\xa0Josefs-Hospital Rheingau GmbH, Rüdesheim am Rhein, Deutschland.'}]",,,,"Thieme. All rights reserved.
Thieme. All rights reserved.",10.1055/a-2009-9755,<Element 'PubmedArticle' at 0x7f05dcc35d10>
54,"36624497
33756057
30497964
34998485
22913619
27014598
29909178
33844047
23348042
27421538
33097048
12413371
12186605
10697060
12459399
12771112
15213206
34622524
32199103
24368217
9343467
8158809
11445633
20619505
28846757
31424388
23715379
29754747
27870425
32856754
26683239
30782589
27702619
24103232
9845158
32010920
23867976
25605659
25913063
33811742
25414002
35226898
33833259
17640473
29994606
19955375
26444348
11705634
18486492
24475827
21163916
27590747
27473135
19139364
22288394
35149372
35416608
33537928
33396472
11172057
32048144
34078163
20065135
23302659
17541023
36149767
17077159
23063453
22249475
27358067
31251078
19908146
27179961
17214869
19729392
23797469
27506836
21280086
34588168
26007613
22393359",Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort.,"The risk of dementia is higher in women than men. The metabolic consequences of estrogen decline during menopause accelerate neuropathology in women. The use of hormone replacement therapy (HRT) in the prevention of cognitive decline has shown conflicting results. Here we investigate the modulating role of APOE genotype and age at HRT initiation on the heterogeneity in cognitive response to HRT.
The analysis used baseline data from participants in the European Prevention of Alzheimer's Dementia (EPAD) cohort (total n= 1906, women= 1178, 61.8%). Analysis of covariate (ANCOVA) models were employed to test the independent and interactive impact of APOE genotype and HRT on select cognitive tests, such as MMSE, RBANS, dot counting, Four Mountain Test (FMT), and the supermarket trolley test (SMT), together with volumes of the medial temporal lobe (MTL) regions by MRI. Multiple linear regression models were used to examine the impact of age of HRT initiation according to APOE4 carrier status on these cognitive and MRI outcomes.
APOE4 HRT users had the highest RBANS delayed memory index score (P-APOE*HRT interaction = 0.009) compared to APOE4 non-users and to non-APOE4 carriers, with 6-10% larger entorhinal (left) and amygdala (right and left) volumes (P-interaction= 0.002, 0.003, and 0.005 respectively). Earlier introduction of HRT was associated with larger right (standardized β= -0.555, p=0.035) and left hippocampal volumes (standardized β= -0.577, p=0.028) only in APOE4 carriers.
HRT introduction is associated with improved delayed memory and larger entorhinal and amygdala volumes in APOE4 carriers only. This may represent an effective targeted strategy to mitigate the higher life-time risk of AD in this large at-risk population subgroup. Confirmation of findings in a fit for purpose RCT with prospective recruitment based on APOE genotype is needed to establish causality.",[],Alzheimer's research & therapy,2023-01-10,"[{'lastname': 'Saleh', 'firstname': 'Rasha N M', 'initials': 'RNM', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK. r.saleh@uea.ac.uk.'}, {'lastname': 'Hornberger', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'lastname': 'Ritchie', 'firstname': 'Craig W', 'initials': 'CW', 'affiliation': 'Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Minihane', 'firstname': 'Anne Marie', 'initials': 'AM', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}]",,HRT introduction is associated with improved delayed memory and larger entorhinal and amygdala volumes in APOE4 carriers only. This may represent an effective targeted strategy to mitigate the higher life-time risk of AD in this large at-risk population subgroup. Confirmation of findings in a fit for purpose RCT with prospective recruitment based on APOE genotype is needed to establish causality.,"APOE4 HRT users had the highest RBANS delayed memory index score (P-APOE*HRT interaction = 0.009) compared to APOE4 non-users and to non-APOE4 carriers, with 6-10% larger entorhinal (left) and amygdala (right and left) volumes (P-interaction= 0.002, 0.003, and 0.005 respectively). Earlier introduction of HRT was associated with larger right (standardized β= -0.555, p=0.035) and left hippocampal volumes (standardized β= -0.577, p=0.028) only in APOE4 carriers.",© 2023. The Author(s).,"10.1186/s13195-022-01121-5
10.1016/S1474-4422(18)30403-4
10.1016/S2468-2667(21)00249-8
10.1080/13803395.2012.712676
10.5498/wjp.v6.i1.54
10.1016/j.neurobiolaging.2018.05.017
10.1007/s00018-021-03830-w
10.1016/j.molmed.2012.12.007
10.1186/s12974-020-01998-9
10.1001/jama.288.17.2123
10.1001/jama.288.7.872
10.1001/jama.283.8.1007
10.1016/S0002-9343(02)01270-6
10.1001/jama.289.20.2651
10.1001/jama.291.24.2947
10.1016/j.neuron.2020.02.034
10.1016/j.neulet.2013.12.032
10.1001/jama.1997.03550160069041
10.1001/jama.1994.03510410028015
10.1212/WNL.57.1.89
10.1016/j.neurobiolaging.2010.05.017
10.1001/jamaneurol.2017.2188
10.3233/JAD-180859
10.1097/GME.0b013e3182960cf8
10.1016/j.neurobiolaging.2018.04.004
10.1002/jnr.23827
10.1002/hbm.25180
10.1016/S2215-0366(15)00454-X
10.1136/bmjopen-2017-021017
10.1016/j.jalz.2016.07.154
10.1017/S1355617713001094
10.1076/jcen.20.3.310.823
10.1093/arclin/act057
10.1002/hipo.22417
10.1016/j.cortex.2015.03.016
10.1002/alz.12292
10.3174/ajnr.A4169
10.1159/000521898
10.1038/s41598-021-86397-7
10.1002/alz.041482
10.1111/j.1745-7254.2007.00618.x
10.1109/RBME.2018.2796598
10.1523/JNEUROSCI.3252-09.2009
10.1515/revneuro-2015-0019
10.1016/S0197-4580(01)00271-8
10.1016/j.neuroimage.2008.03.039
10.1148/radiol.13131041
10.1148/radiol.10100307
10.1007/s00234-016-1740-8
10.1212/WNL.0000000000002970
10.1212/01.wnl.0000339037.76336.cf
10.1162/jocn_a_00200
10.1016/j.autneu.2022.102948
10.1007/s11682-020-00434-z
10.3390/ijms22010373
10.1007/s11682-019-00245-x
10.1177/0271678X211020863
10.1001/archneurol.2009.913
10.3233/JAD-121897
10.1161/ATVBAHA.107.145383
10.1093/cercor/bhl103
10.1016/j.neuroimage.2012.10.010
10.6061/clinics/2012(01)03
10.1186/s13195-016-0194-x
10.1096/fj.201900423R
10.1007/s11065-009-9118-x
10.1016/j.jalz.2016.02.010
10.1111/j.1365-2826.2006.01508.x
10.1093/gerona/glp128
10.1001/jamainternmed.2013.7727
10.1002/ana.22239
10.1136/bmj.n2182
10.1038/nrendo.2015.82
10.1371/journal.pone.0031267",<Element 'PubmedArticle' at 0x7f05dcc258b0>
55,"36581897
30396512
32567952
23942470
26525751
25767910
19411368
26422005
17429407
19914605
27871668
25173629
19423079
29184215
29454579
29390063
34971757
12359772
12524533
21393509
26462672
24591016
25626394
31114443
24896343
24788181
29625085
28011648
11130078
11861616
12526812
21613335
20737593
35120524
35039149
33969679
16862115
16862116
20667979
35573340
28300056
27778404
27367257
35732696
35656409
11846609
31626970
17851537
35349959
35019161
34826653
33404617
23239020
10858277
23830905
19946692
23041626
30326935
22028881
26701296
31937580
24163244
21645364
20026663
25556567
25261995
28438992
35996956
29993042
35362178
27215202
8637636
11745662
17956738
18923511
22509390
34898994
32171293
32503416
35146924",Progranulin from different gliocytes in the nucleus accumbens exerts distinct roles in FTD- and neuroinflammation-induced depression-like behaviors.,"Neuroinflammation in the nucleus accumbens (NAc) is well known to influence the progression of depression. However, the molecular mechanisms triggering NAc neuroinflammation in depression have not been fully elucidated. Progranulin (PGRN) is a multifunctional growth factor that is linked to the innate immune response and inflammation, and PGRN plays a key role in neurodegenerative diseases such as frontotemporal dementia (FTD). Here, the purpose of this study was to validate whether PGRN was involved in the NAc neuroinflammation-promoted depressive-like phenotype.
A NAc neuroinflammation-relevant depression-like model was established using wild-type (WT) and PGRN-knockout (KO) mice after NAc injection with lipopolysaccharide (LPS), and various behavioral tests related to cognition, social recognition, depression and anxiety were performed with WT and PGRNKO mice with or without NAc immune challenge. RT‒PCR, ELISA, western blotting and immunofluorescence staining were used to determine the expression and function of PGRN in the neuroinflammatory reaction in the NAc after LPS challenge. The morphology of neurons in the NAc from WT and PGRNKO mice under conditions of NAc neuroinflammation was analyzed using Golgi-Cox staining, followed by Sholl analyses. The potential signaling pathways involved in NAc neuroinflammation in PGRNKO mice were investigated by western blotting.
Under normal conditions, PGRN deficiency induced FTD-like behaviors in mice and astrocyte activation in the NAc, promoted the release of the inflammatory cytokines interleukin (IL)-6 and IL-10 and increased dendritic complexity and synaptic protein BDNF levels in the NAc. However, NAc neuroinflammation enhanced PGRN expression, which was located in astrocytes and microglia within the NAc, and PGRN deficiency in mice alleviated NAc neuroinflammation-elicited depression-like behaviors, seemingly inhibiting astrocyte- and microglia-related inflammatory reactions and neuroplasticity complexity in the NAc via the p38 and nuclear factor of kappa (NF-κB) signaling pathways present in the NAc after neuroinflammation.
Our results suggest that PGRN exerts distinct function on different behaviors, showing protective roles in the FTD-like behavior and detrimental effects on the neuroinflammation-related depression-like behavior, resulting from mediating astrocyte and microglial functions from the NAc in different status.","['Depressive-like behaviors', 'FTD-like behaviors', 'NAc neuroinflammation', 'Neuroplasticity', 'Progranulin', 'p38 and NF-κB pathways']",Journal of neuroinflammation,2022-12-30,"[{'lastname': 'Wang', 'firstname': 'Jing', 'initials': 'J', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.""}, {'lastname': 'Lai', 'firstname': 'Simin', 'initials': 'S', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.""}, {'lastname': 'Zhou', 'firstname': 'Ting', 'initials': 'T', 'affiliation': ""Department of Laboratory Medicine, The Second Affiliated Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, People's Republic of China.""}, {'lastname': 'Xia', 'firstname': 'Zhihao', 'initials': 'Z', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Weina', 'initials': 'W', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.""}, {'lastname': 'Sha', 'firstname': 'Wenqi', 'initials': 'W', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China.""}, {'lastname': 'Liu', 'firstname': 'Jingjie', 'initials': 'J', 'affiliation': ""Department of Neurology, The Second Affiliated Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, People's Republic of China.""}, {'lastname': 'Chen', 'firstname': 'Yanjiong', 'initials': 'Y', 'affiliation': ""Department of Immunology and Pathogenic Biology, College of Basic Medicine, Xi'an Jiaotong University Health Science Center, Xi'an, 710061, People's Republic of China. chenyanjiong@126.com.""}]",,,"Under normal conditions, PGRN deficiency induced FTD-like behaviors in mice and astrocyte activation in the NAc, promoted the release of the inflammatory cytokines interleukin (IL)-6 and IL-10 and increased dendritic complexity and synaptic protein BDNF levels in the NAc. However, NAc neuroinflammation enhanced PGRN expression, which was located in astrocytes and microglia within the NAc, and PGRN deficiency in mice alleviated NAc neuroinflammation-elicited depression-like behaviors, seemingly inhibiting astrocyte- and microglia-related inflammatory reactions and neuroplasticity complexity in the NAc via the p38 and nuclear factor of kappa (NF-κB) signaling pathways present in the NAc after neuroinflammation.",© 2022. The Author(s).,"10.1186/s12974-022-02684-8
10.1016/S0140-6736(18)31948-2
10.1080/08870446.2020.1782410
10.1038/nrn3381
10.1007/s40473-015-0044-3
10.1038/npp.2015.75
10.1176/appi.ajp.2008.08081201
10.1016/j.biopsych.2015.08.009
10.1038/sj.npp.1301408
10.1016/j.biopsych.2009.09.013
10.1016/j.biopsych.2016.09.007
10.1016/j.biopsych.2014.07.021
10.1016/j.biopsych.2009.03.015
10.1038/s41593-017-0010-3
10.1016/j.molmet.2018.01.018
10.1093/ijnp/pyy005
10.1016/j.bbi.2021.12.019
10.1038/nm816
10.1126/science.1199214
10.1007/s00296-015-3372-4
10.1007/s10620-014-3089-3
10.1111/imm.12446
10.2741/4274
10.1007/978-1-4939-0669-7_14
10.1016/j.yexcr.2018.04.001
10.1096/fj.201601134R
10.1038/35047123
10.1146/annurev.immunol.20.100301.064842
10.1016/S0092-8674(02)01141-8
10.1177/1352458511406164
10.1002/cne.22430
10.1186/s13024-021-00513-9
10.1016/j.tips.2021.11.015
10.5114/fn.2021.105137
10.1038/nature05017
10.1038/nature05016
10.3389/fpsyt.2022.864391
10.1038/srep43594
10.1002/glia.23091
10.1016/j.intimp.2016.06.022
10.1038/s41380-022-01662-z
10.3389/fncel.2022.892757
10.1006/meth.2001.1262
10.1016/j.bbi.2019.10.016
10.1038/sj.npp.1301574
10.1016/j.intimp.2022.108694
10.15252/embj.2021109108
10.1016/j.conb.2021.10.001
10.1001/jamanetworkopen.2020.30194
10.1007/s12035-012-8380-8
10.1177/002215540004800713
10.1016/j.neuroscience.2013.06.049
10.1007/s00401-009-0616-y
10.1172/JCI63113
10.1186/s13024-018-0288-y
10.1371/journal.pone.0026454
10.1016/j.neuroscience.2015.12.006
10.1136/jnnp-2019-321954
10.1093/hmg/ddt534
10.1186/1742-2094-8-65
10.1084/jem.20091568
10.1016/j.stemcr.2014.12.001
10.1038/nm.3672
10.1073/pnas.1700477114
10.15252/msb.202110473
10.1038/s41386-018-0115-8
10.1002/glia.24175
10.1007/s12035-016-9939-6
10.1016/0306-4522(95)00259-L
10.1002/neu.1079
10.1016/j.cell.2007.09.018
10.1038/nature07455
10.1371/journal.pone.0035115
10.2147/JIR.S339254
10.1186/s12974-020-01754-z
10.1186/s12865-020-00355-y
10.1111/cns.13810",<Element 'PubmedArticle' at 0x7f05dcd2cea0>
56,36580744,"Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids.","Here, we have designed and synthesized a series of melatonin-alkylbenzylamine hybrids as multitarget agents for the treatment of Alzheimer's disease (AD). Most of them exhibited a potent multifunctional profile involving cholinesterase inhibition and antioxidant effects. Among these compounds, compound 5 was most the potent antioxidant (ORAC = 5.13) and also an excellent selective inhibitor of BuChE (huBuChE IC","['Alzheimer’s disease', 'Butyrylcholinesterase', 'Melatonin', 'Nrf2', 'Scavenge free radicals']",Bioorganic & medicinal chemistry,2022-12-30,"[{'lastname': 'Liu', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Cheng', 'firstname': 'Maojun', 'initials': 'M', 'affiliation': 'School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Guo', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Cao', 'firstname': 'Duanyuan', 'initials': 'D', 'affiliation': 'National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Luo', 'firstname': 'Jinchong', 'initials': 'J', 'affiliation': 'School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Wan', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Fang', 'firstname': 'Yuanying', 'initials': 'Y', 'affiliation': 'National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Jin', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China.'}, {'lastname': 'Xie', 'firstname': 'Sai-Sai', 'initials': 'SS', 'affiliation': 'National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China. Electronic address: xiesaisainanchang@hotmail.com.'}, {'lastname': 'Liu', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China. Electronic address: liujing860828@163.com.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.bmc.2022.117146,<Element 'PubmedArticle' at 0x7f05dd4f15e0>
57,"36568118
33031512
36141228
28130199
32575116
25506234
32207804
32437302
27734845
27506744
30692905
15941884
32323378
28661198
27718173
29024348
28807765
29348666
19114008
34335565
32655368
25221640
19506566
12370461
21348917
34201465
28318543
25142458
31577960
8963753
26995317
26551716
30886019
31149894
32617142
26525923
27818937
17116209
33306149
35258803
35163653
26548909
32139503
32447261
28003714
28045402
34199596
34071270",Exploring the common gene signatures and pathogeneses of obesity with Alzheimer's disease ,"Obesity is a complex condition that influences several organ systems and physiologic systems. Obesity (OB) is closely linked to Alzheimer's disease (AD). However, the interrelationship between them remains unclear. The purpose of this study is to explore the key genes and potential molecular mechanisms in obesity and AD.
The microarray data for OB and AD were downloaded from the Gene Expression Omnibus (GEO) database. Weighted gene correlation network analysis (WGCNA) was used to delineate the co-expression modules related to OB and AD. The shared genes existing in obesity and AD were identified through biological process analyses using the DAVID website, which then constructed the Protein-Protein Interaction (PPI) Network and selected the hub genes by Cytoscape. The results were validated in other microarray data by differential gene analysis. Moreover, the hub gene expressions were further determined in mice by qPCR.
The WGCNA identifies five modules and four modules as significant modules with OB and AD, respectively. Functional analysis of shared genes emphasized that inflammation response and mitochondrial functionality were common features in the pathophysiology of OB and AD. The results of differential gene analysis in other microarray data were extremely similar to them. Then six important hub genes were selected and identified using cytoHubba, including MMP9, PECAM1, C3AR1, IL1R1, PPARGC1α, and COQ3. Finally, we validated the hub gene expressions 
Our work revealed the high inflammation/immune response and mitochondrial impairment in OB patients, which might be a crucial susceptibility factor for AD. Meanwhile, we identified novel gene candidates such as MMP9, PECAM1, C3AR1, IL1R1, PPARGC1α, and COQ3 that could be used as biomarkers or potential therapeutic targets for OB with AD.","['Alzheimer’s Disease', 'differential gene analysis', 'hub genes', 'obesity', 'weighted gene correlation network analysis (WGCNA)']",Frontiers in endocrinology,2022-12-27,"[{'lastname': 'Li', 'firstname': 'Ting', 'initials': 'T', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Qu', 'firstname': 'Jingru', 'initials': 'J', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Xu', 'firstname': 'Chaofei', 'initials': 'C', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Fang', 'firstname': 'Ting', 'initials': 'T', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Sun', 'firstname': 'Bei', 'initials': 'B', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Liming', 'initials': 'L', 'affiliation': 'NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.'}]",,,"The WGCNA identifies five modules and four modules as significant modules with OB and AD, respectively. Functional analysis of shared genes emphasized that inflammation response and mitochondrial functionality were common features in the pathophysiology of OB and AD. The results of differential gene analysis in other microarray data were extremely similar to them. Then six important hub genes were selected and identified using cytoHubba, including MMP9, PECAM1, C3AR1, IL1R1, PPARGC1α, and COQ3. Finally, we validated the hub gene expressions ","Copyright © 2022 Li, Qu, Xu, Fang, Sun and Chen.","10.3389/fendo.2022.1072955
10.1001/jamainternmed.2020.4334
10.3390/healthcare10091616
10.1016/j.bbadis.2017.01.016
10.1093/ije/dyaa099
10.2147/dmso.S67400
10.1001/jama.2020.2298
10.1161/circresaha.120.316101
10.1038/nrdp.2016.72
10.1016/j.metabol.2016.05.018
10.3389/fnins.2018.01027
10.1093/ajcn/81.6.1335
10.1111/ejn.14758
10.1089/ars.2017.7060
10.1007/s40520-016-0637-z
10.1111/obr.12629
10.1016/j.taap.2017.08.005
10.1038/nrn.2017.170
10.1186/1471-2105-9-559
10.3389/fimmu.2021.658341
10.3389/fncel.2020.00138
10.1155/2014/780179
10.1038/ijo.2009.104
10.1212/wnl.59.7.1051
10.1111/j.1467-789X.2010.00825.x
10.3390/diseases9030045
10.1016/j.tins.2017.02.005
10.1016/s1474-4422(14)70085-7
10.1016/j.arr.2019.100966
10.1159/000097202
10.1016/j.bbi.2016.03.010
10.1042/bst20140319
10.1523/jneurosci.2506-18.2019
10.1080/1028415x.2019.1616436
10.1155/2020/7856318
10.1111/jnc.13415
10.1016/j.molmet.2016.09.001
10.1111/j.1468-1331.2006.01640.x
10.1007/s11033-020-06043-9
10.1007/s12975-022-00993-x
10.3390/ijms23031731
10.1038/srep16262
10.1212/wnl.0000000000009236
10.1016/j.redox.2020.101558
10.1155/2016/9340637
10.1172/jci92035
10.3390/ijms22116025
10.3390/ijms22115769",<Element 'PubmedArticle' at 0x7f05dec29040>
58,36566957,Insulin resistance in Alzheimer's disease: The genetics and metabolomics links.,"Alzheimer's disease (AD) is a neurodegenerative disease with significant socioeconomic burden worldwide. Although genetics and environmental factors play a role, AD is highly associated with insulin resistance (IR) disorders such as metabolic syndrome (MS), obesity, and type two diabetes mellitus (T2DM). These findings highlight a shared pathogenesis. The use of metabolomics as a downstream systems' biology (omics) approach can help to identify these shared metabolic traits and assist in the early identification of at-risk groups and potentially guide therapy. Targeting the shared AD-IR metabolic trait with lifestyle interventions and pharmacological treatments may offer promising AD therapeutic approach. In this narrative review, we reviewed the literature on the AD-IR pathogenic link, the shared genetics and metabolomics biomarkers between AD and IR disorders, as well as the lifestyle interventions and pharmacological treatments which target this pathogenic link.","['Alzheimer’s disease', 'Diabetes', 'Genetic', 'Insulin resistance', 'Metabolomics', 'Obesity', 'Therapeutics']",Clinica chimica acta; international journal of clinical chemistry,2022-12-26,"[{'lastname': 'Amin', 'firstname': 'Arwa M', 'initials': 'AM', 'affiliation': 'Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Madinah, Saudi Arabia. Electronic address: arwa.amin.m@gmail.com.'}, {'lastname': 'Mostafa', 'firstname': 'Hamza', 'initials': 'H', 'affiliation': ""Biomarkers and Nutrimetabolomics Laboratory, Department of Nutrition, Food Sciences and Gastronomy, Food Innovation Network (XIA), Nutrition and Food Safety Research Institute (INSA), Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid 28029, Spain.""}, {'lastname': 'Khojah', 'firstname': 'Hani M J', 'initials': 'HMJ', 'affiliation': 'Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Madinah, Saudi Arabia.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.cca.2022.12.016,<Element 'PubmedArticle' at 0x7f05dec0f180>
59,"36558531
31200785
30995776
33393375
34624428
31532659
32220751
36163376
30614249
33477894
33773665
29936690
34493333
36348274
35068042
35945702
34200756
32605083
36192946
11815407
31614630
25658514
12612151
33445760
31191482
1883711
12468591
11959436
12070764
29315886
30400297
25347327
15333716
30595029
26689795
27655073
35940941
18641202
21776473
33336996
28072821
33069740
34636875
32559841
33141510
29559385
33381005
30054537
19690987
33709697
29332042
32095862
27911317
29051531
27776263
36034698
17077308
23315270
20167206
21778691
33328965
24722352
34569225
34731656
33554649
24668475
33913925
21732396
33936013
25550456
21876150
33643026
33557896
33074224
27392632
33804088
20663292
1513457
6124895",The Interaction of Polyphenols and the Gut Microbiota in Neurodegenerative Diseases.,"Polyphenols are secondary metabolites of plants and play a potential role in the prevention and treatment of neurodegenerative diseases (NND) such as Alzheimer's disease (AD) and Parkinson's disease (PD) due to their unique physiological functions such as acting as antioxidants, being anti-inflammatory, being neuroprotective, and promoting intestinal health. Since dietary polyphenols exist in plant foods in the form of glycosylation or esterification or are combined with polymers, they need to undergo extensive metabolism through phase I and phase II biotransformations by various intestinal enzymes, as well as metabolism by the intestinal microbiota before they can be fully absorbed. Polyphenols improve intestinal microbiota disorders by influencing the structure and function of intestinal microbiota, inducing beneficial bacteria to produce a variety of metabolites such as short-chain fatty acids (SCFAs), promoting the secretion of hormones and neurotransmitters, and playing an important role in the prevention and treatment of NND by affecting the microbe-gut-brain axis. We review the ways in which some polyphenols can change the composition of the intestinal microbiota and their metabolites in AD or PD animal models to exert the role of slowing down the progression of NND, aiming to provide evidence for the role of polyphenols in slowing the progression of NND via the microbiota-gut-brain (MGB) axis.","['intestinal microbiota', 'microbe–gut–brain axis', 'neurodegenerative diseases', 'polyphenols']",Nutrients,2022-12-24,"[{'lastname': 'Zhang', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Deng Zhou Road 38, Qingdao 266021, China.'}, {'lastname': 'Yu', 'firstname': 'Wanpeng', 'initials': 'W', 'affiliation': 'Medical College, Qingdao University, Qingdao 266021, China.'}, {'lastname': 'Zhang', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Deng Zhou Road 38, Qingdao 266021, China.'}, {'lastname': 'Wang', 'firstname': 'Man', 'initials': 'M', 'affiliation': 'Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Deng Zhou Road 38, Qingdao 266021, China.'}, {'lastname': 'Chang', 'firstname': 'Wenguang', 'initials': 'W', 'affiliation': 'Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Deng Zhou Road 38, Qingdao 266021, China.'}]",,,,,"10.3390/nu14245373
10.5740/jaoacint.19-0133
10.3390/ijms20081883
10.1080/10408398.2020.1865870
10.1016/j.pharmthera.2021.108013
10.1021/acs.jafc.9b01970
10.1016/j.envpol.2020.114207
10.1007/s00109-022-02257-5
10.1080/10408398.2018.1546669
10.3390/nu13010273
10.1016/j.foodres.2021.110189
10.1007/s12035-018-1188-4
10.1186/s40168-021-01115-9
10.1186/s10020-022-00560-y
10.1111/jcmm.17196
10.1111/jfbc.14376
10.3390/foods10061343
10.3390/nu12071908
10.1016/j.foodres.2022.111800
10.3390/nu11102426
10.1016/j.jchromb.2015.01.014
10.1093/jn/133.3.773
10.3390/nu13010206
10.3389/fmicb.2019.01145
10.1099/00207713-41-3-355
10.1093/jn/132.12.3577
10.1111/j.1574-6968.2002.tb11081.x
10.1007/s00203-002-0414-6
10.1002/biof.1410
10.3390/nu10111651
10.3109/03602532.2014.978080
10.1093/jn/134.9.2275
10.1080/10408398.2018.1533517
10.1007/s00394-015-1133-5
10.2174/0929867323666160919111559
10.1016/j.mam.2022.101109
10.1093/jn/138.8.1529S
10.1039/c0fo00132e
10.1111/1541-4337.12444
10.1371/journal.pone.0169509
10.1016/j.bbr.2020.112968
10.1093/jn/nxab328
10.1016/j.biopha.2020.110147
10.1002/mnfr.202000660
10.1016/j.neuroscience.2018.03.008
10.3389/fnins.2020.549037
10.1038/s41598-018-29744-5
10.1007/s12031-009-9235-2
10.1021/acs.jafc.0c07637
10.3233/JAD-170512
10.1007/s00253-020-10461-x
10.3233/JAD-160884
10.1038/s41598-017-13601-y
10.1016/j.neurobiolaging.2016.08.019
10.3389/fcimb.2022.887407
10.1007/s12035-013-8401-2
10.1016/j.brainres.2010.02.031
10.1159/000328516
10.3389/fnagi.2020.588044
10.1039/c3fo60630a
10.1021/acsami.1c14818
10.1016/j.cmet.2021.10.010
10.1177/1535370221989263
10.1097/WNR.0000000000001637
10.1002/bies.201100024
10.3389/fmicb.2021.656895
10.1096/fj.14-259598
10.1073/pnas.1102999108
10.3389/fnagi.2021.636545
10.1186/s13024-021-00427-6
10.3233/JAD-200306
10.1016/j.neuropharm.2016.07.002
10.3390/ijms22062973
10.1179/174329210X12650506623645
10.1212/WNL.42.9.1702
10.1227/00006123-198204000-00021",<Element 'PubmedArticle' at 0x7f05debfcd60>
60,"36551821
30741683
19595937
34456336
31974905
63862
144789
719462
30569080
3513895
10071091
33420680
20498822
8139084
27567878
18218341
21913048
29299792
32778792
35444256
35932841
27582220
34535787
34930757
29473493
3767313
8592643
31481869
3587615
27432942
8544907
24719484
26453765
3026562
3495748
3506828
14991846
16914231
2565040
18463254
24966833
24373987
25322206
28012089
9667777
19877000
18393444
19371353
11182300
24619420
24860495
9275217
35987203
35303422
25896766
10214977
29079292
31787900
31824296
1742020
16362629
27701410
28386117
9116211
10198825
9507943
32488129
10867782
29675957
33069740
32006534
32770070
23296339
25045655
31805308
17132744
27599230
35021306
16943563
30459541
18691381
31394203
11560301
17376589
18413150
35236988
27436369
28485842
35203552
36324409
30344477
31146008
31682854
33564880
31827422
32595454
18394470
10320715
35917875
16904135
29100462
19318226
34852271
29425728
9334392
25206918
15836615
28154533
22527793
23970097
32425755
31537707
19758844
1091131
30914845
17466428
30610352
32879508
25750611
11248122
22578782
23481590
35609517
17674129
27847314
19943850
26172857
18430994
8245220
29274741
33421486
11257240
11592122
16125145
15059975
30641077
29491368
17107752
18703254
34635841
31890855
16365303
26154489
11099831
20505099
35777535
33691594
30632505
31746286
11520916
11529497
15883381
12367511
12671646
12451139
19927149
20146080
32052374
27216821
7703418
19726646
8497318
7991629
7886457
10072368
15541880
25942043
19843173
7955419
11156744
13412736
15071553
1645948
2551901
8508924
7523951
22535247
9641314
15056721
22982314
15995701
25033184
28845311
27640997
27069691
30026680
30191401
35522844
35870681
10443553
27151236
11959398
34879266
28356893
24349942
25406732
30878533
19667196
29077793
32709155
23115049
21824141
9117397
9749714
19133238
22028985
14642282
31650248
28353636
33572579
11113504
17114041
15891778
8962159
22072659
15359010
16738253
17005717
19826435
33057378
29865061
21296883
29472855
22145082
22699848
28096459
18030462
25352456
24860501
32570820
19862561
28536976
6162062
8073293
18289347
10678753
15812314
21934536
20130173
29081415
16942750
18466351
23262393
16629179
23396168
23681231
22136135
26620558
25611954
21074575
16401644
21593432
30498985
35596040
35510352
18627032
25008180
32113968
27566183
30859123
25622751
27459932
23312564
28575011
20332818
15917105
25462800
15212841
36088959
26890746
36209948
24601954
28941188
34686310
30794079
23954394
28382744
25046994
27334657
34838668
25261783
32517647
29121589
8078930
24411134
29035351
30990952
23673233
29551684
23461850
27258307
32516126
25193238
22048123
32775897
14676042
11430801
12925530
15465629
14680763
30687008
27461050
34488599
26793112
36117475
32165212
28417590
18424366
28886995
29130686
16770728
12771112
23459573
26549211
25326800
20142765
30579679
34689040
27400746
35090576
24035740
32853175
7666206
26224839
26519903
10860929
19666625
19363258
1674295
30744931
33607107
30456989
28696167
27038926
30132203
26090073
29097195
33389339
34156230
25031641
22826038
19303882
35710950
26345528
35378156
23410989
26440805
19221692
16919875
9811481",Alternative Pharmacological Strategies for the Treatment of Alzheimer's Disease: Focus on Neuromodulator Function.,"Alzheimer's disease (AD) is a neurodegenerative disorder, comprising 70% of dementia diagnoses worldwide and affecting 1 in 9 people over the age of 65. However, the majority of its treatments, which predominantly target the cholinergic system, remain insufficient at reversing pathology and act simply to slow the inevitable progression of the disease. The most recent neurotransmitter-targeting drug for AD was approved in 2003, strongly suggesting that targeting neurotransmitter systems alone is unlikely to be sufficient, and that research into alternate treatment avenues is urgently required. Neuromodulators are substances released by neurons which influence neurotransmitter release and signal transmission across synapses. Neuromodulators including neuropeptides, hormones, neurotrophins, ATP and metal ions display altered function in AD, which underlies aberrant neuronal activity and pathology. However, research into how the manipulation of neuromodulators may be useful in the treatment of AD is relatively understudied. Combining neuromodulator targeting with more novel methods of drug delivery, such as the use of multi-targeted directed ligands, combinatorial drugs and encapsulated nanoparticle delivery systems, may help to overcome limitations of conventional treatments. These include difficulty crossing the blood-brain-barrier and the exertion of effects on a single target only. This review aims to highlight the ways in which neuromodulator functions are altered in AD and investigate how future therapies targeting such substances, which act upstream to classical neurotransmitter systems, may be of potential therapeutic benefit in the sustained search for more effective treatments.","['ATP', 'Alzheimer’s disease', 'hormones', 'metal ions', 'neuromodulation', 'neuropeptides', 'neurotrophins', 'synaptic plasticity', 'therapeutics']",Biomedicines,2022-12-24,"[{'lastname': 'Cunliffe', 'firstname': 'Grace', 'initials': 'G', 'affiliation': 'Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138667, Singapore.\nDivision of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.'}, {'lastname': 'Lim', 'firstname': 'Yi Tang', 'initials': 'YT', 'affiliation': 'Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138667, Singapore.\nFaculty of Science, National University of Singapore, Singapore 117546, Singapore.'}, {'lastname': 'Chae', 'firstname': 'Woori', 'initials': 'W', 'affiliation': 'Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138667, Singapore.\nDepartment of BioNano Technology, Gachon University, 1342 Seongnam-daero, Seongnam-si 13120, Republic of Korea.'}, {'lastname': 'Jung', 'firstname': 'Sangyong', 'initials': 'S', 'affiliation': 'Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore 138667, Singapore.\nDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.'}]",,,,,"10.3390/biomedicines10123064
10.3233/JAD-180903
10.1016/j.jalz.2007.04.381
10.1038/s41380-021-01249-0
10.1007/s10571-020-00796-4
10.1016/S0140-6736(76)91936-X
10.1016/0022-510X(77)90073-9
10.1136/bmj.2.6150.1457
10.14283/jpad.2018.43
10.1093/oxfordjournals.bmb.a072100
10.1136/jnnp.66.2.137
10.1007/s12031-020-01747-w
10.1001/jama.1994.03510370044030
10.3233/JAD-160612
10.1016/j.molmed.2007.12.002
10.1007/s12640-011-9272-9
10.1007/s10571-017-0574-1
10.1038/s41593-020-0687-6
10.1038/s41380-022-01565-z
10.1016/j.lfs.2022.120861
10.1038/nature19323
10.1038/s41582-021-00557-x
10.1136/bmj.n3127
10.2174/0929867325666180221125759
10.1002/ana.410200303
10.1016/0304-3940(95)11973-Z
10.3389/fnins.2019.00869
10.1212/WNL.37.6.1001
10.1084/jem.20160493
10.1016/0197-4580(95)00043-E
10.1212/WNL.0000000000000417
10.1016/j.neulet.2015.10.006
10.1016/0006-8993(86)90647-5
10.1212/WNL.37.6.905
10.1002/bmc.1130010405
10.1002/jnr.20020
10.1016/j.neurobiolaging.2006.07.002
10.1073/pnas.86.8.2948
10.1523/JNEUROSCI.0590-08.2008
10.3389/fnagi.2014.00119
10.1016/j.neulet.2013.12.036
10.1001/jamaneurol.2014.2510
10.1016/S0022-510X(98)00092-6
10.1002/cbic.200900321
10.1021/bi702423h
10.1111/j.1750-3639.2009.00283.x
10.1016/S0891-5849(00)00494-9
10.1074/jbc.M113.525212
10.3389/fnagi.2014.00077
10.1073/pnas.94.18.9866
10.1016/j.cmet.2022.07.014
10.1016/j.cmet.2022.02.013
10.1016/j.neuropharm.2015.04.005
10.1016/S0304-3940(98)00654-5
10.1016/j.neuropharm.2017.10.027
10.3389/fphar.2019.01330
10.3389/fnagi.2019.00311
10.1016/0896-6273(91)90273-3
10.1007/s00702-005-0397-y
10.1038/tp.2016.186
10.1038/s41598-017-00794-5
10.1097/00001756-199611250-00024
10.1016/S0736-5748(98)00088-4
10.1016/S0304-3940(98)00019-6
10.1038/s41380-020-0797-2
10.1001/archneur.57.6.846
10.1111/jcmm.13626
10.1016/j.bbr.2020.112968
10.1016/j.bbamcr.2020.118664
10.1038/s41598-020-70153-4
10.1038/nrneurol.2012.263
10.1155/2014/103906
10.1016/j.mce.2019.110671
10.1530/eje.1.02306
10.1080/15287394.2016.1193113
10.5534/wjmh.210175
10.1523/JNEUROSCI.2797-06.2006
10.3389/fnins.2018.00739
10.1111/j.1471-4159.2008.05613.x
10.1016/j.nbd.2019.104568
10.1016/S0025-6196(11)62109-5
10.1016/j.mce.2006.06.013
10.1016/j.yhbeh.2008.02.006
10.1038/s41586-022-04463-0
10.1177/1933719116658705
10.1111/head.13084
10.3390/biomedicines10020343
10.1016/j.cccb.2021.100035
10.3389/fnmol.2018.00361
10.1016/j.neuroscience.2019.05.033
10.1016/j.neuropharm.2019.107836
10.1042/CS20201438
10.3389/fncel.2019.00524
10.3389/fncel.2020.00153
10.1016/S0079-6123(07)00006-4
10.1016/S0006-8993(99)01302-5
10.1016/j.neuropharm.2022.109201
10.1016/j.neuropharm.2006.06.011
10.18632/oncotarget.20606
10.1016/j.npep.2009.02.002
10.1016/j.lfs.2021.120186
10.1016/j.phrs.2018.01.018
10.1523/JNEUROSCI.17-21-08169.1997
10.4103/1673-5374.133140
10.1111/j.1471-4159.2005.03057.x
10.3389/fnagi.2016.00327
10.1007/s12017-012-8180-3
10.1159/000353848
10.3389/fncel.2020.00088
10.1523/JNEUROSCI.0617-19.2019
10.1016/j.coph.2009.08.007
10.1093/ajcn/28.4.333
10.21315/mjms2018.25.4.3
10.1016/j.bandc.2007.02.007
10.1007/s00213-018-5116-0
10.1038/s41583-020-0362-7
10.3389/fnins.2015.00037
10.1073/pnas.051003698
10.1016/j.euroneuro.2012.04.013
10.1016/j.yhbeh.2013.02.007
10.1159/000525038
10.1007/s10735-007-9125-2
10.1016/j.yhbeh.2016.11.007
10.1111/j.1471-4159.2009.06502.x
10.1016/j.yhbeh.2015.06.020
10.3233/JAD-2008-13304
10.1002/cne.903360210
10.1016/j.nbd.2017.12.009
10.1016/j.neulet.2020.135619
10.1016/S0006-3223(00)01015-5
10.1002/jnr.1219
10.1016/j.biopsych.2005.06.017
10.1096/fj.03-1378fje
10.1016/j.neuropharm.2019.01.010
10.1016/j.coemr.2022.100365
10.1038/s41398-018-0101-2
10.1016/j.mehy.2006.09.038
10.1016/j.neurobiolaging.2008.07.011
10.1038/s41582-021-00573-x
10.1016/j.trci.2019.09.004
10.1073/pnas.0505203102
10.1007/s12035-015-9315-y
10.1016/S0304-3940(00)01622-0
10.1523/JNEUROSCI.1180-10.2010
10.1016/j.neuroscience.2022.06.034
10.1080/13685538.2021.1892625
10.4103/1673-5374.245477
10.1080/15287394.2019.1683988
10.1146/annurev.neuro.24.1.677
10.1007/PL00000919
10.1073/pnas.0502460102
10.1016/S0896-6273(02)00942-X
10.1038/nrn1078
10.1523/JNEUROSCI.22-23-10399.2002
10.1038/nrn2738
10.1007/s00018-010-0278-x
10.1007/s40263-020-00705-9
10.1111/jnc.13676
10.1097/00001756-199412300-00007
10.1523/JNEUROSCI.2594-09.2009
10.1038/363350a0
10.1073/pnas.91.25.12341
10.1126/science.7886457
10.1016/S0959-4388(99)80013-0
10.1016/j.neuroscience.2004.07.036
10.1038/tp.2015.55
10.1111/j.1742-4658.2009.07367.x
10.1016/0009-8981(94)90132-5
10.1016/S0736-5748(00)00046-0
10.1016/0006-3002(57)90343-8
10.1038/nrm1354
10.1146/annurev.ph.53.030191.003025
10.1016/S0021-9258(18)71510-X
10.1016/0014-5793(93)81397-I
10.1038/371516a0
10.1038/nature11010
10.1016/S0378-5955(97)00206-2
10.1523/JNEUROSCI.5429-03.2004
10.1016/j.bbrc.2012.08.119
10.1038/nn1498
10.1016/j.neuron.2014.06.005
10.1155/2017/9454275
10.1038/srep33609
10.1155/2016/1207393
10.3389/fnins.2018.00441
10.1007/s00401-018-1903-2
10.1002/alz.12683
10.1016/j.pneurobio.2022.102327
10.1007/s007020050174
10.1038/ncomms11483
10.1016/S0197-4580(01)00314-1
10.1016/j.celrep.2021.110102
10.1002/wmts.12
10.1038/ncomms6422
10.1016/j.nbd.2019.03.008
10.1073/pnas.0903563106
10.1093/brain/awx258
10.3390/brainsci10070460
10.1002/jnr.23143
10.1111/j.1471-4159.2011.07417.x
10.1016/S0006-8993(96)01009-8
10.1046/j.1460-9568.1998.00057.x
10.1016/j.brainres.2008.12.041
10.4061/2011/864753
10.1016/S0896-6273(03)00687-1
10.1007/s00775-019-01731-9
10.3390/antiox6020024
10.3390/nu13020478
10.1016/S0165-0173(00)00044-8
10.1016/j.neuron.2006.11.007
10.1038/nrn1671
10.1073/pnas.93.25.14934
10.1523/JNEUROSCI.3454-11.2011
10.1177/1073858404263463
10.1523/JNEUROSCI.0475-06.2006
10.1073/pnas.0607131103
10.1038/nrn2734
10.1371/journal.pone.0240697
10.3233/JAD-179944
10.1074/jbc.M110.213785
10.3389/fnagi.2017.00446
10.4061/2011/345614
10.3233/JAD-2012-120766
10.1074/jbc.M116.754101
10.1007/s00249-007-0234-3
10.3233/JAD-141776
10.3389/fnagi.2014.00092
10.3390/biom10060924
10.1007/s00775-009-0600-y
10.1007/s12035-017-0619-y
10.1016/S0140-6736(81)90062-3
10.1126/science.8073293
10.1111/j.1471-4159.2007.05061.x
10.1016/S0006-8993(99)02096-X
10.1097/00001756-200504250-00015
10.1097/WNR.0b013e32834c0a2d
10.1523/JNEUROSCI.5255-09.2010
10.3233/JAD-161143
10.1016/j.bbrc.2006.08.077
10.1111/j.1582-4934.2008.00356.x
10.1016/j.neuint.2012.12.005
10.4067/S0716-97602006000100021
10.1016/j.bbr.2013.01.039
10.1038/cddis.2013.160
10.1186/1742-2094-8-169
10.1074/jbc.M115.678185
10.1002/ana.24361
10.1016/j.bbr.2010.11.017
10.1096/fj.05-4812fje
10.1096/fj.10-180133
10.1007/s12031-018-1226-8
10.1007/s11064-022-03624-x
10.1021/acsami.2c00007
10.1002/jnr.21787
10.2337/db14-0375
10.1016/j.neuropharm.2020.108017
10.1016/j.bbr.2016.08.041
10.1016/j.trci.2019.01.003
10.1038/npp.2015.25
10.1016/j.neurobiolaging.2016.05.018
10.1016/j.biopsych.2012.12.003
10.1371/journal.pone.0178490
10.1007/s12264-010-0913-4
10.1016/j.neurobiolaging.2004.11.009
10.1016/j.neuroimage.2014.11.003
10.1016/j.neurobiolaging.2003.10.010
10.1016/j.brainres.2022.148079
10.3233/JAD-150756
10.1016/j.nbd.2022.105888
10.1111/jnc.12706
10.1111/cns.12757
10.1016/j.bja.2021.08.028
10.1089/neu.2018.6266
10.1016/j.yhbeh.2013.08.002
10.1111/jnc.14034
10.1016/j.nbd.2014.07.001
10.1016/j.neuropharm.2016.06.015
10.1016/j.nbd.2021.105563
10.1016/j.neuropharm.2014.09.019
10.1186/s12576-020-00757-y
10.1016/j.redox.2017.10.010
10.1073/pnas.91.18.8607
10.1016/j.jalz.2013.09.004
10.3390/ijms18102154
10.1002/cbdv.201900085
10.1186/alzrt179
10.1016/j.bbrc.2018.03.119
10.1016/j.ejphar.2013.02.015
10.3390/nu8060333
10.18632/aging.103306
10.1016/j.neuroscience.2014.08.036
10.1016/j.neurobiolaging.2011.09.040
10.1021/acsomega.0c02235
10.1001/archneur.60.12.1685
10.1016/S0896-6273(01)00317-8
10.1074/jbc.M305494200
10.1016/j.neurobiolaging.2004.01.005
10.1016/j.neuropharm.2003.09.005
10.3389/fnmol.2018.00493
10.1016/j.nbd.2016.07.022
10.2174/1570159X19666210906120302
10.3389/fphar.2015.00321
10.1002/npr2.12292
10.1016/j.lfs.2020.117540
10.1111/cns.12696
10.1016/j.bmc.2017.08.031
10.1021/jacs.7b08417
10.1007/s11064-006-9055-5
10.5897/JNBH2017.0148
10.1001/jama.289.20.2651
10.3389/fphar.2013.00016
10.1038/ncomms9762
10.1038/nm.3700
10.1097/NEN.0b013e3181d072cf
10.1016/j.npep.2018.12.003
10.1016/j.conb.2021.09.003
10.1186/s13024-016-0119-y
10.1186/s40035-022-00279-0
10.1016/j.neubiorev.2013.09.003
10.18632/aging.103867
10.1523/JNEUROSCI.15-09-06239.1995
10.1073/pnas.1421182112
10.1016/j.neuropharm.2015.10.031
10.1124/mol.58.1.82
10.1073/pnas.0902531106
10.3233/JAD-2009-1068
10.1016/0140-6736(91)92978-B
10.1016/j.bmc.2019.01.025
10.1016/j.ejphar.2021.173950
10.1080/14786419.2018.1510925
10.1080/10286020.2017.1339349
10.1007/s11064-016-1896-y
10.1007/s10753-018-0876-6
10.1155/2015/976908
10.1016/j.physbeh.2017.10.028
10.1016/j.ccr.2016.04.013
10.1007/s10534-020-00277-7
10.1021/acschemneuro.1c00182
10.1186/alzrt265
10.1002/syn.21588
10.1016/j.yhbeh.2009.03.003
10.1038/s41565-022-01129-w
10.2147/IJN.S87148
10.1016/j.ijbiomac.2022.03.203
10.1016/j.ijpharm.2013.02.014
10.1007/s10571-015-0276-5
10.1007/s00702-009-0189-x
10.1016/j.neulet.2006.07.020
10.1021/js980084y",<Element 'PubmedArticle' at 0x7f05df547c70>
61,36519649,Hormones and depression in the advanced age.,"In older people, depression and mental disability are more frequently present than in younger subjects. It is found that depressionis a risk factor for dementia, just as dementia is a risk factor for depression. In turn, both disturbances are known to be influenced by hormones. The present study aimed to see whether the hormonal changes in subjects over 75 years old correlate with the symptoms of depression measured using the Geriatric Depression Scale (GDS).
In a group of patients aged over 75 years, concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), oestradiol, testosterone, dehydroepiandrosterone sulphate (DHEAs), and cortisol were measured in serum with the use of chemiluminescence. The symptoms of depression were estimated by GDS, and the mental functions were assessed by the Mini-Mental State Examination (MMSE). The correlations between the obtained results were estimated by Spearman's test.
A significant correlation between GDS and MMSE scores was observed in the investigated patients. Some statistically significant correlations concerning cortisol and testosterone with GDS were observed in women, but not in men. On the other hand, no significant correlations between concentrations of FSH, LH, DHEAs, and oestradiol with GDS were noticed. Our data support the role of cortisol (possibly secreted during chronic stress) in the risk of depression. The gender difference in the mechanism of depression and stress in older age could be also hypothesized.","['GDS', 'MMSE', 'aging', 'depression', 'hormones']",Endokrynologia Polska,2022-12-16,"[{'lastname': 'Winczyk', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': 'Department of Neuroendocrinology, Chair of Laboratory and Molecular Diagnostics, Medical University of Lodz, Poland. katarzyna.winczyk@umed.lodz.pl.'}, {'lastname': 'Kostka', 'firstname': 'Tomasz', 'initials': 'T', 'affiliation': 'Department of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Poland.'}, {'lastname': 'Pisarek', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': None}, {'lastname': 'Pisarek', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': None}, {'lastname': 'Guligowska', 'firstname': 'Agnieszka', 'initials': 'A', 'affiliation': None}, {'lastname': 'Guligowska', 'firstname': 'Agnieszka', 'initials': 'A', 'affiliation': None}, {'lastname': 'Piechocka-Wochniak', 'firstname': 'Edyta', 'initials': 'E', 'affiliation': None}, {'lastname': 'Piechocka-Wochniak', 'firstname': 'Edyta', 'initials': 'E', 'affiliation': None}, {'lastname': 'Świętosławski', 'firstname': 'Jacek', 'initials': 'J', 'affiliation': None}, {'lastname': 'Świętosławski', 'firstname': 'Jacek', 'initials': 'J', 'affiliation': None}, {'lastname': 'Pawlikowski', 'firstname': 'Marek', 'initials': 'M', 'affiliation': 'Department of Neuroendocrinology, Chair of Laboratory and Molecular Diagnostics, Medical University of Lodz, Poland.'}]",,,,,10.5603/EP.a2022.0094,<Element 'PubmedArticle' at 0x7f05dd1ed4f0>
62,36512265,The Interaction Between NF-κB and Estrogen in Alzheimer's Disease.,"Post-menopausal women are at a higher risk of developing Alzheimer's disease (AD) than males. The higher rates of AD in women are associated with the sharp decline in the estrogen levels after menopause. Estrogen has been shown to downregulate inflammatory cytokines in the central nervous system (CNS), which has a neuroprotective role against neurodegenerative diseases including AD. Sustained neuroinflammation is associated with neurodegeneration and contributes to AD. Nuclear factor kappa-B (NF-κB) is a transcription factor involved with the modulation of inflammation and interacts with estrogen to influence the progression of AD. Application of 17β-estradiol (E2) has been shown to inhibit NF-κB, thereby reducing transcription of NF-κB target genes. Despite accumulating evidence showing that estrogens have beneficial effects in pre-clinical AD studies, there are mixed results with hormone replacement therapy in clinical trials. Furthering our understanding of how NF-κB interacts with estrogen and alters the progression of neurodegenerative disorders including AD, should be beneficial and result in the development of novel therapeutics.","['ApoE4', 'Dementia', 'Estrogen', 'Inflammation', 'NF-κB', 'Neurodegeneration', 'Nrf2']",Molecular neurobiology,2022-12-14,"[{'lastname': 'Mishra', 'firstname': 'Pranav', 'initials': 'P', 'affiliation': 'Division of Neurodegenerative Disorders, St. Boniface Hospital Research, Winnipeg, MB, Canada.\nDepartment of Pharmacology & Therapeutics, College of Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'lastname': 'Davies', 'firstname': 'Don A', 'initials': 'DA', 'affiliation': 'Department of Biology, York University, Toronto, ON, Canada.'}, {'lastname': 'Albensi', 'firstname': 'Benedict C', 'initials': 'BC', 'affiliation': 'Division of Neurodegenerative Disorders, St. Boniface Hospital Research, Winnipeg, MB, Canada. balbensi@sbrc.ca.\nDepartment of Pharmacology & Therapeutics, College of Medicine, University of Manitoba, Winnipeg, MB, Canada. balbensi@sbrc.ca.\nDepartment of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA. balbensi@sbrc.ca.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",10.1007/s12035-022-03152-3,<Element 'PubmedArticle' at 0x7f05dd215b80>
63,36461380,Effects of distinct n-6 to n-3 polyunsaturated fatty acid ratios on insulin resistant and AD-like phenotypes in high-fat diets-fed APP/PS1 mice.,"Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are prevalent diseases with similar pathophysiological characteristics and genetic predispositions. Polyunsaturated fatty acids (PUFAs) are essential in maintaining normal brain function. However, little is known about the effect of dietary n-6/n-3 PUFA ratio on AD-like pathology, particularly in high-fat diet (HFD)-fed AD model mice. In the present study, the APP/PS1 mice were fed with 60 % HFD for 3.5 months to induce insulin resistance. After that, 45 % HFD with various n-6/n-3 PUFA ratios (n-6/n-3 = 1:1, 5:1 or 16:1) was applied for an additional 3.5 months of treatment. The behavior of mice was observed using the water maze after dietary intervention. The animals were euthanized after behavioral testing, and serum and tissue samples were collected for biochemical, histological, and pathological tests and evaluation. HFD caused insulin resistance, increased serum IL-6 and TNF-α levels, cortical soluble Aβ","['AD-like pathology', 'APP/PS1 mice', 'High-fat diet', 'Insulin resistance', 'N-6/n-3 PUFA ratio']","Food research international (Ottawa, Ont.)",2022-12-04,"[{'lastname': 'Ma', 'firstname': 'Xiaojun', 'initials': 'X', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Guo', 'firstname': 'Yujie', 'initials': 'Y', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Xu', 'firstname': 'Jingjing', 'initials': 'J', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Wang', 'firstname': 'Xixiang', 'initials': 'X', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Dong', 'firstname': 'Shengqi', 'initials': 'S', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Gao', 'firstname': 'Yanyan', 'initials': 'Y', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China.'}, {'lastname': 'Van Halm-Lutterodt', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'School of Professional Studies, Brown University, Providence, RI, United States.'}, {'lastname': 'Yuan', 'firstname': 'Linhong', 'initials': 'L', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, China; Beijing Key Laboratory of Environmental Toxicology, Capital Medical University, Beijing, China. Electronic address: ylhmedu@126.com.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.foodres.2022.112207,<Element 'PubmedArticle' at 0x7f05df05d040>
64,"36448463
33309175
35078371
19926881
26031297
33340915
25800587
28865775
26144940
19556457
27885003
32746705
31390550
36028773
36115370
32440958
30650649
35156088
31768006
29712746
30827125
21474818
9544879
11247116
5592693
5772109
1017359
85815
2095380
29215023
17920917
31464800
31057391
23248146
21079049
25904648
23039824
26425836
20520575
17576859
35301870
30719843
30402904
32973085
28643350
26912547
32295824
33550821
24136970
31672896
30451853
32370572
17261645
30678763
24029863
33710173
31873973
25492833
11863243
32555001
27930440
22695508
35708294
29685848
23710111
24725531
33356955
34161259
23142808
26902495
29198725
32306766
17360665
34601963
31635525
35104800
35575250
24652800
27056296
31904281
32338037
19273720
20829506
18768761
16230482
7624393
12460708
24060894
11157182
12551876
15911742
17762657
31466622
23536538
10571976
18378684
22773442
24526702
35195849
32237904
21127246
25829393
25870193
33070663
32336227
33792901
32450738
32567509
32961201
34201492
23969502
14506343
30614503
32927020
22134389
18484373
31737282
33712841
27115377
19357324
33506911
30564370
26858430
19255424
9843836
18272659
27254002
35766027
24244756
23710339
16585410
33447783
32188307
34738991
28169885
33775114
30300651
26061588
31739848
23171375
34498675
29420078
32192382
33846490
31480717
25582849
24918372
18321934
33647771
29164122
26457954
33611935
29754952
18316653
32645850
9323073
30712475
34096425
28107043
32705594
28585194
35443107
35511946
22907695
33415319
25525750
17954807
18550999
15939805
25499058
16738273
8931842
17485018
23098178
26311166
8608603
30278816
18753291
19218356
18708447
22140039
25660131
27076076
15309293
10639539
9869017
9297994
20854139
24373519
31641769
34232677
33027108
33354718
35983870
26861939
35210352
28439010
24687134
31602405
21565639
35438082
14732734
33219353
21068740
19657283
24892410
29973135
25410879
27821618
26414676
30571238
26769233
29198723
32520614
24420542
30354815
34994206
34120454
31139831
33462391
33328030
28413148
32821856
24635449
28549929
31694150",Toward Precision Medicine: Circadian Rhythm of Blood Pressure and Chronotherapy for Hypertension - 2021 NHLBI Workshop Report.,"Healthy individuals exhibit blood pressure variation over a 24-hour period with higher blood pressure during wakefulness and lower blood pressure during sleep. Loss or disruption of the blood pressure circadian rhythm has been linked to adverse health outcomes, for example, cardiovascular disease, dementia, and chronic kidney disease. However, the current diagnostic and therapeutic approaches lack sufficient attention to the circadian rhythmicity of blood pressure. Sleep patterns, hormone release, eating habits, digestion, body temperature, renal and cardiovascular function, and other important host functions as well as gut microbiota exhibit circadian rhythms, and influence circadian rhythms of blood pressure. Potential benefits of nonpharmacologic interventions such as meal timing, and pharmacologic chronotherapeutic interventions, such as the bedtime administration of antihypertensive medications, have recently been suggested in some studies. However, the mechanisms underlying circadian rhythm-mediated blood pressure regulation and the efficacy of chronotherapy in hypertension remain unclear. This review summarizes the results of the National Heart, Lung, and Blood Institute workshop convened on October 27 to 29, 2021 to assess knowledge gaps and research opportunities in the study of circadian rhythm of blood pressure and chronotherapy for hypertension.","['circadian clock', 'kidney', 'microbiota', 'sleep', 'vasculature']","Hypertension (Dallas, Tex. : 1979)",2022-12-01,"[{'lastname': 'Gumz', 'firstname': 'Michelle L', 'initials': 'ML', 'affiliation': 'Department of Physiology and Aging; Center for Integrative Cardiovascular and Metabolic Disease, Department of Medicine, Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, FL (M.L.G.).'}, {'lastname': 'Shimbo', 'firstname': 'Daichi', 'initials': 'D', 'affiliation': 'Department of Medicine, The Columbia Hypertension Center, Columbia University Irving Medical Center, New York, NY (D.S.).'}, {'lastname': 'Abdalla', 'firstname': 'Marwah', 'initials': 'M', 'affiliation': 'Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York, NY (M.A.).'}, {'lastname': 'Balijepalli', 'firstname': 'Ravi C', 'initials': 'RC', 'affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD (R.C.B., Y.H., J.W., Y.S.O.).'}, {'lastname': 'Benedict', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Department of Pharmaceutical Biosciences, Molecular Neuropharmacology, Uppsala University, Sweden (C.B.).'}, {'lastname': 'Chen', 'firstname': 'Yabing', 'initials': 'Y', 'affiliation': 'Department of Pathology, University of Alabama at Birmingham, and Research Department, Birmingham VA Medical Center, AL (Y.C.).'}, {'lastname': 'Earnest', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neuroscience & Experimental Therapeutics, Texas A&M University, Bryan, TX (D.J.E.).'}, {'lastname': 'Gamble', 'firstname': 'Karen L', 'initials': 'KL', 'affiliation': 'Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, AL (K.L.G.).'}, {'lastname': 'Garrison', 'firstname': 'Scott R', 'initials': 'SR', 'affiliation': 'Department of Family Medicine, University of Alberta, Canada (S.R.G.).'}, {'lastname': 'Gong', 'firstname': 'Ming C', 'initials': 'MC', 'affiliation': 'Department of Physiology, University of Kentucky, Lexington, KY (M.C.G.).'}, {'lastname': 'Hogenesch', 'firstname': 'John B', 'initials': 'JB', 'affiliation': 'Department of Pediatrics, University of Cincinnati, OH (J.B.H.).'}, {'lastname': 'Hong', 'firstname': 'Yuling', 'initials': 'Y', 'affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD (R.C.B., Y.H., J.W., Y.S.O.).'}, {'lastname': 'Ivy', 'firstname': 'Jessica R', 'initials': 'JR', 'affiliation': ""University/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, The University of Edinburgh, United Kingdom (J.R.I.).""}, {'lastname': 'Joe', 'firstname': 'Bina', 'initials': 'B', 'affiliation': 'Department of Physiology and Pharmacology and Center for Hypertension and Precision Medicine, University of Toledo College of Medicine and Life Sciences, OH (B.J.).'}, {'lastname': 'Laposky', 'firstname': 'Aaron D', 'initials': 'AD', 'affiliation': 'National Center on Sleep Disorders Research, Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD (A.D.L.).'}, {'lastname': 'Liang', 'firstname': 'Mingyu', 'initials': 'M', 'affiliation': 'Center of Systems Molecular Medicine, Department of Physiology, Medical College of Wisconsin, Milwaukee, WI (M.L.).'}, {'lastname': 'MacLaughlin', 'firstname': 'Eric J', 'initials': 'EJ', 'affiliation': 'Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Amarillo, TX (E.J.M.).'}, {'lastname': 'Martino', 'firstname': 'Tami A', 'initials': 'TA', 'affiliation': 'Center for Cardiovascular Investigations, Department of Biomedical Sciences, University of Guelph, Ontario, Canada (T.A.M.).'}, {'lastname': 'Pollock', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, AL (D.M.P.).'}, {'lastname': 'Redline', 'firstname': 'Susan', 'initials': 'S', 'affiliation': ""Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.R.).""}, {'lastname': 'Rogers', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Division of Molecular and Clinical Medicine, University of Dundee, United Kingdom (A.R.).'}, {'lastname': 'Dan Rudic', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Department of Pharmacology and Toxicology, Augusta University, GA (R.D.R.).'}, {'lastname': 'Schernhammer', 'firstname': 'Eva S', 'initials': 'ES', 'affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (E.S.S.).""}, {'lastname': 'Stergiou', 'firstname': 'George S', 'initials': 'GS', 'affiliation': 'Hypertension Center, STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece (G.S.S.).'}, {'lastname': 'St-Onge', 'firstname': 'Marie-Pierre', 'initials': 'MP', 'affiliation': ""Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center' New York, NY (M.-P.S.-O.).""}, {'lastname': 'Wang', 'firstname': 'Xiaoling', 'initials': 'X', 'affiliation': 'Georgia Prevention Institute, Department of Medicine, Augusta University, GA (X.W.).'}, {'lastname': 'Wright', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD (R.C.B., Y.H., J.W., Y.S.O.).'}, {'lastname': 'Oh', 'firstname': 'Young S', 'initials': 'YS', 'affiliation': 'Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD (R.C.B., Y.H., J.W., Y.S.O.).'}]",,,,,"10.1161/HYPERTENSIONAHA.122.19372
10.1016/j.jacc.2020.11.010
10.1161/CIR.0000000000001052
10.1161/CIRCRESAHA.109.206201
10.1016/j.cjca.2015.01.015
10.1016/j.coph.2020.11.007
10.1177/0748730415575246
10.1016/j.hfc.2017.05.002
10.2174/1381612821666150706105926
10.1152/japplphysiol.00426.2009
10.1126/science.aal2613
10.1177/0748730420946501
10.1016/j.cmet.2019.06.019
10.1038/s41576-022-00519-z
10.1016/S0140-6736(22)00877-7
10.1007/s11906-020-01043-3
10.3390/ijms20020343
10.1038/s41580-019-0179-2
10.1161/HYPERTENSIONAHA.118.10971
10.1161/HYP.0000000000000087
10.1161/CIRCRESAHA.110.233668
10.1016/s0895-7061(97)00461-5
10.1081/cbi-100001178
10.1016/s0140-6736(78)92998-7
10.1038/s41598-017-17362-6
10.1016/S0140-6736(07)61538-4
10.1097/HJH.0000000000002221
10.3389/fnagi.2019.00054
10.1161/HYPERTENSIONAHA.111.00217
10.1161/HYPERTENSIONAHA.109.133900
10.1093/ajh/hpv058
10.3109/07420528.2012.701127
10.1097/HJH.0000000000000690
10.1097/HJH.0b013e32833b49fe
10.1161/HYPERTENSIONAHA.107.087767
10.1161/JAHA.121.024785
10.1111/jch.13474
10.1111/ejn.14255
10.1681/ASN.2020030236
10.1111/jsr.12573
10.2215/CJN.08530815
10.1212/WNL.0000000000009316
10.1161/HYPERTENSIONAHA.120.16711
10.1126/science.1241224
10.1126/science.aax5440
10.1038/s41467-018-07318-3
10.1161/HYPERTENSIONAHA.120.15026
10.1161/01.HYP.0000258215.26755.20
10.1016/j.jacc.2018.10.069
10.1097/HJH.0b013e328363e964
10.1097/HJH.0000000000002843
10.1111/jch.13772
10.1016/j.jash.2014.09.020
10.1016/s0895-7061(01)02324-x
10.1097/HJH.0000000000002522
10.1097/HJH.0000000000001189
10.1038/ajh.2012.82
10.1097/HJH.0000000000003224
10.1016/j.repc.2018.03.007
10.1080/09291010600903692
10.1186/1742-4682-11-16
10.1152/ajprenal.00421.2020
10.1073/pnas.2015873118
10.1210/en.2012-1835
10.1161/HYPERTENSIONAHA.115.06981
10.1016/j.freeradbiomed.2017.11.024
10.1161/HYPERTENSIONAHA.119.13908
10.1161/HYPERTENSIONAHA.121.14519
10.1146/annurev-physiol-021119-034446
10.1172/JCI148277
10.1152/physrev.00045.2021
10.1681/ASN.2013060641
10.1681/ASN.2015091055
10.1152/ajprenal.00364.2019
10.1152/ajprenal.00014.2020
10.1161/circulationaha.108.827477
10.1161/ATVBAHA.110.214379
10.1152/ajpregu.90572.2008
10.1161/CIRCULATIONAHA.105.568626
10.1152/physrev.1995.75.3.519
10.1016/s0895-7061(02)03029-7
10.1161/HYPERTENSIONAHA.113.01744
10.1161/01.str.32.2.454
10.1161/01.cir.0000048894.99865.02
10.1161/01.HYP.0000168052.00426.65
10.1097/HJH.0b013e3281fbd15e
10.1016/j.jacc.2019.07.012
10.1098/rsif.2012.1004
10.1161/01.cir.100.21.2168
10.1074/jbc.M800021200
10.1161/CIRCRESAHA.112.267237
10.1161/CIRCRESAHA.114.302968
10.1007/s13668-022-00403-6
10.1161/ATVBAHA.120.313131
10.1126/science.1195027
10.1152/physiolgenomics.00136.2014
10.1161/HYPERTENSIONAHA.115.05315
10.1161/HYPERTENSIONAHA.120.15939
10.1161/HYPERTENSIONAHA.120.13896
10.1002/cphy.c200009
10.1161/HYPERTENSIONAHA.120.14830
10.1152/physiolgenomics.00039.2020
10.1016/j.yjmcc.2020.09.006
10.3390/ijerph18136738
10.1097/JOM.0b013e31829731fd
10.1097/01.jom.0000085893.98441.96
10.5271/sjweh.3788
10.1016/j.cjca.2020.09.003
10.1097/HJH.0b013e32834e1ea3
10.35371/aoem.2019.31.e27
10.1093/ije/dyab031
10.1001/jama.2016.4454
10.1093/aje/kwp056
10.26355/eurrev_202101_24388
10.1186/s40557-018-0279-z
10.1073/pnas.1516953113
10.1073/pnas.0808180106
10.1152/ajpheart.1998.275.6.H2334
10.1210/en.2016-1130
10.1161/CIR.0000000000001078
10.1007/s12170-013-0330-0
10.1155/2013/436502
10.1161/01.HYP.0000217362.34748.e0
10.1016/j.ijchy.2020.100062
10.1161/JAHA.119.015062
10.1097/HJH.0000000000002956
10.1097/HJH.0000000000001284
10.1161/HYPERTENSIONAHA.120.16370
10.1016/j.chest.2018.09.018
10.3109/07420528.2015.1041597
10.5664/jcsm.8018
10.1111/jsr.12011
10.1093/aje/kwab232
10.1080/10641963.2017.1411495
10.1080/07420528.2020.1740723
10.1038/s41598-021-87200-3
10.3390/jcm8091367
10.1111/jch.12472
10.1056/NEJMoa1306766
10.1183/09031936.00138207
10.1016/j.ebiom.2021.103248
10.3389/fmed.2017.00187
10.7326/M15-1270
10.1161/HYPERTENSIONAHA.120.14479
10.1016/j.cmet.2018.04.010
10.1161/HYPERTENSIONAHA.107.105510
10.3390/nu12072013
10.1161/01.cir.96.6.1859
10.1177/0748730419826694
10.1080/07420528.2021.1936542
10.1080/07420528.2016.1259242
10.1007/978-981-15-6082-8_5
10.1007/978-3-319-48382-5_2
10.1056/NEJMoa2114833
10.1126/science.abk0297
10.1038/ijo.2012.137
10.1093/function/zqaa034
10.7554/eLife.04617
10.1001/archinte.167.19.2116
10.1097/HJH.0b013e3282f97854
10.1161/01.HYP.0000170138.56903.7a
10.1093/ajh/hpu241
10.1056/NEJMra060433
10.1016/0895-7061(96)00302-0
10.1016/j.amjhyper.2006.10.010
10.3109/07420528.2012.701489
10.1038/hr.2015.89
10.1016/s0092-8674(00)81294-5
10.1177/0748730418803719
10.1152/ajprenal.90417.2008
10.1113/expphysiol.2008.046474
10.1152/ajpheart.00257.2008
10.1152/ajpheart.00825.2011
10.1111/micc.12192
10.1016/j.cmet.2016.03.007
10.1007/s00125-004-1461-0
10.1056/NEJM200001203420301
10.1097/00004872-199816120-00016
10.1016/s0140-6736(97)05381-6
10.3109/07420528.2010.510230
10.1111/jch.12238
10.1093/eurheartj/ehz754
10.1161/HYPERTENSIONAHA.121.17356
10.1097/HJH.0000000000002671
10.1093/eurheartj/ehaa963
10.1097/HJH.0000000000003240
10.1136/bmjopen-2015-010313
10.1136/bmjopen-2021-059711
10.1073/pnas.1619320114
10.1161/CIRCRESAHA.114.302995
10.1038/s42003-019-0595-z
10.1016/j.jacc.2010.11.022
10.1097/MBP.0000000000000598
10.1161/01.HYP.0000113293.15186.3b
10.1038/s41569-020-00466-4
10.1038/hr.2010.218
10.1097/HJH.0b013e328330e84d
10.1371/journal.pone.0097919
10.1186/s12881-018-0624-7
10.1038/hr.2014.152
10.1161/HYPERTENSIONAHA.116.07958
10.1038/ng.3406
10.1161/HYPERTENSIONAHA.118.11171
10.1001/jama.2015.18359
10.1016/j.ajhg.2017.09.028
10.1161/HYPERTENSIONAHA.120.14973
10.1161/HYPERTENSIONAHA.113.02637
10.1161/HYPERTENSIONAHA.118.11650
10.1161/HYPERTENSIONAHA.121.18584
10.1161/HYPERTENSIONAHA.120.17351
10.1093/sleep/zsz101
10.1016/j.cophys.2018.05.003
10.1038/s41371-020-00469-1
10.1016/S2589-7500(20)30200-4
10.1016/j.clinthera.2017.03.018
10.1038/s41746-020-0302-y
10.1111/joim.12211
10.1016/j.jclinepi.2016.12.023
10.3390/healthcare7040134",<Element 'PubmedArticle' at 0x7f05df0652c0>
65,36444683,Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.,"Key pathological features of Alzheimer's disease (AD) include build-up of amyloid β (Aβ), which promotes synaptic abnormalities and ultimately leads to neuronal cell death. Metabolic dysfunction is known to influence the risk of developing AD. Impairments in the leptin system have been detected in AD patients, which has fuelled interest in targeting this system to treat AD. Increasing evidence supports pro-cognitive and neuroprotective actions of leptin and these beneficial effects of leptin are mirrored by a bioactive leptin fragment (leptin","[""Alzheimer's disease"", 'amyloid', 'hippocampus', 'leptin', 'memory', 'synaptic plasticity', 'tau']",Journal of neurochemistry,2022-11-30,"[{'lastname': 'Doherty', 'firstname': 'Gayle', 'initials': 'G', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Holiday', 'firstname': 'Alison', 'initials': 'A', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Malekizadeh', 'firstname': 'Yasaman', 'initials': 'Y', 'affiliation': 'Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.'}, {'lastname': 'Manolescu', 'firstname': 'Cosmin', 'initials': 'C', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Duncan', 'firstname': 'Stephen', 'initials': 'S', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Flewitt', 'firstname': 'Iona', 'initials': 'I', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Hamilton', 'firstname': 'Kirsty', 'initials': 'K', 'affiliation': 'Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.'}, {'lastname': 'MacLeod', 'firstname': 'Beth', 'initials': 'B', 'affiliation': 'Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.'}, {'lastname': 'Ainge', 'firstname': 'James A', 'initials': 'JA', 'affiliation': 'School of Psychology & Neuroscience, St Andrews, UK.'}, {'lastname': 'Harvey', 'firstname': 'Jenni', 'initials': 'J', 'affiliation': 'Division of Systems Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.'}]",,,,© 2022 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.,10.1111/jnc.15733,<Element 'PubmedArticle' at 0x7f05df3cd4f0>
66,36368460,"The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: A systematic review.","Many regions of the brain have a high density of glucocorticoid receptors, and the prolonged elevation of endogenous glucocorticoids may cause neurotoxicity and increase risk for cognitive decline and dementia. However, despite synthetic glucocorticoids being the first line of treatment for many inflammatory diseases, few studies have addressed whether therapeutic glucocorticoids may have similar undesirable effects on the brain. Thus, our systematic review investigated the impact of long-term glucocorticoid usage on adult brain structure, cognitive function, and dementia risk. We identified 13 studies that met our eligibility criteria and found conflicting results dependent on the outcome studied. In particular, all but one study on hippocampal and amygdalar volumes found significant atrophy of both structures occurred in those who took glucocorticoids. Additionally, executive function, particularly working memory, and global cognitive function were significantly poorer in those taking long-term glucocorticoids. Notably, declines in episodic memory were not associated with long-term usage. Furthermore, most studies of dementia (all-cause) and Alzheimer's disease, excluding vascular dementia, showed null to negative associations with glucocorticoids, suggesting a potential protective effect. Therefore, glucocorticoid therapy in those with inflammatory disease may impair certain brain structures and specific cognitive functions, but could lead to a significantly reduced risk of dementia.","[""Alzheimer's disease"", 'Amygdala', 'Cognitive function', 'Dementia', 'Glucocorticoid', 'Hippocampus']",Brain research,2022-11-12,"[{'lastname': 'Shorey', 'firstname': 'Carrie L', 'initials': 'CL', 'affiliation': 'University of Waterloo, School of Public Health Sciences, Waterloo, Ontario, Canada. Electronic address: carrie.shorey@uwaterloo.ca.'}, {'lastname': 'Mulla', 'firstname': 'Reem T', 'initials': 'RT', 'affiliation': 'University of Waterloo, School of Public Health Sciences, Waterloo, Ontario, Canada.'}, {'lastname': 'Mielke', 'firstname': 'John G', 'initials': 'JG', 'affiliation': 'University of Waterloo, School of Public Health Sciences, Waterloo, Ontario, Canada.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2022.148157,<Element 'PubmedArticle' at 0x7f05dc74b540>
67,"36356843
19381305
24265455
24550796
26303142
15914711
24679540
20674387
22254103
35334951
19150388
21976778
26271515
19321517
19282384
15550512
16823488
23362264
26119689
15295589
30932888
22037588
29954063
29701781
31130840
34813976
17001693
24582848
15882777
19519313
34763094
34505123
11773448
14673133
17909266
30595381
19111595
21047949
16901926
18787026
34432046
17875487
17200939
20738289
22985940
19549740
21502974
23438832
35267980
20654663
20077419
22419567
22221326
24393720
21410762
12141930
16402912
20364093
12790807
17208362
30497016
27320328
27448243
33488352
33022416
33157321
34781166
34246776
33412267
34559191",Regulation of retinoid mediated StAR transcription and steroidogenesis in hippocampal neuronal cells: Implications for StAR in protecting Alzheimer's disease.,"Retinoids (vitamin A and its derivatives) play pivotal roles in diverse processes, ranging from homeostasis to neurodegeneration, which are also influenced by steroid hormones. The rate-limiting step in steroid biosynthesis is mediated by the steroidogenic acute regulatory (StAR) protein. In the present study, we demonstrate that retinoids enhanced StAR expression and pregnenolone biosynthesis, and these parameters were markedly augmented by activation of the PKA pathway in mouse hippocampal neuronal HT22 cells. Deletion and mutational analyses of the 5'-flanking regions of the StAR gene revealed the importance of a retinoic acid receptor (RAR)/retinoid X receptor (RXR)-liver X receptor (LXR) heterodimeric motif at -200/-185 bp region in retinoid responsiveness. The RAR/RXR-LXR sequence motif can bind RARα and RXRα, and retinoid regulated transcription of the StAR gene was found to be influenced by the LXR pathway, representing signaling cross-talk in hippocampal neurosteroid biosynthesis. Steroidogenesis decreases during senescence due to declines in the central nervous system and the endocrine system, and results in hormone deficiencies, inferring the need for hormonal balance for healthy aging. Loss of neuronal cells, involving accumulation of amyloid beta (Aβ) and/or phosphorylated Tau within the brain, is the pathological hallmark of Alzheimer's disease (AD). HT22 cells overexpressing either mutant APP (mAPP) or mutant Tau (mTau), conditions mimetic to AD, enhanced toxicities, and resulted in attenuation of both basal and retinoid-responsive StAR and pregnenolone levels. Co-expression of StAR with either mAPP or mTau diminished cytotoxicity, and concomitantly elevated neurosteroid biosynthesis, pointing to a protective role of StAR in AD. These findings provide insights into the molecular events by which retinoid signaling upregulates StAR and steroid levels in hippocampal neuronal cells, and StAR, by rescuing mAPP and/or mTau-induced toxicities, modulates neurosteroidogenesis and restores hormonal balance, which may have important implications in protecting AD and age-related complications and diseases.","[""Alzheimer's disease"", 'Hippocampal neuronal cells', 'Neurosteroid biosynthesis', 'RAR/RXR', 'Retinoids', 'StAR', 'mAPP', 'mTau']",Biochimica et biophysica acta. Molecular basis of disease,2022-11-11,"[{'lastname': 'Manna', 'firstname': 'Pulak R', 'initials': 'PR', 'affiliation': 'Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: pulak.manna@ttuhsc.edu.'}, {'lastname': 'Reddy', 'firstname': 'Arubala P', 'initials': 'AP', 'affiliation': 'Nutritional Sciences Department, College of Human Sciences, Texas Tech University, 1301 Akron Ave, Lubbock, TX 79409, USA.'}, {'lastname': 'Pradeepkiran', 'firstname': 'Jangampalli Adi', 'initials': 'JA', 'affiliation': 'Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.'}, {'lastname': 'Kshirsagar', 'firstname': 'Sudhir', 'initials': 'S', 'affiliation': 'Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.'}, {'lastname': 'Reddy', 'firstname': 'P Hemachandra', 'initials': 'PH', 'affiliation': 'Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Nutritional Sciences Department, College of Human Sciences, Texas Tech University, 1301 Akron Ave, Lubbock, TX 79409, USA; Neurology, Departments of School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Public Health Department of Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Speech, Language and Hearing Sciences, School Health Professions, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA; Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. Electronic address: hemachandra.reddy@ttuhsc.edu.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2022.166596,<Element 'PubmedArticle' at 0x7f05dc75b2c0>
68,"36337024
20107219
30775973
27025652
24853936
15983176
28941188
27599231
30632505
25045655
27599230
25281013
25703239
22238626
26529502
26154489
28692878
15219659
2324335
11099831
31746286
20505099
26198711
23563222
15190103
20552051
11421594
31502112
32903757
15827095
10946891
11606422
8709781
12413371
32210745
28202700
28274328
30842086
12771112
30317535
20392807
23348042
18703472
11063905
19412477
18001721
20167003
31918180
32865575
31268539
31784699
31040681
30637900
30025445
30080934
29477720
30325986
28841388
27583806
27232853
28188757
27737437
27870566
27019142
27062333
26644522
25964245
11325319
29410294
32690473
28349979
29689315
20044001
29338083
28241356
26553159
27377542
25921747
25392187
25143719
19880786
18167405
17609296
17726086
17145137
16344336
15653010
14718489
12809076
11585606
11445632
28914204
17132744
27662450
23089633
19428144
14624021
33281745
24710799
27907849
15582279
29339527
14992810
24428527",[Testosterone and Alzheimer's disease].,"Alzheimer's disease (AD) is a neurodegenerative disease that causes dementia in half of the cases. Asthma is usually found in people over 65 years of age. The etiopathogenesis of the disease is multifactorial and includes genetic factors, nutritional disorders, mitochondrial dysfunction, oxidative stress, and aging. Sex hormones have an important influence on the development of AD, as evidenced by a higher incidence in women than in men. Considering the significant influence of T on the maintenance of normal brain function, the present study is aimed at evaluating the impact of androgen deprivation therapy (ADT), as well as testosterone therapy, on the risk of AD development and progression. Although there is some clinical inconsistency between studies, androgens have a significant effect on brain function and are beneficial for AD patients. Low levels of circulating androgens should be considered as a significant risk factor for the development of AD and memory loss. With a reduced level of T in the plasma of men, its administration improves cognitive performance and memory, treatment should be started at an early stage of the disease. In men and women with AD, androgens improve mental state and slow the progression of the disease, providing a protective effect. In the future, it is necessary to conduct studies on a large population, taking into account personality factors and a more specific approach to assessing cognitive functions and the causal relationship of T administration in AD.
Болезнь Альцгеймера (БА) является нейродегенеративным заболеванием, которое становится причиной деменции в половине случаев ее возникновения. БА, как правило, обнаруживается у людей старше 65 лет. Этиопатогенез заболевания является многофакторным и включает генетические факторы, нарушения питания, митохондриальную дисфункцию, окислительный стресс и старение. Половые гормоны оказывают важное влияние на развитие БА, о чем свидетельствует большая заболеваемость у женщин, чем у мужчин. Учитывая значительное влияние тестостерона (Т) на поддержание нормального функционирования головного мозга, настоящее исследование направлено на оценку влияния андроген-депривационной терапии, а также терапии тестостероном на риск развития и прогрессирования БА. Хотя между исследованиями существует некоторое клиническое несоответствие, андрогены оказывают значительное влияние на функцию головного мозга и полезны для пациентов с БА. Низкие уровни циркулирующих андрогенов следует рассматривать как существенный фактор риска развития БА и потери памяти. При сниженном уровне Т в плазме мужчин его введение способствует повышению когнитивной работоспособности и памяти, лечение следует начинать на ранней стадии заболевания. У мужчин и женщин с БА андрогены улучшают психическое состояние и замедляют прогрессирование заболевания, оказывая протективное действие. В будущем необходимо проведение исследований на большой популяции с учетом факторов индивидуальности и более конкретным подходом к оценке когнитивных функций и причинной-следственной связи введения Т при БА.",[],Problemy endokrinologii,2022-11-08,"[{'lastname': 'Kuznetsov', 'firstname': 'K O', 'initials': 'KO', 'affiliation': 'N.I. Pirogov Russian national research medical university.'}, {'lastname': 'Khaidarova', 'firstname': 'R R', 'initials': 'RR', 'affiliation': 'Bashkir state medical university.'}, {'lastname': 'Khabibullina', 'firstname': 'R H', 'initials': 'RH', 'affiliation': 'First Pavlov state medical university of St. Petersburg.'}, {'lastname': 'Stytsenko', 'firstname': 'E S', 'initials': 'ES', 'affiliation': 'Saint Petersburg state pediatric medical university.'}, {'lastname': 'Filosofova', 'firstname': 'V I', 'initials': 'VI', 'affiliation': 'First Pavlov state medical university of St. Petersburg.'}, {'lastname': 'Nuriakhmetova', 'firstname': 'I R', 'initials': 'IR', 'affiliation': 'Bashkir state medical university.'}, {'lastname': 'Hisameeva', 'firstname': 'E M', 'initials': 'EM', 'affiliation': 'Bashkir state medical university.'}, {'lastname': 'Vazhorov', 'firstname': 'G S', 'initials': 'GS', 'affiliation': 'I.N. Ulyanov Chuvash State University.'}, {'lastname': 'Khaibullin', 'firstname': 'F R', 'initials': 'FR', 'affiliation': 'Bashkir state medical university.'}, {'lastname': 'Ivanova', 'firstname': 'E A', 'initials': 'EA', 'affiliation': 'Kursk State Medical University.'}, {'lastname': 'Gorbatova', 'firstname': 'K V', 'initials': 'KV', 'affiliation': 'Kursk State Medical University.'}]",,,,,"10.14341/probl13136
10.1056/nejmra0909142
10.3233/JAD-181052
10.15252/emmm.201606210
10.1016/j.neuron.2014.05.004
10.1093/gerona/60.6.736
10.1111/cns.12757
10.1080/15287394.2016.1193114
10.4103/1673-5374.245477
10.1155/2014/103906
10.1080/15287394.2016.1193113
10.1016/j.bbadis.2014.09.013
10.1007/s11011-015-9655-3
10.1371/journal.pone.0029598
10.1080/15287394.2015.1085839
10.1007/s12035-015-9315-y
10.1016/j.neurobiolaging.2017.06.005
10.1016/j.psyneuen.2003.11.002
10.1002/cne.902940107
10.1016/s0304-3940(00)01622-0
10.1080/15287394.2019.1683988
10.1523/jneurosci.1180-10.2010
10.1007/s00018-015-1988-x
10.1016/j.yfrne.2013.03.001
10.1523/jneurosci.0913-04.2004
10.3389/fnagi.2010.00015
10.1006/exnr.2001.7687
10.1007/s10571-019-00733-0
10.3389/fnagi.2020.00240
10.1210/jc.2005-0212
10.1210/jcem.85.8.6740
10.1210/endo.142.11.8547
10.1016/s0140-6736(96)03356-9
10.1001/jama.288.17.2123
10.3389/fnins.2020.00157
10.1212/wnl.0000000000003696
10.1016/j.maturitas.2017.01.002
10.1136/bmj.l665
10.1001/jama.289.20.2651
10.1007/s40266-018-0591-x
10.1124/pr.109.002071
10.1016/j.molmed.2012.12.007
10.1056/nejmoa0800743
10.1016/s0378-5122(00)00147-x
10.2147/nedt.2006.2.3.299
10.1016/j.fertnstert.2007.05.061
10.2174/1874609811003020113
10.1016/j.canep.2019.101657
10.1001/jamanetworkopen.2020.15189
10.1001/jamanetworkopen.2019.6562
10.1038/s41391-019-0189-3
10.2147/ndt.s200501
10.1111/bju.14666
10.4143/crt.2018.119
10.1002/phar.2168
10.1016/j.juro.2018.02.073
10.1001/jamaoncol.2018.4423
10.1200/jco.2017.72.6109
10.1002/cncr.30320
10.4103/1008-682x.179528
10.1016/j.urology.2016.12.060
10.1001/jamaoncol.2016.3662
10.1200/jco.2016.69.6203
10.1016/j.socscimed.2016.03.016
10.1111/andr.12187
10.1200/jco.2015.63.6266
10.1200/jco.2014.60.1963
10.1001/jama.285.17.2195-a
10.1016/j.juro.2017.11.136
10.1016/j.euf.2020.05.014
10.1038/pcan.2017.10
10.1016/j.phrs.2018.04.017
10.1016/j.nbd.2009.12.016
10.1002/cncr.31153
10.1001/jama.2016.21044
10.2174/1871527315666151110125704
10.1016/s2213-8587(16)30102-4
10.2174/1871527314666150429112112
10.1177/1533317514556874
10.2147/cia.s61760
10.1210/jc.2009-1346
10.1001/jama.2007.51
10.2164/jandrol.107.002931
10.1210/jc.2006-1805
10.1016/j.psyneuen.2006.10.008
10.1001/archneur.63.2.nct50002
10.1016/j.maturitas.2004.05.002
10.1093/gerona/59.1.m75
10.1080/tam.6.1.13.17
10.1016/s0028-3932(01)00067-7
10.1212/wnl.57.1.80
10.2174/1389450118666170913162739
10.1530/eje.1.02306
10.1097/wnn.0000000000000104
10.1038/mp.2012.147
10.1016/j.neurobiolaging.2009.04.008
10.3233/jad-2003-5401
10.3389/fendo.2020.586909
10.1177/1352458514527864
10.1016/j.psyneuen.2016.11.014
10.1016/j.exger.2004.06.019
10.1530/eje-17-0673
10.1016/j.molbrainres.2003.08.022
10.1210/en.2013-1725",<Element 'PubmedArticle' at 0x7f05dc98a400>
69,36328067,Early time course of oxidative stress in hippocampal synaptosomes and cognitive loss following impaired insulin signaling in rats: Development of sporadic Alzheimer's disease.,"Oxidative stress, caused by impaired insulin signaling, plays a pivotal role in the pathogenesis of sporadic Alzheimer's disease (sAD). We investigated the oxidative stress parameters in the synaptosomes prepared from the hippocampus tissue in order to identify their potential role in sAD development in intraperitoneal (IP) and intracerebroventricular (ICV) streptozotocin (STZ) injections models of insulin signaling impairment. Rats were harvested 1, 3, or 6 weeks post treatment. Spatial learning and memory, several antioxidants and oxidative stress markers were analyzed. Results showed a significant deficit in learning and memory in rats injected with STZ through IP and ICV routes. Glutathione, glutathione/oxidized glutathione, glutathione S-transferase, glutathione peroxidase, glutathione reductase, catalase, superoxide dismutase(SOD)-total, Zn/Cu(SOD), Mn/Fe(SOD) are significantly decreased in IP-STZ and ICV-STZ groups at 1, 3, and 6 weeks after STZ injection. Oxidized glutathione, thiobarbituric acid reactive species, glucose 6-Phosphate dehydrogenase, protein carbonyls, 4-Hydroxynonenal, and 3-Nitrotyrosine are significantly increased in IP-STZ and ICV-STZ groups at 1,3, and 6 weeks after STZ injection. Changes in oxidative stress parameters in ICV-STZ groups are greater than IP-STZ groups. STZ treatment induced cognitive impairments by 3-W and 6-W, and it was significantly correlated with the extent of oxidative damage. In conclusion, STZ administration through ICV route is deleterious in causing early synaptosomal oxidative damage that exacerbated with time and correlated with cognitive impairments. Our data implicate the involvement of oxidative stress as an early feature of sAD and provide insights into the behavioral and biochemical changes over the course of disease development.","['Alzheimer’s Disease', 'Cognitive impairment', 'Oxidative stress', 'Streptozotocin', 'Synaptosomes']",Brain research,2022-11-04,"[{'lastname': 'Ansari', 'firstname': 'Mubeen A', 'initials': 'MA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait City 13110, Kuwait. Electronic address: mubeen.ansari@ku.edu.kw.'}, {'lastname': 'Rao', 'firstname': 'Muddanna S', 'initials': 'MS', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Kuwait University, Kuwait City 13110, Kuwait.'}, {'lastname': 'Al-Jarallah', 'firstname': 'Aishah', 'initials': 'A', 'affiliation': 'Department of Biochemistry, Faculty of Medicine, Kuwait University, Kuwait City 13110, Kuwait.'}, {'lastname': 'Babiker', 'firstname': 'Fawzi M', 'initials': 'FM', 'affiliation': 'Department of Physiology, Faculty of Medicine, Kuwait University, Kuwait City 13110, Kuwait.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2022.148134,<Element 'PubmedArticle' at 0x7f05dcfc7a90>
70,"36324151
31083442
31823877
21439035
32758917
25410359
16787929
27323783
11433375
19161911
24186934
26525923
12909304
19915485
12689599
17697439
32790155
25897080
25008761
31209784
22890115
32538846
20576109
32603972
30010124
22913619
26843008
30715078
31803046
21760532
11245665
27196727
16023653
22402435
25676562
19296504
20451875
25150730
20496206
26151887
8987819
27632792
11689174
22727497
33682714
25822631
19657019
29660938
26451386
28906407
22622580
24030206
24623176
32788242
26969397
15361365",Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.,"Studies have reported higher plasma matrix metalloproteinase-9 (MMP-9) levels in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Despite evidence that MMP-9 activity and its influence on AD pathophysiology may be modulated by sex hormones, sex differences in the association between MMP-9 and AD biomarkers and cognition have not been explored.
Our sample included 238 amyloid-β (Aβ)-positive participants with MCI or AD dementia from the Alzheimer's Disease Neuroimaging Initiative (37.4% women, 74.6 ± 7.3 years). We used linear regression models to examine whether sex modified free and total plasma MMP-9 associations with CSF t-tau, p-tau181, and Aβ
Total and free MMP-9 levels did not differ by sex, but AD dementia patients had higher total MMP-9 levels than participants with MCI (β = 0.06 [-0.11 to -0.01], p = 0.031). Sex modified the association of CSF t-tau with total (β = 128.68 [55.37 to 201.99], p < 0.001) and free MMP-9 (β = 98.61 [33.61 to 163.62], p = 0.003), whereby higher total and free MMP-9 correlated with higher CSF t-tau in women and lower CSF t-tau in men. Higher free MMP-9 correlated with lower CSF p-tau181 among men (β = -14.98 [-27.37 to -2.58], p = 0.018), but not women. In participants with MCI, higher free MMP-9 levels were associated with higher CSF Aβ
MMP-9 may have more detrimental effects on AD-related pathological and cognitive changes in women. If replicated, our findings could help uncover potential mechanisms contributing to women's elevated susceptibility to AD.","['Alzheimer’s disease', 'Amyloid-β', 'Cognitive decline', 'Fluid biomarkers', 'Matrix metalloproteinase-9', 'Mild cognitive impairment', 'Sex differences', 'Tau']",Alzheimer's research & therapy,2022-11-04,"[{'lastname': 'Tsiknia', 'firstname': 'Amaryllis A', 'initials': 'AA', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Sundermann', 'firstname': 'Erin E', 'initials': 'EE', 'affiliation': 'Research Service, VA San Diego Healthcare System, San Diego, CA, 92161, USA.\nDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, 92093, USA.'}, {'lastname': 'Reas', 'firstname': 'Emilie T', 'initials': 'ET', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Edland', 'firstname': 'Steven D', 'initials': 'SD', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.\nDivision of Biostatistics, School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, 92093, USA.'}, {'lastname': 'Brewer', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Galasko', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Banks', 'firstname': 'Sarah J', 'initials': 'SJ', 'affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA. sbanks@health.ucsd.edu.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Total and free MMP-9 levels did not differ by sex, but AD dementia patients had higher total MMP-9 levels than participants with MCI (β = 0.06 [-0.11 to -0.01], p = 0.031). Sex modified the association of CSF t-tau with total (β = 128.68 [55.37 to 201.99], p < 0.001) and free MMP-9 (β = 98.61 [33.61 to 163.62], p = 0.003), whereby higher total and free MMP-9 correlated with higher CSF t-tau in women and lower CSF t-tau in men. Higher free MMP-9 correlated with lower CSF p-tau181 among men (β = -14.98 [-27.37 to -2.58], p = 0.018), but not women. In participants with MCI, higher free MMP-9 levels were associated with higher CSF Aβ",© 2022. The Author(s).,"10.1186/s13195-022-01106-4
10.3390/jcm8050651
10.4103/1673-5374.270306
10.1186/1742-2094-8-26
10.1016/j.neurobiolaging.2020.06.018
10.1016/B978-0-444-63486-3.00009-8
10.1074/jbc.M602440200
10.1177/0271678X16655551
10.1038/35081571
10.1016/S1474-4422(09)70016-X
10.1152/physiol.00029.2013
10.1111/jnc.13415
10.1016/S0361-9230(03)00097-2
10.1097/NEN.0b013e3181c22569
10.1016/S0197-0186(03)00004-4
10.1017/S1041610207005790
10.1002/acn3.51155
10.1074/jbc.M114.610931
10.1016/j.nbd.2014.06.021
10.1007/s12035-019-01672-z
10.1016/j.expneurol.2012.07.018
10.3233/JAD-200146
10.1186/alzrt44
10.1016/j.jns.2020.116989
10.3233/JAD-180141
10.1080/13803395.2012.712676
10.1007/s11682-016-9523-8
10.1001/jamaneurol.2018.4693
10.3389/fnagi.2019.00315
10.2310/JIM.0b013e3182279e4b
10.1523/JNEUROSCI.21-06-01809.2001
10.1210/er.2016-1007
10.1016/j.atherosclerosis.2005.06.011
10.1016/j.mcn.2012.02.005
10.1002/prca.201400178
10.1002/ana.21610
10.1016/j.jalz.2010.03.013
10.1016/j.jalz.2014.05.1754
10.1080/10543401003618819
10.3109/00365513.2015.1057760
10.1523/JNEUROSCI.16-24-07910.1996
10.1111/jne.12432
10.1016/S0006-8993(01)03024-4
10.1016/j.atherosclerosis.2012.05.031
10.3233/JAD-201382
10.1001/jamaneurol.2014.4477
10.1523/JNEUROSCI.2234-09.2009
10.3233/JAD-170991
10.1016/j.trci.2015.07.001
10.1097/MD.0000000000008072
10.1038/nature11087
10.1001/jamaneurol.2013.3841
10.1002/ana.24135
10.1212/WNL.0000000000010629
10.1016/j.jsbmb.2016.03.012
10.1164/rccm.200402-193OC",<Element 'PubmedArticle' at 0x7f05dcfb6a40>
71,36322277,Brown adipose tissue and alzheimer's disease.,"Alzheimer's disease (AD), the most common type of senile dementia, is a chronic neurodegenerative disease characterized by cognitive dysfunction and behavioral disability. The two histopathological hallmarks in this disease are the extraneuronal accumulation of amyloid-β (Aβ) and the intraneuronal deposition of neurofibrillary tangles (NFTs). Despite this, central and peripheral metabolic dysfunction, such as abnormal brain signaling, insulin resistance, inflammation, and impaired glucose utilization, have been indicated to be correlated with AD. There is solid evidence that the age-associated thermoregulatory deficit induces diverse metabolic changes associated with AD development. Brown adipose tissue (BAT) has been known as a thermoregulatory organ particularly vital during infancy. However, in recent years, BAT has been accepted as an endocrine organ, being involved in various functions that prevent AD, such as regulating energy metabolism, secreting hormones, improving insulin sensitivity, and increasing glucose utilization in adult humans. This review focuses on the mechanisms of BAT activation and the effect of aging on BAT production and signaling. Specifically, the evidence demonstrating the effect of BAT on pathological mechanisms influencing the development of AD, including insulin pathway, thermoregulation, and other hormonal pathways, are reviewed in this article.","['Aging', 'Alzheimer’s disease', 'Brown adipose tissue', 'Glucose metabolism', 'Insulin', 'Metabolic alteration', 'Thermogenesis']",Metabolic brain disease,2022-11-03,"[{'lastname': 'Tayanloo-Beik', 'firstname': 'Akram', 'initials': 'A', 'affiliation': 'Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Nikkhah', 'firstname': 'Amirabbas', 'initials': 'A', 'affiliation': 'School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Alaei', 'firstname': 'Setareh', 'initials': 'S', 'affiliation': 'Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Goodarzi', 'firstname': 'Parisa', 'initials': 'P', 'affiliation': 'Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Rezaei-Tavirani', 'firstname': 'Mostafa', 'initials': 'M', 'affiliation': 'Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Mafi', 'firstname': 'Ahmad Rezazadeh', 'initials': 'AR', 'affiliation': 'Department of Radiation Oncology, Imam Hossein Hospital, Shaheed Beheshti Medical University, Tehran, Iran.'}, {'lastname': 'Larijani', 'firstname': 'Bagher', 'initials': 'B', 'affiliation': 'Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical sciences, Tehran, Iran. emrc@tums.ac.ir.'}, {'lastname': 'Shouroki', 'firstname': 'Fatemeh Fazeli', 'initials': 'FF', 'affiliation': 'Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Arjmand', 'firstname': 'Babak', 'initials': 'B', 'affiliation': 'Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. barjmand@sina.tums.ac.ir.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s11011-022-01097-z
10.1016/j.metabol.2017.11.009
10.1016/j.ijcard.2016.11.074
10.1016/b978-0-444-64074-1.00044-6
10.1007/s12640-018-9914-2
10.1074/jbc.M114.565358
10.2967/jnumed.115.165829
10.1007/s10561-020-09826-3
10.1007/s10561-020-09826-3
10.1152/ajpendo.00600.2009
10.1016/j.mce.2011.03.016
10.1016/j.arr.2018.11.002
10.1038/srep00480
10.1152/physrev.00015.2003
10.1080/23328940.2015.1096438
10.1016/j.redox.2019.101133
10.1016/j.autneu.2016.01.001
10.1210/endo.138.2.4908
10.1177/1536012117704557
10.1111/acel.12948
10.1056/NEJMoa0810780
10.1016/j.cmet.2014.12.009
10.1007/s11906-018-0894-7
10.1042/cs0950213
10.1007/s10571-015-0239-x
10.1007/s11892-018-1049-6
10.1016/j.bbalip.2018.04.013
10.1016/0006-8993(94)90218-6
10.7554/eLife.08428
10.1016/j.nbd.2016.01.005
10.2174/138161207781039634
10.22088/ijmcm.Bums.8.2.30
10.22088/IIJMCM.BUMS.8.2.30
10.1007/s10561-019-09773-8
10.1007/164_2018_151
10.1159/000366557
10.1016/j.nbd.2016.10.004
10.1016/j.neulet.2009.03.066
10.1590/0004-2730000003492
10.1016/0006-8993(90)91579-6
10.1038/nm.3891
10.1007/s12031-020-01542-7
10.1093/ajcn/80.2.475
10.1016/0006-8993(92)90422-6
10.2220/biomedres.34.173
10.2174/1871527316666170807130011
10.2147/cmar.S188661
10.1007/s40520-015-0521-2
10.1210/clinem/dgab037
10.1007/s11011-020-00622-2
10.1007/5584_2021_624
10.22088/ijmcm.Bums.8.2.41
10.1016/j.bbamcr.2020.118664
10.1111/j.1749-6632.2011.06274.x
10.2337/db14-0513
10.1038/emm.2013.163
10.1111/joim.12255
10.18632/aging.100706
10.2527/jas.2007-0462
10.1016/j.cca.2015.08.009
10.1038/nrdp.2015.56
10.1097/med.0000000000000191
10.1111/j.1755-5949.2010.00177.x
10.1177/2333721420932432
10.1210/en.2003-0537
10.1096/fj.03-1086fje
10.2174/1573399812666160517115450
10.1097/CRD.0b013e31829cabff
10.1016/j.neulet.2019.04.022
10.1016/bs.irn.2015.05.008
10.1152/ajpendo.00691.2006
10.1186/s12974-018-1313-3
10.1016/0091-3057(95)02039-x
10.1038/s41366-020-0616-5
10.1038/s41366-020-0616-5
10.2337/db10-0004
10.1016/j.freeradbiomed.2015.05.005
10.1523/JNEUROSCI.5561-03.2004
10.1523/jneurosci.5561-03.2004
10.3390/ph13110401
10.3233/jad-180837
10.1016/j.cell.2014.03.066
10.1515/revneuro-2017-0063
10.1007/s00484-013-0785-1
10.3233/jad-200837
10.1002/cphy.c170001
10.1016/j.yhbeh.2016.08.006
10.2337/db12-1430
10.1159/000321319
10.1016/j.beem.2016.08.003
10.1007/s12035-019-01858-5
10.2174/1570159x18666200207120949
10.1016/j.bcp.2018.07.022
10.3389/fnmol.2014.00016
10.1016/s0303-7207(00)00276-8
10.1172/jci62308
10.3233/jad-2009-0991
10.1073/pnas.0610615104
10.2147/IJN.S200490
10.1016/j.neurobiolaging.2016.09.024
10.2174/1381612826666201118092422
10.1016/j.ejphar.2017.03.051
10.1016/j.neurobiolaging.2016.03.024
10.2337/db14-0375
10.1111/joim.12803
10.1038/nrendo.2016.136
10.1152/ajpendo.00250.2013
10.2337/db12-0288
10.1038/s41598-019-45509-0
10.1038/s41598-019-45509-0
10.1152/ajpendo.00049.2017
10.1016/j.mam.2019.06.004
10.2174/156720510793611646
10.1038/s41419-019-1706-y
10.1080/15548627.2018.1511263
10.3109/07853890.2014.911595
10.1073/pnas.1523236113
10.33549/physiolres.933650
10.3389/fendo.2015.00136
10.1186/alzrt211
10.3389/fendo.2019.00368
10.3389/fnins.2019.00378",<Element 'PubmedArticle' at 0x7f05dcbca720>
72,"36269295
32487284
31851800
12606496
14747300
24489845
26216873
19885299
23968694
15734146
24931034
32445739
32557841
30233156
30553010
16778001
27106830
30919343
29377010
33845179
28923931
29847142
7000502
9291119
22476197
15094070
12425944
32314178
30168804
23146889
33637536
15504987
12021765
16054044
28385803
19752162
22344561
10903566
12426561
29536605
22056385
25288674
35482079
33739944
31211691
28372335
16707912
16639425
9663454
24101698
25337926
25374101
18230654
23907764
25249577
32568367
11076791
29991649
32950427
19387108
22685618
30271528
30781611
15750215
21598254
14981233
22329651
16361024
20837822
30627769
26284161
17167157
31978826
21282661
31120807
30062523
29667159
34260606
33921094
33873267
35661882
31311133
31534057
28108329
22982624
18923051
25434013
15983193
15735205
32296068
28959911
21244124
1141674
618962
10440369
12661673
23467962
29203421
25469685
23806438
29538632
35044793
21683721
23371746
21878600
32409017
12586857
19123237
29113943
33315276
23593210
24041490
31680149
21894161
24619151
35304603
10195220
17765329
8836544
15896913
21531985
16177036
15548201
26912638
27130419
26545456
8855791
11222653
19681661
20571405
21481871
14656329
31942854
22458300
30149446
31778170
31897861
31437816
32562683
25771249",Brain insulin resistance and cognitive function: influence of exercise.,"Exercise has systemic health benefits in people, in part, through improving whole body insulin sensitivity. The brain is an insulin-sensitive organ that is often underdiscussed relative to skeletal muscle, liver, and adipose tissue. Although brain insulin action may have only subtle impacts on peripheral regulation of systemic glucose homeostasis, it is important for weight regulation as well as mental health. In fact, brain insulin signaling is also involved in processes that support healthy cognition. Furthermore, brain insulin resistance has been associated with age-related declines in memory and executive function as well as Alzheimer's disease pathology. Herein, we provide an overview of brain insulin sensitivity in relation to cognitive function from animal and human studies, with particular emphasis placed on the impact exercise may have on brain insulin sensitivity. Mechanisms discussed include mitochondrial function, brain growth factors, and neurogenesis, which collectively help combat obesity-related metabolic disease and Alzheimer's dementia.","['executive function', 'intranasal insulin', 'memory', 'mitochondrial function', 'physical activity']","Journal of applied physiology (Bethesda, Md. : 1985)",2022-10-22,"[{'lastname': 'Malin', 'firstname': 'Steven K', 'initials': 'SK', 'affiliation': 'Department of Kinesiology & Health, Rutgers University, New Brunswick, New Jersey.\nDivision of Endocrinology, Metabolism & Nutrition, Rutgers University, New Brunswick, New Jersey.\nNew Jersey Institute for Food, Nutrition and Health, Rutgers University, New Brunswick, New Jersey.\nInstitute of Translational Medicine and Science, Rutgers University, New Brunswick, New Jersey.'}, {'lastname': 'Stewart', 'firstname': 'Nathan R', 'initials': 'NR', 'affiliation': 'Department of Kinesiology & Health, Rutgers University, New Brunswick, New Jersey.'}, {'lastname': 'Ude', 'firstname': 'Andrew A', 'initials': 'AA', 'affiliation': 'Department of Kinesiology & Health, Rutgers University, New Brunswick, New Jersey.'}, {'lastname': 'Alderman', 'firstname': 'Brandon L', 'initials': 'BL', 'affiliation': 'Department of Kinesiology & Health, Rutgers University, New Brunswick, New Jersey.\nCenter of Alcohol and Substance Use Studies, Rutgers University, New Brunswick, New Jersey.'}]",,,,,"10.1152/japplphysiol.00375.2022
10.1056/NEJMsa1909301
10.2337/diabetes.52.3.581
10.2337/diabetes.53.2.474
10.1371/journal.pone.0087095
10.2337/dc15-0491
10.1177/193229680800200619
10.1016/j.tins.2013.07.001
10.1016/j.tem.2005.01.008
10.2337/db14-0568
10.1016/S2213-8587(20)30113-3
10.1002/ana.25826
10.2147/CIA.S169565
10.1016/j.rehab.2018.11.001
10.1152/japplphysiol.00500.2006
10.1007/s11154-016-9352-5
10.1007/978-3-030-12668-1_15
10.1038/nrneurol.2017.185
10.1016/j.molmet.2021.101234
10.1073/pnas.1710625114
10.1152/ajpcell.00240.2017
10.1002/ar.1090780203
10.1210/endo-107-6-1827
10.1042/bj3260463
10.1172/JCI59903
10.1016/j.ejphar.2004.02.041
10.1016/S0169-328X(02)00487-4
10.1007/s11064-020-03031-0
10.1172/JCI120843
10.1038/embor.2012.174
10.1126/sciadv.abf4100
10.2337/diabetes.53.11.3024
10.1038/nn0602-861
10.1016/j.cmet.2004.11.001
10.2337/db16-1238
10.2337/db09-0638
10.2337/db11-1390
10.1038/77660
10.1038/nm1202-798
10.1111/dom.13289
10.1172/JCI58035
10.2337/db14-0685
10.1007/s00415-022-11119-6
10.1249/JES.0000000000000242
10.1172/jci.insight.129700
10.3233/JAD-161256
10.1159/000093338
10.1038/sj.jcbfm.9600316
10.1016/S0196-9781(98)00018-7
10.2337/dc13-1672
10.1210/jc.2014-3018
10.3233/JAD-141791
10.1210/jc.2007-2606
10.1002/hbm.22304
10.2337/db14-1000
10.1001/jamaneurol.2020.1840
10.1152/ajplung.2000.279.6.L1005
10.1126/scisignal.aaq0702
10.1016/j.redox.2020.101696
10.3233/JAD-2009-0984
10.1155/2012/428010
10.1155/2018/6940515
10.3390/ijms20040874
10.3233/jad-2005-7107
10.1002/path.2912
10.1073/pnas.0308724101
10.2174/156720512799015037
10.1016/S1474-4422(05)70284-2
10.1001/archneurol.2010.225
10.1007/s00426-019-01145-x
10.1186/s40798-015-0016-x
10.1093/gerona/61.11.1166
10.1016/j.nicl.2020.102182
10.1073/pnas.1015950108
10.1152/japplphysiol.00249.2019
10.1007/s00415-018-8981-x
10.1007/s40279-018-0920-6
10.1371/journal.pone.0253733
10.3390/ijerph18084204
10.1016/j.clnu.2020.10.006
10.1093/gerona/glac121
10.3390/nu11071603
10.1172/jci.insight.130681
10.1016/j.exger.2017.01.013
10.1016/j.neuroscience.2012.09.001
10.1523/JNEUROSCI.2744-08.2008
10.1152/advan.00080.2014
10.2337/diabetes.54.7.1942
10.2337/diacare.28.3.662
10.1038/s41467-020-15686-y
10.1177/0271678X17734998
10.1037/a0021769
10.1093/geronj/30.4.435
10.1093/geronj/33.1.26
10.1038/22682
10.1111/1467-9280.t01-1-01430
10.1136/bjsports-2012-091441
10.1016/j.neubiorev.2017.11.020
10.1097/PSY.0000000000000103
10.1016/j.neubiorev.2013.06.012
10.1093/abm/kax035
10.1146/annurev-clinpsy-072720-014213
10.1016/j.neuropharm.2011.06.003
10.1007/s00221-013-3409-4
10.4065/mcp.2011.0252
10.1016/j.tins.2020.04.010
10.1093/gerona/58.2.m176
10.1002/hipo.20547
10.1016/j.neuroimage.2017.11.007
10.1002/hipo.23292
10.1371/journal.pone.0060393
10.1016/j.pscychresns.2013.06.004
10.1093/scan/nsz085
10.1038/ijo.2011.175
10.1093/gerona/glu031
10.1038/s41574-022-00641-2
10.1038/6368
10.1016/j.tins.2007.06.011
10.1016/0006-8993(96)00273-9
10.1016/j.neuroscience.2005.03.026
10.1177/1073858410397054
10.1523/JNEUROSCI.1731-05.2005
10.1111/j.1460-9568.2004.03720.x
10.1093/brain/awv407
10.1016/bs.pbr.2016.03.010
10.1016/j.neuroimage.2015.10.084
10.1210/jcem.81.10.8855791
10.1523/JNEUROSCI.21-05-01628.2001
10.33549/physiolres.931764
10.1097/HJR.0b013e32833ba654
10.1016/j.atherosclerosis.2011.03.018
10.1111/j.1460-9568.2003.03041.x
10.2174/1381612826666200114102524
10.1111/j.1532-5415.2012.03916.x
10.3233/JAD-180263
10.1210/clinem/dgz234
10.1007/s11357-019-00146-3
10.1530/EJE-19-0259
10.1016/S1474-4422(20)30173-3
10.1016/S0140-6736(15)60461-5",<Element 'PubmedArticle' at 0x7f05dcb89950>
73,"36258018
22198405
33302541
27188934
26236139
30890425
30287052
31906949
33184908
19074620
34323288
26290108
21329743
30573675
30372907
25331995
23728174
28085521
12629557
32755557
25027491
29364586
26228460
33068776
31600725
32213703
25202980
33738783
31680842
27715341
27630114
26666230
31767182
17084085
14622093
29402504
24694879
23785355
33764504
25385322
26111974
31813360
33942194
21525299
23973293
25869785
32143329
29435980
33895160
33556642
33467075
31004737
31082410
33222922
28315374
26746341
27252647
30099030
30944040
31189511
32562683
15616236
19171735
26937541
32674367
24252804
27713036
32602947
26851597
30938196
32412796
28991675
11861804
19570816
19164583
17803225
30741689
28927992
25544681
33723752
26141845
24662192
28781108
30070753
28588440
30640362
28577987
23564922
21437936
22476197
28058769
34512508
32250322
17098089
8243312
24843404
24843404
34176784
17498508
30603316
21273318
23103794
27913104
32050617
32175781
31958096
30282365
29551659
32959677
29462693
28666800
32445758
34125470
26351802
29050859
29473979
32147454
9258263
20080301
31730763
28345670
30044494
25346723
33724579
33100956
11075717
29691988
34069890
29377010
32092326
15094078
30542257
25342129
31305918
30964050
30511349
24315369
30781611
27868170
33845179
27320287
31062332
22002425
29932983
28957663
21703262
21422926
24220636
32911247
32192190
29614702
33344443
32730766
21911655
32568367
25374101
31022213
23507773",Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.,"Despite an ever-growing prevalence and increasing economic burden of Alzheimer's disease (AD) and Parkinson's disease (PD), recent advances in drug development have only resulted in minimally effective treatment. In AD, along with amyloid and tau phosphorylation, there is an associated increase in inflammation/glial activation, a decrease in synaptic function, an increase in astrocyte activation, and a state of insulin resistance. In PD, along with α-synuclein accumulation, there is associated inflammation, synaptic dysfunction, dopaminergic neuronal loss, and some data to suggest insulin resistance. Therapeutic strategies for neurodegenerative disorders have commonly targeted individual pathological processes. An effective treatment might require either utilization of multiple drugs which target the individual pathological processes which underlie the neurodegenerative disease or the use of a single agent which could influence multiple pathological processes. Insulin and incretins are compounds with multiple effects on neurodegenerative processes. Preclinical studies have demonstrated that GLP-1 receptor agonists reduce neuroinflammation, reduce tau phosphorylation, reduce amyloid deposition, increase synaptic function, and improve memory formation. Incretin mimetics may act through the restoration of insulin signaling pathways, inducing further neuroprotective effects. Currently, phase 2 and phase 3 trials are underway in AD and PD populations. Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.",[],Molecular psychiatry,2022-10-19,"[{'lastname': 'Nowell', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'Division of Neurology, Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Blunt', 'firstname': 'Eleanor', 'initials': 'E', 'affiliation': 'Division of Neurology, Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Edison', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Division of Neurology, Department of Brain Sciences, Imperial College London, London, UK. paul.edison@imperial.ac.uk.\nSchool of Medicine, Cardiff University, Cardiff, UK. paul.edison@imperial.ac.uk.'}]",,,,© 2022. The Author(s).,"10.1038/s41380-022-01792-4
10.1177/1533317520953041",<Element 'PubmedArticle' at 0x7f05dcf27e50>
74,36240091,Use of Hormone Replacement Therapy and Risk of Dementia: A Nationwide Cohort Study.,"Estrogen has the potential to influence brain physiology implicated in dementia pathogenesis. Hormone replacement therapy (HRT) might be expected to influence the risk of dementia. Observational data indicated that HRT was associated with reductions in dementia risk, but experimental evidence demonstrates that HRT increases the incidence of dementia. To determine the effect of HRT on the risk of dementia, a retrospective cohort study was performed using a nationwide claims dataset in Taiwan.
A population-based longitudinal study was performed using data from the Longitudinal Health Insurance Database in Taiwan. A total of 35,024 women with HRT were enrolled as the exposed cohort and 70,048 women without HRT were selected on the basis of propensity matching as the comparison cohort. All participants were followed up until the diagnosis of dementia, death, or at the end of December 31, 2013, whichever occurred first. Overall, the average duration of follow-up (±SD) in the HRT and comparison cohorts was 12.3 (±2.3) and 12.2 (±2.4), respectively. The Cox proportional hazards regression models were conducted to produce hazard ratios (HRs) with 95% CIs to evaluate the association of HRT with the risk of dementia.
In the follow-up period, the cumulative incidence of dementia for the HRT cohort (20.04 per 1,000) was significantly higher than the corresponding cumulative incidence for the comparison cohort (15.79 per 1,000), resulting in an adjusted HR of 1.35 (95% CI 1.13-2.62). There was an increased risk of dementia with a higher cumulative dose of HRT prescription (
This cohort study documented that HRT was associated with an increased risk of dementia. The clinical implications of this study merit further investigations.",[],Neurology,2022-10-15,"[{'lastname': 'Sung', 'firstname': 'Yueh-Feng', 'initials': 'YF', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Tsai', 'firstname': 'Chun-Teng', 'initials': 'CT', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Kuo', 'firstname': 'Cheng-Yi', 'initials': 'CY', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Lee', 'firstname': 'Jiunn-Tay', 'initials': 'JT', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Chou', 'firstname': 'Chung-Hsing', 'initials': 'CH', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Chen', 'firstname': 'Yong-Chen', 'initials': 'YC', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Chou', 'firstname': 'Yu-Ching', 'initials': 'YC', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.'}, {'lastname': 'Sun', 'firstname': 'Chien-An', 'initials': 'CA', 'affiliation': 'From the Department of Neurology (Y.-F.S., J.-T.L., C.-H.C.), Tri-Service General Hospital, School of Public Health (C.-T.T., Y.-C. Chou), Department and Graduate Institute of Biology and Anatomy (C.-Y.K.), and Graduate Institute of Medical Sciences (C.-H.C.), National Defense Medical Center; Department of Medicine (Y.-C. Chen), Data Science Center (Y.-C. Chen, C.-A.S.), and Department of Public Health (C.-A.S.), College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan. 040866@mail.fju.edu.tw.'}]",,,"In the follow-up period, the cumulative incidence of dementia for the HRT cohort (20.04 per 1,000) was significantly higher than the corresponding cumulative incidence for the comparison cohort (15.79 per 1,000), resulting in an adjusted HR of 1.35 (95% CI 1.13-2.62). There was an increased risk of dementia with a higher cumulative dose of HRT prescription (",© 2022 American Academy of Neurology.,10.1212/WNL.0000000000200960,<Element 'PubmedArticle' at 0x7f05dcf924f0>
75,36210429,"Cinnamaldehyde Regulates Insulin and Caspase-3 Signaling Pathways in the Sporadic Alzheimer's Disease Model: Involvement of Hippocampal Function via IRS-1, Akt, and GSK-3β Phosphorylation.","Insulin signaling disruption and caspase-3 cleavage play a pathologic role in Alzheimer's disease (AD). Evidence suggested that cinnamaldehyde (Cin), the major component of cinnamon, has the ability to act as a neuroprotective agent. However, little evidence is available to demonstrate its effectiveness in regulating the insulin and caspase-3 signaling pathways and underlying molecular mechanisms. Therefore, the present study was conducted to correlate the molecular mechanisms of these signaling pathways and Cin treatment on animal behavioral performance in an intracerebroventricular (ICV)-streptozotocin (STZ, 3 mg/kg) model. The sporadic AD rat model was treated with Cin (10 and 100 mg/kg; intraperitoneal, i.p) daily for 2 weeks. Novel object recognition (NOR), Morris water maze (MWM), and elevated plus maze (EPM) tests were performed to assess recognition/spatial memory and anxiety-like behavior, respectively. Hippocampal Aβ aggregation was assessed using Congo red staining. The activity of hippocampal caspase-3 and IRS-1/Akt/GSK-3β signaling pathways were analyzed using the Western blot technique. The results revealed that Cin (100 mg/kg, effective dose) improved recognition/spatial memory deficits and anxiety-like behavior. In addition, Cin negated the effects of STZ on Aβ aggregation and caspase-3 cleavage in the hippocampus. Furthermore, the Western blot method showed that hippocampal IRS-1/AKT/GSK-3β phosphorylation was altered in ICV-STZ animal model, while Cin modulated this signaling pathway through decreasing Phospho.IRS-1","['Alzheimer’s disease', 'Apoptosis', 'Cinnamaldehyde', 'Hippocampus', 'Insulin signaling pathway']",Journal of molecular neuroscience : MN,2022-10-10,"[{'lastname': 'Bagheri-Mohammadi', 'firstname': 'Saeid', 'initials': 'S', 'affiliation': 'Department of Physiology and Neurophysiology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Askari', 'firstname': 'Sahar', 'initials': 'S', 'affiliation': 'Department of Physiology and Neurophysiology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\nNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Alani', 'firstname': 'Behrang', 'initials': 'B', 'affiliation': 'Department of Applied Cell Sciences, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Moosavi', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. marmoosavi@sums.ac.ir.'}, {'lastname': 'Ghasemi', 'firstname': 'Rasoul', 'initials': 'R', 'affiliation': 'Department of Physiology and Neurophysiology Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. rghasemi60@sbmu.ac.ir.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12031-022-02075-x
10.1016/j.neuropharm.2009.01.005
10.1016/j.brainresbull.2020.08.001
10.1007/s10787-019-00681-7
10.1007/s11064-020-03162-4
10.1007/s10561-020-09896-3
10.1007/s11033-019-04883-8
10.1007/s12035-012-8375-5
10.1007/s13258-020-00987-9
10.1016/j.neurobiolaging.2005.08.021
10.1177/193229680800200619
10.3233/JAD-170211
10.1016/j.fitote.2019.104405
10.1074/jbc.M111.331181
10.1007/s12035-013-8404-z
10.1016/j.brainres.2018.12.011
10.1111/j.1471-4159.2007.05194.x
10.1016/j.bbr.2021.113260
10.1080/01616412.2019.1709142
10.1091/mbc.e08-07-0777
10.1016/j.diabres.2007.01.033
10.3791/55718
10.1016/j.ejphar.2017.09.009
10.1038/nature02621
10.1007/s00406-008-0828-5
10.3233/JAD-2011-111127
10.1080/01478885.2019.1652994
10.22088/IJMCM.BUMS.10.1.1
10.1016/j.exger.2013.02.025
10.1007/s00401-002-0657-y
10.1155/2018/3570830
10.1093/jnen/60.9.829
10.22038/IJBMS.2018.35368.8427
10.1007/s11011-020-00608-0
10.1074/jbc.M008363200
10.1016/j.ejphar.2019.172530
10.5483/BMBRep.2009.42.8.475
10.1074/jbc.M610390200
10.1016/j.nbd.2020.104772
10.1007/s12035-021-02283-3
10.1080/01616412.2016.1250459
10.1038/nrn1100
10.1016/j.neuropharm.2016.08.013
10.1074/jbc.M109.011015
10.1016/j.bbi.2019.07.032",<Element 'PubmedArticle' at 0x7f05dcf7e900>
76,"36199077
28963611
27546235
34584899
33028563
19670412
19272197
30361803
32461674
30298180
33986301
23622250
28549481
28714976
30617256
30820047
31986256
30184509
29924994
28341582
29139169
30827729
29275859
31541153
33608526
28618077
30133465
30367955
34537225
27338705
30082275
31018141
34112929
31214167
29020624
35431903
25682174
18728636
29022598
34767070
29785013
33609158
26653891
31951107
31917687
33897406
28602351
25129075
25129077
23323831
23291110
28591653
24438232
31722210
31230049
34321081
33850148
31042697
20127681
29180997
16291918
28456479
31026622
18832152
34910900
23951090
29977068
16928728
25885710
34601555
23586463
17784955
28991892
25605792
19617889
25516281
25633503",Alzheimer's disease-related transcriptional sex differences in myeloid cells.,"Sex differences have been identified in many diseases associated with dysregulated immune responses, including Alzheimer's disease (AD), for which approximately two-thirds of patients are women. An accumulating body of research indicates that microglia may play a causal role in the pathogenesis of this disease. We hypothesised that sex differences in the transcriptome of human myeloid cells may contribute to the sex difference observed in AD prevalence. To explore this, we assessed bulk and single-nuclear RNA sequencing data sets generated from four human derived myeloid cell populations: post-mortem microglial nuclei, peripheral monocytes, monocyte-derived macrophages (MDMs) and induced pluripotent stem cell derived microglial-like cells (MGLs). We found that expression of AD risk genes, gene signatures associated with the inflammatory response in AD, and genes related to proinflammatory immune responses were enriched in microglial nuclei isolated from aged female donors without ante-mortem neurological disease, relative to those from males. In addition, these inflammation-associated gene sets were found to be enriched in peripheral monocytes isolated from postmenopausal women and in MDMs obtained from premenopausal individuals relative to age-matched males. Expression of these gene sets did not differ in MDMs derived from women whose blood was sampled across the menstrual cycle or in MGLs cultured with 17β-oestradiol. This suggests that the observed gene set enrichments in myeloid cells from women were not being driven by acute hormonal influences. Together, these data support the hypothesis that the increased prevalence of AD in women may be partly explained by a myeloid cell phenotype biased towards expression of biological processes relevant to AD.","['Microglia', 'Neurodegeneration', 'Neuroinflammation', 'Sex']",Journal of neuroinflammation,2022-10-06,"[{'lastname': 'Coales', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': ""Department of Brain Sciences, Imperial College London, London, UK.\nCentre for Host Microbiome Interactions, King's College London, London, SE1 9RT, UK.""}, {'lastname': 'Tsartsalis', 'firstname': 'Stergios', 'initials': 'S', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.\nDepartment of Psychiatry, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Fancy', 'firstname': 'Nurun', 'initials': 'N', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.\nUK Dementia Research Centre at Imperial College London, London, UK.'}, {'lastname': 'Weinert', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK.'}, {'lastname': 'Clode', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'UK Dementia Research Centre at Imperial College London, London, UK.'}, {'lastname': 'Owen', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK. d.owen@imperial.ac.uk.\nClinical Research Facility, Hammersmith Hospital, ICTM Building, DuCane Road, London, W12 0NN, UK. d.owen@imperial.ac.uk.'}, {'lastname': 'Matthews', 'firstname': 'Paul M', 'initials': 'PM', 'affiliation': 'Department of Brain Sciences, Imperial College London, London, UK. p.matthews@imperial.ac.uk.\nUK Dementia Research Centre at Imperial College London, London, UK. p.matthews@imperial.ac.uk.\nHammersmith Hospital, E502, Burlington Danes Building, DuCane Road, London, W12 0NN, UK. p.matthews@imperial.ac.uk.'}]",,,,© 2022. The Author(s).,"10.1186/s12974-022-02604-w
10.1007/s12016-017-8648-x
10.1038/nri.2016.90
10.1093/ofid/ofab448
10.1136/bmjopen-2020-040129
10.1002/hep.23163
10.1017/S0950268809002143
10.1007/s00281-018-0725-6
10.1038/s41577-020-0338-x
10.1038/s41572-021-00269-y
10.1016/j.cell.2013.03.030
10.1186/s13024-017-0184-x
10.1038/ng.3916
10.1038/s41588-018-0311-9
10.1038/s41588-019-0358-2
10.1016/S1474-4422(19)30435-1
10.1016/j.celrep.2018.08.001
10.1016/j.celrep.2018.05.048
10.1016/j.bbi.2017.03.010
10.1002/glia.23263
10.1016/j.neuron.2019.02.006
10.1016/j.cell.2017.11.042
10.1038/s41467-019-12348-6
10.1038/s41467-021-21407-w
10.1002/glia.23176
10.1371/journal.pone.0201375
10.1016/j.neulet.2018.10.044
10.1016/j.jneumeth.2021.109359
10.1126/science.aad8670
10.1084/jem.20180653
10.1016/j.celrep.2019.03.099
10.1038/s42003-021-02259-y
10.3389/fimmu.2019.01170
10.1016/j.celrep.2017.09.039
10.3389/fnagi.2022.868448/full
10.1016/j.cellimm.2015.01.018
10.1038/nri2394
10.1038/nature24265
10.1007/s00401-021-02372-6
10.1038/s41588-018-0129-5
10.1007/s00401-021-02263-w
10.1186/s13059-015-0844-5
10.15252/emmm.201910606
10.1172/JCI133737DS1
10.3389/fnagi.2021.631827
10.1016/j.cell.2017.05.018
10.1038/nn.3786
10.1038/nn.3782
10.1186/1471-2105-14-7
10.1016/j.jsbmb.2012.12.014
10.1016/j.stemcr.2017.05.017
10.1186/1471-2164-15-33
10.1016/j.celrep.2019.10.019
10.1159/000499840
10.1186/s13293-021-00387-y
10.1038/s41531-021-00180-z
10.1038/s41586-019-1195-2
10.1002/eji.200940203
10.3389/fimmu.2017.01455
10.1136/jnnp.2005.082867
10.1016/S1474-4422(17)30077-7
10.1016/j.neurobiolaging.2019.02.020
10.1073/pnas.0806883105
10.1016/j.stemcr.2021.11.010
10.1371/journal.pone.0071098
10.1038/s41583-018-0030-3
10.1101/2021.10.27.465860
10.1101/2021.08.16.456499
10.1093/aje/kwj282
10.1371/journal.pcbi.1004219
10.1093/bioinformatics/btab665
10.1186/1471-2105-14-128
10.1186/gb-2007-8-9-r183
10.1038/nmeth.4463
10.1093/nar/gkv007
10.1038/nprot.2009.97
10.1186/s13059-014-0550-8
10.1038/nmeth.3252
10.1101/060012v3",<Element 'PubmedArticle' at 0x7f05dcf6fa40>
77,"36122793
21781995
22160349
12689611
27468347
22738250
6828535
28842269
12202959
12600702
18034657
29086767
22915794
35338255
12470640
6580662
29689315
21557946
31144017
19317179
16138108
17151169
23582312
2899791
16491079
31193557
19584430
18571864
21983104
28212495
22815126
17029828
17275340
25447293
16943563
23989795
31830473
27080550
35718217
30949563
23458287
23474132
24157379
23026495
9263193
17499446
34206322
15919583
31221426
28899446
26096665
29653606
14645205
15917461
14692698
11566220
20488887
22286853
29888308
23505511
16540188
17430248
29429452
19428622
26946981
23506735
27569580
24126924
9629527
20930280
24747741
15358445
24887203
26003667
24456941
12600700
7137397
33381011
32993686
21855175
3527687
15755686
15667454
9722327
26822304
24067928
35355924
28584278
22404854
23384773
7870970
22404853
14678749
24795750
9386855
16974109
21427641
14663028
17562829",Hypothalamic-pituitary-adrenal (HPA) axis activity and anxiety-like behavior during aging: A test of the glucocorticoid cascade hypothesis in amyloidogenic APPswe/PS1dE9 mice.,"Alzheimer's disease (AD) is a progressive, dementing, whole-body disorder that presents with decline in cognitive, behavioral, and emotional functions, as well as endocrine dysregulation. The etiology of AD is not fully understood but stress- and anxiety-related hormones may play a role in its development and trajectory. The glucocorticoid cascade hypothesis posits that levels of glucocorticoids increase with age, leading to dysregulated negative feedback, further elevated glucocorticoids, and resulting neuropathology. We examined the impact of age (from 2 to 10 months) and stressor exposure (predator odor) on hormone levels (corticosterone and ghrelin), anxiety-like behavior (open field and light dark tests), and memory-related behavior (novel object recognition; NOR), and whether these various measures correlated with neuropathology (hippocampus and cortex amyloid beta, Aβ) in male and female APPswe/PS1dE9 transgenic and non-transgenic mice. Additionally, we performed exploratory analyses to probe if the open field and light dark test as commonly used tasks to assess anxiety levels were correlated. Consistent with the glucocorticoid cascade hypothesis, baseline corticosterone increased with age. Predator odor exposure elevated corticosterone at each age, but in contrast to the glucocorticoid cascade hypothesis, the magnitude of stressor-induced elevations in corticosterone levels did not increase with age. Overall, transgenic mice had higher post-stressor, but not baseline, corticosterone than non-transgenic mice, and across both genotypes, females consistently had higher (baseline and post-stressor) corticosterone than males. Behavior in the open field test primarily showed decreased locomotion with age, and this was pronounced in transgenic females. Anxiety-like behaviors in the light dark test were exacerbated following predator odor, and female transgenic mice were the most impacted. Compared to transgenic males, transgenic females had higher Aβ concentrations and showed more anxiety-like behavior. Performance on the NOR did not differ significantly between genotypes. Lastly, we did not find robust, statistically significant correlations among corticosterone, ghrelin, recognition memory, anxiety-like behaviors, or Aβ, suggesting outcomes are not strongly related on the individual level. Our data suggest that despite Aβ accumulation in the hippocampus and cortex, male and female APPswePS1dE9 transgenic mice do not differ robustly from their non-transgenic littermates in physiological, endocrine, and behavioral measures at the range of ages studied here.","['Aging', 'Anxiety', 'Between-task correlations', 'Corticosterone', 'Ghrelin', 'Predator odor', 'Within-task correlations']",General and comparative endocrinology,2022-09-20,"[{'lastname': 'Harris', 'firstname': 'Breanna N', 'initials': 'BN', 'affiliation': 'Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States. Electronic address: breanna.n.harris@ttu.edu.'}, {'lastname': 'Roberts', 'firstname': 'Breanna R', 'initials': 'BR', 'affiliation': 'Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States.'}, {'lastname': 'DiMarco', 'firstname': 'Giuliana M', 'initials': 'GM', 'affiliation': 'Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States; Center for Molecular and Behavioral Neuroscience, Rutgers, The State University of New Jersey, Newark, NJ, United States.'}, {'lastname': 'Maldonado', 'firstname': 'Kaylee Alers', 'initials': 'KA', 'affiliation': 'Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States.'}, {'lastname': 'Okwunwanne', 'firstname': 'Zenobia', 'initials': 'Z', 'affiliation': 'Department of Biological Sciences, Texas Tech University, Lubbock, TX, United States.'}, {'lastname': 'Savonenko', 'firstname': 'Alena V', 'initials': 'AV', 'affiliation': 'Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'lastname': 'Soto', 'firstname': 'Paul L', 'initials': 'PL', 'affiliation': 'Department of Psychology, Louisiana State University, Baton Rouge, LA, United States.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,"10.1016/j.ygcen.2022.114126
10.1007/s10339-011-0430-z
10.1186/2045-5380-1-9
10.1016/j.bbr.2017.08.029
10.1007/s00213-002-1155-6
10.1016/S0014-2999(03)01274-3
10.1111/j.1472-8206.2007.00526.x
10.1038/mp.2017.204
10.1093/fampra/cms044
10.1016/J.PHRS.2018.04.017
10.1038/nrd1825
10.1016/j.psyneuen.2013.03.006
10.1016/j.ynstr.2019.100167
10.1016/j.neuroscience.2008.05.017
10.1016/j.peptides.2011.09.019
10.1002/gps.3845
10.1016/j.nbd.2006.08.017
10.1016/j.ynstr.2019.100154
10.3390/ijms22136656
10.1016/j.biopsych.2019.04.028
10.1016/j.jalz.2018.02.018
10.1016/S0031-9384(01)00524-8
10.1016/j.ynstr.2018.04.002
10.2174/156720507780362083
10.5483/BMBRep.2018.51.4.034
10.1016/j.bbr.2009.01.037
10.1016/j.jagp.2015.12.003
10.1016/j.bbadis.2014.04.012
10.1016/j.psyneuen.2004.06.002
10.1016/S0014-2999(03)01272-X
10.3389/fnins.2020.614828
10.1016/j.neurobiolaging.2011.07.005
10.1210/edrv-7-3-284
10.1016/j.nbd.2004.10.022
10.1186/s13041-016-0191-9
10.1016/j.neuropharm.2013.09.015
10.1038/s41598-017-03016-0
10.1016/j.jalz.2012.02.001
10.1016/j.nbd.2003.08.009
10.1159/000095761
10.1212/01.WNL.0000096167.56734.59
10.1212/01.wnl.0000264930.97061.82",<Element 'PubmedArticle' at 0x7f05dd932630>
78,"36115494
28422298
1566067
32508595
23930978
18218341
29080524
33863993
28099083
29440986
30675901
32730766
35167685
33069326
30911599
30336988
19236314
17485646
31884487
28154105
27042905
31929166
31190841
30106209
32250293
31379558
34520451
28731034
8973004
30878483
9259593
5560675
1132600
20060897
7396040
7484927
28403222
26728181
34955810
33037968
31365104
26957302
21374699
20966215
34002023
14523244
25205593
11120756
29950572
29462587
33506556
29562533
29036828
32448104
33874826
29253591
33739944
30968756
26964834
27095270
25346723
24931034
26657615
11598383
22424621
17130206
19135149
16399206
18077675
31462971
20413862
31330313
15747152
20202480
23876631
18436709
24292971
28164134
25988150
27567931
34808290
30406177
31131037
26685314
34171492
30692925
9590317
19259110
19228962
22766509
30737462
29235507
25043908
31356838
35701180
31656947
33132154
34767745
25592535
30248361
29321682
26617514
33233502
31244753
30273821
32121111
19171901
10331679
32712699
27484357
31075323
25237654
28763509
23670794
26086182
33434704
25771249
30527596
32925045
34668644
31164160
30463018
26718486
34127689
27693377
32688339
31333086
34444699
27130207
29734182
31906949
17003306
12050251
33080602
29951589
15997411
24899709
20357044
27721479
27552971
31131364
24786309
29351469
31693798
17329620
23801246
25888859
29616709
21192237
24423155
30067154
25008180
26211973
23238038
22289199
24881967
10591291
17942819
15964100
18430999
21911655
32568367
34101779
14733947
1318856
12765945
16159895
19923038
30738020
31198956
28776086
30958364
29253574
28538088
26890736
19748064
23973293
22476196
21525299
27252647
30099030
30944040
29790638
30768625
29053215
29508509
31885353
31976646
22975005
30610276
30217519
33626869
30170601
28325798
18479783
9720972
15750215
9443474
20966918
34454830
1572948
32098382
18945929
34203094
32358220
31241312
28460576
30775997
26330810
20504892
29896424
19292929
28794151
34154615",Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics.,"Many people living with dementia and cognitive impairment have dysfunctional mitochondrial and insulin-glucose metabolism resembling type 2 diabetes mellitus and old age. Evidence from human trials shows that nutritional interventions and anti-diabetic medicines that target nutrient-sensing pathways overcome these deficits in glucose and energy metabolism and can improve cognition and/or reduce symptoms of dementia. The liver is the main organ that mediates the systemic effects of diets and many diabetic medicines; therefore, it is an intermediate target for such dementia interventions. A challenge is the efficacy of these treatments in older age. Solutions include the targeted hepatic delivery of diabetic medicines using nanotechnologies and titration of macronutrients to optimize hepatic energy metabolism.","['Alzheimer’s disease', 'Diet', 'Mitochondrial dysfunction', 'Neuroinflammation', 'Oxidative stress', 'Precision medicine', 'Prevention']",Advanced drug delivery reviews,2022-09-18,"[{'lastname': 'Hunt', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2008, Australia; Sydney Nano Institute, The University of Sydney, Sydney, NSW 2008, Australia; ANZAC Research Institute & Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.'}, {'lastname': 'Wahl', 'firstname': 'Devin', 'initials': 'D', 'affiliation': 'Department of Health and Exercise Science & Centre for Healthy Aging, Colorado State University, CO 80523, United States.'}, {'lastname': 'Westwood', 'firstname': 'Lara J', 'initials': 'LJ', 'affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia; ANZAC Research Institute & Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.'}, {'lastname': 'Lockwood', 'firstname': 'Glen P', 'initials': 'GP', 'affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia; ANZAC Research Institute & Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.'}, {'lastname': 'Le Couteur', 'firstname': 'David G', 'initials': 'DG', 'affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2008, Australia; ANZAC Research Institute & Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.'}, {'lastname': 'Cogger', 'firstname': 'Victoria C', 'initials': 'VC', 'affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2008, Australia; ANZAC Research Institute & Centre for Education and Research on Ageing, Concord Repatriation General Hospital, Concord, NSW 2139, Australia. Electronic address: victoria.cogger@sydney.edu.au.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.addr.2022.114537,<Element 'PubmedArticle' at 0x7f05dd8eac70>
79,36088959,Membrane estrogen receptor ERα activation improves tau clearance via autophagy induction in a tauopathy cell model.,"Alzheimer's disease (AD) is the most prevalent aging-associated neurodegenerative disease, with a higher incidence in women than men. There is evidence that sex hormone replacement therapy, particularly estrogen, reduces memory loss in menopausal women. Neurofibrillary tangles are associated with tau protein aggregation, a characteristic of AD and other tauopathies. In this sense, autophagy is a promising cellular process to remove these protein aggregates. This study evaluated the autophagy mechanisms involved in neuroprotection induced by 17β-estradiol (E2) in a Tet-On inducible expression tauopathy cell model (EGFP-tau WT or with the P301L mutation, 0N4R isoform). The results indicated that 17β-estradiol induces autophagy by activating AMPK in a concentration-dependent manner, independent of mTOR signals. The estrogen receptor α (ERα) agonist, PPT, also induced autophagy, while the ERα antagonist, MPP, substantially attenuated the 17β-estradiol-mediated autophagy induction. Notably, 17β-estradiol increased LC3-II levels and phosphorylated and total tau protein clearance in the EGFP-tau WT cell line but not in EGPF-tau P301L. Similar results were observed with E2-BSA, a plasma membrane-impermeable estrogen, suggesting membrane ERα involvement in non-genomic estrogenic pathway activation. Furthermore, 17β-estradiol-induced autophagy led to EGFP-tau protein clearance. These results demonstrate that modulating autophagy via the estrogenic pathway may represent a new therapeutic target for treating AD.","['17β-estradiol', ""Alzheimer's Disease"", 'Autophagy', 'Neuroprotection', 'Tauopathy']",Brain research,2022-09-12,"[{'lastname': 'Costa', 'firstname': 'Angelica Jardim', 'initials': 'AJ', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Pharmacology, São Paulo, SP, Brazil.'}, {'lastname': 'Oliveira', 'firstname': 'Rafaela Brito', 'initials': 'RB', 'affiliation': 'Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Biological Sciences, Diadema, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Laboratory of Molecular and Translational Endocrinology, São Paulo, SP, Brazil.'}, {'lastname': 'Wachilewski', 'firstname': 'Patrícia', 'initials': 'P', 'affiliation': 'Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Biological Sciences, Diadema, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Laboratory of Molecular and Translational Endocrinology, São Paulo, SP, Brazil.'}, {'lastname': 'Nishino', 'firstname': 'Michelle Sayuri', 'initials': 'MS', 'affiliation': 'Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Biological Sciences, Diadema, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Laboratory of Molecular and Translational Endocrinology, São Paulo, SP, Brazil.'}, {'lastname': 'Bassani', 'firstname': 'Taysa Bervian', 'initials': 'TB', 'affiliation': 'Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Biological Sciences, Diadema, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Laboratory of Molecular and Translational Endocrinology, São Paulo, SP, Brazil.'}, {'lastname': 'Stilhano', 'firstname': 'Roberta Sessa', 'initials': 'RS', 'affiliation': 'Department of Physiological Sciences, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.'}, {'lastname': 'Cerutti', 'firstname': 'Janete Maria', 'initials': 'JM', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Morphology and Genetics, São Paulo, SP, Brazil.'}, {'lastname': 'Nozima', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Morphology and Genetics, São Paulo, SP, Brazil.'}, {'lastname': 'Porto', 'firstname': 'Catarina Segreti', 'initials': 'CS', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Pharmacology, São Paulo, SP, Brazil.'}, {'lastname': 'Pereira', 'firstname': 'Gustavo Jose da Silva', 'initials': 'GJDS', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Pharmacology, São Paulo, SP, Brazil.'}, {'lastname': 'Ramirez', 'firstname': 'Ana Lopez', 'initials': 'AL', 'affiliation': 'Cambridge Institute for Medical Research, Cambridge, United Kingdom.'}, {'lastname': 'Smaili', 'firstname': 'Soraya Soubhi', 'initials': 'SS', 'affiliation': 'Universidade Federal de São Paulo, Escola Paulista de Medicina, Department of Pharmacology, São Paulo, SP, Brazil.'}, {'lastname': 'Ureshino', 'firstname': 'Rodrigo Portes', 'initials': 'RP', 'affiliation': 'Universidade Federal de São Paulo, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Biological Sciences, Diadema, SP, Brazil; Universidade Federal de São Paulo, Escola Paulista de Medicina, Laboratory of Molecular and Translational Endocrinology, São Paulo, SP, Brazil. Electronic address: rpureshino@gmail.com.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2022.148079,<Element 'PubmedArticle' at 0x7f05df174c70>
80,36076399,Black mulberry (Morus nigra) fruit extract alleviated AD-Like symptoms induced by toxic Aβ protein in transgenic Caenorhabditis elegans via insulin DAF-16 signaling pathway.,"Alzheimer's disease (AD) is one of the most severe neurodegenerative disorders. Recently, there is no effective treatment drug for AD. Morus nigra (M. nigra) is a black mulberry and widely distributed fruit in the Moraceae family with various undiscovered biological activities. The study aimed to investigate the potential anti-AD effect of M. nigra. Mulberry fruit extract (MF) was obtained from M. nigra and treated up to 1.00 mg/mL on transgenic AD Caenorhabditis elegans (C. elegans) models. MF inhibited Amyloid-β (Aβ)-induced paralysis symptoms by about 55.65 %, reduced Aβ accumulation more than 50 % via immunoblotting, and suppressed over-sensitivity to exogenous serotonin in C. elegans. Furthermore, MF decreased the Aβ oligomeric depositions in worm CL2006. MF activated the DAF-16 nuclear translocation and its downstream SOD-3 and GST-4. AD is a major age-related disorder. Therefore, MF treated for an aging test and proved to be expanded the lifespan of the worms up to 34.7 %. Besides, we have evaluated the MF in vivo antioxidative properties, where MF reduced reactive oxygen species (ROS) generations in C. elegans and remitted the activation of HSP-16.2 induced by the oxidative action of Juglone. Gene knockout and extended the lifespan of AD worms. However, RNA interference (RNAi) successfully silenced the daf-16 on the Aβ phenotypic paralysis proved by MF effect. Our results indicate that MF alleviates AD-Like symptoms by activating the DAF-16 insulin signal pathway in C. elegans. Therefore, this MF study may provide new insights for mulberry application in safe AD treatment and clinical study.","['Alzheimer’s disease', 'Amyloid-β', 'Antioxidant stress', 'Caenorhabditis elegans', 'Morus nigra', 'Mulberry']","Food research international (Ottawa, Ont.)",2022-09-10,"[{'lastname': 'Wang', 'firstname': 'Enhui', 'initials': 'E', 'affiliation': 'School of Life Sciences, Lanzhou University, China.'}, {'lastname': 'Wang', 'firstname': 'Ningbo', 'initials': 'N', 'affiliation': 'School of Life Sciences, Lanzhou University, China.'}, {'lastname': 'Zou', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'School of Pharmacy, Lanzhou University, China.'}, {'lastname': 'Fahim', 'firstname': 'Muhammad', 'initials': 'M', 'affiliation': 'School of Life Sciences, Lanzhou University, China.'}, {'lastname': 'Zhou', 'firstname': 'Yongtao', 'initials': 'Y', 'affiliation': 'Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.'}, {'lastname': 'Yang', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Institute of Biology, Gansu Academy of Sciences, China.'}, {'lastname': 'Liu', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'School of Pharmacy, Lanzhou University, China. Electronic address: liuyanly@lzu.edu.cn.'}, {'lastname': 'Li', 'firstname': 'Hongyu', 'initials': 'H', 'affiliation': 'School of Life Sciences, Lanzhou University, China; School of Pharmacy, Lanzhou University, China. Electronic address: lihy@lzu.edu.cn.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.foodres.2022.111696,<Element 'PubmedArticle' at 0x7f05df18e5e0>
81,36075474,Chronic glucocorticoid exposure accelerates Aβ generation and neurotoxicity by activating calcium-mediated CN-NFAT1 signaling in hippocampal neurons in APP/PS1 mice.,"Glucocorticoid (GC) exposure can lead to deterioration of the structure and function of hippocampal neurons and is closely involved in Alzheimer's disease (AD). Amyloid-β (Aβ) overproduction is an important aspect of AD pathogenesis. Our study mainly investigated the mechanism of chronic GC exposure in accelerating Aβ production in primary cultured hippocampal neurons from APP/PS1 mice. The results indicated that chronic dexamethasone (DEX, 1 μM) significantly accelerated neuronal damage and Aβ accumulation in hippocampal neurons from APP/PS1 mice. Meanwhile, DEX exposure markedly upregulated APP, NCSTN, BACE1 and p-Tau/Tau expression in hippocampal neurons from APP/PS1 mice. Our study also indicated that chronic DEX exposure significantly increased intracellular Ca","[""Alzheimer's disease"", 'Aβ generation', 'Calcium homeostasis disorder', 'Glucocorticoids', 'Nuclear factor of activated T cells 1 (NFAT1)']",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,2022-09-09,"[{'lastname': 'Ding', 'firstname': 'Shixin', 'initials': 'S', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China; Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University, Nanjing, 211166, China.'}, {'lastname': 'Yang', 'firstname': 'Liu', 'initials': 'L', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Huang', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Kong', 'firstname': 'Liangliang', 'initials': 'L', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Chen', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Su', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Li', 'firstname': 'Xuewang', 'initials': 'X', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Dong', 'firstname': 'Xianan', 'initials': 'X', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Han', 'firstname': 'Yuli', 'initials': 'Y', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Li', 'firstname': 'Weiping', 'initials': 'W', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China.'}, {'lastname': 'Li', 'firstname': 'Weizu', 'initials': 'W', 'affiliation': 'Department of Pharmacology, Basic Medicine College, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230032, China. Electronic address: liweizu@126.com.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.fct.2022.113407,<Element 'PubmedArticle' at 0x7f05db9eb270>
82,"36033603
33323410
31389176
26122294
24623176
28192686
32029743
32047510
30940202
27752081
33522313
34228042
32613076
21614513
30735665
24336141
30120040
31206160
11390632
30947113
30715078
29319430
30285785
16944323
34302785
25245209
29630554
32447011
28482213
20110600
15246987
34468992
32370112
20413653
32848093
33967040
2360787
24733023
28985718
27983553
30137840
18005332
33008530
27231129
27245352
8545445
11858695
29985474
27307128
33206953
34687637
30967444
9785038
11040417
30923235
8780008
31199475
2529544
28245458
27755974
28882786
33567261
23102120
32995465
28935420
29195510
11159157
30452414
25173806
34266591
8175728
10672233
32435685
14723654
20061618
26843008
10430422
32995462
32680774
21403005
26079411
32944999
26539087
24871624
28673336
33858381
23296339
30733618
26154489
26321046
32805333
12191805
16879635
30941031
27092707
27534871
33097048
12017552
34279450
31811073
31668594
1837924
32376954
30643288
29159043
20563821
30249283
30334074
33226181
33337378
32626817
28179815
18824866
9506555
28946567
7919207
32580974
29563239
30309905
24631131
30890171
29753092
9566384
28843780
14520653
16926067
22538356
27692800
21984253
32250387
22642964
31973697
30581976
24036060
8709781
16485178
1789684
31682983
33163613
33510253
11526384
21280086
26103884
26593849
17261779
23957314
34182407
26307455
23949829",Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome.,"Women are disproportionately affected by Alzheimer's disease (AD), yet little is known about sex-specific effects on the development of AD in the Down syndrome (DS) population. DS is caused by a full or partial triplication of chromosome 21, which harbors the amyloid precursor protein (APP) gene, among others. The majority of people with DS in their early- to mid-40s will accumulate sufficient amyloid-beta (Aβ) in their brains along with neurofibrillary tangles (NFT) for a neuropathological diagnosis of AD, and the triplication of the APP gene is regarded as the main cause. Studies addressing sex differences with age and impact on dementia in people with DS are inconsistent. However, women with DS experience earlier age of onset of menopause, marked by a drop in estrogen, than women without DS. This review focuses on key sex differences observed with age and AD in people with DS and a discussion of possible underlying mechanisms that could be driving or protecting from AD development in DS. Understanding how biological sex influences the brain will lead to development of dedicated therapeutics and interventions to improve the quality of life for people with DS and AD.","['aging', 'amyloid beta', 'estrogen', 'hormones', 'inflammation', 'metabolism', 'tau tangles', 'vascular']",Frontiers in neuroscience,2022-08-30,"[{'lastname': 'Andrews', 'firstname': 'Elizabeth J', 'initials': 'EJ', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States.'}, {'lastname': 'Martini', 'firstname': 'Alessandra C', 'initials': 'AC', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States.'}, {'lastname': 'Head', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States.\nInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, United States.'}]",,,,"Copyright © 2022 Andrews, Martini and Head.","10.3389/fnins.2022.954999
10.1126/scisignal.abd2494
10.1002/dneu.22715
10.1016/j.yhbeh.2015.06.010
10.1002/ana.24135
10.1177/1745506518817995
10.1016/j.neurobiolaging.2017.01.009
10.1038/s41572-019-0143-7
10.3389/fgene.2019.01368
10.1186/s13075-019-1870-6
10.1038/mp.2016.185
10.1080/13697137.2021.1875426
10.1001/jamaneurol.2021.1893
10.1002/dad2.12047
10.1007/s00439-011-1011-z
10.1016/j.cca.2019.02.005
10.1212/WNL.0000000000000033
10.1016/j.jalz.2018.06.2857
10.1001/jamaneurol.2019.1534
10.1101/lm.39601
10.1016/j.neurobiolaging.2019.02.019
10.1001/jamaneurol.2018.4693
10.1002/alz.054966
10.1080/08952841.2018.1419476
10.1186/s13024-018-0284-2
10.1007/s10571-006-9112-2
10.1016/S1474-4422(21)00129-0
10.1016/j.brainresbull.2014.09.004
10.3233/JAD-180025
10.1016/j.neurobiolaging.2020.04.018
10.1016/j.neurobiolaging.2017.04.006
10.3233/JAD-2010-1247
10.1196/annals.1297.005
10.1111/jnc.15499
10.3390/ijms21093219
10.1093/hmg/ddq160
10.1002/alz.055785
10.3233/JAD-201427
10.1002/ana.410270502
10.1038/nrg3687
10.1186/s12881-017-0475-7
10.3233/JAD-160836
10.1111/j.1365-2990.2007.00899.x
10.1016/B978-0-444-64123-6.00018-7
10.1016/j.ajhg.2016.05.014
10.1080/15592294.2016.1192736
10.1007/s007260170001
10.1038/s41582-018-0032-9
10.1017/cjn.2016.36
10.1093/brain/awaa326
10.1016/S1474-4422(21)00245-3
10.1136/jnnp-2018-320106
10.1016/S0739-7240(98)00028-9
10.1016/S0301-0082(00)00025-3
10.1212/WNL.0000000000007326
10.1046/j.1471-4159.1996.66051836.x
10.1093/brain/awz162
10.1073/pnas.86.19.7611
10.1159/000452912
10.1016/j.jalz.2016.08.012
10.1016/j.freeradbiomed.2017.08.028
10.1016/j.immuni.2021.01.013
10.1016/j.jalz.2011.09.229
10.1002/dad2.12096
10.1016/j.freeradbiomed.2017.09.013
10.1186/s40478-017-0499-4
10.1093/aje/153.2.132
10.3233/JAD-180589
10.1016/j.nbd.2014.08.025
10.1016/B978-0-12-819973-2.00012-5
10.1016/S0021-9258(17)36796-0
10.1111/j.1749-6632.1999.tb07821.x
10.1002/dad2.12013
10.1111/1467-8721.ep10769964
10.1111/j.1365-2788.2004.00500.x
10.3233/JAD-2010-1337
10.1007/s11682-016-9523-8
10.1212/WNL.53.2.331
10.1002/dad2.12084
10.1016/j.dhjo.2020.100947
10.1001/archneurol.2011.36
10.1016/j.jalz.2015.05.013
10.1002/ana.25905
10.3389/fnbeh.2015.00264
10.1177/1073858414536468
10.1186/s13195-017-0271-9
10.1186/s12883-021-02189-6
10.1038/nrneurol.2012.263
10.1038/s41582-018-0132-6
10.1007/s12035-015-9315-y
10.1016/j.bbi.2015.08.020
10.1016/j.mce.2020.110985
10.1016/S0166-4328(02)00026-8
10.1111/j.1601-183X.2005.00175.x
10.3389/fnagi.2019.00059
10.1038/ncomms11398
10.15252/emmm.201606540
10.1186/s12974-020-01998-9
10.1210/rp.57.1.357
10.3390/jcm10132966
10.1373/jalm.2019.030023
10.1016/j.jalz.2019.07.009
10.3109/15513819109065483
10.1038/s41586-020-2247-3
10.1038/s41591-018-0297-y
10.1016/j.nicl.2017.10.022
10.1007/s00415-010-5630-4
10.1186/s12974-018-1313-3
10.1007/s00401-018-1920-1
10.1002/alz.12229
10.3233/JAD-201167
10.1002/dad2.12039
10.31887/DCNS.2016.18.4/cepperson
10.1159/000157874
10.1002/ana.410430316
10.3233/JAD-170390
10.1097/00001756-199406270-00025
10.1212/WNL.0000000000009781
10.1523/JNEUROSCI.1136-17.2017
10.1126/science.aau1810
10.1016/j.cca.2014.03.002
10.1186/s12916-019-1299-4
10.1016/j.ejmg.2018.05.013
10.1212/WNL.50.4.991
10.1016/j.freeradbiomed.2017.08.019
10.1002/ana.10677
10.1016/j.neulet.2006.07.062
10.1159/000338409
10.1016/j.jalz.2016.08.004
10.1124/mol.111.074021
10.1001/jamaneurol.2020.0387
10.1352/1934-9556-50.2.92
10.1186/s11689-019-9306-9
10.1016/j.trci.2018.10.006
10.1016/j.neuint.2013.08.010
10.1016/S0140-6736(96)03356-9
10.1007/s10519-006-9047-x
10.1002/ana.410300410
10.1016/j.neuroimage.2019.116327
10.1002/trc2.12096
10.1038/s41598-021-82016-7
10.1038/ni0901-777
10.1002/ana.22239
10.1016/j.neurobiolaging.2015.05.016
10.1016/j.bbadis.2015.11.007
10.1196/annals.1386.036
10.1111/and.12147
10.1016/j.nicl.2021.102740
10.1016/j.arr.2015.08.001
10.1002/ddrr.1128",<Element 'PubmedArticle' at 0x7f05db9fb680>
83,35988518,Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer's disease.,"Researchers continue to explore drug targets to treat the characteristic pathologies of Alzheimer's disease (AD). Some drugs relieve the pathological processes of AD to some extent, but the failed clinical trials indicate that multifunctional agents seem more likely to achieve the therapy goals for this neurodegenerative disease. Herein, a novel compound named melatonin-trientine (TM) has been covalently synthesized with the natural antioxidant compounds melatonin and the metal ion chelator trientine. After toxicological and pharmacokinetic verification, we elucidated the effects of intraperitoneal administration of TM on AD-like pathology in 6-month-old mice that express both the β-amyloid (Aβ) precursor protein and presenilin-1 (APP/PS1). We found that TM significantly decreased Aβ deposition and neuronal degeneration in the brains of the APP/PS1 double transgenic mice. This result may be due to the upregulation of iron regulatory protein-2 (IRP2), insulin degrading enzyme (IDE), and low density lipoprotein receptor related protein 1 (LRP1), which leads to decreases in APP and Aβ levels. Additionally, TM may promote APP non-amyloidogenic processing by activating the melatonin receptor-2 (MT2)-dependent signaling pathways, but not MT1. In addition, TM plays an important role in blocking γ-secretase, tau hyperphosphorylation, neuroinflammation, oxidative stress, and metal ion dyshomeostasis. Our results suggest that TM may effectively maximize the therapeutic efficacy of targeting multiple mechanisms associated with AD pathology.","[""Alzheimer's disease"", 'Antioxidant', 'Chelator', 'Conjugates', 'Melatonin receptor-2', 'β-amyloid']",Bioorganic chemistry,2022-08-22,"[{'lastname': 'Li', 'firstname': 'Lin-Bo', 'initials': 'LB', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Fan', 'firstname': 'Yong-Gang', 'initials': 'YG', 'affiliation': 'Institute of Health Sciences, Key Laboratory of Medical Cell Biology of Ministry of Education, China Medical University, Shenyang 110122, China.'}, {'lastname': 'Wu', 'firstname': 'Wen-Xi', 'initials': 'WX', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Bai', 'firstname': 'Chen-Yang', 'initials': 'CY', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Jia', 'firstname': 'Meng-Yu', 'initials': 'MY', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Hu', 'firstname': 'Jiang-Ping', 'initials': 'JP', 'affiliation': 'Department of Histology and Embryology, Mudanjiang Medical University, Mudanjiang 157011, China.'}, {'lastname': 'Gao', 'firstname': 'Hui-Ling', 'initials': 'HL', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Wang', 'firstname': 'Tao', 'initials': 'T', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Zhong', 'firstname': 'Man-Li', 'initials': 'ML', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.'}, {'lastname': 'Huang', 'firstname': 'Xue-Shi', 'initials': 'XS', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China. Electronic address: huangxs@mail.neu.edu.cn.'}, {'lastname': 'Guo', 'firstname': 'Chuang', 'initials': 'C', 'affiliation': 'College of Life and Health Sciences, Northeastern University, Shenyang 110819, China. Electronic address: guoc@mail.neu.edu.cn.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.bioorg.2022.106100,<Element 'PubmedArticle' at 0x7f05dc769860>
84,35985445,Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy.,"Alzheimer's disease (AD) and prostate cancer (PCa) are considered the leading causes of death in elderly people worldwide. Although both these diseases have striking differences in their pathologies, a few underlying mechanisms are similar when cell survival is considered. In the current study, we employed an in-silico approach to decipher the possible role of bacterial proteins in the initiation and progression of AD and PCa. We further analyzed the molecular connections between these two life-threatening diseases. The androgen deprivation therapy used against PCa has been shown to promote castrate resistant PCa as well as AD. In addition, cell signaling pathways, such as Akt, IGF, and Wnt contribute to the progression of both AD and PCa. Besides, various proteins and genes are also common in disease progression. One such similarity is mTOR signaling. mTOR is the common downstream target for many signaling pathways and plays a vital role in both PCa and AD. Targeting mTOR can be a favorable line of treatment for both AD and PCa. However, drug resistance is one of the challenges in effective drug therapy. A few drugs that target mTOR have now become ineffective due to the development of resistance. In that regard, phytochemicals can be a rich source of novel drug candidates as they can act via multiple mechanisms. This review also presents mTOR targeting phytochemicals with promising anti-PCa, anti-AD activities, and approaches to overcome the issues associated with phytochemical-based therapies in clinical trials.","[""Alzheimer's disease"", 'In-silico', 'Nano-drug delivery', 'Phytochemicals', 'Prostate cancer', 'mTOR']",Biochimica et biophysica acta. Molecular basis of disease,2022-08-20,"[{'lastname': 'Poddar', 'firstname': 'Nitesh Kumar', 'initials': 'NK', 'affiliation': 'Department of Biosciences, Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan 303007, India. Electronic address: niteshkumar.poddar@jaipur.manipal.edu.'}, {'lastname': 'Agarwal', 'firstname': 'Disha', 'initials': 'D', 'affiliation': 'Department of Biosciences, Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan 303007, India.'}, {'lastname': 'Agrawal', 'firstname': 'Yamini', 'initials': 'Y', 'affiliation': 'Department of Biosciences, Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan 303007, India.'}, {'lastname': 'Wijayasinghe', 'firstname': 'Yasanandana Supunsiri', 'initials': 'YS', 'affiliation': 'Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.'}, {'lastname': 'Mukherjee', 'firstname': 'Arunima', 'initials': 'A', 'affiliation': 'Department of Biosciences, Manipal University Jaipur, Dehmi Kalan, Jaipur-Ajmer Expressway, Jaipur, Rajasthan 303007, India.'}, {'lastname': 'Khan', 'firstname': 'Shahanavaj', 'initials': 'S', 'affiliation': 'Department of Health Sciences, Novel Global Community Educational Foundation, NSW, Australia; Department of Pharmaceutics, College of Pharmacy, PO Box 2457, King Saud University, Riyadh 11451, Saudi Arabia; Department of Medical Lab Technology, Indian Institute of health and Technology (IIHT), Deoband, 247554 Saharanpur, UP, India. Electronic address: sdkhan@ksu.edu.sa.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2022.166524,<Element 'PubmedArticle' at 0x7f05dc7c6ea0>
85,"35927217
31576349
29848485
23390181
29433981
34836334
33281745
25867811
11971659
34978125
26864717
14644069
34790110
26806389
11158037
7195404
1390292
19733622
11155090
10523012
28700478
9207127
11534928
17973937
15753424
20079740
16865684
8054493
19346137
17287097
30124583
14764758
17520786
21632481
15053941
15668427
27599230
32485235
9008150
8723131
27209182
18235425
19782476
22999654
15862203",Associations of Bioavailable Serum Testosterone With Cognitive Function in Older Men: Results From the National Health and Nutrition Examination Survey.,"Age-associated cognitive decline may be influenced by testosterone status. However, studies evaluating the impact of bioavailable testosterone, the active, free testosterone, on cognitive function are scarce. Our study determined the relationship between calculated bioavailable testosterone and cognitive performance in older men.
We used data from the U.S. National Health and Nutrition Examination Survey (NHANES) between 2013 and 2014. This study consisted of 208 men aged ≥60 years. Bioavailable serum testosterone was calculated based on the total serum testosterone, sex hormone-binding globulin, and albumin levels, whereas cognitive performance was assessed through the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Learning Test (WLLT), Word List Recall Test (WLRT), and Intrusion Word Count Test (WLLT-IC and WLRT-IC), the Animal Fluency Test (AFT), and the Digit Symbol Substitution Test (DSST). Multiple linear regression analyses were performed upon adjustment for age, ethnicity, socioeconomic status, education level, medical history, body mass index, energy, alcohol intake, physical activity levels, and sleep duration.
A significant positive association between bioavailable testosterone and DSST (β: 0.049, p = .002) score was detected, with no signs of a plateau effect. No significant associations with CERAD WLLT (p = .132), WLRT (p = .643), WLLT-IC (p = .979), and WLRT-IC (p = .387), and AFT (p = .057) were observed.
Calculated bioavailable testosterone presented a significant positive association with processing speed, sustained attention, and working memory in older men above 60 years of age. Further research is warranted to elucidate the impact of the inevitable age-related decline in testosterone on cognitive function in older men.","['Aging', 'Bioavailable testosterone', 'Cognition', 'Dementia', 'Older men']","The journals of gerontology. Series A, Biological sciences and medical sciences",2022-08-05,"[{'lastname': 'Giannos', 'firstname': 'Panagiotis', 'initials': 'P', 'affiliation': 'Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK.\nSociety of Meta-research and Biomedical Innovation, London, UK.'}, {'lastname': 'Prokopidis', 'firstname': 'Konstantinos', 'initials': 'K', 'affiliation': 'Society of Meta-research and Biomedical Innovation, London, UK.\nDepartment of Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.'}, {'lastname': 'Church', 'firstname': 'David D', 'initials': 'DD', 'affiliation': 'Department of Geriatrics, Donald W. Reynolds Institute on Aging, Center for Translational Research in Aging and Longevity, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.'}, {'lastname': 'Kirk', 'firstname': 'Ben', 'initials': 'B', 'affiliation': 'Department of Medicine-Western Health, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.\nAustralian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St. Albans, Melbourne, Victoria, Australia.'}, {'lastname': 'Morgan', 'firstname': 'Paul T', 'initials': 'PT', 'affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.\nDepartment of Sport and Exercise Sciences, Manchester Metropolitan University, Manchester, UK.'}, {'lastname': 'Lochlainn', 'firstname': 'Mary Ni', 'initials': 'MN', 'affiliation': ""Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.""}, {'lastname': 'Macpherson', 'firstname': 'Helen', 'initials': 'H', 'affiliation': 'Deakin University, Geelong, Victoria, Australia.\nInstitute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Burwood, Victoria, Australia.'}, {'lastname': 'Woods', 'firstname': 'David R', 'initials': 'DR', 'affiliation': 'Defence Medical Services, Lichfield, UK.\nCarnegie School of Sport, Leeds Beckett University, Leeds, UK.'}, {'lastname': 'Ispoglou', 'firstname': 'Theocharis', 'initials': 'T', 'affiliation': 'Carnegie School of Sport, Leeds Beckett University, Leeds, UK.'}]",,"Calculated bioavailable testosterone presented a significant positive association with processing speed, sustained attention, and working memory in older men above 60 years of age. Further research is warranted to elucidate the impact of the inevitable age-related decline in testosterone on cognitive function in older men.","A significant positive association between bioavailable testosterone and DSST (β: 0.049, p = .002) score was detected, with no signs of a plateau effect. No significant associations with CERAD WLLT (p = .132), WLRT (p = .643), WLLT-IC (p = .979), and WLRT-IC (p = .387), and AFT (p = .057) were observed.",© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.,"10.1093/gerona/glac162
10.21037/atm.2019.06.19
10.1523/JNEUROSCI.1627-17.2018
10.1212/WNL.0b013e31828726f5
10.1016/j.jalz.2017.12.006
10.3390/nu13114080
10.3389/fendo.2020.586909
10.1210/jc.2015-1016
10.1006/hbeh.2002.1770
10.1002/alz.12529
10.1038/srep21306
10.1016/s0306-4530(03)00053-2
10.3389/fnagi.2021.712237
10.1016/j.jalz.2015.12.010
10.1210/jcem.86.2.7219
10.1210/jcem-53-1-58
10.1016/0960-0760(92)90081-s
10.1016/j.mce.2009.08.025
10.1046/j.1365-2265.2000.01159.x
10.1210/jcem.84.10.6079
10.1097/MD.0000000000007411
10.1073/pnas.94.14.7537
10.1111/j.1365-2265.2007.03094.x
10.1212/01.Wnl.0000153072.54068.E3
10.1016/j.yhbeh.2010.01.004
10.1002/ana.20918
10.1017/s1041610294001602
10.1016/j.critrevonc.2009.03.005
10.1016/j.maturitas.2006.12.007
10.1097/JCP.0000000000000941
10.1210/jc.2003-031287
10.1093/sleep/30.4.427
10.1001/jama.2011.710
10.1016/j.yhbeh.2003.12.003
10.1212/01.WNL.0000149639.25136.CA
10.1080/15287394.2016.1193113
10.1016/j.brs.2020.05.013
10.1002/(sici)1097-4547(19970115)47:2<198::aid-jnr8>3.0.co;2-a
10.1002/(SICI)1098-2396(199605)23:1<10::AID-SYN2>3.0.CO;2-K
10.1016/j.jsxm.2016.04.068
10.1038/npp.2008.2
10.1016/j.psyneuen.2009.09.007
10.1016/j.psyneuen.2012.09.005
10.1016/j.neuroimage.2005.01.022",<Element 'PubmedArticle' at 0x7f05dc7d8400>
86,35840041,Sex bias and omission exists in Batten disease research: Systematic review of the use of animal disease models.,"Batten disease, also known as the neuronal ceroid lipofuscinoses (NCL), is a group of inherited neurodegenerative disorders mainly affecting children. NCL are characterised by seizures, loss of vision, and progressive motor and cognitive decline, and are the most common form of childhood dementia. At least one type of Batten disease and three types of mouse disease models show sex differences in their severity and progression. Scientific research has a recognised prevalent omission of female animals when using model organisms for basic and preclinical research. Sex bias and omission in research using animal models of Batten disease may affect understanding and treatment development. We conducted a systematic review of research publications since the first identification of NCL genes in 1995, identifying those using animal models. We found that <10 % of these papers considered sex as a biological variable. There was consistent omission of female model organisms in studies. This varied over the period but is improving; one third of papers considered sex as a biological variable in the last decade, and there is a noticeable increase in the last 5 years. The wide-ranging reasons for this published sex bias are discussed, including misunderstanding regarding oestrogen, impact on sample size, and the underrepresentation of female scientists. Their implications for Batten disease and future research are considered. Recommendations going forward support requirements by funders for consideration of sex in all stages of experimental design and implementation, and a role for publishers, families and others with a particular interest in Batten disease.","['Animal', 'Mouse', 'Neuronal ceroid lipofuscinosis', 'Sex']",Biochimica et biophysica acta. Molecular basis of disease,2022-07-16,"[{'lastname': 'McShane', 'firstname': 'Annie', 'initials': 'A', 'affiliation': 'Division of Biosciences, University College London, London WC1E 6BT, UK.'}, {'lastname': 'Mole', 'firstname': 'Sara E', 'initials': 'SE', 'affiliation': 'MRC Laboratory for Molecular Cell Biology and Great Ormond Street Institute of Child Health, University College London, London WC1E 6BT, UK. Electronic address: s.mole@ucl.ac.uk.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2022.166489,<Element 'PubmedArticle' at 0x7f05dc7a9cc0>
87,"35821621
30131604
26610858
19198621
17085125
29700388
18952456
28067607
34743290
25741229
33094209
17132744
31268539
30215697
17658612
16983113
32865575
26811448
30653980
28483987
33378113
28841388
20075244
18400188
11256745
18613831
30673121
32951005
27369327",Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.,"Androgen deprivation therapy (ADT) is a standard treatment modality for locally advanced, high-risk, and metastatic hormone-sensitive prostate cancer. Long-term ADT treatment likely develops side-effects that include changes in cognition or onset of dementia. However, the molecular understanding of this effect remains elusive. We attempt to establish a link between ADT and changes in cognitive function using patient databases and bioinformatics analyses.
Gene expression profiling was performed using RNA sequencing data from Alzheimer patient cohort and compared with the data from advanced-stage prostate cancer patients receiving neoadjuvant antiandrogen therapy. Differentially expressed genes (DEGs) were analyzed using the Ingenuity knowledge database.
A total of 1952 DEGs in the Alzheimer patient cohort and 101 DEGs were identified in ADT treated prostate cancer patients. Comparing both data sets provided a subset of 33 commonly expressed genes involving cytokine-cytokine signaling with an over representation of cytokine-cytokine receptor interaction, inflammatory cytokines, signaling by interleukins together with alterations in the circulating lymphocyte repertoire, adaptive immune responses, regulation of cytokine production, and changes in T-cell subsets. Additionally, lipopolysaccharide, tumor necrosis factor, and toll-like receptors were identified as upstream transcriptional regulators of these pathways. The most commonly expressed genes viz. IL-17A, CCL2, IL-10, IL-6, IL-1RN, LIF/LIFR were further validated by quantitative RT-PCR exhibited higher expression in antiandrogen treated neuronal, glial, and androgen-responsive prostate cancer cells, compared to no-androgen antagonist treatment.
Our findings suggest that changes in cytokine signaling under the influence of ADT in prostate cancer patients may be linked with cognitive impairment presenting new avenues for diagnostic and therapeutic development in combating brain deficits.","['androgen deprivation therapy', 'antiandrogens', 'brain deficits', 'cognitive impairment', 'proinflammatory cytokines', 'prostate cancer']",The Prostate,2022-07-14,"[{'lastname': 'Verma', 'firstname': 'Shiv', 'initials': 'S', 'affiliation': 'Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.\nThe Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'lastname': 'Kushwaha', 'firstname': 'Prem Prakash', 'initials': 'PP', 'affiliation': 'Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.\nThe Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'lastname': 'Shankar', 'firstname': 'Eswar', 'initials': 'E', 'affiliation': 'Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.\nThe Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'lastname': 'Ponsky', 'firstname': 'Lee E', 'initials': 'LE', 'affiliation': 'Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.\nThe Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'lastname': 'Gupta', 'firstname': 'Sanjay', 'initials': 'S', 'affiliation': 'Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.\nThe Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.\nDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.\nDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.\nDepartment of Nutrition, Case Western Reserve University, Cleveland, Ohio, USA.\nDivision of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, Ohio, USA.\nDepartment of Urology, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.'}]",,,"A total of 1952 DEGs in the Alzheimer patient cohort and 101 DEGs were identified in ADT treated prostate cancer patients. Comparing both data sets provided a subset of 33 commonly expressed genes involving cytokine-cytokine signaling with an over representation of cytokine-cytokine receptor interaction, inflammatory cytokines, signaling by interleukins together with alterations in the circulating lymphocyte repertoire, adaptive immune responses, regulation of cytokine production, and changes in T-cell subsets. Additionally, lipopolysaccharide, tumor necrosis factor, and toll-like receptors were identified as upstream transcriptional regulators of these pathways. The most commonly expressed genes viz. IL-17A, CCL2, IL-10, IL-6, IL-1RN, LIF/LIFR were further validated by quantitative RT-PCR exhibited higher expression in antiandrogen treated neuronal, glial, and androgen-responsive prostate cancer cells, compared to no-androgen antagonist treatment.",© 2022 The Authors. The Prostate published by Wiley Periodicals LLC.,10.1002/pros.24411,<Element 'PubmedArticle' at 0x7f05dd99a4f0>
88,"35771431
33048427
22945636
28472304
24692351
29434028
23970761
33491659
35448523
23769708
29945885
25772646
31993098
25878727
28153799
19079273
31165302
34969638
24098341
30296914
28102101
30616423
31894081
34955723
31681160
11481455
32773177
26528968
24883315
12843297
28243193
29407439
26089777
25855519
20064485
23696256
20739380
19837933
11836274
8548047
22294347
31316753
31485975
28336049
35059548
34365481
19435829
30242734
33510336
35278981
30875138
32040963
34860176
34855191
31287527
30742580
27689250
26321946
21993832
27324276
33409091
31801687
17850170
21196016
15607202
20943237
27038492
29569622
32206604
19057795
34899214
16968792
34752624
24161779
33667416
31863504
33219130
34146214
23159010
28818092
21458529
30943231
32889491
30982132
29044647
30792501
31852003
33011590
26362394
34371143
23411150
11124444
24128677
30262417
33600668
9551783
34750814
30194856
29508221
26437373
32021626
33711432
15345082
30396512
27528460
32247527
31548961
34856305
34147730
33343282
33562494
34129186
31977066
33848468
32576618
32186220
25987207
32500445
32901909
26243185
31190170
33493504
29111262
31182964
32120028
31541140",Relationship between thyroid hormones and central nervous system metabolism in physiological and pathological conditions.,"Thyroid hormones (THs) play an important role in the regulation of energy metabolism. They also take part in processes associated with the central nervous system (CNS), including survival and differentiation of neurons and energy expenditure. It has been reported that a correlation exists between the functioning of the thyroid gland and the symptoms of CNS such as cognitive impairment, depression, and dementia. Literature data also indicate the influence of THs on the pathogenesis of CNS diseases, such as Alzheimer's disease, epilepsy, depression, and Parkinson's disease. This review describes the relationship between THs and metabolism in the CNS, the effect of THs on the pathological conditions of the CNS, and novel options for treating these conditions with TH derivatives.","['Central nervous system', 'Hyperthyroidism', 'Hypothyroidism', 'Metabolism', 'Thyroid hormones']",Pharmacological reports : PR,2022-07-01,"[{'lastname': 'Sawicka-Gutaj', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland. nsawicka@ump.edu.pl.'}, {'lastname': 'Zawalna', 'firstname': 'Natalia', 'initials': 'N', 'affiliation': 'Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.'}, {'lastname': 'Gut', 'firstname': 'Paweł', 'initials': 'P', 'affiliation': 'Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.'}, {'lastname': 'Ruchała', 'firstname': 'Marek', 'initials': 'M', 'affiliation': 'Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.'}]",,,,© 2022. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.,"10.1007/s43440-022-00377-w
10.3389/fendo.2014.00082",<Element 'PubmedArticle' at 0x7f05dd9957c0>
89,"35733193
29903972
31182610
29694884
32569784
28060355
27498156
26630005
26215989
27849045
23312564
32939050
26519901
22592800
32778792
25822789
30742116
14583441
34611532
27986873
29379017
21930780
28888073
22388814
16943563
26352471
32755268
23022538
29632168
35177833
29133811
22196336
20820185
30862072
23878391
34503674
29491368
29022880
23624512
31326084
30975859
30881301
22609535
30551997
27459932
16906128
11039938
26982728
29078397
34803589
27621459
32139504
28973308
25497454",Loss of glucocorticoid receptor phosphorylation contributes to cognitive and neurocentric damages of the amyloid-β pathway.,"Aberrant cortisol and activation of the glucocorticoid receptor (GR) play an essential role in age-related progression of Alzheimer's disease (AD). However, the GR pathways required for influencing the pathobiology of AD dementia remain unknown. To address this, we studied an early phase of AD-like progression in the well-established APP/PS1 mouse model combined with targeted mutations in the BDNF-dependent GR phosphorylation sites (serines 134/267) using molecular, behavioral and neuroimaging approaches. We found that disrupting GR phosphorylation (S134A/S267A) in mice exacerbated the deleterious effects of the APP/PS1 genotype on mortality, neuroplasticity and cognition, without affecting either amyloid-β deposition or vascular pathology. The dynamics, maturation and retention of task-induced new dendritic spines of cortical excitatory neurons required GR phosphorylation at the BDNF-dependent sites that amyloid-β compromised. Parallel studies in postmortem human prefrontal cortex revealed AD subjects had downregulated BDNF signaling and concomitant upregulated cortisol pathway activation, which correlated with cognitive decline. These results provide key evidence that the loss of neurotrophin-mediated GR phosphorylation pathway promotes the detrimental effects of the brain cortisol response that contributes to the onset and/or progression of AD dementia. These findings have important translational implications as they provide a novel approach to treating AD dementia by identifying drugs that increase GR phosphorylation selectively at the neurotrophic sites to improve memory and cognition.","['BDNF', 'Glucocorticoid receptor', 'Memory', 'Neuroimaging', 'Spine dynamics']",Acta neuropathologica communications,2022-06-23,"[{'lastname': 'Dromard', 'firstname': 'Yann', 'initials': 'Y', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France.'}, {'lastname': 'Arango-Lievano', 'firstname': 'Margarita', 'initials': 'M', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France.'}, {'lastname': 'Borie', 'firstname': 'Amelie', 'initials': 'A', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France.'}, {'lastname': 'Dedin', 'firstname': 'Maheva', 'initials': 'M', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France.'}, {'lastname': 'Fontanaud', 'firstname': 'Pierre', 'initials': 'P', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France.\nImagerie du Petit Animal de Montpellier, 34090, Montpellier, France.'}, {'lastname': 'Torrent', 'firstname': 'Joan', 'initials': 'J', 'affiliation': 'Institut de Neuroscience de Montpellier, INSERM, 34090, Montpellier, France.'}, {'lastname': 'Garabedian', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': 'Department of Microbiology, New York University Grossman School of Medicine, New York, NY, 10016, USA.'}, {'lastname': 'Ginsberg', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': 'Nathan Kline Institute, Orangeburg, NY, 10962, USA.\nDepartments of Psychiatry, Neuroscience & Physiology, NYU Neuroscience Institute, New York University Grossman School of Medicine, New York, NY, 10016, USA.'}, {'lastname': 'Jeanneteau', 'firstname': 'Freddy', 'initials': 'F', 'affiliation': 'Institut de Génomiqueénomique Fonctionnelle, Université de Montpellier, INSERM, CNRS, 34090, Montpellier, France. freddy.jeanneteau@igf.cnrs.fr.'}]",,,,© 2022. The Author(s).,"10.1186/s40478-022-01396-7
10.1126/science.aat3810
10.1073/pnas.1903203116
10.1016/j.celrep.2018.03.110
10.1080/10253890.2020.1806226
10.3791/54796
10.1016/j.phrs.2016.08.005
10.1073/pnas.1509045112
10.1007/978-1-4939-2895-8_2
10.1038/srep37231
10.1016/j.biopsych.2012.12.003
10.1038/s41582-020-0397-4
10.1016/j.neuropharm.2015.10.034
10.1073/pnas.1206171109
10.1038/s41593-020-0687-6
10.1038/nature14251
10.1038/s41593-018-0329-4
10.1093/hmg/ddg361
10.1016/j.ynstr.2021.100402
10.1212/WNL.0000000000003537
10.1038/s41467-017-02751-2
10.1128/MCB.05866-11
10.1002/hipo.22802
10.1038/nature10849
10.1523/JNEUROSCI.2797-06.2006
10.1038/nature15257
10.1080/10253890.2020.1806226
10.1016/j.neuroscience.2012.09.017
10.1073/pnas.1714239115
10.1038/s41573-022-00391-w
10.1038/s41598-017-15549-5
10.1016/j.neuron.2011.10.015
10.1038/nrn2913
10.3390/biom9030095
10.1128/MCB.00150-13
10.1016/j.biopsych.2021.04.010
10.1038/s41398-018-0101-2
10.7554/eLife.30688
10.1038/nn.3387
10.1016/j.biopsych.2019.04.032
10.1126/science.aat8078
10.3389/fnagi.2019.00043
10.1016/j.neuropharm.2012.05.010
10.1016/j.neuron.2018.11.029
10.1016/j.neurobiolaging.2016.05.018
10.1038/sj.embor.7400784
10.1126/science.290.5491.533
10.1038/nature17172
10.1073/pnas.1714248114
10.3389/fnins.2021.752594
10.1073/pnas.1605104113
10.1212/WNL.0000000000009249
10.1093/hmg/ddx299
10.1016/j.neuropharm.2014.12.005",<Element 'PubmedArticle' at 0x7f05dd0d5180>
90,"35709192
32109013
32444460
32442528
32645348
32242115
32422204
33431495
32911500
33542473
33311702
32640463
32074416
30277217
15550597
3558716
32444366
32543702
32667669
33377817
33072682
31607599
21330339
16224307
33661862
33536325
33185244
33536436
33026219
33559975
33141872
34308411
18371537
19034303
21346373
32325025
23530738
34343191
28125629
29408191
14700705
34049240
33057040
24966193
28223406
24966190
24966189
24966195
6058395
32376634
21099686
34393019
34108716",Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia.,"COVID-19 pandemic has led to overloading of health systems all over the world. For reliable risk stratification, knowledge on factors predisposing to SARS-CoV-2 infection and to severe COVID-19 disease course is needed for decision-making at the individual, provider, and government levels. Data to identify these factors should be easily obtainable.
Retrospective cohort study of nationwide e-health databases in Estonia. We used longitudinal health records from 66,295 people tested positive for SARS-CoV-2 RNA from 26 February 2020 to 28 February 2021 and 254,958 randomly selected controls from the reference population with no known history of SARS-CoV-2 infection or clinical COVID-19 diagnosis (case to control ratio 1:4) to predict risk factors of infection and severe course of COVID-19. We analysed sociodemographic and health characteristics of study participants. The SARS-CoV-2 infection risk was slightly higher among women, and was higher among those with comorbid conditions or obesity. Dementia (RRR 3.77, 95%CI 3.30⎼4.31), renal disease (RRR 1.88, 95%CI 1.56⎼2.26), and cerebrovascular disease (RRR 1.81, 95%CI 1.64⎼2.00) increased the risk of infection. Of all SARS-CoV-2 infected people, 92% had a non-severe disease course, 4.8% severe disease (requiring hospitalisation), 1.7% critical disease (needing intensive care), and 1.5% died. Male sex, increasing age and comorbid burden contributed significantly to more severe COVID-19, and the strength of association for male sex increased with the increasing severity of COVID-19 outcome. The strongest contributors to critical illness (expressed as RRR with 95% CI) were renal disease (7.71, 4.71⎼12.62), the history of previous myocardial infarction (3.54, 2.49⎼5.02) and obesity (3.56, 2.82⎼4.49). The strongest contributors to a lethal outcome were renal disease (6.48, 3.74⎼11.23), cancer (3.81, 3.06⎼4.75), liver disease (3.51, 1.36⎼9.02) and cerebrovascular disease (3.00, 2.31⎼3.89).
We found divergent effect of age and gender on infection risk and severity of COVID-19. Age and gender did not contribute substantially to infection risk, but did so for the risk of severe disease Co-morbid health conditions, especially those affecting renin-angiotensin system, had an impact on both the risk of infection and severe disease course. Age and male sex had the most significant impact on the risk of severe COVID-19. Taking into account the role of ACE2 receptors in the pathogenesis of SARS-CoV-2 infection, as well as its modulating action on the renin-angiotensin system in cardiovascular and renal diseases, further research is needed to investigate the influence of hormonal status on ACE2 expression in different tissues, which may be the basis for the development of COVID-19 therapies.",[],PloS one,2022-06-17,"[{'lastname': 'Meister', 'firstname': 'Tatjana', 'initials': 'T', 'affiliation': 'Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Pisarev', 'firstname': 'Heti', 'initials': 'H', 'affiliation': 'Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Kolde', 'firstname': 'Raivo', 'initials': 'R', 'affiliation': 'Institute of Computer Science, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Kalda', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': 'Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Suija', 'firstname': 'Kadri', 'initials': 'K', 'affiliation': 'Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Milani', 'firstname': 'Lili', 'initials': 'L', 'affiliation': 'Institute of Genomics, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Karo-Astover', 'firstname': 'Liis', 'initials': 'L', 'affiliation': 'Institute of Genomics, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Piirsoo', 'firstname': 'Marko', 'initials': 'M', 'affiliation': 'Institute of Technology, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Uusküla', 'firstname': 'Anneli', 'initials': 'A', 'affiliation': 'Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.'}]",,,,,"10.1371/journal.pone.0270192
10.1056/NEJMoa2002032
10.1136/bmj.m1985
10.1016/S0140-6736(20)31189-2
10.1016/S0140-6736(20)31482-3
10.1038/d41586-020-01003-6
10.1101/2020.12.27.20248896
10.1016/S1473-3099(20)30371-6
10.1136/bmjopen-2020-044640
10.1371/journal.pmed.1003321
10.1038/s41746-021-00383-x
10.1038/s41591-020-01191-8
10.1038/s41586-020-2521-4
10.1056/NEJMp2002125
10.1136/oem.2004.014472
10.1016/0021-9681(87)90171-8
10.1136/bmj.m1966
10.1001/jamanetworkopen.2020.12270
10.1001/jamainternmed.2020.3539
10.1080/21645515.2020.1852010
10.3389/fpubh.2020.00444
10.1016/j.vaccine.2019.10.005
10.1093/aje/kwq433
10.1097/01.mlr.0000182534.19832.83
10.15585/mmwr.mm7009a4
10.1128/mSphere.01207-20
10.1093/cid/ciaa1166
10.1101/2020.08.26.20182303
10.1038/s41467-021-21100-y
10.1002/wps.20806
10.1002/alz.12296
10.1371/journal.pone.0241827
10.1016/j.lanepe.2021.100158
10.1053/j.ajkd.2007.11.022
10.1038/ki.2008.497
10.1159/000324521
10.1016/j.immuni.2020.04.003
10.1111/hsc.12036
10.1371/journal.pone.0255541
10.1371/journal.pone.0170550
10.1016/j.puhe.2017.12.007
10.1016/j.amepre.2003.09.020
10.1016/j.ebiom.2021.103403
10.1038/s41597-020-00668-y
10.1093/infdis/jiu159
10.4049/jimmunol.1601166
10.1093/infdis/jit610
10.1093/infdis/jiu147
10.1093/infdis/jiu175
10.1093/oxfordjournals.aje.a120753
10.1073/pnas.2003138117
10.1097/MNH.0b013e328341164a
10.1016/j.vaccine.2021.07.093
10.1038/s41591-021-01410-w",<Element 'PubmedArticle' at 0x7f05dd45ce00>
91,35705005,Plasma Oxytocin Is Not Associated with Social Cognition or Behavior in Frontotemporal Dementia and Alzheimer's Disease Syndromes.,"Changes in social behavior and emotion processing are common in frontotemporal dementia (FTD) and semantic dementia (SD), and less so in Alzheimer's disease (AD). Recent research has investigated oxytocin as a potential treatment for these symptoms; however, whether plasma oxytocin is associated with social-emotional symptoms of dementia remains underexplored.
Thirty behavioral-variant FTD (bvFTD), 28 SD, 39 AD, and 24 controls underwent blood sampling to measure oxytocin. Participants completed an emotion processing battery. Carers completed the Cambridge Behavioral Inventory and the Neuropsychiatric Inventory.
Patients with bvFTD were severely impaired in emotion processing and behavioral ratings, with milder impairment in SD and AD. No difference in plasma oxytocin was observed between groups (p = 0.632). No significant associations were found between oxytocin and social behavior or emotion processing (r values between -0.241 and 0.227, all p values >0.099).
Our results indicate that plasma oxytocin is not reduced in dementia and is unrelated to social, emotional, and behavioral features. We noted high interindividual variability in our data; hence, future investigations should consider methodological influences such as serum versus saliva and diurnal variation on oxytocin function. These results demonstrate that current measurement measures of plasma oxytocin have limited utility in determining the role of oxytocin in FTD. Alternative oxytocin measures may prove more sensitive and should be considered when conducting clinical trials.","['Behavioural-variant frontotemporal dementia', 'Emotion processing', 'Hypothalamus', 'Social cognition']",Dementia and geriatric cognitive disorders,2022-06-16,"[{'lastname': 'Johnson', 'firstname': 'Emma G', 'initials': 'EG', 'affiliation': 'School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.\nBrain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.'}, {'lastname': 'Kuiper', 'firstname': 'Wytse', 'initials': 'W', 'affiliation': 'Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'lastname': 'Ahmed', 'firstname': 'Rebekah M', 'initials': 'RM', 'affiliation': 'Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.\nSydney Medical School, The University of Sydney Central Clinical School, Sydney, New South Wales, Australia.'}, {'lastname': 'Halliday', 'firstname': 'Glenda M', 'initials': 'GM', 'affiliation': 'Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.\nSydney Medical School, The University of Sydney Central Clinical School, Sydney, New South Wales, Australia.'}, {'lastname': 'Burrell', 'firstname': 'James R', 'initials': 'JR', 'affiliation': 'Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.\nThe University of Sydney Concord Clinical School, Sydney, New South Wales, Australia.\nConcord General Hospital, Sydney, New South Wales, Australia.'}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': 'Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.\nSydney Medical School, The University of Sydney Central Clinical School, Sydney, New South Wales, Australia.'}, {'lastname': 'Guastella', 'firstname': 'Adam J', 'initials': 'AJ', 'affiliation': ""Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.\nChildren's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.""}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.\nBrain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.'}, {'lastname': 'Kumfor', 'firstname': 'Fiona', 'initials': 'F', 'affiliation': 'School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.\nBrain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.'}]",,"Our results indicate that plasma oxytocin is not reduced in dementia and is unrelated to social, emotional, and behavioral features. We noted high interindividual variability in our data; hence, future investigations should consider methodological influences such as serum versus saliva and diurnal variation on oxytocin function. These results demonstrate that current measurement measures of plasma oxytocin have limited utility in determining the role of oxytocin in FTD. Alternative oxytocin measures may prove more sensitive and should be considered when conducting clinical trials.","Patients with bvFTD were severely impaired in emotion processing and behavioral ratings, with milder impairment in SD and AD. No difference in plasma oxytocin was observed between groups (p = 0.632). No significant associations were found between oxytocin and social behavior or emotion processing (r values between -0.241 and 0.227, all p values >0.099).","© 2022 S. Karger AG, Basel.",10.1159/000525087,<Element 'PubmedArticle' at 0x7f05dd426e00>
92,"35619714
11721091
18571301
25207999
25988948
33610813
30924977
33378563
26971528
31434991
34536490
32341472
30519748
31488882
33711509
21356829
11846609
34278886
29086028
33675023
29890840
27489225
35235649
1835632
28389511
26490311
31543403
30852460
27912057
33121040
28875556
29861127
31191296
23046210
31257151
30249283
31712703
30060474
30240535
25473159
33674141
29231905
30230594
28270609
32354071
28178378
16831601
32994688
31532834
22493442
26068396
33441834
29648538
20667128
22583695
32768573
32825966
24762590
23095882
19509333
20213691",Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity.,"Lifestyle choices, external environment, aging, and other factors influence the synthesis of melatonin. Although the physiological functions of melatonin have been widely studied in relation to specific organs, the systemic effects of endogenous melatonin reduction has not been reported. This study evaluates the systemic changes and possible pathogenic risks in an endogenous melatonin reduction (EMR) mouse model deficient in the rate limiting enzyme in melatonin production, arylalkylamine N-acetyltransferase ","[""alzheimer's disease"", 'fecal microbiota transplantation', 'gut- brain axis', 'melatonin', 'microbiota dysbiosis', 'obesity', 'systemic inflammation']",Frontiers in immunology,2022-05-28,"[{'lastname': 'Zhang', 'firstname': 'Boqi', 'initials': 'B', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Chen', 'firstname': 'Tong', 'initials': 'T', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Cao', 'firstname': 'Maosheng', 'initials': 'M', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Yuan', 'firstname': 'Chenfeng', 'initials': 'C', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Reiter', 'firstname': 'Russel J', 'initials': 'RJ', 'affiliation': 'Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, United States.'}, {'lastname': 'Zhao', 'firstname': 'Zijiao', 'initials': 'Z', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Zhao', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Chen', 'firstname': 'Lu', 'initials': 'L', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Fan', 'firstname': 'Wenjing', 'initials': 'W', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Wang', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Zhou', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}, {'lastname': 'Li', 'firstname': 'Chunjin', 'initials': 'C', 'affiliation': 'College of Animal Sciences, Jilin University, Changchun, China.'}]",,,,"Copyright © 2022 Zhang, Chen, Cao, Yuan, Reiter, Zhao, Zhao, Chen, Fan, Wang, Zhou and Li.","10.3389/fimmu.2022.900132
10.1021/ja01543a060
10.1159/000046903
10.1016/j.pneurobio.2008.04.001
10.1039/C4FO00317A
10.1111/jpi.12248
10.1016/j.arr.2021.101304
10.1111/jpi.12573
10.1111/jpi.12714
10.1002/mds.26592
10.1038/s41385-019-0193-x
10.1016/j.pharmthera.2021.107988
10.1038/s41396-020-0651-1
10.1007/s00535-018-1529-0
10.1038/s41422-019-0216-x
10.1016/j.arr.2021.101317
10.1101/pdb.prot4986
10.1006/meth.2001.1262
10.1080/21691401.2021.1952212
10.1007/s00586-017-5363-5
10.1007/s12035-021-02311-2
10.1089/ars.2018.7506
10.1136/annrheumdis-2016-209428
10.1093/cercor/bhac036
10.1016/0277-5379(91)90319-9
10.1158/1078-0432.CCR-17-0146
10.1158/1078-0432.CCR-15-1110
10.1016/j.cmet.2019.08.018
10.1016/j.nut.2018.11.018
10.1016/j.cell.2016.11.018
10.3390/jcm9113452
10.1111/jpi.12448
10.1016/j.jaut.2018.05.008
10.3389/fnagi.2019.00122
10.1111/j.1365-2990.2012.01307.x
10.1016/j.cmet.2019.06.005
10.1186/s12974-018-1313-3
10.1038/s41598-019-52893-0
10.3390/nu10080975
10.1111/jcpe.13013
10.3748/wjg.v20.i43.16079
10.1016/j.tim.2021.02.001
10.3390/nu9121348
10.1111/jpi.12524
10.1073/pnas.1700172114
10.3390/pharmaceutics12050403
10.1111/jpi.12398
10.1053/j.gastro.2006.04.025
10.3748/wjg.v26.i35.5287
10.1111/jpi.12610
10.1074/jbc.M111.334730
10.1038/bjc.2015.194
10.1038/s41598-020-80336-8
10.7554/eLife.34362.001
10.1186/1476-4598-9-201
10.1186/1479-5876-10-91
10.1016/j.freeradbiomed.2020.06.037
10.1016/j.prp.2020.153101
10.3760/cma.j.issn.0366-6999.20132949
10.1242/dev.078972
10.1073/pnas.0901700106
10.1002/dvg.20620",<Element 'PubmedArticle' at 0x7f05dd745e00>
93,35585820,The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease.,"Alzheimer's disease (AD) is an age-dependent neurodegenerative disease with progressive cognition and memory loss, insomnia, and other abnormal behavioral changes. Amongst various hypotheses for AD pathophysiology, occupational stress-induced Alzheimer's has recently been reported in many AD cases.
Studies pertaining to the same suggest that stress leads to insomnia or sleep disruption, which further leads to neuroinflammation due to oxidative stress, both of which are major harbingers of AD. Additionally, overall sleep deficit is associated with progressive cognitive and memory decline, which adds more inconvenience to Alzheimer's disease. Based on this, any triumphant AD management needs a pharmacological intervention that can not only antagonize the amyloid betainduced neurotoxicity but also correct the sleep-wake cycle disruption. Chronobiotic therapeutics like melatonin offer vital neuroprotective effects by eliciting its action through more than one of the pathologies of AD. This is also bolstered by the finding that endogenous melatonin levels are lower in AD patients. This melatonin replacement therapy can be especially useful in AD treatment, but only in the early phases of the disease and in cases where the melatonin receptors are intact and functioning.
To negate such limitations and extend the action and therapeutic efficacy of melatonin- mediated actions towards AD treatment, melatonin analogue like tasimelteon can pose a high therapeutic value in AD treatment superior to that provided by melatonin. This review encapsulates all details about how AD is believed to occur and how current situations influence it, along with how melatonin and tasimelteon act towards treating Alzheimer's.","['Alzheimer’s disease', 'melatonin', 'neuroinflammatory diseases', 'oxidative stress', 'sleep initiation and maintenance disorders', 'tasimelteon']",Current drug safety,2022-05-20,"[{'lastname': 'Ravikumar', 'firstname': 'Mrinalini', 'initials': 'M', 'affiliation': 'Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, India.'}, {'lastname': 'Mohan', 'firstname': 'Sumithra', 'initials': 'S', 'affiliation': 'Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, India.'}, {'lastname': 'Velpandian', 'firstname': 'Chitra', 'initials': 'C', 'affiliation': 'Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, 603203, India.'}]",,"To negate such limitations and extend the action and therapeutic efficacy of melatonin- mediated actions towards AD treatment, melatonin analogue like tasimelteon can pose a high therapeutic value in AD treatment superior to that provided by melatonin. This review encapsulates all details about how AD is believed to occur and how current situations influence it, along with how melatonin and tasimelteon act towards treating Alzheimer's.",,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1574886317666220517125644,<Element 'PubmedArticle' at 0x7f05dd733270>
94,"35582669
27366724
28695003
28522654
28205574
25344293
30106209
27660698
17599421
27398023
24526623
22476197
19366776
21179532
19653027
21778438
30655669
25792818
24394151
16361024
31744008
28275702
24267647
25037289
21471435
25385447
21091952
18801863
27062261
26039846
25728442
16283246
10599761
16116114
24843720
22572745
24489845
19280172
24622753
23340883
22372522
28088029
25766618
19135149
20444434
15033922
19777393
27432942
27988872
25043908
27739227
27235734
32722232
30067154
29149058
29691988
24931034
29535161
22275369
15750215
24735819
20842183
18479783
18430999
25597881
32256316
24849348
29950970
28515688
30565508
20004026
12904469
28272510
28927992
28652303
31669775
31511851
31433485
33521236
31376172
30904011
28427557
15541710
12882932
15755688
24747740
31534057
25960150
25733901",Cognitive disorder and dementia in type 2 diabetes mellitus.,"Insulin, a key pleiotropic hormone, regulates metabolism through several signaling pathways in target tissues including skeletal muscle, liver, and brain. In the brain, insulin modulates learning and memory, and impaired insulin signaling is associated with metabolic dysregulation and neurodegenerative diseases. At the receptor level, in aging and Alzheimer's disease (AD) models, the amount of insulin receptors and their functions are decreased. Clinical and animal model studies suggest that memory improvements are due to changes in insulin levels. Furthermore, diabetes mellitus (DM) and insulin resistance are associated with age-related cognitive decline, increased levels of β-amyloid peptide, phosphorylation of tau protein; oxidative stress, pro-inflammatory cytokine production, and dyslipidemia. Recent evidence shows that deleting brain insulin receptors leads to mild obesity and insulin resistance without influencing brain size and apoptosis development. Conversely, deleting insulin-like growth factor 1 receptor (IGF-1R) affects brain size and development, and contributes to behavior changes. Insulin is synthesized locally in the brain and is released from the neurons. Here, we reviewed proposed pathophysiological hypotheses to explain increased risk of dementia in the presence of DM. Regardless of the exact sequence of events leading to neurodegeneration, there is strong evidence that mitochondrial dysfunction plays a key role in AD and DM. A triple transgenic mouse model of AD showed mitochondrial dysfunction, oxidative stress, and loss of synaptic integrity. These alterations are comparable to those induced in wild-type mice treated with sucrose, which is consistent with the proposal that mitochondrial alterations are associated with DM and contribute to AD development. Alterations in insulin/IGF-1 signaling in DM could lead to mitochondrial dysfunction and low antioxidant capacity of the cell. Thus, insulin/IGF-1 signaling is important for increased neural processing and systemic metabolism, and could be a specific target for therapeutic strategies to decrease alterations associated with age-related cognitive decline.","['Alzheimer´s disease', 'Cognitive decline', 'Diabetes mellitus', 'Insulin', 'Vascular dementia']",World journal of diabetes,2022-05-19,"[{'lastname': 'Ortiz', 'firstname': 'Genaro G', 'initials': 'GG', 'affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Huerta', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': 'University Biomedical Research Center, University of Colima, Colima 28040, Mexico.'}, {'lastname': 'González-Usigli', 'firstname': 'Héctor A', 'initials': 'HA', 'affiliation': 'Department of Neurology, Movement Disorders Clinic, Sub-Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute (IMSS), Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Torres-Sánchez', 'firstname': 'Erandis D', 'initials': 'ED', 'affiliation': ""Department of Medical and Life Sciences, University Center of 'La Ciénega', University of Guadalajara, Ocotlán 47810, Jalisco, Mexico.""}, {'lastname': 'Delgado-Lara', 'firstname': 'Daniela Lc', 'initials': 'DL', 'affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Pacheco-Moisés', 'firstname': 'Fermín P', 'initials': 'FP', 'affiliation': 'Department of Chemistry, University Center of Exact Sciences and Engineering, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Mireles-Ramírez', 'firstname': 'Mario A', 'initials': 'MA', 'affiliation': 'Department of Neurology, Movement Disorders Clinic, Sub-Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute (IMSS), Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Torres-Mendoza', 'firstname': 'Blanca Mg', 'initials': 'BM', 'affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Moreno-Cih', 'firstname': 'Roxana I', 'initials': 'RI', 'affiliation': 'Gerontology Postgraduate Program, Public Health Department, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}, {'lastname': 'Velázquez-Brizuela', 'firstname': 'Irma E', 'initials': 'IE', 'affiliation': 'Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.'}]",,,,©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.,10.4239/wjd.v13.i4.319,<Element 'PubmedArticle' at 0x7f05dd724680>
95,"35490297
26595641
20971753
12030310
30837838
25549971
28112502
31920533
17981595
11285240
14667816
29765078
31462091
20948999
19765185
29483269
27289443
18989115
18535185
17023659
19383787
25788357
19164285
30820574
29961577
23625794
15371533
12928786
23089745
18378771
30696728
28073925
21204008
10397269
19860916
22781549
17345602
10404983
29378861
28404863
21052700
29053785
12526812
28743268
33812000
28828399
2236009
21497117
24186875
26109656
31911437
29044416
26444430
25982564
27545621
28608407
29414699
24817693
33252789
28098204
33771571
32237272
29860432
28076807
20054825
1618805
11121440
30853299
27602576
32649883
31272829
28396410
33097688
32004090
31634364
34759379
27392146
29511089
33149109
27452472
29438978
26735904
27291647
29886015
31260322
25531225
33814344
12509452
33909608
28988034
18039473
28280572
33558506
2268320
9771457
31640144
28435163
21092856
33300249
30814253
27096426
33653957
35120524
27635780
32302571
16847328
11279269
12525699
17291356",Charge and redox states modulate granulin-TDP-43 coacervation toward phase separation or aggregation.,"Cytoplasmic inclusions containing aberrant proteolytic fragments of TDP-43 are associated with frontotemporal lobar degeneration (FTLD) and other related pathologies. In FTLD, TDP-43 is translocated into the cytoplasm and proteolytically cleaved to generate a prion-like domain (PrLD) containing C-terminal fragments (C25 and C35) that form toxic inclusions. Under stress, TDP-43 partitions into membraneless organelles called stress granules (SGs) by coacervating with RNA and other proteins. To study the factors that influence the dynamics between these cytoplasmic foci, we investigated the effects of cysteine-rich granulins (GRNs 1-7), which are the proteolytic products of progranulin, a protein implicated in FTLD, on TDP-43. We show that extracellular GRNs, typically generated during inflammation, internalize and colocalize with PrLD as puncta in the cytoplasm of neuroblastoma cells but show less likelihood of their presence in SGs. In addition, we show GRNs and PrLD coacervate to undergo liquid-liquid phase separation (LLPS) or form gel- or solid-like aggregates. Using charge patterning and conserved cysteines among the wild-type GRNs as guides, along with specifically engineered mutants, we discover that the negative charges on GRNs drive LLPS while the positive charges and the redox state of cysteines modulate these phase transitions. Furthermore, RNA and GRNs compete and expel one another from PrLD condensates, providing a basis for GRN's absence in SGs. Together, the results help uncover potential modulatory mechanisms by which extracellular GRNs, formed during chronic inflammatory conditions, could internalize and modulate cytoplasmic TDP-43 inclusions in proteinopathies.",[],Biophysical journal,2022-05-02,"[{'lastname': 'Bhopatkar', 'firstname': 'Anukool A', 'initials': 'AA', 'affiliation': 'Department of Chemistry and Biochemistry, School of Mathematics and Natural Sciences, University of Southern Mississippi, Hattiesburg, Mississippi.'}, {'lastname': 'Dhakal', 'firstname': 'Shailendra', 'initials': 'S', 'affiliation': 'Department of Chemistry and Biochemistry, School of Mathematics and Natural Sciences, University of Southern Mississippi, Hattiesburg, Mississippi.'}, {'lastname': 'Abernathy', 'firstname': 'Hannah G', 'initials': 'HG', 'affiliation': 'School of Polymer Science and Engineering, University of Southern Mississippi, Hattiesburg, Mississippi.'}, {'lastname': 'Morgan', 'firstname': 'Sarah E', 'initials': 'SE', 'affiliation': 'School of Polymer Science and Engineering, University of Southern Mississippi, Hattiesburg, Mississippi.'}, {'lastname': 'Rangachari', 'firstname': 'Vijayaraghavan', 'initials': 'V', 'affiliation': 'Department of Chemistry and Biochemistry, School of Mathematics and Natural Sciences, University of Southern Mississippi, Hattiesburg, Mississippi; Center for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi. Electronic address: Vijay.rangachari@usm.edu.'}]",,,,Copyright © 2022 Biophysical Society. Published by Elsevier Inc. All rights reserved.,"10.1016/j.bpj.2022.04.034
10.1016/s0140-6736(15)00461-4
10.1136/jnnp.2010.212225
10.1017/s1355617702814357
10.3389/fnmol.2019.00025
10.1007/s00401-014-1380-1
10.1021/acs.biochem.6b01088
10.3389/fnmol.2019.00301
10.2741/2727
10.1093/emboj/20.7.1774
10.1016/s0888-7543(03)00214-3
10.1038/s41598-018-25767-0
10.1161/atvbaha.119.313034
10.1371/journal.pone.0013250
10.1111/j.1471-4159.2009.06383.x
10.1073/pnas.1800038115
10.1016/j.tcb.2016.05.004
10.1097/wco.0b013e3283168d1d
10.2353/ajpath.2008.080003
10.1126/science.1134108
10.1073/pnas.0900688106
10.1007/s00401-015-1412-5
10.1074/jbc.m809462200
10.1016/j.cell.2018.06.006
10.1002/jcp.24395
10.1091/mbc.e04-08-0715
10.1007/s00109-003-0474-3
10.1189/jlb.0812429
10.1083/jcb.200712039
10.1523/JNEUROSCI.3498-17.2019
10.1093/hmg/ddx011
10.1007/s13238-010-0067-1
10.1186/1471-2202-10-130
10.1186/1750-1326-7-33
10.1002/humu.9484
10.1001/archneur.56.7.817
10.1523/jneurosci.3081-17.2018
10.1126/scitranslmed.aah5642
10.1007/s00401-010-0764-0
10.1093/brain/awx198
10.1016/s0092-8674(02)01141-8
10.1186/s13024-017-0196-6
10.1016/j.nbd.2021.105360
10.1523/eneuro.0100-17.2017
10.1073/pnas.87.20.7912
10.1016/j.immuni.2011.01.018
10.1152/ajplung.00221.2013
10.1523/jneurosci.4808-14.2015
10.1074/jbc.ra119.011501
10.1093/jnen/nlx085
10.1371/journal.pone.0140248
10.1016/j.neuroscience.2015.05.013
10.1016/j.str.2016.07.007
10.1002/pro.3212
10.1016/j.bpj.2017.11.3778
10.1073/pnas.1315346111
10.1002/prot.26031
10.1038/srep40787
10.1016/j.jmb.2021.166953
10.1002/cpbi.99
10.1093/nar/gky384
10.1016/j.bpj.2016.11.3200
10.1002/jcp.22031
10.1016/s0021-9258(18)42382-4
10.1083/jcb.151.6.1257
10.1016/j.neuron.2019.02.038
10.7554/elife.18413
10.1016/j.molcel.2020.06.019
10.1016/j.neuron.2019.05.048
10.1073/pnas.1613854114
10.1038/s41419-020-03116-2
10.1146/annurev-biophys-121219-081629
10.1371/journal.pcbi.1007028
10.1038/s41594-021-00677-4
10.1016/j.molcel.2016.05.042
10.1074/jbc.ac117.001037
10.1038/s41467-020-19211-z
10.1016/j.celrep.2016.06.088
10.15252/embj.201797452
10.1371/journal.pbio.1002338
10.1016/j.cis.2016.05.012
10.1016/j.jmb.2018.06.010
10.1021/acs.jpclett.9b01731
10.1038/nphys3532
10.1038/nrm3920
10.1128/mcb.23.2.534-542.2003
10.1371/journal.pbio.3001198
10.1016/j.bbapap.2017.10.001
10.1016/j.bbamcr.2007.10.013
10.1098/rsos.160696
10.1038/s41467-021-21089-4
10.1016/s0006-291x(05)80908-8
10.1677/joe.0.1580145
10.3390/ijms20205210
10.1038/nrn.2017.36
10.1016/j.neuron.2010.09.034
10.1111/bpa.12923
10.1074/jbc.ra118.007222
10.1371/journal.pbio.1002447
10.1073/pnas.2017184118
10.1101/2021.01.08.425959
10.1021/acs.jpcb.6b08109
10.1016/j.cell.2020.03.046
10.1128/mcb.00224-06
10.1046/j.1471-4159.2001.00231.x
10.1073/pnas.0237313100
10.1186/1742-2094-4-7",<Element 'PubmedArticle' at 0x7f05dd838770>
96,"35487587
30032161
26578659
27694265
22033996
16844717
27402600
29594711
31744377
12482100
15501092
27170700
29549466
23867200
24374381
30042721
33074242",The Epidermal Growth Factor Domain of the Mutation Does Not Appear to Influence Disease Progression in CADASIL When Brain Volume and Sex Are Taken into Account.,"By studying the evolution of brain volume across the life span in male and female patients, we aimed to understand how sex, brain volume, and the epidermal growth factor repeat domain of the mutation, the 3 major determinants of disability in CADASIL, interact in driving disease evolution.
We used validated methods to model the evolution of normalized brain volume with age in male and female patients using nonparametric regression in a large, monocentric cohort with prospectively collected clinical and high-resolution MR imaging data. We used k-means clustering to test for the presence of different clinical course profiles.
We included 229 patients (mean age, 53 [SD, 12] years; 130 women). Brain volume was larger in women (mean size, 1024 [SD, 62] cm
Our results demonstrate a detrimental effect of male sex on brain volume throughout life in CADASIL. We identified a subgroup of male patients whose brain volume and clinical outcomes were similar to those of age-matched women. They did not have a specific distribution of the epidermal growth factor repeat domain, suggesting that yet-unidentified predictors may interact with sex and brain volume in driving disease evolution.",[],AJNR. American journal of neuroradiology,2022-04-30,"[{'lastname': 'Lebenberg', 'firstname': 'J', 'initials': 'J', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.\nFederation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.""}, {'lastname': 'Guichard', 'firstname': 'J-P', 'initials': 'JP', 'affiliation': 'Neuroradiology (J.P.G., A.G.).'}, {'lastname': 'Guillonnet', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Neuroradiology (J.P.G., A.G.).'}, {'lastname': 'Hervé', 'firstname': 'D', 'initials': 'D', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.\nFederation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.""}, {'lastname': 'Alili', 'firstname': 'N', 'initials': 'N', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.""}, {'lastname': 'Taleb', 'firstname': 'A', 'initials': 'A', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.""}, {'lastname': 'Dias-Gastellier', 'firstname': 'N', 'initials': 'N', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.\nFederation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.""}, {'lastname': 'Chabriat', 'firstname': 'H', 'initials': 'H', 'affiliation': ""the Centre de Neurologie Vasculaire Translationel (J.L., D.H., N.A., A.T., N.D.-G., H.C.), Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; L'Institut National de la Santé et de la RechercheMédicale INSERM U1141, Université Paris Cité, Paris, France.\nFederation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.""}, {'lastname': 'Jouvent', 'firstname': 'E', 'initials': 'E', 'affiliation': 'From the Department of Neurology (E.J.) eric.jouvent@aphp.fr.\nFederation Hospitalo-Universitaire NeuroVasc (J.L., N.D.-G., D.H., H.C., E.J.), Paris, France.'}]",,,"We included 229 patients (mean age, 53 [SD, 12] years; 130 women). Brain volume was larger in women (mean size, 1024 [SD, 62] cm",© 2022 by American Journal of Neuroradiology.,"10.3174/ajnr.A7499
10.1038/s41436-018-0088-3
10.1161/STROKEAHA.115.010696
10.1212/WNL.0000000000003252
10.1161/STROKEAHA.111.631028
10.1093/brain/awl177
10.1016/j.neuroimage.2016.07.018
10.1007/s12021-018-9372-2
10.1177/0271678X19888967
10.1006/nimg.2002.1040
10.1016/j.neuroimage.2004.07.051
10.1177/0271678X16647396
10.1007/s00415-018-8825-8
10.1016/S1474-4422(13)70124-8
10.1080/01621459.1979.10481038
10.1016/0377-0427(87)90125-7
10.18637/jss.v045.i07
10.1016/j.neubiorev.2013.12.004
10.3389/fneur.2018.00526
10.3233/JAD-201086",<Element 'PubmedArticle' at 0x7f05dec74e00>
97,35483222,Overexpression of progranulin increases pathological protein accumulation by suppressing autophagic flux.,"Progranulin (PGRN) haploinsufficiency from autosomal dominant mutations in the PGRN gene causes frontotemporal lobar degeneration, which is characterized by cytoplasmic inclusions predominantly containing TDP-43 (FTLD-TDP). PGRN supplementation for patients with a PGRN gene mutation has recently been proposed as a therapeutic strategy to suppress FTLD-TDP. However, it currently remains unclear whether excessive amounts of PGRN are beneficial or harmful. We herein report the effects of PGRN overexpression on autophagic flux in a cultured cell model. PGRN overexpression increased the level of an autophagosome marker without promoting autophagosome formation and decreased the signal intensity of an autolysosome marker, indicating the suppression of autophagic flux due to reductions in the formation of autolysosomes. Assessments of lysosome numbers and biogenesis using LysoTracker and cells stably expressing TFEB-GFP, respectively, indicated that PGRN overexpression increased the lysosome numbers without lysosomal biogenesis. These results suggest that PGRN overexpression suppressed autophagic flux by inhibiting autophagosome-lysosome fusion. Moreover, PGRN overexpression enhanced polyglutamine aggregation and aggregate-prone TDP-43 accumulation, indicating that the suppression of autophagic flux by excessive amounts of PGRN worsens the pathology of neurodegenerative diseases.","['Autophagic flux', 'Lysosome biogenesis', 'Progranulin', 'TDP-43']",Biochemical and biophysical research communications,2022-04-29,"[{'lastname': 'Tanaka', 'firstname': 'Yoshinori', 'initials': 'Y', 'affiliation': 'Biochemistry Unit, Faculty of Veterinary Medicine, Okayama University of Science, Imabari-shi, Ehime, Japan. Electronic address: y-tanaka@ous.ac.jp.'}, {'lastname': 'Kusumoto', 'firstname': 'Shun-Ya', 'initials': 'SY', 'affiliation': 'Biochemistry Unit, Faculty of Veterinary Medicine, Okayama University of Science, Imabari-shi, Ehime, Japan.'}, {'lastname': 'Honma', 'firstname': 'Yuki', 'initials': 'Y', 'affiliation': 'Biochemistry Unit, Faculty of Veterinary Medicine, Okayama University of Science, Imabari-shi, Ehime, Japan.'}, {'lastname': 'Takeya', 'firstname': 'Kosuke', 'initials': 'K', 'affiliation': 'Biochemistry Unit, Faculty of Veterinary Medicine, Okayama University of Science, Imabari-shi, Ehime, Japan.'}, {'lastname': 'Eto', 'firstname': 'Masumi', 'initials': 'M', 'affiliation': 'Biochemistry Unit, Faculty of Veterinary Medicine, Okayama University of Science, Imabari-shi, Ehime, Japan.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.bbrc.2022.04.064,<Element 'PubmedArticle' at 0x7f05debe4400>
98,"35482727
31151462
29767636
8387282
16769769
11390861
10782362
26144371
29324626
12364390
23002189
30843353
26577429
31354956
29932477
27382803
17584073
11358941
33148300
31625979
16099941
24533868
29856470
34605947
16356231
18080871
19662382
27282767
28411114
30583748
31037864
17962242
17318497
32796765
30592365
34605947
30736862
31665092
33554514
32331426
22874067
30798282
33736553
34173962
18064739
23353941
32630976
3203132
26511878
22777516","Bioactive adrenomedullin in sepsis patients in the emergency department is associated with mortality, organ failure and admission to intensive care.","Adrenomedullin is a vasoactive hormone with potentially prognostic and therapeutic value, which mainly has been investigated in intensive care unit (ICU) settings. The triaging in the emergency department (ED) of patients to the right level of care is crucial for patient outcome.
The primary aim of this study was to investigate the association of bioactive adrenomedullin (bio-ADM) with mortality among sepsis patients in the ED. Secondary aims were to investigate the association of bio-ADM with multiple organ failure (MOF), ICU admission and ED discharge.
In this prospective observational cohort study, adult sepsis patients in the ED (2013-2015) had blood samples collected for later batch analysis of bio-ADM. Odds ratios (OR) with 95% confidence interval (CI) for bio-ADM were calculated.
Bio-ADM in 594 sepsis patients was analyzed of whom 51 died within 28 days (8.6%), 34 developed severe MOF, 27 were ICU admitted and 67 were discharged from the ED. The median (interquartile range) bio-ADM was 36 (26-56) and 63 (42-132) pg/mL among survivors and non-survivors, respectively, 81 (56-156) pg/mL for patients with severe MOF and 77 (42-133) pg/mL for ICU admitted patients. Each log-2 increment of bio-ADM conferred an OR of 2.30 (95% CI 1.74-3.04) for mortality, the adjusted OR was 2.39 (95% CI 1.69-3.39). The area under the receiver operating characteristic curve of a prognostic mortality model based on demographics and biomarkers increased from 0.80 to 0.86 (p = 0.02) when bio-ADM was added. Increasing bio-ADM was associated with severe MOF, ICU admission and ED discharge with adjusted ORs of 3.30 (95% CI 2.13-5.11), 1.75 (95% CI 1.11-2.77) and 0.46 (95% CI 0.32-0.68), respectively.
Bio-ADM in sepsis patients in the ED is associated with mortality, severe MOF, ICU admission and ED discharge, and may be of clinical importance for triage of sepsis patients in the ED.",[],PloS one,2022-04-29,"[{'lastname': 'Lundberg', 'firstname': 'Oscar H M', 'initials': 'OHM', 'affiliation': 'Department of Clinical Sciences, Anaesthesiology and Intensive Care, Medical Faculty, Lund University, Lund, Sweden.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, Malmö, Sweden.'}, {'lastname': 'Rosenqvist', 'firstname': 'Mari', 'initials': 'M', 'affiliation': 'Department of Clinical Sciences, Medical Faculty, Lund University, Malmö, Sweden.\nDepartment of Infectious Diseases, Skåne University Hospital, Malmö, Sweden.'}, {'lastname': 'Bronton', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Department of Clinical Sciences, Medical Faculty, Lund University, Malmö, Sweden.\nDepartment of Internal Medicine, Skåne University Hospital, Malmö, Sweden.'}, {'lastname': 'Schulte', 'firstname': 'Janin', 'initials': 'J', 'affiliation': 'SphingoTec GmbH, Hennigsdorf, Germany.'}, {'lastname': 'Friberg', 'firstname': 'Hans', 'initials': 'H', 'affiliation': 'Department of Clinical Sciences, Anaesthesiology and Intensive Care, Medical Faculty, Lund University, Lund, Sweden.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, Malmö, Sweden.'}, {'lastname': 'Melander', 'firstname': 'Olle', 'initials': 'O', 'affiliation': 'Department of Clinical Sciences, Medical Faculty, Lund University, Malmö, Sweden.\nDepartment of Infectious Diseases, Skåne University Hospital, Malmö, Sweden.\nDepartment of Internal Medicine, Skåne University Hospital, Malmö, Sweden.'}]",,"Bio-ADM in sepsis patients in the ED is associated with mortality, severe MOF, ICU admission and ED discharge, and may be of clinical importance for triage of sepsis patients in the ED.","Bio-ADM in 594 sepsis patients was analyzed of whom 51 died within 28 days (8.6%), 34 developed severe MOF, 27 were ICU admitted and 67 were discharged from the ED. The median (interquartile range) bio-ADM was 36 (26-56) and 63 (42-132) pg/mL among survivors and non-survivors, respectively, 81 (56-156) pg/mL for patients with severe MOF and 77 (42-133) pg/mL for ICU admitted patients. Each log-2 increment of bio-ADM conferred an OR of 2.30 (95% CI 1.74-3.04) for mortality, the adjusted OR was 2.39 (95% CI 1.69-3.39). The area under the receiver operating characteristic curve of a prognostic mortality model based on demographics and biomarkers increased from 0.80 to 0.86 (p = 0.02) when bio-ADM was added. Increasing bio-ADM was associated with severe MOF, ICU admission and ED discharge with adjusted ORs of 3.30 (95% CI 2.13-5.11), 1.75 (95% CI 1.11-2.77) and 0.46 (95% CI 0.32-0.68), respectively.",,"10.1371/journal.pone.0267497
10.1186/s13054-019-2478-6
10.1097/CCM.0000000000003119
10.1006/bbrc.1993.1451
10.1189/jlb.0206123
10.1152/physiologyonline.1999.14.6.255
10.1210/edrv.21.2.0396
10.1016/j.ejphar.2015.06.061
10.1097/SHK.0000000000001103
10.1161/01.res.0000036603.61868.f9
10.1530/EJE-12-0472
10.1002/ejhf.1437
10.1016/j.ajem.2015.10.033
10.1136/openhrt-2019-001048
10.1002/ejhf.1245
10.2174/092986707780830943
10.1161/01.hyp.37.5.1279
10.1186/s13054-020-03351-1
10.1097/CCM.0000000000004044
10.1373/clinchem.2005.051110
10.1186/cc13731
10.1111/bcp.13655
10.1007/s00134-021-06537-5
10.1186/cc3885
10.1080/10623320701678326
10.1007/s00134-009-1610-5
10.1186/s13054-016-1361-y
10.1016/j.chest.2017.03.035
10.1186/s13054-018-2243-2
10.3343/alm.2019.39.5.454
10.1093/bja/aem295
10.1007/s00134-007-0561-y
10.3390/biom10081171
10.1002/ejhf.1366
10.1186/s13054-019-2329-5
10.1186/s13054-019-2613-4
10.1515/cclm-2020-1566
10.3390/jcm9041205
10.1186/1471-2334-12-184
10.1136/bmjopen-2017-020337
10.1080/14737159.2021.1902312
10.1007/s11739-021-02776-y
10.1016/S0140-6736(07)61602-X
10.1097/CCM.0b013e31827e83af
10.1373/jalm.2017.023655
10.1093/biomet/69.3.553
10.1016/j.patrec.2005.10.010
10.1186/s13054-015-1098-z
10.1007/s00134-012-2627-8",<Element 'PubmedArticle' at 0x7f05debd85e0>
99,"35453610
15940278
11467972
29518692
28969926
18313505
11485114
11381135
25582356
29520604
28527569
22648069
33318078
21514383
24418360
22217824
23291110
10874567
25905282
30030052
29874629
3754034
3753802
8248223
8650195
8769313
10588810
3283939
7979245
17615392
9048584
9058381
11250728
17662459
9388012
33835469
30465854
29155215
22669893
17855608
26522827
9367686
16125968
11043579
17379646
15705806
22495674
27010632
32077170
1536890
10751636
11581496
15269596
8779723
11821512
29360755
15031323
30468654
15893655
12586759
17470805
18534740
4295833
9927501
12835716
16343790
16867183
12431978
11044445
12398989
14512434
34791100
34763099
22295107
8102791
10872467
26069273
8078914
15131017
32406031
27745704
7494882
9718051
15082697
12771112
15213206
32721007
31884487
23770320
22913619
10368772
10833057
27870425
26294005
34538724
24042430
9875839
15213207
15721829
19932751
34534317
10732328
9111183
24817260
18193254
24161998
591813
6861130
9605801
21802721
22058644
17420779
8164053
16446340
30424783
3205265
23886572
27554391
30223003
8393156
25936229
23904760
11358807
10517716
15572757
11402435
21737572
23536434
20569451
32858306
34310353
10650964
32576800
20181970
24373794
16965913
9217716
30156931
30893792
16837885
9413932
28633868
18818291
23948892
30257383
10728366
17306449
29289555
21501600
32968620
26947331
21075433
26039356
33479648
12017554
24040818
18606537
16203130
21791565
26879842
16520733
25532911
34076791
20304826
32899453
24718936
19430488
21782022
20616198
31696669
15319488
1450879
32893509
11216643
28859530
1702704
18006629
31947687
32240664
2666871
22895714
794737
22286004
19687121
14749439
18990386
11450438
21844907
20508064
17640985
18499747
33503294
23420106
21809103
21427217
27059507
35107089
29928930
29393299
16414323
17630397
22043127
19903037
34225982
19094085
17488799
14764001
29996088
18192670
23872331
33791998
32329400
30509754
33331798
33734035
30718804
27126198
12725453
34195039
34626258
34619336
33814075
31655365
34371120
34344176
33971475
22763872
25585035
33844047
17135285
26526225
17376107
21320576
29740398
24508637
23706961
25223867
32817249
28099414
11172057
24637260
25926772
33324181
25845398
26112336
25763638
26367454
28662830
26973468
19549588
24838692
30406178
22138012
30992373
21664255
19293395
34399010
22681685
26109716
34631701
19575680
23103216
21790809
34440676
34876274
33995936
34749277
34242875
19299024
19071993
9386140
2005736
8635273
8672166
30280667
1634685
8772695
8149515
12039798
10218948
12821541
11160157
12379958
9724274
11238534
20212268
21374595
9686763
11884370
22542504
31075756
22315451
20656216
22271294
7530174
15774510
30559345
22465948
10924048
7923686
11958789
10077589
10342489
10982795
27369115
33058919
11119394
12904517
12090863
34674807
34033603
20427327
19696765
28333235
9240936
35163282
34754368
34805608
26133657
33058909
22252940
34051210
26370252
33242128
21970508
23435032
29659549
25392269
35103527
33300371
32576803
18825402
20335737
18089703
34788147
35058781
34096979
27388455
16313351
24042328
35053189
12117397
33167497
21790611
27807202
11257226
22595550
28744019
15280347
32788914
34840950
34382489
34424415
35213521
27141994
20685883
33762910
20644089
26692764
35007301
34360578
28861319
29352052
30250760
33841325
8411230
15094757
34435651
10960636
34860414
23845225
18550773
24819599
31538301
26861465
30326857
29422491
28654894
29743815
30306580
24833920
19108875
13752346
31042159
4625049
29094395
10433957
32413498
12497580
11454669
26575018
15369453
20133657
22460098
20016365
26526623
26373825
23872207
27260185
30563895
27490565
33129007",Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions.,"Estrogen is one of the most important female sex hormones, and is indispensable for reproduction. However, its role is much wider. Among others, due to its neuroprotective effects, estrogen protects the brain against dementia and complications of traumatic injury. Previously, it was used mainly as a therapeutic option for influencing the menstrual cycle and treating menopausal symptoms. Unfortunately, hormone replacement therapy might be associated with detrimental side effects, such as increased risk of stroke and breast cancer, raising concerns about its safety. Thus, tissue-selective and non-classical estrogen analogues have become the focus of interest. Here, we review the current knowledge about estrogen effects in a broader sense, and the possibility of using selective estrogen-receptor modulators (SERMs), selective estrogen-receptor downregulators (SERDs), phytoestrogens, and activators of non-genomic estrogen-like signaling (ANGELS) molecules as treatment.","['ANGELS', 'SERMs', 'alternative therapies', 'estrogen', 'menopause', 'non-classical actions', 'osteoporosis', 'phytoestrogens', 'tissue-selectivity']",Biomedicines,2022-04-24,"[{'lastname': 'Farkas', 'firstname': 'Szidónia', 'initials': 'S', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.'}, {'lastname': 'Szabó', 'firstname': 'Adrienn', 'initials': 'A', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nJános Szentágothai School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Hegyi', 'firstname': 'Anita Emőke', 'initials': 'AE', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nDepartment of Dentistry, Oral and Maxillofacial Surgery, Medical School, University of Pécs, 7624 Pécs, Hungary.'}, {'lastname': 'Török', 'firstname': 'Bibiána', 'initials': 'B', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nJános Szentágothai School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Fazekas', 'firstname': 'Csilla Lea', 'initials': 'CL', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.\nJános Szentágothai School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.'}, {'lastname': 'Ernszt', 'firstname': 'Dávid', 'initials': 'D', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.'}, {'lastname': 'Kovács', 'firstname': 'Tamás', 'initials': 'T', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.'}, {'lastname': 'Zelena', 'firstname': 'Dóra', 'initials': 'D', 'affiliation': 'Centre for Neuroscience, Szentágothai Research Center, Institute of Physiology, Medical School, University of Pécs, 7624 Pécs, Hungary.'}]",,,,,"10.3390/biomedicines10040861
10.1016/S0021-9258(18)76871-3
10.1016/S0021-9258(18)73338-3
10.1007/BF01506919
10.1038/sj.embor.7400444
10.1530/rep.0.1220215
10.1016/j.psyneuen.2018.02.028
10.1016/j.tins.2017.09.001
10.1016/S0140-6736(08)60346-3
10.1097/00006842-200107000-00013
10.1073/pnas.121180498
10.1016/j.jbiomech.2014.12.007
10.1007/s00198-018-4414-z
10.1016/bs.ctdb.2016.12.005
10.1007/s00204-012-0868-5
10.1124/jpet.120.000216
10.1016/j.jsbmb.2011.03.022
10.1016/j.mce.2013.12.018
10.1016/0960-0760(92)90307-5
10.1016/j.jsbmb.2012.12.014
10.1093/humupd/6.3.225
10.1016/j.steroids.2018.06.015
10.1016/j.scitotenv.2018.05.301
10.1038/320134a0
10.1126/science.3753802
10.1073/pnas.90.23.11162
10.1073/pnas.93.12.5925
10.1016/0014-5793(96)00782-X
10.1677/joe.0.1630379
10.1126/science.3283939
10.1146/annurev.bi.63.070194.002315
10.1152/physrev.00026.2006
10.1210/endo.138.3.4979
10.1210/mend.11.3.9902
10.1186/bcr80
10.1016/j.brainresrev.2007.05.013
10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
10.1016/j.jsbmb.2018.11.007
10.1016/j.steroids.2017.10.014
10.1210/en.2012-1312
10.1523/JNEUROSCI.1647-07.2007
10.1016/j.ejcb.2015.10.001
10.1006/geno.1997.4972
10.1016/j.tem.2005.08.005
10.1210/mend.14.10.0532
10.1210/en.2006-1605
10.1126/science.1106943
10.1210/en.2012-1061
10.1159/000443890
10.1111/jne.12837
10.1095/biolreprod46.2.163
10.1016/S0039-128X(99)00107-5
10.1152/physrev.2001.81.4.1535
10.1097/01.cad.0000136876.11928.be
10.1038/383099a0
10.1056/NEJMra000471
10.3390/ijms19020306
10.1210/me.2003-0044
10.2741/4716
10.1016/j.neuroscience.2005.02.024
10.1210/en.2002-220899
10.1073/pnas.0611514104
10.1016/j.mce.2008.04.003
10.1073/pnas.58.4.1711
10.1172/JCI5347
10.1038/sj.leu.2402945
10.1016/j.neuroscience.2005.10.019
10.1111/j.1365-2826.2006.01447.x
10.1074/jbc.M210828200
10.1074/jbc.M005036200
10.1016/S0039-128X(02)00040-5
10.1210/en.2003-0547
10.1210/endocr/bqab233
10.1016/j.vph.2021.106932
10.1371/journal.pone.0030725
10.1038/364821a0
10.1146/annurev.biochem.68.1.821
10.1530/JME-15-0086
10.1073/pnas.91.18.8517
10.1210/en.2004-0149
10.1007/978-3-030-38474-6_7
10.1016/j.atherosclerosis.2016.10.005
10.1016/S0033-0620(95)80012-3
10.1001/jama.280.7.605
10.1001/jama.291.14.1701
10.1001/jama.289.20.2651
10.1001/jama.291.24.2947
10.1001/jama.2020.9482
10.3233/JAD-191092
10.1016/j.jsbmb.2013.06.001
10.1080/13803395.2012.712676
10.1210/er.20.3.279
10.1089/neu.2000.17.367
10.1002/jnr.23827
10.1136/jnnp-2015-310548
10.1016/j.beem.2021.101565
10.1093/epirev/mxt008
10.1016/S0197-2456(98)00038-5
10.1001/jama.291.24.2959
10.1016/S1474-4422(05)70022-3
10.1016/j.jsbmb.2009.11.007
10.1210/clinem/dgab689
10.1016/S1071-5576(99)00054-4
10.1093/humupd/2.6.483
10.1007/s11934-014-0417-2
10.1007/s00404-007-0534-y
10.1016/j.juro.2013.10.070
10.1677/joe.0.0750305
10.1016/S0140-6736(97)11423-4
10.1016/S0140-6736(11)60993-8
10.4103/0974-1208.86085
10.1038/sj.bjp.0707232
10.1200/JCO.1994.12.5.992
10.1200/JCO.2005.02.3515
10.1186/s13058-018-1061-4
10.1056/NEJM198812293192601
10.1016/j.brainresbull.2013.07.007
10.1038/srep31599
10.1016/j.yfrne.2018.09.001
10.1016/0020-7292(94)90160-0
10.1517/14740338.2015.1014799
10.3747/co.20.1231
10.1001/jama.282.7.637
10.1093/jnci/djh319
10.1016/S0093-7754(01)90118-6
10.1124/mol.111.072249
10.1158/1078-0432.CCR-12-3771
10.1186/1471-2474-11-130
10.1016/j.psyneuen.2020.104830
10.1097/GRF.0000000000000647
10.1210/endo.141.2.7342
10.1097/GME.0000000000001585
10.1056/NEJMoa0808692
10.1016/j.jsbmb.2013.12.011
10.1016/j.jsbmb.2006.06.020
10.1016/S0140-6736(96)09480-9
10.1080/13697137.2018.1472566
10.3390/molecules24061076
10.1097/01.gme.0000191882.59799.67
10.1016/S0006-2952(97)00402-4
10.1016/j.nutres.2017.04.009
10.1210/en.2008-0715
10.3233/JAD-122341
10.1016/j.biopha.2018.08.100
10.1016/S0008-6363(99)00359-4
10.1016/j.mce.2006.12.037
10.1016/j.pharmthera.2017.12.012
10.1016/j.bcp.2011.03.031
10.21037/tcr-20-2166
10.1016/S1470-2045(15)00613-0
10.1016/j.ygyno.2010.10.015
10.1021/acs.jmedchem.5b00760
10.1039/C9MD00570F
10.1210/rp.57.1.385
10.2174/187152731131200123
10.1016/j.jsbmb.2008.05.003
10.1016/j.jsbmb.2005.08.003
10.1210/en.2011-1017
10.1038/srep21101
10.1038/nchembio775
10.1038/srep07564
10.1007/s11064-021-03336-8
10.4049/jimmunol.0902339
10.3390/ijms21186490
10.1007/s12672-014-0174-1
10.1038/nchembio.168
10.1016/j.jsbmb.2011.07.002
10.1093/annonc/mdq337
10.1111/andr.12725
10.1093/toxsci/kfh257
10.1093/oxfordjournals.bmb.a072555
10.6118/jmm.20000
10.1385/ENDO:13:3:315
10.1080/10253890.2017.1369523
10.1210/endo-128-1-509
10.1210/en.2007-1139
10.3390/ijms21020529
10.1016/j.yfrne.2020.100837
10.1159/000125203
10.1523/JNEUROSCI.1333-12.2012
10.1038/264461a0
10.1159/000332822
10.1113/jphysiol.2009.179838
10.1523/JNEUROSCI.1366-03.2004
10.1016/j.fertnstert.2008.09.059
10.1159/000061038
10.1038/nrendo.2011.122
10.1093/molehr/gaq043
10.1210/en.2007-0727
10.1210/en.2008-0441
10.1111/jpi.12718
10.1007/s10815-013-9942-z
10.1007/s00418-011-0846-7
10.1210/en.2010-0979
10.1016/j.ajog.2016.03.047
10.1358/dot.2022.58.1.3353167
10.1016/j.mce.2018.06.010
10.1038/nrendo.2017.180
10.1016/j.amjmed.2005.09.031
10.1093/humupd/dmm020
10.5665/sleep.1398
10.1080/09513590802632514
10.1016/B978-0-12-819975-6.00029-7
10.1111/j.1365-2826.2008.01796.x
10.1210/jc.2007-0553
10.1111/j.0953-8194.2004.01143.x
10.1016/j.celrep.2018.06.037
10.1093/humrep/dem408
10.1016/j.yfrne.2013.07.003
10.1055/s-0041-1726467
10.1080/09513590.2020.1757058
10.1016/j.maturitas.2018.11.017
10.1080/19390211.2020.1853648
10.1080/07315724.2021.1884143
10.1038/s41430-019-0398-9
10.1007/s12020-016-0968-8
10.34172/hpp.2021.20
10.1007/s11920-021-01286-0
10.1016/j.tcm.2021.09.009
10.1016/j.mayocp.2020.10.004
10.1016/j.copsyc.2019.09.004
10.1016/j.alcohol.2021.08.001
10.1098/rspb.2021.0318
10.1016/j.psyneuen.2021.105249
10.14670/HH-27.985
10.1176/appi.ajp.2014.14070918
10.1007/s00018-021-03830-w
10.1093/humupd/dml042
10.1111/j.1468-2982.2007.01279.x
10.1016/j.neuroscience.2011.02.012
10.3389/fendo.2018.00183
10.1016/j.mce.2013.12.019
10.1016/j.psyneuen.2013.04.016
10.1016/j.yfrne.2014.08.005
10.1523/JNEUROSCI.0115-20.2020
10.1038/nature21029
10.1073/pnas.041483198
10.1016/j.brainres.2014.03.002
10.3389/fncel.2015.00137
10.3389/fnbeh.2020.00157
10.1089/neu.2014.3730
10.1016/j.intimp.2015.05.046
10.1210/en.2014-1832
10.1016/j.physbeh.2015.08.037
10.1016/bs.pmbts.2017.04.001
10.3389/fncel.2016.00056
10.1016/j.mce.2009.03.008
10.1007/s00232-014-9670-z
10.1523/ENEURO.0258-18.2018
10.1016/j.jsbmb.2011.11.010
10.1523/JNEUROSCI.2772-18.2019
10.1016/j.neuroscience.2011.05.045
10.1093/cercor/bhp048
10.1002/hipo.23383
10.1016/j.neuron.2012.03.035
10.1212/WNL.0000000000001776
10.3389/fcell.2021.708715
10.1146/annurev.physiol.010908.163140
10.1016/j.neuroscience.2012.10.038
10.1111/j.1365-2826.2011.02193.x
10.3390/cells10081907
10.1016/j.mam.2021.101055
10.32598/bcn.12.1.2354.1
10.1016/j.yhbeh.2021.105085
10.1016/j.yhbeh.2021.105016
10.1016/j.tips.2008.12.006
10.1037/a0014501
10.1161/01.CIR.96.9.2795
10.1001/jama.1991.03460140089033
10.1161/01.CIR.93.10.1928
10.1056/NEJM199608153350701
10.2174/1570161116666181002145340
10.1016/0735-1097(92)90116-5
10.1161/01.CIR.94.4.727
10.1161/01.CIR.89.4.1501
10.1161/01.RES.0000021114.92282.FA
10.1210/endo.140.5.6694
10.1161/01.CIR.0000079311.39939.94
10.1172/JCI11320
10.1016/S0306-3623(02)00135-0
10.1152/ajpheart.1998.275.3.H731
10.1210/jcem.86.3.7317
10.1161/HYPERTENSIONAHA.109.146399
10.1002/jcp.22712
10.1161/01.RES.83.2.224
10.1161/hh0402.105096
10.1016/j.steroids.2012.04.013
10.1530/JME-19-0018
10.1210/en.2011-1939
10.1016/j.tcm.2010.03.008
10.1055/s-0031-1299597
10.1161/01.CIR.91.3.755
10.1113/jphysiol.2005.086439
10.1038/s12276-018-0193-z
10.1038/aps.2012.4
10.1152/ajpheart.2000.279.2.H511
10.1161/01.CIR.90.4.1964
10.1016/S0039-128X(01)00185-4
10.1073/pnas.96.6.2788
10.1006/niox.1998.0202
10.1074/jbc.M004691200
10.1016/j.jsbmb.2016.06.014
10.1016/j.lfs.2020.118584
10.7326/0003-4819-133-12-200012190-00008
10.1056/NEJMoa030808
10.1001/jama.288.1.58
10.1016/j.maturitas.2021.06.013
10.1097/GME.0000000000001792
10.1093/aje/kwq049
10.1038/oby.2009.251
10.1093/humupd/dmw045
10.1146/annurev.nutr.17.1.457
10.3390/ijms23031357
10.4239/wjd.v12.i10.1622
10.1253/circrep.CR-21-0082
10.1016/j.biochi.2015.06.018
10.1016/j.lfs.2020.118573
10.1152/ajpendo.00327.2011
10.1016/j.bcp.2021.114619
10.1017/S0007114515003359
10.1007/s13555-020-00468-7
10.3109/09513590.2011.613970
10.1097/gme.0b013e318269898c
10.3390/nu10040495
10.1096/fj.14-251363
10.1177/20533691211065808
10.1080/09513590.2020.1853695
10.1097/GME.0000000000001600
10.1007/s00418-008-0512-x
10.1097/JES.0b013e3181d496bc
10.1210/jc.2007-1322
10.1152/ajpcell.00333.2021
10.3389/fphar.2021.797892
10.1001/jamainternmed.2021.2617
10.1038/srep29473
10.1111/j.0105-2896.2005.00334.x
10.1038/nrendo.2013.179
10.3390/biom12010041
10.1001/JAMA.288.3.321
10.3390/ijms21218301
10.1111/j.1753-4887.2011.00400.x
10.1152/physrev.00033.2015
10.1016/S0092-8674(02)08100-X
10.1016/j.tem.2012.03.008
10.1038/s41598-017-06614-0
10.1001/jama.292.4.490
10.17179/EXCLI2020-2591
10.1016/j.imr.2021.100803
10.1080/13697137.2021.1951697
10.1007/s00774-021-01259-6
10.1097/GME.0000000000001921
10.1038/srep25282
10.1210/jc.2010-0856
10.3389/fncel.2021.636176
10.1200/JCO.2009.27.4290
10.4137/GEG.S35500
10.1371/journal.pone.0262485
10.3390/ijms22157812
10.1634/theoncologist.2017-0423
10.1186/s40164-018-0116-7
10.3389/fendo.2021.599586
10.1093/jnci/85.19.1558
10.1038/sj.bjc.6601629
10.3892/or.2021.8174
10.1016/S0029-7844(00)00917-0
10.1002/path.5843
10.1016/S1470-2045(13)70253-5
10.1210/me.2007-0512
10.1530/JOE-13-0500
10.1007/s11033-019-05073-2
10.1007/s00404-016-4027-8
10.1186/s12885-018-4898-0
10.1038/s41389-018-0027-9
10.18632/oncotarget.18442
10.1186/s12935-018-0559-2
10.1007/978-1-4757-3889-6_12
10.1007/978-1-4419-0489-8_8
10.1002/ijgo.12612
10.2147/IJWH.S40942
10.1016/j.ygyno.2008.10.032
10.1056/NEJM196102022640503
10.1172/JCI125755
10.3322/canjclin.22.4.232
10.1002/pros.23446
10.1016/S0002-9440(10)65160-7
10.1016/j.trsl.2020.04.003
10.1002/pros.10171
10.18632/oncotarget.6317
10.1677/erc.1.00800
10.1073/pnas.0905524107
10.12659/MSM.882626
10.1097/CAD.0b013e3283355211
10.1186/s12885-015-1871-z
10.3109/1061186X.2015.1086360
10.1016/j.jsbmb.2013.06.009
10.1111/andr.12196
10.1128/mBio.02272-18
10.3390/v8080206
10.1016/j.mehy.2020.110354",<Element 'PubmedArticle' at 0x7f05deb3d270>
100,"35406804
31011037
28166278
29386200
16710759
28268148
21197408
25830558
28164854
34256527
30646475
32323181
29130504
27346602
31460832
24956966
25078296
34107468
34107140
17183309
27799253
24824547
29687645
29857583
31022973
29267402
28092661
27090305
32670191
27065999
24729765
26499895
27541692
22162969
29051531
26918908
25974299
26372511
18242222
24226773
22674334
29846130
27019327
33806556
34536490
31407808
21090962
19404271
31123355
24388214
19366864
22190648
24226770
28836619
25411471
26030851
26711739
29733457
25870193
26424567
29552561
22731712
30915065
34266472
31803054
23614584
21475195
27228955
26972052
29957250
19859064
26029209
27928878
19222573
24757212
31910709
27413153
22968153
29018410
25157157
32323183
12656175
25784704
23000955
21303428
27725185
25651995
26438800
27664734
28703640
15133062
24477489
26760398
29291606
17453246
29467611
25415497
26125644
29330443
24315484
28768369
26733300
27037183
26457021
18305141
20404851
23943858
27060191
26597155
31068891
32473086
31426765
23212374
20937873
28640714
21738161
22664787
17183312
25865856
19648929
29963048
22976954
27115295
25828455
28263786
25128861
28296819
30202015
21243012
17072327
19528876
29867078
28612842
14988572
21220710
26646285
23972823
29665049
28615382
27694934
25589753
22833743
33795522
16107039
21278760
23604540
30673716
30967657
27067014
27056982
32899353
31272315
30881590
31025371
30381241
30353470
34040060
27554295
30192713
29330424
30778376
32404038
31809996
23489554
32000366
33419368
31340158
33166735
31156537
25612858
23759244
26604335
17823788
28123798
21995448
25047574
29410236
15749854
26450608
29398750
10908618
10428835
22528459
17073643
24495527
15668359
27927713
30397344
31889008
24355537
28195180
23323867
28087657
30909689
32266160
22183182
32354259
31425750
33510784
24621068
31091784
27692558
18160071
23031363
28289069
26419687
28042007
25576625
26593569
31389456
28453191
32331689
26874072
30651162
25393425
31540440
28874782
30323140
26686249
27719659
23692769
29360387
31881005
25724882
26656757
25908459
26814915
26228251",The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke.,"Recent research on the gut microbiome has revealed the influence of gut microbiota (GM) on ischemic stroke pathogenesis and treatment outcomes. Alterations in the diversity, abundance, and functions of the gut microbiome, termed gut dysbiosis, results in dysregulated gut-brain signaling, which induces intestinal barrier changes, endotoxemia, systemic inflammation, and infection, affecting post-stroke outcomes. Gut-brain interactions are bidirectional, and the signals from the gut to the brain are mediated by microbially derived metabolites, such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs); bacterial components, such as lipopolysaccharide (LPS); immune cells, such as T helper cells; and bacterial translocation via hormonal, immune, and neural pathways. Ischemic stroke affects gut microbial composition via neural and hypothalamic-pituitary-adrenal (HPA) pathways, which can contribute to post-stroke outcomes. Experimental and clinical studies have demonstrated that the restoration of the gut microbiome usually improves stroke treatment outcomes by regulating metabolic, immune, and inflammatory responses via the gut-brain axis (GBA). Therefore, restoring healthy microbial ecology in the gut may be a key therapeutic target for the effective management and treatment of ischemic stroke.","['cerebral stroke', 'gut dysbiosis', 'gut immune cells', 'gut leakiness', 'gut microbiota', 'gut-derived metabolites', 'gut–brain axis']",Cells,2022-04-13,"[{'lastname': 'Chidambaram', 'firstname': 'Saravana Babu', 'initials': 'SB', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.\nCentre for Experimental Pharmacology and Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Rathipriya', 'firstname': 'Annan Gopinath', 'initials': 'AG', 'affiliation': 'Food and Brain Research Foundation, Chennai 600094, Tamil Nadu, India.'}, {'lastname': 'Mahalakshmi', 'firstname': 'Arehally M', 'initials': 'AM', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Sharma', 'firstname': 'Sonali', 'initials': 'S', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.\nCentre for Experimental Pharmacology and Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Hediyal', 'firstname': 'Tousif Ahmed', 'initials': 'TA', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.\nCentre for Experimental Pharmacology and Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Ray', 'firstname': 'Bipul', 'initials': 'B', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.\nCentre for Experimental Pharmacology and Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Sunanda', 'firstname': 'Tuladhar', 'initials': 'T', 'affiliation': 'Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.\nCentre for Experimental Pharmacology and Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India.'}, {'lastname': 'Rungratanawanich', 'firstname': 'Wiramon', 'initials': 'W', 'affiliation': 'Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20892, USA.'}, {'lastname': 'Kashyap', 'firstname': 'Rajpal Singh', 'initials': 'RS', 'affiliation': 'Research Centre, Dr G. M. Taori Central India Institute of Medical Sciences (CIIMS), Nagpur 440 010, Maharashtra, India.'}, {'lastname': 'Qoronfleh', 'firstname': 'M Walid', 'initials': 'MW', 'affiliation': 'Q3CG Research Institute (QRI), Research & Policy Division, 7227 Rachel Drive, Ypsilanti, MI 48917, USA.\n21 HealthStreet, Consulting Services, 1 Christian Fields, London SW16 3JY, UK.'}, {'lastname': 'Essa', 'firstname': 'Musthafa Mohamed', 'initials': 'MM', 'affiliation': 'Department of Food Science and Nutrition, CAMS, Sultan Qaboos University, Muscat 123, Oman.\nAging and Dementia Research Group, Sultan Qaboos University, Muscat 123, Oman.'}, {'lastname': 'Song', 'firstname': 'Byoung-Joon', 'initials': 'BJ', 'affiliation': 'Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20892, USA.'}, {'lastname': 'Monaghan', 'firstname': 'Tanya M', 'initials': 'TM', 'affiliation': 'National Institute for Health Research Nottingham Biomedical Research Centre, University of Nottingham, Nottingham NG7 2UH, UK.\nNottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.'}]",,,,,"10.3390/cells11071239
10.3390/geriatrics2030027
10.1371/journal.pone.0171521
10.1161/CIR.0000000000000558
10.1007/s10571-006-9008-1
10.1016/j.jocn.2017.01.018
10.23937/2378-3001/1410096
10.4061/2011/879817
10.1016/j.gtc.2016.09.007
10.1016/j.jalz.2018.06.945
10.5056/jnm18087
10.1007/978-981-15-2385-4_6
10.1002/mas.21553
10.1016/j.neuint.2016.06.011
10.1152/physrev.00018.2018
10.1016/j.molmed.2014.05.002
10.1016/j.bbr.2014.07.027
10.1159/000516398
10.1111/ijcp.14477
10.1038/4441022a
10.1161/CIRCRESAHA.116.309006
10.2337/dc13-2817
10.1002/oby.22175
10.3390/nu10060708
10.3390/nu11040923
10.1371/journal.ppat.1006654
10.1038/nn.4476
10.1038/mp.2016.50
10.5217/ir.2012.10.4.332
10.3389/fneur.2020.00598
10.3389/fmicb.2016.00455
10.1038/nrmicro3552
10.1371/journal.pbio.1002533
10.3389/fphys.2011.00094
10.1038/s41598-017-13601-y
10.1111/cmi.12585
10.1016/j.chom.2015.04.011
10.1097/MCO.0000000000000221
10.1053/j.gastro.2007.11.059
10.1038/nature12726
10.1126/science.1223490
10.1177/0271678X18780130
10.1038/nm.4068
10.3390/antiox10030384
10.1016/j.pharmthera.2021.107988
10.1111/acer.14176
10.1146/annurev-med-012309-103958
10.1038/nrgastro.2009.35
10.1038/s41575-019-0157-3
10.1016/B978-0-12-800100-4.00003-9
10.2337/db08-1637
10.2337/db11-1019
10.1038/nature12721
10.1038/nrcardio.2017.120
10.1126/scitranslmed.3009759
10.1038/nn.4030
10.1161/HYPERTENSIONAHA.115.06672
10.1002/ana.25250
10.1161/HYPERTENSIONAHA.115.05315
10.1126/scitranslmed.aab2271
10.3389/fmed.2018.00053
10.1111/j.1749-6632.2012.06538.x
10.3389/fimmu.2019.00277
10.1186/s12986-021-00598-5
10.3389/fphar.2019.01360
10.1056/NEJMoa1109400
10.1038/nature09922
10.1038/srep26745
10.1016/j.cell.2016.02.011
10.1016/j.ijcard.2018.04.128
10.1038/nri2634
10.3389/fimmu.2015.00223
10.1111/1462-2920.13589
10.1111/j.1574-6968.2009.01514.x
10.1128/mBio.00889-14
10.1177/0271678X19899577
10.1523/JNEUROSCI.1114-16.2016
10.1038/nrn3346
10.3389/fmicb.2017.01765
10.1073/pnas.1412008111
10.1007/978-981-15-2385-4_8
10.1099/ijs.0.02362-0
10.1128/mBio.02481-14
10.1038/nrmicro2876
10.1111/j.1365-2982.2010.01664.x
10.1016/j.jinf.2016.09.010
10.3402/mehd.v26.25877
10.1093/ijnp/pyv114
10.1016/j.micres.2016.07.001
10.1080/19490976.2017.1353849
10.1113/jphysiol.2004.063388
10.1007/s00415-013-7231-5
10.1097/MOG.0000000000000244
10.5056/jnm17105
10.1007/s00441-007-0413-7
10.3389/fnins.2018.00049
10.1097/YCO.0000000000000117
10.1097/MNH.0000000000000149
10.1038/s41598-017-18904-8
10.1016/j.cell.2013.11.024
10.1111/nyas.13416
10.1016/j.neulet.2015.12.047
10.1016/j.brainres.2016.03.042
10.3748/wjg.v21.i37.10609
10.2337/db07-1403
10.1038/ni.1863
10.1530/JME-13-0079
10.1016/j.bbi.2016.04.003
10.1161/JAHA.115.002699
10.3389/fneur.2019.00397
10.1002/jpen.1861
10.1186/s12866-019-1552-1
10.1038/ncomms2266
10.1073/pnas.1011383107
10.1080/19490976.2017.1344809
10.1038/nm.2399
10.1038/nrneurol.2012.98
10.1038/nature05414
10.1586/14737175.2015.1035712
10.1038/nm.1999
10.3389/fimmu.2018.01330
10.1182/blood-2012-02-412726
10.18632/aging.100952
10.22159/ijpps.2021v13i5.41110
10.1038/ncomms7734
10.1016/j.bbi.2017.03.002
10.1016/j.jad.2014.07.032
10.1097/MIB.0000000000001078
10.1038/s41564-018-0229-0
10.1038/cr.2011.13
10.1038/sj.onc.1209943
10.1097/MOG.0b013e328324f857
10.1038/s41385-018-0042-3
10.1038/mi.2017.49
10.1161/01.STR.0000120732.45951.26
10.1161/HYPERTENSIONAHA.110.158709
10.1371/journal.pone.0144659
10.1186/1742-2094-10-105
10.1002/jcb.26790
10.3945/jn.116.240754
10.1038/nm.4194
10.1523/JNEUROSCI.2439-14.2015
10.3389/fimmu.2012.00132
10.18632/aging.202763
10.1038/cmi.2010.67
10.1007/s00284-013-0360-3
10.1371/journal.pone.0210016
10.1038/s41598-019-42183-0
10.1038/mp.2016.44
10.1161/STROKEAHA.115.011800
10.3390/microorganisms8091347
10.1161/STROKEAHA.119.025140
10.1155/2019/4248529
10.1111/jphp.13096
10.1016/j.biocel.2018.10.011
10.1007/s12275-018-8327-5
10.1038/s41598-021-90463-5
10.1038/mi.2016.75
10.1152/physiolgenomics.00070.2018
10.1038/s41598-017-18756-2
10.3389/fcimb.2019.00004
10.1161/STROKEAHA.120.029262
10.1016/j.conb.2019.10.002
10.1016/j.maturitas.2013.02.004
10.1097/MD.0000000000018608
10.3390/ijms21249737
10.1016/j.celrep.2019.06.075
10.1016/j.phrs.2020.105277
10.3389/fneur.2019.00504
10.1016/S0140-6736(14)62456-9
10.1016/j.biopsych.2013.05.001
10.1007/s13197-015-1921-1
10.1007/s00125-007-0791-0
10.1515/tnsci-2015-0014
10.1186/1475-2859-10-S1-S10
10.1161/HYPERTENSIONAHA.114.03469
10.1016/j.phrs.2018.01.020
10.4049/jimmunol.174.6.3237
10.1099/jmm.0.000184
10.1523/JNEUROSCI.20-15-05775.2000
10.1074/jbc.274.32.22569
10.1007/s12031-012-9769-6
10.2174/092986706778521814
10.1017/S0029665113003911
10.1001/archinte.165.2.150
10.1161/CIRCULATIONAHA.116.024545
10.1038/s41564-018-0272-x
10.1523/JNEUROSCI.1359-19.2019
10.1136/bmj.f6879
10.1038/ajg.2017.6
10.1056/NEJMoa1205037
10.1136/gutjnl-2016-313017
10.5946/ce.2019.009
10.3389/fcimb.2020.00098
10.1038/nrgastro.2011.244
10.1161/CIRCRESAHA.119.316448
10.1016/j.phrs.2019.104403
10.1155/2021/6699268
10.1179/1476830513Y.0000000099
10.3390/molecules24101854
10.1016/j.numecd.2016.07.011
10.1016/j.atherosclerosis.2007.11.008
10.1016/j.atherosclerosis.2012.09.006
10.1161/CIR.0000000000000482
10.1016/j.jnutbio.2015.08.001
10.1016/j.bbr.2016.12.037
10.1152/ajpheart.00239.2014
10.1016/j.foodchem.2015.09.072
10.1039/C9FO01481K
10.1111/1440-1681.12775
10.1016/j.foodres.2020.109114
10.1016/j.brainres.2016.02.013
10.5740/jaoacint.18-0418
10.1111/jnc.12986
10.3390/antiox8090410
10.1038/s41598-017-11181-5
10.4103/1673-5374.241463
10.1016/j.mvr.2015.12.008
10.2174/1389450117666161005150650
10.1016/j.foodchem.2012.10.023
10.1080/10408398.2017.1422111
10.18632/aging.102578
10.1177/1753944715572958
10.1016/j.ejphar.2015.12.003
10.1161/STROKEAHA.115.008921
10.1039/C5FO01244A
10.1002/mnfr.201500181",<Element 'PubmedArticle' at 0x7f05df26e1d0>
101,35373417,Antiamyloid β toxicity effect of genistein via activation of DAF-16 and HSP-16.2 signal pathways in Caenorhabditis elegans.,"β-Amyloid toxicity (Aβ) is an important pathological factor of Alzheimer's disease (AD). Studies have shown that genistein can reduce the toxicity of Aβ to a certain extent; however, the specific mechanism is still uncertain. In the study, we applied Caenorhabditis elegans strains expressing Aβ peptides to evaluate the role of genistein inhibiting Aβ toxicity and the undying mechanism. Genistein influencing the sterol metabolism pathway, the HSP-16.2 pathway, and lipofuscin in different strains of C. elegans were studied using reverse transcription-polymerase chain reaction, fluorescence labeling, RNA interference (RNAi), and so forth. Our results showed that genistein alleviated the paralysis of transgenic C. elegans strains. Furthermore, in AD C. elegans, genistein reduced the fluorescence of lipofuscin, downregulated the messenger RNA (mRNA) level of vit-3 and vit-6 which were related to the sterol metabolism pathway, significantly increased the mRNA level and protein level of HSP-16.2, increased the nuclear translocation of the DAF-16 transcription factor and increased the survival rate after heat stress, which was closely associated with HSP-16.2 levels. However, the paralysis-alleviating effect of genistein was greatly reduced because of RNAi-mediated inhibition of hsp-16.2, indicating that the anti-Aβ toxicity effect of genistein was greatly dependent on HSP-16.2. The above results suggest that genistein inhibiting the toxicity of Aβ in C. elegans, is involved in the modulation of the sterol metabolism pathway by promoting transcription factor DAF-16 translocation into the nucleus, increasing the expression level of HSP-16.2, and reducing the levels of lipofuscin through its antioxidant activity.","[""Alzheimer's disease"", 'lipofuscin', 'phytoestrogen', 'sterol metabolism', 'vitellogenin']",Journal of biochemical and molecular toxicology,2022-04-05,"[{'lastname': 'Li', 'firstname': 'Ke', 'initials': 'K', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Zhang', 'firstname': 'Saiya', 'initials': 'S', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Sun', 'firstname': 'Yiyang', 'initials': 'Y', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Yusi', 'initials': 'Y', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Chen', 'firstname': 'Wenbo', 'initials': 'W', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Ruan', 'firstname': 'Weibin', 'initials': 'W', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}, {'lastname': 'Liu', 'firstname': 'Yanqiang', 'initials': 'Y', 'affiliation': 'Department of Zoology and Developmental Biology, College of Life Sciences, Nankai University, Tianjin, China.'}]",,,,© 2022 Wiley Periodicals LLC.,10.1002/jbt.23055,<Element 'PubmedArticle' at 0x7f05dc9d08b0>
102,"35370604
30849371
32152337
22622580
30844401
32139434
2517380
32630431
31181302
30190379
21122682
27766082
9343467
31726991
18604453
26823333
25757756
20854843
20531185
28111074
31623648
18195144
30165362
28602351
29948724
10359567
30232327
19114008
23050260
19261174
17151600
14702107
29216449
22933021
25516281
25410905
11701639
15229191
24561529
32376954
8127865
30540774
26870778
30595332
19560099
25030513
26188538
26808606
22312429
11916953
16291938
29522768
26969397
25120729
29264400
28959956
26512759
9218423
18594512
29443965
8821037
27757081
32005122
22455463
19524672
29246793
25186741
26687838
32199103
30611282
31651333",The ,"Restrictions on existing 
As a part of MODEL-AD, we created and validated new versions of humanized 
Expression of human APOE isoforms were confirmed in ","['APOE4 and AD risk', 'APOE4 and APOE3', 'Alzheimer’s disease', 'cerebral cortex', 'dementia', 'dementia - Alzheimer’s disease', 'exercise', 'transcriptome (RNA-seq)']",Frontiers in aging neuroscience,2022-04-05,"[{'lastname': 'Foley', 'firstname': 'Kate E', 'initials': 'KE', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.\nSchool of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States.'}, {'lastname': 'Hewes', 'firstname': 'Amanda A', 'initials': 'AA', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.\nDepartment of Psychology, University of Maine, Orono, ME, United States.'}, {'lastname': 'Garceau', 'firstname': 'Dylan T', 'initials': 'DT', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.'}, {'lastname': 'Kotredes', 'firstname': 'Kevin P', 'initials': 'KP', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.'}, {'lastname': 'Carter', 'firstname': 'Gregory W', 'initials': 'GW', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.\nSchool of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States.\nGraduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States.'}, {'lastname': 'Sasner', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.'}, {'lastname': 'Howell', 'firstname': 'Gareth R', 'initials': 'GR', 'affiliation': 'The Jackson Laboratory, Bar Harbor, ME, United States.\nSchool of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, United States.\nGraduate School of Biomedical Sciences and Engineering, University of Maine, Orono, ME, United States.'}]",,,Expression of human APOE isoforms were confirmed in ,"Copyright © 2022 Foley, Hewes, Garceau, Kotredes, Carter, Sasner and Howell.","10.3389/fnagi.2022.838436
10.1016/j.cell.2019.01.021
10.1038/s41598-020-61142-8
10.1038/nature11087
10.1016/j.neuron.2019.01.056
10.3324/haematol.2018.214239
10.1142/S0192415X89000255
10.3390/antiox9060553
10.1016/j.neulet.2019.134306
10.1126/science.aan8821
10.1016/j.jacl.2010.08.003
10.3389/fphys.2016.00453
10.1186/s12864-019-6230-z
10.1111/j.1745-7270.2008.00442.x
10.1016/j.cytogfr.2015.12.005
10.1038/jcbfm.2015.44
10.1016/j.plipres.2010.09.001
10.1097/MOL.0b013e32833af368
10.1016/j.cell.2016.12.044
10.1186/s13024-019-0337-1
10.1001/archneurol.2007.29
10.1159/000492571
10.1016/j.cell.2017.05.018
10.1007/s11064-018-2571-2
10.1172/JCI6172
10.1038/s41467-018-06301-2
10.1186/1471-2105-9-559
10.1186/gb-2009-10-3-r25
10.1172/JCI19684
10.1016/j.neuron.2017.11.013
10.1152/ajpregu.00219.2012
10.1186/s13059-014-0550-8
10.14348/molcells.2014.0265
10.1146/annurev.genom.1.1.507
10.1093/hmg/ddh199
10.1038/onc.2014.2
10.1038/s41586-020-2247-3
10.1073/pnas.91.5.1677
10.1371/journal.pone.0207885
10.1016/j.ebiom.2015.11.006
10.1016/j.neuron.2018.11.040
10.1016/j.jalz.2009.02.006
10.1016/S1474-4422(14)70136-X
10.1016/j.atherosclerosis.2015.06.058
10.1016/j.bbr.2016.01.049
10.1371/journal.pone.0030619
10.2337/diabetes.51.4.1256
10.1523/JNEUROSCI.1922-05.2005
10.1016/j.lfs.2018.03.007
10.1016/j.jsbmb.2016.03.012
10.23937/2378-3001/1410067
10.1038/nature24016
10.1371/journal.pbio.1002279
10.1074/jbc.272.29.17972
10.1038/nature07083
10.3109/15419069509081020
10.3389/fnagi.2016.00232
10.1186/s13024-020-0358-9
10.1089/omi.2011.0118
10.1016/j.nbd.2009.06.002
10.1016/j.neulet.2017.12.025
10.1016/j.neuron.2015.11.013
10.1186/s12944-018-0933-z
10.1186/s13041-019-0506-8",<Element 'PubmedArticle' at 0x7f05dc9c6d10>
103,35364449,Brain insulin resistance as a mechanistic mediator links peripheral metabolic disorders with declining cognition.,"Studies continue to investigate the underlying mechanism of the association between the increased risk of different types of cognitive decline and metabolic dysregulation. Brain insulin resistance (BIR) has been suggested to explain this association. The vital role of insulin in the body has been examined intensively and extensively; however, its role in the brain requires further investigation. Herein, we confined our focus to summarize the role of brain insulin signaling and the negative effect of dysmetabolism on insulin functioning in the brain.
Published scientific manuscripts between 1998 and 2020 that discussed the effect of selected metabolic disorder conditions such as obesity, type 2 diabetes mellitus (T2DM), and high-fat diet (HFD) on brain functions were reviewed. The main keywords used were insulin resistance, brain insulin resistance, obesity, T2DM, and cognition.
Various metabolic disorders were linked to the increased risk of BIR, and was suggested to increase the probability of cognition impairment occurrence. Several proposed mechanisms explain this association among which insulin resistance and hyperinsulinemia were primary factors attributed to an increased risk of BIR among various metabolic disorders.
Understanding the trajectory of the association between metabolic disorders and alternation in cognition status could expand our vision of those overlapping conditions and pave the road to both treatment and preventative strategies for cognitive disorders.","['Brain insulin resistance', 'Cognition', 'Dementia', 'Hyperinsulinemia', 'Obesity', 'T3DM']",Diabetes & metabolic syndrome,2022-04-02,"[{'lastname': 'Al Haj Ahmad', 'firstname': 'Reem M', 'initials': 'RM', 'affiliation': 'Department of Nutrition and Food Technology, School of Agriculture, The University of Jordan, Amman, Jordan. Electronic address: alhaj.reem@hotmail.com.'}, {'lastname': 'Ababneh', 'firstname': 'Nidaa A', 'initials': 'NA', 'affiliation': 'Cell Therapy Center (CTC), The University of Jordan, Amman, Jordan. Electronic address: nidaaanwar@gmail.com.'}, {'lastname': 'Al-Domi', 'firstname': 'Hayder A', 'initials': 'HA', 'affiliation': 'Department of Nutrition and Food Technology, School of Agriculture, The University of Jordan, Amman, Jordan. Electronic address: h.aldomi@ju.edu.jo.'}]",,,"Various metabolic disorders were linked to the increased risk of BIR, and was suggested to increase the probability of cognition impairment occurrence. Several proposed mechanisms explain this association among which insulin resistance and hyperinsulinemia were primary factors attributed to an increased risk of BIR among various metabolic disorders.",Copyright © 2022. Published by Elsevier Ltd.,10.1016/j.dsx.2022.102468,<Element 'PubmedArticle' at 0x7f05dcc8c130>
104,"35269879
34337138
32244523
32157811
33855048
33543127
27502908
28299725
26648866
26836178
28228568
7826280
33632444
29997190
28555103
34506227
26233915
30135561
33020217
34667263
35195964
28569205
23969178
31869274
19798089
19179203
28991365
32083583
33373359
26754644
24687165
25485738
23477989
33461314
31723422
27521823
33000520
14752447
27596834
26502817
30991105
24807206
32362228
28476949
30858796
29910746
33551785
33964307
25228801
20613859
12542676
16290194
18846043
25194332
27256450",Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimer's Disease.,"Given the unprecedented rise in the world's population, the prevalence of prominent age-related disorders, like cardiovascular disease and dementia, will further increase. Recent experimental and epidemiological evidence suggests a mechanistic overlap between cardiovascular disease and dementia with a specific focus on the linkage between arterial stiffness, a strong independent predictor of cardiovascular disease, and/or hypertension with Alzheimer's disease. In the present study, we investigated whether pharmacological induction of arterial stiffness and hypertension with angiotensin II (1 µg·kg","['Alzheimer’s disease', 'amyloid', 'angiotensin II', 'arterial stiffness', 'cognition', 'hypertension']",International journal of molecular sciences,2022-03-11,"[{'lastname': 'Hendrickx', 'firstname': 'Jhana O', 'initials': 'JO', 'affiliation': 'Laboratory of Physiopharmacology, University of Antwerp, 2610 Antwerp, Belgium.'}, {'lastname': 'Calus', 'firstname': 'Elke', 'initials': 'E', 'affiliation': 'Laboratory of Neurochemistry and Behaviour, University of Antwerp, 2610 Antwerp, Belgium.'}, {'lastname': 'De Deyn', 'firstname': 'Peter Paul', 'initials': 'PP', 'affiliation': 'Laboratory of Neurochemistry and Behaviour, University of Antwerp, 2610 Antwerp, Belgium.\nDepartment of Neurology and Alzheimer Center, University of Groningen, 9713 GZ Groningen, The Netherlands.\nUniversity Medical Center Groningen, 9700 RB Groningen, The Netherlands.'}, {'lastname': 'Van Dam', 'firstname': 'Debby', 'initials': 'D', 'affiliation': 'Laboratory of Neurochemistry and Behaviour, University of Antwerp, 2610 Antwerp, Belgium.\nDepartment of Neurology and Alzheimer Center, University of Groningen, 9713 GZ Groningen, The Netherlands.\nUniversity Medical Center Groningen, 9700 RB Groningen, The Netherlands.'}, {'lastname': 'De Meyer', 'firstname': 'Guido R Y', 'initials': 'GRY', 'affiliation': 'Laboratory of Physiopharmacology, University of Antwerp, 2610 Antwerp, Belgium.'}]",,,,,"10.3390/ijms23052738
10.1002/trc2.12200
10.3390/ijms21072431
10.1002/alz.12068
10.3389/fmolb.2021.651215
10.1093/braincomms/fcaa114
10.1161/CIRCULATIONAHA.115.018912
10.1007/s11906-017-0724-3
10.3389/fnagi.2015.00221
10.3233/JAD-150831
10.1212/WNL.0000000000003746
10.1001/archneur.1995.00540250089017
10.1016/B978-0-12-819814-8.00018-4
10.1212/WNL.0000000000005951
10.3389/fnagi.2017.00132
10.1152/ajpheart.00254.2021
10.1016/j.atherosclerosis.2015.07.025
10.1038/s41598-018-31000-9
10.1523/JNEUROSCI.0304-20.2020
10.1038/s41380-021-01326-4
10.17219/acem/146756
10.1186/s13195-017-0262-x
10.1016/j.neurobiolaging.2013.06.011
10.1080/14737175.2020.1708195
10.1038/jhh.2009.76
10.1016/j.jacc.2008.09.046
10.1111/jnc.14235
10.3233/JAD-191073
10.1371/journal.pmed.1003467
10.1161/HYPERTENSIONAHA.115.06610
10.1001/jamaneurol.2014.186
10.1016/j.atherosclerosis.2014.10.089
10.1016/S1474-4422(13)70044-9
10.1161/HYPERTENSIONAHA.120.16556
10.12688/f1000research.20072.2
10.1016/j.avsg.2016.04.019
10.1111/cpf.12667
10.1016/j.jtcvs.2003.08.022
10.1177/0271678X16667364
10.2174/1567205012666151027130135
10.1016/j.phrs.2019.04.014
10.1016/j.nbd.2014.04.018
10.1161/HYPERTENSIONAHA.119.14431
10.1523/JNEUROSCI.0329-17.2017
10.3389/fnins.2019.00093
10.3389/fpsyt.2018.00201
10.3389/fnagi.2020.578339
10.1016/j.neubiorev.2021.04.036
10.2147/CIA.S68544
10.4103/0976-500X.72351
10.1046/j.1460-9568.2003.02444.x
10.1016/j.nlm.2005.09.006
10.1038/ajh.2008.301
10.1016/j.atherosclerosis.2014.08.033
10.1113/JP272623",<Element 'PubmedArticle' at 0x7f05dcc851d0>
105,"35253750
24729694
34420505
34383042
32709243
34421687
28326151
23666172
27372648
25932012
30746447
20209079
27225182
13678674
28744452
27784770
29051531
31063846
29758946
28035935
32727612
28176819
27443609
28874832
31097468
15829582
29267402
25514304
25160795
27929229
23930978
28643167
27070911
30967657
33504065
20563285
8406157
24388214
22254083
24412651
11557510
4712154
487569
25882911
27776263
31434623
29273951
25618518
24668475
22968153
21282636
21054680
26679775
30075011
22688187
15133062
25411471
26323633
24440934
34173726
32539741
29471030
32600151
32908211
27067014
31391545
29976412
27688852
33805484
19716187
18456279
30266270
23500100
29723105
32858844
30857316
32951067
32839527
30958695
32819031
29535205
33074224
32358220
31477562
31064831
28546539
28969160
32623399
28695537
30101706
30980044
30717153
27891089
33384986
29555333
28549787
26086182
30826160
34527222
31686099
31327302
27173924
27858930
32313261
3678950
29095058
29036812
21593570
31958090
33551257
33845942
27912057
29436731
26030851
20966022",Influence of the Microbiota-Gut-Brain Axis on Cognition in Alzheimer's Disease.,"The gut microbiota is made up of trillions of microbial cells including bacteria, viruses, fungi, and other microbial bodies and is greatly involved in the maintenance of proper health of the host body. In particular, the gut microbiota has been shown to not only be involved in brain development but also in the modulation of behavior, neuropsychiatric disorders, and neurodegenerative diseases including Alzheimer's disease. The precise mechanism by which the gut microbiota can affect the development of Alzheimer's disease is unknown, but the gut microbiota is thought to communicate with the brain directly via the vagus nerve or indirectly through signaling molecules such as cytokines, neuroendocrine hormones, bacterial components, neuroactive molecules, or microbial metabolites such as short-chain fatty acids. In particular, interventions such as probiotic supplementation, fecal microbiota transfer, and supplementation with microbial metabolites have been used not only to study the effects that the gut microbiota has on behavior and cognitive function, but also as potential therapeutics for Alzheimer's disease. A few of these interventions, such as probiotics, are promising candidates for the improvement of cognition in Alzheimer 's disease and are the focus of this review.","['Alzheimer’s disease', 'cognition', 'microbiota-gut-brain axis', 'mild cognitive impairment']",Journal of Alzheimer's disease : JAD,2022-03-08,"[{'lastname': 'Escobar', 'firstname': 'Yael-Natalie H', 'initials': 'YH', 'affiliation': 'Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.\nCollege of Nursing, The Ohio State University, Columbus, OH, USA.'}, {'lastname': ""O'Piela"", 'firstname': 'Devin', 'initials': 'D', 'affiliation': 'Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.\nCollege of Nursing, The Ohio State University, Columbus, OH, USA.'}, {'lastname': 'Wold', 'firstname': 'Loren E', 'initials': 'LE', 'affiliation': 'Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.\nCollege of Nursing, The Ohio State University, Columbus, OH, USA.\nDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.'}, {'lastname': 'Mackos', 'firstname': 'Amy R', 'initials': 'AR', 'affiliation': 'Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA.\nCollege of Nursing, The Ohio State University, Columbus, OH, USA.'}]",,,,,"10.3233/JAD-215290
10.1093/gerona/glab231",<Element 'PubmedArticle' at 0x7f05dc4dfa40>
106,35232367,Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease.,"For the development and maintenance of neuron networks in the brain, epigenetic mechanisms are necessary, as indicated by recent findings. This includes some of the high-order brain processes, such as behavior and cognitive functions. Epigenetic mechanisms could influence the pathophysiology or etiology of some neuronal diseases, altering disease susceptibility and therapy responses. Recent studies support epigenetic dysfunctions in neurodegenerative and psychiatric conditions, such as Alzheimer's disease (AD). These dysfunctions in epigenetic mechanisms also play crucial roles in the transgenerational effects of the environment on the brain and subsequently in the inheritance of pathologies. The possible role of gonadal steroids in the etiology and progression of neurodegenerative diseases, including Alzheimer's disease, has become the subject of a growing body of research over the last 20 years. Recent scientific findings suggest that epigenetic changes, driven by estrogen and androgens, play a vital role in brain functioning. Therefore, exploring the role of estrogen and androgen-based epigenetic changes in the brain is critical for the deeper understanding of AD. This review highlights the epigenetic modifications caused by these two gonadal steroids and the possible therapeutic strategies for AD.","[""Alzheimer's disease"", 'androgen', 'brain', 'epigenetic modifications', 'estrogen', 'neuronal diseases']",CNS & neurological disorders drug targets,2022-03-03,"[{'lastname': 'Kumar', 'firstname': 'Rajnish', 'initials': 'R', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Fatima', 'firstname': 'Faiza', 'initials': 'F', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Yadav', 'firstname': 'Garima', 'initials': 'G', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Singh', 'firstname': 'Simran', 'initials': 'S', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Haldar', 'firstname': 'Subhagata', 'initials': 'S', 'affiliation': 'Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Uttar Pradesh, India.'}, {'lastname': 'Alexiou', 'firstname': 'Athanasios', 'initials': 'A', 'affiliation': 'Novel Global Community Educational Foundation, Hebersham, 2770 NSW, Australia, and AFNP Med Austria, 1010 Wien, Austria.'}, {'lastname': 'Ashraf', 'firstname': 'Ghulam Md', 'initials': 'GM', 'affiliation': 'Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.\nDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1871527321666220225110501,<Element 'PubmedArticle' at 0x7f05dc4995e0>
107,35158177,Gut microbiota modulation in Alzheimer's disease: Focus on lipid metabolism.,"Alzheimer's disease (AD) and age-related dementias represent a major and increasing global health challenge. Unhealthy diet and lifestyle can unbalance the intestinal microbiota composition and, consequently energy metabolism, contributing to AD pathogenesis. Impairment of cerebral cholesterol metabolism occurs in both aging and AD, and lipid-lowering agents have been associated to a lower risk of neurodegenerative diseases, but the link between blood lipid profile and AD remains a matter of debate. Recently, probiotics have emerged as a promising and safe strategy to manipulate gut microbiota composition and increase the host health status through a multi-level mechanism that is currently under investigation. Specifically, oral supplementation with a multi-strain probiotic formulation (SLAB51) reduced amyloid beta aggregates and brain damages in a triple transgenic mouse model of AD (3xTg-AD). Treated mice showed improved cognitive functions in response to an enrichment of gut anti-inflammatory metabolites, increased plasma concentrations of neuroprotective gut hormones, and ameliorated glucose uptake and metabolism.
This work focuses on the evaluation of the effects of SLAB51 chronic administration on lipid metabolism in 3xTg-AD mice and the respective wild-type counterpart. On this purpose, 8 weeks old mice were orally administered with SLAB51 for 4 and 12 months to analyze the plasma lipid profile (using lipidomic analyses and enzymatic colorimetric assays), along with the cerebral and hepatic expression levels of key regulators of cholesterol metabolism (through Western blotting and ELISA).
Upon probiotics administration, cholesterol biosynthesis was inhibited in AD mice with a process involving sterol regulatory element binding protein 1c and liver X receptors mediated pathways. Decreased plasma and brain concentration of 27-hydroxycholesterol and increased brain expression of cholesterol 24S-hydroxylase indicated that alternative pathways of bile acid synthesis are influenced. The plasmatic increase of arachidonic acid in treated AD mice reflects dynamic interactions among several actors of a complex inflammatory response, in which polyunsaturated fatty acids can compete each other and simultaneously co-operate in the resolution of inflammation.
These evidence, together with the hypocholesterolemic effects, the ameliorated fatty acids profile and the decreased omega 6/omega 3 ratio successfully demonstrated that microbiota modulation through probiotics can positively change lipid composition in AD mice, with arachidonic acid representing one important hub metabolite in the interactions among probiotic-induced lipid profile changes, insulin sensitivity, and inflammation.","[""Alzheimer's disease"", 'Cholesterol', 'Lipid metabolism', 'Microbiota modulation', 'Probiotics']","Clinical nutrition (Edinburgh, Scotland)",2022-02-15,"[{'lastname': 'Bonfili', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy. Electronic address: laura.bonfili@unicam.it.'}, {'lastname': 'Cuccioloni', 'firstname': 'Massimiliano', 'initials': 'M', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}, {'lastname': 'Gong', 'firstname': 'Chunmei', 'initials': 'C', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}, {'lastname': 'Cecarini', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}, {'lastname': 'Spina', 'firstname': 'Michele', 'initials': 'M', 'affiliation': 'Laboratorio Analisi Dr. Fioroni, Viale A. de Gasperi, 19, 63074, San Benedetto Del Tronto AP, Italy.'}, {'lastname': 'Zheng', 'firstname': 'Yadong', 'initials': 'Y', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}, {'lastname': 'Angeletti', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}, {'lastname': 'Eleuteri', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Via Gentile III da Varano, 62032 Camerino MC, Italy.'}]",,,"Upon probiotics administration, cholesterol biosynthesis was inhibited in AD mice with a process involving sterol regulatory element binding protein 1c and liver X receptors mediated pathways. Decreased plasma and brain concentration of 27-hydroxycholesterol and increased brain expression of cholesterol 24S-hydroxylase indicated that alternative pathways of bile acid synthesis are influenced. The plasmatic increase of arachidonic acid in treated AD mice reflects dynamic interactions among several actors of a complex inflammatory response, in which polyunsaturated fatty acids can compete each other and simultaneously co-operate in the resolution of inflammation.",Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.,10.1016/j.clnu.2022.01.025,<Element 'PubmedArticle' at 0x7f05dc4848b0>
108,35137074,"Relationship Between Adipokines, Cognition, and Brain Structures in Old Age Depending on Obesity.","Adipokines such as leptin and adiponectin are associated with cognitive function. Although adiposity crucially affects adipokine levels, it remains unclear whether the relationship between adipokines and cognition is influenced by obesity.
We enrolled 171 participants and divided them into participants with obesity and without obesity to explore the effect of obesity on the relationship between adipokines and cognition. In addition to plasma levels of leptin and adiponectin, multidomain cognitive functions and brain structures were assessed using neuropsychological testing and magnetic resonance imaging. Association between levels of these adipokines and Alzheimer's disease (AD) was then assessed by logistic regression.
We found that cognitive function was negatively associated with leptin levels and leptin-to-adiponectin ratio (LAR). Such correlations between leptin and cognitive domains were prominent in participants with obesity but were not observed in those without obesity. Leptin levels were associated with lower hippocampal volumes in participants with obesity. A significant interaction of leptin and obesity was found mostly in the medial temporal lobe. Both leptin and LAR were positively associated with insulin resistance and inflammation markers in all participants. Of note, LAR was associated with a higher risk of AD after adjusting for demographic variables, Apolipoprotein E genotype, and body mass index.
Obesity might be a factor that determines how adipokines affect brain structure and cognition. Leptin resistance might influence the relationship between adipokines and cognition. In addition, LAR rather than each adipokine levels alone may be a better indicator of AD risk in older adults with metabolic stress.","['Adipokines', 'Adiponectin', 'Alzheimer’s disease', 'Brain atrophy', 'Leptin', 'Obesity']","The journals of gerontology. Series A, Biological sciences and medical sciences",2022-02-10,"[{'lastname': 'Ha', 'firstname': 'Junghee', 'initials': 'J', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Kwak', 'firstname': 'Seyul', 'initials': 'S', 'affiliation': 'Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.\nPusan National University, Department of Psychology, Busan, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Keun You', 'initials': 'KY', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Hyunjeong', 'initials': 'H', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Cho', 'firstname': 'So Yeon', 'initials': 'SY', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.\nGraduate School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Minae', 'initials': 'M', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Lee', 'firstname': 'Jun-Young', 'initials': 'JY', 'affiliation': 'Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Eosu', 'initials': 'E', 'affiliation': 'Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.\nGraduate School of Medical Science, Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.'}]",,,"We found that cognitive function was negatively associated with leptin levels and leptin-to-adiponectin ratio (LAR). Such correlations between leptin and cognitive domains were prominent in participants with obesity but were not observed in those without obesity. Leptin levels were associated with lower hippocampal volumes in participants with obesity. A significant interaction of leptin and obesity was found mostly in the medial temporal lobe. Both leptin and LAR were positively associated with insulin resistance and inflammation markers in all participants. Of note, LAR was associated with a higher risk of AD after adjusting for demographic variables, Apolipoprotein E genotype, and body mass index.","© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",10.1093/gerona/glac021,<Element 'PubmedArticle' at 0x7f05dc47d680>
109,"35101701
24887405
33756057
10599770
11164808
573741
19321148
17659183
11281317
24655396
20619937
7409333
9921852
18513142
30524268
22246233
12724459
12600700
16906128
15708438
17761551
18322406
27870424
27693591
25742564
20400205
7913324
20558146
29969907
10462166
16554740
23060451",APOE4 genotype or ovarian hormone loss influence open field exploration in an EFAD mouse model of Alzheimer's disease.,"Anxiety is a prominent and debilitating symptom in Alzheimer's disease (AD) patients. Carriers of APOE4, the greatest genetic risk factor for late-onset AD, may experience increased anxiety relative to carriers of other APOE genotypes. However, whether APOE4 genotype interacts with other AD risk factors to promote anxiety-like behaviors is less clear. Here, we used open field exploration to assess anxiety-like behavior in an EFAD mouse model of AD that expresses five familial AD mutations (5xFAD) and human APOE3 or APOE4. We first examined whether APOE4 genotype exacerbates anxiety-like exploratory behavior in the open field relative to APOE3 genotype in a sex-specific manner among six-month-old male and female E3FAD (APOE3","[""Alzheimer's disease"", 'Anxiety', 'Apolipoprotein E', 'Open Field', 'Ovariectomy']",Hormones and behavior,2022-02-02,"[{'lastname': 'Taxier', 'firstname': 'Lisa R', 'initials': 'LR', 'affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America. Electronic address: ltaxier@uwm.edu.'}, {'lastname': 'Philippi', 'firstname': 'Sarah M', 'initials': 'SM', 'affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America.'}, {'lastname': 'York', 'firstname': 'Jason M', 'initials': 'JM', 'affiliation': 'Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, United States of America. Electronic address: jmyork@uic.edu.'}, {'lastname': 'LaDu', 'firstname': 'Mary Jo', 'initials': 'MJ', 'affiliation': 'Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, United States of America. Electronic address: mladu@uic.edu.'}, {'lastname': 'Frick', 'firstname': 'Karyn M', 'initials': 'KM', 'affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, United States of America. Electronic address: frickk@uwm.edu.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,"10.1016/j.yhbeh.2022.105124
10.1016/j.yfrne.2014.05.004
10.1212/wnl.53.9.1992
10.1016/S0006-8993(00)03186-3
10.1016/0018-506x(79)90017-5
10.1016/j.physbeh.2009.03.016
10.1016/j.ncl.2007.03.009
10.1177/089198870101400111
10.1111/gbb.12133
10.1016/j.neurobiolaging.2010.05.027
10.1002/dev.420130512
10.1212/wnl.52.1.78
10.1037/0735-7044.122.3.716
10.3389/fnagi.2018.00382
10.3233/JAD-2011-110554
10.1176/jnp.15.2.180
10.1016/s0014-2999(03)01272-x
10.1038/sj.embor.7400784
10.1016/j.neurobiolaging.2004.06.003
10.1212/01.wnl.0000276984.19542.e6
10.1159/000113718
10.1002/jnr.23896
10.1016/j.physbeh.2016.09.026
10.3791/52434
10.1016/j.neurobiolaging.2010.03.002
10.1016/0166-4328(94)90008-6
10.1016/j.brainres.2010.06.011
10.1177/1533317518783278
10.1093/gerona/54.7.m348
10.1038/sj.npp.1301067
10.1074/jbc.M112.407957",<Element 'PubmedArticle' at 0x7f05dc46cd60>
110,35078110,Occlusal disharmony transiently decrease cognition via cognitive suppressor molecules and partially restores cognitive ability via clearance molecules.,"Occlusal disharmony has been reported to be affected not only by cytokine and steroid hormone secretion and sympathetic activation in peripheral organs, but also by neurotransmitter release in the central nervous system. However, little is known about whether occlusal disharmony can decrease cognitive ability. We hypothesized that hyperocclusion decreases cognition via Alzheimer's disease-associated molecule expression in the brain. The present study is aimed to elucidate the relationships among occlusal disharmony, cytokine and cognitive-regulated molecule expression in the brain, and the impairment of learning and memory cognition. We examined the effect of hyperocclusion on the relationships among cytokine expression, cognitive suppressor molecules in the hippocampus, and cognition in behavior using a hyperocclusion mouse model. Hyperocclusion dramatically increased interleukin-1β expression in the serum and hippocampus 1 week after hyperocclusal loading in 2-month-old mice, but no effects in 12-month-old mice. The social and long-term cognitive abilities of the 2-month-old mice were transiently downregulated close to the level of the 12-month-old mice 1 week after hyperocclusion and recovered to close to basal level via the expression of cognitive suppressor clearing proteins. The expression levels of amyloid-β and phosphorylated tau were significantly upregulated 1 week after hyperocclusal loading in the hippocampus of 2-month-old mice but were constant in 12-month-old mice. Occlusal disharmony-induced interleukin-1β expression may contribute to accumulation of cognitive suppressor molecules such as amyloid-β and phosphorylated tau and activate their clearance proteins, resulting in protection against transient dementia in young but not older individuals.","['Amyloid-β', 'Cognition', 'Hyperocclusion', 'Interleukin-1β', 'Phosphorylated tau']",Biochemical and biophysical research communications,2022-01-26,"[{'lastname': 'Maeshiba', 'firstname': 'Munehisa', 'initials': 'M', 'affiliation': 'Oral Medicine Research Center, Fukuoka Dental College, Fukuoka, Japan; Department of Oral Rehabilitation, Fukuoka Dental College, Fukuoka, Japan.'}, {'lastname': 'Kajiya', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'Oral Medicine Research Center, Fukuoka Dental College, Fukuoka, Japan; Department of Physiological Science and Molecular Biology, Fukuoka Dental College, Fukuoka, Japan. Electronic address: kajiya@college.fdcnet.ac.jp.'}, {'lastname': 'Tsutsumi', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Visiting Dentistry Center, Fukuoka Dental College, Fukuoka, Japan.'}, {'lastname': 'Migita', 'firstname': 'Keisuke', 'initials': 'K', 'affiliation': 'Department of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.'}, {'lastname': 'Goto-T', 'firstname': 'Kazuko', 'initials': 'K', 'affiliation': 'Department of Dental Hygiene, Fukuoka College of Health Sciences, Fukuoka, Japan.'}, {'lastname': 'Kono', 'firstname': 'Yuri', 'initials': 'Y', 'affiliation': 'Oral Medicine Research Center, Fukuoka Dental College, Fukuoka, Japan.'}, {'lastname': 'Tsuzuki', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Department of Oral Rehabilitation, Fukuoka Dental College, Fukuoka, Japan.'}, {'lastname': 'Ohno', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Oral Medicine Research Center, Fukuoka Dental College, Fukuoka, Japan.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.bbrc.2022.01.048,<Element 'PubmedArticle' at 0x7f05df623450>
111,"35057804
32387193
18953685
27924077
29760106
28092669
22265398
30001904
29668680
26039447
25703630
22580297
19461003
27357947
27760311
27806287
31805015
30878283
21935442
32680559
19695338
29030587
26666750
32942614
30858358
27799288
22231784
4321379
24829468
19787704
29459863
29925420
21403394
30181290
30679586
19388675
9620104
34785778
21922053
27166281
26935102
8223268
27730574
25329475
21300783
3899825
25562692
32444835
25514388
11157321
20823452
26710334
17629673
15718470
12434148
9000691
10342815
15864352
24622385
24622670
16563942
23344726
17136098
30312553
32694731
28832533
22693562
23892279
13428781
16448051
17257054
17625558
17545981
30917324
28273089
31159817",Histone acetyltransferase NAA40 modulates acetyl-CoA levels and lipid synthesis.,"Epigenetic regulation relies on the activity of enzymes that use sentinel metabolites as cofactors to modify DNA or histone proteins. Thus, fluctuations in cellular metabolite levels have been reported to affect chromatin modifications. However, whether epigenetic modifiers also affect the levels of these metabolites and thereby impinge on downstream metabolic pathways remains largely unknown. Here, we tested this notion by investigating the function of N-alpha-acetyltransferase 40 (NAA40), the enzyme responsible for N-terminal acetylation of histones H2A and H4, which has been previously implicated with metabolic-associated conditions such as age-dependent hepatic steatosis and calorie-restriction-mediated longevity.
Using metabolomic and lipidomic approaches, we found that depletion of NAA40 in murine hepatocytes leads to significant increase in intracellular acetyl-CoA levels, which associates with enhanced lipid synthesis demonstrated by upregulation in de novo lipogenesis genes as well as increased levels of diglycerides and triglycerides. Consistently, the increase in these lipid species coincide with the accumulation of cytoplasmic lipid droplets and impaired insulin signalling indicated by decreased glucose uptake. However, the effect of NAA40 on lipid droplet formation is independent of insulin. In addition, the induction in lipid synthesis is replicated in vivo in the Drosophila melanogaster larval fat body. Finally, supporting our results, we find a strong association of NAA40 expression with insulin sensitivity in obese patients.
Overall, our findings demonstrate that NAA40 affects the levels of cellular acetyl-CoA, thereby impacting lipid synthesis and insulin signalling. This study reveals a novel path through which histone-modifying enzymes influence cellular metabolism with potential implications in metabolic disorders.","['Drosophila melanogaster', 'Epigenetics', 'Fat body', 'Histone acetyltransferases', 'Lipid metabolism', 'Metabolic disorders', 'NAA40', 'acetyl-CoA']",BMC biology,2022-01-22,"[{'lastname': 'Charidemou', 'firstname': 'Evelina', 'initials': 'E', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Tsiarli', 'firstname': 'Maria A', 'initials': 'MA', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Theophanous', 'firstname': 'Andria', 'initials': 'A', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Yilmaz', 'firstname': 'Vural', 'initials': 'V', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Pitsouli', 'firstname': 'Chrysoula', 'initials': 'C', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Strati', 'firstname': 'Katerina', 'initials': 'K', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus.'}, {'lastname': 'Griffin', 'firstname': 'Julian L', 'initials': 'JL', 'affiliation': 'Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, CB2 1GA, UK.\nHammersmith Campus, UK Dementia Research Institute at Imperial College, Burlington Danes Building, Imperial College London, Du Cane Road, London, W12 0NN, UK.\nSection of Biomolecular Medicine, Department of Metabolism, Division of Systems Medicine, Digestion and Reproduction, The Sir Alexander Fleming Building, Exhibition Road, South Kensington, Imperial College London, London, SW7 2AZ, UK.'}, {'lastname': 'Kirmizis', 'firstname': 'Antonis', 'initials': 'A', 'affiliation': 'Department of Biological Sciences, University of Cyprus, 2109, Nicosia, Cyprus. kirmizis@ucy.ac.cy.'}]",,,"Using metabolomic and lipidomic approaches, we found that depletion of NAA40 in murine hepatocytes leads to significant increase in intracellular acetyl-CoA levels, which associates with enhanced lipid synthesis demonstrated by upregulation in de novo lipogenesis genes as well as increased levels of diglycerides and triglycerides. Consistently, the increase in these lipid species coincide with the accumulation of cytoplasmic lipid droplets and impaired insulin signalling indicated by decreased glucose uptake. However, the effect of NAA40 on lipid droplet formation is independent of insulin. In addition, the induction in lipid synthesis is replicated in vivo in the Drosophila melanogaster larval fat body. Finally, supporting our results, we find a strong association of NAA40 expression with insulin sensitivity in obese patients.",© 2022. The Author(s).,10.1186/s12915-021-01225-8,<Element 'PubmedArticle' at 0x7f05df622f90>
112,"34968250
23507120
30010124
10599770
18381051
21606896
31293377
27567877
30210435
28173793
25654504
24524276
30555513
22543304
11253071
31416905
32868857
25131640
26704082
19434510
21782924
24792119
19390085
20421462
33645582
29594187
19275939
30446010
19451168
20110278
30923821
25765347
27079975
15169908
25559153
18167544
12098640
27453991
33192286
30991105
29154269
12707936
29480196
26448035
30082505
9466423
31426549
14678749
26707129
26519428
30099679
32579922
19318467
15809269
17236127
30696992
20219993
21614513
9499428","The Histone H3 K4me3, K27me3, and K27ac Genome-Wide Distributions Are Differently Influenced by Sex in Brain Cortexes and Gastrocnemius of the Alzheimer's Disease PSAPP Mouse Model.","Women represent the majority of Alzheimer's disease patients and show typical symptoms. Genetic, hormonal, and behavioral mechanisms have been proposed to explain sex differences in dementia prevalence. However, whether sex differences exist in the epigenetic landscape of neuronal tissue during the progression of the disease is still unknown.
To investigate the differences of histone H3 modifications involved in transcription, we determined the genome-wide profiles of H3K4me3, H3K27ac, and H3K27me3 in brain cortexes of an Alzheimer mouse model (PSAPP). Gastrocnemius muscles were also tested since they are known to be different in the two sexes and are affected during the disease progression.
Correlation analysis distinguished the samples based on sex for H3K4me3 and H3K27me3 but not for H3K27ac. The analysis of transcription starting sites (TSS) signal distribution, and analysis of bounding sites revealed that gastrocnemius is more influenced than brain by sex for the three histone modifications considered, exception made for H3K27me3 distribution on the X chromosome which showed sex-related differences in promoters belonging to behavior and cellular or neuronal spheres in mice cortexes.
H3K4me3, H3K27ac, and H3K27me3 signals are slightly affected by sex in brain, with the exception of H3K27me3, while a higher number of differences can be found in gastrocnemius.","['Alzheimer’s disease', 'PSAPP mice', 'histone marks', 'sex differences']",Epigenomes,2021-12-31,"[{'lastname': 'Casciaro', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Biomedical Sciences, University of Padua, Via Ugo Bassi 58/B, 35131 Padova, Italy.'}, {'lastname': 'Persico', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Department of Experimental Oncology, IRCCS-European Institute of Oncology, Via Adamello 16, 20139 Milano, Italy.'}, {'lastname': 'Rusin', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Department of Experimental Oncology, IRCCS-European Institute of Oncology, Via Adamello 16, 20139 Milano, Italy.\nMolecular Pathology Laboratory ""PaoLa"", Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Arco d\'Augusto 2, 61032 Fano (PU), Italy.'}, {'lastname': 'Amatori', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'Molecular Pathology Laboratory ""PaoLa"", Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Arco d\'Augusto 2, 61032 Fano (PU), Italy.'}, {'lastname': 'Montgomery', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'School of Veterinary Medicine, University of California, Davis, CA 95616, USA.'}, {'lastname': 'Rutkowsky', 'firstname': 'Jennifer R', 'initials': 'JR', 'affiliation': 'School of Veterinary Medicine, University of California, Davis, CA 95616, USA.'}, {'lastname': 'Ramsey', 'firstname': 'Jon J', 'initials': 'JJ', 'affiliation': 'School of Veterinary Medicine, University of California, Davis, CA 95616, USA.'}, {'lastname': 'Cortopassi', 'firstname': 'Gino', 'initials': 'G', 'affiliation': 'School of Veterinary Medicine, University of California, Davis, CA 95616, USA.'}, {'lastname': 'Fanelli', 'firstname': 'Mirco', 'initials': 'M', 'affiliation': 'Molecular Pathology Laboratory ""PaoLa"", Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Arco d\'Augusto 2, 61032 Fano (PU), Italy.'}, {'lastname': 'Giorgio', 'firstname': 'Marco', 'initials': 'M', 'affiliation': 'Department of Biomedical Sciences, University of Padua, Via Ugo Bassi 58/B, 35131 Padova, Italy.\nDepartment of Experimental Oncology, IRCCS-European Institute of Oncology, Via Adamello 16, 20139 Milano, Italy.'}]",,,"Correlation analysis distinguished the samples based on sex for H3K4me3 and H3K27me3 but not for H3K27ac. The analysis of transcription starting sites (TSS) signal distribution, and analysis of bounding sites revealed that gastrocnemius is more influenced than brain by sex for the three histone modifications considered, exception made for H3K27me3 distribution on the X chromosome which showed sex-related differences in promoters belonging to behavior and cellular or neuronal spheres in mice cortexes.",,"10.3390/epigenomes5040026
10.1016/j.jalz.2013.02.003
10.3233/JAD-180141
10.1212/WNL.53.9.1992
10.1097/JGP.0b013e3181faec23
10.3389/fnins.2019.00659
10.3233/JAD-160572
10.3389/fneur.2018.00710
10.1186/s12915-017-0352-z
10.2174/1567205012666150204124852
10.1186/1471-2202-15-24
10.3389/fgene.2018.00579
10.1136/postgradmedj-2011-130363
10.1038/35047580
10.1101/lm.048850.118
10.1038/s41598-020-71229-x
10.1016/j.expneurol.2014.08.006
10.1016/j.tig.2015.10.007
10.1007/s10522-009-9231-5
10.1016/j.exger.2011.07.001
10.1016/j.stem.2014.03.002
10.1101/gad.1742609
10.1073/pnas.1001702107
10.3791/61941
10.21769/BioProtoc.2654
10.1016/j.ymeth.2009.03.001
10.1186/s13148-018-0576-y
10.1093/bioinformatics/btp324
10.1093/bioinformatics/btq033
10.1093/bioinformatics/btz232
10.1093/bioinformatics/btv145
10.1093/nar/gkw257
10.1128/MCB.24.12.5475-5484.2004
10.1152/physiol.00024.2014
10.1371/journal.pone.0001385
10.1016/S0304-3940(02)00258-6
10.1186/s12859-016-1093-7
10.3389/fnmol.2020.00134
10.1016/j.phrs.2019.04.014
10.3233/JAD-170211
10.1002/ajmg.b.10068
10.3233/JAD-170974
10.1002/ana.24540
10.18632/aging.101518
10.1016/S0306-4522(97)00353-9
10.3390/nu11081942
10.1016/j.nbd.2003.08.009
10.1007/s12640-015-9589-x
10.1177/0023677215615269
10.1007/s12264-018-0268-9
10.1016/j.celrep.2020.107795
10.1101/lm.918309
10.1093/hmg/ddi112
10.1086/511441
10.1038/s41583-019-0121-9
10.1523/JNEUROSCI.3732-09.2010
10.1007/s00439-011-1011-z
10.1093/hmg/7.4.737",<Element 'PubmedArticle' at 0x7f05dc882450>
113,"34935299
30911572
15295781
29026002
33737526
22460880
32583696
19306035
20234357
24575040
30564498
11522556
15263088
7852887
23317354
16293343
29067321
34638645
29081604
16469809
21460597
9796811
34162436
22578468
24141148
31838219
27400276
24973427
16873701
32528241
33956876
24833719
33602093
32507583
31849093
18505770
20157255
23954172
28663573
26198021
33093517
21607987
32147204
33487251
19923038
22495349
24843404
20736350
20051227
20621187
7566151
25177274
28119559
33431046
29549424
23827948
19833869
26629397
29357132
7984236
31130833",The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS).,"Targeting leptin could represent a rational strategy to treat amyotrophic lateral sclerosis (ALS), as previously clinical studies have shown its levels to be associated with a lower risk of ALS disease. However, very little is known about the potential influence of leptin in altering disease progression in ALS, as it has thus far been correlated with the protection exerted by increased fat mass stores.
We studied the impact of leptin treatment beginning at 42-days of age (asymptomatic stage of disease) in the TDP-43 (TDP43
Our study shows that leptin treatment was associated with altered expression of adipokines and metabolic proteins in TDP43
Collectively, our results support leptin as a potential novel treatment approach for ALS.","['TAR DNA binding protein (TDP-43)', 'amyotrophic lateral sclerosis (ALS)']",Brain and behavior,2021-12-23,"[{'lastname': 'Ferrer-Donato', 'firstname': 'Agueda', 'initials': 'A', 'affiliation': 'Neurometabolism Research Lab., Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain.'}, {'lastname': 'Contreras', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Centro de Investigación en Salud (CEINSA), Universidad de Almería, Almería, Spain.'}, {'lastname': 'Fernandez', 'firstname': 'Paloma', 'initials': 'P', 'affiliation': 'Institute of Applied Molecular Medicine (IMMA), Faculty of Medicine, Universidad San Pablo CEU, Madrid, Spain.'}, {'lastname': 'Fernandez-Martos', 'firstname': 'Carmen M', 'initials': 'CM', 'affiliation': 'Neurometabolism Research Lab., Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain.\nWicking Dementia Research and Education Centre, College of Health and Medicine, University of Tasmania, Hobart, Australia.'}]",,,Our study shows that leptin treatment was associated with altered expression of adipokines and metabolic proteins in TDP43,© 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC.,"10.1002/brb3.2465
10.1002/acn3.721
10.1002/jps.20123
10.1042/CS20160722
10.1038/s41598-021-85395-z
10.1038/483531a
10.1080/14737175.2020.1788389
10.1007/s00415-009-5100-z
10.1038/nrneurol.2010.18
10.3389/fnagi.2014.00015
10.1212/CPJ.0000000000000521
10.1093/ajcn/74.3.328
10.1073/pnas.0402026101
10.1677/joe.0.1380159
10.1111/iep.12006
10.1016/S0196-9781(05)00475-4
10.1016/j.peptides.2005.10.006
10.1016/j.trci.2016.11.002
10.3390/ijms221910305
10.1155/2017/7821672
10.1210/en.2005-1016
10.1210/en.2005-1016
10.2302/kjm.60.1
10.1038/27376
10.1186/s40035-021-00246-1
10.1016/j.brainres.2012.04.003
10.1016/j.brainres.2013.10.013
10.1016/j.peptides.2019.170230
10.1159/000446502
10.1074/jbc.L114.572651
10.2337/db06-0116
10.3389/fnins.2020.00428
10.1371/journal.pone.0251087
10.1093/hmg/ddu214
10.2174/1567205018666210218163857
10.1016/j.clnu.2020.05.014
10.1002/ana.25661
10.1152/physiolgenomics.90207.2008
10.3233/JAD-2010-1298
10.1016/j.neurobiolaging.2013.07.006
10.1038/s41598-017-04706-5
10.1016/j.jns.2015.06.053
10.1038/s41598-020-74999-6
10.1002/mus.22114
10.1016/j.neurol.2019.09.008
10.1016/j.clnesp.2020.11.001
10.1101/2021.02.12.430915
10.1016/j.neurobiolaging.2009.10.009S0197-4580(09)00339-X
10.3233/JAD-2012-11166107T40865VP760877
10.1111/j.2040-1124.2010.00022.x
10.1073/pnas.1003459107
10.1016/j.bbrc.2009.12.158
10.1016/j.nbd.2010.06.017
10.1038/377530a0
10.3389/fncel.2014.00241
10.3389/fnins.2016.00611
10.1186/s13578-020-00511-2
10.1007/s00401-018-1835-x
10.1093/hmg/ddt319
10.1073/pnas.0908767106
10.4103/2152-7806.169561
10.1002/cphy.c160041
10.1038/372425a0
10.3389/fnins.2019.00378",<Element 'PubmedArticle' at 0x7f05dc86da40>
114,"34849527
19487648
20336135
31501588
21304480
9343467
27570871
27692800
31219687
30529508
30853718
13070576
21159842
16414322
21419147
3067252
8675575
20689282
17761551
24336141
27683911
17010478
17279058
12707448
10867223
21078303
10794855
14501601
1484915
19468050
11104644
10199429
23797469
26035291
27421538
16522699
15213206
12771112
28898378
18562950
6095154
25929443
10071091
7925844
8774454
8050041
10391490
12460585
15137470
15780466
15795051
16482084
17964576
7786762
17490963
12668679
17456783
20861172
32086667
24132975
21068006
14608048
27733825
19262590
27347995
3474663
19727886
3035983
21059658
16816108
24671709
2010061
23193625
28788094
31560162
31298459
30622336
28715642
33192323
29167670
29097166
31360988
11190987
22071706
12637119
26108618
29217669
29750367
12459399
27506836
29846283
31417982",Perspective: Estrogen and the Risk of Cognitive Decline: A Missing Choline(rgic) Link?,"Factors that influence the risk of neurocognitive decline and Alzheimer's disease (AD) may provide insight into therapies for both disease treatment and prevention. Although age is the most striking risk factor for AD, it is notable that the prevalence of AD is higher in women, representing two-thirds of cases. To explore potential underlying biological underpinnings of this observation, the intent of this article is to explore the interplay between cognitive aging and sex hormones, the cholinergic system, and novel hypotheses related to the essential nutrient choline. Mechanistic evidence points toward estrogen's neuroprotective effects being strongly dependent on its interactions with the cholinergic system, a modulator of attentional functioning, learning, and memory. Estrogen has been shown to attenuate anticholinergic-induced impairments in verbal memory and normalize patterns of frontal and occipital cortex activation, resulting in a more ""young adult"" phenotype. However, similar to estrogen replacement's effect in cardiovascular diseases, its putative protective effects may be restricted to early postmenopausal women only, a finding supportive of the ""critical window hypothesis."" Estrogen's impact on the cholinergic system may act both locally in the brain but also through peripheral tissues. Estrogen is critical for inducing endogenous choline synthesis via the phosphatidylethanolamine N-methyltransferase (PEMT) gene-mediated pathway of phosphatidylcholine (PC) synthesis. PEMT is dramatically induced in response to estrogen, producing not only a PC molecule and source of choline for the brain but also a key source of the long-chain ω-3 fatty acid, DHA. Herein, we highlight novel hypotheses related to hormone replacement therapy and nutrient metabolism aimed at directing future preclinical and clinical investigation.","[""Alzheimer's disease"", 'brain', 'choline', 'cognitive disorders', 'estrogen']","Advances in nutrition (Bethesda, Md.)",2021-12-02,"[{'lastname': 'Bortz', 'firstname': 'Jonathan', 'initials': 'J', 'affiliation': 'Balchem Corporation, New Hampton, NY, USA.'}, {'lastname': 'Klatt', 'firstname': 'Kevin C', 'initials': 'KC', 'affiliation': 'Baylor College of Medicine, Houston, TX, USA.'}, {'lastname': 'Wallace', 'firstname': 'Taylor C', 'initials': 'TC', 'affiliation': 'Think Healthy Group, Washington, DC, USA; Department of Nutrition and Food Studies, George Mason University, Fairfax, VA, USA. Electronic address: taylor.wallace@me.com.'}]",,,,Copyright © 2021 © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. Published by Elsevier Inc. All rights reserved.,10.1093/advances/nmab145,<Element 'PubmedArticle' at 0x7f05dcd02f90>
115,34848278,A meal enriched in saturated fat acutely impairs cognitive performance in obese men.,"Diets chronically high in saturated fat (SFA) associate with obesity and insulin resistance (IR), which in turn associate with cognitive decline and dementia. However, understanding how acute SFA consumption influences cognition is less clear despite short-term SFA-enriched diets inducing whole-body IR. We examined how consuming meals enriched with SFA or monounsaturated fat (MUFA) acutely influence cognitive function in lean and obese men. We hypothesized that greater diet-induced IR following a SFA-enriched meal would associate with decreased cognitive performance.
Twelve lean and 12 obese males ingested meals containing no fat (CTL), enriched with SFA, or enriched with MUFA in a single-blind, randomized fashion. Cognitive testing and blood sampling were performed pre- and 2 h post-meal. Oral glucose tolerance (OGTT) and body composition were also assessed.
At baseline, fasting glucose, insulin, HOMA-IR, triglyceride, IL-6, and 2-hr glucose during an OGTT were higher in obese men (p < 0.001), while executive function (Stroop Test and Trail Making Test B-A) and working memory (Digit Span Test) were lower in obese men (p < 0.05). In response to the CTL and MUFA-enriched, no differences in cognitive measures were observed in lean or obese subjects. Following a SFA-enriched meal, obese subjects scored worse during cognitive testing (Stroop Test, Trail Making Test B-A, and Digit Span Test) compared to pre-meal scores (p < 0.05). These impairments in cognitive testing scores following the SFA-enriched meal associated with increased HOMA-IR (p < 0.01) and decreased plasma IL-6 (p < 0.05). No changes in cognitive function were observed in lean subjects following a SFA-enriched meal.
These data demonstrate that cognitive performance of obese men acutely worsens following a high-SFA meal. Reductions in cognitive performance associated with increased IR, suggesting that diet-induced IR may acutely decrease cognitive function.","['Dietary fat', 'Executive function', 'Insulin resistance', 'Memory', 'Nutrition']",Physiology & behavior,2021-12-02,"[{'lastname': 'Ruegsegger', 'firstname': 'Gregory N', 'initials': 'GN', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States. Electronic address: gregory.ruegsegger@uwrf.edu.'}, {'lastname': 'Rappaport', 'firstname': 'Chapin I', 'initials': 'CI', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States.'}, {'lastname': 'Hill', 'firstname': 'Justin J', 'initials': 'JJ', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States.'}, {'lastname': 'Jochum', 'firstname': 'Kelly A', 'initials': 'KA', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States.'}, {'lastname': 'Challeen', 'firstname': 'Erik S', 'initials': 'ES', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States.'}, {'lastname': 'Roth', 'firstname': 'Michael C', 'initials': 'MC', 'affiliation': 'Department of Health and Human Performance, University of Wisconsin-River Falls, River Falls, WI 54022 United States.'}]",,,"At baseline, fasting glucose, insulin, HOMA-IR, triglyceride, IL-6, and 2-hr glucose during an OGTT were higher in obese men (p < 0.001), while executive function (Stroop Test and Trail Making Test B-A) and working memory (Digit Span Test) were lower in obese men (p < 0.05). In response to the CTL and MUFA-enriched, no differences in cognitive measures were observed in lean or obese subjects. Following a SFA-enriched meal, obese subjects scored worse during cognitive testing (Stroop Test, Trail Making Test B-A, and Digit Span Test) compared to pre-meal scores (p < 0.05). These impairments in cognitive testing scores following the SFA-enriched meal associated with increased HOMA-IR (p < 0.01) and decreased plasma IL-6 (p < 0.05). No changes in cognitive function were observed in lean subjects following a SFA-enriched meal.",Copyright © 2021. Published by Elsevier Inc.,10.1016/j.physbeh.2021.113664,<Element 'PubmedArticle' at 0x7f05dd3a9540>
116,"34769144
33233627
20872026
28751584
26903338
31736978
23103127
15894280
26403194
16139256
25157255
32161622
24073214
18390726
23580425
17229698
16362885
32473235
33012653
23898465
20151841
19060785
20369765
19234212
32592501
17558345
21212175
18390695
28256612
12897138
24248597
32244785
24970271
27312737
24698685
25444557
32208989
28638350
26059377
19451232
21206488
23270646
18495054
23647169
30675874
33562472
34063611
31941836
23889107
32768490
15288356
34098376
30120222
32122523
31304024",Tryptophan: A Unique Role in the Critically Ill.,"Tryptophan is an essential amino acid whose metabolites play key roles in diverse physiological processes. Due to low reserves in the body, especially under various catabolic conditions, tryptophan deficiency manifests itself rapidly, and both the serotonin and kynurenine pathways of metabolism are clinically significant in critically ill patients. In this review, we highlight these pathways as sources of serotonin and melatonin, which then regulate neurotransmission, influence circadian rhythm, cognitive functions, and the development of delirium. Kynurenines serve important signaling functions in inter-organ communication and modulate endogenous inflammation. Increased plasma kynurenine levels and kynurenine-tryptophan ratios are early indicators for the development of sepsis. They also influence the regulation of skeletal muscle mass and thereby the development of polyneuromyopathy in critically ill patients. The modulation of tryptophan metabolism could help prevent and treat age-related disease with low grade chronic inflammation as well as post intensive care syndrome in all its varied manifestations: cognitive decline (including delirium or dementia), physical impairment (catabolism, protein breakdown, loss of muscle mass and tone), and mental impairment (depression, anxiety or post-traumatic stress disorder).","['delirium', 'inflammation', 'kynurenine pathway', 'polyneuromyopathy', 'post intensive care syndrome', 'rapamycin', 'sepsis', 'serotonin pathway', 'tryptophan metabolism']",International journal of molecular sciences,2021-11-14,"[{'lastname': 'Kanova', 'firstname': 'Marcela', 'initials': 'M', 'affiliation': 'Department of Anaesthesiology and Intensive Care Medicine, University Hospital Ostrava, 708 52 Ostrava, Czech Republic.\nInstitute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic.'}, {'lastname': 'Kohout', 'firstname': 'Pavel', 'initials': 'P', 'affiliation': 'Department of Internal Medicine, 3rd Faculty of Medicine, Charles University Prague and Teaching Thomayer Hospital, 140 59 Prague, Czech Republic.'}]",,,,,"10.3390/ijms222111714
10.3390/ijms21228776
10.1007/s00726-010-0752-7
10.1126/science.aaf9794
10.1001/jama.2016.0287
10.3389/fimmu.2019.02565
10.1016/j.it.2012.10.001
10.1016/j.immuni.2005.03.013
10.1038/nri3901
10.1016/j.cca.2005.06.013
10.3389/fimmu.2014.00384
10.1186/s11658-020-00211-2
10.1371/journal.pone.0074551
10.4049/jimmunol.180.8.5439
10.1099/vir.0.053124-0
10.1128/JVI.02248-06
10.1086/498911
10.1016/j.jinf.2020.05.046
10.1016/j.jmii.2020.09.004
10.3389/fcimb.2013.00032
10.1086/650996
10.1097/SHK.0b013e31819714fa
10.1177/0310057X1003800213
10.4049/jimmunol.0803104
10.1002/jmv.26232
10.1097/shk.0b013e31804f5921
10.1167/iovs.10-5793
10.4049/jimmunol.180.8.5157
10.1038/srep43337
10.1128/MCB.23.16.5651-5663.2003
10.1128/MCB.00946-13
10.3390/nu12040978
10.1093/bja/aeu187
10.1016/j.chest.2016.06.006
10.1016/j.tcb.2014.03.003
10.1016/j.clnu.2014.09.016
10.1152/ajpcell.00580.2019
10.3389/fphys.2017.00390
10.1016/j.nut.2015.02.011
10.1128/MCB.00165-09
10.1038/ajg.2010.480
10.1186/2110-5820-2-49
10.1186/cc6149
10.1111/bph.12230
10.1016/j.bbi.2018.10.003
10.3390/ijms22041597
10.3390/ijms22094837
10.1172/jci.insight.131487
10.1111/jpi.12075
10.1016/j.virusres.2020.198108
10.1016/j.mehy.2004.01.033
10.1016/j.jpsychores.2021.110530
10.1038/s41467-018-05470-4
10.1002/ams2.415
10.34297/AJBSR.2020.10.001577",<Element 'PubmedArticle' at 0x7f05dd3c8900>
117,"34732544
29985474
31803046
23183885
30540774
28855400
32580974
34108509
26007613
17035515
30923235
24064221
27543884
15808925
14990773
32573980
11255424
18802446
29489847
17116223
18079025
18648334
27716751
23332364
22343510
12747807
27272226
10860804
15955934
12707448
30889095
18073776
20034703
9191758
16607094
21280086
11255426
25538545
12771112
15213207
31453973
27421538
23892107
20550945
25191220
29393299
19142763
24508665
30326011
31677936
10810964",Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife.,"To examine associations between indicators of estrogen exposure from women's reproductive history and brain MRI biomarkers of Alzheimer disease (AD) in midlife.
We evaluated 99 cognitively normal women 52 ± 6 years of age and 29 men 52 ± 7 years of age with reproductive history data, neuropsychological testing, and volumetric MRI scans. We used multiple regressions to examine associations among reproductive history indicators, voxel-wise gray matter volume (GMV), and memory and global cognition scores, adjusting for demographics and midlife health indicators. Exposure variables were menopause status, age at menarche, age at menopause, reproductive span, hysterectomy status, number of children and pregnancies, and use of menopause hormonal therapy (HT) and hormonal contraceptives (HC).
All menopausal groups exhibited lower GMV in AD-vulnerable regions compared to men, with perimenopausal and postmenopausal groups also exhibiting lower GMV in temporal cortex compared to the premenopausal group. Reproductive span, number of children and pregnancies, and use of HT and HC were positively associated with GMV, chiefly in temporal cortex, frontal cortex, and precuneus, independent of age, 
Reproductive history events signaling more estrogen exposure such as premenopausal status, longer reproductive span, higher number of children, and use of HT and HC were associated with larger GMV in women in midlife. Further studies are needed to elucidate sex-specific biological pathways through which reproductive history influences cognitive aging and AD risk.",[],Neurology,2021-11-05,"[{'lastname': 'Schelbaum', 'firstname': 'Eva', 'initials': 'E', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Loughlin', 'firstname': 'Lacey', 'initials': 'L', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Jett', 'firstname': 'Steven', 'initials': 'S', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Zhang', 'firstname': 'Cenai', 'initials': 'C', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Jang', 'firstname': 'Grace', 'initials': 'G', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Malviya', 'firstname': 'Niharika', 'initials': 'N', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Hristov', 'firstname': 'Hollie', 'initials': 'H', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Pahlajani', 'firstname': 'Silky', 'initials': 'S', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Isaacson', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Dyke', 'firstname': 'Jonathan P', 'initials': 'JP', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Kamel', 'firstname': 'Hooman', 'initials': 'H', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Brinton', 'firstname': 'Roberta Diaz', 'initials': 'RD', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson.'}, {'lastname': 'Mosconi', 'firstname': 'Lisa', 'initials': 'L', 'affiliation': 'From the Departments of Neurology (E.S., L.L., S.J., C.Z., G.J., N.M., H.H., S.P., R.I., H.K., L.M.) and Radiology (J.P.D., L.M.), Weill Cornell Medicine, New York, NY; Department of Pharmacology (R.D.B.), University of Arizona, Tucson. lim2035@med.cornell.edu.'}]",,,"All menopausal groups exhibited lower GMV in AD-vulnerable regions compared to men, with perimenopausal and postmenopausal groups also exhibiting lower GMV in temporal cortex compared to the premenopausal group. Reproductive span, number of children and pregnancies, and use of HT and HC were positively associated with GMV, chiefly in temporal cortex, frontal cortex, and precuneus, independent of age, ",© 2021 American Academy of Neurology.,10.1212/WNL.0000000000012941,<Element 'PubmedArticle' at 0x7f05dd6a43b0>
118,34664252,"Progranulin/GP88, A Complex and Multifaceted Player of Tumor Growth by Direct Action and via the Tumor Microenvironment.","Investigation of the role of progranulin/GP88 on the proliferation and survival of a wide variety of cells has been steadily increasing. Several human diseases stem from progranulin dysregulation either through its overexpression in cancer or its absence as in the case of null mutations in some form of frontotemporal dementia. The present review focuses on the role of progranulin/GP88 in cancer development, progression, and drug resistance. Various aspects of progranulin identification, biology, and signaling pathways will be described. Information will be provided about its direct role as an autocrine growth and survival factor and its paracrine effect as a systemic factor as well as via interaction with extracellular matrix proteins and with components of the tumor microenvironment to influence drug resistance, migration, angiogenesis, inflammation, and immune modulation. This chapter will also describe studies examining progranulin/GP88 tumor tissue expression as well as circulating level as a prognostic factor for several cancers. Due to the wealth of publications in progranulin, this review does not attempt to be exhaustive but rather provide a thread to lead the readers toward more in-depth exploration of this fascinating and unique protein.","['Acrogranin', 'GP88', 'Granulin-epithelin precursor', 'PCDGF', 'Progranulin', 'Tumor microenvironment, Autocrine, Paracrine, Prognosis, Cancer, Drug resistance, Tumorigenesis.']",Advances in experimental medicine and biology,2021-10-20,"[{'lastname': 'Serrero', 'firstname': 'Ginette', 'initials': 'G', 'affiliation': 'A&G Pharmaceutical Inc., Columbia, MD, USA. gserrero@agpharma.com.'}]",,,,"© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.",10.1007/978-3-030-73119-9_22,<Element 'PubmedArticle' at 0x7f05dd6c2680>
119,"34660336
31882890
26708324
24613533
26872610
28778332
30099552
16000722
5149713
28122885
33643006
10101725
12123857
11006429
12493549
14674857
15301598
32051033
17524404
31341288
27368418
27033119
23230098
27214047
34235345
22572830
26265751
22587940
20100548
31263284
12135777
27641441
32483366
30026268
30401548
32015261
31652073
22522079
31636122
11893842
25845383
31795776
28586297
12927766
25960081
24450613
30897366
26811603
7938239
24480908
14635215
8983332
11189026
17342777
19470968
514688
8672166
26270318
21080139
19223011
27994949
32170068
28548658
29054797
16364196
29018189
19124498
29547587
4870316
30424806
28122648
18034701
32169105
27491067
22354218
28528886
26122297
27013283
32949557
31862208
30535329
23563705
26149525
16112947
27107051
29134359
7284494
23975157
26323480
28333235
26085670
16033867
1665561
24734243
30891563
16893466
25205317
32035072
9799625
16488547
21078303
32484785
22134646
25679306
25159107
21983070
21869457
3593987
11445026
29701810
25400333
17035515
8545054
26321261
30555441
28650869
25757366
25561744
30572569
17234057
16771855
31196177
15765388
26785481
29762673
19702455
31845185
29573619
19603518
31402327
28587152
29316527
31081896
31726457
23994581
26969397
17761551
22269187
19179442
17364594
16825636
10659874
21702898
25440054
27814521
12700177
3973604
31178843
26859772
26828626
11747678
31811292
29377008
25559083
29024170
30214170
5058966
17183312
31622559
18522863
29051531
4556652
16934233
23615642
9626634
13784790
9238857
23240018
22572831
24117923
32153527
25118885
14917674
25851728
3572204","Surgical Menopause and Estrogen Therapy Modulate the Gut Microbiota, Obesity Markers, and Spatial Memory in Rats.","Menopause in human females and subsequent ovarian hormone deficiency, particularly concerning 17β-estradiol (E2), increase the risk for metabolic dysfunctions associated with obesity, diabetes type 2, cardiovascular diseases, and dementia. Several studies indicate that these disorders are also strongly associated with compositional changes in the intestinal microbiota; however, how E2 deficiency and hormone therapy affect the gut microbial community is not well understood. Using a rat model, we aimed to evaluate how ovariectomy (OVX) and subsequent E2 administration drive changes in metabolic health and the gut microbial community, as well as potential associations with learning and memory. Findings indicated that OVX-induced ovarian hormone deficiency and E2 treatment had significant impacts on several health-affecting parameters, including (a) the abundance of some intestinal bacterial taxa (e.g., ","['estrogen', 'gut microbiome', 'gut-brain axis', 'hormone therapy', 'memory', 'menopause', 'ovariectomy']",Frontiers in cellular and infection microbiology,2021-10-19,"[{'lastname': 'Zeibich', 'firstname': 'Lydia', 'initials': 'L', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.'}, {'lastname': 'Koebele', 'firstname': 'Stephanie V', 'initials': 'SV', 'affiliation': ""Department of Psychology, Arizona State University, Tempe, AZ, United States.\nArizona Alzheimer's Consortium, Phoenix, AZ, United States.""}, {'lastname': 'Bernaud', 'firstname': 'Victoria E', 'initials': 'VE', 'affiliation': ""Department of Psychology, Arizona State University, Tempe, AZ, United States.\nArizona Alzheimer's Consortium, Phoenix, AZ, United States.""}, {'lastname': 'Ilhan', 'firstname': 'Zehra Esra', 'initials': 'ZE', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.'}, {'lastname': 'Dirks', 'firstname': 'Blake', 'initials': 'B', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.'}, {'lastname': 'Northup-Smith', 'firstname': 'Steven N', 'initials': 'SN', 'affiliation': ""Department of Psychology, Arizona State University, Tempe, AZ, United States.\nArizona Alzheimer's Consortium, Phoenix, AZ, United States.""}, {'lastname': 'Neeley', 'firstname': 'Rachel', 'initials': 'R', 'affiliation': ""Department of Psychology, Arizona State University, Tempe, AZ, United States.\nArizona Alzheimer's Consortium, Phoenix, AZ, United States.""}, {'lastname': 'Maldonado', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.\nGenomics Core, Arizona State University, Tempe, AZ, United States.'}, {'lastname': 'Nirmalkar', 'firstname': 'Khemlal', 'initials': 'K', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.'}, {'lastname': 'Files', 'firstname': 'Julia A', 'initials': 'JA', 'affiliation': ""Division of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, United States.""}, {'lastname': 'Mayer', 'firstname': 'Anita P', 'initials': 'AP', 'affiliation': ""Division of Women's Health Internal Medicine, Mayo Clinic, Scottsdale, AZ, United States.""}, {'lastname': 'Bimonte-Nelson', 'firstname': 'Heather A', 'initials': 'HA', 'affiliation': ""Department of Psychology, Arizona State University, Tempe, AZ, United States.\nArizona Alzheimer's Consortium, Phoenix, AZ, United States.""}, {'lastname': 'Krajmalnik-Brown', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Biodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, United States.'}]",,,,"Copyright © 2021 Zeibich, Koebele, Bernaud, Ilhan, Dirks, Northup-Smith, Neeley, Maldonado, Nirmalkar, Files, Mayer, Bimonte-Nelson and Krajmalnik-Brown.","10.3389/fcimb.2021.702628
10.1038/s41598-019-56723-1
10.1017/S1355617715001265
10.1016/j.fertnstert.2014.02.032
10.3109/13697137.2015.1129166
10.1016/j.maturitas.2017.06.025
10.1093/ijnp/pyy067
10.1099/mic.0.27712-0
10.1016/0031-9384(71)90231-9
10.1161/CIR.0000000000000485
10.3389/fnbeh.2021.610078
10.1016/S0306-4530(98)00068-7
10.1016/S0304-3940(02)00442-1
10.1016/S0031-9384(00)00259-6
10.1007/978-1-4939-2159-1_2
10.1016/S0197-4580(02)00015-5
10.1037/0735-7044.117.6.1395
10.1037/0735-7044.118.4.707
10.1186/s40168-020-0785-4
10.1016/j.yhbeh.2007.04.010
10.1038/s41587-019-0209-9
10.1016/j.bbr.2016.06.053
10.1152/ajpgi.00424.2015
10.2337/dc12-1020
10.1038/nmeth.3869
10.1097/PR9.0000000000000943
10.4161/gmic.20168
10.14814/phy2.12488
10.1016/j.yhbeh.2012.05.003
10.1016/j.bbagen.2010.01.007
10.1038/s41591-019-0495-2
10.1016/S0168-0102(02)00059-7
10.1113/JP273106
10.1038/s41587-020-0548-6
10.1161/ATVBAHA.118.311017
10.1016/j.ogc.2018.07.006
10.1097/GME.0000000000001472
10.1161/JAHA.119.012763
10.1016/j.yhbeh.2012.04.004
10.1074/jbc.RA119.010950
10.1016/0006-3207(92)91201-3
10.1159/000048652
10.3109/13697137.2015.1020484
10.1080/17425247.2020.1700949
10.1080/19490976.2017.1334033
10.1016/S0197-4580(03)00014-9
10.1016/j.yhbeh.2015.05.001
10.1186/2049-2618-1-14
10.1016/j.neuron.2019.02.008
10.3748/wjg.v22.i2.501
10.1016/0031-9384(94)90196-1
10.1099/ijs.0.059543-0
10.1002/jnr.10811
10.1515/JBCPP.1996.7.1.1
10.1016/S1566-0702(00)00219-8
10.1002/bdrb.20106
10.1212/WNL.0b013e3181a71193
10.1203/00006450-197911000-00005
10.1056/NEJM199608153350701
10.1016/j.tcm.2015.01.008
10.1007/s13105-010-0056-0
10.1016/j.neuroscience.2009.02.024
10.1099/00207713-24-4-478
10.1080/21623945.2016.1252011
10.1038/s41522-020-0122-5
10.1038/ismej.2017.71
10.1016/j.yhbeh.2017.10.005
10.1111/j.1582-4934.2005.tb00385.x
10.1038/s41467-017-00900-1
10.1158/1055-9965.EPI-08-0596
10.3390/genes9030167
10.2466/pr0.1968.22.2.547
10.1186/s40168-018-0587-0
10.1186/s40168-016-0225-7
10.1111/j.1530-0277.2007.00541.x
10.1186/s40168-020-00821-0
10.1016/j.jpsychires.2016.07.019
10.1159/000335994
10.1016/j.rec.2017.04.007
10.1016/j.yhbeh.2015.06.009
10.1016/j.maturitas.2016.01.015
10.1016/j.yhbeh.2020.104854
10.1016/j.yhbeh.2019.104656
10.1210/en.2018-00709
10.1038/nm.3145
10.1016/j.yhbeh.2015.06.017
10.1080/13697130500148875
10.1093/jnci/djw029
10.1007/s13311-017-0585-0
10.1159/000241475
10.1038/nbt.2676
10.1093/femsre/fuv036
10.1093/humupd/dmw045
10.1242/jeb.114223
10.1073/pnas.0504978102
10.1111/j.1600-0773.1991.tb01290.x
10.1155/2014/757461
10.1002/ame2.12033
10.1186/1471-2105-7-371
10.1016/j.yhbeh.2014.08.011
10.1016/j.yhbeh.2020.104711
10.1006/hbeh.1998.1473
10.1016/j.neuroscience.2006.01.001
10.1016/j.brainres.2010.11.030
10.18632/aging.103290
10.1038/ismej.2011.139
10.1016/j.psyneuen.2015.01.002
10.1016/j.steroids.2014.08.010
10.4161/gmic.2.4.16108
10.18632/aging.100361
10.1007/BF01807334
10.1089/152460901750269670
10.1093/nutrit/nuy009
10.1155/2014/615917
10.1523/JNEUROSCI.3369-06.2006
10.1016/0304-3940(95)11881-V
10.1016/S0140-6736(15)61340-X
10.3389/fmicb.2018.02897
10.1097/GME.0000000000000921
10.1016/j.maturitas.2015.02.003
10.1242/dmm.017400
10.3390/nu10122009
10.1258/002367707779399518
10.1111/j.1365-2567.2006.02358.x
10.1186/s40168-019-0704-8
10.1053/j.gastro.2004.11.050
10.1126/science.aac8469
10.1093/gigascience/giy055
10.2217/WHE.09.42
10.1007/s12975-019-00760-5
10.1016/j.biopha.2018.03.078
10.1002/iub.230
10.1016/j.molmet.2019.05.012
10.3390/ani7060044
10.1016/j.neurobiolaging.2017.11.015
10.1210/er.2018-00280
10.1159/000504495
10.1016/j.yfrne.2013.08.001
10.1016/j.jsbmb.2016.03.012
10.1212/01.wnl.0000276984.19542.e6
10.1159/000334764
10.1210/en.2008-1405
10.1080/13697130601114917
10.1099/ijs.0.64192-0
10.1001/jama.283.4.485
10.1186/gb-2011-12-6-r60
10.1016/j.cmet.2014.10.016
10.1016/j.cell.2016.10.027
10.1210/er.2001-0016
10.1111/j.1471-4159.1985.tb08724.x
10.3389/fmicb.2019.01137
10.1038/ismej.2015.249
10.1016/j.coph.2016.01.002
10.1089/152460901753285732
10.1093/gerona/glz281
10.1038/nrneurol.2017.188
10.1080/19490976.2014.1000080
10.1111/jne.12548
10.2147/CIA.S139163
10.1093/jnci/48.3.605
10.1038/nature05414
10.1146/annurev-pathol-020117-043559
10.1016/j.yfrne.2008.04.001
10.1038/s41598-017-13601-y
10.1016/0031-9384(72)90340-X
10.1016/j.brainres.2006.07.064
10.1091/gme.0b013e31827655e5
10.1359/jbmr.1998.13.6.1023
10.1038/bjc.1960.51
10.1080/08910600310018823
10.1371/journal.pone.0051385
10.4161/gmic.19934
10.1111/1574-6941.12228
10.3389/fmicb.2020.00219
10.1038/nrmicro3330
10.1016/S0021-9258(18)55930-5
10.1111/jgs.13310",<Element 'PubmedArticle' at 0x7f05dd294e50>
120,34614155,The Relationship Between Fertility History and Incident Dementia in the U.S. Health and Retirement Study.,"An emerging literature suggests that fertility history, which includes measures of parity and birth timing, may influence cognitive health in older ages, especially among women given their differential exposure to pregnancy and sex hormones. Yet, few studies have examined associations between measures of fertility history and incident dementia in population-based samples.
We examined the associations between parity, younger age at first birth, and older age at last birth with incident dementia over a 16-year period in a prospective sample of 15,361 men and women aged 51-100 years at baseline drawn from the Health and Retirement Study. We used Cox regression and the Fine and Gray model to obtain cause-specific hazard ratios (csHRs) and subdistribution hazard ratios for incident dementia from gender-stratified models, with the latter method accounting for the semicompeting risk of death.
During the follow-up period (median 13.0 years), the crude incidence rate for dementia was 16.6 and 19.9 per 1,000 person-years for men and women, respectively. In crude models estimating csHRs, higher parity (vs parity 2) and younger age at first birth were associated with increased risk of dementia for both genders. These associations did not persist after adjusting for sociodemographic characteristics, smoking status, and health conditions, with much of the attenuation in estimates occurring after adjustment for sociodemographic characteristics.
In this population-based, multiethnic cohort, we observed limited evidence for an association between measures of fertility history and incident dementia among men and women after adjusting for potential confounders.","['Cognitive health', 'Gender', 'Parity', 'Postreproductive health']","The journals of gerontology. Series B, Psychological sciences and social sciences",2021-10-07,"[{'lastname': 'Gemmill', 'firstname': 'Alison', 'initials': 'A', 'affiliation': 'Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'lastname': 'Weiss', 'firstname': 'Jordan', 'initials': 'J', 'affiliation': 'Department of Demography, University of California, Berkeley, California, USA.'}]","We examined the associations between parity, younger age at first birth, and older age at last birth with incident dementia over a 16-year period in a prospective sample of 15,361 men and women aged 51-100 years at baseline drawn from the Health and Retirement Study. We used Cox regression and the Fine and Gray model to obtain cause-specific hazard ratios (csHRs) and subdistribution hazard ratios for incident dementia from gender-stratified models, with the latter method accounting for the semicompeting risk of death.",,"During the follow-up period (median 13.0 years), the crude incidence rate for dementia was 16.6 and 19.9 per 1,000 person-years for men and women, respectively. In crude models estimating csHRs, higher parity (vs parity 2) and younger age at first birth were associated with increased risk of dementia for both genders. These associations did not persist after adjusting for sociodemographic characteristics, smoking status, and health conditions, with much of the attenuation in estimates occurring after adjustment for sociodemographic characteristics.","© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",10.1093/geronb/gbab183,<Element 'PubmedArticle' at 0x7f05dd4a9e50>
121,"34594430
28924333
12577276
28935660
22716913
26099657
30983960
23089645
24732419
21747771
19539719
27609090
14569273
21206761
25532494
16183085
15464754
11503148
20595033
26394891
21294659
31304198
3562707
19428610
17671613
21519389
27569603
29976248
16522198
23579318
27473936
9826549
28685774
25742564
28892027
27423017
32101698
26608570
21912367
29163055
30778289
22248569
21403628
21948013
16343296
18081617
17222489
10974491
15666335
17919130
2781295
5639909
24036168
30165122
24434111
16365303
21288473
17434919
11172776
1747750
9618522",Endogenous Estrogen Influences Predator Odor-Induced Impairment of Cognitive and Social Behaviors in Aromatase Gene Deficiency Mice.,"Epidemiological studies have suggested that traumatic stress increases vulnerability to various mental disorders, such as dementia and psychiatric disorders. While women are more vulnerable than men to depression and anxiety, it is unclear whether endogenous estrogens are responsible for the underlying sex-specific mechanisms. In this study, the aromatase gene heterozygous (Ar+/-) mice were used as an endogenous estrogen deficiency model and age- and sex-matched wild type mice (WT) as controls to study the predator odor 2,3,5-trimethyl-3-thiazoline- (TMT-) induced short- and long-term cognitive and social behavior impairments. In addition, the changes in brain regional neurotransmitters and their associations with TMT-induced changes in behaviors were further investigated in these animals. Our results showed TMT induced immediate fear response in both Ar+/- and WT mice regardless of sexes. TMT induced an acute impairment of novel object recognition memory and long-term social behavior impairment in WT mice, particularly in females, while Ar+/- mice showed impaired novel object recognition in both sexes and TMT-elevated social behaviors, particularly in males. TMT failed to induce changes in the prepulse inhibition (PPI) test in both groups. TMT resulted in a slight increase of DOPAC/DA ratio in the cortex and a significant elevation of this ratio in the striatum of WT mice. In addition, the ratio of HIAA/5-HT was significantly elevated in the cortex of TMT-treated WT mice, which was not found in TMT-treated Ar+/- mice. Taken together, our results indicate that TMT exposure can cause cognitive and social behavior impairments as well as change catecholamine metabolism in WT mice, and endogenous estrogen deficiency might desensitize the behavioral and neurochemical responses to TMT in Ar+/- mice.",[],Behavioural neurology,2021-10-02,"[{'lastname': 'Gao', 'firstname': 'Yaner', 'initials': 'Y', 'affiliation': 'Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.'}, {'lastname': 'Ma', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Gao', 'firstname': 'Feng', 'initials': 'F', 'affiliation': 'School of Life Sciences, University of Science and Technology of China, Hefei, China.'}, {'lastname': 'Sun', 'firstname': 'Zuoli', 'initials': 'Z', 'affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Zhang', 'firstname': 'Zhengrong', 'initials': 'Z', 'affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Li', 'firstname': 'Yuhong', 'initials': 'Y', 'affiliation': 'Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.'}, {'lastname': 'Li', 'firstname': 'Rena', 'initials': 'R', 'affiliation': 'Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.\nThe National Clinical Research Center for Mental Disorders & Beijing key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.'}]",,,,Copyright © 2021 Yaner Gao et al.,"10.1155/2021/5346507
10.1111/cpsp.12190
10.1002/da.10077
10.1192/bjp.bp.116.197640
10.1017/S0033291712000785
10.1016/j.psychres.2015.04.052
10.3389/fnins.2019.00274
10.1016/j.bbr.2012.10.014
10.1016/j.physbeh.2014.04.009
10.3389/fpsyt.2011.00039
10.1016/j.neulet.2009.06.025
10.1038/srep32935
10.1038/sj.mp.4001435
10.1016/j.brainres.2014.12.030
10.4236/jbbs.2015.57032
10.1016/j.physbeh.2005.08.044
10.1016/j.brainres.2004.07.079
10.1002/cne.1297
10.1016/j.bbr.2010.05.047
10.1002/dev.21362
10.3109/10253890.2010.541539
10.1016/j.ynstr.2019.100177
10.1037/0033-2909.101.2.259
10.1080/20008198.2017.1351204
10.1016/j.bbr.2009.01.019
10.1155/2007/71203
10.3389/fnbeh.2011.00017
10.1016/j.pbb.2016.08.008
10.1186/s13293-018-0191-9
10.1186/1744-9081-2-8
10.1016/j.neubiorev.2016.07.030
10.1006/bbrc.1998.9672
10.1038/ncomms16011
10.3791/52434
10.3791/55718
10.1016/j.eplepsyres.2016.06.010
10.1016/j.neuron.2020.01.033
10.1186/s12868-015-0221-z
10.3791/3446
10.3389/fncel.2017.00344
10.3389/fncel.2019.00024
10.1016/j.beproc.2012.01.002
10.3791/2473
10.1080/j.1440-1614.2005.01714.x
10.1111/j.1440-1819.2007.01722.x
10.1016/j.cpr.2006.09.005
10.1016/S0361-9230(00)00290-2
10.1002/mrdd.20039
10.1111/j.1750-3639.2007.00096.x
10.1126/science.2781295
10.1016/0003-3472(68)90116-4
10.1016/j.bbr.2013.09.014
10.1016/j.pnpbp.2018.08.026
10.1016/j.yfrne.2014.01.002
10.1073/pnas.0505203102
10.1016/j.neuropharm.2011.01.040
10.1093/cercor/bhm033
10.1016/S0006-8993(00)03262-5
10.1016/0006-8993(91)90129-J
10.1073/pnas.95.12.6965",<Element 'PubmedArticle' at 0x7f05dd4db590>
122,"34592924
33225839
29923184
19585957
30541602
18763166
27809746
30070363
12421115
15488459
33200673
31623294
32924825
34502340
33984802
33375412
31480727
23282245
21421841
28082792
26400175
30406177
24981612
32884235
28685762
28572049
32924840
34027534
30068281
12553894
19455183
17553629
33829779
8670860
15980490
18631749
19402770
32935230
27569426
32008882
26081713",Evaluation of selected carotenoids of Lycopersicon esculentum variants as therapeutic targets for 'Alzheimer's disease: an in silico approach.,"The seriousness and menace of the worldwide weight of 'Alzheimer's disease have been related to a few factors, which incorporate antioxidant system depletion, mutation of proteins, and high expression of cholinesterases due to aging, environmental influence, diet, infectious agents, and hormonal imbalance. Overexpression of cholinesterases has been emphatically connected to 'Alzheimer's disease because of the unreasonable hydrolysis of acetylcholine and butyrylcholine. Certain plant phytochemicals, for example, beta-carotenoids, lutein, neoxanthin, and viola-xanthine from Lycopersicon esculentum Mill. Var. esculentum (ESC) and Lycopersicon esculentum Mill. Var. cerasiforme (CER) has been utilized altogether as a therapeutic candidate for the treatment of 'Alzheimer's disease. Therefore, this research sought to investigate the drug-likeness of the individual carotenoids as detailed for cholinesterase inhibition in the treatment of 'Alzheimer's disease. Four potential cholinesterase inhibitors from ESC and CER were retrieved from the PubChem database. Investigation of their drug-likeness, toxicity prediction, molecular docking, and dynamic simulations were carried out using Molinspiration, PreADMET V.2.0, Patchdock server, and Schrodinger Maestro software respectively. Neoxanthin was ranked the safest with a greater tendency to inhibit the cholinesterases with high binding affinity. In addition, its stability after simulation in a mimicked biological environment suggests its relevance as a potential drug candidate for the treatment of 'Alzheimer's disease through the inhibition of cholinesterases.","['Carotenoids', 'Drug-likeness', 'In silico', 'Inhibitors', 'Ligands', 'Phytochemicals', 'Therapeutic', 'Toxicity', '‘Alzheimer’s']",BMC molecular and cell biology,2021-10-02,"[{'lastname': 'Bakare', 'firstname': 'Olalekan Olanrewaju', 'initials': 'OO', 'affiliation': 'Bioinformatics research group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, Cape Town, 7535, South Africa. lekanbakare77@gmail.com.\nEnvironmental Biotechnology Laboratory (EBL), Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa. lekanbakare77@gmail.com.'}, {'lastname': 'Fadaka', 'firstname': 'Adewale Oluwaseun', 'initials': 'AO', 'affiliation': 'Bioinformatics research group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, Cape Town, 7535, South Africa.\nDepartment of Science and Technology/Mintek Nanotechnology Innovation Centre, Biolabels Node, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa.'}, {'lastname': 'Akanbi', 'firstname': 'Musa Oyebowale', 'initials': 'MO', 'affiliation': 'Environmental Biotechnology Laboratory (EBL), Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa.'}, {'lastname': 'Akinyede', 'firstname': 'Kolajo Adedamola', 'initials': 'KA', 'affiliation': 'Department of Medical Bioscience, University of the Western Cape, Bellville, Cape Town, 7535, South Africa.'}, {'lastname': 'Klein', 'firstname': 'Ashwil', 'initials': 'A', 'affiliation': 'Plant Omics group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, Cape Town, 7535, South Africa.'}, {'lastname': 'Keyster', 'firstname': 'Marshall', 'initials': 'M', 'affiliation': 'Environmental Biotechnology Laboratory (EBL), Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa.'}]",,,,© 2021. The Author(s).,"10.1186/s12860-021-00386-2
10.1016/j.jalz.2018.02.001
10.31887/DCNS.2009.11.2/hbrodaty
10.1186/s13024-018-0299-8
10.1166/jpsp.2015.1066
10.1080/10717540802039113
10.2174/1389450117666161102121553
10.1111/jphp.12984
10.2165/00023210-200216120-00003
10.1016/S1474-4422(04)00906-8
10.1063/1.470117
10.3390/ijms20194899
10.1016/j.ejmech.2021.113492
10.3390/molecules26010080
10.3390/biom9090441
10.1186/1471-2105-13-S17-S7
10.1073/pnas.1017033108
10.4103/0973-7847.194040
10.1093/nar/gkv951
10.1016/j.ddtec.2004.11.007
10.2147/DDDT.S257494
10.1038/nrd.2017.111
10.1016/j.foodchem.2010.03.130
10.1016/j.autrev.2017.05.015
10.2174/1570163815666180801152110
10.1038/nrneurol.2009.53
10.1016/j.mehy.2007.03.032
10.1021/acs.jmedchem.1c00048
10.1002/j.1460-2075.1996.tb00726.x
10.1093/nar/gki481
10.1016/S0072-9752(07)01223-7
10.1586/ern.09.23
10.1007/s12035-020-02116-9
10.13172/2054-4057-1-1-1119
10.1016/j.bcp.2016.08.015
10.1016/j.bmc.2020.115324
10.12691/ajmo-5-1-3",<Element 'PubmedArticle' at 0x7f05dd4ac720>
123,"34588168
26007613
29311911
24622517
26209223
15213206
12771112
27421538
28274328
30842086
31604711
30626577
33115755
15460170
15252064
28735855
26061376
10582940
9624763
10597998
32210745",Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.,"To assess the risks of developing dementia associated with different types and durations of menopausal hormone therapy.
Two nested case-control studies.
UK general practices contributing to QResearch or the Clinical Practice Research Datalink (CPRD), using all links to hospital, mortality, and social deprivation data.
118 501 women aged 55 and older with a primary diagnosis of dementia between 1998 and 2020, matched by age, general practice, and index date to 497 416 female controls.
Dementia diagnoses from general practice, mortality, and hospital records; odds ratios for menopausal hormone treatments adjusted for demographics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs.
Overall, 16 291 (14%) women with a diagnosis of dementia and 68 726 (14%) controls had used menopausal hormone therapy more than three years before the index date. Overall, no increased risks of developing dementia associated with menopausal hormone therapy were observed. A decreased global risk of dementia was found among cases and controls younger than 80 years who had been taking oestrogen-only therapy for 10 years or more (adjusted odds ratio 0.85, 95% confidence interval 0.76 to 0.94). Increased risks of developing specifically Alzheimer's disease were found among women who had used oestrogen-progestogen therapy for between five and nine years (1.11, 1.04 to 1.20) and for 10 years or more (1.19, 1.06 to 1.33). This was equivalent to, respectively, five and seven extra cases per 10 000 woman years. Detailed risk associations for the specific progestogens studied are also provided.
This study gives estimates for risks of developing dementia and Alzheimer's disease in women exposed to different types of menopausal hormone therapy for different durations and has shown no increased risks of developing dementia overall. It has shown a slightly increased risk of developing Alzheimer's disease among long term users of oestrogen-progestogen therapies.",[],BMJ (Clinical research ed.),2021-10-01,"[{'lastname': 'Vinogradova', 'firstname': 'Yana', 'initials': 'Y', 'affiliation': 'Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, NG2 7RD, UK Yana.Vinogradova@nottingham.ac.uk.'}, {'lastname': 'Dening', 'firstname': 'Tom', 'initials': 'T', 'affiliation': 'Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Hippisley-Cox', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, OX2 6GG, UK.'}, {'lastname': 'Taylor', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': 'Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, NG2 7RD, UK.'}, {'lastname': 'Moore', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Primary Care Research Centre, Primary Care, Population Sciences and Medical Education (PPM), Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'lastname': 'Coupland', 'firstname': 'Carol', 'initials': 'C', 'affiliation': 'Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, NG2 7RD, UK.'}]",,This study gives estimates for risks of developing dementia and Alzheimer's disease in women exposed to different types of menopausal hormone therapy for different durations and has shown no increased risks of developing dementia overall. It has shown a slightly increased risk of developing Alzheimer's disease among long term users of oestrogen-progestogen therapies.,"Overall, 16 291 (14%) women with a diagnosis of dementia and 68 726 (14%) controls had used menopausal hormone therapy more than three years before the index date. Overall, no increased risks of developing dementia associated with menopausal hormone therapy were observed. A decreased global risk of dementia was found among cases and controls younger than 80 years who had been taking oestrogen-only therapy for 10 years or more (adjusted odds ratio 0.85, 95% confidence interval 0.76 to 0.94). Increased risks of developing specifically Alzheimer's disease were found among women who had used oestrogen-progestogen therapy for between five and nine years (1.11, 1.04 to 1.20) and for 10 years or more (1.19, 1.06 to 1.33). This was equivalent to, respectively, five and seven extra cases per 10 000 woman years. Detailed risk associations for the specific progestogens studied are also provided.",© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.,"10.1136/bmj.n2182
10.1038/nrendo.2015.82
10.3389/fnagi.2017.00430
10.1371/journal.pone.0089095
10.1016/j.jagp.2015.05.009
10.1001/jama.291.24.2947
10.1001/jama.289.20.2651
10.1212/WNL.0000000000002980
10.1016/j.maturitas.2017.01.002
10.1136/bmj.l665
10.1136/bmj.l5928
10.1136/bmj.k4810
10.1136/bmj.m3873
10.1592/phco.24.13.1105.38083
10.1136/jech.2003.008466
10.1016/S0140-6736(17)31363-6
10.1177/1536867X0400400301
10.1002/jrsm.12
10.1136/bmj.319.7223.1492
10.1093/ije/28.5.964
10.3389/fnins.2020.00157",<Element 'PubmedArticle' at 0x7f05dd37fea0>
124,"34576151
20697751
29377010
15094069
28601906
22820012
2681272
3070584
3551804
22500228
25346723
2249648
9810512
3653038
2553069
2771055
3005298
7556975
27489306
19752219
11000114
22430016
9355755
22956272
26297026
33810179
24931034
24931033
27038749
20638297
10660596
19679110
11287608
10816121
11289486
31062330
10460236
29163128
22329651
27881773
31974905
20176121
21738722
31417349
12271485
11911870
19262152
16092951
29439247
11248117
10545776
11978812
29222408
10574963
21458499
15288712
29382127
18402935
16916571
26927389
18549783
21683721
17329210
15657639
16890939
17544173
10995824
9778565
26159205
20720504
24803647
9809557
12466205
23372544
21183078
21346761
14550766
10679768
19943139
12231073
15935073
34069890
12111436
19885299
1057175
16914857
26170022
11580206
27615390
23412472
29187252
18466052
12904469
30538427
22675648
12615961
24759912
19712582
28652303
29053786
24005412
22286308
23239816
19406747
11932745
22191795
21199446
33224105
22805374
29563239
23223021
27025652
25297091
25617315
27076423
30975165
12084635
12006603
9114067
12761548
32864980
20692646
27988872
15831717
11440311
12505419
20698820
33597002
11270668
21440603
15764591
26693205
16894049
26175217
12808450
25014735
12509807
12176746
24529521
28485801
33344887
24380887
21443795
24095978
22669748
24733654
10950123
32083135
23850509
24949886
19667196
22037588
15750215
23335160
21115952
25661087
26216852
33203727
22476197
33446523
27488909
26214150
20919769
32730766
25869922
17942819
28372335
21911655
15964100
27042676
32175781
30542257
19923038
16286438
16446752
21592048
20337586
27252647
26010513
22458300
19805629
28124574
10591291
21670398
20396634
19262950
16616038
28049634
31534057
30081082",Insulin and Insulin Resistance in Alzheimer's Disease.,"Insulin plays a range of roles as an anabolic hormone in peripheral tissues. It regulates glucose metabolism, stimulates glucose transport into cells and suppresses hepatic glucose production. Insulin influences cell growth, differentiation and protein synthesis, and inhibits catabolic processes such as glycolysis, lipolysis and proteolysis. Insulin and insulin-like growth factor-1 receptors are expressed on all cell types in the central nervous system. Widespread distribution in the brain confirms that insulin signaling plays important and diverse roles in this organ. Insulin is known to regulate glucose metabolism, support cognition, enhance the outgrowth of neurons, modulate the release and uptake of catecholamine, and regulate the expression and localization of gamma-aminobutyric acid (GABA). Insulin is also able to freely cross the blood-brain barrier from the circulation. In addition, changes in insulin signaling, caused inter alia insulin resistance, may accelerate brain aging, and affect plasticity and possibly neurodegeneration. There are two significant insulin signal transduction pathways: the PBK/AKT pathway which is responsible for metabolic effects, and the MAPK pathway which influences cell growth, survival and gene expression. The aim of this study is to describe the role played by insulin in the CNS, in both healthy people and those with pathologies such as insulin resistance and Alzheimer's disease.","['Alzheimer’s disease', 'central nervous system', 'insulin', 'insulin resistance', 'insulin-like growth factor', 'type 2 diabetes mellitus']",International journal of molecular sciences,2021-09-29,"[{'lastname': 'Sędzikowska', 'firstname': 'Aleksandra', 'initials': 'A', 'affiliation': 'Chair and Department of General Biology and Parasitology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland.'}, {'lastname': 'Szablewski', 'firstname': 'Leszek', 'initials': 'L', 'affiliation': 'Chair and Department of General Biology and Parasitology, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland.'}]",,,,,"10.3390/ijms22189987
10.1007/s00702-010-0456-x
10.1038/nrneurol.2017.185
10.1016/j.ejphar.2004.02.040
10.1007/s00125-017-4285-4
10.1016/j.pharmthera.2012.07.006
10.1172/JCI114339
10.1016/0031-9384(88)90139-4
10.1146/annurev.ph.49.030187.002003
10.1155/2012/384017
10.3389/fendo.2014.00161
10.1210/endo-127-6-3234
10.1210/endo-121-4-1562
10.1007/BF02935589
10.1016/0306-4522(89)90036-5
10.1016/S0021-9258(17)35711-3
10.1007/s001250050349
10.1152/physrev.00032.2015
10.1210/er.2008-0047
10.1126/science.289.5487.2122
10.1038/nrn3209
10.1042/bj3270209
10.1007/s12035-012-8339-9
10.1186/s13041-015-0138-6
10.3390/life11030262
10.2337/db14-0568
10.2337/db13-1954
10.1016/j.neuroscience.2016.03.056
10.1016/j.tem.2010.06.005
10.1074/jbc.275.6.4283
10.1016/j.brainres.2009.08.005
10.1128/MCB.21.9.3025-3036.2001
10.1042/bst0280170
10.2337/diacare.24.3.588
10.3389/fnagi.2017.00345
10.2174/156720512799015037
10.1523/JNEUROSCI.1700-16.2016
10.1007/s10571-020-00796-4
10.1016/j.nlm.2010.02.002
10.1371/journal.pone.0021594
10.3389/fnins.2019.00788
10.1002/cne.10368
10.1016/S0006-8993(02)02308-9
10.4161/cam.2.4.6354
10.1111/j.1471-4159.2005.03269.x
10.1159/000487641
10.1073/pnas.051634698
10.1007/BF02253672
10.1523/JNEUROSCI.22-09-03359.2002
10.1038/s41467-017-02221-9
10.1074/jbc.274.49.34893
10.1016/j.bbr.2011.03.052
10.1016/j.psyneuen.2004.04.003
10.3390/ph11010011
10.1016/j.ejphar.2008.01.051
10.1016/j.pneurobio.2006.06.003
10.1007/978-981-15-3556-7_8
10.1186/s40659-016-0075-6
10.1016/j.neuron.2008.04.014
10.1016/j.neuropharm.2011.06.003
10.1016/j.neuron.2007.01.029
10.1007/s00702-004-0163-6
10.1016/j.yhbeh.2006.06.025
10.1016/j.neurobiolaging.2007.04.013
10.1523/JNEUROSCI.20-18-06804.2000
10.1159/000017324
10.2174/1567205012666150710104428
10.1097/NEN.0b013e3181ef3be4
10.1242/dev.104596
10.1038/3305
10.1242/dev.00203
10.3389/fncel.2013.00005
10.1016/j.cell.2010.12.007
10.1038/nature09867
10.1016/S1044-7431(03)00082-4
10.1002/(SICI)1097-4547(20000201)59:3<332::AID-JNR6>3.0.CO;2-2
10.1007/s11357-006-9009-5
10.1016/S0002-9149(02)02553-5
10.1111/j.1471-4159.2005.03155.x
10.3390/cells10051236
10.1007/s007020200082
10.1177/193229680800200619
10.1073/pnas.72.5.1858
10.3233/JAD-2006-9S321
10.1186/s13024-015-0025-8
10.1016/j.brainresbull.2016.08.018
10.1038/embor.2013.15
10.1186/s40478-017-0489-6
10.1586/14789450.5.2.207
10.1523/JNEUROSCI.23-18-07084.2003
10.1155/2012/578373
10.1242/jcs.00384
10.1039/C4CS00038B
10.5483/BMBRep.2009.42.8.475
10.1084/jem.20161731
10.1093/brain/awx256
10.1038/nature12481
10.1038/nm.2613
10.1210/en.2012-1661
10.1074/jbc.M109.011015
10.1038/416535a
10.2165/11597760-000000000-00000
10.1111/j.1755-5949.2010.00221.x
10.3389/fendo.2020.560375
10.1186/1756-6606-5-25
10.1523/JNEUROSCI.1136-17.2017
10.2337/db12-0670
10.15252/emmm.201606210
10.1523/JNEUROSCI.1353-14.2014
10.15252/emmm.201404183
10.1523/JNEUROSCI.4640-14.2016
10.1186/s13024-019-0315-7
10.1016/S0165-6147(02)02037-0
10.1523/JNEUROSCI.22-10-j0001.2002
10.1073/pnas.94.9.4772
10.1038/nature01640
10.1177/1533317520937542
10.1016/j.biopsych.2010.06.012
10.1007/s40265-016-0674-0
10.1126/science.1110647
10.1080/bih.76.2.97.106
10.1006/nbdi.2002.0538
10.2174/138161210793176572
10.1186/s13195-021-00784-w
10.1007/s001250051591
10.1016/j.bbagen.2011.03.014
10.1093/glycob/cwi053
10.1155/2015/105828
10.1161/CIRCULATIONAHA.106.621854
10.1007/s10571-015-0233-3
10.1038/nm890
10.1002/glia.10178
10.1152/ajpcell.00293.2001
10.1016/j.jalz.2013.12.004
10.3233/ADR-200238
10.1016/j.bcp.2013.12.012
10.1186/1756-6606-4-13
10.1016/j.nbd.2013.09.018
10.1007/s12640-012-9331-x
10.1007/s12264-013-1424-x
10.1038/labinvest.3780140
10.1155/2020/4981814
10.1016/j.pneurobio.2013.06.004
10.1016/j.bbadis.2014.06.010
10.1073/pnas.0903563106
10.1016/j.bbadis.2011.10.011
10.3233/JAD-2005-7107
10.1007/s12035-013-8404-z
10.1212/WNL.0b013e3181ffe4f6
10.1016/j.cca.2015.01.027
10.2337/db15-0596
10.1136/bmjdrc-2020-001741
10.1172/JCI59903
10.2337/dc20-1549
10.1177/0271678X16663214
10.1001/jamaneurol.2015.0613
10.1037/a0020859
10.1016/S1474-4422(20)30231-3
10.3233/JAD-141791
10.1212/01.WNL.0000265401.62434.36
10.3233/JAD-161256
10.1001/archneurol.2011.233
10.1016/j.neurobiolaging.2005.03.016
10.1002/acn3.274
10.1080/13543784.2020.1738383
10.3389/fnins.2018.00830
10.1016/j.neurobiolaging.2009.10.009
10.1176/appi.ajgp.13.11.950
10.2174/156720511796391935
10.2174/157488910791213130
10.3389/fnagi.2016.00108
10.1111/cns.12404
10.1111/j.1532-5415.2012.03916.x
10.1083/jcb.200903124
10.1111/ncn3.12369
10.1177/0394632016688025
10.1001/archpsyc.56.12.1135
10.1001/archneurol.2011.125
10.2147/CIA.S5231
10.1007/s12603-009-0056-3
10.1016/j.amjcard.2005.12.031
10.1093/gerona/glw251
10.1172/jci.insight.130681
10.1016/j.brainresbull.2018.08.001",<Element 'PubmedArticle' at 0x7f05dd36b130>
125,"34527172
30756119
29790571
31637009
31034802
33756057
31616296
21514250
16801647
29423193
32143137
20668433
24845946
27169802
30987146
31089065
20176130
29080524
27316747
16534775
30321505
28257929
30675901
26651821
26890772
28972881
26923416
26544531
22733974
28870443
22419778
28367067
23154064
11960004
33920428
25852213
29605435
30976975
28787707
31792807
28959644
27389644
11162939
11602649
28159674
21053929
25447798
16982738
24373791
28657580
21175082
9848496
27884790
28817364
29051735
25003621
12792289
26401779
30516108
11605103
32527846
19480732
32884237
27809235
30599903
30597930
31344808
31783026
10081916
30311580
28655710
27120593
20493918
15081021
15464088
28264445
32761299
31905923
26576219
32580379
32272581
28733814
27514990
23966081
25666032
26124853
26361743
29468975
27878186
32419519
31019651
30468814
27417698
33679381
29214114
9227685
18976694
25861940
27193940
23704811
24323422
23983668
31803046
27870425
32297302
33097048
30298180
32210745
27823753
17761551
28202700
34112537
31976839
32677442
30842086
9465806
20230416
19465669
24583026
18412992
23526725
18457947
30001606
28570028
32124607
19072500
32708394
17287517
26075609
16084662
27211874
33123315
27723080
31502112
29505099
16024764
32385548
33301850
19627200
31795012
29089994
29535608
22940884
30804738
30809111
29155216
1505465
20212036
29137685
31620438
28678552",The Beneficial Role of Natural Endocrine Disruptors: Phytoestrogens in Alzheimer's Disease.,"Alzheimer's disease (AD) is the most common form of dementia with a growing incidence rate primarily among the elderly. It is a neurodegenerative, progressive disorder leading to significant cognitive loss. Despite numerous pieces of research, no cure for halting the disease has been discovered yet. Phytoestrogens are nonestradiol compounds classified as one of the endocrine-disrupting chemicals (EDCs), meaning that they can potentially disrupt hormonal balance and result in developmental and reproductive abnormalities. Importantly, phytoestrogens are structurally, chemically, and functionally akin to estrogens, which undoubtedly has the potential to be detrimental to the organism. What is intriguing, although classified as EDCs, phytoestrogens seem to have a beneficial influence on Alzheimer's disease symptoms and neuropathologies. They have been observed to act as antioxidants, improve visual-spatial memory, lower amyloid-beta production, and increase the growth, survival, and plasticity of brain cells. This review article is aimed at contributing to the collective understanding of the role of phytoestrogens in the prevention and treatment of Alzheimer's disease. Importantly, it underlines the fact that despite being EDCs, phytoestrogens and their use can be beneficial in the prevention of Alzheimer's disease.",[],Oxidative medicine and cellular longevity,2021-09-17,"[{'lastname': 'Domańska', 'firstname': 'Anita', 'initials': 'A', 'affiliation': 'Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.\nDepartment of Physiological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Nowoursynowska 166, 02-787 Warsaw, Poland.'}, {'lastname': 'Orzechowski', 'firstname': 'Arkadiusz', 'initials': 'A', 'affiliation': 'Department of Physiological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Nowoursynowska 166, 02-787 Warsaw, Poland.'}, {'lastname': 'Litwiniuk', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.'}, {'lastname': 'Kalisz', 'firstname': 'Małgorzata', 'initials': 'M', 'affiliation': 'Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.'}, {'lastname': 'Bik', 'firstname': 'Wojciech', 'initials': 'W', 'affiliation': 'Department of Neuroendocrinology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.'}, {'lastname': 'Baranowska-Bik', 'firstname': 'Agnieszka', 'initials': 'A', 'affiliation': 'Department of Endocrinology, Centre of Postgraduate Medical Education, Cegłowska 80, 01-809 Warsaw, Poland.'}]",,,,Copyright © 2021 Anita Domańska et al.,"10.1155/2021/3961445
10.14283/jpad.2019.7
10.33588/rn.6611.2017519
10.1038/s41392-019-0063-8
10.1016/j.clinbiochem.2019.04.015
10.1002/alz.12328
10.3389/fphar.2019.01062
10.1016/j.jalz.2011.03.005
10.1212/01.wnl.0000219668.47116.e6
10.1186/s40035-018-0107-y
10.1016/j.nicl.2020.102210
10.1038/npp.2010.104
10.1517/14740338.2014.914168
10.1126/scitranslmed.aaf2362
10.3390/ijms20071664
10.4103/1673-5374.255995
10.1016/j.bbalip.2010.02.005
10.1016/j.redox.2017.10.014
10.1016/j.brainresbull.2016.06.005
10.1002/gps.1469
10.1016/j.jalz.2018.08.005
10.1016/j.neuroimage.2017.02.058
10.1111/bph.14585
10.1186/s40478-015-0258-3
10.3233/JAD-151007
10.1016/j.jalz.2017.08.014
10.1016/j.neurobiolaging.2015.12.017
10.1016/j.jveb.2015.08.003
10.17340/jkna.2018.3.1
10.1210/er.2015-1010
10.1210/en.2012-1422
10.1016/j.physbeh.2017.08.029
10.1210/er.2011-1050
10.2147/DMSO.S95296
10.1289/ehp.1205597
10.1073/pnas.082121499
10.3390/ijms22083939
10.1124/dmd.115.063826
10.1016/j.metabol.2018.03.022
10.1007/s00401-019-01978-1
10.1016/j.envpol.2017.07.091
10.1007/s11154-019-09521-z
10.1016/j.toxrep.2017.05.004
10.1017/S0029665116000677
10.1016/s0960-0760(00)00108-4
10.1016/j.jsbmb.2017.01.014
10.1021/tx100231n
10.1016/j.steroids.2014.11.003
10.1158/0008-5472.CAN-06-2432
10.1016/j.jsbmb.2013.12.010
10.3390/ijms18071381
10.1515/jpem.2010.138
10.1021/jf00044a017
10.1093/ajcn/68.6.1333S
10.1016/j.fct.2016.11.020
10.1080/13685538.2017.1365834
10.3389/fphar.2017.00699
10.1097/GME.0000000000000290
10.1097/00042192-200310030-00004
10.3233/JAD-142958
10.2174/1573403X15666181205104717
10.1007/s002130100845
10.3174/ajnr.A6601
10.1017/S0007114509990201
10.2147/DDDT.S249608
10.3390/nu8110692
10.1016/j.phymed.2018.09.207
10.3390/pharmaceutics11010008
10.3390/nu11081702
10.1016/j.yhbeh.2019.104637
10.1016/s0304-3940(98)00994-x
10.1615/CritRevEukaryotGeneExpr.2018025847
10.1096/fj.201700353
10.3390/molecules21050548
10.1016/j.neuint.2010.05.006
10.1016/j.bmcl.2004.02.003
10.1016/j.ejphar.2004.08.043
10.3390/nu9030207
10.1007/s11130-020-00840-0
10.3390/biom10010059
10.1155/2015/314560
10.3390/antiox9060545
10.3390/biom10040562
10.1007/s00213-017-4690-x
10.1038/srep31450
10.3390/molecules18089949
10.1016/j.neuropharm.2015.01.027
10.4172/2161-0525.100035
10.1155/2015/354326
10.1016/j.brainresbull.2015.09.002
10.2174/1570163815666180219115453
10.1039/c6cs00731g
10.1080/14756366.2020.1760262
10.4103/pm.pm_497_19
10.1155/2019/3640753
10.1016/j.taap.2018.11.009
10.1007/s12640-016-9648-y
10.3389/fnagi.2021.636653
10.4172/2161-0460.1000374
10.1161/01.str.28.7.1367
10.1016/j.neuroscience.2008.10.003
10.1016/j.neuint.2015.03.009
10.1007/s12017-016-8403-0
10.3164/jcbn.12-126
10.1007/s12975-013-0271-4
10.2203/dose-response.12-030.Wiegant
10.3389/fnagi.2019.00315
10.1002/jnr.23827
10.1007/s12035-020-01911-8
10.1186/s12974-020-01998-9
10.14283/jpad.2018.34
10.3389/fnins.2020.00157
10.1016/j.maturitas.2016.09.009
10.1212/01.wnl.0000276984.19542.e6
10.1212/WNL.0000000000003696
10.1016/j.regg.2021.04.005
10.2174/1570159X18666200123165652
10.1177/1533317520938585
10.1136/bmj.l665
10.1016/s0002-9378(98)70629-5
10.1111/j.1538-7836.2010.03839.x
10.1258/mi.2009.009018
10.1016/j.jsbmb.2014.01.016
10.1017/S0029665108007027
10.1002/ptr.4970
10.1016/j.jsbmb.2008.03.032
10.1016/j.ijbiomac.2018.06.190
10.1111/cns.12707
10.1021/acs.jmedchem.9b01970
10.2217/17455057.4.4.337
10.3390/antiox9070635
10.1523/JNEUROSCI.2382-06.2007
10.1371/journal.pone.0129880
10.1016/j.neuroscience.2004.12.027
10.1016/j.jchemneu.2016.05.005
10.1155/2020/7635291
10.1111/bph.13622
10.1007/s10571-019-00733-0
10.1111/bpa.12599
10.1196/annals.1347.016
10.1007/s10571-020-00859-6
10.1016/j.ijbiomac.2020.12.030
10.1089/jmf.2008.1069
10.1002/ptr.6560
10.4103/1673-5374.215260
10.3389/fnmol.2018.00059
10.1007/s12035-012-8310-9
10.3389/fnins.2019.00038
10.3389/fnins.2019.00062
10.1016/j.steroids.2017.11.005
10.1210/endo.131.3.1505465
10.1074/jbc.R109.080895
10.1017/S0029665117000404
10.3389/fcell.2019.00197
10.1080/14740338.2017.1351540",<Element 'PubmedArticle' at 0x7f05dd472ea0>
126,34508876,Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach.,"Alzheimer's disease (AD) includes a long asymptomatic stage, which precedes the formal diagnosis of dementia. AD biomarker models provide a framework for precision medicine approaches during this stage. However, such approaches have ignored the possible influence of sex on cognition and brain health, despite female sex noted as a major risk factor. Since AD-related changes may emerge in midlife, intervention efforts are being redirected around this period. Midlife coincides with several endocrinological changes, such as the menopausal transition experienced by women. In this narrative review, we discuss evidence for sex-differences in AD neuropathological burden and outline key endocrinological mechanisms for both sexes, focussing on hormonal events throughout the lifespan that may influence female susceptibility to AD neuropathology and dementia onset. We further consider common non-modifiable (genetic) and modifiable (lifestyle and health) risk factors, highlighting possible sex-dependent differential effects for the AD disease course. Finally, we evaluate the studies selected for this review demonstrating sex-differences in cognitive, pathological and health factors, summarising the state of sex differences in AD risk factors. We further provide recommendations for targeted research on female-specific risk factors, to inform personalised strategies for AD-prevention and the promotion of female brain health.","[""Alzheimer's disease"", 'Cognition', 'Risk factors', 'Sex hormones']",Ageing research reviews,2021-09-12,"[{'lastname': 'Udeh-Momoh', 'firstname': 'Chinedu', 'initials': 'C', 'affiliation': 'Ageing Epidemiology Research Unit, School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK; Translational Health Sciences, School of Clinical Sciences, University of Bristol, Bristol, UK. Electronic address: c.udeh@imperial.ac.uk.'}, {'lastname': 'Watermeyer', 'firstname': 'Tam', 'initials': 'T', 'affiliation': 'Department of Psychology, Faculty of Health and Life Sciences, Northumbria University, Newcastle, UK; Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. Electronic address: tamlyn.watermeyer@northumbria.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2021. Published by Elsevier B.V.,10.1016/j.arr.2021.101459,<Element 'PubmedArticle' at 0x7f05dece3220>
127,"34445515
12956285
16978590
28179809
25423896
32560398
29065927
15947175
28465157
23528478
19255502
28645930
27807199
29961863
27438106
16198847
8996300
31131389
24957921
27289011
26899494
23094720
23835257
24549549
28228467
29623299
25828301
25421165
30351414
16353438
12565061
17636302
23315605
27923804
26864458
27395082
16412224
27146694
23953257
21659634
12504811
19075634
17616482
26392434
18440994
26271031
8823008
26205295
22245795
24954242
23355885
8070496
12380933
25351109
11273990
12871825
14661166
26964804
11844293
9246386
25510382
27591113
29446769
25927318
21832998
27364648
25879880
32875057
28275198
19211488
26681727
30471324
10599770
23455986
28798261
11445258
12028245
27899749
25663222
12417368
22431153
10854354
15753114
19404548
29036816
15637449
15026494
11506541
24568942
29201811
32032361
16300856
15708630
29895246
24374381
7724690
7824953
22359372
25057823
21442040
12124914
16410199
16426865
11375910
8545497
17951075
28756758
20739645
27159875
24704273
29169013
23254630
29162363
27806705
20375505
30181149
570666
22863685
7936242
9099197
12215596
29934733
33922776
31442075
15246635
15246642
28498720
10356104
24095158
25309746
11158037
16846397
24610804
19143004
29808758
28786078
17084891
15114516
15262106
32985552
31685432
33611480
27053455
13679667
27076563
29759316
25461368
16827771
12423819
26252951
15024130
3379822
23417603
20453102
9236206
10385243
19351733
8640402
20592293
23605065
14551047
15764681
9259579
24794794
28652059
27737437
20672465
31876682
18222446
33281745
30653980
14573323
10644611
9445346
19223913
9689481
11744660
10625733
24246902
24106772
21673906
19458604
22581460
25280774
27884727
28419990
28202255
23211559
16511588
11955468
19473078
15637314
23284717
27052889
28988211
11113421
11942597
28487389
19460074
25037694
29149179
28801526
24271937
25205317
26007613
10453048
29846283
21280086
32007576
23348042",Revealing the Influences of Sex Hormones and Sex Differences in Atrial Fibrillation and Vascular Cognitive Impairment.,"The impacts of sex differences on the biology of various organ systems and the influences of sex hormones on modulating health and disease have become increasingly relevant in clinical and biomedical research. A growing body of evidence has recently suggested fundamental sex differences in cardiovascular and cognitive function, including anatomy, pathophysiology, incidence and age of disease onset, symptoms affecting disease diagnosis, disease severity, progression, and treatment responses and outcomes. Atrial fibrillation (AF) is currently recognized as the most prevalent sustained arrhythmia and might contribute to the pathogenesis and progression of vascular cognitive impairment (VCI), including a range of cognitive deficits, from mild cognitive impairment to dementia. In this review, we describe sex-based differences and sex hormone functions in the physiology of the brain and vasculature and the pathophysiology of disorders therein, with special emphasis on AF and VCI. Deciphering how sex hormones and their receptor signaling (estrogen and androgen receptors) potentially impact on sex differences could help to reveal disease links between AF and VCI and identify therapeutic targets that may lead to potentially novel therapeutic interventions early in the disease course of AF and VCI.","['androgen receptor', 'atrial fibrillation', 'estrogen receptor', 'sex differences', 'sex hormones', 'vascular cognitive impairment']",International journal of molecular sciences,2021-08-28,"[{'lastname': 'Chang', 'firstname': 'Ya-Ting', 'initials': 'YT', 'affiliation': 'Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.\nDepartment of Psychiatry, Osaka University Graduate School of Medicine, Suita 565-0871, Osaka, Japan.'}, {'lastname': 'Chen', 'firstname': 'Yung-Lung', 'initials': 'YL', 'affiliation': 'Section of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.\nGraduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.'}, {'lastname': 'Kang', 'firstname': 'Hong-Yo', 'initials': 'HY', 'affiliation': 'Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.\nCenter for Hormone and Reproductive Medicine Research, Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.'}]",,,,,"10.3390/ijms22168776
10.1016/j.brainres.2006.07.098
10.1038/nrn3856
10.3390/ijms21124314
10.1186/s13293-017-0152-8
10.1126/science.1112062
10.1016/j.jsbmb.2017.04.012
10.1530/JOE-13-0052
10.1159/000204096
10.1042/CS20170090
10.1152/physrev.00021.2015
10.1093/europace/euy067
10.1001/jamacardio.2016.0529
10.1016/j.jacc.2005.05.078
10.1016/S0735-1097(96)00454-8
10.1093/europace/euz141
10.1093/europace/euu155
10.1016/j.hrthm.2016.06.005
10.1016/j.amjcard.2016.01.040
10.1056/NEJMoa1113566
10.1016/j.hrthm.2013.07.002
10.1001/jama.2014.467
10.1136/heartjnl-2016-310406
10.1016/j.jacep.2016.04.014
10.1016/j.ijcard.2015.03.341
10.1038/nrcardio.2014.178
10.1093/europace/euy215
10.1080/10976640500295516
10.1053/euje.4.1.36
10.1093/europace/eum144
10.1055/s-0032-1332795
10.1161/CIRCEP.116.004378
10.1111/echo.13193
10.1016/j.cjca.2016.03.017
10.1186/1475-2840-5-1
10.1136/heartjnl-2015-308927
10.1016/j.ijcard.2013.07.183
10.1161/CIRCEP.111.961995
10.1016/S0008-6363(02)00673-9
10.2174/187152908786786160
10.1016/S1474-4422(07)70178-3
10.1093/eurheartj/ehv475
10.1113/jphysiol.2007.150367
10.1093/eurheartj/ehv371
10.1161/01.CIR.94.6.1471
10.1016/j.yjmcc.2015.07.013
10.1016/j.hrthm.2012.01.009
10.1016/j.hrthm.2014.06.023
10.1371/journal.pone.0054635
10.1093/eurheartj/15.suppl_A.9
10.1046/j.1540-8167.2002.00918.x
10.3233/JAD-141629
10.1161/01.CIR.103.12.1638
10.1038/sj.bjp.0705338
10.1016/S0022-0736(03)00078-5
10.1016/j.neubiorev.2016.03.007
10.1111/j.1542-474X.2001.tb00140.x
10.1046/j.1365-201X.1997.00142.x
10.1016/j.jalz.2014.10.008
10.1093/brain/aww214
10.1038/nrdp.2018.3
10.1186/s12883-014-0244-6
10.1038/hr.2011.118
10.1177/1545968316656054
10.1186/s12883-015-0288-2
10.1002/dad2.12090
10.1161/STROKEAHA.116.015913
10.1161/STROKEAHA.108.540781
10.2337/dc15-1588
10.1016/j.neuint.2018.11.014
10.1212/WNL.53.9.1992
10.3233/JAD-121819
10.1161/STROKEAHA.117.018187
10.1016/S0197-4580(01)00231-7
10.1046/j.1532-5415.2002.50006.x
10.1161/STROKEAHA.116.015242
10.1212/WNL.0000000000001331
10.1016/S0022-510X(02)00264-2
10.1093/ageing/afs040
10.1056/NEJMoa050613
10.3233/JAD-170221
10.1159/000082999
10.1136/jnnp.2003.010223
10.1006/nimg.2001.0857
10.1016/j.neubiorev.2014.02.005
10.5535/arm.2017.41.5.734
10.1371/journal.pone.0227820
10.1016/j.neurobiolaging.2005.10.004
10.1016/j.brainresrev.2004.08.006
10.2174/1567205015666180613111504
10.1016/j.neubiorev.2013.12.004
10.1037/0033-2909.117.2.250
10.1037/0033-2909.104.1.53
10.1126/science.7824953
10.1002/hbm.21514
10.1371/journal.pone.0103492
10.3389/fnsys.2011.00002
10.1002/ajpa.10092
10.1016/j.jocn.2005.02.013
10.1016/j.neuroimage.2005.11.042
10.1093/cercor/11.6.490
10.1016/0925-4927(95)02634-A
10.1016/j.neuroimage.2007.09.017
10.1177/1747493017724626
10.1212/WNL.0b013e3181f4d7f8
10.1210/er.2015-1137
10.1016/j.euroneuro.2014.03.002
10.1016/j.jalz.2017.09.016
10.3233/JAD-121228
10.1016/j.numecd.2017.10.001
10.1186/s12916-016-0725-0
10.1159/000285166
10.1503/cmaj.180066
10.1212/01.wnl.0000407150.80523.a4
10.1016/j.hrthm.2012.07.026
10.1212/WNL.44.10.1885
10.1161/01.STR.28.4.785
10.1161/01.STR.0000028235.91778.95
10.1007/s11357-018-0029-8
10.3390/diagnostics11050760
10.1161/CIRCEP.119.007197
10.1016/j.ehj.2004.04.014
10.1016/j.ehj.2004.04.007
10.1146/annurev-biochem-061516-045115
10.1161/01.STR.30.6.1223
10.1016/j.ijcard.2013.08.078
10.7243/2055-2394-1-1
10.1210/jcem.86.2.7219
10.1111/j.1742-1241.2006.00992.x
10.1161/CIRCEP.113.001322
10.1002/clc.20423
10.1177/2047487318778346
10.1007/s12020-017-1385-3
10.1016/j.ceca.2006.09.003
10.1016/S0140-6736(04)16678-6
10.1038/s41598-020-72678-0
10.1016/j.acvd.2019.09.006
10.1177/2047487320922927
10.1038/nrcardio.2016.45
10.1159/000073591
10.1161/JAHA.115.003182
10.1016/j.jacep.2015.04.013
10.1016/j.ejogrb.2014.10.042
10.1111/j.1471-0528.2006.00964.x
10.1097/00006250-200211001-00016
10.1073/pnas.0306948101
10.1016/S0021-5198(19)43326-X
10.1007/s00424-013-1233-0
10.1152/ajpheart.00299.2010
10.1085/jgp.110.2.135
10.1038/sj.bjp.0702576
10.1210/jc.2008-2416
10.1161/01.ATV.16.6.749
10.1056/NEJMoa1000485
10.1007/s00424-013-1267-3
10.1152/ajpheart.00663.2003
10.1152/ajpheart.00958.2004
10.1172/JCI119595
10.1007/s10571-014-0066-5
10.1016/j.jstrokecerebrovasdis.2017.05.041
10.1001/jamaoncol.2016.3662
10.1111/j.1532-5415.2010.02946.x
10.1097/WNR.0000000000001385
10.1016/j.yhbeh.2007.11.006
10.3389/fendo.2020.586909
10.1016/j.yhbeh.2019.01.002
10.1016/S0006-3223(03)00115-X
10.1152/ajpheart.2000.278.1.H290
10.1161/01.STR.29.1.159
10.1038/jcbfm.2009.5
10.1016/S0006-8993(98)00327-8
10.1152/jappl.2002.92.1.195
10.1161/01.STR.31.1.161
10.1016/j.neulet.2013.11.007
10.1186/1471-2202-14-118
10.3390/ijms12031533
10.1038/jcbfm.2009.66
10.1210/en.2011-1859
10.1016/j.toxlet.2014.09.024
10.1016/j.jsbmb.2016.11.018
10.1159/000475433
10.1016/j.brainres.2017.02.004
10.1016/j.neuroscience.2012.11.042
10.1172/JCI27987
10.1016/S0006-3223(01)01289-6
10.1089/gtmb.2008.0129
10.1161/01.STR.0000153795.38388.72
10.1371/journal.pone.0051580
10.1038/srep24132
10.1136/heartjnl-2016-311002
10.1016/S0002-9149(00)01251-0
10.1046/j.1540-8167.2002.00276.x
10.1161/JAHA.116.004880
10.1111/j.1540-8167.2009.01474.x
10.1016/j.ijcard.2014.06.054
10.1371/journal.pmed.1002445
10.1152/ajpheart.00383.2017
10.1007/s00520-013-2041-y
10.1016/j.yhbeh.2014.08.011
10.1038/nrendo.2015.82
10.1002/(SICI)1097-4695(19990915)40:4<446::AID-NEU3>3.0.CO;2-J
10.1097/GME.0000000000001140
10.1002/ana.22239
10.1016/j.lfs.2020.117388
10.1016/j.molmed.2012.12.007",<Element 'PubmedArticle' at 0x7f05decdbbd0>
128,34435519,Hyper-religiosity and visual hallucinations in a patient with frontotemporal dementia carrying a double variant in GRN gene.,,"['Frontotemporal dementia', 'brain MRI', 'hyper-religiosity', 'progranulin', 'visual hallucinations']",Amyotrophic lateral sclerosis & frontotemporal degeneration,2021-08-27,"[{'lastname': 'Morelli', 'firstname': 'Maurizio', 'initials': 'M', 'affiliation': 'Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy.\nNeuroscience Centre, Magna Graecia University, Catanzaro, Italy, and.'}, {'lastname': 'Quattrone', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy.'}, {'lastname': 'Arabia', 'firstname': 'Gennarina', 'initials': 'G', 'affiliation': 'Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy.'}, {'lastname': 'Manna', 'firstname': 'Ida', 'initials': 'I', 'affiliation': 'Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.'}, {'lastname': 'Gambardella', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Department of Medical and Surgical Sciences, Institute of Neurology, Magna Graecia University, Catanzaro, Italy.\nInstitute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.'}, {'lastname': 'Quattrone', 'firstname': 'Aldo', 'initials': 'A', 'affiliation': 'Neuroscience Centre, Magna Graecia University, Catanzaro, Italy, and.\nInstitute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy.'}]",,,,,10.1080/21678421.2021.1946087,<Element 'PubmedArticle' at 0x7f05dea15ef0>
129,"34384375
20107219
27019327
27641441
27912057
27814521
24370461
30775438
29051531
29302204
29962999
30700769
31434623
28176819
23852569
22699609
21034976
22968153
23000955
21750565
21303428
25118885
31235863
29808030
29039142
27634977
31488882
28530140
31559142
30191186
29035044
23023125
25437406
10599761
15750214
9811898
22637478
28120374
18936492
19222573
24021287
27687331
23719380
18624900
27271491
23044767
26296733
20368278
9153165
9566385
29674032
25895140
23719714
24753374
23044255
19494436
17517969
16461843
15381647
16007267
26284939
2175195
9759853
31332392
28266645
25376362
6610841
24613707
19349959
17343679
19004872
20383131
21702898
33467557
29969035
28143587",Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome.,"Gut microbiota (GMB) alteration has been reported to influence the Alzheimer's disease (AD) pathogenesis through immune, endocrine, and metabolic pathways. This study aims to investigate metabolic output of the dysbiosis of GMB in AD pathogenesis. In this study, the fecal microbiota and metabolome from 21 AD participants and 44 cognitively normal control participants were measured. Untargeted GMB taxa was analyzed through 16S ribosomal RNA gene profiling based on next-generation sequencing and fecal metabolites were quantified by using ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS).
Our analysis revealed that AD was characterized by 15 altered gut bacterial genera, of which 46.7% (7/15 general) was significantly associated with a series of metabolite markers. The predicted metabolic profile of altered gut microbial composition included steroid hormone biosynthesis, N-Acyl amino acid metabolism and piperidine metabolism. Moreover, a combination of 2 gut bacterial genera (Faecalibacterium and Pseudomonas) and 4 metabolites (N-Docosahexaenoyl GABA, 19-Oxoandrost-4-ene-3,17-dione, Trigofoenoside F and 22-Angeloylbarringtogenol C) was able to discriminate AD from NC with AUC of 0.955 in these 65 subjects.
These findings demonstrate that gut microbial alterations and related metabolic output changes may be associated with pathogenesis of AD, and suggest that fecal markers might be used as a non-invasive examination to assist screening and diagnosis of AD.","['Alzheimer’s disease', 'Fecal markers', 'Fecal metabolome', 'Gut microbiota', 'Inflammatory cytokines']",BMC microbiology,2021-08-14,"[{'lastname': 'Xi', 'firstname': 'Jianxiong', 'initials': 'J', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Ding', 'firstname': 'Ding', 'initials': 'D', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China. dingding@huashan.org.cn.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China. dingding@huashan.org.cn.'}, {'lastname': 'Zhu', 'firstname': 'Huiwei', 'initials': 'H', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Wang', 'firstname': 'Ruru', 'initials': 'R', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Su', 'firstname': 'Feng', 'initials': 'F', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Wu', 'firstname': 'Wanqing', 'initials': 'W', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China.'}, {'lastname': 'Xiao', 'firstname': 'Zhenxu', 'initials': 'Z', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China.'}, {'lastname': 'Liang', 'firstname': 'Xiaoniu', 'initials': 'X', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China.'}, {'lastname': 'Zhao', 'firstname': 'Qianhua', 'initials': 'Q', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China.'}, {'lastname': 'Hong', 'firstname': 'Zhen', 'initials': 'Z', 'affiliation': 'Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.\nNational Clinical Research Center for Aging Diseases, Shanghai, 200040, China.'}, {'lastname': 'Fu', 'firstname': 'Hua', 'initials': 'H', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Xiao', 'firstname': 'Qianyi', 'initials': 'Q', 'affiliation': 'Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai, 200032, China. xiaoqianyi@fudan.edu.cn.'}]",,,"Our analysis revealed that AD was characterized by 15 altered gut bacterial genera, of which 46.7% (7/15 general) was significantly associated with a series of metabolite markers. The predicted metabolic profile of altered gut microbial composition included steroid hormone biosynthesis, N-Acyl amino acid metabolism and piperidine metabolism. Moreover, a combination of 2 gut bacterial genera (Faecalibacterium and Pseudomonas) and 4 metabolites (N-Docosahexaenoyl GABA, 19-Oxoandrost-4-ene-3,17-dione, Trigofoenoside F and 22-Angeloylbarringtogenol C) was able to discriminate AD from NC with AUC of 0.955 in these 65 subjects.",© 2021. The Author(s).,"10.1186/s12866-021-02286-z
10.1056/NEJMra0909142
10.1038/nm.4068
10.1113/JP273106
10.1016/j.cell.2016.11.018
10.1016/j.cell.2016.10.027
10.1016/j.bbi.2013.12.015
10.1038/s41598-017-13601-y
10.5607/en.2017.26.6.369
10.3389/fneur.2018.00412
10.1016/j.jalz.2019.07.002
10.1038/srep41802
10.1007/s11894-013-0337-1
10.1038/nature11234
10.1016/B978-0-12-381300-8.00008-3
10.1038/nrn3346
10.1038/nrmicro2876
10.1038/nrn3071
10.1111/j.1365-2982.2010.01664.x
10.1038/nrmicro3330
10.1038/s41598-019-45592-3
10.1038/s41588-018-0135-7
10.1007/s11910-017-0802-6
10.1093/nutrit/nuw023
10.1038/s41422-019-0216-x
10.1164/rccm.201701-0071OC
10.1002/advs.201901441
10.1016/j.tjem.2018.08.001
10.1021/acs.chemrestox.7b00162
10.1038/nature11450
10.7326/M14-0737
10.1212/WNL.53.9.1937
10.3233/JAD-2005-7106
10.1073/pnas.95.23.13899
10.1074/jbc.M111.301440
10.1111/mpp.12539
10.1073/pnas.0804812105
10.1111/j.1574-6968.2009.01514.x
10.1136/gutjnl-2013-304833
10.1080/00365521.2016.1216587
10.1038/nature12198
10.1111/j.1440-1746.2008.05490.x
10.1097/MIB.0000000000000776
10.1038/ajg.2012.335
10.1128/AEM.02006-15
10.4049/jimmunol.0903382
10.1212/WNL.48.5_Suppl_7.36S
10.1212/WNL.50.4.996
10.1016/j.talanta.2018.03.002
10.1007/s00204-015-1517-6
10.1039/c3fo60094g
10.1002/biof.1166
10.1016/j.ab.2012.09.031
10.3233/JAD-2009-1017
10.1084/jem.20062481
10.1161/CIRCULATIONAHA.105.563668
10.1161/01.CIR.0000142616.07367.66
10.1172/JCI23559
10.1038/ncomms8967
10.1089/vim.1990.3.225
10.1038/s41591-019-0509-0
10.1038/srep44182
10.1159/000366163
10.1212/WNL.34.7.939
10.1016/j.jalz.2013.11.002
10.1038/nature07940
10.1111/j.1574-6941.2007.00283.x
10.1093/nar/gkn879
10.1038/nmeth.f.303
10.1890/0012-9658(2001)082[0290:FMMTCD]2.0.CO;2
10.1186/gb-2011-12-6-r60
10.3390/ijerph18020710
10.1021/acs.jproteome.8b00190
10.1186/s40168-016-0209-7",<Element 'PubmedArticle' at 0x7f05dea0b860>
130,34378892,[From glioblastoma to COVID-19 – role of oxysterols in the human organism].,"Cholesterol is a precursor molecule for vitamin D, bile acids, and steroid hormones. Its oxidized forms, called oxysterols are by-products for synthesis, but also regulate cholesterolâs metabolism through different cell receptors. Cholesterol and oxysterols are important cell membrane components. Oxysterols show more biological activity than cholesterol itself, due to their pleiotropic cell effects. Oxysterol, contrary to cholesterol can cross the blood-brain barier and influence the nervous system. The etiology and pathogenesis of cancer can also be influenced by oxysterols. Elevated levels of oxysterol is often observed in many pathological state: diabetes, atherosclerosis, dementia, or endometriosis. Cholesterolâs oxidized forms can regulate immunity by activation or suppression of the immune cell during virus infection and inflammation.
Cholesterol jest prekursorem w syntezie witaminy D, kwasów żółciowych i hormonów sterydowych. Jego utlenione formy zwane oksysterolami są produktem pośrednim w syntezach, ale także regulują metabolizmem cholesterolu poprzez oddziaływanie na receptory komórkowe. Cholesterol jest ważnym składnikiem błon komórkowych. Oksysterole wykazują większą aktywność biologiczną niż sam cholesterol, mając działanie plejotropowe na różne typy komórek organizmu wywołują często przeciwstawne efekty. Oksysterole w przeciwieństwie do cholesterolu mogą przenikać barierę krew-mózg i wpływać na działanie układu nerwowego. Utlenione formy cholesterolu mogą oddziaływać na etiopatogenezę chorób nowotworowych. Podwyższony poziom oksysteroli w tkankach często towarzyszy wielu stanom patologicznym: jak cukrzyca, miażdżyca, demencja lub endometrioza. Utlenione formy cholesterolu mogą hamować lub aktywować różne komórki układu odpornościowego regulując procesami odpowiedzi immunologicznej w przebiegu chorób wirusowych i zapalnych.",[],Postepy biochemii,2021-08-12,"[{'lastname': 'Gonet-Surówka', 'firstname': 'Agnieszka', 'initials': 'A', 'affiliation': 'Wydział Chemii UJ. agnieszka.gonet-surowka@uj.edu.pl.'}, {'lastname': 'Dynarowicz-Łątka', 'firstname': 'Patrycja', 'initials': 'P', 'affiliation': '. agnieszka.gonet-surowka@uj.edu.pl.'}]",,,,,10.18388/pb.2021_379,<Element 'PubmedArticle' at 0x7f05ded13d10>
131,"34313292
12942175
23337872
9223292
7961799
14767490
17660321
19796805
9398206
19741169
22404938
20483339
19260715
20100601
21454575
18408164
15385542
15722360
11731221
12298020
24817693
26526393
22579281
18370402
19916492
26406374
28819146
29472250
32414928
26317470
23455423
27535008
6754085
11179900
10679465
10620277
15362105
22988239
11943202
11751863
19748895
23922768
29650702
29298433
8527678
22930834
22743772
18573087
31506351
18252208
21563783
21249221
16241805
30061688
15937275
3783684
18579777
12700355
18665616
30791483
30498217
22787008
24015785",The kinetics of islet amyloid polypeptide phase-separated system and hydrogel formation are critically influenced by macromolecular crowding.,"Many protein misfolding diseases (e.g. type II diabetes and Alzheimer's disease) are characterised by amyloid deposition. Human islet amyloid polypeptide (hIAPP, involved in type II diabetes) spontaneously undergoes liquid-liquid phase separation (LLPS) and a kinetically complex hydrogelation, both catalysed by hydrophobic-hydrophilic interfaces (e.g. air-water interface and/or phospholipids-water interfaces). Gelation of hIAPP phase-separated liquid droplets initiates amyloid aggregation and the formation of clusters of interconnected aggregates, which grow and fuse to eventually percolate the whole system. Droplet maturation into irreversible hydrogels via amyloid aggregation is thought to be behind the pathology of several diseases. Biological fluids contain a high volume fraction of macromolecules, leading to macromolecular crowding. Despite crowding agent addition in in vitro studies playing a significant role in changing protein phase diagrams, the mechanism underlying enhanced LLPS, and the effect(s) on stages beyond LLPS remain poorly or not characterised.We investigated the effect of macromolecular crowding and increased viscosity on the kinetics of hIAPP hydrogelation using rheology and the evolution of the system beyond LLPS by microscopy. We demonstrate that increased viscosity exacerbated the kinetic variability of hydrogelation and of the phase separated-aggregated system, whereas macromolecular crowding abolished heterogeneity. Increased viscosity also strengthened the gel meshwork and accelerated aggregate cluster fusion. In contrast, crowding either delayed cluster fusion onset (dextran) or promoted it (Ficoll). Our study highlights that an in vivo crowded environment would critically influence amyloid stages beyond LLPS and pathogenesis.","['IAPP', 'amyloid', 'gelation', 'macromolecular crowding', 'phase separation']",The Biochemical journal,2021-07-28,"[{'lastname': 'Pytowski', 'firstname': 'Lior', 'initials': 'L', 'affiliation': 'Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, U.K.'}, {'lastname': 'Vaux', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, U.K.'}, {'lastname': 'Jean', 'firstname': 'Létitia', 'initials': 'L', 'affiliation': 'Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, U.K.'}]",,,,© 2021 The Author(s).,"10.1042/BCJ20210384
10.1007/s00109-003-0464-5
10.1016/j.febslet.2013.01.017
10.1073/pnas.94.15.7942
10.1016/S0021-9258(19)61939-3
10.1038/labinvest.3700054
10.1529/biophysj.107.110635
10.1016/j.biomaterials.2009.09.005
10.1021/la035308t
10.1021/bi971843e
10.1096/fj.09-137653
10.1016/j.bpj.2012.01.041
10.1016/j.bpj.2010.01.056
10.1021/jp8085792
10.1016/j.bbapap.2010.01.012
10.1074/jbc.M110.214197
10.1073/pnas.0708354105
10.1074/jbc.C400260200
10.1074/jbc.M500997200
10.1016/S0925-4439(01)00078-3
10.1002/1521-3765(20020916)8:18<4285::AID-CHEM4285>3.0.CO;2-0
10.1073/pnas.1315346111
10.1016/j.neuron.2015.10.030
10.1016/j.cell.2012.04.017
10.1021/bi8000616
10.1021/la903340v
10.1016/j.cell.2015.09.015
10.1038/s41467-017-00480-0
10.15252/embj.201798049
10.1073/pnas.1916716117
10.1016/j.cell.2015.07.047
10.1038/nature11922
10.1038/srep32124
10.1016/0092-8674(82)90231-8
10.1016/S0959-440X(00)00172-X
10.1016/S0959-440X(99)00045-7
10.1016/S0006-3495(00)76576-3
10.1002/jmr.699
10.1074/jbc.M112.400580
10.1016/S0014-5793(02)02446-8
10.1074/jbc.M110429200
10.1074/jbc.M109.002832
10.1371/journal.pone.0069652
10.1126/science.aar7366
10.1016/j.celrep.2017.12.036
10.1016/S0006-3495(95)79940-4
10.1038/nmeth.2089
10.1038/nmeth.2019
10.1146/annurev.biophys.37.032807.125817
10.1021/acs.macromol.8b02476
10.1073/pnas.1907849116
10.1016/j.bbapap.2008.01.004
10.1021/jp201877d
10.1371/journal.pone.0015608
10.1063/1.2781603
10.1103/PhysRevLett.95.164503
10.1038/s41467-018-05403-1
10.1110/ps.041266605
10.1016/0022-2836(86)90324-4
10.1073/pnas.0711664105
10.1073/pnas.0835307100
10.1021/bi8008399
10.3390/biom9020071
10.1038/s41467-018-07530-1
10.1098/rsif.2012.0368
10.1016/j.eurpolymj.2018.10.010
10.1042/BJ20130605",<Element 'PubmedArticle' at 0x7f05ded09770>
132,"34311759
30147722
22178787
31604107
32552864
17804962
33430419
28527218
27583652
19196745
28578785
24418360
32646017
17353226
33312335
30661858
31072403
30866655
29125115
20851172
30605907
25859241
23636330
19890493
23727128
30319538
26007613
22289042
22451324
25159676
21694454
23822747
29273352
31149181
15380141
4734160
27579037
30515996
29932397
32584004
29564739
26031357
23089633
31593698
18430994
16634983
14752302
17037948
26517932
32590339
21346761
18537700
31641124
31417349
16823473
21443795
27988872
32962205
31420039
23900753
31654430
12840187
28504110
18779278
24070815
11440311
12505419
15555488
29377005
25188896
30994836
30763274
11238505
21890115
18599386
19955752
24246334
19255602
22264851
30147722
31516314
24945655
28890168
19779148
24136970
30014344
28179129
26680599
27176073
33113105
30513089
29574473
29094433
29577107
25203615
25673992
25098535
27176073
28860512
31733195
24945113
19249030
19279045
18729532
26866639
28941188
33139661
7195404
31525346
19403562
21644052
27233760
28104402
31486807
10946879
28589443
28203479
27929271",Investigation of common risk factors between polycystic ovary syndrome and Alzheimer's disease: a narrative review.,"The most common endocrine and metabolic disorders in premenopausal women is polycystic ovary syndrome (PCOS), characterized by hyperandrogenism, chronic anovulation, and/or ultrasound evidence of small ovarian cysts. Obesity and insulin resistance are also the main factors influencing the clinical manifestations of this syndrome. Alzheimer's disease (AD) is the most typical progressive neurodegenerative disorder of the brain, and recent studies suggest a relationship between endocrinal dysregulation and neuronal loss during AD pathology.
This study aimed to evaluate the common risk factors for Alzheimer's and PCOS based on previous studies. Knowing the common risk factors and eliminating them may prevent neurodegenerative Alzheimer's disease in the future.
In this narrative review, international databases, including Google Scholar, Scopus, PubMed, and the Web of Science, were searched to retrieve the relevant studies. The relevant studies' summaries were categorized to discuss the possible pathways that may explain the association between Alzheimer's and PCOS signs/symptoms and complications.
According to our research, the factors involved in Alzheimer's and PCOS disorders may share some common risk factors. In patients with PCOS, increased LH to FSH ratio, decreased vitamin D, insulin resistance, and obesity are some of the most important factors that may increase the risk of Alzheimer's disease.
Polycystic ovary syndrome is a disorder of the female reproductive system that can be caused by hormonal disorders. The disease is detected by an ultrasound of the ovaries with small ovarian cysts. Obesity and insulin resistance are among the factors that can affect the clinical symptoms of this disease. Obesity due to high-fat consumption can affect cognitive functions with age. Alzheimer’s is the most common disease associated with disorders in brain cells; a link between hormonal disorders and Alzheimer’s has recently been reported. We conducted a review of reports and articles published in connection with polycystic ovary syndrome and neurodegenerative disorders in reputable scientific databases. Studies have shown that the factors involved in polycystic ovary syndrome and Alzheimer’s disease may indicate that both diseases have common risk factors. It may be linked to the symptoms and/or complications of Alzheimer’s disease and polycystic ovary syndrome. Future preclinical studies are needed to closely examine the mechanisms associated with polycystic ovary syndrome and the association with Alzheimer’s. The novelty of our study is from the fact that the PCOS may be to some extent considered as a cause (exposure) among others of AD’s (outcome) and the association might be confounded by some or all the risk factors assessed in this review. The nature of the method—the narrative review—is relatively subjective (in the determination of which studies to include, the way the studies are analyzed, and the conclusions drawn) and hence may not help mitigate bias.","['Alzheimer disease', 'Hyperandrogenism', 'Insulin resistance', 'Polycystic ovary syndrome', 'Review']",Reproductive health,2021-07-28,"[{'lastname': 'Sarahian', 'firstname': 'Nahid', 'initials': 'N', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Sarvazad', 'firstname': 'Hosna', 'initials': 'H', 'affiliation': 'Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'lastname': 'Sajadi', 'firstname': 'Elham', 'initials': 'E', 'affiliation': 'Department of Basic Science, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.'}, {'lastname': 'Rahnejat', 'firstname': 'Nasrin', 'initials': 'N', 'affiliation': 'Faculty of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'lastname': 'Eskandari Roozbahani', 'firstname': 'Narges', 'initials': 'N', 'affiliation': 'Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. neskandari32@gmail.com.'}]","In this narrative review, international databases, including Google Scholar, Scopus, PubMed, and the Web of Science, were searched to retrieve the relevant studies. The relevant studies' summaries were categorized to discuss the possible pathways that may explain the association between Alzheimer's and PCOS signs/symptoms and complications.",,"According to our research, the factors involved in Alzheimer's and PCOS disorders may share some common risk factors. In patients with PCOS, increased LH to FSH ratio, decreased vitamin D, insulin resistance, and obesity are some of the most important factors that may increase the risk of Alzheimer's disease.","© 2021. The Author(s).
© 2021. The Author(s).","10.1186/s12978-021-01203-x
10.1155/2018/1349868
10.1016/j.steroids.2011.12.003
10.1016/j.lfs.2019.116940
10.1186/s13048-020-00670-3
10.1097/WAD.0b013e31813e89d5
10.3390/ijms22020546
10.3233/JAD-170188
10.1016/j.jalz.2016.07.150
10.1136/bmj.b158
10.1016/j.mce.2013.12.018
10.3390/ijms21134812
10.1155/2020/2638130
10.1016/S1474-4422(18)30450-2
10.1186/s12929-019-0524-y
10.1096/fj.201802653RR
10.1016/j.exger.2010.09.007
10.1159/000495521
10.3389/fendo.2015.00045
10.1038/nature12143
10.1177/1756285608100427
10.1016/j.jsbmb.2013.05.010
10.3389/fendo.2018.00544
10.1038/nrendo.2015.82
10.1037/a0026708
10.3233/JAD-2012-120283
10.3233/JAD-141875
10.3233/JAD-2011-110341
10.1111/jne.12070
10.1016/j.ygcen.2017.12.007
10.4183/aeb.2017.237
10.1016/j.bpobgyn.2004.05.004
10.7326/0003-4819-78-1-39
10.1155/2016/6306410
10.1111/andr.12567
10.1007/s10815-018-1162-0
10.1016/j.yhbeh.2015.05.010
10.1038/mp.2012.147
10.1016/j.yhbeh.2019.104590
10.3233/JAD-2008-13304
10.1111/j.1463-1326.2005.00521.x
10.1097/01.OGX.0000109523.25076.E2
10.2165/00148581-200608050-00004
10.1042/BST20150115
10.1530/JOE-20-0155
10.1038/nature09867
10.2174/187153008784534367
10.1038/s41467-019-12793-3
10.3389/fnins.2019.00788
10.1172/JCI29063
10.1186/1756-6606-4-13
10.1007/s40265-016-0674-0
10.3390/jcm9093024
10.1186/s12958-019-0509-4
10.1093/molehr/gat051
10.1111/imcb.12301
10.1093/jn/133.7.2244
10.1016/S1474-4422(17)30084-4
10.1093/ajcn/88.3.638
10.1016/j.ejphar.2013.08.008
10.1080/bih.76.2.97.106
10.1006/nbdi.2002.0538
10.1016/S1543-5946(04)90017-7
10.1097/YCO.0000000000000106
10.1590/1806-9282.65.3.375
10.1530/EJE-18-0693
10.1016/j.brainres.2011.07.060
10.1016/j.resp.2008.06.006
10.1159/000262524
10.4158/EP12366.OR
10.1016/j.jsmc.2007.11.001
10.1016/j.fertnstert.2011.12.024
10.1155/2018/1349868
10.1177/1179558119871269
10.1371/journal.pone.0100421
10.1016/j.smrv.2017.06.010
10.1126/science.1180962
10.1126/science.1241224
10.1007/s11910-018-0868-9
10.1016/j.neubiorev.2017.01.032
10.1002/gps.4406
10.3233/JAD-150943
10.1007/s43032-020-00369-2
10.1371/journal.pone.0204748
10.18544/PEDM-23.04.0094
10.1111/jog.13516
10.1210/js.2018-00015
10.3109/13697137.2014.949232
10.2147/NDT.S75546
10.1212/WNL.0000000000000755
10.3233/JAD-150943
10.1038/s41598-017-09880-0
10.1016/j.cca.2019.11.003
10.1016/j.steroids.2014.06.005
10.1016/j.fertnstert.2008.12.138
10.1093/humupd/dmp008
10.2165/00003495-200868130-00001
10.1097/MED.0000000000000245
10.1111/cns.12757
10.3390/ijms21218191
10.1210/jcem-53-1-58
10.1016/j.cca.2019.09.010
10.1093/humrep/dep113
10.1007/7854_2011_136
10.1016/j.fertnstert.2016.05.003
10.1016/j.ajog.2017.01.003
10.1093/hropen/hoy021
10.1210/jcem.85.8.6738
10.1007/s11095-017-2199-y
10.14336/AD.2016.1010",<Element 'PubmedArticle' at 0x7f05df833040>
133,"34298984
12540909
13054692
29727582
29475564
29307592
17682831
27891070
1749579
30120418
20828831
20626335
34099360
15728838
27069541
8853085
31714483
9580630
11113590
7903191
10837822
15261107
23221863
11489269
23442092
7595503
32712627
20504637
8720689
8787136
33748200
3146779
27316344
33519395
10845072
32038164
26790349
21295057
22717696
2890403
229514
25716845
33589583
29552726
26843180
33035532
25633602
28652219
33190318
28646018
32891188
21757762
31941827
25404298
17115048
1705151
11007727
12860778
24955552
9136253
17224716
8854297
18480686
24021498
18591575
28945120
24971004
12928714
12019347
32579500
14715451
17434919
26808441
29593511
31289857
21210839
17277774
30181587
31079238
4116781
33128416
21098808
29873961
24727402
27622970
33310541",Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer's Disease.,"While much of biomedical research since the middle of the twentieth century has focused on molecular pathways inside the cell, there is increasing evidence that extracellular signaling pathways are also critically important in health and disease. The neuromodulators norepinephrine (NE), serotonin (5-hydroxytryptamine, 5HT), dopamine (DA), acetylcholine (ACH), and melatonin (MT) are extracellular signaling molecules that are distributed throughout the brain and modulate many disease processes. The effects of these five neuromodulators on Alzheimer's disease (AD) are briefly examined in this paper, and it is hypothesized that each of the five molecules has a u-shaped (or Janus-faced) dose-response curve, wherein too little or too much signaling is pathological in AD and possibly other diseases. In particular it is suggested that NE is largely functionally opposed to 5HT, ACH, MT, and possibly DA in AD. In this scenario, physiological ""balance"" between the noradrenergic tone and that of the other three or four modulators is most healthy. If NE is largely functionally opposed to other prominent neuromodulators in AD, this may suggest novel combinations of pharmacological agents to counteract this disease. It is also suggested that the ","['cholinesterase inhibitors', 'clonidine', 'cognitive impairment', 'dementia', 'guanfacine', 'locus coeruleus', 'neurodegeneration', 'noradrenaline', 'prazosin', 'propranolol', 'terazosin']",International journal of molecular sciences,2021-07-25,"[{'lastname': 'Fitzgerald', 'firstname': 'Paul J', 'initials': 'PJ', 'affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA.'}]",,,,,"10.3390/ijms22147364
10.1038/nature01399
10.1038/171737a0
10.1146/annurev-biochem-060614-033923
10.1016/j.tins.2018.01.010
10.1016/j.brainres.2018.01.001
10.1007/s10552-007-9045-1
10.3389/fnins.2016.00492
10.1159/000226978
10.1038/s41380-018-0219-x
10.1016/j.jad.2010.08.009
10.2174/156720510792231775
10.1016/j.semcdb.2021.05.013
10.1523/JNEUROSCI.4307-04.2005
10.1097/00000542-199609000-00014
10.1097/WNR.0000000000001366
10.1016/S0361-9230(00)00353-1
10.1111/j.1460-9568.1993.tb00540.x
10.1016/S0006-8993(00)02298-8
10.1016/j.brainres.2004.05.027
10.1097/ALN.0b013e318277a81c
10.1016/S0006-8993(01)02653-1
10.1111/ejn.12160
10.1046/j.1471-4159.1995.65052165.x
10.1038/s41398-020-00928-w
10.1016/0197-0186(90)90019-P
10.1159/000109446
10.1016/0166-2236(96)81862-5
10.3389/fcvm.2021.652634
10.1007/BF00216074
10.1016/j.bbr.2016.06.022
10.3389/fnbeh.2020.620119
10.1146/annurev.neuro.23.1.473
10.3389/fnmol.2019.00334
10.1016/j.brainres.2016.01.005
10.1016/j.pbb.2011.01.020
10.1007/s11064-012-0818-x
10.1016/0006-8993(87)90094-1
10.1016/S0079-6123(08)64638-5
10.1523/JNEUROSCI.4525-13.2015
10.1038/s41398-020-01171-z
10.1007/s12035-018-1004-1
10.1124/mol.115.101808
10.1016/j.neuropharm.2020.108352
10.1007/s00401-015-1392-5
10.1016/j.brainres.2017.06.023
10.1111/ejn.15045
10.1096/fj.201700346R
10.1016/j.neuron.2020.08.011
10.1074/jbc.M111.244335
10.1126/scitranslmed.aay6931
10.1073/pnas.1409513111
10.1038/nm1485
10.1192/bjp.157.6.894
10.1176/appi.ajp.157.10.1686
10.1001/archpsyc.60.7.737
10.1055/s-0034-1377041
10.1016/S0033-3182(97)71461-0
10.1097/JCP.0b013e31802e0002
10.1097/JCP.0b013e318172b479
10.4088/JCP.12m08099
10.1097/JGP.0b013e318170a6d1
10.1176/appi.ajp.2017.17030316
10.2147/CIA.S65625
10.1272/jnms.70.334
10.2174/1567205017666200624201356
10.1007/BF03033152
10.1093/cercor/bhm033
10.1016/j.nlm.2016.01.009
10.3389/fnbeh.2018.00043
10.1007/s00210-019-01684-5
10.1111/j.1600-079X.2010.00839.x
10.1038/nn1846
10.1038/s41398-018-0239-y
10.1007/s00221-019-05556-5
10.1016/S0140-6736(72)93021-8
10.1002/hbm.25264
10.3758/CABN.10.4.470
10.4088/JCP.18f12351
10.1016/j.pbb.2014.04.001
10.1016/j.parkreldis.2016.09.004
10.1016/j.cortex.2020.10.021",<Element 'PubmedArticle' at 0x7f05dd9f77c0>
134,"34227023
23305823
24470773
33756057
15068977
29985474
29907423
30571227
33028606
26667417
31023435
26801467
30333106
26908863
33380500
31350162
32145044
28094840
32573980
16785602
27377060
30060670
30021919
26926956
31603514
30779636
32581769
17321422
32396982
30923235
31561818
27996108
18947934
29489847
24064221
32112728
19939362
11323317
29994973
29643079
12724456
15808925
31613825
11255424
15633582
26122296
22994984
26444784
23246919
21185655
28650869
9496988
15213206
12771112
30842090
23715379
28898378
26035291
23797469
27421538
28274328
30842086
27906568
32497876
17761551
24336141
30334074
32520734
32580974
18774188
33854369
15800139
26537053
33150798
26007613
24012626
23676633
27338648
24496085
31455107
17194963
18562950
33110036
15673636
20442205
33071945
29390899
32585222
26057822
31863110
19470968
24508665
27054925
22067716
27693001
22692332
12028247
11255424
27183047
20689282
24802975
30326011
18815889
31516689
31606366",A Lifecourse Perspective on Female Sex-Specific Risk Factors for Later Life Cognition.,"The prevalence of Alzheimer's disease and related dementias is greater in women compared to men. We provide a review of female sex-specific risk factors across the lifecourse for cognition in older adulthood, highlighting areas that need further study.
Pregnancy may affect late-life cognition, with adverse pregnancy outcomes associated with an increased risk of cognitive decline but parity providing a protective effect. Cumulative estrogen exposure, influenced by age of menarche, menopause, and exogenous estrogen use, may modify a woman's risk for dementia. Menopause transition-associated symptoms may impact cognitive health at the time of the symptoms, but long-term effects remain unknown. As compared to natural menopause, surgical menopause seems to increase the risk for cognitive impairment. Studies that have assessed the association between women's reproductive health and cognition have produced conflicting results. Future studies that address these inconsistencies among diverse populations are needed to better care for women throughout their lives.","['Alzheimer’s disease', 'Dementia', 'Reproductive health', 'Risk factors', 'Sex', 'Women']",Current neurology and neuroscience reports,2021-07-07,"[{'lastname': 'Peterson', 'firstname': 'Amalia', 'initials': 'A', 'affiliation': 'Department of Neurology, College of Physicians and Surgeons, Columbia University, 622 W. 168th Street, New York, NY, 10032, USA. ajp2260@cumc.columbia.edu.'}, {'lastname': 'Tom', 'firstname': 'Sarah E', 'initials': 'SE', 'affiliation': 'Department of Neurology, College of Physicians and Surgeons, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.'}]",,,,,10.1007/s11910-021-01133-y,<Element 'PubmedArticle' at 0x7f05dc6bb4a0>
135,"34215708
24094295
24940051
19424767
27261160
27957701
28955705
19249160
31396033
21788499
2070776
32971258
23720292
32815190
32103064
32210785
15099151
9777473
1543577
19506003
24399138
30819148
26673129
29284238
21798044
25372399
31948261
32321436
21163541
25174686
32218729
25160649
32598489
23891367
23888111
29859364
25462902
22153978
28377990
10195112","[Influences of Autonomic Function, Salivary Cortisol and Physical Activity on Cognitive Functions in Institutionalized Older Adults with Mild Cognitive Impairment: Based on Neurovisceral Integration Model].","This study aimed to investigate objectively measured physical activity (PA) in institutionalized older adults with mild cognitive impairment (MCI) and to elucidate the influence of autonomic nervous function, salivary cortisol, and PA on cognitive functions based on neurovisceral integration model.
Overall cognitive function was evaluated using the mini-mental state examination (MMSE) and executive function was evaluated using semantic verbal fluency test and clock drawing test. Actigraph for PA, HRV and sAA for autonomous function, and the geriatric depression scale for depression were used. Saliva specimens were collected in the morning for sAA and cortisol.
Ninety-eight older adults from four regional geriatric hospitals participated in the study. They took 4,499 steps per day on average. They spent 753.93 minutes and 23.12 minutes on average in sedentary and moderate-to-vigorous activity, respectively. In the multiple regression analysis, lower salivary cortisol level (β = - .33, 
Salivary cortisol, sAA and physical activity were significantly associated with cognitive functions. To prevent older adults from developing dementia, strategies are needed to increase their overall PA amount by decreasing sedentary time and to decrease salivary cortisol for cognitive function, and to maintain their sympathetic nervous activity for executive function.","['Autonomic Nervous System', 'Cognitive Dysfunction', 'Cortisol', 'Salivary alpha-Amylases', 'Sedentary Behavior']",Journal of Korean Academy of Nursing,2021-07-04,"[{'lastname': 'Suh', 'firstname': 'Minhee', 'initials': 'M', 'affiliation': 'Department of Nursing, College of Medicine, Inha University, Incheon, Korea. mhsuh@inha.ac.kr.'}]",,"Salivary cortisol, sAA and physical activity were significantly associated with cognitive functions. To prevent older adults from developing dementia, strategies are needed to increase their overall PA amount by decreasing sedentary time and to decrease salivary cortisol for cognitive function, and to maintain their sympathetic nervous activity for executive function.","Ninety-eight older adults from four regional geriatric hospitals participated in the study. They took 4,499 steps per day on average. They spent 753.93 minutes and 23.12 minutes on average in sedentary and moderate-to-vigorous activity, respectively. In the multiple regression analysis, lower salivary cortisol level (β = - .33, ",© 2021 Korean Society of Nursing Science.,10.4040/jkan.20282,<Element 'PubmedArticle' at 0x7f05dc60a3b0>
136,"34183019
29614878
30704681
27179961
28157094
31487775
26286145
26509334
30131755
28476157
21891870
32510331
6940133
6954532
31054361
18461449
25470401
20536472
27450729
30405628
27044335
17409235
27449092
22847556
25586141
26064215
33136892
28892027
30535688
31273711
21808223
30535682
30010645
30535683
25867960
29246456
25598354
29939190
29038483
22520439
26431692
18295562
23407936
31392674
28099414
31585084
30359599
28521126
30381423
17270176
29926672
30266970
19559767
19491240
11273004
30341179
31617375
20405578
23555730
23252647
31093687
28923083
17184520
31698022
24937047
17495247
31472195
23075524
26363149
26654366
26241337
11516773
28384498
29286104
31781286
19943905
30031930
27255539
23596391
32143008
17254567
21343177
29954581
30063850",Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice.,"Thymosin β4 (Tβ4) is the most abundant member of the β-thymosins and plays an important role in the control of actin polymerization in eukaryotic cells. While its effects in multiple organs and diseases are being widely investigated, the safety profile has been established in animals and humans, currently, little is known about its influence on Alzheimer's disease (AD) and the possible mechanisms. Thus, we aimed to evaluate the effects and mechanisms of Tβ4 on glial polarization and cognitive performance in APP/PS1 transgenic mice.
Behavior tests were conducted to assess the learning and memory, anxiety and depression in APP/PS1 mice. Thioflavin S staining, Nissl staining, immunohistochemistry/immunofluorescence, ELISA, qRT-PCR, and immunoblotting were performed to explore Aβ accumulation, phenotypic polarization of glial cells, neuronal loss and function, and TLR4/NF-κB axis in APP/PS1 mice.
We demonstrated that Tβ4 protein level elevated in all APP/PS1 mice. Over-expression of Tβ4 alone alleviated AD-like phenotypes of APP/PS1 mice, showed less brain Aβ accumulation and more Insulin-degrading enzyme (IDE), reversed phenotypic polarization of microglia and astrocyte to a healthy state, improved neuronal function and cognitive behavior performance, and accidentally displayed antidepressant-like effect. Besides, Tβ4 could downregulate both TLR4/MyD88/NF-κB p65 and p52-dependent inflammatory pathways in the APP/PS1 mice. While combination drug of TLR4 antagonist TAK242 or NF-κB p65 inhibitor PDTC exerted no further effects.
These results suggest that Tβ4 may exert its function by regulating both classical and non-canonical NF-κB signaling and is restoring its function as a potential therapeutic target against AD.","['Alzheimer’s disease', 'Cognition and emotion', 'NF-κB signaling pathway', 'Phenotypic polarization of glial cells and neuroinflammation', 'Thymosin β4']",Journal of neuroinflammation,2021-06-30,"[{'lastname': 'Wang', 'firstname': 'Meng', 'initials': 'M', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Feng', 'firstname': 'Li-Rong', 'initials': 'LR', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Li', 'firstname': 'Zi-Long', 'initials': 'ZL', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Ma', 'firstname': 'Kai-Ge', 'initials': 'KG', 'affiliation': ""Institute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neurobiology, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Chang', 'firstname': 'Ke-Wei', 'initials': 'KW', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Chen', 'firstname': 'Xin-Lin', 'initials': 'XL', 'affiliation': ""Institute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neurobiology, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Yang', 'firstname': 'Peng-Bo', 'initials': 'PB', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Ji', 'firstname': 'Sheng-Feng', 'initials': 'SF', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Ma', 'firstname': 'Yan-Bing', 'initials': 'YB', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Han', 'firstname': 'Hua', 'initials': 'H', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Ruganzua', 'firstname': 'John Bosco', 'initials': 'JB', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.""}, {'lastname': 'Yang', 'firstname': 'Wei-Na', 'initials': 'WN', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China.""}, {'lastname': 'Qian', 'firstname': 'Yi-Hua', 'initials': 'YH', 'affiliation': ""Department of Human Anatomy and Histology-Embryology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China. qianyh38@mail.xjtu.edu.cn.\nInstitute of Neuroscience, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China. qianyh38@mail.xjtu.edu.cn.\nKey Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of Education of China, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Xi'an, 710061, Shaanxi, China. qianyh38@mail.xjtu.edu.cn.""}]",,,"We demonstrated that Tβ4 protein level elevated in all APP/PS1 mice. Over-expression of Tβ4 alone alleviated AD-like phenotypes of APP/PS1 mice, showed less brain Aβ accumulation and more Insulin-degrading enzyme (IDE), reversed phenotypic polarization of microglia and astrocyte to a healthy state, improved neuronal function and cognitive behavior performance, and accidentally displayed antidepressant-like effect. Besides, Tβ4 could downregulate both TLR4/MyD88/NF-κB p65 and p52-dependent inflammatory pathways in the APP/PS1 mice. While combination drug of TLR4 antagonist TAK242 or NF-κB p65 inhibitor PDTC exerted no further effects.",,"10.1186/s12974-021-02166-3
10.1177/1039856218762308
10.1016/j.mcna.2018.10.009
10.1016/j.jalz.2016.02.010
10.3233/JAD-160869
10.1186/s13195-015-0139-9
10.1111/jnc.13411
10.3389/fneur.2018.00625
10.1186/s12974-017-0871-0
10.3233/JAD-2011-110725
10.1073/pnas.78.2.1162
10.1073/pnas.79.7.2172
10.1016/j.gene.2019.04.083
10.1007/s11064-008-9712-y
10.2174/1871527313666141130224206
10.1111/j.1749-6632.2010.05474.x
10.1016/bs.vh.2016.04.006
10.3389/fimmu.2018.02434
10.1016/j.bbi.2016.03.026
10.1523/JNEUROSCI.0059-07.2007
10.18632/oncotarget.10699
10.1038/jcbfm.2014.240
10.1097/SCS.0000000000006777
10.1007/978-1-4939-8994-2_10
10.1007/978-1-4939-9554-7_22
10.1007/978-1-4939-8994-2_4
10.1007/978-1-4939-8994-2_5
10.1016/j.bbi.2017.12.007
10.1007/s12035-014-9070-5
10.1038/s41598-017-13581-z
10.1186/1742-2094-9-71
10.1016/j.bbi.2015.09.017
10.1016/j.bone.2007.12.216
10.1523/JNEUROSCI.1268-12.2013
10.1007/978-1-4939-9658-2_2
10.1038/nature21029
10.1016/j.cell.2019.09.011
10.1016/j.neuron.2018.10.018
10.1016/j.neuron.2017.04.009
10.1523/JNEUROSCI.2119-18.2018
10.1016/j.expneurol.2006.12.002
10.12047/j.cjap.5541.2018.027
10.1038/s41583-018-0067-3
10.1016/j.brainresbull.2009.06.009
10.1113/jphysiol.2009.172866
10.1093/jnen/60.2.161
10.1523/JNEUROSCI.1409-18.2018
10.1089/ars.2019.7754
10.1111/j.1471-4159.2010.06615.x
10.1371/journal.pone.0059626
10.1111/nan.12011
10.1007/s00018-019-03132-2
10.1186/s13024-017-0210-z
10.1186/1471-2202-7-81
10.1016/j.neuroscience.2019.09.032
10.1016/j.neuropharm.2014.06.004
10.1196/annals.1415.020
10.1016/j.bbr.2019.112182
10.1098/rsbl.2012.0784
10.1016/j.neuroscience.2015.09.017
10.1016/j.cub.2015.10.049
10.1016/j.neuroscience.2015.07.084
10.1016/S0165-0173(01)00067-4
10.1016/j.nlm.2017.03.019
10.3892/mmr.2017.8339
10.1155/2019/9475384
10.1111/j.1365-2958.2009.06980.x
10.1016/j.neurobiolaging.2018.06.020
10.1016/j.bbi.2016.05.016
10.3389/fncel.2013.00034
10.1016/j.intimp.2020.106354
10.1016/j.exer.2006.12.004
10.1096/fj.10-167940
10.1016/j.cellimm.2018.06.009
10.1080/14712598.2018.1486817",<Element 'PubmedArticle' at 0x7f05dc5e2130>
137,34159699,"Chronic stress and Alzheimer's disease: the interplay between the hypothalamic-pituitary-adrenal axis, genetics and microglia.","Chronic psychosocial stress is increasingly being recognised as a risk factor for sporadic Alzheimer's disease (AD). The hypothalamic-pituitary-adrenal axis (HPA axis) is the major stress response pathway in the body and tightly regulates the production of cortisol, a glucocorticoid hormone. Dysregulation of the HPA axis and increased levels of cortisol are commonly found in AD patients and make a major contribution to the disease process. The underlying mechanisms remain poorly understood. In addition, within the general population there are interindividual differences in sensitivities to glucocorticoid and stress responses, which are thought to be due to a combination of genetic and environmental factors. These differences could ultimately impact an individuals' risk of AD. The purpose of this review is first to summarise the literature describing environmental and genetic factors that can impact an individual's HPA axis reactivity and function and ultimately AD risk. Secondly, we propose a mechanism by which genetic factors that influence HPA axis reactivity may also impact inflammation, a key driver of neurodegeneration. We hypothesize that these factors can mediate glucocorticoid priming of the immune cells of the brain, microglia, to become pro-inflammatory and promote a neurotoxic environment resulting in neurodegeneration. Understanding the underlying molecular mechanisms and identifying these genetic factors has implications for evaluating stress-related risk/progression to neurodegeneration, informing the success of interventions based on stress management and potential risks associated with the common use of glucocorticoids.","[""Alzheimer's disease"", 'HPA axis reactivity', 'chronic stress', 'cortisol', 'glucocorticoids', 'microglia', 'neuroinflammation']",Biological reviews of the Cambridge Philosophical Society,2021-06-24,"[{'lastname': 'Milligan Armstrong', 'firstname': 'Ayeisha', 'initials': 'A', 'affiliation': 'Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCurtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.'}, {'lastname': 'Porter', 'firstname': 'Tenielle', 'initials': 'T', 'affiliation': 'Curtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia.'}, {'lastname': 'Quek', 'firstname': 'Hazel', 'initials': 'H', 'affiliation': 'QIMR Berghofer Medical Institute, 300 Herston Rd, Herston, QLD, Australia.'}, {'lastname': 'White', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'QIMR Berghofer Medical Institute, 300 Herston Rd, Herston, QLD, Australia.'}, {'lastname': 'Haynes', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.'}, {'lastname': 'Jackaman', 'firstname': 'Connie', 'initials': 'C', 'affiliation': 'Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCurtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.'}, {'lastname': 'Villemagne', 'firstname': 'Victor', 'initials': 'V', 'affiliation': 'School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia.\nThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, VIC, 3052, Australia.'}, {'lastname': 'Munyard', 'firstname': 'Kylie', 'initials': 'K', 'affiliation': 'Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCurtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.'}, {'lastname': 'Laws', 'firstname': 'Simon M', 'initials': 'SM', 'affiliation': 'Curtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia.'}, {'lastname': 'Verdile', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCurtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nSchool of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia.'}, {'lastname': 'Groth', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA, 6102, Australia.\nCurtin Medical School, Curtin University, Kent St, Bentley, WA, 6102, Australia.'}]",,,,© 2021 Cambridge Philosophical Society.,10.1111/brv.12750,<Element 'PubmedArticle' at 0x7f05dcb26a90>
138,"34146214
26902870
18680156
16113586
28855863
9804800
20515500
31033998
16246041
21058882
2105332
29809231
29796989
29929471
23739900
28740088
19064291
26668118
17870208
15750214
1933305
26061389
31894080
28124751
18631955
25895684
26460339
15374226
7910560
11836274
31068799
26897535
27123241
21514247
29653606
22437199
25512794
23159010
29440986
20975518
21343417
9607774
6721060
1401246
28553588
22908189
6610841
21514250
23968694
24951474
16890939
2771064
28949931
25285290
30943231
30157487
29132997
19585947
30223192
7141356
28390960
8094895
26519433
23407453
14774460
13211797
17684054
21514248
15673845
18097751
17911171
22857384
20442494
18663163
27185594
30982132
29743975
23345094
15785248
20739404
30848934
23360840
22964311",Association between thyroid function and Alzheimer's disease: A systematic review.,"Alterations in metabolic parameters have been associated with an increased risk of dementia, among which thyroid function has gained great importance in Alzheimer's disease (AD) pathology in recent years. However, it remains unclear whether thyroid dysfunctions could influence and contribute to the beginning and/or progression of AD or if it results from AD. This systematic review was conducted to examine the association between thyroid hormone (TH) levels and AD. Medline, ISI Web of Science, EMBASE, Cochrane library, Scopus, Scielo, and LILACS were searched, from January 2010 to March 2020. A total of 17 articles were selected. The studies reported alterations in TH and circadian rhythm in AD patients. Behavior, cognition, cerebral blood flow, and glucose consumption were correlated with TH deficits in AD patients. Whether thyroid dysfunctions and AD have a cause-effect relationship was inconclusive, however, the literature was able to provide enough data to corroborate a relationship between TH and AD. Although further studies are needed in this field, the current systematic review provides information that could help future investigations.","['Alzheimer’s disease', 'Cognition', 'Hyperthyroidism', 'Hypothyroidism', 'Thyroid function', 'Thyroid hormone']",Metabolic brain disease,2021-06-20,"[{'lastname': 'Figueroa', 'firstname': 'Paulina Belén Sepulveda', 'initials': 'PBS', 'affiliation': 'Department of Preclinical Science, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile. p.sepulveda.fi@gmail.com.\nLaboratory of Neuronal Communication, Departamento de Fisiologia e Biofisica, Universidade de Sao Paulo, Av. Professor Lineu Prestes, 1524 - Cidade Universitária, São Paulo, SP, Brasil, 05508900. p.sepulveda.fi@gmail.com.'}, {'lastname': 'Ferreira', 'firstname': 'Ana Flávia Fernandes', 'initials': 'AFF', 'affiliation': 'Laboratory of Cellular Neurobiology, Departamento de Fisiologia e Biofisica, Universidade de Sao Paulo, Av. Professor Lineu Prestes, 1524 - Cidade Universitária, São Paulo, SP, Brasil, 05508900. anaffernandesf@gmail.com.'}, {'lastname': 'Britto', 'firstname': 'Luiz Roberto', 'initials': 'LR', 'affiliation': 'Laboratory of Cellular Neurobiology, Departamento de Fisiologia e Biofisica, Universidade de Sao Paulo, Av. Professor Lineu Prestes, 1524 - Cidade Universitária, São Paulo, SP, Brasil, 05508900.'}, {'lastname': 'Doussoulin', 'firstname': 'Arlette Patricia', 'initials': 'AP', 'affiliation': 'Department of Pediatrics and Child Surgery, Universidad de La Frontera, Temuco, Chile.'}, {'lastname': 'Torrão', 'firstname': 'Andréa da Silva', 'initials': 'ADS', 'affiliation': 'Laboratory of Neuronal Communication, Departamento de Fisiologia e Biofisica, Universidade de Sao Paulo, Av. Professor Lineu Prestes, 1524 - Cidade Universitária, São Paulo, SP, Brasil, 05508900.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s11011-021-00760-1
10.1007/s12020-016-0897-6
10.1002/hipo.20476
10.1159/000087648
10.3389/fncel.2017.00240
10.1002/jcp.28198
10.1074/jbc.273.46.30366
10.1186/1471-2458-10-298
10.1210/er.2018-00275
10.1042/BST0331041
10.1089/thy.2010.0092
10.1210/jcem-70-2-403
10.1590/0004-282x20180003
10.1007/s12035-018-1111-z
10.1186/s12868-018-0436-x
10.1007/s40520-013-0025-x
10.1038/s41598-017-06138-7
10.1016/j.jad.2008.10.019
10.1038/nrendo.2015.205
10.1016/j.neurobiolaging.2007.07.019
10.3233/JAD-2005-7106
10.1016/0006-8993(91)90194-Z
10.1089/thy.2014.0589
10.1542/neo.21-1-e30
10.1007/s11011-016-9947-2
10.1016/j.jalz.2007.08.005
10.1159/000375298
10.1038/nrendo.2015.173
10.1016/0167-4943(95)00646-3
10.1111/j.1365-2362.1994.tb02059.x
10.1210/jcem.87.2.8182
10.3389/fnagi.2019.00088
10.1186/s12902-016-0092-z
10.3892/br.2016.630
10.1016/j.jalz.2011.03.004
10.1016/j.jalz.2018.02.018
10.1007/s11011-012-9291-0
10.4239/wjd.v5.i6.901
10.1016/j.psyneuen.2012.10.012
10.1046/j.1365-2265.2000.01146.x
10.3389/fnins.2018.00025
10.1097/WAD.0b013e3181f9aff2
10.1016/j.trci.2018.06.014
10.1373/clinchem.2010.161240
10.1016/j.trci.2017.07.001
10.1210/endo.139.6.6033
10.3390/ijerph16162828
10.1002/cne.903220405
10.4103/ijem.IJEM_15_17
10.1101/cshperspect.a006239
10.1212/WNL.34.7.939
10.1016/j.jalz.2011.03.005
10.1016/j.tins.2013.07.001
10.1371/journal.pmed.1000097
10.1212/WNL.0000000000000650
10.1016/j.yhbeh.2006.06.025
10.1212/WNL.39.9.1159
10.1515/revneuro-2017-0036
10.1371/journal.pone.0214676
10.1111/apha.12647
10.1159/000492129
10.1016/j.lfs.2017.11.013
10.31887/DCNS.2009.11.2/cqiu
10.1016/j.psyneuen.2018.09.002
10.3389/fendo.2019.00506
10.4103/0972-2327.116916
10.3390/jcm9030792
10.1016/j.ygcen.2017.04.001
10.3389/fendo.2014.00062
10.1212/WNL.43.2.250
10.3233/JAD-150429
10.1210/en.2012-1930
10.7897/2230-8407.100110
10.1172/JCI102351
10.3389/fendo.2014.00040
10.1172/JCI103021
10.1210/jc.2007-0287
10.1016/j.jalz.2011.03.003
10.1093/toxsci/kfi095
10.1007/s11064-007-9551-2
10.1210/jc.2007-1499
10.3109/07435800.2012.710696
10.3233/JAD-2010-100339
10.1001/archinte.168.14.1514
10.1016/j.nbd.2016.05.008
10.1007/s10072-019-03863-x
10.1155/2018/2089404
10.1210/jc.2012-3191
10.1089/thy.2005.15.279
10.1210/me.2010-0175
10.1096/fj.201801751R
10.2310/JIM.0b013e318280aafb
10.1089/thy.2017.0600",<Element 'PubmedArticle' at 0x7f05dcd71a40>
139,34126620,Prolactin and Its Altered Action in Alzheimer's Disease and Parkinson's Disease.,"Prolactin (PRL) is one of the most diverse pituitary hormones and is known to modulate normal neuronal function and neurodegenerative conditions. Many studies have described the influence that PRL has on the central nervous system and addressed its contribution to neurodegeneration, but little is known about the mechanisms responsible for the effects of PRL on neurodegenerative disorders, especially on Alzheimer's disease (AD) and Parkinson's disease (PD).
We review and summarize the existing literature and current understanding of the roles of PRL on various PRL aspects of AD and PD.
In general, PRL is viewed as a promising molecule for the treatment of AD and PD. Modulation of PRL functions and targeting of immune mechanisms are needed to devise preventive or therapeutic strategies.","['Alzheimer’s disease', 'Neurodegenerative diseases', 'Parkinson’s disease', 'Prolactin levels']",Neuroendocrinology,2021-06-15,"[{'lastname': 'Duc Nguyen', 'firstname': 'Hai', 'initials': 'H', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.'}, {'lastname': 'Pal Yu', 'firstname': 'Byung', 'initials': 'B', 'affiliation': 'Department of Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'lastname': 'Hoang', 'firstname': 'Ngoc Hong Minh', 'initials': 'NHM', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.'}, {'lastname': 'Jo', 'firstname': 'Won Hee', 'initials': 'WH', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.'}, {'lastname': 'Young Chung', 'firstname': 'Hae', 'initials': 'H', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Min-Sun', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea.'}]",,,,"© 2021 S. Karger AG, Basel.",10.1159/000517798,<Element 'PubmedArticle' at 0x7f05dee456d0>
140,34119528,"Sex hormones, vascular factors and cognition.","After more than a century of research, we have failed to develop a pharmacological prevention or cure for dementia. There are strong indicators that sex hormones influence cognition. In this paper we discuss the role of these hormones at the intersection between vascular disease and dementia, in light of the mounting literature covering the shared risk factors, pathological features alongside the timeline of hormonal change with the evolution of vascular and neurodegenerative disease. Interactive risk factors and the role of inflammation over the duration of disease evolution are highlighted. Our summary tables assessing the impact of estrogen-based hormone therapy on cognition over the past 45 years illustrate the effort expended to determine the ideal age for intervention and the type, dose, administration, and duration of therapy that might improve or protect cognition as well as alleviate menopausal symptoms. As the prevalence of dementia is rising and is higher in women, it is crucial we advance our knowledge from the ""inconclusive"" position statement on menopausal hormone therapy of the US Preventive Services Task Force.","['Cardiovascular', 'Cerebrovascular', 'Cognition', 'Cognitive decline', 'Dementia', 'Heart', 'Hormone', 'Hormone therapy', 'Inflammation', 'Menopause', 'Mild cognitive impairment', 'Sex', 'Vascular']",Frontiers in neuroendocrinology,2021-06-14,"[{'lastname': 'Szoeke', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Healthy Ageing Program, Centre for Medical Research (Royal Melbourne Hospital), Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia. Electronic address: cszoeke@unimelb.edu.au.'}, {'lastname': 'Downie', 'firstname': 'S J', 'initials': 'SJ', 'affiliation': 'Healthy Ageing Program, Centre for Medical Research (Royal Melbourne Hospital), Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.'}, {'lastname': 'Parker', 'firstname': 'A F', 'initials': 'AF', 'affiliation': 'Department of Psychology, University of Victoria, Victoria, British Columbia, Canada.'}, {'lastname': 'Phillips', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Healthy Ageing Program, Centre for Medical Research (Royal Melbourne Hospital), Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia.'}]",,,,Copyright © 2021 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2021.100927,<Element 'PubmedArticle' at 0x7f05dee396d0>
141,34112537,[Effects of the use of 17 β-estradiol and genistein in Alzheimer's disease in women with menopause].,"The use of 17 β-estradiol and genistein in women with menopause helps in the reduction of vasomotor symptoms and cognitive improvement. There is evidence on the use of certain flavonoids such as genistein, which has a potentially neuroprotective role in neurodegenerative diseases such as Alzheimer's. Scientific evidence on the effects of phytoestrogens and genistein during menopause and their effect on cognition are scarce, however, in the present review it was found that the intervention with 17 β-estradiol has positive effects on cognition in women with Alzheimer's disease. In addition, the use of genistein, daidzein or any supplement based on isoflavones may influence vasomotor symptoms. 17 β-estradiol supplements in women in early menopause and with some degree of cognitive impairment may have beneficial effects.","['17 β-estradiol', ""Alzheimer's disease"", 'Enfermedad de Alzheimer', 'Genistein', 'Genisteína', 'Menopause', 'Menopausia']",Revista espanola de geriatria y gerontologia,2021-06-12,"[{'lastname': 'Chávez-Pérez', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Facultad en Ciencias de la Nutrición, Universidad de Morelia, Morelia, Michoacán, México.'}, {'lastname': 'Ceballos-Ramírez', 'firstname': 'Araceli', 'initials': 'A', 'affiliation': 'Facultad en Ciencias de la Nutrición, Universidad de Morelia, Morelia, Michoacán, México.'}, {'lastname': 'Suárez-Castro', 'firstname': 'Abel', 'initials': 'A', 'affiliation': 'Laboratorio de Diseño Molecular, Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México. Electronic address: abel.suarez@umich.mx.'}]",,,,"Copyright © 2021 SEGG. Publicado por Elsevier España, S.L.U. All rights reserved.",10.1016/j.regg.2021.04.005,<Element 'PubmedArticle' at 0x7f05dd1d9810>
142,"34103390
20522652
26114578
30878483
27021778
25260700
31870439
30092616
16862116
19795409
28453791
28738171
23136129
28856541
30291623
30690031
27693506
17179653
28226226
16862115
28916533
29775591
32531244
31399126
23104886
20463744
29346778
16950801
30180904
24619111
26124111
32973454
30995509
17965659
29196460
24962261
30258234
28828399
28845019
21047645
21092856
33028409
30340518
31813797
22890097
27425031
28435163
27170638
17764761
28930663
24485249
28743268
29859318
27114033
21841757
23874106
23041626
30559339
30760929
31042697
30862089
25261995
19046946
30149180
29426702
28656016
19946692
27252382
28159556
31039256
22277331
17021169
29744576
19557827
23609919
22062772
21107132
21224065
23396349
33127097
28330615
19910308
11746512
33012625
24680777
18184915
22608501
27421577
29378960
32610143
27097852
19721334
11825061
9530922
28070672
25022663
18359860
29036611
31600775
30586924
28837568
19016491
29028540
28404863
24532802
26820675
11466313
20026663
29155950
28493053
28835281
31291241
26370502
28541286
31932797",A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses.,"Haploinsufficiency of progranulin (PGRN) is a leading cause of frontotemporal lobar degeneration (FTLD). PGRN polymorphisms are associated with Alzheimer's disease. PGRN is highly expressed in the microglia near Aβ plaques and influences plaque dynamics and microglial activation. However, the detailed mechanisms remain elusive. Here we report that PGRN deficiency reduces human APP and Aβ levels in the young male but not female mice. PGRN-deficient microglia exhibit increased expression of markers associated with microglial activation, including CD68, galectin-3, TREM2, and GPNMB, specifically near Aβ plaques. In addition, PGRN loss leads to up-regulation of lysosome proteins and an increase in the nuclear localization of TFE3, a transcription factor involved in lysosome biogenesis. Cultured PGRN-deficient microglia show enhanced nuclear translocation of TFE3 and inflammation in response to Aβ fibril treatment. Taken together, our data revealed a sex- and age-dependent effect of PGRN on APP metabolism and a role of PGRN in regulating lysosomal activities and inflammation in plaque-associated microglia.",[],Life science alliance,2021-06-10,"[{'lastname': 'Du', 'firstname': 'Huan', 'initials': 'H', 'affiliation': 'Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Wong', 'firstname': 'Man Ying', 'initials': 'MY', 'affiliation': 'Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.'}, {'lastname': 'Zhang', 'firstname': 'Tingting', 'initials': 'T', 'affiliation': 'Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Santos', 'firstname': 'Mariela Nunez', 'initials': 'MN', 'affiliation': 'Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Hsu', 'firstname': 'Charlene', 'initials': 'C', 'affiliation': 'Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Zhang', 'firstname': 'Junke', 'initials': 'J', 'affiliation': 'Department of Computational Biology, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Yu', 'firstname': 'Haiyuan', 'initials': 'H', 'affiliation': 'Department of Computational Biology, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, NY, USA.'}, {'lastname': 'Luo', 'firstname': 'Wenjie', 'initials': 'W', 'affiliation': 'Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.'}, {'lastname': 'Hu', 'firstname': 'Fenghua', 'initials': 'F', 'affiliation': 'Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA fh87@cornell.edu.'}]",,,,© 2021 Du et al.,"10.26508/lsa.202000874
10.2353/ajpath.2010.090915
10.1080/15548627.2015.1063871
10.1016/j.jmb.2019.03.006
10.1016/j.neurobiolaging.2016.02.019
10.1093/bioinformatics/btu638
10.1186/s40478-019-0872-6
10.1111/jnc.14564
10.1038/nature05016
10.1002/bies.200900086
10.1093/hmg/ddx162
10.1080/15548627.2017.1313943
10.1093/hmg/dds475
10.1007/s12035-017-0707-z
10.1002/cne.24551
10.1016/j.jmb.2019.01.027
10.1016/j.devcel.2016.08.003
10.1262/jrd.18108
10.1146/annurev-immunol-051116-052358
10.1038/nature05017
10.1212/WNL.0000000000004494
10.1016/j.cell.2018.05.003
10.1016/j.cell.2020.05.003
10.1186/s13195-019-0524-x
10.1093/bioinformatics/bts635
10.1038/gene.2010.18
10.1016/j.celrep.2017.12.066
10.1093/hmg/ddl241
10.1186/s13024-018-0281-5
10.1007/s00401-014-1262-6
10.1073/pnas.1510329112
10.3389/fncel.2020.00260
10.1016/j.immuni.2019.03.016
10.1038/nn1997
10.1083/jcb.201709069
10.1038/nri3705
10.1038/s41593-018-0242-x
10.1523/ENEURO.0100-17.2017
10.1538/expanim.17-0060
10.1016/j.jns.2010.10.009
10.1016/j.neuron.2010.09.034
10.1186/s40478-020-01037-x
10.1186/s40478-018-0612-3
10.1016/j.devcel.2019.10.025
10.3233/JAD-2012-120946
10.1016/j.bbadis.2016.07.007
10.1038/nrn.2017.36
10.1152/ajpcell.00298.2015
10.1016/j.bbr.2007.07.020
10.1016/j.immuni.2017.08.008
10.1186/gb-2014-15-2-r29
10.1186/s13024-017-0196-6
10.1016/j.nbd.2018.05.015
10.1016/j.cell.2016.04.001
10.3791/2831
10.2147/OTT.S44906
10.1172/JCI63113
10.1038/s41467-018-07741-6
10.1038/s41586-019-0924-x
10.1038/s41586-019-1195-2
10.3390/cells8030230
10.1038/nm.3672
10.1016/j.brainres.2008.10.021
10.1016/j.nbd.2018.08.013
10.1016/j.immuni.2018.01.011
10.1007/s00401-009-0616-y
10.1242/jcs.146365
10.1016/j.bbrc.2017.01.176
10.1093/brain/awz099
10.1186/alzrt102
10.1523/JNEUROSCI.1202-06.2006
10.1007/s00401-018-1861-8
10.1002/path.2580
10.1001/2013.jamaneurol.393
10.1016/j.nbd.2011.10.016
10.1097/NEN.0b013e3181fc9aea
10.1016/j.ajpath.2010.11.002
10.3233/JAD-121606
10.1016/j.tins.2020.10.002
10.1016/j.cels.2017.02.009
10.1093/bioinformatics/btp616
10.1002/jcb.1259
10.1016/j.tibs.2020.09.004
10.1016/j.gene.2014.03.041
10.1212/01.wnl.0000289191.54852.75
10.1016/j.ajhg.2012.04.021
10.1016/j.arr.2016.07.002
10.1073/pnas.1719808115
10.1016/j.celrep.2020.107843
10.1038/ncomms11295
10.1262/jrd.20249
10.1006/mgme.2001.3274
10.1016/s0304-3940(98)00008-1
10.1007/s00401-017-1668-z
10.1186/s40478-014-0078-x
10.1110/ps.073295308
10.1093/hmg/ddx364
10.1093/hmg/ddz229
10.3390/ijms20010066
10.1371/journal.pone.0182896
10.1002/ajmg.b.30889
10.1016/j.conb.2017.09.005
10.1126/scitranslmed.aah5642
10.1074/jbc.M113.531202
10.1007/s12035-016-9698-4
10.1074/jbc.M104350200
10.1084/jem.20091568
10.1093/nar/gkx1098
10.1007/s00401-017-1719-5
10.1186/s13024-017-0205-9
10.1371/journal.pone.0212382
10.1083/jcb.201502029
10.1038/ncomms15277
10.1038/s41591-019-0695-9",<Element 'PubmedArticle' at 0x7f05dd1a7e50>
143,"34065168
28118636
33845179
32825356
23073831
22476197
26698666
21241799
26993509
16966511
22105948
29293568
20359775
24990930
27143423
17021169
16420434
20089133
26265617
29796992
25076872
31004319
28710249
22776039
17536190
27180970
15483213
30906281
18032666
24384568
26786898
17726024
21436046
27752996
14651849
10766253
11840218
23935621
15148148
9549720
24251397
26990757
31551756
29324460
33003412
33677013
32993686
9777903
17315079
22045479
28450713
23352355
31126170
32979927
10681274
27318134
30426678
26519432
25381750
20164583
11706109
1759558
31075308
27458370
22201683
29570615
31310797
21266511
18781083
30096853
21787319
29950970
19885299
29997193
18401020
15277613
26906354
22912823
27715341
31705913
29402504
26090621
28108113
29912176
24404511
26740596
28138112
15809509
15058305
32638485
16690869
25339759
15953364
23155049
25661995
28123835
30686983
26806339
31537707
15470140
25637807
19604604
29914038
18559859
28274859
25210460
30589509
32954972
32650579
33167441
24159189","A Negative Energy Balance Is Associated with Metabolic Dysfunctions in the Hypothalamus of a Humanized Preclinical Model of Alzheimer's Disease, the 5XFAD Mouse.","Increasing evidence links metabolic disorders with neurodegenerative processes including Alzheimer's disease (AD). Late AD is associated with amyloid (Aβ) plaque accumulation, neuroinflammation, and central insulin resistance. Here, a humanized AD model, the 5xFAD mouse model, was used to further explore food intake, energy expenditure, neuroinflammation, and neuroendocrine signaling in the hypothalamus. Experiments were performed on 6-month-old male and female full transgenic (Tg","['5xFAD', 'Alzheimer’s disease', 'energy expenditure', 'hypothalamus', 'insulin signaling', 'neuroinflammation']",International journal of molecular sciences,2021-06-03,"[{'lastname': 'López-Gambero', 'firstname': 'Antonio J', 'initials': 'AJ', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.\nDepartamento de Biología Celular, Genética y Fisiología, Campus de Teatinos s/n, Universidad de Málaga, Andalucia Tech, 29071 Málaga, Spain.'}, {'lastname': 'Rosell-Valle', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.'}, {'lastname': 'Medina-Vera', 'firstname': 'Dina', 'initials': 'D', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.\nDepartamento de Biología Celular, Genética y Fisiología, Campus de Teatinos s/n, Universidad de Málaga, Andalucia Tech, 29071 Málaga, Spain.\nFacultad de Medicina, Campus de Teatinos s/n, Universidad de Málaga, Andalucia Tech, 29071 Málaga, Spain.\nUGC Corazón, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain.'}, {'lastname': 'Navarro', 'firstname': 'Juan Antonio', 'initials': 'JA', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.\nFacultad de Medicina, Campus de Teatinos s/n, Universidad de Málaga, Andalucia Tech, 29071 Málaga, Spain.'}, {'lastname': 'Vargas', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.'}, {'lastname': 'Rivera', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.'}, {'lastname': 'Sanjuan', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'EURONUTRA S.L, Parque Tecnológico de Andalucía, 29590 Campanillas, Spain.'}, {'lastname': 'Rodríguez de Fonseca', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nUGC Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.'}, {'lastname': 'Suárez', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Instituto de investigación Biomédica de Málaga-IBIMA, 29010 Málaga, Spain.\nFacultad de Medicina, Campus de Teatinos s/n, Universidad de Málaga, Andalucia Tech, 29071 Málaga, Spain.\nDepartamento de Anatomía Humana, Medicina Legal e Historia de la Ciencia, Universidad de Málaga, 29071 Málaga, Spain.'}]",,,,,"10.3390/ijms22105365
10.1159/000454924
10.1016/j.molmet.2021.101234
10.3390/biomedicines8090295
10.1096/fj.12-211896
10.1172/JCI59903
10.1016/j.freeradbiomed.2015.12.012
10.1016/j.bbadis.2011.01.005
10.1007/s10571-015-0282-7
10.1001/archneur.63.9.1312
10.1212/WNL.0b013e318238eec1
10.1371/journal.pone.0190205
10.1016/j.neurobiolaging.2010.02.003
10.1523/JNEUROSCI.0872-14.2014
10.1016/j.neurobiolaging.2016.02.011
10.1523/JNEUROSCI.1202-06.2006
10.1111/j.1460-9568.2005.04551.x
10.1111/j.1471-4159.2010.06608.x
10.4103/0366-6999.162507
10.1007/s12035-018-1099-4
10.3389/fnmol.2014.00065
10.1007/s12035-019-1594-2
10.1530/JOE-17-0122
10.1111/j.1463-1326.2012.01663.x
10.1159/000103273
10.1111/jdi.12431
10.1038/oby.2004.185
10.3389/fendo.2019.00140
10.1523/JNEUROSCI.2443-07.2007
10.1101/cshperspect.a009191
10.1007/s00018-016-2133-1
10.1074/jbc.M702838200
10.1073/pnas.1013660108
10.1007/s13277-016-5433-z
10.1016/S0092-8674(03)00929-2
10.1038/35007534
10.1038/sj.ijo.0801913
10.1155/2013/983964
10.1001/archneur.61.5.705
10.1159/000026149
10.2174/1567205010666131120110930
10.1371/journal.pone.0151710
10.3389/fnagi.2019.00236
10.1097/YCO.0000000000000401
10.3390/nu12102977
10.1016/j.bbr.2021.113214
10.1186/s12974-020-01956-5
10.1111/j.1532-5415.1998.tb04537.x
10.3233/JAD-2011-110713
10.1038/s41598-017-01327-w
10.1016/j.jamda.2012.12.004
10.3390/nu11051161
10.1186/s13195-020-00687-2
10.1093/ajcn/71.2.650s
10.1016/j.neurobiolaging.2016.04.013
10.1111/gbb.12538
10.3233/JAD-150292
10.1002/mnfr.201400636
10.3233/JAD-2010-1364
10.1212/WNL.57.9.1669
10.1007/BF00308809
10.1016/j.phrs.2019.104255
10.3389/fnagi.2016.00160
10.1172/JCI59660
10.3390/ijms19040956
10.1016/j.bbi.2019.07.017
10.1210/en.2010-0659
10.1159/000153423
10.3390/ijms19082333
10.1042/BST0390891
10.3389/fnins.2018.00383
10.1177/193229680800200619
10.1016/B978-0-12-809454-9.00010-Xpp
10.1212/WNL.0000000000005911
10.1212/01.wnl.0000310646.32212.3a
10.1212/01.WNL.0000129989.28404.9B
10.2174/156720501303160217111434
10.1371/journal.pone.0043193
10.1080/14737175.2017.1246183
10.1016/j.peptides.2019.170184
10.1016/j.neuropharm.2018.01.040
10.1038/srep11452
10.1016/j.tins.2016.12.003
10.3390/ijms19061800
10.4093/dmj.2013.37.6.404
10.2337/db15-1029
10.9758/cpn.2017.15.1.59
10.1159/000084871
10.1038/nature02440
10.1111/adb.12936
10.1126/science.1124147
10.1523/JNEUROSCI.2567-14.2014
10.1111/j.1471-4159.2005.03187.x
10.1074/jbc.M112.409250
10.1111/jnc.13056
10.1515/tnsci-2016-0022
10.3389/fnins.2018.01017
10.1016/j.neuint.2016.01.005
10.1523/JNEUROSCI.0617-19.2019
10.1523/JNEUROSCI.2268-04.2004
10.1016/j.neuroscience.2015.01.035
10.1016/j.neurobiolaging.2009.06.003
10.3233/JAD-180241
10.1073/pnas.0710823105
10.1016/j.neulet.2017.03.003
10.4137/BCI.S13025
10.1111/apha.13244
10.1080/1028415X.2020.1821519
10.3390/nu12072030
10.3390/biology9110377
10.1242/dmm.013110",<Element 'PubmedArticle' at 0x7f05dcf06540>
144,34061772,Altered endocannabinoid-dynamics in craniopharyngioma patients and their association with HPA-axis disturbances.,"Patients with craniopharyngioma (CP) frequently suffer from morbid obesity. Endocannabinoids (ECs) are involved in weight gain and rewarding behavior but have not been investigated in this context.
Cross-sectional single-center study.
Eighteen patients with CP and 16 age- and sex-matched controls were included. Differences in endocannabinoids (2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA)) and endocannabinoid-like molecules (oleoyl ethanolamide (OEA), palmitoylethanolamide (PEA), and arachidonic acid (AA) were measured at baseline and following endurance exercise. We further explored ECs-dynamics in relation to markers of HPA-axis activity (ACTH, cortisol, copeptin) and hypothalamic damage.
Under resting conditions, independent of differences in BMI, 2-AG levels were more than twice as high in CP patients compared to controls. In contrast, 2-AG and OEA level increased in response to exercise in controls but not in CP patients, while AEA levels decreased in controls. As expected, exercise increased ACTH and copeptin levels in controls only. In a mixed model analysis across time and group, HPA measures did not provide additional information for explaining differences in 2-AG levels. However, AEA levels were negatively influenced by ACTH and copeptin levels, while OEA levels were negatively predicted by copeptin levels only. There were no significant differences in endocannabinoids depending on hypothalamic involvement.
Patients with CP show signs of a dysregulated endocannabinoid system under resting conditions as well as following exercise in comparison to healthy controls. Increased 2-AG levels under resting conditions and the missing response to physical activity could contribute to the metabolic phenotype of CP patients.",[],European journal of endocrinology,2021-06-02,"[{'lastname': 'Auer', 'firstname': 'Matthias K', 'initials': 'MK', 'affiliation': 'Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany.'}, {'lastname': 'Gebert', 'firstname': 'Dorothea', 'initials': 'D', 'affiliation': 'Research Group Clinical Neuroendocrinology, Max Planck Institute of Psychiatry, Munich, Germany.'}, {'lastname': 'Biedermann', 'firstname': 'Sarah V', 'initials': 'SV', 'affiliation': 'Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.\nHuman Behavior Laboratory, Institute for Sex Research and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Germany.'}, {'lastname': 'Bindila', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.'}, {'lastname': 'Stalla', 'firstname': 'Günter', 'initials': 'G', 'affiliation': 'Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany.\nMedicover Neuroendocrinology, Munich, Germany.'}, {'lastname': 'Reisch', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany.'}, {'lastname': 'Kopczak', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.'}, {'lastname': 'Fuss', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Human Behavior Laboratory, Institute for Sex Research and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf, Germany.'}]",,Patients with CP show signs of a dysregulated endocannabinoid system under resting conditions as well as following exercise in comparison to healthy controls. Increased 2-AG levels under resting conditions and the missing response to physical activity could contribute to the metabolic phenotype of CP patients.,"Under resting conditions, independent of differences in BMI, 2-AG levels were more than twice as high in CP patients compared to controls. In contrast, 2-AG and OEA level increased in response to exercise in controls but not in CP patients, while AEA levels decreased in controls. As expected, exercise increased ACTH and copeptin levels in controls only. In a mixed model analysis across time and group, HPA measures did not provide additional information for explaining differences in 2-AG levels. However, AEA levels were negatively influenced by ACTH and copeptin levels, while OEA levels were negatively predicted by copeptin levels only. There were no significant differences in endocannabinoids depending on hypothalamic involvement.",,10.1530/EJE-21-0178,<Element 'PubmedArticle' at 0x7f05dceaebd0>
145,"34056921
16876668
21045163
21471435
22908189
30196887
24470773
27143423
31502112
31948671
12117397
11860494
18218341
15295589
27086128
31385768
26830040
23348042
23994581
22778219
11452016
23771838
24672198
1262439
20523023
8175728
18276750
18243555
7479947
27185594
1742020
17161830
9390517
29865052
32717151
25030513
26404616
28814391
21282661
22197104
15858047
31033251
22889922
19133315
15548201
31815833
19666694
28382744
29726700
24120943
31697961",Exercise and estrogen: common pathways in Alzheimer's disease pathology.,"Alzheimer's disease (AD) is a neurodegenerative disease that is characterized by progressive declines in cognitive function. Current epidemiological data indicate significant sex-linked disparities, where females have a higher risk of developing AD compared with male counterparts. This disparity necessitates further investigations to uncover the pathological and molecular factors influencing these sex differences. Although the underlying pathways behind this observed disparity remain elusive, recent research points to menopausal estrogen loss as a potential factor. Estrogen holds a significant role in amyloid precursor protein (APP) processing and overall neuronal health through the regulation of brain-derived neurotrophic factor (BDNF), a factor that is also reduced in postmenopausal women. BDNF is a known contributor to neuronal health and its reduced expression is typically linked to AD disorders. Exercise is known to increase BDNF and may provide an accessible activity for postmenopausal women to reduce their risk of AD. This review aims to discuss the relationship between estrogen, exercise, and BDNF in AD pathology.","['BDNF', 'amyloid precursor protein', 'estrogen', 'neurodegeneration', 'sex']",American journal of physiology. Endocrinology and metabolism,2021-06-01,"[{'lastname': 'Bagit', 'firstname': 'Ahmed', 'initials': 'A', 'affiliation': 'Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada.'}, {'lastname': 'Hayward', 'firstname': 'Grant C', 'initials': 'GC', 'affiliation': 'Faculty of Medicine, Ottawa University, Ottawa, Ontario, Canada.'}, {'lastname': 'MacPherson', 'firstname': 'Rebecca E K', 'initials': 'REK', 'affiliation': 'Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada.\nCentre for Neuroscience, Brock University, St. Catharines, Ontario, Canada.'}]",,,,,"10.1152/ajpendo.00008.2021
10.1016/S0140-6736(06)69113-7
10.1177/0891988710383571
10.1126/scitranslmed.3002369
10.1101/cshperspect.a006239
10.1016/j.jalz.2018.08.003
10.2147/CLEP.S37929
10.1016/j.neurobiolaging.2016.02.011
10.1007/s10571-019-00733-0
10.1016/j.neurobiolaging.2019.12.014
10.1001/jama.288.3.321
10.1046/j.0953-816x.2001.01825.x
10.1016/j.molmed.2007.12.002
10.1038/nature02940
10.1016/j.brainresbull.2016.04.009
10.2174/1389450120666190806153206
10.4149/bll_2016_019
10.1016/j.molmed.2012.12.007
10.1016/j.yfrne.2013.08.001
10.1210/en.2012-1435
10.1093/nar/29.14.2905
10.1007/s12035-013-8484-9
10.4103/0976-7800.127779
10.1210/jcem-42-4-629
10.1159/000282279
10.1016/S0021-9258(17)36796-0
10.1210/en.2007-1346
10.1016/j.neulet.2007.12.060
10.1073/pnas.92.24.11110
10.1016/j.nbd.2016.05.008
10.1016/0896-6273(91)90273-3
10.1016/j.brainres.2006.11.027
10.1016/S0896-6273(00)80395-5
10.3233/JAD-171150
10.1139/apnm-2019-0910
10.1016/S1474-4422(14)70136-X
10.1152/japplphysiol.00299.2015
10.1152/ajpregu.00255.2017
10.1073/pnas.1015950108
10.1016/j.neurobiolaging.2011.10.028
10.1523/JNEUROSCI.0496-05.2005
10.14814/phy2.14084
10.1038/mp.2012.107
10.1016/j.neulet.2008.12.043
10.1111/j.1460-9568.2004.03720.x
10.1249/MSS.0000000000002242
10.1113/expphysiol.2009.048512
10.1111/jnc.14034
10.1139/apnm-2018-0108
10.1016/j.cmet.2013.09.008
10.1016/j.pbb.2019.172819",<Element 'PubmedArticle' at 0x7f05dd020ef0>
146,"34034803
24495607
15358445
24886127
29495898
28924185
28024274
26543368
20482300
31333583
21051590
15126546
24302749
26184920
21316860
30626913
17383500
20940425
24507187
15941864
22687339
14754827
24193727
9881538
12634292
19327033
1202204
23254630
31730745
33245660",Steroid 21-hydroxylase gene variants and late-life depression.,"A feature of late-life depression is alterations of the stress hormone system. The CYP21A2 gene encodes for the steroid 21-hydroxylase enzyme which is required for the biosynthesis of mineralocorticoids and glucocorticoids, two main components of the stress response in humans. Variants in the CYP21A2 gene could influence risk of late-life depression, but this has not been examined. This study investigated possible associations between five variants in the CYP21A2 gene and late-life depression in 1007 older community-dwelling men and women.
In multivariate logistic regression model, significant associations were found between three single-nucleotide polymorphisms (rs389883, rs437179, and rs630379) and depression in women specifically (OR ranging from 1.51 to 1.68, p-values 0.025 to 0.0045), and the two latter remained significant after correction for multiple testing. Variants of the CYP21A2 gene appear as susceptibility factors for late-life depression in a sex-specific manner, independently of somatic and neuropsychiatric comorbidity.","['Corticosteroids', 'Late-life depression', 'Older adults', 'Population-based study', 'Single-nucleotide polymorphisms', 'Stress']",BMC research notes,2021-05-27,"[{'lastname': 'Ancelin', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'INM, Univ Montpellier, INSERM, Montpellier, France. marie-laure.ancelin@inserm.fr.'}, {'lastname': 'Norton', 'firstname': 'Joanna', 'initials': 'J', 'affiliation': 'INM, Univ Montpellier, INSERM, Montpellier, France.'}, {'lastname': 'Ritchie', 'firstname': 'Karen', 'initials': 'K', 'affiliation': 'INM, Univ Montpellier, INSERM, Montpellier, France.\nCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Chaudieu', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'INM, Univ Montpellier, INSERM, Montpellier, France.'}, {'lastname': 'Ryan', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Biological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.'}]",,,"In multivariate logistic regression model, significant associations were found between three single-nucleotide polymorphisms (rs389883, rs437179, and rs630379) and depression in women specifically (OR ranging from 1.51 to 1.68, p-values 0.025 to 0.0045), and the two latter remained significant after correction for multiple testing. Variants of the CYP21A2 gene appear as susceptibility factors for late-life depression in a sex-specific manner, independently of somatic and neuropsychiatric comorbidity.",,"10.1186/s13104-021-05616-6
10.1016/j.psyneuen.2013.12.004
10.1016/j.psyneuen.2004.06.002
10.1186/1741-7015-12-73
10.1176/appi.ajp.2017.17060621
10.1038/mp.2017.195
10.1016/j.psyneuen.2016.11.016
10.2147/NDT.S90369
10.1515/CCLM.2010.239
10.3389/fendo.2019.00432
10.1210/er.2010-0013
10.1210/jc.2003-031322
10.1210/jc.2013-3707
10.1016/j.psyneuen.2015.06.017
10.1016/j.psyneuen.2011.01.003
10.1038/s41380-018-0336-6
10.1016/j.jpsychores.2006.12.019
10.1126/scisignal.3143pe36
10.1016/j.neuron.2014.01.027
10.1210/jc.2005-0384
10.1017/S0033291712001286
10.1192/bjp.184.2.147
10.1038/tp.2013.95
10.1177/014662167700100306
10.1093/gerona/58.3.M249
10.1146/annurev.clinpsy.032408.153621
10.1016/0022-3956(75)90026-6
10.3233/JAD-121228
10.1002/da.22974
10.1503/jpn.190177",<Element 'PubmedArticle' at 0x7f05dcffa220>
147,33899866,Molecular mechanism of amyloidogenicity and neurotoxicity of a pro-aggregated tau mutant in the presence of histidine tautomerism ,"The accumulation of ΔK280 tau mutant resulting in neurotoxic oligomeric aggregates is an important but yet mysterious procedure in Alzheimer's disease (AD) development. Recently, we proposed a histidine tautomerization hypothesis of tau fibrillogenesis for the pathobiology of AD and other neuro diseases. However, the influence of neutral histidine tautomeric states on tau mutation is still unclear. Herein, we performed replica-exchange molecular dynamics (REMD) simulations to characterize structural features as well as the mode of toxic action of the ΔK280 tau mutant in the presence of histidine tautomerism. Molecular dynamics (MD) simulation results show that the δε tautomeric isomer (having a distinct global energy minimum) had the highest β-sheet structure, which adopts a sheet-rich conformer and may have significant influence on the structural behaviors of ΔK280 tau monomers. Furthermore, clustering, residual contact map, mobility and structural analysis exhibited that the presence of β-strand interactions between stable lysine 8 (K8)-asparagine 13 (N13) and valine 39 (V39)-tyrosine 43 (Y43) residues plus K31-histidine 32 (H32) and K8-N13 (strand-loop-strand [β-meander] structure) helped δε to form toxic aggregates. Moreover, H299 played a more critical role in the conformational instability of the δε than H268. Overall, the results obtained from this study may be used to arrest neurodegeneration in ΔK280 tau mutation carriers as well as increase the understanding of AD-related tau pathogenesis and strengthen the histidine tautomerism hypothesis of misfolded peptide accumulation.",[],Physical chemistry chemical physics : PCCP,2021-04-27,"[{'lastname': 'Chatterjee', 'firstname': 'Sompriya', 'initials': 'S', 'affiliation': 'Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Korea. jinylee@skku.edu.'}, {'lastname': 'Salimi', 'firstname': 'Abbas', 'initials': 'A', 'affiliation': 'Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Korea. jinylee@skku.edu.'}, {'lastname': 'Lee', 'firstname': 'Jin Yong', 'initials': 'JY', 'affiliation': 'Department of Chemistry, Sungkyunkwan University, Suwon 440-746, Korea. jinylee@skku.edu.'}]",,,,,10.1039/d1cp00105a,<Element 'PubmedArticle' at 0x7f05dd9cd130>
148,"33895632
23920254
32184751
25662776
29172163
26977398
29889066
30788410
31696638
31914218
25879909
25936807
25776214
30121337
28479476
31552724
32853816
19457380
20965257
25255942
29197216
28337409
27797809
28482638
32759310
28238272
26463677
24077574
12803969
23335884
25134682
27306735
28653793
28100023
26338813
22369786
21387376
25556536
32143137
15588615
22366795
31784375
20045477
21808630
26971127
33112398
30508042
25683866",Differential early subcortical involvement in genetic FTD within the GENFI cohort.,"Studies have previously shown evidence for presymptomatic cortical atrophy in genetic FTD. Whilst initial investigations have also identified early deep grey matter volume loss, little is known about the extent of subcortical involvement, particularly within subregions, and how this differs between genetic groups.
480 mutation carriers from the Genetic FTD Initiative (GENFI) were included (198 GRN, 202 C9orf72, 80 MAPT), together with 298 non-carrier cognitively normal controls. Cortical and subcortical volumes of interest were generated using automated parcellation methods on volumetric 3 T T1-weighted MRI scans. Mutation carriers were divided into three disease stages based on their global CDR® plus NACC FTLD score: asymptomatic (0), possibly or mildly symptomatic (0.5) and fully symptomatic (1 or more).
In all three groups, subcortical involvement was seen at the CDR 0.5 stage prior to phenoconversion, whereas in the C9orf72 and MAPT mutation carriers there was also involvement at the CDR 0 stage. In the C9orf72 expansion carriers the earliest volume changes were in thalamic subnuclei (particularly pulvinar and lateral geniculate, 9-10%) cerebellum (lobules VIIa-Crus II and VIIIb, 2-3%), hippocampus (particularly presubiculum and CA1, 2-3%), amygdala (all subregions, 2-6%) and hypothalamus (superior tuberal region, 1%). In MAPT mutation carriers changes were seen at CDR 0 in the hippocampus (subiculum, presubiculum and tail, 3-4%) and amygdala (accessory basal and superficial nuclei, 2-4%). GRN mutation carriers showed subcortical differences at CDR 0.5 in the presubiculum of the hippocampus (8%).
C9orf72 expansion carriers show the earliest and most widespread changes including the thalamus, basal ganglia and medial temporal lobe. By investigating individual subregions, changes can also be seen at CDR 0 in MAPT mutation carriers within the limbic system. Our results suggest that subcortical brain volumes may be used as markers of neurodegeneration even prior to the onset of prodromal symptoms.","['Brain volumetry', 'Genetic frontotemporal dementia', 'MRI imaging', 'Presymptomatic stage']",NeuroImage. Clinical,2021-04-26,"[{'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Todd', 'firstname': 'Emily G', 'initials': 'EG', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Peakman', 'firstname': 'Georgia', 'initials': 'G', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.'}, {'lastname': 'Convery', 'firstname': 'Rhian S', 'initials': 'RS', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Russell', 'firstname': 'Lucy L', 'initials': 'LL', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Thomas', 'firstname': 'David L', 'initials': 'DL', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.'}, {'lastname': 'Eugenio Iglesias', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, USA; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, USA.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, the Netherlands.'}, {'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, the Netherlands.'}, {'lastname': 'Seelaar', 'firstname': 'Harro', 'initials': 'H', 'affiliation': 'Department of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, the Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Sanchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': ""Neurology Department, Hospital Clinic, Institut d'Investigacions Biomèdiques, Barcelona, Spain.""}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Faculté de Médecine, Université Laval, Québec, Canada.'}, {'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Hospital Universitario Donostia, San Sebastian, Spain.'}, {'lastname': 'Synofzik', 'firstname': 'Matthis', 'initials': 'M', 'affiliation': 'Department of Cognitive Neurology, Center for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Karolinska Institutet, Department NVS, Division of Neurogeriatrics, Stockholm, Sweden; Unit for Hereditray Dementia, Theme Aging, Karolinska University Hospital-Solna Stockholm Sweden.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada.'}, {'lastname': 'Carmela Tartaglia', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, ON, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.'}, {'lastname': 'Vandenberghe', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Neurology Department, Centro Hospitalar e Universitário de Coimbra, Portugal.'}, {'lastname': 'Butler', 'firstname': 'Chris R', 'initials': 'CR', 'affiliation': 'Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom.'}, {'lastname': 'Ducharme', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Gerhard', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom; Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Germany.'}, {'lastname': 'Danek', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich German Center for Neurodegenerative Diseases (DZNE), Munich Munich Cluster of Systems Neurology, Munich, Germany.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich German Center for Neurodegenerative Diseases (DZNE), Munich Munich Cluster of Systems Neurology, Munich, Germany.'}, {'lastname': 'Otto', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neurology, University Hospital Ulm, Ulm, Germany.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.'}, {'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Sorbonne Université, Paris Brain Institute - Institut du Cerveau- ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre deréférence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Pasquier', 'firstname': 'Florence', 'initials': 'F', 'affiliation': 'Univ Lille, France; Inserm 1172 Lille, France; CHU, CNR-MAJ, Labex Distalz, LiCENDLille, France.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom. Electronic address: j.rohrer@ucl.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"In all three groups, subcortical involvement was seen at the CDR 0.5 stage prior to phenoconversion, whereas in the C9orf72 and MAPT mutation carriers there was also involvement at the CDR 0 stage. In the C9orf72 expansion carriers the earliest volume changes were in thalamic subnuclei (particularly pulvinar and lateral geniculate, 9-10%) cerebellum (lobules VIIa-Crus II and VIIIb, 2-3%), hippocampus (particularly presubiculum and CA1, 2-3%), amygdala (all subregions, 2-6%) and hypothalamus (superior tuberal region, 1%). In MAPT mutation carriers changes were seen at CDR 0 in the hippocampus (subiculum, presubiculum and tail, 3-4%) and amygdala (accessory basal and superficial nuclei, 2-4%). GRN mutation carriers showed subcortical differences at CDR 0.5 in the presubiculum of the hippocampus (8%).",Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.,"10.1016/j.nicl.2021.102646
10.1109/TMI.4210.1109/TMI.2015.2418298
10.1016/j.neuroimage.2020.117287
10.1001/jamaneurol.2017.4266
10.1136/jnnp-2020-323279
10.1016/j.nicl.2020.102210
10.1001/jamanetworkopen.2020.22847",<Element 'PubmedArticle' at 0x7f05dd9df090>
149,"33875615
28735855
29935546
25030513
20051527
27689250
28850708
32411312
31984866
30223192
21430364
18663163
25514105
16636121
27558885
24285689
10789670
19621072
20652370
1626547
9310563
22977271
19797897
16869339
11155096
21346066
27638924
17870208
24144964
31643080
20515500
15055159
19545916
28368540
25772646
28822529
25447738
21519910
30562095
31119696
31513261","Spectrum of thyroid dysfunction and dementia: a dose-response meta-analysis of 344,248 individuals from cohort studies.","Thyroid hormone, as a modifiable risk factor for dementia, promotes neurocognitive function and regulates metabolic processes. Various studies have defined different thyroid-stimulating hormone cutoffs, but the safest thyroid-stimulating hormone concentration was absent. A dose-response meta-analysis describing the overall functional relation and identifying exposure intervals associated with a higher or lower disease risk is thus desirable. Therefore, our current analysis was conducted to understand the influence of thyroid dysfunction on dementia risk. We searched PubMed, Embase, and Web of Science before May 1, 2020 for human studies published in English. Studies were considered for inclusion if they used a cohort study design to measure the risk of dementia in different thyroid function status groups, diagnosed thyroid functional status and all-cause dementia, included participants aged >18 years, and provided quantitative measures of data. The analysis contained 17 articles with 344,248 individuals with a 7.8-year mean follow-up. Ten studies with 329,287 participants indicated that only subclinical hyperthyroidism was associated with an increased risk of dementia. In contrast, subclinical hypothyroidism, clinical hyperthyroidism, and clinical hypothyroidism did not affect dementia. In the dose-response meta-analysis with 46,417 samples from 11 studies, the association of thyroid-stimulating hormone with the risk of dementia exhibited a U-shaped curve. Our study indicated that subclinical hyperthyroidism was associated with the risk of dementia and the thyroid-stimulating hormone concentration at around 1.55-1.60 mU/L as the optimum range for the risk of dementia.","['dementia', 'dose–response', 'meta-analysis', 'thyroid dysfunction']",Endocrine connections,2021-04-21,"[{'lastname': 'Tang', 'firstname': 'Xingyao', 'initials': 'X', 'affiliation': 'Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Song', 'firstname': 'Zhi-Hui', 'initials': 'ZH', 'affiliation': 'Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Wang', 'firstname': 'Dawei', 'initials': 'D', 'affiliation': 'General Practice Department, Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Yang', 'firstname': 'Jinkui', 'initials': 'J', 'affiliation': 'Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Augusto Cardoso', 'firstname': 'Marly', 'initials': 'M', 'affiliation': 'Department of Nutrition, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.'}, {'lastname': 'Zhou', 'firstname': 'Jian-Bo', 'initials': 'JB', 'affiliation': 'Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Simó', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron, Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.""}]",,,,,"10.1530/EC-21-0047
10.1016/S0140-6736(1731363-6
10.1186/s13195-018-0394-7
10.1016/S1474-4422(1470136-X
10.1210/er.2009-0007
10.1210/jc.2016-2129
10.1111/cen.13458
10.14740/jem588
10.1089/thy.2019.0672
10.1016/j.psyneuen.2018.09.002
10.1159/000324522
10.1001/archinte.168.14.1514
10.1210/jc.2014-3586
10.1210/jc.2006-0449
10.1038/srep31975
10.1210/jc.2013-3385
10.1001/jama.283.15.2008
10.1371/journal.pmed.1000097
10.1007/s10654-010-9491-z
10.1093/oxfordjournals.aje.a116237
10.1136/bmj.315.7109.629
10.1210/jc.2012-2108
10.1159/000242439
10.1177/1533317506289282
10.1046/j.1365-2265.2000.01146.x
10.1210/jc.2010-2693
10.1212/WNL.0000000000003227
10.1016/j.neurobiolaging.2007.07.019
10.1530/EJE-13-0722
10.1186/1471-2458-10-298
10.1016/j.archger.2009.05.015
10.1210/jc.2017-00166
10.1111/jnc.13093
10.1016/j.ihj.2017.07.004
10.1002/jnr.23519
10.1007/s12020-011-9472-3
10.1161/CIRCHEARTFAILURE.118.005266
10.1007/s40520-019-01217-3
10.1210/endrev/bnz003",<Element 'PubmedArticle' at 0x7f05dd0fbe00>
150,33839319,Stressed mitochondria: A target to intrude alzheimer's disease.,"Alzheimer's disease (AD) is the inoperable, incapacitating, neuropsychiatric, and degenerative manifestation that drastically affects human life quality. The current medications target extra-neuronal senile plaques, oxidative stress, neuroinflammation, intraneuronal neurofibrillary tangles, cholinergic deficits, and excitotoxicity. Among novel pathways and targets, bioenergetic and resultant mitochondrial dysfunction has been recognized as essential factors that decide the neuronal fate and consequent neurodegeneration in AD. The crucial attributes of mitochondria, including bioenergesis, signaling, sensing, integrating, and transmitting biological signals contribute to optimum networking of neuronal dynamics and make them indispensable for cell survival. In AD, mitochondrial dysfunction and mitophagy are a preliminary and critical event that aggravates the pathological cascade. Stress is known to promote and exaggerate the neuropathological alteration during neurodegeneration and metabolic impairments, especially in the cortico-limbic system, besides adversely affecting the normal physiology and mitochondrial dynamics. Stress involves the allocation of energy resources for neuronal survival. Chronic and aggravated stress response leads to excessive release of glucocorticoids by activation of the hypothalamic-pituitaryadrenal (HPA) axis. By acting through their receptors, glucocorticoids influence adverse mitochondrial changes and alter mtDNA transcription, mtRNA expression, hippocampal mitochondrial network, and ultimately mitochondrial physiology. Chronic stress also affects mitochondrial dynamics by changing metabolic and neuro-endocrinal signalling, aggravating oxidative stress, provoking inflammatory mediators, altering tropic factors, influencing gene expression, and modifying epigenetic pathways. Thus, exploring chronic stress-induced glucocorticoid dysregulation and resultant bio-behavioral and psychosomatic mitochondrial alterations may be a feasible narrative to investigate and unravel the mysterious pathobiology of AD.","['Alzheimer’s disorder', 'Bioenergetics', 'Glucocorticoids', 'Mitochondria', 'Stress', 'mtDNA']",Mitochondrion,2021-04-12,"[{'lastname': 'Sharma', 'firstname': 'Vivek Kumar', 'initials': 'VK', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab, India; Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh 171207, India.'}, {'lastname': 'Singh', 'firstname': 'Thakur Gurjeet', 'initials': 'TG', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab, India. Electronic address: gurjeet.singh@chitkara.edu.in.'}, {'lastname': 'Mehta', 'firstname': 'Vineet', 'initials': 'V', 'affiliation': 'Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh 171207, India.'}]",,,,Copyright © 2021 Elsevier B.V. and Mitochondria Research Society. All rights reserved. All rights reserved.,10.1016/j.mito.2021.04.004,<Element 'PubmedArticle' at 0x7f05dd336b30>
151,"33750863
16925587
27637496
19174491
19319184
23180175
25565388
20713132
24074804
9416776
15358442
12689474
12727959
31031659
22566599
19646924
31250284
28549269
31538087
21858921
9153534
19548255
22366690
24513702
23702309
20629137
24275012
27359327
31265872
31236517
14742591
9023876
16271821
18829696
20682340
21623544
22760557
29929086
26563991","Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington's disease.","Salivary cortisol dysrhythmias have been reported in some, but not all studies assessing hypothalamic-pituitary-adrenal (HPA) axis function in Huntington's disease (HD). These differences are presumed to be due to environmental influences on temporal salivary cortisol measurement. Further exploration of HPA-axis function using a more stable and longer-term measure, such as hair cortisol, is needed to confirm earlier findings. This study aimed to evaluate hair and salivary cortisol concentrations and their associations with clinical and lifestyle outcomes in individuals with premanifest HD (n = 26) compared to healthy controls (n = 14). Participants provided saliva and hair samples and data were collected on clinical disease outcomes, mood, cognition, physical activity, cognitive reserve, sleep quality and social network size to investigate relationships between clinical and lifestyle outcomes and cortisol concentrations. Hair and salivary cortisol concentrations did not significantly differ between the premanifest HD and control groups. No significant associations were observed between hair or salivary cortisol concentrations and cognitive, mood or lifestyle outcomes. However, hair cortisol concentrations were significantly associated with disease outcomes in individuals with premanifest HD. Significant associations between hair cortisol concentrations and measures of disease burden and onset may suggest a potential disease marker and should be explored longitudinally in a larger sample of individuals with HD.",[],Scientific reports,2021-03-23,"[{'lastname': 'Cruickshank', 'firstname': 'Travis', 'initials': 'T', 'affiliation': 'Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, Australia.\nPerron Institute for Neurological and Translational Science, Nedlands, WA, Australia.'}, {'lastname': 'Porter', 'firstname': 'Tenielle', 'initials': 'T', 'affiliation': 'Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, Australia.\nSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia.'}, {'lastname': 'Laws', 'firstname': 'Simon M', 'initials': 'SM', 'affiliation': 'Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, Australia.\nSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia.'}, {'lastname': 'Ziman', 'firstname': 'Mel', 'initials': 'M', 'affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.\nSchool of Biomedical Science, University of Western Australia, Crawley, WA, Australia.'}, {'lastname': 'Bartlett', 'firstname': 'Danielle M', 'initials': 'DM', 'affiliation': 'Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia. d.bartlett@ecu.edu.au.\nCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, Australia. d.bartlett@ecu.edu.au.'}]",,,,,"10.1038/s41598-021-84726-4
10.1111/j.1460-9568.2006.04985.x
10.1016/j.neubiorev.2016.09.006
10.1210/jc.2008-2543
10.1371/journal.pone.0004962
10.1007/s00415-012-6732-y
10.1111/jne.12255
10.1016/j.brainresbull.2010.08.006
10.1016/j.psyneuen.2012.10.020
10.1016/S0024-3205(97)01008-4
10.1016/j.psyneuen.2004.04.007
10.1210/jc.2002-021176
10.3389/fpsyt.2019.00221
10.1136/jnnp-2011-301940
10.1016/s1474-4422(09)70170-x
10.1007/s00702-019-02040-w
10.1016/j.psyneuen.2017.05.013
10.1002/mdc3.12808
10.1002/ajmg.b.31232
10.1002/ana.410410521
10.1002/ajmg.b.30992
10.1016/j.bbi.2012.02.002
10.3791/50882
10.1017/s1355617713000507
10.1002/mds.23108
10.1016/j.psyneuen.2013.10.007
10.1016/j.jpsychires.2016.06.014
10.1016/j.neulet.2019.134359
10.1016/j.nbscr.2018.07.001
10.1016/S0166-2236(96)10069-2
10.1016/j.pnpbp.2005.08.006
10.1093/brain/awn244
10.1016/j.nbd.2010.07.013
10.1080/08870446.2010.529141
10.1038/tp.2012.58
10.1016/j.psyneuen.2018.06.008
10.1016/j.psyneuen.2015.10.010",<Element 'PubmedArticle' at 0x7f05dd35f4a0>
152,"33721199
24941010
25489296
28442790",Intranasal administration of 40 and 80 units of insulin does not cause hypoglycemia during cardiac surgery: a randomized controlled trial.,"Intranasal insulin administration may improve cognitive function in patients with dementia and may prevent cognitive problems after surgery. Although the metabolic effects of intranasal insulin in non-surgical patients have been studied, its influence on glucose concentration during surgery is unknown.
We conducted a randomized, double-blind, placebo-contolled trial in patients scheduled for elective cardiac surgery. Patients with type 2 diabetes mellitus (T2DM) and non-T2DM patients were randomly allocated to one of three groups (normal saline, 40 international units [IU] of intranasal insulin, and 80 IU intranasal insulin). Insulin was given after the induction of general anesthesia. Glucose and plasma insulin concentrations were measured in ten-minute intervals during the first hour and every 30 min thereafter. The primary outcome was the change in glucose concentration 30 min after intranasal insulin administration.
A total of 115 patients were studied, 43 of whom had T2DM. In non-T2DM patients, 40 IU intranasal insulin did not affect glucose concentration, while 80 IU intranasal insulin led to a statistically significant but not clinically important decrease in blood glucose levels (mean difference, 0.4 mMol·L
In patients with and without T2DM undergoing elective cardiac surgery, intranasal insulin administration at doses as high as 80 IU did not cause clinically important hypoglycemia.
www.ClinicalTrials.gov (NCT02729064); registered 5 April 2016.
RéSUMé: OBJECTIF: L’administration intranasale d’insuline pourrait améliorer la fonction cognitive des patients souffrant de démence et pourrait prévenir les problèmes cognitifs après une chirurgie. Bien que les effets métaboliques de l’insuline intranasale chez les patients non chirurgicaux aient été étudiés, son influence sur la glycémie pendant une chirurgie est inconnue. MéTHODE: Nous avons réalisé une étude randomisée, à double insu, contrôlée par placebo auprès de patients devant subir une chirurgie cardiaque non urgente. Des patients atteints de diabète de type 2 et des patients non diabétiques ont été randomisés dans l’un de trois groupes (solution physiologique salée, 40 unités internationales [UI] d’insuline intranasale et 80 UI d’insuline intranasale). La solution intranasale a été administrée après l’induction de l’anesthésie générale. Les concentrations de glucose et d’insuline plasmatique ont été mesurées à des intervalles de dix minutes pendant la première heure et toutes les 30 minutes par la suite. Le critère d’évaluation principal était le changement de glycémie 30 min après l’administration intranasale d’insuline. RéSULTATS: Un total de 115 patients ont été étudiés, dont 43 souffraient de diabète de type 2. Chez les patients non diabétiques, 40 UI d’insuline intranasale n’ont pas affecté la glycémie, alors que 80 UI d’insuline intranasale ont entraîné une réduction statistiquement significative mais non cliniquement importante de la glycémie (différence moyenne, 0,4 mMol·L","['cardiac surgery', 'delirium', 'glycemia', 'intranasal insulin']",Canadian journal of anaesthesia = Journal canadien d'anesthesie,2021-03-16,"[{'lastname': 'Roque', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'School of Human Nutrition, McGill University, Ste-Anne-de-Bellevue, Montreal, QC, Canada.'}, {'lastname': 'Nakadate', 'firstname': 'Yosuke', 'initials': 'Y', 'affiliation': 'Department of Anesthesiology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. ynakadate@yamanashi.ac.jp.'}, {'lastname': 'Sato', 'firstname': 'Hiroaki', 'initials': 'H', 'affiliation': 'Department of Anesthesia, McGill University Health Centre Glen Site, Royal Victoria Hospital, Montreal, QC, Canada.'}, {'lastname': 'Sato', 'firstname': 'Tamaki', 'initials': 'T', 'affiliation': 'Department of Anesthesia, McGill University Health Centre Glen Site, Royal Victoria Hospital, Montreal, QC, Canada.'}, {'lastname': 'Wykes', 'firstname': 'Linda', 'initials': 'L', 'affiliation': 'School of Human Nutrition, McGill University, Ste-Anne-de-Bellevue, Montreal, QC, Canada.'}, {'lastname': 'Kawakami', 'firstname': 'Akiko', 'initials': 'A', 'affiliation': 'Department of Anesthesia, McGill University Health Centre Glen Site, Royal Victoria Hospital, Montreal, QC, Canada.'}, {'lastname': 'Yokomichi', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'Department of Health science, University of Yamanashi, Shimokato, Chuo, Yamanashi, Japan.'}, {'lastname': 'Matsukawa', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Department of Health science, University of Yamanashi, Shimokato, Chuo, Yamanashi, Japan.'}, {'lastname': 'Schricker', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Anesthesia, McGill University Health Centre Glen Site, Royal Victoria Hospital, Montreal, QC, Canada.'}]",,,"A total of 115 patients were studied, 43 of whom had T2DM. In non-T2DM patients, 40 IU intranasal insulin did not affect glucose concentration, while 80 IU intranasal insulin led to a statistically significant but not clinically important decrease in blood glucose levels (mean difference, 0.4 mMol·L",,"10.1007/s12630-021-01969-5
10.1093/bja/aeu296
10.3109/00207454.2013.833919
10.1371/journal.pone.0099661
10.1007/s00125-012-2528-y
10.1038/nn0602-849
10.1016/j.neurobiolaging.2005.03.016
10.1007/s40263-013-0076-8
10.1212/01.WNL.0000265401.62434.36
10.1007/s12630-010-9418-x
10.1210/jc.2009-1677
10.1016/j.bpa.2015.03.003
10.1089/dia.2005.7.124
10.1007/s12630-016-0749-0
10.1097/00003246-200107000-00012
10.1111/j.2042-7158.1994.tb03877.x
10.1210/jc.2013-2061
10.1038/npp.2015.312
10.1016/s1010-7940(02)00807-2
10.1097/SLA.0000000000001900
10.1097/01.anes.0000296071.19434.1e
10.1016/j.jcrc.2014.03.014
10.3389/fnagi.2014.00100
10.1038/srep21186
10.1016/j.exger.2006.01.014
10.3233/JAD-2005-8304
10.1172/JCI59903
10.1212/WNL.50.1.164
10.1016/j.trsl.2016.12.005
10.1016/j.brainres.2016.12.027
10.1177/193229680800200613
10.1016/j.brainres.2015.04.054
10.1016/j.jtcvs.2011.10.070
10.2337/dc14-1199
10.2337/dc15-0303",<Element 'PubmedArticle' at 0x7f05dd33e2c0>
153,"33711010
17245412
28498720
30250260
25789869
12506200
24938782
32284577
32414930
26188543
25198136
30059119
26228450
28538095
31928730
24471163
27844078
17941703
27616019
26910367
27365453
29235346
32345723
29596915
28109327
22121920
15778722
20164562
28650319
29192843
32915532
18233698
22463145
22488640
19178154
27398307
27469165
24034249
24782311
15854654
8744570
20408171
30865832
21869604
23825939",Aggregation of Aβ40/42 chains in the presence of cyclic neuropeptides investigated by molecular dynamics simulations.,"Alzheimer's disease is associated with the formation of toxic aggregates of amyloid beta (Aβ) peptides. Despite tremendous efforts, our understanding of the molecular mechanisms of aggregation, as well as cofactors that might influence it, remains incomplete. The small cyclic neuropeptide somatostatin-14 (SST14) was recently found to be the most selectively enriched protein in human frontal lobe extracts that binds Aβ42 aggregates. Furthermore, SST14's presence was also found to promote the formation of toxic Aβ42 oligomers in vitro. In order to elucidate how SST14 influences the onset of Aβ oligomerization, we performed all-atom molecular dynamics simulations of model mixtures of Aβ42 or Aβ40 peptides with SST14 molecules and analyzed the structure and dynamics of early-stage aggregates. For comparison we also analyzed the aggregation of Aβ42 in the presence of arginine vasopressin (AVP), a different cyclic neuropeptide. We observed the formation of self-assembled aggregates containing the Aβ chains and small cyclic peptides in all mixtures of Aβ42-SST14, Aβ42-AVP, and Aβ40-SST14. The Aβ42-SST14 mixtures were found to develop compact, dynamically stable, but small aggregates with the highest exposure of hydrophobic residues to the solvent. Differences in the morphology and dynamics of aggregates that comprise SST14 or AVP appear to reflect distinct (1) regions of the Aβ chains they interact with; (2) propensities to engage in hydrogen bonds with Aβ peptides; and (3) solvent exposures of hydrophilic and hydrophobic groups. The presence of SST14 was found to impede aggregation in the Aβ42-SST14 system despite a high hydrophobicity, producing a stronger ""sticky surface"" effect in the aggregates at the onset of Aβ42-SST14 oligomerization.",[],PLoS computational biology,2021-03-13,"[{'lastname': 'Wu', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada.'}, {'lastname': 'Dorosh', 'firstname': 'Lyudmyla', 'initials': 'L', 'affiliation': 'Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada.'}, {'lastname': 'Schmitt-Ulms', 'firstname': 'Gerold', 'initials': 'G', 'affiliation': 'Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.'}, {'lastname': 'Wille', 'firstname': 'Holger', 'initials': 'H', 'affiliation': 'Department of Biochemistry, University of Alberta, Edmonton, Canada.\nCentre for Prions and Protein Folding Diseases, Edmonton, Canada.\nNeuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada.'}, {'lastname': 'Stepanova', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Canada.'}]",,,,,"10.1371/journal.pcbi.1008771
10.1038/nrm2101
10.1038/s41593-018-0235-9
10.1021/cr500638n
10.1073/pnas.222681699
10.1073/pnas.1401564111
10.1038/s41557-020-0452-1
10.1073/pnas.1922267117
10.1021/bi5003579
10.1039/c8cp02685h
10.1021/acs.jpcb.5b05593
10.1021/acs.jpcb.7b04689
10.1016/bs.apcsb.2019.10.001
10.1039/c3cc48704k
10.1039/c6mb00441e
10.1371/journal.pcbi.0030173
10.1038/srep33156
10.1002/cbic.201500623
10.1126/science.aac4354
10.1021/jacs.7b10343
10.1073/pnas.1911153117
10.1016/j.jmb.2018.03.015
10.1016/bs.ircmb.2016.08.011
10.1111/j.1471-4159.2011.07478.x
10.1038/nm1206
10.7554/eLife.28401
10.1080/19336896.2017.1405207
10.1021/acschemneuro.0c00470
10.1103/PhysRevE.76.051918
10.1103/PhysRevE.85.020901
10.1002/prot.24082
10.1021/bi802043h
10.1002/2211-5463.12069
10.1073/pnas.1600749113
10.1016/j.cell.2013.08.035
10.1074/jbc.M114.548354
10.1016/j.jmb.2005.03.034
10.1016/0263-7855(96)00018-5
10.1002/prot.22711
10.1021/acs.jctc.8b01123
10.1371/journal.pcbi.1003114",<Element 'PubmedArticle' at 0x7f05dd41d8b0>
154,"33673927
30242384
9334293
10028999
26327890
20865657
6683165
21397002
24101058
7554308
14749457
20592293
27348867
22433122
19171901
3794202
17881524
17710727
18761053
21058750
1637726
447850
12573810
7491931
8637535
10372695
11158037
11818427
9403124
7714119
9253308
11836290
17148559
26921861
10474123
16368750
1719016
11155090
21411558
10197292
30029733
2969362
3005357
8969932
4262849
9253337
2144295
9246938
12128283
6235241
1987784
5675428
3127426
6149116
25302229
8514857
11373355
5071338
1939523
8491152
11159816
19589948
12183514
18359741
16310628
16550721
11571935
22510779
16261188
18480825
25982085
338622
20418719
18063002
8281222
9514370
1824869
2687691
1424196
17479164
17200169
16960025
15096581
20923909
26187233
7063854
3958810
24198220
7536210
15111519
11679460
15687322
19846742
19661128
7666785
8636267
8281699
8597465
2146310
11159150
12972442
6804492
2650561
10868952
27600826
30753114
377005
19401446
18716044
28273480
10619972
15211024
16732018
17093155
26324180
28158621
1400882
1859095
19801385
23067400
15935587
9510519
3289318
10668050
15800038
10652323
12496142
27462049
15983313
24726723
28359952
23240002
9618795
10682942
15784718
18000087
2361923
12974656
7327965
3558232
11153730
30161005
28817510
23065759
4008419
21921265
29045325
16706647
15955841
11427495
23217257
6646161
10220041
10749826
8352031
26781353
2245969
12044358
15125842
19339977
12970377
3379447
21131862
16614355
7462421
7119111
8093403
8166806
8504369
11248665
3819257
8453329
19174532
9312174
10995046
9467546
9525351
10657819
8289606
19252142
1491398
1400032
9927006
8054494
11099707
8643477
17020935
20425309
31534057
2299115
14978288
25068671
19111937
22186664
26581787
22155655
24525424
15906153
19707253
26886521
27355400
25548978
1400877
15572415
30366567
9177359
29253154
28241231
16842700
21632903
18349113
5780084
12955028
18477661
17050889
16332938
28241356
28241355
17496236
16339333
10959222
19523145
11694019
18812486
11106916
15989411
16787962
9660430
19410392
17327446
11581005
12843164
2355952
1806490
15135778
17227934
11836279
8633830
12425705
20228036
9597057
8548521
23794576
23835813
16507602
28514618
9535580
10737684
21070797
17194250
17024619
9562359
28937309
8776203
8550252
12889843
19528872
12165694
7900788
12180315
8191900
2796409
22248672
23533227
14514704
11909881
22105939
19299840
8028507
20863330
18029465
985395
6662758
4474159
1639942
22727808
10484567
12457419
16384836
7959609
9140905
9916184
12797841
1550219
7864103
18516767
20579529
20096034
19007855
24606898
27338461
18697911",Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications.,"Increased life expectancy combined with the aging baby boomer generation has resulted in an unprecedented global expansion of the elderly population. The growing population of older adults and increased rate of age-related chronic illness has caused a substantial socioeconomic burden. The gradual and progressive age-related decline in hormone production and action has a detrimental impact on human health by increasing risk for chronic disease and reducing life span. This article reviews the age-related decline in hormone production, as well as age-related biochemical and body composition changes that reduce the bioavailability and actions of some hormones. The impact of hormonal changes on various chronic conditions including frailty, diabetes, cardiovascular disease, and dementia are also discussed. Hormone replacement therapy has been attempted in many clinical trials to reverse and/or prevent the hormonal decline in aging to combat the progression of age-related diseases. Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events that outweigh its potential health benefits. Therefore, except in some specific individual cases, hormone replacement is not recommended. Rather, positive lifestyle modifications such as regular aerobic and resistance exercise programs and/or healthy calorically restricted diet can favorably affect endocrine and metabolic functions and act as countermeasures to various age-related diseases. We provide a critical review of the available data and offer recommendations that hopefully will form the groundwork for physicians/scientists to develop and optimize new endocrine-targeted therapies and lifestyle modifications that can better address age-related decline in heath.",[],Mayo Clinic proceedings,2021-03-07,"[{'lastname': 'Pataky', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': 'Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN.'}, {'lastname': 'Young', 'firstname': 'William F', 'initials': 'WF', 'affiliation': 'Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN.'}, {'lastname': 'Nair', 'firstname': 'K Sreekumaran', 'initials': 'KS', 'affiliation': 'Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN. Electronic address: nair@mayo.edu.'}]",,,,Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.,10.1016/j.mayocp.2020.07.033,<Element 'PubmedArticle' at 0x7f05dd3ef400>
155,"33541270
32147814
20927731
30265372
26440803
2344534
26050254
15898131
32665386
363229
28494097
31650125
30439975",Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England.,"Trials of novel agents are required to improve the care of patients with rare diseases, but trial feasibility may be uncertain due to concerns over insufficient patient numbers. We aimed to determine the size of the pool of potential participants in England 2015-2017 for trials in the autoimmune blistering skin disease bullous pemphigoid.
The size of the pool of potential participants was estimated using routinely collected healthcare data from linked primary care (Clinical Practice Research Datalink; CPRD) and secondary care (Hospital Episode Statistics; HES) databases. Thirteen consultant dermatologists were surveyed to determine the likelihood that a patient would be eligible for a trial based on the presence of cautions or contra-indications to prednisolone use. These criteria were applied to determine how they influenced the potential pool of participants.
Extrapolated to the population of England, we would expect approximately 10,800 (point estimate 10,747; 95% CI 7191 to 17,239) new cases of bullous pemphigoid to be identified in a three-year period. For a future trial involving oral prednisolone (standard care), the application of cautions to its use as exclusion criteria would result in approximately 365 potential participants unlikely to be recruited, a further 5332 could be recruited with caution, and 5104 in whom recruitment is still possible. 11-17% of potential participants may have pre-existing dementia and require an alternative consent process.
Routinely collected electronic health records can be used to inform the feasibility of clinical trials in rare diseases, such as whether recruitment is feasible nationally and how long recruitment might take to meet recruitment targets. Future trials of bullous pemphigoid in England may use the data presented to inform trial design, including eligibility criteria and consent processes for enrolling people with dementia.","['Bullous pemphigoid', 'Clinical practice research Datalink', 'Electronic health records', 'Hospital episode Statistics', 'Oral prednisolone', 'Rare disease', 'Trial design']",BMC medical research methodology,2021-02-06,"[{'lastname': 'Persson', 'firstname': 'M S M', 'initials': 'MSM', 'affiliation': 'Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Harman', 'firstname': 'K E', 'initials': 'KE', 'affiliation': 'Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Thomas', 'firstname': 'K S', 'initials': 'KS', 'affiliation': 'Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Chalmers', 'firstname': 'J R', 'initials': 'JR', 'affiliation': 'Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Vinogradova', 'firstname': 'Y', 'initials': 'Y', 'affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Langan', 'firstname': 'S M', 'initials': 'SM', 'affiliation': 'Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.'}, {'lastname': 'Hippisley-Cox', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'lastname': 'Gran', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham, Nottingham, UK. sonia.gran@nottingham.ac.uk.'}]",,,"Extrapolated to the population of England, we would expect approximately 10,800 (point estimate 10,747; 95% CI 7191 to 17,239) new cases of bullous pemphigoid to be identified in a three-year period. For a future trial involving oral prednisolone (standard care), the application of cautions to its use as exclusion criteria would result in approximately 365 potential participants unlikely to be recruited, a further 5332 could be recruited with caution, and 5104 in whom recruitment is still possible. 11-17% of potential participants may have pre-existing dementia and require an alternative consent process.",,"10.1186/s12874-021-01212-1
10.2340/00015555-3052
10.1371/journal.pmed.1001885
10.1136/bmj.300.6732.1092
10.1093/ije/dyv098
10.1002/pds.1115
10.1136/bmj.2.6146.1190
10.1111/bjd.15649
10.1016/S2589-7500(19)30012-3
10.1371/journal.pone.0207183",<Element 'PubmedArticle' at 0x7f05dd633c70>
156,33484007,Increased risk of dementia in hypothyroidism: A Danish nationwide register-based study.,"Globally, the prevalence of individuals with dementia is increasing, and identification of risk factors is of paramount interest. Using population-based registers, we evaluated whether hypothyroidism is a risk factor for dementia.
Register-based cohort study.
Risk of dementia was evaluated in two cohorts. The DNPR cohort comprises 111,565 hypothyroid patients, diagnosed between 1995 and 2012, and 446,260 euthyroid age- and sex-matched individuals (median follow-up 6.2 years). The OPENTHYRO cohort comprises 233,844 individuals with at least one measurement of serum thyrotropin (TSH) between 1995 and 2011, of whom 2,894 had hypothyroidism (median follow-up 7.2 years). Primary outcome was dementia defined as an International Classification of Diseases 10 code, or prescription of medicine for dementia.
In the DNPR cohort, risk of dementia was significantly increased in subjects with hypothyroidism (HR 1.22; 95% CI: 1.17-1.27), which attenuated after adjusting for pre-existing comorbidity (HR 0.82; 95% CI: 0.79-0.86). Stratification of age into ≤56 and >56 years showed an inverse relationship between age and risk of dementia (HR
Hypothyroidism is associated with increased risk of dementia. The association is influenced by comorbidity and age. Every 6 months of elevated TSH increased the risk of dementia by 12%, suggesting that also the length of hypothyroidism influences the risk of dementia.","[""Alzheimer's disease"", ""Hashimoto's disease"", 'Hypothyroidism', 'autoimmunity', 'register study', 'vascular dementia']",Clinical endocrinology,2021-01-24,"[{'lastname': 'Thvilum', 'firstname': 'Marianne', 'initials': 'M', 'affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.\nDepartment of Endocrinology, Odense University Hospital, Odense, Denmark.'}, {'lastname': 'Brandt', 'firstname': 'Frans', 'initials': 'F', 'affiliation': 'Department of Internal Medicine, Hospital of Southern Jutland, Sønderborg, Denmark.\nInstitute of Regional Health Research, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Lillevang-Johansen', 'firstname': 'Mads', 'initials': 'M', 'affiliation': 'Department of Endocrinology, Odense University Hospital, Odense, Denmark.\nInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Folkestad', 'firstname': 'Lars', 'initials': 'L', 'affiliation': 'Department of Endocrinology, Odense University Hospital, Odense, Denmark.\nInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Brix', 'firstname': 'Thomas H', 'initials': 'TH', 'affiliation': 'Department of Endocrinology, Odense University Hospital, Odense, Denmark.\nInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.'}, {'lastname': 'Hegedüs', 'firstname': 'Laszlo', 'initials': 'L', 'affiliation': 'Department of Endocrinology, Odense University Hospital, Odense, Denmark.\nInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.'}]",,,"In the DNPR cohort, risk of dementia was significantly increased in subjects with hypothyroidism (HR 1.22; 95% CI: 1.17-1.27), which attenuated after adjusting for pre-existing comorbidity (HR 0.82; 95% CI: 0.79-0.86). Stratification of age into ≤56 and >56 years showed an inverse relationship between age and risk of dementia (HR",© 2021 John Wiley & Sons Ltd.,10.1111/cen.14424,<Element 'PubmedArticle' at 0x7f05dd7ffb30>
157,"33443646
30241998
33328324
29279202
31324897
25770704
27765468
29278891
27941174
29478591
26735553
19625741
17524614
29889573
17975198
19520155
18561896
26215834
28899014
22890097
25777512
30039452
31901236
30365112
26847980
26224201
24239499
27905159
26833831
31127154
26682689
24771538
28835407
29744576
23396349
27823749
29153862
9628141
32171590
29849087
19721334
29956281
27568802
27760429
31879285
28300056
28905231",Sleep Characteristics and Cerebrospinal Fluid Progranulin in Older Adults: The CABLE Study.,"Cerebrospinal fluid (CSF) progranulin (PGRN) is related to various neurodegeneration diseases. And sleep problems can cause abnormality in protein metabolism in vivo. We aim to explore the potential associations between the self-reported sleep characteristics and CSF PGRN in cognitively intact older adults. Our study recruited 747 participants (mean (standard deviation (SD)) age, 61.99 (10.52) years, 329 (42.89%) females) who had normal cognition from the Chinese Alzheimer's Biomarker and LifestylE (CABLE) study with CSF PGRN and sleep characteristics measured. The multiple linear regression and nonlinear regression adjusted for age, gender, education, and apolipoprotein E-epsilon 4 gene (APOE4) status were used to assess the associations between sleep characteristics and PGRN. Interaction effects were explored between APOE4 status and sleep characteristics on CSF PGRN level. Sleep disturbances indicated lower CSF PGRN (β = - 0.0186, p = 0.0160). For detailed items in sleep disturbances, lower CSF PGRN was found in males who woke up during sleep (β = - 0.0121, p = 0.0062) and in females who had breathing difficulties (β = - 0.0258, p = 0.0271). Meanwhile, sleep efficiency was associated with CSF PGRN (β = - 0.0512, p = 0.0497). No significant interaction effects between sleep characteristics and APOE4 status were found. Meanwhile, we did not find a nonlinear relationship between nocturnal sleep duration and CSF PGRN. Sleep problems may influence the metabolism of PGRN, thus attenuating the protective effects of PGRN on neurodegeneration diseases.","['Alzheimer’s disease', 'Cerebrospinal fluid', 'Frontotemporal dementia', 'Progranulin', 'Sleep']",Neurotoxicity research,2021-01-15,"[{'lastname': 'Wang', 'firstname': 'Meng', 'initials': 'M', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Sun', 'firstname': 'Fu-Rong', 'initials': 'FR', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Bi', 'firstname': 'Yan-Lin', 'initials': 'YL', 'affiliation': 'Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Ma', 'firstname': 'Ya-Hui', 'initials': 'YH', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Yin', 'firstname': 'Jian-Jun', 'initials': 'JJ', 'affiliation': 'Department of Neurology, Qingdao Hiser Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Shen', 'firstname': 'Xue-Ning', 'initials': 'XN', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'lastname': 'Wang', 'firstname': 'Xiao-Tong', 'initials': 'XT', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. dr.tanlan@163.com.'}, {'lastname': 'Yu', 'firstname': 'Jin-Tai', 'initials': 'JT', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. jintai_yu@fudan.edu.cn.'}]",,,,,"10.1007/s12640-020-00326-6
10.1016/j.smrv.2018.08.001
10.1212/wnl.0000000000008866
10.1016/j.biopsych.2017.11.031
10.1038/s41582-019-0231-z
10.1016/j.psyneuen.2015.02.010
10.1016/j.smrv.2016.09.003
10.3233/jad-170032
10.1515/jpem-2016-0378
10.1016/b978-0-444-64076-5.00027-2
10.1159/000442418
10.3233/jad-2009-1170
10.1016/j.bbi.2007.04.003
10.1080/14728222.2018.1487951
10.1164/rccm.200608-1190PP
10.1016/j.neurobiolaging.2019.05.008
10.1016/j.bbi.2009.06.001
10.1016/j.biopsych.2008.05.004
10.1007/s12035-015-9358-0
10.1093/brain/awx148
10.3233/jad-2012-120946
10.3233/jad-150069
10.1007/s40520-018-1005-y
10.1186/s13195-019-0571-3
10.3892/ijmm.2018.3935
10.1016/j.sleep.2015.08.021
10.3109/07853890.2015.1074271
10.1016/j.sleep.2013.08.784
10.1111/jsr.12474
10.1098/rstb.2015.0110
10.1038/s41598-019-44173-8
10.3233/jad-150746
10.1212/wnl.0000000000000445
10.1212/wnl.0000000000004373
10.1007/s00401-018-1861-8
10.3233/jad-121606
10.1016/j.maturitas.2016.09.002
10.1016/j.smrv.2017.10.005
10.1111/j.1440-1819.1998.tb01020.x
10.1016/j.neurobiolaging.2020.02.014
10.1038/s41598-018-26630-y
10.1262/jrd.20249
10.1007/978-1-4939-8559-3_17
10.5665/sleep.6240
10.1159/000448896
10.1136/jnnp-2019-321896
10.1038/srep43594
10.1007/s11325-017-1562-x",<Element 'PubmedArticle' at 0x7f05dd81f1d0>
158,"33418170
24731779
16862116
18234697
22130207
18593276
26401709
29172163
31918955
16862115
18328591
9931268
23390180
21178100
10984517
11832223
15501102
29793546
31810826
23218900
27543298
29984158
30711674
24418059
24343233
24012408
25662776
15219578
20154673
19255408",Disease-related cortical thinning in presymptomatic granulin mutation carriers.,"Mutations in the granulin gene (GRN) cause familial frontotemporal dementia. Understanding the structural brain changes in presymptomatic GRN carriers would enforce the use of neuroimaging biomarkers for early diagnosis and monitoring. We studied 100 presymptomatic GRN mutation carriers and 94 noncarriers from the Genetic Frontotemporal dementia initiative (GENFI), with MRI structural images. We analyzed 3T MRI structural images using the FreeSurfer pipeline to calculate the whole brain cortical thickness (CTh) for each subject. We also perform a vertex-wise general linear model to assess differences between groups in the relationship between CTh and diverse covariables as gender, age, the estimated years to onset and education. We also explored differences according to TMEM106B genotype, a possible disease modifier. Whole brain CTh did not differ between carriers and noncarriers. Both groups showed age-related cortical thinning. The group-by-age interaction analysis showed that this age-related cortical thinning was significantly greater in GRN carriers in the left superior frontal cortex. TMEM106B did not significantly influence the age-related cortical thinning. Our results validate and expand previous findings suggesting an increased CTh loss associated with age and estimated proximity to symptoms onset in GRN carriers, even before the disease onset.","['Cortical thickness', 'Frontotemporal dementia', 'GRN', 'Genetic mutations', 'Presymptomatic']",NeuroImage. Clinical,2021-01-09,"[{'lastname': 'Borrego-Écija', 'firstname': 'Sergi', 'initials': 'S', 'affiliation': ""Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain.""}, {'lastname': 'Sala-Llonch', 'firstname': 'Roser', 'initials': 'R', 'affiliation': 'Departament de Biomedicina, Institute of Neuroscience, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.'}, {'lastname': 'van Swieten', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Moreno', 'firstname': 'Fermín', 'initials': 'F', 'affiliation': 'Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Tartaglia', 'firstname': 'Carmela', 'initials': 'C', 'affiliation': 'Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Biomedical, Surgical and Dental Sciences, University of Milan, Centro Dino Ferrari, Milan, Italy; Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy.""}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Université Laval, Québec, Canada.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences and Medical Research Council, Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.'}, {'lastname': 'Vandenberghe', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Tagliavini', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologica Carlo Besta, Milano, Italy.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Faculty of Medicine, University of Coimbra, Coimbra, Portugal.'}, {'lastname': 'Synofzik', 'firstname': 'Matthis', 'initials': 'M', 'affiliation': 'Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.'}, {'lastname': 'Ducharme', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada; McConnell Brain Imaging Centre, Montreal Neurological Institut, McGill University, Montreal, Québec, Canada.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Department of Neurology, Ludwig-Maximilians-University, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Site Munich, Munich, Germany; SyNergy,Munich Cluster for Systems Neurology, Munich, Germany.'}, {'lastname': 'Danek', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Department of Neurology, Ludwig-Maximilians-University, Munich, Germany.'}, {'lastname': 'Gerhard', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK.'}, {'lastname': 'Otto', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neurology, University of Ulm, Ulm, Germany.'}, {'lastname': 'Butler', 'firstname': 'Chris', 'initials': 'C', 'affiliation': 'Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom.'}, {'lastname': 'Frisoni', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Don Carlo Gnocchi, Florence, Italy.'}, {'lastname': 'Heller', 'firstname': 'Carolin', 'initials': 'C', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Cash', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Convery', 'firstname': 'Rhian S', 'initials': 'RS', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Moore', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK.'}, {'lastname': 'Sanchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': ""Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Departament de Biomedicina, Institute of Neuroscience, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain. Electronic address: rsanchez@clinic.cat.""}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2020. Published by Elsevier Inc.,"10.1016/j.nicl.2020.102540
10.1016/j.biopsych.2014.03.006
10.1038/nature05016
10.1093/brain/awm320
10.1016/J.NEUROBIOLAGING.2011.10.031
10.1089/rej.2007.0623
10.3233/JAD-150270
10.1016/J.NEUROBIOLAGING.2017.10.008
10.1016/j.neurobiolaging.2019.12.004
10.1038/nature05017
10.1016/j.tig.2008.01.004
10.1006/nimg.1998.0395
10.1212/WNL.0b013e31828407bc
10.1212/WNL.0b013e31820a0e3b
10.1073/pnas.200033797
10.1016/j.neuroimage.2004.07.016
10.1186/s13195-018-0376-9
10.1016/S1474-4422(19)30394-1
10.1016/J.NEUROBIOLAGING.2012.11.005
10.1007/s00401-016-1610-9
10.1016/j.nicl.2018.05.017
10.1016/J.NEUROBIOLAGING.2018.12.017
10.1016/j.jalz.2013.09.009
10.1001/jamaneurol.2013.4835
10.1016/j.neurol.2013.07.010
10.1016/S1474-4422(14)70324-2
10.1016/j.neuroimage.2004.03.032
10.1038/ng.536
10.1212/01.wnl.0000343851.46573.67",<Element 'PubmedArticle' at 0x7f05dd7e87c0>
159,"33318950
18398493
32537632
29743967
25980574
32640331
29620235
22556454
24454289
25050288
12857005
25482064
17498941
11795092
12408732
7222048
17849357
18344904
17849358
30956682
14522442
18055147
19041789
17909878
18519851
22492668
22648266
9396413
11453041
15211364
11029269
24386634",Subacute oral toxicity of ayurvedic anti-diabetic preparation ,"Jambadyarista is an Ayurvedic polyherbal formulation widely prescribed by Ayurvedic practitioners for the management of diabetes and its associated complications. About 39 companies have marketed this formulation in Bangladesh with consent from the Directorate General of Drug Administration (DGDA).
This study investigated the sub-acute oral toxicity of Jambadyarista in the Sprague-Dawley rat model.
The sub-acute toxicity studies were executed in Sprague-Dawley rats. Jambadyarista formulation was given for 28-days through oral gavage at 10 mL/kg and 20 mL/kg dose to two different groups comprising 6 rats of both sex/groups. Across the experimental period mortality, adverse reactions were closely monitored. After 28-day feeding hematological, biochemical, and relative organ weights were quantified.
No mortality and/or signs of morbidity were observed for 28-day of repeated-dose sub-acute toxicity. Any pernicious change in body weight, biochemical, and hematological parameters along with relative organ weight were not observed for Jambadyarista. Correlation study among parameters of the renal profile, liver profile, lipid profile also metabolic hormones (T
Jambadyarista preparation did not cause any potential toxic effect in repeated dose subacute toxicity study over Sprague-Dawley rats orally. Therefore, low dose administration of Jambadyarista could have a beneficial effect on diabetes and can be considered safe before the chronic study.","['Ayurvedic', 'Biochemical parameters', 'Hematological parameters', 'Jambadyarista', 'Sub acute toxicity']",Toxicology reports,2020-12-16,"[{'lastname': 'Hasan', 'firstname': 'Mahedi', 'initials': 'M', 'affiliation': 'Department of Pharmacy, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.'}, {'lastname': 'Mahmud', 'firstname': 'Abdullah Al', 'initials': 'AA', 'affiliation': 'Department of Pharmacy, Manarat International University, Ashulia Model Town, Khagan, Ashulia, Dhaka, Bangladesh.'}, {'lastname': 'Alam', 'firstname': 'Md Jahir', 'initials': 'MJ', 'affiliation': 'Department of Pharmacy, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.'}, {'lastname': 'Siddiqui', 'firstname': 'Shafayet Ahmed', 'initials': 'SA', 'affiliation': 'Department of Pharmacy, Atish Dipankar University of Science and Technology, Dhaka, 1230, Bangladesh.'}, {'lastname': 'Arman', 'firstname': 'Md Saiful Islam', 'initials': 'MSI', 'affiliation': 'Department of Pharmacy, International Islamic University Chittagong, Chattogram, 4318, Bangladesh.'}, {'lastname': 'Mahmud', 'firstname': 'Muhammed Hasan', 'initials': 'MH', 'affiliation': 'Department of Pharmacy, International Islamic University Chittagong, Chattogram, 4318, Bangladesh.'}, {'lastname': 'Amin', 'firstname': 'Mohammad Nurul', 'initials': 'MN', 'affiliation': 'Department of Pharmacy, Atish Dipankar University of Science and Technology, Dhaka, 1230, Bangladesh.'}, {'lastname': 'Imtiaz', 'firstname': 'Omar', 'initials': 'O', 'affiliation': 'Department of Pharmacy, Manarat International University, Ashulia Model Town, Khagan, Ashulia, Dhaka, Bangladesh.'}, {'lastname': 'Shahriar', 'firstname': 'Masum', 'initials': 'M', 'affiliation': 'Department of Pharmacy, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.'}, {'lastname': 'Jakaria', 'firstname': 'Md', 'initials': 'M', 'affiliation': 'Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia.'}]",,"Jambadyarista preparation did not cause any potential toxic effect in repeated dose subacute toxicity study over Sprague-Dawley rats orally. Therefore, low dose administration of Jambadyarista could have a beneficial effect on diabetes and can be considered safe before the chronic study.","No mortality and/or signs of morbidity were observed for 28-day of repeated-dose sub-acute toxicity. Any pernicious change in body weight, biochemical, and hematological parameters along with relative organ weight were not observed for Jambadyarista. Correlation study among parameters of the renal profile, liver profile, lipid profile also metabolic hormones (T",© 2020 The Author(s).,10.1016/j.toxrep.2020.11.011,<Element 'PubmedArticle' at 0x7f05dea31770>
160,33222922,Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.,"Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue with an extended half-life of approximately 1 week has being come into clinic trial to treat parkingson's disease but little is known about its effect to prevent against Alzheimer's disease (AD). The goal of the present study was to explore the potential mechanisms of semaglutide to protect against AD.
We treated SH-SY5Y cell line with Aβ
Semaglutide enhanced autophagy by increasing the expression of LC3II, Atg7, Beclin-1 and P62 which were inhibited by Aβ
Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ ","['Alzheimer’s disease', 'Apoptosis', 'Autophagy', 'Aβ', 'SH-SY5Y cell line', 'Semaglutide']",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,2020-11-24,"[{'lastname': 'Chang', 'firstname': 'Yan-Fang', 'initials': 'YF', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China.'}, {'lastname': 'Zhang', 'firstname': 'Di', 'initials': 'D', 'affiliation': 'Chemistry Department, Shanxi Medical University, Taiyuan, Shanxi, China.'}, {'lastname': 'Hu', 'firstname': 'Wei-Min', 'initials': 'WM', 'affiliation': 'Neurology Department, Second Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.'}, {'lastname': 'Liu', 'firstname': 'Dong-Xing', 'initials': 'DX', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China; Neurology Department, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.'}, {'lastname': 'Li', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China. Electronic address: lilinsubmission@163.com.'}]",,Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ ,"Semaglutide enhanced autophagy by increasing the expression of LC3II, Atg7, Beclin-1 and P62 which were inhibited by Aβ",Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.jocn.2020.09.054,<Element 'PubmedArticle' at 0x7f05dec659f0>
161,"33197149
16862116
16862115
16950801
22608501
27021778
28000352
30922528
31855245
18768919
19158106
28404863
24619111
29036611
31870439
31600775
31291241
28453791
28778989
28073925
20026663
23830905
28438992
31467413
24959705
27238186
20554533
21303699
27679482
29348617
31479861
22920859
23831027
26436904
26598621
27535912
29934873
26973102
28851452
31278881
23129776
28804598
23041626
23516300
29378861
19924424
21644037
9855500
21810890
21325651
21514250
18228490
12403597
14632076
15703444
15253663
15979981
15262778
19131956
19033363
25516281
20522652
20667979
22733568
25022663
28379303
29929528
30180904
26434508
25186741
25401692
31870439
27789271
27515686
17071926
23201826
27778404
21645191
24694258
27035808
22895706
29434051
27601437
25130657
25342129
26062630
27511944
29406582
16446100
21111824
27114033
21763610
20223751
26358247
29028540
29158309
30602770
26858453",Elevated levels of extracellular vesicles in progranulin-deficient mice and FTD-GRN Patients.,"The goal of this study was to investigate the effect of progranulin insufficiency on extracellular vesicles (EVs), a heterogeneous population of vesicles that may contribute to progression of neurodegenerative disease. Loss-of-function mutations in progranulin (GRN) are a major cause of frontotemporal dementia (FTD), and brains from GRN carriers with FTD (FTD-GRN) exhibit signs of lysosomal dysfunction. Lysosomal dysfunction may induce compensatory increases in secretion of exosomes, EVs secreted from the endolysosomal system, so we hypothesized that progranulin insufficiency would increase EV levels in the brain.
We analyzed levels and protein contents of brain EVs from Grn
Grn
These data show that symptomatic FTD-GRN patients have elevated levels of brain and plasma EVs, and that this effect is modeled in the brain of Grn","['exosome', 'extracellular vesicle', 'frontotemporal dementia', 'progranulin']",Annals of clinical and translational neurology,2020-11-17,"[{'lastname': 'Arrant', 'firstname': 'Andrew E', 'initials': 'AE', 'affiliation': ""Departments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.""}, {'lastname': 'Davis', 'firstname': 'Skylar E', 'initials': 'SE', 'affiliation': ""Departments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.""}, {'lastname': 'Vollmer', 'firstname': 'Rachael M', 'initials': 'RM', 'affiliation': ""Departments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.""}, {'lastname': 'Murchison', 'firstname': 'Charles F', 'initials': 'CF', 'affiliation': ""Departments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.\nDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.""}, {'lastname': 'Mobley', 'firstname': 'James A', 'initials': 'JA', 'affiliation': 'Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'lastname': 'Nana', 'firstname': 'Alissa L', 'initials': 'AL', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Spina', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Grinberg', 'firstname': 'Lea T', 'initials': 'LT', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.\nDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Karydas', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Miller', 'firstname': 'Bruce L', 'initials': 'BL', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Seeley', 'firstname': 'William W', 'initials': 'WW', 'affiliation': 'Department of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.\nDepartment of Pathology, University of California, San Francisco, San Francisco, California, USA.'}, {'lastname': 'Roberson', 'firstname': 'Erik D', 'initials': 'ED', 'affiliation': ""Departments of Neurology and Neurobiology, Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Evelyn F. McKnight Brain Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.""}]",,,Grn,© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.,10.1002/acn3.51242,<Element 'PubmedArticle' at 0x7f05dec52130>
162,"33154085
28735855
22753214
30688979
28299725
29927845
27492370
29306604
28509727
27402894
29452176
26886565
27163195
30618724
30383807
27492369
29562545
30264910
17488768
28694144
29873596
16636899
21175580
29733881
26993506
25523424
27474376
20528637
29141174
2933950
29146535
25146097
30676631
29912013
25030513
25344354
27393848
28441185
21464050
21930719
28509727
27666598
29330643
23911756
18378359
23911753
30909218
22964777
22818266
30814348",Association of Angiotensin II-Stimulating Antihypertensive Use and Dementia Risk: Post Hoc Analysis of the PreDIVA Trial.,"To assess whether angiotensin II-stimulating antihypertensives (thiazides, dihydropyridine calcium channel blockers, and angiotensin I receptor blockers) convey a lower risk of incident dementia compared to angiotensin II-inhibiting antihypertensives (angiotensin-converting enzyme inhibitors, β-blockers, and nondihydropyridine calcium channel blockers), in accordance with the ""angiotensin hypothesis.""
We performed Cox regression analyses of incident dementia (or mortality as competing risk) during 6-8 years of follow-up in a population sample of 1,909 community-dwelling individuals (54% women) without dementia, aged 70-78 (mean 74.5 ± 2.5) years.
After a median of 6.7 years of follow-up, dementia status was available for 1,870 (98%) and mortality for 1,904 (>99%) participants. Dementia incidence was 5.6% (27/480) in angiotensin II-stimulating, 8.2% (59/721) in angiotensin II-inhibiting, and 6.9% (46/669) in both antihypertensive type users. Adjusted for dementia risk factors including blood pressure and medical history, angiotensin II-stimulating antihypertensive users had a 45% lower incident dementia rate (hazard ratio [HR], 0.55; 95% CI, 0.34-0.89) without excess mortality (HR, 0.86; 95% CI, 0.64-1.16), and individuals using both types had a nonsignificant 20% lower dementia rate (HR, 0.80; 95% CI,0.53-1.20) without excess mortality (HR, 0.97; 95% CI, 0.76-1.24), compared to angiotensin II-inhibiting antihypertensive users. Results were consistent for subgroups based on diabetes and stroke history, but may be specific for individuals without a history of cardiovascular disease.
Users of angiotensin II-stimulating antihypertensives had lower dementia rates compared to angiotensin II-inhibiting antihypertensive users, supporting the angiotensin hypothesis. Confounding by indication must be examined further, although subanalyses suggest this did not influence results. If replicated, dementia prevention could become a compelling indication for older individuals receiving antihypertensive treatment.",[],Neurology,2020-11-07,"[{'lastname': 'van Dalen', 'firstname': 'Jan Willem', 'initials': 'JW', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle. j.vandalen@amc.nl.'}, {'lastname': 'Marcum', 'firstname': 'Zachary A', 'initials': 'ZA', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Gray', 'firstname': 'Shelly L', 'initials': 'SL', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Barthold', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Moll van Charante', 'firstname': 'Eric P', 'initials': 'EP', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'van Gool', 'firstname': 'Willem A', 'initials': 'WA', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Crane', 'firstname': 'Paul K', 'initials': 'PK', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Larson', 'firstname': 'Eric B', 'initials': 'EB', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}, {'lastname': 'Richard', 'firstname': 'Edo', 'initials': 'E', 'affiliation': 'From the Departments of Neurology (J.W.v.D., W.A.v.G., E.R.) and General Practice (E.P.M.v.C.), Amsterdam UMC, University of Amsterdam; Department of Neurology (J.W.v.D., E.R.), Donders Institute for Brain, Behaviour and Cognition, Radboud University Medical Centre, Nijmegen, the Netherlands; Schools of Pharmacy (Z.A.M., S.L.G., D.B.) and Medicine (P.K.C.), University of Washington; and Kaiser Permanente Washington Health Research Institute (E.B.L.), Seattle.'}]",,,"After a median of 6.7 years of follow-up, dementia status was available for 1,870 (98%) and mortality for 1,904 (>99%) participants. Dementia incidence was 5.6% (27/480) in angiotensin II-stimulating, 8.2% (59/721) in angiotensin II-inhibiting, and 6.9% (46/669) in both antihypertensive type users. Adjusted for dementia risk factors including blood pressure and medical history, angiotensin II-stimulating antihypertensive users had a 45% lower incident dementia rate (hazard ratio [HR], 0.55; 95% CI, 0.34-0.89) without excess mortality (HR, 0.86; 95% CI, 0.64-1.16), and individuals using both types had a nonsignificant 20% lower dementia rate (HR, 0.80; 95% CI,0.53-1.20) without excess mortality (HR, 0.97; 95% CI, 0.76-1.24), compared to angiotensin II-inhibiting antihypertensive users. Results were consistent for subgroups based on diabetes and stroke history, but may be specific for individuals without a history of cardiovascular disease.","Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",10.1212/WNL.0000000000010996,<Element 'PubmedArticle' at 0x7f05ded5e270>
163,"33148300
31104070
8387282
10782362
11390861
16769769
10720032
11754960
29324626
16356231
19662382
24533868
27282767
28411114
30583748
31037864
17418290
21867843
20529344
18490402
26577429
26766169
29932477
30843353
16099941
12364390
17962242
17318497
26266901
26266791
30782906
17938396
32463121
26903338
32630976
16132892
3203132
20400903
30059504
32111263
31625979
28101605","Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness.","Biomarkers can be of help to understand critical illness and to identify and stratify sepsis. Adrenomedullin is a vasoactive hormone, with reported prognostic and potentially therapeutic value in sepsis. The primary aim of this study was to investigate the association of circulating bioactive adrenomedullin (bio-ADM) levels at intensive care unit (ICU) admission with mortality in sepsis patients and in a general ICU population. Secondary aims included the association of bio-ADM with organ failure and the ability of bio-ADM to identify sepsis.
In this retrospective observational study, adult patients admitted to one of four ICUs during 2016 had admission bio-ADM levels analysed. Age-adjusted odds ratios (OR) with 95% CI for log-2 transformed bio-ADM, and Youden's index derived cut-offs were calculated. The primary outcome was 30-day mortality, and secondary outcomes included the need for organ support and the ability to identify sepsis.
Bio-ADM in 1867 consecutive patients were analysed; 632 patients fulfilled the sepsis-3 criteria of whom 267 had septic shock. The median bio-ADM in the entire ICU population was 40 pg/mL, 74 pg/mL in sepsis patients, 107 pg/mL in septic shock and 29 pg/mL in non-septic patients. The association of elevated bio-ADM and mortality in sepsis patients and the ICU population resulted in ORs of 1.23 (95% CI 1.07-1.41) and 1.22 (95% CI 1.12-1.32), respectively. The association with mortality remained after additional adjustment for lactate in sepsis patients. Elevated bio-ADM was associated with an increased need for dialysis with ORs of 2.28 (95% CI 2.01-2.59) and 1.97 (95% CI 1.64-2.36) for the ICU population and sepsis patients, respectively, and with increased need of vasopressors, OR 1.33 (95% CI 1.23-1.42) (95% CI 1.17-1.50) for both populations. Sepsis was identified with an OR of 1.78 (95% CI 1.64-1.94) for bio-ADM, after additional adjustment for severity of disease. A bio-ADM cut-off of 70 pg/mL differentiated between survivors and non-survivors in sepsis, but a Youden's index derived threshold of 108 pg/mL performed better.
Admission bio-ADM is associated with 30-day mortality and organ failure in sepsis patients as well as in a general ICU population. Bio-ADM may be a morbidity-independent sepsis biomarker.","['Adrenomedullin', 'Bioactive adrenomedullin', 'Biomarkers', 'Critical illness', 'Cut-off', 'Sepsis', 'Septic shock']","Critical care (London, England)",2020-11-06,"[{'lastname': 'Lundberg', 'firstname': 'Oscar H M', 'initials': 'OHM', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden. oscar.lundberg@med.lu.se.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, 20502, Malmö, Sweden. oscar.lundberg@med.lu.se.'}, {'lastname': 'Lengquist', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, 20502, Malmö, Sweden.'}, {'lastname': 'Spångfors', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.\nDepartment of Anaesthesia and Intensive Care, Kristianstad Hospital, 29133, Kristianstad, Sweden.'}, {'lastname': 'Annborn', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.\nDepartment of Anaesthesia and Intensive Care, Helsingborg Hospital, 25437, Helsingborg, Sweden.'}, {'lastname': 'Bergmann', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': 'SphingoTec GmbH, 16761, Henningsdorf, Germany.'}, {'lastname': 'Schulte', 'firstname': 'Janin', 'initials': 'J', 'affiliation': 'SphingoTec GmbH, 16761, Henningsdorf, Germany.'}, {'lastname': 'Levin', 'firstname': 'Helena', 'initials': 'H', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.'}, {'lastname': 'Melander', 'firstname': 'Olle', 'initials': 'O', 'affiliation': 'Department of Infectious diseases, Skåne University Hospital, 20502, Malmö, Sweden.\nDepartment of Internal medicine, Skåne University Hospital, 20502, Malmö, Sweden.'}, {'lastname': 'Frigyesi', 'firstname': 'Attila', 'initials': 'A', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, 20502, Malmö, Sweden.'}, {'lastname': 'Friberg', 'firstname': 'Hans', 'initials': 'H', 'affiliation': 'Department of Clinical Medicine, Anaesthesiology and Intensive Care, Lund University, 22185, Lund, Sweden.\nDepartment of Intensive and Perioperative Care, Skåne University Hospital, 20502, Malmö, Sweden.'}]",,,"Bio-ADM in 1867 consecutive patients were analysed; 632 patients fulfilled the sepsis-3 criteria of whom 267 had septic shock. The median bio-ADM in the entire ICU population was 40 pg/mL, 74 pg/mL in sepsis patients, 107 pg/mL in septic shock and 29 pg/mL in non-septic patients. The association of elevated bio-ADM and mortality in sepsis patients and the ICU population resulted in ORs of 1.23 (95% CI 1.07-1.41) and 1.22 (95% CI 1.12-1.32), respectively. The association with mortality remained after additional adjustment for lactate in sepsis patients. Elevated bio-ADM was associated with an increased need for dialysis with ORs of 2.28 (95% CI 2.01-2.59) and 1.97 (95% CI 1.64-2.36) for the ICU population and sepsis patients, respectively, and with increased need of vasopressors, OR 1.33 (95% CI 1.23-1.42) (95% CI 1.17-1.50) for both populations. Sepsis was identified with an OR of 1.78 (95% CI 1.64-1.94) for bio-ADM, after additional adjustment for severity of disease. A bio-ADM cut-off of 70 pg/mL differentiated between survivors and non-survivors in sepsis, but a Youden's index derived threshold of 108 pg/mL performed better.",,"10.1186/s13054-020-03351-1
10.1001/jama.2019.5791
10.1006/bbrc.1993.1451
10.1210/edrv.21.2.0396
10.1189/jlb.0206123
10.1016/S0196-9781(01)00508-3
10.1097/SHK.0000000000001103
10.1186/cc3885
10.1007/s00134-009-1610-5
10.1186/cc13731
10.1186/s13054-016-1361-y
10.1016/j.chest.2017.03.035
10.3343/alm.2019.39.5.454
10.1016/j.jacc.2006.12.038
10.1016/j.jacc.2011.06.006
10.1186/cc9055
10.1378/chest.08-0047
10.1016/j.ajem.2015.10.033
10.2459/JCM.0000000000000299
10.1002/ejhf.1245
10.1002/ejhf.1437
10.1373/clinchem.2005.051110
10.1161/01.RES.0000036603.61868.F9
10.1093/bja/aem295
10.1007/s00134-007-0561-y
10.1186/2197-425X-2-1
10.1186/2197-425X-1-3
10.1136/bmjopen-2018-024475
10.7326/0003-4819-147-8-200710160-00010
10.1111/aas.13647
10.1001/jama.2016.0287
10.1373/jalm.2017.023655
10.1007/s00134-005-2763-5
10.1093/biomet/69.3.553
10.1016/j.patrec.2005.10.010
10.2307/2531595
10.1097/CCM.0b013e3181de4406
10.1371/journal.pone.0198847
10.1097/CCM.0000000000004044
10.1007/s00134-017-4683-6",<Element 'PubmedArticle' at 0x7f05df0288b0>
164,"33094632
29377010
24704273
30117532
8855991
22329649
28006935
25015014
31969813
29267309
30775986
29217283
22967480
30692905
22484365
30400097
17315079
21945934
31651303
27434652
30006491
31068799
16823476
28332351
24625795
23237984
31913419
19584347
24995977
26906354
26279362
3899825
28987937
12485966
24397811
25349150
16914228
31925754
3165237
26186410
23110988
27927801
25352450
22213409
27982680
31539648
30746502
28812049
32194507
22232009
24933398
12802337","Plasma levels of adipokines in patients with Alzheimer's disease - where is the ""breaking point"" in Alzheimer's disease pathogenesis?","Peripheral insulin resistance is associated with decreasing adiponectin and increasing leptin plasma levels, and also with cognitive decline. The effects of adipokines on brain function have been published from both animal and human studies. In particular, the influence of leptin and adiponectin on the development of Alzheimer's disease (AD) has been extensively investigated. However, the association between adipsin and AD is as yet unknown. In 37 patients with AD and 65 controls that followed the same study protocol, we tested whether adiponectin, leptin, and adipsin could be used as biomarkers in the early stages of AD. In contrast with conclusions of cognition studies in insulin resistant states, our study found a correlation of impaired neuropsychological performance with increasing adiponectin and decreasing leptin in AD patients. Nevertheless, no significant differences between patients and controls were found. AD women had significantly increased adipsin compared to controls, and there was a positive correlation of adipsin with age and disease duration. Although adipokines do not appear to be suitable biomarkers for early AD diagnosis, they certainly play a role in the pathogenesis of AD. Further studies will be needed to explain the cause of the adipokine ""breaking point"" that leads to the pathogenesis of overt AD.",[],Physiological research,2020-10-24,"[{'lastname': 'Vaňková', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic. mvankova@endo.cz.'}, {'lastname': 'Vacínová', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Včelák', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Vejražková', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Lukášová', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Rusina', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Holmerová', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Jarolímová', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Vaňková', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Bendlová', 'firstname': 'B', 'initials': 'B', 'affiliation': None}]",,,,,"10.33549/physiolres.934536
10.1038/nrneurol.2017.185
10.1016/j.euroneuro.2014.03.002
10.5603/EP.a2018.0055
10.1111/j.1532-5415.1996.tb01362.x
10.2174/156720512799015064
10.33549/physiolres.933538
10.1016/j.maturitas.2014.06.008
10.3389/fnagi.2019.00356
10.1371/journal.pone.0186205
10.3233/JAD-180906
10.1016/j.neuropharm.2017.12.001
10.1530/JME-12-0151
10.3389/fnins.2018.01027
10.1038/oby.2012.81
10.3233/JAD-180533
10.1016/j.bbrc.2011.09.050
10.1186/s12902-019-0431-y
10.1111/cen.13157
10.1161/JAHA.117.008108
10.3389/fnagi.2019.00088
10.1172/JCI29126
10.3349/ymj.2017.58.3.479
10.3233/JAD-140006
10.1016/j.exger.2012.11.014
10.1001/jama.2019.20939
10.1001/jama.2009.976
10.1016/j.cell.2014.06.005
10.2174/156720501303160217111434
10.1016/j.cca.2015.08.009
10.1007/BF00280883
10.1016/j.neuropharm.2017.09.038
10.1161/circ.106.25.3143
10.33549/physiolres.932602
10.1093/ageing/afu160
10.1016/j.peptides.2006.07.001
10.1007/s40618-019-01168-6
10.1016/0002-9149(88)90248-2
10.1111/cen.12856
10.1017/S0029665112002753
10.1152/physiol.00012.2016
10.3233/JAD-141503
10.1001/archneurol.2011.670
10.33549/physiolres.933366
10.1016/j.neurobiolaging.2019.08.012
10.1210/js.2018-00359
10.1002/acn3.436
10.3389/fendo.2020.00108
10.3233/JAD-2012-111385
10.1016/j.metabol.2014.05.001
10.1038/nature01705",<Element 'PubmedArticle' at 0x7f05df005ef0>
165,"33041964
18344392
27401947
30618654
29043468
20925068
24607323
28974386
30959072
31900464
11087781
16533144
17098842
17635983
19246476
22237822
24117192
25814509
28257128
29951580
32269747
19733364
18577547
11709484
12417456
25578289
12633150
10945804
19538208
22484304
23224635
11752477
24363137
25737166
16247051
23794682
17542011
24757109
10968298
15242420
18231798
15551331
24038502
26577652
31054380
29948903
23573795
23383629
27498084
31009465
23682773
26796792
24459407
26743859
19401959
22913619
27014598
29324460
24490118
28054129
29478836
16102980
31943448
19914295
27235739
10199626
11056468
17169383
12659010
9457787
11324860
11935429
14982120
31180695
2183097
17850456
18513207
19685169
29946108
31342271
30111811
30949564
17702614
20385172
25466681
25930683
27693137
24837746
23576971
27870451
27566290
18031771
15704151
19318467
26799371
28501551
27870431
12535954
19538962
22654803
26708712
11215753
12544829
12777705
22749492
21586296
17449457
18595767
18817851
21310234
22236386
12121811
15939479
21262271
21953489
23977020
3737744
31487491
29113830
10527068
32298711
15817188
20553724
25136294
25685848
31282427
28017549
7613632
24969022
25421206
24937438
21907204
26006269
11377730
11445632
16386941
23481590
25260707
12898124
16263125
12007746
15869947
16942768
21940701
16310964
16670842
21531388
30711326
19776728
23616754
23038420
30660957
11823060
21769723
25416742
17417939
22065409
22546523
22537775
23986669
24333647
30153249
24035904
26048953
28384498
16290193
18511051
22265851
12020264
16682542","Biological Sex and Sex Hormone Impacts on Deficits in Episodic-Like Memory in a Rat Model of Early, Pre-motor Stages of Parkinson's Disease.","Episodic memory deficits are among the earliest appearing and most commonly occurring examples of cognitive impairment in Parkinson's disease (PD). These enduring features can also predict a clinical course of rapid motor decline, significant cognitive deterioration, and the development of PD-related dementia. The lack of effective means to treat these deficits underscores the need to better understand their neurobiological bases. The prominent sex differences that characterize episodic memory in health, aging and in schizophrenia and Alzheimer's disease suggest that neuroendocrine factors may also influence episodic memory dysfunction in PD. However, while sex differences have been well-documented for many facets of PD, sex differences in, and sex hormone influences on associated episodic memory impairments have been less extensively studied and have never been examined in preclinical PD models. Accordingly, we paired bilateral neostriatal 6-hydroxydopamine (6-OHDA) lesions with behavioral testing using the What-Where-When Episodic-Like Memory (ELM) Task in adult rats to first determine whether episodic-like memory is impaired in this model. We further compared outcomes in gonadally intact female and male subjects, and in male rats that had undergone gonadectomy-with and without hormone replacement, to determine whether biological sex and/or sex hormones influenced the expression of dopamine lesioned-induced memory deficits. These studies showed that 6-OHDA lesions profoundly impaired recall for all memory domains in male and female rats. They also showed that in males, circulating gonadal hormones powerfully modulated the negative impacts of 6-OHDA lesions on What, Where, and When discriminations in domain-specific ways. Specifically, the absence of androgens was shown to fully attenuate 6-OHDA lesion-induced deficits in ELM for ""Where"" and to partially protect against lesion-induced deficits in ELM for ""What."" In sum, these findings show that 6-OHDA lesions in rats recapitulate the vulnerability of episodic memory seen in early PD. Together with similar evidence recently obtained for spatial working memory, the present findings also showed that diminished androgen levels provide powerful, highly selective protections against the harmful effects that 6-OHDA lesions have on memory functions in male rats.","['6-OHDA', 'androgen', 'dopamine', 'estrogen', 'mild cognitive impairment', 'neostriatum']",Frontiers in neurology,2020-10-13,"[{'lastname': 'Conner', 'firstname': 'Meagan R', 'initials': 'MR', 'affiliation': 'Graduate Program in Neuroscience, Stony Brook University, Stony Brook, NY, United States.\nDepartment of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY, United States.'}, {'lastname': 'Jang', 'firstname': 'Doyeon', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY, United States.'}, {'lastname': 'Anderson', 'firstname': 'Brenda J', 'initials': 'BJ', 'affiliation': 'Department of Psychology, Stony Brook University, Stony Brook, NY, United States.'}, {'lastname': 'Kritzer', 'firstname': 'Mary F', 'initials': 'MF', 'affiliation': 'Department of Neurobiology and Behavior, Stony Brook University, Stony Brook, NY, United States.'}]",,,,"Copyright © 2020 Conner, Jang, Anderson and Kritzer.","10.3389/fneur.2020.00942
10.1136/jnnp.2007.131045
10.1111/jnc.13691
10.3389/fnana.2018.00113
10.1007/s10072-017-3154-8
10.1002/mds.23388
10.1016/j.yfrne.2014.02.002
10.1016/j.yfrne.2017.09.002
10.1016/j.neubiorev.2019.04.003
10.1038/s41582-019-0294-x
10.1212/WNL.55.9.1358
10.1586/14737175.6.3.407
10.1136/jnnp.2006.103788
10.1136/jnnp.2006.104695
10.1136/jnnp.2008.168211
10.1007/s00415-011-6392-3
10.1111/ane.12189
10.1136/postgradmedj-2015-133247
10.1038/nrneurol.2017.27
10.1038/s41531-018-0055-3
10.1155/2020/2076942
10.1016/j.jns.2009.08.034
10.1093/brain/awn112
10.1093/cercor/11.12.1136
10.1016/S0028-3932(02)00108-2
10.1016/j.parkreldis.2014.12.018
10.1001/archneur.60.3.387
10.1136/jnnp.69.3.308
10.1111/j.1468-1331.2009.02707.x
10.1016/j.nbd.2012.03.029
10.1007/s00702-012-0928-2
10.1146/annurev.psych.53.100901.135114
10.1212/WNL.0000000000000066
10.1002/mds.26170
10.1212/01.wnl.0000180516.69442.95
10.1212/WNL.0b013e31829c5c86
10.1002/mds.21507
10.1002/mds.25853
10.1111/j.1532-5415.2000.tb06891.x
10.1111/j.1600-0404.2004.00292.x
10.1007/s00401-008-0344-8
10.1002/mds.20324
10.1002/mds.25633
10.3233/JPD-150652
10.1016/j.nicl.2019.101824
10.1007/s11682-018-9909-x
10.1080/87565641.2012.759580
10.1080/09658211.2013.765892
10.1016/j.neubiorev.2016.07.035
10.1371/journal.pone.0214945
10.1111/ggi.12093
10.1037/pag0000070
10.1016/j.neubiorev.2015.10.013
10.1055/s-0029-1216281
10.1080/13803395.2012.712676
10.5498/wjp.v6.i1.54
10.1097/YCO.0000000000000401
10.14336/AD.2014.050063
10.1007/s00415-016-8384-9
10.1016/j.parkreldis.2018.02.007
10.5772/17693
10.1590/S1980-65742014000400014
10.1016/j.nlm.2005.07.002
10.1111/ejn.14676
10.1016/j.bbr.2009.11.020
10.1016/j.neuroscience.2016.05.041
10.1016/S0306-4522(98)00341-8
10.1002/1096-9861(20001127)427:4&lt;617::AID-CNE9&gt;3.0.CO;2-#
10.1016/j.physbeh.2006.10.010
10.1590/S1519-69842002000400008
10.1007/BF00289314
10.1037/0022-3514.60.6.831
10.1093/chemse/17.5.519
10.1037/0022-3514.74.1.262
10.1037/0894-4105.15.2.165
10.1076/jcen.24.1.107.970
10.1080/09658210244000117
10.1002/acp.1104
10.1037/bul0000197
10.1016/S0149-7634(05)80157-5
10.1111/j.1365-2826.2007.01594.x
10.1111/j.1365-2826.2008.01710.x
10.1007/s11357-009-9114-3
10.1038/s41386-018-0125-6
10.3758/s13415-019-00736-w
10.1038/s41386-018-0167-9
10.1016/j.ynstr.2019.100155
10.1016/B978-0-12-802175-0.00032-2
10.1016/j.nlm.2007.06.006
10.1016/j.bbr.2010.04.009
10.1016/j.cub.2014.10.074
10.1016/j.pneurobio.2015.04.002
10.1016/j.cub.2016.08.023
10.1016/j.bbr.2014.04.032
10.3389/fnhum.2013.00123
10.1002/jnr.23861
10.1016/j.pbb.2016.08.005
10.1016/j.physbeh.2007.10.020
10.1002/hbm.20092
10.1101/lm.918309
10.1111/nyas.12996
10.1016/j.psyneuen.2017.05.002
10.1002/jnr.23811
10.1016/S0306-4522(02)00578-X
10.1016/j.yhbeh.2009.06.002
10.3389/fendo.2011.00035
10.1016/j.neubiorev.2015.09.024
10.1007/s007020070084
10.1097/00001756-200301200-00009
10.1385/ENDO:21:1:67
10.1016/j.neurobiolaging.2012.05.022
10.1016/j.neuropharm.2011.04.031
10.1007/BF03033565
10.1016/j.parkreldis.2008.04.015
10.1016/j.neuroscience.2008.08.035
10.1016/j.nbd.2011.01.024
10.1016/j.nbd.2011.12.040
10.1016/S0361-9230(02)00754-2
10.1016/j.jneumeth.2005.04.005
10.1016/j.bbr.2011.01.028
10.1007/s12640-011-9278-3
10.1371/journal.pone.0071341
10.1016/j.biopha.2017.01.159
10.1016/0031-9384(86)90239-8
10.1016/j.physbeh.2019.112670
10.1016/j.mce.2017.11.001
10.1037/0894-4105.13.4.590
10.1016/j.neubiorev.2020.04.007
10.1016/j.bbr.2004.11.006
10.1016/j.yhbeh.2010.05.013
10.3389/fncel.2014.00211
10.1155/2015/787451
10.3233/JPD-191683
10.1016/j.parkreldis.2016.12.008
10.1111/j.1460-9568.1995.tb01085.x
10.1016/j.nbd.2014.06.009
10.1007/s12035-014-8927-y
10.1016/j.yhbeh.2014.06.006
10.1016/j.yhbeh.2011.08.012
10.1016/j.neuropharm.2015.05.015
10.1016/S0166-4328(01)00195-4
10.1212/WNL.57.1.80
10.1016/j.tics.2005.12.010
10.1016/j.yhbeh.2013.02.007
10.1093/cercor/bhu222
10.1007/s00213-003-1537-4
10.1016/j.yhbeh.2005.09.008
10.1016/S0893-133X(01)00420-1
10.1016/j.expneurol.2005.01.007
10.1016/j.yhbeh.2006.07.005
10.1093/cercor/bhr258
10.1016/j.neuroscience.2005.09.028
10.1007/s00213-006-0404-5
10.1016/j.biopsych.2011.03.028
10.1016/j.tics.2018.12.006
10.1038/npp.2009.126
10.3389/fnbeh.2013.00033
10.1159/000341998
10.1016/j.cortex.2018.11.021
10.1016/S0306-4522(01)00513-9
10.1007/7854_2010_95
10.1177/1073858414558065
10.1146/annurev.neuro.30.051606.094328
10.3389/fnbeh.2011.00069
10.1016/j.bbr.2012.04.022
10.1016/j.bbr.2012.04.018
10.3389/fnbeh.2013.00112
10.1016/j.nlm.2013.12.001
10.1371/journal.pbio.2006100
10.1093/cercor/bht245
10.1093/cercor/bhv112
10.1016/j.nlm.2017.03.019
10.1016/j.nlm.2005.10.002
10.1016/j.yhbeh.2008.04.001
10.1016/j.yhbeh.2012.01.003
10.1001/archneur.59.5.807
10.1001/archneur.63.5.729",<Element 'PubmedArticle' at 0x7f05dee9f900>
166,33008530,"Sex difference in Alzheimer's disease: An updated, balanced and emerging perspective on differing vulnerabilities.","Sex biology influences Alzheimer's disease (AD). Sex differences exist in the epidemiologic, imaging, biomarker, and pathology studies of this uniquely human condition. The mandate to understand sex differences in major diseases like AD is important for many reasons. First, AD is the most common neurodegenerative condition and a devastating disease-experienced as an insidious and progressive erosion of memory, cognition, and other brain functions. Second, since true sex differences in AD exist, their precise understanding could reveal what protects one sex or makes the other vulnerable-and this knowledge could inform development of new therapeutic approaches to benefit both sexes. Third, AD develops in the aging brain in a milieu of decreased circulating gonadal hormones. Thus, how sex-specific depletion affects the brain along with how replacement of androgens in men and estrogens and progestins in women alters vulnerability to AD are relevant questions, with clinical implications in a future of personalized medicine. This review will highlight advances in sex differences in AD in human populations with a focused perspective on epidemiology, biomarkers, and clinical trials. A thorough and concise overview of sex differences reviewed here indicates varying vulnerabilities in men and women. This review examines several lines of recent and strong evidence that collectively indicate the following: (1) men die faster with AD, (2) more women live with AD, (3) both sexes show similar risk of developing AD until advanced ages when women show increased risk, (4) both sexes show largely similar AD biomarker burden with notable exceptions for higher tau levels in subgroups of women with high amyloid, (5) women show brain reserve and resilience to tau pathology, (6) both sexes are vulnerable to the genetic risk of carrying APOE4, with women showing higher risk, and (7) neither sex has shown clear benefit of hormone replacement for AD or dementia risk in randomized clinical trials to date.","['Aging', ""Alzheimer's disease"", 'Androgen', 'Biomarkers', 'Dementia', 'Estrogen', 'Gender', 'Sex', 'Sex difference', 'Testosterone']",Handbook of clinical neurology,2020-10-04,"[{'lastname': 'Dubal', 'firstname': 'Dena B', 'initials': 'DB', 'affiliation': 'Department of Neurology, Endowed Chair in Aging and Neurodegenerative Disease, University of California San Francisco, San Francisco, CA, United States. Electronic address: Dena.Dubal@ucsf.edu.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/B978-0-444-64123-6.00018-7,<Element 'PubmedArticle' at 0x7f05df078630>
167,32969566,Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease.,"The gut microbiota coevolves with its host, and numerous factors like diet, lifestyle, drug intake and geographical location continuously modify its composition, deeply influencing host health. Recent studies demonstrated that gut dysbiosis can alter normal brain function through the so-called gut-brain axis, a bidirectional communication network between the central nervous system and the gastrointestinal tract, thus playing a key role in the pathogenesis of neurodegenerative disorders, such as Alzheimer's disease (AD). In this perspective, in the constant search for novel treatments in AD, the rational modulation of gut microbiota composition could represent a promising approach to prevent or delay AD onset or to counteract its progression. Preclinical and human studies on microbiota modulation through oral bacteriotherapy and faecal transplantation showed anti-inflammatory and antioxidant effects, upregulation of plasma concentration of neuroprotective hormones, restoration of impaired proteolytic pathways, amelioration of energy homeostasis with consequent decrease of AD molecular hallmarks and improvement of behavioural and cognitive performances. In this review, we dissect the role of gut microbiota in AD and highlight recent advances in the development of new multitarget strategies for microbiota modulation to be used as possible preventative and therapeutic approaches in AD.","['Alzheimer’s disease', 'dysbiosis', 'gut-brain axis', 'inflammation', 'microbiota modulation', 'oxidative stress', 'prebiotics', 'probiotics', 'proteolysis', 'therapeutic approaches']",The FEBS journal,2020-09-25,"[{'lastname': 'Bonfili', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Cecarini', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Gogoi', 'firstname': 'Olee', 'initials': 'O', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Gong', 'firstname': 'Chunmei', 'initials': 'C', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Cuccioloni', 'firstname': 'Massimiliano', 'initials': 'M', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Angeletti', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Rossi', 'firstname': 'Giacomo', 'initials': 'G', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}, {'lastname': 'Eleuteri', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.'}]",,,,© 2020 Federation of European Biochemical Societies.,10.1111/febs.15571,<Element 'PubmedArticle' at 0x7f05df070a40>
168,32926928,Insulin resistance and bioenergetic manifestations: Targets and approaches in Alzheimer's disease.,"Insulin has a well-established role in cognition, neuronal detoxification and synaptic plasticity. Insulin transduction affect neurotransmitter functions, influence bioenergetics and regulate neuronal survival through regulating glucose energy metabolism and downward pathways.
A systematic literature review of PubMed, Medline, Bentham, Scopus and EMBASE (Elsevier) databases was carried out with the help of the keywords like ""Alzheimer's disease; Hypometabolism; Oxidative stress; energy failure in AD, Insulin; Insulin resistance; Bioenergetics"" till June 2020. The review was conducted using the above keywords to collect the latest articles and to understand the nature of the extensive work carried out on insulin resistance and bioenergetic manifestations in Alzheimer's disease.
The article sheds light on insulin resistance mediated hypometabolic state on pathological progression of AD. The disrupted insulin signaling has pathological outcome in form of disturbed glucose homeostasis, altered bioenergetic state which increases build-up of senile plaques (Aβ), neurofibrillary tangles (τ), decline in transportation of glucose and activation of inflammatory pathways. The mechanistic link of insulin resistant state with therapeutically explorable potential transduction pathways is the focus of the reviewed work.
The present work opines that the mechanism by which the insulin resistance mediates dysregulation of bioenergetics and progresses to neurodegenerative state holds the tangible potential to succeed in the development of novel dementia therapies. Further, hypometabolic complications and altered insulin signaling may be explored as a mechanistic relation between bioenergetic deficits and AD.","[""Alzheimer's disease"", 'Biliverdin reductase', 'Bioenergetics', 'GLUT', 'Hypometabolism', 'Insulin resistance', 'mTOR']",Life sciences,2020-09-15,"[{'lastname': 'Sharma', 'firstname': 'Vivek Kumar', 'initials': 'VK', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab, India; Govt. College of Pharmacy, Rohru, District Shimla, Himachal Pradesh 171207, India.'}, {'lastname': 'Singh', 'firstname': 'Thakur Gurjeet', 'initials': 'TG', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab, India. Electronic address: gurjeet.singh@chitkara.edu.in.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2020.118401,<Element 'PubmedArticle' at 0x7f05df1c5130>
169,"32912799
21435064
16327351
1798880
15600135
23825454
20133762
26828569
22238079
18711114
22219286
8456235
20121976
21896732
27174984
22002422
27580631
21170538
22272986
22811426
27020605
16973878
12019347
11347869
21226772
30405860
29220627
21715678
10938176
32214167
10754229
27190654
24732109
17083302
21056216
23702407
7721257
10966694
6338589
20083042
16944667
21225347
12350438
21896732
14573378
28045040
24629673
20046194
19251443
19998869
18070004
16050432
25995467
21236314
23810208
18246972
9052713
25325492
23924666
9343467
6056816
23574165
10880801
10580714
27815989
11843995
7481413
17384317
17339595
30387527
19749750
25037297
27066274
15326239
10625043
22415141
16122950
21906017
16116137
9208261
14998915
23997365
3759914
28217760
21514358
11068230
12126998
28955219
17342210
22877673
25212464
29490913
22896675
29427050
29552421
25947369
30538617
30538617
28899014
28899014
11401610
26609179
22573105
30106239
15037057
25610772
8548511
30037830
30037830
30037830
23739969
2495925
4008448
27381076
28637840
8955514
25538616
10607155
2065140
28364428
25322206
25142380
23814339
24145819
18559405
23522038
9920102
7170053
26030524
29220873
16399217
32005347
26030850
23354332
27325209
28384471
12794739
17086200
22809452
17483481
26947521
19622817
12531038
25704951
15174015
11231989
16077155
15062210
11382871
7610309
21383234
16182904
32173186
23583623
25926443
16218081
15586779
15586779
27318231
25878183
16183237
28337134
28835407
27247261
27247261
21819181
24846773
15172204
8080387
23283336
8103819
25435336
9157887
7170052
15459246
18596620
14980992
14980992
32139543
12716936
2244798
24094295
30469495
18081622
9588436
22402932
19833552
23856323
26617321
16251950
21172606
17332710
1353313
19913428
22163023
28093830
23801740
22661967
17464473
14655926
15271264
18047498
24145859
26059712
26901503
26901503
25632088
10068311
26193084
56267
4041816
25669188
27221544
28928634
20441796
22619736
16376591
15910515
22162057
26054060
16493235
22496749
22496749
15172206
2665912
24971004
22392034
25921596
16494088
10027692
31848209
26116933
22300710
20032062
23486878
25480798
15725334
24136970
21828324
15018693
6715806
8544907",The Sleep Side of Aging and Alzheimer's Disease.,"As we age, sleep patterns undergo significant modifications in micro and macrostructure, worsening cognition and quality of life. These are associated with remarkable brain changes, like deterioration in synaptic plasticity, gray and white matter, and significant modifications in hormone levels. Sleep alterations are also a core component of mild cognitive impairment (MCI) and Alzheimer's Disease (AD). AD night time is characterized by a gradual decrease in slow-wave activity and a substantial reduction of REM sleep. Sleep abnormalities can accelerate AD pathophysiology, promoting the accumulation of amyloid-β (Aβ) and phosphorylated tau. Thus, interventions that target sleep disturbances in elderly people and MCI patients have been suggested as a possible strategy to prevent or decelerate conversion to dementia. Although cognitive-behavioral therapy and pharmacological medications are still first-line treatments, despite being scarcely effective, new interventions have been proposed, such as sensory stimulation and Noninvasive Brain Stimulation (NiBS). The present review outlines the current state of the art of the relationship between sleep modifications in healthy aging and the neurobiological mechanisms underlying age-related changes. Furthermore, we provide a critical analysis showing how sleep abnormalities influence the prognosis of AD pathology by intensifying Aβ and tau protein accumulation. We discuss potential therapeutic strategies to target sleep disruptions and conclude that there is an urgent need for testing new therapeutic sleep interventions.",[],Sleep medicine,2020-09-12,"[{'lastname': 'Romanella', 'firstname': 'S M', 'initials': 'SM', 'affiliation': 'Siena Brain Investigation and Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Italy.'}, {'lastname': 'Roe', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'lastname': 'Tatti', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Molecular, Cellular & Biomedical Sciences, CUNY, School of Medicine, New York, NY, USA.'}, {'lastname': 'Cappon', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Paciorek', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Testani', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Sleep Medicine Center, Department of Neurology, Policlinico Santa Maria Le Scotte, Siena, Italy.'}, {'lastname': 'Rossi', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Siena Brain Investigation and Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Italy; Human Physiology Section, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.'}, {'lastname': 'Rossi', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Siena Brain Investigation and Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Italy; Human Physiology Section, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.'}, {'lastname': 'Santarnecchi', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Siena Brain Investigation and Neuromodulation Lab (Si-BIN Lab), Department of Medicine, Surgery and Neuroscience, Neurology and Clinical Neurophysiology Section, University of Siena, Italy; Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: esantarn@bidmc.harvard.edu.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,"10.1016/j.sleep.2020.05.029
10.1097/01.wad.0000189052.48688.36
10.1093/sleep/14.6.486
10.1207/S15402010BSM0101_4
10.1073/pnas.0911531107
10.1016/j.neubiorev.2016.01.009
10.1523/JNEUROSCI.4122-11.2012
10.1212/01.wnl.0000324283.57261.37
10.1523/JNEUROSCI.4792-11.2012
10.1093/sleep/16.1.40
10.1126/science.aad5252
10.1016/j.jpsychires.2012.01.008
10.1111/j.1460-9568.2010.07543.x
10.1155/2018/5174815
10.1080/07317115.2017.1384777
10.1038/s41598-020-62374-4
10.1016/S0304-3940(00)00961-7
10.1155/2016/6936381
10.1159/000358083
10.1016/B978-0-444-52006-7.00041-1
10.1016/j.ecl.2013.02.009
10.1159/000184232
10.1148/radiology.216.3.r00au37672
10.1007/s11065-010-9154-6
10.1016/S1388-2457(02)00237-7
10.1073/pnas.1112503108
10.1053/smrv.2002.0252
10.1038/srep39688
10.1016/j.neurobiolaging.2014.02.011
10.1038/nrn2762
10.1111/j.1532-5415.2007.01543.x
10.1017/S1041610205001584
10.1523/JNEUROSCI.3956-14.2015
10.1016/j.brs.2013.05.006
10.1093/sleep/30.12.1617
10.1177/1073858413498936
10.1016/0022-3956(67)90027-1
10.2174/18715273113129990065
10.1016/S0304-3940(99)00765-X
10.1016/j.neurobiolaging.2016.10.009
10.1093/sleep/18.6.425
10.1097/01.JGP.0000249385.50101.67
10.1002/ana.25373
10.1038/nn.2384
10.1016/j.cger.2014.04.007
10.1093/brain/awh129
10.5665/sleep.2956
10.1016/j.nbscr.2016.08.002
10.1016/S0031-9384(02)00733-3
10.3389/fnagi.2017.00292
10.1371/journal.pone.0000276
10.1016/B978-0-444-59427-3.00018-6
10.1016/j.neurobiolaging.2014.08.010
10.1212/WNL.0000000000005193
10.1126/scitranslmed.3003748
10.1007/s11920-018-0866-2
10.1007/s11064-015-1581-6
10.3389/fnins.2018.00867
10.3389/fnins.2018.00867
10.2967/jnumed.115.166439
10.1002/brb3.967
10.1093/gerona/51A.1.M3
10.1523/JNEUROSCI.0273-18.2018
10.1523/JNEUROSCI.0273-18.2018
10.1523/JNEUROSCI.0273-18.2018
10.1523/JNEUROSCI.4988-12.2013
10.1016/j.neuroimage.2016.06.057
10.1523/JNEUROSCI.0260-17.2017
10.1016/S0006-8993(96)00770-6
10.1016/0006-3223(91)90355-P
10.1093/sleep/zsx003
10.1093/brain/awu222
10.5665/sleep.2802
10.1001/jamaneurol.2013.4215
10.1093/schbul/sbn060
10.1016/j.neuron.2013.03.007
10.1038/nature14432
10.1016/j.neurobiolaging.2005.01.015
10.1016/j.jsmc.2019.11.002
10.1038/nn.3324
10.1016/j.tins.2016.05.002
10.1016/j.neuron.2017.02.004
10.1002/cne.10714
10.1016/j.jsmc.2010.12.003
10.1038/nature05278
10.1016/j.neurobiolaging.2012.05.020
10.1073/pnas.0702495104
10.1016/j.tem.2016.02.003
10.1001/jama.2009.1064
10.1053/smrv.2000.0127
10.1016/j.neuron.2015.01.025
10.1177/0748730405277378
10.1111/j.1751-5823.2008.00061.x
10.1093/cercor/bhr025
10.1016/j.neurobiolaging.2005.03.004
10.1016/j.sleep.2020.01.028
10.1016/j.neuron.2013.03.006
10.1523/JNEUROSCI.3133-14.2015
10.1093/sleep/27.7.1255
10.1093/sleep/27.7.1255
10.1016/j.sleep.2015.10.016
10.1016/j.exger.2005.08.009
10.3389/fnhum.2017.00109
10.1016/j.brs.2016.04.016
10.1016/j.brs.2016.04.016
10.1016/j.smrv.2014.03.007
10.1016/j.jpsychores.2004.02.001
10.1001/archneur.1994.00540210046012
10.1523/JNEUROSCI.2030-12.2013
10.1126/science.276.5316.1265
10.1016/0197-4580(82)90024-0
10.1001/archinte.164.4.406
10.1001/archinte.164.4.406
10.1523/JNEUROSCI.23-08-03295.2003
10.1016/j.cger.2013.07.003
10.3390/brainsci8120204
10.1111/j.1440-1819.2007.01729.x
10.1001/archinte.158.9.1021
10.1007/s12017-012-8175-0
10.1016/j.clinph.2009.08.016
10.1016/j.jneumeth.2015.11.007
10.1016/j.neuron.2010.11.032
10.1016/j.cub.2009.08.062
10.1371/journal.pone.0028489
10.1111/jsr.12478
10.1007/s10072-007-0794-0
10.1177/1073858404263960
10.1371/journal.pone.0149770
10.1371/journal.pone.0149770
10.1212/WNL.0000000000001358
10.1016/0006-8993(85)91350-2
10.5665/sleep.4818
10.1016/j.arr.2016.05.006
10.3389/fncel.2017.00214
10.1016/j.neuroimage.2010.04.258
10.1155/2012/415250
10.1371/journal.pone.0033477
10.1371/journal.pone.0033477
10.1111/j.1467-8721.2009.01659.x
10.1002/ana.24432
10.1016/S0304-3940(98)00851-9
10.1523/ENEURO.0235-19.2019
10.1016/j.neurobiolaging.2015.05.014
10.1017/S135561771200001X
10.1126/science.1241224
10.1016/0197-4580(95)00043-E",<Element 'PubmedArticle' at 0x7f05df1b9d10>
170,32912048,Endocrine Insights into the Pathophysiology of Autism Spectrum Disorder.,"Autism spectrum disorder (ASD) is a class of neurodevelopmental disorders that affects males more frequently than females. Numerous genetic and environmental risk factors have been suggested to contribute to the development of ASD. However, no one factor can adequately explain either the frequency of the disorder or the male bias in its prevalence. Gonadal, thyroid, and glucocorticoid hormones all contribute to normal development of the brain, hence perturbations in either their patterns of secretion or their actions may constitute risk factors for ASD. Environmental factors may contribute to ASD etiology by influencing the development of neuroendocrine and neuroimmune systems during early life. Emerging evidence suggests that the placenta may be particularly important as a mediator of the actions of environmental and endocrine risk factors on the developing brain, with the male being particularly sensitive to these effects. Understanding how various risk factors integrate to influence neural development may facilitate a clearer understanding of the etiology of ASD.","['androgen', 'autism spectrum disorder', 'neuroinflammation', 'sex differences', 'stress', 'thyroid hormone']","The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry",2020-09-12,"[{'lastname': 'Wilson', 'firstname': 'Hayley A', 'initials': 'HA', 'affiliation': 'Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.\nDepartment of Integrative Biology, University of Guelph, Guelph, Ontario, Canada.'}, {'lastname': 'Creighton', 'firstname': 'Carolyn', 'initials': 'C', 'affiliation': 'Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'lastname': 'Scharfman', 'firstname': 'Helen', 'initials': 'H', 'affiliation': 'Departments of Child & Adolescent Psychiatry, Neuroscience & Physiology, and Psychiatry, New York University Langone Health, New York, NY, USA.\nCenter for Dementia Research, The Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.'}, {'lastname': 'Choleris', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Department of Psychology, University of Guelph, Guelph, Ontario, Canada.'}, {'lastname': 'MacLusky', 'firstname': 'Neil J', 'initials': 'NJ', 'affiliation': 'Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.'}]",,,,,10.1177/1073858420952046,<Element 'PubmedArticle' at 0x7f05df72fb80>
171,"32856754
29079522
24623176
27713470
12160084
3857369
26007613
30305743
16916950
23384741
28765056
7655334
15917105
11832223
30060670
31474922
20070949
25039797
14635215
27437579
26035291
17030475
30659178
27498201
12580706
24883213
27028912
27991897
27473135
31551603
27863266
18266940
31615888
29324460
26057590
12850338
30903549
27103599
16607096
10690972
27643430
30356809
21401634
31200807
944062
25191220
15345733
19139364
29278774
30842086
27377060
12052919
10101041
31201988
32210745
9407129
9547226
28135244
19285755
22315714
11795356
10822435","Women's brain aging: Effects of sex-hormone exposure, pregnancies, and genetic risk for Alzheimer's disease.","Sex hormones such as estrogen fluctuate across the female lifespan, with high levels during reproductive years and natural decline during the transition to menopause. Women's exposure to estrogen may influence their heightened risk of Alzheimer's disease (AD) relative to men, but little is known about how it affects normal brain aging. Recent findings from the UK Biobank demonstrate less apparent brain aging in women with a history of multiple childbirths, highlighting a potential link between sex-hormone exposure and brain aging. We investigated endogenous and exogenous sex-hormone exposure, genetic risk for AD, and neuroimaging-derived biomarkers for brain aging in 16,854 middle to older-aged women. The results showed that as opposed to parity, higher cumulative sex-hormone exposure was associated with more evident brain aging, indicating that i) high levels of cumulative exposure to sex-hormones may have adverse effects on the brain, and ii) beneficial effects of pregnancies on the female brain are not solely attributable to modulations in sex-hormone exposure. In addition, for women using hormonal replacement therapy (HRT), starting treatment earlier was associated with less evident brain aging, but only in women with a genetic risk for AD. Genetic factors may thus contribute to how timing of HRT initiation influences women's brain aging trajectories.","['apolipoproteins E', 'estrogens', 'neuroimaging', 'parity', ""women's brain aging""]",Human brain mapping,2020-08-29,"[{'lastname': 'de Lange', 'firstname': 'Ann-Marie G', 'initials': 'AG', 'affiliation': 'Department of Psychology, University of Oslo, Oslo, Norway.\nNORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.\nDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.'}, {'lastname': 'Barth', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'lastname': 'Kaufmann', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'lastname': 'Maximov', 'firstname': 'Ivan I', 'initials': 'II', 'affiliation': 'Department of Psychology, University of Oslo, Oslo, Norway.\nNORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.'}, {'lastname': 'van der Meer', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.\nSchool of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'Agartz', 'firstname': 'Ingrid', 'initials': 'I', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.\nDepartment of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway.\nDepartment of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Institute, Stockholm, Sweden.\nKG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway.'}, {'lastname': 'Westlye', 'firstname': 'Lars T', 'initials': 'LT', 'affiliation': 'Department of Psychology, University of Oslo, Oslo, Norway.\nNORMENT, Institute of Clinical Medicine, University of Oslo, & Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.\nKG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway.'}]",,,,© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.,"10.1002/hbm.25180
10.1038/srep32833",<Element 'PubmedArticle' at 0x7f05dc3f0900>
172,32781196,"Osteocalcin, ovarian senescence, and brain health.","Menopause, an inevitable event in a woman's life, significantly increases risk of bone resorption and diseases such as Alzheimer's, vascular dementia, cardiac arrest, and stroke. The sole role of bones, as traditionally regarded, is to provide structural support for skeletal muscles and allow for ambulation, however this concept is becoming quickly outdated. New literature has emerged that suggests the bone cell-derived hormone osteocalcin (OCN) plays a pivotal role in cognition. OCN levels are correlated with bone mass density and bone turnover, and thus are strongly influenced by the changes associated with menopause. The goal of the current review is to discuss potential gaps in our knowledge of OCN and cognition, discrepancies in methods of OCN quantification, and therapies to enhance circulating OCN. A discussion on implementing exercise or low frequency vibration interventions at the menopausal transition to reduce risk and severity of neurological diseases and associated cognitive decline is included.","['Alzheimer’s disease', 'Frailty', 'Menopause', 'Physical exercise', 'Stroke', 'Vascular dementia', 'Whole body vibration']",Frontiers in neuroendocrinology,2020-08-12,"[{'lastname': 'Schatz', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Department of Orthopaedic Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.'}, {'lastname': 'Saravanan', 'firstname': 'Sharnikha', 'initials': 'S', 'affiliation': 'Peritz Scheinberg Cerebral Vascular Disease Research Laboratory, Department of Neurology, Miami, FL 33136, USA.'}, {'lastname': ""d'Adesky"", 'firstname': 'Nathan D', 'initials': 'ND', 'affiliation': 'Peritz Scheinberg Cerebral Vascular Disease Research Laboratory, Department of Neurology, Miami, FL 33136, USA.'}, {'lastname': 'Bramlett', 'firstname': 'Helen', 'initials': 'H', 'affiliation': 'Department of Neurological Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL 33136, USA; Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, FL 33136, USA.'}, {'lastname': 'Perez-Pinzon', 'firstname': 'Miguel A', 'initials': 'MA', 'affiliation': 'Peritz Scheinberg Cerebral Vascular Disease Research Laboratory, Department of Neurology, Miami, FL 33136, USA.'}, {'lastname': 'Raval', 'firstname': 'Ami P', 'initials': 'AP', 'affiliation': 'Peritz Scheinberg Cerebral Vascular Disease Research Laboratory, Department of Neurology, Miami, FL 33136, USA. Electronic address: ARaval@med.miami.edu.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2020.100861,<Element 'PubmedArticle' at 0x7f05dc3f6b30>
173,"32777867
12231037
19516032
23210129
32048059
12629162
27942448
11158037
19625884
12755998
15668427
30388596
12667885
19926311
14745052
25867811
19468050
17145137
31911085
14718489
27069075
14532781
20047689
29700388
23977199
15582279
19022535
11445632
26644522
28803700
31268539
31624049
27870566
24756149
28841388
30480255
27062333
27232853
29338083
28169490
12175403
15569988
15963119
15219659
28188757
25964245
25711542
27737437
29282534
21041708
27583806
28581399
23550669
26720308
24859915
28349979
29410294
18664536",How Does Androgen Deprivation Therapy Affect Mental Health including Cognitive Dysfunction in Patients with Prostate Cancer?,"Androgen deprivation therapy (ADT) is used to block the release of androgen in prostate cancer to promote the regression of cancer cells, and hence, disease progression. Its indication has been widened from the metastatic setting to the localized setting in prostate cancer. Long-term ADT for suppressing androgen release leads to a rapid decrease in androgen, termed as andropause, resulting in several dose and duration dependent adverse effects, including cognitive dysfunction such as dementia. Many retrospective and prospective studies, as well as meta-analyses, have attempted to confirm the crucial relationship between ADT and cognitive dysfunction, but pro and contrary opinions regarding this issue are ongoing owing to the absence of randomized controlled trials. Additionally, several recent studies have suggested the negative effects of dose- and duration-dependent ADT on cognitive dysfunction, especially in 40-65-year-old patients with prostate cancer, who are currently active workers in the society. This review article discusses several studies examining the influence of ADT on mental health based on diverse significant perspectives, especially cognitive dysfunction.","['Androgens', 'Cognition', 'Dementia', 'Hormone therapy', 'Prostatic neoplasms']",The world journal of men's health,2020-08-11,"[{'lastname': 'Lee', 'firstname': 'Hyung Ho', 'initials': 'HH', 'affiliation': 'Department Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, Goyang, Korea.'}, {'lastname': 'Park', 'firstname': 'Sahyun', 'initials': 'S', 'affiliation': 'Department Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, Goyang, Korea.'}, {'lastname': 'Joung', 'firstname': 'Jae Young', 'initials': 'JY', 'affiliation': 'Department Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, Goyang, Korea.'}, {'lastname': 'Kim', 'firstname': 'Sung Han', 'initials': 'SH', 'affiliation': 'Department Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, Goyang, Korea. 12112@ncc.re.kr.'}]",,,,Copyright © 2021 Korean Society for Sexual Medicine and Andrology.,"10.5534/wjmh.200092
10.1016/j.euf.2019.11.010
10.1016/j.euo.2019.08.003
10.1111/ecc.12642",<Element 'PubmedArticle' at 0x7f05dc3e5180>
174,"32730766
28099083
28066098
7897397
28276776
29163128
31213970
31647782
24269535
16011472
3899825
29377010
382871
16216936
26460339
23146033
30796294
27489306
22245457
22476197
25107476
25342129
28034760
8786794
26693205
25965336
15750215
25043908
29476033
30103324
31305918
26907971
30106209
28984587
29424027
18765651
19139294
30364261
31356213
28852028
29453339
24735819
27231710
28105773
25130657
28494972
31275108
28382978
21532539
20837822
28154105
29273521
29084064
31929166
26657615
22684034
27079723
31211691
25249577
24101698
31923471
30073505
15288712
16936707
17942819
25869922
28372335
21911655
23507773
28957663
31978603
32568367
30449731
29036824
27042676
29253574
30958364
26890736
16286438
16446752
21592048
19617854
11108273
12749025
29912996
23719722
25869785
29435980
27252647
28697569
21241723
14600817
21670398
31209456
29555333
28049634
31534057
30081082
27870425
15930959
18230654
30958348
31519494",Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.,"Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well understood, less is known about its multifactorial role in the brain. However, emerging evidence from human and animal studies indicate that insulin influences cerebral bioenergetics, enhances synaptic viability and dendritic spine formation, and increases turnover of neurotransmitters, such as dopamine. Insulin also has a role in proteostasis, influencing clearance of the amyloid β peptide and phosphorylation of tau, which are hallmarks of Alzheimer's disease. Insulin also modulates vascular function through effects on vasoreactivity, lipid metabolism, and inflammation. Through these multiple pathways, insulin dysregulation could contribute to neurodegeneration. Thus, new approaches to restore cerebral insulin function that could offer therapeutic benefit to adults with Alzheimer's disease, vascular cognitive impairment, or related disorders are being investigated.",[],The Lancet. Neurology,2020-07-31,"[{'lastname': 'Kellar', 'firstname': 'Derek', 'initials': 'D', 'affiliation': 'Department of Physiology and Pharmacology, Wake Forest School of Medicine, NC, USA.'}, {'lastname': 'Craft', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': 'Internal Medicine-Geriatrics, Wake Forest School of Medicine, NC, USA. Electronic address: suzcraft@wakehealth.edu.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,"10.1016/S1474-4422(20)30231-3
10.1001/jamaneurol.2020.1840",<Element 'PubmedArticle' at 0x7f05dc3c3130>
175,"32726319
9226606
15172205
17452665
9337448
12622846
9406034
19165750
18353574
5110825
11960020
10746727
22350798
8587874
15282997
12015603
20429945
16147896
23872254
11090991
26068429
22207903
15069204
18301778
29329646
27479324
25148297
23658190
23019586
30483448
24846773
30537760
10707978
20075256
16376591
23595750
3687838
2813579
31668619
12531038
20171069
19165747
16821116
27635118
26102564
28004351
7606278
11296096
12198538
10068311
4041816
20471965
25766673",Screening of sleep assisting drug candidates with a Drosophila model.,"Lately, Drosophila has been favored as a model in sleep and circadian rhythm research due to its conserved mechanism and easily manageable operation. These studies have revealed the sophisticated parameters in whole-day sleep profiles of Drosophila, drawing connections between Drosophila sleep and human sleep. In this study, we tested several sleep deprivation protocols (mechanical shakes and light interruptions) on Drosophila and delineated their influences on Drosophila sleep. We applied a daytime light-deprivation protocol (DD) mimicking jet-lag to screen drugs that alleviate sleep deprivation. Characteristically, classical sleep-aid compounds exhibited different forms of influence: phenobarbital and pentobarbital modified total sleep time, while melatonin only shortened the latency to sleep. Such results construct the basis for further research on sleep benefits in other treatments in Drosophila. We screened seven herb extracts, and found very diverse results regarding their effect on sleep regulation. For instance, Panax notoginseng and Withania somnifera extracts displayed potent influence on total sleep time, while Melissa officinalis increased the number of sleep episodes. By comparing these treatments, we were able to rank drug potency in different aspects of sleep regulation. Notably, we also confirmed the presence of sleep difficulties in a Drosophila Alzheimer's disease (AD) model with an overexpression of human Abeta, and recognized clear differences between the portfolios of drug screening effects in AD flies and in the control group. Overall, potential drug candidates and receipts for sleep problems can be identified separately for normal and AD Drosophila populations, outlining Drosophila's potential in drug screening tests in other populations if combined with the use of other genetic disease tools.",[],PloS one,2020-07-30,"[{'lastname': 'Wang', 'firstname': 'Yan-Ying', 'initials': 'YY', 'affiliation': 'Research Department, Suzhou Joekai Biotech LLC, Kunshan City, Jiangsu, China.'}, {'lastname': 'Ma', 'firstname': 'Wei-Wei', 'initials': 'WW', 'affiliation': 'Research Department, Suzhou Joekai Biotech LLC, Kunshan City, Jiangsu, China.\nSchool of Life Science, Tsinghua University, Beijing, China.'}, {'lastname': 'Peng', 'firstname': 'I-Feng', 'initials': 'IF', 'affiliation': 'Research Department, Suzhou Joekai Biotech LLC, Kunshan City, Jiangsu, China.'}]",,,,,"10.1371/journal.pone.0236318
10.1016/s0022-3999(97)00004-4
10.1016/j.jpsychores.2004.02.010
10.1503/cmaj.060792
10.1177/106002809703101015
10.1046/j.1365-2826.2003.00989.x
10.1177/074873049701200614
10.1002/ptr.2773
10.1016/j.jep.2008.02.006
10.1016/0041-008x(71)90086-x
10.1073/pnas.082102599
10.1038/35006074
10.1007/s00439-012-1146-6
10.1098/rspb.1995.0153
10.1093/sleep/27.4.628
10.1038/417287a
10.1186/1471-2202-11-56
10.1080/07420520500179423
10.1016/j.jep.2013.07.005
10.1016/s0378-8741(00)00277-4
10.1016/j.jep.2015.05.045
10.1007/s12349-010-0045-4
10.1073/pnas.0400895101
10.1371/journal.pone.0001703
10.1016/S1875-5364(18)30005-0
10.1038/nature19097
10.1371/journal.pone.0105678
10.1523/JNEUROSCI.0253-13.2013
10.1073/pnas.1208011109
10.1007/s10068-018-0431-0
10.1016/j.smrv.2014.03.007
10.1159/000494921
10.1016/s0896-6273(00)80877-6
10.1126/science.1183090
10.1016/j.smrv.2005.05.002
10.1523/JNEUROSCI.0061-13.2013
10.1142/S0192415X87000047
10.1055/s-2006-962058
10.1016/j.cub.2019.08.079
10.1053/smrv.2000.0127
10.1016/j.phymed.2010.01.012
10.1002/ptr.2712
10.1007/s10522-006-9023-0
10.1016/j.jgr.2015.07.007
10.1016/j.ejphar.2015.06.037
10.1007/s11010-016-2900-1
10.1159/000106930
10.1001/archpsyc.58.4.353
10.1038/nature00965
10.1097/00005072-199901000-00004
10.1016/0006-8993(85)91350-2
10.1016/j.brainres.2010.05.013
10.1016/j.nbd.2015.02.012",<Element 'PubmedArticle' at 0x7f05dc5de810>
176,"32700634
22823870
24449876
26059855
25197809
26554015
31820826
18350967
8596632
25058693
30201705
30872489
24095125
26847016
31390550
22526883
30804433
10381883
2325721
10548874
2734611
22308371
24224578
29784788
7751928
22363414
11796701
9457658
31837013
21536890
11837947
10198570
8866371
16077152
28332253
25570442
23606614
23544070
30995463
15039146
14582858
22371527
29460036
31776259
28241858
10643746
2002845
22927403
24388969
21601566
30366868
8769811
12002165
10447306
21252366
22891656
31150621
10712296
20036836
8092328
7058927
29038118
30872467
30247731
28218891
23216995
30784558
29167393
10452335
26466871
30459365
28478762
29776774
18077435
30648736
27312974
19487679
22483041
23440187
23899592
21939733
26951388
31102499
29439024
27749086
21042402
19786369
31138694
31109762
29195759
22445311
27079518
18725185
31873098
8403074
27218855
18041480
18041481
31300477
29404219
31729636
28345624
24966219
28865784
17531270
31363110
31358781
29856365
15273285
17542944
12465887
29953415
28452285
15834113
30377266
10922269",Novel Approaches for Assessing Circadian Rhythmicity in Humans: A Review.,"The temporal organization of molecular and physiological processes is driven by environmental and behavioral cycles as well as by self-sustained molecular circadian oscillators. Quantification of phase, amplitude, period, and disruption of circadian oscillators is essential for understanding their contribution to sleep-wake disorders, social jet lag, interindividual differences in entrainment, and the development of chrono-therapeutics. Traditionally, assessment of the human circadian system, and the output of the SCN in particular, has required collection of long time series of univariate markers such as melatonin or core body temperature. Data were collected in specialized laboratory protocols designed to control for environmental and behavioral influences on rhythmicity. These protocols are time-consuming, expensive, and not practical for assessing circadian status in patients or in participants in epidemiologic studies. Novel approaches for assessment of circadian parameters of the SCN or peripheral oscillators have been developed. They are based on machine learning or mathematical model-informed analyses of features extracted from 1 or a few samples of high-dimensional data, such as transcriptomes, metabolomes, long-term simultaneous recording of activity, light exposure, skin temperature, and heart rate or ","['biomarkers', 'data science', 'heart rate', 'light', 'machine learning', 'mathematical models', 'skin temperature', 'transcriptomics']",Journal of biological rhythms,2020-07-24,"[{'lastname': 'Dijk', 'firstname': 'Derk-Jan', 'initials': 'DJ', 'affiliation': 'Surrey Sleep Research Centre, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.\nUK Dementia Research Institute, University of Surrey.'}, {'lastname': 'Duffy', 'firstname': 'Jeanne F', 'initials': 'JF', 'affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.\nDivision of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.""}]",,,,,"10.1177/0748730420940483
10.1111/imm.13166
10.1101/622050v2",<Element 'PubmedArticle' at 0x7f05dc5aa310>
177,"32699184
26679858
21504130
14749131
29125490
15582279
19022535
14745052
2673754
18956301
7028469
16980625
27306650
22732134
29075555
16969359
16817831
20042704
20451871
20451868
19296504
18302232
19689234
22644789
22782295
6610841
9724073
27371494
29499171",Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease.,"It was unclear whether sex hormone-binding globulin (SHBG) was a circulating biomarker of Alzheimer's disease (AD). We tested the cross-sectional relationships between plasma SHBG and cerebrospinal fluid (CSF) AD biomarkers in 707 non-demented adults. Next, the influences of plasma SHBG on dynamic changes of CSF Aβ42, hippocampus volume, brain metabolism, and cognition were explored in 448 non-demented adults from the Alzheimer's disease Neuroimaging Initiative (ADNI). Finally, the predictive and diagnostic values of plasma SHBG in AD were explored. A positive correlation was found between SHBG levels in plasma and CSF. Individuals with higher plasma SHBG levels had lower CSF Aβ42 (p < 0.005), after adjusting for age, gender, education, ","['Alzheimer’s disease', 'biomarker', 'cerebrospinal fluid', 'plasma', 'sex hormone-binding globulin']",Aging,2020-07-24,"[{'lastname': 'Xu', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Su', 'firstname': 'Bing-Jie', 'initials': 'BJ', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Shen', 'firstname': 'Xue-Ning', 'initials': 'XN', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'lastname': 'Bi', 'firstname': 'Yan-Lin', 'initials': 'YL', 'affiliation': 'Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Tan', 'firstname': 'Chen-Chen', 'initials': 'CC', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Li', 'firstname': 'Jie-Qiong', 'initials': 'JQ', 'affiliation': 'Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'lastname': 'Cao', 'firstname': 'Xi-Peng', 'initials': 'XP', 'affiliation': 'Clinical Research Center, Qingdao Municipal Hospital, Qingdao, China.'}, {'lastname': 'Dong', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'Jin-Tai', 'initials': 'JT', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}]",,,,,"10.18632/aging.103497
10.2174/1567205013666151218145752
10.3233/jad-2010-100027
10.1016/s0197-4580(03)00046-0
10.3233/JAD-170426
10.1016/j.exger.2004.06.019
10.1016/j.neurobiolaging.2008.10.001
10.1212/wnl.62.2.188
10.1210/edrv-10-3-232
10.1055/s-0028-1093351
10.1210/edrv-2-1-103
10.1128/MCB.00400-06
10.1111/jne.12402
10.1016/j.yhbeh.2012.06.003
10.1002/brb3.765
10.1038/sj.ijo.0803465
10.1111/j.1365-2265.2006.02560.x
10.1212/WNL.0b013e3181cb3e25
10.1016/j.jalz.2010.03.008
10.1016/j.jalz.2010.03.007
10.1002/ana.21610
10.1002/jmri.21049
10.2174/156720509788929273
10.1007/s11682-012-9176-1
10.1007/s11682-012-9186-z
10.1212/wnl.34.7.939
10.1530/eje.0.1390178
10.1212/WNL.0000000000002923
10.1016/j.jalz.2018.01.010",<Element 'PubmedArticle' at 0x7f05dc53d5e0>
178,"32678846
28686856
21115973
23300413
20647212
19812666
22223662
20479774
21376301
28622505
29906445
21764832
16611749
18381899
21490723
25915600
22836096
26125594
29200198
24952745
24952909
21536720
18045462
23094030
28428554
29966015
21249183
25352553
30445434
27866947
2270482
7545954
7894493
28632866
1671712
1925564
1944558
28286704
27575716
10319874
10967135
10531061
24843467
21159338
26582918
18794107
29691392
24416649
28158411
12483461
9684736
30371878
28890946
31691823
24390350
27924014
27899670
20110278
26771021",Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.,"Genome wide association studies (GWAS) of human diseases have generally identified many loci associated with risk with relatively small effect sizes. The omnigenic model attempts to explain this observation by suggesting that diseases can be thought of as networks, where genes with direct involvement in disease-relevant biological pathways are named 'core genes', while peripheral genes influence disease risk via their interactions or regulatory effects on core genes. Here, we demonstrate a method for identifying candidate core genes solely from genes in or near disease-associated SNPs (GWAS hits) in conjunction with protein-protein interaction network data. Applied to 1,381 GWAS studies from 5 ancestries, we identify a total of 1,865 candidate core genes in 343 GWAS studies. Our analysis identifies several well-known disease-related genes that are not identified by GWAS, including BRCA1 in Breast Cancer, Amyloid Precursor Protein (APP) in Alzheimer's Disease, INS in A1C measurement and Type 2 Diabetes, and PCSK9 in LDL cholesterol, amongst others. Notably candidate core genes are preferentially enriched for disease relevance over GWAS hits and are enriched for both Clinvar pathogenic variants and known drug targets-consistent with the predictions of the omnigenic model. We subsequently use parent term annotations provided by the GWAS catalog, to merge related GWAS studies and identify candidate core genes in over-arching disease processes such as cancer-where we identify 109 candidate core genes.",[],PLoS genetics,2020-07-18,"[{'lastname': 'Ratnakumar', 'firstname': 'Abhirami', 'initials': 'A', 'affiliation': 'Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.'}, {'lastname': 'Weinhold', 'firstname': 'Nils', 'initials': 'N', 'affiliation': 'Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.'}, {'lastname': 'Mar', 'firstname': 'Jessica C', 'initials': 'JC', 'affiliation': 'Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Australia.'}, {'lastname': 'Riaz', 'firstname': 'Nadeem', 'initials': 'N', 'affiliation': 'Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.'}]",,,,,"10.1371/journal.pgen.1008903
10.1016/j.ajhg.2017.06.005
10.1534/genetics.110.120907
10.1371/journal.pcbi.1002822
10.1056/NEJMra0905980
10.1038/nature08494
10.1073/pnas.1119675109
10.1038/nrg2809
10.1016/j.ajhg.2011.02.002
10.1016/j.cell.2017.05.038
10.1016/j.cell.2018.05.051
10.1093/bfgp/elr024
10.1136/jmg.2006.041376
10.1101/gr.071852.107
10.1371/journal.pgen.1001353
10.1038/ng.3259
10.1038/ng.2355
10.1038/nmeth.3440
10.1038/nmeth.4514
10.1038/ng.3014
10.1038/nmeth.2997
10.1101/gr.118992.110
10.1186/gb-2007-8-11-r253
10.1371/journal.pone.0046730
10.1038/s41598-017-01058-y
10.1371/journal.pone.0199987
10.1371/journal.pgen.1001273
10.1093/nar/gku1003
10.1093/nar/gky1120
10.1016/j.cels.2016.10.014
10.1126/science.2270482
10.1126/science.7545954
10.1038/ng1294-399
10.1001/jama.2017.7112
10.1038/349704a0
10.1126/science.1925564
10.1038/353844a0
10.1007/s40142-016-0097-y
10.1146/annurev-pharmtox-010716-104944
10.1038/8820
10.1007/s003350010123
10.1126/science.286.5440.768
10.1111/j.2040-1124.2011.00100.x
10.1016/j.atherosclerosis.2010.11.026
10.1093/nar/gkv1222
10.1158/1078-0432.CCR-08-0429
10.1038/s41467-018-03910-9
10.4161/jkst.25530
10.1093/ecco-jcc/jjx003
10.1093/nar/gky1015
10.1093/nar/gkz981
10.1038/nature12912
10.1093/nar/gkw937
10.1093/nar/gkw1133
10.1093/bioinformatics/btq033
10.1016/j.cels.2015.12.004",<Element 'PubmedArticle' at 0x7f05dce3b8b0>
179,"32605602
24267647
20944627
21835339
23740386
24252464
23434588
23695293
21851428
20823238
8065934
24454369
28645930
17662459
15764600
19307418
19996532
30192631
30580011
25428524
27168746
23117931
22542504
22869326
29938113
17406656
18590437
24508640
17803706
27830013
24190051
19374632
12086642
10924060
14551047
15764681
28256950
30742658
18941467
21856910
16006544
22238626
23723256
20071503
25058601
11557563
12534364
11834621
7850954
7570021
21192961
8439117
16879620
25561720
17360813
17311081
16192992
16357866
21196259
16516917
20103743
22451474
30127734
20599910
14633623
17971636
14522500
17825336
3192645
23658641
19211495
32216612
28880858
2266360
19211488
23068990
30010821
12874397
24512750
20033984
20035500
19351733
25268392
12958327
8640402
28968166
20592293
31900485
23637864
29852978
9445346
27844273
1997500
19531872
23994069
15689952
19471280
12388607
25388681
19436313
19002196
9689481
11744660
27405096
15862533
16239182
27172148
25385447
23842566
10789274
12480728
23902701
11445258
12028245
10854354
12414864
17011077
16865684
30144781
26798014
31671430
10103123
11172772
11689174
11389183
11835321
24565925
19339612
31011859
29107990
27930320
15041543
18636121
20682445
17638384
23782943
29411916
30471324
24566422
11836290
11158037
10895840
31499509
7714119
10690870
32295637
18230193
23728669
26574952
9988290
27777357
3379300
23636018
19275679
29155686
23254630
19818414
23422242
7731386
20521886
30073551
25562264
16432708
22535586
18836152
20739645
11916953
26681727
29973163
27159875
29233816
28359952
25755205
17804962
21931106
21836099
28319156
17430231
21878600
24970568
29570750
14763914
31499497
29463918
25982085
15253956
19011290
18445673
21118287
31502758
31616498
29957125
23088810",Androgens' effects on cerebrovascular function in health and disease.,"Androgens affect the cerebral vasculature and may contribute to sex differences in cerebrovascular diseases. Men are at a greater risk for stroke and vascular contributions to cognitive impairment and dementia (VCID) compared to women throughout much of the lifespan. The cerebral vasculature is a target for direct androgen actions, as it expresses several sex steroid receptors and metabolizing enzymes. Androgens' actions on the cerebral vasculature are complex, as they have been shown to have both protective and detrimental effects, depending on factors such as age, dose, and disease state. When administered chronically, androgens are shown to be pro-angiogenic, promote vasoconstriction, and influence blood-brain barrier permeability. In addition to these direct effects of androgens on the cerebral vasculature, androgens also influence other vascular risk factors that may contribute to sex differences in cerebrovascular diseases. In men, low androgen levels have been linked to metabolic and cardiovascular diseases including hypertension, diabetes, hyperlipidemia, and obesity, which greatly increase the risk of stroke and VCID. Thus, a better understanding of androgens' interactions with the cerebral vasculature under physiological and pathological conditions is of key importance.","['Androgens', 'Blood-brain barrier', 'Cerebral vasculature', 'Cerebrovascular disease', 'Dihydrotestosterone', 'Endothelial', 'Hormone therapy', 'Stroke', 'Testosterone', 'Vascular contributions to cognitive impairment and dementia']",Biology of sex differences,2020-07-02,"[{'lastname': 'Abi-Ghanem', 'firstname': 'Charly', 'initials': 'C', 'affiliation': 'Department of Neuroscience & Experimental Therapeutics, Albany Medical College, 47 New Scotland Avenue, MC-136, Albany, NY, 12208, USA.'}, {'lastname': 'Robison', 'firstname': 'Lisa S', 'initials': 'LS', 'affiliation': 'Department of Neuroscience & Experimental Therapeutics, Albany Medical College, 47 New Scotland Avenue, MC-136, Albany, NY, 12208, USA.'}, {'lastname': 'Zuloaga', 'firstname': 'Kristen L', 'initials': 'KL', 'affiliation': 'Department of Neuroscience & Experimental Therapeutics, Albany Medical College, 47 New Scotland Avenue, MC-136, Albany, NY, 12208, USA. zuloagk@amc.edu.'}]",,,,,10.1186/s13293-020-00309-4,<Element 'PubmedArticle' at 0x7f05dce2e0e0>
180,"32560743
10599770
3324647
26451386
26984945
28106548
10609670
8644745
8103819
30334074
30715078
29801024
24623176
26962052
20807511
9192613
11805297
12943723
19427328
26553159
23089633
14523358
11449190
14745052
16865684
19744108
20060437
16487665
11982672
10523014
23996907
12325053
21504130
31296441
11445632
15985573
28241356
12077215
16054121
20819998
24444806
1566067
20042704
12214000
21188275
18262185
14724248
27599230
23782943
12629162
16698125
11172772
26198711
17658612
14622134
22238626
1782548
9034367
7090745
10806312
26854967
7644022
26667418
27793189
21914720
29559905
20160456
29673549
31277708
26207229
229880
220803
28846757
26220940
31410194
15246987
25162367
15522251
20373342
26481403
26298664
11689174
18295935
16673391",Sex differences in Alzheimer's-related Tau biomarkers and a mediating effect of testosterone.,"Women show greater pathological Tau biomarkers than men along the Alzheimer's disease (AD) continuum, particularly among apolipoprotein ε-E4 (APOE4) carriers; however, the reason for this sex difference in unknown. Sex differences often indicate an underlying role of sex hormones. We examined whether testosterone levels might influence this sex difference and the modifying role of APOE4 status. Analyses included 172 participants (25 cognitively normal, 97 mild cognitive impairment, 50 AD participants) from the Alzheimer's Disease Neuroimaging Initiative (34% female, 54% APOE4 carriers, aged 55-90). We examined the separate and interactive effects of plasma testosterone levels and APOE4 on cerebrospinal fluid phosphorylated-tau181 (p-Tau) levels in the overall sample and the sex difference in p-Tau levels before and after adjusting for testosterone. A significant APOE4-by-testosterone interaction revealed that lower testosterone levels related to higher p-Tau levels among APOE4 carriers regardless of sex. As expected, women had higher p-Tau levels than men among APOE4 carriers only, yet this difference was eliminated upon adjustment for testosterone. Results suggest that testosterone is protective against p-Tau particularly among APOE4 carriers. The lower testosterone levels that typically characterize women may predispose them to pathological Tau, particularly among female APOE4 carriers.","['APOE', 'Alzheimer’s disease', 'Cerebrospinal fluid', 'Phosphorylated-Tau', 'Sex', 'Testosterone']",Biology of sex differences,2020-06-21,"[{'lastname': 'Sundermann', 'firstname': 'Erin E', 'initials': 'EE', 'affiliation': 'Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA. esundermann@health.ucsd.edu.'}, {'lastname': 'Panizzon', 'firstname': 'Matthew S', 'initials': 'MS', 'affiliation': 'Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.'}, {'lastname': 'Chen', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.'}, {'lastname': 'Andrews', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neuroscience, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Galasko', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': 'Department of Neuroscience, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': 'Banks', 'firstname': 'Sarah J', 'initials': 'SJ', 'affiliation': 'Department of Neuroscience, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.1186/s13293-020-00310-x,<Element 'PubmedArticle' at 0x7f05dd320a90>
181,"32526197
25707927
27727239
29107053
30136084
26844934
16862116
29865057
22471860
22471867
24508835
26537052
28285767
22895706
16862115
30084846
23104886
26549511
29056226
30545856
29022597
26545828
28488154
30275531
28728022
19261174
17907809
29229983
31456032
31114916
26250685
29270443
29802388
29716643
31039256
28869584
23742080
27543298
26149713
31097038
28668092
29744576
26581719
21358643
20634204
30297968
29970152
28330615
30613398
23065790
23609508
29186371
22608501
20463871
16199517
28332094
23128226
21358640
20154673
22064851
30422173
24013639
28441426
29700475
30093249
25653292
29908079",Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology.,"Here, we perform a genome-wide screen for variants that regulate the expression of gene co-expression modules in the aging human brain; we discover and replicate such variants in the TMEM106B and RBFOX1 loci. The TMEM106B haplotype is known to influence the accumulation of TAR DNA-binding protein 43 kDa (TDP-43) proteinopathy, and the haplotype's large-scale transcriptomic effects include the dysregulation of lysosomal genes and alterations in synaptic gene splicing that are also seen in the pathophysiology of TDP-43 proteinopathy. Further, a variant near GRN, another TDP-43 proteinopathy susceptibility gene, shows concordant effects with the TMEM106B haplotype. Leveraging neuropathology data from the same participants, we also show that TMEM106B and APOE-amyloid-β effects converge to alter myelination and lysosomal gene expression, which then contributes to TDP-43 accumulation. These results advance our mechanistic understanding of the TMEM106B TDP-43 risk haplotype and uncover a transcriptional program that mediates the converging effects of APOE-amyloid-β and TMEM106B on TDP-43 aggregation in older adults.","[""Alzheimer's disease"", 'Amyloid-β', 'GRN', 'RBFOX1', 'TDP-43', 'TMEM106B', 'co-expression module', 'cognitive resilience', 'eQTL', 'expression quantitative trait loci', 'sQTL', 'splicing quantitative trait loci']",Neuron,2020-06-12,"[{'lastname': 'Yang', 'firstname': 'Hyun-Sik', 'initials': 'HS', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.""}, {'lastname': 'White', 'firstname': 'Charles C', 'initials': 'CC', 'affiliation': ""The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.""}, {'lastname': 'Klein', 'firstname': 'Hans-Ulrich', 'initials': 'HU', 'affiliation': ""The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.""}, {'lastname': 'Yu', 'firstname': 'Lei', 'initials': 'L', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.""}, {'lastname': 'Gaiteri', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.""}, {'lastname': 'Ma', 'firstname': 'Yiyi', 'initials': 'Y', 'affiliation': ""The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.""}, {'lastname': 'Felsky', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': ""The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.""}, {'lastname': 'Mostafavi', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Statistics, Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada; Canadian Institute for Advanced Research, Toronto, ON M5G 1M1, Canada.'}, {'lastname': 'Petyuk', 'firstname': 'Vladislav A', 'initials': 'VA', 'affiliation': 'Pacific Northwest National Laboratory, Richland, WA 99354, USA.'}, {'lastname': 'Sperling', 'firstname': 'Reisa A', 'initials': 'RA', 'affiliation': ""Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.""}, {'lastname': 'Ertekin-Taner', 'firstname': 'Nilüfer', 'initials': 'N', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.'}, {'lastname': 'Schneider', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.""}, {'lastname': 'Bennett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.""}, {'lastname': 'De Jager', 'firstname': 'Philip L', 'initials': 'PL', 'affiliation': ""The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: pld2115@cumc.columbia.edu.""}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,"10.1016/j.neuron.2020.05.010
10.1101/510420
10.1101/566307",<Element 'PubmedArticle' at 0x7f05dd2e5590>
182,32512138,Sex Hormone Depletion Augments Glucocorticoid Induction of Tau Hyperphosphorylation in Male Rat Brain.,"Steroid hormones secreted by the gonads (sex steroids) and adrenal glands (glucocorticoids, GC) are known to influence brain structure and function. While levels of sex steroids wane in late adulthood, corticosteroid levels tend to rise in many individuals due to age-related impairments in their feedback on central mechanisms regulating adrenal function. These fluctuations in sex and adrenal steroid secretion may be relevant to age-related neurodegenerative disorders such as Alzheimer's disease (AD) in which hyperphosphorylation of Tau protein is a key pathological event. We here report that both, long-term GC deprivation (by adrenalectomy) and exogenous GC administration with natural or synthetic glucocorticoid receptor ligands (corticosterone and dexamethasone, respectively) induce Tau hyperphosphorylation in the hippocampus and frontocortical regions at epitopes associated with disruption of cytoskeletal and synaptic function. Interestingly, we observed that the changes in Tau induced by manipulation of the GC milieu of male rats were exacerbated by testosterone depletion (by orchiectomy). While this finding supports previous suggestions of a neuroprotective role of male sex hormones, this is the first study to address interactions between adrenal and sex steroids on Tau hyperphosphorylation and accumulation that are known to endanger neuronal function and plasticity. These results are particularly important for understanding the mechanisms that can precipitate AD because, besides being modulated by age, GC are elevated by stress, a phenomenon now established as a trigger of deficits in neural plasticity and survival, cognitive behaviour and AD-like Tau pathology.","['Tau', 'glucocorticoids', 'hippocampus', 'hyperphosphorylation', 'male gonadal hormones', 'prefrontal cortex']",Neuroscience,2020-06-09,"[{'lastname': 'Monteiro-Fernandes', 'firstname': 'D', 'initials': 'D', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Sousa', 'firstname': 'N', 'initials': 'N', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.""}, {'lastname': 'Almeida', 'firstname': 'O F X', 'initials': 'OFX', 'affiliation': 'Max Plank Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany.'}, {'lastname': 'Sotiropoulos', 'firstname': 'I', 'initials': 'I', 'affiliation': ""Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal; Max Plank Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. Electronic address: ioannis@med.uminho.pt.""}]",,,,Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2020.05.049,<Element 'PubmedArticle' at 0x7f05dce70220>
183,32506471,Prevalence of insulin as a first-line therapy and associated factors in people with type 2 diabetes in German primary care practices.,"To evaluate how many people with type 2 diabetes receive a treatment regimen with insulin as a first-line therapy and the factors associated with this.
This retrospective study was based on data from the Disease Analyzer database and included 10 497 people with type 2 diabetes with an initial prescription of anti-hyperglycaemic therapy from 859 general and diabetologist practices in Germany between January 2014 and December 2018. The main outcome of the study was the prevalence of insulin as a first-line therapy. A multivariable logistic regression model was performed to investigate the association between predefined variables and the probability of receiving insulin as a first-line therapy.
A total of 7.1% of participants received insulin as a first-line therapy. Diabetologist practice [odds ratio (OR) 2.71, 95% confidence interval (CI) 1.81-4.06], age > 80 years (OR 2.35, 95% CI 1.20-4.61) compared with age ≤ 40 years, HbA
Insulin is rarely used as a first-line therapy in people with type 2 diabetes. Furthermore, a person's likelihood of receiving insulin as a first-line therapy is significantly influenced by diabetologist practice, age, HbA",[],Diabetic medicine : a journal of the British Diabetic Association,2020-06-09,"[{'lastname': 'van den Boom', 'firstname': 'L', 'initials': 'L', 'affiliation': 'DRK children`s hospital Siegen, Siegen, Germany.'}, {'lastname': 'Kaiser', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Diabetologische Schwerpunktpraxis, Frankfurt, Germany.'}, {'lastname': 'Kostev', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Epidemiology, IQVIA, Frankfurt, Germany.'}]",,"Insulin is rarely used as a first-line therapy in people with type 2 diabetes. Furthermore, a person's likelihood of receiving insulin as a first-line therapy is significantly influenced by diabetologist practice, age, HbA","A total of 7.1% of participants received insulin as a first-line therapy. Diabetologist practice [odds ratio (OR) 2.71, 95% confidence interval (CI) 1.81-4.06], age > 80 years (OR 2.35, 95% CI 1.20-4.61) compared with age ≤ 40 years, HbA",© 2020 Diabetes UK.,10.1111/dme.14338,<Element 'PubmedArticle' at 0x7f05dce63e00>
184,"32469976
24084921
10213546
30842086
29286985
24934885
9351144
16037754
17059606
21054635
21278356
31474332
21888299
21423581
20838656
16489281
8233253
14709575
26382314","""I'm going to stay young"":  Belief in anti-aging efficacy of menopausal hormone therapy drives prolonged use despite medical risks.","Over a third of menopausal hormone therapy (HT) prescriptions in the US are written for women over age 60. Use of HT more than 5 years is associated with increased risk for cardiovascular disease; breast, ovarian, and endometrial cancers; thromboembolic stroke; gallbladder disease; dementia; and incontinence.
To explore older women's perceptions of the benefits and risks of long-term HT and examine factors influencing their decisions to use HT > 5 years despite medical risks.
A qualitative approach was selected to broadly explore thought processes and social phenomena underlying long-term users' decisions not to discontinue HT. Interviews were conducted with 30 women over age 60 reporting use of systemic HT more than 5 years recruited from an urban area in California and a small city in the Rocky Mountain region. Transcripts of interviews were analyzed using conventional grounded theory methods.
Women reported using HT to preserve youthful physical and mental function and prevent disease. Gynecologists had reassured participants regarding risk, about which all 30 expressed little concern. Participants, rather than providers, were the principal drivers of long-term use.
Participants perceived estrogen to have anti-aging efficacy, and using HT imparted a sense of control over various aspects of aging. Maintaining this sense of control was prioritized over potential risk from prolonged use. Our findings provide an additional perspective on previous work suggesting the pharmaceutical industry has leveraged older women's self-esteem, vanity, and fear of aging to sell hormones through marketing practices designed to shape the beliefs of both clinicians and patients. Efforts are needed to: 1) address misconceptions among patients and providers about medically supported uses and risks of prolonged HT, and 2) examine commercial influences, such as medical ghostwriting, that may lead to distorted views of HT efficacy and risk.",[],PloS one,2020-05-30,"[{'lastname': 'Hunter', 'firstname': 'Mary M', 'initials': 'MM', 'affiliation': 'Department of Physiological Nursing, School of Nursing, University of California San Francisco, San Francisco, California, United States of America.'}, {'lastname': 'Huang', 'firstname': 'Alison J', 'initials': 'AJ', 'affiliation': 'Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, California, United States of America.'}, {'lastname': 'Wallhagen', 'firstname': 'Margaret I', 'initials': 'MI', 'affiliation': 'Department of Physiological Nursing, School of Nursing, University of California San Francisco, San Francisco, California, United States of America.'}]",,,"Women reported using HT to preserve youthful physical and mental function and prevent disease. Gynecologists had reassured participants regarding risk, about which all 30 expressed little concern. Participants, rather than providers, were the principal drivers of long-term use.",,"10.1371/journal.pone.0233703
10.1353/pbm.2006.0006",<Element 'PubmedArticle' at 0x7f05dd197680>
185,32450287,The anti-Alzheimer effect of telmisartan in a hyperglycemic ovariectomized rat model; role of central angiotensin and estrogen receptors.,"The central renin angiotensin system (RAS) is implicated in Alzheimer's disease (AD). Here, induction of experimental AD simulation was performed by D-galactose (D-Gal) injection to ovariectomized (OVX) rats fed on high fat high fructose diet (HFFD). Telmisartan administration to OVX/HFFD/D-Gal rats lowered the expression of hippocampal angiotensin 1 and 2 receptors and glucose transporter 2 in addition to lowering of the peripheral and central glucose levels. Furthermore, it improved cognitive impairment and suppressed hippocampal amyloidogenic markers including amyloid-beta level, phosphorylated tau protein and beta site amyloid precursor protein cleaving enzyme 1 expression, while elevated levels of insulin degrading enzyme and recovered permeability of blood brain barrier (BBB). In addition, it inhibited hippocampal oxido-nitrosative stress as well as neuroinflammatory and apoptotic biomarkers. Telmisartan improved memory and cognitive impairment as shown in the behavioral Morris water maze, Y-maze, novel object recognition and open field tests in addition to amelioration of depressive like behavior as shown in forced swimming test. Histopathological examination of brain and immune expression of glial fibrillary acidic protein were also improved together with astrogliosis improvement. In conclusion, telmisartan improved memory and cognitive impairment, recovered amyloidogenesis-hyperglycemic axis, astrogliosis, integrity of BBB, memory deficit and oxidonitrosative stress induced in OVX/HFFD/D-Gal rats.","['Amyloidogenesis', 'Cognitive impairment', 'Estrogen receptor', 'Hyperglycemia', 'Oxidonitrosative stress', 'Telmisartan']",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,2020-05-26,"[{'lastname': 'Abo-Youssef', 'firstname': 'Amira M', 'initials': 'AM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.'}, {'lastname': 'Khallaf', 'firstname': 'Waleed A', 'initials': 'WA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.'}, {'lastname': 'Khattab', 'firstname': 'Mahmoud M', 'initials': 'MM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.'}, {'lastname': 'Messiha', 'firstname': 'Basim A S', 'initials': 'BAS', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Electronic address: drbasimanwar2006@yahoo.com.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.fct.2020.111441,<Element 'PubmedArticle' at 0x7f05dd183ae0>
186,32450141,"The effects of melatonin, serotonin, tryptophan and NAS on the biophysical properties of DPPC monolayers.","Melatonin is a neurohormone that has been shown to be protective in Alzheimer's diseases against amyloid-β (Aβ) toxicity, which involves interaction of Aβ with neuronal membrane. Non-specific interactions of melatonin with cell membrane may play a physiological role in this process by preserving membrane fluidity. In the brain, melatonin is derived from the amino acid tryptophan through a pathway that includes serotonin and N-acetylserotonin (NAS). How these molecules affect the membrane properties is not understood. In this work, we studied interactions of melatonin and its metabolic precursors tryptophan, serotonin and NAS with dipalmitoylphosphatidylcholine (DPPC) monolayers at the air-water interface using Langmuir monolayer technique. Analysis of compression isotherms, phase transitions and compressibility moduli indicate that all four molecules alter the DPPC monolayer properties in a structure and concentration dependent manner. This effect was most pronounced for melatonin followed by NAS. Melatonin and NAS both decreased the compressibility modulus and shifted the LE/LC phase transition suggesting an increase in the membrane fluidity. Tryptophan and serotonin caused less pronounced effects on the DPPC isotherm. These differences suggest different interaction mechanisms and may be attributed to the interplay between electrostatic and hydrophobic interactions of these molecules with the zwitterionic DPPC headgroups which correlate with water solubility and oil partition coefficients (LogS and LogP) of each the four molecules. The results here demonstrate how the physiochemical properties of indoles can affect lipid membranes which may shed light on the functional significance of these important neurochemicals and the neuroprotective mechanisms of melatonin.","[""Alzheimer's disease"", 'DPPC', 'Fluidity', 'Langmuir technique', 'Melatonin', 'N-acetylserotonin', 'Serotonin', 'Tryptophan']",Biochimica et biophysica acta. Biomembranes,2020-05-26,"[{'lastname': 'Robinson', 'firstname': 'Morgan', 'initials': 'M', 'affiliation': 'Department of Physics and Astronomy, University of Waterloo, Waterloo, Canada. Electronic address: m9robins@uwaterloo.ca.'}, {'lastname': 'Turnbull', 'firstname': 'Stephen', 'initials': 'S', 'affiliation': 'Department of Physics and Astronomy, University of Waterloo, Waterloo, Canada.'}, {'lastname': 'Lee', 'firstname': 'Brenda Yasie', 'initials': 'BY', 'affiliation': 'Department of Physics and Astronomy, University of Waterloo, Waterloo, Canada.'}, {'lastname': 'Leonenko', 'firstname': 'Zoya', 'initials': 'Z', 'affiliation': 'Department of Physics and Astronomy, University of Waterloo, Waterloo, Canada; Department of Biology, University of Waterloo, Waterloo, Canada. Electronic address: zleonenk@uwaterloo.ca.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.bbamem.2020.183363,<Element 'PubmedArticle' at 0x7f05dd178c20>
187,"32440785
25311618
18535283
23204143
22569939
24007975
25854637
30399527
28154100
21899409
29279888
19468217
16043803
7723951
23160885
23760212
7839388
15769776
8898801
29354802
2215945
27960190
9712924
20396467
21868729
23691210
1859294
28651523
15472098
16269952
12687327
21054480
12032136
15140421
24330659
20930713
27224208
16990411
23590551
24843760
20516205
20395949
21594755
23936408
21048783
21799892
24949311
23970789
28797616
23010677
26125557
22688066
31590595
27253870
21349439
23296339
17878422
17376122
10441097
1680392
18301447
21296594
9508150
15375298
15699381
24365247
20540798
18705898
12444918
31744111
18427110
30409089
22045424
28963520
28360116
15947278
26839351
26828698
29330520
20825473
11441189
22541364
18590804
21816453
15699449
15201536
9413464
20145305
17082469
23540412
18550062
8610309
9489536
23049705
25206436
12865608
17416265
24296623
20598712
23135028
20123934
28959485
20538696
19265054
24788967
25613305
21347282
30797237
11739273
16329997
18998106
22550613
25727672
24033266",Genetic Risk Factors of Intracranial Atherosclerosis.,"Intracranial atherosclerosis (ICAS) is the most common cause of stroke throughout the world. It also increases the risk of recurrent stroke and dementia. As a complex and multifactorial disease, ICAS is influenced by multiple genetic, biological, and environmental factors. This review summarizes the candidate gene and genome-wide studies aimed at discovering genetic risk factors of ICAS.
Numerous studies have focused on the association between single-nucleotide polymorphisms (SNPs) of atherosclerosis-related genes and the risk of ICAS. Variants in adiponectin Q (ADIPOQ), ring finger protein 213 (RNF213), apolipoprotein E (APOE), phosphodiesterase 4D (PDE4D), methylenetetrahydrofolate reductase (MTHFR), lipoprotein lipase (LPL), α-adducin (ADD1) genes, angiotensin-converting enzyme (ACE), and other genes related to renin-angiotensin-aldosterone system have been associated with ICAS. We review the available evidences on the candidate genes and SNPs associated with genetic susceptibility to ICAS, and point out future developments of this field. Genetic discoveries could have clinical implications for intracranial atherosclerotic disease.","['Adiponectin Q', 'Genetic factor', 'Genome-wide association study', 'Intracranial atherosclerosis', 'Ring finger protein 213']",Current atherosclerosis reports,2020-05-23,"[{'lastname': 'Liu', 'firstname': 'Minghua', 'initials': 'M', 'affiliation': 'Department of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, 710 W 168th Street, 6th floor, Suite 639, New York, NY, 10032, USA.'}, {'lastname': 'Gutierrez', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Department of Neurology, College of Physicians and Surgeons, Columbia University Irving Medical Center, 710 W 168th Street, 6th floor, Suite 639, New York, NY, 10032, USA. jg3233@cumc.columbia.edu.'}]",,,,,"10.1007/s11883-020-0831-5
10.1161/CIRCULATIONAHA.114.011147
10.1161/STROKEAHA.107.505776
10.1093/brain/aws271
10.1161/STROKEAHA.111.648667
10.1016/s0140-6736(13)61088-0
10.1111/ijs.12496
10.1016/j.carpath.2018.09.003
10.1161/CIRCRESAHA.116.308441
10.1056/NEJMoa1105335
10.1001/jamaneurol.2017.3960
10.1159/000219299
10.1212/01.wnl.0000168862.09764.9f
10.1212/wnl.45.4.659
10.1161/strokeaha.112.658500
10.1161/strokeaha.113.001522
10.1161/01.CIR.0000157736.19739.D0
10.1016/j.cdtm.2017.09.003
10.1212/wnl.40.10.1540
10.1159/000448272
10.1159/000015864
10.3988/jcn.2005.1.1.1
10.1161/strokeaha.111.620104
10.1371/journal.pone.0064395
10.1001/archneur.1991.00530190033011
10.1186/s12883-017-0873-7
10.1161/01.STR.0000144681.46696.b3
10.1097/01.hjh.0000186024.12364.2e
10.1007/s00125-003-1074-z
10.1111/j.1365-2265.2010.03902.x
10.1074/jbc.C200251200
10.1016/j.coph.2004.03.003
10.1186/1471-2350-14-127
10.1038/oby.2010.229
10.1080/00207454.2016.1190716
10.1373/clinchem.2006.074476
10.1186/1475-2840-12-67
10.1111/jdi.12133
10.1530/EJE-10-0251
10.1038/oby.2010.85
10.1007/s12020-011-9488-8
10.1371/journal.pone.0070335
10.1038/jhg.2010.132
10.1371/journal.pone.0022542
10.5853/jos.2014.16.2.65
10.1161/strokeaha.113.002477
10.1016/j.jstrokecerebrovasdis.2017.06.043
10.1161/STROKEAHA.112.663864
10.1371/journal.pone.0130663
10.2176/nmc.52.299
10.1161/JAHA.119.011996
10.1371/journal.pone.0156607
10.1016/S1474-4422(10)70325-2
10.1038/nrneurol.2012.263
10.1001/jama.298.11.1300
10.1111/j.1600-0404.2006.00779.x
10.1161/01.cir.100.6.608
10.1038/ejhg.2008.27
10.1016/j.jstrokecerebrovasdis.2010.10.002
10.1161/01.STR.0000143317.70478.b3
10.1016/j.jns.2013.12.012
10.1186/1471-2350-11-93
10.1111/j.1747-4949.2008.00199.x
10.1042/BJ20021698
10.3390/cells8111447
10.1073/pnas.0800105105
10.1177/1753425918809155
10.3233/DMA-2011-0810
10.1038/s41598-017-12668-x
10.1161/STROKEAHA.116.015324
10.1161/01.STR.0000169946.31639.af
10.1161/strokeaha.115.011545
10.12659/msm.895296
10.1038/s41598-017-19125-9
10.1111/j.1468-1331.2010.03188.x
10.1161/01.str.32.7.1481
10.1016/j.jns.2012.04.006
10.1016/j.neuroscience.2008.06.007
10.1016/j.thromres.2011.07.016
10.1161/01.HYP.0000156497.39375.37
10.1097/01.hjh.0000125443.28861.0d
10.1016/S0140-6736(97)05189-1
10.1161/01.STR.0000248760.67039.2b
10.1179/1743132813Y.0000000161
10.1016/j.atherosclerosis.2008.04.038
10.1136/jnnp.64.2.227
10.1371/journal.pone.0046495
10.3969/j.issn.1673-5374.2013.15.008
10.1159/000071119
10.1016/S0140-6736(07)60242-6
10.1038/nrneph.2013.251
10.1016/j.jns.2010.06.013
10.4103/0028-3886.103196
10.1177/1470320309358109
10.1136/svn-2016-000049
10.1161/strokeaha.110.583534
10.1161/strokeaha.108.535245
10.1161/STR.0000000000000024
10.1161/strokeaha.114.007930
10.1371/journal.pgen.1001300
10.1186/s12883-019-1259-9
10.1161/hh2401.101272
10.1016/j.bbrc.2005.11.092
10.1007/s00109-008-0412-5
10.1155/2012/362941
10.1016/j.jstrokecerebrovasdis.2014.10.019
10.1111/cge.12257",<Element 'PubmedArticle' at 0x7f05dd16fc70>
188,"32398333
26385186
26918290
23775354
28945276
16118337
22977273
24098015
26963953
21982312
24423283
17825717
19401373
25268392
19351733
24428256
27106765
24645738
24628549
25584720
27729576
30097782
20451981
30144781
26615472
19744108
30358898
27581270
27510348
29562364
28241356
28241237
26886521
29522088
28241231
28241355
30017800
20139215
8094183
27747915
23585842
29316881
25919529
10789670
7578538
18316347
23785097
18328041
16598372
2646917
1669507
474565
16084776
19621070
18652544
22139814
14567601
17419953
7575054
20346001
9004393
510638
12290053
22214758
25555855
21784880
21816776
23943774
26779889
25019163
20870782
29454638
20807333
17285783
26509870
16181230
26154489
21177660",Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men.,"This study aims to clarify the role(s) of endogenous sex hormones to influence health outcomes in men, specifically to define the associations of plasma testosterone with incidence of cardiovascular events, cancer, dementia and mortality risk, and to identify factors predicting testosterone concentrations. Data will be accrued from at least three Australian, two European and four North American population-based cohorts involving approximately 20 000 men.
Eligible studies include prospective cohort studies with baseline testosterone concentrations measured using mass spectrometry and 5 years of follow-up data on incident cardiovascular events, mortality, cancer diagnoses or deaths, new-onset dementia or decline in cognitive function recorded. Data for men, who were not taking androgens or drugs suppressing testosterone production, metabolism or action; and had no prior orchidectomy, are eligible. Systematic literature searches were conducted from 14 June 2019 to 31 December 2019, with no date range set for searches. Aggregate level data will be sought where individual participant data (IPD) are not available. One-stage IPD random-effects meta-analyses will be performed, using linear mixed models, generalised linear mixed models and either stratified or frailty-augmented Cox regression models. Heterogeneity in estimates from different studies will be quantified and bias investigated using funnel plots. Effect size estimates will be presented in forest plots and non-negligible heterogeneity and bias investigated using subgroup or meta-regression analyses.
Ethics approvals obtained for each of the participating cohorts state that participants have consented to have their data collected and used for research purposes. The Androgens In Men Study has been assessed as exempt from ethics review by the Human Ethics office at the University of Western Australia (file reference number RA/4/20/5014). Each of the component studies had obtained ethics approvals; please refer to respective component studies for details. Research findings will be disseminated to the scientific and broader community via the publication of four research articles, with each involving a separate set of IPD meta-analyses (articles will investigate different, distinct outcomes), at scientific conferences and meetings of relevant professional societies. Collaborating cohort studies will disseminate findings to study participants and local communities.
CRD42019139668.","['epidemiology', 'general endocrinology', 'sex steroids & HRT']",BMJ open,2020-05-14,"[{'lastname': 'Yeap', 'firstname': 'Bu Beng', 'initials': 'BB', 'affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia bu.yeap@uwa.edu.au.\nDepartment of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia.'}, {'lastname': 'Marriott', 'firstname': 'Ross James', 'initials': 'RJ', 'affiliation': 'School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia.'}, {'lastname': 'Adams', 'firstname': 'Robert J', 'initials': 'RJ', 'affiliation': 'Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South Australia, Australia.'}, {'lastname': 'Antonio', 'firstname': 'Leen', 'initials': 'L', 'affiliation': 'Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.'}, {'lastname': 'Ballantyne', 'firstname': 'Christie M', 'initials': 'CM', 'affiliation': 'Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'lastname': 'Bhasin', 'firstname': 'Shalender', 'initials': 'S', 'affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.'}, {'lastname': 'Cawthon', 'firstname': 'Peggy M', 'initials': 'PM', 'affiliation': 'San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California, USA.'}, {'lastname': 'Couper', 'firstname': 'David John', 'initials': 'DJ', 'affiliation': 'Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.'}, {'lastname': 'Dobs', 'firstname': 'Adrian S', 'initials': 'AS', 'affiliation': 'School of Medicine, Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'lastname': 'Flicker', 'firstname': 'Leon', 'initials': 'L', 'affiliation': 'WA Centre for Health & Ageing, University of Western Australia, Perth, Western Australia, Australia.'}, {'lastname': 'Karlsson', 'firstname': 'Magnus', 'initials': 'M', 'affiliation': 'Department of Clinical Sciences and Orthopedic Surgery, Lund University, Lund, Sweden.'}, {'lastname': 'Martin', 'firstname': 'Sean A', 'initials': 'SA', 'affiliation': ""Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia, Australia.""}, {'lastname': 'Matsumoto', 'firstname': 'Alvin M', 'initials': 'AM', 'affiliation': 'Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA.\nDepartment of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington School of Medicine, Seattle, Washington, USA.'}, {'lastname': 'Mellström', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Goteborg, Sweden.'}, {'lastname': 'Norman', 'firstname': 'Paul E', 'initials': 'PE', 'affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'lastname': 'Ohlsson', 'firstname': 'Claes', 'initials': 'C', 'affiliation': 'Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Institute of Medicine, University of Gothenburg, Goteborg, Sweden.'}, {'lastname': 'Orwoll', 'firstname': 'Eric S', 'initials': 'ES', 'affiliation': 'Oregon Health & Science University, Portland, Oregon, USA.'}, {'lastname': ""O'Neill"", 'firstname': 'Terence W', 'initials': 'TW', 'affiliation': 'Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester & NIHR Manchester Biomedical Research Centre, Manchester, UK.\nManchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.'}, {'lastname': 'Shores', 'firstname': 'Molly M', 'initials': 'MM', 'affiliation': 'VA Puget Sound Health Care System, Seattle, Washington, USA.\nSchool of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.'}, {'lastname': 'Travison', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Harvard Medical School, Boston, Massachusetts, USA.\nInstitute for Aging Research, Hebrew SeniorLife, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.'}, {'lastname': 'Vanderschueren', 'firstname': 'Dirk', 'initials': 'D', 'affiliation': 'Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Flanders, Belgium.'}, {'lastname': 'Wittert', 'firstname': 'Gary A', 'initials': 'GA', 'affiliation': ""Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia, Australia.""}, {'lastname': 'Wu', 'firstname': 'Frederick C W', 'initials': 'FCW', 'affiliation': 'Division of Diabetes, Endocrinology and Gastroenterology, The University of Manchester, Manchester, UK.'}, {'lastname': 'Murray', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia.'}]",,,,© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.,"10.1136/bmjopen-2019-034777
10.1530/EJE-15-0380
10.1210/jc.2015-3810
10.1210/jc.2012-3842
10.1111/cen.13484
10.1210/jc.2005-0962
10.1210/jc.2012-2265
10.1210/jc.2013-3375
10.1210/jc.2016-1025
10.1016/j.jacc.2011.07.019
10.1210/jc.2013-2052
10.1016/j.jacc.2007.04.088
10.1210/jc.2008-2650
10.1210/jc.2014-2664
10.1210/jc.2008-2416
10.1111/cen.12407
10.1111/cen.13089
10.1111/cen.12452
10.1210/jc.2013-3576
10.1210/jc.2014-3934
10.1161/STROKEAHA.116.014088
10.1007/s12672-018-0346-5
10.1016/j.urology.2010.01.086
10.1016/j.psyneuen.2018.08.013
10.1016/j.psyneuen.2015.11.012
10.1111/j.1365-2265.2009.03692.x
10.1111/cen.13888
10.5694/mja16.00448
10.5694/mja16.00393
10.1210/jc.2018-00229
10.1001/jama.2016.21044
10.1001/jamainternmed.2016.9540
10.1056/NEJMoa1506119
10.1210/er.2017-00234
10.1001/jamainternmed.2016.9539
10.1001/jama.2016.21043
10.1016/S2213-8587(17)30416-3
10.1136/bmj.c221
10.1016/0140-6736(93)93004-K
10.1002/sim.7141
10.1371/journal.pone.0060650
10.1186/s12874-017-0468-4
10.1001/jama.2015.3656
10.1111/j.1753-6405.1995.tb00389.x
10.1093/ije/dyn041
10.1093/ije/dyt064
10.1111/j.1365-2605.2008.00879.x
10.1359/jbmr.060110
10.1093/oxfordjournals.aje.a115184
10.1016/1047-2797(91)90005-W
10.1093/oxfordjournals.aje.a112813
10.1016/j.cct.2005.05.006
10.1371/journal.pmed.1000100
10.1146/annurev.psych.58.110405.085530
10.1080/10629360600810434
10.1002/sim.4413
10.3171/jns.2003.99.4.0666
10.1016/j.jclinepi.2006.09.009
10.1111/j.1365-2265.2010.03804.x
10.1002/(SICI)1097-0258(19970130)16:2&lt;215::AID-SIM481&gt;3.0.CO;2-J
10.2307/2061224
10.1080/08898489509525394
10.1136/bmj.d7762
10.1136/bmj.g7647
10.1136/bmj.d4002
10.1210/jc.2011-1137
10.1136/bmjopen-2013-003127
10.1111/bju.13417
10.1371/journal.pone.0100409
10.1093/ije/dyq158
10.1016/j.clgc.2018.01.005
10.1111/j.1743-6109.2010.01991.x
10.1016/S0025-6196(11)60964-6
10.1210/jc.2015-2687
10.1111/j.1365-2265.2005.02350.x
10.1007/s12035-015-9315-y
10.1136/hrt.2010.210757",<Element 'PubmedArticle' at 0x7f05dd79e900>
189,32278163,Ozone increases plasma kynurenine-tryptophan ratio and impacts hippocampal serotonin receptor and neurotrophic factor expression: Role of stress hormones.,"Air pollution is associated with adverse impacts on the brain, including cognitive decline and increased incidence of dementia, depression and anxiety; however, underlying mechanisms remain unclear. We have shown that both ozone and particulate matter activate the hypothalamic-pituitary-adrenal (HPA) axis, increasing plasma glucocorticoids and altering mRNA profiles in multiple tissues including the brain. HPA axis dysregulation has been associated with central nervous system impacts, including key effects in the hippocampus; accordingly, we hypothesized that pollutant-dependent increases in glucocorticoid levels impact biological pathways relevant to brain health. Fischer-344 rats were treated with metyrapone (0 or 50 mg/kg), a glucocorticoid synthesis inhibitor, and exposed to ozone (0 or 0.8 ppm) for 4 h (n = 5/group) to investigate the role of glucocorticoids in ozone-dependent effects on tryptophan metabolism and expression of serotonin receptors and neurotrophic factors. Ozone increased plasma levels of the tryptophan metabolite kynurenine (~2-fold) and decreased tryptophan levels (~1.2 fold). Hippocampal expression of serotonin receptors exhibited differential regulation following exposure, and expression of key neurotrophic factors (brain-derived neurotrophic factor, vascular endothelial growth factor A, insulin-like growth factor-1, tyrosine kinase receptor B, b-cell lymphoma 2) was decreased. Some, but not all effects were abrogated by metyrapone treatment, suggesting both glucocorticoid-dependent and -independent regulation. Exposure to exogenous corticosterone (10 mg/kg) followed by clean air reproduced the ozone effects that were blocked with metyrapone, confirming the specificity of effects to glucocorticoids. These results indicate that ozone can modify pathways relevant to brain health and establish a role for the HPA axis in mediating these effects.","['Air pollution', 'Brain', 'Glucocorticoids', 'Neurotoxicity', 'Rat']",Environmental research,2020-04-12,"[{'lastname': 'Rose', 'firstname': 'Mercedes', 'initials': 'M', 'affiliation': 'Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, K1A 0K9, Canada; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada.'}, {'lastname': 'Filiatreault', 'firstname': 'Alain', 'initials': 'A', 'affiliation': 'Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, K1A 0K9, Canada.'}, {'lastname': 'Guénette', 'firstname': 'Josée', 'initials': 'J', 'affiliation': 'Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, K1A 0K9, Canada.'}, {'lastname': 'Williams', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, K1A 0K9, Canada.'}, {'lastname': 'Thomson', 'firstname': 'Errol M', 'initials': 'EM', 'affiliation': 'Environmental Health Science and Research Bureau, Healthy Environments and Consumer Safety Branch, Health Canada, Ottawa, K1A 0K9, Canada; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. Electronic address: errol.thomson@canada.ca.'}]",,,,Copyright © 2020. Published by Elsevier Inc.,10.1016/j.envres.2020.109483,<Element 'PubmedArticle' at 0x7f05dd88f270>
190,32278031,Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa.,"Cistanche tubulosa is a precious traditional Chinese medicine that has been widely used in the treatment of osteoporosis and Alzheimer's disease. Echinacoside and acteoside are the main active constituents in Cistanche tubulosa that have the pharmacological activities with research value. It has been reported that echinacoside and acteoside could improve the learning and memory ability, promote the proliferation and differentiation of osteoblast.
Echinacoside and acteoside from Cistanche tubulosa have shown significant activities of anti-osteoporosis and anti-Alzheimer's disease, while these effects have not been studied concurrently in a rat model. The aim of this study was to establish and verify the model of osteoporosis combined with Alzheimer's disease in rat, and to investigate the double effects of echinacoside and acteoside on this concurrent model.
Three model groups of ovariectomy (OVX), sham surgery with D-galactose and AlCl
Compared with Sham group, OVX + D group could significantly reduce the learning and memory ability by causing oxidative damage, impairing neurons in hippocampus and affecting the hydrolysis and synthesis of acetylcholine. Meanwhile, the activities of BALP and TRAP in OVX + D group increased significantly (P < 0.001) as compared to Sham group. In addition, compared with Sham group, the mean bone mineral density obviously decreased (P < 0.05), the trabecular bone mass and microarchitecture were also destroyed significantly in OVX + D group. Furthermore, the maximum load and maximum stress significantly reduced (P < 0.01) and the energy absorption also decreased greatly as compared to Sham group. After administrated with echinacoside and acteoside, the typical pathological features of osteoporosis and Alzheimer's disease were ameliorated.
The model of osteoporosis combined with Alzheimer's disease in rat was feasible and successfully established. Echinacoside and acteoside also showed some significant effects on this concurrent model, and they could be potential candidates from Cistanche tubulosa with double effects for further study.","['Acteoside', ""Alzheimer's disease"", 'Cistanche tubulosa', 'Dual-effects', 'Echinacoside', 'Osteoporosis']",Journal of ethnopharmacology,2020-04-12,"[{'lastname': 'Chen', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.'}, {'lastname': 'Li', 'firstname': 'Ying-Qi', 'initials': 'YQ', 'affiliation': 'State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.'}, {'lastname': 'Fang', 'firstname': 'Jia-Yi', 'initials': 'JY', 'affiliation': 'State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.'}, {'lastname': 'Li', 'firstname': 'Ping', 'initials': 'P', 'affiliation': 'State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: liping2004@126.com.'}, {'lastname': 'Li', 'firstname': 'Fei', 'initials': 'F', 'affiliation': 'State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; College of Pharmacy, Xinjiang Medical University, Urumqi, 830011, China. Electronic address: lifeicpu@163.com.'}]",,,"Compared with Sham group, OVX + D group could significantly reduce the learning and memory ability by causing oxidative damage, impairing neurons in hippocampus and affecting the hydrolysis and synthesis of acetylcholine. Meanwhile, the activities of BALP and TRAP in OVX + D group increased significantly (P < 0.001) as compared to Sham group. In addition, compared with Sham group, the mean bone mineral density obviously decreased (P < 0.05), the trabecular bone mass and microarchitecture were also destroyed significantly in OVX + D group. Furthermore, the maximum load and maximum stress significantly reduced (P < 0.01) and the energy absorption also decreased greatly as compared to Sham group. After administrated with echinacoside and acteoside, the typical pathological features of osteoporosis and Alzheimer's disease were ameliorated.",Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.jep.2020.112834,<Element 'PubmedArticle' at 0x7f05dd89e8b0>
191,32278002,Rutin protects Huntington's disease through the insulin/IGF1 (IIS) signaling pathway and autophagy activity: Study in Caenorhabditis elegans model.,"Huntington's disease (HD) is inherited neurodegenerative disease, it is characterized by excessive motor movements and cognitive and emotional deficits. HD is caused by an abnormally long polyglutamine (polyQ) expansion in the huntingtin (Htt) protein, which confers toxic functions to mutant Htt leading to neurodegeneration. Rutin is a flavonoid found in plants, buckwheat, some teas and also in apples. Although previous studies have already indicated that rutin has some protective effects in HD's models, the underlying mechanisms are still unknown. In our study, we investigated the effects of rutin in Caenorhabditis elegans model of HD. We assessed polyQ aggregation, oxidative damage, neurodegeneration level and lifespan, and investigated the possible role of autophagy and insulin/IGF1 (IIS) signaling pathways in the beneficial effects induced by rutin. Overall, our data demonstrate that chronic rutin treatment reduced polyglutamine (polyQ) protein aggregation in muscle, reduced polyQ-mediated neuronal death in ASH sensory neurons, and extended lifespan. The possible mechanisms involved are antioxidant activity, activation of protein degradation (autophagy) and insulin/IGF1 (IIS) signaling pathways. These findings indicate that rutin consumption might be helpful in preventing HD and also provide possible pathways to be explored to search for new therapies against proteinopathies related to aging.","['C. elegans', 'Flavonoids', 'Neurodegeration', 'Proteinopathies']",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,2020-04-12,"[{'lastname': 'Cordeiro', 'firstname': 'Larissa Marafiga', 'initials': 'LM', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'Machado', 'firstname': 'Marina Lopes', 'initials': 'ML', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'da Silva', 'firstname': 'Aline Franzen', 'initials': 'AF', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'Obetine Baptista', 'firstname': 'Fabiane Bicca', 'initials': 'FB', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'da Silveira', 'firstname': 'Tássia Limana', 'initials': 'TL', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'Soares', 'firstname': 'Felix Alexandre Antunes', 'initials': 'FAA', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil.'}, {'lastname': 'Arantes', 'firstname': 'Leticia Priscilla', 'initials': 'LP', 'affiliation': 'Universidade Federal de Santa Maria, Centro de Ciências Naturais e Exatas, Departamento de Bioquímica e Biologia Molecular, Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica, Camobi, 97105-900, Santa Maria, RS, Brazil. Electronic address: leti.ufsm@gmail.com.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.fct.2020.111323,<Element 'PubmedArticle' at 0x7f05dd88d2c0>
192,32175837,The Influence of Vitamin D on Neurodegeneration and Neurological Disorders: A Rationale for its Physio-pathological Actions.,"Vitamin D is a steroid hormone implicated in the regulation of neuronal integrity and many brain functions. Its influence, as a nutrient and a hormone, on the physiopathology of the most common neurodegenerative diseases is continuously emphasized by new studies. This review addresses what is currently known about the action of vitamin D on the nervous system and neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis. Further vitamin D research is necessary to understand how the action of this ""neuroactive"" steroid can help to optimize the prevention and treatment of several neurological diseases.","[""Alzheimer's disease"", ""Parkinson's disease"", 'Vitamin D', 'amyotrophic lateral sclerosis', 'multiple\nsclerosis', 'neurodegenerative diseases.']",Current pharmaceutical design,2020-03-17,"[{'lastname': 'Morello', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Clinical Biochemistry, Department of Experimental Medicine, Faculty of Medicine, University of Rome ""Tor Vergata"" and University Hospital of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Pieri', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'Clinical Biochemistry, Department of Experimental Medicine, Faculty of Medicine, University of Rome ""Tor Vergata"" and University Hospital of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Zenobi', 'firstname': 'Rossella', 'initials': 'R', 'affiliation': 'Clinical Biochemistry, Department of Experimental Medicine, Faculty of Medicine, University of Rome ""Tor Vergata"" and University Hospital of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Talamo', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': 'Psychiatric Clinic, University Hospital of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Stephan', 'firstname': 'Delphine', 'initials': 'D', 'affiliation': 'Aix Marseille University, CNRS, INP, UMR 7051, Marseille, France.'}, {'lastname': 'Landel', 'firstname': 'Verena', 'initials': 'V', 'affiliation': 'Aix Marseille University, CNRS, INP, UMR 7051, Marseille, France.'}, {'lastname': 'Féron', 'firstname': 'François', 'initials': 'F', 'affiliation': 'Aix Marseille University, CNRS, INP, UMR 7051, Marseille, France.'}, {'lastname': 'Millet', 'firstname': 'Pascal', 'initials': 'P', 'affiliation': 'Aix Marseille University, CNRS, INP, UMR 7051, Marseille, France.\nAssociation UNIVI (Agirc-Arrco), 75010 Paris, France.\nHôpital Gériatrique les Magnolias, Ballainvilliers, France.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1381612826666200316145725,<Element 'PubmedArticle' at 0x7f05dd878090>
193,32171891,"Diet, inflammation and the gut microbiome: Mechanisms for obesity-associated cognitive impairment.","Poor diet and obesity are associated with cognitive impairment throughout adulthood, and increased dementia risk in aging. Here we review the current literature interrogating the mechanisms by which diets high in fat, or fat and sugar lead to cognitive impairment, focusing on changes to gut microbiome composition, inflammatory signalling and blood-brain barrier integrity. Preclinical studies indicate weight gain is not necessary for diet-induced cognitive impairment. Rather, gut microbiome composition, and systemic and central inflammatory processes appear to contribute to diet-induced cognitive impairment. While both obese humans and rodents exhibit reduced blood-brain barrier integrity, cognitive impairments precede these changes, suggesting other mechanisms may underly diet-induced cognitive changes. Other potential candidates include hormone, glucoregulatory and cardiovascular changes. Poor diet and obesity act through multiple mechanisms to affect cognitive health and the challenge for future research is to identify key processes that can be reversed to improve cognition and quality of life.","['Cognitive impairment', 'Diet', 'Gut microbiome', 'Gut-brain axis', 'Inflammation', 'Obesity']",Biochimica et biophysica acta. Molecular basis of disease,2020-03-17,"[{'lastname': 'Leigh', 'firstname': 'Sarah-Jane', 'initials': 'SJ', 'affiliation': 'School of Medical Sciences, UNSW Sydney, NSW 2052, Australia.'}, {'lastname': 'Morris', 'firstname': 'Margaret J', 'initials': 'MJ', 'affiliation': 'School of Medical Sciences, UNSW Sydney, NSW 2052, Australia. Electronic address: m.morris@unsw.edu.au.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2020.165767,<Element 'PubmedArticle' at 0x7f05dd865360>
194,32171590,Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience.,"GRN mutations are frequent causes of familial frontotemporal degeneration. Although there is no clear consensual threshold, plasma progranulin levels represent an efficient biomarker for predicting GRN mutations when decreased. We evaluated plasma levels to determine whether it could also predict age at onset, clinical phenotype, or disease progression in 160 GRN carriers. Importantly, progranulin levels were influenced by gender, with lower levels in male than in female patients in our study. Although we found no correlation with age at onset or with clinical phenotype, we confirmed that decreased level predicts GRN mutations, even in presymptomatic carriers more than four decades before disease onset. We also provided first evidence for the stability of levels throughout longitudinal trajectory in carriers, over a 4-year time span. Finally, we confirmed that progranulin levels constitute a reliable, cost-effective marker, suitable as a screening tool in patients with familial frontotemporal degeneration, and more broadly in patients without family history or with atypical presentations who are less likely to be referred for molecular diagnosis.","['C9orf72', 'Frontotemporal dementia', 'Frontotemporal lobar degeneration', 'Plasma progranulin levels', 'Progranulin (GRN)']",Neurobiology of aging,2020-03-17,"[{'lastname': 'Sellami', 'firstname': 'Leila', 'initials': 'L', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Rucheton', 'firstname': 'Benoît', 'initials': 'B', 'affiliation': 'UF de Biochimie des Maladies Neurométaboliques et Neurodégénératives, Service de Biochimie Métabolique, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Ben Younes', 'firstname': 'Imen', 'initials': 'I', 'affiliation': 'UF de Biochimie des Maladies Neurométaboliques et Neurodégénératives, Service de Biochimie Métabolique, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Camuzat', 'firstname': 'Agnès', 'initials': 'A', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; EPHE, PSL Research University, Paris, France.'}, {'lastname': 'Saracino', 'firstname': 'Dario', 'initials': 'D', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team, Inria Research Center of Paris, Paris, France.'}, {'lastname': 'Rinaldi', 'firstname': 'Daisy', 'initials': 'D', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Epelbaum', 'firstname': 'Stephane', 'initials': 'S', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Aramis Project Team, Inria Research Center of Paris, Paris, France.'}, {'lastname': 'Azuar', 'firstname': 'Carole', 'initials': 'C', 'affiliation': 'Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.'}, {'lastname': 'Levy', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.'}, {'lastname': 'Auriacombe', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'CMRR Nouvelle Aquitaine, Institut des Maladies Neurodégénératives clinique (IMNc), CHU de Bordeaux Hôpital Pellegrin, Bordeaux, France.'}, {'lastname': 'Hannequin', 'firstname': 'Didier', 'initials': 'D', 'affiliation': 'Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Rouen, France.'}, {'lastname': 'Pariente', 'firstname': 'Jérémie', 'initials': 'J', 'affiliation': 'Department of Neurology, Toulouse University Hospital, Toulouse, France; ToNIC, Toulouse NeuroImaging Centre, University of Toulouse, Inserm, UPS, Toulouse, France.'}, {'lastname': 'Barbier', 'firstname': 'Mathieu', 'initials': 'M', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Boutoleau-Bretonnière', 'firstname': 'Claire', 'initials': 'C', 'affiliation': 'CHU Nantes, Inserm CIC04, Department of Neurology, Centre Mémoire de Ressources et Recherche, Nantes, France.'}, {'lastname': 'Couratier', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'CMRR Service de Neurologie, CHU de Limoges, Limoges, France.'}, {'lastname': 'Pasquier', 'firstname': 'Florence', 'initials': 'F', 'affiliation': 'Univ Lille, CHU, Inserm, DISTALZ, LiCEND, Lille, France.'}, {'lastname': 'Deramecourt', 'firstname': 'Vincent', 'initials': 'V', 'affiliation': 'Univ Lille, CHU, Inserm, DISTALZ, LiCEND, Lille, France.'}, {'lastname': 'Sauvée', 'firstname': 'Mathilde', 'initials': 'M', 'affiliation': 'CMRR Arc Alpin, Service de Neurologie, Hôpital Michallon, Grenoble, France; Laboratoire de Psychologie et Neurocognition, LPNC UMR 5105, Université de Grenoble, Grenoble, France.'}, {'lastname': 'Sarazin', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Unit of Neurology of Memory and Language, GHU Paris Psychiatrie et Neurosciences, University of Paris, Paris, France; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.'}, {'lastname': 'Lagarde', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Unit of Neurology of Memory and Language, GHU Paris Psychiatrie et Neurosciences, University of Paris, Paris, France; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.'}, {'lastname': 'Roué-Jagot', 'firstname': 'Carole', 'initials': 'C', 'affiliation': 'Unit of Neurology of Memory and Language, GHU Paris Psychiatrie et Neurosciences, University of Paris, Paris, France; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.'}, {'lastname': 'Forlani', 'firstname': 'Sylvie', 'initials': 'S', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Jornea', 'firstname': 'Ludmila', 'initials': 'L', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'David', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'UF de Neurogénétique Moléculaire et Cellulaire, Département de Génétique, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Paris, France.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'LeGuern', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.'}, {'lastname': 'Dubois', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.'}, {'lastname': 'Brice', 'firstname': 'Alexis', 'initials': 'A', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Clot', 'firstname': 'Fabienne', 'initials': 'F', 'affiliation': 'Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.'}, {'lastname': 'Lamari', 'firstname': 'Foudil', 'initials': 'F', 'affiliation': 'UF de Biochimie des Maladies Neurométaboliques et Neurodégénératives, Service de Biochimie Métabolique, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.'}, {'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Sorbonne Université, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Centre de Référence des Démences Rares ou Précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France; Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France. Electronic address: isabelle.leber@upmc.fr.'}]",,,,Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2020.02.014,<Element 'PubmedArticle' at 0x7f05deacc220>
195,32165212,Insulin mediated novel therapies for the treatment of Alzheimer's disease.,"Alzheimer's disease, a progressive neurodegenerative disorder, is one of the leading causes of death in the USA, along with cancer and cardiac disorders. AD is characterized by various neurological factors like amyloid plaques, tau hyperphosphorylation, mitochondrial dysfunction, acetylcholine deficiency, etc. Together, impaired insulin signaling in the brain is also observed as essential factor to be considered in AD pathophysiology. Hence, currently researchers focused on studying the effect of brain insulin metabolism and relation of diabetes with AD. Based on the investigations, AD is also considered as type 3 or brain diabetes. Besides the traditional view of correlating AD with aging, a better understanding of various pathological factors and effects of other physical ailments is necessary to develop a promising therapeutic approach. There is a vast scope of studying the relation of systemic insulin level, insulin signaling, its neuroprotective potency and effect of diabetes on AD progression. The present work describes worldwide status of AD and its relation with diabetes mellitus and insulin metabolism; pathophysiology of AD; different metabolic pathways associating insulin metabolism with AD; insulin receptor and signaling in the brain; glucose metabolism; insulin resistance; and various preclinical and clinical studies reported insulin-based therapies to treat AD via systemic route and through direct intranasal delivery to the brain.","[""Alzheimer's disease"", 'Blood-brain barrier', 'Diabetes', 'Glucose metabolism', 'Insulin', 'Insulin resistance']",Life sciences,2020-03-14,"[{'lastname': 'Dubey', 'firstname': 'Sunil Kumar', 'initials': 'SK', 'affiliation': 'Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. Electronic address: skdubey@pilani.bits-pilani.ac.in.'}, {'lastname': 'Lakshmi', 'firstname': 'K K', 'initials': 'KK', 'affiliation': 'Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.'}, {'lastname': 'Krishna', 'firstname': 'Kowthavarapu Venkata', 'initials': 'KV', 'affiliation': 'Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.'}, {'lastname': 'Agrawal', 'firstname': 'Mukta', 'initials': 'M', 'affiliation': 'Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh 490 024, India.'}, {'lastname': 'Singhvi', 'firstname': 'Gautam', 'initials': 'G', 'affiliation': 'Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.'}, {'lastname': 'Saha', 'firstname': 'Ranendra Narayana', 'initials': 'RN', 'affiliation': 'Department of Biotechnology, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Dubai Campus, Dubai, United Arab Emirates.'}, {'lastname': 'Saraf', 'firstname': 'Swarnlata', 'initials': 'S', 'affiliation': 'University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492010, India.'}, {'lastname': 'Saraf', 'firstname': 'Shailendra', 'initials': 'S', 'affiliation': 'University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh 492010, India.'}, {'lastname': 'Shukla', 'firstname': 'Rahul', 'initials': 'R', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER-R), New Transit Campus, Bijnor Road, Sarojini Nagar, Lucknow 226002, India.'}, {'lastname': 'Alexander', 'firstname': 'Amit', 'initials': 'A', 'affiliation': 'National Institute of Pharmaceutical Education and Research (NIPER-Guwahati), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India, NH 37, NITS Mirza, Kamrup-781125, Guwahati, Assam, India. Electronic address: itsmeamitalex@gmail.com.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2020.117540,<Element 'PubmedArticle' at 0x7f05deade130>
196,"32127481
14392225
15784668
24794371
15557509
24622753
24534521
24367577
19885299
3520377
20837822
8786794
14411854
3746406
27458340
26766547
10891595
2381501
26596563
28483672
28178565
24140022
14769489
7768357
17881524
21068832
27974609
30747911
26375206
27199643
3899825
26893218
30532080
17560126
21616982
29884650
29668865
1202204
28414271
28507319
27629100
16460967
28242634
8967461
28069540
17132822
29321682
749914
21233852
14504252
6776000
12634421","Diet modulates brain network stability, a biomarker for brain aging, in young adults.","Epidemiological studies suggest that insulin resistance accelerates progression of age-based cognitive impairment, which neuroimaging has linked to brain glucose hypometabolism. As cellular inputs, ketones increase Gibbs free energy change for ATP by 27% compared to glucose. Here we test whether dietary changes are capable of modulating sustained functional communication between brain regions (network stability) by changing their predominant dietary fuel from glucose to ketones. We first established network stability as a biomarker for brain aging using two large-scale (","['beta-hydroxybutyrate', 'brain', 'glucose', 'ketone', 'neural']",Proceedings of the National Academy of Sciences of the United States of America,2020-03-05,"[{'lastname': 'Mujica-Parodi', 'firstname': 'Lilianne R', 'initials': 'LR', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794; Lilianne.Strey@stonybrook.edu dill@laufercenter.org.\nLaufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794.\nDepartment of Physics and Astronomy, Stony Brook University, Stony Brook, NY 11794.\nAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.'}, {'lastname': 'Amgalan', 'firstname': 'Anar', 'initials': 'A', 'affiliation': 'Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794.\nDepartment of Physics and Astronomy, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Sultan', 'firstname': 'Syed Fahad', 'initials': 'SF', 'affiliation': 'Department of Computer Science, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Antal', 'firstname': 'Botond', 'initials': 'B', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Sun', 'firstname': 'Xiaofei', 'initials': 'X', 'affiliation': 'Department of Computer Science, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Skiena', 'firstname': 'Steven', 'initials': 'S', 'affiliation': 'Department of Computer Science, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Lithen', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Adra', 'firstname': 'Noor', 'initials': 'N', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Ratai', 'firstname': 'Eva-Maria', 'initials': 'EM', 'affiliation': 'Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.'}, {'lastname': 'Weistuch', 'firstname': 'Corey', 'initials': 'C', 'affiliation': 'Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794.\nDepartment of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Govindarajan', 'firstname': 'Sindhuja Tirumalai', 'initials': 'ST', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Strey', 'firstname': 'Helmut H', 'initials': 'HH', 'affiliation': 'Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794.\nLaufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794.'}, {'lastname': 'Dill', 'firstname': 'Ken A', 'initials': 'KA', 'affiliation': 'Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794; Lilianne.Strey@stonybrook.edu dill@laufercenter.org.'}, {'lastname': 'Stufflebeam', 'firstname': 'Steven M', 'initials': 'SM', 'affiliation': 'Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.'}, {'lastname': 'Veech', 'firstname': 'Richard L', 'initials': 'RL', 'affiliation': 'Laboratory of Metabolic Control, NIH/National Institute on Alcohol Abuse and Alcoholism, Rockville, MD 20852.'}, {'lastname': 'Clarke', 'firstname': 'Kieran', 'initials': 'K', 'affiliation': 'Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom.'}]",,,,Copyright © 2020 the Author(s). Published by PNAS.,10.1073/pnas.1913042117,<Element 'PubmedArticle' at 0x7f05dead6090>
197,32092326,Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease.,"Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Its major pathological hallmarks, neurofibrillary tangles (NFT), and amyloid-β plaques can result from dysfunctional insulin signaling. Insulin is an important growth factor that regulates cell growth, energy utilization, mitochondrial function, autophagy, oxidative stress, synaptic plasticity, and cognitive function. Insulin and its downstream signaling molecules are located majorly in the regions of cortex and hippocampus. The major molecules involved in impaired insulin signaling include IRS, PI3K, Akt, and GSK-3β. Activation or inactivation of these major molecules through increased or decreased phosphorylation plays a role in insulin signaling abnormalities or insulin resistance. Insulin resistance, therefore, is considered as a major culprit in generating the hallmarks of AD arising from neuroinflammation and oxidative stress, etc. Moreover, caspases, Nrf2, and NF-κB influence this pathway in an indirect way. Various studies also suggest a strong link between Diabetes Mellitus and AD due to the impairment of insulin signaling pathway. Moreover, studies also depict a strong correlation of other neurodegenerative diseases such as Parkinson's disease and Huntington's disease with insulin resistance. Hence this review will provide an insight into the role of insulin signaling pathway and related molecules as therapeutic targets in AD and other neurodegenerative diseases.","[""Alzheimer's disease"", 'Diabetes mellitus', 'Insulin resistance', 'Neurodegeneration', 'Neuroinflammation']",Neurochemistry international,2020-02-25,"[{'lastname': 'Akhtar', 'firstname': 'Ansab', 'initials': 'A', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), UGC Centre of Advanced Study (UGC-CAS), Panjab University, Chandigarh, 160014, India. Electronic address: ansabakhtar@gmail.com.'}, {'lastname': 'Sah', 'firstname': 'Sangeeta Pilkhwal', 'initials': 'SP', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences (UIPS), UGC Centre of Advanced Study (UGC-CAS), Panjab University, Chandigarh, 160014, India. Electronic address: spilkhwal@rediffmail.com.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.neuint.2020.104707,<Element 'PubmedArticle' at 0x7f05deba7130>
198,32065104,Elevated Testosterone Level and Urine Scent Marking in Male 5xFAD Alzheimer Model Mice.,"Function of the Amyloid Precursor Protein (AβPP) and its various cleavage products still is not unraveled down to the last detail. While its role as a source of the neurotoxic Amyloid beta (Aβ) peptides in Alzheimer's Disease (AD) is undisputed and its property as a cell attachment protein is intriguing, while functions outside the neuronal context are scarcely investigated. This is particularly noteworthy because AβPP has a ubiquitous expression profile and its longer isoforms, AβPP750 and 770, are found in various tissues outside the brain and in non-neuronal cells.
Here, we aimed at analyzing the 5xFAD Alzheimer's disease mouse model in regard to male sexual function. The transgenes of this mouse model are regulated by Thy1 promoter activity and Thy1 is expressed in testes, e.g. by Sertoli cells. This allows speculation about an influence on sexual behavior.
We analyzed morphological as well as biochemical properties of testicular tissue from 5xFAD mice and wild type littermates and testosterone levels in serum, testes and the brain. Sexual behavior was assessed by a urine scent marking test at different ages for both groups.
While sperm number, testes weight and morphological phenotypes of sperms were nearly indistinguishable from those of wild type littermates, testicular testosterone levels were significantly increased in the AD model mice. This was accompanied by elevated and prolonged sexual interest as displayed within the urine scent marking test.
We suggest that overexpression of AβPP, which mostly is used to mimic AD in model mice, also affects male sexual behavior as assessed additional by the Urine Scent Marking (USM) test. The elevated testosterone levels might have an additional impact on central nervous system androgen receptors and also have to be considered when assessing learning and memory capabilities.","[""Alzheimer's disease"", 'amyloid precursor protein', 'mice', 'sexual behavior', 'testosterone', 'urine scent marking test.']",Current Alzheimer research,2020-02-18,"[{'lastname': 'Gadomsky', 'firstname': 'Lisa', 'initials': 'L', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Johannes Gutenberg- University, Mainz, Germany.'}, {'lastname': 'Dos Santos Guilherme', 'firstname': 'Malena', 'initials': 'M', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Johannes Gutenberg- University, Mainz, Germany.'}, {'lastname': 'Winkler', 'firstname': 'Jakob', 'initials': 'J', 'affiliation': 'German Institute for Dementia Prevention (GIDP), Neurodegeneration and Neurobiology, Saarland University, Homburg/Saar, Germany and Experimental Neurology, Saarland University, Homburg/Saar, Germany.'}, {'lastname': 'van der Kooij', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Johannes Gutenberg- University, Mainz, Germany.'}, {'lastname': 'Hartmann', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'German Institute for Dementia Prevention (GIDP), Neurodegeneration and Neurobiology, Saarland University, Homburg/Saar, Germany and Experimental Neurology, Saarland University, Homburg/Saar, Germany.'}, {'lastname': 'Grimm', 'firstname': 'Marcus', 'initials': 'M', 'affiliation': 'German Institute for Dementia Prevention (GIDP), Neurodegeneration and Neurobiology, Saarland University, Homburg/Saar, Germany and Experimental Neurology, Saarland University, Homburg/Saar, Germany.'}, {'lastname': 'Endres', 'firstname': 'Kristina', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Johannes Gutenberg- University, Mainz, Germany.'}]",,"We suggest that overexpression of AβPP, which mostly is used to mimic AD in model mice, also affects male sexual behavior as assessed additional by the Urine Scent Marking (USM) test. The elevated testosterone levels might have an additional impact on central nervous system androgen receptors and also have to be considered when assessing learning and memory capabilities.","While sperm number, testes weight and morphological phenotypes of sperms were nearly indistinguishable from those of wild type littermates, testicular testosterone levels were significantly increased in the AD model mice. This was accompanied by elevated and prolonged sexual interest as displayed within the urine scent marking test.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1567205017666200217105537,<Element 'PubmedArticle' at 0x7f05deba23b0>
199,"32035072
26122294
28833901
7046051
25554518
24975924
29875637
26687218
22131419
21839780
20074655
1482548
18753366
24878494
25128537
23904598
25993604
25960081
26286657
15814198
2329377
20609373
22569790
20553724
26844375
18395274
5238991
24151456
23276632
16005000
26122297
26149525
18768812
11967893
12533625
21392135
24837746
26241030
16945354
23079626
29669258
2990988
25205317
22981654
12810538
26140715
17070772
5647596
22669167
21285321
26655342
6785075
15251264
27084356
5070805
14704219
4681745
26843632
16934233
11848717
2269895
1613547
16750837
30992373
20097718",Estrogenic regulation of memory: The first 50 years.,"This review highlights fifty years of progress in research on estradiol's role in regulating behavior(s). It was initially thought that estradiol was only involved in regulating estrus/menstrual cycles and concomitant sexual behavior, but it is now clear that estradiol also influences the higher order neural function of cognition. We provide a brief overview of estradiol's regulation of memory and some mechanisms which underlie its effects. Given systemically or directly into the hippocampus, to ovariectomized female rodents, estradiol or specific agonists, enhance learning and/or memory in a variety of rodent cognitive tasks. Acute (within minutes) or chronic (days) treatments enhance cognitive functions. Under the same treatment conditions, dendritic spine density on pyramidal neurons in the CA1 area of the hippocampus and medial prefrontal cortex increase which suggests that these changes are an important component of estrogen's ability to impact memory processes. Noradrenergic, dopaminergic and serotoninergic activity are also altered in these areas following estrogen treatments. Memory enhancements and increased spine density by estrogens are not limited to females but are also present in castrate males. In the next fifty years, neuroscientists need to determine how currently described neural changes mediate improved memory, how interactions among areas important for memory promote memory and the potential significance of neurally derived estrogens in normal cognitive processing. Answering these questions may provide significant advances for treatment of dementias as well as age and neuro-degenerative disease related memory loss.","['Dendritic spines', 'Estrogen', 'Memory', 'Monoamines', 'Plasticity']",Hormones and behavior,2020-02-09,"[{'lastname': 'Luine', 'firstname': 'Victoria', 'initials': 'V', 'affiliation': 'Department of Psychology, Hunter College of CUNY, New York, NY, USA. Electronic address: vluine@hunter.cuny.edu.'}, {'lastname': 'Frankfurt', 'firstname': 'Maya', 'initials': 'M', 'affiliation': 'Department of Science Education, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.yhbeh.2020.104711,<Element 'PubmedArticle' at 0x7f05deb97bd0>
200,31902364,Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies.,"The aim of this study is to assess the association between midlife risk factors and dementia.
PubMed and Cochrane library were systematically searched on May 24, 2018, to retrieve prospective cohort studies. The summary Relative Risk (RR) and 95% Confidence Interval (CI) were calculated by the random-effect model to explore the association between midlife risk factors and dementia. Sensitivity analysis and meta-regression were conducted to explore the source of heterogeneity. Publication bias was examined using Begg's and Egger's tests.
Thirty-four prospective cohort studies were included, among which 24 were eligible for metaanalysis. A total of 159,594 non-demented adults were enrolled at baseline before 65 years and 13,540 people were diagnosed with dementia after follow-up. The pooled results revealed that five factors could significantly increase the dementia risk by 41 to 78%, including obesity (RR, 1.78; 95% CI: 1.31-2.41), diabetes mellitus (RR, 1.69; 95% CI: 1.38-2.07), current smoking (RR, 1.61; 95%, CI: 1.32-1.95), hypercholesterolemia (RR, 1.57; 95% CI: 1.19-2.07), and hypertension (borderline blood pressure RR, 1.41; 95% CI: 1.23-1.62 and high Systolic Blood Pressure (SBP) RR, 1.72; 95% CI: 1.25-2.37). However, the sensitivity analyses found that the results of hypercholesterolemia and high SBP were not reliable, which need to be confirmed by more high-quality studies. No influences due to publication bias were revealed. In the systematic review, another three factors (hyperhomocysteinemia, psychological stress, and heavy drinking) were found to be associated with elevated dementia risk. In addition, physical exercise, a healthy diet, and hormone therapy in middle age were associated with the reduction of dementia risk.
Middle-aged people with obesity, diabetes, hypertension, or hypercholesterolemia, and current smokers in midlife are at higher risk of developing dementia later in life.","['Dementia', 'meta-analysis', 'midlife risk factors', 'prospective cohort studies', 'subgroup analyses', 'systematic review.']",Current Alzheimer research,2020-01-07,"[{'lastname': 'Li', 'firstname': 'Xiao-Ying', 'initials': 'XY', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Zhang', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Xu', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'College of Medicine and Pharmaceutics, Ocean University of China, Qingdao, China.'}, {'lastname': 'Li', 'firstname': 'Jie-Qiong', 'initials': 'JQ', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Cao', 'firstname': 'Xi-Peng', 'initials': 'XP', 'affiliation': 'Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'lastname': 'Yu', 'firstname': 'Jin-Tai', 'initials': 'JT', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.\nDepartment of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.\nCollege of Medicine and Pharmaceutics, Ocean University of China, Qingdao, China.'}]",,,"Thirty-four prospective cohort studies were included, among which 24 were eligible for metaanalysis. A total of 159,594 non-demented adults were enrolled at baseline before 65 years and 13,540 people were diagnosed with dementia after follow-up. The pooled results revealed that five factors could significantly increase the dementia risk by 41 to 78%, including obesity (RR, 1.78; 95% CI: 1.31-2.41), diabetes mellitus (RR, 1.69; 95% CI: 1.38-2.07), current smoking (RR, 1.61; 95%, CI: 1.32-1.95), hypercholesterolemia (RR, 1.57; 95% CI: 1.19-2.07), and hypertension (borderline blood pressure RR, 1.41; 95% CI: 1.23-1.62 and high Systolic Blood Pressure (SBP) RR, 1.72; 95% CI: 1.25-2.37). However, the sensitivity analyses found that the results of hypercholesterolemia and high SBP were not reliable, which need to be confirmed by more high-quality studies. No influences due to publication bias were revealed. In the systematic review, another three factors (hyperhomocysteinemia, psychological stress, and heavy drinking) were found to be associated with elevated dementia risk. In addition, physical exercise, a healthy diet, and hormone therapy in middle age were associated with the reduction of dementia risk.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1567205017666200103111253,<Element 'PubmedArticle' at 0x7f05df78b7c0>
201,"31819070
4399447
27491309
10727395
6179090
10523761
24866693
19342614
15677400
15240392
11517215
10569954
19396395
19627998
9208378
19046987
3524379
16581032
19922550
19710631
24904434
9771763
25954517
29463026
24070602
20398338
28187365
20335226
31284621
28763556
27068697
30589871
31101854
29718319
25512792
26907971
21284695
16932542
16246041
12954480
14702004
23850509
28922161
24931035
21284695
25191613
21736778
24571922
29666700
30401897
11106812
14506001
16326638
23572765
23433062
21736792
7545067
20965158
16854387
28429209
28259623
29857583
29091972
28549787
28843021
27912057
28195358
25550539
29550564",Palm Fruit Bioactives augment expression of Tyrosine Hydroxylase in the Nile Grass Rat basal ganglia and alter the colonic microbiome.,"Tyrosine hydroxylase (TH) catalyzes the hydroxylation of L-tyrosine to L-DOPA. This is the rate-limiting step in the biosynthesis of the catecholamines - dopamine (DA), norepinephrine (NE), and epinephrine (EP). Catecholamines (CA) play a key role as neurotransmitters and hormones. Aberrant levels of CA are associated with multiple medical conditions, including Parkinson's disease. Palm Fruit Bioactives (PFB) significantly increased the levels of tyrosine hydroxylase in the brain of the Nile Grass rat (NGR), a novel and potentially significant finding, unique to PFB among known botanical sources. Increases were most pronounced in the basal ganglia, including the caudate-putamen, striatum and substantia nigra. The NGR represents an animal model of diet-induced Type 2 Diabetes Mellitus (T2DM), exhibiting hyperglycemia, hyperinsulinemia, and insulin resistance associated with hyperphagia and accelerated postweaning weight gain induced by a high-carbohydrate diet (hiCHO). The PFB-induced increase of TH in the basal ganglia of the NGR was documented by immuno-histochemical staining (IHC). This increase in TH occurred equally in both diabetes-susceptible and diabetes-resistant NGR fed a hiCHO. PFB also stimulated growth of the colon microbiota evidenced by an increase in cecal weight and altered microbiome.  The metabolites of colon microbiota, e.g. short-chain fatty acids, may influence the brain and behavior significantly.",[],Scientific reports,2019-12-11,"[{'lastname': 'Weinberg', 'firstname': 'Robert P', 'initials': 'RP', 'affiliation': 'Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. rweinber@mit.edu.\nBiomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. rweinber@mit.edu.'}, {'lastname': 'Koledova', 'firstname': 'Vera V', 'initials': 'VV', 'affiliation': 'Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.\nBiomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.'}, {'lastname': 'Subramaniam', 'firstname': 'Avinaash', 'initials': 'A', 'affiliation': 'Department of Biology, Brandeis University, Waltham, Massachusetts 02453, USA.'}, {'lastname': 'Schneider', 'firstname': 'Kirsten', 'initials': 'K', 'affiliation': 'Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.\nBiomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.'}, {'lastname': 'Artamonova', 'firstname': 'Anastasia', 'initials': 'A', 'affiliation': 'Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.\nBiomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.'}, {'lastname': 'Sambanthamurthi', 'firstname': 'Ravigadevi', 'initials': 'R', 'affiliation': 'Advanced Biotechnology and Breeding Centre, Malaysian Palm Oil Board, 6, Persiaran Institusi, Bandar Baru Bangi, 43000, Kajang, Selangor, Malaysia.'}, {'lastname': 'Hayes', 'firstname': 'K C', 'initials': 'KC', 'affiliation': 'Department of Biology, Brandeis University, Waltham, Massachusetts 02453, USA.'}, {'lastname': 'Sinskey', 'firstname': 'Anthony J', 'initials': 'AJ', 'affiliation': 'Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.\nBiomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA.'}, {'lastname': 'Rha', 'firstname': 'ChoKyun', 'initials': 'C', 'affiliation': 'Biomaterials Science and Engineering Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. ckrha@mit.edu.'}]",,,,,"10.1038/s41598-019-54461-y
10.1146/annurev.bi.40.070171.002341
10.1007/s00702-016-1596-4
10.1042/bj3470001
10.1073/pnas.79.12.3881
10.1002/(SICI)1098-2396(19991201)34:3<241::AID-SYN8>3.0.CO;2-E
10.1007/s00702-014-1238-7
10.1152/physrev.00042.2006
10.1196/annals.1314.010
10.1196/annals.1296.046
10.1074/jbc.M102237200
10.1021/bi9914255
10.1007/s00702-009-0227-8
10.1016/j.neuropharm.2009.07.026
10.1177/026988119701100208
10.1016/j.neubiorev.2008.10.010
10.1111/j.1749-6632.1986.tb14630.x
10.1016/j.biopsych.2005.12.017
10.1111/j.1399-5618.2009.00760.x
10.1038/npp.2009.110
10.4236/psych.2014.51001
10.1136/jnnp.65.4.436
10.1155/2011/403039
10.3390/nu10020235
10.1016/j.jnutbio.2013.06.004
10.1186/1743-7075-7-29
10.1016/j.jnutbio.2017.01.007
10.3390/nu11071538
10.1167/iovs.17-21929
10.1530/JOE-15-0517
10.1371/journal.pone.0208987
10.1038/s41374-019-0264-3
10.1093/jnen/nly030
10.4239/wjd.v5.i6.889
10.1111/j.1365-2125.2010.03830.x
10.1038/ncpneuro0124
10.1042/BST0331041
10.1016/S0531-5565(03)00153-0
10.1017/S1092852900019258
10.1016/j.pneurobio.2013.06.004
10.3233/JAD-170440
10.2337/db14-0287
10.1111/j.1365-2125.2010.03830.x
10.1017/jns.2014.3
10.1017/S0007114511002133
10.1155/2018/7608038
10.1038/s41598-018-34763-3
10.1016/S0163-7827(00)00015-1
10.1007/s13197-011-0251-1
10.1080/87559120802304269
10.1179/1476830512Y.0000000047
10.1016/0006-8993(95)00215-C
10.1016/j.brainres.2010.10.034
10.1016/j.brainres.2006.05.097
10.1007/s10517-017-3700-7
10.1016/j.parkreldis.2017.02.026
10.3390/nu10060708
10.1371/journal.pone.0187307
10.1016/j.ejphar.2017.05.042
10.1002/mds.27105
10.1016/j.cell.2016.11.018
10.1002/mds.26942
10.1016/j.jff.2015.06.008
10.1016/j.jff.2014.01.002
10.1016/j.exger.2018.03.013",<Element 'PubmedArticle' at 0x7f05df778e00>
202,"31810826
23920254
24142474
19884572
29264395
28990425
28128768
25662776
16950801
28522837
14595646
21343707
17712160
18307268
16862116
16862115
29370822
28192553
24011653
25712133
30337192
26481318
23117491
24928124
30949567
17949857
18234697
18245784
27543298
29724592
20711061
21645364
23041626
23543794
27778404
25388784
28439722
30252044",Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.,"Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72.
In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried.
Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years (11·3; death) in the MAPT group, 58·2 years (9·8; onset) and 65·3 years (10·9; death) in the C9orf72 group, and 61·3 years (8·8; onset) and 68·8 years (9·7; death) in the GRN group. Mean disease duration was 6·4 years (SD 4·9) in the C9orf72 group, 7·1 years (3·9) in the GRN group, and 9·3 years (6·4) in the MAPT group. Individual age at onset and at death was significantly correlated with both parental age at onset and at death and with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT group (r=0·45 between individual and parental age at onset, r=0·63 between individual and mean family age at onset, r=0·58 between individual and parental age at death, and r=0·69 between individual and mean family age at death) than in either the C9orf72 group (r=0·32 individual and parental age at onset, r=0·36 individual and mean family age at onset, r=0·38 individual and parental age at death, and r=0·40 individual and mean family age at death) or the GRN group (r=0·22 individual and parental age at onset, r=0·18 individual and mean family age at onset, r=0·22 individual and parental age at death, and r=0·32 individual and mean family age at death). Modelling showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific mutation (48%, 95% CI 35-62, for age at onset; 61%, 47-73, for age at death), and even more by family membership (66%, 56-75, for age at onset; 74%, 65-82, for age at death). In the GRN group, only 2% (0-10) of the variability of age at onset and 9% (3-21) of that of age of death was explained by the specific mutation, whereas 14% (9-22) of the variability of age at onset and 20% (12-30) of that of age at death was explained by family membership. In the C9orf72 group, family membership explained 17% (11-26) of the variability of age at onset and 19% (12-29) of that of age at death.
Our study showed that age at symptom onset and at death of people with genetic frontotemporal dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried and by family membership. Although estimation of age at onset will be an important factor in future pre-symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying both genetic and environmental factors that modify phenotype in all groups will be important to improve such estimates.
UK Medical Research Council, National Institute for Health Research, and Alzheimer's Society.",[],The Lancet. Neurology,2019-12-08,"[{'lastname': 'Moore', 'firstname': 'Katrina M', 'initials': 'KM', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Nicholas', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'McMillan', 'firstname': 'Corey T', 'initials': 'CT', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Irwin', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Massimo', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': 'Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Fox', 'firstname': 'Nick C', 'initials': 'NC', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Rossor', 'firstname': 'Martin N', 'initials': 'MN', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Mead', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Institute of Prion Diseases, University College London, London, UK.'}, {'lastname': 'Bocchetta', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.'}, {'lastname': 'Boeve', 'firstname': 'Bradley F', 'initials': 'BF', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Knopman', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Graff-Radford', 'firstname': 'Neill R', 'initials': 'NR', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Forsberg', 'firstname': 'Leah K', 'initials': 'LK', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'Wszolek', 'firstname': 'Zbigniew K', 'initials': 'ZK', 'affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.'}, {'lastname': 'van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Jiskoot', 'firstname': 'Lize C', 'initials': 'LC', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Meeter', 'firstname': 'Lieke H', 'initials': 'LH', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Dopper', 'firstname': 'Elise Gp', 'initials': 'EG', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Papma', 'firstname': 'Janne M', 'initials': 'JM', 'affiliation': 'Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.'}, {'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'Cerebral Function Unit, Salford Royal NHS Foundation Trust and Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'lastname': 'Saxon', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'Cerebral Function Unit, Salford Royal NHS Foundation Trust and Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'lastname': 'Jones', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Cerebral Function Unit, Salford Royal NHS Foundation Trust and Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'Cerebral Function Unit, Salford Royal NHS Foundation Trust and Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK.'}, {'lastname': 'Le Ber', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': ""Institut du Cerveau et de la Moelle épinière & Centre de Référence des Démences Rares ou précoces, Institut de la Mémoire et de la Maladie d'Alzheimer, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Camuzat', 'firstname': 'Agnès', 'initials': 'A', 'affiliation': ""Institut du Cerveau et de la Moelle épinière & Centre de Référence des Démences Rares ou précoces, Institut de la Mémoire et de la Maladie d'Alzheimer, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Brice', 'firstname': 'Alexis', 'initials': 'A', 'affiliation': ""Institut du Cerveau et de la Moelle épinière & Centre de Référence des Démences Rares ou précoces, Institut de la Mémoire et de la Maladie d'Alzheimer, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Caroppo', 'firstname': 'Paola', 'initials': 'P', 'affiliation': ""Institut du Cerveau et de la Moelle épinière & Centre de Référence des Démences Rares ou précoces, Institut de la Mémoire et de la Maladie d'Alzheimer, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Ghidoni', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': 'Molecular Markers Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Pievani', 'firstname': 'Michela', 'initials': 'M', 'affiliation': ""Alzheimer's Neuroimaging & Epidemiology Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.""}, {'lastname': 'Benussi', 'firstname': 'Luisa', 'initials': 'L', 'affiliation': 'Molecular Markers Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Binetti', 'firstname': 'Giuliano', 'initials': 'G', 'affiliation': 'Molecular Markers Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Dickerson', 'firstname': 'Bradford C', 'initials': 'BC', 'affiliation': 'Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Lucente', 'firstname': 'Diane', 'initials': 'D', 'affiliation': 'Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Krivensky', 'firstname': 'Samantha', 'initials': 'S', 'affiliation': 'Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Center for Alzheimer Research, Division of Neurogenetics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.'}, {'lastname': 'Öijerstedt', 'firstname': 'Linn', 'initials': 'L', 'affiliation': 'Center for Alzheimer Research, Division of Neurogenetics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.'}, {'lastname': 'Fallström', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Center for Alzheimer Research, Division of Neurogenetics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.'}, {'lastname': 'Thonberg', 'firstname': 'Håkan', 'initials': 'H', 'affiliation': 'Center for Alzheimer Research, Division of Neurogenetics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.'}, {'lastname': 'Ghoshal', 'firstname': 'Nupur', 'initials': 'N', 'affiliation': ""Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.""}, {'lastname': 'Morris', 'firstname': 'John C', 'initials': 'JC', 'affiliation': ""Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.""}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Benussi', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Padovani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Department of Biomedical, Surgical and Dental Sciences, Centro Dino Ferrari, University of Milan, Milan, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': ""Department of Pathophysiology and Transplantation, Centro Dino Ferrari, University of Milan, Milan, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Fumagalli', 'firstname': 'Giorgio G', 'initials': 'GG', 'affiliation': ""Department of Pathophysiology and Transplantation, Centro Dino Ferrari, University of Milan, Milan, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.""}, {'lastname': 'Mackenzie', 'firstname': 'Ian R', 'initials': 'IR', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'lastname': 'Hsiung', 'firstname': 'Ging-Yuek R', 'initials': 'GR', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'lastname': 'Sengdy', 'firstname': 'Pheth', 'initials': 'P', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'lastname': 'Boxer', 'firstname': 'Adam L', 'initials': 'AL', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Rosen', 'firstname': 'Howie', 'initials': 'H', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Taylor', 'firstname': 'Joanne B', 'initials': 'JB', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA.'}, {'lastname': 'Synofzik', 'firstname': 'Matthis', 'initials': 'M', 'affiliation': 'Department of Neurodegenerative Diseases, Center for Neurology and Hertie-Institute for Clinical Brain Research, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.'}, {'lastname': 'Wilke', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': 'Department of Neurodegenerative Diseases, Center for Neurology and Hertie-Institute for Clinical Brain Research, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.'}, {'lastname': 'Sulzer', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Department of Neurodegenerative Diseases, Center for Neurology and Hertie-Institute for Clinical Brain Research, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.'}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': 'Brain and Mind Centre & Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'lastname': 'Halliday', 'firstname': 'Glenda', 'initials': 'G', 'affiliation': 'Brain and Mind Centre & Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'lastname': 'Kwok', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Brain and Mind Centre & Central Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'lastname': 'Sanchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': ""Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'lastname': 'Lladó', 'firstname': 'Albert', 'initials': 'A', 'affiliation': ""Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'lastname': 'Borrego-Ecija', 'firstname': 'Sergi', 'initials': 'S', 'affiliation': ""Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.'}, {'lastname': 'Almeida', 'firstname': 'Maria Rosário', 'initials': 'MR', 'affiliation': 'Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.'}, {'lastname': 'Tábuas-Pereira', 'firstname': 'Miguel', 'initials': 'M', 'affiliation': 'Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.'}, {'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain; Center for Networked Biomedical Research on Neurodegenerative Disease, Carlos III Health Institute, Madrid, Spain.'}, {'lastname': 'Barandiaran', 'firstname': 'Myriam', 'initials': 'M', 'affiliation': 'Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain; Center for Networked Biomedical Research on Neurodegenerative Disease, Carlos III Health Institute, Madrid, Spain.'}, {'lastname': 'Indakoetxea', 'firstname': 'Begoña', 'initials': 'B', 'affiliation': 'Cognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain; Center for Networked Biomedical Research on Neurodegenerative Disease, Carlos III Health Institute, Madrid, Spain.'}, {'lastname': 'Levin', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Neurodegenerative Diseases, Munich, Germany; Munich Cluster for Systems Neurology, Munich, Germany.'}, {'lastname': 'Danek', 'firstname': 'Adrian', 'initials': 'A', 'affiliation': 'Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.'}, {'lastname': 'Rowe', 'firstname': 'James B', 'initials': 'JB', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Cope', 'firstname': 'Thomas E', 'initials': 'TE', 'affiliation': 'Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Otto', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neurology, University of Ulm, Ulm, Germany.'}, {'lastname': 'Anderl-Straub', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Neurology, University of Ulm, Ulm, Germany.'}, {'lastname': 'de Mendonça', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'lastname': 'Maruta', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'lastname': 'Masellis', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Black', 'firstname': 'Sandra E', 'initials': 'SE', 'affiliation': 'Division of Neurology, Department of Medicine, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Couratier', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Centre de Compétence Démences Rares, Centre Hospitalier et Universitaire Limoges, Limoges, France.'}, {'lastname': 'Lautrette', 'firstname': 'Geraldine', 'initials': 'G', 'affiliation': 'Centre de Compétence Démences Rares, Centre Hospitalier et Universitaire Limoges, Limoges, France.'}, {'lastname': 'Huey', 'firstname': 'Edward D', 'initials': 'ED', 'affiliation': 'Departments of Psychiatry and Neurology, Columbia University, New York, NY, USA.'}, {'lastname': 'Sorbi', 'firstname': 'Sandro', 'initials': 'S', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy; Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Don Carlo Gnocchi, Florence, Italy.'}, {'lastname': 'Nacmias', 'firstname': 'Benedetta', 'initials': 'B', 'affiliation': 'Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.'}, {'lastname': 'Laforce', 'firstname': 'Robert', 'initials': 'R', 'affiliation': ""Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Hôpital de l'Enfant-Jésus, and Faculté de Médecine, Université Laval, Québec, QC, Canada.""}, {'lastname': 'Tremblay', 'firstname': 'Marie-Pier L', 'initials': 'ML', 'affiliation': ""Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Hôpital de l'Enfant-Jésus, and Faculté de Médecine, Université Laval, Québec, QC, Canada.""}, {'lastname': 'Vandenberghe', 'firstname': 'Rik', 'initials': 'R', 'affiliation': 'Department of Neurology, University Hospitals Leuven, Leuven, Belgium.'}, {'lastname': 'Damme', 'firstname': 'Philip Van', 'initials': 'PV', 'affiliation': 'Department of Neurology, University Hospitals Leuven, Leuven, Belgium; Center for Brain & Disease Research, VIB, Leuven, Belgium.'}, {'lastname': 'Rogalski', 'firstname': 'Emily J', 'initials': 'EJ', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago, IL, USA.""}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago, IL, USA.""}, {'lastname': 'Gerhard', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK; Departments of Nuclear Medicine and Geriatric Medicine, University Hospital Essen, Essen, Germany.'}, {'lastname': 'Onyike', 'firstname': 'Chiadi U', 'initials': 'CU', 'affiliation': 'Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Ducharme', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Montreal Neurological Institute, McConnell Brain Imaging Centre, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'lastname': 'Papageorgiou', 'firstname': 'Sokratis G', 'initials': 'SG', 'affiliation': 'Cognitive Disorders/Dementia Unit, 2nd Department of Neurology, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.'}, {'lastname': 'Ng', 'firstname': 'Adeline Su Lyn', 'initials': 'ASL', 'affiliation': 'Department of Neurology, National Neuroscience Institute, Singapore, Singapore.'}, {'lastname': 'Brodtmann', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia.'}, {'lastname': 'Finger', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.'}, {'lastname': 'Guerreiro', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'lastname': 'Bras', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': 'Dementia Research Centre, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK. Electronic address: j.rohrer@ucl.ac.uk.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/S1474-4422(19)30394-1,<Element 'PubmedArticle' at 0x7f05defaeae0>
203,31796679,Ovariectomy Influences Cognition and Markers of Alzheimer's Disease.,"Alzheimer's disease (AD) is one of the most devastating and costly diseases, and prevalence of AD increases with age. Furthermore, females are twice as likely to suffer from AD compared to males. The cessation of reproductive steroid hormone production during menopause is hypothesized to cause this difference. Two rodent AD models, APP21 and APP+PS1, and wild type (WT) rats underwent an ovariectomy or sham surgery. Changes in learning and memory, brain histology, amyloid-β (Aβ) deposition, levels of mRNAs involved in Aβ production and clearance, and synaptic and cognitive function were determined. Barnes maze results showed that regardless of ovariectomy status, APP+PS1 rats learned slower and had poor memory retention. Ovariectomy caused learning impairment only in the APP21 rats. High levels of Aβ42 and very low levels of Aβ40 were observed in the brain cortices of APP+PS1 rats indicating limited endogenous PS1. The APP+PS1 rats had 43-fold greater formic acid soluble Aβ42 than Aβ40 at 17 months. Furthermore, levels of formic acid soluble Aβ42 increased 57-fold in ovariectomized APP+PS1 rats between 12 and 17 months of age. The mRNA encoding Grin1 significantly decreased due to ovariectomy whereas levels of Bace1, Chat, and Prkcb all decreased with age. The expression levels of mRNAs involved in Aβ degradation and AβPP cleavage (Neprilysin, Ide, Adam9, and Psenen) were found to be highly correlated with each other as well as hippocampal Aβ deposition. Taken together, these results indicate that both ovariectomy and genotype influence AD markers in a complex manner.","['Alzheimer’s disease', 'amyloid-β\n', 'estrogen', 'gene expression', 'ovarian hormones', 'ovariectomy', 'progesterone', 'rat', 'transgenic']",Journal of Alzheimer's disease : JAD,2019-12-05,"[{'lastname': 'Agca', 'firstname': 'Cansu', 'initials': 'C', 'affiliation': 'Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.'}, {'lastname': 'Klakotskaia', 'firstname': 'Diana', 'initials': 'D', 'affiliation': 'Department of Psychological Sciences, University of Missouri, Columbia, MO, USA.'}, {'lastname': 'Stopa', 'firstname': 'Edward G', 'initials': 'EG', 'affiliation': 'Departments of Pathology and Neurosurgery, Brown University, Rhode Island Hospital, Providence, RI, USA.'}, {'lastname': 'Schachtman', 'firstname': 'Todd R', 'initials': 'TR', 'affiliation': 'Department of Psychological Sciences, University of Missouri, Columbia, MO, USA.'}, {'lastname': 'Agca', 'firstname': 'Yuksel', 'initials': 'Y', 'affiliation': 'Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.'}]",,,,,10.3233/JAD-190935,<Element 'PubmedArticle' at 0x7f05ded9df40>
204,31744009,Hormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature.,"Numerous observational studies have suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and Alzheimer's disease (AD). However, because of the significant disparity between results, especially those between observational and randomized controlled trials (RCT), this postulate remains unproven. A significant contributing factor to these inconsistencies is the loose use of the generic definitions of estrogens and progestogens with most studies not delineating the clear differences between non-endogenous and endogenously identical (bioidentical) hormones, their molecular binding affinities and actions, and resultant metabolites. This is highlighted by the generalized terminological use of HT, which is often used to encompass significantly disparate hormonal formulations without clear demarcation. This has impacted and continues to significantly influence interpretations of data, meta-analyses, observational studies, etc., relevant to AD. To progress forward and allow unbiased interpretation, it is no longer acceptable to group HT formulations together as a homogenous group. This will also allow differentiation between compounds that exhibit beneficial actions and those that do not and whether these effects are specific or generalized. The role of the endogenous hormones, 17 beta-oestradiol (E2) and progesterone (P4), in the development of sporadic AD in postmenopausal women is also examined.","['17 beta-oestradiol', 'Alzheimer’s disease', 'conjugated equine estrogens', 'hormone therapy', 'progesterone', 'progestins']",Journal of Alzheimer's disease : JAD,2019-11-21,"[{'lastname': 'Yare', 'firstname': 'Katrine', 'initials': 'K', 'affiliation': 'Austin Health, Heidelberg Repatriation Hospital, Victoria, Australia.'}, {'lastname': 'Woodward', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Austin Health, Heidelberg Repatriation Hospital, Victoria, Australia.'}]",,,,,10.3233/JAD-190896,<Element 'PubmedArticle' at 0x7f05ded8f720>
205,31730745,"Aromatase (CYP19A1) gene variants, sex steroid levels, and late-life depression.","Sex differences in psychiatric disorders are common and could involve sex steroids. Aromatase, the product of the CYP19A1 gene, is the key enzyme in the conversion of androgen to estrogen. Whether CYP19A1 variants could be associated with depression differently in men and women has not been examined.
This population-based study included 405 men and 602 women aged ≥65 years. A clinical level of depression (DEP) was defined as having a score ≥16 on the Center for Epidemiology Studies Depression scale or a diagnosis of current major depression based on the Mini-International Neuropsychiatric Interview and according to DSM-IV criteria. Seven single-nucleotide polymorphisms (SNPs) spanning the CYP19A1 gene were genotyped and circulating levels of estradiol and testosterone were determined. Multivariable analyses were adjusted for age, body mass index, ischemic pathologies, cognitive impairment, and anxiety.
Five SNPs were associated with DEP in women specifically and this varied according to a history of major depression (p-values .01 to .0005). Three SNPs were associated with an increased risk of late-life DEP in women without a history of major depression, while two SNPs were associated with a decreased DEP risk in women with a history of major depression and were also associated with higher estradiol levels.
Variants of the CYP19A1 gene appear to be susceptibility factors for late-life depression in a sex-specific manner. The polymorphisms decreasing the risk of recurrent depression in postmenopausal women also influence estradiol levels.","['aromatase', 'elderly', 'estradiol', 'late-life depression', 'population-based study', 'sex difference']",Depression and anxiety,2019-11-16,"[{'lastname': 'Ancelin', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'Inserm, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France.'}, {'lastname': 'Norton', 'firstname': 'Joanna', 'initials': 'J', 'affiliation': 'Inserm, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France.'}, {'lastname': 'Canonico', 'firstname': 'Marianne', 'initials': 'M', 'affiliation': 'Centre for Research Epidemiology and Population Health,\xa0UVSQ, Inserm, Paris-Saclay University, Paris-South University, Villejuif, France.'}, {'lastname': 'Scarabin', 'firstname': 'Pierre-Yves', 'initials': 'PY', 'affiliation': 'Centre for Research Epidemiology and Population Health,\xa0UVSQ, Inserm, Paris-Saclay University, Paris-South University, Villejuif, France.'}, {'lastname': 'Ritchie', 'firstname': 'Karen', 'initials': 'K', 'affiliation': 'Inserm, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France.\nCenter for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Ryan', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Inserm, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France.\nBiological Neuropsychiatry and Dementia Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}]",,,"Five SNPs were associated with DEP in women specifically and this varied according to a history of major depression (p-values .01 to .0005). Three SNPs were associated with an increased risk of late-life DEP in women without a history of major depression, while two SNPs were associated with a decreased DEP risk in women with a history of major depression and were also associated with higher estradiol levels.","© 2019 Wiley Periodicals, Inc.",10.1002/da.22974,<Element 'PubmedArticle' at 0x7f05ded7cd60>
206,31726177,Hypertension accelerates cerebral tissue PO,"This study measured stimulus-evoked brain tissue oxygenation changes in a mouse model of Alzheimer disease (AD) and further explored the influence of exercise and angiotensin II-induced hypertension on these changes. in vivo two-photon phosphorescence lifetime microscopy was used to investigate local changes in brain tissue oxygenation following whisker stimulation. During rest periods, PO","['Alzheimer’s disease', 'Cerebral tissue oxygenation', 'Exercise', 'Hypertension', 'Stimulation', 'Two-photon microscopy']",Neuroscience letters,2019-11-15,"[{'lastname': 'Lu', 'firstname': 'Xuecong', 'initials': 'X', 'affiliation': 'Biomedical Engineering Institute, École Polytechnique de Montréal, Montréal, QC, Canada; Montreal Heart Institute, Research Center, Montreal, Quebec, Canada.'}, {'lastname': 'Moeini', 'firstname': 'Mohammad', 'initials': 'M', 'affiliation': 'Department of Biomedical Engineering, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran.'}, {'lastname': 'Li', 'firstname': 'Baoqiang', 'initials': 'B', 'affiliation': 'Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.'}, {'lastname': 'Thorin', 'firstname': 'Éric', 'initials': 'É', 'affiliation': 'Montreal Heart Institute, Research Center, Montreal, Quebec, Canada; Department of Surgery, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.'}, {'lastname': 'Lesage', 'firstname': 'Frédéric', 'initials': 'F', 'affiliation': 'Biomedical Engineering Institute, École Polytechnique de Montréal, Montréal, QC, Canada; Montreal Heart Institute, Research Center, Montreal, Quebec, Canada. Electronic address: frederic.lesage@polymtl.ca.'}]",,,,Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.neulet.2019.134626,<Element 'PubmedArticle' at 0x7f05deec34a0>
207,"31680842
29364586
26851597
30640362
29843254
28781108
28258522
30673988
17803225
29331730
31256135
22476196
22262078
24583037
29175324
26666230
23485579
30946847
23158895
30222190
12960095
30024276
31474827
16306348
18466898
27252647
30863012
26497034
31327392
27421117
25869785
18492290
5959122
25904081
27186358
25556713
12867498
25728442
29305122
25195184
19297401
19164583
26141845
30826352
26183127
23254291
23973293
26205827
12007541
22776039
18479783
27871675
30643288
20871975
10202534
28062257
23536825
31139316
27131827
18948395
25834231
28342971
31002893
26386291
21356520
29050859
27715341
10657518
25008180
29223528
29916537
29598932
30017231
30741689",Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.,"Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis of brain impairment caused by chronic hyperglycemia is complex and includes mitochondrial dysfunction, neuroinflammation, neurotransmitters' alteration, and vascular disease, which lead to cognitive impairment, neurodegeneration, loss of synaptic plasticity, brain aging, and dementia. Glucagon-like peptide-1 (GLP-1), a gut released hormone, is attracting attention as a possible link between metabolic and brain impairment. Several studies have shown the influence of GPL-1 on neuronal functions such as thermogenesis, blood pressure control, neurogenesis, neurodegeneration, retinal repair, and energy homeostasis. Moreover, modulation of GLP-1 activity can influence amyloid β peptide aggregation in Alzheimer's disease (AD) and dopamine (DA) levels in Parkinson's disease (PD). GLP-1 receptor agonists (GLP-1RAs) showed beneficial actions on brain ischemia in animal models, such as the reduction of cerebral infarct area and the improvement of neurological deficit, acting mainly through inhibition of oxidative stress, inflammation, and apoptosis. They might also exert a beneficial effect on the cognitive impairment induced by diabetes or obesity improving learning and memory by modulating synaptic plasticity. Moreover, GLP-1RAs reduced hippocampal neurodegeneration. Besides this, there are growing evidences on neuroprotective effects of these agonists in animal models of neurodegenerative diseases, regardless of diabetes. In PD animal models, GPL-1RAs were able to protect motor activity and dopaminergic neurons whereas in AD models, they seemed to improve nearly all neuropathological features and cognitive functions. Although further clinical studies of GPL-1RAs in humans are needed, they seem to be a promising therapy for diabetes-associated cognitive decline.","['Alzheimer’s disease', 'GLP-1 receptor agonists', 'Parkinson’s disease', 'glucagon-like peptide-1', 'neurodegenerative diseases', 'type 2 diabetes']",Frontiers in neuroscience,2019-11-05,"[{'lastname': 'Grieco', 'firstname': 'Maddalena', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Giorgi', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Gentile', 'firstname': 'Maria Cristina', 'initials': 'MC', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}, {'lastname': ""d'Erme"", 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Morano', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Maras', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Filardi', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}]",,,,"Copyright © 2019 Grieco, Giorgi, Gentile, d’Erme, Morano, Maras and Filardi.","10.3389/fnins.2019.01112
10.1111/dom.13162
10.1016/j.drudis.2016.01.013
10.1001/jamaneurol.2018.4304
10.3233/JPD-181329
10.1016/S0140-6736(17)31585-4
10.1007/s10787-017-0331-6
10.1007/s12640-019-9998-3
10.1002/jnr.21483
10.1016/j.neurobiolaging.2017.12.009
10.3233/JAD-190237
10.1172/JCI57256
10.1900/RDS.2011.8.418
10.1016/j.neuroscience.2014.02.022
10.1016/j.bbrc.2017.11.114
10.1007/s40263-015-0301-8
10.1172/JCI64595
10.1016/j.neuropharm.2019.03.035
10.1002/ddr.21439
10.1210/en.2003-323
10.1177/1479164118788079
10.3389/fnins.2019.00868
10.2337/diabetes.54.12.3343
10.1016/j.ejphar.2008.03.025
10.3389/fnagi.2016.00108
10.2147/DDDT.S165372
10.1007/s12035-015-9494-6
10.1016/j.jalz.2019.06.001
10.1371/journal.pone.0158205
10.3233/JAD-143090
10.1186/1742-2094-5-19
10.1007/bf00577838
10.1016/S0140-6736(14)61393-3
10.1111/jdi.12464
10.1111/micc.12186
10.1523/jneurosci.23-15-06163.2003
10.1016/S1474-4422(14)70249-2
10.1016/j.neuropharm.2018.01.001
10.1016/j.peptides.2014.08.014
10.1093/hmg/ddp012
10.1073/pnas.0806720106
10.1016/j.neuroscience.2015.06.054
10.1016/j.brainres.2019.02.030
10.1111/jnc.13248
10.1038/cddis.2012.189
10.1016/j.neuropharm.2013.08.005
10.1016/j.bbr.2015.07.024
10.1016/s0014-2999(02)01434-6
10.1111/j.1463-1326.2012.01663.x
10.1016/j.neurobiolaging.2008.04.002
10.1016/j.tem.2016.10.001
10.1038/s41591-018-0297-y
10.1007/s00125-010-1896-4
10.1146/annurev.neuro.22.1.123
10.1016/j.bbr.2017.01.004
10.1371/journal.pone.0058784
10.4239/wjd.v10.i5.291
10.1016/j.ejphar.2016.04.052
10.1210/en.2008-1221
10.1152/physrev.00013.2014
10.1016/j.bbr.2017.03.032
10.1016/j.neuint.2019.04.010
10.1016/j.ejphar.2015.09.024
10.1016/j.cmet.2011.02.002
10.1016/j.brainres.2017.10.012
10.1080/14737175.2017.1246183
10.1054/npep.1999.0053
10.2337/db14-0375
10.1016/j.neuropharm.2017.11.048
10.3892/mmr.2018.9180
10.1016/j.dsx.2018.03.002
10.1016/j.npep.2018.07.003
10.3233/JPD-181503",<Element 'PubmedArticle' at 0x7f05deee6e50>
208,"31677609
18284372
18073185
25170153
14694190
11459806
12958311
17919783
20382181
24484697
20388076
9023877
16572394
23628345
23434911
18727047
9881851
29044447
11550742
2967880
8831298
25485772
23773059
2638633
7333338
6115326
17923630
21331174
11891823
15118105
25959522
23573795
21411205
23488281
22820676
10887978
20925068
21463042
20153425
25712639
27001133
26635213
11274343
27188934
28960209
20946954
19446073
19446080
9208405
12493707
3549275
10529900
23157556
834244
2080192
15678158
2644044
9872937
10965881
8125934
15219700
6147898
18054400
23481590
16487665
17917157
19042092
15727517
15860479
16771043
10064172
16387720
15582112
11282357
7582815
7557918
8891311
8943785
2253030
9409701
15753424
14644069
11971659
20552051
23023216
24250491
19252678
19900488
19067676
9768651
10588579
11739250
10854906
18649493
17851537
19063914
18771935
20399839
23253178
16855455
20540592
17054283
17018237
24363726
12471243
19818674
23524293
23985307
20027184
28473255
22964758
26687711
17089919
20493887
15555642
17207788
22306745
22209852
15622518
19895879
23197040
8051084
20431074
21035454
16635641
21733754
21389984
17565007
12397090
11153812
19552485
20540694
16254221
14762097
15207847
9576922
1943460
16698938
11467851
17541419
16914869
10873588
17218018
17553691
27103044
21978545
7737456
7592622
10506528
23905995
16707559
21820043
10558990
11598293
15829628
10411321
10407026
12244210
12086646
12764111
10707967
10985282
15263086
15466214
14584725
18222446
12971891
16361258
5576164
7891098
17303658
15585562
15189137
10931172
14580317
12831855
11880503
19837873
12130773
14622134
11099831
10655508
17595254
15383512
18855662
12700769
14690523
27863808
22710914
17078951
12000125",The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer’s Disease-Induced Cognitive Dysfunction.,"Aging, as a major risk factor of memory deficiency, affects neural signaling pathways in hippocampus. In particular, age-dependent androgens deficiency causes cognitive impairments. Several enzymes like protein kinase C (PKC) are involved in memory deficiency. Indeed, PKC regulatory process mediates α-secretase activation to cleave APP in β-amyloid cascade and tau proteins phosphorylation mechanism. Androgens and cortisol regulate PKC signaling pathways, affecting the modulation of receptor for activated C kinase 1. Mitogen-activated protein kinase/ERK signaling pathway depends on CREB activity in hippocampal neurons and is involved in regulatory processes via PKC and androgens. Therefore, testosterone and PKC contribute in the neuronal apoptosis. The present review summarizes the current status of androgens, PKC, and their influence on cognitive learning. Inconsistencies in experimental investigations related to this fundamental correlation are also discussed, with emphasis on the mentioned contributors as the probable potent candidates for learning and memory improvement.","['Androgens', 'Cognition', 'Hippocampus', 'Protein kinase C', 'Spatial memory']",Iranian biomedical journal,2019-11-05,"[{'lastname': 'Amiri', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.'}, {'lastname': 'Azadmanesh', 'firstname': 'Kayhan', 'initials': 'K', 'affiliation': 'Department of Virology, Pasteur Institute of Iran, Tehran, Iran.'}, {'lastname': 'Dehghan Shasaltaneh', 'firstname': 'Marzieh', 'initials': 'M', 'affiliation': 'Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.'}, {'lastname': 'Mayahi', 'firstname': 'Vafa', 'initials': 'V', 'affiliation': 'Department of Microbiology, Islamic Azad University, Karaj, Iran.'}, {'lastname': 'Naghdi', 'firstname': 'Nasser', 'initials': 'N', 'affiliation': 'Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.'}]",,,,,10.29252/ibj.24.2.64,<Element 'PubmedArticle' at 0x7f05deeb2720>
209,"31613825
25984581
24470773
23895362
25205317
1613547
18947934
16390773
12724456
16169406
24064221
17116223
23948914
22647576
12413371
23100399
11756599
12771112
26035291
15511602
22079780
10430421
11877549
2594878
6610841
9179095
21343770
12928347
12086747
24007951
17671236
17762377
10839339
12578468
18450052
23079626
22840752
30842086
27823753
12117397
19142763",Lifetime estrogen exposure and cognition in late life: the Cache County Study.,"Prevalence of Alzheimer's disease (AD) is higher for women, possibly influenced by sex-dependent effects of the estrogen. We examined the association between estrogen and cognitive decline in over 2,000 older adult women in a 12-year population-based study in Cache County, Utah.
The baseline sample included 2,114 women (mean age = 74.94 y, SD = 6.71) who were dementia-free at baseline and completed a women's health questionnaire, asking questions regarding reproductive history and hormone therapy (HT). Endogenous estrogen exposure (EEE) was calculated taking the reproductive window (age at menarche to age at menopause), adjusted for pregnancy and breastfeeding. HT variables included duration of use, HT type (unopposed; opposed), and time of HT initiation. A modified version of the Mini-Mental State Examination (3MS) was administered at four triennial waves to assess cognitive status. Linear mixed-effects models examined the relationship between estrogen exposure and 3MS score over time.
EEE was positively associated with cognitive status (β = 0.03, P = 0.054). In addition, longer duration of HT use was positively associated with cognitive status (β = 0.02, P = 0.046) and interacted with age; older women had greater benefit compared with younger women. The timing of HT initiation was significantly associated with 3MS (β = 0.55, P = 0.048), with higher scores for women who initiated HT within 5 years of menopause compared with those initiating HT 6-or-more years later.
Our results suggest that longer EEE and HT use, especially in older women, are associated with higher cognitive status in late life.",[],"Menopause (New York, N.Y.)",2019-10-16,"[{'lastname': 'Matyi', 'firstname': 'Joshua M', 'initials': 'JM', 'affiliation': 'Department of Psychology, Utah State University, Logan, UT.'}, {'lastname': 'Rattinger', 'firstname': 'Gail B', 'initials': 'GB', 'affiliation': 'School of Pharmacy and Pharmaceutical Sciences, Health Outcomes and Administrative Sciences, Binghamton University, Binghamton, NY.'}, {'lastname': 'Schwartz', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Psychology, Utah State University, Logan, UT.'}, {'lastname': 'Buhusi', 'firstname': 'Mona', 'initials': 'M', 'affiliation': 'Department of Psychology, Utah State University, Logan, UT.'}, {'lastname': 'Tschanz', 'firstname': 'JoAnn T', 'initials': 'JT', 'affiliation': 'Department of Psychology, Utah State University, Logan, UT.'}]",,,"EEE was positively associated with cognitive status (β = 0.03, P = 0.054). In addition, longer duration of HT use was positively associated with cognitive status (β = 0.02, P = 0.046) and interacted with age; older women had greater benefit compared with younger women. The timing of HT initiation was significantly associated with 3MS (β = 0.55, P = 0.048), with higher scores for women who initiated HT within 5 years of menopause compared with those initiating HT 6-or-more years later.",,10.1097/GME.0000000000001405,<Element 'PubmedArticle' at 0x7f05df519900>
210,31583774,Raloxifene alleviates amyloid-β-induced cytotoxicity in HT22 neuronal cells via inhibiting oligomeric and fibrillar species formation.,"Raloxifene, a selective estrogen receptor modulator, displays benefits for Alzheimer's disease (AD) prevention in postmenopausal women as hormonal changes during menopause have the potential to influence AD pathogenesis, but the underlying mechanism of its neuroprotection is not entirely clear. In this study, the effects of raloxifene on amyloid-β (Aβ) amyloidogenesis were evaluated. The results demonstrated that raloxifene inhibits Aβ","[""Alzheimer's disease"", 'aggregate disassembly', 'amyloid-β', 'cytotoxicity', 'raloxifene']",Journal of biochemical and molecular toxicology,2019-10-05,"[{'lastname': 'Liu', 'firstname': 'Ziyi', 'initials': 'Z', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Wang', 'firstname': 'Youqiao', 'initials': 'Y', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Qin', 'firstname': 'Wenjing', 'initials': 'W', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Chen', 'firstname': 'Daoyuan', 'initials': 'D', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Feng', 'firstname': 'Yanqiao', 'initials': 'Y', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Su', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Shao', 'firstname': 'Weiyan', 'initials': 'W', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Zhou', 'firstname': 'Binhua', 'initials': 'B', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}, {'lastname': 'Bu', 'firstname': 'Xianzhang', 'initials': 'X', 'affiliation': 'School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.'}]",,,,"© 2019 Wiley Periodicals, Inc.",10.1002/jbt.22395,<Element 'PubmedArticle' at 0x7f05df4fca40>
211,"31467332
28931491
20005526
26446953
26795439
28571614
26333932
28396265
29074032
28439103
29892055
26684672
26917166
24126515
20668685
20711490
26869150
16919689
25441628
23826273
27045845
27410431
28410487
19748805
9880050
15795047
16276050
11396800
15385603
16275022
16396259
28707338
28361057
18647158
20469545
10332828
9482358
23063452
8660125
25469789
21182120
12716936
29771288
19570593
27027839
29407456
23396475
29853553
28552356
24026177
28257443
20224736
22876193
25062362
17967053
19798086
20211243
24465370
27853544
29494619
26509577
22749114
24886598
28445722
28122014
29365066
29463250
28244335
29056744
23782324
17172139
25938575
9304373
23865437
9402710
26123886
20536691
26987699
9745633
28399939
19160224
26035291
27979354
21280086
24138928
29885742
27776265
26401331
25083989
22277186
18669428
18282803
25477213
27231129
28424864",Network analysis of canine brain morphometry links tumour risk to oestrogen deficiency and accelerated brain ageing.,"Structural 'brain age' is a valuable but complex biomarker for several brain disorders. The dog is an unrivalled comparator for neurological disease modeling, however canine brain morphometric diversity creates computational and statistical challenges. Using a data-driven approach, we explored complex interactions between patient metadata, brain morphometry, and neurological disease. Twenty-four morphometric parameters measured from 286 canine brain magnetic resonance imaging scans were combined with clinical parameters to generate 9,438 data points. Network analysis was used to cluster patients according to their brain morphometry profiles. An 'aged-brain' profile, defined by a small brain width and volume combined with ventriculomegaly, was revealed in the Boxer breed. Key features of this profile were paralleled in neutered female dogs which, relative to un-neutered females, had an 11-fold greater risk of developing brain tumours. Boxer dog and geriatric dog groups were both enriched for brain tumour diagnoses, despite a lack of geriatric Boxers within the cohort. Our findings suggest that advanced brain ageing enhances brain tumour risk in dogs and may be influenced by oestrogen deficiency-a risk factor for dementia and brain tumours in humans. Morphometric features of brain ageing in dogs, like humans, might better predict neurological disease risk than patient chronological age.",[],Scientific reports,2019-08-31,"[{'lastname': 'Rzechorzek', 'firstname': 'Nina M', 'initials': 'NM', 'affiliation': ""Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK. ninar@mrc-lmb.cam.ac.uk.\nCentre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, Edinburgh, Midlothian, EH16 4SB, UK. ninar@mrc-lmb.cam.ac.uk.\nMedical Research Council Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge, CB2 0QH, UK. ninar@mrc-lmb.cam.ac.uk.""}, {'lastname': 'Saunders', 'firstname': 'Olivia M', 'initials': 'OM', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}, {'lastname': 'Hiscox', 'firstname': 'Lucy V', 'initials': 'LV', 'affiliation': 'Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 7 George Square, Edinburgh, Scotland, EH8 9JZ, UK.\nDepartment of Biomedical Engineering, University of Delaware, Newark, DE, 19716, USA.'}, {'lastname': 'Schwarz', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}, {'lastname': 'Marioni-Henry', 'firstname': 'Katia', 'initials': 'K', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}, {'lastname': 'Argyle', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}, {'lastname': 'Schoenebeck', 'firstname': 'Jeffrey J', 'initials': 'JJ', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}, {'lastname': 'Freeman', 'firstname': 'Tom C', 'initials': 'TC', 'affiliation': 'Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian, EH25 9RG, UK.'}]",,,,,"10.1038/s41598-019-48446-0
10.1016/S1474-4422(17)30299-5
10.1016/j.jcpa.2009.10.011
10.1126/scitranslmed.aaa9116
10.1038/ncomms10460
10.1016/j.tins.2017.05.003
10.1126/scitranslmed.aab0215
10.1016/j.ebiom.2017.03.046
10.1016/j.tins.2017.10.001
10.1038/mp.2017.62
10.1038/s41380-018-0098-1
10.18632/aging.100864
10.1176/appi.ajp.2015.15070922
10.1093/schbul/sbt142
10.1371/journal.pone.0011946
10.1371/journal.pbio.1000451
10.1016/j.rvsc.2006.06.005
10.1016/j.cvsm.2014.07.008
10.1371/journal.pone.0067346
10.1038/tp.2016.39
10.1371/journal.pone.0157514
10.1016/j.eplepsyres.2017.03.007
10.1016/j.tvjl.2009.08.009
10.1016/S0197-4580(98)00081-5
10.1016/j.pnpbp.2004.12.005
10.1292/jvms.67.961
10.1016/S0940-9602(01)80236-3
10.1523/JNEUROSCI.1339-04.2004
10.1016/j.neuroimage.2005.07.043
10.1111/j.1740-8261.2005.00083.x
10.1111/vru.12528
10.3389/fvets.2017.00030
10.1111/j.1939-1676.2008.0138.x
10.1111/j.1740-8261.2009.01655.x
10.1354/vp.36-3-202
10.1001/archneur.55.2.169
10.1016/j.neuroimage.2012.10.008
10.1001/archpsyc.1996.01830070031007
10.1371/journal.pone.0114478
10.1002/jmri.22328
10.1523/JNEUROSCI.23-08-03295.2003
10.1093/cercor/bhy109
10.1016/j.neurobiolaging.2009.05.013
10.2460/ajvr.77.4.395
10.1016/j.neuroimage.2018.01.066
10.1534/genetics.112.145284
10.1126/science.aar2578
10.1016/j.cub.2017.04.057
10.1101/gr.157339.113
10.1371/journal.pgen.1006661
10.1371/journal.pone.0009632
10.1371/journal.pgen.1002849
10.1146/annurev-cellbio-100913-012927
10.1371/journal.pcbi.0030206
10.1038/nprot.2009.177
10.1016/j.ygeno.2010.03.002
10.1371/journal.pone.0081229
10.1098/rsos.160268
10.1371/journal.pcbi.1005934
10.1371/journal.pone.0137496
10.1016/j.tvjl.2012.05.014
10.1186/1751-0147-56-30
10.1016/j.celrep.2017.03.079
10.1371/journal.pone.0170315
10.1093/brain/awx341
10.1186/s12917-018-1373-8
10.1556/004.2017.001
10.3390/vetsci3040036
10.1111/vru.12063
10.1371/journal.pone.0124174
10.1111/j.1439-0264.1997.tb00114.x
10.1111/jvim.12136
10.1111/j.1740-8261.1997.tb00868.x
10.1111/j.1740-8261.1994.tb00191.x
10.1007/s00247-015-3318-8
10.1111/j.1748-5827.2010.00952.x
10.1016/S1474-4422(16)00067-3
10.1016/S0140-6736(05)76894-X
10.1186/s13059-017-1203-5
10.1371/journal.pmed.1001833
10.1016/S1474-4422(16)30356-8
10.1002/ana.22239
10.1186/gb-2013-14-10-r115
10.1016/j.tins.2018.05.005
10.1016/j.neurobiolaging.2016.09.013
10.1186/s40575-015-0014-9
10.1172/JCI71048
10.1186/2042-6410-3-3
10.1056/NEJMra0708126
10.1016/S1470-2045(08)70033-0
10.1126/science.1262092
10.1016/j.ajhg.2016.05.014
10.1007/s00439-017-1799-2",<Element 'PubmedArticle' at 0x7f05df42d540>
212,"31361008
19015862
17579875
16718704
19204154
19455346
17021754
21644037
17279000
17003490
17071926
18379440
17278999
16950801
16983677
17436289
16862116
16862115
2268320
1542665
2236009
12928786
24800652
21813674
18378771
20026663
23041626
19649643
29044416
11708987
19924424
11310619
14561797
21810890
21514250
22101365
21707362
27693922
24423638
16930776
2300243
9630473
10980247
11327303
26001591
10192781
2818255
19860916
21204008
21813674
22781549
22062772
22509390
27114033
22608501
21051630",FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology.,"Heterozygous loss-of-function mutations in the GRN gene lead to progranulin (PGRN) haploinsufficiency and cause frontotemporal lobar degeneration with TDP-43 pathology type A (FTLD-TDP type A). PGRN is a highly conserved, secreted glycoprotein and functions in the central nervous system as a key modulator of microglial function. Hence, altered microglial function caused by PGRN deficiency may be tied to the pathogenesis of FTLD-TDP. Our previous studies showed that haploinsufficiency of GRN mutations extends to microglial PGRN expression in the hippocampal CA1 region. In this study, we found that the CA1 sector was associated with less neuronal loss and more frequent TDP-43 inclusions in FTLD-TDP type A cases with GRN mutations than in sporadic cases. In addition, the CA1 region in GRN mutation cases contained more rod-like microglia, which also had reduced PGRN expression. These findings suggest that the profile of TDP-43 inclusions, neuronal number, and microgliosis in the CA1 sector of FTLD-TDP type A cases may be influenced by GRN gene expression status.","['Frontotemporal lobar degeneration', 'Hippocampal sclerosis', 'Microglia', 'Neuroinflammation', 'Progranulin', 'TAR DNA-binding protein 43']",Journal of neuropathology and experimental neurology,2019-07-31,"[{'lastname': 'Mao', 'firstname': 'Qinwen', 'initials': 'Q', 'affiliation': 'Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}, {'lastname': 'Zheng', 'firstname': 'Xiaojing', 'initials': 'X', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China.""}, {'lastname': 'Gefen', 'firstname': 'Tamar', 'initials': 'T', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Rogalski', 'firstname': 'Emily', 'initials': 'E', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Spencer', 'firstname': 'Callen L', 'initials': 'CL', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Fought', 'firstname': 'Angela J', 'initials': 'AJ', 'affiliation': 'Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine.'}, {'lastname': 'Kohler', 'firstname': 'Missia', 'initials': 'M', 'affiliation': 'Cook County Medical Examiner, Chicago, Illinois.'}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Xia', 'firstname': 'Haibin', 'initials': 'H', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China.""}, {'lastname': 'Mesulam', 'firstname': 'Marek-Marsel', 'initials': 'MM', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': ""Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.\nMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}]",,,,"© 2019 American Association of Neuropathologists, Inc. All rights reserved.",10.1093/jnen/nlz059,<Element 'PubmedArticle' at 0x7f05df8711d0>
213,"31354380
26590661
28303911
29353550
28148632
29458916
29307294
26769066
27325604
28731372
27116717
27942348
20373291
29185533
23917100
23377209
24376275
25583845
29158119
28627962
26462862
20015486
27750060
27416110
28202503
28914205
22805247
22372707
29259169
26784322
29117961
29093064
28931645
25995241
28986128
28202713
29057787
22592374
27446548
19858462
27919248
23029191
22592374
28947637
27525980
23278659
21646368
24570191
25920326
29095651
23202962
24730754
28620421
21934610
26090099
22644131
23024814
25877626
26418341
29491716
30266889
26554936
28188842
18177949
27182982
18844840
28320120
28828221
30317548
19106272
30202597
29694267
25823947
26414080
10636497
23149846
16869934
27548554
26634939
26988993
23556539
22523507
27614264
29381115
28283112
30248593
26346797
28167237
28572730
29041864
29576505
25795002
28600188
28600189
24655729
26598277
22926855
26458124
29307295
26708262
27922139
24891051
27454804
29495467
28975580
26683589
28869033
28034764
28619429
28328526
28734988
17823429
22933544
18689406
26243188
26892983
30303036
28842450
24376275
16217073
29325121
27903816
29243029
24729696
25635171
26849357
29929117
30050382
29491723
29508133
28303911
30245372
30284038",Comorbidities in multiple sclerosis-a plea for interdisciplinary collaboration to improve the quality of life of MS patients.,"The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (","['comorbidities in multiple sclerosis', 'improving quality of life', 'pregnancy in MS', 'vitamin D therapy']",Degenerative neurological and neuromuscular disease,2019-07-30,"[{'lastname': 'Goischke', 'firstname': 'Hans-Klaus', 'initials': 'HK', 'affiliation': 'Independent Researcher, Bad Brückenau, Bavaria, Germany.'}]",,,,,"10.2147/DNND.S204555
10.20364/VA-17.09
10.1016/j.msard.2015.08.005
10.1038/nrneurol.2017.33
10.1177/1352458517751049
10.1212/WNL.0000000000003653
10.1016/j.ctim.2017.12.006
10.1177/1352458517737373
10.1177/1352458515624269
10.1177/1352458516654310
10.1177/1352458517722646
10.1055/s-0036-1579693
10.1080/19381980.2016.1248324
10.1002/mnfr.200900494
10.1212/CPJ.0000000000000349
10.1192/bjp.bp.111.106666
10.1212/WNL.0000000000000013
10.1177/1352458514564487
10.1016/j.msard.2017.10.012
10.1177/1352458515606986
10.1016/j.biopsych.2009.09.033
10.1016/j.jad.2016.08.082
10.1111/ene.13102
10.1124/pr.116.013227
10.2174/1389450118666170913161030
10.1177/0883073812450750
10.1111/j.1651-2227.2012.02655.x
10.1038/s41467-017-02119-6
10.1159/000442203
10.1212/WNL.0000000000004686
10.1212/WNL.0000000000004508
10.1136/bmjopen-2015-007806
10.1016/S2213-2600(17)30306-5
10.1136/bmj.i6583
10.3390/ijms18102170
10.1212/WNL.0b013e318259e0ff
10.3892/br.2016.697
10.1212/WNL.0b013e3181beece8
10.1371/journal.pone.0045703
10.1212/WNL.0b013e318259e0ff
10.1111/ane.12028
10.1210/jc.2011-0385
10.1055/s-0033-1360073
10.1007/s40122-015-0036-8
10.1080/19390211.2017.1375060
10.3390/ijms131013461
10.1111/pme.12454
10.1177/1759720X17708124
10.1097/MCO.0b013e32834be798
10.1017/jns.2015.10
10.1007/s10072-012-1119-5
10.1371/journal.pone.0045295
10.1016/j.msard.2012.10.003
10.1002/ana.24534
10.2147/JPR.S146717
10.1212/WNL0000000000006384
10.1016/j.jsbmb.2015.10.022
10.1016/j.mce.2017.01.039
10.1016/j.jneuroim.2007
10.1111/j.1753-4887.2008.00097.x
10.1016/j.jns.2017.01.059
10.1002/brb3.761
10.1111/ane.13037
10.14740/jcgo473w
10.1210/jc.2008-1217
10.1192/bjo.2018.48
10.2217/nmt-2017-0047
10.1159/000381212
10.1097/MED.0000000000000199
10.1182/blood-2012-08-448944
10.1111/j.1538-7836.2006.02147.x
10.3238/arztebl.2015.0795
10.1016/j.autrev.2016.03.015
10.1155/2012/619381
10.1016/j.molimm.2016.08.014
10.1016/j.msard.2017.01.008
10.1016/j.msard.2018.09.008
10.1016/j.msard.2015.07.014
10.1016/S1474-4422(17)30162-X
10.1016/S1474-4422(17)30113-8
10.1016/S0140-6736(13)62242-4
10.1016/j.jsbmb.2015.11.009
10.1002/ana.23591
10.1001/jamaneurol.2015.2742
10.1177/1352458517738131
10.1080/13803395.2015.1125452
10.1039/C6PP00294C
10.1016/j.det.2014.03.005
10.1111/pcmr.12511
10.3390/nu10030268
10.1007/s13760-017-0834-3
10.1177/1352458515621624
10.1016/j.jsbmb.2016.12.011
10.1016/j.msard.2017.03.014
10.1515/cclm-2016-1129
10.1016/j.jsbmb.2017.07.006
10.1093/ajcn/86.3.645
10.1210/jc.2012-2276
10.1093/ajcn/88.2.582S
10.1186/s12883-015-0394-1
10.3174/ajnr.A4681
10.1177/1352458518803785
10.1212/WNL.0000000000004411
10.1212/WNL.0000000000000013
10.1212/01.wnl.0000178998.95293.29
10.1210/jc.2017-02328
10.1212/WNL.0000000000003693
10.1007/s40120-017-0086-4
10.1371/journal.pone.0148573
10.1016/j.genhosppsych.2018.06.001
10.1016/pjnns.2018.09.003
10.2147/DNND.S109251
10.2147/PROM.S148387
10.1007/s00415-018-8811-1
10.1038/nrneurol.2017.33
10.1016/j.psychres.2018.09.024
10.1007/s00415-018-9074-6",<Element 'PubmedArticle' at 0x7f05df8604f0>
214,31351441,Factors Influencing the Incubation of an Infectious Form of Creutzfeldt-Jakob Disease.,"The French epidemics of iatrogenic Creutzfeldt-Jakob disease after growth hormone (GH) treatment provide an opportunity to understand factors governing the inter-human transmission of prions. The present analysis relying on truncated Weibull distribution supports a relationship between host genetics, dose of the at-risk GH, age at treatment onset, and duration of the incubation period.","['Iatrogenic Creutzfeldt-Jakob disease', 'human growth hormone', 'incubation period', 'prion']",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2019-07-28,"[{'lastname': 'Peckeu', 'firstname': 'Laurène', 'initials': 'L', 'affiliation': 'Sorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM.'}, {'lastname': 'Brandel', 'firstname': 'Jean-Philippe', 'initials': 'JP', 'affiliation': 'Sorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM.\nAP-HP, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière.'}, {'lastname': 'Welaratne', 'firstname': 'Arlette', 'initials': 'A', 'affiliation': 'Sorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM.\nAP-HP, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière.'}, {'lastname': 'Amar', 'firstname': 'Elodie', 'initials': 'E', 'affiliation': 'AP-HP, Hôpital Lariboisière, Service de Biochimie et Biologie Moléculaire, Université Paris Descartes, Paris, France.'}, {'lastname': 'Costagliola', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': ""Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique.""}, {'lastname': 'Haïk', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': 'Sorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM.\nAP-HP, Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière.\nAP-HP, Hôpital de la Pitié-Salpêtrière, Laboratoire de Neuropathologie R Escourolle.'}]",,,,"© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",10.1093/cid/ciz692,<Element 'PubmedArticle' at 0x7f05df32d9a0>
215,"31349033
23493086
29185425
8764598
29377010
25300732
29392460
22869065
21371747
26858121
15288712
29233480
27863851
10751445
12415260
22427376
27403417
27554603
28159472
25374101
28372335
27207082
28697184
19188609
27802237
22503992
18388910
9114067
18348871
10336671
22430016
30542257
27307128
29233786
11297574
20421697
11306609
12900169
26710325
28595357
26290229
10357572
29739805
28382978
15705736
21762376
28381495
17459648
9235959
27379655
19819959
22245457
25766618
26100639
21810948
21194385
28538088
18076866
14557249
16627931
22425595
25792818
26402010
26040423
19638508
29398615
24315369
23165862
30825797
27188934
22511769
26744412
28460541
27767036
28607354
18479783
26941597
30446513
24615439
20691755
23239816
27188415
27730514
11273707
27177549
18430999
19896443
19203442
22315723
19015485
17431643
27676071
25604425
26967226
22829447
30414017
16024298
30549303
30684218
8131745
19515410
22476197
11912189
17848918
27076121
16916571
22396862
23477989
24977973
24706014
10491414
22936005
16169744
21916834
26349470
25445849",The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.,"Alzheimer's disease (AD) is a growing problem worldwide, and there are currently no effective treatments for this devastating disease. The neurotrophic growth factors insulin and insulin-like growth factor-I (IGF-I) are currently being investigated as potential therapeutic approaches for AD in preclinical and clinical studies. However, given that the metabolic syndrome (MetS) and diabetes are risk factors for AD, it is unknown how associated insulin resistance (IR) in the brain may impact the effectiveness of these therapies for AD. In this report, we therefore investigated the mechanisms underlying the effects of insulin and IGF-I on AD-associated pathology in the context of IR, with particular emphasis on phosphorylation of amyloid precursor protein (APP), a key step in promoting amyloid plaque formation in AD. Both insulin and IGF-I decreased APP phosphorylation in cultured primary cortical neurons, supporting their therapeutic use in AD. Induction of IR blocked the beneficial effect of insulin and reduced the effect of IGF-I on APP dephosphorylation. These effects were mediated by the phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (Akt) pathway, as inhibition of this pathway during IR restored the effect of IGF-I on APP dephosphorylation. Finally, we explored the translational relevance of these results in vivo by demonstrating that high fat diet fed mice, a robust model of IR and MetS, exhibited the expected increased brain APP phosphorylation. Overall, these data suggest that the beneficial therapeutic effect of insulin and IGF-I on APP phosphorylation is negatively impacted by IR, and suggest that insulin and IGF-I alone may not be appropriate therapies for AD patients with IR, MetS, or diabetes.","[""Alzheimer's disease"", 'Amyloid precursor protein', 'IGF-I', 'Insulin', 'Insulin resistance']",Neurobiology of disease,2019-07-28,"[{'lastname': 'Kim', 'firstname': 'Bhumsoo', 'initials': 'B', 'affiliation': 'Department of Neurology, University of Michigan, Ann Arbor, MI 48109-2200, United States of America.'}, {'lastname': 'Elzinga', 'firstname': 'Sarah E', 'initials': 'SE', 'affiliation': 'Department of Neurology, University of Michigan, Ann Arbor, MI 48109-2200, United States of America.'}, {'lastname': 'Henn', 'firstname': 'Rosemary E', 'initials': 'RE', 'affiliation': 'Department of Neurology, University of Michigan, Ann Arbor, MI 48109-2200, United States of America.'}, {'lastname': 'McGinley', 'firstname': 'Lisa M', 'initials': 'LM', 'affiliation': 'Department of Neurology, University of Michigan, Ann Arbor, MI 48109-2200, United States of America.'}, {'lastname': 'Feldman', 'firstname': 'Eva L', 'initials': 'EL', 'affiliation': 'Department of Neurology, University of Michigan, Ann Arbor, MI 48109-2200, United States of America. Electronic address: efeldman@umich.edu.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2019.104541,<Element 'PubmedArticle' at 0x7f05df94fea0>
216,"31333434
28478324
26122294
20034703
25998101
24510074
2125712
18079025
20620164
1312814
9238064
3857369
30332613
11259856
16688123
30663172
22617337
23384741
15298949
24834516
17116223
25917862
24988816
26556545
22814829
23892107
20738280
22994984
21820247
23836935
28755863
26419496
25039797
10064825
24608267
15982524
28322310
23036056
16826559
11323317
21454017
21961718
24011502
16510735
21030115
26109339
26791219
18030631
21185655
27991897
25113601
27683911
27178194
21471363
30271832
24988814
27996108
20939669
18266940
16005000
27707975
16887188
27109356
21078303
18195084
11717247
9153161
10368772
12724456
17035515
22395804
11827871
16216005
17869008
25832993
14534338
25191220
20550945
25446458
24456941
12510204
23831531
12843274
15808925
27824681
27306650
18947934
27377060
10984655
23238908
10199429
10101041
14990773
23246919
8158125
16554740
20861381
23770320
2269895
8245220
21967374
30326011",Applying a Women's Health Lens to the Study of the Aging Brain.,"A major challenge in neuroscience is to understand what happens to a brain as it ages. Such insights could make it possible to distinguish between individuals who will undergo typical aging and those at risk for neurodegenerative disease. Over the last quarter century, thousands of human brain imaging studies have probed the neural basis of age-related cognitive decline. ""Aging"" studies generally enroll adults over the age of 65, a historical precedent rooted in the average age of retirement. A consequence of this research tradition is that it overlooks one of the most significant neuroendocrine changes in a woman's life: the transition to menopause. The menopausal transition is marked by an overall decline in ovarian sex steroid production-up to 90% in the case of estradiol-a dramatic endocrine change that impacts multiple biological systems, including the brain. Despite sex differences in the risk for dementia, the influence that biological sex and sex hormones have on the aging brain is historically understudied, leaving a critical gap in our understanding of the aging process. In this ","['cognitive aging', 'estradiol', 'memory', 'menopause', 'neuroimaging', 'reproductive aging', 'sex steroid hormones', 'women’s health']",Frontiers in human neuroscience,2019-07-25,"[{'lastname': 'Taylor', 'firstname': 'Caitlin M', 'initials': 'CM', 'affiliation': 'Department of Psychological and Brain Sciences, University of California, Santa Barbara, Santa Barbara, CA, United States.\nThe Sage Center for the Study of the Mind, University of California, Santa Barbara, Santa Barbara, CA, United States.'}, {'lastname': 'Pritschet', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Psychological and Brain Sciences, University of California, Santa Barbara, Santa Barbara, CA, United States.'}, {'lastname': 'Yu', 'firstname': 'Shuying', 'initials': 'S', 'affiliation': 'Department of Psychological and Brain Sciences, University of California, Santa Barbara, Santa Barbara, CA, United States.'}, {'lastname': 'Jacobs', 'firstname': 'Emily G', 'initials': 'EG', 'affiliation': 'Department of Psychological and Brain Sciences, University of California, Santa Barbara, Santa Barbara, CA, United States.\nNeuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, CA, United States.'}]",,,,,"10.3389/fnhum.2019.00224
10.1016/j.neurobiolaging.2017.03.033
10.1016/j.yhbeh.2015.06.010
10.1016/j.neurobiolaging.2009.12.004
10.1016/j.neurobiolaging.2015.04.007
10.1177/1073858413519865
10.1016/0304-3940(90)90618-j
10.1016/j.neurobiolaging.2007.11.011
10.1016/j.neubiorev.2010.07.002
10.1007/bf02718274
10.1073/pnas.94.16.8836
10.1093/jnci/74.4.741
10.1016/j.neuroimage.2018.10.009
10.1016/s0306-4530(01)00003-8
10.1038/nrn1909
10.1002/hbm.24513
10.1097/gme.0b013e31824d1fc4
10.1016/j.beem.2012.11.004
10.1038/509282a
10.1111/j.1468-1331.2006.01520.x
10.1016/j.yhbeh.2015.04.012
10.1007/s00330-012-2572-5
10.1016/j.brainres.2013.07.034
10.1111/j.1749-6632.2010.05529.x
10.1089/jwh.2012.3522
10.1016/j.psyneuen.2011.07.007
10.1210/jc.2013-1808
10.1016/j.physbeh.2017.07.028
10.1016/j.tics.2015.07.008
10.1111/jne.12177
10.1016/s0006-8993(99)01100-2
10.1038/npp.2014.56
10.1016/j.brainresbull.2005.03.016
10.1038/srep44917
10.1089/jwh.2011.3206
10.1002/hipo.20193
10.1093/aje/153.9.865
10.1016/j.psyneuen.2011.03.001
10.1016/j.ogc.2011.05.007
10.1016/j.psyneuen.2013.07.020
10.1523/jneurosci.3440-05.2006
10.1016/j.neurobiolaging.2010.09.014
10.1152/physrev.00036.2014
10.1523/JNEUROSCI.3480-13.2016
10.1080/13803390701612209
10.1016/j.psyneuen.2010.11.009
10.1038/nn.4458
10.1038/npp.2014.203
10.1523/JNEUROSCI.0951-16.2016
10.1093/cercor/bhw127
10.1523/JNEUROSCI.6394-10.2011
10.1016/j.cobeha.2018.03.009
10.1111/jgs.14658
10.1037/a0020884
10.1111/j.1365-2826.2008.01667.x
10.1016/j.yhbeh.2005.05.017
10.1523/JNEUROSCI.0909-16.2016
10.1016/j.neubiorev.2006.06.001
10.1016/j.neuroimage.2016.04.042
10.1016/j.brainres.2010.11.030
10.1152/physrev.00010.2007
10.1152/jappl.2001.91.6.2785
10.1212/wnl.48.5_suppl_7.8s
10.1210/edrv.20.3.0365
10.1176/jnp.15.2.161
10.1523/jneurosci.3369-06.2006
10.1038/nrn3200
10.1080/00455091.1994.10717393
10.1002/neu.20194
10.1016/j.neuroscience.2007.07.031
10.1002/hbm.22797
10.1056/NEJMcp030751
10.3389/fnins.2014.00256
10.1016/j.brainres.2010.06.019
10.1016/j.brainres.2014.11.025
10.1016/j.neubiorev.2014.01.001
10.1007/s00737-002-0142-6
10.1016/j.neuroimage.2013.06.074
10.1523/jneurosci.23-13-05708.2003
10.1016/j.psyneuen.2005.01.004
10.1097/GME.0000000000000771
10.1111/jne.12402
10.1016/j.psyneuen.2008.09.008
10.1186/s12884-016-0937-5
10.1016/s0387-7604(00)00149-2
10.1002/hbm.22218
10.1001/jama.281.13.1197
10.1006/brcg.1999.1078
10.1176/jnp.16.1.120-a
10.3233/jad-122062
10.1046/j.1471-4159.1994.62051750.x
10.1038/sj.npp.1301067
10.1523/jneurosci.3192-10.2010
10.1016/j.jsbmb.2013.06.001
10.1523/jneurosci.10-12-04035.1990
10.1002/cne.903360210
10.1037/a0025538
10.1001/jamaneurol.2018.3057",<Element 'PubmedArticle' at 0x7f05df6b4950>
217,31333136,Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation.,"Amylin is a neuroendocrine peptide hormone secreted by pancreatic ß-cells; however, amylin is toxic to ß-cells when it is aggregated in type 2 diabetes mellitus (T2DM). It is important to understand amylin's structures and aggregation mechanism for the discovery and design of effective drugs to inhibit amylin aggregation. In this review, we investigated experimental and computational studies on amylin structures and inhibitors. Our review provides some novel insights into amylin, particularly for the design of its aggregation inhibitors to treat T2DM. We detailed the potential inhibitors that have been studied hitherto and highlighted the neglected need to consider different amylin attributes that depend on the presence/absence of physiologically relevant conditions, such as membranes. These conditions and the experimental methods can greatly influence the results of studies on amylininhibitor complexes. Text-mining over 3,000 amylin-related PubMed abstracts suggests the combined therapeutic potential of amylin with leptin and glucagon-like peptide-1, which are two key hormones in obesity. The results also suggest that targeting amylin aggregation can contribute to therapeutic efforts for Alzheimer's disease (AD). Therefore, we have also reviewed the role of amylin in other conditions including obesity and AD. Finally, we provided insights for designing inhibitors of different types (small molecules, proteins, peptides/mimetics, metal ions) to inhibit amylin aggregation.","[""Alzheimer's disease therapy"", 'Amylin', 'IAPP', 'aggregation inhibitors', 'conformation of amylin', 'islet amyloid polypeptide', 'literature review', 'type 2 diabetes therapy.']",Current drug targets,2019-07-25,"[{'lastname': 'Kumar', 'firstname': 'Ammu Prasanna', 'initials': 'AP', 'affiliation': 'Department of Chemistry, College of Arts and Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.\nResearch Unit in Bioinformatics, Department of Biochemistry and Microbiology, Rhodes University, South Africa.'}, {'lastname': 'Lee', 'firstname': 'Sungmun', 'initials': 'S', 'affiliation': 'Department of Biomedical Engineering and Healthcare Engineering Innovation Center, College of Engineering, Khalifa University, Abu Dhabi, United Arab Emirates.'}, {'lastname': 'Lukman', 'firstname': 'Suryani', 'initials': 'S', 'affiliation': 'Department of Chemistry, College of Arts and Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1389450120666190719164316,<Element 'PubmedArticle' at 0x7f05df4b2130>
218,"31259233
23008308
28850754
20832978
26353040
22211832
19760150
22396443
19019972
21910555
28521364
17878127
21818124
24716504
21600374
20820813
22927526
19500722
25030263
19136326
28027862
29497579
26658913
25259847
17974553
22901546
18415683",Verbal Learning and Memory Function and the Influencing Factors on Breast Cancer Survivors: A Cross-Sectional Study.,"Impairment of cognitive function is a common complaint by post-chemotherapy breast cancer survivors, specifically impairment of verbal learning and memory. The objective of this study was to identify the association between age, duration of education, chemotherapy type, hormone therapy usage, menopausal status, sleep quality, fatigue, stress, and hemoglobin (Hb) levels to memory and verbal learning function. This cross-sectional study consisted of 82 post-chemotherapy breast cancer survivors, 81 non-chemotherapy survivors, and 80 non-cancer female patients in two hospitals. The data were collected using the Hopkins Verbal Learning Test in Indonesian, Pittsburgh Sleep Quality Index, 10-item Perceived Stress Scale, and the Piper Fatigue Scale-12. All instruments were already adopted into Indonesian. Characteristic data were obtained from hospital reports. The mean age of the respondents was 43.06 (8.18) years, 197 (81.1%) had been educated for ≤12 years, 82 (33.7%) were post-chemotherapy survivors, 46 (18.9%) were using hormonal therapy, and 125 (51.4%) had gone through menopause. Among the remaining respondents, 91 (37.4%) were anemic, 124 (51.0%) had poor sleep quality, and 115 (47.3%) experienced moderate fatigue. Twenty-one (25.6%) of post-chemotherapy survivors had a high possibility of having dementia. The significant variables associated with memory and verbal learning function included age, stress, survivor type, chemotherapy category, sleep quality, and fatigue. The insignificant variables included the length of education, hormone therapy usage, menopausal status, and hemoglobin levels. A logistic regression analysis showed that stress was the most influential variable with an odds ratio of 1.159. It is recommended that nurses consider the significant variables when providing services to post-chemotherapy breast cancer survivors.","['chemotherapy', 'memory function', 'survivors', 'verbal learning function']",Asian/Pacific Island nursing journal,2019-07-02,"[{'lastname': 'Syarif', 'firstname': 'Hilman', 'initials': 'H', 'affiliation': 'Doctoral Student in the Faculty of Nursing, Universitas Indonesia, Indonesia.\nDepartment of Medical Surgical Nursing, Faculty of Nursing, Universitas Syiah Kuala, Indonesia.'}, {'lastname': 'Waluyo', 'firstname': 'Agung Hilman', 'initials': 'AH', 'affiliation': 'Department of Medical Surgical Nursing, Faculty of Nursing, Universitas Indonesia, Indonesia.'}, {'lastname': 'Afiyanti', 'firstname': 'Yati', 'initials': 'Y', 'affiliation': 'Department of Maternity Nursing, Faculty of Nursing, Universitas Indonesia, Indonesia.'}, {'lastname': 'Mansyur', 'firstname': 'Muchtaruddin', 'initials': 'M', 'affiliation': 'Faculty of Medicine, Universitas Indonesia, Indonesia.'}]",,,,,"10.31372/20190402.1036
10.1200/JCO.2012.43.0116
10.1111/ecc.12749
10.1016/j.jpainsymman.2010.04.021
10.1111/j.1365-2354.2011.01320.x
10.1007/s11764-009-0098-x
10.1093/annonc/mds029
10.1634/theoncologist.2008-0130
10.1037/a0025268
10.5176/2345-718X_4.2.146
10.1093/jnci/djx057
10.1188/07.ONF.981-994
10.3109/09540261.2013.864260
10.1053/j.seminoncol.2011.03.014
10.1007/s00520-010-0997-4
10.1200/JCO.2011.39.5640
10.1016/j.jpainsymman.2008.07.012
10.1016/S1976-1317(11)60022-4
10.1016/j.ejon.2016.12.007
10.1016/B978-1-4160-6645-3.00029-3
10.1007/s11764-015-0505-4
10.1371/journal.pone.0108002
10.1093/annonc/mdm500
10.1016/j.ejon.2012.06.002
10.1007/s11065-008-9058-x",<Element 'PubmedArticle' at 0x7f05df4ba270>
219,"31209782
7979220
8010585
24112071
2245336
25247581
19627456
29621412
18336929
23985544
17588956
23402899
12121487
24406245
12928714
15977985
20035627
20643941
354581
21358967
31055770
18818379
16217125
30362531
15725334
20136701
18636984
16943564
10378882
11732920
19796045
10899440
7946354
12399581
17350477
19421166
11782987
25401971
15519758
25726952
15467968
1865836
8103819
9885996
11698691
10607136
15189344
11976199
20663047
12622847
10678086
9406036
8158521
30221441
11060493
15066211
17439558
9243598
24374373
24728926
15194435
9130329
15615650
24454482
25641096
20626592
20005925
9915562
19104446
10376127
30032423
16120107
11733217
12887656
15298664
22257024
19779148
29907977
8738265
22310309
19558452
11386204
12543278
23043890
5378455
11168903
10672259
23190173
7568007
18698410
11255456
11814408
2570759
28442538
9051762
3615902
16837102
15719129
10085474
22418058
19945548
25888034
26100529
14671188
9694397
29887680
12761548
25587567
11467851
20308563
22085194
11092838
18231852
28994117
146092
14751768
16751189
7481413
17553422
19240035
16609073
1629745
9920102
12071472
1530909
28599069
28293167
12025858
17245412
4041816
7903586
10847561
22107053
9002996
23857055
12887649
10607943
11879773
17692828
12507730
11703561
21517957
9482801
15066046
8746452
1899488
12566926
12074101
11909680
7694279
11562447
19308922
19774434
20130848
12753069
29416502
26514267
16458180
12957828
14741406
12198538
9169522
8159737
20581818
11231989
8666165
10198158
8624085
15246822
16527442
15763401
16289675
12390504
20553310
8076698
7507613
6577819
30414087
10652477
22192775
12126998
11927634
11899100
12071511
16481071
10702641
15750290
23609496
31073315
15854745
24966809
11113604
15298672
24147912
19542221
20689579
10759187
21289177
27211547
10451025
12693870
14963227
12472904
9262874
8810256
9572310
12220952
8866675
16432155
1330213
15649735
1859093
25491598
10526127
9406982
26159703
22335196
8757267
15617532
15623694
25160468
9144231
12531038
23270879
9207249
15706607
1370967
10483925
7556503
25501601
16809342
8622788
12019347
21358971
15973543
9407389
16412535
9030627
19144697
8750345
9247266
21954831
10079193
16289476
27780989
8756120
16251967
25352148
6655558
9516407
8544907
15189333
16050977
10978169
16337883
22131947
19555648
11193793
17017945
18654881
28294066
16818472
7778188
16150105
22034091
15232344
21358972
14643375
9714810
16621166
16432899
11027741
24956284
9379344
21044348
25518303
16364209
9339668
8395408
18367454
15964511
12562500
12149444
17072839
15842767
21718363
10071710
11455329
26402759
16945113",Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.,"Melatonin, a pineal gland synthesized neurohormone is known as a multifunctioning pleiotropic agent which has a wide range of neuroprotective role in manifold age-related neurodegenerative disorders especially Alzheimer's diseases (AD). AD is a devastating neurodegenerative disorder and common form of dementia which is defined by abnormal and excessive accumulation of several toxic peptides including amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs). The Alzheimer's dementia relates to atrophic changes in the brain resulting in loss of memory, cognitive dysfunction, and impairments of the synapses. Aging, circadian disruption, Aβ accumulation, and tau hyperphosphorylation are the utmost risk factor regarding AD pathology. To date, there is no exact treatment against AD progression. In this regard, melatonin plays a crucial role for the inhibition of circadian disruption by controlling clock genes and also attenuates Aβ accumulation and tau hyperphosphorylation by regulating glycogen synthase kinase-3 (GSK3) and cyclin-dependent kinase-5 (CDK5) signaling pathway. In this review, we highlight the possible mechanism of AD etiology and how melatonin influences neurogenesis by attenuating circadian disruption, Aβ formation, as well as tau hyperphosphorylation. Furthermore, we also find out and summarize the neuroprotective roles of melatonin by the blockage of Aβ production, Aβ oligomerization and fibrillation, tau hyperphosphorylation, synaptic dysfunction, oxidative stress, and neuronal death during AD progression.","['Alzheimer’s disease', 'Amyloid β', 'Circadian rhythm', 'Melatonin', 'Neurofibrillary tangles']",Molecular neurobiology,2019-06-19,"[{'lastname': 'Hossain', 'firstname': 'Md Farhad', 'initials': 'MF', 'affiliation': 'Department of Physical Therapy, Graduate School of Inje University, Gimhae, South Korea.'}, {'lastname': 'Uddin', 'firstname': 'Md Sahab', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh. msu-neuropharma@hotmail.com.\nPharmakon Neuroscience Research Network, Dhaka, Bangladesh. msu-neuropharma@hotmail.com.'}, {'lastname': 'Uddin', 'firstname': 'G M Sala', 'initials': 'GMS', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Sumsuzzman', 'firstname': 'Dewan Md', 'initials': 'DM', 'affiliation': 'Department of Rehabilitation Science, Graduate School of Inje University, Gimhae, South Korea.'}, {'lastname': 'Islam', 'firstname': 'Md Siddiqul', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Barreto', 'firstname': 'George E', 'initials': 'GE', 'affiliation': 'Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá DC, Colombia.\nInstituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile.'}, {'lastname': 'Mathew', 'firstname': 'Bijo', 'initials': 'B', 'affiliation': 'Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India.'}, {'lastname': 'Ashraf', 'firstname': 'Ghulam Md', 'initials': 'GM', 'affiliation': 'King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. ashraf.gm@gmail.com.\nDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. ashraf.gm@gmail.com.'}]",,,,,10.1007/s12035-019-01660-3,<Element 'PubmedArticle' at 0x7f05df4cee00>
220,31162487,The complex interaction between atrial fibrillation and heart failure in elderly patients.,"Heart failure (HF) and atrial fibrillation (AF) often coexist. Subjects with permanent AF show the highest prevalence of HF. Patients with incident AF have HF in a great number of cases and, reciprocally, in patients with incident HF, an AF can be frequently found. The simultaneous presence of the two conditions is associated with mortality rates higher than those observed in individuals with only one or none of them. Interestingly, HF and AF could synergistically promote in elderly patients the development of disability and dementia. Inflammatory mechanisms coupled with changes of renin-angiotensin system, hormonal pathways and neuro-mediators could simultaneously promote left atrium remodeling and sustain both HF and AF. Beta-blockers and digoxin seem to have small therapeutic effect and limited influence on prognosis in these very complex patients. Sinus rhythm restoration could slow down the progression of disability in symptomatic subjects. Recent evidence seem to suggest that upstream therapy coupled with rehabilitation, and that AV node ablation associated with cardiac resynchronization therapy could benefit subjects with HF and AF. In conclusion, elderly patients simultaneously presenting problems of cardiac function and arrhythmia are an important challenge for geriatric medicine, and request important efforts to improve their functional profile and prognosis.",[],Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace,2019-06-05,"[{'lastname': 'Fumagalli', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'University of Florence, AOU Careggi, Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit. stefano.fumagalli@unifi.it.'}, {'lastname': 'Pelagalli', 'firstname': 'Giulia', 'initials': 'G', 'affiliation': None}, {'lastname': 'Migliorini', 'firstname': 'Marta', 'initials': 'M', 'affiliation': None}, {'lastname': 'Boni', 'firstname': 'Serena', 'initials': 'S', 'affiliation': None}, {'lastname': 'Nigro', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Marozzi', 'firstname': 'Irene', 'initials': 'I', 'affiliation': None}, {'lastname': 'Pupo', 'firstname': 'Simone', 'initials': 'S', 'affiliation': None}, {'lastname': 'Marchionni', 'firstname': 'Niccolò', 'initials': 'N', 'affiliation': None}]",,,,,10.4081/monaldi.2019.1050,<Element 'PubmedArticle' at 0x7f05df4a04a0>
221,31102743,Tackling Alzheimer's disease: Hypothetical synergism between anti-inflammatory and anti-diabetic agents.,"Alzheimer's disease (AD) remains one of the greatest global concerns. Current treatment of AD - the acetylcholinesterase inhibitors - provides temporary improvement of cognitive functions, but does not affect the core of the underlying pathological process. There is still the need for alternative approaches, preferably ones based on the upstream events in the AD pathogenesis. The nature of AD pathogenesis remains complicated and not entirely explained. It is assumed to comprise of many interrelated events which can sequentially lead to further pathologies - as a kind of vicious cycle. The solution in this case could be to interact with these processes on multiple levels at the same time. The proposed approach hopes to achieve the state of equilibrium between two pathological pathways via reducing their dynamics on appropriate levels. The first step is to inhibit Tumor Necrosis Factor signaling related to inflammatory response. The second is to take advantage of the influence of insulin signaling on amyloid-β processing to restore its proper clearance. Employing two only partially-beneficial approaches into a novel approach aims at breaking the ""vicious cycle"" and eliciting synergistic effect via working on different levels simultaneously. The effect of such therapy could allow physicians to completely inhibit neural damage. The proposed strategy may prove easily introducible as an efficacious clinical approach employing novel anti-TNF agents in combination with anti-diabetic agents. Data is needed on its influence on cognitive functions, any occurrence of adverse effects, and the development of models of optimal doses and their temporal location.","[""Alzheimer's disease"", 'Anti-inflammatory agents', 'Dementia', 'Drug synergism', 'Hypoglycemic agents', 'Insulin']",Life sciences,2019-05-19,"[{'lastname': 'Łuc', 'firstname': 'Mateusz', 'initials': 'M', 'affiliation': 'Department of Psychiatry, Wrocław Medical University, Wybrzeże L. Pasteura 10, 50-367 Wrocław, Poland. Electronic address: mateusz.luc@student.umed.wroc.pl.'}, {'lastname': 'Woźniak', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Pathology, Wrocław Medical University, K. Marcinkowskiego 1, 50-368 Wrocław, Poland.'}, {'lastname': 'Helemejko', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': 'Department of Psychiatry, Wrocław Medical University, Wybrzeże L. Pasteura 10, 50-367 Wrocław, Poland.'}, {'lastname': 'Rymaszewska', 'firstname': 'Joanna', 'initials': 'J', 'affiliation': 'Department of Psychiatry, Wrocław Medical University, Wybrzeże L. Pasteura 10, 50-367 Wrocław, Poland.'}]",,,,Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.lfs.2019.05.039,<Element 'PubmedArticle' at 0x7f05df4aa4a0>
222,30958350,Chronic Angiotensin 1-7 Infusion Prevents Angiotensin-II-Induced Cognitive Dysfunction and Skeletal Muscle Injury in a Mouse Model of Alzheimer's Disease.,"Alzheimer's disease (AD) is increasingly viewed as a neurological disease accompanied by a systemic disorder. Accumulating evidence supports that angiotensin II and angiotensin 1-7 exert opposite effects on various organs including the brain. However, the interaction between angiotensin II and angiotensin 1-7 in AD remains to be defined. The present study was undertaken to examine the interaction between these peptides in AD. 5XFAD mice, a useful model of AD, were separated into three groups: 1) saline-infused, 2) angiotensin II-infused, and 3) angiotensin II-infused and angiotensin 1-7-co-infused. These peptides were systemically given to 5XFAD mice via osmotic minipump for 4 weeks. Systemic angiotensin II infusion for 4 weeks induced significant hypertension in both wild-type and 5XFAD mice. Angiotensin II induced cognitive abnormality in 5XFAD mice as estimated by the Morris water maze test and the nest building test, and this effect was associated with cerebral blood flow reduction, cortical arterial amyloid-β deposition, hippocampal inflammation, and neuron loss in 5XFAD mice. In addition, angiotensin II infusion led to gastrocnemius muscle atrophy in 5XFAD mice. Co-infusion of angiotensin 1-7 prevented the above mentioned detrimental effects of angiotensin II in the brain and gastrocnemius muscle in 5XFAD mice, without significant influence on blood pressure. The left ventricular hypertrophic response to angiotensin II was attenuated in 5XFAD mice compared with wild-type mice, which was not significantly altered by co-administration of angiotensin 1-7. Our results show that angiotensin 1-7 counteracts angiotensin II-induced cognitive impairment, brain injury, and skeletal muscle injury in AD mice.","['Alzheimer’s disease', 'amyloid-β peptides', 'angiotensin 1-7', 'angiotensin II', 'left ventricular hypertrophy', 'sarcopenia']",Journal of Alzheimer's disease : JAD,2019-04-09,"[{'lastname': 'Cao', 'firstname': 'Cheng', 'initials': 'C', 'affiliation': 'Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Chuo-ku, Kumamoto, Japan.\nProgram for Leading Graduate Schools ""HIGO (Health life Science: Interdisciplinary and Glocal Oriented) Program"", Kumamoto University, Chuo-ku, Kumamoto, Japan.'}, {'lastname': 'Hasegawa', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': 'Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Chuo-ku, Kumamoto, Japan.'}, {'lastname': 'Hayashi', 'firstname': 'Kenyu', 'initials': 'K', 'affiliation': 'Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Chuo-ku, Kumamoto, Japan.'}, {'lastname': 'Takemoto', 'firstname': 'Yushin', 'initials': 'Y', 'affiliation': 'Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Chuo-ku, Kumamoto, Japan.'}, {'lastname': 'Kim-Mitsuyama', 'firstname': 'Shokei', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, Chuo-ku, Kumamoto, Japan.'}]",,,,,10.3233/JAD-181000,<Element 'PubmedArticle' at 0x7f05df4365e0>
223,"30911572
26987909
21989247
21296405
24927875
26822748
29735514
27260291
29706605
24522445
26810632
25329012
26377252
28596251
21914052
18752088
21810890
15642901
24336140
23427327
28054827
17846114
20849323
22214356
16977673
12235302
24687694
9952907
17448988
21387376
21726573
11287098
23759334
8401787
28294153
18469020
17690262
23685313
28663573
23826340
24833719
29254092
12913196
29248481
25305153
25900666
25600257
20074230
24070404",Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia.,"Physiological changes potentially influence disease progression and survival along the Amyotrophic Lateral Sclerosis (ALS)-Frontotemporal dementia (FTD) spectrum. The peripheral peptides that regulate eating and metabolism may provide diagnostic, metabolic, and progression biomarkers. The current study aimed to examine the relationships and biomarker potential of hormonal peptides.
One hundred and twenty-seven participants (36 ALS, 26 ALS- cognitive, patients with additional cognitive behavioral features, and 35 behavioral variant FTD (bvFTD) and 30 controls) underwent fasting blood analyses of leptin, ghrelin, neuropeptide Y (NPY), peptide YY (PYY), and insulin levels. Relationships between endocrine measures, cognition, eating behaviors, and body mass index (BMI) were investigated. Biomarker potential was evaluated using multinomial logistic regression for diagnosis and correlation to disease duration.
Compared to controls, ALS and ALS-cognitive had higher NPY levels and bvFTD had lower NPY levels, while leptin levels were increased in all patient groups. All groups had increased insulin levels and a state of insulin resistance compared to controls. Lower NPY levels correlated with increasing eating behavioral change and BMI, while leptin levels correlated with BMI. On multinomial logistic regression, NPY and leptin levels were found to differentiate between diagnosis. Reduced Neuropeptide Y levels correlated with increasing disease duration, suggesting it may be useful as a potential marker of disease progression.
ALS-FTD is characterized by changes in NPY and leptin levels that may impact on the underlying regional neurodegeneration as they were predictive of diagnosis and disease duration, offering the potential as biomarkers and for the development of interventional treatments.",[],Annals of clinical and translational neurology,2019-03-27,"[{'lastname': 'Ahmed', 'firstname': 'Rebekah M', 'initials': 'RM', 'affiliation': 'Memory and Cognition Clinic Institute of Clinical Neurosciences Royal Prince Alfred Hospital Sydney New South Wales Australia.\nBrain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.\nARC Centre of Excellence in Cognition and its Disorders Sydney New South Wales Australia.'}, {'lastname': 'Phan', 'firstname': 'Katherine', 'initials': 'K', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Highton-Williamson', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Strikwerda-Brown', 'firstname': 'Cherie', 'initials': 'C', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.\nARC Centre of Excellence in Cognition and its Disorders Sydney New South Wales Australia.\nThe University of Sydney School of Psychology and Brain and Mind Centre Sydney New South Wales Australia.'}, {'lastname': 'Caga', 'firstname': 'Jashelle', 'initials': 'J', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Ramsey', 'firstname': 'Eleanor', 'initials': 'E', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Zoing', 'firstname': 'Margaret', 'initials': 'M', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Devenney', 'firstname': 'Emma', 'initials': 'E', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Kim', 'firstname': 'Woojin S', 'initials': 'WS', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Hodges', 'firstname': 'John R', 'initials': 'JR', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.\nARC Centre of Excellence in Cognition and its Disorders Sydney New South Wales Australia.'}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'ARC Centre of Excellence in Cognition and its Disorders Sydney New South Wales Australia.\nThe University of Sydney School of Psychology and Brain and Mind Centre Sydney New South Wales Australia.'}, {'lastname': 'Halliday', 'firstname': 'Glenda M', 'initials': 'GM', 'affiliation': 'Brain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}, {'lastname': 'Kiernan', 'firstname': 'Matthew C', 'initials': 'MC', 'affiliation': 'Memory and Cognition Clinic Institute of Clinical Neurosciences Royal Prince Alfred Hospital Sydney New South Wales Australia.\nBrain and Mind Centre Sydney Medical School The University of Sydney Sydney New South Wales Australia.'}]",,,"Compared to controls, ALS and ALS-cognitive had higher NPY levels and bvFTD had lower NPY levels, while leptin levels were increased in all patient groups. All groups had increased insulin levels and a state of insulin resistance compared to controls. Lower NPY levels correlated with increasing eating behavioral change and BMI, while leptin levels correlated with BMI. On multinomial logistic regression, NPY and leptin levels were found to differentiate between diagnosis. Reduced Neuropeptide Y levels correlated with increasing disease duration, suggesting it may be useful as a potential marker of disease progression.",,10.1002/acn3.721,<Element 'PubmedArticle' at 0x7f05df442130>
224,"30842086
10599770
27823753
27870425
17559807
16365303
19427328
24336141
8709781
10102413
12413371
23100399
28274328
28202700
12771112
15213206
23715379
21396500
25803671
19104361
27172432
27906568
24042430
23238854
28191467
22762015
25223701
30021919
27163830
28898378
27823727
10738542
14718482
10515670
22946521
10854354
17616482
24608822",Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.,"To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.
Nationwide case-control study.
Finnish national population and drug register, between 1999 and 2013.
All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician, and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.
Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.
Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.
In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60 years or older, and 47 239 (55.7%) women had been over 80 years of age at diagnosis. Use of systemic hormone therapy was associated with a 9-17% increased risk of Alzheimer's disease. The risk of the disease did not differ significantly between users of estradiol only (odds ratio 1.09, 95% confidence interval 1.05 to 1.14) and those of oestrogen-progestogen (1.17, 1.13 to 1.21). The risk increases in users of oestrogen-progestogen therapy were not related to different progestogens (norethisterone acetate, medroxyprogesterone acetate, or other progestogens); but in women younger than 60 at hormone therapy initiation, these risk increases were associated with hormone therapy exposure over 10 years. Furthermore, the age at initiation of systemic hormone therapy was not a decisive determinant for the increase in risk of Alzheimer's disease. The exclusive use of vaginal estradiol did not affect the risk of the disease (0.99, 0.96 to 1.01).
Long term use of systemic hormone therapy might be accompanied with an overall increased risk of Alzheimer's disease, which is not related to the type of progestogen or the age at initiation of systemic hormone therapy. By contrast, use of vaginal estradiol shows no such risk. Even though the absolute risk increase for Alzheimer's disease is small, our data should be implemented into information for present and future users of hormone therapy.",[],BMJ (Clinical research ed.),2019-03-08,"[{'lastname': 'Savolainen-Peltonen', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': 'University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Helsinki, Finland.\nFolkhälsan Research Center, Biomedicum, Helsinki, Finland.'}, {'lastname': 'Rahkola-Soisalo', 'firstname': 'Päivi', 'initials': 'P', 'affiliation': 'University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Helsinki, Finland.'}, {'lastname': 'Hoti', 'firstname': 'Fabian', 'initials': 'F', 'affiliation': 'EPID Research Oy, Espoo, Finland.'}, {'lastname': 'Vattulainen', 'firstname': 'Pia', 'initials': 'P', 'affiliation': 'EPID Research Oy, Espoo, Finland.'}, {'lastname': 'Gissler', 'firstname': 'Mika', 'initials': 'M', 'affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.\nKarolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Family Medicine, Huddinge, Sweden.\nUniversity of Turku, Research Centre for Child Psychiatry, Turku, Finland.'}, {'lastname': 'Ylikorkala', 'firstname': 'Olavi', 'initials': 'O', 'affiliation': 'University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Helsinki, Finland.'}, {'lastname': 'Mikkola', 'firstname': 'Tomi S', 'initials': 'TS', 'affiliation': 'University of Helsinki and Helsinki University Hospital, Obstetrics and Gynecology, Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Helsinki, Finland tomi.mikkola@hus.fi.\nFolkhälsan Research Center, Biomedicum, Helsinki, Finland.'}]",,,"In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60 years or older, and 47 239 (55.7%) women had been over 80 years of age at diagnosis. Use of systemic hormone therapy was associated with a 9-17% increased risk of Alzheimer's disease. The risk of the disease did not differ significantly between users of estradiol only (odds ratio 1.09, 95% confidence interval 1.05 to 1.14) and those of oestrogen-progestogen (1.17, 1.13 to 1.21). The risk increases in users of oestrogen-progestogen therapy were not related to different progestogens (norethisterone acetate, medroxyprogesterone acetate, or other progestogens); but in women younger than 60 at hormone therapy initiation, these risk increases were associated with hormone therapy exposure over 10 years. Furthermore, the age at initiation of systemic hormone therapy was not a decisive determinant for the increase in risk of Alzheimer's disease. The exclusive use of vaginal estradiol did not affect the risk of the disease (0.99, 0.96 to 1.01).",Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.,"10.1136/bmj.l665
10.1212/WNL.53.9.1992
10.1016/j.maturitas.2016.09.009
10.1002/jnr.23827
10.1016/j.bbrc.2007.05.158
10.1073/pnas.0505203102
10.1016/j.yfrne.2009.04.015
10.1212/WNL.0000000000000033
10.1016/S0140-6736(96)03356-9
10.1212/WNL.52.5.965
10.1001/jama.288.17.2123
10.1212/WNL.0b013e318271f823
10.1016/j.maturitas.2017.01.002
10.1212/WNL.0000000000003696
10.1001/jama.289.20.2651
10.1001/jama.291.24.2947
10.1097/GME.0b013e3182960cf8
10.1016/j.amjmed.2010.09.021
10.1097/GME.0000000000000450
10.1097/AOG.0b013e31818e8cd6
10.1210/jc.2015-4149
10.1093/epirev/mxt008
10.1210/er.2012-1008
10.1155/2017/8630764
10.1101/cshperspect.a006338
10.1016/j.tins.2014.08.004
10.1212/WNL.0000000000006000
10.3233/JAD-160258
10.1001/jama.2017.11217
10.1016/j.maturitas.2016.09.015
10.1046/j.1469-1809.1999.6340301.x
10.1093/gerona/59.1.B16
10.1016/S0378-5122(99)00027-4
10.1037/a0029857
10.1016/S1474-4422(07)70178-3
10.1097/YIC.0000000000000032",<Element 'PubmedArticle' at 0x7f05df465040>
225,"30763368
28733960
29562526
18541980
18675769
24856805
25107566
24231519
25908019
25700178
28433667
16355919
17168346
29682806
17452702
24781675
24957908
27894487
15142976
12807847
18340200
11300427
12079712
12417542
9398103
16893713
19424098
21683832
22855860
22479261
24333505
21165148
24768341
24121966
1202204
29213645
27612177
18044137
28794835
29599943
28715462
30020924
20106935
23729490
25216268
26969397
12807847
29601787
21375692
25523424
24748882
25514304
27371673",SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients.,"Alzheimer's disease represents the most common age-related neurodegenerative disorder and a leading cause of progressive cognitive impairment. Predicting cognitive decline is challenging but would be invaluable in an increasingly aging population which also experiences a rising cardiovascular risk. In order to examine whether plasma measurements of one of the established biomarkers of heart failure, brain natriuretic peptide (BNP), reflect a decline in cognitive function, associated with Alzheimer's disease neurodegeneration, BNP levels were analysed, by using a novel assay called a SOMAscan, in 1. cognitively healthy, control subjects; 2. subjects with mild cognitive impairment, and 3. subjects with Alzheimer's disease. The results of our study show that the levels of the BNP were significantly different between the three types of diagnoses (p < 0.05), whereby subjects with mild cognitive impairment had the lowest mean BNP value, and healthy subjects had the highest BNP value. Importantly, our results show that the levels of the BNP are influenced by the presence of at least one APOE4 allele in the healthy (p < 0.05) and in the Alzheimer's disease groups of subjects (p < 0.1). As the levels of the BNP appear to be independent of the APOE4 genotype in subjects with mild cognitive impairment, the results of our study support inclusion of measurements of plasma levels of the BNP in the list of the core Alzheimer's disease biomarkers for identification of the mild cognitive impairment group of patients. In addition, the results of our study warrant further investigations into molecular links between Alzheimer's disease-type cognitive decline and cardiovascular disorders.",[],PloS one,2019-02-15,"[{'lastname': 'Begic', 'firstname': 'Edin', 'initials': 'E', 'affiliation': 'Department of Pharmacology, Sarajevo Medical School, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.\nDepartment of Cardiology, General Hospital ""Prim.Dr. Abdulah Nakas"", Sarajevo, Bosnia and Herzegovina.'}, {'lastname': 'Hadzidedic', 'firstname': 'Suncica', 'initials': 'S', 'affiliation': 'Computer Science and Information Systems Department, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.'}, {'lastname': 'Kulaglic', 'firstname': 'Ajla', 'initials': 'A', 'affiliation': 'Computer Science and Information Systems Department, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.'}, {'lastname': 'Ramic-Brkic', 'firstname': 'Belma', 'initials': 'B', 'affiliation': 'Computer Science and Information Systems Department, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.'}, {'lastname': 'Begic', 'firstname': 'Zijo', 'initials': 'Z', 'affiliation': 'Department of Pediatric Cardiology, University Clinical Center, Sarajevo, Bosnia and Herzegovina.'}, {'lastname': 'Causevic', 'firstname': 'Mirsada', 'initials': 'M', 'affiliation': 'Department of Pharmacology, Sarajevo Medical School, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina.'}]",,,,,"10.1371/journal.pone.0212261
10.3233/JAD-170531
10.1097/WNN.0b013e3181799dc8
10.1016/j.amjopharm.2008.06.004
10.1016/j.ijcard.2014.05.004
10.1016/j.arr.2014.07.003
10.1016/j.neurobiolaging.2013.10.084
10.1016/j.cardfail.2015.04.006
10.1161/CIRCULATIONAHA.114.012438
10.1016/j.cardfail.2017.04.007
10.1111/joim.12756
10.1136/emj.2006.041368
10.1515/cclm-2013-0791
10.1007/s10741-014-9447-6
10.1373/clinchem.2003.028316
10.1097/01.hpc.0000174912.89563.ba
10.1016/j.amjcard.2006.02.062
10.1097/WNR.0b013e328326f82f
10.1212/WNL.0b013e318266fa70
10.1016/j.exger.2013.12.001
10.1371/journal.pone.0015004
10.1590/S1980-57642009DN30400008
10.1002/ejhf.631
10.1155/2018/1817479
10.1371/journal.pone.0181349
10.1371/journal.pmed.1002609
10.1093/aje/kwp425
10.1093/ndt/gft221
10.1371/journal.pone.0106716
10.1111/j.1742-4658.2011.08082.x
10.3969/j.issn.1671-5411.2014.01.004
10.1001/jama.2014.13806
10.2337/dc16-0316",<Element 'PubmedArticle' at 0x7f05df2830e0>
226,30703399,Influence of sex and hormonal status on initial impact and neurocognitive outcome after subarachnoid haemorrhage in rats.,"The aim of this study was to detect differences in functional outcome after experimental subarachnoid haemorrhage (SAH) in rodents with different hormonal status. For this purpose, the endovascular perforation model was applied to four groups of Sprague-Dawley-Rats: male intact, male neutered, female intact and female neutered animals. Initial impact was measured by ICP, CPP and cerebral blood flow in the first hour after SAH. From day 4-14, the modified hole board test was applied to assess functional and neuro-cognitive outcome. Histological outcome was examined in the motor cortex and hippocampus of each hemisphere. Mortality was highest in the female intact group albeit not statistically significant. Physiologic parameters did not differ significantly between groups either. In the modified hole board test, male intact animals showed a greater impairment of declarative memory than the female intact and neutered groups. However, male intact animals showed greater avoidance behaviour and male animals revealed higher anxiety levels independent of hormonal status. No differences in histological damage of hippocampus and motor cortex between groups could be shown. We therefore speculate that the marginal deficits in cognitive performance that are shown by the male intact group in the modified hole board test are mostly caused by higher anxiety levels and cannot be interpreted as pure cognitive impairment.","['Endovascular perforation', 'Functional outcome', 'Modified hole board test', 'Sex', 'Sprague-Dawley-Rats', 'Subarachnoid haemorrhage']",Behavioural brain research,2019-02-01,"[{'lastname': 'Kagerbauer', 'firstname': 'Simone Maria', 'initials': 'SM', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany. Electronic address: simone.kagerbauer@tum.de.'}, {'lastname': 'Kadera', 'firstname': 'Vojtech', 'initials': 'V', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Gordan', 'firstname': 'Lucia Maria', 'initials': 'LM', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Blobner', 'firstname': 'Manfred', 'initials': 'M', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Török', 'firstname': 'Elisabeth', 'initials': 'E', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Neurosurgery, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Schmid', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Podtschaske', 'firstname': 'Armin Horst', 'initials': 'AH', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}, {'lastname': 'Jungwirth', 'firstname': 'Bettina', 'initials': 'B', 'affiliation': 'Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Anaesthesiology and Intensive Care Medicine, Ismaninger Str. 22, 81675 München, Germany.'}]",,,,Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2019.01.050,<Element 'PubmedArticle' at 0x7f05df2a6b80>
227,30689572,Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset.,"We report the case of two monozygotic twins with Thr272fs mutation in progranulin gene. Both patients developed frontotemporal dementia with 5 years difference in age at onset (Twin 1:73 years, Twin 2:68 years), with early behavioral, language, dysexecutive, and memory problems. They had the same formal education (5 years), but while Twin 1 dedicated more to social and leisure activity, Twin 2 worked all her life. At neuroimaging (MRI for Twin 1 and CT for Twin 2), they both showed asymmetric atrophy with left predominance. The two were discordant for total tau levels in cerebrospinal fluid, neuropsychological testing, and smoking habits. The description of the twins can help identify environmental factors that influence the onset and phenotype of frontotemporal dementia.","['Age at onset', 'atrophy', 'cerebrospinal fluid', 'frontotemporal dementia', 'progranulin (GRN)', 'twins']",Journal of Alzheimer's disease : JAD,2019-01-29,"[{'lastname': 'Fumagalli', 'firstname': 'Giorgio Giulio', 'initials': 'GG', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.\nDepartment of Neurosciences, University of Florence, Psychology, Drug Research and Child Health (NEUROFARBA), Florence, Italy.'}, {'lastname': 'Sacchi', 'firstname': 'Luca', 'initials': 'L', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Basilico', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Arighi', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Carandini', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Scarioni', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Colombi', 'firstname': 'Annalisa', 'initials': 'A', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Pietroboni', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Ghezzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Serpente', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': ""D'anca"", 'firstname': 'Marianna', 'initials': 'M', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Arcaro', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Mercurio', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Triulzi', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Scola', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Marotta', 'firstname': 'Giorgio', 'initials': 'G', 'affiliation': ""Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'University of Milan, ""Dino Ferrari"" Center, Milan, Italy.\nFoundation IRCCS Ca\' Granda Ospedale Maggiore Policlinico, Milan, Italy.'}]",,,,,10.3233/JAD-180723,<Element 'PubmedArticle' at 0x7f05defb4bd0>
228,30688198,"Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease.","In recent decades, clinical trials in Alzheimer's disease (AD) have failed at an unprecedented rate. The etiology of AD has since come under renewed scrutiny, both to elucidate the underlying pathologies and to identify novel therapeutic strategies. Here, diet has emerged as a potential causative/protective agent. A variety of nutrients, including lipids, minerals, vitamins, antioxidants and sugars as well as broader dietary patterns and microbiotal interactions have demonstrated associations with AD. Although clinical trials have yet to definitively implicate any singular dietary element as therapeutic or causative, it is apparent that dietary preferences, likely in complex synergies, may influence the risk, onset and course of AD. This review catalogs the impact of major dietary elements on AD. It further examines an unexplored reciprocal association where AD may modulate diet, as well as how potential therapeutics may complicate these interactions. In doing so, we observe diet may have profound effects on the outcome of a clinical trial, either as a confounder of a drug/disease interaction or as a generally disruptive covariate. We therefore conclude that future clinical trials in AD should endeavor to control for diet, either in study design or subsequent analyses.
Les interactions entre l’alimentation et la prise de médicaments dans le cas de la maladie d’Alzheimer. Au cours des dernières décennies, les essais cliniques liés à la maladie d’Alzheimer (MA) ont échoué à un rythme sans précédent. Depuis, l’étiologie de cette maladie a fait l’objet d’un examen plus attentif à la fois pour mieux comprendre les troubles sous-jacents de la MA et pour identifier de nouvelles stratégies thérapeutiques. À cet égard, l’alimentation est apparue au fil des années comme un agent potentiellement causal/protecteur dans le cas de la MA. On a ainsi pu démontrer qu’une variété de nutriments, ce qui inclut des lipides, des minéraux, des vitamines, des antioxydants et des sucres, de même que des habitudes alimentaires plus variées et des interactions propres à la flore intestinale, pouvaient être associées à l’évolution de la MA. Bien que l’on doive encore établir de façon définitive au moyen d’essais cliniques le rôle causal et thérapeutique de quelque élément nutritif que ce soit, il est clair que les choix alimentaires que l’on fait, probablement dans le cadre de synergies complexes, pourraient avoir une influence sur le risque d’être atteint de la MA, sur son apparition et son évolution. Cette étude entend donc se pencher sur l’impact des principaux éléments nutritifs en ce qui a trait à la MA. Elle examinera en outre les associations réciproques peu abordées en vertu desquelles il est possible que la MA ait un impact sur l’alimentation ; elle cherchera aussi à savoir dans quelle mesure d’éventuelles options thérapeutiques peuvent affecter ces interactions. Ce faisant, nous sommes d’avis que l’alimentation pourrait avoir de profonds effets sur les résultats d’essais cliniques, que ce soit à titre d’élément perturbant les interactions entre un médicament et la maladie ou, le plus souvent, à titre de covariable perturbatrice. En somme, nous sommes amenés à conclure que les essais cliniques du futur portant sur la MA devraient s’efforcer de tenir compte de l’alimentation, que ce soit dans leur méthodologie ou lors d’analyses ultérieures.","['Alzheimer’s disease', 'Cholesterol', 'Clinical trials', 'Diet', 'Lipids', 'Medications', 'Microbiota', 'Minerals', 'Sugar', 'Vitamins']",The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,2019-01-29,"[{'lastname': 'Liyanage', 'firstname': 'S Imindu', 'initials': 'SI', 'affiliation': 'Krembil Research Institute, University Health Network, Toronto, ON, Canada.'}, {'lastname': 'Vilekar', 'firstname': 'Prachi', 'initials': 'P', 'affiliation': 'Krembil Research Institute, University Health Network, Toronto, ON, Canada.'}, {'lastname': 'Weaver', 'firstname': 'Donald F', 'initials': 'DF', 'affiliation': 'Krembil Research Institute, University Health Network, Toronto, ON, Canada.\nFaculty of Medicine, University of Toronto, Toronto, ON, Canada.'}]",,,,,10.1017/cjn.2018.353,<Element 'PubmedArticle' at 0x7f05defc49a0>
229,30597139,Sex differences in sleep and sleep loss-induced cognitive deficits: The influence of gonadal hormones.,"Males and females can respond differentially to the same environmental stimuli and experimental conditions. Chronic sleep loss is a frequent and growing problem in many modern societies and has a broad variety of negative outcomes for health and well-being. While much has been done to explore the deleterious effects of sleep deprivation (SD) on cognition in both human and animal studies over the last few decades, very little attention has been paid to the part played by sex differences and gonadal steroids in respect of changes in cognitive functions caused by sleep loss. The effects of gonadal hormones on sleep regulation and cognitive performances are well established. Reduced gonadal function in menopausal women and elderly men is associated with sleep disturbances and cognitive decline as well as dementia, which suggests that sex steroids play a key role in modulating these conditions. Finding out whether there are sex differences in respect of the effect of insufficient sleep on cognition, and how neuroendocrine mediators influence cognitive impairment induced by SD could provide valuable insights into the best therapies for each sex. In this review, we aim to highlight the involvement of sex differences and gonadal hormone status on the severity of cognitive deficits induced by sleep deficiency in both human and animal studies.","['Cognitive function', 'Gonadal steroids', 'Sex differences', 'Sleep and memory', 'Sleep deprivation']",Hormones and behavior,2019-01-01,"[{'lastname': 'Hajali', 'firstname': 'Vahid', 'initials': 'V', 'affiliation': 'Department of Neuroscience, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hajaliV@mums.ac.ir.'}, {'lastname': 'Andersen', 'firstname': 'Monica L', 'initials': 'ML', 'affiliation': 'Departamento de Psicobiologia, Universidade Federal de São Paulo - UNIFESP, Brazil.'}, {'lastname': 'Negah', 'firstname': 'Sajad Sahab', 'initials': 'SS', 'affiliation': 'Department of Neuroscience, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'lastname': 'Sheibani', 'firstname': 'Vahid', 'initials': 'V', 'affiliation': 'Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.yhbeh.2018.12.013,<Element 'PubmedArticle' at 0x7f05defcf680>
230,30580011,Contributions of sex to cerebrovascular function and pathology.,"Sex differences exist in how cerebral blood vessels function under both physiological and pathological conditions, contributing to observed sex differences in risk and outcomes of cerebrovascular diseases (CBVDs), such as vascular contributions to cognitive impairment and dementia (VCID) and stroke. Throughout most of the lifespan, women are protected from CBVDs; however, risk increases following menopause, suggesting sex hormones may play a significant role in this protection. The cerebrovasculature is a target for sex hormones, including estrogens, progestins, and androgens, where they can influence numerous vascular functions and pathologies. While there is a plethora of information on estrogen, the effects of progestins and androgens on the cerebrovasculature are less well-defined. Estrogen decreases cerebral tone and increases cerebral blood flow, while androgens increase tone. Both estrogens and androgens enhance angiogenesis/cerebrovascular remodeling. While both estrogens and androgens attenuate cerebrovascular inflammation, pro-inflammatory effects of androgens under physiological conditions have also been demonstrated. Sex hormones exert additional neuroprotective effects by attenuating oxidative stress and maintaining integrity and function of the blood brain barrier. Most animal studies utilize young, healthy, gonadectomized animals, which do not mimic the clinical conditions of aging individuals likely to get CBVDs. This is also concerning, as sex hormones appear to mediate cerebrovascular function differently based on age and disease state (e.g. metabolic syndrome). Through this review, we hope to inspire others to consider sex as a key biological variable in cerebrovascular research, as greater understanding of sex differences in cerebrovascular function will assist in developing personalized approaches to prevent and treat CBVDs.","['Cerebrovascular disease', 'Dementia', 'Sex differences', 'Sex hormones', 'Stroke', 'Vascular']",Brain research,2018-12-24,"[{'lastname': 'Robison', 'firstname': 'Lisa S', 'initials': 'LS', 'affiliation': 'Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, United States. Electronic address: robisol@amc.edu.'}, {'lastname': 'Gannon', 'firstname': 'Olivia J', 'initials': 'OJ', 'affiliation': 'Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, United States. Electronic address: gannono@amc.edu.'}, {'lastname': 'Salinero', 'firstname': 'Abigail E', 'initials': 'AE', 'affiliation': 'Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, United States. Electronic address: salinea@amc.edu.'}, {'lastname': 'Zuloaga', 'firstname': 'Kristen L', 'initials': 'KL', 'affiliation': 'Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, United States. Electronic address: zuloagk@amc.edu.'}]",,,,Copyright © 2018 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2018.12.030,<Element 'PubmedArticle' at 0x7f05defdc4a0>
231,30571958,"Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice.","Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with insulin resistance and glucose hypometabolism in the brain. Oral administration of galactose, a nutrient that provides an alternative source of energy, prevents and ameliorates early cognitive impairment in a streptozotocin-induced model (STZ-icv) of the sporadic AD (sAD). Here we explored the influence of 2-month oral galactose treatment (200 mg/kg/day) in the familial AD (fAD) by using 5- (5M) and 10- (10M) month-old transgenic Tg2576 mice mimicking the presymptomatic and the mild stage of fAD, and compared it to that observed in 7-month old STZ-icv rats mimicking mild-to-moderate sAD. Cognitive and behavioral performance was tested by Morris Water Maze, Open Field and Elevated Plus Maze tests, and metabolic status by intraperitoneal glucose tolerance test and fluorodeoxyglucose Positron-Emission Tomography scan. The level of insulin, glucagon-like peptide-1 (GLP-1) and soluble amyloid β1-42 (sAβ1-42) was measured by ELISA and the protein expression of insulin receptor (IR), glycogen synthase kinase-3β (GSK-3β), and pre-/post-synaptic markers by Western blot analysis. Although galactose normalized alterations in cerebral glucose metabolism in all Tg2576 mice (5M+2M; 10M+2M) and STZ-icv rats, it did not improve cognitive impairment in either model. Improvement of reduced grooming behavior and normalization in reduced plasma insulin levels were seen only in 5M+2M Tg2576 mice while in 10M+2M Tg2576 mice oral galactose induced metabolic exacerbation at the level of plasma insulin, GLP-1 homeostasis and glucose intolerance, and additionally increased hippocampal sAβ1-42 level, decreased IR expression and increased GSK-3β activity. The results indicate that therapeutic potential of oral galactose seems to depend on the stage and the type/model of AD and to differ in the absence and the presence of AD-like pathology.","['Alzheimer disease', 'Cognition', 'Galactose', 'Metabolism', 'Positron-emission tomography', 'Transgenic mice']",Neuropharmacology,2018-12-21,"[{'lastname': 'Babic Perhoc', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Pharmacology, University of Zagreb School of Medicine, Salata 11, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Osmanovic Barilar', 'firstname': 'Jelena', 'initials': 'J', 'affiliation': 'Department of Pharmacology, University of Zagreb School of Medicine, Salata 11, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Knezovic', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Pharmacology, University of Zagreb School of Medicine, Salata 11, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Farkas', 'firstname': 'Vladimir', 'initials': 'V', 'affiliation': 'Department of Experimental Physics, Rudjer Boskovic Institute, Bijenicka 54, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Bagaric', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Experimental Physics, Rudjer Boskovic Institute, Bijenicka 54, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Svarc', 'firstname': 'Alfred', 'initials': 'A', 'affiliation': 'Department of Experimental Physics, Rudjer Boskovic Institute, Bijenicka 54, HR-10 000, Zagreb, Croatia.'}, {'lastname': 'Grünblatt', 'firstname': 'Edna', 'initials': 'E', 'affiliation': 'Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland; Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland.'}, {'lastname': 'Riederer', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Würzburg, Füchsleinstrasse 15, 97080, Würzburg, Germany; Department of Clinical Research and Psychiatry, University of Southern Denmark Odense, Odense, Denmark.'}, {'lastname': 'Salkovic-Petrisic', 'firstname': 'Melita', 'initials': 'M', 'affiliation': 'Department of Pharmacology, University of Zagreb School of Medicine, Salata 11, HR-10 000, Zagreb, Croatia; Research Centre of Excellence of Fundamental, Clinical and Translational Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Salata 12, HR-10 000, Zagreb, Croatia. Electronic address: melitas@mef.hr.'}]",,,,Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2018.12.018,<Element 'PubmedArticle' at 0x7f05defe5b80>
232,"30564546
19595937
24102028
26912638
12661673
23831175
25171577
28442274
28179815
25628598
26836168
20620666
9736007
19020040
15939846
15324362
22282647
18184916
23110866
22156756
14728627
27708128
26984945
18608129
9343467
28846757
26343475
24623176
15246987
20619505
25024337
26686669
25351109
27149905
25788555
26681727
23403534
8843881
21853262
18430978
21968867
18832152
28732515
12426043
28618077
21345170
11836290
27831823
28855400
17761551
20965156
18774188
19847162
22938820
20100545
8139057
10599762
15708201
17954781
24470773
26987701
15574496
20722820
17765329
25251492
24029446
28438770
12657064
27580146
28263868
28263362
15468033
16490256
20223924
24862109
25900537
20065132
27760869
21282661
23509628
10440369
26865880
26114906
20890449
24711660
28713255
28432077
29354050
20101012
26581787
17762374
18795987
22529236
21741129
26456233
23333772
22155655
15662209
12086747
16648603
17638929
20433212
17096007
20083961
10683094
11701302
15914419
28868969
28614695
29036816
18308888
25483019
27009597
26989000
21527670
25455510
23600729
22749404
20726622
24999318
25416742
25451089
27870419
27870399
26989000
27870449
29287628
8245220
12629162
14724248
9316021
23849196
19361542
23219473
19188598
20665592
18353559
7479947
23276673
23660230
18707012
12553913
19504537
21695421
16388901
22593075
20142488
18317379
15294007
16497840
15047671
18317381
17077199
26420238
27354538
23223011
27852617
26917537
18718688
1860209
2272974
10993851
20642454
24092827",Exercise and the Aging Brain: Considerations for Sex Differences.,"Engaging in targeted exercise interventions is a promising, non-pharmacological strategy to mitigate the deleterious effects of aging and disease on brain health. However, despite its therapeutic potential, a large amount of variation exists in exercise efficacy in older adults aged 55 and older. In this review, we present the argument that biological sex may be an important moderator of the relationship between physical activity and cognition. Sex differences exist in dementia as well as in several associated risk factors, including genetics, cardiovascular factors, inflammation, hormones and social and psychological factors. Different exercise interventions, such as aerobic training and resistance training, influence cognition and brain health in older adults and these effects may be sex-dependent. The biological mechanisms underlying the beneficial effects of exercise on the brain may be different in males and females. Specifically, we examine sex differences in neuroplasticity, neurotrophic factors and physiological effects of exercise to highlight the possible mediators of sex differences in exercise efficacy on cognition. Future studies should address the potential sex difference in exercise efficacy if we are to develop effective, evidence-based exercise interventions to promote healthy brain aging for all individuals.","['Alzheimer’s disease', 'Exercise', 'aging', 'brain', 'cognition', 'dementia', 'neuroplasticity', 'neurotrophic factors', 'physical activity', 'sex differences']","Brain plasticity (Amsterdam, Netherlands)",2018-12-20,"[{'lastname': 'Barha', 'firstname': 'Cindy K', 'initials': 'CK', 'affiliation': 'Djavad Mowafaghian Centre for Brain Health, Vancouver, Canada.\nDepartment of Physical Therapy, University of British Columbia, Vancouver, Canada.'}, {'lastname': 'Liu-Ambrose', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Djavad Mowafaghian Centre for Brain Health, Vancouver, Canada.\nDepartment of Physical Therapy, University of British Columbia, Vancouver, Canada.\nCentre for Hip Health and Mobility, Vancouver, Canada.'}]",,,,,10.3233/BPL-180067,<Element 'PubmedArticle' at 0x7f05dedf64f0>
233,30554086,Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice.,"Type 2 diabetes mellitus (T2DM) increases the risk for Alzheimer's disease (AD). Human AD brains show reduced glucose metabolism as measured by [18F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET). Here, we used 14-month-old wild-type (WT) and APP","['Akt2', ""Alzheimer's disease"", 'FDG-PET', 'Hippocampus', 'Homeostatic microglia', 'Insulin signaling']",Neurobiology of aging,2018-12-17,"[{'lastname': 'Gabbouj', 'firstname': 'Sami', 'initials': 'S', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Natunen', 'firstname': 'Teemu', 'initials': 'T', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Koivisto', 'firstname': 'Hennariikka', 'initials': 'H', 'affiliation': 'A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Jokivarsi', 'firstname': 'Kimmo', 'initials': 'K', 'affiliation': 'A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Takalo', 'firstname': 'Mari', 'initials': 'M', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Marttinen', 'firstname': 'Mikael', 'initials': 'M', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Wittrahm', 'firstname': 'Rebekka', 'initials': 'R', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Kemppainen', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Naderi', 'firstname': 'Reyhaneh', 'initials': 'R', 'affiliation': 'A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland; Department of Biology, Shahid Bahonar University, Kerman, Iran.'}, {'lastname': 'Posado-Fernández', 'firstname': 'Adrián', 'initials': 'A', 'affiliation': 'STAB VIDA Lda, Madan Parque, Rua dos Inventores, Caparica, Portugal.'}, {'lastname': 'Ryhänen', 'firstname': 'Simo', 'initials': 'S', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Mäkinen', 'firstname': 'Petra', 'initials': 'P', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Paldanius', 'firstname': 'Kaisa M A', 'initials': 'KMA', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Doria', 'firstname': 'Gonçalo', 'initials': 'G', 'affiliation': 'STAB VIDA Lda, Madan Parque, Rua dos Inventores, Caparica, Portugal.'}, {'lastname': 'Poutiainen', 'firstname': 'Pekka', 'initials': 'P', 'affiliation': 'Diagnostic Imaging Centre, PET Radiopharmacy, Kuopio University Hospital, Kuopio, Finland.'}, {'lastname': 'Flores', 'firstname': 'Orfeu', 'initials': 'O', 'affiliation': 'STAB VIDA Lda, Madan Parque, Rua dos Inventores, Caparica, Portugal.'}, {'lastname': 'Haapasalo', 'firstname': 'Annakaisa', 'initials': 'A', 'affiliation': 'A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Tanila', 'firstname': 'Heikki', 'initials': 'H', 'affiliation': 'A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'lastname': 'Hiltunen', 'firstname': 'Mikko', 'initials': 'M', 'affiliation': 'Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. Electronic address: mikko.hiltunen@uef.fi.'}]",,,,Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2018.11.008,<Element 'PubmedArticle' at 0x7f05dda2e310>
234,30551397,Neuroprotective effects of 1`δ-1`-acetoxyeugenol acetate on Aβ,"The progressive accumulation of amyloid beta (Aβ) peptide is neurotoxic and leads to Alzheimer's type dementia. Accumulation of Aβ has been associated with dysfunction of hypothalamic-pituitary-adrenal (HPA) axis and elevated pro-inflammatory cytokines. In this study, we investigated the effect of 1`δ-1`-acetoxyeugenol acetate (DAEA), isolated from Alpinia galanga (L.), on Aβ","['1`δ-1`-acetoxyeugenol acetate', 'Acetylcholinesterase enzyme', ""Alzheimer's Disease"", 'Aβ((25-35))', 'Corticosterone', 'Oxidative stress', 'TNF-α']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2018-12-16,"[{'lastname': 'Jayasingh Chellammal', 'firstname': 'Hanish Singh', 'initials': 'HS', 'affiliation': 'Unit of Pharmacology, School of Pharmacy, KPJ Healthcare University College, Kota Seriemas, Nilai, Negeri Sembilan, 71800, Malaysia.'}, {'lastname': 'Veerachamy', 'firstname': 'Alagarsamy', 'initials': 'A', 'affiliation': 'Medicinal Chemistry Research Laboratory, MNR College of Pharmacy, Sangareddy, Telangana, 502294, India.'}, {'lastname': 'Ramachandran', 'firstname': 'Dhani', 'initials': 'D', 'affiliation': 'Unit of Pathology, International Medical School, Management & Science University, University Drive, Section 13, Shah Alam, Selangor, 40100, Malaysia.'}, {'lastname': 'Gummadi', 'firstname': 'Sridhar Babu', 'initials': 'SB', 'affiliation': 'Department of Pharmaceutical Analysis, Sri Shivani College of Pharmacy, Warangal, Telangana, 506007, India.'}, {'lastname': 'Manan', 'firstname': 'Mohamed Mansor', 'initials': 'MM', 'affiliation': 'Unit of Pharmacology, School of Pharmacy, KPJ Healthcare University College, Kota Seriemas, Nilai, Negeri Sembilan, 71800, Malaysia.'}, {'lastname': 'Yellu', 'firstname': 'Narsimha Reddy', 'initials': 'NR', 'affiliation': 'Department of Pharmacology, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana, 506009, India. Electronic address: ynrku@kakatiya.ac.in.'}]",,,,Copyright © 2018 Elsevier Masson SAS. All rights reserved.,10.1016/j.biopha.2018.10.189,<Element 'PubmedArticle' at 0x7f05dda3db80>
235,"30510168
24137020
23139325
17515961
19729219
28129536
16604073
20658468
16282533
20870717
28669928
20683944
23029472
19176632
19684573
15849193
22767605
21841161
8108387
21767813
15766575
21478870
22036566
23193274
18621530
16710296
25307056
19385672
22731491
22711689
25463548
19307177
17433261
22611157
28893916
22806943
18941237
23853601
15637067
15272411
23110054
19286138
27009955
22371602
29117564
15887125
17101330
10426188
25526531",Antiviral activity of bone morphogenetic proteins and activins.,"Understanding the control of viral infections is of broad importance. Chronic hepatitis C virus (HCV) infection causes decreased expression of the iron hormone hepcidin, which is regulated by hepatic bone morphogenetic protein (BMP)/SMAD signalling. We found that HCV infection and the BMP/SMAD pathway are mutually antagonistic. HCV blunted induction of hepcidin expression by BMP6, probably via tumour necrosis factor (TNF)-mediated downregulation of the BMP co-receptor haemojuvelin. In HCV-infected patients, disruption of the BMP6/hepcidin axis and genetic variation associated with the BMP/SMAD pathway predicted the outcome of infection, suggesting that BMP/SMAD activity influences antiviral immunity. Correspondingly, BMP6 regulated a gene repertoire reminiscent of type I interferon (IFN) signalling, including upregulating interferon regulatory factors (IRFs) and downregulating an inhibitor of IFN signalling, USP18. Moreover, in BMP-stimulated cells, SMAD1 occupied loci across the genome, similar to those bound by IRF1 in IFN-stimulated cells. Functionally, BMP6 enhanced the transcriptional and antiviral response to IFN, but BMP6 and related activin proteins also potently blocked HCV replication independently of IFN. Furthermore, BMP6 and activin A suppressed growth of HBV in cell culture, and activin A inhibited Zika virus replication alone and in combination with IFN. The data establish an unappreciated important role for BMPs and activins in cellular antiviral immunity, which acts independently of, and modulates, IFN.",[],Nature microbiology,2018-12-05,"[{'lastname': 'Eddowes', 'firstname': 'Lucy A', 'initials': 'LA', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Al-Hourani', 'firstname': 'Kinda', 'initials': 'K', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Ramamurthy', 'firstname': 'Narayan', 'initials': 'N', 'affiliation': 'Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.'}, {'lastname': 'Frankish', 'firstname': 'Jamie', 'initials': 'J', 'affiliation': 'Research Group ""Dynamics of Early Viral Infection and the Innate Antiviral Response"", Division Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'lastname': 'Baddock', 'firstname': 'Hannah T', 'initials': 'HT', 'affiliation': 'Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.'}, {'lastname': 'Sandor', 'firstname': 'Cynthia', 'initials': 'C', 'affiliation': 'Dementia Research Institute, Cardiff University, Cardiff, UK.'}, {'lastname': 'Ryan', 'firstname': 'John D', 'initials': 'JD', 'affiliation': 'Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland.\nTranslational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK.'}, {'lastname': 'Fusco', 'firstname': 'Dahlene N', 'initials': 'DN', 'affiliation': 'Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Arezes', 'firstname': 'João', 'initials': 'J', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Giannoulatou', 'firstname': 'Eleni', 'initials': 'E', 'affiliation': 'Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Boninsegna', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.\nDepartment of Surgical Gastroenterological Science, University of Padua, Padova, Italy.'}, {'lastname': 'Chevaliez', 'firstname': 'Stephane', 'initials': 'S', 'affiliation': 'Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Owens', 'firstname': 'Benjamin M J', 'initials': 'BMJ', 'affiliation': 'Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK.'}, {'lastname': 'Sun', 'firstname': 'Chia Chi', 'initials': 'CC', 'affiliation': 'Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Fabris', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': 'Department of Infectious Diseases and Tropical Medicine, San Bortolo Hospital, Vicenza, Italy.'}, {'lastname': 'Giordani', 'firstname': 'Maria Teresa', 'initials': 'MT', 'affiliation': 'Department of Infectious Diseases and Tropical Medicine, San Bortolo Hospital, Vicenza, Italy.'}, {'lastname': 'Martines', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Department of Surgical Gastroenterological Science, University of Padua, Padova, Italy.'}, {'lastname': 'Vukicevic', 'firstname': 'Slobodan', 'initials': 'S', 'affiliation': 'Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia.'}, {'lastname': 'Crowe', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin, Ireland.'}, {'lastname': 'Lin', 'firstname': 'Herbert Y', 'initials': 'HY', 'affiliation': 'Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Rehwinkel', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'McHugh', 'firstname': 'Peter J', 'initials': 'PJ', 'affiliation': 'Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.'}, {'lastname': 'Binder', 'firstname': 'Marco', 'initials': 'M', 'affiliation': 'Research Group ""Dynamics of Early Viral Infection and the Innate Antiviral Response"", Division Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'lastname': 'Babitt', 'firstname': 'Jodie L', 'initials': 'JL', 'affiliation': 'Program in Anemia Signaling Research, Nephrology Division, Program in Membrane Biology, and Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Chung', 'firstname': 'Raymond T', 'initials': 'RT', 'affiliation': 'Liver Center, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Lawless', 'firstname': 'Matthew W', 'initials': 'MW', 'affiliation': 'Experimental Medicine, UCD School of Medicine and Medical Science, Mater Misericordiae University Hospital, Dublin, Ireland.'}, {'lastname': 'Armitage', 'firstname': 'Andrew E', 'initials': 'AE', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Webber', 'firstname': 'Caleb', 'initials': 'C', 'affiliation': 'Dementia Research Institute, Cardiff University, Cardiff, UK.\nDepartment of Physiology, Anatomy & Genetics, Oxford University, Oxford, UK.'}, {'lastname': 'Klenerman', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.\nTranslational Gastroenterology Unit, Experimental Medicine Division, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford, UK.\nNIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.'}, {'lastname': 'Drakesmith', 'firstname': 'Hal', 'initials': 'H', 'affiliation': 'MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK. alexander.drakesmith@imm.ox.ac.uk.\nHaematology Theme Oxford Biomedical Research Centre, Oxford, UK. alexander.drakesmith@imm.ox.ac.uk.'}]",,,,,"10.1038/s41564-018-0301-9
10.1152/physrev.00008.2013
10.1126/science.1224577
10.1016/j.cell.2016.12.034
10.1002/hep.23814
10.1189/jlb.0405194
10.1074/jbc.M110.132415
10.1016/j.gene.2017.06.051
10.1002/hep.23733
10.1371/journal.pone.0046307
10.1128/JVI.01844-08
10.1074/jbc.M414305200
10.1074/jbc.M112.349415
10.1182/blood-2011-03-339952
10.1016/j.chom.2011.06.006
10.1016/j.bbrc.2005.02.138
10.1038/nature09907
10.1016/j.cell.2011.09.044
10.1093/nar/gks1172
10.1016/j.bmcl.2008.06.052
10.1038/sj.emboj.7601149
10.1038/nature13801
10.1021/ol900350k
10.1042/BJ20120541
10.1002/hep.25908
10.1016/j.jhep.2014.11.007
10.1074/jbc.M109.000414
10.1182/blood-2012-02-411470
10.1128/IAI.00191-17
10.1002/hep.25954
10.1371/journal.ppat.1003494
10.1371/journal.pone.0046631
10.1128/JVI.02557-15
10.1073/pnas.1114981109
10.1016/j.celrep.2017.10.054
10.1053/j.gastro.2006.08.043
10.1016/j.molcel.2014.11.027",<Element 'PubmedArticle' at 0x7f05dda51590>
236,"30400097
23305823
23167948
26863354
24704273
22701480
24553879
21348917
26138167
19093925
19273752
25147111
23110988
17315079
10993579
28450713
25142458
22213409
22254146
26993509
22013440
18801339
21335656
22859388
25349150
19584347
20875649
20842535
22232009
28421328
25589716
1202204
24986342
20385908
21666429
25866264
27516116
22211890
17937601
18367451
20157255
15713712
24625795
20009056
26906354
25502764
24359504
9249540
21088422
23055000
12882876
12882866
17646605
17951289
26682770
17242917
20727007
27556936
19353221
21528162",Association between Peripheral Leptin and Adiponectin Levels and Cognitive Decline in Patients with Neurocognitive Disorders ≥65 Years.,"There is evidence that adipokines have roles in brain functioning and cognitive decline.
Assess the role of leptin and adiponectin levels in predicting changes in neuro-cognitive disorders (NCD).
The study included 205 patients over 65 years of age presenting for a one-day hospitalization for current assessment of cognitive function. Peripheral blood leptin and adiponectin levels were measured at admission. Demographic variables, body mass index (BMI), and history of hypertension were also recorded. Cognitive function was assessed by the Mini-Mental State Examination (MMSE) at admission and at later scheduled visits over a median follow-up period of 14.5 months. Conventional univariate comparisons were made between diagnosis groups (Alzheimer's disease (AD), mild NCD, vascular/mixed dementia). Changes in MMSE scores over time were examined with regard to the above variables using a linear mixed model.
The mean BMI was significantly lower (by 2 kg/m2, p = 0.01) in patients with AD than in patients with either mild-NCD or vascular/mixed dementia. Leptin levels were significantly higher (p = 0.043) and adiponectin levels significantly lower (p = 0.045) in patients with mild-NCD than in patients with major-NCD (AD or vascular/mixed dementia). However, the mixed model suggested no influence of the baseline levels of these two biomarkers on the course of cognitive decline.
The present study confirms the associations between leptin and adiponectin and AD or AD-related disorders but did not confirm that these peptides may be used as predictive biomarkers of cognitive decline.","['Adiponectin', 'alzheimer’s disease', 'body composition', 'dementia', 'leptin']",Journal of Alzheimer's disease : JAD,2018-11-08,"[{'lastname': 'Gilbert', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Service de Médecine Gériatrique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.\nUniversité Claude Bernard Lyon 1, Lyon, France.\nHealth Services and Performance Research HESPER EA7425, Lyon, France.'}, {'lastname': 'Roche', 'firstname': 'Sylvain', 'initials': 'S', 'affiliation': 'Université Lyon 1, Villeurbanne, France.\nService de Biostatistique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.\nCNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Villeurbanne, France.'}, {'lastname': 'Blond', 'firstname': 'Emilie', 'initials': 'E', 'affiliation': 'Service de Biochimie et de Biologie Moléculaire, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.'}, {'lastname': 'Bar', 'firstname': 'Jean-Yves', 'initials': 'JY', 'affiliation': 'Service de Médecine Gériatrique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.'}, {'lastname': 'Drai', 'firstname': 'Jocelyne', 'initials': 'J', 'affiliation': 'Service de Biochimie et de Biologie Moléculaire, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.\nINSERM U1060. Laboratoire CarMeN cardiovasculaire, métabolisme, diabétologie et nutrition, Pierre-Bénite, France.'}, {'lastname': 'Cuerq', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': 'Service de Biochimie et de Biologie Moléculaire, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.\nINSERM U1060. Laboratoire CarMeN cardiovasculaire, métabolisme, diabétologie et nutrition, Pierre-Bénite, France.'}, {'lastname': 'Haution-Bitker', 'firstname': 'Marine', 'initials': 'M', 'affiliation': 'Service de Médecine Gériatrique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.'}, {'lastname': 'Ecochard', 'firstname': 'René', 'initials': 'R', 'affiliation': 'Université Lyon 1, Villeurbanne, France.\nService de Biostatistique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.\nCNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Villeurbanne, France.'}, {'lastname': 'Bonnefoy', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Service de Médecine Gériatrique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.\nUniversité Claude Bernard Lyon 1, Lyon, France.\nINSERM U1060. Laboratoire CarMeN cardiovasculaire, métabolisme, diabétologie et nutrition, Pierre-Bénite, France.'}]",,The present study confirms the associations between leptin and adiponectin and AD or AD-related disorders but did not confirm that these peptides may be used as predictive biomarkers of cognitive decline.,"The mean BMI was significantly lower (by 2 kg/m2, p = 0.01) in patients with AD than in patients with either mild-NCD or vascular/mixed dementia. Leptin levels were significantly higher (p = 0.043) and adiponectin levels significantly lower (p = 0.045) in patients with mild-NCD than in patients with major-NCD (AD or vascular/mixed dementia). However, the mixed model suggested no influence of the baseline levels of these two biomarkers on the course of cognitive decline.",,10.3233/JAD-180533,<Element 'PubmedArticle' at 0x7f05dd7be450>
237,"30223703
23627757
25352419
21945916
24824997
27733642
24854124
26044748
22535332
24298267
21091655
23416700
23127917
22817481
26802771
27662851
19795377
24052108
29673549
27350397
27663285
27540165
29667931
27038740
26238445
28476949
22129598
29038523
25590749
25209104
25476732
8877817
25455861
21719467
23055539",Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion.,"This study aimed to evaluate the influence of central angiotensin IV (Ang IV) infusion on chronic cerebral hypoperfusion (CCH)-related neuropathological changes including amyloid-β (Aβ), hyperphosphorylated tau (p-tau) and the inflammatory response.
Rats with CCH received central infusion of Ang IV, its receptor AT
Rats with CCH exhibited higher levels of Aβ
This study demonstrates for the first time that Ang IV dose-dependently suppresses inflammation through AT","['Alzheimer’s disease', 'Angiotensin IV', 'chronic cerebral hypoperfusion', 'inflammation', 'vascular dementia']",Journal of the renin-angiotensin-aldosterone system : JRAAS,2018-09-19,"[{'lastname': 'Wang', 'firstname': 'Qing-Guang', 'initials': 'QG', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.\n2 Department of Neurology, Jiangyin People's Hospital, Nanjing Medical University, People's Republic of China.""}, {'lastname': 'Xue', 'firstname': 'Xiao', 'initials': 'X', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.""}, {'lastname': 'Yang', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.""}, {'lastname': 'Gong', 'firstname': 'Peng-Yu', 'initials': 'PY', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.""}, {'lastname': 'Jiang', 'firstname': 'Teng', 'initials': 'T', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Ying-Dong', 'initials': 'YD', 'affiliation': ""1 Department of Neurology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.""}]",,This study demonstrates for the first time that Ang IV dose-dependently suppresses inflammation through AT,Rats with CCH exhibited higher levels of Aβ,,10.1177/1470320318799587,<Element 'PubmedArticle' at 0x7f05dd5e7720>
238,"30186862
17098089
11110887
17498508
24003936
8381211
17575559
21114598
16490580
15634008
30764059
17001471
25991443
27166859
10858586
28565810
17293054
17905482
17982277
14597556
17318230
16157451
19688332
18586243
20561356
25071777
17183360
11059791
22745245
17693552
20552234
29032011
25721294
25229125
23386232
23062489
9209268
29196460
15762998
27179961
26197403
24528486
28237860
28065853
16876913
8993688
11796747
10486579
15857702
10893301
10419857
25613502
15883033
28261618
28984748
24795568
21471435
20005285
22143872
22245388
23603201
22427376
23086037
21478880
27156888
26119563
19477245
29132916
26968463
9061036
19778613
29080524
23867771
16211247
17255335
8782901
9176408
28943197
25142458
24704273
28404516
19144836
20706689
24043885
20566663
27085899
20652060
28056430
25580570
25034511",Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease.,Sitagliptin is a member of a class of drugs that inhibit dipeptidyl peptidase (DPP-4). It increases the levels of the active form of incretins such as GLP-1 (glucagon-like peptide-1) or GIP (gastric inhibitory polypeptide) and by their means positively affects glucose metabolism. It is successfully applied in the treatment of diabetes mellitus type 2. The most recent scientific reports suggest beneficial effect of sitagliptin on diseases in which neuron damage occurs. Result of experimental studies may indicate a reducing influence of sitagliptin on inflammatory response within encephalon area. Sitagliptin decreased the levels of proinflammatory factors: TNF-,[],BioMed research international,2018-09-07,"[{'lastname': 'Wiciński', 'firstname': 'Michał', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}, {'lastname': 'Wódkiewicz', 'firstname': 'Eryk', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}, {'lastname': 'Słupski', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': 'Department of Hepatobiliary and General Surgery, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}, {'lastname': 'Walczak', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}, {'lastname': 'Socha', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': 'Department of Obstetrics, Gynecology and Gynecological Oncology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Ujejskiego 75, 85-168 Bydgoszcz, Poland.'}, {'lastname': 'Malinowski', 'firstname': 'Bartosz', 'initials': 'B', 'affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}, {'lastname': 'Pawlak-Osińska', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': 'Department of Pathophysiology of Hearing and Balance System, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland.'}]",,,,,"10.1155/2018/6091014
10.1016/S0140-6736(06)69705-5
10.1093/jn/130.12.3127S
10.1053/j.gastro.2007.03.054
10.1111/dom.12165
10.1038/361362a0
10.1002/bdd.560
10.1111/j.1463-1326.2010.01306.x
10.1016/j.clinthera.2006.01.015
10.1586/17446651.3.6.691
10.1007/s00125-006-0416-z
10.1038/nrn3880
10.1016/j.pneurobio.2016.05.001
10.1016/S0197-4580(00)00124-X
10.3892/etm.2017.4180
10.1016/j.neuroscience.2007.01.004
10.1016/j.neurobiolaging.2007.08.018
10.1159/000110455
10.1038/nri2038
10.1016/j.neulet.2005.08.047
10.1016/j.expneurol.2008.05.014
10.1111/j.1365-2567.2009.03225.x
10.3389/fimmu.2014.00316
10.1038/nrm2083
10.1023/a:1007627725251
10.1210/jc.2012-1544
10.1073/pnas.0702553104
10.1007/s00702-010-0433-4
10.1016/j.neuint.2017.10.006
10.1016/j.lfs.2015.01.030
10.1016/j.regpep.2014.09.006
10.1253/circj.CJ-12-1168
10.1016/j.metabol.2012.09.004
10.1016/S0165-5728(97)00054-4
10.1186/1742-2094-2-9
10.1016/j.jalz.2016.02.010
10.1016/j.ijcard.2015.07.044
10.1016/j.diabres.2017.02.010
10.1016/j.ejps.2016.12.040
10.1016/j.neurobiolaging.2006.06.021
10.1046/j.0022-3042.2001.00681.x
10.1016/s0014-5793(99)01028-5
10.1016/j.neuroscience.2005.01.053
10.1021/jm000007r
10.1016/S1367-5931(99)80065-9
10.2174/1871527314666150116113647
10.1016/j.bbrc.2005.04.057
10.1155/2017/9202954
10.1016/j.exger.2009.12.004
10.1007/s00221-011-2968-5
10.1016/j.nbd.2011.12.043
10.1016/j.neuropharm.2013.04.008
10.2337/db11-1186
10.2337/db12-0420
10.1038/ni.2022
10.1016/j.bbadis.2016.04.017
10.1016/j.brainresbull.2009.05.017
10.1016/j.bbagen.2016.03.010
10.1016/S0925-4439(96)00062-2
10.1016/j.nbd.2009.09.008
10.1016/j.redox.2017.10.014
10.1016/j.neuroscience.2013.07.009
10.2353/ajpath.2007.060378
10.1016/0006-8993(96)00156-4
10.1016/j.jalz.2017.06.2637
10.1016/s1474-4422(14)70085-7
10.1016/j.euroneuro.2014.03.002
10.1016/j.dsx.2017.03.032
10.1523/JNEUROSCI.2760-08.2009
10.1155/2010/289645
10.4049/jimmunol.1300298
10.2337/db09-0138
10.1016/j.ejphar.2016.04.024
10.1155/2010/592760
10.1016/j.diabres.2016.12.010
10.1111/dom.12432
10.1159/000362917",<Element 'PubmedArticle' at 0x7f05dd5feea0>
239,30045957,Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France.,"To identify, among the available data concerning host characteristics and exposure, risk factors influencing the susceptibility for developing iatrogenic Creutzfeldt-Jakob disease (iCJD) in a cohort of patients treated with human cadaver-sourced growth hormone (hGH) in France.
This study included all 1,443 individuals treated in France with hGH from January 1982 to December 1985, out of which 119 cases of hGH-iCJD have been identified so far. We applied a 3 sequential step Cox analysis involving univariable, stepwise, and nonstepwise multivariable procedures. The variables studied were sex, age at hGH treatment initiation, and treatment characteristics (batches and doses).
While no effect of age at treatment initiation was observed, a significant effect of sex on disease susceptibility was unexpectedly evidenced with a 2-fold increase of disease occurrence in male patients. This effect did not depend on differences of exposure between male and female patients. We identified 4 categories of hormone batches from high risk to no association with susceptibility. A relationship between the dose received from at-risk hormone batches and the attack rate (number of patients developing the disease among exposed individuals) was demonstrated.
Studying the hGH-exposed patients in France provides epidemiologic evidence of a relationship between dose of inoculum and disease occurrence in humans and suggests an unexpected effect of sex on individual susceptibility.",[],Neurology,2018-07-27,"[{'lastname': 'Peckeu', 'firstname': 'Laurène', 'initials': 'L', 'affiliation': ""From INSERM U1127 (L.P., J.-P.B., A.W., S.H.), CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, Sorbonne Universités; AP-HP (J.-P.B., A.W., S.H.), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière; INSERM (D.C.), Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Universités; and AP-HP (S.H.), Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Brandel', 'firstname': 'Jean-Philippe', 'initials': 'JP', 'affiliation': ""From INSERM U1127 (L.P., J.-P.B., A.W., S.H.), CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, Sorbonne Universités; AP-HP (J.-P.B., A.W., S.H.), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière; INSERM (D.C.), Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Universités; and AP-HP (S.H.), Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Welaratne', 'firstname': 'Arlette', 'initials': 'A', 'affiliation': ""From INSERM U1127 (L.P., J.-P.B., A.W., S.H.), CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, Sorbonne Universités; AP-HP (J.-P.B., A.W., S.H.), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière; INSERM (D.C.), Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Universités; and AP-HP (S.H.), Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Costagliola', 'firstname': 'Dominique', 'initials': 'D', 'affiliation': ""From INSERM U1127 (L.P., J.-P.B., A.W., S.H.), CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, Sorbonne Universités; AP-HP (J.-P.B., A.W., S.H.), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière; INSERM (D.C.), Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Universités; and AP-HP (S.H.), Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, Paris, France.""}, {'lastname': 'Haïk', 'firstname': 'Stéphane', 'initials': 'S', 'affiliation': ""From INSERM U1127 (L.P., J.-P.B., A.W., S.H.), CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, Sorbonne Universités; AP-HP (J.-P.B., A.W., S.H.), Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Groupe Hospitalier Pitié-Salpêtrière; INSERM (D.C.), Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Sorbonne Universités; and AP-HP (S.H.), Laboratoire de Neuropathologie R Escourolle, Hôpital de la Pitié-Salpêtrière, Paris, France. stephane.haik@upmc.fr.""}]",,,"While no effect of age at treatment initiation was observed, a significant effect of sex on disease susceptibility was unexpectedly evidenced with a 2-fold increase of disease occurrence in male patients. This effect did not depend on differences of exposure between male and female patients. We identified 4 categories of hormone batches from high risk to no association with susceptibility. A relationship between the dose received from at-risk hormone batches and the attack rate (number of patients developing the disease among exposed individuals) was demonstrated.",© 2018 American Academy of Neurology.,10.1212/WNL.0000000000006028,<Element 'PubmedArticle' at 0x7f05dd57b7c0>
240,29975000,Effect of particulate matter 2.5 on gene expression profile and cell signaling in JEG-3 human placenta cells.,"Particulate matter the environmental toxicant, with a diameter less than or equal to 2.5 μm (PM","['cytokine', 'female reproductive disorder', 'mitogen-activated protein kinase', 'particulate matter 2.5', 'steroid hormone synthesis']",Environmental toxicology,2018-07-06,"[{'lastname': 'Kim', 'firstname': 'Woong', 'initials': 'W', 'affiliation': 'Center for Environment, Health and Welfare Research, Cellular and Molecular Toxicology Laboratory, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.\nDepartment of Life Science, College of Natural Sciences, Hangyang University, Seoul, South Korea.'}, {'lastname': 'Cho', 'firstname': 'Yoon', 'initials': 'Y', 'affiliation': 'Center for Environment, Health and Welfare Research, Cellular and Molecular Toxicology Laboratory, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.'}, {'lastname': 'Song', 'firstname': 'Mi-Kyung', 'initials': 'MK', 'affiliation': 'National Center for Efficacy evaluation for Respiratory disease product, Jeonbuk Department of Inhalation Research, Korea Institute of Toxicology, Jeongeup, Jeollabuk-do, Republic of Korea.'}, {'lastname': 'Lim', 'firstname': 'Jung-Hee', 'initials': 'JH', 'affiliation': 'Center for Environment, Health and Welfare Research, Cellular and Molecular Toxicology Laboratory, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Jin Young', 'initials': 'JY', 'affiliation': 'Fuel Cell Research Center, Korea Institute of Science and Technology, Seongbuk-gu, Seoul, Republic of Korea.'}, {'lastname': 'Gye', 'firstname': 'Myung Chan', 'initials': 'MC', 'affiliation': 'Department of Life Science, College of Natural Sciences, Hangyang University, Seoul, South Korea.'}, {'lastname': 'Ryu', 'firstname': 'Jae-Chun', 'initials': 'JC', 'affiliation': 'Center for Environment, Health and Welfare Research, Cellular and Molecular Toxicology Laboratory, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.\nDepartment of Pharmacology and Toxicology, Human and Environmental Toxicology, Korea University of Science and Technology, Daejeon, Republic of Korea.'}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/tox.22591,<Element 'PubmedArticle' at 0x7f05dd587630>
241,29909178,The effect of APOE genotype on Alzheimer's disease risk is influenced by sex and docosahexaenoic acid status.,"An apolipoprotein E ε4 (APOE-ε4) genotype is the strongest common genetic determinant of Alzheimer's disease (AD). The pleiotropic nature of apolipoprotein E has made elucidation of the aetiological basis difficult to establish, which is further complicated by the fact that the penetrance of the APOE-ε4 allele is modulated by sex, age, and nutrition. A greater metabolic consequence of the APOE-ε4 allele is likely to contribute to the fact that two-thirds of AD patients are female. A higher tissue status of the marine n-3 fatty acid docosahexaenoic acid (DHA) is associated with a lower AD risk. However, APOE-ε4 carriers appear less sensitive to the neurocognitive benefits, which may be due to defective blood-brain barrier transport of DHA exacerbated by aging and possibly sex. This suggests higher DHA requirements in this large population subgroup. This narrative review will consider the influence of sex and DHA in modulating APOE-ε4-mediated AD risk.","['Apolipoprotein E', 'Blood-brain barrier', 'Docosahexaenoic acid', 'Lipid metabolism', 'Lipid transport', 'Polyunsaturated fatty acids']",Neurobiology of aging,2018-06-18,"[{'lastname': 'Pontifex', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: m.pontifex@uea.ac.uk.'}, {'lastname': 'Vauzour', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'lastname': 'Minihane', 'firstname': 'Anne-Marie', 'initials': 'AM', 'affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}]",,,,Crown Copyright © 2018. Published by Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2018.05.017,<Element 'PubmedArticle' at 0x7f05dd593b80>
242,29895246,Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.,"This review has two aims. First, to examine whether or not sex and gender may influence the brain cholinergic system in animals and in humans. Second, to examine the available evidence of sexually dimorphic response to the therapeutic and toxic effects of cholinesterase inhibitors. Animal research reveals no marked difference in the general morphology of the brain cholinergic system but subtle functional gender differences have been reported. In humans, gender differences in nucleus basalis of Meynert (NBM) exist. In animals, some cholinergic neurons express estrogen alpha receptors in females and androgens in males. It is known that sex hormones exert trophic effects on the cholinergic system. Females show higher frontal cortex cholinergic activity whereas males have higher activity in the hippocampus. Gender differences in the pharmacological effects result in higher sensitivity to the toxic effects of organophosphate cholinesterase inhibitors in males. A stronger and more selective benefit of ChEI treatment in AD has been reported in men by several authors. Sex and estrogen receptor phenotype may both influence the response to donepezil and rivastigmine. Hence, aged male and female individuals might respond differently to ChEI due to either sex-specific differences in structures and function of the cholinergic system, pharmacokinetics, memory function or in the way aging or AD affects these processes.","['Acetylcholine', 'aging', 'cholinesterase inhibitors', 'estrogens', 'nerve growth factor', 'nucleus basalis magnocellularis', 'organophosphates.']",Current Alzheimer research,2018-06-14,"[{'lastname': 'Giacobini', 'firstname': 'Ezio', 'initials': 'E', 'affiliation': 'Department of Internal Medicine, Geriatrics and Rehabilitation, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Pepeu', 'firstname': 'Giancarlo', 'initials': 'G', 'affiliation': 'Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",10.2174/1567205015666180613111504,<Element 'PubmedArticle' at 0x7f05dd5a0540>
243,29689315,Stress as risk factor for Alzheimer's disease.,"Prolonged stress predisposes susceptible individuals to a number of physiological disorders including cardiovascular disease, obesity and gastrointestinal disorders, as well as psychiatric and neurodegenerative disorders. Preclinical studies have suggested that manipulation of the glucocorticoid milieu can trigger cellular, molecular and behavioral derangement resembling the hallmarks of Alzheimer's Disease (AD). For example, stress or glucocorticoid administration can increase amyloid ß precursor protein and tau phosphorylation which are involved in synaptic dysfunction and neuronal death associated with AD. Although since AD was first described in 1906 at a conference in Tubingen, Germany by Alois Alzheimer our knowledge of neuropathological and neurochemical alterations of AD has been impressively increased, at present, pharmacotherapy is symptomatic at best and has no influence on the progression of the disorder. It is generally believed that most of the drugs developed as disease modifiers have failed in clinical trials because treatment started too late, i.e., after the clinical onset of AD. Because AD pathology begins several years prior to the clinical diagnosis, it is imperative to identify subjects at high risk to develop the disorder. Consequently, the search for putative risk factors has gained importance. ApoE4, diabetes/metabolic syndrome, cardiovascular disorders, and a low cognitive reserve are established risk factors for AD. The focus of this review is on stress and glucocorticoids as potential factors increasing the risk to develop AD.","['Alzheimer’s disease', 'Animal model', 'Glucocorticoids', 'Risk factor', 'Stress']",Pharmacological research,2018-04-25,"[{'lastname': 'Caruso', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza Università di Roma, Italy.'}, {'lastname': 'Nicoletti', 'firstname': 'Ferdinando', 'initials': 'F', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza Università di Roma, Italy; I.R.C.C.S. Neuromed, Pozzilli, Italy.'}, {'lastname': 'Mango', 'firstname': 'Dalila', 'initials': 'D', 'affiliation': 'Pharmacology of Synaptic Disease Lab, European Brain Research Institute, Italy.'}, {'lastname': 'Saidi', 'firstname': 'Amira', 'initials': 'A', 'affiliation': 'Pharmacology of Synaptic Disease Lab, European Brain Research Institute, Italy.'}, {'lastname': 'Orlando', 'firstname': 'Rosamaria', 'initials': 'R', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza Università di Roma, Italy.'}, {'lastname': 'Scaccianoce', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza Università di Roma, Italy. Electronic address: sergio.scaccianoce@uniroma1.it.'}]",,,,Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.phrs.2018.04.017,<Element 'PubmedArticle' at 0x7f05dd069220>
244,"29681765
19387106
15477536
15094078
28500217
24380887
23850509
19273747
6345584
1952826
26175217
24475194
1378843
19292913
27325408
18657529
11754999
26295040
11581294
24634591
12488575
22998137
22687952
18603587
12495433
14767995
27522371
23964833
16286548
28811295
18506386
27323891
21537426
26683643
19346482
23794448
25802195
25750761
22500019
26136651
16926247
16969649
15677489
20672051
22145907
19674846
11578776
9137895
20105309
24723555
6401741
6340793
16740441
2986724",Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer's Disease.,"Although there is evidence for metabolic dysfunction and chronic inflammation in Alzheimer's disease (AD), circulating levels of soluble receptor for advanced glycation end products (sRAGE) and the receptor for advanced glycation end products (RAGE) ligand S100B have not been characterized. sRAGE is an important mediator in disease as it can act as a ligand decoy for RAGE and attenuate downstream inflammatory signaling. Cognitively healthy elderly and AD participants with and without type 2 diabetes (",[],Mediators of inflammation,2018-04-24,"[{'lastname': 'Fuller', 'firstname': 'Kelly N Z', 'initials': 'KNZ', 'affiliation': 'Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.'}, {'lastname': 'Miranda', 'firstname': 'Edwin R', 'initials': 'ER', 'affiliation': 'Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.'}, {'lastname': 'Thyfault', 'firstname': 'John P', 'initials': 'JP', 'affiliation': 'Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'lastname': 'Morris', 'firstname': 'Jill K', 'initials': 'JK', 'affiliation': 'Department of Neurology, University of Kansas Medical Center, Fairway, KS, USA.'}, {'lastname': 'Haus', 'firstname': 'Jacob M', 'initials': 'JM', 'affiliation': 'Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.'}]",,,,,"10.1155/2018/2061376
10.3233/JAD-2009-1022
10.1212/01.WNL.0000140292.04932.87
10.1016/j.ejphar.2004.02.049
10.2337/dc16-2203
10.1016/j.bcp.2013.12.012
10.1016/j.pneurobio.2013.06.004
10.1001/archneurol.2009.27
10.1172/JCI110908
10.1002/ana.410300310
10.1007/s10571-015-0233-3
10.1371/journal.pone.0086903
10.1186/1479-5876-7-17
10.1007/s10719-016-9690-2
10.1016/j.brainres.2008.06.124
10.1016/S0197-4580(01)00293-7
10.1155/2015/508342
10.1172/JCI200114002
10.4196/kjpp.2014.18.1.1
10.1155/S1110724302203010
10.2174/1871527311201070926
10.1016/j.neuroscience.2012.05.050
10.1096/fj.08-109033
10.1042/bj20021371
10.1002/hep.20045
10.1007/s00394-016-1291-0
10.1186/1472-6823-13-32
10.1001/archneur.62.11.1734
10.1152/ajpendo.00146.2017
10.1007/s00702-008-0069-9
10.1080/00207454.2016.1193861
10.4239/wjd.v1.i2.36
10.1212/WNL.0000000000002287
10.1073/pnas.0900345106
10.1002/ana.23956
10.1016/j.cyto.2015.02.022
10.4172/2155-6156.1000458
10.1074/jbc.M111.331181
10.3389/fnins.2015.00216
10.1210/jc.2005-2559
10.1007/s00125-006-0394-1
10.2337/diabetes.54.2.333
10.1155/2010/539581
10.1111/j.1471-4159.2011.07612.x
10.1016/j.psyneuen.2009.07.012
10.1016/S0197-0186(01)00048-1
10.1159/000106627
10.1186/1742-2094-7-6
10.1161/ATVBAHA.113.302281
10.1016/0006-8993(83)91032-6
10.1016/j.arcmed.2005.11.005
10.1016/0167-4889(85)90193-4",<Element 'PubmedArticle' at 0x7f05dd072590>
245,29628040,[Patterns of brain ageing].,"Neuroplasticity lends the brain a strong ability to adapt to changes in the environment that occur during ageing. Animal models have shown alterations in neurotransmission and imbalances in the expression of neural growth factor. Changes at the morphometric level are not constant. Volume loss is related to alterations in neuroplasticity and involvement of the cerebral neuropil. Although there are no conclusive data, physical exercise improves the molecular, biological, functional and behavioural-cognitive changes associated with brain ageing. The aged human brain has been described as showing weight and volume loss and increased ventricular size. However, neuroimaging shows significant variation and many healthy elderly individuals show no significant macroscopic changes. In most brain regions, the number of neurons remains stable throughout life. Neuroplasticity does not disappear with ageing, and changes in dendritic arborization and the density of spines and synapses are more closely related to brain activity than to age. At the molecular level, although the presence of altered Tau and β-amyloid proteins is used as a biomarker of neurodegenerative disease, postmortem studies show that these abnormal proteins are common in the brains of elderly people without dementia. Finally, due to the relationship between neurodegenerative diseases and metabolic alterations, this article analyses the influence of insulin-like growth factor and ageing, both in animal models and in humans, and the possible neuroprotective effect of insulin.","['Ageing', 'Animal models', 'Brain', 'Cerebro', 'Envejecimiento', 'Insulin', 'Insulina', 'Modelos animales', 'Neuroplasticidad', 'Neuroplasticity', 'Neurotransmisores', 'Neurotransmitters']",Revista espanola de geriatria y gerontologia,2018-04-10,"[{'lastname': 'Fernández Viadero', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Servicio de Psiquiatría, Hospital Universitario Marqués de Valdecilla, Servicio Cántabro de Salud, Santander, España; Biogerontología, Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, España. Electronic address: cfdezviadero@ono.com.'}, {'lastname': 'Verduga Vélez', 'firstname': 'Rosario', 'initials': 'R', 'affiliation': 'Áreas de Psicobiología y Educación para la Salud, UNED, Cantabria, España.'}, {'lastname': 'Crespo Santiago', 'firstname': 'Dámaso', 'initials': 'D', 'affiliation': 'Biogerontología, Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Santander, España.'}]",,,,"Copyright © 2017 Sociedad Española de Geriatría y Gerontología. Publicado por Elsevier España, S.L.U. All rights reserved.",10.1016/S0211-139X(18)30073-8,<Element 'PubmedArticle' at 0x7f05dd097450>
246,29580826,Protein aggregates and proteostasis in aging: Amylin and β-cell function.,"The ubiquitin-proteasomal-system (UPS) and the autophagy-lysosomal-system (ALS) are both highly susceptible for disturbances leading to the accumulation of cellular damage. A decline of protein degradation during aging results in the formation of oxidatively damaged and aggregated proteins finally resulting in failure of cellular functionality. Besides protein aggregation in response to oxidative damage, amyloids are a different type of protein aggregates able to distract proteostasis and interfere with cellular functionality. Amyloids are clearly linked to the pathogenesis of age-related degenerative diseases such as Alzheimer's disease. Human amylin is one of the peptides forming fibrils in β-sheet conformation finally leading to amyloid formation. In contrast to rodent amylin, human amylin is prone to form amyloidogenic aggregates, proposed to play a role in the pathogenesis of Type 2 Diabetes by impairing β-cell functionality. Since aggregates such as lipofuscin and β-amyloid are known to impair proteostasis, it is likely to assume similar effects for human amylin. In this review, we focus on the effects of IAPP on UPS and ALS and their role in amylin degradation, since both systems play a crucial role in maintaining proteome balance thereby influencing, at least in part, cellular fate and aging.","['Aging', 'Autophagy', 'Human amylin', 'Proteasome', 'Protein aggregates', 'Proteostasis']",Mechanisms of ageing and development,2018-03-28,"[{'lastname': 'Press', 'firstname': 'Michaela', 'initials': 'M', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany; German Center for Diabetes Research (DZD), 85764 Muenchen-Neuherberg, Germany. Electronic address: michaela.press@dife.de.'}, {'lastname': 'Jung', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany; German Center for Cardiovascular Research (DZHK), 10117 Berlin, Germany. Electronic address: tobias.jung@dife.de.'}, {'lastname': 'König', 'firstname': 'Jeannette', 'initials': 'J', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany. Electronic address: jeannette.könig@dife.de.'}, {'lastname': 'Grune', 'firstname': 'Tilman', 'initials': 'T', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany; German Center for Diabetes Research (DZD), 85764 Muenchen-Neuherberg, Germany; German Center for Cardiovascular Research (DZHK), 10117 Berlin, Germany; NutriAct - Competence Cluster Nutrition Research Berlin-Potsdam, 14558 Nuthetal, Germany; Institute of Nutrition, University of Potsdam, 14558 Nuthetal, Germany. Electronic address: tilman.grune@dife.de.'}, {'lastname': 'Höhn', 'firstname': 'Annika', 'initials': 'A', 'affiliation': 'Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), 14558 Nuthetal, Germany; German Center for Diabetes Research (DZD), 85764 Muenchen-Neuherberg, Germany. Electronic address: annika.hoehn@dife.de.'}]",,,,Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.mad.2018.03.010,<Element 'PubmedArticle' at 0x7f05dd0a0400>
247,"29505099
9990854
24623176
16877355
15993515
21508957
22201929
1759558
21255744
11238065
22927427
11279122
24211352
21113149
17659878
29169609
23982319
23639788
23126652
15213207
9343467
21079415
24211851
26035291
11099831
10655508
26041910
21948247
27327541
27312772
18486110
22913619
23217709
20046096
20087369
10513583
12507964
11741394
28692878
10987824
26451386
12944500
24470773
8427562
7706247
27866325
11689174
27870425
19427328
18304749
23939249
9724804
14622134
22282647
17182789
15383512
9556608
19931595
27692800
22972991
23507120
28802038
14678749
21186265
18346198
28890695
27143423",Higher levels of kallikrein-8 in female brain may increase the risk for Alzheimer's disease.,"Women seem to have a higher vulnerability to Alzheimer's disease (AD), but the underlying mechanisms of this sex dichotomy are not well understood. Here, we first determined the influence of sex on various aspects of Alzheimer's pathology in transgenic CRND8 mice. We demonstrate that beta-amyloid (Aβ) plaque burden starts to be more severe around P180 (moderate disease stage) in female transgenics when compared to males and that aging aggravates this sex-specific difference. Furthermore, we show that female transgenics suffer from higher levels of neurovascular dysfunction around P180, resulting in impaired Aβ peptide clearance across the blood-brain-barrier at P360. Female transgenics show also higher levels of diffuse microgliosis and inflammation, but the density of microglial cells surrounding Aβ plaques is less in females. In line with this finding, testosterone compared to estradiol was able to improve microglial viability and Aβ clearance in vitro. The spatial memory of transgenics was in general poorer than in wildtypes and at P360 worse in females irrespective of their genotype. This difference was accompanied by a slightly diminished dendritic complexity in females. While all the above-named sex-differences emerged after the onset of Aβ pathology, kallikrein-8 (KLK8) protease levels were, as an exception, higher in female than in male brains very early when virtually no plaques were detectable. In a second step, we quantified cerebral KLK8 levels in AD patients and healthy controls, and could ascertain, similar to mice, higher KLK8 levels not only in AD-affected but also in healthy brains of women. Accordingly, we could demonstrate that estradiol but not testosterone induces KLK8 synthesis in neuronal and microglial cells. In conclusion, multiple features of AD are more pronounced in females. Here, we show for the first time that this sex-specific difference may be meditated by estrogen-induced KLK8 overproduction long before AD pathology emerges.","[""Alzheimer's disease"", 'Aβ metabolism', 'kallikrein-8', 'microglial phagocytosis', 'neuroinflammation', 'neuroplasticity', 'neuropsin', 'neurovascular dysfunction', 'sex hormones', 'sex-specific differences', 'tau pathology and autophagy']","Brain pathology (Zurich, Switzerland)",2018-03-06,"[{'lastname': 'Keyvani', 'firstname': 'Kathy', 'initials': 'K', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Münster', 'firstname': 'Yvonne', 'initials': 'Y', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Kurapati', 'firstname': 'Nirup K', 'initials': 'NK', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Rubach', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Schönborn', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Kocakavuk', 'firstname': 'Emre', 'initials': 'E', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Karout', 'firstname': 'Mohamed', 'initials': 'M', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Hammesfahr', 'firstname': 'Pia', 'initials': 'P', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Wang', 'firstname': 'Ya-Chao', 'initials': 'YC', 'affiliation': 'Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Hermann', 'firstname': 'Dirk M', 'initials': 'DM', 'affiliation': 'Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Teuber-Hanselmann', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}, {'lastname': 'Herring', 'firstname': 'Arne', 'initials': 'A', 'affiliation': 'Institute of Neuropathology, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany.'}]",,,,© 2018 International Society of Neuropathology.,"10.1111/bpa.12599
10.1038/nprot.2007.390",<Element 'PubmedArticle' at 0x7f05dcdeac20>
248,"29489847
26109339
10101041
15963061
18947934
21185655
22647576
12724456
24508665
24802975
16390773
24898656
12510204
17116223
8030628
11255424
17659078
27154633
22389633
22626851
12648969
3515380
9147167
18657855
25672767
18577205
20473137
12111919
16371514
15671702
25277502
15126510
26994961
25935728
23715379","Reproductive period, endogenous estrogen exposure and dementia incidence among women in Latin America and China; A 10/66 population-based cohort study.","Exposure to endogenous estrogen may protect against dementia, but evidence remains equivocal. Such effects may be assessed more precisely in settings where exogenous estrogen administration is rare. We aimed to determine whether reproductive period (menarche to menopause), and other indicators of endogenous estrogen exposure are inversely associated with dementia incidence.
Population-based cohort studies of women aged 65 years and over in urban sites in Cuba, Dominican Republic, Puerto Rico and Venezuela, and rural and urban sites in Peru, Mexico and China. Sociodemographic and risk factor questionnaires were administered to all participants, including ages at menarche, birth of first child, and menopause, and parity, with ascertainment of incident 10/66 dementia, and mortality, three to five years later.
9,428 women participated at baseline, with 72-98% responding by site. The 'at risk' cohort comprised 8,466 dementia-free women. Mean age varied from 72.0 to 75.4 years, lower in rural than urban sites and in China than in Latin America. Mean parity was 4.1 (2.4-7.2 by site), generally higher in rural than urban sites. 6,854 women with baseline reproductive period data were followed up for 26,463 person years. There were 692 cases of incident dementia, and 895 dementia free deaths. Pooled meta-analysed fixed effects, per year, for reproductive period (Adjusted Sub-Hazard Ratio [ASHR] 1.001, 95% CI 0.988-1.015) did not support any association with dementia incidence, with no evidence for effect modification by APOE genotype. No association was observed between incident dementia and; ages at menarche, birth of first child, and menopause: nulliparity; or index of cumulative endogenous estrogen exposure. Greater parity was positively associated with incident dementia (ASHR 1.030, 95% CI 1.002-1.059, I2 = 0.0%).
We found no evidence to support the theory that natural variation in cumulative exposure to endogenous oestrogens across the reproductive period influences dementia incidence in late life.",[],PloS one,2018-03-01,"[{'lastname': 'Prince', 'firstname': 'Martin J', 'initials': 'MJ', 'affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.""}, {'lastname': 'Acosta', 'firstname': 'Daisy', 'initials': 'D', 'affiliation': 'Internal Medicine Department, Geriatric Section, Universidad Nacional Pedro Henriquez Ureña (UNPHU), Santo Domingo, Dominican Republic.'}, {'lastname': 'Guerra', 'firstname': 'Mariella', 'initials': 'M', 'affiliation': 'Instituto de la Memoria y Desordenes Relacionados, Lima, Perú.'}, {'lastname': 'Huang', 'firstname': 'Yueqin', 'initials': 'Y', 'affiliation': 'Peking University, Institute of Mental Health, Beijing, China.'}, {'lastname': 'Jimenez-Velazquez', 'firstname': 'Ivonne Z', 'initials': 'IZ', 'affiliation': 'Internal Medicine Dept, School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.'}, {'lastname': 'Llibre Rodriguez', 'firstname': 'Juan J', 'initials': 'JJ', 'affiliation': 'Facultad de Medicina Finley-Albarran, Medical University of Havana, Havana, Cuba.'}, {'lastname': 'Salas', 'firstname': 'Aquiles', 'initials': 'A', 'affiliation': 'Medicine Department, Caracas University Hospital, Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela.'}, {'lastname': 'Sosa', 'firstname': 'Ana Luisa', 'initials': 'AL', 'affiliation': 'The Cognition and Behavior Unit, National Institute of Neurology and Neurosurgery of Mexico and Autonomous National University of Mexico, Mexico City, Mexico.'}, {'lastname': 'Chua', 'firstname': 'Kia-Chong', 'initials': 'KC', 'affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.""}, {'lastname': 'Dewey', 'firstname': 'Michael E', 'initials': 'ME', 'affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.""}, {'lastname': 'Liu', 'firstname': 'Zhaorui', 'initials': 'Z', 'affiliation': 'Internal Medicine Dept, School of Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.'}, {'lastname': 'Mayston', 'firstname': 'Rosie', 'initials': 'R', 'affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.""}, {'lastname': 'Valhuerdi', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': 'Medical University of Matanzas, Matanzas, Cuba.'}]",,,"9,428 women participated at baseline, with 72-98% responding by site. The 'at risk' cohort comprised 8,466 dementia-free women. Mean age varied from 72.0 to 75.4 years, lower in rural than urban sites and in China than in Latin America. Mean parity was 4.1 (2.4-7.2 by site), generally higher in rural than urban sites. 6,854 women with baseline reproductive period data were followed up for 26,463 person years. There were 692 cases of incident dementia, and 895 dementia free deaths. Pooled meta-analysed fixed effects, per year, for reproductive period (Adjusted Sub-Hazard Ratio [ASHR] 1.001, 95% CI 0.988-1.015) did not support any association with dementia incidence, with no evidence for effect modification by APOE genotype. No association was observed between incident dementia and; ages at menarche, birth of first child, and menopause: nulliparity; or index of cumulative endogenous estrogen exposure. Greater parity was positively associated with incident dementia (ASHR 1.030, 95% CI 1.002-1.059, I2 = 0.0%).",,"10.1371/journal.pone.0192889
10.1152/physrev.00036.2014
10.1006/brcg.1999.1078
10.1016/j.psyneuen.2008.09.008
10.1016/j.psyneuen.2010.11.009
10.1016/j.bandc.2012.05.001
10.1176/jnp.15.2.161
10.1016/j.mce.2014.01.020
10.1111/1471-0528.12828
10.1080/13697130500345240
10.3233/JAD-140336
10.1007/s00737-002-0142-6
10.1111/j.1468-1331.2006.01520.x
10.1186/1471-2458-7-165
10.1093/ije/dyw056
10.1371/journal.pmed.1001179
10.1016/S0140-6736(12)60399-7
10.1016/S0140-6736(08)61002-8
10.3233/JAD-142769
10.1186/1471-2458-8-219
10.1002/sim.1186
10.1093/aje/kwj048
10.1159/000365172
10.1210/jc.2003-031372
10.1016/j.socscimed.2016.02.043
10.1097/GME.0b013e3182960cf8",<Element 'PubmedArticle' at 0x7f05dce18400>
249,"29432613
19661621
22334060
25115539
9855465
15642856
12534843
10522949
19468818
25655764
17693256
24074871
26406918
15557525
17101887
25253756
17035694
16209420
16227534
12061405
20921133
27515675
18395508
15106011
9603945
15094456
15138623
11713196
16413220
9242610
9082980
12655302
16936710
26675645
19294332
16125364
16060827
24459411
23389618
10967351
24549157
23395445
7617154
26825924
10508135
5054463
11694245
19362543","Circulating Dkk1 and TRAIL Are Associated With Cognitive Decline in Community-Dwelling, Older Adults With Cognitive Concerns.","Osteoporosis and Alzheimer's disease are common diseases of aging that would seem to be unrelated, but may be linked through the influence of bone-derived signals on brain function. The aim of the current study is to investigate the relationship between circulating levels of bone-related biomarkers and cognition.
The population included 103 community-dwelling older individuals with memory concerns but without cognitive impairment. A global cognition summary measure was collected at baseline and 6, 12, and 18 months post-enrollment by converting raw scores from 19 cognitive function tests to z-scores and averaging. Baseline plasma concentrations of bone-related biomarkers, including undercarboxylated, carboxylated, and total osteocalcin, parathyroid hormone, C-terminal telopeptide of collagen 1 (CTX-1), procollagen type 1 amino-terminal propeptide, osteoprotegrin, osteopontin, Dickkopf WNT signaling pathway inhibitor 1 (Dkk1), sclerostin, and amyloid β peptides (Aβ40 and Aβ42), were measured.
Using sex, age, and education-adjusted mixed-effects models, we found that baseline levels of TNF-related apoptosis-inducing ligand (TRAIL; p < .001), Dkk1 (p = .014), and CTX-1 (p = .046) were related to the annual rate of change of global cognition over the 18 month follow-up. In cognitive domain-specific analysis, baseline TRAIL was found to be positively related to the annual rate of change in episodic (p < .001) and working memory (p = .016), and baseline Dkk1 was positively related to semantic memory (p = .027) and negatively related to working memory (p = .016).
These results further confirm the link between bone and brain health and suggest that circulating levels of bone-related biomarkers may have diagnostic potential to predict worsening cognition.",[],"The journals of gerontology. Series A, Biological sciences and medical sciences",2018-02-13,"[{'lastname': 'Ross', 'firstname': 'Ryan D', 'initials': 'RD', 'affiliation': 'Department of Cell and Molecular Medicine, Rush University Medical Center, Chicago, Illinois.'}, {'lastname': 'Shah', 'firstname': 'Raj C', 'initials': 'RC', 'affiliation': ""Department of Family Medicine, Rush University Medical Center, Chicago, Illinois.\nRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Leurgans', 'firstname': 'Sue', 'initials': 'S', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.\nDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Bottiglieri', 'firstname': 'Teodoro', 'initials': 'T', 'affiliation': 'Baylor Research Institute, Institute of Metabolic Disease, Dallas, Texas.'}, {'lastname': 'Wilson', 'firstname': 'Robert S', 'initials': 'RS', 'affiliation': ""Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.\nDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.\nDepartment of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.""}, {'lastname': 'Sumner', 'firstname': 'Dale Rick', 'initials': 'DR', 'affiliation': 'Department of Cell and Molecular Medicine, Rush University Medical Center, Chicago, Illinois.\nDepartment of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois.'}]",,,"Using sex, age, and education-adjusted mixed-effects models, we found that baseline levels of TNF-related apoptosis-inducing ligand (TRAIL; p < .001), Dkk1 (p = .014), and CTX-1 (p = .046) were related to the annual rate of change of global cognition over the 18 month follow-up. In cognitive domain-specific analysis, baseline TRAIL was found to be positively related to the annual rate of change in episodic (p < .001) and working memory (p = .016), and baseline Dkk1 was positively related to semantic memory (p = .027) and negatively related to working memory (p = .016).",,10.1093/gerona/glx252,<Element 'PubmedArticle' at 0x7f05dcdbb180>
250,29384214,Effects of insulin on transcriptional response and permeability in an in vitro model of human blood-brain barrier.,"Alzheimer's disease (AD) is the most prevalent form of dementia worldwide and is an emerging global epidemic. Active and passive immune therapies targeting beta amyloid (Aβ) have shown very limited evidence in human studies of clinical benefits from these approaches. Epidemiological studies have shown that subjects with type 2 diabetes (T2D) are at higher risk of developing AD. However, whether and how these two conditions are causally linked is unknown. With the purpose of confirming the relationship between T2D and AD, this study specifically focused on effects of insulin in an in vitro model of the human blood-brain barrier (BBB) and on potential mechanisms of action in the treatment of AD. By using a series of assays to establish a BBB model, we demonstrated that insulin treatment alone could induce the increase of brain endothelial barrier properties. The transcriptional response of hCMEC/D3 cells to activation with different concentrations of insulin was determined by RT-PCR, and expression levels of genes involved in the control of barrier permeability, including inter-brain endothelial junctions, integrin-focal adhesions complexes, and transporter system, were found to be altered by the treatment. Notably, the influence of insulin on expression of the ATP-binding cassette (ABC) transporter which contributes to the clearance of Aβ was investigated. Insulin up-regulated adherens junction and tight junction transmembrane proteins, as well as the ABC transporter. By treatment with insulin, the models have major advantages: it is fast, it has low cost, it is fit for considerable samples, and its conditions are under control.","[""Alzheimer's disease"", 'human blood-brain barrier', 'insulin', 'permeability', 'transcriptional response', 'type 2 diabetes']",Journal of cellular biochemistry,2018-02-01,"[{'lastname': 'Kuai', 'firstname': 'Ziyu', 'initials': 'Z', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Xu', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Zhao', 'firstname': 'Qi', 'initials': 'Q', 'affiliation': 'Faculty of Health Sciences, University of Macau, Macau, China.'}, {'lastname': 'Liu', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Faculty of Health Sciences, University of Macau, Macau, China.'}, {'lastname': 'Guan', 'firstname': 'Shanshan', 'initials': 'S', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Qiao', 'firstname': 'Yongbo', 'initials': 'Y', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Gong', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Nie', 'firstname': 'Jiaojiao', 'initials': 'J', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Li', 'firstname': 'Pengju', 'initials': 'P', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Liu', 'firstname': 'Dongni', 'initials': 'D', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Xing', 'firstname': 'Yifan', 'initials': 'Y', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Li', 'firstname': 'Huiwen', 'initials': 'H', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Sun', 'firstname': 'Zixiao', 'initials': 'Z', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Wang', 'firstname': 'Wenqi', 'initials': 'W', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Ning', 'firstname': 'Chunan', 'initials': 'C', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Shi', 'firstname': 'Yuhua', 'initials': 'Y', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Kong', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.\nKey Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}, {'lastname': 'Shan', 'firstname': 'Yaming', 'initials': 'Y', 'affiliation': 'National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, China.\nKey Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, China.'}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/jcb.26744,<Element 'PubmedArticle' at 0x7f05dd602ef0>
251,"29357308
15832099
10858586
16681555
18245760
20600995
11467904
22695063
17192785
21843630
25130658
24836855
19004525
16033812
20589103
24523541
19835956
27086703
23134888
19605830
20373343
20980669
20375505
17167157
24474665
7920638
7874780
9931268
16530430
10751265
26857805
24952993
20944075
21282661
20573574
21997383
12634421
24848386
11293693
11832223
9931269
24548606
19853041
12192226
1669507
25267715
11306609
21818123
26340961
23150934
15557505
25792098
20715081
21460840
19584447
23018453
20074603
23959201
22474610
23150908
25376331
27636853
18395201
22888310
19595974
8086986
17332786
18768414
20693633
14568808
12566948
27777039
18514163
25882911
19667321
20061650
6610841
21088973
25822631
11192058
25393045
20124113
16545583
21177953
17374720
17242490
26821081
19662657
15703252
17210814
9708558
11282915
10733371
8482924
11692019
25990058
21825241
22169231
22357713
24204343
12210786
15093872
15219578
17427739
9617910
19297430
18223623
748370
12507782
12821592
17716081
15623693
22213409
11532280
26082010
26104658
20352396
26130946
25917100","Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.","Inflammatory processes may contribute to risk for Alzheimer's disease (AD) and age-related brain degeneration. Metabolic and genetic risk factors, and physical activity may, in turn, influence these inflammatory processes. Some of these risk factors are modifiable, and interact with each other. Understanding how these processes together relate to brain aging will help to inform future interventions to treat or prevent cognitive decline. We used brain magnetic resonance imaging (MRI) to scan 335 older adult humans (mean age 77.3 ± 3.4 years) who remained non-demented for the duration of the 9-year longitudinal study. We used structural equation modeling (SEM) in a subset of 226 adults to evaluate whether measures of baseline peripheral inflammation (serum C-reactive protein levels; CRP), mediated the baseline contributions of genetic and metabolic risk, and physical activity, to regional cortical thickness in AD-relevant brain regions at study year 9. We found that both baseline metabolic risk and AD risk variant apolipoprotein E ε4 (APOE4), modulated baseline serum CRP. Higher baseline CRP levels, in turn, predicted thinner regional cortex at year 9, and mediated an effect between higher metabolic risk and thinner cortex in those regions. A higher polygenic risk score composed of variants in immune-associated AD risk genes (other than APOE) was associated with thinner regional cortex. However, CRP levels did not mediate this effect, suggesting that other mechanisms may be responsible for the elevated AD risk. We found interactions between genetic and environmental factors and structural brain health. Our findings support the role of metabolic risk and peripheral inflammation in age-related brain decline.","['AD', ""Alzheimer's disease"", 'Brain structure', 'Brain volume', 'C-reactive protein', 'CRP', 'Cholesterol', 'Cognitive aging', 'Cortical thickness', 'Gene', 'Genetic risk', 'Inflammation', 'Insulin', 'Metabolic risk', 'Neuroinflammation', 'Obesity', 'Physical activity', 'Polygenic risk score']",NeuroImage,2018-01-23,"[{'lastname': 'Corlier', 'firstname': 'Fabian', 'initials': 'F', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Hafzalla', 'firstname': 'George', 'initials': 'G', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Faskowitz', 'firstname': 'Joshua', 'initials': 'J', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Kuller', 'firstname': 'Lewis H', 'initials': 'LH', 'affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.'}, {'lastname': 'Becker', 'firstname': 'James T', 'initials': 'JT', 'affiliation': 'Departments of Neurology, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15139, USA.'}, {'lastname': 'Lopez', 'firstname': 'Oscar L', 'initials': 'OL', 'affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.'}, {'lastname': 'Thompson', 'firstname': 'Paul M', 'initials': 'PM', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA; Depts. of Neurology, Psychiatry, Engineering, Radiology, & Ophthalmology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.'}, {'lastname': 'Braskie', 'firstname': 'Meredith N', 'initials': 'MN', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA. Electronic address: meredith.braskie@ini.usc.edu.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,"10.1016/j.neuroimage.2017.12.027
10.1016/S0197-4580(00)00124-X
10.1111/j.1464-5491.2006.01858.x
10.1016/j.neuroimage.2010.06.025
10.1006/nimg.2001.0848
10.1186/1742-2094-9-125
10.1038/ng1934
10.1016/j.bbi.2011.07.240
10.1016/j.jalz.2014.02.009
10.1016/j.neuroscience.2014.05.005
10.1016/j.neurobiolaging.2008.09.012
10.1189/jlb.0505247
10.3389/fnagi.2010.00023
10.1523/JNEUROSCI.2830-13.2014
10.1016/j.bbadis.2009.10.004
10.1080/14737175.2016.1179582
10.3945/ajcn.112.043240
10.1056/NEJMoa0809437
10.1002/ana.21955
10.1212/WNL.0b013e3181ffe4d1
10.1159/000285166
10.1093/gerona/61.11.1166
10.1177/2150131913520328
10.1038/ng0694-180
10.1006/nimg.1998.0395
10.1016/j.neuroimage.2006.01.021
10.1212/WNL.54.7.1492
10.1002/jcla.21920
10.1016/j.neurobiolaging.2014.03.034
10.1212/WNL.0b013e3181f88359
10.1073/pnas.1015950108
10.1016/j.neulet.2010.05.092
10.1007/s00018-011-0840-1
10.1073/pnas.0230450100
10.1109/42.906426
10.1016/S0896-6273(02)00569-X
10.1006/nimg.1998.0396
10.1016/j.pneurobio.2014.02.004
10.1016/j.neuroimage.2009.10.043
10.1016/1047-2797(91)90005-W
10.1016/j.jalz.2014.05.1756
10.1038/nri3041
10.1177/1533317515602087
10.1056/NEJMoa1211851
10.1212/01.WNL.0000141850.47773.5F
10.1016/S1474-4422(15)70016-5
10.3132/dvdr.2007.019
10.1002/hbm.21113
10.1038/ng.803
10.3233/JAD-2009-1163
10.1159/000343302
10.1016/j.humimm.2010.01.008
10.1016/j.neuroimage.2013.08.022
10.1101/cshperspect.a006213
10.1056/NEJMoa1211103
10.1056/NEJMoa1211103
10.1007/s11682-014-9330-z
10.3233/JAD-160665
10.1016/j.ejphar.2008.02.049
10.1016/j.jalz.2007.01.008
10.1136/bmj.309.6955.636
10.1139/h06-113
10.1001/jama.300.9.1027
10.3233/JAD-2010-100201
10.1001/archneur.60.10.1385
10.1159/000067110
10.1016/j.arr.2016.10.001
10.1016/j.biopsych.2008.04.016
10.1016/j.bbi.2015.03.015
10.1212/WNL.0b013e3181b16431
10.3233/JAD-2010-1219
10.1212/WNL.34.7.939
10.1007/s00421-010-1724-z
10.1001/jamaneurol.2014.4477
10.1080/10705511.2014.935842
10.1007/s004210000312
10.1016/j.soard.2014.06.010
10.1001/archgenpsychiatry.2009.193
10.1016/j.neuroimage.2006.01.047
10.1242/jeb.048074
10.1073/pnas.0611721104
10.1080/00273170701341316
10.1002/hbm.20870
10.1093/cercor/bhi044
10.1001/archneur.64.1.93
10.1002/ana.410440226
10.1161/01.CIR.103.13.1813
10.1056/NEJM200003233421202
10.1631/jzus.B1400219
10.1001/archneurol.2011.167
10.1093/cercor/bhr348
10.1212/WNL.0b013e318248e50f
10.3389/fnagi.2013.00064
10.1002/ana.10265
10.1016/j.jacc.2003.10.061
10.1002/(SICI)1096-8652(199707)55:3<134::AID-AJH3>3.0.CO;2-T/abstract
10.1109/TMI.2006.887364
10.1109/42.668698
10.3945/jn.108.098251
10.1016/0021-9681(78)90058-9
10.1016/S0165-5728(02)00398-3
10.1161/01.ATV.0000089628.63625.D4
10.1146/annurev.clinpsy.1.102803.144239
10.1212/01.WNL.0000147474.29994.35
10.1001/archneurol.2011.670
10.1016/S0161-5890(01)00042-6
10.1038/jcbfm.2015.125
10.1161/JAHA.114.001140
10.1007/s12640-010-9175-1
10.3346/jkms.2015.30.7.860
10.4049/jimmunol.1402909
10.1086/651257",<Element 'PubmedArticle' at 0x7f05deae7900>
252,"29192843
2881207
17245412
22286176
22179788
26719327
17551515
15087549
28650319
17911027
19541956
26812143
27708338
28882996
17468747
1648719
20164562
15104567
21971153
15190254
24748561
19559700
6107862
2858056
2862952
15778722
17987251
19733630
24025483
22734715
18769546
20357103
8831674
15921860
24782311
18254658
15299335
19595735",Somatostatin in Alzheimer's disease: A new Role for an Old Player.,The amyloid beta (Aβ) peptide is central to the pathogenesis of Alzheimer's disease (AD). Insights into Aβ-interacting proteins are critical for understanding the molecular mechanisms underlying Aβ-mediated toxicity. We recently undertook an in-depth in vitro interrogation of the Aβ1-42 interactome using human frontal lobes as the biological source material and taking advantage of advances in mass spectrometry performance characteristics. These analyses uncovered the small cyclic neuropeptide somatostatin (SST) to be the most selectively enriched binder to oligomeric Aβ1-42. Subsequent validation experiments revealed that SST interferes with Aβ fibrillization and promotes the formation of Aβ assemblies characterized by a 50-60 kDa SDS-resistant core. The distributions of SST and Aβ overlap in the brain and SST has been linked to AD by several additional observations. This perspective summarizes this body of literature and draws attention to the fact that SST is one of several neuropeptide hormones that acquire amyloid properties before their synaptic release. The latter places the interaction between SST and Aβ among an increasing number of observations that attest to the ability of amyloidogenic proteins to influence each other. A model is presented which attempts to reconcile existing data on the involvement of SST in the AD etiology.,"[""Alzheimer's disease"", 'Aβ', 'amyloids', 'senile plaques', 'somatostatin']",Prion,2017-12-02,"[{'lastname': 'Solarski', 'firstname': 'Michael', 'initials': 'M', 'affiliation': ""a Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Centre , 6th Floor, 60 Leonard Avenue, Toronto , Ontario M5T 2S8 , Canada.\nb Department of Laboratory Medicine & Pathobiology , University of Toronto , Medical Sciences Building, 6th Floor, 1 King's College Circle, Toronto , Ontario M5S 1A8 , Canada.""}, {'lastname': 'Wang', 'firstname': 'Hansen', 'initials': 'H', 'affiliation': 'a Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Centre , 6th Floor, 60 Leonard Avenue, Toronto , Ontario M5T 2S8 , Canada.'}, {'lastname': 'Wille', 'firstname': 'Holger', 'initials': 'H', 'affiliation': 'c Department of Biochemistry , University of Alberta , Edmonton , Alberta T6G 2M8 , Canada.\nd Centre for Prions and Protein Folding Diseases, University of Alberta , Edmonton , Alberta T6G 2M8 , Canada.'}, {'lastname': 'Schmitt-Ulms', 'firstname': 'Gerold', 'initials': 'G', 'affiliation': ""a Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Centre , 6th Floor, 60 Leonard Avenue, Toronto , Ontario M5T 2S8 , Canada.\nb Department of Laboratory Medicine & Pathobiology , University of Toronto , Medical Sciences Building, 6th Floor, 1 King's College Circle, Toronto , Ontario M5S 1A8 , Canada.""}]",,,,,"10.1080/19336896.2017.1405207
10.1038/325733a0
10.1038/nrm2101
10.1038/nsmb.2191
10.1074/jbc.R115.702704
10.1038/nrn2168
10.1126/science.1091230
10.7554/eLife.2840
10.1016/j.jsb.2007.08.006
10.1126/science.1173155
10.1371/journal.pbio.1002361
10.1038/srep34477
10.1126/science.aao2825
10.1038/nature05695
10.1016/S1043-6618(05)80080-5
10.3233/JAD-2010-1385
10.1111/j.1365-2265.2004.02024.x
10.1210/en.2011-1542
10.1038/nature02661
10.1007/s00429-014-0771-3
10.1016/j.expneurol.2009.06.010
10.1038/288279a0
10.1038/314090a0
10.1016/0006-8993(85)90249-5
10.1038/nm1206
10.1007/s00415-007-0539-2
10.1016/j.neulet.2009.09.002
10.4161/pri.26415
10.1111/j.1471-4159.2012.07847.
10.1371/journal.pone.0003135
10.1523/JNEUROSCI.5924-09.2010
10.1006/bbrc.1996.1413
10.1016/j.mehy.2005.02.045
10.1074/jbc.M114.548354
10.1371/journal.pbio.0060017
10.1107/S0907444994006104
10.1016/j.pneurobio.2009.07.002",<Element 'PubmedArticle' at 0x7f05dc4f06d0>
253,"29164314
23926155
19819951
27192513
22563845
18203126
20631003
27750190
20083312
23154605
27121425
20737609
24677324
23972912
24113579
21547078
24236143
21195362
27565149
28383757
25984655
9853845
25300052
18410167
26060570
26754259
21730975
22990654
21445935
23218867
27804078
26463360
21765573
17380377
19718667
22240244
24968011
19846613
21896736","Cross-national gender variations of digit ratio (2D:4D) correlate with life expectancy, suicide rate, and other causes of death.","The second-to-fourth finger length ratio (2D:4D) is an indication of prenatal sex hormone exposure, and has sex-specifically been associated with several lethal illnesses including ischemic heart disease, diverse cancers, and suicide. Our primary aim was to verify that 2D:4D sex-specifically relates to life expectancy and suicide numbers on a national level (23 countries). We also used a hypothesis-free approach to investigate associations with other causes of death [p value adjustment for multiple hypothesis testing using the false discovery rate procedure (FDR)]. All parameters were normalized to the national mean (of males and females) and analyzed across nations. Normalized male 2D:4D correlated positively with normalized male life expectancy (at birth, r = 0.46, p = 0.029; at the age of 60, r = 0.44, p = 0.038) and negatively with normalized male suicide rates (r = - 0.49, p = 0.017). In the exploratory analyses, the normalized male 2D:4D values were negatively associated with the normalized male deaths rates from communicable, maternal, perinatal, and nutritional conditions [r = - 0.65, p(FDR) = 0.011], respiratory infections [r = - 0.69, p(FDR) = 0.008], asthma [r = - 0.65, p(FDR) = 0.011], neurological conditions [r = - 0.56, p(FDR) = 0.046], and Alzheimer's disease and other dementias [r = - 0.59, p(FDR) = 0.036]. The normalized female parameters showed the same cross-national correlations. In line with the previous individual level findings, the results suggest that prenatal sex hormone effects are sex-specifically involved in suicide and neurological conditions. Moreover, we provide novel national level evidence that prenatal sex hormone priming may sex-specifically influence life expectancy and death risk from respiratory diseases.","['Asthma', 'Causes of death', 'Digit ratio', 'Life expectancy', 'Respiratory infections', 'Suicide']","Journal of neural transmission (Vienna, Austria : 1996)",2017-11-23,"[{'lastname': 'Lenz', 'firstname': 'Bernd', 'initials': 'B', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. bernd.lenz@uk-erlangen.de.'}, {'lastname': 'Kornhuber', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany.'}]",,,,,"10.1007/s00702-017-1815-7
10.1098/rspb.2013.1532
10.1016/j.paid.2004.12.017
10.3102/10769986025001060
10.1210/en.2009-0774
10.1590/abd1806-4841.20164622
10.1037/a0028087
10.1016/j.paid.2013.05.020
10.1002/ajhb.20731
10.1210/en.2010-0041
10.1016/j.earlhumdev.2016.10.003
10.1016/j.psychres.2009.08.023
10.9758/cpn.2016.14.2.148
10.1002/ajhb.21054
10.1002/ajhb.22546
10.1016/j.injury.2013.07.018
10.1177/147470491301100502
10.1371/journal.pone.0019332
10.1371/journal.pone.0079539
10.1016/j.genm.2010.11.008
10.1007/s00702-016-1608-4
10.1111/acps.12725
10.1016/j.earlhumdev.2015.04.009
10.1016/j.paid.2010.10.016
10.1093/humrep/13.11.3000
10.1037/0735-7044.122.2.273
10.1016/S1090-5138(99)00006-9
10.1186/s13229-015-0028-x
10.1038/pcan.2015.62
10.1038/bjc.2011.253
10.1038/bjc.2012.418
10.1002/ajhb.21144
10.1016/j.earlhumdev.2012.11.002
10.1007/s11845-016-1524-5
10.1111/j.2041-210X.2010.00061.x
10.1016/j.biopsycho.2015.09.013
10.1016/j.paid.2010.07.024
10.1016/j.paid.2017.03.009
10.1007/s10508-006-9143-2
10.1177/1474704916632536
10.1016/j.paid.2014.06.039
10.1002/eat.20736
10.1210/er.2010-0031
10.1097/WNN.0000000000000024
10.1210/en.2009-0986
10.1073/pnas.1108312108",<Element 'PubmedArticle' at 0x7f05dc50d310>
254,"29107848
28249936
27629733
26321946
15592144
17804958
15592144
16214936
16906426
10695693
27603906
28520952
27601558
27638924
22529182
24205791
17870208
28322173
27577238
18495692
17547723
28536577
23369133
26714213
22265587
15240616
8232972
20886273
25905409
18525131
16237129
2011243
27118278
24285689
27815632
20563821
27209644
26305618
27389191
27766119
27689250
4662273
15483087
4026469
16179578
14722150
18663163
19276542
12084879
15184598
25690560
21893493
28124062
23702402
27558885
22977271
23853210
28543314",Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults.,"Thyroid hormone disease is common among older adults and is associated with cognitive impairment. However, pathologic correlates are not well understood. We studied pathologic and clinical factors associated with hypothyroidism, the most common manifestation of thyroid disease, in research subjects seen annually for clinical evaluations at U.S. Alzheimer's Disease Centers. Thyroid disease and treatment status were assessed during clinician interviews. Among autopsied subjects, there were 555 participants with treated hypothyroidism and 2146 without known thyroid disease; hypothyroidism was associated with severe atherosclerosis (odds ratio: 1.35; 95% confidence interval: 1.02, 1.79) but not Alzheimer's disease pathologies (amyloid plaques or neurofibrillary tangles). Among participants who did not undergo autopsy (4598 with treated hypothyroidism and 20,945 without known thyroid hormone disease), hypercholesterolemia and cerebrovascular disease (stroke and/or transient ischemic attack) were associated with hypothyroidism, complementing findings in the smaller autopsy sample. This is the first large-scale evaluation of neuropathologic concomitants of hypothyroidism in aged individuals. Clinical hypothyroidism was prevalent (>20% of individuals studied) and was associated with cerebrovascular disease but not Alzheimer's disease-type neuropathology.","['CARTS', 'Cerebrovascular disease', 'DLB', 'Endocrine', 'Thyroxine']",Neurobiology of aging,2017-11-07,"[{'lastname': 'Brenowitz', 'firstname': 'Willa D', 'initials': 'WD', 'affiliation': ""National Alzheimer's Coordinating Center (NACC), Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: willa.brenowitz@ucsf.edu.""}, {'lastname': 'Han', 'firstname': 'Fang', 'initials': 'F', 'affiliation': 'Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.'}, {'lastname': 'Kukull', 'firstname': 'Walter A', 'initials': 'WA', 'affiliation': ""National Alzheimer's Coordinating Center (NACC), Department of Epidemiology, University of Washington, Seattle, WA, USA.""}, {'lastname': 'Nelson', 'firstname': 'Peter T', 'initials': 'PT', 'affiliation': 'Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, KY, USA; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA. Electronic address: Peter.nelson@uky.edu.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2017.10.004,<Element 'PubmedArticle' at 0x7f05db9a8cc0>
255,"29093028
27074515
25540137
21868780
24089547
14693979
17502538
16978367
21159786
21205110
15223977
16567569
27136580
27876822
23619906
20228001
19812536
24856029
12193151
28888328
10390358
17033971
12032568
12032570
20700443
25886283
26058915
8538226
26322160
27707767
20598278
15902302
11438681
14576148
16524949
18322540
23568368
25673412
20011104
24097068
24509480
22885924
18568054
20686565
17506703
23636770
9622570
27852607
24812437
22841760
27017625
27927203
26919891
27329332
23485414
16855264
20616382
24126174
20714348
24586186
17921354
24699222",Genome-Wide Meta-Analysis Unravels Interactions between Magnesium Homeostasis and Metabolic Phenotypes.,Magnesium (Mg,"['Gene-environment interaction', 'Genetic determinants', 'Magnesium homeostasis', 'Metabolic syndrome', 'Tubular transport', 'zebrafish']",Journal of the American Society of Nephrology : JASN,2017-11-03,"[{'lastname': 'Corre', 'firstname': 'Tanguy', 'initials': 'T', 'affiliation': 'Institute of Social and Preventive Medicine.\nDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.'}, {'lastname': 'Arjona', 'firstname': 'Francisco J', 'initials': 'FJ', 'affiliation': 'Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Hayward', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine.'}, {'lastname': 'Youhanna', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': 'Institute of Physiology, University of Zürich, Zurich, Switzerland.'}, {'lastname': 'de Baaij', 'firstname': 'Jeroen H F', 'initials': 'JHF', 'affiliation': 'Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Belge', 'firstname': 'Hendrica', 'initials': 'H', 'affiliation': 'Institute of Physiology, University of Zürich, Zurich, Switzerland.'}, {'lastname': 'Nägele', 'firstname': 'Nadine', 'initials': 'N', 'affiliation': 'Institute of Physiology, University of Zürich, Zurich, Switzerland.'}, {'lastname': 'Debaix', 'firstname': 'Huguette', 'initials': 'H', 'affiliation': 'Institute of Physiology, University of Zürich, Zurich, Switzerland.'}, {'lastname': 'Blanchard', 'firstname': 'Maxime G', 'initials': 'MG', 'affiliation': 'Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Traglia', 'firstname': 'Michela', 'initials': 'M', 'affiliation': 'Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.'}, {'lastname': 'Harris', 'firstname': 'Sarah E', 'initials': 'SE', 'affiliation': 'Centre for Cognitive Ageing and Cognitive Epidemiology.\nMedical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine and Medical Research Council Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, Scotland, UK.'}, {'lastname': 'Ulivi', 'firstname': 'Sheila', 'initials': 'S', 'affiliation': 'Department of Medical Genetics, Institute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifico ""Burlo Garofolo,"" Trieste, Italy.'}, {'lastname': 'Rueedi', 'firstname': 'Rico', 'initials': 'R', 'affiliation': 'Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.'}, {'lastname': 'Lamparter', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.'}, {'lastname': 'Macé', 'firstname': 'Aurélien', 'initials': 'A', 'affiliation': 'Institute of Social and Preventive Medicine.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.'}, {'lastname': 'Sala', 'firstname': 'Cinzia', 'initials': 'C', 'affiliation': 'Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.'}, {'lastname': 'Lenarduzzi', 'firstname': 'Stefania', 'initials': 'S', 'affiliation': 'Department of Medical Genetics, Institute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifico ""Burlo Garofolo,"" Trieste, Italy.'}, {'lastname': 'Ponte', 'firstname': 'Belen', 'initials': 'B', 'affiliation': 'Service of Nephrology and.'}, {'lastname': 'Pruijm', 'firstname': 'Menno', 'initials': 'M', 'affiliation': 'Service of Nephrology, University Hospital of Lausanne, Lausanne, Switzerland.'}, {'lastname': 'Ackermann', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'University Clinic for Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'lastname': 'Ehret', 'firstname': 'Georg', 'initials': 'G', 'affiliation': 'Division of Cardiology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland.'}, {'lastname': 'Baptista', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Division of Cardiology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland.'}, {'lastname': 'Polasek', 'firstname': 'Ozren', 'initials': 'O', 'affiliation': 'Faculty of Medicine, University of Split, Split, Croatia.'}, {'lastname': 'Rudan', 'firstname': 'Igor', 'initials': 'I', 'affiliation': 'Usher Institute of Population Health Sciences and Informatics.'}, {'lastname': 'Hurd', 'firstname': 'Toby W', 'initials': 'TW', 'affiliation': 'Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine.'}, {'lastname': 'Hastie', 'firstname': 'Nicholas D', 'initials': 'ND', 'affiliation': 'Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine.'}, {'lastname': 'Vitart', 'firstname': 'Veronique', 'initials': 'V', 'affiliation': 'Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine.'}, {'lastname': 'Waeber', 'firstname': 'Geràrd', 'initials': 'G', 'affiliation': 'Department of Medicine, Internal Medicine, and.'}, {'lastname': 'Kutalik', 'firstname': 'Zoltán', 'initials': 'Z', 'affiliation': 'Institute of Social and Preventive Medicine.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.'}, {'lastname': 'Bergmann', 'firstname': 'Sven', 'initials': 'S', 'affiliation': 'Department of Computational Biology, University of Lausanne, Lausanne, Switzerland.\nSwiss Institute of Bioinformatics, Lausanne, Switzerland.\nDepartment of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa.'}, {'lastname': 'Vargas-Poussou', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': ""Department of Genetics, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.\nCentre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte, Paris, France.""}, {'lastname': 'Konrad', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Department of General Pediatrics, University Hospital Münster, Munster, Germany.'}, {'lastname': 'Gasparini', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': 'Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; and.\nDepartment of Experimental Genetics, Sidra, Doha, Qatar.'}, {'lastname': 'Deary', 'firstname': 'Ian J', 'initials': 'IJ', 'affiliation': 'Centre for Cognitive Ageing and Cognitive Epidemiology.\nDepartment of Psychology, and.'}, {'lastname': 'Starr', 'firstname': 'John M', 'initials': 'JM', 'affiliation': 'Centre for Cognitive Ageing and Cognitive Epidemiology.\nAlzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, Scotland, UK.'}, {'lastname': 'Toniolo', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.'}, {'lastname': 'Vollenweider', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Department of Medicine, Internal Medicine, and.'}, {'lastname': 'Hoenderop', 'firstname': 'Joost G J', 'initials': 'JGJ', 'affiliation': 'Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Bindels', 'firstname': 'René J M', 'initials': 'RJM', 'affiliation': 'Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Bochud', 'firstname': 'Murielle', 'initials': 'M', 'affiliation': 'Institute of Social and Preventive Medicine, olivier.devuyst@uzh.ch murielle.bochud@chuv.ch.'}, {'lastname': 'Devuyst', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'Institute of Physiology, University of Zürich, Zurich, Switzerland; olivier.devuyst@uzh.ch murielle.bochud@chuv.ch.'}]",,,,Copyright © 2018 by the American Society of Nephrology.,"10.1681/ASN.2017030267
10.1016/j.kint.2017.06.020",<Element 'PubmedArticle' at 0x7f05db9cf630>
256,29073556,Glucocorticoid may influence amyloid β metabolism in patients with depression.,"Epidemiological studies have demonstrated that depression may be a risk factor for Alzheimer's disease (AD); however, the biological mechanisms of the transition from depression to AD are still not clear. Changes of amyloid β protein (Aβ) metabolism and increased glucocorticoid (GC) levels have been found in both depression and AD. Moreover, several studies in animal models have demonstrated that GC administration changes Aβ metabolism. To reveal whether GC affects amyloid metabolism in patients with depression, we evaluated serum levels of Aβ40, Aβ42 and cortisol at admission in 187 inpatients with major depressive disorder (MDD) and 224 healthy comparisons. Additionally, we re-evaluated the serum levels of Aβs in 27 patients with MDD 1 year later. The results of multiple regression analyses revealed that serum cortisol and Aβ levels are not correlated at the time of admission. However, serum cortisol levels at admission correlated with serum Aβ42 levels and Aβ40/Aβ42 ratio 1 year later. These findings suggest that increased cortisol in patients with MDD may influence the metabolism of Aβ over prolonged periods of time.","[""Alzheimer's disease"", 'Amyloid', 'Cortisol', 'Depression', 'Glucocorticoid', 'Serum']",Psychiatry research,2017-10-27,"[{'lastname': 'Ishijima', 'firstname': 'Satoko', 'initials': 'S', 'affiliation': 'Department of Psychiatry & Behavioral Science, Juntendo Graduate School of Medicine, Tokyo, Japan; Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan.'}, {'lastname': 'Baba', 'firstname': 'Hajime', 'initials': 'H', 'affiliation': 'Department of Psychiatry & Behavioral Science, Juntendo Graduate School of Medicine, Tokyo, Japan; Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan. Electronic address: hbaba@juntendo.ac.jp.'}, {'lastname': 'Maeshima', 'firstname': 'Hitoshi', 'initials': 'H', 'affiliation': 'Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan.'}, {'lastname': 'Shimano', 'firstname': 'Takahisa', 'initials': 'T', 'affiliation': 'Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan.'}, {'lastname': 'Inoue', 'firstname': 'Megumi', 'initials': 'M', 'affiliation': 'Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan.'}, {'lastname': 'Suzuki', 'firstname': 'Toshihito', 'initials': 'T', 'affiliation': 'Department of Psychiatry & Behavioral Science, Juntendo Graduate School of Medicine, Tokyo, Japan; Juntendo University Mood Disorder Project (JUMP), Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan.'}, {'lastname': 'Arai', 'firstname': 'Heii', 'initials': 'H', 'affiliation': 'Department of Psychiatry & Behavioral Science, Juntendo Graduate School of Medicine, Tokyo, Japan.'}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.psychres.2017.10.008,<Element 'PubmedArticle' at 0x7f05db982f40>
257,29071993,[Influence of Electroacupuncture Stimulation with Different Intensities and Therapeutic Intervals on Learning-memory Ability and Expression of Aβ 1-40 and Arginine Vasopressin Genes in the Hippocampal CA 1 Region in VD Rats].,"To observe the influence of electroacupuncture (EA) stimulation with different electrical current intensities and therapeutic intervals on learning-memory ability and expression of β-amyloid peptide Aβ 1-40 and arginine vasopressin (AVP) genes in the hippocampal CA 1 region in vascular dementia (VD) rats, so as to provide evidence for treatment of VD.
A total of 48 male SD rats were randomly divided into sham, model, 0.5 mA-5 d-EA, 1.5 mA-5 d-EA, 0.5 mA-1 d-EA and 1.5 mA-1 d-EA groups (
In comparison with the sham group, the average escape latency of place navigation task, and the duration for crossing the target-platform for the 1
EA can improve the learning-memory ability of VD rats, which Feb be related to its effects in inhibiting the expression of Aβ 1-40 mRNA and up-regulating the expression of AVP mRNA in hippocampal CA 1 region; and the therapeutic effects of higher stimulating intensity and higher intervention frequency are obviously better than those of lower stimulating intensity and lower therapeutic frequency.",[],Zhen ci yan jiu = Acupuncture research,2017-10-27,"[{'lastname': 'Jiang', 'firstname': 'Ling-Ge', 'initials': 'LG', 'affiliation': 'Clinical Medical College of Acu-moxibustion Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.'}, {'lastname': 'Zhang', 'firstname': 'Hua-Wei', 'initials': 'HW', 'affiliation': 'Clinical Medical College of Acu-moxibustion Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.'}, {'lastname': 'Zhang', 'firstname': 'Zheng', 'initials': 'Z', 'affiliation': 'Clinical Medical College of Acu-moxibustion Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.'}, {'lastname': 'Shao', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Clinical Medical College of Acu-moxibustion Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. shaoying@gzucm.edu.cn.'}]",,,"In comparison with the sham group, the average escape latency of place navigation task, and the duration for crossing the target-platform for the 1",,,<Element 'PubmedArticle' at 0x7f05db990770>
258,29038028,Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links.,"Obesity has been consistently associated with Alzheimer's disease (AD) though the exact mechanisms by which it influences cognition are still elusive and subject of current research. Adiponectin, the most abundant adipokine in circulation, is inversely correlated with adipose tissue dysfunction and seems to be a central player in this association. In fact, different signalling pathways are shared by adiponectin and proteins involved in AD pathophysiology and considerable amount of evidence supports its direct and indirect influence on β-amyloid and tau aggregates formation. In this paper we present a critical review of cellular, animal and clinical studies which have contributed to a more thorough understanding of the extent to which adiponectin influences the risk of developing AD as well as its progression. Finally, the effect of acetylcholinesterase inhibitors on circulating adiponectin levels, possible therapeutic applications and future research strategies are also discussed.","['Adipokine', 'Adiponectin', 'Alzheimer’s disease', 'BMI', 'Cognition', 'Dementia', 'Memory', 'Obesity']",Frontiers in neuroendocrinology,2017-10-19,"[{'lastname': 'Letra', 'firstname': 'Liliana', 'initials': 'L', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Neurology Department, Centro Hospitalar do Baixo Vouga - Aveiro, Av. Artur Ravara, 3814-501 Aveiro, Portugal. Electronic address: lrletra@fmed.uc.pt.'}, {'lastname': 'Rodrigues', 'firstname': 'Tiago', 'initials': 'T', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: tiagodarodrigues@gmail.com.'}, {'lastname': 'Matafome', 'firstname': 'Paulo', 'initials': 'P', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: paulomatafome@gmail.com.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Neurology Department, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3000-075 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; CNC, Center for Neuroscience and Cell Biology, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: isabeljsantana@gmail.com.'}, {'lastname': 'Seiça', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Electronic address: rseica@fmed.uc.pt.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2017.10.002,<Element 'PubmedArticle' at 0x7f05db999ef0>
259,"29033789
28088535
12752792
9019544
16957069
22628224
21174483
17241270
21145006
21615193
21736918
21115064
16467370
19339973
17502912
18037003
19332034
12522207
9620801
15959917
21423510
8942969
17522319
19261881
19587269
21216393
21080413
22454617
22227061
28449208
2145426
10202533
22293568
7696630
12000121
8955517
7477948
20082290
24141570
25815975
19187707
20182419
21613497
18849021
16125856
15975053",Stress and Corticosteroids Modulate Muscarinic Long Term Potentiation (mLTP) in the Hippocampus.,"Stress influences synaptic plasticity, learning and memory in a steroid hormone receptor dependent manner. Based on these findings it has been proposed that stress could be a major risk factor for the development of cognitive decline and dementia. Interestingly, evidence has been provided that stress also affects muscarinic, i.e., acetylcholine (ACh)-mediated neurotransmission. To learn more about the impact of stress and steroids on synaptic plasticity, in this study, we investigated the effects of stress on muscarinic long term potentiation (mLTP). We report that multiple, unpredictable exposure to stress depresses carbachol (0.5 μM)-induced mLTP, while this effect of stress is not observed in hippocampal slices prepared from mice exposed only to a single stressful procedure. Furthermore, we demonstrate that activation of distinct steroid hormone receptors is involved in stress-mediated alterations of mLTP. Activation of mineralocorticoid receptors (MR) promotes mLTP, while glucocorticoid receptor (GR) activity impairs mLTP. These effects of multiple unpredictable stress on mLTP are long-lasting since they are detected even two weeks after the last stressful experience. Thus, multiple unpredictable events rather than a single stressful experience affect mLTP in a steroid hormone receptor dependent manner, suggesting that chronic unpredictable stress can lead to lasting alterations in hippocampal cholinergic plasticity.","['Alzheimer’s disease', 'cholinergic transmission', 'corticosteroids', 'hippocampus', 'muscarinic LTP', 'stress']",Frontiers in cellular neuroscience,2017-10-17,"[{'lastname': 'Shavit Stein', 'firstname': 'Efrat', 'initials': 'E', 'affiliation': 'Department of Neurology, The Chaim Sheba Medical Center at Tel HashomerRamat Gan, Israel.'}, {'lastname': 'Itsekson Hayosh', 'firstname': ""Ze'Ev"", 'initials': 'Z', 'affiliation': 'Department of Neurology, The Chaim Sheba Medical Center at Tel HashomerRamat Gan, Israel.'}, {'lastname': 'Vlachos', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Faculty of Medicine, University of FreiburgFreiburg, Germany.'}, {'lastname': 'Maggio', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Department of Neurology, The Chaim Sheba Medical Center at Tel HashomerRamat Gan, Israel.\nDepartment of Neurology and Neurosurgery, Sackler School of Medicine, Tel Aviv UniversityTel Aviv, Israel.\nSagol School of Neuroscience, Tel Aviv UniversityTel Aviv, Israel.\nTalpiot Medical Leadership Program, The Chaim Sheba Medical Center at Tel HashomerRamat Gan, Israel.'}]",,,,,"10.3389/fncel.2017.00299
10.1016/j.neubiorev.2017.01.005
10.1046/j.1460-9568.2003.02622.x
10.1113/jphysiol.1996.sp021323
10.1523/JNEUROSCI.1628-06.2006
10.1002/emmm.201100995
10.2165/11586390-000000000-00000
10.1111/j.1460-9568.2006.05249.x
10.1016/j.neuron.2010.09.004
10.4149/endo_2011_0_91
10.1016/j.mce.2011.06.020
10.1016/j.bbr.2010.11.039
10.1096/fj.05-4265fje
10.1038/nrn2632
10.1155/2007/93202
10.1016/s0079-6123(07)67001-0
10.1016/j.brainres.2009.03.036
10.1152/jn.00691.2002
10.1038/30741
10.1002/hipo.20092
10.3389/fnsyn.2010.00024
10.1073/pnas.93.24.13541
10.1523/JNEUROSCI.0155-07.2007
10.1523/JNEUROSCI.4399-08.2009
10.1523/JNEUROSCI.1901-09.2009
10.1016/j.biopsych.2010.11.026
10.1002/hipo.20893
10.3389/fncel.2012.00012
10.1016/j.expneurol.2011.12.035
10.1002/hipo.22736
10.1113/jphysiol.1990.sp018177
10.1146/annurev.neuro.22.1.105
10.1038/nrd3628
10.1097/00001756-199412000-00067
10.1002/hipo.1116
10.1016/s0006-8993(96)00776-7
10.1016/0306-4522(95)00151-8
10.1002/hipo.20751
10.1038/npp.2013.292
10.3109/10253890.2015.1023789
10.1007/s11920-009-0007-z
10.1038/npp.2010.13
10.1523/JNEUROSCI.0730-11.2011
10.1016/j.biopsych.2008.08.021
10.1016/j.neuroscience.2005.05.039
10.2174/1567205043331992",<Element 'PubmedArticle' at 0x7f05db925400>
260,28987937,Food for thought: Leptin regulation of hippocampal function and its role in Alzheimer's disease.,"Accumulating evidence indicates that diet and body weight are important factors associated with Alzheimer's disease (AD), with a significant increase in AD risk linked to mid-life obesity, and weight loss frequently occurring in the early stages of AD. This has fuelled interest in the hormone leptin, as it is an important hypothalamic regulator of food intake and body weight, but leptin also markedly influences the functioning of the hippocampus; a key brain region that degenerates in AD. Increasing evidence indicates that leptin has cognitive enhancing properties as it facilitates the cellular events that underlie hippocampal-dependent learning and memory. However, significant reductions in leptin's capacity to regulate hippocampal synaptic function occurs with age and dysfunctions in the leptin system are associated with an increased risk of AD. Moreover, leptin is a potential novel target in AD as leptin treatment has beneficial effects in various models of AD. Here we summarise recent advances in leptin neurobiology with particular focus on regulation of hippocampal synaptic function by leptin and the implications of this for neurodegenerative disorders like AD. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'","['AMPA receptor trafficking', ""Alzheimer's disease"", 'Excitatory synaptic transmission', 'Hippocampus', 'Leptin', 'Synaptic plasticity']",Neuropharmacology,2017-10-11,"[{'lastname': 'McGregor', 'firstname': 'Gemma', 'initials': 'G', 'affiliation': 'Division of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom.'}, {'lastname': 'Harvey', 'firstname': 'Jenni', 'initials': 'J', 'affiliation': 'Division of Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom. Electronic address: j.z.harvey@dundee.ac.uk.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2017.09.038,<Element 'PubmedArticle' at 0x7f05db944b30>
261,"28982044
23390181
25437325
26546479
21091952
25089278
15031312
22465060
23163581
23416173
15173684
22342984
18343878
24727735
10398359
17595026
12558712
3611032
10791861
6610841
1549205
25650694
22781427
24625538
10230392
19247260
28516248
23705196
25460642
23777200
21632574
17439927
20458069
12615605
12900071
21071550
22688349
24417951
19584347
23300647
21088422
24386594
23055000","Cognitive decline, mortality, and organophosphorus exposure in aging Mexican Americans.","Cognitive impairment is a major health concern among older Mexican Americans, associated with significant morbidity and mortality, and may be influenced by environmental exposures.
To investigate whether agricultural based ambient organophosphorus (OP) exposure influences 1) the rate of cognitive decline and mortality and 2) whether these associations are mediated through metabolic or inflammatory biomarkers.
In a subset of older Mexican Americans from the Sacramento Area Latino Study on Aging (n = 430), who completed modified mini-mental state exams (3MSE) up to 7 times (1998-2007), we examined the relationship between estimated ambient OP exposures and cognitive decline (linear repeated measures model) and time to dementia or being cognitively impaired but not demented (CIND) and time to mortality (cox proportional hazards model). We then explored metabolic and inflammatory biomarkers as potential mediators of these relationships (additive hazards mediation). OP exposures at residential addresses were estimated with a geographic information system (GIS) based exposure assessment tool.
Participants with high OP exposure in the five years prior to baseline experienced faster cognitive decline (β = 0.038, p = 0.02) and higher mortality over follow-up (HR = 1.91, 95% CI = 1.12, 3.26). The direct effect of OP exposure was estimated at 241 (95% CI = 27-455) additional deaths per 100,000 person-years, and the proportion mediated through the metabolic hormone adiponectin was estimated to be 4% 1.5-19.2). No other biomarkers were associated with OP exposure.
Our study provides support for the involvement of OP pesticides in cognitive decline and mortality among older Mexican Americans, possibly through biologic pathways involving adiponectin.","['Adiponectin', 'Cognitive decline', 'Mediation', 'Mexican Americans', 'Mortality', 'Organophosphates']",Environmental research,2017-10-06,"[{'lastname': 'Paul', 'firstname': 'Kimberly C', 'initials': 'KC', 'affiliation': 'Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.'}, {'lastname': 'Ling', 'firstname': 'Chenxiao', 'initials': 'C', 'affiliation': 'Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.'}, {'lastname': 'Lee', 'firstname': 'Anne', 'initials': 'A', 'affiliation': 'Department of Epidemiology & Biostatistics, UCSF, San Francisco, CA, USA.'}, {'lastname': 'To', 'firstname': 'Tu My', 'initials': 'TM', 'affiliation': 'Department of Epidemiology & Biostatistics, UCSF, San Francisco, CA, USA.'}, {'lastname': 'Cockburn', 'firstname': 'Myles', 'initials': 'M', 'affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, CA, USA.'}, {'lastname': 'Haan', 'firstname': 'Mary', 'initials': 'M', 'affiliation': 'Department of Epidemiology & Biostatistics, UCSF, San Francisco, CA, USA.'}, {'lastname': 'Ritz', 'firstname': 'Beate', 'initials': 'B', 'affiliation': 'Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA; Department of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA. Electronic address: britz@ucla.edu.'}]",,,"Participants with high OP exposure in the five years prior to baseline experienced faster cognitive decline (β = 0.038, p = 0.02) and higher mortality over follow-up (HR = 1.91, 95% CI = 1.12, 3.26). The direct effect of OP exposure was estimated at 241 (95% CI = 27-455) additional deaths per 100,000 person-years, and the proportion mediated through the metabolic hormone adiponectin was estimated to be 4% 1.5-19.2). No other biomarkers were associated with OP exposure.",Copyright © 2017 Elsevier Inc. All rights reserved.,"10.1016/j.envres.2017.09.017
10.1212/WNL.0b013e31828726f5
10.1016/j.bbadis.2015.10.029
10.1111/j.1753-4887.2010.00352.x
10.1155/2014/908915
10.1093/gerona/59.3.M268
10.1016/j.pharmthera.2012.03.001
10.3109/10408444.2012.738645
10.1016/j.tox.2013.02.002
10.1016/j.neuro.2012.02.002
10.1093/aje/kwn028
10.1136/oemed-2013-101659
10.1021/es950608l
10.1002/(SICI)1099-1166(199906)14:6<481::AID-GPS959>3.0.CO;2-5
10.1002/mds.21537
10.1046/j.1532-5415.2003.51054.x
10.1037/0894-4105.14.2.209
10.1176/appi.books.9780890423349
10.1212/WNL.42.3.473
10.1097/WAD.0000000000000083
10.1093/aje/kwr525
10.1002/9781119945710.ch12
10.1097/EDE.0000000000000080
10.1080/109374099281205
10.1007/s00204-017-1979-9
10.2478/10004-1254-64-2013-2296
10.1016/j.envres.2014.09.030
10.1080/10937404.2013.783383
10.1177/0748233711407243
10.1177/0960327107070582
10.1212/WNL.0b013e3181dd4423
10.1093/aje/kwf216
10.1016/S0161-813X(03)00055-X
10.1177/0960327110388959
10.1007/s00125-012-2598-x
10.1016/j.beem.2013.08.00611
10.1001/jama.2009.976
10.1371/journal.pone.0052354
10.1159/000321985
10.5115/acb.2013.46.4.229
10.1007/s12017-012-8201-2",<Element 'PubmedArticle' at 0x7f05db94c5e0>
262,"28963439
22722203
23507120
8601610
17478559
9753099
20133875
11910117
21532579
22785400
22476196
17076895
15695241
14501013
8450562
15707899
21911655
22323736
23485579
17308309
19188609
17403556
28356893
23055518
25042347
28607171
24650793
15814795
21068831
21834854
10922077
11954667
21914486
23739959
24835997
18234983
20847404
9932871
17448147
156737
20075918
17176037
10077666
23512416
20451869
23332364
16549764
25988462
18549781
18627032
22801501
17406484
21852788
12702875
20421303
18413242
19710315
15525768
19228947
15537891
17251419
9600986
17116235
15663919
19242475
16541076
23011726
24315369
19605645
15166000
22836247
12356760
11701931
21148344
16611017
18479783
22762015
19010410
20233208
16282321
10599761
21855979
7911978
27234656
19631677
23073831
25853174
10072051
9830016
16837572
20547131
16340083
15634213
22457491
6993474
22235132
27025652
27582220
16636103
17360908
10189373
23036017
18400893
23640054
22476197
1789684
20371804
18300294
17855343
26490863
23173076
8330623
11932745
8245121
21538118
25928376
17065436
22303002
1281495
20826658
14659095
17720802
19406747
20032460",Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers.,"Synaptopathy underlying memory deficits in Alzheimer's disease (AD) is increasingly thought to be instigated by toxic oligomers of the amyloid beta peptide (AβOs). Given the long latency and incomplete penetrance of AD dementia with respect to Aβ pathology, we hypothesized that factors present in the CNS may physiologically protect neurons from the deleterious impact of AβOs. Here we employed physically separated neuron-astrocyte cocultures to investigate potential non-cell autonomous neuroprotective factors influencing AβO toxicity. Neurons cultivated in the absence of an astrocyte feeder layer showed abundant AβO binding to dendritic processes and associated synapse deterioration. In contrast, neurons in the presence of astrocytes showed markedly reduced AβO binding and synaptopathy. Results identified the protective factors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1). The protective mechanism involved release of newly bound AβOs into the extracellular medium dependent upon trafficking that was sensitive to exosome pathway inhibitors. Delaying insulin treatment led to AβO binding that was no longer releasable. The neuroprotective potential of astrocytes was itself sensitive to chronic AβO exposure, which reduced insulin/IGF1 expression. Our findings support the idea that physiological protection against synaptotoxic AβOs can be mediated by astrocyte-derived insulin/IGF1, but that this protection itself is vulnerable to AβO buildup.",[],Molecular biology of the cell,2017-10-01,"[{'lastname': 'Pitt', 'firstname': 'Jason', 'initials': 'J', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.\nDepartment of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.'}, {'lastname': 'Wilcox', 'firstname': 'Kyle C', 'initials': 'KC', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'Tortelli', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.'}, {'lastname': 'Diniz', 'firstname': 'Luan Pereira', 'initials': 'LP', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.'}, {'lastname': 'Oliveira', 'firstname': 'Maira S', 'initials': 'MS', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.'}, {'lastname': 'Dobbins', 'firstname': 'Cassandra', 'initials': 'C', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'Yu', 'firstname': 'Xiao-Wen', 'initials': 'XW', 'affiliation': 'Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.'}, {'lastname': 'Nandamuri', 'firstname': 'Sathwik', 'initials': 'S', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'Gomes', 'firstname': 'Flávia C A', 'initials': 'FCA', 'affiliation': 'Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.'}, {'lastname': 'DiNunno', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'Viola', 'firstname': 'Kirsten L', 'initials': 'KL', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208.'}, {'lastname': 'De Felice', 'firstname': 'Fernanda G', 'initials': 'FG', 'affiliation': ""Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.\nCentre for Neuroscience Studies, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.""}, {'lastname': 'Ferreira', 'firstname': 'Sergio T', 'initials': 'ST', 'affiliation': 'Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.\nInstitute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro RJ 21944-590, Brazil.'}, {'lastname': 'Klein', 'firstname': 'William L', 'initials': 'WL', 'affiliation': 'Department of Neurobiology, Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL 60208 wklein@northwestern.edu.'}]",,,,© 2017 Pitt et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,10.1091/mbc.E17-06-0416,<Element 'PubmedArticle' at 0x7f05db8f1040>
263,28933064,"The Influence of Adipose Tissue on Brain Development, Cognition, and Risk of Neurodegenerative Disorders.","The brain is a highly metabolic organ and thus especially vulnerable to changes in peripheral metabolism, including those induced by obesity-associated adipose tissue dysfunction. In this context, it is likely that the development and maturation of neurocognitive circuits may also be affected and modulated by metabolic environmental factors, beginning in utero. It is currently recognized that maternal obesity, either pre-gestational or gestational, negatively influences fetal brain development and elevates the risk of cognitive impairment and neuropsychiatric disorders in the offspring. During infancy and adolescence, obesity remains a limiting factor for healthy neurodevelopment, especially affecting executive functions but also attention, visuospatial ability, and motor skills. In middle age, obesity seems to induce an accelerated brain aging and thus may increase the risk of age-related neurodegenerative diseases such as Alzheimer's disease. In this chapter we review and discuss experimental and clinical evidence focusing on the influence of adipose tissue dysfunction on neurodevelopment and cognition across lifespan, as well as some possible mechanistic links, namely the role of the most well studied adipokines.","['Alzheimer’s disease', 'Cognition', 'Lifespan', 'Neurodegenerative disorders', 'Neurodevelopment', 'Obesity']",Advances in neurobiology,2017-09-22,"[{'lastname': 'Letra', 'firstname': 'Liliana', 'initials': 'L', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences-IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. lrletra@fmed.uc.pt.\nNeurology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal. lrletra@fmed.uc.pt.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.\nFaculty of Medicine, University of Coimbra, Coimbra, Portugal.\nCNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.'}]",,,,,10.1007/978-3-319-63260-5_6,<Element 'PubmedArticle' at 0x7f05db8b4bd0>
264,28933063,Diabesity and Brain Energy Metabolism: The Case of Alzheimer's Disease.,"It is widely accepted that high calorie diets and a sedentary lifestyle sturdily influence the incidence and outcome of type 2 diabetes and obesity, which can occur simultaneously, a situation called diabesity. Tightly linked with metabolic and energy regulation, a close association between diabetes and Alzheimer's disease (AD) has been proposed. Among the common pathogenic mechanisms that underpin both conditions, insulin resistance, brain glucose hypometabolism, and metabolic dyshomeostasis appear to have a pivotal role. This century is an unprecedented diabetogenic period in human history, so therapeutic strategies and/or approaches to control and/or revert this evolving epidemic is of utmost importance. This chapter will make a brief contextualization about the impact that diabetes and obesity can exert in brain structure and function alongside with a brief survey about the role of insulin in normal brain function, exploring its roles in cognition and brain glucose metabolism. Later, attention will be given to the intricate relation of diabesity, insulin resistance, and AD. Finally, both pharmacological and lifestyle interventions will also be reviewed as strategies aimed at fighting diabesity and/or AD-related metabolic effects.","['Alzheimer’s disease', 'Brain', 'Diabesity', 'Glucose metabolism', 'Insulin resistance']",Advances in neurobiology,2017-09-22,"[{'lastname': 'Cardoso', 'firstname': 'Susana', 'initials': 'S', 'affiliation': 'Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal. susana.t.cardoso@gmail.com.\nCNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. susana.t.cardoso@gmail.com.'}, {'lastname': 'Seiça', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': 'Institute of Physiology, Institute for Biomedical Imaging and Life Sciences-IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.'}, {'lastname': 'Moreira', 'firstname': 'Paula I', 'initials': 'PI', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.\nInstitute of Physiology, Institute for Biomedical Imaging and Life Sciences-IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.'}]",,,,,10.1007/978-3-319-63260-5_5,<Element 'PubmedArticle' at 0x7f05db8c1040>
265,28914204,A Review on the Effects of Testosterone Supplementation in Hypogonadal Men with Cognitive Impairment.,"Cognitive function and testosterone level of men decline concurrently with age. Low testosterone levels are associated with higher risk of Alzheimer's disease and mild cognitive impairment in men. There are continuous debates on whether this relationship is casual. This paper aims to summarize the current evidence on the association between testosterone level and cognitive function in elderly men. The presence of testosterone, androgen receptor and its responsive genes indicates that testosterone has biological functions in the central nervous system. The ability of the body to convert testosterone into estrogen suggests that part of the actions of testosterone could be mediated by estrogen. Observational studies generally showed that low endogenous testosterone levels were associated with poor cognitive performance in healthy elderly men. Testosterone substitution exerted positive effects on certain cognitive domains in normal and hypogonadal elderly men. In conclusion, testosterone may influence cognitive function in elderly men and its substitution may be considered in men with cognitive impairment and testosterone deficiency.","['Aging', 'Alzheimer', 'brain', 'cognitive ability', 'hypogonadism', 'testosterone.']",Current drug targets,2017-09-16,"[{'lastname': 'Mohamad', 'firstname': 'Nur Vaizura', 'initials': 'NV', 'affiliation': 'Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'lastname': 'Ima-Nirwana', 'firstname': 'Soelaiman', 'initials': 'S', 'affiliation': 'Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}, {'lastname': 'Chin', 'firstname': 'Kok-Yong', 'initials': 'KY', 'affiliation': 'Department of Pharmacology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",10.2174/1389450118666170913162739,<Element 'PubmedArticle' at 0x7f05db8c8cc0>
266,"28883857
23912530
12773942
19829160
19428144
11937111
21641727
22554955
18262185
19254689
21188275
15843602
15606892
19837873
17303658
16011741
17055174
14622899
12893816
20136692
20561156
21907204
11325319
15219659
18780973
20807511
11099831
10655508
24704258
17145649
12865324
19372016
18073302
11823322
21952537
22694803
18549781
17077814
19679070
17089130
11106581
19008959
21493755
16226751
19339712
15033916
22581594
17014981
17643539
26408498
16487665
22607736
24061050
12077215
15028864
16054121
14523358
24444806
17658612
20819998
12325053
18039320
19508596
16837882
12414884
11403980
19711196
22533414
16997284
18477662
20488256",Postmenopausal cognitive changes and androgen levels in the context of apolipoprotein E polymorphism.,"The focus of this study was to assess cognitive functions in relation to androgens and specifically testosterone and dehydroepiandrosterone in postmenopausal women as well as the correlation between cognitive functions and these two androgens according to polymorphism of the apolipoprotein E gene (APOE).
A group of 402 women was recruited to the study (minimum 2 years after the last menstruation, follicle-stimulating hormone (FSH) more than 30 U/ml and no dementia signs on Montreal Cognitive Assessment). The computerized battery of the Central Nervous System Vital Signs test was used to diagnose cognitive functions. APOE genotyping was performed by multiplex polymerase chain reaction (PCR). Testosterone (TTE) and dehydroepiandrosterone (DHEA) in the blood serum were assessed for further statistical correlations analysis.
In the group of postmenopausal women, higher testosterone concentration was associated with lower scores for Neurocognition Index (NCI) (
Hormonal balance variations after menopause may influence brain processes concerned with cognition, especially memory and psychomotor speed. The observed effects may be related to androgens' influence on higher cortical functions in the changed hormonal dynamics of the postmenopausal period.","['apolipoprotein E', 'cognitive functions', 'dehydroepiandrosterone', 'menopause', 'testosterone']",Archives of medical science : AMS,2017-09-09,"[{'lastname': 'Bojar', 'firstname': 'Iwona', 'initials': 'I', 'affiliation': 'Department for Women Health, Institute of Rural Health, Lublin, Poland.'}, {'lastname': 'Pinkas', 'firstname': 'Jarosław', 'initials': 'J', 'affiliation': 'School of Public Health, Center of Postgraduate Medical Education, Warsaw, Poland.'}, {'lastname': 'Gujski', 'firstname': 'Mariusz', 'initials': 'M', 'affiliation': 'Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.'}, {'lastname': 'Owoc', 'firstname': 'Alfred', 'initials': 'A', 'affiliation': 'Center for Public Health and Health Promotion, Institute of Rural Health, Lublin, Poland.'}, {'lastname': 'Raczkiewicz', 'firstname': 'Dorota', 'initials': 'D', 'affiliation': 'Institute of Statistics and Demography, Warsaw School of Economics, Warsaw, Poland.'}, {'lastname': 'Gustaw-Rothenberg', 'firstname': 'Kasia', 'initials': 'K', 'affiliation': 'Lou Ruvo Brain Wellness Center, Neurological Institute, The Cleveland Clinic Foundation, Cleveland, OH, USA.\nDepartment of Neurodegenerative Diseases, Institute of Rural Health, Lublin, Poland.'}]",,,"In the group of postmenopausal women, higher testosterone concentration was associated with lower scores for Neurocognition Index (NCI) (",,10.5114/aoms.2016.62869,<Element 'PubmedArticle' at 0x7f05db8d1db0>
267,"28845019
16862116
17157414
17923627
18565828
19683260
18752597
12889069
19625741
19158106
2116006
12524533
25575133
23285020
28473694
8810256
17278999
17764761
17949857
20142525
18245784
21212639
27114033
17030534
25261995
16983685
12973694
23609919
21224065
21943601
19288468
17917583
28070672
25022663
23830905
28073925
18378771
20026663
12526812",Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.,"Granulin (Grn) mutations were identified in familial frontotemporal lobar degeneration (FTLD) patients with TAR DNA-binding protein of 43 kd (TDP-43) pathology. Grn transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein. Thus, these mutations are strongly involved in FTLD pathogenesis. Moreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease. To investigate the influence of PGRN on amyloid beta (Aβ) accumulation, amyloid precursor protein (APP) transgenic mice were interbred with Grn-deficient mice, producing APP transgenic mice harboring the Grn hemizygote (APP/Grn","['Alzheimer’s disease', 'amyloid beta (Aβ)', 'granulin', 'haploinsufficiency', 'progranulin']",Experimental animals,2017-08-29,"[{'lastname': 'Hosokawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia research project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.'}, {'lastname': 'Tanaka', 'firstname': 'Yoshinori', 'initials': 'Y', 'affiliation': 'Dementia research project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.'}, {'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': 'Dementia research project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.\nDepartment of Neuropsychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8576 Japan.'}, {'lastname': 'Kondo', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': 'Histology center, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.'}, {'lastname': 'Akiyama', 'firstname': 'Haruhiko', 'initials': 'H', 'affiliation': 'Dementia research project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.'}, {'lastname': 'Hasegawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia research project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.'}]",,,,,"10.1538/expanim.17-0060
10.1038/nature05016
10.1016/j.neurobiolaging.2006.10.028
10.1001/archneur.64.10.1436
10.1212/01.wnl.0000319688.89790.7a
10.1016/j.jns.2009.07.011
10.1111/j.1468-1331.2008.02266.x
10.1002/dvdy.10341
10.3233/JAD-2009-1170
10.1093/brain/awn352
10.1038/nm816
10.1097/NEN.0000000000000158
10.1371/journal.pone.0052389
10.1038/s41598-017-01587-6
10.1126/science.274.5284.99
10.1097/nen.0b013e31803020cf
10.1016/j.bbr.2007.07.020
10.1016/j.neurobiolaging.2007.08.022
10.1001/archneurol.2010.113
10.1093/brain/awn012
10.1159/000322538
10.1016/j.cell.2016.04.001
10.1093/brain/awl276
10.1038/nm.3672
10.1002/ana.20963
10.1001/2013.jamaneurol.393
10.1016/j.ajpath.2010.11.002
10.1016/j.neuron.2011.07.021
10.1002/ana.21621
10.1097/nen.0b013e3181567873
10.1007/s00401-017-1668-z
10.1186/s40478-014-0078-x
10.1016/j.neuroscience.2013.06.049
10.1083/jcb.200712039
10.1084/jem.20091568
10.1016/S0092-8674(02)01141-8",<Element 'PubmedArticle' at 0x7f05db874900>
268,"28803147
24028961
16453981
12182498
11301518
19300585
15772561
24101897
24887405
26774208
11588948
11512029
11158285
17383933
17969462
26142241
8918993
26142241
9238064
9106667
12782002
15301598
10341383
19302341
16611709
7185792
19926225
24322821
24048848
11253359
12003166
23764458
20679498
6504414
11347869
25249948
24571027
27627762
19021853
20219635
16453983
14585490
20102786
18835663
24189140
15341799
16877007
25642589
25256933
26079775
18675521
21461331
19639749
23454003
24786726
2595173
8636295
15687230
10688201
16911028
15555679
11104644
21536890
19460089
23658713
9358400
17417939
19127287
25325454
7218488
11856559
10208377
8896835
331844
18753366
21636297
16636276
24012626
14706945
26286657
27039345
11704257
22153362
27321161
24012943
27619737
17583704
10794855
21889940
16298775
8941956
19470968
15560771
26719236
25481384
18371078
19416674
24011502
27347894
17592140
22338612
16785427
23727128
10727779
15288228
23997365
22850608
12369813
27213559
25123440
9484355
20535591
10931767
12930479
24293774
12531154
18714074
8190445
27634562
19779148
16541085
11403979
21075236
16489997
19238808
17955944
20808148
17040010
12749544
27707975
15464412
26149525
25921587
16831520
15499681
27321783
12892656
10883801
19101578
12009508
24617856
11403982
16408411
18513142
25322206
20438143
18591490
9302720
26795582
25218407
24837746
9799625
26446113
25409102
26433715
18562950
22612612
23715379
11156805
27325209
12486194
15586779
21875679
17310865
18579142
8630703
11766158
19340944
15087212
26833831
22072663
11201509
8983028
27885006
7951197
16801508
21061861
12082358
9322259
9331907
16423541
17040009
19647784
12061414
11742260
15504332
22669167
27473839
1484916
1484915
2543656
10231049
21295422
20416343
24028960
7170052
7547766
20817338
23717620
22990656
12843274
17347444
15910510
9799627
7792492
12373437
17412678
9223100
24508665
25422493
17936039
25747332
12183218
16673174
22761784
14669843
11345963
27091961
9152569
226735
15694110
8909345
23678032
21722658
9804908
9396940
17548802
3148991
22004260
3067252
21703613
17980408
22754045
16730465
12531156
9619997
24741037
11730734
27692800
23841841
18006139
26743325
26569029
16903132
18485753
338104
24935559
18780201
24411729
20120620
25131507
27178577
21881567
4091955
22285935
11142640
11996304
18554815
19692611
19338508
18929316
21281713
19631212
18729633
9106666
23615642
22300710
15325778
8036517
15748783
24136970
21828324
6101987
12615621
14572118
16453985
17052857","Ovarian hormones, sleep and cognition across the adult female lifespan: An integrated perspective.","Loss of ovarian function in women is associated with sleep disturbances and cognitive decline, which suggest a key role for estrogens and/or progestins in modulating these symptoms. The effects of ovarian hormones on sleep and cognitive processes have been studied in separate research fields that seldom intersect. However, sleep has a considerable impact on cognitive function. Given the tight connections between sleep and cognition, ovarian hormones may influence selective aspects of cognition indirectly, via the modulation of sleep. In support of this hypothesis, a growing body of evidence indicates that the development of sleep disorders following menopause contributes to accelerated cognitive decline and dementia in older women. This paper draws from both the animal and human literature to present an integrated view of the effects of ovarian hormones on sleep and cognition across the adult female lifespan.","['Estrogens', 'Executive function', 'Hormone replacement therapy', 'Human', 'Memory', 'Menopause', 'Primate', 'Progesterone', 'Rodent', 'Sleep loss']",Frontiers in neuroendocrinology,2017-08-15,"[{'lastname': 'Gervais', 'firstname': 'Nicole J', 'initials': 'NJ', 'affiliation': 'Department of Psychological and Brain Sciences, University of Massachusetts, Amherst, 135 Hicks Way, Amherst, MA 01003, United States. Electronic address: nicole.gervais@utoronto.ca.'}, {'lastname': 'Mong', 'firstname': 'Jessica A', 'initials': 'JA', 'affiliation': 'Department of Pharmacology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, United States.'}, {'lastname': 'Lacreuse', 'firstname': 'Agnès', 'initials': 'A', 'affiliation': 'Department of Psychological and Brain Sciences, University of Massachusetts, Amherst, 135 Hicks Way, Amherst, MA 01003, United States.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,"10.1016/j.yfrne.2017.08.002
10.1016/j.cub.2013.07.025
10.1081/CBI-120005390
10.1097/01.GME.0000142439.30302.9A
10.3389/fnbeh.2013.00136
10.1016/j.yfrne.2016.01.002
10.1007/s004240100582
10.1111/j.1469-7793.2001.0565k.x
10.1016/j.sleep.2006.09.011
10.1016/j.psyneuen.2015.06.005
10.1037//0735-7044.111.2.267
10.1016/S0014-4886(03)00061-X
10.1037/0735-7044.118.4.707
10.1111/j.1365-2869.2008.00713.x
10.1016/j.psyneuen.2009.10.010
10.1007/s00221-013-3797-5
10.1523/JNEUROSCI.1716-13.2013
10.1038/35049064
10.1016/j.bbr.2013.06.007
10.1177/0748730410374943
10.1111/1469-8986.3820232
10.3389/fnsys.2014.00160
10.1111/psyp.12167
10.1111/jgs.14316
10.1111/j.1365-2869.2008.00698.x
10.1016/S0167-8760(03)00168-5
10.1016/j.psyneuen.2009.12.012
10.1016/j.psyneuen.2008.08.006
10.1210/en.2013-1624
10.1016/j.concog.2006.06.011
10.1210/jc.2014-3892
10.1016/j.fertnstert.2014.08.016
10.1210/jc.2015-1844
10.1016/j.psyneuen.2008.04.014
10.1016/j.yhbeh.2013.02.011
10.1111/jgs.12790
10.1101/lm.83805
10.1111/j.1365-2869.2006.00535.x
10.1016/j.neubiorev.2004.09.002
10.1073/pnas.1010666108
10.1111/j.1532-5415.2009.02303.x
10.1371/journal.pone.0062205
10.1046/j.1365-2869.1997.00041.x
10.1146/annurev.neuro.30.051606.094328
10.1371/journal.pone.0004117
10.5665/sleep.4332
10.1016/S0149-7634(01)00067-7
10.1016/0006-8993(96)00652-X
10.1523/JNEUROSCI.1968-08.2008
10.1016/j.smrv.2011.03.008
10.1073/pnas.0602006103
10.1016/j.jsbmb.2013.08.010
10.1101/lm.037267.114
10.1016/j.actamat.2015.02.029
10.1016/S0166-4328(01)00255-8
10.1016/j.psyneuen.2011.11.006
10.1016/j.yhbeh.2013.08.010
10.1016/j.neuroscience.2016.08.056
10.1016/j.yhbeh.2007.05.011
10.1016/j.yhbeh.2011.08.010
10.1080/07420520500263235
10.1212/WNL.0b013e3181a71193
10.1111/j.1365-2869.2004.00418.x
10.1016/j.maturitas.2014.11.002
10.1111/j.1460-9568.2008.06142.x
10.1016/j.expneurol.2009.01.013
10.1016/j.psyneuen.2013.07.020
10.1002/cphy.c150031
10.1073/pnas.0704757104
10.1016/j.jsbmb.2013.05.010
10.1016/j.actpsy.2004.04.005
10.5665/sleep.2956
10.1016/j.bbr.2012.07.033
10.1016/j.psyneuen.2016.05.008
10.1016/j.neulet.2014.08.004
10.1016/j.immuni.2010.12.017
10.1162/089892900562228
10.5665/sleep.3244
10.1053/smrv.2001.0203
10.1111/jsr.12455
10.1038/sj.npp.1301056
10.1016/B978-0-444-53702-7.00007-5
10.1111/j.1365-2869.2006.00487.x
10.3357/ASEM.2106.2007
10.1097/JGP.0b013e3181e9b976
10.1523/JNEUROSCI.0909-16.2016
10.1016/j.yhbeh.2015.06.017
10.1016/j.yhbeh.2015.04.017
10.1016/j.psyneuen.2006.05.007
10.1016/j.beproc.2004.05.004
10.1016/j.bbr.2016.06.032
10.1037//0735-7044.114.3.506
10.1016/j.physbeh.2008.11.018
10.1111/jne.12147
10.1037/0735-7044.122.3.716
10.1037/a0018883.A
10.1196/annals.1417.002
10.1037/bne0000119
10.1016/j.patbio.2014.07.005
10.1016/j.bbr.2014.04.032
10.5665/sleep.5434
10.5665/sleep.4404
10.1016/j.maturitas.2015.07.023
10.1097/gme.0b013e31816d815e
10.3109/13697137.2012.660613
10.1097/GME.0b013e3182960cf8
10.1176/appi.ajp.158.2.227
10.1016/j.tins.2016.05.002
10.1080/16506073.2015.1026386
10.1016/j.nlm.2011.07.004
10.1016/j.yhbeh.2008.04.010
10.1093/gerona/51A.3.M108
10.1016/j.nlm.2009.01.008
10.1016/j.mcna.2004.01.009
10.1098/rstb.2015.0110
10.1523/JNEUROSCI.4175-11.2011
10.1001/archinte.166.12.1262
10.1093/sleep/33.10.1381
10.1097/01.GME.0000015809.11124.C5
10.1006/nlme.1997.3785
10.1097/00001756-199709290-00004
10.1016/j.nlm.2005.11.005
10.1016/j.neulet.2009.07.081
10.1037/0882-7974.17.2.299
10.1016/j.neuron.2004.10.007
10.1038/npp.2012.82
10.1186/s13195-016-0190-1
10.1016/0306-4530(92)90008-U
10.1016/j.maturitas.2010.12.009
10.1016/j.bbr.2010.04.018
10.1016/j.cub.2013.05.041
10.1016/j.bandc.2010.08.003
10.1371/journal.pone.0064493
10.1126/science.1138581
10.1006/hbeh.1998.1476
10.1098/rstb.2007.2097
10.1097/00001756-199705260-00048
10.1016/j.mce.2014.01.020
10.1016/j.smrv.2007.07.005
10.1016/j.sleep.2014.12.001
10.1007/s11064-005-9004-8
10.1371/journal.pone.0039410
10.1037/0735-7044.115.2.384
10.1073/pnas.1521637113
10.1001/jama.242.22.2405
10.1016/j.psyneuen.2004.08.007
10.1152/ajpregu.00474.2012
10.1016/j.physbeh.2011.06.016
10.1016/S0006-8993(98)00991-3
10.1037/a0025539
10.1016/0306-4530(88)90060-1
10.1016/j.fertnstert.2011.05.079
10.1016/j.yfrne.2007.08.002
10.5665/sleep.1966
10.1016/j.nlm.2006.04.003
10.1006/nlme.1997.3809
10.1523/JNEUROSCI.0014-14.2014
10.1016/S0015-0282(01)02902-02908
10.1016/j.jalz.2016.08.004
10.1146/annurev-neuro-062111-150439
10.1016/j.biopsycho.2007.09.011
10.1093/arclin/acv087
10.1037/neu0000250
10.1017/S1355617706060474
10.1016/j.nlm.2008.04.002
10.1186/1471-244X-14-177
10.1080/07420520802394191
10.1016/j.neuron.2013.12.025
10.1016/j.bbr.2014.08.001
10.1016/j.reaurg.2009.08.010
10.1038/npp.2011.176
10.1016/0166-4328(85)90167-6
10.1016/j.yhbeh.2012.01.010
10.1037//0735-7044.114.6.1078
10.1037/0735-7044.116.2.187
10.1016/j.neuroscience.2008.04.064
10.1523/JNEUROSCI.1591-09.2009
10.1111/j.1749-6632.2009.04416.x
10.1016/j.ntt.2011.01.003
10.1016/j.yhbeh.2009.07.005
10.1037/0735-7044.111.2.259
10.1097/gme.0b013e31827655e5
10.1016/j.neurobiolaging.2004.09.012
10.1016/0006-8993(80)91076-8
10.1164/rccm.200209-1055OC
10.1016/j.neuroscience.2006.09.002",<Element 'PubmedArticle' at 0x7f05db895220>
269,"28768841
11950412
7797535
24480627
23402353
19451355
25562577
26612442
16680584
26010883
27651008
27176073
24846449
2646917
25173540
19820128
26509869
2916953
24759546
26866794
26949733
7137077
22762315
26825350
21225900
19934619
15985571
25171458
24861877
1384776",Association of parathyroid hormone with 20-year cognitive decline: The ARIC study.,"We hypothesized that elevated parathyroid hormone (PTH) levels will be independently associated with 20-year cognitive decline in a large population-based cohort.
We studied 12,964 middle-aged white and black ARIC participants without a history of prior stroke who, in 1990-1992 (baseline), had serum PTH levels measured and cognitive function testing, with repeat cognitive testing performed at up to 2 follow-up visits. Cognitive testing included the Delayed Word Recall, the Digit Symbol Substitution, and the Word Fluency tests, which were summed as a global 
The mean (SD) age of our cohort was 57 (6) years, 57% were women, and 24% were black. There was no cross-sectional association of elevated PTH with cognitive global 
Our work does not support an independent influence of PTH on cognitive decline in this population-based cohort study.",[],Neurology,2017-08-05,"[{'lastname': 'Kim', 'firstname': 'Samuel M', 'initials': 'SM', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Zhao', 'firstname': 'Di', 'initials': 'D', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Schneider', 'firstname': 'Andrea L C', 'initials': 'ALC', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Korada', 'firstname': 'Sai Krishna', 'initials': 'SK', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Lutsey', 'firstname': 'Pamela L', 'initials': 'PL', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Guallar', 'firstname': 'Eliseo', 'initials': 'E', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Alonso', 'firstname': 'Alvaro', 'initials': 'A', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Windham', 'firstname': 'B Gwen', 'initials': 'BG', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Gottesman', 'firstname': 'Rebecca F', 'initials': 'RF', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson.'}, {'lastname': 'Michos', 'firstname': 'Erin D', 'initials': 'ED', 'affiliation': 'From the Ciccarone Center for the Prevention of Heart Disease (S.M.K., E.D.M.) and Department of Neurology (A.L.C.S., R.F.G.), Johns Hopkins University School of Medicine; Department of Epidemiology (D.Z., E.G., R.F.G., E.D.M.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Northeast Ohio Medical University (S.K.K.), Rootstown; Division of Epidemiology and Community Health (P.L.L.), School of Public Health, University of Minnesota, Minneapolis; Department of Epidemiology (A.A.), Rollins School of Public Health, Emory University, Atlanta, GA; and Department of Medicine (B.G.W.), Division of Geriatrics, University of Mississippi Medical Center, Jackson. edonnell@jhmi.edu.'}]",,,"The mean (SD) age of our cohort was 57 (6) years, 57% were women, and 24% were black. There was no cross-sectional association of elevated PTH with cognitive global ",© 2017 American Academy of Neurology.,10.1212/WNL.0000000000004290,<Element 'PubmedArticle' at 0x7f05db7a4a90>
270,"28710249
25984581
1763893
22424227
8999882
19079679
22147523
26136647
7600184
10749877
12941771
16361024
15585341
942051
16461897
10399926
25617315
25374101
23924004
24931033
25088942
21878106
26342176
22133278
12054559
21907142
12214042
19117266
21606494
2960782
11822882
27531392
12921743
24849570
14612490
24358169
15033922
24529523
1776759
12551920
11316808
11083922
10868931
18987201
21460223
8083748
18926603
27807285
1587857
7543026
27829662
8152488
25938784
27511018
21912665
18950899
1406710
27076423
18468996
14657333
18393365
25912430
25700985
27138913
19542221
22846461
25408221
22124967
9830016
17942819
1625772
27667667
3140239
9562470
10767725
10591214
20302643
23506624
22987198
18989427
20231468
22476197
23236292
26108977
25008180
21044348
10842711
2649245
3328723
24022491
11423558
23894546
25249577",Amyloid precursor protein in pancreatic islets.,"The amyloid precursor protein (APP) has been extensively investigated for its role in the production of amyloid beta (Aβ), a plaque-forming peptide in Alzheimer's disease (AD). Epidemiological evidence suggests type 2 diabetes is a risk factor for AD. The pancreas is an essential regulator of blood glucose levels through the secretion of the hormones insulin and glucagon. Pancreatic dysfunction is a well-characterized consequence of type 1 and type 2 diabetes. In this study, we have examined the expression and processing of pancreatic APP to test the hypothesis that APP may play a role in pancreatic function and the pathophysiology of diabetes. Our data demonstrate the presence of APP within the pancreas, including pancreatic islets in both mouse and human samples. Additionally, we report that the APP/PS1 mouse model of AD overexpresses APP within pancreatic islets, although this did not result in detectable levels of Aβ. We compared whole pancreas and islet culture lysates by Western blot from C57BL/6 (WT), APP","['Alzheimer', 'BACE2', 'amyloid', 'diabetes', 'insulin', 'pancreas']",The Journal of endocrinology,2017-07-16,"[{'lastname': 'Kulas', 'firstname': 'Joshua A', 'initials': 'JA', 'affiliation': 'Department of Biomedical SciencesUniversity of North Dakota School of Medicine and Health Sciences, Grand Forks, USA.'}, {'lastname': 'Puig', 'firstname': 'Kendra L', 'initials': 'KL', 'affiliation': 'Department of Biomedical SciencesUniversity of North Dakota School of Medicine and Health Sciences, Grand Forks, USA.'}, {'lastname': 'Combs', 'firstname': 'Colin K', 'initials': 'CK', 'affiliation': 'Department of Biomedical SciencesUniversity of North Dakota School of Medicine and Health Sciences, Grand Forks, USA colin.combs@med.und.edu.'}]",,,,© 2017 Society for Endocrinology.,10.1530/JOE-17-0122,<Element 'PubmedArticle' at 0x7f05db7bca40>
271,"28688899
9838087
16914850
26969101
10995469
21435176
18728222
19251043
26468204
18505838
17942401
28232179
22427376
10455013
20638297
22191795
23175826
25237037
11404397
22087313
24150286
17640949
15773910
18282324
15733744
16932542
15023346
8910387
26651341
25974006
17100583
22790092
15033922
16820027
8810256
27727467
24623782
14747300
17167471
27567931
19936237
23254634
12160362
24931034
22864021
24443745
12151510
15823755
23011726
20888602
23583109
21629747
18076373
17496363
24526357
28515688
16515522
14643377
19020010
24411482
21519521
15571985
11147790
12761548
27131827
20107219
27177549
20709114
27660698
20682696
21886036
25471187
27321346
15750215
21307309
25472611
19251044
22476197
19683471
21204788
26108977
27412291
20957377
19047061
15094077
11880515
14657487
26243569
24931035
25107476
27185631
23223021
22522613
27491830",Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. While the causes of AD are not known, several risk factors have been identified. Among these, type two diabetes (T2D), a chronic metabolic disease, is one of the most prevalent risk factors for AD. Insulin resistance, which is associated with T2D, is defined as diminished or absent insulin signaling and is reflected by peripheral blood hyperglycemia and impaired glucose clearance. In this study, we used complementary approaches to probe for peripheral insulin resistance, central nervous system (CNS) insulin sensitivity and energy homeostasis in Tg2576 and 3xTg-AD mice, two widely used animal models of AD. We report that CNS insulin signaling abnormalities are evident months before peripheral insulin resistance. In addition, we find that brain energy metabolism is differentially altered in both mouse models, with 3xTg-AD mice showing more extensive changes. Collectively, our data suggest that early AD may reflect engagement of different signaling networks that influence CNS metabolism, which in turn may alter peripheral insulin signaling.","['3xTg-AD', 'Aging', ""Alzheimer's disease"", 'Energy metabolism', 'Glucose tolerance test', 'Insulin resistance', 'Neurodegeneration', 'Tg2576', 'Type two diabetes']",Neurobiology of aging,2017-07-10,"[{'lastname': 'Velazquez', 'firstname': 'Ramon', 'initials': 'R', 'affiliation': 'Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, AZ, USA.'}, {'lastname': 'Tran', 'firstname': 'An', 'initials': 'A', 'affiliation': 'Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, AZ, USA.'}, {'lastname': 'Ishimwe', 'firstname': 'Egide', 'initials': 'E', 'affiliation': 'Department of Neurology, Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch at Galveston (UTMB), Galveston, TX, USA.'}, {'lastname': 'Denner', 'firstname': 'Larry', 'initials': 'L', 'affiliation': 'Internal Medicine, Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch at Galveston (UTMB), Galveston, TX, USA.'}, {'lastname': 'Dave', 'firstname': 'Nikhil', 'initials': 'N', 'affiliation': 'Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, AZ, USA.'}, {'lastname': 'Oddo', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': 'Arizona State University-Banner Neurodegenerative Disease Research Center at the Biodesign Institute, Arizona State University, Tempe, AZ, USA; School of Life Sciences, Arizona State University, Tempe, AZ, USA. Electronic address: oddo@asu.edu.'}, {'lastname': 'Dineley', 'firstname': 'Kelly T', 'initials': 'KT', 'affiliation': 'Department of Neurology, Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch at Galveston (UTMB), Galveston, TX, USA. Electronic address: ktdinele@utmb.edu.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,"10.1016/j.neurobiolaging.2017.06.003
10.1016/j.neubiorev.2016.03.005
10.1111/j.1582-4934.2011.01318.x
10.1152/ajpendo.90437.2008
10.1016/S0083-6729(08)00612-2
10.1523/JNEUROSCI.2781-15.2015
10.1073/pnas.0802908105
10.1074/jbc.M703561200
10.1016/j.ceb.2017.01.005
10.2337/db11-1186
10.1016/j.tem.2010.06.005
10.2165/11597760-000000000-00000
10.1523/JNEUROSCI.2153-12.2012
10.1016/j.nbd.2014.09.001
10.1371/journal.pone.0027424
10.18632/aging.100611
10.1124/jpet.107.125492
10.1111/j.1471-4159.2004.02949.x
10.1017/S1355617708080302
10.1016/j.biochi.2004.10.019
10.1038/ncpneuro0124
10.1016/j.bbapap.2003.11.009
10.1074/jbc.271.44.27879
10.1002/ana.24439
10.1016/j.pharmthera.2012.07.001
10.1096/fj.03-0978fje
10.1111/j.1460-9568.2006.04859.x
10.1111/dme.13270
10.1523/JNEUROSCI.4024-13.2014
10.1038/nature05482
10.1016/j.bbadis.2016.08.018
10.1371/journal.pone.0007917
10.3233/JAD-121669
10.2337/db14-0568
10.1242/dmm.010173
10.1101/lm.033332.113
10.1016/j.molmed.2005.02.009
10.1007/s12017-012-8199-5
10.1016/j.jns.2010.08.063
10.1016/j.neuron.2013.02.003
10.4061/2011/479249
10.1517/14728222.12.1.91
10.4414/smw.2014.13917
10.3389/fnagi.2017.00118
10.1523/JNEUROSCI.2464-08.2008
10.1016/j.neurobiolaging.2013.12.006
10.3988/jcn.2011.7.1.10
10.1016/j.nbd.2004.08.003
10.2337/diabetes.50.1.24
10.1038/nature01640
10.2337/db06-S019
10.1016/j.ejphar.2016.04.052
10.1056/NEJMra0909142
10.1007/s12035-016-9921-3
10.1016/j.bbr.2010.08.002
10.4239/wjd.v7.i17.412
10.2337/db09-1870
10.1097/SMJ.0b013e318213e92b
10.3233/JAD-141008
10.1016/j.diabres.2016.04.004
10.1073/pnas.1014715108
10.14814/phy2.12236
10.1016/S0083-6729(08)00613-4
10.1172/JCI59903
10.1016/j.coph.2009.07.004
10.1042/BJ20101485
10.1096/fj.14-268482
10.1186/s13024-016-0118-z
10.1007/s00401-010-0759-x
10.1074/jbc.M806336200
10.1016/j.ejphar.2004.02.048
10.1126/science.1092952
10.1038/nrn3983
10.2337/db14-0287
10.1007/s00401-014-1328-5
10.1016/j.gene.2016.05.018
10.2337/db12-0670
10.2337/db11-0499
10.1007/s11892-016-0775-x",<Element 'PubmedArticle' at 0x7f05db76fcc0>
272,28624654,Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.,"Alzheimer's disease (AD) is progressive neurodegenerative disorder characterized by accumulation of senile plaques, neurofibrillary tangles (NFT) and neurodegeneration. The diabetes mellitus (DM) is one of the risk factors for AD pathogenesis by impairment in insulin signaling and glucose metabolism in central as well as peripheral system. Insulin resistance, impaired glucose and lipid metabolism are leading to the Aβ (Aβ) aggregation, Tau phosphorylation, mitochondrial dysfunction, oxidative stress, protein misfolding, memory impairment and also mark over Aβ transport through central to peripheral and vice versa. Several pathways, like enzymatic degradation of Aβ, forkhead box protein O1 (FOXO) signaling, insulin signaling shared common pathological mechanism for both AD and DM. Recent evidence showed that hyperinsulinemia and hyperglycemia affect the onset and progression of AD differently. Some researchers have suggested that hyperglycemia influences vascular tone, while hyperinsulinemia may underlie mitochondrial deficit. The objective of this review is to determine whether existing evidence supports the concept that impairment in insulin signaling and glucose metabolism play an important role in pathogenesis of AD. In the first part of this review, we tried to explain the interconnecting link between AD and DM, whereas the second part includes more information on insulin resistance and its involvement in AD pathogenesis. In the final part of this review, we have focused more toward the AD treatment by targeting insulin signaling like anti-diabetic, antioxidant, nutraceuticals and dietary supplements. To date, more researches should be done in this field in order to explore the pathways in insulin signaling, which might ameliorate the treatment options and reduce the risk of AD due to DM.","['Alzheimer disease', 'Aβ', 'Diabetes mellitus', 'Insulin degrading enzyme', 'Insulin resistance', 'Oxidative stress']",Psychoneuroendocrinology,2017-06-19,"[{'lastname': 'Pardeshi', 'firstname': 'Rohit', 'initials': 'R', 'affiliation': 'Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India.'}, {'lastname': 'Bolshette', 'firstname': 'Nityanand', 'initials': 'N', 'affiliation': 'Institutional Level Biotech hub (IBT hub), Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India.'}, {'lastname': 'Gadhave', 'firstname': 'Kundlik', 'initials': 'K', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India.'}, {'lastname': 'Ahire', 'firstname': 'Ashutosh', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India.'}, {'lastname': 'Ahmed', 'firstname': 'Sahabuddin', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India.'}, {'lastname': 'Cassano', 'firstname': 'Tommaso', 'initials': 'T', 'affiliation': 'Department of Clinical and Experimental Medicine, University of Foggia, Via Luigi Pinto, c/o Ospedali Riuniti, 71122 Foggia, Italy.'}, {'lastname': 'Gupta', 'firstname': 'Veer Bala', 'initials': 'VB', 'affiliation': ""Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith-Cowan University, Joondalup, WA 6027, Australia.""}, {'lastname': 'Lahkar', 'firstname': 'Mangala', 'initials': 'M', 'affiliation': 'Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India; Institutional Level Biotech hub (IBT hub), Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati 781032, Assam, India. Electronic address: ibthubniperg@gmail.com.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.psyneuen.2017.05.004,<Element 'PubmedArticle' at 0x7f05db7325e0>
273,"28598847
24004341
21902597
2166249
11312286
11694153
8271029
18846505
18375192
19682571
21790611
23428542
22409590
21341397
22469418
21514250
21841246
21157026
21648328
8856684
9778562
23650561
25832828
17123871
14402073
5553400
6061404
14291073
5773057
15817019
26836180
17447205
18048642
17083736
9510525","A Mitochondrial Biomarker-Based Study of S-Equol in Alzheimer's Disease Subjects: Results of a Single-Arm, Pilot Trial.","Reductions in bioenergetic fluxes, mitochondrial enzyme activities, and mitochondrial number are observed in Alzheimer's disease (AD). Preclinical work indicates estrogen pathway signaling by either estrogen or selective β estrogen receptor (ERβ) agonists benefits these parameters. To assess whether an ERβ agonist could improve mitochondrial function in actual AD subjects, we administered S-equol (10 mg twice daily) to 15 women with AD and determined the platelet mitochondria cytochrome oxidase (COX) activity before initiating S-equol (lead-in), after two weeks of S-equol (active treatment), and two weeks after stopping S-equol (wash-out). Because the intra-individual variation of this enzyme across samples taken at different times was unknown we used a nonparametric, single-arm, dichotomous endpoint that classified subjects whose active treatment COX activity exceeded the average of their lead-in and wash-out measures as positive responders. Eleven positive responses were observed (p < 0.06). The implications of this finding on our null hypothesis (that S-equol does not influence platelet mitochondria COX activity) are discussed. To our knowledge, this is the first time a direct mitochondrial target engagement biomarker has been utilized in an AD clinical study.","['Alzheimer’s disease', 'S-equol', 'biomarker', 'cytochrome oxidase', 'mitochondria']",Journal of Alzheimer's disease : JAD,2017-06-10,"[{'lastname': 'Wilkins', 'firstname': 'Heather M', 'initials': 'HM', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.\nDepartment of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.""}, {'lastname': 'Mahnken', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.\nDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.""}, {'lastname': 'Welch', 'firstname': 'Paul', 'initials': 'P', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.""}, {'lastname': 'Bothwell', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.""}, {'lastname': 'Koppel', 'firstname': 'Scott', 'initials': 'S', 'affiliation': 'Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.'}, {'lastname': 'Jackson', 'firstname': 'Richard L', 'initials': 'RL', 'affiliation': 'Ausio Pharmaceuticals LLC, Cincinnati, OH, USA.'}, {'lastname': 'Burns', 'firstname': 'Jeffrey M', 'initials': 'JM', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.\nDepartment of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.\nDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.""}, {'lastname': 'Swerdlow', 'firstname': 'Russell H', 'initials': 'RH', 'affiliation': ""University of Kansas Alzheimer's Disease Center, Kansas City, KS, USA.\nDepartment of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.\nDepartment of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA.\nDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS, USA.""}]",,,,,10.3233/JAD-170077,<Element 'PubmedArticle' at 0x7f05db73cc20>
274,"28594853
17950702
19858458
17826340
18771956
21482928
26444794
22556362
23518664
24319659
27594585
21810890
21325651
12833363
1202204
3249766
15891946
11254454
15700229
11404350
12053178
25440984
17458552
21644037
22101365
22595371
23692670
21176711
24861427
23053135
27435172
22550220
22892647
23053136
24286341
24703252
24027057",The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics.,"The co-occurrence of the c.709-1G>A GRN mutation and the p.A152T MAPT variant has been identified in 18 Basque families affected by frontotemporal dementia (FTD). We aimed to investigate the influence of the p.A152T MAPT variant on the clinical and neuropathological features of these Basque GRN families.
We compared clinical characteristics of 14 patients who carried the c.709-1G>A GRN mutation (GRN+/A152T-) with 21 patients who carried both the c.709-1G>A GRN mutation and the p.A152T MAPT variant (GRN+/A152T+). Neuropsychological data (n = 17) and plasma progranulin levels (n = 23) were compared between groups, and 7 subjects underwent neuropathological studies. We genotyped six short tandem repeat markers in the two largest families. By the analysis of linkage disequilibrium decay in the haplotype block we estimated the time when the first ancestor to carry both genetic variants emerged. GRN+/A152T+ and GRN+/A152T- patients shared similar clinical and neuropsychological features and plasma progranulin levels. All were diagnosed with an FTD disorder, including behavioral variant FTD or non fluent / agrammatic variant primary progressive aphasia, and shared a similar pattern of neuropsychological deficits, predominantly in executive function, memory, and language. All seven participants with available brain autopsies (6 GRN+/A152T+, 1 GRN+/A152T-) showed frontotemporal lobar degeneration with TDP-43 inclusions (type A classification), which is characteristic of GRN carriers. Additionally, all seven showed mild to moderate tau inclusion burden: five cases lacked β-amyloid pathology and two cases had Alzheimer's pathology. The co-occurrence of both genes within one individual is recent, with the birth of the first GRN+/A152T+ individual estimated to be within the last 50 generations (95% probability).
In our sample, the p.A152T MAPT variant does not appear to show a discernible influence on the clinical phenotype of GRN carriers. Whether p.A152T confers a greater than expected propensity for tau pathology in these GRN carriers remains an open question.",[],PloS one,2017-06-09,"[{'lastname': 'Moreno', 'firstname': 'Fermin', 'initials': 'F', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Indakoetxea', 'firstname': 'Begoña', 'initials': 'B', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Barandiaran', 'firstname': 'Myriam', 'initials': 'M', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Caballero', 'firstname': 'María Cristina', 'initials': 'MC', 'affiliation': 'Department of Pathology, Hospital Universitario Donostia, San Sebastián, Spain.\nBrain Bank Hospital Universitario Donostia, from the Basque Biobank for Research (OEHUN), San Sebastian, Spain.'}, {'lastname': 'Gorostidi', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Calafell', 'firstname': 'Francesc', 'initials': 'F', 'affiliation': 'Institute of Evolutionary Biology (CSIC-UPF), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.'}, {'lastname': 'Gabilondo', 'firstname': 'Alazne', 'initials': 'A', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurology, Hospital de Bidasoa, Irun, Spain.'}, {'lastname': 'Tainta', 'firstname': 'Mikel', 'initials': 'M', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Zulaica', 'firstname': 'Miren', 'initials': 'M', 'affiliation': 'Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.'}, {'lastname': 'Martí Massó', 'firstname': 'José F', 'initials': 'JF', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurosciences, Universidad del País Vasco UPV-EHU, San Sebastian, Spain.'}, {'lastname': 'López de Munain', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': 'Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.\nCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Institute Carlos III, Madrid, Spain.\nNeuroscience Area, Institute Biodonostia, San Sebastian, Spain.\nDepartment of Neurosciences, Universidad del País Vasco UPV-EHU, San Sebastian, Spain.'}, {'lastname': 'Sánchez-Juan', 'firstname': 'Pascual', 'initials': 'P', 'affiliation': ""Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla' (IDIVAL), Santander, Spain.""}, {'lastname': 'Lee', 'firstname': 'Suzee E', 'initials': 'SE', 'affiliation': 'Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, United States of America.'}]",,,,,"10.1371/journal.pone.0178093
10.1016/j.biopsych.2007.08.015
10.1212/WNL.0b013e3181bd82a7
10.1016/S1474-4422(07)70221-1
10.1016/S1474-4422(08)70194-7
10.1001/archneurol.2011.53
10.1093/hmg/dds161
10.1097/WAD.0b013e31828cc357
10.1016/j.stemcr.2013.08.001
10.1016/j.stemcr.2016.08.001
10.1093/brain/awr179
10.1212/WNL.0b013e31821103e6
10.1086/319501
10.1086/428594
10.1038/ng917
10.1111/ahg.12088
10.1007/s00401-007-0223-8
10.1007/s00401-011-0845-8
10.1007/s00401-011-0910-3
10.1016/j.parkreldis.2013.04.023
10.1111/nan.12155
10.1007/s00401-012-1048-7
10.1186/s40478-016-0345-0
10.1136/jnnp-2012-302219
10.1097/WAD.0b013e318266fae5
10.1007/s00401-012-1050-0
10.1016/j.jns.2014.03.030
10.1212/WNL.0b013e3182a8250c",<Element 'PubmedArticle' at 0x7f05db756f40>
275,"28582864
26979082
16906426
12498954
16237129
17023659
19330340
12084879
26810071
18849605
26649319
25224501
27181391
27917876
22847497
27648178
27660698
26967215
24440525
28044060
18346114
15933386
26333802
19184666
11895043
12502659
2198187
27895533
27423001
26812281
27021820
27815632
21326809
17195931
23967244
20639693
21051541
24240737
18950899
23794448
28106068
26249371
27893041
27600683
17101823
11916953
17159101
9371913
10794849
20739645
19139294
26233574
22265587
22101365",Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus.,"A link between diabetes mellitus (DM) related islet amyloid polypeptide (IAPP) and Alzheimer's disease (AD) related amyloid-β (Aβ) has been suggested in epidemiological and clinical studies. In 2017, proof for existing interaction between type 2 DM and AD on a molecular level was provided based on research carried out in experimental animal models. We assessed aging-related neurodegenerative lesions, i.e., misfolded proteins, associated with dementia such as hyperphosphorylated τ (HPτ), Aβ, α-synuclein (αS), and phosphorylated transactive DNA binding protein 43 (pTDP43) seen in the brain and IAPP seen in the pancreas in subjects with and without DM applying immunohistochemical techniques. HPτ in the brain and IAPP in the pancreas were observed in most subjects. The prevalence and the extent of all misfolded proteins increased with age but this increase was not influenced by DM. Interestingly the extent of misfolded proteins in the brain was higher in non-diabetics when compared with diabetics in demented. A significant correlation was observed between HPτ, Aβ, αS, and pTDP43, whereas IAPP showed no association with HPτ, Aβ, and αS. In subjects with DM, the extent of pTDP43 in brain correlated with the extent of IAPP in pancreas. Thus, there is no evidence of a link between AD-related pathology and DM in humans, whereas an association was found between pTDP43 and IAPP in DM. TDP43 is ubiquitously expressed in all organs but whether TDP43 is phosphorylated in other organs in DM or whether the phosphorylation of TDP43 is influenced by glucose metabolism is yet unknown.","['amyloid-β', 'diabetes mellitus', 'hyperphosphorylated τ', 'islet amyloid polypeptide', 'phosphorylated transactive DNA binding protein 43', 'α-synuclein']",Journal of Alzheimer's disease : JAD,2017-06-07,"[{'lastname': 'Leino', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}, {'lastname': 'Popova', 'firstname': 'Svetlana N', 'initials': 'SN', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}, {'lastname': 'Alafuzoff', 'firstname': 'Irina', 'initials': 'I', 'affiliation': 'Department of Pathology, Uppsala University Hospital, Sweden.\nDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.'}]",,,,,"10.3233/JAD-170192
10.1038/mp.2016.230",<Element 'PubmedArticle' at 0x7f05db6fd630>
276,"28546539
22867901
20411034
24095740
22797007
24528254
25998028
22555794
25173805
20930280
23274884
15576490
20308782
12379512
12749025
19573562
18234983
23601582
24062644
24370461
25217888
25592987
26099807
25460016
24722235
25793324
23489554
23202796
23026980
21338538
23400224
24315484
23500100
25202975
22254083
27389418
2535672
14206227
12895417
15417279
17140720
24263092
24678976
25502280
3110839
23174539
25279695
22134646
27267560
25946042
942051
10686146
1986788
22930834
15882795
15483108
20386568
16861106
22982042
19500657
24437518
24595198
19064719
21311563
22966490
19200883
19288120
19542626
22404222
23691109
22040047
19335551
28196097
23473646
22612585
9811366
19240960
24298156
22976078
16775153
24529525
19938193
28215162
26939763
21069780
24781306
24694020
10854289
9125193
15548589
9395128
17399897
26033219
19681160
26351673
9838127
21282636",Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels.,"Gut microbiota has a proven role in regulating multiple neuro-chemical pathways through the highly interconnected gut-brain axis. Oral bacteriotherapy thus has potential in the treatment of central nervous system-related pathologies, such as Alzheimer's disease (AD). Current AD treatments aim to prevent onset, delay progression and ameliorate symptoms. In this work, 3xTg-AD mice in the early stage of AD were treated with SLAB51 probiotic formulation, thereby affecting the composition of gut microbiota and its metabolites. This influenced plasma concentration of inflammatory cytokines and key metabolic hormones considered therapeutic targets in neurodegeneration. Treated mice showed partial restoration of two impaired neuronal proteolytic pathways (the ubiquitin proteasome system and autophagy). Their cognitive decline was decreased compared with controls, due to a reduction in brain damage and reduced accumulation of amyloid beta aggregates. Collectively, our results clearly prove that modulation of the microbiota induces positive effects on neuronal pathways that are able to slow down the progression of Alzheimer's disease.",[],Scientific reports,2017-05-27,"[{'lastname': 'Bonfili', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy. laura.bonfili@unicam.it.'}, {'lastname': 'Cecarini', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy.'}, {'lastname': 'Berardi', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy.'}, {'lastname': 'Scarpona', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy.'}, {'lastname': 'Suchodolski', 'firstname': 'Jan S', 'initials': 'JS', 'affiliation': 'Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, USA.'}, {'lastname': 'Nasuti', 'firstname': 'Cinzia', 'initials': 'C', 'affiliation': 'School of Pharmacy, Pharmacology Unit, University of Camerino, via Madonna delle Carceri, 62032, Camerino, (MC), Italy.'}, {'lastname': 'Fiorini', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': 'Division of Chemistry, School of Science and Technology, University of Camerino, I-62032, Camerino, MC, Italy.'}, {'lastname': 'Boarelli', 'firstname': 'Maria Chiara', 'initials': 'MC', 'affiliation': 'Division of Chemistry, School of Science and Technology, University of Camerino, I-62032, Camerino, MC, Italy.'}, {'lastname': 'Rossi', 'firstname': 'Giacomo', 'initials': 'G', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy.'}, {'lastname': 'Eleuteri', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, (MC), Italy.'}]",,,,,"10.1038/s41598-017-02587-2
10.1016/j.bbadis.2012.07.015
10.1016/j.celrep.2013.08.042
10.1016/j.neuint.2012.07.007
10.1111/jne.12138
10.1007/s12603-012-0058-4
10.1016/j.bbadis.2012.12.009
10.1096/fj.04-2572com
10.3233/JAD-2010-1308
10.1677/joe.0.175R001
10.1002/jnr.10611
10.1016/j.bbr.2009.06.035
10.1152/jn.01161.2007
10.1186/alzrt174
10.3389/fncel.2013.00153
10.1016/j.bbi.2013.12.015
10.1186/1750-1326-9-36
10.1371/journal.pone.0094699
10.1097/MIB.0000000000000346
10.1016/j.maturitas.2013.02.004
10.4161/gmic.22973
10.1038/nrneurol.2012.194
10.1017/S0007114511000158
10.1001/jamapediatrics.2013.497
10.1016/j.cell.2013.11.024
10.1016/j.neuroscience.2013.02.055
10.1371/journal.pone.0106503
10.3390/nu3100858
10.1016/S0896-6273(03)00434-3
10.1016/j.tox.2006.10.015
10.1038/nprot.2013.155
10.1186/1866-1955-6-7
10.1038/srep07467
10.1016/j.tox.2012.09.016
10.1371/journal.pone.0108729
10.1038/ismej.2011.139
10.1016/j.ab.2016.05.023
10.1371/journal.pone.0126317
10.1016/0003-2697(76)90527-3
10.1006/prep.1999.1187
10.1016/0167-4838(91)90232-O
10.1038/nmeth.2089
10.1016/j.neulet.2005.02.002
10.1073/pnas.0406788101
10.1038/mp.2010.44
10.1016/j.brainresbull.2006.04.008
10.1016/j.anaerobe.2012.09.002
10.1016/j.neuroscience.2009.05.071
10.1089/ars.2013.5802
10.1124/jpet.108.147082
10.1038/cdd.2010.191
10.4161/auto.19496
10.1016/S0076-6879(08)03612-4
10.1007/s00401-009-0517-0
10.3233/JAD-2009-1090
10.1111/j.1365-2982.2012.01906.x
10.1371/journal.pone.0063893
10.1111/j.1348-0421.2011.00398.x
10.1111/j.1365-2613.2008.00632.x
10.1371/journal.pone.0171350
10.1016/j.vetmic.2013.02.002
10.1111/j.1365-2672.2012.05344.x
10.1016/S0031-9384(98)00145-0
10.1007/s00415-009-5011-z
10.1098/rstb.2013.0155
10.1523/JNEUROSCI.5126-05.2006
10.1016/j.jalz.2013.12.009
10.3748/wjg.15.5549
10.1016/j.neuint.2016.02.014
10.1002/hipo.20883
10.1038/ncomms4611
10.1179/1476830514Y.0000000122
10.1046/j.1471-4159.2000.0750436.x
10.1006/bbrc.1997.6301
10.1016/S0022-510X(97)00131-7
10.1016/j.neulet.2007.03.026
10.1073/pnas.1510456112
10.1016/S0006-8993(98)01042-7
10.1073/pnas.1010529108",<Element 'PubmedArticle' at 0x7f05db71f5e0>
277,"28522837
17261678
27510634
25924979
21944778
21944779
22406228
27349438
22564974
20801718
22445326
2232913
19237701
22366792
17634215
23379621
1745327
23254636",Age-related penetrance of the C9orf72 repeat expansion.,"A pathogenic hexanucleotide repeat expansion within the C9orf72 gene has been identified as the major cause of two neurodegenerative syndromes, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This mutation is known to have incomplete penetrance, with some patients developing disease in their twenties and a small portion of carriers surviving to their ninth decade without developing symptoms. Describing penetrance by age among C9orf72 carriers and identifying parameters that alter onset age are essential to better understanding this locus and to enhance predictive counseling. To do so, data from 1,170 individuals were used to model penetrance. Our analysis showed that the penetrance was incomplete and age-dependent. Additionally, familial and sporadic penetrance did not significantly differ from one another; ALS cases exhibited earlier age of onset than FTD cases; and individuals with spinal-onset exhibited earlier age of onset than those with bulbar-onset. The older age of onset among female cases in general, and among female bulbar-onset cases in particular, was the most striking finding, and there may be an environmental, lifestyle, or hormonal factor that is influencing these penetrance patterns. These results will have important applications for future clinical research, the identification of disease modifiers, and genetic counseling.",[],Scientific reports,2017-05-20,"[{'lastname': 'Murphy', 'firstname': 'Natalie A', 'initials': 'NA', 'affiliation': 'Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 20892, USA.'}, {'lastname': 'Arthur', 'firstname': 'Karissa C', 'initials': 'KC', 'affiliation': 'Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, 18509, USA.'}, {'lastname': 'Tienari', 'firstname': 'Pentti J', 'initials': 'PJ', 'affiliation': 'Department of Neurology, Helsinki University Hospital, Helsinki, FIN-02900, Finland.\nMolecular Neurology Research Program Unit, University of Helsinki, Helsinki, FIN-02900, Finland.'}, {'lastname': 'Houlden', 'firstname': 'Henry', 'initials': 'H', 'affiliation': 'Department of Molecular Neurosciences, Institute of Neurology, University College London, Queen Square House, London, WC1N 3BG, UK.'}, {'lastname': 'Chiò', 'firstname': 'Adriano', 'initials': 'A', 'affiliation': 'Department of Neuroscience, University of Turin, 10126, Turin, Italy.'}, {'lastname': 'Traynor', 'firstname': 'Bryan J', 'initials': 'BJ', 'affiliation': 'Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 20892, USA. traynorb@mail.nih.gov.\nBrain Science Institute, Department of Neurology, Johns Hopkins University, Baltimore, Maryland, 21205, USA. traynorb@mail.nih.gov.'}]",,,,,"10.1038/s41598-017-02364-1
10.1212/01.wnl.0000252807.38124.a3
10.1038/ncomms12408
10.1586/14737167.2015.1039941
10.1016/j.neuron.2011.09.011
10.1016/j.neuron.2011.09.010
10.1016/S1474-4422(12)70043-1
10.1097/WNR.0b013e3283544718
10.1016/S1474-4422(10)70184-8
10.1016/0047-6374(90)90149-A
10.1212/01.wnl.0000343008.26874.d1
10.1093/brain/awr365
10.1136/jnnp.2007.117788
10.1111/cge.12117
10.1159/000110267",<Element 'PubmedArticle' at 0x7f05db6df090>
278,"28473694
20026663
12524533
12526812
12889069
18378771
12973694
21224065
16862116
16862115
16950801
16983685
17923627
18245784
17949857
17826340
19288468
19158106
19683260
18752597
20142525
19625741
21212639
17030534
17917583
17157414
23609919
17439980
25575133
20703815
25619230
1759558
21644037
10483782
17071926
17591968
17278999
22699850
25022663
12000724
28073925",Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation.,"In 2006, mutations in the granulin gene were identified in patients with familial Frontotemporal Lobar Degeneration. Granulin transcript haploinsufficiency has been proposed as a disease mechanism that leads to the loss of functional progranulin protein. Granulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration. Moreover, a reduction in progranulin in tau transgenic mice is associated with increasing tau accumulation. To investigate the influence of a decline in progranulin protein on other forms of neurodegenerative-related protein accumulation, human granulin mutation cases were investigated by histochemical and biochemical analyses. Results showed a neuronal and glial tau accumulation in granulin mutation cases. Tau staining revealed neuronal pretangle forms and glial tau in both astrocytes and oligodendrocytes. Furthermore, phosphorylated α-synuclein-positive structures were also found in oligodendrocytes and the neuropil. Immunoblot analysis of fresh frozen brain tissues revealed that tau was present in the sarkosyl-insoluble fraction, and composed of three- and four-repeat tau isoforms, resembling Alzheimer's disease. Our data suggest that progranulin reduction might be the cause of multiple proteinopathies due to the accelerating accumulation of abnormal proteins including TDP-43 proteinopathy, tauopathy and α-synucleinopathy.",[],Scientific reports,2017-05-06,"[{'lastname': 'Hosokawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan. hosokawa-ms@igakuken.or.jp.'}, {'lastname': 'Kondo', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': 'Histology Center, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Serrano', 'firstname': 'Geidy E', 'initials': 'GE', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.'}, {'lastname': 'Beach', 'firstname': 'Thomas G', 'initials': 'TG', 'affiliation': 'Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.'}, {'lastname': 'Robinson', 'firstname': 'Andrew C', 'initials': 'AC', 'affiliation': 'Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Neuroscience & Experimental Psychology, University of Manchester, Clinical Sciences Building, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Mann', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'Faculty of Biology, Medicine and Health, School of Biological Sciences, Division of Neuroscience & Experimental Psychology, University of Manchester, Clinical Sciences Building, Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.'}, {'lastname': 'Akiyama', 'firstname': 'Haruhiko', 'initials': 'H', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Hasegawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.'}, {'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': 'Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan.\nDepartment of Neuropsychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8576, Japan.'}]",,,,,"10.1038/s41598-017-01587-6
10.1084/jem.20091568
10.1038/nm816
10.1016/S0092-8674(02)01141-8
10.1002/dvdy.10341
10.1083/jcb.200712039
10.1016/j.ajpath.2010.11.002
10.1038/nature05016
10.1038/nature05017
10.1093/hmg/ddl241
10.1002/ana.20963
10.1001/archneur.64.10.1436
10.1093/brain/awn012
10.1016/j.neurobiolaging.2007.08.022
10.1016/S1474-4422(07)70221-1
10.1002/ana.21621
10.1093/brain/awn352
10.1016/j.jns.2009.07.011
10.1111/j.1468-1331.2008.02266.x
10.1001/archneurol.2010.113
10.3233/JAD-2009-1170
10.1159/000322538
10.1093/brain/awl276
10.1097/nen.0b013e3181567873
10.1016/j.neurobiolaging.2006.10.028
10.1001/2013.jamaneurol.393
10.1093/brain/awm069
10.1097/NEN.0000000000000158
10.1007/s10561-010-9210-8
10.1111/neup.12189
10.1007/BF00308809
10.1007/s00401-011-0845-8
10.1007/s004010051077
10.1093/brain/awl271
10.2353/ajpath.2007.070182
10.1097/nen.0b013e31803020cf
10.1186/s40478-014-0078-x
10.1016/S0002-9440(10)61119-4
10.1093/hmg/ddx011",<Element 'PubmedArticle' at 0x7f05db674680>
279,28467893,Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions.,"Accurate interpretation and appropriate expression of emotions are key aspects of social-cognition. Several mental disorders are characterised by transdiagnostic difficulties in these areas and, recently, there has been increasing interest in exploring the effects of oxytocin on social-emotional functioning. This review consists of 33 studies. Fifteen of the studies included people with autism spectrum disorder, schizophrenia, borderline personality disorder, frontotemporal dementia, anorexia nervosa, bulimia nervosa, post-traumatic stress disorder, depression, and opioid and alcohol dependence. We conducted ten meta-analyses examining the effects of intranasal oxytocin on expression of emotions, emotional theory of mind, sensitivity to recognise basic emotions, and recognition of basic emotions. A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals. Oxytocin did not significantly influence theory of mind or the expression of negative emotions among the healthy individuals. Finally, intranasal oxytocin did not significantly influence interpretation or expression of emotions among the clinical populations.","['Emotion expression', 'Emotion recognition', 'Oxytocin', 'Theory of mind']",Neuroscience and biobehavioral reviews,2017-05-04,"[{'lastname': 'Leppanen', 'firstname': 'Jenni', 'initials': 'J', 'affiliation': ""King's College London, Institute of Psychiatry, Psychology, and Neuroscience, Department of Psychological Medicine, London, United Kingdom. Electronic address: jenni.leppanen@kcl.ac.uk.""}, {'lastname': 'Ng', 'firstname': 'Kah Wee', 'initials': 'KW', 'affiliation': 'Singapore General Hospital,20 College Road, Academia, 169865, Singapore.'}, {'lastname': 'Tchanturia', 'firstname': 'Kate', 'initials': 'K', 'affiliation': ""King's College London, Institute of Psychiatry, Psychology, and Neuroscience, Department of Psychological Medicine, London, United Kingdom; Department of Psychology, Illia State University, Tbilisi, Georgia.""}, {'lastname': 'Treasure', 'firstname': 'Janet', 'initials': 'J', 'affiliation': ""King's College London, Institute of Psychiatry, Psychology, and Neuroscience, Department of Psychological Medicine, London, United Kingdom.""}]",,,,Copyright © 2017. Published by Elsevier Ltd.,10.1016/j.neubiorev.2017.04.010,<Element 'PubmedArticle' at 0x7f05db695db0>
280,"28427413
25594180
27012931
26118345
18061654
24655651
25126588
26209808
24582565
20701790
24481440
26322226
24927875
23754387
25567201
25582291
21035400
27400276
23967244
23848967
18560390
26822748
27498188
11464847
26121170
22892641
21810890
21325651
19462523
26198021
16819528
21195356
24344910
22975021
23669350
25489489
26935478
27093924
19581422
22213409
26682770
20727007
27079710
24771538
22213409",Adiponectin levels in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients: possible influence on neuroinflammation?,"Adiponectin (APN) is a key player in energy homeostasis strictly associated with cerebrovascular and neurodegenerative diseases. Since APN also belongs to anti-inflammatory-acting adipokines and may influence both neuroinflammation and neurodegenerative processes, we decided to study the APN levels in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
We assessed APN levels by ELISA immunoassay in both the serum and cerebrospinal fluid of a cohort of familial and sporadic ALS patients, characterized by normal body mass index and absence of dysautonomic symptoms. The screening of serum APN levels was also performed in patients affected by other neurological disorders, including fronto-temporal dementia (FTD) patients. Means were compared using the non-parametric Wilcoxon test, and Pearson's or Spearman's rho was used to assess correlations between variables.
In the whole ALS group, serum APN levels were not different when compared to the age- and sex-matched control group (CTR), but a gender-specific analysis enlightened a significant opposite APN trend between ALS males, characterized by lower values (ALS 9.8 ± 5.2 vs. CTR 15 ± 9.7 μg/ml), and ALS females, showing higher amounts (ALS 26.5 ± 11.6 vs. CTR 14.6 ± 5.2 μg/ml). This sex-linked difference was significantly enhanced in familial ALS cases (p ≤ 0.01). The APN levels in ALS cerebrospinal fluids were unrelated to serum values and not linked to sex and/or familiarity of the disease. Finally, the screening of serum APN levels in patients affected by other neurological disorders revealed the highest serum values in FTD patients.
Opposite serum APN levels are gender-related in ALS and altered in several neurological disorders, with the highest values in FTD, which shares with ALS several overlapping and neuropathological features. Further investigations are needed to clarify the possible involvement of APN in neuroinflammation and neurodegeneration. Possible involvement of APN in neuroinflammatory neurodegenerative diseases.","['Adipokine', 'Adiponectin', 'Fronto-temporal dementia', 'Motor neuron disease', 'Neurodegeneration', 'Neuroinflammation']",Journal of neuroinflammation,2017-04-22,"[{'lastname': 'Bossolasco', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, piazzale Brescia 20, 20149, Milan, Italy.'}, {'lastname': 'Cancello', 'firstname': 'Raffaella', 'initials': 'R', 'affiliation': 'Diabetes Research Laboratory, IRCCS, Istituto Auxologico Italiano, via Ariosto 13, 20145, Milan, Italy.'}, {'lastname': 'Doretti', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, piazzale Brescia 20, 20149, Milan, Italy.'}, {'lastname': 'Morelli', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, piazzale Brescia 20, 20149, Milan, Italy.'}, {'lastname': 'Silani', 'firstname': 'Vincenzo', 'initials': 'V', 'affiliation': 'Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, piazzale Brescia 20, 20149, Milan, Italy.\n""Dino Ferrari"" Centre, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, via Sforza 35, 20122, Milan, Italy.'}, {'lastname': 'Cova', 'firstname': 'Lidia', 'initials': 'L', 'affiliation': 'Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, piazzale Brescia 20, 20149, Milan, Italy. l.cova@auxologico.it.\nLaboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, via Zucchi 18, 20095, Cusano Milanino, Milan, Italy. l.cova@auxologico.it.'}]",,,"In the whole ALS group, serum APN levels were not different when compared to the age- and sex-matched control group (CTR), but a gender-specific analysis enlightened a significant opposite APN trend between ALS males, characterized by lower values (ALS 9.8 ± 5.2 vs. CTR 15 ± 9.7 μg/ml), and ALS females, showing higher amounts (ALS 26.5 ± 11.6 vs. CTR 14.6 ± 5.2 μg/ml). This sex-linked difference was significantly enhanced in familial ALS cases (p ≤ 0.01). The APN levels in ALS cerebrospinal fluids were unrelated to serum values and not linked to sex and/or familiarity of the disease. Finally, the screening of serum APN levels in patients affected by other neurological disorders revealed the highest serum values in FTD patients.",,"10.1186/s12974-017-0861-2
10.1016/j.cell.2014.12.019
10.1186/s12974-016-0530-x
10.1016/j.apsb.2012.06.008
10.1016/j.jaci.2007.10.018
10.1016/j.jaac.2013.12.025
10.1002/acn3.77
10.1016/j.bbi.2015.07.018
10.1016/j.bbrc.2014.02.077
10.1186/2040-7378-2-15
10.1038/cddis.2013.538
10.1186/s13619-015-0019-6
10.1016/j.tins.2014.05.006
10.1073/pnas.1308421110
10.1007/s13311-014-0329-3
10.1016/j.neuropharm.2014.12.023
10.1016/S1474-4422(10)70224-6
10.1159/000446502
10.1371/journal.pone.0071793
10.1186/1471-2377-13-84
10.1038/ncpneuro0853
10.1016/S1474-4422(15)00380-4
10.1016/j.molmed.2016.07.005
10.1080/146608200300079536
10.3109/21678421.2015.1049183
10.1001/archneurol.2012.254
10.2217/dmt.14.30
10.1093/brain/awr179
10.1212/WNL.0b013e31821103e6
10.1080/17482960802654364
10.1016/j.jns.2015.06.053
10.1038/sj.ijo.0803427
10.1016/j.genm.2010.11.010
10.3109/21678421.2013.865749
10.1016/j.nbd.2012.08.015
10.1093/hmg/ddt202
10.1038/srep24493
10.2337/db08-1750
10.1001/archneurol.2011.670
10.1111/ene.12915
10.1111/j.1468-1331.2010.03194.x
10.3233/JAD-151116
10.1212/WNL.0000000000000445
10.1001/archneurol.2011.670",<Element 'PubmedArticle' at 0x7f05db69eb80>
281,"28324298
24366271
26214150
15602591
27476067
24433933
8539624
16251950
27718103
9989497
10440971
10404920
25766617
10759187
26568126
12198538
25888034
24493463
25963004
10071710
15485355
25675494
26834500
8544907
26947521
17943086
27981356
9920102
15725334
26402759
9822755
21532579
9818303
24145859
12887656
25813842
23273723
3014578
18070004
25515641
16887746
21482364
25034185
24495406
4041816
25002497
25921596
24971004
9419374
16364896
8280909
1496005
26505992
2465060
23279149
11704081
26935586
22956200
15522910
12670422
16837102
3951711
24574061
23390181
27821764
16014733
27568802
18395623
19779148
26606319
26376345
20219426
21115064
25754641
10068311
21911660
15078551
17596638
7681871
25599827
23479184
12928714
23950941
23857055
24136970
27645169
21037585
22575905
7638622
19726652
15978517",Circadian Disruption Associated with Alzheimer's Disease.,"Alzheimer's disease (AD) is increasing in prevalence and has a significant impact on caregivers and the healthcare system. One of the many physiologic process affected by AD is the circadian system, with disruption reflected in abnormalities of the sleep-wake cycle. This interaction is bidirectional, with circadian and sleep disruption influencing disease progression. Understanding the bidirectional relationship between AD and circadian disruption may allow for earlier recognition of the potential to develop dementia as well as improved targeted approaches for therapy. Therapies including melatonin and bright light therapy may be advantageous in improving sleep and circadian rhythms and preventing the progression of disease. However, unfortunately, these modalities are not curative, and additional research is needed to improve treatment options for these individuals.","['Alzheimer’s disease', 'Bright light therapy', 'Circadian disruption', 'Melatonin', 'β-Amyloid']",Current neurology and neuroscience reports,2017-03-23,"[{'lastname': 'Saeed', 'firstname': 'Yumna', 'initials': 'Y', 'affiliation': 'Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'lastname': 'Abbott', 'firstname': 'Sabra M', 'initials': 'SM', 'affiliation': 'Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. sabra.abbott@northwestern.edu.'}]",,,,,10.1007/s11910-017-0745-y,<Element 'PubmedArticle' at 0x7f05db6403b0>
282,28215174,The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism.,"Cancer and Alzheimer's disease (AD) are both associated with aging, but do not often occur together. Obesity is a shared risk factor for both diseases and may be involved in this curious clinical observation. Fat cells produce many active substances, including leptin and adiponectin; leptin has cancer stimulating and AD inhibiting properties, while adiponectin can inhibit cancer but stimulate AD.
To describe the opposing effects of leptin and adiponectin on cancer and AD, to outline signaling pathways involved in these effects and to suggest new research on effective control strategies for both diseases.
A review was conducted to document the inverse cancer/AD relationship and the role of excess body fat as a common risk factor. Previous studies have suggested the involvement of p53, Wnt and other cell signaling pathways in this inverse relationship. The opposing effects of leptin and adiponectin on these signaling pathways in cancer and AD were evaluated.
The inverse cancer/AD relationship is well documented, as is the role of excess body fat, especially central obesity, in increasing risk for both diseases. Leptin and adiponectin have opposing effects in cancer and AD mediated by signaling factors that influence apoptosis, angiogenesis, and other cell growth controls. Wnt and p53 are prominent among these signaling factors.
Opposing effects of leptin and adiponectin, mediated by specific cell signaling pathways, are involved in the inverse cancer/Ad relationship. Future research aimed at modifying the leptin/adiponectin ratio may lead to important treatment and control approaches in both cancer and AD.","[""Alzheimer's disease"", 'Cancer', 'Wnt', 'adipokines', 'adiponectin', 'leptin', 'p53']",Current Alzheimer research,2017-02-22,"[{'lastname': 'Nixon', 'firstname': 'Daniel W', 'initials': 'DW', 'affiliation': ""Adjunct Clinical Professor of Medicine, Morehouse School of Medicine, 1611 Atlantic Ave, Sullivan's Island, SC 29482, United States.""}]",,"Opposing effects of leptin and adiponectin, mediated by specific cell signaling pathways, are involved in the inverse cancer/Ad relationship. Future research aimed at modifying the leptin/adiponectin ratio may lead to important treatment and control approaches in both cancer and AD.","The inverse cancer/AD relationship is well documented, as is the role of excess body fat, especially central obesity, in increasing risk for both diseases. Leptin and adiponectin have opposing effects in cancer and AD mediated by signaling factors that influence apoptosis, angiogenesis, and other cell growth controls. Wnt and p53 are prominent among these signaling factors.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",10.2174/1567205014666170216152905,<Element 'PubmedArticle' at 0x7f05db65d180>
283,"28140738
11578524
1765629
22315239
23904406
19375070
18407136
25753264
26207078
19294424
19059511
1202204
21295410
23684478
22475549
12652000
17430248
16478564
15157348
15219652
1607586
9807058
3527687
26317554
26219886
2126355
20102654
19128884
17669595
12906940","Stress in childhood, adolescence and early adulthood, and cortisol levels in older age.","The glucocorticoid hypothesis suggests that overexposure to stress may cause permanent upregulation of cortisol. Stress in youth may therefore influence cortisol levels even in older age. Using data from the 6-Day Sample, we investigated the effects of high stress in childhood, adolescence and early adulthood - as well as individual variables contributing to these measures; parental loss, social deprivation, school and home moves, illness, divorce and job instability - upon cortisol levels at age 77 years. Waking, waking +45 min (peak) and evening salivary cortisol samples were collected from 159 participants, and the 150 who were not using steroid medications were included in this study. After correcting for multiple comparisons, the only significant association was between early-adulthood job instability and later-life peak cortisol levels. After excluding participants with dementia or possible mild cognitive impairment, early-adulthood high stress showed significant associations with lower evening and mean cortisol levels, suggesting downregulation by stress, but these results did not survive correction for multiple comparisons. Overall, our results do not provide strong evidence of a relationship between stress in youth and later-life cortisol levels, but do suggest that some more long-term stressors, such as job instability, may indeed produce lasting upregulation of cortisol, persisting into the mid-to-late seventies.","['6-Day Sample', 'Childhood stress', 'adolescent stress', 'early-adulthood stress', 'older-age cortisol']","Stress (Amsterdam, Netherlands)",2017-02-01,"[{'lastname': 'Harris', 'firstname': 'Mathew A', 'initials': 'MA', 'affiliation': 'a Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh , Edinburgh, UK.\nb Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh, UK.'}, {'lastname': 'Cox', 'firstname': 'Simon R', 'initials': 'SR', 'affiliation': 'a Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh , Edinburgh, UK.\nc Department of Psychology , University of Edinburgh , Edinburgh, UK.'}, {'lastname': 'Brett', 'firstname': 'Caroline E', 'initials': 'CE', 'affiliation': 'a Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh , Edinburgh, UK.\nd School of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK.'}, {'lastname': 'Deary', 'firstname': 'Ian J', 'initials': 'IJ', 'affiliation': 'a Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh , Edinburgh, UK.\nc Department of Psychology , University of Edinburgh , Edinburgh, UK.'}, {'lastname': 'MacLullich', 'firstname': 'Alasdair M J', 'initials': 'AM', 'affiliation': 'a Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh , Edinburgh, UK.\ne Edinburgh Delirium Research Group, Geriatric Medicine Unit , University of Edinburgh , Edinburgh, UK.\nf Endocrinology Unit , University of Edinburgh , Edinburgh, UK.'}]",,,,,10.1080/10253890.2017.1289168,<Element 'PubmedArticle' at 0x7f05db5e6ea0>
284,28121365,Research on the role of GLP-2 in the central nervous system EPK signal transduction pathway of mice with vascular dementia.,"To investigate the role of Glucagon-like peptide-2 (GLP-2) in the central nervous system eukaryotic protein kinase (EPK) signal transduction pathway of mice with vascular dementia.
We take the 3-week-old mice raised in the laboratory as the object of study in this research and then divide them into four groups in random, including sham operation group, control group, GLP-2 group, and GLP-2+ERK (extracellular-signal-regulated kinase) inhibitor intervention group, with 30 in each group. The step-down test, water-maze test, electron microscopy observation, immunohistochemical method, and Western-blotting are adopted to investigate the role of GLP-2 in the central nervous system EPK signal transduction pathway of mice with vascular dementia.
The step-down test, as well as the water-maze learning and memory test, shows that the mice injected with GLP-2 in the experiment group have their learning and memory ability improved significantly when compared with other three groups, which is greatly different from that of other three groups (p < 0.05); the electron microscopy observation shows that the injection of GLP can partially reverse the reduction of vesicles while ERK inhibitor removes the said protection; the immunohistochemical result and image analysis result show that the EPK expression quantity in GLP-2 group has no significant difference from that of other three groups (p > 0.05). However, the content of pi-EPK in the GLP-2 group is significantly higher than that in VD group and GLP-2+PD98095 group and is significantly different from them (p < 0.05), and such result is in line with the result of Western-blotting.
GLP can influence the change in hippocampus cells extensions and finally influence their cognitive function by activating the EPK signal transduction pathway of hippocampal neuron in the central nervous system.",[],European review for medical and pharmacological sciences,2017-01-26,"[{'lastname': 'Chi', 'firstname': 'C-L', 'initials': 'CL', 'affiliation': 'Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. chi_chunling1@163.com.'}, {'lastname': 'Zhang', 'firstname': 'S-A', 'initials': 'SA', 'affiliation': None}, {'lastname': 'Liu', 'firstname': 'Z', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Chang', 'firstname': 'M-X', 'initials': 'MX', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Huang', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}]",,,"The step-down test, as well as the water-maze learning and memory test, shows that the mice injected with GLP-2 in the experiment group have their learning and memory ability improved significantly when compared with other three groups, which is greatly different from that of other three groups (p < 0.05); the electron microscopy observation shows that the injection of GLP can partially reverse the reduction of vesicles while ERK inhibitor removes the said protection; the immunohistochemical result and image analysis result show that the EPK expression quantity in GLP-2 group has no significant difference from that of other three groups (p > 0.05). However, the content of pi-EPK in the GLP-2 group is significantly higher than that in VD group and GLP-2+PD98095 group and is significantly different from them (p < 0.05), and such result is in line with the result of Western-blotting.",,,<Element 'PubmedArticle' at 0x7f05db5fe860>
285,28102934,Crosstalk between angiotensin and the nonamyloidogenic pathway of Alzheimer's amyloid precursor protein.,"The association between hypertension and an increased risk for Alzheimer's disease (AD) and dementia is well established. Many data suggest that modulation of the renin-angiotensin system may be meaningful for the prevention and therapy of neurodegenerative disorders, in particular AD. Proteolytic cleavage of the amyloid precursor protein (APP) by α-secretase precludes formation of neurotoxic Aβ peptides and is expected to counteract the development of AD. An established approach for the up-regulation of α-secretase cleavage is the activation of G protein-coupled receptors (GPCRs). Therefore, our study aimed to analyze whether stimulation of angiotensin AT","[""Alzheimer's disease"", 'alpha-secretase ADAM10', 'angiotensin receptor', 'renin-angiotensin system']",The FEBS journal,2017-01-20,"[{'lastname': 'Kanarek', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'Institute of Pharmacy and Biochemistry, Johannes Gutenberg-University, Mainz, Germany.'}, {'lastname': 'Wagner', 'firstname': 'Annika', 'initials': 'A', 'affiliation': 'Institute of Pharmacy and Biochemistry, Johannes Gutenberg-University, Mainz, Germany.'}, {'lastname': 'Küppers', 'firstname': 'Jim', 'initials': 'J', 'affiliation': 'Pharmaceutical Institute, Pharmaceutical Chemistry, University of Bonn, Germany.'}, {'lastname': 'Gütschow', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Pharmaceutical Institute, Pharmaceutical Chemistry, University of Bonn, Germany.'}, {'lastname': 'Postina', 'firstname': 'Rolf', 'initials': 'R', 'affiliation': 'Institute of Pharmacy and Biochemistry, Johannes Gutenberg-University, Mainz, Germany.'}, {'lastname': 'Kojro', 'firstname': 'Elzbieta', 'initials': 'E', 'affiliation': 'Institute of Pharmacy and Biochemistry, Johannes Gutenberg-University, Mainz, Germany.'}]",,,,© 2017 Federation of European Biochemical Societies.,10.1111/febs.14015,<Element 'PubmedArticle' at 0x7f05db606040>
286,28093992,Effects of Thyroid Hormones and their Metabolites on Learning and Memory in Normal and Pathological Conditions.,"Classical thyroid hormones have an established necessary role in the normal development of the central nervous system, and they have been recently considered as decisive factors influencing cognitive functions in the adult brain and involved in the development of Alzheimer's disease. The picture summarizing thyroid hormone effects on the adult brain, however, does not only include classical thyroid hormones but also the products of their peripheral metabolism. These latter have been considered as inactive breakdown products for long but recently were proved to produce significant biological effects.
In this review article we presented recent evidence supporting the hypothesis that thyroid hormones exert a neuroprotective effect in the brain areas involved in learning and memory. Moreover, we summarized the evidence that suggests that non-classical thyroid hormones produce significant neurological effects in the adult brain. We also discussed the possible role of thyroid hormones in the cognitive impairment, typical of Alzheimer's disease.
A comprehensive review of the literature based on the current knowledge of the effects of classical and nonclassical thyroid hormones on the adult brain and their role in Alzheimer's disease was performed.
The available literature suggests that both classical and non-classical thyroid hormones act as neuroprotective agents in the brain areas related to learning and memory. Their role in these areas supports the idea that they may be involved in the development of Alzheimer's disease.
Thyroid hormones produce significant neurological effects, act as neuroprotective agents and might be considered as future diagnostic and therapeutic tools for Alzheimer's disease.","['3-iodothyronamine', 'Thyroid hormone', 'dementia.', 'hippocampus', 'memory', 'neuroprotection']",Current drug metabolism,2017-01-18,"[{'lastname': 'Accorroni', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Institute of Life Sciences, Scuola Superiore Sant`Anna, 56127 Pisa. Italy.'}, {'lastname': 'Chiellini', 'firstname': 'Grazia', 'initials': 'G', 'affiliation': 'Department of Pathology, University of Pisa, 56126 Pisa. Italy.'}, {'lastname': 'Origlia', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Institute of Neuroscience, CNR, 56124 Pisa. Italy.'}]",,"Thyroid hormones produce significant neurological effects, act as neuroprotective agents and might be considered as future diagnostic and therapeutic tools for Alzheimer's disease.",The available literature suggests that both classical and non-classical thyroid hormones act as neuroprotective agents in the brain areas related to learning and memory. Their role in these areas supports the idea that they may be involved in the development of Alzheimer's disease.,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",10.2174/1389200218666170116112407,<Element 'PubmedArticle' at 0x7f05db6160e0>
287,28074678,"Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy.","Alzheimer's disease, cerebrovascular disease and aging-related cognitive impairment and dementia (ARCID) increase in prevalence in women with advancing age. The development of Alzheimer's disease, cerebrovascular disease and ARCID may be postponed or prevented by protective measures including the active treatment of vascular risk factors and continuing exercise and healthy lifestyle from early- and mid-life onward. Bilateral oophorectomy before the natural menopause is associated with an increased incidence of ARCID and the increased risk is significantly reduced by estrogen therapy. Recent advances in menopause hormone therapy including transdermal estrogen therapy have favorably influenced the balance of benefits and risks. A case can be made for menopause hormone therapy in healthy postmenopausal women for 5-10 years starting during the menopausal transition (the 'window of opportunity'), together with all other protective measures, to delay or prevent the development of ARCID in later life.","[""Alzheimer's disease"", 'cerebrovascular disease', 'dementia', 'estrogen', 'menopause', 'prevention']",Neurodegenerative disease management,2017-01-12,"[{'lastname': 'Davey', 'firstname': 'Dennis A', 'initials': 'DA', 'affiliation': 'Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Western Cape 7925, South Africa.'}]",,,,,10.2217/nmt-2016-0044,<Element 'PubmedArticle' at 0x7f05db61eb30>
288,"27999310
4415090
13567043
13234368
11717247
12843274
22915112
16510735
16750837
18297067
17046690
21791565
11906788
15893308
8050041
8030628
20965156
9191758
9566385
2169269
2558781
9799621
19560872
1316615
19912958
12694373
25415243
12143394
6382047
1672782
23964066
10322180
8782539
7472485
7597126
3183710
2420562
11871
719462
9075237
7470857
4041042
3774818
3399046
7509608
7845585
2533089
8423470
16096020
9187280
16149083
11821512
8848287
20478440
9472688
837883
748049
891467
3455786
21320576
20045216
15582747
15364411
17010478
19815003
21114983
17406656
4600633
4134992
22217824
7554147
3388021
1954907
9576759
6110089
2422449
8090165
8248223
8650195
9398750
10588810
9048584
8521509
20019181
10657006
9388012
17615392
20506473
20875808
24009071
23196064
12571449
16651814
8446107
10368774
11452016
10447781
10681512
4295833
10323667
19317180
19207809
12351713
21844907
14573532
9367686
8920907
11043579
11773440
8078914
15539556
18420744
18579753
23362079
8642406
10511696
11488923
16611827
10368772
16203092
1613547
9809515
9689481
11172057
10077336
22165673
14580942
12753077
26879842
15213206
27327261
19427328
8780008
9546791
16365303
23771838
2990988
8782897
11152678
12787319
9927421
7890832
22019477
10899288
15609090
18199491
1382329
1850549
7605062
1706478
2171894
1649007
1742028
1327010
11729324
8332899
10851172
9852160
14824426
8144877
8325866
9768588
7188352
2779653
7598845
8486743
7671302
9252024
9398443
7701324
10477751
10066247
10508738
8702822
12169297
8614802
9454839
10430489
9547236
9852573
9915784
10234043
11520181
15217092
1422811
15966860
9410912
16893414
27521573
23769397
2411537
1688328
2842704
3746405
3798108
8027442
6136314
1432101
22442072
2556457
2158008
9315882
8137419
16855103
2183081
8468401
9733161
7283399
21816388
27371762
21145918
9200493
9628764
9130295
10833325
7058341
7479947
7925844
8774454
9573399
9733072
10683408
11378248
9051746
16539663
10683291
16288118
27317847
10675382
12117397
24172877
24680650
16024751
18700946
24040818
15837589
8931004
8915574
3532929
8117429
22377499
22655593
25147108",Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer's Disease.,"The basal forebrain is home to the largest population of cholinergic neurons in the brain. These neurons are involved in a number of cognitive functions including attention, learning and memory. Basal forebrain cholinergic neurons (BFCNs) are particularly vulnerable in a number of neurological diseases with the most notable being Alzheimer's disease, with evidence for a link between decreasing cholinergic markers and the degree of cognitive impairment. The neurotrophin growth factor system is present on these BFCNs and has been shown to promote survival and differentiation on these neurons. Clinical and animal model studies have demonstrated the neuroprotective effects of 17β-estradiol (E2) on neurodegeneration in BFCNs. It is believed that E2 interacts with neurotrophin signaling on cholinergic neurons to mediate these beneficial effects. Evidence presented in our recent study confirms that altering the levels of circulating E2 levels via ovariectomy and E2 replacement significantly affects the expression of the neurotrophin receptors on BFCN. However, we also showed that E2 differentially regulates neurotrophin receptor expression on BFCNs with effects depending on neurotrophin receptor type and neuroanatomical location. In this review, we aim to survey the current literature to understand the influence of E2 on the neurotrophin system, and the receptors and signaling pathways it mediates on BFCN. In addition, we summarize the physiological and pathophysiological significance of E2 actions on the neurotrophin system in BFCN, especially focusing on changes related to Alzheimer's disease.","['Alzheimer’s disease', 'basal forebrain cholinergic neurons 4', 'estradiol 1', 'neurotrophin receptors 3', 'neurotrophins 2']",International journal of molecular sciences,2016-12-22,"[{'lastname': 'Kwakowsky', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand. a.kwakowsky@auckland.ac.nz.'}, {'lastname': 'Milne', 'firstname': 'Michael R', 'initials': 'MR', 'affiliation': 'School of Biomedical Sciences, Queensland Brain Institute, Clem Jones Centre for Ageing Dementia Research, The University of Queensland, Brisbane 4072, QLD, Australia. milnemichael834@gmail.com.'}, {'lastname': 'Waldvogel', 'firstname': 'Henry J', 'initials': 'HJ', 'affiliation': 'Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand. h.waldvogel@auckland.ac.nz.'}, {'lastname': 'Faull', 'firstname': 'Richard L', 'initials': 'RL', 'affiliation': 'Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand. rlm.faull@auckland.ac.nz.'}]",,,,,"10.3390/ijms17122122
10.1530/jrf.0.0400133
10.1016/S0140-6736(55)90060-X
10.1523/JNEUROSCI.1881-12.2012
10.1523/JNEUROSCI.3440-05.2006
10.1016/j.lfs.2006.04.020
10.1038/nn2057
10.1016/j.neuron.2006.07.023
10.1210/en.2011-1017
10.1016/S0306-4522(01)00560-7
10.1016/j.expneurol.2005.03.015
10.1016/0006-8993(94)91694-2
10.1016/j.brainres.2010.10.031
10.1212/WNL.48.6.1517
10.1212/WNL.50.4.996
10.1016/0896-6273(90)90166-D
10.1016/0006-8993(89)90112-1
10.1006/hbeh.1998.1451
10.1016/j.psyneuen.2009.05.024
10.1073/pnas.89.10.4668
10.1006/mcne.1993.1063
10.1046/j.1365-2826.2003.01012.x
10.1210/en.2014-1669
10.1016/0306-4522(84)90163-5
10.1002/syn.890070209
10.1093/cercor/bht210
10.1016/S0959-4388(99)80024-5
10.1007/BF02245253
10.1016/0013-4694(86)90128-8
10.1093/brain/99.3.459
10.1136/bmj.2.6150.1457
10.1006/nlme.1996.3757
10.1016/0165-0173(80)90011-9
10.1016/0091-3057(85)90139-X
10.1016/0091-3057(86)90134-6
10.1016/0028-3932(88)90083-8
10.1016/0166-4328(93)90128-D
10.1016/0306-4522(94)90342-5
10.1007/PL00005653
10.1002/hipo.20118
10.1056/NEJMra000471
10.1016/0168-0102(96)81278-8
10.1093/carcin/19.1.1
10.1210/endo-100-4-1214
10.1210/endo-103-6-2283
10.1210/endo-101-3-841
10.1073/pnas.83.2.513
10.1016/j.neuroscience.2011.02.012
10.1016/j.neurobiolaging.2009.12.014
10.1016/j.neurobiolaging.2004.03.010
10.1016/j.neulet.2004.07.010
10.1016/j.neurobiolaging.2006.07.024
10.1016/j.brainres.2009.09.111
10.1016/j.ejphar.2010.11.001
10.1038/sj.jcbfm.9600483
10.1111/1523-1747.ep12678099
10.1111/j.1365-2265.1974.tb03298.x
10.1016/0960-0760(92)90307-5
10.1161/01.RES.77.5.936
10.1126/science.3388021
10.1210/endo-129-6-3313
10.1172/JCI1039
10.1016/S0140-6736(81)91848-1
10.1016/0022-4731(86)90035-X
10.1056/NEJM199410203311604
10.1073/pnas.90.23.11162
10.1073/pnas.93.12.5925
10.1210/jc.82.12.4258
10.1677/joe.0.1630379
10.1016/0092-8674(95)90201-5
10.1677/JOE-09-0379
10.1677/jme.0.0240145
10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
10.1152/physrev.00026.2006
10.1002/cne.22361
10.1016/j.brainres.2010.09.069
10.1007/s11154-013-9263-7
10.1016/j.jsbmb.2012.11.006
10.1097/01.WCB.0000043341.09081.37
10.1159/000091703
10.1210/er.20.3.321
10.1093/nar/29.14.2905
10.1046/j.1365-2796.1999.00545.x
10.1074/jbc.275.8.5379
10.1073/pnas.58.4.1711
10.1016/S0039-128X(98)00107-X
10.1515/REVNEURO.2008.19.6.413
10.1111/j.1365-2826.2009.01838.x
10.1038/nrendo.2011.122
10.1006/geno.1997.4972
10.1006/bbrc.1996.1654
10.1210/mend.14.10.0532
10.1210/mend.16.1.0758
10.1073/pnas.91.18.8517
10.1210/en.2004-1064
10.1210/en.2007-1663
10.1124/pr.107.08002
10.1161/STROKEAHA.112.678177
10.1016/S1043-2760(99)00190-3
10.1046/j.1432-1327.2001.02346.x
10.1523/JNEUROSCI.0222-06.2006
10.1210/er.20.3.279
10.1016/j.neulet.2005.09.023
10.1097/00004647-199811000-00012
10.1016/S0006-8993(98)00327-8
10.1073/pnas.98.4.1952
10.1016/S0306-4522(98)00340-6
10.1016/S0306-4522(03)00464-0
10.1046/j.1471-4159.2003.01767.x
10.1038/srep21101
10.1001/jama.291.24.2947
10.1080/13697137.2016.1201319
10.1016/j.yfrne.2009.04.015
10.1046/j.1471-4159.1996.66051836.x
10.1038/nm0498-447
10.1073/pnas.0505203102
10.1007/s12035-013-8484-9
10.1016/0014-4886(85)90108-6
10.1016/0006-8993(96)00106-0
10.1074/jbc.M008104200
10.1046/j.1365-2990.2003.00487.x
10.1093/emboj/18.3.616
10.1002/cne.903500407
10.1016/j.neuint.2011.10.002
10.1016/S0006-8993(00)02428-8
10.1007/s10735-004-0778-9
10.1016/j.tins.2007.11.005
10.1016/0166-2236(92)90047-C
10.1126/science.1850549
10.1146/annurev.ne.18.030195.001255
10.1038/350158a0
10.1016/0092-8674(91)90149-S
10.1016/0896-6273(91)90287-A
10.1016/0896-6273(92)90023-7
10.1126/science.1065057
10.1126/science.8332899
10.1016/S0959-4388(00)00092-1
10.1083/jcb.143.6.1691
10.1002/jez.1401160206
10.1016/S0091-6749(98)70135-6
10.1038/341149a0
10.1016/S0167-7799(00)88949-0
10.1083/jcb.121.3.665
10.1016/0092-8674(95)90470-0
10.1016/S0006-8993(97)00329-6
10.1006/dbio.1997.8771
10.1126/science.7701324
10.1083/jcb.146.5.955
10.1016/S0959-4388(99)00010-0
10.1074/jbc.271.34.20713
10.1016/S0301-0082(02)00016-3
10.1126/science.272.5261.542
10.1016/S0306-4522(99)00156-6
10.1074/jbc.274.5.2597
10.1006/mcne.2001.1016
10.1093/jnen/63.6.641
10.1016/0006-8993(92)91169-F
10.1042/BJ20050700
10.1172/JCI119772
10.1111/j.1471-4159.2006.03905.x
10.1093/brain/aww200
10.1016/j.neurobiolaging.2013.05.006
10.1126/science.1688328
10.1016/0304-3940(88)90787-2
10.1126/science.3798108
10.1002/cne.903430206
10.1016/0165-3806(83)90107-4
10.1523/JNEUROSCI.6314-11.2012
10.1002/cne.902890408
10.1016/0306-4522(90)90305-N
10.1016/0092-8674(94)90378-6
10.1523/JNEUROSCI.1560-06.2006
10.1016/0197-4580(90)90056-6
10.1002/cne.903300103
10.1016/S0197-4580(98)00066-9
10.1002/ana.410100203
10.1016/j.biopsych.2011.06.019
10.1093/cercor/bhw195
10.1016/j.bbr.2010.11.058
10.1016/S0006-8993(96)01432-1
10.1006/exnr.1998.6789
10.1016/S0091-3057(96)00431-5
10.1006/exnr.2000.7397
10.1126/science.7058341
10.1073/pnas.92.24.11110
10.1006/exnr.1994.1148
10.1016/S0006-8993(98)00142-5
10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V
10.1016/S0306-4522(99)00520-5
10.1016/S0197-4580(00)00255-4
10.1097/00001756-199612200-00006
10.1111/j.1471-4159.2006.03764.x
10.1006/exnr.1999.7252
10.1093/jnci/dji372
10.1016/j.brainres.2016.06.016
10.1093/jnci/92.4.328
10.1001/jama.288.3.321
10.1016/j.jsbmb.2013.10.009
10.1016/j.fertnstert.2014.02.043
10.1196/annals.1347.005
10.1111/j.1526-4610.2008.01200.x
10.2174/187152731131200123
10.1016/j.nbd.2005.01.011
10.1016/0306-4522(96)00273-4
10.1016/S0169-328X(96)00040-X
10.1002/ana.410200302
10.1016/0166-4328(93)90141-C
10.1159/000336051
10.3171/2012.2.JNS11714",<Element 'PubmedArticle' at 0x7f05db5a3f90>
289,"27923524
26098405
25670354
19246357
14569042
25703112
25970728
25015037
25988468
10546691
19389313
23653255
22328681
11078767
23365063
19901247
18367704
15863436
17430231
16216938
10601882
15374445
1510377
8295932
12361782
11406187
12392783
12502486
17993459
15654602
22252943
24949886
19148619
11261806
24947026
22414803
10799482
15864338
16731815
16823477
19116375
8622964
10230646
15823755
25984581
10653284
6236805
19387110
16873962
21765811
16649845
16186530
19273752
21666429
25700985
16340083
22476197
12507914
2675614
2668761
26768593
1991575
1936601
20948514
11103847
8971073
12750520
17167471
12634421
9392846
9396070
8408635
3536982
9720971
1905936
15734146
15750215
22083962
14726444
3292322
14679177
14698276
19340313
9793760
6360769
9070242
10684867
16511862
10973971
11440853
12765971
17293876
17192720
16915364
26401706
21911655
25373630
16932309
8532024
17937601
9681499
9619505
9192681
11916920
18502454
18042720
19387109
10729790
17618127
16522636
18367451
15064420
18752642
17600230
12482897
18550292
19023096
17895242
11734601
20009056
18358569
21633502
23895348
19429119
19166821
18801339
17306982
19699265
15748777
16229744
15650008
20308782
18458326
18669592
11641114
21550355
16697020
18252898
9005972
16492543
15498087
23197731
15292279
11786016
23964237
11904665
22500019
9790190
10899427
20698575
12610038
7892213
18820693
24239383
15735200
21880018
27138913",The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.,"Aging leads to a number of physiological alterations, specifically changes in circulating hormone levels, increases in fat deposition, decreases in metabolism, changes in inflammatory responses, and reductions in growth factors. These progressive changes in physiology and metabolism are exacerbated by modern culture and Western diet and give rise to diseases such as obesity, metabolic syndrome, and type 2 (non-insulin-dependent) diabetes (T2D). These age and lifestyle-related metabolic diseases are often accompanied by insulin and leptin resistance, as well as aberrant amylin production and signaling. Many of these alterations in hormone production and signaling are directly influenced by an increase in both oxidative stress and inflammation. Importantly, changes in hormone production and signaling have direct effects on brain function and the development of age-related neurologic disorders. Therefore, this review aims to present evidence on the effects that diet and metabolic disease have on age-related cognitive decline and the development of cognitive diseases, particularly Alzheimer disease. This review will focus on the metabolic hormones insulin, leptin, and amylin and their role in cognitive decline, as well as the therapeutic potential of these hormones in treating cognitive disease. Future investigations targeting the long-term effects of insulin and leptin treatment may reveal evidence to reduce risk of cognitive decline and Alzheimer disease.","['Alzheimer disease', 'Amylin', 'Diabetes', 'Insulin', 'Leptin', 'Obesity']","Nutrition research (New York, N.Y.)",2016-12-08,"[{'lastname': 'Grizzanti', 'firstname': 'John', 'initials': 'J', 'affiliation': 'School of Biomedical Sciences, Kent State University, Kent, OH, USA.'}, {'lastname': 'Lee', 'firstname': 'Hyoung-Gon', 'initials': 'HG', 'affiliation': 'Department of Biology, University of Texas, San Antonio, TX, USA.'}, {'lastname': 'Camins', 'firstname': 'Antoni', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Therapeutic Chemistry, Universitat de Barcelona, Barcelona, Spain.'}, {'lastname': 'Pallas', 'firstname': 'Merce', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Therapeutic Chemistry, Universitat de Barcelona, Barcelona, Spain.'}, {'lastname': 'Casadesus', 'firstname': 'Gemma', 'initials': 'G', 'affiliation': 'School of Biomedical Sciences, Kent State University, Kent, OH, USA; Department of Biological Sciences, Kent State University, Kent, OH, USA. Electronic address: Gcasades@kent.edu.'}]",,,,Copyright © 2016. Published by Elsevier Inc.,10.1016/j.nutres.2016.11.002,<Element 'PubmedArticle' at 0x7f05db52e900>
290,"27911303
19457065
22424230
24239383
24614496
9663454
17614161
23183359
8606530
12805660
20962049
7564878
10907112
23595620
19361613
22897878
14769913
18048135
19114008
21943601
17567613
12925520
17576678
17784955
15028117
15980487
22500019
18786637
2606943
21166690
11124442
8713135
17341475
19513731
23943781
25430817
27033548
26436904
12111820
22210083
25620700
12900169
19494434
25964739
25120481
16840705
19853658
22466004
19638972
18332434
17151600
24653673
23551972
19866952
23794448
8245987
9623635
21671898
10026261
20518811
26136651
24896327",Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model.,"Our recent study has demonstrated that peripheral amylin treatment reduces the amyloid pathology in the brain of Alzheimer's disease (AD) mouse models, and improves their learning and memory. We hypothesized that the beneficial effects of amylin for AD was beyond reducing the amyloids in the brain, and have now directly tested the actions of amylin on other aspects of AD pathogenesis, especially neuroinflammation. A 10-week course of peripheral amylin treatment significantly reduced levels of cerebral inflammation markers, Cd68 and Iba1, in amyloid precursor protein (APP) transgenic mice. Mechanistic studies indicated the protective effect of amylin required interaction with its cognate receptor because silencing the amylin receptor expression blocked the amylin effect on Cd68 in microglia. Using weighted gene co-expression network analysis, we discovered that amylin treatment influenced two gene modules linked with amyloid pathology: 1) a module related to proinflammation and transport/vesicle process that included a hub gene of Cd68, and 2) a module related to mitochondria function that included a hub gene of Atp5b. Amylin treatment restored the expression of most genes in the APP cortex toward levels observed in the wild-type (WT) cortex in these two modules including Cd68 and Atp5b. Using a human dataset, we found that the expression levels of Cd68 and Atp5b were significantly correlated with the neurofibrillary tangle burden in the AD brain and with their cognition. These data suggest that amylin acts on the pathological cascade in animal models of AD, and further supports the therapeutic potential of amylin-type peptides for AD.","['Alzheimer’s disease', 'WGCNA', 'amylin', 'hub gene', 'transcriptome']",Journal of Alzheimer's disease : JAD,2016-12-03,"[{'lastname': 'Wang', 'firstname': 'Erming', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Zhu', 'firstname': 'Haihao', 'initials': 'H', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Wang', 'firstname': 'Xiaofan', 'initials': 'X', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Gower', 'firstname': 'Adam C', 'initials': 'AC', 'affiliation': 'Clinical and Translational Science Institute, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Wallack', 'firstname': 'Max', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Blusztajn', 'firstname': 'Jan Krzysztof', 'initials': 'JK', 'affiliation': 'Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA.'}, {'lastname': 'Kowall', 'firstname': 'Neil', 'initials': 'N', 'affiliation': ""Department of Neurology, Boston University School of Medicine, Boston, MA, USA.\nAlzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.""}, {'lastname': 'Qiu', 'firstname': 'Wei Qiao', 'initials': 'WQ', 'affiliation': ""Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.\nAlzheimer's Disease Center, Boston University School of Medicine, Boston, MA, USA.\nDepartment of Psychiatry, Boston University School of Medicine, Boston, MA, USA.""}]",,,,,10.3233/JAD-160677,<Element 'PubmedArticle' at 0x7f05db4f7db0>
291,27823753,"Alzheimer's disease, apolipoprotein E and hormone replacement therapy.","Alzheimer's disease is the most frequent cause of dementia in older patients. The prevalence is higher in women than in men. This may be the result of both the higher life expectancy of women and the loss of neuroprotective estrogen after menopause. Earlier age at menopause (spontaneous or surgical) is associated with an enhanced risk of developing Alzheimer's disease. Therefore, it is postulated that estrogen could be protective against it. If so, increasing exposure to estrogen through the use of postmenopausal hormone replacement could also be protective against Alzheimer's disease. The results of the clinical studies that have examined this hypothesis are inconclusive, however. One explanation for this is that estrogen treatment is protective only if it is initiated in the years immediately after menopause. Another possibility is that the neuroprotective effects of estrogen are negated by a particular genotype of apolipoprotein E. This protein plays an important role in cholesterol transport to the neurons. Studies that have examined the link between estrogen replacement therapy, Alzheimer's disease and the E4 allele of ApoE are inconclusive. This article reviews the literature on the influence of hormone replacement therapy on the incidence and progression of Alzheimer's disease.","['APO lipoprotein', 'Alzheimer’s disease', 'Hormone therapy']",Maturitas,2016-11-09,"[{'lastname': 'Depypere', 'firstname': 'H', 'initials': 'H', 'affiliation': 'Department of Gynaecology, University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: herman.depypere@ugent.be.'}, {'lastname': 'Vierin', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Gynaecology, University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.'}, {'lastname': 'Weyers', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Department of Gynaecology, University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.'}, {'lastname': 'Sieben', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Neurology, University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; Institute Born-Bunge, University of Antwerp, Biobank and Laboratory of Neurochemistry and Behavior, Antwerp, Belgium.'}]",,,,Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.maturitas.2016.09.009,<Element 'PubmedArticle' at 0x7f05db4a5810>
292,"27812793
24377702
20035629
20547859
12867116
22607808
26108478
17991853
18849289
16907955
2863752
8419831
16627534
17709374
20089646
24252157
24685293
25609817
26669818
22288561
26840342
19718500
20823086
22744790
22031526
25331173
2862420
3554880
6801762
26268531
24252329
14504321
26878132
25419482",UK Iatrogenic Creutzfeldt-Jakob disease: investigating human prion transmission across genotypic barriers using human tissue-based and molecular approaches.,"Creutzfeldt-Jakob disease (CJD) is the prototypic human prion disease that occurs most commonly in sporadic and genetic forms, but it is also transmissible and can be acquired through medical procedures, resulting in iatrogenic CJD (iCJD). The largest numbers of iCJD cases that have occurred worldwide have resulted from contaminated cadaveric pituitary-derived human growth hormone (hGH) and its use to treat primary and secondary growth hormone deficiency. We report a comprehensive, tissue-based and molecular genetic analysis of the largest series of UK hGH-iCJD cases reported to date, including in vitro kinetic molecular modelling of genotypic factors influencing prion transmission. The results show the interplay of prion strain and host genotype in governing the molecular, pathological and temporal characteristics of the UK hGH-iCJD epidemic and provide insights into the adaptive mechanisms involved when prions cross genotypic barriers. We conclude that all of the available evidence is consistent with the hypothesis that the UK hGH-iCJD epidemic resulted from transmission of the V2 human prion strain, which is associated with the second most common form of sporadic CJD.","['Agent strain', 'Creutzfeldt–Jakob disease', 'Disease phenotype', 'Growth hormone', 'Iatrogenic', 'Prion']",Acta neuropathologica,2016-11-05,"[{'lastname': 'Ritchie', 'firstname': 'Diane L', 'initials': 'DL', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Barria', 'firstname': 'Marcelo A', 'initials': 'MA', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Peden', 'firstname': 'Alexander H', 'initials': 'AH', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Yull', 'firstname': 'Helen M', 'initials': 'HM', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Kirkpatrick', 'firstname': 'James', 'initials': 'J', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Adlard', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'University College London Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.'}, {'lastname': 'Ironside', 'firstname': 'James W', 'initials': 'JW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Head', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, UK. m.w.head@ed.ac.uk.\nNational CJD Research & Surveillance Unit, University of Edinburgh, Bryan Matthews Building, Western General Hospital, Edinburgh, EH4 2XU, UK. m.w.head@ed.ac.uk.'}]",,,,,"10.1007/s00401-016-1638-x
10.3201/eid2001.130858
10.1186/1471-2350-10-146
10.1073/pnas.1004688107
10.1016/S0140-6736(03)13867-6
10.3201/eid1806.120116
10.1186/s40478-015-0214-2
10.1126/science.1138718
10.1098/rstb.2008.0068
10.1111/j.1439-0450.2006.00966.x
10.1056/NEJM198509193131207
10.1056/NEJM199302043280520
10.1136/jnnp.2005.073395
10.1074/jbc.M704597200
10.1128/JVI.02387-09
10.1186/2051-5960-1-74
10.1186/2051-5960-2-32
10.1128/JVI.03183-14
10.1111/j.1750-3639.2012.00572.x
10.1371/journal.ppat.1005416
10.1007/s00401-009-0585-1
10.1093/brain/awq234
10.1007/s00401-012-1002-8
10.1099/vir.0.033365-0
10.1186/s40478-014-0152-4
10.1016/S0140-6736(85)90292-2
10.1007/BF00687261
10.1126/science.6801762
10.1093/brain/awv235
10.1186/2051-5960-1-44
10.1212/01.WNL.0000084000.27403.15
10.1038/labinvest.2016.27",<Element 'PubmedArticle' at 0x7f05db4aeb80>
293,27792015,Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan.,"Age-related changes in brain structure are a question of interest to a broad field of research. Structural decline has been consistently, but not unambiguously, linked to functional consequences, including cognitive impairment and dementia. One of the areas considered of crucial importance throughout this process is the medial temporal lobe, and primarily the hippocampal region. Gender also has a considerable effect on volume deterioration of subcortical grey matter (GM) structures, such as the hippocampus. The influence of age×gender interaction on disproportionate GM volume changes might be mediated by hormonal effects on the brain. Hippocampal volume loss appears to become accelerated in the postmenopausal period. This decline might have significant influences on neuroplasticity in the CA1 region of the hippocampus highly vulnerable to pathological influences. Additionally, menopause has been associated with critical pathobiochemical changes involved in neurodegeneration. The micro- and macrostructural alterations and consequent functional deterioration of critical hippocampal regions might result in clinical cognitive impairment-especially if there already is a decline in the cognitive reserve capacity. Several lines of potential vulnerability factors appear to interact in the menopausal period eventually leading to cognitive decline, mild cognitive impairment, or Alzheimer's disease. This focused review aims to delineate the influence of unmodifiable risk factors of neurodegenerative processes, i.e., age and gender, on critical subcortical GM structures in the light of brain derived estrogen effects. The menopausal period appears to be of key importance for the risk of cognitive decline representing a time of special vulnerability for molecular, structural, and functional influences and offering only a narrow window for potential protective effects.","['Aging', 'cognitive decline', 'gender', 'hippocampus CA1 region', 'subcortical grey matter']",Journal of Alzheimer's disease : JAD,2016-10-30,"[{'lastname': 'Nemeth', 'firstname': 'Viola Luca', 'initials': 'VL', 'affiliation': 'Department of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Must', 'firstname': 'Anita', 'initials': 'A', 'affiliation': 'Department of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Horvath', 'firstname': 'Szatmar', 'initials': 'S', 'affiliation': 'Department of Psychiatry, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Király', 'firstname': 'Andras', 'initials': 'A', 'affiliation': 'Department of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Kincses', 'firstname': 'Zsigmond Tamas', 'initials': 'ZT', 'affiliation': ""Department of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.\nInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.""}, {'lastname': 'Vécsei', 'firstname': 'László', 'initials': 'L', 'affiliation': 'Department of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.\nMTA-SZTE Neuroscience Research Group, Szeged, Hungary.'}]",,,,,10.3233/JAD-160812,<Element 'PubmedArticle' at 0x7f05db4cd770>
294,27767986,Serum SHBG Levels are not Associated with Longitudinal Cognitive Decline in Mild Cognitive Impairment.,"Prior studies have noted gender differences in cognition, imaging, and pathological markers in mild cognitive impairment (MCI) subjects. Sex hormone-binding globulin (SHBG), a major controlling factor in the proportion of bioavailable versus bound testosterone and estrogen, has been proposed to contribute to links between hormones and dementia, but has not yet been investigated fully in a prospective biomarker trial.
This study examined whether, among subjects with MCI, SHBG levels predict future rate of cognitive decline.
We examine the effect of gender on cognitive decline and factors modulating potential gender differences in 378 MCI subjects (134 females, 244 males) in the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI-1), followed for up to 8 years (mean ± SE, 4.0 ± 0.1 years). Cognition was assessed using the ADAS-cog-11. Multivariate models examined the effect of gender covarying for age, ApoE4, baseline cognition, years of education, and SHBG levels.
MCI women declined significantly faster than men in cognition over the follow up period. Baseline SHBG levels differed significantly between men and women (p < 0.0001), and by age in men, but not by ApoE4 status. In the multivariate models, SHBG levels were not a significant predictor of cognitive decline in men or women but ApoE4 status, baseline cognition, years of education, and female gender were.
SHBG levels did not influence the rate of cognitive decline in MCI. Further studies to confirm these findings and uncover other potential mechanisms of gender differences in the risk for AD may be warranted.","['Amyloid-β', 'apolipoprotein E4', 'secondary prevention', 'sex differences', 'sex hormone-binding globulin']",Journal of Alzheimer's disease : JAD,2016-10-22,"[{'lastname': 'Lin', 'firstname': 'Katherine Amy', 'initials': 'KA', 'affiliation': 'Department of Psychiatry, Duke University Medical Center, Durham, NC, USA.\nDuke Institute for Brain Sciences, Duke University, Durham, NC, USA.'}, {'lastname': 'Rundel', 'firstname': 'Colin', 'initials': 'C', 'affiliation': 'Department of Statistical Science, Duke University, Durham, NC, USA.'}, {'lastname': 'Doraiswamy', 'firstname': 'P Murali', 'initials': 'PM', 'affiliation': 'Department of Psychiatry, Duke University Medical Center, Durham, NC, USA.\nDuke Institute for Brain Sciences, Duke University, Durham, NC, USA.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,SHBG levels did not influence the rate of cognitive decline in MCI. Further studies to confirm these findings and uncover other potential mechanisms of gender differences in the risk for AD may be warranted.,"MCI women declined significantly faster than men in cognition over the follow up period. Baseline SHBG levels differed significantly between men and women (p < 0.0001), and by age in men, but not by ApoE4 status. In the multivariate models, SHBG levels were not a significant predictor of cognitive decline in men or women but ApoE4 status, baseline cognition, years of education, and female gender were.",,10.3233/JAD-160513,<Element 'PubmedArticle' at 0x7f05db4d6450>
295,"27752112
25220842
12126818
12231037
26393854
19996060
25964245
26644522
27026303
25079103
24859915
11325319
9111537
22554955
18945929
12196314
17557956
25042117
20556875
20819998",Influence of age on androgen deprivation therapy-associated Alzheimer's disease.,"We recently found an association between androgen deprivation therapy (ADT) and Alzheimer's disease. As Alzheimer's disease is a disease of advanced age, we hypothesize that older individuals on ADT may be at greatest risk. We conducted a retrospective multi-institutional analysis among 16,888 individuals with prostate cancer using an informatics approach. We tested the effect of ADT on Alzheimer's disease using Kaplan-Meier age stratified analyses in a propensity score matched cohort. We found a lower cumulative probability of remaining Alzheimer's disease-free between non-ADT users age ≥70 versus those age <70 years (p < 0.001) and between ADT versus non-ADT users ≥70 years (p = 0.034). The 5-year probability of developing Alzheimer's disease was 2.9%, 1.9% and 0.5% among ADT users ≥70, non-ADT users ≥70 and individuals <70 years, respectively. Compared to younger individuals older men on ADT may have the greatest absolute Alzheimer's disease risk. Future work should investigate the ADT Alzheimer's disease association in advanced age populations given the greater potential clinical impact.",[],Scientific reports,2016-10-19,"[{'lastname': 'Nead', 'firstname': 'Kevin T', 'initials': 'KT', 'affiliation': 'Stanford Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.\nDepartment of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA.'}, {'lastname': 'Gaskin', 'firstname': 'Greg', 'initials': 'G', 'affiliation': 'Stanford Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.'}, {'lastname': 'Chester', 'firstname': 'Cariad', 'initials': 'C', 'affiliation': 'Stanford Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.'}, {'lastname': 'Swisher-McClure', 'firstname': 'Samuel', 'initials': 'S', 'affiliation': 'Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA.'}, {'lastname': 'Dudley', 'firstname': 'Joel T', 'initials': 'JT', 'affiliation': 'Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, 10029, USA.'}, {'lastname': 'Leeper', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Stanford Cardiovascular Institute, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, USA.'}, {'lastname': 'Shah', 'firstname': 'Nigam H', 'initials': 'NH', 'affiliation': 'Stanford Center for Biomedical Informatics Research, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.'}]",,,,,"10.1038/srep35695
10.1002/ijc.29210
10.1001/jama.2015.8577
10.1093/jnci/djp404
10.1200/JCO.2014.60.1963
10.1200/JCO.2015.63.6266
10.1016/j.ijrobp.2016.02.003
10.1016/S1470-2045(14)70018-X
10.1007/s00520-014-2285-1
10.1016/S0140-6736(96)09328-2
10.1016/j.yhbeh.2012.04.006
10.2337/dc08-0272
10.1200/JCO.2006.09.3369
10.1002/cncr.28926
10.1212/WNL.0b013e3181f11deb",<Element 'PubmedArticle' at 0x7f05db4e0680>
296,27744092,Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration.,"Sex-steroid hormones are primarily involved in sexual differentiation and development and are thought to underlie processes related to cognition and emotion. However, divergent results have been reported concerning the effects of hormone administration on brain structure including side effects like brain atrophy and dementia. Cross-sex hormone therapy in transgender subjects offers a unique model for studying the effects of sex hormones on the living human brain. In this study, 25 Female-to-Male (FtM) and 14 Male-to-Female (MtF) subjects underwent MRI examinations at baseline and after a period of at least 4-months of continuous cross-sex hormone administration. While MtFs received estradiol and anti-androgens, FtM subjects underwent high-dose testosterone treatment. The longitudinal processing stream of the FreeSurfer software suite was used for the automated assessment and delineation of brain volumes to assess the structural changes over the treatment period of cross-sex hormone administration. Most prominent results were found for MtFs receiving estradiol and anti-androgens in the form of significant decreases in the hippocampal region. Further analysis revealed that these decreases were reflected by increases in the ventricles. Additionally, changes in progesterone levels correlated with changes in gray matter structures in MtF subjects. In line with prior studies, our results indicate hormonal influences on subcortical structures related to memory and emotional processing. Additionally, this study adds valuable knowledge that progesterone may play an important role in this process.","['Gray matter volume', 'Hormone therapy', 'Hormones', 'Transgender', 'Transsexuals']",Psychoneuroendocrinology,2016-10-17,"[{'lastname': 'Seiger', 'firstname': 'Rene', 'initials': 'R', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Hahn', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Hummer', 'firstname': 'Allan', 'initials': 'A', 'affiliation': 'MR Centre of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Kranz', 'firstname': 'Georg S', 'initials': 'GS', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Ganger', 'firstname': 'Sebastian', 'initials': 'S', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Woletz', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'MR Centre of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Kraus', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Sladky', 'firstname': 'Ronald', 'initials': 'R', 'affiliation': 'MR Centre of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Kautzky', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Kasper', 'firstname': 'Siegfried', 'initials': 'S', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Windischberger', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'MR Centre of Excellence, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, 1090 Vienna, Austria.'}, {'lastname': 'Lanzenberger', 'firstname': 'Rupert', 'initials': 'R', 'affiliation': 'Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: rupert.lanzenberger@meduniwien.ac.at.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.psyneuen.2016.09.028,<Element 'PubmedArticle' at 0x7f05db4776d0>
297,27712893,Two years in IGF research.,"The last two years of insulin-like growth factor (IGF) research has yielded a vast literature highlighting the central role IGFs factors play in processes such as development, growth, aging and neurological function. It also provides our latest understanding of how IGF system perturbation is linked to diseases including growth deficiency, cancer, and neurological and cardiovascular diseases. A snapshot of the highlights is presented in this review, focussing on the topics of IGFs and growth, comparative and structural biology to understand insulin-like peptide function, IGFs and cancer, and IGFs and neurological function. New revelations in the IGF field include the unexpected discovery that the gut microbiome has a remarkable influence on the GH/IGF axis to influence growth, that the insulin of cone snails provides novel insight into the mechanism of receptor binding, and that macrophages in the tumour microenvironment can provide IGF-I to promote drug resistance. These advances and many others provide the exciting basis for future development of disease treatments and for biomarkers of disease.","['Cancer', 'Comparative biology', 'Growth', 'Insulin', 'Insulin-like growth factor', 'Insulin-like peptide', 'Neuron', 'Structural biology']",Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,2016-10-08,"[{'lastname': 'Forbes', 'firstname': 'Briony E', 'initials': 'BE', 'affiliation': 'Department of Medical Biochemistry, School of Medicine, Flinders University of South Australia, Bedford Park 5042, South Australia, Australia. Electronic address: Briony.forbes@flinders.edu.au.'}]",,,,Copyright © 2016. Published by Elsevier Ltd.,10.1016/j.ghir.2016.09.006,<Element 'PubmedArticle' at 0x7f05db486770>
298,27685894,Cortical inhibitory deficits in Huntington's disease are not influenced by gender.,"Huntington's disease (HD) affects GABA-mediated inhibitory circuitry in the cortex. As there is evidence that sex hormones affect GABAergic function, we investigated whether gender modulates GABA-related pathophysiological changes in HD. Fifteen premanifest HD, 11 symptomatic HD and 16 healthy control participants were assessed with paired-pulse transcranial magnetic stimulation applied to the primary motor cortex. Cortical inhibition was significantly reduced in symptomatic HD, compared with premanifest HD and controls. There was reduced inhibition in females overall, but no Group-by-Sex interaction. These findings suggest that sex hormones do not exert a direct influence on the mechanisms underpinning cortical inhibitory deficits in HD.","['GABA', 'Sex difference', 'Transcranial magnetic stimulation']",Psychiatry research. Neuroimaging,2016-09-30,"[{'lastname': 'Philpott', 'firstname': 'April L', 'initials': 'AL', 'affiliation': 'School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.'}, {'lastname': 'Cummins', 'firstname': 'Tarrant D R', 'initials': 'TD', 'affiliation': 'School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia.'}, {'lastname': 'Bailey', 'firstname': 'Neil W', 'initials': 'NW', 'affiliation': 'Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash University and the Alfred, Melbourn, VIC, Australia.'}, {'lastname': 'Churchyard', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Department of Neurology, Monash Medical Centre, Clayton, VIC, Australia.'}, {'lastname': 'Fitzgerald', 'firstname': 'Paul B', 'initials': 'PB', 'affiliation': 'Monash Alfred Psychiatry Research Centre, Central Clinical School, Monash University and the Alfred, Melbourn, VIC, Australia.'}, {'lastname': 'Georgiou-Karistianis', 'firstname': 'Nellie', 'initials': 'N', 'affiliation': 'School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia. Electronic address: nellie.georgiou-karistianis@monash.edu.'}]",,,,Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.pscychresns.2016.04.018,<Element 'PubmedArticle' at 0x7f05db48fe50>
299,27599805,Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer's Disease: The Relationship with Other Atherosclerosis Risk Factors.,"The growing body of evidence suggests that atherosclerosis risk factors are important in cognitive decline.
To analyse insulin sensitivity, insulin secretion capacity, plasma insulin, adiponectin and lipid levels in normoglycaemic, nonobese patients with Alzheimer's disease (AD) (group A, n=62), mild cognitive impairment (MCI) (group B, n=41), and healthy controls (group C, n=25).
Insulin sensitivity was determined by euglycemic hyperinsulinaemic clamp (M value) and homeostasis model assessment (HOMA-IR), insulin secretion capacity by first-phase insulin response (FPIR), plasma insulin by RIA, adiponectin by ELISA, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides by enzymatic method.
Insulin sensitivity was the lowest in group A (M value: A: 6.2±2.5; B:7.7±2.7; C:8.2±1.5 mg/min/kg, p<0.001; HOMA-IR: A: 4.6±2.2; B: 3.3±1.7; C: 1.5±1.0, p<0.001) as well as FPIR (A:68.9±27.8; B:112.5±47.1; C:147.4±56.0 mU/l, p<0.001). Plasma insulin was higher in group A vs B vs C, while adiponectin was lower in group A vs B vs C. Simultaneously, total and LDL-C were higher and HDL-C levels were lower in groups A and B vs C, with no difference between groups A and B. Triglycerides did not differ between the groups. Binary logistic regression analysis identified only M value, FPIR and plasma insulin as independent predictors of AD and MCI.
These results imply that in AD and MCI insulin resistance with increased plasma insulin and decreased FPIR may be associated with the development of AD and MCI, accompanied with milder influence of low adiponectin levels and atherogenic lipid profile.","['Alzheimer’s disease', 'cardiovascular risk factors', 'insulin resistance', 'mild cognitive impairment']",Current vascular pharmacology,2016-09-08,"[{'lastname': 'Macesic', 'firstname': 'Marija', 'initials': 'M', 'affiliation': None}, {'lastname': 'Lalic', 'firstname': 'Nebojsa M', 'initials': 'NM', 'affiliation': 'Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Dr Subotica, 1311000 Belgrade, Serbia.'}, {'lastname': 'Kostic', 'firstname': 'Vladimir S', 'initials': 'VS', 'affiliation': None}, {'lastname': 'Jotic', 'firstname': 'Aleksandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lalic', 'firstname': 'Katarina', 'initials': 'K', 'affiliation': None}, {'lastname': 'Stefanova', 'firstname': 'Elka', 'initials': 'E', 'affiliation': None}, {'lastname': 'Milicic', 'firstname': 'Tanja', 'initials': 'T', 'affiliation': None}, {'lastname': 'Lukic', 'firstname': 'Ljiljana', 'initials': 'L', 'affiliation': None}, {'lastname': 'Gajovic', 'firstname': 'Jelena Stanarcic', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Krako', 'firstname': 'Nina', 'initials': 'N', 'affiliation': None}]","Insulin sensitivity was determined by euglycemic hyperinsulinaemic clamp (M value) and homeostasis model assessment (HOMA-IR), insulin secretion capacity by first-phase insulin response (FPIR), plasma insulin by RIA, adiponectin by ELISA, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides by enzymatic method.","These results imply that in AD and MCI insulin resistance with increased plasma insulin and decreased FPIR may be associated with the development of AD and MCI, accompanied with milder influence of low adiponectin levels and atherogenic lipid profile.","Insulin sensitivity was the lowest in group A (M value: A: 6.2±2.5; B:7.7±2.7; C:8.2±1.5 mg/min/kg, p<0.001; HOMA-IR: A: 4.6±2.2; B: 3.3±1.7; C: 1.5±1.0, p<0.001) as well as FPIR (A:68.9±27.8; B:112.5±47.1; C:147.4±56.0 mU/l, p<0.001). Plasma insulin was higher in group A vs B vs C, while adiponectin was lower in group A vs B vs C. Simultaneously, total and LDL-C were higher and HDL-C levels were lower in groups A and B vs C, with no difference between groups A and B. Triglycerides did not differ between the groups. Binary logistic regression analysis identified only M value, FPIR and plasma insulin as independent predictors of AD and MCI.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",10.2174/1570161114666160905170644,<Element 'PubmedArticle' at 0x7f05db49b040>
300,27599231,Protective effects of testosterone on cognitive dysfunction in Alzheimer's disease model rats induced by oligomeric beta amyloid peptide 1-42.,"Cognitive dysfunction is known to be influenced by circulating sex steroidal hormones. The aim of this study was to examine the protective effect and possible protective mechanism of testosterone (T) on cognitive performance in male rats induced by intrahippocampal injections of beta amyloid 1-42 oligomers (Aβ1-42). Treatment with T as evidenced by the Morris water maze (MWM) test significantly shortened escape latency and reduced path length to reach the platform compared to the control (C). During probe trials, the T group displayed a significantly greater percent of time in the target quadrant and improved the number of platform crossings compared with C, flutamide (F), an antiandrogen, and a combined F and T group. Flutamide markedly inhibited the influence of T on cognitive performance. Following Nissl staining, the number of intact pyramidal cells was significantly elevated in the T group, and the effect of T was blocked by F. Immunohistochemisty and Western blot analysis showed that the protein expression level of Aβ 1-42 was markedly decreased and expression levels of synaptophysin (SYN) significantly increased with T, while F inhibited all T-mediated effects. Our data suggest that the influence of T on cognitive performance was mediated via androgen receptors (AR) to remove beta amyloid, which leads to enhanced synaptic plasticity.",[],Journal of toxicology and environmental health. Part A,2016-09-07,"[{'lastname': 'Huo', 'firstname': 'Dong-Sheng', 'initials': 'DS', 'affiliation': 'a Department of Human Anatomy, Baotou Medical College, Baotou , Inner Mongolia , China.'}, {'lastname': 'Sun', 'firstname': 'Jian-Fang', 'initials': 'JF', 'affiliation': 'b The First Affiliated Hospital of Baotou Medical College, Baotou , Inner Mongolia , China.'}, {'lastname': 'Zhang', 'firstname': 'Baifeng', 'initials': 'B', 'affiliation': 'a Department of Human Anatomy, Baotou Medical College, Baotou , Inner Mongolia , China.'}, {'lastname': 'Yan', 'firstname': 'Xu-Sheng', 'initials': 'XS', 'affiliation': 'a Department of Human Anatomy, Baotou Medical College, Baotou , Inner Mongolia , China.'}, {'lastname': 'Wang', 'firstname': 'He', 'initials': 'H', 'affiliation': 'c School of Health Sciences , University of Newcastle , Newcastle , Australia.'}, {'lastname': 'Jia', 'firstname': 'Jian-Xin', 'initials': 'JX', 'affiliation': 'a Department of Human Anatomy, Baotou Medical College, Baotou , Inner Mongolia , China.'}, {'lastname': 'Yang', 'firstname': 'Zhan-Jun', 'initials': 'ZJ', 'affiliation': 'a Department of Human Anatomy, Baotou Medical College, Baotou , Inner Mongolia , China.'}]",,,,,10.1080/15287394.2016.1193114,<Element 'PubmedArticle' at 0x7f05db4294a0>
301,27582327,"The Effect of Yokukansan, a Traditional Herbal Preparation Used for the Behavioral and Psychological Symptoms of Dementia, on the Drug-Metabolizing Enzyme Activities in Healthy Male Volunteers.","The concomitant use of herb and prescription medications is increasing globally. Herb-drug interactions are therefore a clinically important problem. Yokukansan (YKS), a Japanese traditional herbal medicine, is one of the most frequently used herbal medicines. It is effective for treating the behavioral and psychological symptoms of dementia. We investigated the potential effects of YKS on drug-metabolizing enzyme activities in humans. An open-label repeat-dose study was conducted in 26 healthy Japanese male volunteers (age: 22.7±2.3 years) with no history of smoking. An 8-h urine sample was collected after a 150-mg dose of caffeine and a 30-mg dose of dextromethorphan before and after the administration of YKS (2.5 g, twice a day for 1 week). The activities of cytochrome P450 (CYP) 1A2, CYP2D6, CYP3A, xanthine oxidase (XO) and N-acetyltransferase 2 (NAT2) were assessed based on the urinary metabolic indices of caffeine and dextromethorphan, and the urinary excretion ratio of 6β-hydroxycortisol to cortisol. There were no statistically significant differences in the activities of the examined enzymes before or after the 7-d administration of YKS. Although further studies assessing the influence of YKS on the pharmacokinetics and pharmacodynamics of the substrates of the drug-metabolizing enzymes are needed to verify the present results, YKS is unlikely that a pharmacokinetic interaction will occur with concomitantly administered medications that are predominantly metabolized by the CYP1A2, CYP2D6, CYP3A, XO and NAT2.",[],Biological & pharmaceutical bulletin,2016-09-02,"[{'lastname': 'Soraoka', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': 'Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University.'}, {'lastname': 'Oniki', 'firstname': 'Kentaro', 'initials': 'K', 'affiliation': None}, {'lastname': 'Matsuda', 'firstname': 'Kazuki', 'initials': 'K', 'affiliation': None}, {'lastname': 'Ono', 'firstname': 'Tatsumasa', 'initials': 'T', 'affiliation': None}, {'lastname': 'Taharazako', 'firstname': 'Kosuke', 'initials': 'K', 'affiliation': None}, {'lastname': 'Uchiyashiki', 'firstname': 'Yoshihiro', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Kamihashi', 'firstname': 'Ryoko', 'initials': 'R', 'affiliation': None}, {'lastname': 'Kita', 'firstname': 'Ayana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Takashima', 'firstname': 'Ayaka', 'initials': 'A', 'affiliation': None}, {'lastname': 'Nakagawa', 'firstname': 'Kazuko', 'initials': 'K', 'affiliation': None}, {'lastname': 'Yasui-Furukori', 'firstname': 'Norio', 'initials': 'N', 'affiliation': None}, {'lastname': 'Kadowaki', 'firstname': 'Daisuke', 'initials': 'D', 'affiliation': None}, {'lastname': 'Miyata', 'firstname': 'Keishi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Saruwatari', 'firstname': 'Junji', 'initials': 'J', 'affiliation': None}]",,,,,10.1248/bpb.b16-00248,<Element 'PubmedArticle' at 0x7f05db434130>
302,27539597,The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease.,"Alzheimer's disease (AD) is characterized by neuronal degeneration, vascular pathology and cognitive decline. Furthermore, deficits in cerebral glucose metabolism and insulin resistance are being increasingly recognized in AD. Many lifestyle-modifying approaches, including diet and exercise, have yielded promising results in modulating brain morphology and function for the prevention and early treatment of AD.
This review focuses on the effects of physical exercise on rescuing cognition and limiting the progression of AD pathology. Specifically, the impact of exercise, in human and animal models of AD, on the stimulation and preservation of cognition, neurotransmission, neurogenesis, vasculature, glucose metabolism and insulin signaling is discussed.
Studies have highlighted the potential of physical activity to improve overall brain health, which could delay or lessen AD-related cognitive deficits and pathology. Physical activity influences cognitive function, vascular health and brain metabolism, which taken together offers benefits for the aging population, including AD patients.",[],Current Alzheimer research,2016-08-20,"[{'lastname': 'Maliszewska-Cyna', 'firstname': 'Ewelina', 'initials': 'E', 'affiliation': None}, {'lastname': 'Lynch', 'firstname': 'Madelaine', 'initials': 'M', 'affiliation': None}, {'lastname': 'Oore', 'firstname': 'Jonathan Jordan', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Nagy', 'firstname': 'Paul Michael', 'initials': 'PM', 'affiliation': None}, {'lastname': 'Aubert', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Sunnybrook Research Institute, 2075 Bayview Ave, S112, Toronto, ON, Canada M4N 3M5.'}]",,"Studies have highlighted the potential of physical activity to improve overall brain health, which could delay or lessen AD-related cognitive deficits and pathology. Physical activity influences cognitive function, vascular health and brain metabolism, which taken together offers benefits for the aging population, including AD patients.",,,10.2174/1567205013666160819125400,<Element 'PubmedArticle' at 0x7f05db440540>
303,"27506601
8458085
8401589
17240289
6454826
12427878
14742590
15941884
15038601
16613897
11152662
19124532
15888475
19460884
17557337
10196370
12586550
15649949
17126554
17051205
136379
12165557
16251441
17067733
2932916
2526577
14962685
18050496
8898202
17055784
22511757
10587574
11607033
9029064
10672239
21285522
15112229
10221987
8832812
18469287
12004130
15166157
17908555
23874700
15374818
22275878
25173182
25116616",Altered lipid metabolism in Drosophila model of Huntington's disease.,"Huntington's disease (HD) is late-onset, progressive neurodegenerative disorder caused by expansion of polyglutamine (polyQ) repeat within Huntingtin (Htt) protein. In HD patients, energy-related manifestations such as modulation of weight during entire course of disease with energy deficit at terminal stage have been reported, however, underlying reason remains elusive till date. Lipids, carbohydrate and protein constitute a predominant fraction of body's energy reservoir and perturbation in their homeostasis may influence weight. To discern role of these energy molecules in weight alteration, we quantified them in an in vivo transgenic Drosophila model of HD. We document that diseased flies exhibit change in weight due to an altered lipid metabolism, as evident from considerably high lipid levels at the time of disease onset followed by a pathologic decline at end-stage. An alteration in intracellular lipid droplet size suggested altered cellular lipid turnover. Furthermore, diseased flies displayed substantial changes in carbohydrate and protein content. Interestingly, alteration in weight and lipid levels are independent of the feeding pattern in diseased condition and exhibit weak correlation with insulin-like peptide or adipokinetic hormone producing cells. We propose that therapeutic intervention aimed at restoring lipid levels and associated metabolic pathways may improve longevity and quality of patient's life.",[],Scientific reports,2016-08-11,"[{'lastname': 'Aditi', 'firstname': 'Kumari', 'initials': 'K', 'affiliation': 'Department of Zoology, University of Delhi, Delhi, 110007, India.'}, {'lastname': 'Shakarad', 'firstname': 'Mallikarjun N', 'initials': 'MN', 'affiliation': 'Department of Zoology, University of Delhi, Delhi, 110007, India.'}, {'lastname': 'Agrawal', 'firstname': 'Namita', 'initials': 'N', 'affiliation': 'Department of Zoology, University of Delhi, Delhi, 110007, India.'}]",,,,,10.1038/srep31411,<Element 'PubmedArticle' at 0x7f05db448270>
304,27489306,Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans.,"Ever since the brain was identified as an insulin-sensitive organ, evidence has rapidly accumulated that insulin action in the brain produces multiple behavioral and metabolic effects, influencing eating behavior, peripheral metabolism, and cognition. Disturbances in brain insulin action can be observed in obesity and type 2 diabetes (T2D), as well as in aging and dementia. Decreases in insulin sensitivity of central nervous pathways, i.e., brain insulin resistance, may therefore constitute a joint pathological feature of metabolic and cognitive dysfunctions. Modern neuroimaging methods have provided new means of probing brain insulin action, revealing the influence of insulin on both global and regional brain function. In this review, we highlight recent findings on brain insulin action in humans and its impact on metabolism and cognition. Furthermore, we elaborate on the most prominent factors associated with brain insulin resistance, i.e., obesity, T2D, genes, maternal metabolism, normal aging, inflammation, and dementia, and on their roles regarding causes and consequences of brain insulin resistance. We also describe the beneficial effects of enhanced brain insulin signaling on human eating behavior and cognition and discuss potential applications in the treatment of metabolic and cognitive disorders.",[],Physiological reviews,2016-08-05,"[{'lastname': 'Kullmann', 'firstname': 'Stephanie', 'initials': 'S', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}, {'lastname': 'Heni', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}, {'lastname': 'Hallschmid', 'firstname': 'Manfred', 'initials': 'M', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}, {'lastname': 'Fritsche', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}, {'lastname': 'Preissl', 'firstname': 'Hubert', 'initials': 'H', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}, {'lastname': 'Häring', 'firstname': 'Hans-Ulrich', 'initials': 'HU', 'affiliation': 'Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD e.V.), Tübingen, Germany; Department of Internal Medicine IV, University of Tübingen, Tübingen, Germany; Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; and Department of Pharmacy and Biochemistry, Faculty of Science, Eberhard Karls Universität Tübingen, Tübingen, Germany.'}]",,,,Copyright © 2016 the American Physiological Society.,10.1152/physrev.00032.2015,<Element 'PubmedArticle' at 0x7f05db3e5270>
305,27483434,Luminescent platforms for monitoring changes in the solubility of amylin and huntingtin in living cells.,"Luminescent, cell-based assays capable of monitoring the aggregation potential of the disease-relevant proteins known as amylin (type 2 diabetes) and huntingtin (Huntington's disease) are presented. These sensitive platforms report on the influence of mutations as well as small molecules on protein solubility.",[],Molecular bioSystems,2016-08-03,"[{'lastname': 'Zhao', 'firstname': 'Jia', 'initials': 'J', 'affiliation': 'Department of Chemistry, University of Nebraska - Lincoln, Lincoln, NE 68588, USA. cstains2@unl.edu.'}, {'lastname': 'Vu', 'firstname': 'Quyen', 'initials': 'Q', 'affiliation': None}, {'lastname': 'Stains', 'firstname': 'Cliff I', 'initials': 'CI', 'affiliation': None}]",,,,,10.1039/c6mb00454g,<Element 'PubmedArticle' at 0x7f05db3f0220>
306,"27482300
18626751
23134607
20337892
19039610
21523227
17940622
16298220
18478344
19895866
25576662
11889109
21220789
22009989
22009990
22761885
23335968
23954158
23954159
25680274
9813727
15987522
22367402
22271008
22010579
22990306
23843038
20331797
18832296
18005240
19811501
21911459
23241000
21723642
23991831
17419719
15213114
7826013
8162357
10793105
21969503
21777945
25283302
25488179
19320589
10880031
22252715
12044010
23199966
9284524
20592731
14107961
16614233
17049016
15581545
15265787
11176064
9253628
9067735
8600040
2546458
11091847
11505266
19013346
18076594
10399411
7858080
817005
3652390
1586990",Oral environment and cancer.,"Cancer is now the leading cause of death in Japan. A rapid increase in cancer mortality is expected as Japan is facing a super-aged society. Many causes of cancer are known to be closely linked to life style factors, such as smoking, drinking, and diet. The oral environment is known to be involved in the pathogenesis and development of various diseases such as bronchitis, pneumonia, diabetes, heart disease, and dementia. Because the oral cavity acts as the bodily entrance for air and food, it is constantly exposed to foreign substances, including bacteria and viruses. A large number of bacteria are endemic to the oral cavity, and indigenous oral flora act to prevent the settlement of foreign bacteria. The oral environment is influenced by local factors, including dental plaque, tartar, teeth alignment, occlusion, an incompatible prosthesis, and bad lifestyle habits, and systemic factors, including smoking, consumption of alcohol, irregular lifestyle and eating habits, obesity, stress, hormones, and heredity. It has recently been revealed that the oral environment is associated with cancer. In particular, commensal bacteria in the oral cavity are involved in the development of cancer. Moreover, Candida, human papilloma virus and Epstein-Barr virus as well as commensal bacteria have been reported to be associated with the pathogenesis of cancer. In this review, we introduce recent findings of the correlation between the oral environment and cancer.","['Bacteria', 'Cancer', 'Candida', 'Epstein-Barr virus', 'Human papilloma virus', 'Oral environment']",Genes and environment : the official journal of the Japanese Environmental Mutagen Society,2016-08-03,"[{'lastname': 'Kudo', 'firstname': 'Yasusei', 'initials': 'Y', 'affiliation': 'Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.'}, {'lastname': 'Tada', 'firstname': 'Hidesuke', 'initials': 'H', 'affiliation': 'Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan ; Tada Dental Clinic, Kakogawa, Japan.'}, {'lastname': 'Fujiwara', 'firstname': 'Natsumi', 'initials': 'N', 'affiliation': 'Department of Oral Healthcare Promotion, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.'}, {'lastname': 'Tada', 'firstname': 'Yoshiko', 'initials': 'Y', 'affiliation': 'Tada Dental Clinic, Kakogawa, Japan.'}, {'lastname': 'Tsunematsu', 'firstname': 'Takaaki', 'initials': 'T', 'affiliation': 'Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.'}, {'lastname': 'Miyake', 'firstname': 'Yoichiro', 'initials': 'Y', 'affiliation': 'Department of Oral Microbiology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.'}, {'lastname': 'Ishimaru', 'firstname': 'Naozumi', 'initials': 'N', 'affiliation': 'Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.'}]",,,,,"10.1186/s41021-016-0042-z
10.1007/s11095-008-9661-9
10.1111/j.2041-1014.2012.00663.x
10.1111/j.1600-0765.2009.01250.x
10.1007/s10096-008-0662-8
10.3402/jom.v2i0.5195
10.1016/S0140-6736(05)67728-8
10.1007/s10552-008-9163-4
10.1016/j.jdent.2009.10.007
10.1016/j.mib.2014.11.013
10.1128/JB.184.7.2005-2018.2002
10.1101/gr.126516.111
10.1101/gr.126573.111
10.1371/journal.pone.0039743
10.1371/journal.pone.0053653
10.1016/j.chom.2013.07.012
10.1016/j.chom.2013.07.007
10.1016/j.immuni.2015.01.010
10.1016/S1368-8375(98)80012-2
10.1186/1479-5876-3-27
10.1093/carcin/bgs112
10.1007/s10552-011-9892-7
10.4248/IJOS11075
10.1136/gutjnl-2012-303006
10.1093/carcin/bgt249
10.1111/j.2041-1014.2010.00569.x
10.1099/mic.0.2008/021220-0
10.1111/j.1462-5822.2007.01089.x
10.1111/j.1462-5822.2009.01390.x
10.1128/IAI.05016-11
10.1111/cmi.12089
10.1016/j.imbio.2011.05.005
10.1111/cmi.12211
10.1111/j.1462-5822.2007.00931.x
10.1128/IAI.72.7.3743-3751.2004
10.1146/annurev.mi.48.100194.002235
10.1093/jnci/92.9.690
10.1200/JCO.2011.36.4596
10.1016/j.humpath.2011.03.009
10.1002/ijc.29254
10.1016/j.oraloncology.2014.11.011
10.1086/597755
10.1023/A:1008918223334
10.1002/lary.21899
10.1038/nrc798
10.1016/j.vaccine.2012.06.083
10.1006/scbi.1996.0041
10.1006/smvy.1996.0037
10.1038/nrc2886
10.1016/S0140-6736(64)91524-7
10.1634/theoncologist.11-4-375
10.1517/14712598.6.11.1193
10.1016/S1470-2045(04)01650-X
10.1182/blood-2004-02-0405
10.1097/00000478-200102000-00003
10.1046/j.1365-2559.1997.5830814.x
10.1046/j.1365-2559.1997.d01-582.x
10.1016/S0046-8177(96)90066-0
10.1097/00000478-198908000-00001
10.1136/mp.53.5.238
10.1067/moe.2001.116155
10.1016/S0924-8579(08)70006-2
10.1016/S0300-5712(99)00002-0
10.1111/j.1600-0714.1975.tb01750.x
10.1093/carcin/8.10.1543
10.1093/carcin/13.5.783",<Element 'PubmedArticle' at 0x7f05db3f6bd0>
307,27432231,Involvement of hippocampal excitability in amyloid β-induced behavioral and psychological symptoms of dementia.,"In patients with Alzheimer's disease, in addition to the core symptoms, i.e., cognitive dysfunction, behavioral and psychological symptoms of dementia (BPSD) such as aggression, anxiety, and hallucinations are known to occur frequently. Because various environmental factors influence the onset and progression of Alzheimer's disease, in the present study, BPSD-like behavioral abnormality of Amyloid β (Aβ)1-42-injected mice was assessed under social isolation, which induces behavioral abnormality. Aβ protein (500 pmol) was injected into the lateral ventricle of mice, which were individually housed. Two and three weeks after injection into adult mice, the rate of mice that exhibited aggressive behavior, i.e., biting attacks and wrestling, to the total mice, was markedly increased by Aβ injection. Aβ-injected adult mice also showed anxiety-like behavior, in addition to cognitive decline. Serum corticosterone level was markedly increased by Aβ injection. When excitability of hippocampal neurons was checked using hippocampal slices, KCl-induced presynaptic activity was enhanced in hippocampal slices prepared from Aβ-injected mice. These results suggest that social isolation housing of Aβ1-42-injected adult mice induces BPSD-like behavioral abnormality in addition to cognitive decline. It is likely that behavioral abnormality of Aβ1-42-injected adult mice is associated with excitability of hippocampal glutamatergic neurons, which is associated with the elevated corticosterone level.",[],The Journal of toxicological sciences,2016-07-20,"[{'lastname': 'Tamano', 'firstname': 'Haruna', 'initials': 'H', 'affiliation': 'Department of Neurophysiology, School of Pharmaceutical Sciences, University of Shizuoka.'}, {'lastname': 'Ide', 'firstname': 'Kazuki', 'initials': 'K', 'affiliation': None}, {'lastname': 'Adlard', 'firstname': 'Paul Anthony', 'initials': 'PA', 'affiliation': None}, {'lastname': 'Bush', 'firstname': 'Ashley Ian', 'initials': 'AI', 'affiliation': None}, {'lastname': 'Takeda', 'firstname': 'Atsushi', 'initials': 'A', 'affiliation': None}]",,,,,10.2131/jts.41.449,<Element 'PubmedArticle' at 0x7f05db3a2590>
308,30695519,[Endogenous Cannabinoid System of the Brain as the Target for Influences at Neurodegenerate Diseases].,"The review represents the analysis of works about role of endogenous cannabinoid (EC) system in the neuro- degenerate diseases (ND), in which the cellular death and disturbances of neuronal functions of the hippo- campus, neocortex and striatum are observed. Here, the diseases.ofAlzheimer, of Parkinson, of Hangtington, and the temporal lobe epilepsy are considered. Data, on the known or assumed mechanisms of these diseases are provided. In spite of the fact that the etiology.of the listed ND varies, their pathogenesis is characterized by common features: neural hyperexcitability, trophic deprivation, oxidative stress and energy deficite. Cognitive violations and/or deficiency of senso-motor integration are characteristic of patients with ND. Now reliable medicines for treatment of ND are absent. In recent years the fundamental role of EC system in regu- lation of neuroexcitability, energy metabolism, inflammatory and many other processes has been opened in ND pathogenesis. It points to possibility of development of therapeutic approaches which use the prepara- tions for activation of EC system. In the review various mechanisms of cellular survival and their reparations provided to EC system during action of pathological factors are stated.",[],Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova,2016-07-01,"[{'lastname': 'Kitchigina', 'firstname': 'V F', 'initials': 'VF', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05db3af270>
309,27347894,Sex Hormones and Cognition: Neuroendocrine Influences on Memory and Learning.,"Sex differences in neurological disease exist in incidence, severity, progression, and symptoms and may ultimately influence treatment. Cognitive disturbances are frequent in neuropsychiatric disease with men showing greater cognitive impairment in schizophrenia, but women showing more severe dementia and cognitive decline with Alzheimer's disease. Although there are no overall differences in intelligence between the sexes, men, and women demonstrate slight but consistent differences in a number of cognitive domains. These include a male advantage, on average, in some types of spatial abilities and a female advantage on some measures of verbal fluency and memory. Sex differences in traits or behaviors generally indicate the involvement of sex hormones, such as androgens and estrogens. We review the literature on whether adult levels of testosterone and estradiol influence spatial ability in both males and females from rodent models to humans. We also include information on estrogens and their ability to modulate verbal memory in men and women. Estrone and progestins are common components of hormone therapies, and we also review the existing literature concerning their effects on cognition. We also review the sex differences in the hippocampus and prefrontal cortex as they relate to cognitive performance in both rodents and humans. There has been greater recognition in the scientific literature that it is important to study both sexes and also to analyze study findings with sex as a variable. Only by examining these sex differences can we progress to finding treatments that will improve the cognitive health of both men and women. © 2016 American Physiological Society. Compr Physiol 6:1295-1337, 2016.",[],Comprehensive Physiology,2016-06-28,"[{'lastname': 'Hamson', 'firstname': 'Dwayne K', 'initials': 'DK', 'affiliation': 'Department of Psychology, Centre for Brain Health, Program in Neuroscience the University of British Columbia.'}, {'lastname': 'Roes', 'firstname': 'Meighen M', 'initials': 'MM', 'affiliation': 'Department of Psychology, Centre for Brain Health, Program in Neuroscience the University of British Columbia.'}, {'lastname': 'Galea', 'firstname': 'Liisa A M', 'initials': 'LA', 'affiliation': 'Department of Psychology, Centre for Brain Health, Program in Neuroscience the University of British Columbia.'}]",,,,"Copyright © 2016 John Wiley & Sons, Inc.",10.1002/cphy.c150031,<Element 'PubmedArticle' at 0x7f05db3ba4f0>
310,27343999,"Life stress, glucocorticoid signaling, and the aging epigenome: Implications for aging-related diseases.","Life stress has been associated with accelerated cellular aging and increased risk for developing aging-related diseases; however, the underlying molecular mechanisms remain elusive. A highly relevant process that may underlie this association is epigenetic regulation. In this review, we build upon existing evidence to propose a model whereby exposure to life stress, in part via its effects on the hypothalamic-pituitary axis and the glucocorticoid signaling system, may alter the epigenetic landscape across the lifespan and, consequently, influence genomic regulation and function in ways that are conducive to the development of aging-related diseases. This model is supported by recent studies showing that life stressors and stress-related phenotypes can accelerate epigenetic aging, a measure that is based on DNA methylation prediction of chronological age and has been associated with several aging-related disease phenotypes. We discuss the implications of this model for the prevention and treatment of aging-related diseases, as well as the challenges and limitations of this line of research.","['Aging', 'Cancer', 'Cardiovascular disease', 'DNA methylation', 'Dementia', 'Epigenetics', 'Glucocorticoid signaling', 'Stress']",Neuroscience and biobehavioral reviews,2016-06-28,"[{'lastname': 'Gassen', 'firstname': 'Nils C', 'initials': 'NC', 'affiliation': 'Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.'}, {'lastname': 'Chrousos', 'firstname': 'George P', 'initials': 'GP', 'affiliation': 'First Department of Pediatrics, University of Athens Medical School, Athens, Greece.'}, {'lastname': 'Binder', 'firstname': 'Elisabeth B', 'initials': 'EB', 'affiliation': 'Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany; Department of Psychiatry and Behavioral Sciences, Emory University Medical School, Atlanta, GA, USA.'}, {'lastname': 'Zannas', 'firstname': 'Anthony S', 'initials': 'AS', 'affiliation': 'Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA. Electronic address: anthony_zannas@psych.mpg.de.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.neubiorev.2016.06.003,<Element 'PubmedArticle' at 0x7f05db3c3770>
311,"27317847
19446073
9106616
7804599
25245209
26891883
3786638
6889421
10071091
9676739
26035291
8079377
8945754
9459189
3753802
7729815
8080389
19737574
394816
1115999
2990988
3724953
22612612
24084921
1633405
10594838
15757637
12413378
9344403
9347981
15472107
8050041
7720680
17307903
10700514
11176283
9518671",Reprint of: From the 90׳s to now: A brief historical perspective on more than two decades of estrogen neuroprotection.,"Historical perspective abstract:From the 90׳s to now: a historical perspective on more than two decades of estrogen neuroprotection: In the early 90׳s, estrogens were known to exert organizational and activational effects on reproductive tissues and sexual behavior. As well, the role of sex and gonadal hormones in altering the risk for developing Alzheimer׳s Disease (AD) was only beginning to be elucidated. Preliminary investigations suggested that estrogen-containing therapies typically given for the management of disruptive menopausal symptoms could reduce AD risk, attenuate disease-associated cognitive deficits, and modulate brain substrates known to be dysregulated by the condition, such as the cholingeric system. The findings from our seminal paper demonstrating cognitive benefits and cholinergic impacts with exogenous estrogen treatment in a rodent model of surgical hormone depletion provided initial support for use of estrogen-containing therapies as a treatment for age-related brain disorders. We then went on to demonstrate neuroprotective actions of estrogen in several other in vivo and in vitro models of neurological challenge, including stroke and AD. Further, our findings of the chemical structure requirements for estrogen׳s neuroprotective effects identified a novel approach for optimizing future estrogen-containing hormone therapy options. These early efforts laid the groundwork for later, large-scale clinical investigations into the potential of estrogen-based menopausal hormone therapies for the prevention of a variety of age-related disorders. Although findings of these studies were equivocal, the neuroprotective actions of estrogen, and specifically 17β-estradiol, identified by early investigations, remain well-documented. Future development of interventions that optimize cognitive aging are crucial and, with proper understanding of the factors that influence the realization of beneficial impacts, estrogen-containing treatments may still be among these.
Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats: We hypothesized that estradiol (E2) serves as a neurotrophomodulatory substance for basal forebrain cholinergic neurons thought to be involved in learning and memory. Learning/memory was assessed using the two-way active avoidance paradigm and the Morris water task. Female Sprague-Dawley rats were either ovariectomized (OVX) or OVX for 3 weeks, followed by s.c. implantation of a Silastic pellet containing 17-βE2 (E2 pellet), resulting in a replacement of E2 to physiological levels. Ovary-intact (INTACT) animals served as our positive control. Active avoidance behavior and choline acetyltransferase (ChAT) activity in the frontal cortex and hippocampus were assessed at 5 and 28 weeks postovariectomy while performance on the Morris water task and high-affinity choline uptake (HACU) were measured only at the 5-week time point. At the 5-week time point, E2 replacement caused a significant elevation in the level of active avoidance performance relative to OVX animals. At the 28-week time point, OVX animals demonstrated a significantly lower number of avoidances relative to controls (61%) whereas E2-pellet animals not only demonstrated superior performance relative to OVX animals but also showed an accelerated rate of learning. Morris water task performance, on the other hand, was not significantly affected by estrogenic milieu despite a trend towards better performance in the E2-pellet group. Neurochemical analyses revealed that 5 weeks of ovariectomy was sufficient to reduce HACU in both the frontal cortex and hippocampus by 24 and 34%, respectively, while E2 replacement was successful in elevating HACU relative to OVX animals in both regions. ChAT activity was decreased in the hippocampus but not the frontal cortex of 5-week OVX animals. E2 replacement resulted in a reversal of this effect. At the 28-week time period, an unexpected decrease in ChAT activity was observed across all treatment groups. Interestingly, E2-pellet animals demonstrated the least severe decline in ChAT. This phenomenon was most evident in the frontal cortex where ChAT decreased by 61 and 56% in INTACT and OVX animals, respectively, whereas the decline in E2-pellet animals was only 16% over the same time period, suggesting a previously unreported cytoprotective effect of E2. Taken together, these findings demonstrate important effects of estrogens on cholinergic neurons and support the potential use of estrogen therapy in treatment of dementias in postmenopausal women. © 1994. This article is part of a Special Issue entitled SI:50th Anniversary Issue.","['Alzheimer׳s disease', 'Choline acetyltransferase', 'Cognition', 'Estrogen', 'High-affinity choline uptake', 'Memory']",Brain research,2016-06-19,"[{'lastname': 'Engler-Chiurazzi', 'firstname': 'E B', 'initials': 'EB', 'affiliation': 'Center for Basic and Translational Stroke Research, West Virginia University, Morgantown, WV 26506, USA; Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, USA. Electronic address: elengler@hsc.wvu.edu.'}, {'lastname': 'Singh', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Neuroscience, University of North Texas, Fort Worth, TX 76107, USA. Electronic address: Meharvan.Singh@unthsc.edu.'}, {'lastname': 'Simpkins', 'firstname': 'J W', 'initials': 'JW', 'affiliation': 'Center for Basic and Translational Stroke Research, West Virginia University, Morgantown, WV 26506, USA; Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, USA. Electronic address: jwsimpkins@hsc.wvu.edu.'}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2016.06.016,<Element 'PubmedArticle' at 0x7f05db3cc810>
312,27257014,DTB Select: 6 | June 2016.,"EMA reviews risk of pneumonia with inhaled corticosteroids for COPD ● Updated USA guidance on opioids for chronic pain ● Tackling high-risk prescribing ● Influencing antibiotic prescribing in primary care ● Commuting, BMI and obesity ● Cardiovascular effects of antidepressants ● PPI use and dementia ● Older people and risk of drug interactions.",[],Drug and therapeutics bulletin,2016-06-04,[],,,,Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/,10.1136/dtb.2016.6.0404,<Element 'PubmedArticle' at 0x7f05db3df4a0>
313,"27225696
18597549
19837255
25287883
14725950
23220273
22323502
12373420
16572123
17680367
21321675
23829369
23129391
16723194
1071379
10090646
10340534
913022
11682259
18719045
20600251
21049267
25745105
22588253
24106872
22972702
6125971
6232345
5297174
15808009
18713514
23876288
17497559
22553980
21975580
22589524",Cannabis and tolerance: acute drug impairment as a function of cannabis use history.,"Cannabis use history as predictor of neurocognitive response to cannabis intoxication remains subject to scientific and policy debates. The present study assessed the influence of cannabis on neurocognition in cannabis users whose cannabis use history ranged from infrequent to daily use. Drug users (N = 122) received acute doses of cannabis (300 μg/kg THC), cocaine HCl (300 mg) and placebo. Cocaine served as active control for demonstrating neurocognitive test sensitivity. Executive function, impulse control, attention, psychomotor function and subjective intoxication were significantly worse after cannabis administration relative to placebo. Cocaine improved psychomotor function and attention, impaired impulse control and increased feelings of intoxication. Acute effects of cannabis and cocaine on neurocognitive performance were similar across cannabis users irrespective of their cannabis use history. Absence of tolerance implies that that frequent cannabis use and intoxication can be expected to interfere with neurocognitive performance in many daily environments such as school, work or traffic.",[],Scientific reports,2016-05-27,"[{'lastname': 'Ramaekers', 'firstname': 'J G', 'initials': 'JG', 'affiliation': 'Dept Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'van Wel', 'firstname': 'J H', 'initials': 'JH', 'affiliation': 'Dept Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'Spronk', 'firstname': 'D B', 'initials': 'DB', 'affiliation': 'Dept of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Nijmegen, The Netherlands.'}, {'lastname': 'Toennes', 'firstname': 'S W', 'initials': 'SW', 'affiliation': 'Dept of Forensic Toxicology, Institute of Legal Medicine, Goethe University of Frankfurt, Frankfurt, Germany.'}, {'lastname': 'Kuypers', 'firstname': 'K P C', 'initials': 'KP', 'affiliation': 'Dept Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'Theunissen', 'firstname': 'E L', 'initials': 'EL', 'affiliation': 'Dept Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.'}, {'lastname': 'Verkes', 'firstname': 'R J', 'initials': 'RJ', 'affiliation': 'Dept of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Nijmegen, The Netherlands.\nThe Netherlands Forensic Psychiatric Centre Pompestichting, Nijmegen, The Netherlands.'}]",,,,,10.1038/srep26843,<Element 'PubmedArticle' at 0x7f05db364ae0>
314,27038867,[Alzheimer's disease and diabetes - the common pathogenesis].,"Epidemiological studies presented evidence that Alzheimer's disease and type 2 diabetes share common features in their pathophysiology and clinical patterns. Insulin resistance is a characteristic feature of both diseases. According to the pathomechanism, inflammatory, metabolic, and an atypical form based on the deficiency of zinc ions can be distinguished. Glucose metabolic disorders, related to Alzheimer's disease, are type 2 diabetes, and prediabetes/metabolic syndrome. Based on the common pathophysiological patterns of these two diseases, Alzheimer's disease is customary called type 3 diabetes. In the research on dementias, insulin resistance stands in the highlight for its documented harmful effects on cognitive function and causes dementia. Insulin-like growth factor also influences cognitive functions. Reduced input of this hormone into the brain may also cause dementia, however literary data are controversial. In Alzheimer's disease, deposition of amyloid ß in the brain, hyperphosphorylation of tau proteins and dysruption of neurofibrilles are characteristic. Amyloid ß is co-secreted in the ß-cells of the pancreas with insulin. Amyloid ß and hyperphosphorylated tau protein were detected in the Langerhans islets by autopsy. Amyloid deposits, found in the pancreas and brain presented similarities. As a consequence of hyperglycemia, glycation endproducts cause the development of amyloid plaques, dysruption of neurofibrilles, and activated microglia, all are typical to Alzheimer's disease. Continuous hyperglycemia leads to oxidative stress, which used to play significant role in the development of both diseases. Low-grade inflammation is also a significant pathophysiological factor in both disorders. The sources of inflammation are proinflammatorical adipocytokines, dysbacteriosis, metabolic endotoxaemia, caused by lipopolysaccharides, and high fat diet which also lead to insulin resistance. Based on recent data, microbial amyloid, the main product of bacteria, is also contributing to the pathophysiology of the human central nervous system. Alzheimer's disease is a heterogeneous disorder, and as yet there is no effective therapy. Encouraging results have emerged by using intranasal insulin spray. Insulin sensitizers like metformin, thiazolidines have also resulted in improvements in cognitive functions, mainly in animal experiments. Glucagon-like peptide-1, beyond its insulin-stimulating effect, also has central pleiotropic influences. Research results with the application of these molecules seem to be enouraging. More recently, glucagon-like peptide-1, and glucose-dependent insulinotropic peptide were administered together, with promising early results. The real breakthrough has not yet arrived. For the time being we have to endeavour to the prevention of both chronic diseases via a more healthy life-style.",[],Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology,2016-04-04,"[{'lastname': 'Halmos', 'firstname': 'Tamas', 'initials': 'T', 'affiliation': 'MAZSIHISZ Szeretetkórház, Metabolikus Ambulancia, Budapest, Hungary. fishwash@t-online.hu.'}, {'lastname': 'Suba', 'firstname': 'Ilona', 'initials': 'I', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05db380220>
315,"27014598
24381154
10599770
10854354
10372669
9736007
16217699
7724690
15992253
16887790
15939182
16995832
16981602
10369099
15358792
18722007
4075870
24434111
15939846
16855037
17351741
16670182
14566579
2090463
19203431
12760521
9988286
8461117
10607973
8505462
9883462
22223828
12796530
18808250
21154078
10985290
17402820
1449404
20512721
18609337
18202815
8290098
17164189
19586563
18761139
17454349
20121990
14590575
14590576
8726536
8624219
15896384
12822064
17613980
22042707
16465054
16909626
17876402
15178173
19560132
2959682
17897685
20230126
18999343
8799853
9805326
8811952
18472044
8323481
11475426
7854529
10485572
8844880
17934882
7264241
7560697
10527068
7609938
2139054
15686606
18616392
17545737
7845568
2258431
9777472
10561930
10928745
2771064
9460732
17785667
22264384
19889648
21486518
22913619
8423876
9482358
9699949
2011592
8046448
11150336
24297904
16328506
17479980
19071194
8346443
21124030
10609670
8572669
8644745
24623176
26451386
11884660
8687193
15956166
11425936
19956426
3067252
11156805
1484915
8064097
18030631
10422039
12911102
20304563
21928875
9344402
11078105",Sex differences in cognitive impairment in Alzheimer's disease.,"Sex differences in neurocognitive abilities have been extensively explored both in the healthy population and in many disorders. Until recently, however, little work has examined such differences in people with Alzheimer's disease (AD). This is despite clear evidence that AD is more prevalent in women, and converging lines of evidence from brain imaging, post-mortem analyses, hormone therapy and genetics suggesting that AD affects men and women differently. We provide an overview of evidence attesting to the poorer cognitive profiles in women than in men at the same stage of AD. Indeed, men significantly outperform women in several cognitive domains, including: Language and semantic abilities, visuospatial abilities and episodic memory. These differences do not appear to be attributable to any differences in age, education, or dementia severity. Reasons posited for this female disadvantage include a reduction of estrogen in postmenopausal women, greater cognitive reserve in men, and the influence of the apolipoprotein E ε4 allele. Assessment of cognitive abilities contributes to the diagnosis of the condition and thus, it is crucial to identify the role of sex differences if potentially more accurate diagnoses and treatments are to emerge.","['Cognition', 'Dementia', 'Gender', 'Sex differences']",World journal of psychiatry,2016-03-26,"[{'lastname': 'Laws', 'firstname': 'Keith R', 'initials': 'KR', 'affiliation': 'Keith R Laws, Karen Irvine, Tim M Gale, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, United Kingdom.'}, {'lastname': 'Irvine', 'firstname': 'Karen', 'initials': 'K', 'affiliation': 'Keith R Laws, Karen Irvine, Tim M Gale, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, United Kingdom.'}, {'lastname': 'Gale', 'firstname': 'Tim M', 'initials': 'TM', 'affiliation': 'Keith R Laws, Karen Irvine, Tim M Gale, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire AL10 9AB, United Kingdom.'}]",,,,,10.5498/wjp.v6.i1.54,<Element 'PubmedArticle' at 0x7f05db385540>
316,"26993509
10342866
21514249
25232147
25984581
1549228
25218974
8801538
26070219
24913896
8855991
22437338
16361024
21633502
8784108
23895348
18927166
17159099
16186530
11706109
17942401
8532024
22935803
25024750
23770129
24780498
25057204
24877561
11742217
17324488
22921154
16086687
25147111
21684041
10486419
15576490
25121999
21054328
24528254
24729662
20308782
21945934
19429119
18801339
19166821
17993459
22748937
7624777
19506566
9412531
11861497
18358569
22424230
19451529
24298156
26365177
24990930
16966511
24359504
18926603
9311777
24991952
19936237
24625795
25142458
25766618
24880214
24719781
25088942
9054233
12150780
9142131
20009056
25502764
16973275
7584987
25453257
23506735
20670375
20157255
21651786
24874077
15713712
3917560
6610841
21514250
9202122
21752339
26007213
25766617
22326217
19026409
23274884
25349150
25116704
16914228
8923837
10599761
22530983
25199978
25156686
18769731
11916953
12021250
24430238
21335656
23151427
25866264
24398425
18458326
9024258
2436113
8603777
8787671
11734601
10485707
21514248
12453501
15642850
25173805
20231468
18239178
25352450
26135065
25007719
22105948
20194735
17895242
9777903
8600194
18367704
21536637
25039425
18779578
22859388
18752642
17600230
7984236","Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies.","There is accumulating evidence from epidemiological studies that changes in body weight are associated with Alzheimer's disease (AD) from mid-life obesity increasing the risk of developing AD to weight loss occurring at the earliest stages of AD. Therefore, factors that regulate body weight are likely to influence the development and progression of AD. The adipocyte-derived hormone leptin has emerged as a major regulator of body weight mainly by activating hypothalamic neural circuits. Leptin also has several pleotropic effects including regulating cognitive function and having neuroprotective effects, suggesting a potential link between leptin and AD. Here, we will examine the relationship between leptin and AD by reviewing the recent evidence from cellular and animal models to human studies. We present a model where leptin has a bidirectional role in AD. Not only can alterations in leptin levels and function worsen cognitive decline and progression of AD pathology, but AD pathology, in of itself, can disrupt leptin signaling, which together would lead to a downward spiral of progressive neurodegeneration and worsening body weight and systemic metabolic deficits. Collectively, these studies serve as a framework to highlight the importance of understanding the molecular mechanisms underlying the body weight and systemic metabolic deficits in AD, which has the potential to open new avenues that may ultimately lead to novel therapeutic targets and diagnostic tools.","['Alzheimer’s disease', 'Amyloid', 'Body weight', 'Leptin', 'Metabolism', 'Tau']",Cellular and molecular neurobiology,2016-03-20,"[{'lastname': 'McGuire', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': 'Feil Family Brain and Mind Research Institute, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY, 10065, USA.'}, {'lastname': 'Ishii', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': 'Feil Family Brain and Mind Research Institute, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY, 10065, USA. mishii@med.cornell.edu.'}]",,,,,"10.1007/s10571-015-0282-7
10.1210/endo.140.6.6774
10.1016/j.jalz.2011.03.008
10.1530/JOE-14-0404
10.1016/j.jalz.2015.02.003
10.1016/j.jchemneu.2014.08.006
10.1016/0196-9781(96)00025-3
10.1016/j.npep.2015.05.006
10.1016/j.neurobiolaging.2014.03.033
10.1097/NEN.0b013e31824b211b
10.1016/S1474-4422(05)70284-2
10.1371/journal.pone.0020286
10.1210/jcem.81.9.8784108
10.1111/jnc.12380
10.1136/bjsm.2008.046151
10.1212/01.wnl.0000247046.90574.0f
10.1212/01.wnl.0000176061.33817.90
10.1074/jbc.M703561200
10.1056/NEJM199602013340503
10.1038/nrd3757
10.1186/alzrt269
10.1016/j.cmet.2013.05.010
10.1016/j.nbd.2014.04.012
10.1523/JNEUROSCI.2868-13.2014
10.1210/me.2013-1332
10.1016/j.neurobiolaging.2007.01.008
10.1016/j.neurobiolaging.2012.08.003
10.1111/j.1471-4159.2005.03375.x
10.3233/JAD-141086
10.1016/j.neurobiolaging.2011.05.005
10.1155/2014/302712
10.1056/NEJM199909163411204
10.1096/fj.04-2572com
10.1530/JOE-14-0405
10.1111/j.1532-5415.2010.03169.x
10.1111/jne.12138
10.1155/2014/750860
10.3233/JAD-2010-1308
10.1016/j.bbrc.2011.09.050
10.1016/j.neulet.2009.03.066
10.1016/j.bbrc.2008.09.026
10.1016/j.bbrc.2009.01.041
10.1074/jbc.M703753200
10.1016/j.jalz.2011.05.2411
10.1038/ijo.2009.104
10.1210/endo.143.3.8669
10.1016/j.neurobiolaging.2007.11.024
10.1016/j.cell.2012.02.040
10.1212/WNL.0b013e3181a60a58
10.1098/rstb.2013.0155
10.1016/j.cmet.2015.08.016
10.1523/JNEUROSCI.0872-14.2014
10.1001/archneur.63.9.1312
10.1016/j.neurobiolaging.2008.08.022
10.1038/38717
10.1016/j.neuron.2014.05.041
10.1371/journal.pone.0007917
10.3233/JAD-140006
10.1016/S1474-4422(14)70085-7
10.1038/emm.2015.3
10.1038/nn.3725
10.4161/adip.27552
10.1016/j.euroneuro.2014.06.008
10.1001/jama.2009.1836
10.3233/JAD-141836
10.1016/j.neulet.2006.08.053
10.1038/nm1195-1155
10.1111/acel.12281
10.1016/j.neuroscience.2013.02.062
10.1111/j.1471-4159.2010.06929.x
10.3233/JAD-2010-1298
10.1186/1750-1326-6-41
10.1016/j.bbadis.2014.05.015
10.1210/jc.2004-1979
10.1016/j.jalz.2011.03.005
10.1038/43185
10.1016/j.neuropharm.2011.06.021
10.1038/nn.4018
10.1038/emm.2014.121
10.1016/j.cmet.2012.01.002
10.1016/j.biopsych.2008.10.006
10.1016/j.bbadis.2012.12.009
10.1093/ageing/afu160
10.1210/en.2014-1172
10.1016/j.peptides.2006.07.001
10.1210/jcem.81.11.8923837
10.1111/j.1749-6632.2012.06472.x
10.1016/j.metabol.2014.08.004
10.1016/j.metabol.2014.07.014
10.1371/journal.pone.0003098
10.1172/JCI15001
10.1038/gt.2013.85
10.3233/JAD-2011-102070
10.1017/S1041610212001834
10.1016/S2213-8587(15)00033-9
10.1016/j.bcp.2013.12.024
10.1073/pnas.0706473105
10.1172/JCI118891
10.1038/43448
10.1016/j.jalz.2011.03.003
10.1001/archneur.62.1.55
10.1007/BF01667908
10.1016/j.nbd.2014.08.026
10.1073/pnas.1000645107
10.1161/STROKEAHA.107.494542
10.3233/JAD-141503
10.1016/j.yhbeh.2015.06.013
10.1016/j.jchemneu.2014.05.004
10.1212/WNL.0b013e318238eec1
10.1073/pnas.0909422107
10.1074/jbc.M705426200
10.1212/01.wnl.0000306313.89165.ef
10.1212/WNL.0b013e3182190d09
10.1111/jnc.12828
10.1073/pnas.0806993105
10.1093/gerona/gls155
10.1111/j.1471-4159.2008.05645.x
10.1161/STROKEAHA.107.482786
10.1038/372425a0",<Element 'PubmedArticle' at 0x7f05db33e8b0>
317,26988999,"Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms.","Neurogenesis within the adult hippocampus is modulated by endogenous and exogenous factors. Here, we review the role of sex hormones in the regulation of adult hippocampal neurogenesis in males and females. The review is framed around the potential functional implications of sex hormone regulation of adult hippocampal neurogenesis, with a focus on cognitive function and mood regulation, which may be related to sex differences in incidence and severity of dementia and depression. We present findings from preclinical studies of endogenous fluctuations in sex hormones relating to reproductive function and ageing, and from studies of exogenous hormone manipulations. In addition, we discuss the modulating roles of sex, age, and reproductive history on the relationship between sex hormones and neurogenesis. Because sex hormones have diverse targets in the central nervous system, we overview potential mechanisms through which sex hormones may influence hippocampal neurogenesis. Lastly, we advocate for a more systematic consideration of sex and sex hormones in studying the functional implications of adult hippocampal neurogenesis.","['Androgens', 'Dementia', 'Depression', 'Estradiol', 'Estrogens', 'Estrone', 'Hippocampus', 'Learning and memory', 'Neurogenesis', 'Parity', 'Progesterone', 'Sex differences', 'Stress', 'Testosterone']",Frontiers in neuroendocrinology,2016-03-19,"[{'lastname': 'Mahmoud', 'firstname': 'Rand', 'initials': 'R', 'affiliation': 'Graduate Program in Neuroscience, University of British Columbia, Vancouver, Canada.'}, {'lastname': 'Wainwright', 'firstname': 'Steven R', 'initials': 'SR', 'affiliation': 'Graduate Program in Neuroscience, University of British Columbia, Vancouver, Canada.'}, {'lastname': 'Galea', 'firstname': 'Liisa A M', 'initials': 'LA', 'affiliation': 'Department of Psychology, University of British Columbia, Vancouver, Canada; Centre for Brain Health, University of British Columbia, Vancouver, Canada. Electronic address: lgalea@psych.ubc.ca.'}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2016.03.002,<Element 'PubmedArticle' at 0x7f05db30fd60>
318,26944172,Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.,"Huntington's disease (HD) is a dominantly inherited, progressive neurological disorder caused by a CAG repeat elongation in the huntingtin gene. In addition to motor-, psychiatric- and cognitive dysfunction, peripheral disease manifestations in the form of metabolic changes and cellular dysfunction are seen. Blood levels of a wide range of hormones, metabolites and proteins have been analyzed in HD patients, identifying several changes associated with the disease. However, a comprehensive panel of liver function tests (LFT) has not been performed. We investigated a cohort of manifest and premanifest HD gene-expansion carriers and controls, using a clinically applied panel of LFTs. Here, we demonstrate that the level of alkaline phosphatase is increased in manifest HD gene-expansion carriers compared to premanifest HD gene-expansion carriers and correlate with increased disease severity indicated by the Unified Huntington's disease rating scale-Total Functional Capacity Score (UHDRS-TFC). For gamma-glutamyl transferase, elevated levels were more frequent in the manifest groups than in both the HD gene-expansion negative controls and premanifest HD gene-expansion carriers. Finally, the manifest HD gene-expansion carriers displayed moderate increases in total cholesterol and blood glucose relative to the premanifest HD gene-expansion carriers, as well as increased C-reactive protein relative to HD gene-expansion negative controls. Our results show that LFT values are elevated more frequently in manifest compared to premanifest HD gene-expansion carriers and controls. The majority of the manifest HD gene-expansion carriers receive medication, and it is possible that this can influence the liver function tests performed in this study.","['Alkaline phosphatase', 'Gamma-glutamyl transferase', 'Hepatotoxicity', ""Huntington's disease"", 'Liver', 'Liver function test']",Journal of the neurological sciences,2016-03-06,"[{'lastname': 'Nielsen', 'firstname': 'Signe Marie Borch', 'initials': 'SM', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; The Bartholin Institute, Rigshospitalet, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark. Electronic address: smborch@sund.ku.dk.'}, {'lastname': 'Vinther-Jensen', 'firstname': 'Tua', 'initials': 'T', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Neurogenetics Clinic, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Section 6922, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.'}, {'lastname': 'Nielsen', 'firstname': 'Jørgen E', 'initials': 'JE', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Neurogenetics Clinic, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Section 6922, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.'}, {'lastname': 'Nørremølle', 'firstname': 'Anne', 'initials': 'A', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.'}, {'lastname': 'Hasholt', 'firstname': 'Lis', 'initials': 'L', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.'}, {'lastname': 'Hjermind', 'firstname': 'Lena E', 'initials': 'LE', 'affiliation': 'Section of Neurogenetics, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark; Neurogenetics Clinic, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, University of Copenhagen, Section 6922, Blegdamsvej 9, Copenhagen, DK-2100, Denmark.'}, {'lastname': 'Josefsen', 'firstname': 'Knud', 'initials': 'K', 'affiliation': 'The Bartholin Institute, Rigshospitalet, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark.'}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.jns.2016.02.018,<Element 'PubmedArticle' at 0x7f05db31b130>
319,"26840342
22394291
8570627
21584652
22710755
22505361
10443888
12764055
22744790
8651649
20823086
20547859
22288561
10762506
1439789
1677164
15174020
14616310
8707291
12867116
26268531
21931554
19734292
24252157
9142120
17420324
1977523
15722549
20518029
21805638
18008391
15253663
20121475
18624793
9061687
7494285
17614097
18955905
10581259
22971821
8797472
26022925
15131108
16847141
15862295
15123682
20685658
19659941
25609817
17643109
11476832
16497169
15703444
15979981",The Distribution of Prion Protein Allotypes Differs Between Sporadic and Iatrogenic Creutzfeldt-Jakob Disease Patients.,"Sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP(Sc)). The origin of sCJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP(C)) into infectious PrP(Sc). By contrast, human growth hormone-associated cases of iatrogenic CJD (iCJD) in the United Kingdom (UK) are associated with exposure to an exogenous source of PrP(Sc). In both forms of CJD, heterozygosity at residue 129 for methionine (M) or valine (V) in the prion protein gene may affect disease phenotype, onset and progression. However, the relative contribution of each PrP(C) allotype to PrP(Sc) in heterozygous cases of CJD is unknown. Using mass spectrometry, we determined that the relative abundance of PrP(Sc) with M or V at residue 129 in brain specimens from MV cases of sCJD was highly variable. This result is consistent with PrP(C) containing an M or V at residue 129 having a similar propensity to misfold into PrP(Sc) thus causing sCJD. By contrast, PrP(Sc) with V at residue 129 predominated in the majority of the UK human growth hormone associated iCJD cases, consistent with exposure to infectious PrP(Sc) containing V at residue 129. In both types of CJD, the PrP(Sc) allotype ratio had no correlation with CJD type, age at clinical onset, or disease duration. Therefore, factors other than PrP(Sc) allotype abundance must influence the clinical progression and phenotype of heterozygous cases of CJD.",[],PLoS pathogens,2016-02-04,"[{'lastname': 'Moore', 'firstname': 'Roger A', 'initials': 'RA', 'affiliation': 'Rocky Mountain Laboratories, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.'}, {'lastname': 'Head', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Ironside', 'firstname': 'James W', 'initials': 'JW', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Ritchie', 'firstname': 'Diane L', 'initials': 'DL', 'affiliation': 'National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, United Kingdom.'}, {'lastname': 'Zanusso', 'firstname': 'Gianluigi', 'initials': 'G', 'affiliation': 'Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.'}, {'lastname': 'Choi', 'firstname': 'Young Pyo', 'initials': 'YP', 'affiliation': None}, {'lastname': 'Priola', 'firstname': 'Suzette A', 'initials': 'SA', 'affiliation': 'Rocky Mountain Laboratories, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.'}]",,,,,"10.1371/journal.ppat.1005416
10.1111/j.1365-2990.2012.01265.x
10.1007/s12031-011-9543-1
10.1016/S1474-4422(12)70063-7
10.1007/s00401-012-1002-8
10.1093/brain/awq234
10.1073/pnas.1004688107
10.1111/j.1750-3639.2012.00572.x
10.1371/journal.ppat.1002242
10.1093/brain/awp196
10.1002/pmic.201000104
10.1002/pmic.201100253
10.1586/epr.09.69
10.1111/j.1750-3639.2008.00187.x
10.1097/WNR.0b013e328318edfa
10.1099/vir.0.039008-0
10.1007/s00401-015-1447-7
10.1074/jbc.C110.158303
10.1111/j.1440-1789.2008.00973.x
10.1128/JVI.03183-14",<Element 'PubmedArticle' at 0x7f05db2a7130>
320,26769830,"Crossfit training changes brain-derived neurotrophic factor and irisin levels at rest, after wingate and progressive tests, and improves aerobic capacity and body composition of young physically active men and women.","Brain-derived neurotrophic factor (BDNF) is a protein that stimulates processes of neurogenesis, the survival of neurons and microglia, stimulates neuroplasticity, and takes part in the differentiation of cells developed in the hippocampus. BDNF is also released from skeletal muscles during exercise and can facilitate cross-talk between the nervous and muscular system. Irisin, the exercise hormone, is also released from skeletal muscles and is involved in oxidation processes in the organism. It is a vital issue from the point of view of prophylaxis and treatment through exercise of age-related diseases (e.g. senile dementia), obesity, type-2 diabetes. The aim of the study was to assess the changes in BDNF and irisin levels in young people after a 3-month CrossFit training program. At baseline and after the training, levels of BDNF and irisin were assayed before and after Wingate and progressive tests. Physical performance, body mass and composition, and muscle circumferences were also measured. There were noted: an improvement in aerobic capacity, an increase in VO2max, a reduction in adipose tissue percentage in women and an increase in LBM in all subjects. After CrossFit training the resting BDNF level increased significantly in all subjects while the resting level of irisin decreased in women, without changes in men. The resting level of BDNF at baseline was higher in men than in women. At baseline we observed an increased level of BDNF in women after Wingate and progressive tests, but in men only after the progressive test. After 3 months of CrossFit training the level of BDNF increased in all subjects, and also was higher in men than in women. In women we did not observe significant differences after both tests in comparison to rest. After the training BDNF was lower in men after Wingate and progressive tests than at rest. At baseline irisin level decreased in women after the Wingate and progressive tests. Changes in men were not observed after both tests. There were no differences in irisin levels between the baseline and 3 months after the training after Wingate and progressive tests. A beneficial influence of CrossFit training on the subjects' body composition, anaerobic capacity and cardiovascular fitness as well as an increase in BDNF makes it possible to assume that this type of training could have a very high application value, especially in a therapeutic process leading to improving a patient's wellbeing.",[],Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,2016-01-16,"[{'lastname': 'Murawska-Cialowicz', 'firstname': 'E', 'initials': 'E', 'affiliation': 'University School of Physical Education, Department of Physiology and Biochemistry, Wroclaw, Poland.'}, {'lastname': 'Wojna', 'firstname': 'J', 'initials': 'J', 'affiliation': 'University School of Physical Education, Department of Physiology and Biochemistry, Wroclaw, Poland. wojna.joanna@gmail.com.'}, {'lastname': 'Zuwala-Jagiello', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Medical University, Department of Pharmaceutical Biochemistry, Wroclaw, Poland.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05db2ca310>
321,"26740397
19446073
9106616
7804599
25245209
26891883
3786638
6889421
10071091
9676739
26035291
8079377
8945754
9459189
3753802
7729815
8080389
19737574
394816
1115999
2990988
3724953
22612612
24084921
1633405
10594838
15757637
12413378
9344403
9347981
15472107
8050041
7720680
17307903
10700514
11176283
9518671",From the 90's to now: A brief historical perspective on more than two decades of estrogen neuroprotection.,"Historical perspective abstract:From the 90's to now: a historical perspective on more than two decades of estrogen neuroprotection: In the early 90's, estrogens were known to exert organizational and activational effects on reproductive tissues and sexual behavior. As well, the role of sex and gonadal hormones in altering the risk for developing Alzheimer's Disease (AD) was only beginning to be elucidated. Preliminary investigations suggested that estrogen-containing therapies typically given for the management of disruptive menopausal symptoms could reduce AD risk, attenuate disease-associated cognitive deficits, and modulate brain substrates known to be dysregulated by the condition, such as the cholingeric system. The findings from our seminal paper demonstrating cognitive benefits and cholinergic impacts with exogenous estrogen treatment in a rodent model of surgical hormone depletion provided initial support for use of estrogen-containing therapies as a treatment for age-related brain disorders. We then went on to demonstrate neuroprotective actions of estrogen in several other in vivo and in vitro models of neurological challenge, including stroke and AD. Further, our findings of the chemical structure requirements for estrogen's neuroprotective effects identified a novel approach for optimizing future estrogen-containing hormone therapy options. These early efforts laid the groundwork for later, large-scale clinical investigations into the potential of estrogen-based menopausal hormone therapies for the prevention of a variety of age-related disorders. Although findings of these studies were equivocal, the neuroprotective actions of estrogen, and specifically 17β-estradiol, identified by early investigations, remain well-documented. Future development of interventions that optimize cognitive aging are crucial and, with proper understanding of the factors that influence the realization of beneficial impacts, estrogen-containing treatments may still be among these.
Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats: We hypothesized that estradiol (E2) serves as a neurotrophomodulatory substance for basal forebrain cholinergic neurons thought to be involved in learning and memory. Learning/memory was assessed using the two-way active avoidance paradigm and the Morris water task. Female Sprague-Dawley rats were either ovariectomized (OVX) or OVX for 3 weeks, followed by s.c. implantation of a Silastic pellet containing 17-βE2 (E2 pellet), resulting in a replacement of E2 to physiological levels. Ovary-intact (INTACT) animals served as our positive control. Active avoidance behavior and choline acetyltransferase (ChAT) activity in the frontal cortex and hippocampus were assessed at 5 and 28 weeks postovariectomy while performance on the Morris water task and high-affinity choline uptake (HACU) were measured only at the 5-week time point. At the 5-week time point, E2 replacement caused a significant elevation in the level of active avoidance performance relative to OVX animals. At the 28-week time point, OVX animals demonstrated a significantly lower number of avoidances relative to controls (61%) whereas E2-pellet animals not only demonstrated superior performance relative to OVX animals but also showed an accelerated rate of learning. Morris water task performance, on the other hand, was not significantly affected by estrogenic milieu despite a trend towards better performance in the E2-pellet group. Neurochemical analyses revealed that 5 weeks of ovariectomy was sufficient to reduce HACU in both the frontal cortex and hippocampus by 24 and 34%, respectively, while E2 replacement was successful in elevating HACU relative to OVX animals in both regions. ChAT activity was decreased in the hippocampus but not the frontal cortex of 5-week OVX animals. E2 replacement resulted in a reversal of this effect. At the 28-week time period, an unexpected decrease in ChAT activity was observed across all treatment groups. Interestingly, E2-pellet animals demonstrated the least severe decline in ChAT. This phenomenon was most evident in the frontal cortex where ChAT decreased by 61 and 56% in INTACT and OVX animals, respectively, whereas the decline in E2-pellet animals was only 16% over the same time period, suggesting a previously unreported cytoprotective effect of E2. Taken together, these findings demonstrate important effects of estrogens on cholinergic neurons and support the potential use of estrogen therapy in treatment of dementias in postmenopausal women. © 1994. This article is part of a Special Issue entitled SI:50th Anniversary Issue.","['Alzheimer׳s disease', 'Choline acetyltransferase', 'Cognition', 'Estrogen', 'High-affinity choline uptake', 'Memory']",Brain research,2016-01-08,"[{'lastname': 'Engler-Chiurazzi', 'firstname': 'E B', 'initials': 'EB', 'affiliation': 'Center for Basic and Translational Stroke Research, West Virginia University, Morgantown, WV 26506, USA; Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, USA. Electronic address: elengler@hsc.wvu.edu.'}, {'lastname': 'Singh', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Neuroscience, University of North Texas, Fort Worth, TX 76107, USA. Electronic address: Meharvan.Singh@unthsc.edu.'}, {'lastname': 'Simpkins', 'firstname': 'J W', 'initials': 'JW', 'affiliation': 'Center for Basic and Translational Stroke Research, West Virginia University, Morgantown, WV 26506, USA; Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, USA. Electronic address: jwsimpkins@hsc.wvu.edu.'}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2015.12.044,<Element 'PubmedArticle' at 0x7f05db2cfdb0>
322,26738349,Plasma 8-isoPGF2α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease.,"F2α-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not.
Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels were measured by radioimmunoassay method, and plasma total 8-isoPGF2α levels were measured by enzyme immunoassay method.
Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF2α levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF2a levels (r = -0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found.
Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.",[],Turkish journal of medical sciences,2016-01-08,"[{'lastname': 'Sirin', 'firstname': 'Fevziye Burcu', 'initials': 'FB', 'affiliation': None}, {'lastname': 'Kumbul Doğuç', 'firstname': 'Duygu', 'initials': 'D', 'affiliation': None}, {'lastname': 'Vural', 'firstname': 'Hüseyin', 'initials': 'H', 'affiliation': None}, {'lastname': 'Eren', 'firstname': 'Ibrahim', 'initials': 'I', 'affiliation': None}, {'lastname': 'Inanli', 'firstname': 'Ikbal', 'initials': 'I', 'affiliation': None}, {'lastname': 'Sütçü', 'firstname': 'Recep', 'initials': 'R', 'affiliation': None}, {'lastname': 'Delibaş', 'firstname': 'Namik', 'initials': 'N', 'affiliation': None}]",,"Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.","Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF2α levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF2a levels (r = -0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found.",,10.3906/sag-1406-134,<Element 'PubmedArticle' at 0x7f05db269b80>
323,"26701291
22533436
17151290
12234175
11837744
20837822
10799542
23132321
11085989
10729790
7624778
23798682
16413228
24614172
22704263
16249434
8584938
9442812
8532024
18614690
16690869
9380271
16266773
24858405
11742217
19367261
10482243
16293343
24529528
9247005
11563964
16306348
23152597
11013246
20308782
18801339
17993459
9873206
7624777
16942441
23029293
18024215
12726816
15615638
21281635
19936237
19819959
17955025
14695347
14695347
21123564
20472896
2424016
11904757
23050084
22211890
10938436
17108166
10932182
12150780
20009056
12507904
19471248
20558294
16406150
20042680
20042680
20157255
16236384
2734001
12503980
7822317
11708988
12697721
24916066
23274884
11677594
17472708
16914228
8923837
18769731
21335656
18077675
23619198
9629852
19358976
12623993
21163346
18335524
10890871
14988302
10617129
16873679
21366474
11734601
15542619
9535108
10775532
10229302
16522636
20643941
10194465
15203246
1057175
16958643
16300445
2424015
18952836
15326238
17600230
12101402
18414476","Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease.","Obesity and type 2 diabetes mellitus (T2DM) convey an increased risk for developing dementia. The microtubule-associated protein tau is implicated in neurodegenerative disease by undergoing hyperphosphorylation and aggregation, leading to cytotoxicity and neurodegeneration. Enzymes involved in the regulation of tau phosphorylation, such as GSK3β, are tightly associated with pathways found to be dysregulated in T2DM. We have shown previously that leptin-resistant mice, which develop obesity and a diabetic phenotype, display elevated levels of tau phosphorylation. Here we show cells cultured with leptin, an adipokine shown to have neuroprotective effects, reduces tau phosphorylation. To explore how this mechanism works in vivo we transduced an existing diabetic mouse line (Lepr(db/db)) with a tau mutant (tau(P301L)) via adeno-associated virus (AAV). The resulting phenotype included a striking increase in tau phosphorylation and the number of neurofibrillary tangles (NFTs) found within the hippocampus. We conclude that leptin resistance-induced obesity and diabetes accelerates the development of tau pathology. This model of metabolic dysfunction and tauopathy provides a new system in which to explore the mechanisms underlying the ways in which leptin resistance and diabetes influence development of tau pathology, and may ultimately be related to the development of NFTs.","['Alzheimer’s disease', 'diabetes', 'leptin', 'obesity', 'tau']",Neuroscience,2015-12-25,"[{'lastname': 'Platt', 'firstname': 'T L', 'initials': 'TL', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States.'}, {'lastname': 'Beckett', 'firstname': 'T L', 'initials': 'TL', 'affiliation': 'Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Kohler', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Niedowicz', 'firstname': 'D M', 'initials': 'DM', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States; Sanders Brown Center on Aging, University of Kentucky, United States.'}, {'lastname': 'Murphy', 'firstname': 'M P', 'initials': 'MP', 'affiliation': 'Department of Molecular and Cellular Biochemistry, University of Kentucky, United States; Sanders Brown Center on Aging, University of Kentucky, United States. Electronic address: mpmurp3@email.uky.edu.'}]",,,,Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2015.12.011,<Element 'PubmedArticle' at 0x7f05db273ef0>
324,"26699276
20844536
25496880
9720489
3049945
25985800
16026957
8786441
9539132
23796660
388422
25022604
16126912
21325529
25140287
24209629
1383826
10206639
12130773
17403034
1840698
3258248
23851714
24436056
12621152
11337275
12882410
21421841
12205680
6640289
10657694
10510187
9756916
8626743
10097040
16541076
26051935
15190117
7630400
22288401
22192775
19776077
17883393
21945083
12228720
1432110
1553558
8702810
11432974
9019820
10392577
23870132
1406936
11897565
7618085
18374455
14066623
7311623
881947
8755489
7618084
21056616
25297105
24198336
22645129
20305711
25151380
3131485
22410735
17986138",Ganglioside-Dependent Neural Stem Cell Proliferation in Alzheimer's Disease Model Mice.,"The aggregation and formation of amyloid plaques by amyloid β-peptides (Aβs) is believed to be one of the pathological hallmarks of Alzheimer's disease (AD). Intriguingly, Aβs have also been shown to possess proliferative effects on neural stem cells (NSCs). Many essential cellular processes in NSCs, such as fate determination and proliferation, are heavily influenced by cell surface glycoconjugates, including gangliosides. It has recently been shown that Aβ1-42 alters several key glycosyltransferases and glycosidases. To further define the effects of Aβs and to clarify the potential mechanisms of action of those peptides on NSCs, NSCs were cultured from embryonic brains of the double-transgenic mouse model of AD [B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J] coexpressing mutants of amyloid precursor protein (APPswe) and presenilin1 (PSEN1dE9). We found that Aβs not only promoted cell proliferation but also altered expression of several key glycogenes for glycoconjugate metabolism, such as sialyltransferases II and III (ST-II & -III) in AD NSCs. In addition, we found upregulation of epidermal growth factor receptor and Notch1 intracellular domain. Moreover, the increased expression of ST-II and -III coincided with the elevated levels of c-series gangliosides (A2B5+ antigens) in AD NSCs. Further, we revealed that epidermal growth factor signaling and gangliosides are necessary components on Aβ-stimulated NSC proliferation. Our present study has thus provided a novel mechanism for the upregulation of c-series ganglioside expression and increases in several NSC markers to account for the proliferative effect of Aβs on NSCs in AD mouse brain. These observations support the potential beneficial effects of Aβs and gangliosides in promoting neurogenesis in AD brain.","['Alzheimer’s disease', 'amyloid β-peptide', 'cell proliferation', 'glycogene', 'glycosyltransferase', 'neural stem cell']",ASN neuro,2015-12-25,"[{'lastname': 'Koon', 'firstname': 'Noah A', 'initials': 'NA', 'affiliation': 'Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA ryu@gru.edu.'}, {'lastname': 'Itokazu', 'firstname': 'Yutaka', 'initials': 'Y', 'affiliation': 'Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.'}, {'lastname': 'Yu', 'firstname': 'Robert K', 'initials': 'RK', 'affiliation': 'Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.'}]",,,,© The Author(s) 2015.,10.1177/1759091415618916,<Element 'PubmedArticle' at 0x7f05db231900>
325,26682689,Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.,"Progranulin is implicated in frontotemporal dementia (FTD), but its role in other neurodegenerative disorders is unknown.
To investigate the levels of progranulin (PGRN) in cerebrospinal fluid (CSF) in different neurodegenerative dementias and their correlation with levels in plasma in cognitively normal subjects.
We measured PGRN in CSF in 229 patients with amnestic mild cognitive impairment, Alzheimer's disease dementia, sporadic FTD, dementia with Lewy bodies, corticobasal syndrome, or progressive supranuclear palsy. We also measured PGRN in CSF and plasma in 74 cognitively normal individuals. We examined the correlation between PGRN levels in CSF and diagnosis, cortical thickness, genetic factors and other CSF biomarkers. We also investigated the correlation between plasma and CSF levels of PGRN in cognitively normal individuals.
CSF levels did not differ across diagnoses or correlate with cortical thickness. Polymorphism rs5848 in GRN influenced CSF PGRN levels, but APOEɛ4 allele did not. Amyloid-β42, t-tau, p-tau, and YKL-40 levels correlated weakly with PGRN in CSF. We found a weak correlation (r = 0.362) between plasma and CSF PGRN levels in cognitively normal individuals.
Our findings do not support a diagnostic value of CSF PGRN in neurodegenerative diseases. Our data confirm that levels of PGRN in plasma do not reflect accurately levels in CSF in cognitively normal controls. These data should be considered in clinical trials aiming to increase PGRN.","['Alzheimer’s disease', 'amyloid-β', 'biomarker', 'cerebrospinal fluid', 'dementia', 'plasma', 'progranulin', 'tau']",Journal of Alzheimer's disease : JAD,2015-12-20,"[{'lastname': 'Morenas-Rodríguez', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Cervera-Carles', 'firstname': 'Laura', 'initials': 'L', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Vilaplana', 'firstname': 'Eduard', 'initials': 'E', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Alcolea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Carmona-Iragui', 'firstname': 'María', 'initials': 'M', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Dols-Icardo', 'firstname': 'Oriol', 'initials': 'O', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Ribosa-Nogué', 'firstname': 'Roser', 'initials': 'R', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Muñoz-Llahuna', 'firstname': 'Laia', 'initials': 'L', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Sala', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Belén Sánchez-Saudinós', 'firstname': 'M', 'initials': 'M', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Blesa', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Clarimón', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Fortea', 'firstname': 'Juan', 'initials': 'J', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}, {'lastname': 'Lleó', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.\nCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain.""}]",,,"CSF levels did not differ across diagnoses or correlate with cortical thickness. Polymorphism rs5848 in GRN influenced CSF PGRN levels, but APOEɛ4 allele did not. Amyloid-β42, t-tau, p-tau, and YKL-40 levels correlated weakly with PGRN in CSF. We found a weak correlation (r = 0.362) between plasma and CSF PGRN levels in cognitively normal individuals.",,10.3233/JAD-150746,<Element 'PubmedArticle' at 0x7f05db25bc20>
326,26630390,Salivary cortisol and explicit memory in postmenopausal women using hormone replacement therapy.,"Circulating cortisol levels are known to influence explicit memory in humans and other primates. The present study investigated salivary cortisol and its association with explicit memory performance in 99 postmenopausal women (64 treated with conjugated equine estrogens or estradiol, and 35 matched controls not using any form of hormone therapy). Controls were compared with treated women taking estrogens alone (n=39), or taking estrogens in combination with a progestin (n=25). Mean time on hormone therapy was approximately 5 years, with initiation of treatment in close proximity to the onset of menopause. Explicit memory was assessed with the California Verbal Learning Test (CVLT). Saliva was collected before (basal or resting sample) and after (post-test sample) completing a set of cognitive tasks. Cortisol was measured using a high-sensitivity radioimmunoassay. Treated women were found to have higher resting cortisol concentrations than controls matched for time of day. Basal cortisol was a modest predictor of learning and memory on the CVLT. Higher cortisol was associated with better recall and fewer memory errors, which is consistent with experimental studies examining explicit memory under small increases in circulating cortisol load. Potential cumulative effects on the central nervous system of sustained exposure to mildly increased cortisol in conjunction with the long-term use of oral estrogens are discussed in the context of aging and dementia.","['Estrogen', 'Hormone replacement', 'Hormone therapy', 'Menopause', 'Salivary cortisol']",Psychoneuroendocrinology,2015-12-03,"[{'lastname': 'Hampson', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': 'Department of Psychology and Graduate Program in Neuroscience, University of Western Ontario, London, N6A 5C2, Canada. Electronic address: ehampson@uwo.ca.'}, {'lastname': 'Duff-Canning', 'firstname': 'Sarah J', 'initials': 'SJ', 'affiliation': 'Neuropsychology Clinic, Toronto Western Hospital, Toronto, M5T 2S8, Canada.'}]",,,,Copyright © 2015 Elsevier Ltd. All rights reserved.,10.1016/j.psyneuen.2015.11.009,<Element 'PubmedArticle' at 0x7f05db1ef6d0>
327,26519437,Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer's Disease.,"Current evidence suggests that lipid homeostasis in the hippocampus is affected by different genetic, dietary, and hormonal factors, and that its deregulation may be associated with the onset and progression of Alzheimer's disease (AD). However, the precise levels of influence of each of these factors and their potential interactions remain largely unknown, particularly during neurodegenerative processes. In the present study, we have performed multifactorial analyses of the combined effects of diets containing different doses of docosahexaenoic acid (DHA), estrogen status (ovariectomized animals receiving vehicle or 17β-estradiol), and genotype (wild-type or transgenic APP/PS1 mice) in hippocampal lipid profiles. We have observed that the three factors affect lipid classes and fatty acid composition to different extents, and that strong interactions between these factors exist. The most aberrant lipid profiles were observed in APP/PS1 animals receiving DHA-poor diets and deprived of estrogens. Conversely, wild-type animals under a high-DHA diet and receiving estradiol exhibited a lipid profile that closely resembled that of the hippocampus of control animals. Interestingly, though the lipid signatures of APP/PS1 hippocampi markedly differed from wild-type, administration of a high-DHA diet in the presence of estrogens gave rise to a lipid profile that approached that of control animals. Paralleling changes in lipid composition, patterns of gene expression of enzymes involved in lipid biosynthesis were also altered and affected by combination of experimental factors. Overall, these results indicate that hippocampal lipid homeostasis is strongly affected by hormonal and dietary conditions, and that manipulation of these factors might be incorporated in AD therapeutics.","['17β-estradiol', 'Alzheimer’s disease', 'docosahexaenoic acid', 'hippocampal lipids', 'multifactor analyses']",Journal of Alzheimer's disease : JAD,2015-11-01,"[{'lastname': 'Díaz', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Animal Physiology, Laboratory of Membrane Physiology and Biophysics, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Fabelo', 'firstname': 'Noemí', 'initials': 'N', 'affiliation': 'Department of Animal Physiology, Laboratory of Membrane Physiology and Biophysics, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Casañas-Sánchez', 'firstname': 'Verónica', 'initials': 'V', 'affiliation': 'Department of Genetics, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Marin', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': 'Department of Physiology, Laboratory of Cellular Neurobiology, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Gómez', 'firstname': 'Tomás', 'initials': 'T', 'affiliation': 'Department of Animal Physiology, Laboratory of Membrane Physiology and Biophysics, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Quinto-Alemany', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Animal Physiology, Laboratory of Membrane Physiology and Biophysics, University of La Laguna, Tenerife, Spain.'}, {'lastname': 'Pérez', 'firstname': 'José A', 'initials': 'JA', 'affiliation': 'Department of Genetics, University of La Laguna, Tenerife, Spain.'}]",,,,,10.3233/JAD-150470,<Element 'PubmedArticle' at 0x7f05db1f8e50>
328,"26487801
15261843
24794824
9449250
1661387
25246123
12128283
22032408
25125389
12899651
25443702
19620821
16702789
20610590
20498139
7723675
1491383
11427700
17701157
23680224
10443703
15983313
21493151
21505041
21586137
11006185
16997936
18071895
21067609
20729538
24932478
25330837
7515387
9253308
15635501
6235241
11288048
19276095
8550794
9762876
15943823
18574233
12660892",Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization.,"Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in the circulation and has potent multifunctional activity. Epidemiological evidence suggests that levels of serum DHEA decrease with advancing age, and this has been associated with onset or progression of various age-related ailments, including cognitive decline and dementia, cardiovascular disease, and obesity. Consequently, these findings have sparked intense research interest in DHEA supplementation as an ""antiaging"" therapy. Currently, DHEA is being used by 25% of in vitro fertilization (IVF) clinicians as an adjuvant in assisted reproductive programs, yet the therapeutic benefit of DHEA is unclear. Here, we examined the use of novel DHEA-containing oral troches in patients undertaking IVF and investigated the impact of these troches on their serum androgen profile. This retrospective study determined the androgen profile of 31 IVF patients before (baseline) and after DHEA supplementation (with DHEA). Baseline serum measurements of testosterone (total and free), DHEA sulfate (DHEAS), sex hormone-binding globulin (SHBG), and androstenedione were made before and after supplementation. Each patient received DHEA troches containing 25 mg of micronized DHEA, and troches were administered sublingually twice daily for a period of no greater than 4 months. Adjuvant treatment with DHEA boosted the serum concentration of a number of androgen-related analytes, including total and free testosterone, androstenedione, and DHEAS, while serum SHBG remained unchanged. Supplementation also significantly increased the free-androgen index in IVF patients. Interestingly, the increase in serum analyte concentration following DHEA supplementation was found to be dependent on body mass index (BMI), but not individual age. Patients with the lowest BMI (<20.0 kg/m(2)) tended to have lower testosterone and DHEAS, but higher SHBG and androstenedione levels in comparison with other BMI groups postsupplementation. However, patients in the highest BMI group (>30.0 kg/m(2)) tended to have lower androgen responses following DHEA supplementation, but these were not statistically different from the corresponding baseline level. This method of DHEA administration results in a similar enhancement of testosterone, DHEAS, and androstenedione levels in comparison with other methods of administration. Furthermore, we showed that BMI significantly influences DHEA uptake and metabolism, and that BMI should be carefully considered during dosage calculation to ensure a significant and robust androgen-profile boost.","['IVF', 'androstenedione', 'drug delivery', 'oral troches', 'sex hormone-binding globulin', 'testosterone']","Drug design, development and therapy",2015-10-22,"[{'lastname': 'Keane', 'firstname': 'Kevin N', 'initials': 'KN', 'affiliation': 'School of Biomedical Sciences, Curtin Health Innovation Research Institute - Biosciences, Curtin University, Perth, Australia ; PIVET Medical Centre, Perth, Australia.'}, {'lastname': 'Hinchliffe', 'firstname': 'Peter M', 'initials': 'PM', 'affiliation': 'PIVET Medical Centre, Perth, Australia.'}, {'lastname': 'Namdar', 'firstname': 'Navid', 'initials': 'N', 'affiliation': 'PIVET Medical Centre, Perth, Australia.'}, {'lastname': 'Conceicao', 'firstname': 'Jason L', 'initials': 'JL', 'affiliation': 'PIVET Medical Centre, Perth, Australia.'}, {'lastname': 'Newsholme', 'firstname': 'Philip', 'initials': 'P', 'affiliation': 'School of Biomedical Sciences, Curtin Health Innovation Research Institute - Biosciences, Curtin University, Perth, Australia.'}, {'lastname': 'Yovich', 'firstname': 'John L', 'initials': 'JL', 'affiliation': 'School of Biomedical Sciences, Curtin Health Innovation Research Institute - Biosciences, Curtin University, Perth, Australia ; PIVET Medical Centre, Perth, Australia.'}]",,,,,10.2147/DDDT.S92467,<Element 'PubmedArticle' at 0x7f05db207180>
329,26473392,"Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations.","Our objective was to compare the clinical and pathological characteristics of frontotemporal dementia patients with MAPT, GRN and C9orf72 gene mutations. We carried out a cross-sectional comparative study of 74 gene-positive patients (15 MAPT, 17 GRN and 42 C9orf72). Thirty had post mortem pathological data permitting clinico-pathological correlation. MAPT patients were younger than other groups, and showed more frequent behavioural disinhibition, repetitive and stereotyped behaviours, semantic impairment and temporal predominance of atrophy. GRN patients were older at death and more likely to present with non-fluent aphasia. C9orf72 patients alone showed a co-occurrence of ALS. They showed more psychotic symptoms and irrational behaviour, yet were more often reported clinically as socially appropriate and warm. They showed less dietary change than other groups. C9orf72 patients with and without ALS differed only in frequency of psychosis. Greater clinical overlap was observed between GRN and C9orf72 compared to MAPT cases. MAPT cases had tau and GRN and C9orf72, with one exception, TDP-43 pathology. Non-fluent aphasia was linked to TDP subtype A in both GRN and C9orf72 cases and ALS with subtype B. In conclusion, the findings reinforce clinical heterogeneity in FTD and strengthen evidence that genotype influences clinical presentation. Clinical features may inform targeted genetic testing.","['Frontotemporal dementia', 'behaviour', 'clinical phenotype', 'gene mutation', 'neuropathology']",Amyotrophic lateral sclerosis & frontotemporal degeneration,2015-10-17,"[{'lastname': 'Snowden', 'firstname': 'Julie S', 'initials': 'JS', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Adams', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Harris', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Thompson', 'firstname': 'Jennifer C', 'initials': 'JC', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Rollinson', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Richardson', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Jones', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.\nb Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Neary', 'firstname': 'David', 'initials': 'D', 'affiliation': 'a Manchester Academic Health Sciences Centre, Cerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal NHS Foundation Trust , Salford.'}, {'lastname': 'Mann', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}, {'lastname': 'Pickering-Brown', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'b Institute of Brain, Behaviour and Mental Health, Faculty of Human and Medical Sciences, University of Manchester , Manchester , UK.'}]",,,,,10.3109/21678421.2015.1074700,<Element 'PubmedArticle' at 0x7f05db1a1db0>
330,"26390057
23245609
19342607
19106393
16972045
23303523
21572416
22100073
21909115
21909110
19430483
21060006
19609347
19430479
23972371
21082022
19960030
20529999
23782920
21677658
22748066
22125221
20308177
20562413
22064851
23151460
23990415
24690455
23168336
11956507
23883380
16537907
23383064
21911940
21821672
22190696
20383145
24006081
23034089
20502693
25853392
22568884
26095709
14870823
14660243
23384616
23919675
23912809
22964528
24709820
23104008",Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation.,"We carried out a trans-ancestry genome-wide association and replication study of blood pressure phenotypes among up to 320,251 individuals of East Asian, European and South Asian ancestry. We find genetic variants at 12 new loci to be associated with blood pressure (P = 3.9 × 10(-11) to 5.0 × 10(-21)). The sentinel blood pressure SNPs are enriched for association with DNA methylation at multiple nearby CpG sites, suggesting that, at some of the loci identified, DNA methylation may lie on the regulatory pathway linking sequence variation to blood pressure. The sentinel SNPs at the 12 new loci point to genes involved in vascular smooth muscle (IGFBP3, KCNK3, PDE3A and PRDM6) and renal (ARHGAP24, OSR1, SLC22A7 and TBX2) function. The new and known genetic variants predict increased left ventricular mass, circulating levels of NT-proBNP, and cardiovascular and all-cause mortality (P = 0.04 to 8.6 × 10(-6)). Our results provide new evidence for the role of DNA methylation in blood pressure regulation.",[],Nature genetics,2015-09-22,"[{'lastname': 'Kato', 'firstname': 'Norihiro', 'initials': 'N', 'affiliation': 'Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'lastname': 'Loh', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Institute of Health Sciences, University of Oulu, Oulu, Finland.\nDepartment of Epidemiology and Biostatistics, Imperial College London, London, UK.\nTranslational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (ASTAR), Singapore.'}, {'lastname': 'Takeuchi', 'firstname': 'Fumihiko', 'initials': 'F', 'affiliation': 'Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'lastname': 'Verweij', 'firstname': 'Niek', 'initials': 'N', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Wang', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'lastname': 'Zhang', 'firstname': 'Weihua', 'initials': 'W', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.\nEaling Hospital National Health Service (NHS) Trust, Middlesex, UK.'}, {'lastname': 'Kelly', 'firstname': 'Tanika N', 'initials': 'TN', 'affiliation': 'Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.'}, {'lastname': 'Saleheen', 'firstname': 'Danish', 'initials': 'D', 'affiliation': 'Center for Non-Communicable Diseases, Karachi, Pakistan.\nDepartment of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.\nCardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'lastname': 'Lehne', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.'}, {'lastname': 'Leach', 'firstname': 'Irene Mateo', 'initials': 'IM', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Drong', 'firstname': 'Alexander W', 'initials': 'AW', 'affiliation': 'Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.'}, {'lastname': 'Abbott', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Bioinformatics Support Service, Imperial College London, London, UK.'}, {'lastname': 'Wahl', 'firstname': 'Simone', 'initials': 'S', 'affiliation': 'Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nResearch Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nGerman Center for Diabetes Research (DZD), Neuherberg, Germany.'}, {'lastname': 'Tan', 'firstname': 'Sian-Tsung', 'initials': 'ST', 'affiliation': 'Ealing Hospital National Health Service (NHS) Trust, Middlesex, UK.\nNational Heart and Lung Institute, Imperial College London, London, UK.'}, {'lastname': 'Scott', 'firstname': 'William R', 'initials': 'WR', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.\nNational Heart and Lung Institute, Imperial College London, London, UK.'}, {'lastname': 'Campanella', 'firstname': 'Gianluca', 'initials': 'G', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.'}, {'lastname': 'Chadeau-Hyam', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.'}, {'lastname': 'Afzal', 'firstname': 'Uzma', 'initials': 'U', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.\nEaling Hospital National Health Service (NHS) Trust, Middlesex, UK.'}, {'lastname': 'Ahluwalia', 'firstname': 'Tarunveer S', 'initials': 'TS', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.\nCopenhagen Prospective Studies on Asthma in Childhood (COSPAC), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.\nSteno Diabetes Center, Gentofte, Denmark.'}, {'lastname': 'Bonder', 'firstname': 'Marc Jan', 'initials': 'MJ', 'affiliation': 'Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Chen', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'lastname': 'Dehghan', 'firstname': 'Abbas', 'initials': 'A', 'affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Edwards', 'firstname': 'Todd L', 'initials': 'TL', 'affiliation': 'Vanderbilt Epidemiology Center, Center for Human Genetics Research, Division of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'Esko', 'firstname': 'Tõnu', 'initials': 'T', 'affiliation': ""Estonian Genome Center, University of Tartu, Tartu, Estonia.\nDivision of Endocrinology, Children's Hospital Boston, Boston, Massachusetts, USA.\nDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA.\nProgram in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA.""}, {'lastname': 'Go', 'firstname': 'Min Jin', 'initials': 'MJ', 'affiliation': 'Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.'}, {'lastname': 'Harris', 'firstname': 'Sarah E', 'initials': 'SE', 'affiliation': 'Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental Medicine and Medical Research Council (MRC) Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK.\nCentre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Hartiala', 'firstname': 'Jaana', 'initials': 'J', 'affiliation': 'Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.\nInstitute for Genetic Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.'}, {'lastname': 'Kasela', 'firstname': 'Silva', 'initials': 'S', 'affiliation': 'Estonian Genome Center, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Kasturiratne', 'firstname': 'Anuradhani', 'initials': 'A', 'affiliation': 'Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.'}, {'lastname': 'Khor', 'firstname': 'Chiea-Chuen', 'initials': 'CC', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nGenome Institute of Singapore, ASTAR, Singapore.\nDepartment of Ophthalmology, National University of Singapore, Singapore.\nDepartment of Paediatrics, National University of Singapore, Singapore.'}, {'lastname': 'Kleber', 'firstname': 'Marcus E', 'initials': 'ME', 'affiliation': 'Medical Clinic V, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Li', 'firstname': 'Huaixing', 'initials': 'H', 'affiliation': 'Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.'}, {'lastname': 'Yu Mok', 'firstname': 'Zuan', 'initials': 'Z', 'affiliation': 'Cancer Science Institute of Singapore, National University of Singapore, Singapore.'}, {'lastname': 'Nakatochi', 'firstname': 'Masahiro', 'initials': 'M', 'affiliation': 'Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.'}, {'lastname': 'Sapari', 'firstname': 'Nur Sabrina', 'initials': 'NS', 'affiliation': 'Cancer Science Institute of Singapore, National University of Singapore, Singapore.'}, {'lastname': 'Saxena', 'firstname': 'Richa', 'initials': 'R', 'affiliation': 'Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'lastname': 'Stewart', 'firstname': 'Alexandre F R', 'initials': 'AFR', 'affiliation': 'University of Ottawa Heart Institute, Cardiovascular Research Methods Centre, Ottawa, Ontario, Canada.\nRuddy Canadian Cardiovascular Genetics Centre, Ottawa, Ontario, Canada.'}, {'lastname': 'Stolk', 'firstname': 'Lisette', 'initials': 'L', 'affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Tabara', 'firstname': 'Yasuharu', 'initials': 'Y', 'affiliation': 'Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'lastname': 'Teh', 'firstname': 'Ai Ling', 'initials': 'AL', 'affiliation': 'Singapore Institute for Clinical Sciences (SICS), ASTAR, Singapore.'}, {'lastname': 'Wu', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.'}, {'lastname': 'Wu', 'firstname': 'Jer-Yuarn', 'initials': 'JY', 'affiliation': 'Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.\nSchool of Chinese Medicine, China Medical University, Taichung, Taiwan.'}, {'lastname': 'Zhang', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Medical Genetics, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\nShanghai Institute of Hypertension, Shanghai, China.'}, {'lastname': 'Aits', 'firstname': 'Imke', 'initials': 'I', 'affiliation': 'Institute of Epidemiology and Biobank popgen, Christian Albrechts University of Kiel, Kiel, Germany.'}, {'lastname': 'Da Silva Couto Alves', 'firstname': 'Alexessander', 'initials': 'A', 'affiliation': 'Department of Epidemiology and Biostatistics, MRC Health Protection Agency (PHE) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.'}, {'lastname': 'Das', 'firstname': 'Shikta', 'initials': 'S', 'affiliation': 'Department of Epidemiology and Biostatistics, MRC Health Protection Agency (PHE) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.'}, {'lastname': 'Dorajoo', 'firstname': 'Rajkumar', 'initials': 'R', 'affiliation': 'Genome Institute of Singapore, ASTAR, Singapore.'}, {'lastname': 'Hopewell', 'firstname': 'Jemma C', 'initials': 'JC', 'affiliation': 'Clinical Trials Support Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'lastname': 'Kim', 'firstname': 'Yun Kyoung', 'initials': 'YK', 'affiliation': 'Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.'}, {'lastname': 'Koivula', 'firstname': 'Robert W', 'initials': 'RW', 'affiliation': 'Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University Hospital Malmö, Malmö, Sweden.'}, {'lastname': 'Luan', 'firstname': ""Jian'an"", 'initials': 'J', 'affiliation': 'MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Lyytikäinen', 'firstname': 'Leo-Pekka', 'initials': 'LP', 'affiliation': 'Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.\nDepartment of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Nguyen', 'firstname': 'Quang N', 'initials': 'QN', 'affiliation': 'Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam.'}, {'lastname': 'Pereira', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': 'School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'lastname': 'Postmus', 'firstname': 'Iris', 'initials': 'I', 'affiliation': 'Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.\nNetherlands Consortium for Healthy Ageing, Leiden, the Netherlands.'}, {'lastname': 'Raitakari', 'firstname': 'Olli T', 'initials': 'OT', 'affiliation': 'Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland.\nResearch Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.'}, {'lastname': 'Scannell Bryan', 'firstname': 'Molly', 'initials': 'M', 'affiliation': 'Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.'}, {'lastname': 'Scott', 'firstname': 'Robert A', 'initials': 'RA', 'affiliation': 'MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Sorice', 'firstname': 'Rossella', 'initials': 'R', 'affiliation': 'Institute of Genetics and Biophysics A Buzzati-Traverso, CNR, Naples, Italy.'}, {'lastname': 'Tragante', 'firstname': 'Vinicius', 'initials': 'V', 'affiliation': 'Division of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'lastname': 'Traglia', 'firstname': 'Michela', 'initials': 'M', 'affiliation': ""Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.\nInstitute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 'Burlo Garofolo', Trieste, Italy.""}, {'lastname': 'White', 'firstname': 'Jon', 'initials': 'J', 'affiliation': 'University College London Genetics Institute, Department of Genetics, Environment and Evolution, University College London, London, UK.'}, {'lastname': 'Yamamoto', 'firstname': 'Ken', 'initials': 'K', 'affiliation': 'Division of Genomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.'}, {'lastname': 'Zhang', 'firstname': 'Yonghong', 'initials': 'Y', 'affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'lastname': 'Adair', 'firstname': 'Linda S', 'initials': 'LS', 'affiliation': 'Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, USA.'}, {'lastname': 'Ahmed', 'firstname': 'Alauddin', 'initials': 'A', 'affiliation': 'UChicago Research Bangladesh, Uttara, Dhaka, Bangladesh.'}, {'lastname': 'Akiyama', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': 'Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'lastname': 'Asif', 'firstname': 'Rasheed', 'initials': 'R', 'affiliation': 'Center for Non-Communicable Diseases, Karachi, Pakistan.'}, {'lastname': 'Aung', 'firstname': 'Tin', 'initials': 'T', 'affiliation': 'Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.'}, {'lastname': 'Barroso', 'firstname': 'Inês', 'initials': 'I', 'affiliation': ""Metabolic Disease Group, Wellcome Trust Sanger Institute, Cambridge, UK.\nNational Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.\nUniversity of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.""}, {'lastname': 'Bjonnes', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'lastname': 'Braun', 'firstname': 'Timothy R', 'initials': 'TR', 'affiliation': 'Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.'}, {'lastname': 'Cai', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Vanderbilt Epidemiology Center, Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA.\nVanderbilt-Ingram Cancer Center, Division of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'Chang', 'firstname': 'Li-Ching', 'initials': 'LC', 'affiliation': 'Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.'}, {'lastname': 'Chen', 'firstname': 'Chien-Hsiun', 'initials': 'CH', 'affiliation': 'Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.\nSchool of Chinese Medicine, China Medical University, Taichung, Taiwan.'}, {'lastname': 'Cheng', 'firstname': 'Ching-Yu', 'initials': 'CY', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nDepartment of Ophthalmology, National University of Singapore, Singapore.\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.\nCentre for Quantitative Medicine, Office of Clinical Sciences, Duke-National University of Singapore Graduate Medical School, Singapore.'}, {'lastname': 'Chong', 'firstname': 'Yap-Seng', 'initials': 'YS', 'affiliation': 'Singapore Institute for Clinical Sciences (SICS), ASTAR, Singapore.\nYong Loo Lin School of Medicine, National University of Singapore, Singapore.'}, {'lastname': 'Collins', 'firstname': 'Rory', 'initials': 'R', 'affiliation': 'Clinical Trials Support Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'lastname': 'Courtney', 'firstname': 'Regina', 'initials': 'R', 'affiliation': 'Vanderbilt Epidemiology Center, Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA.\nVanderbilt-Ingram Cancer Center, Division of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'Davies', 'firstname': 'Gail', 'initials': 'G', 'affiliation': 'Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.\nDepartment of Psychology, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Delgado', 'firstname': 'Graciela', 'initials': 'G', 'affiliation': 'Medical Clinic V, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Do', 'firstname': 'Loi D', 'initials': 'LD', 'affiliation': 'Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam.'}, {'lastname': 'Doevendans', 'firstname': 'Pieter A', 'initials': 'PA', 'affiliation': 'Division of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'lastname': 'Gansevoort', 'firstname': 'Ron T', 'initials': 'RT', 'affiliation': 'Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Gao', 'firstname': 'Yu-Tang', 'initials': 'YT', 'affiliation': 'Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.'}, {'lastname': 'Grammer', 'firstname': 'Tanja B', 'initials': 'TB', 'affiliation': 'Medical Clinic V, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Grarup', 'firstname': 'Niels', 'initials': 'N', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Grewal', 'firstname': 'Jagvir', 'initials': 'J', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.\nEaling Hospital National Health Service (NHS) Trust, Middlesex, UK.'}, {'lastname': 'Gu', 'firstname': 'Dongfeng', 'initials': 'D', 'affiliation': 'Fu Wai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'lastname': 'Wander', 'firstname': 'Gurpreet S', 'initials': 'GS', 'affiliation': 'Dayanand Medical College and Hospital Unit, Hero DMC Heart Institute, Ludhiana, India.'}, {'lastname': 'Hartikainen', 'firstname': 'Anna-Liisa', 'initials': 'AL', 'affiliation': 'Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.\nMedical Research Center, University of Oulu, Oulu, Finland.\nUnit of Primary Care, Oulu University Hospital, Oulu, Finland.'}, {'lastname': 'Hazen', 'firstname': 'Stanley L', 'initials': 'SL', 'affiliation': 'Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.\nDepartment of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'lastname': 'He', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'Heng', 'firstname': 'Chew-Kiat', 'initials': 'CK', 'affiliation': 'Department of Paediatrics, Yong Loo Lin School of Medicine, Singapore.'}, {'lastname': 'Hixson', 'firstname': 'James E', 'initials': 'JE', 'affiliation': 'Human Genetics Center, University of Texas School of Public Health at Houston, Houston, Texas, USA.'}, {'lastname': 'Hofman', 'firstname': 'Albert', 'initials': 'A', 'affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Hsu', 'firstname': 'Chris', 'initials': 'C', 'affiliation': 'University of Southern California Keck School of Medicine, Los Angeles, California, USA.'}, {'lastname': 'Huang', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Genetics, Chinese National Human Genomic Center, Shanghai, China.'}, {'lastname': 'Husemoen', 'firstname': 'Lise L N', 'initials': 'LLN', 'affiliation': 'Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark.'}, {'lastname': 'Hwang', 'firstname': 'Joo-Yeon', 'initials': 'JY', 'affiliation': 'Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.'}, {'lastname': 'Ichihara', 'firstname': 'Sahoko', 'initials': 'S', 'affiliation': 'Graduate School of Regional Innovation Studies, Mie University, Tsu, Japan.'}, {'lastname': 'Igase', 'firstname': 'Michiya', 'initials': 'M', 'affiliation': 'Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.'}, {'lastname': 'Isono', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'lastname': 'Justesen', 'firstname': 'Johanne M', 'initials': 'JM', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Katsuya', 'firstname': 'Tomohiro', 'initials': 'T', 'affiliation': 'Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan.\nDepartment of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'lastname': 'Kibriya', 'firstname': 'Muhammad G', 'initials': 'MG', 'affiliation': 'Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.'}, {'lastname': 'Kim', 'firstname': 'Young Jin', 'initials': 'YJ', 'affiliation': 'Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.'}, {'lastname': 'Kishimoto', 'firstname': 'Miyako', 'initials': 'M', 'affiliation': 'National Center for Global Health and Medicine, Toyama, Japan.'}, {'lastname': 'Koh', 'firstname': 'Woon-Puay', 'initials': 'WP', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nDuke-National University of Singapore Graduate Medical School, Singapore.'}, {'lastname': 'Kohara', 'firstname': 'Katsuhiko', 'initials': 'K', 'affiliation': 'Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.'}, {'lastname': 'Kumari', 'firstname': 'Meena', 'initials': 'M', 'affiliation': 'Department of Epidemiology and Public Health, University College London, London, UK.'}, {'lastname': 'Kwek', 'firstname': 'Kenneth', 'initials': 'K', 'affiliation': ""K.K. Women's and Children's Hospital, Singapore.""}, {'lastname': 'Lee', 'firstname': 'Nanette R', 'initials': 'NR', 'affiliation': 'University of San Carlos Office of Population Studies Foundation, University of San Carlos, Cebu City, Philippines.\nDepartment of Anthropology, Sociology and History, University of San Carlos, Cebu City, Philippines.'}, {'lastname': 'Lee', 'firstname': 'Jeannette', 'initials': 'J', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'lastname': 'Liao', 'firstname': 'Jiemin', 'initials': 'J', 'affiliation': 'Department of Ophthalmology, National University of Singapore, Singapore.\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.'}, {'lastname': 'Lieb', 'firstname': 'Wolfgang', 'initials': 'W', 'affiliation': 'Institute of Epidemiology and Biobank popgen, Christian Albrechts University of Kiel, Kiel, Germany.'}, {'lastname': 'Liewald', 'firstname': 'David C M', 'initials': 'DCM', 'affiliation': 'Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.\nDepartment of Psychology, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Matsubara', 'firstname': 'Tatsuaki', 'initials': 'T', 'affiliation': 'Department of Internal Medicine, Aichi-Gakuin University School of Dentistry, Nagoya, Japan.'}, {'lastname': 'Matsushita', 'firstname': 'Yumi', 'initials': 'Y', 'affiliation': 'National Center for Global Health and Medicine, Toyama, Japan.'}, {'lastname': 'Meitinger', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Institute of Human Genetics, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nInstitute of Human Genetics, Technische Universität München, Munich, Germany.'}, {'lastname': 'Mihailov', 'firstname': 'Evelin', 'initials': 'E', 'affiliation': 'Estonian Genome Center, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Milani', 'firstname': 'Lili', 'initials': 'L', 'affiliation': 'Estonian Genome Center, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Mills', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': 'Ealing Hospital National Health Service (NHS) Trust, Middlesex, UK.'}, {'lastname': 'Mononen', 'firstname': 'Nina', 'initials': 'N', 'affiliation': 'Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.\nDepartment of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Müller-Nurasyid', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Institute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nDepartment of Medicine I, Ludwig Maximilians University Munich, Munich, Germany.\nGerman Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.'}, {'lastname': 'Nabika', 'firstname': 'Toru', 'initials': 'T', 'affiliation': 'Department of Functional Pathology, Shimane University Faculty of Medicine, Izumo, Japan.'}, {'lastname': 'Nakashima', 'firstname': 'Eitaro', 'initials': 'E', 'affiliation': 'Division of Endocrinology and Diabetes, Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.\nDepartment of Diabetes and Endocrinology, Chubu Rosai Hospital, Nagoya, Japan.'}, {'lastname': 'Ng', 'firstname': 'Hong Kiat', 'initials': 'HK', 'affiliation': 'Cancer Science Institute of Singapore, National University of Singapore, Singapore.'}, {'lastname': 'Nikus', 'firstname': 'Kjell', 'initials': 'K', 'affiliation': 'Heart Centre, Department of Cardiology, Tampere University Hospital and University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Nutile', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Institute of Genetics and Biophysics A Buzzati-Traverso, CNR, Naples, Italy.'}, {'lastname': 'Ohkubo', 'firstname': 'Takayoshi', 'initials': 'T', 'affiliation': 'Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.'}, {'lastname': 'Ohnaka', 'firstname': 'Keizo', 'initials': 'K', 'affiliation': 'Department of Geriatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'lastname': 'Parish', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Clinical Trials Support Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'lastname': 'Paternoster', 'firstname': 'Lavinia', 'initials': 'L', 'affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.'}, {'lastname': 'Peng', 'firstname': 'Hao', 'initials': 'H', 'affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'lastname': 'Peters', 'firstname': 'Annette', 'initials': 'A', 'affiliation': 'Institute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nGerman Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.'}, {'lastname': 'Pham', 'firstname': 'Son T', 'initials': 'ST', 'affiliation': 'Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Vietnam.'}, {'lastname': 'Pinidiyapathirage', 'firstname': 'Mohitha J', 'initials': 'MJ', 'affiliation': 'Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.'}, {'lastname': 'Rahman', 'firstname': 'Mahfuzar', 'initials': 'M', 'affiliation': 'UChicago Research Bangladesh, Uttara, Dhaka, Bangladesh.\nResearch and Evaluation Division, Bangladesh Rehabilitation Assistance Committee (BRAC), Dhaka, Bangladesh.'}, {'lastname': 'Rakugi', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': 'Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'lastname': 'Rolandsson', 'firstname': 'Olov', 'initials': 'O', 'affiliation': 'Department of Public Health and Clinical Medicine, Section for Family Medicine, Umeå Universitet, Umeå, Sweden.'}, {'lastname': 'Ann Rozario', 'firstname': 'Michelle', 'initials': 'M', 'affiliation': 'Cancer Science Institute of Singapore, National University of Singapore, Singapore.'}, {'lastname': 'Ruggiero', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Institute of Genetics and Biophysics A Buzzati-Traverso, CNR, Naples, Italy.'}, {'lastname': 'Sala', 'firstname': 'Cinzia F', 'initials': 'CF', 'affiliation': 'Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.'}, {'lastname': 'Sarju', 'firstname': 'Ralhan', 'initials': 'R', 'affiliation': 'Dayanand Medical College and Hospital Unit, Hero DMC Heart Institute, Ludhiana, India.'}, {'lastname': 'Shimokawa', 'firstname': 'Kazuro', 'initials': 'K', 'affiliation': 'Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'lastname': 'Snieder', 'firstname': 'Harold', 'initials': 'H', 'affiliation': 'Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Sparsø', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Spiering', 'firstname': 'Wilko', 'initials': 'W', 'affiliation': 'Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.'}, {'lastname': 'Starr', 'firstname': 'John M', 'initials': 'JM', 'affiliation': 'Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.\nAlzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Stott', 'firstname': 'David J', 'initials': 'DJ', 'affiliation': 'Academic Section of Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, UK.'}, {'lastname': 'Stram', 'firstname': 'Daniel O', 'initials': 'DO', 'affiliation': 'University of Southern California Keck School of Medicine, Los Angeles, California, USA.'}, {'lastname': 'Sugiyama', 'firstname': 'Takao', 'initials': 'T', 'affiliation': 'Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan.'}, {'lastname': 'Szymczak', 'firstname': 'Silke', 'initials': 'S', 'affiliation': 'Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany.'}, {'lastname': 'Tang', 'firstname': 'W H Wilson', 'initials': 'WHW', 'affiliation': 'Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA.\nDepartment of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.'}, {'lastname': 'Tong', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.'}, {'lastname': 'Trompet', 'firstname': 'Stella', 'initials': 'S', 'affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Turjanmaa', 'firstname': 'Väinö', 'initials': 'V', 'affiliation': 'Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.\nDepartment of Clinical Physiology, University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Ueshima', 'firstname': 'Hirotsugu', 'initials': 'H', 'affiliation': 'Department of Health Science, Shiga University of Medical Science, Otsu, Japan.\nCenter for Epidemiologic Research in Asia, Shiga University of Medical Science, Otsu, Japan.'}, {'lastname': 'Uitterlinden', 'firstname': 'André G', 'initials': 'AG', 'affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.\nDepartment of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Umemura', 'firstname': 'Satoshi', 'initials': 'S', 'affiliation': 'Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'lastname': 'Vaarasmaki', 'firstname': 'Marja', 'initials': 'M', 'affiliation': 'Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.\nMedical Research Center, University of Oulu, Oulu, Finland.\nUnit of Primary Care, Oulu University Hospital, Oulu, Finland.'}, {'lastname': 'van Dam', 'firstname': 'Rob M', 'initials': 'RM', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'lastname': 'van Gilst', 'firstname': 'Wiek H', 'initials': 'WH', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'van Veldhuisen', 'firstname': 'Dirk J', 'initials': 'DJ', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Viikari', 'firstname': 'Jorma S', 'initials': 'JS', 'affiliation': 'Division of Medicine, Turku University Hospital, Turku, Finland.\nDepartment of Medicine, University of Turku, Turku, Finland.'}, {'lastname': 'Waldenberger', 'firstname': 'Melanie', 'initials': 'M', 'affiliation': 'Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nInstitute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.'}, {'lastname': 'Wang', 'firstname': 'Yiqin', 'initials': 'Y', 'affiliation': 'Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.'}, {'lastname': 'Wang', 'firstname': 'Aili', 'initials': 'A', 'affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'lastname': 'Wilson', 'firstname': 'Rory', 'initials': 'R', 'affiliation': 'Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nInstitute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.'}, {'lastname': 'Wong', 'firstname': 'Tien-Yin', 'initials': 'TY', 'affiliation': 'Department of Ophthalmology, National University of Singapore, Singapore.\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.'}, {'lastname': 'Xiang', 'firstname': 'Yong-Bing', 'initials': 'YB', 'affiliation': 'Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.'}, {'lastname': 'Yamaguchi', 'firstname': 'Shuhei', 'initials': 'S', 'affiliation': 'Third Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.'}, {'lastname': 'Ye', 'firstname': 'Xingwang', 'initials': 'X', 'affiliation': 'Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.'}, {'lastname': 'Young', 'firstname': 'Robin D', 'initials': 'RD', 'affiliation': 'Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.'}, {'lastname': 'Young', 'firstname': 'Terri L', 'initials': 'TL', 'affiliation': 'Neuroscience and Behavioural Disorders (NBD) Program, Duke-National University of Singapore Graduate Medical School, Singapore.\nDuke Eye Center, Duke University Medical Center, Durham, North Carolina, USA.'}, {'lastname': 'Yuan', 'firstname': 'Jian-Min', 'initials': 'JM', 'affiliation': 'Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.'}, {'lastname': 'Zhou', 'firstname': 'Xueya', 'initials': 'X', 'affiliation': 'Bioinformatics Division, Tsinghua National Laboratory for Informatics Science and Technology (TNLIST), Ministry of Education Key Laboratory of Bioinformatics, Department of Automation, Tsinghua University, Beijing, China.\nCenter for Synthetic and Systems Biology, TNLIST, Ministry of Education Key Laboratory of Bioinformatics, Department of Automation, Tsinghua University, Beijing, China.\nDepartment of Psychiatry, University of Hong Kong, Hong Kong.'}, {'lastname': 'Asselbergs', 'firstname': 'Folkert W', 'initials': 'FW', 'affiliation': 'Division of Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.\nDurrer Center for Cardiogenetic Research, Interuniversity Cardiology Institute of the Netherlands (ICIN)-Netherlands Heart Institute, Utrecht, the Netherlands.\nInstitute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK.'}, {'lastname': 'Ciullo', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Institute of Genetics and Biophysics A Buzzati-Traverso, CNR, Naples, Italy.'}, {'lastname': 'Clarke', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Clinical Trials Support Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'lastname': 'Deloukas', 'firstname': 'Panos', 'initials': 'P', 'affiliation': 'William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.\nKing Abdulaziz University, Jeddah, Saudi Arabia.'}, {'lastname': 'Franke', 'firstname': 'Andre', 'initials': 'A', 'affiliation': 'Institute of Clinical Molecular Biology, Christian Albrechts University of Kiel, Kiel, Germany.'}, {'lastname': 'Franks', 'firstname': 'Paul W', 'initials': 'PW', 'affiliation': 'Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Skåne University Hospital Malmö, Malmö, Sweden.\nDepartment of Public Health and Clinical Medicine, Section for Family Medicine, Umeå Universitet, Umeå, Sweden.\nDepartment of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.'}, {'lastname': 'Franks', 'firstname': 'Steve', 'initials': 'S', 'affiliation': 'Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK.'}, {'lastname': 'Friedlander', 'firstname': 'Yechiel', 'initials': 'Y', 'affiliation': 'Hebrew University, School of Public Health, Jerusalem, Israel.'}, {'lastname': 'Gross', 'firstname': 'Myron D', 'initials': 'MD', 'affiliation': 'School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'lastname': 'Guo', 'firstname': 'Zhirong', 'initials': 'Z', 'affiliation': 'Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.'}, {'lastname': 'Hansen', 'firstname': 'Torben', 'initials': 'T', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Jarvelin', 'firstname': 'Marjo-Riitta', 'initials': 'MR', 'affiliation': 'Institute of Health Sciences, University of Oulu, Oulu, Finland.\nDepartment of Epidemiology and Biostatistics, MRC Health Protection Agency (PHE) Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.\nUnit of Primary Care, Oulu University Hospital, Oulu, Finland.\nBiocenter Oulu, University of Oulu, Oulu, Finland.\nCenter for Life Course Epidemiology, Faculty of Medicine, University of Oulu, Oulu, Finland.'}, {'lastname': 'Jørgensen', 'firstname': 'Torben', 'initials': 'T', 'affiliation': 'Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark.'}, {'lastname': 'Jukema', 'firstname': 'J Wouter', 'initials': 'JW', 'affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.\nDurrer Center for Cardiogenetic Research, Interuniversity Cardiology Institute of the Netherlands (ICIN)-Netherlands Heart Institute, Utrecht, the Netherlands.\nICIN, Utrecht, the Netherlands.'}, {'lastname': 'Kähönen', 'firstname': 'Mika', 'initials': 'M', 'affiliation': 'Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.\nDepartment of Clinical Physiology, University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Kajio', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'National Center for Global Health and Medicine, Toyama, Japan.'}, {'lastname': 'Kivimaki', 'firstname': 'Mika', 'initials': 'M', 'affiliation': 'Department of Epidemiology and Public Health, University College London, London, UK.'}, {'lastname': 'Lee', 'firstname': 'Jong-Young', 'initials': 'JY', 'affiliation': 'Ministry of Health and Welfare, Seoul, Republic of Korea.\nTHERAGEN ETEX Bio Institute, Suwon, Republic of Korea.'}, {'lastname': 'Lehtimäki', 'firstname': 'Terho', 'initials': 'T', 'affiliation': 'Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.\nDepartment of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland.'}, {'lastname': 'Linneberg', 'firstname': 'Allan', 'initials': 'A', 'affiliation': 'Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark.\nDepartment of Clinical Experimental Research, Rigshospitalet, Copenhagen, Denmark.\nDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Miki', 'firstname': 'Tetsuro', 'initials': 'T', 'affiliation': 'Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.'}, {'lastname': 'Pedersen', 'firstname': 'Oluf', 'initials': 'O', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'lastname': 'Samani', 'firstname': 'Nilesh J', 'initials': 'NJ', 'affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.\nNIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK.'}, {'lastname': 'Sørensen', 'firstname': 'Thorkild I A', 'initials': 'TIA', 'affiliation': 'Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.\nMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.\nInstitute of Preventive Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'lastname': 'Takayanagi', 'firstname': 'Ryoichi', 'initials': 'R', 'affiliation': 'Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan.'}, {'lastname': 'Toniolo', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.\nInstitute of Molecular Genetics, National Research Council (CNR), Pavia, Italy.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Ahsan', 'firstname': 'Habibul', 'initials': 'H', 'affiliation': 'Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.'}, {'lastname': 'Allayee', 'firstname': 'Hooman', 'initials': 'H', 'affiliation': 'Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.\nInstitute for Genetic Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA.'}, {'lastname': 'Chen', 'firstname': 'Yuan-Tsong', 'initials': 'YT', 'affiliation': 'Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.'}, {'lastname': 'Danesh', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.\nWellcome Trust Sanger Institute, Hinxton, UK.'}, {'lastname': 'Deary', 'firstname': 'Ian J', 'initials': 'IJ', 'affiliation': 'Centre for Cognitive Aging and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.\nDepartment of Psychology, University of Edinburgh, Edinburgh, UK.'}, {'lastname': 'Franco', 'firstname': 'Oscar H', 'initials': 'OH', 'affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Franke', 'firstname': 'Lude', 'initials': 'L', 'affiliation': 'Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Heijman', 'firstname': 'Bastiaan T', 'initials': 'BT', 'affiliation': 'Molecular Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'lastname': 'Holbrook', 'firstname': 'Joanna D', 'initials': 'JD', 'affiliation': 'Singapore Institute for Clinical Sciences (SICS), ASTAR, Singapore.'}, {'lastname': 'Isaacs', 'firstname': 'Aaron', 'initials': 'A', 'affiliation': 'Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Kim', 'firstname': 'Bong-Jo', 'initials': 'BJ', 'affiliation': 'Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.'}, {'lastname': 'Lin', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.'}, {'lastname': 'Liu', 'firstname': 'Jianjun', 'initials': 'J', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nGenome Institute of Singapore, ASTAR, Singapore.'}, {'lastname': 'März', 'firstname': 'Winfried', 'initials': 'W', 'affiliation': 'Medical Clinic V, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.\nClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.\nSynlab Academy, Synlab Services, Mannheim, Germany.'}, {'lastname': 'Metspalu', 'firstname': 'Andres', 'initials': 'A', 'affiliation': 'Estonian Genome Center, University of Tartu, Tartu, Estonia.'}, {'lastname': 'Mohlke', 'firstname': 'Karen L', 'initials': 'KL', 'affiliation': 'Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.'}, {'lastname': 'Sanghera', 'firstname': 'Dharambir K', 'initials': 'DK', 'affiliation': 'Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.'}, {'lastname': 'Shu', 'firstname': 'Xiao-Ou', 'initials': 'XO', 'affiliation': 'Vanderbilt Epidemiology Center, Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA.\nVanderbilt-Ingram Cancer Center, Division of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'van Meurs', 'firstname': 'Joyce B J', 'initials': 'JBJ', 'affiliation': 'Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'lastname': 'Vithana', 'firstname': 'Eranga', 'initials': 'E', 'affiliation': 'Department of Ophthalmology, National University of Singapore, Singapore.\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.\nNeuroscience and Behavioural Disorders (NBD) Program, Duke-National University of Singapore Graduate Medical School, Singapore.'}, {'lastname': 'Wickremasinghe', 'firstname': 'Ananda R', 'initials': 'AR', 'affiliation': 'Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.'}, {'lastname': 'Wijmenga', 'firstname': 'Cisca', 'initials': 'C', 'affiliation': 'Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Wolffenbuttel', 'firstname': 'Bruce H W', 'initials': 'BHW', 'affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'lastname': 'Yokota', 'firstname': 'Mitsuhiro', 'initials': 'M', 'affiliation': 'Department of Genome Science, Aichi-Gakuin University School of Dentistry, Nagoya, Japan.'}, {'lastname': 'Zheng', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Vanderbilt Epidemiology Center, Division of Epidemiology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, Tennessee, USA.\nVanderbilt-Ingram Cancer Center, Division of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.'}, {'lastname': 'Zhu', 'firstname': 'Dingliang', 'initials': 'D', 'affiliation': 'State Key Laboratory of Medical Genetics, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\nShanghai Institute of Hypertension, Shanghai, China.'}, {'lastname': 'Vineis', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.'}, {'lastname': 'Kyrtopoulos', 'firstname': 'Soterios A', 'initials': 'SA', 'affiliation': 'National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, Athens, Greece.'}, {'lastname': 'Kleinjans', 'firstname': 'Jos C S', 'initials': 'JCS', 'affiliation': 'Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands.'}, {'lastname': 'McCarthy', 'firstname': 'Mark I', 'initials': 'MI', 'affiliation': 'Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.\nOxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, UK.'}, {'lastname': 'Soong', 'firstname': 'Richie', 'initials': 'R', 'affiliation': 'Cancer Science Institute of Singapore, National University of Singapore, Singapore.\nDepartment of Pathology, National University of Singapore, Singapore.'}, {'lastname': 'Gieger', 'firstname': 'Christian', 'initials': 'C', 'affiliation': 'Research Unit of Molecular Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.\nInstitute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.'}, {'lastname': 'Scott', 'firstname': 'James', 'initials': 'J', 'affiliation': 'National Heart and Lung Institute, Imperial College London, London, UK.'}, {'lastname': 'Teo', 'firstname': 'Yik-Ying', 'initials': 'YY', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nGenome Institute of Singapore, ASTAR, Singapore.\nSingapore Eye Research Institute, Singapore National Eye Centre, Singapore.\nNational University of Singapore Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore.\nLife Sciences Institute, National University of Singapore, Singapore.\nDepartment of Statistics and Applied Probability, National University of Singapore, Singapore.'}, {'lastname': 'He', 'firstname': 'Jiang', 'initials': 'J', 'affiliation': 'Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.'}, {'lastname': 'Elliott', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.'}, {'lastname': 'Tai', 'firstname': 'E Shyong', 'initials': 'ES', 'affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.\nDepartment of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan.\nDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.'}, {'lastname': 'van der Harst', 'firstname': 'Pim', 'initials': 'P', 'affiliation': 'Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.\nDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.\nDurrer Center for Cardiogenetic Research, Interuniversity Cardiology Institute of the Netherlands (ICIN)-Netherlands Heart Institute, Utrecht, the Netherlands.'}, {'lastname': 'Kooner', 'firstname': 'Jaspal S', 'initials': 'JS', 'affiliation': 'Ealing Hospital National Health Service (NHS) Trust, Middlesex, UK.\nNational Heart and Lung Institute, Imperial College London, London, UK.\nImperial College Healthcare NHS Trust, London, UK.'}, {'lastname': 'Chambers', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Department of Epidemiology and Biostatistics, Imperial College London, London, UK.\nEaling Hospital National Health Service (NHS) Trust, Middlesex, UK.\nImperial College Healthcare NHS Trust, London, UK.'}]",,,,,10.1038/ng.3405,<Element 'PubmedArticle' at 0x7f05db1b4680>
331,26381432,The prevalence of mild cognitive impairment with type 2 diabetes mellitus among elderly people in China: A cross-sectional study.,"In absence of curative treatments for dementia with type 2 diabetes mellitus (T2DM), mild cognitive impairment (MCI) in T2DM, the preclinical transitional states of dementia with T2DM has attracted dramatic attention. Our study was to estimate the prevalence and distribution of MCI in T2DM subjects from China, and identify influencing factors of subjects in MCI with T2DM.
In the present study, we performed cluster random sampling of 8213 people aged 65 years and older in Tianjin, a metropolitan city, located in northern China. All participants were interviewed and screened for T2DM. 1109 subjects with T2DM were initially screened with American Diabetes Association criteria for diagnosis of diabetes mellitus and were diagnosed with MCI and dementia according to the criteria of DSM-IIIR. The prevalence of MCI and dementia in subjects with T2DM were compared with that in ordinary subjects. Logistic regression analyses were performed to evaluate risk of MCI with T2DM.
Among all 8213 subjects, overall MCI and dementia with T2DM prevalence were 13.5% and 2.34%, respectively. Compared with ordinary subjects, the prevalence of MCI in the present study was more frequent than the prevalence of MCI for the general population in almost each age group. In the univariate analyses, among all diabetic subjects, compared with cognitive intactly subjects, MCI subjects had significantly higher levels of age, current smoking, mean waist circumference, duration from onset of diabetes, insulin intake, systolic BP, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c) and immunoreactive insulin (IRI). In multivariate logistic regression analyses, variables including current smoking, duration from onset of diabetes, FPG, HbA1c and IRI were significantly associated with increased risk for MCI with T2DM, the ORs were 1.36,1.33,1.17,1.25 and 1.33, respectively (all P<0.05).
The present study confirms the high prevalence of MCI with T2DM among the elderly population of China. T2DM is related to a higher risk of MCI in a population with a high prevalence of this disorder and may aggravate the clinical picture as a concomitant factor.","['Cross-sectional study', 'Dementia', 'Mild cognitive impairment', 'Prevalence', 'Type 2 diabetes mellitus']",Archives of gerontology and geriatrics,2015-09-19,"[{'lastname': 'Gao', 'firstname': 'Yuxia', 'initials': 'Y', 'affiliation': 'Department of Cardiology, General Hospital of Tianjin Medical University, Tianjin 300052, China.'}, {'lastname': 'Xiao', 'firstname': 'Yanyu', 'initials': 'Y', 'affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin 30070, China.'}, {'lastname': 'Miao', 'firstname': 'Rujuan', 'initials': 'R', 'affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China.'}, {'lastname': 'Zhao', 'firstname': 'Jiangang', 'initials': 'J', 'affiliation': 'Community Health Service Center, Sanhuailu Street, Binhai New District, Tianjin 300450, China.'}, {'lastname': 'Cui', 'firstname': 'Mingfei', 'initials': 'M', 'affiliation': 'Community Health Service Center, Sanhuailu Street, Binhai New District, Tianjin 300450, China.'}, {'lastname': 'Huang', 'firstname': 'Guowei', 'initials': 'G', 'affiliation': 'Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin 30070, China. Electronic address: huangguowei@tmu.edu.cn.'}, {'lastname': 'Fei', 'firstname': 'Ma', 'initials': 'M', 'affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China. Electronic address: mf2002245mf@aliyun.com.'}]",,,"Among all 8213 subjects, overall MCI and dementia with T2DM prevalence were 13.5% and 2.34%, respectively. Compared with ordinary subjects, the prevalence of MCI in the present study was more frequent than the prevalence of MCI for the general population in almost each age group. In the univariate analyses, among all diabetic subjects, compared with cognitive intactly subjects, MCI subjects had significantly higher levels of age, current smoking, mean waist circumference, duration from onset of diabetes, insulin intake, systolic BP, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c) and immunoreactive insulin (IRI). In multivariate logistic regression analyses, variables including current smoking, duration from onset of diabetes, FPG, HbA1c and IRI were significantly associated with increased risk for MCI with T2DM, the ORs were 1.36,1.33,1.17,1.25 and 1.33, respectively (all P<0.05).",Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.archger.2015.09.003,<Element 'PubmedArticle' at 0x7f05db13a950>
332,26363351,Caenorhabditis elegans DAF-16/FOXO transcription factor and its mammalian homologs associate with age-related disease.,"The insulin/IGF-1 signaling pathway is evolutionarily conserved and its function is mediated largely by FOXO transcription factors. Reduced insulin/IGF-1 signaling leads to translocation of FOXO proteins from the cytoplasm to the nucleus where they activate a set of genes that mediate oxidative stress, heat shock, and xenobiotic responses, innate immunity, metabolism, and autophagy. Disruptions in the insulin/IGF-1 signaling pathway affect lifespan in many species. Over the past two decades, the function of these FOXO proteins in age-related diseases has been extensively studied, in the model organism Caenorhabditis elegans as well as in humans. In this review we investigate the mechanisms by which FOXO proteins influence the development of age-related disease pathways in both species.","['Age-related disease', 'Aging', 'C. elegans', 'Daf-16/FOXO', 'Human', 'Translational']",Experimental gerontology,2015-09-13,"[{'lastname': 'Hesp', 'firstname': 'Kylie', 'initials': 'K', 'affiliation': 'Laboratory of Nematology, Wageningen University, Droevendaalsesteeg 1, 6708PB Wageningen, The Netherlands.'}, {'lastname': 'Smant', 'firstname': 'Geert', 'initials': 'G', 'affiliation': 'Laboratory of Nematology, Wageningen University, Droevendaalsesteeg 1, 6708PB Wageningen, The Netherlands.'}, {'lastname': 'Kammenga', 'firstname': 'Jan E', 'initials': 'JE', 'affiliation': 'Laboratory of Nematology, Wageningen University, Droevendaalsesteeg 1, 6708PB Wageningen, The Netherlands. Electronic address: jan.kammenga@wur.nl.'}]",,,,Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.exger.2015.09.006,<Element 'PubmedArticle' at 0x7f05db1468b0>
333,"26348500
17075058
20471032
12547866
21300408
17481591
15728214
12697033
15961250
21300732
20469800
19022335
19488073
23835138
25199880
17050085
18854200
20688111
12214795
24996408
19850688
14749096
18854708
24924160
21722644
14511168
17287134
9520929
18517044
19450933
20647348
16251950
10328525
15039505
25116426
19890706
12531174
16876958
19515498
17408865
12689474
21642593",Sleep duration and the cortisol awakening response in dementia caregivers utilizing adult day services.,"Sleep complaints are common among caregivers and are associated with detriments in mental and physical health. Cortisol, a biomarker of the stress process, may link sleep with subsequent health changes in caregivers. The current study examines whether sleep duration is directly associated with the cortisol awakening response (CAR), or whether it is moderated by Adult Day Services (ADS) use, an intervention found previously to influence daily CAR by reducing stressor exposure.
Associations were examined in caregivers (N = 158) of individuals with dementia (IWD) on days when IWDs attended ADS and days when IWDs did not attend ADS. Data were gathered over 8 consecutive days. Caregivers were primarily female (87.3%) with a mean age of 61.59. A multilevel growth curve model tested the association of an interaction of today's ADS use and last night's sleep duration with today's CAR as the outcome.
The interaction between ADS use and within-person sleep duration was significant such that when an individual sleeps longer than their average but does not use ADS, they have a smaller or blunted CAR. On the other hand when an individual sleeps longer than their average and uses ADS, they have a higher but nonsignificant CAR. Sleeping shorter than usual was associated with a dynamic rise regardless of ADS use.
Findings indicate that ADS use moderates the association between sleep duration and CAR such that longer than average sleep is associated with blunted, dysregulated cortisol patterns only on non-ADS days.",[],"Health psychology : official journal of the Division of Health Psychology, American Psychological Association",2015-09-09,"[{'lastname': 'Leggett', 'firstname': 'Amanda N', 'initials': 'AN', 'affiliation': 'Department of Psychiatry, University of Michigan.'}, {'lastname': 'Liu', 'firstname': 'Yin', 'initials': 'Y', 'affiliation': 'Department of Human Development and Family Studies, Pennsylvania State University.'}, {'lastname': 'Klein', 'firstname': 'Laura Cousino', 'initials': 'LC', 'affiliation': 'Department of Biobehavioral Health, Pennsylvania State University.'}, {'lastname': 'Zarit', 'firstname': 'Steven H', 'initials': 'SH', 'affiliation': 'Department of Human Development and Family Studies, Pennsylvania State University.'}]",Associations were examined in caregivers (N = 158) of individuals with dementia (IWD) on days when IWDs attended ADS and days when IWDs did not attend ADS. Data were gathered over 8 consecutive days. Caregivers were primarily female (87.3%) with a mean age of 61.59. A multilevel growth curve model tested the association of an interaction of today's ADS use and last night's sleep duration with today's CAR as the outcome.,,"The interaction between ADS use and within-person sleep duration was significant such that when an individual sleeps longer than their average but does not use ADS, they have a smaller or blunted CAR. On the other hand when an individual sleeps longer than their average and uses ADS, they have a higher but nonsignificant CAR. Sleeping shorter than usual was associated with a dynamic rise regardless of ADS use.","(c) 2016 APA, all rights reserved).","10.1037/hea0000276
10.1073/pnas.0605053103
10.1016/j.jpsychires.2010.04.015
10.2337/diacare.26.2.380
10.1016/j.jad.2011.01.011
10.1016/j.biopsych.200611.033
10.1210/jc.2004-1056
10.1677/joe.0.1770017
10.1016/j.psyneuen2005.02.010
10.1093/eurheratj/ehr007
10.1016/j.biopsycho.2008.10.004
10.1038/nrendo.2009.106
10.1016/j.smrv.2013.05.001
10.1136/jech-2013-203256
10.1080/13607860600638107
10.1016/j.ijpsycho.2008.03.014
10.2174/978160805342111201010116
10.1016/j.ijpsycho.2010.07.009
10.1080/15427600902911189
10.1111/j.1479-8425.2008.00341.x
10.1017/S0033291702006074
10.1093/geront/gnu060
10.1210/jc.2009-0555
10.1016/S0306-4530(03)00072-6
10.1097/EDE.0b013e318187a7b0
10.1093/geronb/gbu070
10.1016/j.smrv.2006.09.002
10.1093/geronb/53B.2.P122
10.1016/j.psyneuen.2009.04.005
10.1093/geronb/gbq049
10.1097/01.psy.0000116715.78238.56
10.1007/s10803-009-0887-0
10.1016/j.psyneuen.2006.05.012
10.1016/j.psyneuen.2009.04.024
10.1016/j.psyneuen.2007.01.008
10.1093/geronb/gbr030",<Element 'PubmedArticle' at 0x7f05db1519f0>
334,"26335813
21664255
23024364
20807511
21613495
18276750
23100400
1993074
16365303
21374014
21296668
21267651
21220023
18596167
22002425",The role of lysosomal proteinases and estradiol in neurodegeneration induced by beta-amyloid.,"Activation of lysosomal degradation process in nervous tissue may be neuroprotective. One of the factors that may influence on expression of lysosomal proteinases is the sex hormone, estradiol (E2). In this regard the expression of lysosomal proteinases after intracerebral injection of beta-amyloid peptide (Aβ) was investigated as well as the neuroprotective effect of E2 in Aβ-induced neurodegeneration. Intracerebral injection of Aβ was shown to cause the significant increase in expression of cathepsin D in rat hippocampus and cerebral cortex. On the background of Aβ intoxication, E2 treatment resulted in further increase in cathepsin D gene expression in hippocampus region and in its lowering to the control level in cerebral cortex. It was demonstrated for the first time that neuroprotective effect of E2 may be mediated by cathepsin D up-regulation.",[],Doklady. Biochemistry and biophysics,2015-09-04,"[{'lastname': 'Rendakov', 'firstname': 'N L', 'initials': 'NL', 'affiliation': 'Institute of Biology, Karelian Research Center, Russian Academy of Sciences, ul. Pushkinskaya 11, Petrozavodsk, Karelia, 185910, Russia, nlrend@mail.ru.'}, {'lastname': 'Lysenko', 'firstname': 'L A', 'initials': 'LA', 'affiliation': None}, {'lastname': 'Lyupina', 'firstname': 'Yu V', 'initials': 'YV', 'affiliation': None}, {'lastname': 'Sharova', 'firstname': 'N P', 'initials': 'NP', 'affiliation': None}, {'lastname': ""Sel'verova"", 'firstname': 'N B', 'initials': 'NB', 'affiliation': None}, {'lastname': 'Nemova', 'firstname': 'N N', 'initials': 'NN', 'affiliation': None}]",,,,,10.1134/S160767291504002X,<Element 'PubmedArticle' at 0x7f05db0f2310>
335,26159205,Insulin Modulates In Vitro Secretion of Cytokines and Cytotoxins by Human Glial Cells.,"Alzheimer's disease (AD) is the most common form of dementia worldwide. Type 2 diabetes (T2D) has been implicated as a risk factor for AD. Since T2D is a peripheral inflammatory condition, and AD brains exhibit exacerbated neuroinflammation, we hypothesized that inflammatory mechanisms could contribute to the observed link between T2D and AD. Abnormal peripheral and brain insulin concentrations have been reported in both T2D and AD. The neurotrophic role of insulin has been described; however, this hormone can also regulate inflammatory responses in the periphery. Therefore we used in vitro human cell culture systems to elucidate the possible effects of insulin on neuroinflammation. We show that human astrocytes and microglia express both isoforms of the insulin receptor as well as the insulin-like growth factor (IGF)-1 receptor. They also express insulin receptor substrate (IRS)-1 and IRS-2, which are required for propagation of insulin/IGF- 1 signaling. We show that at low nanomolar concentrations, insulin could be pro-inflammatory by upregulating secretion of interleukin (IL)-6 and IL-8 from stimulated human astrocytes and secretion of IL-8 from stimulated human microglia. This effect dissipates at higher insulin concentrations. In contrast, insulin at a broader concentration range (10 pM - 1 μM) reduces the toxicity of stimulated human microglia and THP-1 monocytic cells towards SH-SY5Y neuronal cells. These data show that insulin may regulate the inflammatory status of glial cells by modulating their select functions, which in turn can influence the survival of neurons contributing to the observed link between T2D and AD.",[],Current Alzheimer research,2015-07-15,"[{'lastname': 'Spielman', 'firstname': 'Lindsay J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Bahniwal', 'firstname': 'Manpreet', 'initials': 'M', 'affiliation': None}, {'lastname': 'Little', 'firstname': 'Jonathan P', 'initials': 'JP', 'affiliation': None}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Klegeris', 'firstname': 'Andis', 'initials': 'A', 'affiliation': 'Department of Biology, University of British Columbia Okanagan Campus, 3187 University Way, Kelowna, BC, Canada, V1V 1V7. andis.klegeris@ubc.ca.'}]",,,,,10.2174/1567205012666150710104428,<Element 'PubmedArticle' at 0x7f05db0fed10>
336,"26154489
18845400
23954394
18167405
22997326
23351237
24034249
23150934
21371747
3802833
20060437
20807511
14745052
16387720
12958120
22424230
16917182
21544576
21775213
19404273
25143719
13655060
24035146
19250266
23296339
16279144
16698125
19427328
23571587",Low Testosterone Level and Risk of Alzheimer's Disease in the Elderly Men: a Systematic Review and Meta-Analysis.,"Sex steroids can positively affect the brain function, and low levels of sex steroids may be associated with worse cognitive function in the elderly men. However, previous studies reported contrary findings on the relationship between testosterone level and risk of Alzheimer's disease in the elderly men. The objective of this study was to comprehensively assess the relationship between low testosterone level and Alzheimer's disease risk in the elderly men using a meta-analysis. Only prospective cohort studies assessing the influence of low testosterone level on Alzheimer's disease risk in elderly men were considered eligible. Relative risks (RRs) with 95% confidence intervals (95% CI) were pooled to assess the risk of Alzheimer's disease in elderly men with low testosterone level. Seven prospective cohort studies with a total of 5251 elderly men and 240 cases of Alzheimer's disease were included into the meta-analysis. There was moderate degree of heterogeneity among those included studies (I(2) = 47.2%). Meta-analysis using random effect model showed that low plasma testosterone level was significantly associated with an increased risk of Alzheimer's disease in elderly men (random RR = 1.48, 95% CI 1.12-1.96, P = 0.006). Sensitivity analysis by omitting one study by turns showed that there was no obvious change in the pooled risk estimates, and all pooled RRs were statistically significant. This meta-analysis supports that low plasma testosterone level is significantly associated with increased risk of Alzheimer's disease in the elderly men. Low testosterone level is a risk factor of worse cognitive function in the elderly men.","['Alzheimer’s disease', 'Elderly men', 'Testosterone']",Molecular neurobiology,2015-07-15,"[{'lastname': 'Lv', 'firstname': 'Wenshan', 'initials': 'W', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Du', 'firstname': 'Na', 'initials': 'N', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Liu', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Fan', 'firstname': 'Xinyi', 'initials': 'X', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Wang', 'firstname': 'Yunyang', 'initials': 'Y', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Jia', 'firstname': 'Xiujuan', 'initials': 'X', 'affiliation': 'Department of Gerontology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.'}, {'lastname': 'Hou', 'firstname': 'Xu', 'initials': 'X', 'affiliation': 'Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China. houxqdfy@163.com.'}, {'lastname': 'Wang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': ""Medical Department, Maternal and Children Health's Hospital, Weifang, 261011, China. wangbinwffy@126.com.""}]",,,,,10.1007/s12035-015-9315-y,<Element 'PubmedArticle' at 0x7f05db10bdb0>
337,"26077803
24155300
19455173
20413859
23312564
20028732
16221841
23273603
2113539
21976528
17912249
20043285
8254363
17507558
18337421
20615973
22411227
10822158
17151169
22045482
7700534
15464754
11683906
18571864
22045495
10529444
22222439
16307829
16943563
10348656
16198445
19570680
20881118
19120092
16467370
19339973
17551018
12042880
23839597
15751228
19948164
19401723
22386641
24589888
17615391
12895417
20870017
12000121
17567816
22451915
22791026
17487207
18431482
21855175
21771612
15803159
18691381
21613497
11036168
17286590
12122087
10092043
17562829
15572107
23955525",Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice.,"Alzheimer's disease (AD) is a progressive neurological disorder that impairs memory and other cognitive functions in the elderly. The social and financial impacts of AD are overwhelming and are escalating exponentially as a result of population aging. Therefore, identifying AD-related risk factors and the development of more efficacious therapeutic approaches are critical to cure this neurological disorder. Current epidemiological evidence indicates that life experiences, including chronic stress, are a risk for AD. However, it is unknown if short-term stress, lasting for hours, influences the onset or progression of AD. Here, we determined the effect of short-term, multi-modal 'modern life-like' stress on AD pathogenesis and synaptic plasticity in mice bearing three AD mutations (the 3xTg-AD mouse model). We found that combined emotional and physical stress lasting 5 h severely impaired memory in wild-type mice and tended to impact it in already low-performing 3xTg-AD mice. This stress reduced the number of synapse-bearing dendritic spines in 3xTg-AD mice and increased Aβ levels by augmenting AβPP processing. Thus, short-term stress simulating modern-life conditions may exacerbate cognitive deficits in preclinical AD by accelerating amyloid pathology and reducing synapse numbers. Epidemiological evidence indicates that life experiences, including chronic stress, are a risk for Alzheimer disease (AD). However, it is unknown if short stress in the range of hours influences the onset or progression of AD. Here, we determined the effect of short, multi-modal 'modern-lifelike'stress on AD pathogenesis and synaptic plasticity in mice bearing three AD mutations (the 3xTg-AD mouse model). We found that combined emotional and physical stress lasting 5 h severely impaired memory in wild-type mice and tended to impact it in already low-performing 3xTg-AD mice. This stress reduced the number of synapse-bearing dendritic spines in 3xTg-AD mice and increased Aβ levels by augmenting AβPP processing. Thus, short stress simulating modern-life conditions may exacerbate cognitive deficits in preclinical AD by accelerating amyloid pathology and reducing synapse numbers.","[""Alzheimer's disease"", 'amyloid', 'dementia', 'dendritic spines', 'hippocampus', 'stress']",Journal of neurochemistry,2015-06-17,"[{'lastname': 'Baglietto-Vargas', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Chen', 'firstname': 'Yuncai', 'initials': 'Y', 'affiliation': 'Department of Pediatrics, University of California, Irvine, California, USA.'}, {'lastname': 'Suh', 'firstname': 'Dongjin', 'initials': 'D', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Ager', 'firstname': 'Rahasson R', 'initials': 'RR', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Rodriguez-Ortiz', 'firstname': 'Carlos J', 'initials': 'CJ', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Medeiros', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Myczek', 'firstname': 'Kristoffer', 'initials': 'K', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Green', 'firstname': 'Kim N', 'initials': 'KN', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}, {'lastname': 'Baram', 'firstname': 'Tallie Z', 'initials': 'TZ', 'affiliation': 'Department of Pediatrics, University of California, Irvine, California, USA.\nDepartment of Anatomy/Neurobiology, University of California, Irvine, California, USA.'}, {'lastname': 'LaFerla', 'firstname': 'Frank M', 'initials': 'FM', 'affiliation': 'Department of Neurobiology and Behavior and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA.'}]",,,,© 2015 International Society for Neurochemistry.,10.1111/jnc.13195,<Element 'PubmedArticle' at 0x7f05db11e720>
338,"26077691
19570680
17466428
11275014
9065522
21948247
15554887
23951061
24113652
19012747
23937971
7608248
22487856
22750275
11972430
19469026
24625695
21098983
22313790
16974109
16980541
21976528
22795785
23312564
16554481
16943563
22531419
23357209
11005874
21427641
17553985
17367828
20180948
18423592
23634895
18243386
17151169
11246145
12110446
23901130
8417586
21280074
22738723
22426398
21149712
16085319",Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice.,"Dysregulation of stress hormones, such as glucocorticoids, in adult life increases the risk to develop Alzheimer's disease (AD). However, the effect of prenatal glucocorticoids exposure on AD development in the offspring remains unknown. We studied how gestational dexamethasone exposure influences the AD-like phenotype in the offspring of triple transgenic AD mice (3 × Tg). To this end, female mice received dexamethasone or vehicle during the entire pregnancy time in the drinking water. Offspring from vehicle-treated 3 × Tg (controls) were compared with offspring from dexamethasone-treated 3 × Tg later in life for their memory, learning ability and brain pathology. Compared with controls, offspring from dexamethasone-treated mothers displayed improvement in their memory as assessed by fear conditioning test, both in the cue and recall phases. The same animals had a significant reduction in the insoluble fraction of tau, which was associated with an increase in autophagy. In addition, they showed an activation of the transcription factor cellular response element-binding protein and an increase in brain-derived neurotrophic factor and c-FOS protein levels, key regulators of synaptic plasticity and memory. We conclude that dexamethasone exposure during pregnancy provides long-lasting protection against the onset and development of the AD-like phenotype by improving cognition and tau pathology.",[],Molecular psychiatry,2015-06-17,"[{'lastname': 'Di Meco', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Joshi', 'firstname': 'Y B', 'initials': 'YB', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Lauretti', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}, {'lastname': 'Praticò', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Department of Pharmacology and Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA.'}]",,,,,10.1038/mp.2015.78,<Element 'PubmedArticle' at 0x7f05db0cc090>
339,26037109,"Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease.","Millions of Mexico, US and across the world children are overweight and obese. Exposure to fossil-fuel combustion sources increases the risk for obesity and diabetes, while long-term exposure to fine particulate matter (PM2.5) and ozone (O3) above US EPA standards is associated with increased risk of Alzheimer's disease (AD). Mexico City Metropolitan Area children are chronically exposed to PM2.5 and O3 concentrations above the standards and exhibit systemic, brain and intrathecal inflammation, cognitive deficits, and Alzheimer disease neuropathology. We investigated adipokines, food reward hormones, endothelial dysfunction, vitamin D and apolipoprotein E (APOE) relationships in 80 healthy, normal weight 11.1±3.2 year olds matched by age, gender, BMI and SES, low (n: 26) versus high (n:54) PM2.5 exposures. Mexico City children had higher leptin and endothelin-1 (p<0.01 and p<0.000), and decreases in glucagon-like peptide-1 (GLP 1), ghrelin, and glucagon (<0.02) versus controls. BMI and leptin relationships were significantly different in low versus high PM2.5 exposed children. Mexico City APOE 4 versus 3 children had higher glucose (p=0.009). Serum 25-hydroxyvitamin D<30 ng/mL was documented in 87% of Mexico City children. Leptin is strongly positively associated to PM 2.5 cumulative exposures. Residing in a high PM2.5 and O3 environment is associated with 12h fasting hyperleptinemia, altered appetite-regulating peptides, vitamin D deficiency, and increases in ET-1 in clinically healthy children. These changes could signal the future trajectory of urban children towards the development of insulin resistance, obesity, type II diabetes, premature cardiovascular disease, addiction-like behavior, cognitive impairment and Alzheimer's disease. Increased efforts should be made to decrease pediatric PM2.5 exposures, to deliver health interventions prior to the development of obesity and to identify and mitigate environmental factors influencing obesity and Alzheimer disease.","['APOE', 'Alzheimer', 'Children', 'Fructose', 'Leptin', 'Mexico City', 'Obesity', 'PM(2.5) Air pollution', 'Vitamin D']",Environmental research,2015-06-04,"[{'lastname': 'Calderón-Garcidueñas', 'firstname': 'Lilian', 'initials': 'L', 'affiliation': 'The Center for Structural and Functional Neurosciences, The University of Montana, Missoula, MT 59812, USA; Hospital Central Militar, Mexico City 11649, Mexico. Electronic address: lilian.calderon-garciduenas@umontana.edu.'}, {'lastname': 'Franco-Lira', 'firstname': 'Maricela', 'initials': 'M', 'affiliation': 'Hospital Central Militar, Mexico City 11649, Mexico.'}, {'lastname': ""D'Angiulli"", 'firstname': 'Amedeo', 'initials': 'A', 'affiliation': 'Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada K1S 5B6.'}, {'lastname': 'Rodríguez-Díaz', 'firstname': 'Joel', 'initials': 'J', 'affiliation': 'Escuela de Ciencias de la Salud, Universidad del Valle de México, Saltillo, Coahuila 25204, Mexico.'}, {'lastname': 'Blaurock-Busch', 'firstname': 'Eleonore', 'initials': 'E', 'affiliation': 'Clinical and Environmental Laboratory Micro Trace Minerals (MTM), 91217 Hersbruck, Germany.'}, {'lastname': 'Busch', 'firstname': 'Yvette', 'initials': 'Y', 'affiliation': 'Clinical and Environmental Laboratory Micro Trace Minerals (MTM), 91217 Hersbruck, Germany.'}, {'lastname': 'Chao', 'firstname': 'Chih-kai', 'initials': 'CK', 'affiliation': 'The Center for Structural and Functional Neurosciences, The University of Montana, Missoula, MT 59812, USA.'}, {'lastname': 'Thompson', 'firstname': 'Charles', 'initials': 'C', 'affiliation': 'The Center for Structural and Functional Neurosciences, The University of Montana, Missoula, MT 59812, USA.'}, {'lastname': 'Mukherjee', 'firstname': 'Partha S', 'initials': 'PS', 'affiliation': 'Mathematics Department, Boise State University, Boise, Idaho, USA.'}, {'lastname': 'Torres-Jardón', 'firstname': 'Ricardo', 'initials': 'R', 'affiliation': 'Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, 04510, Mexico.'}, {'lastname': 'Perry', 'firstname': 'George', 'initials': 'G', 'affiliation': 'College of Sciences, University of Texas at San Antonio, San Antonio, TX, USA.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.envres.2015.05.012,<Element 'PubmedArticle' at 0x7f05db062ae0>
340,26021560,Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers.,"Mutations in progranulin gene (GRN) are one of the major causes of autosomal dominant Frontotemporal Lobar Degeneration (FTLD). Progranulin displays anti-inflammatory properties and is likely a ligand of Tumor Necrosis Factor (TNF) receptor 2, expressed on microglia. A few cytokines and chemokines are altered in cerebrospinal fluid (CSF) from patients with sporadic FTLD, whereas no information is available in familial cases. We evaluated, through BioPlex, levels of 27 inflammatory molecules, including cytokines, chemokines, and related receptors, in CSF and matched serum, from FTLD patients carrying GRN mutations as compared with sporadic FTLD with no GRN mutations and controls. Mean±SD Monocyte Chemoattractant Protein-1 (MCP-1) levels were significantly increased in CSF from sporadic FTLD patients as compared with controls (334.27±151.5 versus 159.7±49pg/ml; P⩽0.05). In GRN mutation carriers versus controls, CSF levels of MCP-1 were unchanged, whereas Interferon-γ-inducible protein-10 (IP-10) levels were increased (809.17±240.0 versus 436.61±202.5pg/ml; P=0.012). In the same group, TNFα and Interleukin (IL)-15 levels were decreased (3.18±1.41 versus 35.68±30.5pg/ml; P=0.013 and 9.34±5.54 versus 19.15±10.03pg/ml; P=0.023, respectively). Conversely, Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) levels were decreased in patients, with or without mutations, as compared with controls (4.63±3.30 and 2.58±20 versus 87.57±70pg/ml, respectively; P<0.05). Moreover, IP-10, IL-15 and RANTES CSF levels were not influenced by age, whereas MCP-1 levels increased with age (ρ=0.48; P=0.007). In conclusion, inflammatory de-regulation was observed in both sporadic FTLD and GRN carriers compared to controls, with a specific inflammatory profile for the latter group.","['Cerebrospinal fluid', 'Chemokines', 'Cytokines', 'Frontotemporal Dementia (FTD)', 'Frontotemporal Lobar Degeneration (FTLD)', 'Inflammation', 'Pick dementia', 'Progranulin (GRN)']","Brain, behavior, and immunity",2015-05-30,"[{'lastname': 'Galimberti', 'firstname': 'D', 'initials': 'D', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy. Electronic address: daniela.galimberti@unimi.it.'}, {'lastname': 'Bonsi', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Fenoglio', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Serpente', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Cioffi', 'firstname': 'S M G', 'initials': 'SM', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Fumagalli', 'firstname': 'G', 'initials': 'G', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Arighi', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Ghezzi', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Arcaro', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Mercurio', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Rotondo', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}, {'lastname': 'Scarpini', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2015.05.006,<Element 'PubmedArticle' at 0x7f05db0724f0>
341,"25964433
9354339
21537355
21976528
7472399
15072542
17151169
11830263
15283960
24862368
12724530
15274632
22122678
21262461
23791707
12130773
16918397
19906236
15049707
15652653
22489600
21114967
16467370
6153930
17551018
11160418
12821663
15456788
16234243
15537629
17234594
12130643
17430248
16678274
18160105
9623986
18593777
9668034
16341263
17068112
22908189
11024004
12771123
17115048
17363685
18539594
23043097
15653688
9759500
8090722
24352661
11786305
17567816
22451915
6312319
21855175
23714769
10456290
23202293
6267699
2507928
11064361
15322084
9461064
14636066
11848681
14663028
15668449
17627487",The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity.,"The biological underpinnings linking stress to Alzheimer's disease (AD) risk are poorly understood. We investigated how corticotrophin releasing factor (CRF), a critical stress response mediator, influences amyloid-β (Aβ) production. In cells, CRF treatment increases Aβ production and triggers CRF receptor 1 (CRFR1) and γ-secretase internalization. Co-immunoprecipitation studies establish that γ-secretase associates with CRFR1; this is mediated by β-arrestin binding motifs. Additionally, CRFR1 and γ-secretase co-localize in lipid raft fractions, with increased γ-secretase accumulation upon CRF treatment. CRF treatment also increases γ-secretase activity in vitro, revealing a second, receptor-independent mechanism of action. CRF is the first endogenous neuropeptide that can be shown to directly modulate γ-secretase activity. Unexpectedly, CRFR1 antagonists also increased Aβ. These data collectively link CRF to increased Aβ through γ-secretase and provide mechanistic insight into how stress may increase AD risk. They also suggest that direct targeting of CRF might be necessary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase Aβ and in some cases preferentially increase Aβ42 via complex effects on γ-secretase.","['amyloid‐β', 'corticotrophin releasing factor', 'stress', 'β‐arrestin', 'γ‐secretase']",The EMBO journal,2015-05-13,"[{'lastname': 'Park', 'firstname': 'Hyo-Jin', 'initials': 'HJ', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA Department of Pharmacology and Therapeutics, College of Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Ran', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Jung', 'firstname': 'Joo In', 'initials': 'JI', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Holmes', 'firstname': 'Oliver', 'initials': 'O', 'affiliation': ""Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Price', 'firstname': 'Ashleigh R', 'initials': 'AR', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Smithson', 'firstname': 'Lisa', 'initials': 'L', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Ceballos-Diaz', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Han', 'firstname': 'Chul', 'initials': 'C', 'affiliation': 'Department of Aging and Geriatric Research, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Wolfe', 'firstname': 'Michael S', 'initials': 'MS', 'affiliation': ""Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'lastname': 'Daaka', 'firstname': 'Yehia', 'initials': 'Y', 'affiliation': 'Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Ryabinin', 'firstname': 'Andrey E', 'initials': 'AE', 'affiliation': 'Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, USA.'}, {'lastname': 'Kim', 'firstname': 'Seong-Hun', 'initials': 'SH', 'affiliation': 'Department of Pharmacology and Therapeutics, College of Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.'}, {'lastname': 'Hauger', 'firstname': 'Richard L', 'initials': 'RL', 'affiliation': 'Center of Excellence for Stress and Mental Health, Department of Psychiatry, VA Healthcare System, University of California, San Diego, CA, USA.'}, {'lastname': 'Golde', 'firstname': 'Todd E', 'initials': 'TE', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA tgolde@ufl.edu kfelsenstein0@ufl.edu.'}, {'lastname': 'Felsenstein', 'firstname': 'Kevin M', 'initials': 'KM', 'affiliation': 'Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL, USA tgolde@ufl.edu kfelsenstein0@ufl.edu.'}]",,,,© 2015 The Authors.,10.15252/embj.201488795,<Element 'PubmedArticle' at 0x7f05db082ea0>
342,25936156,[Dementia].,"A female tends to suffer from dementia and dementia is thought as a disease with sex difference clearly. A female has the longer life, so it has been thought that a female prevalence rate is higher than a man seemingly. However, even if sex difference was considered, it was demonstrated clearly in recent years that a female suffer from dementia with high frequencies. Now, it isn't clear yet why such sex difference exists. The strongest hypothesis may be influence by sex hormones, and role of androgen as well as estrogen is pointed out. Now, 15% of more than 65 years old suffer from dementia. Dementia is thought as a common disease"". More than 65-year-old elderly people don' t want to suffer from dementia. Although many people have such great interest of dementia, they do not find the early stage symptom of dementia. Forgetfulness is often overlooked and early detection isn't done. There are many diseases which lead to dementia, but Alzheimer-type dementia accounts for the most part of dementia. Alzheimer-type dementia can be treated by medicines, therefore early detection and an early stage check are necessary. I explain how do general physicians notice dementia in their outpatient clinic and diagnose and treat.",[],Nihon rinsho. Japanese journal of clinical medicine,2015-05-06,"[{'lastname': 'Urakami', 'firstname': 'Katsuya', 'initials': 'K', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05db0334f0>
343,25921747,Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety.,"Testosterone replacement therapy (TRT) has been investigated in older men as a preventative treatment against Alzheimer's disease and dementia. However, previous studies have been contradictory. We assessed TRT physiological effects in 44 older men (aged 61 ± 7.7 years) with subjective memory complaints using a double blind, randomized, crossover, placebo-controlled study. Participants were randomized into 2 groups, one group received transdermal testosterone (50 mg) daily for 24 weeks, followed by a 4 week wash-out period, then 24 weeks of placebo; the other group received the reverse treatment. Blood evaluation revealed significant increases in total testosterone, free (calculated) testosterone, dihydrotestosterone, and a decrease in luteinizing hormone levels (p<0.001) following TRT. Although there were significant increases in red blood cell counts, hemoglobin and prostate specific antigen levels following TRT, they remained within normal ranges. No significant differences in plasma amyloid beta, estradiol, sex hormone binding globulin, insulin levels, body fat percentage, or body mass index were detected. This is the first carefully controlled study that has investigated the influence of TRT in Indonesian men on blood biomarkers linked to dementia risk. Our study suggests TRT is safe and well-tolerated in this Indonesian cohort, yet longitudinal studies with larger cohorts are needed to assess TRT further, and to establish whether TRT reduces dementia risk.",[],CNS & neurological disorders drug targets,2015-04-30,"[{'lastname': 'Asih', 'firstname': 'Prita R', 'initials': 'PR', 'affiliation': None}, {'lastname': 'Wahjoepramono', 'firstname': 'Eka J', 'initials': 'EJ', 'affiliation': None}, {'lastname': 'Aniwiyanti', 'firstname': 'Vilia', 'initials': 'V', 'affiliation': None}, {'lastname': 'Wijaya', 'firstname': 'Linda K', 'initials': 'LK', 'affiliation': None}, {'lastname': 'de Ruyck', 'firstname': 'Karl', 'initials': 'K', 'affiliation': None}, {'lastname': 'Taddei', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': None}, {'lastname': 'Fuller', 'firstname': 'Stephanie J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Sohrabi', 'firstname': 'Hamid', 'initials': 'H', 'affiliation': None}, {'lastname': 'Dhaliwal', 'firstname': 'Satvinder S', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Verdile', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Carruthers', 'firstname': 'Malcolm', 'initials': 'M', 'affiliation': None}, {'lastname': 'Martins', 'firstname': 'Ralph N', 'initials': 'RN', 'affiliation': 'Edith Cowan University, Suite 22, Hollywood Medical Centre, 85 Monash Avenue, Nedlands, WA 6009, Australia. r.martins@ecu.edu.au.'}]",,,,,10.2174/1871527314666150429112112,<Element 'PubmedArticle' at 0x7f05db038130>
344,"25850354
10462619
15041084
16298249
14602815
11306202
17379265
17462646
18551084
14654448
10923060
23669447
11305853
2453958
10964854
22192366
19272398
24570664
6463130
7816540
11104644
24680649
3192705
23954501
11142657
11863380
12051109
13030849
15048687
11255426
14766964
11342677
18201446
2592523
12700177
15213206
11730734
16903132
18620351
21694454
9670866",Influences of hormone replacement therapy on olfactory and cognitive function in postmenopausal women.,"Olfactory dysfunction can be an early sign of Alzheimer's disease. Since hormone replacement therapy (HRT) may protect against Alzheimer's disease in postmenopausal women, the question arises as to whether it also protects against olfactory dysfunction in such women. A total of three olfactory and 12 neurocognitive tests were administered to 432 healthy postmenopausal women with varied HRT histories. Serum levels of reproductive hormones were obtained for all subjects; APOE-ε4 haplotype was determined for 77 women. National Adult Reading Test and Odor Memory/Discrimination Test scores were positively influenced by HRT. Odor Identification and Odor Memory/Discrimination Test scores were lower for women who scored poorly on a delayed recall test, a surrogate for mild cognitive impairment. The Wechsler Adult Intelligence Scale, Revised, as a Neuropsychological Instrument Spatial Span Backwards Test scores were higher in women receiving estrogen and progestin HRT and directly correlated with serum testosterone levels, the latter implying a positive effect of testosterone on spatial memory. APOE-ε4 was associated with poorer odor threshold test scores. These data suggest that HRT positively influences a limited number of olfactory and cognitive measures during menopause.","['Cognition', 'Endocrinology', 'Estrogen', 'Hormone replacement therapy', 'Menopause', 'Olfaction']",Neurobiology of aging,2015-04-09,"[{'lastname': 'Doty', 'firstname': 'Richard L', 'initials': 'RL', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: richard.doty@uphs.upenn.edu.'}, {'lastname': 'Tourbier', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Ng', 'firstname': 'Victoria', 'initials': 'V', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Neff', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Armstrong', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Battistini', 'firstname': 'Michelle', 'initials': 'M', 'affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Sammel', 'firstname': 'Mary D', 'initials': 'MD', 'affiliation': 'Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Gettes', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Evans', 'firstname': 'Dwight L', 'initials': 'DL', 'affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Mirza', 'firstname': 'Natasha', 'initials': 'N', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Moberg', 'firstname': 'Paul J', 'initials': 'PJ', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Connolly', 'firstname': 'Tim', 'initials': 'T', 'affiliation': 'Smell and Taste Center and Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Sondheimer', 'firstname': 'Steven J', 'initials': 'SJ', 'affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2015.02.028,<Element 'PubmedArticle' at 0x7f05db0435e0>
345,"25673853
18514314
17524488
22566581
15667020
23273603
22592800
2399998
21976528
17912249
15808979
17151169
3953862
21059265
15283960
18571864
11454437
11959395
12379862
21898707
16214415
16943563
22336193
16764819
15120860
9436726
22976078
19570680
22531419
18853426
17551018
19779148
19280102
8461968
24052308
17052377
15921918
22593059
22322105
19012747
19948164
17943022
9581947
10861779
19066529
10195112
23583109
21376129
11135011
21883149
8540594
22459791
17115048
20863321
15465465
12815499
17567816
22451915
21855175
9807058
10579633
3527687
18939191
15426759
16435288
20152116
17360908
18568035
9655498
18691381
21281636
9809220
24012003
6267699
23164950
11932745
20530010
19918929
19906232
1661614
20826658
24065130","Posttraumatic stress disorder-like induction elevates β-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses.","Recent studies have found that those who suffer from posttraumatic stress disorder (PTSD) are more likely to experience dementia as they age, most often Alzheimer's disease (AD). These findings suggest that the symptoms of PTSD might have an exacerbating effect on AD progression. AD and PTSD might also share common susceptibility factors such that those who experience trauma-induced disease were already more likely to succumb to dementia with age. Here, we explored these two hypotheses using a mouse model of PTSD in wild-type and AD model animals. We found that expression of human familial AD mutations in amyloid precursor protein and presenilin 1 leads to sensitivity to trauma-induced PTSD-like changes in behavioral and endocrine stress responses. PTSD-like induction, in turn, chronically elevates levels of CSF β-amyloid (Aβ), exacerbating ongoing AD pathogenesis. We show that PTSD-like induction and Aβ elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intact hypothalamic-pituitary-adrenal axis. Furthermore, we show that Aβ species can hyperexcite CRF neurons, providing a mechanism by which Aβ influences stress-related symptoms and PTSD-like phenotypes. Consistent with Aβ causing excitability of the stress circuitry, we attenuate PTSD-like phenotypes in vivo by lowering Aβ levels during PTSD-like trauma exposure. Together, these data demonstrate that exposure to PTSD-like trauma can drive AD pathogenesis, which directly perturbs CRF signaling, thereby enhancing chronic PTSD symptoms while increasing risk for AD-related dementia.","[""Alzheimer's disease"", 'PTSD', 'crf', 'crfr1', 'crh', 'stress']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2015-02-13,"[{'lastname': 'Justice', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Institute of Molecular Medicine, Program in Neuroscience, and Huffington Center on Aging and Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030, and Nicholas.J.Justice@uth.tmc.edu.'}, {'lastname': 'Huang', 'firstname': 'Longwen', 'initials': 'L', 'affiliation': ""Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030, and Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas 77030.""}, {'lastname': 'Tian', 'firstname': 'Jin-Bin', 'initials': 'JB', 'affiliation': 'Department of Integrative Biology and Pharmacology, University of Texas Health Sciences Center, Houston, Texas 77030.'}, {'lastname': 'Cole', 'firstname': 'Allysa', 'initials': 'A', 'affiliation': 'Huffington Center on Aging and.'}, {'lastname': 'Pruski', 'firstname': 'Melissa', 'initials': 'M', 'affiliation': 'Institute of Molecular Medicine.'}, {'lastname': 'Hunt', 'firstname': 'Albert J', 'initials': 'AJ', 'affiliation': 'Institute of Molecular Medicine, Program in Neuroscience, and.'}, {'lastname': 'Flores', 'firstname': 'Rene', 'initials': 'R', 'affiliation': 'Institute of Molecular Medicine.'}, {'lastname': 'Zhu', 'firstname': 'Michael X', 'initials': 'MX', 'affiliation': 'Department of Integrative Biology and Pharmacology, University of Texas Health Sciences Center, Houston, Texas 77030.'}, {'lastname': 'Arenkiel', 'firstname': 'Benjamin R', 'initials': 'BR', 'affiliation': ""Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030, and Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, Texas 77030.""}, {'lastname': 'Zheng', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Huffington Center on Aging and Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas 77030, and.'}]",,,,Copyright © 2015 the authors 0270-6474/15/352612-12$15.00/0.,"10.1523/JNEUROSCI.3333-14.2015
10.1016/j.neubiorev.2008.04.003
10.1016/j.brainresrev.2007.04.005
10.1001/archgenpsychiatry.2011.1481
10.1016/j.neurobiolaging.2012.11.015
10.1073/pnas.1206171109
10.1176/ajp.147.10.1308
10.1523/JNEUROSCI.3836-11.2011
10.1038/sj.mp.4002101
10.1016/j.neuroimage.2004.12.036
10.1176/appi.ajp.163.12.2164
10.1176/ajp.143.3.300
10.1186/1756-6606-3-34
10.1016/j.neuroscience.2004.05.040
10.1016/j.neuroscience.2008.05.017
10.1016/S0301-0511(01)00092-8
10.1016/S0197-4580(01)00330-X
10.1038/nn958
10.1002/da.20880
10.1016/j.it.2005.09.010
10.1523/JNEUROSCI.2797-06.2006
10.1016/j.neurobiolaging.2012.01.002
10.1016/j.abb.2006.05.002
10.1016/j.neuroscience.2004.02.038
10.1136/jnnp.64.1.44
10.3233/JAD-2012-121438
10.1016/j.jocn.2008.12.026
10.3233/JAD-2012-120328
10.1002/cne.21848
10.1073/pnas.0700148104
10.1126/science.1180962
10.1007/s00415-009-5096-4
10.1093/brain/116.2.309
10.1126/science.1242077
10.1017/S0033291706009019
10.1016/j.nbd.2005.04.009
10.1523/JNEUROSCI.4012-11.2012
10.1016/j.biopsych.2011.12.024
10.1111/j.1471-4159.2008.05769.x
10.1016/j.ejphar.2009.11.045
10.1159/000109938
10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO%3B2-Q
10.3791/960
10.1038/271
10.1016/j.neuron.2013.02.003
10.1016/j.nlm.2011.02.016
10.1046/j.1460-9568.2001.01355.x
10.1111/j.1476-5381.2011.01646.x
10.1176/ajp.153.1.64
10.1016/j.cpr.2012.02.002
10.1038/nm1485
10.1111/j.1532-5415.2010.02977.x
10.1016/S1470-2045(04)01597-9
10.1076/jcen.25.5.614.14581
10.1523/JNEUROSCI.5173-06.2007
10.1073/pnas.1203140109
10.1016/j.neurobiolaging.2011.07.005
10.3109/10253899609001092
10.1016/S0531-5565(99)00047-9
10.1210/edrv-7-3-284
10.1136/bmj.1.4667.1383
10.1002/cne.20872
10.1016/j.neuron.2009.11.032
10.1523/JNEUROSCI.4970-06.2007
10.1038/nm1782
10.1016/S0896-6273(00)80491-2
10.1111/j.1471-4159.2008.05613.x
10.1016/j.expneurol.2011.01.016
10.1016/j.neuron.2013.06.036
10.1126/science.6267699
10.1016/j.bbi.2012.10.022
10.1038/416535a
10.1001/archgenpsychiatry.2010.61
10.1002/da.20629
10.1111/j.1749-6632.2009.04979.x
10.1016/0006-3223(91)90123-4
10.1523/JNEUROSCI.2357-10.2010
10.1038/emboj.2013.207",<Element 'PubmedArticle' at 0x7f05db060bd0>
346,"25632146
10723002
21075087
7204652
17765709
22623913
9659999
20100545
2898236
8987772
9495877
24510074
22676718
20626460
23583481
8308742
11259507
160969
12543217
9133574
21056867
1660336
1359112
10592303
17765723
19104150
19133236
21826442
11726235
6311357
10036289
22114260
8915675
11514077
22468144
10594677
22654741
12495858
23276673
1324765
1361330
7923379
17765714
12884965
10579209
10064815
15642623
2466534
1319480
10721682
23978562
19828812
23103216
8857605
8096243
7572212
8388986
19193892
11836067
19596017
16945354
11801187
16503703
1783024
2465635
8867040
7834376
6669222
9860058
17395265
17215502
11275401
21913092
23720407
2731518
19909788
21664381
8255546
15811547
10931523
10401641
24275289
7626478
2501818
1317000
15219759
15527861
11517242
7472450
8917586
9307136
23660230
11440806
14684866
17970745
9804884
25159586
21680031
8894847
21245308
21525279
23392664
16914677
19596521
24776635
14689476
23415935
23183182
7190730
1972143
18691558
19505458
19150393
21254303
1666016
16310960
20618420
10655521
1341673
8719612
8381696
8027776
11343643
21224009
20828542
1353794
9799624
7751946
20357124
11826273",Opioid receptor-dependent sex differences in synaptic plasticity in the hippocampal mossy fiber pathway of the adult rat.,"The mossy fiber (MF) pathway is critical to hippocampal function and influenced by gonadal hormones. Physiological data are limited, so we asked whether basal transmission and long-term potentiation (LTP) differed in slices of adult male and female rats. The results showed small sex differences in basal transmission but striking sex differences in opioid receptor sensitivity and LTP. When slices were made from females on proestrous morning, when serum levels of 17β-estradiol peak, the nonspecific opioid receptor antagonist naloxone (1 μm) enhanced MF transmission but there was no effect in males, suggesting preferential opioid receptor-dependent inhibition in females when 17β-estradiol levels are elevated. The μ-opioid receptor (MOR) antagonist Cys2,Tyr3,Orn5,Pen7-amide (CTOP; 300 nm) had a similar effect but the δ-opioid receptor (DOR) antagonist naltrindole (NTI; 1 μm) did not, implicating MORs in female MF transmission. The GABAB receptor antagonist saclofen (200 μm) occluded effects of CTOP but the GABAA receptor antagonist bicuculline (10 μm) did not. For LTP, a low-frequency (LF) protocol was used because higher frequencies elicited hyperexcitability in females. Proestrous females exhibited LF-LTP but males did not, suggesting a lower threshold for synaptic plasticity when 17β-estradiol is elevated. NTI blocked LF-LTP in proestrous females, but CTOP did not. Electron microscopy revealed more DOR-labeled spines of pyramidal cells in proestrous females than males. Therefore, we suggest that increased postsynaptic DORs mediate LF-LTP in proestrous females. The results show strong MOR regulation of MF transmission only in females and identify a novel DOR-dependent form of MF LTP specific to proestrus.","['area CA3', 'estrous cycle', 'hippocampus', 'long-term potentiation', 'opiate', 'sex differences']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2015-01-30,"[{'lastname': 'Harte-Hargrove', 'firstname': 'Lauren C', 'initials': 'LC', 'affiliation': 'The Nathan Kline Institute for Psychiatric Research, Center of Dementia Research, Orangeburg, New York 10962, New York University, Langone Medical Center, Departments of Child and Adolescent Psychiatry, and.'}, {'lastname': 'Varga-Wesson', 'firstname': 'Ada', 'initials': 'A', 'affiliation': 'The Nathan Kline Institute for Psychiatric Research, Center of Dementia Research, Orangeburg, New York 10962, New York University, Langone Medical Center.'}, {'lastname': 'Duffy', 'firstname': 'Aine M', 'initials': 'AM', 'affiliation': 'The Nathan Kline Institute for Psychiatric Research, Center of Dementia Research, Orangeburg, New York 10962, New York University, Langone Medical Center, Departments of Child and Adolescent Psychiatry, and.'}, {'lastname': 'Milner', 'firstname': 'Teresa A', 'initials': 'TA', 'affiliation': 'Weill Cornell Medical College, Brain and Mind Research Institute, New York, New York 10065, and The Rockefeller University, Laboratory of Neuroendocrinology, New York, New York 10065.'}, {'lastname': 'Scharfman', 'firstname': 'Helen E', 'initials': 'HE', 'affiliation': 'The Nathan Kline Institute for Psychiatric Research, Center of Dementia Research, Orangeburg, New York 10962, New York University, Langone Medical Center, Departments of Child and Adolescent Psychiatry, and Physiology and Neurosci, Psychiatry, New York, New York 10016, hscharfman@nki.rfmh.org.'}]",,,,Copyright © 2015 the authors 0270-6474/15/351723-16$15.00/0.,"10.1523/JNEUROSCI.0820-14.2015
10.1002/(SICI)1096-9861(20000403)419:2<244::AID-CNE8>3.0.CO;2-R
10.1016/j.brainres.2010.11.018
10.1016/S0079-6123(07)63001-5
10.3389/fncir.2012.00023
10.1016/S0166-4328(98)00019-9
10.1016/j.bbagen.2010.01.006
10.1146/annurev.pa.28.040188.001441
10.1177/1073858413519865
10.1186/2042-6410-3-14
10.1111/j.1460-9568.2010.07314.x
10.1016/j.brainres.2013.03.051
10.1046/j.1471-4159.2001.00204.x
10.1016/0024-3205(79)90598-8
10.1016/S0091-3057(02)01039-0
10.1002/(SICI)1096-9861(19970512)381:3<373::AID-CNE8>3.0.CO;2-#
10.1016/j.genm.2010.09.004
10.1016/0361-9230(91)90071-Q
10.1016/S0006-8993(99)01910-1
10.1016/S0079-6123(07)63015-5
10.1172/JCI36059
10.1016/j.brainres.2008.12.043
10.1007/s00441-011-1221-7
10.1006/nlme.2001.4018
10.1016/0361-9230(83)90206-X
10.1523/JNEUROSCI.1264-11.2011
10.1016/S0304-3940(01)02083-3
10.3389/fendo.2011.00018
10.1046/j.1460-9568.1999.00920.x
10.3389/fnint.2012.00023
10.1016/S0166-2236(02)00006-1
10.1016/j.neuroscience.2012.12.029
10.1016/0006-8993(92)90226-Y
10.1016/0092-8674(94)90401-4
10.1016/S0079-6123(07)63006-4
10.1034/j.1601-183X.2003.00013.x
10.1016/S0306-4522(99)00249-3
10.1016/S0006-8993(99)01089-6
10.1016/j.neubiorev.2004.10.006
10.1016/0006-8993(89)91341-3
10.1124/jpet.113.206573
10.1523/JNEUROSCI.3059-09.2009
10.1016/j.neuroscience.2012.10.038
10.1159/000127106
10.1111/j.1748-1716.1995.tb09898.x
10.1523/JNEUROSCI.4688-08.2009
10.1016/S0892-0362(01)00197-0
10.1016/j.neuropharm.2009.07.007
10.1016/j.brainres.2006.07.016
10.1186/1471-2202-2-20
10.1037/1064-1297.14.1.34
10.1016/0166-2236(88)90093-8
10.1016/0306-4522(95)00464-5
10.1016/0006-8993(94)91176-2
10.1016/0143-4179(83)90007-0
10.1111/j.1528-1157.1998.tb01321.x
10.1016/j.brainresrev.2007.02.006
10.1152/jn.01179.2006
10.1016/S0361-9230(00)00415-9
10.1007/978-1-61779-328-8_3
10.1002/syn.21683
10.1016/0920-1211(89)90023-5
10.1016/j.bbagen.2009.11.002
10.1016/j.bbr.2011.05.028
10.1016/0304-3940(93)90138-B
10.1016/j.neures.2005.01.003
10.1002/(SICI)1098-1063(1999)9:3<255::AID-HIPO6>3.0.CO;2-S
10.1016/j.jchemneu.2013.10.004
10.1016/0960-0760(95)00072-8
10.1007/BF00451696
10.1016/j.pbb.2004.03.018
10.1016/j.neubiorev.2004.08.001
10.1073/pnas.93.23.13304
10.1016/j.neuropharm.2013.04.029
10.1016/S0306-4522(01)00132-4
10.1111/j.1460-9568.2007.05848.x
10.1016/S0006-8993(98)00929-9
10.1016/j.yfrne.2014.08.001
10.1016/j.tips.2011.05.002
10.1016/S0074-7742(08)60666-2
10.1073/pnas.1019166108
10.1523/JNEUROSCI.6249-10.2011
10.1523/JNEUROSCI.3857-12.2013
10.1523/JNEUROSCI.5279-05.2006
10.1016/j.psyneuen.2009.06.003
10.1038/nmeth.2935
10.1002/cne.10997
10.1016/j.brainres.2013.02.013
10.1210/en.2012-1870
10.1126/science.7190730
10.1016/S0074-7696(08)60659-2
10.1016/j.brainres.2008.07.058
10.1016/j.expneurol.2009.06.001
10.1016/j.neuroscience.2008.12.023
10.1002/hipo.20918
10.1016/0006-8993(91)91186-5
10.1016/j.neuroscience.2005.07.005
10.1111/j.1528-1167.2010.02629.x
10.1073/pnas.97.3.1275
10.3109/00207459209003283
10.1016/0006-8993(95)01059-9
10.1016/0006-8993(93)91703-U
10.1016/S0896-6273(01)00261-6
10.1016/j.nlm.2011.01.002
10.1016/j.brainres.2010.08.103
10.1006/hbeh.1998.1466
10.1523/JNEUROSCI.5968-09.2010
10.1146/annurev.physiol.64.092501.114547",<Element 'PubmedArticle' at 0x7f05db0198b0>
347,25575133,Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice.,"Granulin (GRN) mutations have been identified in familial frontotemporal lobar degeneration patients with ubiquitin pathology. GRN transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein. Thus, these mutations are strongly involved in frontotemporal lobar degeneration pathogenesis. Moreover, recent findings indicate that GRN mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer disease and corticobasal degeneration. To investigate the potential influence of a decline in PGRN protein on tau accumulation, P301L tau transgenic mice were interbred with GRN-deficient mice, producing P301L tau transgenic mice harboring the GRN hemizygote. Brains were collected from 13- and 19-month-old mice, and sequential extraction of proteins, immunoblotting, and immunohistochemical analyses were performed. Immunoblotting analysis revealed that tau phosphorylation was accelerated in the Tris-saline soluble fraction of 13-month-old and in the sarkosyl-insoluble fraction of 19-month-old P301L tau/GRN hemizygotes compared with those in fractions from P301L tau transgenic mice. Activity of cyclin-dependent kinases was also upregulated in the brains of P301L tau/GRN hemizygote mice. Although the mechanisms involved in these findings remain unknown, our data suggest that a reduction in PGRN protein might contribute to phosphorylation and intraneuronal accumulation of tau.",[],Journal of neuropathology and experimental neurology,2015-01-13,"[{'lastname': 'Hosokawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': 'From the Dementia Research Project (MH, TA, HA), Department of Neuropathology and Cell Biology (MM-S, MH), and Histology Center (HK), Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo; Department of Neuropsychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki (TA); and Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo (TM, MN), Japan.'}, {'lastname': 'Arai', 'firstname': 'Tetsuaki', 'initials': 'T', 'affiliation': None}, {'lastname': 'Masuda-Suzukake', 'firstname': 'Masami', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kondo', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': None}, {'lastname': 'Matsuwaki', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Nishihara', 'firstname': 'Masugi', 'initials': 'M', 'affiliation': None}, {'lastname': 'Hasegawa', 'firstname': 'Masato', 'initials': 'M', 'affiliation': None}, {'lastname': 'Akiyama', 'firstname': 'Haruhiko', 'initials': 'H', 'affiliation': None}]",,,,,10.1097/NEN.0000000000000158,<Element 'PubmedArticle' at 0x7f05daf6f3b0>
348,28509495,[Metabolic syndrome and cognitive impairment in aging patients with dyscirculatory encephalopathy].,"The relationship between metabolic syndrome and its individual components, leptin levels and the severity of cognitive impairment in patients of different age with dyscirculatory encephalopathy (DE) and metabolic syndrome (MS) was studied. There were 503 patients aged 45-89 years with DE enrolled into the study, who were divided into two groups: patients without MS (n=198) and with MS (n=305). All patients were divided into three age subgroups. All patients underwent clinical-neurological examination, laboratory tests, high resolution B-mode ultrasound examination, MRI. Cognitive functions were assessed by Mini Mental State Examination (MMSE). In middle age and elderly patients a significant inverse relationship between the total score of MMSE and the level of blood pressure, blood glucose level was found. A direct significant correlation between blood pressure level and a total score of MMSE was revealed in senile patients. The duration of hypertension significantly influenced on the severity of cognitive impairment in patients of middle and old age. The results obtained indicate a definite relationship between the level of leptin in the blood of patients with MS and the state of their cognitive functions. The influence of leptin level on cognitive function in patients with the metabolic syndrome increases with age. Timely and adequate correction of blood pressure, blood glucose and triglycerides may have a positive effect on cognitive function in patients with MS.
Исследовали взаимосвязь метаболического синдрома (МС) и его отдельных составляющих, уровня лептина с выраженностью когнитивных нарушений у пациентов с дисциркуляторной энцефалопатией при старении. Обследованы 503 пациента 45–89 лет без МС (n=198) и с МС (n=305), которые были разделены на три возрастные подгруппы. Были проведены клинико-неврологическое обследование, лабораторные тесты, дуплексное сканирование брахиоцефальных сосудов, МРТ головного мозга. Для оценки когнитивных функций использовали краткую шкалу оценки психического статуса (Mini Mental State Examination — MMSE). У пациентов среднего и пожилого возраста установлена достоверная обратная связь между общим баллом MMSE, уровнем АД и уровнем гликемии. У пациентов старческого возраста выявлена прямая достоверная корреляционная связь между уровнем АД и общим баллом MMSE. Продолжительность артериальной гипертензии достоверно влияла на тяжесть когнитивных нарушений у пациентов среднего и пожилого возраста. Влияние уровня лептина на состояние когнитивных функций у пациентов с МС усиливается с возрастом. Своевременная и адекватная коррекция АД, уровня глюкозы и триглицеридов может положительно влиять на состояние когнитивных функций у пациентов с МС.","['aging', 'cognitive impairment', 'leptin', 'metabolic syndrome']",Advances in gerontology = Uspekhi gerontologii,2015-01-01,"[{'lastname': 'Korkushko', 'firstname': 'O V', 'initials': 'OV', 'affiliation': 'D. F. Chebotarev Institute of Gerontology, National AMS of Ukraine, Kyiv, 04114, Ukraine; vshatilo@ukr.net.'}, {'lastname': 'Kopchak', 'firstname': 'O O', 'initials': 'OO', 'affiliation': 'D. F. Chebotarev Institute of Gerontology, National AMS of Ukraine, Kyiv, 04114, Ukraine; vshatilo@ukr.net.'}, {'lastname': 'Shatilo', 'firstname': 'V B', 'initials': 'VB', 'affiliation': 'D. F. Chebotarev Institute of Gerontology, National AMS of Ukraine, Kyiv, 04114, Ukraine; vshatilo@ukr.net.'}, {'lastname': 'Bachinskaya', 'firstname': 'N U', 'initials': 'NU', 'affiliation': 'D. F. Chebotarev Institute of Gerontology, National AMS of Ukraine, Kyiv, 04114, Ukraine; vshatilo@ukr.net.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05daf7acc0>
349,25443746,Experimental diabetes mellitus type 1 increases hippocampal content of kynurenic acid in rats.,"Diabetes mellitus (DM) is frequently associated with peripheral and central complications and has recently emerged as a risk factor for cognitive impairment and dementia. Kynurenic acid (KYNA), a unique tryptophan derivative, displays pleiotropic effects including blockade of ionotropic glutamate and α7 nicotinic receptors. Here, the influence of experimental diabetes on KYNA synthesis was studied in rat brain.
DM was induced by i.p. administration of streptozotocin (STZ). Five weeks later, KYNA content and the activity of semi-purified kynurenine aminotransferases (KATs) were measured in frontal cortex, hippocampus and striatum of diabetic and insulin-treated rats, using HPLC-based methods.
Hippocampal but not cortical or striatal KYNA concentration was considerably increased during DM, either untreated or treated with insulin (220% and 170% of CTR, respectively). The activity of kynurenine aminotransferase I (KAT I) was not affected by DM in all of the studied structures. KAT II activity was moderately increased in cortex (145% of CTR) and hippocampus (126% of CTR), but not in striatum of diabetic animals. Insulin treatment normalized cortical but not hippocampal KAT II activity.
A novel factor potentially implicated in diabetic hippocampal dysfunction has been identified. Observed increase of KYNA level may stem from the activation of endogenous neuroprotection, however, it may also have negative impact on cognition.","['Diabetes mellitus type 1', 'Kynurenic acid', 'Memory', 'Neurodegeneration']",Pharmacological reports : PR,2014-12-03,"[{'lastname': 'Chmiel-Perzyńska', 'firstname': 'Iwona', 'initials': 'I', 'affiliation': 'Medical University of Lublin, Lublin, Poland.'}, {'lastname': 'Perzyński', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Medical University of Lublin, Lublin, Poland.'}, {'lastname': 'Urbańska', 'firstname': 'Ewa M', 'initials': 'EM', 'affiliation': 'Medical University of Lublin, Lublin, Poland; Institute of Agricultural Medicine, Lublin, Poland. Electronic address: emurbanska@poczta.onet.pl.'}]",,,"Hippocampal but not cortical or striatal KYNA concentration was considerably increased during DM, either untreated or treated with insulin (220% and 170% of CTR, respectively). The activity of kynurenine aminotransferase I (KAT I) was not affected by DM in all of the studied structures. KAT II activity was moderately increased in cortex (145% of CTR) and hippocampus (126% of CTR), but not in striatum of diabetic animals. Insulin treatment normalized cortical but not hippocampal KAT II activity.","Copyright © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.",10.1016/j.pharep.2014.07.014,<Element 'PubmedArticle' at 0x7f05daf98b30>
350,"25393644
11250914
10232052
22511204
11788660
15277385
15855321
18852329
24423282
22952463
8593833
15071189
20484633
11274359
20943927
24418055
11167432
23506003
19349342
23982627
10675123",11β-Hydroxysteroid dehydrogenase activity in the brain does not contribute to systemic interconversion of cortisol and cortisone in healthy men.,"11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) catalyses regeneration of cortisol in liver, adipose tissue, and skeletal muscle, making a substantial contribution to circulating cortisol as demonstrated in humans by combining stable isotope tracer infusion with arteriovenous sampling. In the brain, 11βHSD1 is a potential therapeutic target implicated in age-associated cognitive dysfunction. We aimed to quantify brain 11βHSD1 activity, both to assess its contribution to systemic cortisol/cortisone turnover and to develop a tool for measuring 11βHSD1 in dementia and following administration of 11βHSD1 inhibitors.
With ethical approval and informed consent, 8 healthy men aged 38.1 years (sd 16.5) underwent an ECG-gated phase-contrast magnetic resonance scan to quantify internal jugular vein blood flow and were infused with 1,2 [(2)H]2-cortisone and 9,11,12,12 [(2)H]4-cortisol for 3 h before samples were obtained from the internal jugular vein and an arterialized hand vein. Steroids were quantified by liquid chromatography-tandem mass spectrometry.
Steady state tracer enrichments were achieved and systemic indices of cortisol/cortisone interconversion were consistent with previous studies in healthy men. However, there was no measurable release or production of cortisol, 9,12,12 [(2)H]3-cortisol or cortisone into the internal jugular vein.
Although cerebral 11βHSD1 reductase activity may be greater in cognitively impaired patients, in healthy men any contribution of 11βHSD1 in the brain to systemic cortisol/cortisone turnover is negligible. The influence of 11βHSD1 in the brain is likely confined to subregions, notably the hippocampus. Alternative approaches are required to quantify pharmacodynamics effects of 11βHSD1 inhibitors in the human brain.",[],The Journal of clinical endocrinology and metabolism,2014-11-14,"[{'lastname': 'Kilgour', 'firstname': 'Alixe H M', 'initials': 'AH', 'affiliation': ""MRC Centre for Cognitive Aging and Cognitive Epidemiology (A.H.M.K.), Geriatric Medicine Unit, and Centre for Clinical Brain Sciences (S.S., I.M., P.A.), University of Edinburgh, Edinburgh, United Kingdom; Clinical Research Imaging Centre (S.S.) and BHF Centre for Cardiovascular Science (S.S., R.A., B.R.W.), Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Critical Care (P.A.), Western General Hospital, NHS Lothian University Hospitals Division, Edinburgh EH4 2XU, United Kingdom.""}, {'lastname': 'Semple', 'firstname': 'Scott', 'initials': 'S', 'affiliation': None}, {'lastname': 'Marshall', 'firstname': 'Ian', 'initials': 'I', 'affiliation': None}, {'lastname': 'Andrews', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Andrew', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': None}, {'lastname': 'Walker', 'firstname': 'Brian R', 'initials': 'BR', 'affiliation': None}]",,,,,10.1210/jc.2014-3277,<Element 'PubmedArticle' at 0x7f05daf253b0>
351,25290346,Leptin: A hormone linking activation of neuroendocrine axes with neuropathology.,"Leptin, a peptide hormone secreted by adipocytes, plays a central role in controlling appetite and weight in both rodents and humans. Basic science and clinical research suggest that this hormone not only affects the regulation of the neuroendocrine axes, but also exerts effects on the central nervous system with subsequent alterations in psychological functions. For instance, leptin suppresses cortisol secretion during stress-related activation of the adrenal axis. As psychiatric disorders like depression are associated with hypercortisolism, leptin is proposed to exert anti-depressant-like effects due to its inhibition of chronically overactive hypothalamo-pituitary-adrenal axis function. Moreover, leptin status of depressed patients could serve as a prognostic marker for therapy response. Besides its influence on neuroendocrine pathways leptin seems to have direct central effects on brain development and neuroplasticity. Low leptin levels have been shown to be associated with increased risk of developing dementia, supporting the idea of a pro-cognitive effect of leptin. These areas may have direct clinical implications and deserve to be studied further in the future.","['Leptin', 'Neuroendocrine axes', 'Neuropsychiatric aspects']",Psychoneuroendocrinology,2014-10-08,"[{'lastname': 'Stieg', 'firstname': 'Mareike R', 'initials': 'MR', 'affiliation': 'Max-Planck-Institute of Psychiatry, Kreapelinstr. 2-10, 80804 Munich, Germany. Electronic address: mareike_stieg@mpipsykl.mpg.de.'}, {'lastname': 'Sievers', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'Max-Planck-Institute of Psychiatry, Kreapelinstr. 2-10, 80804 Munich, Germany.'}, {'lastname': 'Farr', 'firstname': 'Olivia', 'initials': 'O', 'affiliation': 'Division of Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Section of Endocrinology, Boston VA Healthcare System, Boston, USA.'}, {'lastname': 'Stalla', 'firstname': 'Günter K', 'initials': 'GK', 'affiliation': 'Max-Planck-Institute of Psychiatry, Kreapelinstr. 2-10, 80804 Munich, Germany.'}, {'lastname': 'Mantzoros', 'firstname': 'Christos S', 'initials': 'CS', 'affiliation': 'Division of Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Section of Endocrinology, Boston VA Healthcare System, Boston, USA. Electronic address: cmantzor@bidmc.harvard.edu.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.psyneuen.2014.09.004,<Element 'PubmedArticle' at 0x7f05daf35f90>
352,25246229,The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.,"Huntington's disease (HD) is an autosomal dominant, neurodegenerative disease caused by a CAG tandem repeat mutation encoding a polyglutamine tract expansion in the huntingtin protein. Depression is among the most common affective symptoms in HD but the pathophysiology is unclear. We have previously discovered sexually dimorphic depressive-like behaviours in the R6/1 transgenic mouse model of HD at a pre-motor symptomatic age. Interestingly, only female R6/1 mice display this phenotype. Sexual dimorphism has not been explored in the human HD population despite the well-established knowledge that the clinical depression rate in females is almost twice that of males. Female susceptibility suggests a role of sex hormones, which have been shown to modulate stress response. There is evidence suggesting that the gonads are adversely affected in HD patients, which could alter sex hormone levels. The present study examined the role sex hormones play on stress response in the R6/1 mouse model of HD, in particular, its modulatory effect on the hypothalamic-pituitary-adrenal (HPA) axis and depression-like behaviour. We found that the gonads of female R6/1 mice show atrophy at an early age. Expression levels of gonadotropin-releasing hormone (GnRH) were decreased in the hypothalamus of female HD mice, relative to wild-type female littermates, as were serum testosterone levels. Female serum estradiol levels were not significantly changed. Gonadectomy surgery reduced HPA-axis activity in female mice but had no effect on behavioural phenotypes. Furthermore, expression of the oestrogen receptor (ER) α gene was found to be higher in the adrenal cells of female HD mice. Finally, administration of an ERβ agonist diarylpropionitrile (DPN) rescued depressive-like behaviour in the female HD mice. Our findings provide new insight into the pathogenesis of sexually dimorphic neuroendocrine, physiological and behavioural endophenotypes in HD, and suggest a new avenue for therapeutic intervention.","['Adrenal gland', 'Affective symptoms', 'Corticosterone', 'Depression', 'HPA axis', 'HPG axis', ""Huntington's disease"", 'Psychiatric disorder', 'Sex hormones', 'Stress']",Experimental neurology,2014-09-24,"[{'lastname': 'Du', 'firstname': 'X', 'initials': 'X', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia; Dept of Anatomy & Neuroscience, University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: xin.du@florey.edu.au.'}, {'lastname': 'Pang', 'firstname': 'T Y', 'initials': 'TY', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia.'}, {'lastname': 'Mo', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia.'}, {'lastname': 'Renoir', 'firstname': 'T', 'initials': 'T', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia; Dept of Anatomy & Neuroscience, University of Melbourne, Parkville, VIC 3010, Australia.'}, {'lastname': 'Wright', 'firstname': 'D J', 'initials': 'DJ', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia.'}, {'lastname': 'Hannan', 'firstname': 'A J', 'initials': 'AJ', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia; Dept of Anatomy & Neuroscience, University of Melbourne, Parkville, VIC 3010, Australia.'}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.expneurol.2014.09.009,<Element 'PubmedArticle' at 0x7f05daf41270>
353,"25223887
9468119
8988899
11231989
11600532
21596429
20044310
17910609
16453985
16203955
9736007
16499556
10101729
20679498
18725972
11120654
12511033
22948764
10922269
20348462
16079591
12061281
3368532
12002165
16441548
20056462
21681816
9920102
23575383",Lower melatonin secretion in older females: gender differences independent of light exposure profiles.,"Melatonin is associated with a variety of diseases in advanced age, including insomnia, depression, and dementia, and its secretion is influenced by light exposure. Although studies in young and middle-aged subjects have shown that females tend to have higher melatonin levels than males, gender differences in melatonin levels among older people remain unclear.
To determine the gender differences in melatonin levels among older people in home settings, we conducted a cross-sectional study in 528 older people. We measured overnight urinary 6-sulfatoxymelatonin excretion (UME; an index of melatonin secretion), and ambulatory light intensity.
The mean age of females was 1.8 years younger, and average intensity of daytime light exposure was half that in males (P < 0.01). In a univariate comparison, UME was significantly lower in females than in males (P < 0.01). A multivariate model using analysis of covariance showed that log-transformed UME remained significantly lower in females after adjustment for potential confounding factors, including age and daytime and nighttime light exposure profiles (males vs. females: 1.90 vs. 1.73 log µg; adjusted mean difference 0.17 log µg [95% confidence interval [CI] 0.02-0.32]; P = 0.02). This result indicates that older females have 18.4% (95% CI, 2.2-37.4%) lower UME than older males.
Older females have significantly lower UME than older males, an association which is independent of light exposure profiles in home settings. Our findings may be useful as basic data for further research to investigate gender differences in several diseases associated with melatonin in the elderly.
メラトニンは不眠症、うつ病、認知症など高齢者に多い疾患との関連が指摘されており、その分泌は光曝露の影響を受ける。メラトニン分泌量は男性に比べて女性に多いという若年あるいは中高年者を対象にした先行研究はあるが、高齢者におけるメラトニン分泌量の性差は十分分かっていない。
高齢者の日常生活下におけるメラトニン分泌量の性差を明らかにするために、我々は528人を対象に横断解析を行った。我々はメラトニン分泌量の指標として夜間尿中メラトニン主要代謝産物排泄量（6-sufatoxymelatonin）を測定し、同時に光曝露量の測定を行った。
平均年齢は女性の方が1.8歳若く、日中光曝露量は男性と比べて女性で半分程度であった（P < 0.01）。単変量分析では、メラトニン分泌量は有意に女性で低下していた（P < 0.01）。共分散分析を用いた多変量分析においても同様に、メラトニン分泌量は女性で低下しており、その性差は年齢、日中夜間の光曝露量を含む潜在的交絡因子と独立していた（調整後平均：男性 1.90 log μg vs. 女性 1.73 log μg; 調整後平均の差：0.17 log μg, 95信頼区間 0.02-0.32; P = 0.02）。この結果は女性高齢者のメラトニン分泌量が男性高齢者と比べて、18.4%（95信頼区間 2.2-37.4%）低下していたということを示している。
女性高齢者のメラトニン分泌量は男性高齢者と比べて有意に低下しており、その性差は日常生活下の光曝露量と独立していた。これらの結果は高齢者におけるメラトニンが関連する疾患の性差を検討する上で、重要な基礎データになるだろう。",[],Journal of epidemiology,2014-09-17,"[{'lastname': 'Obayashi', 'firstname': 'Kenji', 'initials': 'K', 'affiliation': 'Department of Community Health and Epidemiology, Nara Medical University School of Medicine.'}, {'lastname': 'Saeki', 'firstname': 'Keigo', 'initials': 'K', 'affiliation': None}, {'lastname': 'Tone', 'firstname': 'Nobuhiro', 'initials': 'N', 'affiliation': None}, {'lastname': 'Iwamoto', 'firstname': 'Junko', 'initials': 'J', 'affiliation': None}, {'lastname': 'Miyata', 'firstname': 'Kimie', 'initials': 'K', 'affiliation': None}, {'lastname': 'Ikada', 'firstname': 'Yoshito', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Kurumatani', 'firstname': 'Norio', 'initials': 'N', 'affiliation': None}]",,,"The mean age of females was 1.8 years younger, and average intensity of daytime light exposure was half that in males (P < 0.01). In a univariate comparison, UME was significantly lower in females than in males (P < 0.01). A multivariate model using analysis of covariance showed that log-transformed UME remained significantly lower in females after adjustment for potential confounding factors, including age and daytime and nighttime light exposure profiles (males vs. females: 1.90 vs. 1.73 log µg; adjusted mean difference 0.17 log µg [95% confidence interval [CI] 0.02-0.32]; P = 0.02). This result indicates that older females have 18.4% (95% CI, 2.2-37.4%) lower UME than older males.",,"10.2188/jea.JE20140035
10.1111/j.1600-079X.1998.tb00366.x
10.1056/NEJM199701163360306
10.1210/jcem.86.10.7901
10.1016/S0140-6736(11)60095-0
10.1016/j.sleep.2009.07.013
10.1111/j.1600-079X.2007.00491.x
10.1001/archpsyc.62.10.1097
10.1001/archpsyc.55.9.809
10.1111/j.1600-079X.2005.00301.x
10.1016/S0306-4530(98)00076-6
10.1177/0748730410374943
10.1371/journal.pone.0003055
10.1081/CBI-120015958
10.1210/jc.2012-1873
10.1111/j.1469-7793.2000.00695.x
10.1177/0748730410361916
10.2114/jpa.24.419
10.1159/000060812
10.1016/0031-9384(88)90289-2
10.1177/074873002129002474
10.1111/j.1600-079X.2005.00285.x
10.1016/j.smrv.2009.11.002
10.1038/hr.2013.20",<Element 'PubmedArticle' at 0x7f05daf4dc70>
354,"25188321
11708987
9855500
21810890
21325651
19433738
19414722
16157747
19924424
21908872
22732773
17353379
19255408
18593276
22130207
23687363
24343233
23390180
24418059
24005336
16862116
16862115
21393509
21691802
18378771
15110032
17254803
21907292
18486233
18501969
23565090
20589099
21968567
19782143
23894288
24005300
9648540
23667665
20050899
18392865
21949842
15955494
11707080
8699946
22019881
23085497
22178814
23964193
19211893
17113790
22359372
21077137
21569856
23092697
17070709
21922599
15193596
10466150
18191585
22784277
22992492
23084083
18936426
23558488
23884042
22445334
22890575
23218900
23986673
20410145
24155702
15218136
21170073
21511044
23876425",Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia.,"Monogenic dementias represent a great opportunity to trace disease progression from preclinical to symptomatic stages. Frontotemporal Dementia related to Granulin (GRN) mutations presents a specific framework of brain damage, involving fronto-temporal regions and long inter-hemispheric white matter bundles. Multimodal resting-state functional MRI (rs-fMRI) is a promising tool to carefully describe disease signature from the earliest disease phase.
To define local connectivity alterations in GRN related pathology moving from the presymptomatic (asymptomatic GRN mutation carriers) to the clinical phase of the disease (GRN- related Frontotemporal Dementia).
Thirty-one GRN Thr272fs mutation carriers (14 patients with Frontotemporal Dementia and 17 asymptomatic carriers) and 38 healthy controls were recruited. Local connectivity measures (Regional Homogeneity (ReHo), Fractional Amplitude of Low Frequency Fluctuation (fALFF) and Degree Centrality (DC)) were computed, considering age and gender as nuisance variables as well as the influence of voxel-level gray matter atrophy.
Asymptomatic GRN carriers had selective reduced ReHo in the left parietal region and increased ReHo in frontal regions compared to healthy controls. Considering Frontotemporal Dementia patients, all measures (ReHo, fALFF and DC) were reduced in inferior parietal, frontal lobes and posterior cingulate cortex. Considering GRN mutation carriers, an inverse correlation with age in the posterior cingulate cortex, inferior parietal lobule and orbitofrontal cortex was found.
GRN pathology is characterized by functional brain network alterations even decades before the clinical onset; they involve the parietal region primarily and then spread to the anterior regions of the brain, supporting the concept of molecular nexopathies.",[],PloS one,2014-09-05,"[{'lastname': 'Premi', 'firstname': 'Enrico', 'initials': 'E', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.'}, {'lastname': 'Cauda', 'firstname': 'Franco', 'initials': 'F', 'affiliation': 'Clinical and Experimental Center for Functional Magnetic Resonance Imaging, Koelliker Hospital, Turin, Italy; Department of Psychology, University of Turin, Turin, Italy.'}, {'lastname': 'Gasparotti', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Neuroradiology Unit, University of Brescia, Brescia, Italy.'}, {'lastname': 'Diano', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': 'Clinical and Experimental Center for Functional Magnetic Resonance Imaging, Koelliker Hospital, Turin, Italy; Department of Psychology, University of Turin, Turin, Italy.'}, {'lastname': 'Archetti', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': 'III Laboratory Analyses, Brescia Hospital, Brescia, Italy.'}, {'lastname': 'Padovani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.'}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy.'}]",,,"Asymptomatic GRN carriers had selective reduced ReHo in the left parietal region and increased ReHo in frontal regions compared to healthy controls. Considering Frontotemporal Dementia patients, all measures (ReHo, fALFF and DC) were reduced in inferior parietal, frontal lobes and posterior cingulate cortex. Considering GRN mutation carriers, an inverse correlation with age in the posterior cingulate cortex, inferior parietal lobule and orbitofrontal cortex was found.",,10.1371/journal.pone.0106500,<Element 'PubmedArticle' at 0x7f05daef0860>
355,25173805,"Ghrelin: a link between ageing, metabolism and neurodegenerative disorders.","Along with the increase in life expectancy over the last century comes the increased risk for development of age-related disorders, including metabolic and neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases. These chronic disorders share two main characteristics: 1) neuronal loss in motor, sensory or cognitive systems, leading to cognitive and motor decline; and 2) a strong correlation between metabolic changes and neurodegeneration. In order to treat them, a better understanding of their complexity is required: it is necessary to interpret the neuronal damage in light of the metabolic changes, and to find the disrupted link between the peripheral organs governing energy metabolism and the CNS. This review is an attempt to present ghrelin as part of molecular regulatory interface between energy metabolism, neuroendocrine and neurodegenerative processes. Ghrelin takes part in lipid and glucose metabolism, in higher brain functions such as sleep-wake state, learning and memory consolidation; it influences mitochondrial respiration and shows neuroprotective effect. All these make ghrelin an attractive target for development of biomarkers or therapeutics for prevention or treatment of disorders, in which cell protection and recruitment of new neurons or synapses are needed.","['Ageing', 'Ghrelin', 'Metabolism', 'Neurodegenerative diseases', 'Neuroprotection']",Neurobiology of disease,2014-09-01,"[{'lastname': 'Stoyanova', 'firstname': 'I I', 'initials': 'II', 'affiliation': 'Biomedical Signals and Systems, Faculty of Electrical Engineering, Mathematics and Computer Sciences, Institute for Biomedical Engineering and Technical Medicine MIRA, University of Twente, Enschede, The Netherlands. Electronic address: stoyanovai@yahoo.co.uk.'}]",,,,Copyright © 2014. Published by Elsevier Inc.,10.1016/j.nbd.2014.08.026,<Element 'PubmedArticle' at 0x7f05daf15ef0>
356,25114081,Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer's disease.,"We carried out an association study of transmembrane protein 106B gene (TMEM106B) rs1020004 A/G, rs6966915C/T, and rs1990622 A/G in a population of 656 patients with Alzheimer's disease (AD) and 619 controls, and tested whether the rs1990622 influences plasma progranulin levels. No differences in allele and genotype distribution were observed between cases and controls, even stratifying according to APOE status (p > 0.05). No differences in progranulin plasma levels were found between carriers of the rs1990622 and non-carriers. TMEM106b variability does not influence AD risk or plasma levels. Replication, preferably in a population with pathological confirmation, is required to confirm these results.","[""Alzheimer's disease"", 'TDP-43', 'TMEM106b', 'progranulin']",Journal of Alzheimer's disease : JAD,2014-08-13,"[{'lastname': 'Serpente', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Clerici', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Center for Research and Treatment on Cognitive Dysfunctions, Chair of Neurology, University of Milan, ""Luigi Sacco"" Hospital, Milan, Italy.'}, {'lastname': 'Bonsi', 'firstname': 'Rossana', 'initials': 'R', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Arosio', 'firstname': 'Beatrice', 'initials': 'B', 'affiliation': 'Geriatric Unit, Department of Clinical Sciences and Community Health, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Cioffi', 'firstname': 'Sara M G', 'initials': 'SM', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Rotondo', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Franceschi', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'IRCCS Multimedica, Milan, Italy.'}, {'lastname': 'Martinelli Boneschi', 'firstname': 'Filippo', 'initials': 'F', 'affiliation': 'Laboratory of Neurological Complex disorders, Department of Neuro-rehabilitation & INSPE, Scientific Institute San Raffaele, Milan, Italy.'}, {'lastname': 'Mari', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Geriatric Unit, Department of Clinical Sciences and Community Health, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Mariani', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': 'Center for Research and Treatment on Cognitive Dysfunctions, Chair of Neurology, University of Milan, ""Luigi Sacco"" Hospital, Milan, Italy.'}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Pathophysiology and Transplantation, ""Dino Ferrari"" Center, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy.'}]",,,,,10.3233/JAD-141167,<Element 'PubmedArticle' at 0x7f05daea1180>
357,"25104557
22437338
23990795
9075467
19602640
18565828
10441572
22312439
24336208
9384602
16461860
18667258
20020531
23150934
11406330
19734902
21460840
12552037
22801501
19734903
24162737
19451168
22216764
20644199
21460841
1677164
8100163
7485229
8596319
11524469
20460622
17984093
20601685
16982696","Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease.","The overlapping clinical and neuropathologic features between late-onset apparently sporadic Alzheimer's disease (LOAD), familial Alzheimer's disease (FAD), and other neurodegenerative dementias (frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, and Creutzfeldt-Jakob disease) raise the question of whether shared genetic risk factors may explain the similar phenotype among these disparate disorders. To investigate this intriguing hypothesis, we analyzed rare coding variability in 6 Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP), in 141 LOAD patients and 179 elderly controls, neuropathologically proven, from the UK. In our cohort, 14 LOAD cases (10%) and 11 controls (6%) carry at least 1 rare variant in the genes studied. We report a novel variant in PSEN1 (p.I168T) and a rare variant in PSEN2 (p.A237V), absent in controls and both likely pathogenic. Our findings support previous studies, suggesting that (1) rare coding variability in PSEN1 and PSEN2 may influence the susceptibility for LOAD and (2) GRN, MAPT, and PRNP are not major contributors to LOAD. Thus, genetic screening is pivotal for the clinical differential diagnosis of these neurodegenerative dementias.","['APP', ""Alzheimer's disease"", 'Exome sequencing', 'GRN', 'MAPT', 'Neurodegenerative dementia', 'PRNP', 'PSEN1', 'PSEN2']",Neurobiology of aging,2014-08-12,"[{'lastname': 'Sassi', 'firstname': 'Celeste', 'initials': 'C', 'affiliation': 'Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Electronic address: celeste.sassi.10@ucl.ac.uk.'}, {'lastname': 'Guerreiro', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.'}, {'lastname': 'Gibbs', 'firstname': 'Raphael', 'initials': 'R', 'affiliation': 'Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.'}, {'lastname': 'Ding', 'firstname': 'Jinhui', 'initials': 'J', 'affiliation': 'Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.'}, {'lastname': 'Lupton', 'firstname': 'Michelle K', 'initials': 'MK', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Troakes', 'firstname': 'Claire', 'initials': 'C', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Al-Sarraj', 'firstname': 'Safa', 'initials': 'S', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Niblock', 'firstname': 'Michael', 'initials': 'M', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Gallo', 'firstname': 'Jean-Marc', 'initials': 'JM', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Adnan', 'firstname': 'Jihad', 'initials': 'J', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Killick', 'firstname': 'Richard', 'initials': 'R', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Brown', 'firstname': 'Kristelle S', 'initials': 'KS', 'affiliation': 'Translation Cell Sciences-Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Medway', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': 'Translation Cell Sciences-Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Lord', 'firstname': 'Jenny', 'initials': 'J', 'affiliation': 'Translation Cell Sciences-Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Turton', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Translation Cell Sciences-Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Bras', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}, {'lastname': 'Morgan', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Translation Cell Sciences-Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK.'}, {'lastname': 'Powell', 'firstname': 'John F', 'initials': 'JF', 'affiliation': ""King's College London Institute of Psychiatry, London, UK.""}, {'lastname': 'Singleton', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.'}, {'lastname': 'Hardy', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London, UK.'}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2014.06.002,<Element 'PubmedArticle' at 0x7f05daeae900>
358,25092133,"Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders.","Receptors of leptin, the prototypical adipokine, are expressed throughout the cortex and several other areas of the brain. Although typically studied for its role in energy intake and expenditure, leptin plays a critical role in many other neurocognitive processes and interacts with various other hormones and neurotransmitters to perform these functions. Here, we review the literature on how leptin influences brain development, neural degradation, Alzheimer's disease, psychiatric disorders, and more complicated cognitive functioning and feeding behaviors. We also discuss modulators of leptin and the leptin receptor as they relate to normal cognitive functioning and may mediate some of the actions of leptin in the brain. Although we are beginning to better understand the critical role leptin plays in normal cognitive functioning, there is much to be discovered.","['CNS', 'Depression', 'Leptin', 'Schizophrenia', 'fMRI']",Metabolism: clinical and experimental,2014-08-06,"[{'lastname': 'Farr', 'firstname': 'Olivia M', 'initials': 'OM', 'affiliation': 'Division of Endocrinology, Boston VA Healthcare System/Harvard Medical School, Boston, MA 02215. Electronic address: Olivia.Farr@va.gov.'}, {'lastname': 'Tsoukas', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Division of Endocrinology, Boston VA Healthcare System/Harvard Medical School, Boston, MA 02215.'}, {'lastname': 'Mantzoros', 'firstname': 'Christos S', 'initials': 'CS', 'affiliation': 'Division of Endocrinology, Boston VA Healthcare System/Harvard Medical School, Boston, MA 02215.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.metabol.2014.07.004,<Element 'PubmedArticle' at 0x7f05daed3bd0>
359,24992836,Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.,"Oxidative stress and mitochondrial dysfunction have been described in Huntington's disease, a disorder caused by expression of mutant huntingtin (mHtt). IGF-1 was previously shown to protect HD cells, whereas insulin prevented neuronal oxidative stress. In this work we analyzed the role of insulin and IGF-1 in striatal cells derived from HD knock-in mice on mitochondrial production of reactive oxygen species (ROS) and related antioxidant and signaling pathways influencing mitochondrial function. Insulin and IGF-1 decreased mitochondrial ROS induced by mHtt and normalized mitochondrial SOD activity, without affecting intracellular glutathione levels. IGF-1 and insulin promoted Akt phosphorylation without changing the nuclear levels of phosphorylated Nrf2 or Nrf2/ARE activity. Insulin and IGF-1 treatment also decreased mitochondrial Drp1 phosphorylation, suggesting reduced mitochondrial fragmentation, and ameliorated mitochondrial function in HD cells in a PI-3K/Akt-dependent manner. This was accompanied by increased total and phosphorylated Akt, Tfam, and mitochondrial-encoded cytochrome c oxidase II, as well as Tom20 and Tom40 in mitochondria of insulin- and IGF-1-treated mutant striatal cells. Concomitantly, insulin/IGF-1-treated mutant cells showed reduced apoptotic features. Hence, insulin and IGF-1 improve mitochondrial function and reduce mitochondrial ROS caused by mHtt by activating the PI-3K/Akt signaling pathway, in a process independent of Nrf2 transcriptional activity, but involving enhanced mitochondrial levels of Akt and mitochondrial-encoded complex IV subunit.","['Akt', 'Huntington disease', 'Insulin/IGF-1 signaling', 'Mitochondria', 'Nrf2', 'Oxidative stress', 'Reactive oxygen species', 'Striatal cells']",Free radical biology & medicine,2014-07-06,"[{'lastname': 'Ribeiro', 'firstname': 'Márcio', 'initials': 'M', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.'}, {'lastname': 'Rosenstock', 'firstname': 'Tatiana R', 'initials': 'TR', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.'}, {'lastname': 'Oliveira', 'firstname': 'Ana M', 'initials': 'AM', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal.'}, {'lastname': 'Oliveira', 'firstname': 'Catarina R', 'initials': 'CR', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal.'}, {'lastname': 'Rego', 'firstname': 'A Cristina', 'initials': 'AC', 'affiliation': 'CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal; Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal. Electronic address: a.cristina.rego@gmail.com.'}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.freeradbiomed.2014.06.023,<Element 'PubmedArticle' at 0x7f05daeddbd0>
360,"24862368
22201866
7477348
18413705
15514161
21976528
16698938
17151169
22045482
19012746
19895879
2901426
8834089
15283960
18571864
16876134
18342852
18685145
6149466
22284730
16918397
21985169
16198445
8810256
19660564
15509759
17551018
21274428
19012747
15207847
8663279
16052036
19026668
18803966
22323718
19850930
16122764
8773809
16878401
2477071
12476966
17567816
22451915
11584021
17047935
9464214
16914869
22198801
21248787
23202293
11036168
12895416
3495748
16974109
15668449
18028006
8633020
19807968
15212620
20206287",Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.,"Previous studies indicate that psychosocial stressors could accelerate amyloid-β (Aβ) levels and accelerate plaque deposition in mouse models of Alzheimer disease (AD). Stressors enhanced the release of corticotrophin-releasing factor (CRF), and exogenous CRF administration mimicked the effects of stress on Aβ levels in mouse models of AD. However, whether CRF receptor 1 (CRF1) antagonists could influence the stress-induced acceleration of an AD-like process in mouse models has not been well studied.
We sought to examine whether CRF1 antagonists inhibit the effects of isolation stress on tissue Aβ levels, Aβ plaque deposition, and behaviors related to anxiety and memory in Tg2576 mice, and to investigate the molecular mechanism underlying such effects.
Cohorts of Tg2576 mouse pups were isolated or group-housed at 21 days of age, and then the subgroups of these cohorts received daily intraperitoneal injections of the CRF1 antagonists, antalarmin or R121919 (5, 10, and 20 mg/kg), or vehicle for 1 week. Other cohorts of Tg2576 mouse pups were isolated or group-housed at 21 days of age, and then at 4 months of age, subgroups of these mice were administered antalarmin (20 mg/kg) or vehicle in their drinking water for 6 months. Finally, cultured primary hippocampal neurons from regular Tg2576 pups (P0) were incubated with CRF (0.1, 1, and 10 nM), antalarmin (100 nM) or H-89 (1 μM) for 48 h. Brain tissues or cultured neurons were collected for histological and biochemical analyses, and behavioral measures were collected in the cohorts of mice that were chronically stressed.
Administration of antalarmin at 20 mg/kg dose for 1 week significantly reduced Aβ1-42 levels in isolation stressed mice. Administration of antalarmin for 6 months significantly decreased plasma corticosterone levels, tissue Aβ1-42 levels, and Aβ plaque deposition in the brain and blocked the effects of isolation stress on behaviors related to anxiety and memory. Finally, incubation of neurons with 100 nM antalarmin inhibited the ability of 10 nM CRF to increase Aβ1-42 levels and protein kinase A IIβ expression. The effect of CRF1 on Aβ1-42 levels was also diminished by treatment with H-89, a c-AMP/PKA inhibitor.
These results suggest that CRF1 antagonists can slow an AD-like process in Tg2576 mice and that the c-AMP/PKA signaling pathway may be involved in this effect.",[],Psychopharmacology,2014-05-28,"[{'lastname': 'Dong', 'firstname': 'Hongxin', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Feinberg School Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA, h-dong@northwestern.edu.'}, {'lastname': 'Wang', 'firstname': 'Shirlene', 'initials': 'S', 'affiliation': None}, {'lastname': 'Zeng', 'firstname': 'Ziling', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Fei', 'initials': 'F', 'affiliation': None}, {'lastname': 'Montalvo-Ortiz', 'firstname': 'Janitza', 'initials': 'J', 'affiliation': None}, {'lastname': 'Tucker', 'firstname': 'Christopher', 'initials': 'C', 'affiliation': None}, {'lastname': 'Akhtar', 'firstname': 'Shahzad', 'initials': 'S', 'affiliation': None}, {'lastname': 'Shi', 'firstname': 'Jingshan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Meltzer', 'firstname': 'Herbert Y', 'initials': 'HY', 'affiliation': None}, {'lastname': 'Rice', 'firstname': 'Kenner C', 'initials': 'KC', 'affiliation': None}, {'lastname': 'Csernansky', 'firstname': 'John G', 'initials': 'JG', 'affiliation': None}]",,,"Administration of antalarmin at 20 mg/kg dose for 1 week significantly reduced Aβ1-42 levels in isolation stressed mice. Administration of antalarmin for 6 months significantly decreased plasma corticosterone levels, tissue Aβ1-42 levels, and Aβ plaque deposition in the brain and blocked the effects of isolation stress on behaviors related to anxiety and memory. Finally, incubation of neurons with 100 nM antalarmin inhibited the ability of 10 nM CRF to increase Aβ1-42 levels and protein kinase A IIβ expression. The effect of CRF1 on Aβ1-42 levels was also diminished by treatment with H-89, a c-AMP/PKA inhibitor.",,10.1007/s00213-014-3629-8,<Element 'PubmedArticle' at 0x7f05dae702c0>
361,24800652,Progranulin in neurodegenerative disease.,"Loss-of-function mutations in the progranulin gene are a common cause of familial frontotemporal dementia (FTD). The purpose of this review is to summarize the role of progranulin in health and disease, because the field is now poised to begin examining therapeutics that alter endogenous progranulin levels. We first review the clinical and neuropathological phenotype of FTD patients carrying mutations in the progranulin gene, which suggests that progranulin-mediated neurodegeneration is multifactorial and influenced by other genetic and/or environmental factors. We then examine evidence for the role of progranulin in the brain with a focus on mouse model systems. A better understanding of the complexity of progranulin biology in the brain will help guide the development of progranulin-modulating therapies for neurodegenerative disease.",[],Trends in neurosciences,2014-05-08,"[{'lastname': 'Petkau', 'firstname': 'Terri L', 'initials': 'TL', 'affiliation': ""Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, and Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4.""}, {'lastname': 'Leavitt', 'firstname': 'Blair R', 'initials': 'BR', 'affiliation': ""Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, and Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4; Division of Neurology, Department of Medicine, University of British Columbia Hospital, S 192, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5; Brain Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. Electronic address: bleavitt@cmmt.ubc.ca.""}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.tins.2014.04.003,<Element 'PubmedArticle' at 0x7f05dae986d0>
362,"24704273
18691043
17021375
10342866
10433999
2903678
2831146
9877250
3620933
11786510
15345694
16707729
10827020
10612449
7845624
8801538
12164378
7568127
8710878
17988804
18286589
11910117
12601307
24126214
20810691
9660946
14749508
9405487
17180163
20399755
9846842
22290540
17579277
18178314
10909981
10729790
22701480
14980382
15884015
8684156
21146506
7507336
2109008
12687327
8532024
22410251
8742036
11744348
21971349
16731799
12611609
22013440
10862798
8376546
16293343
19273752
17179198
19060980
2543584
9796811
16336196
16988040
16982425
9304698
18040779
7068178
7549035
21521323
23686164
17224474
20012873
16470013
11751615
21035755
9359467
15029093
19878074
16857578
18423446
20875649
19901247
17986201
12860573
15559756
17536002
18024215
22595506
16772744
20074530
11493024
11861497
23663742
16982424
2991316
8981437
18522829
3543687
1621811
19460404
22747686
12079865
9734405
10612701
10698121
7708716
16216938
17213280
17618856
17242917
1372985
21947364
21615949
2474832
2492381
16423896
2578200
17767903
12068289
22265325
15721751
21823537
15155767
11411806
18514163
9221913
11606482
12138120
12676175
19144836
2377609
9060969
14615545
21728035
10579368
9106236
19130879
16158039
21494606
15856064
14749507
18158361
12771258
22319604
2195550
18665257
16914228
10604883
14624132
12578865
11400913
17540480
16545583
6342529
21070531
10754224
15944202
16078235
15077108
20842535
19662657
456611
21837268
17459524
20808781
12165582
16357100
22806355
20865382
2462832
30651
4356083
9535108
7012657
22612792
15660126
15356668
19132224
11457496
16380487
21183934
22243796
19467298
3201232
20190550
1337194
8548812
22201683
8238453
12436346
16522636
10933310
10878672
12634434
22796520
11399409
399240
1350793
22326556
21595886
18711690
11344187
9020115
17430231
18367704
21450935
10404789
17878708
14557234
18419763
21536637
17493197
15536110
9166683
10617578
23108647
22071160
10961870
22002620
20944545
22859388
17600230
7984236
10746647",Obesity and dementia: adipokines interact with the brain.,"Obesity is a pandemic and a serious global health concern. Obesity is a risk factor for multiple conditions and contributes to multi-morbidities, resulting in increased health costs and millions of deaths each year. Obesity has been associated with changes in brain structure, cognitive deficits, dementia and Alzheimer׳s disease. Adipokines, defined as hormones, cytokines and peptides secreted by adipose tissue, may have more widespread influence and functionality in the brain than previously thought. In this review, six adipokines, and their actions in the obese and non-obese conditions will be discussed. Included are: plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factors alpha (TNF-α), angiotensinogen (AGT), adiponectin and leptin. Their functionality in the periphery, their ability to cross the blood brain barrier (BBB) and their influence on dementia processes within the brain will be discussed.","['Adipokines', 'Alzheimer', 'Brain', 'Dementia', 'Leptin', 'Obesity']",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2014-04-08,"[{'lastname': 'Arnoldussen', 'firstname': 'Ilse A C', 'initials': 'IA', 'affiliation': 'Department of Anatomy, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Geert Grooteplein Noord 21, 6525 EZ Nijmegen, The Netherlands. Electronic address: Ilse.Arnoldussen@Radboudumc.nl.'}, {'lastname': 'Kiliaan', 'firstname': 'Amanda J', 'initials': 'AJ', 'affiliation': 'Department of Anatomy, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Geert Grooteplein Noord 21, 6525 EZ Nijmegen, The Netherlands. Electronic address: Amanda.Kiliaan@Radboudumc.nl.'}, {'lastname': 'Gustafson', 'firstname': 'Deborah R', 'initials': 'DR', 'affiliation': 'Department of Neurology, State University of New York-Downstate Medical Center, 450 Clarkson Avenue, Box 1213, Brooklyn, NY11203, USA; UMS 011 Inserm Versailles Saint Quentin, France; Section for Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy at University of Gothenburg, Institute for Neuroscience and Physiology, NeuroPsychiatric Epidemiology Unit, Wallinsgatan 6, 431 41 Gothenburg, Sweden. Electronic address: deborah.gustafson@neuro.gu.se.'}]",,,,Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.,10.1016/j.euroneuro.2014.03.002,<Element 'PubmedArticle' at 0x7f05dae21680>
363,"24553879
20009056
23055000
8801538
16086687
11553775
17124253
7984236
11734601
11172066
20727007
23071504
19460404
22921944
20388942
20842535
21569380
22425595
23634778
23895348
17656423
18384771
21088422
17256056
18331422
23979024
19429119
19128206
16330136
19682539
22688349
23250356
24223837
23747409
22898768
23300647
22806254
17934323
15305858
16034410
20875649
21115952
15576490
15451921
16857578
21633502
15477536
17001693
21186369
19724019
16531051
15203246
15882777
18430992
23238164
22232009
14698759
15181022
22303443
18358569
18367704
11201732",Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines.,"Alzheimer's disease is the leading cause of dementia and the most prevalent neurodegenerative disease. It is an aging-related multi-factorial disorder and growing evidence support the contribution of metabolic factors to what was formerly thought to be a centrally mediated process. Obesity has already been recognized as an important player in the pathogenesis of this type of dementia, independently of insulin resistance or other vascular risk factors. Although the exact underlying mechanisms are still unknown, adipocyte dysfunction and concomitant alteration in adipocyte-derived protein secretion seem to be involved, since these adipocytokines can cross the blood-brain barrier and influence cognitive-related structures. Very few studies have assessed the role of adipocytokines dysfunction on cognitive impaired patients and yielded contradictory results. Interestingly, extensive research on the central effects of leptin in Alzheimer's disease-transgenic mice has demonstrated its capacity to enhance synaptic plasticity and strength, as well as to prevent beta-amyloid deposition and tau phosphorylation. In addition, adiponectin, the most abundant adipocytokine whose levels are inversely correlated to adiposity, has shown to be neuroprotective to hippocampal cells. Many other adipose-derived cytokines have mainly pro-inflammatory properties, being able to trigger and/or enhance central inflammatory cascades and also to influence the secretion of other adipocytokines involved in cognition. This paper pretends to review the existing evidence on the contribution of adipocytokines dysfunction to the increased risk of dementia associated with mid-life obesity, unraveling its insulin-independent effects on cognition.",[],Metabolic brain disease,2014-02-21,"[{'lastname': 'Letra', 'firstname': 'Liliana', 'initials': 'L', 'affiliation': 'Serviço de Neurologia, Centro Hospitalar e Universitário de Coimbra, Portugal, Av. Bissaya Barreto - Praceta Prof Mota Pinto, 3000-075, Coimbra, Portugal, lilianaletra@gmail.com.'}, {'lastname': 'Santana', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Seiça', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': None}]",,,,,10.1007/s11011-014-9501-z,<Element 'PubmedArticle' at 0x7f05dae01e50>
364,"24496073
16846397
20382680
20410223
10509230
9072584
1400877
23939517
16682542
20881265
23533227
15985573
19011295
12809076
17898800
20592293
25009850
11397827
10875828
15251260
19071157
19837873
11172772
23959938
21907204
22976076
23313927
8710070
12777365
6610841
7740508
20525905
18763169
14709635
18953109
18695059
20837851
10718932
11560301
12391612
23939517
9109845
10199775
21516949
1719016
8943067
18220951
14871891
11835987
16503402
17456570
22150314
11686576
11208935
12424737
13678664
10995836
12591216
16155278
21891867
11342684
11844848
17764625
7644059
9514828
12928050
12213999
16642786
16112415","Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer's disease.","The use of testosterone among aging men has been increasing, but results from studies addressing the effectiveness of testosterone replacement therapy have been equivocal.
Given our prior pre-clinical studies that reported a major influence of oxidative stress on testosterone's neuroprotective effects, we investigated whether the negative effects of testosterone on brain function were predicted by oxidative load.
In order to test our hypothesis, we determined whether circulating total testosterone and luteinizing hormone correlated with cognition in a subset of the Texas Alzheimer's Research & Care Consortium (TARCC) cohort, consisting of Caucasian (n = 116) and Mexican-American (n = 117) men. We also assessed whether oxidative stress (as indexed by homocysteine levels) modified this relationship between sex hormones and cognition, and whether the levels of two antioxidants, superoxide dismutase-1 and glutathione S-transferase (GST), varied as a function of circulating testosterone.
In a low oxidative stress environment, testosterone was positively associated with the level of the antioxidant, GST, while no deleterious effects on cognitive function were noted. In contrast, under conditions of high oxidative stress (homocysteine levels >12 μmol/L), testosterone and luteinizing hormone were associated with cognitive impairment, but only among Caucasians. The ethnic difference was attributed to significantly higher GST levels among Mexican-Americans.
While testosterone may be beneficial under conditions of low oxidative stress, testosterone appears to have negative consequences under conditions of elevated oxidative stress, but only in Caucasians. Mexican-Americans, however, were protected from any deleterious effects of testosterone, potentially due to higher levels of endogenous antioxidant defenses such as GST.","['Androgens', 'Mexican American', 'antioxidants', 'homocysteine', 'luteinizing hormone']",Journal of Alzheimer's disease : JAD,2014-02-06,"[{'lastname': 'Cunningham', 'firstname': 'Rebecca L', 'initials': 'RL', 'affiliation': ""Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Center FOR HER, University of North Texas Health Science Center, Fort Worth, TX, USA.""}, {'lastname': 'Singh', 'firstname': 'Meharvan', 'initials': 'M', 'affiliation': ""Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA Center FOR HER, University of North Texas Health Science Center, Fort Worth, TX, USA.""}, {'lastname': ""O'Bryant"", 'firstname': 'Sid E', 'initials': 'SE', 'affiliation': ""Department of Internal Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.""}, {'lastname': 'Hall', 'firstname': 'James R', 'initials': 'JR', 'affiliation': ""Department of Psychiatry and Behavioral Health, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.""}, {'lastname': 'Barber', 'firstname': 'Robert C', 'initials': 'RC', 'affiliation': ""Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, Fort Worth, TX, USA.""}]",,"While testosterone may be beneficial under conditions of low oxidative stress, testosterone appears to have negative consequences under conditions of elevated oxidative stress, but only in Caucasians. Mexican-Americans, however, were protected from any deleterious effects of testosterone, potentially due to higher levels of endogenous antioxidant defenses such as GST.","In a low oxidative stress environment, testosterone was positively associated with the level of the antioxidant, GST, while no deleterious effects on cognitive function were noted. In contrast, under conditions of high oxidative stress (homocysteine levels >12 μmol/L), testosterone and luteinizing hormone were associated with cognitive impairment, but only among Caucasians. The ethnic difference was attributed to significantly higher GST levels among Mexican-Americans.",,10.3233/JAD-131994,<Element 'PubmedArticle' at 0x7f05dae19810>
365,24464001,"Cognitive functions, apolipoprotein E genotype and hormonal replacement therapy of postmenopausal women.","The results of many studies revealed that estrogen plus progestogen therapy (EPT) may modify dementia development risk in relation to the apolipoprotein E gene (APOE) polymorphisms. However, the mechanism and subsequently clinical importance of such an effect are still unexplained. The objective of this study was to explore the influence of EPT on cognitive functioning of women in their postmenopausal life in relation to APOE polymorphism.
The group of 214 women was recruited (106 out of this group with EPT) to the study. The inclusion criteria were: minimum two years after the last menstruation, FSH concentration over 30 U/ml and no dementia signs on Montreal Cognitive Assessment (MoCA). Computerized battery of Central Nervous System Vital Signs (CNS VS) test was used to diagnostic cognitive functions. APOE genotype was performed by multiplex PCR. Statistical analysis was performed using two-way analysis of variance in STATISTICA software.
The women after menopause have reduced neurocognitive index (NCI) and cognitive functions. NCI and all studied cognitive functions of the patients depended significantly on APOE polymorphisms. The presence of APOE4 corresponded with decreased cognitive functions as opposed to APOE2 which was present in women with better level of cognitive functions. Constantly using EPT correlated with three cognitive functions: memory, verbal memory and processing speed, which were significantly worse for women taking EPT than not taking ones. The interaction between APOE polymorphisms and EPT application was significant only for processing speed. EPT applying women with ε2/ε3 and ε4 obtained better scores in processing speed than women not taking EPT with these APOE polymorphisms. The opposite situation concerned women with ε3/ε3, women taking EPT achieved worse processing scores in comparison with those not taking EPT. It should be noted that APOE polymorphism assessment may be a factor in predicting the effect of EPT on cognitive functioning in postmenopausal period.",[],Neuro endocrinology letters,2014-01-28,"[{'lastname': 'Bojar', 'firstname': 'Iwona', 'initials': 'I', 'affiliation': 'Department for Health Problems of Ageing, Institute of Rural Health in Lublin, Poland. iwonabojar75@gmail.com.'}, {'lastname': 'Gujski', 'firstname': 'Mariusz', 'initials': 'M', 'affiliation': 'Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland.'}, {'lastname': 'Raczkiewicz', 'firstname': 'Dorota', 'initials': 'D', 'affiliation': 'Institute of Statistics and Demography, Warsaw School of Economics, Warsaw, Poland.'}, {'lastname': 'Rothenberg', 'firstname': 'Kasia Gustaw', 'initials': 'KG', 'affiliation': 'Department of Neurodegenerative Diseases, Institute of Rural Health in Lublin, Poland.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05dadc3860>
366,"24442578
23415312
20562461
23136129
11464847
22895706
21520231
21482928
23720273
21220649
23746459
21944778
21178100
23264878
16950801
22154785
21325651
9641683
15502829
12403824
22511793
23329412
8710059
21644037
11708987
23393093
23742080
21810890
21944779
23676768
20971753
17984093
21829372
16041373
22300873
22228244
19462523
23978324
20154673
21354975
21104415
15034582
16050094
15389756
21784346
22533640",TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.,"Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases. Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of FTLD, characterized by inclusions of TAR DNA-binding protein of 43 kDa (FTLD-TDP). Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of disease. Here, we report that rs1990622 genotype affects age at death in a single-site discovery cohort of FTLD patients with C9orf72 expansions (n = 14), with the major allele correlated with later age at death (p = 0.024). We replicate this modifier effect in a 30-site international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n = 75), again finding that the major allele associates with later age at death (p = 0.016), as well as later age at onset (p = 0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis in human neurodegenerative disease.",[],Acta neuropathologica,2014-01-21,"[{'lastname': 'Gallagher', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': 'Cell and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'lastname': 'Suh', 'firstname': 'Eunran', 'initials': 'E', 'affiliation': None}, {'lastname': 'Grossman', 'firstname': 'Murray', 'initials': 'M', 'affiliation': None}, {'lastname': 'Elman', 'firstname': 'Lauren', 'initials': 'L', 'affiliation': None}, {'lastname': 'McCluskey', 'firstname': 'Leo', 'initials': 'L', 'affiliation': None}, {'lastname': 'Van Swieten', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Al-Sarraj', 'firstname': 'Safa', 'initials': 'S', 'affiliation': None}, {'lastname': 'Neumann', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gelpi', 'firstname': 'Ellen', 'initials': 'E', 'affiliation': None}, {'lastname': 'Ghetti', 'firstname': 'Bernardino', 'initials': 'B', 'affiliation': None}, {'lastname': 'Rohrer', 'firstname': 'Jonathan D', 'initials': 'JD', 'affiliation': None}, {'lastname': 'Halliday', 'firstname': 'Glenda', 'initials': 'G', 'affiliation': None}, {'lastname': 'Van Broeckhoven', 'firstname': 'Christine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Seilhean', 'firstname': 'Danielle', 'initials': 'D', 'affiliation': None}, {'lastname': 'Shaw', 'firstname': 'Pamela J', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Frosch', 'firstname': 'Matthew P', 'initials': 'MP', 'affiliation': None}, {'lastname': 'Alafuzoff', 'firstname': 'Irina', 'initials': 'I', 'affiliation': None}, {'lastname': 'Antonell', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Bogdanovic', 'firstname': 'Nenad', 'initials': 'N', 'affiliation': None}, {'lastname': 'Brooks', 'firstname': 'William', 'initials': 'W', 'affiliation': None}, {'lastname': 'Cairns', 'firstname': 'Nigel J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Cooper-Knock', 'firstname': 'Johnathan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Cotman', 'firstname': 'Carl', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cras', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': None}, {'lastname': 'Cruts', 'firstname': 'Marc', 'initials': 'M', 'affiliation': None}, {'lastname': 'De Deyn', 'firstname': 'Peter P', 'initials': 'PP', 'affiliation': None}, {'lastname': 'DeCarli', 'firstname': 'Charles', 'initials': 'C', 'affiliation': None}, {'lastname': 'Dobson-Stone', 'firstname': 'Carol', 'initials': 'C', 'affiliation': None}, {'lastname': 'Engelborghs', 'firstname': 'Sebastiaan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Fox', 'firstname': 'Nick', 'initials': 'N', 'affiliation': None}, {'lastname': 'Galasko', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': None}, {'lastname': 'Gearing', 'firstname': 'Marla', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gijselinck', 'firstname': 'Ilse', 'initials': 'I', 'affiliation': None}, {'lastname': 'Grafman', 'firstname': 'Jordan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hartikainen', 'firstname': 'Päivi', 'initials': 'P', 'affiliation': None}, {'lastname': 'Hatanpaa', 'firstname': 'Kimmo J', 'initials': 'KJ', 'affiliation': None}, {'lastname': 'Highley', 'firstname': 'J Robin', 'initials': 'JR', 'affiliation': None}, {'lastname': 'Hodges', 'firstname': 'John', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hulette', 'firstname': 'Christine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ince', 'firstname': 'Paul G', 'initials': 'PG', 'affiliation': None}, {'lastname': 'Jin', 'firstname': 'Lee-Way', 'initials': 'LW', 'affiliation': None}, {'lastname': 'Kirby', 'firstname': 'Janine', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kofler', 'firstname': 'Julia', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kril', 'firstname': 'Jillian', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kwok', 'firstname': 'John B J', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Levey', 'firstname': 'Allan', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lieberman', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': None}, {'lastname': 'Llado', 'firstname': 'Albert', 'initials': 'A', 'affiliation': None}, {'lastname': 'Martin', 'firstname': 'Jean-Jacques', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Masliah', 'firstname': 'Eliezer', 'initials': 'E', 'affiliation': None}, {'lastname': 'McDermott', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': None}, {'lastname': 'McKee', 'firstname': 'Ann', 'initials': 'A', 'affiliation': None}, {'lastname': 'McLean', 'firstname': 'Catriona', 'initials': 'C', 'affiliation': None}, {'lastname': 'Mead', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Carol A', 'initials': 'CA', 'affiliation': None}, {'lastname': 'Miller', 'firstname': 'Josh', 'initials': 'J', 'affiliation': None}, {'lastname': 'Munoz', 'firstname': 'David G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Murrell', 'firstname': 'Jill', 'initials': 'J', 'affiliation': None}, {'lastname': 'Paulson', 'firstname': 'Henry', 'initials': 'H', 'affiliation': None}, {'lastname': 'Piguet', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': None}, {'lastname': 'Rossor', 'firstname': 'Martin', 'initials': 'M', 'affiliation': None}, {'lastname': 'Sanchez-Valle', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': None}, {'lastname': 'Sano', 'firstname': 'Mary', 'initials': 'M', 'affiliation': None}, {'lastname': 'Schneider', 'firstname': 'Julie', 'initials': 'J', 'affiliation': None}, {'lastname': 'Silbert', 'firstname': 'Lisa C', 'initials': 'LC', 'affiliation': None}, {'lastname': 'Spina', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'van der Zee', 'firstname': 'Julie', 'initials': 'J', 'affiliation': None}, {'lastname': 'Van Langenhove', 'firstname': 'Tim', 'initials': 'T', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'Jason', 'initials': 'J', 'affiliation': None}, {'lastname': 'Wharton', 'firstname': 'Stephen B', 'initials': 'SB', 'affiliation': None}, {'lastname': 'White', 'firstname': 'Charles L', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Woltjer', 'firstname': 'Randall L', 'initials': 'RL', 'affiliation': None}, {'lastname': 'Trojanowski', 'firstname': 'John Q', 'initials': 'JQ', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Virginia M Y', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna', 'initials': 'V', 'affiliation': None}, {'lastname': 'Chen-Plotkin', 'firstname': 'Alice S', 'initials': 'AS', 'affiliation': None}]",,,,,"10.1007/s00401-013-1239-x
10.1016/j.neuron.2013.02.004
10.1136/jnnp.2009.204081
10.1093/hmg/dds475
10.1523/JNEUROSCI.0521-12.2012
10.1002/ana.22271
10.1001/archneurol.2011.53
10.1002/ana.23946
10.1001/archneurol.2010.350
10.1016/j.tins.2013.04.010
10.1016/j.neuron.2011.09.011
10.1212/WNL.0b013e31820a0e3b
10.1038/srep01016
10.1093/hmg/ddl241
10.1016/S1474-4422(11)70261-7
10.1212/WNL.0b013e31821103e6
10.1038/31508
10.1038/ng1451
10.1073/pnas.232565499
10.1074/jbc.M112.365098
10.1093/bioinformatics/bts725
10.1007/s00401-011-0845-8
10.1126/science.1232927
10.1111/jnc.12329
10.1093/brain/awr179
10.1016/j.neuron.2011.09.010
10.1093/molbev/mst096
10.1136/jnnp.2010.212225
10.1074/jbc.M705115200
10.1371/journal.pgen.1002181
10.1038/ng1609
10.1093/brain/awr355
10.1007/s00401-011-0937-5
10.1016/j.jalz.2013.06.003
10.1038/ng.536
10.1093/brain/awr007
10.1007/s00401-010-0782-y
10.1038/ng1332
10.1002/ajmg.b.30087
10.1016/j.jalz.2010.08.233
10.1042/BJ20120136",<Element 'PubmedArticle' at 0x7f05dadcca90>
367,"24434111
18550597
20713504
23500670
8670681
3260856
3780911
19318467
4075870
14585492
16678867
15589108
16328492
23462757
20226788
22520299
18190916
21454017
23261859
10322179
22085881
15708762
17462646
11324860
11322586
23733450
23554482
16267231
19925184
9292185
16187814
17351740
1961837
17564921
16995832
23812171
16887790
17164189
16855037
22913619
18808250
16670182
23800538
23573795
23383629
17368764
22642887
11142657
21472414
23874990
23822747
19185612
20688068
23219473
23063473
23871792
23597827
12044593
11801188
18996418
20801160
15939837
18250252
17619130
23816781
21473905
22641619
11385829
11711248
22129556
2247149
11439180
8751283
18374335
17720235
8329137
8544953
656937
21334362
19190082
15234982
21852955
19446076
21376052
9401339
437385
18947934
23603479
22289044
18074217
17200249
22908911
21418719
15381027
16504970
23271317
20034703
23895362
21784094
18489019
2223043
17261685
11113213
15906058
18262206
23457466
23037957
23978422
23986300
23929807
8624127
22548198
11238065
20442496
2356012
9736007
3324647
8290098
16397184
20689282
21862210
23348042
16365303
15882020
22917473
11534968
20505099
22201929
22451324
15956166
19909788
22701110
22138012
20674095
22075082
22133892
23459573
9952396
10098861
18716201
12515896
23716494
22962256
23798570
20493928
22393359
17988898
20410196
11836290
14641001
11449190
14745052
15383512
19428144
22554955
19829160
19327032
23828104
23581910
23599929
23300939
23318115
23463934
15528485
15131549
23420636
21796048
19365142
23562428
23254630
7821136
11206408
21288982
20625169
20837967
23358884
16399206
21519521
23637108
8279933
12646300
11102321
15732103
20104067
23599941
8300981
23326249
23948909
17544382
17531851
7804599
9347981
10817919
9106616
9252035
10684871
10797534
18078984
8175728
17261779
17287517
11488923
9546791
10987824
20053478
19897485
9445346
9809515
9527626
10625732
11368971
11375837
10566973
9689481
9707210
11751611
11997695
12925744
17549730
8780008
8905174
10794300
15885907
10567046
11825624
9271001
15932748
8620923
10833057
3689284
10543012
12650717
12586554
14611867
11689174
15190103
10655508
10103123
11172772
11805297
14622899
15862533
11389183
23648585
15009673
11744660
21907204
1734291
8709781
12413371
11255424
9191757
8080389
8030628
1484915
9421202
9153163
11156805
11795355
9799627
8649552
9566410
12442669
11040417
7494884
11680444
8422201
1985611
8388207
9755371
14987460
15213207
12771113
15213206
12771112
10697060
12117397
12904517
15082697
16476878
23474850
22728278
22079780
22367731
22367731
17011666
21249708
18522765
21335669
18447940
8865133
3791826
14670641
14667983
2229140
16125839
19325006
9227542
11127455
15689957
12182896
9012659
16024758
12809076
15985573
23089633
23740590
22596080
14718489
16344336
9926814
10442863
10828558
15708213
17351741
20054729
20840231
23848390
23437381
23822582
9659999
12240744
14733897
19361297
19331451
22962857
23938766
8637959
15739810
21744957
20452582
22431972
22877929
14589530
2267058
14589521
14591275
9345702
12585526
12821106
14563060
22874587
22670852
23261419
22770542",Sex differences in cognitive impairment and Alzheimer's disease.,"Studies have shown differences in specific cognitive ability domains and risk of Alzheimer's disease between the men and women at later age. However it is important to know that sex differences in cognitive function during adulthood may have their basis in both organizational effects, i.e., occurring as early as during the neuronal development period, as well as in activational effects, where the influence of the sex steroids influence brain function in adulthood. Further, the rate of cognitive decline with aging is also different between the sexes. Understanding the biology of sex differences in cognitive function will not only provide insight into Alzheimer's disease prevention, but also is integral to the development of personalized, gender-specific medicine. This review draws on epidemiological, translational, clinical, and basic science studies to assess the impact of sex differences in cognitive function from young to old, and examines the effects of sex hormone treatments on Alzheimer's disease in men and women.","['Alzheimer’s disease', 'Cognition', 'Gender', 'Sex difference', 'Steroid hormones']",Frontiers in neuroendocrinology,2014-01-18,"[{'lastname': 'Li', 'firstname': 'Rena', 'initials': 'R', 'affiliation': 'Center for Hormone Advanced Science and Education (CHASE), Roskamp Institute, Sarasota, FL 34243, United States. Electronic address: rli@rfdn.org.'}, {'lastname': 'Singh', 'firstname': 'Meharvan', 'initials': 'M', 'affiliation': ""Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer's Disease Research (IAADR), Center FOR HER, University of North Texas, Health Science Center, Fort Worth, TX 76107, United States.""}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2014.01.002,<Element 'PubmedArticle' at 0x7f05dad818b0>
368,"24363642
17073655
16957069
16003096
21925074
20820913
22548192
17951027
12098181
19534717
16207887
18073775
18495785
18075491
17573218
17389308
17502912
18037003
22985767
22013419
14720213
17522319
17094146
19587269
20305988
21216393
21080413
22454617
22227061
21586125
23039106
21680949
10375654
20400711
17306796
22221983
18520773
19542629
23727506
21853262
20444270
19176811
17910066
18037023
21900767
8906762
7476822",Prolonged systemic inflammation persistently modifies synaptic plasticity in the hippocampus: modulation by the stress hormones.,"Transient systemic inflammation has been shown to cause altered behavior both in humans and in laboratory animals through activation of microglia and heightened level of cytokines detected in the brain and in the body. Furthermore, both activated microglia and the increased cytokines level have been associated with the sudden clinical deterioration in demented people or in aged patients upon systemic inflammation. Whilst it is increasingly becoming clear the role of transient systemic inflammation in promoting dementia in aged individuals, it is still a matter of debate whether prolonged systemic inflammation might persistently modify the brain. In this study, we examined the influence of a systemic long term inflammatory event on synaptic plasticity. We report that while a short exposure to LPS produces transient deficit in long term potentiation (LTP) expression, systemic prolonged inflammation impairs LTP in slices of animals previously primed by a Complete Freund's adjuvant injection. Interestingly, steroids are able to modulate this effect: whereas glucocorticosteroid (GR) activation further reduces LTP, mineralocorticosteroid receptors (MR) activation promotes the full recovery of LTP. We believe that this research advances the current understandings on the role of the immune system in the onset and progression of cognitive deficits following long lasting systemic inflammation, and proposes possible insights on future strategies in order to prevent early dementia in these predisposed individuals.","['LPS', 'LTP', 'corticosterone', 'glucocorticosteroid receptors', 'hippocampus', 'inflammation', 'mineralocorticosteroid receptors', 'synaptic plasticity']",Frontiers in molecular neuroscience,2013-12-24,"[{'lastname': 'Maggio', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Department of Neurology, The Joseph Sagol Neuroscience Center, The Chaim Sheba Medical Center Tel HaShomer, Israel ; Talpiot Medical Leadership Program, The Chaim Sheba Medical Center Tel HaShomer, Israel.'}, {'lastname': 'Shavit-Stein', 'firstname': 'Efrat', 'initials': 'E', 'affiliation': 'Department of Neurology, The Joseph Sagol Neuroscience Center, The Chaim Sheba Medical Center Tel HaShomer, Israel.'}, {'lastname': 'Dori', 'firstname': 'Amir', 'initials': 'A', 'affiliation': 'Department of Neurology, The Joseph Sagol Neuroscience Center, The Chaim Sheba Medical Center Tel HaShomer, Israel ; Talpiot Medical Leadership Program, The Chaim Sheba Medical Center Tel HaShomer, Israel ; Department of Neurology, Washington University School of Medicine Saint Louis, MO, USA.'}, {'lastname': 'Blatt', 'firstname': 'Ilan', 'initials': 'I', 'affiliation': 'Department of Neurology, The Joseph Sagol Neuroscience Center, The Chaim Sheba Medical Center Tel HaShomer, Israel ; Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University Tel Aviv, Israel.'}, {'lastname': 'Chapman', 'firstname': 'Joab', 'initials': 'J', 'affiliation': 'Department of Neurology, The Joseph Sagol Neuroscience Center, The Chaim Sheba Medical Center Tel HaShomer, Israel ; Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University Tel Aviv, Israel.'}]",,,,,"10.3389/fnmol.2013.00046
10.2174/187152706778559345
10.1523/JNEUROSCI.1628-06.2006
10.1097/01.CCM.0000170192.54682.C1
10.1016/j.beem.2011.05.006
10.1007/s11064-010-0252-x
10.1155/2012/348642
10.1016/j.bbi.2007.08.014
10.1053/ajem.2002.33785
10.2174/156720209788970045
10.1523/JNEUROSCI.2614-05.2005
10.1038/nrn2297
10.1189/jlb.0208108
10.1038/sj.npp.1301649
10.1016/j.braindev.2007.05.006
10.1212/01.wnl.0000257815.20548.df
10.1155/2007/93202
10.1016/S0079-6123(07)67001-0
10.1016/j.bbi.2012.09.003
10.3389/fnbeh.2011.00062
10.1046/j.1471-4159.2003.02157.x
10.1523/JNEUROSCI.0155-07.2007
10.1002/hipo.20237
10.1523/JNEUROSCI.1901-09.2009
10.1100/tsw.2010.48
10.1016/j.biopsych.2010.11.026
10.1002/hipo.20893
10.3389/fncel.2012.00012
10.1016/j.expneurol.2011.12.035
10.1186/1742-2094-8-50
10.1111/j.1365-2990.2012.01306.x
10.1164/rccm.201011-1897CI
10.1016/S0006-8993(99)01479-1
10.1177/1073858409355829
10.1016/j.expneurol.2007.01.003
10.1016/j.jemermed.2011.08.015
10.1097/NEN.0b013e31817713cc
10.3233/JAD-2009-1126.
10.1016/j.neuroscience.2013.05.043
10.1007/s11357-011-9301-x
10.1186/cc9001
10.1523/JNEUROSCI.5528-08.2009
10.1002/hipo.20373
10.1016/S0079-6123(07)67021-6
10.1097/MCC.0b013e32834a4aeb
10.1016/S0735-6757(96)90080-7",<Element 'PubmedArticle' at 0x7f05dad127c0>
369,"24336141
23550670
22201929
21533680
21555578
20110600
21865747
17761551
20689282
21198412
11255424
12796530
20965156
18724262
17476147
16801647
16103727
22471860
22471867
17562829
23109154
1202204
12061405
12136057
11851541
6610841
17035694
15753419
15079015
9330978
23100399
12552039
12771113
12724456
11769698
17882682
19401958
15721829
6721012
9255746",Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women.,"To determine the association between age at surgical menopause and both cognitive decline and Alzheimer disease (AD) pathology in 2 longitudinal cohorts.
Female subjects from 2 longitudinal studies of cognitive decline (Religious Orders Study and Rush Memory and Aging Project) were included (total n = 1,884). The primary analysis examined the association between age at surgical menopause and decline in a global cognition score. Secondary analyses examined additional outcomes: 1) decline in 5 cognitive subdomains and 2) a global measure of the burden of AD pathology. In exploratory analyses, we examined the effect of hormone replacement therapy (HRT). We adjusted all models for age, education, smoking, and cohort and stratified by surgical vs natural menopause.
For the 32% of subjects with surgical menopause, earlier age at menopause was associated with faster decline in global cognition (p = 0.0007), specifically episodic memory (p = 0.0003) and semantic memory (p = 0.002). Earlier age at menopause was also associated with increased AD neuropathology (p = 0.038), in particular neuritic plaques (p = 0.013). HRT use for at least 10 years, when administered within a 5-year perimenopausal window, was associated with decreased decline in global cognition. No associations were seen in women who had natural menopause.
Early age at surgical menopause was associated with cognitive decline and AD neuropathology. Ongoing studies should clarify the potential effect of HRT on this relationship.",[],Neurology,2013-12-18,"[{'lastname': 'Bove', 'firstname': 'Riley', 'initials': 'R', 'affiliation': ""From the Program in Translational NeuroPsychiatric Genomics (R.B., E.S., L.B.C., P.L.D.), Institute for the Neurosciences, Department of Neurology, Brigham and Women's Hospital; Harvard Medical School (R.B., L.B.C., P.L.D.), Boston, MA; and the Departments of Neurological Sciences (L.L.B.) and Neuropathology (J.A.S., D.A.B.), Rush University Medical Center, Chicago, IL.""}, {'lastname': 'Secor', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}, {'lastname': 'Chibnik', 'firstname': 'Lori B', 'initials': 'LB', 'affiliation': None}, {'lastname': 'Barnes', 'firstname': 'Lisa L', 'initials': 'LL', 'affiliation': None}, {'lastname': 'Schneider', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Bennett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': None}, {'lastname': 'De Jager', 'firstname': 'Philip L', 'initials': 'PL', 'affiliation': None}]",,,"For the 32% of subjects with surgical menopause, earlier age at menopause was associated with faster decline in global cognition (p = 0.0007), specifically episodic memory (p = 0.0003) and semantic memory (p = 0.002). Earlier age at menopause was also associated with increased AD neuropathology (p = 0.038), in particular neuritic plaques (p = 0.013). HRT use for at least 10 years, when administered within a 5-year perimenopausal window, was associated with decreased decline in global cognition. No associations were seen in women who had natural menopause.",,10.1212/WNL.0000000000000033,<Element 'PubmedArticle' at 0x7f05dacb0ea0>
370,"24318124
19235231
19782477
22610521
19455173
23312564
18786562
17585885
16446741
22608619
16420418
2443979
23776438
20463234
16814555
19606083
22652019
23303074
17406647
11994323
12242056
18037014
22529357
15598548
23380665
17912249
18281193
16230605
22781311
23201228
14625144
19317179
11386983
15940303
15629203
21395861
17401728
11675510
16395301
17164819
18384891
19330847
18073775
21184481
22880630
19555674
20864090
15891777
2899791
18423443
19644122
22520439
22732265
20603482
18704495
22832953
18662748
18513206
9809557
9626140
22525700
20152109
20122698
17669502
9316021
23312397
8812295
17116335
23179864
12379862
11375910
19723561
23392676
15123392
9065509
16943563
22674267
22980941
18602762
14750971
15813940
19765721
14596810
9784981
22214537
23581921
21878486
11027914
23049985
19570680
23419546
16467370
20843871
23023031
22885997
23534055
18382230
21727252
2027050
23187693
21195417
20126454
21316391
15240403
10082835
20828592
11342393
6270791
16934871
21697947
17956742
17306230
10066285
19073626
19139412
23624512
17030472
11159183
15050859
17073656
19748235
20138063
23998452
10195112
17123834
21844357
21079608
20661246
18722590
8627386
20882552
17991865
21383235
18420937
19427352
23219281
16499879
15967994
14615545
21854166
19898468
10803476
11860455
15820716
2153890
8643765
23303069
23390414
20463226
9789081
21934057
17322559
8824343
18222612
21309108
20234358
22127301
15389682
11150336
17686466
19362426
20809212
23137715
22822164
15993654
16095592
7653697
23469922
23146357
11257240
16415915
2998738
15987954
19531786
21827775
10844035
12814376
12907793
3998819
11675480
12404003
3998818
3527687
2398367
21849213
22832955
17762509
21281629
19589050
1666329
21881570
20308989
22427805
22738723
19361488
12900317
20479761
8468409
22760555
21613497
23000140
9876255
10362296
17692926
10624540
15680690
15522247
18536703
7894471
15996533
10540599
18054802
21663538
16871536
22230628
22331913
23512378
2723746
23870425
15318328
9326754
22928804
23612048
9350847
14625145
15464275
15231442
24020974
18427561
21945289
23408420
23290588
23748930
12399952
17699665
23415948
16289354
1705153
17884039
11495096
20970492
21811605
23306181
23613579
16894061
21791259
16415867
22071871",Neuropathology of stress.,"Environmental challenges are part of daily life for any individual. In fact, stress appears to be increasingly present in our modern, and demanding, industrialized society. Virtually every aspect of our body and brain can be influenced by stress and although its effects are partly mediated by powerful corticosteroid hormones that target the nervous system, relatively little is known about when, and how, the effects of stress shift from being beneficial and protective to becoming deleterious. Decades of stress research have provided valuable insights into whether stress can directly induce dysfunction and/or pathological alterations, which elements of stress exposure are responsible, and which structural substrates are involved. Using a broad definition of pathology, we here review the ""neuropathology of stress"" and focus on structural consequences of stress exposure for different regions of the rodent, primate and human brain. We discuss cytoarchitectural, neuropathological and structural plasticity measures as well as more recent neuroimaging techniques that allow direct monitoring of the spatiotemporal effects of stress and the role of different CNS structures in the regulation of the hypothalamic-pituitary-adrenal axis in human brain. We focus on the hypothalamus, hippocampus, amygdala, nucleus accumbens, prefrontal and orbitofrontal cortex, key brain regions that not only modulate emotions and cognition but also the response to stress itself, and discuss disorders like depression, post-traumatic stress disorder, Cushing syndrome and dementia.",[],Acta neuropathologica,2013-12-10,"[{'lastname': 'Lucassen', 'firstname': 'Paul J', 'initials': 'PJ', 'affiliation': 'SILS-Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH, Amsterdam, The Netherlands, p.j.lucassen@uva.nl.'}, {'lastname': 'Pruessner', 'firstname': 'Jens', 'initials': 'J', 'affiliation': None}, {'lastname': 'Sousa', 'firstname': 'Nuno', 'initials': 'N', 'affiliation': None}, {'lastname': 'Almeida', 'firstname': 'Osborne F X', 'initials': 'OF', 'affiliation': None}, {'lastname': 'Van Dam', 'firstname': 'Anne Marie', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Rajkowska', 'firstname': 'Grazyna', 'initials': 'G', 'affiliation': None}, {'lastname': 'Swaab', 'firstname': 'Dick F', 'initials': 'DF', 'affiliation': None}, {'lastname': 'Czéh', 'firstname': 'Boldizsár', 'initials': 'B', 'affiliation': None}]",,,,,10.1007/s00401-013-1223-5,<Element 'PubmedArticle' at 0x7f05dacd10e0>
371,"24298156
7584987
8801538
11239410
8674530
9331926
12482897
9568684
9427338
10579368
8548812
16086687
20237279
19054283
11734601
16914228
12150780
16300445
15203246
10884568
17038557
12163036
18358569
2575162
2567518
6306230
1350090
1419003
18097472
21752339
12765612
17959808
16582904
17972919
17460072
17652419
8866547
20010819
19208634
1350383
15143284
16904707
15356193
18024215
16413128
1933293
12427850
9347351
8789948
15550950
17335914
15152046
17329210
22284190
1425482
10774732
15030406
14976558
16092951
11248117
7675309
11074263
8772732
10218775
10382589
11173891
20009056
16293343
20308782
22921154
17600230
15576490
11279122
18568035
21441921
20571220
17145504
16025111
20862226
21435559",Leptin regulation of hippocampal synaptic function in health and disease.,"The endocrine hormone leptin plays a key role in regulating food intake and body weight via its actions in the hypothalamus. However, leptin receptors are highly expressed in many extra-hypothalamic brain regions and evidence is growing that leptin influences many central processes including cognition. Indeed, recent studies indicate that leptin is a potential cognitive enhancer as it markedly facilitates the cellular events underlying hippocampal-dependent learning and memory, including effects on glutamate receptor trafficking, neuronal morphology and activity-dependent synaptic plasticity. However, the ability of leptin to regulate hippocampal synaptic function markedly declines with age and aberrant leptin function has been linked to neurodegenerative disorders such as Alzheimer's disease (AD). Here, we review the evidence supporting a cognitive enhancing role for the hormone leptin and discuss the therapeutic potential of using leptin-based agents to treat AD.","['AMPA receptor trafficking', ""Alzheimer's disease"", 'hippocampus', 'leptin', 'long-term potentiation', 'synaptic plasticity']","Philosophical transactions of the Royal Society of London. Series B, Biological sciences",2013-12-04,"[{'lastname': 'Irving', 'firstname': 'Andrew J', 'initials': 'AJ', 'affiliation': 'Division of Neuroscience, Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, , Dundee DD1 9SY, UK.'}, {'lastname': 'Harvey', 'firstname': 'Jenni', 'initials': 'J', 'affiliation': None}]",,,,,"10.1098/rstb.2013.0155
10.1038/nm1195-1155
10.1016/0196-9781(96)00025-3
10.1016/S0092-8674(01)00240-9
10.1016/0014-5793(96)00473-5
10.1097/00001756-199709290-00023
10.1113/jphysiol.2002.029488
10.2337/diabetes.47.4.538
10.1097/00001756-199711100-00040
10.1210/en.140.12.5995
10.1016/0092-8674(95)90151-5
10.1111/j.1471-4159.2005.03375.x
10.1523/JNEUROSCI.3614-09.2010
10.1111/j.1471-4159.2008.05810.x
10.1016/j.peptides.2006.07.001
10.1016/S0306-4522(02)00162-8
10.1037/0735-7044.119.5.1389
10.1016/j.peptides.2004.03.018
10.1016/S0028-3908(00)00014-9
10.1210/en.2006-0672
10.1016/S0006-291X(02)00906-3
10.1016/j.neurobiolaging.2007.11.024
10.1073/pnas.89.10.4363
10.1016/0896-6273(92)90248-C
10.1172/JCI33009
10.1016/j.neuropharm.2011.06.021
10.1016/S0896-6273(03)00228-9
10.1523/JNEUROSCI.2671-07.2007
10.1038/nn1678
10.1038/sj.emboj.7601884
10.1523/JNEUROSCI.0325-07.2007
10.1152/jn.00473.2007
10.2337/diab.45.11.1455
10.1038/nn.2462
10.1074/jbc.M806774200
10.1016/j.coph.2006.11.002
10.1016/j.neuroscience.2005.11.042
10.1016/0006-8993(91)90164-Q
10.1002/(SICI)1098-1063(1997)7:5<549::AID-HIPO10>3.0.CO;2-0
10.1016/S0896-6273(00)80051-3
10.1016/j.tins.2007.02.005
10.1523/JNEUROSCI.5407-03.2004
10.1016/j.neuron.2007.01.029
10.1016/j.neuron.2011.11.024
10.1038/sj.emboj.7600126
10.1111/j.1471-4159.2005.03269.x
10.1073/pnas.051634698
10.1016/0304-3940(95)11593-L
10.1159/000051252
10.1001/jama.2009.1836
10.1016/j.peptides.2005.10.006
10.1016/j.neurobiolaging.2012.08.003
10.1161/STROKEAHA.107.482786
10.1096/fj.04-2572com
10.1074/jbc.M100710200
10.1038/nm1782
10.1038/nn.2785
10.1016/j.neuron.2006.10.035
10.1038/nn1503
10.1371/journal.pone.0012845
10.1016/j.neuron.2011.02.002",<Element 'PubmedArticle' at 0x7f05dac399a0>
372,"24178891
11835983
1339062
23546612
11172193
20863360
23438835
15058786
16314199
19933964
598014
2109585
2004476
10695693
17381480
17991805
19158193
17911171
21340114
18653108
22273398
22954017
23681263
19837933
22438233
11567699
20685889
20501682
19054181
16263815
19545916
12436151
15572717
23559085
23162099
17722401
14044222
18209838
12508408
2388204
7175852
6488708
1202204
16906312
7183759
10450349
3337862
17952308
18505765
16174720
22344200
19377752
7383070
17299073
19168226
12100345
22410877",Impact of thyroid status and age on comprehensive geriatric assessment.,"This study aimed to evaluate the prevalence of thyroid dysfunction in elderly subjects attending an outpatient clinic at a tertiary hospital and to assess whether subclinical hypothyroidism (SCH) or aging affected activities of daily living (ADLs), instrumental activities of daily living (IADLs), cognitive status, or depressive symptoms. This crosssectional study included 411 patients recruited in the outpatient geriatric setting. 48 subjects reported levothyroxine use and were evaluated separately. After excluding subjects with diseases or drugs which could influence thyroid status, the 284 subjects remaining were classified as having euthyroidism (n = 235, 82.8 %), subclinical hypothyroidism (n = 43, 15.1 %), subclinical hyperthyroidism (n = 4, 1.4 %), or overt hyperthyroidism (n = 2, 0.7 %). ADLs and IADLs were assessed using the Katz Index (ranging from 0 [independence] to 6 [dependence in all activities]) and Health Assessment Questionnaire (ranging from 0 to 3 [severely disabled]), respectively. Cognition was assessed using the mini mental state depressive symptoms that were assessed using the Geriatric depression scale or cornell scale for depression in dementia. SCH did not reduce performance in ADLs or IADLs in elderly subjects as a whole, but was an independent protective factor against dependence in ADLs (OR = 0.196 [0.045-0.853]; p = 0.003) and IADLs (OR = 0.060 [0.010-0.361]; p = 0.002) in subjects aged ≥85 years. Very old subjects with SCH showed better performance in ADLs than did those with euthyroidism (Katz Index: 0.9 ± 1.6 [median: 0.5] vs. 1.7 ± 1.7 [1.0], p = 0.024; HAQ: 1.2 ± 0.8 [0.9] vs. 1.8 ± 1.0 [1.9], p = 0.015). This putative protective effect of SCH was not found in subjects aged <85 years. The number of falls, number of medications used, depressive symptoms, and cognitive impairment did not differ among thyroid status groups, regardless of age. In conclusion, SCH does not have impact functional performance in the elderly population as a whole, but was associated with better functional status in subjects aged ≥85 years.",[],Endocrine,2013-11-02,"[{'lastname': 'E Silva', 'firstname': 'Silvana Oliveira', 'initials': 'SO', 'affiliation': 'Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho, 373. Edifício do Centro de Ciências da Saúde, Bloco K, Cidade Universitária, Rio de Janeiro, RJ, 21.941-902, Brazil, medsilva@gmail.com.'}, {'lastname': 'Chan', 'firstname': 'I Thien', 'initials': 'IT', 'affiliation': None}, {'lastname': 'Lobo Santos', 'firstname': 'Maryna A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Cohen', 'firstname': 'Marcela', 'initials': 'M', 'affiliation': None}, {'lastname': 'de La Roque P Araujo', 'firstname': 'Mayra', 'initials': 'M', 'affiliation': None}, {'lastname': 'da Silva Almeida', 'firstname': 'Julia', 'initials': 'J', 'affiliation': None}, {'lastname': 'Simões', 'firstname': 'Andressa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Givigi', 'firstname': 'Helder Renato B', 'initials': 'HR', 'affiliation': None}, {'lastname': 'Vaisman', 'firstname': 'Mario', 'initials': 'M', 'affiliation': None}, {'lastname': 'Paixão', 'firstname': 'Carlos M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'de Fatima Dos S Teixeira', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': None}]",,,,,"10.1007/s12020-013-0077-x
10.1016/S0149-7634(01)00037-9
10.1056/NEJM200102153440707
10.1111/j.1532-5415.2010.03040.x
10.1038/nrendo.2013.29
10.1023/B:QURE.0000015315.35184.66
10.1016/j.arcmed.2005.05.008
10.1001/archinternmed.2009.392
10.1111/j.1365-2265.1977.tb01340.x
10.1001/archinte.1990.00390160053012
10.1111/j.1365-2265.1991.tb01739.x
10.1001/archinte.160.4.526
10.1111/j.1365-2265.2007.02816.x
10.1210/er.2006-0043
10.1210/jc.2008-2325
10.1210/jc.2007-1499
10.1590/S0102-311X2011000100016
10.1016/S0167-4943(97)00012-5
10.1016/S0140-6736(11)60276-6
10.1089/thy.2012.0205
10.1590/S0004-27302013000300003
10.1210/jc.2009-0808
10.1210/jc.2011-3047
10.1016/S0140-6736(01)06067-6
10.1210/jc.2010-1242
10.1210/jc.2009-2571
10.1111/j.1532-5415.2008.02080.x
10.1210/jc.2005-1775
10.1016/j.archger.2009.05.015
10.1590/S1516-31802002000100001
10.1001/jama.292.21.2591
10.1210/jc.2012-2180
10.1590/S0080-62342007000200021
10.1001/jama.1963.03060120024016
10.1590/S0102-311X2008000100010
10.1007/BF02032335
10.1016/0022-3956(75)90026-6
10.1590/S0034-89102006000500023
10.1016/0022-3956(82)90033-4
10.1590/S0004-282X1999000300013
10.1016/0006-3223(88)90038-8
10.1590/S0004-282X2007000500037
10.1210/jc.2008-0167
10.1210/jc.2005-0872
10.1210/jc.2011-3020
10.1590/S0034-89102009000300020
10.1056/NEJM198007173030304
10.1210/jc.2006-1869
10.1016/j.jad.2008.12.012
10.1034/j.1600-0447.2002.01250.x
10.1002/gps.3796",<Element 'PubmedArticle' at 0x7f05dabec1d0>
373,"24096619
18948797
20599832
10342866
11024558
9486972
8717038
17357083
21980853
18346114
18191047
17072869
14854036
2087513
20186857
12519845
17159101
20116371
22801496
16377445
16350583
17986612
10718914
21204204
7624769
8735360
12150587
15933386
2991340
21517826
23599282
21315095
21674499
11160951
15064420
18249177
16350581
16353600
9894871
16350582
19463794
16186530
23047490
9761047
20385908
8755567
22237428
12165561
19680540
21076408
11483296
9537324
7745404
7304477
22012072
20133882
7702084
12023994
16353601
14970312
22617494
19357406
21304942
19474413
17825558
17307705
21356305
12589027
11208925
10398297
18267317
3374320
18241989
19123237
21282661
21684041
12161602
22963884
17690262
10486419
12393845
15660521
21209035
19234441
22713813
21056745
18717710
15114059
17904647
8416662
17991826
15722562
10701104
17315079
4795550
22926147
14574341
2779627
22209255
22902836
8649553
9379845
21514177
17993459
22404891
17306982
18826348
18753648
20427492
19049588
23206889
8504780
12887108
9371913
6983505
20404173
10587584
8619542
16216937
9543149
19460404
18376181
21794117
19169174
19679070
23467355
16412483
19808018
9927499
14729128
9620771
14557433
18451093
18437585
22124454
23299713
22211890
21976521
12354284
20351014
1705564
17439362
22940906
15070752
3145124
12612176
3547503
21633179
20152888
18845187
7584987
23627755
8994059
18845651
20650403
15788534
20606678
11342605
15713712
20739649
19622391
23168220
18343627
20680019
4382110
22140494
23201753
11448938
9784500
16350584
9202122
19340313
23549432
19901245
20945071
17179460
14718698
10868966
11525796
10696912
18456557
19054400
16277823
12525731
19332336
18215442
17512090
20817614
10523015
23268509
18258444
18769731
17600374
10737598
11916953
2035524
20584945
12119657
16282359
18317593
22488684
18424096
3782471
19198647
9153440
17656603
17607597
22548651
19716631
10548137
23580652
1978113
8965090
22618995
19761507
19150989
12482897
21987540
22084122
15271497
16888132
8843177
16148162
17056528
15138306
22896638
20935630
12453501
15642850
18278039
19280661
6390266
8446617
9500540
18455351
9401539
7852523
7407584
22880108
21500917
22201683
20220015
4109331
9771699
21515852
19357405
18286389
23620513
22105948
7726240
19357407
18925680
16954358
14506902
19049574
19079261
22415875
23069842
19171901
17909155
10966885
12796784
18097472
23204143
15494731
9771698
18289512
16054086
23636330
18854155",The neuropathology of obesity: insights from human disease.,"Obesity, a pathologic state defined by excess adipose tissue, is a significant public health problem as it affects a large proportion of individuals and is linked with increased risk for numerous chronic diseases. Obesity is the result of fundamental changes associated with modern society including overnutrition and sedentary lifestyles. Proper energy homeostasis is dependent on normal brain function as the master metabolic regulator, which integrates peripheral signals, modulates autonomic outflow and controls feeding behavior. Therefore, many human brain diseases are associated with obesity. This review explores the neuropathology of obesity by examining brain diseases which either cause or are influenced by obesity. First, several genetic and acquired brain diseases are discussed as a means to understand the central regulation of peripheral metabolism. These diseases range from monogenetic causes of obesity (leptin deficiency, MC4R deficiency, Bardet-Biedl syndrome and others) to complex neurodevelopmental disorders (Prader-Willi syndrome and Sim1 deficiency) and neurodegenerative conditions (frontotemporal dementia and Gourmand's syndrome) and serve to highlight the central regulatory mechanisms which have evolved to maintain energy homeostasis. Next, to examine the effect of obesity on the brain, chronic neuropathologic conditions (epilepsy, multiple sclerosis and Alzheimer's disease) are discussed as examples of obesity leading to maladaptive processes which exacerbate chronic disease. Thus, obesity is associated with multiple pathways including abnormal metabolism, altered hormonal signaling and increased inflammation which act in concert to promote downstream neuropathology. Finally, the effect of anti-obesity interventions is discussed in terms of brain structure and function. Together, understanding human diseases and anti-obesity interventions leads to insights into the bidirectional interaction between peripheral metabolism and central brain function, highlighting the need for continued clinicopathologic and mechanistic studies of the neuropathology of obesity.",[],Acta neuropathologica,2013-10-08,"[{'lastname': 'Lee', 'firstname': 'Edward B', 'initials': 'EB', 'affiliation': 'Translational Neuropathology Research Laboratory, Division of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, 605B Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA, 19104, USA, edward.lee@uphs.upenn.edu.'}, {'lastname': 'Mattson', 'firstname': 'Mark P', 'initials': 'MP', 'affiliation': None}]",,,,,"10.1007/s00401-013-1190-x
10.1097/SLA.0b013e3181884308
10.1016/j.brainres.2010.06.034
10.1172/JCI1176
10.1038/382250a0
10.1086/513471
10.1111/j.1365-2990.2008.00948.x
10.1016/j.metabol.2007.08.023
10.1002/humu.20404
10.1002/ana.21798
10.1212/01.wnl.0000247053.45483.4e
10.1016/j.brainres.2010.01.054
10.1038/nature11270
10.1016/j.brainresbull.2005.09.012
10.1073/pnas.0706481104
10.1002/ajmg.a.33773
10.1172/JCI111971
10.1111/j.1399-0004.2011.01688.x
10.1073/pnas.1210192110
10.1016/j.physbeh.2011.01.023
10.1002/cne.22698
10.1126/science.1095004
10.1016/j.cmet.2007.12.001
10.1016/j.brainres.2009.05.032
10.1212/01.wnl.0000176061.33817.90
10.1002/cne.23233
10.3171/jns.1998.89.4.0547
10.1001/archneurol.2010.38
10.1038/gim.0b013e31822bead0
10.1371/journal.pgen.1000599
10.1038/ng.713
10.1038/32911
10.1007/s12035-011-8212-2
10.1073/pnas.0911725107
10.1002/ajmg.1320550105
10.1056/NEJMoa012908
10.1073/pnas.0305799101
10.1056/NEJMoa0810780
10.1371/journal.pone.0016581
10.1212/WNL.0b013e3181ab2b11
10.1016/j.cub.2007.08.034
10.1016/j.immuni.2007.01.011
10.1016/j.bbi.2011.02.008
10.1073/pnas.0536856100
10.1016/j.brainres.2007.12.047
10.1016/j.neulet.2007.12.051
10.1002/hipo.20547
10.1073/pnas.1015950108
10.1016/j.neurobiolaging.2011.05.005
10.1016/j.mce.2012.08.018
10.1126/science.1144599
10.1056/NEJM199909163411204
10.1172/JCI15693
10.1146/annurev.med.56.062904.144924
10.1210/jc.2010-2290
10.1038/nature07848
10.1038/ejhg.2012.115
10.1016/j.yapd.2010.08.003
10.1111/j.1528-1167.2008.01740.x
10.1023/B:JOCI.0000025450.48267.a5
10.1016/j.jneuroim.2007.08.008
10.1126/science.1151710
10.1194/jlr.E500002-JLR200
10.1053/ejpn.1999.0259
10.1007/s10548-012-0248-8
10.1038/sj.ijo.0802420
10.1056/NEJM198910123211503
10.1016/j.neurobiolaging.2011.11.030
10.1016/j.cmet.2012.06.015
10.1016/j.tem.2011.02.009
10.1074/jbc.M703753200
10.1111/j.1474-9726.2012.00817.x
10.1016/j.nbd.2006.12.019
10.3171/JNS/2008/109/10/0625
10.1056/NEJMoa0801119
10.1210/jc.2010-0127
10.1111/j.1528-1167.2008.01835.x
10.1016/j.eplepsyres.2012.10.011
10.1073/pnas.0910878107
10.1002/ana.410390506
10.1001/archneur.62.10.1545
10.1016/j.brainresrev.2009.05.002
10.1097/SLA.0b013e318156f012
10.1186/1471-2350-12-101
10.1097/PHM.0b013e318194f8b5
10.1016/j.neuron.2009.06.026
10.1523/JNEUROSCI.4165-12.2013
10.1016/j.physbeh.2005.10.007
10.1016/j.cmet.2009.08.013
10.1172/JCI4901
10.1038/509
10.1210/me.2008-0067
10.1007/s12031-008-9056-8
10.1038/ijo.2011.217
10.1038/ejcn.2012.208
10.1111/j.1749-6632.2011.06274.x
10.1523/JNEUROSCI.3171-11.2011
10.1677/JOE-10-0040
10.1172/JCI115072
10.1146/annurev.nutr.27.061406.093659
10.1038/ncb2562
10.1073/pnas.0308767101
10.1172/JCI57132
10.1016/j.brainresbull.2010.02.003
10.1016/j.brainresrev.2008.09.002
10.1177/1352458508096680
10.1016/S1474-4422(10)70135-6
10.1073/pnas.0408995102
10.1038/nrneurol.2010.89
10.1210/jc.2004-1979
10.1212/WNL.0b013e3181eee25f
10.1016/j.exger.2009.07.003
10.1016/j.cmet.2012.08.012
10.1016/j.biopha.2007.10.014
10.1038/ijo.2010.139
10.1002/path.1700930106
10.1371/journal.pone.0027968
10.1093/hmg/dds504
10.1038/43185
10.1371/journal.pone.0005045
10.1177/1352458513483889
10.1212/WNL.0b013e3181c0d6e0
10.1007/s00415-010-5783-1
10.1001/jama.296.23.2832
10.1016/S1474-4422(08)70092-9
10.1111/j.1528-1167.2008.01870.x
10.1016/j.nurt.2009.01.021
10.1016/j.peptides.2007.11.020
10.1016/j.peptides.2007.04.003
10.1016/j.yebeh.2010.07.023
10.1001/jama.2012.108099
10.1016/j.nbd.2007.12.008
10.1371/journal.pone.0003098
10.1002/jnr.21382
10.1093/brain/awq147
10.1210/en.2005-1030
10.1172/JCI32357
10.1007/s11695-012-0649-5
10.1016/j.seizure.2008.03.002
10.1172/JCI112749
10.1371/journal.pone.0004377
10.1530/EJE-07-0188
10.1055/s-2007-981466
10.1111/j.1749-6632.2012.06525.x
10.1016/j.neurobiolaging.2009.08.001
10.1074/jbc.M112.439570
10.1007/s00401-012-0996-2
10.1111/j.1467-789X.2009.00654.x
10.1093/hmg/ddp031
10.1001/archneurol.2011.203
10.1001/archneurol.2011.242
10.1016/j.tins.2004.06.005
10.1126/science.1124534
10.1152/physiolgenomics.00003.2004
10.4049/jimmunol.1102925
10.1038/ng.686
10.1001/archneur.62.1.55
10.1038/nn2055
10.1002/hipo.20577
10.1038/ng0398-213
10.1016/j.ijdevneu.2008.01.009
10.1371/journal.pone.0042785
10.1037/a0022733
10.1172/JCI59660
10.1523/JNEUROSCI.5444-09.2010
10.1038/2407
10.2337/db10-1614
10.1056/NEJMoa0808718
10.1007/s12017-008-8028-z
10.1073/pnas.1220484110
10.1212/WNL.0b013e318238eec1
10.1002/ajmg.1320550326
10.1056/NEJMoa0808949
10.1002/ajmg.a.32555
10.1111/j.1528-1167.2008.01821.x
10.1038/ng.287
10.2337/db11-1187
10.2337/dc12-0922
10.1073/pnas.0808587106
10.1212/01.wnl.0000277461.06713.23
10.1038/nn1073
10.1172/JCI33009
10.1093/brain/aws271
10.1038/nn1336
10.1038/2404
10.1016/j.brainres.2008.01.047
10.1016/j.cmet.2005.05.005
10.1038/nature12143
10.1016/j.cell.2008.07.043",<Element 'PubmedArticle' at 0x7f05dac14e50>
374,24059318,The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications.,"Recent data suggest that brains of patients with Alzheimer's disease (AD) are insulin and insulin-like growth factor-1 (IGF-1) resistant. So far, there have been two different approaches to investigate possible therapeutic implications of modulating cerebral insulin/IGF-1 signaling (IIS) in AD. One approach is peripheral or intranasal administration of insulin or IGF-1. Intranasal and peripheral insulin administration has been shown to improve memory in patients with AD. Additionally, peripheral IGF-1 administration resulted in decreased amyloid-beta (Aβ) levels in brains of AD mouse models accompanied by elevated Aβ levels in the cerebrospinal fluid (CSF). Insulin and IGF-1 regulate multicargotransporters influencing trafficking of several molecules including Aβ from the brain to the blood as well as to the CSF and possibly vice versa. Furthermore, insulin and related peptides regulate neurovascular coupling changing regional blood flow. Thus, positive effects of peripheral insulin/IGF-1 administration on AD pathology might be due to changes in the blood-brain-barrier (BBB) and/or in the transport between the CSF/blood and the brain. Clinical and experimental data suggest that increased serum insulin and IGF-1 levels do not necessarily correlate with an upregulation of neuronal insulin/IGF-1 receptor signaling. Therefore, the second approach in investigating the role of neuronal IIS for the pathogenesis of AD analyzes knockout mice lacking components of the IIS in AD models. Haploinsufficiency of the IGF- 1 receptor (IGF-1R) (IGF-1R(+/-) mice) as well as neuronal deficiency of the insulin receptor (IR) (nIR(-/-) mice) or IGF-1R (nIGF-1R(-/-) mice) leads to delayed Aβ accumulation when crossed with mouse models for AD. Furthermore, insulin receptor substrate (IRS)-2 knockout mice (IRS-2(-/-) mice) show reduced Aβ levels in an Alzheimer background. These data suggest beneficial effects of decreased neuronal IIS on Alzheimer-pathology and question the therapeutic outcome of long-term administration of insulin or IGF-1 in patients with AD. Whether the observed phenomenon of cerebral insulin and IGF-1 resistance even at an early stage of Alzheimer's disease is cause, consequence or possibly counter-regulation to AD-pathology needs further investigation and should lead to critical discussions. The current review discusses the pros and cons of targeting insulin/IGF-1 signaling as therapeutic approach for AD.",[],CNS & neurological disorders drug targets,2013-09-26,"[{'lastname': 'Zemva', 'firstname': 'Johanna', 'initials': 'J', 'affiliation': None}, {'lastname': 'Schubert', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'SCIVIAS Hospital St. Josef, Internal Medicine, Eibinger Str. 9, 65385 Rudesheim am Rhein, Germany. markus.schubert@uk-koeln.de.'}]",,,,,10.2174/18715273113126660141,<Element 'PubmedArticle' at 0x7f05dab26180>
375,23948914,Maternal breastfeeding history and Alzheimer's disease risk.,"The effect of early and midlife factors on later-life cognitive function has attracted scientific and public interest in recent years, especially with respect to hormonal risk factors for dementia. There is substantial evidence for reproductive history affecting Alzheimer's disease (AD) etiology. Here, we demonstrate how breastfeeding history affects women's risk of AD. Reproductive history data was collected, and AD diagnostic interviews were performed, for a cohort of elderly British women. Using Cox proportional-hazard models, we find that longer breastfeeding duration corresponded to reduced risk of AD (p < 0.01, n = 81). Women who breastfed had lower AD risk than women who did not breastfeed (p = 0.017, n = 81). Breastfeeding practices are an important modifier of cumulative endogenous hormone exposure for mothers. Ovarian hormone deprivation and/or insulin sensitivity benefits of breastfeeding may be responsible for the observed reduction in AD risk. Future studies concerning hormone effects on AD risk should consider how reproductive history leads to variation in endogenous hormone exposure and how this may influence the relationship between hormones and AD.","[""Alzheimer's disease"", 'breastfeeding', 'estrogen', 'hormones', 'lactation', 'reproductive history', 'risk factors']",Journal of Alzheimer's disease : JAD,2013-08-21,"[{'lastname': 'Fox', 'firstname': 'Molly', 'initials': 'M', 'affiliation': 'Division of Biological Anthropology, University of Cambridge, Cambridge, UK.'}, {'lastname': 'Berzuini', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': None}, {'lastname': 'Knapp', 'firstname': 'Leslie A', 'initials': 'LA', 'affiliation': None}]",,,,,10.3233/JAD-130152,<Element 'PubmedArticle' at 0x7f05dab2de00>
376,"23857055
21193853
22580620
20181214
23026534
23062696
20061649
15725334
14671188
11113605
10376127
9920102
12887656
11841602
15617532
2101296
17692293
10989165
11455329
9885996
12019344
12019347
12019364
14655926
19221418
15516999
11447842
9169588
7522386
15975073
22941973
22286308
1629745
8076698
9832145
17562708
1512244
7566346
18038270
23402899
22487856
15842767
15740721
15009509
20542922
15000877
11866882
15230863
15719129
10878257
15517432
15298664
11462772
11079778
12605413
15665406
20336132
20433638
20536682
19573038
19925580
20626592
20082663
15796769
12153439
10842331
12850542
8645723
21933187
11812653
20142804
21195169
21544200
12399581
9854312
14501019
10231726
12753069
15066046
9407389
15066211
11703561
18231852
15777772
8810256
15170327
14651959
12761548
18086681
16648635
11193155
9689133
8145724
8670088
11732920
11747119
9516407
9191066
1760507
18654881
11141317
1849547
15794636
15528038
12887652
15298672
12071472
12887649
22575905
22552887
22074584
19779148
6803359
6338589
3539000
7969963
10217056
14659500
12805474
20600173
11562447
15357665
12354581
19705549
18686744
21358972
19308922
19774434
10794847
17909628
15285801
1566067
15723159
15474976
22728094
12562500
8747536
8969462
21954831
17350477
19666212
21155625
18070004
10847561
9556099",Melatonin in Alzheimer's disease.,"Alzheimer's disease (AD), an age-related neurodegenerative disorder with progressive cognition deficit, is characterized by extracellular senile plaques (SP) of aggregated β-amyloid (Aβ) and intracellular neurofibrillary tangles, mainly containing the hyperphosphorylated microtubule-associated protein tau. Multiple factors contribute to the etiology of AD in terms of initiation and progression. Melatonin is an endogenously produced hormone in the brain and decreases during aging and in patients with AD. Data from clinical trials indicate that melatonin supplementation improves sleep, ameliorates sundowning and slows down the progression of cognitive impairment in AD patients. Melatonin efficiently protects neuronal cells from Aβ-mediated toxicity via antioxidant and anti-amyloid properties. It not only inhibits Aβ generation, but also arrests the formation of amyloid fibrils by a structure-dependent interaction with Aβ. Our studies have demonstrated that melatonin efficiently attenuates Alzheimer-like tau hyperphosphorylation. Although the exact mechanism is still not fully understood, a direct regulatory influence of melatonin on the activities of protein kinases and protein phosphatases is proposed. Additionally, melatonin also plays a role in protecting the cholinergic system and in anti-inflammation. The aim of this review is to stimulate interest in melatonin as a potentially useful agent in the prevention and treatment of AD.",[],International journal of molecular sciences,2013-07-17,"[{'lastname': 'Lin', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Key Laboratory of Neurological Disease of National Education Ministry and Hubei Province, Department of Pathology and Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. linli@jsu.edu.cn'}, {'lastname': 'Huang', 'firstname': 'Qiong-Xia', 'initials': 'QX', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'Shu-Sheng', 'initials': 'SS', 'affiliation': None}, {'lastname': 'Chu', 'firstname': 'Jiang', 'initials': 'J', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jian-Zhi', 'initials': 'JZ', 'affiliation': None}, {'lastname': 'Tian', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': None}]",,,,,"10.3390/ijms140714575
10.4076/1757-1626-2-8679
10.1186/1742-2094-1-14",<Element 'PubmedArticle' at 0x7f05dab375e0>
377,23735822,Molecular mechanisms of depression: perspectives on new treatment strategies.,"Depression is a multicausal disorder and has been associated with the risk to develop cancer, dementia, diabetes, epilepsy and stroke. As a metabolic disorder depression has been associated with obesity, diabetes, insulin sensitivity, neuropeptide Y, glucose regulation, poor glycemic control, glucagone-like peptide-1, cholezystokinin, ghrelin, leptin, the endocannabinoid system, insulin-like growth factor and gastrin-releasing peptide. As a cardiovascular disease a close relationship exists between depression and blood pressure, heart rate, norepinephrine, sympathetic tone, vascular resistance, blood viscosity, plasma volume, intima thickness and atherosclerosis. Additionally blood coagulation, fibrinolysis, D-dimers, plasminogen activator inhibitor-1 protein, platelet activation, VEGF, plasma nitric oxide and its synthase are changed in depressed patients. As an endocrinological and stress disorder depression has been connected with the concentration of free T4, TSH, CRH, arginine vasopressin, corticotrophin, corticosteroid release and ACTH. Depression as an inflammatory disorder is mediated by pro-inflammatory cytokines, interleukin-1, interleukin-6, TNF-alpha, soluble interleukin-2 receptors, interferon-alpha, interleukin 8, interleukin-10, hs-CRP, acute phase proteins, haptoglobin, toll like receptor 4, interleukin-1beta, mammalian target of rapamycin pathway, substance P, cyclooxygenase-2, prostaglandin-E2, lipid peroxidation levels and acid sphingomyelinase. Nutritional factors might influence depression risk, i.e. the consumption of folate, omega-3 fatty acids, monounsaturated fatty acids, olive oil, fish, fruits, vegetables, nuts, legumes, vitamin B6 and vitamin B12. The neurodegenerative hypothesis of depression explains decreased hippocampal volumes in depressed patients and changes of neurotrophic support by BDNF, erythropoietin, GDNF, FGF-2, NT3, NGF and growth hormone. In this context, a fast neuroprotective and antidepressant effect has also been observed by ketamine, which acts via the glutamatergic system. Hence, GABA, AMPA, EAAT, NMDA- and metabotropic glutamate receptors (mGluR1 to mGluR8) have gained interest in depression recently. Alternative, causative or also easy available treatment strategies beyond serotonin and noradrenaline reuptake inhibition might be a major topic of future psychiatric care. In this review, an attempt is made to overview concepts of the disease and search for perspectives on antidepressant treatment strategies beyond approved medications.",[],"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology",2013-06-06,"[{'lastname': 'Lang', 'firstname': 'Undine E', 'initials': 'UE', 'affiliation': 'University Hospital of Basel, Department of Psychiatry and Psychotherapy, Basel, Switzerland. undine.lang@upkbs.ch'}, {'lastname': 'Borgwardt', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': None}]",,,,"Copyright © 2013 S. Karger AG, Basel.",10.1159/000350094,<Element 'PubmedArticle' at 0x7f05daaf4d10>
378,"23727128
7925749
10946891
22554955
10683408
9388012
18253054
19464786
17873880
17261778
21304480
10867781
8290098
7854529
11520988
9921852
12433261
9343467
10609670
9056393
21559182
7619525
12614344
7566000
11274343
6338589
22784036
17568013
16365303
16024764
20100545
19096158
11172057
8780008
10098861
1961846
22395804
18094246
8080389
8844880
9191757
8649552
3786638
2560521
8528351
10399774
11524467
21694454
10697060
12525745
10668686
10851363
20094015
14927905
9153165
19160224
22840752
12707448
19470968
22415562
12374497
9521184
8885820
8709781
9566385
16917183
17761551
20689282
12028247
16607095
17476147
12771112
15213206
15800139
11113299
11255426
8030629
10102413
9191758
11255447
23100399
16310963
10794855
11795355
12413378
15668595
15608005
21280086
9751507
22665144
10763906
12925744
16916950
22915112
23238854
17541023
17925335
11730394
17438515
17405972
23048011
19277902
8030628
12413371",Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause.,"Hormonal changes associated with the menopausal transition and postmenopause have the potential to influence processes linked to Alzheimer's disease symptoms and pathogenesis, but effects of menopause on Alzheimer risk can be addressed only indirectly. Nine randomized clinical trials of estrogen-containing hormone therapy in Alzheimer's disease patients were identified by a systematic literature search. Findings suggest that hormone therapy does not improve cognitive symptoms of women with Alzheimer's disease. No clinical trials of hormone therapy address Alzheimer prevention, but one clinical trial provides moderate evidence that continuous, combined estrogen plus progestogen initiated at age 65 years or older increases the risk of dementia. The timing, or critical window, hypothesis suggests that hormone therapy initiated at a younger age in closer temporal proximity to menopause may reduce the risk of Alzheimer's disease. This hypothesis is supported by observational research but is not addressed by clinical trial data. Unrecognized confounding is of concern in interpreting observational results, and research that helps resolve this issue will have important public health implications. Well-designed cohort studies, convergent evidence from appropriate laboratory models, and long-term clinical trials using surrogate biomarkers of brain function and neural pathology could provide relevant answers. Other estrogenic compounds are of theoretical interest with respect to Alzheimer treatment and risk. Effects of selective estrogen receptor modulators such as raloxifene may differ from those of estrogens; potential effects of phytoestrogens are not well studied. This article is part of a Special Issue entitled 'Menopause'.","[""Alzheimer's disease"", 'Estrogen', 'Hormone therapy', 'Menopause', 'Selective estrogen receptor modulator']",The Journal of steroid biochemistry and molecular biology,2013-06-04,"[{'lastname': 'Henderson', 'firstname': 'Victor W', 'initials': 'VW', 'affiliation': 'Department of Health Research & Policy (Epidemiology), Stanford University, Stanford, CA, USA; Department of Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: vhenderson@stanford.edu.'}]",,,,Copyright © 2013 Elsevier Ltd. All rights reserved.,"10.1016/j.jsbmb.2013.05.010
10.4061/2011/974361",<Element 'PubmedArticle' at 0x7f05dab020e0>
379,23701539,Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia.,"Neurodegenerative disorders are associated with different neurochemical and morphological alterations in the brain leading to cognitive and behavioural impairments. New therapeutic strategies comprise multifunctional drugs. The aim of the presented studies is to evaluate in vivo the novel compounds - ASS188 and ASS234 - which combine the benzylpiperidine moiety of the acetylcholinesteras (AChE) inhibitor donepezil and the indolyl propargylamino moiety of the monoaminooxidase (MAO) inhibitor, N-[(5-benzyloxy-1- methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine, with respect to their influence on cerebral amine neurotransmitters systems and neuroprotective activity. The presumed therapeutic potential of these compounds has been evaluated following their administration to rats with experimental vascular dementia. A rat model of the permanent bilateral occlusion of the common carotid arteries (BCCAO) and the holeboard memory test were employed for this purpose. Wistar rats were used, either intact or 1 day after BCCAO. ASS188 (1 mg/kg) and ASS234 (5 mg/kg) were given s.c. for 5 consecutive days. Working and reference memory in rats was evaluated by holeboard tests before- and 7 and 12 days after BCCAO. The activities of MAOs, AChE and histamine N-methyltransferase (HMT), as well as cerebral amines concentrations were assayed. A significant inhibition of brain MAO A (>95%) and weaker MAO B (ca 60%) and HMT (<30%) and reduced AChE activities were recorded with a pronounced (2 - 10 fold) increase in the cerebral concentrations of serotonin, dopamine, and noradrenaline and smaller rises (up to 30%) of histamine. The BCCAO rats treated with ASS188 or ASS234 tended to perform holeboard tests better than the BCCAO untreated group, indicating a beneficial effect of the administered therapeutics.",[],Current pharmaceutical design,2013-05-25,"[{'lastname': 'Stasiak', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Mussur', 'firstname': 'Mirosław', 'initials': 'M', 'affiliation': None}, {'lastname': 'Unzeta', 'firstname': 'Mercedes', 'initials': 'M', 'affiliation': None}, {'lastname': 'Samadi', 'firstname': 'Abdelouahid', 'initials': 'A', 'affiliation': None}, {'lastname': 'Marco-Contelles', 'firstname': 'José L', 'initials': 'JL', 'affiliation': None}, {'lastname': 'Fogel', 'firstname': 'W Agnieszka', 'initials': 'WA', 'affiliation': 'Department of Hormone Biochemistry, Medical University of Lodz, Zeligowskiego 7/9 Str., 90-752 Lodz, Poland. anna.stasiak@umed.lodz.pl.'}]",,,,,10.2174/13816128113199990026,<Element 'PubmedArticle' at 0x7f05daab4270>
380,"23644927
16899370
12837845
18667359
16627931
22654727
11795862
19459046
16966548
19672057
21392524
16988486
17609417
22957413
21519521
22533436
12432919
16787414
18541797
16857570
18945929
15365131
7984357
12873852
22001983
12507914
12634421
21374699
21252113
19132099
655387
21044774
20030463",Association between the characteristics of metabolic syndrome and Alzheimer's disease.,"Various epidemiological studies have shown that type 2 diabetes and metabolic syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to assess the impact of metabolic syndrome characteristics on the progression of AD. Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY, hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD), and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were sacrificed and samples of the blood, liver, and brain were collected for further biological analysis. During the 15-week period of induction, the STZ and DM groups (animals injected with low-dose STZ) had significantly higher fasting glucose levels; the HFD group had elevated insulin levels, but normal blood glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic levels of triglycerides and cholesterol. Additionally, correlations between HFD and elevated brain amyloid-beta 42 (Aβ-42), hyperglycemia and down-regulation of brain insulin receptor, and serum Aβ-42 and hepatic triglyceride concentrations (r(2) = 0.41, p < 0.05) were observed. Serum C-reactive protein and malondialdehyde did not appear to have a significant influence on the association with biomarkers of AD. Thus, our study demonstrated that rats with characteristics of metabolic syndrome had a large number of biomarkers predicting AD; however, no relationship between traditional inflammatory and oxidative markers and AD was found. Further studies are necessary to prove that these findings in rats are relevant to AD processes in humans.",[],Metabolic brain disease,2013-05-07,"[{'lastname': 'Yang', 'firstname': 'Hui-Ting', 'initials': 'HT', 'affiliation': 'Department of Nutrition, China Medical University, No.91 Hsueh-Shih Road, Taichung, Taiwan, 40402, Republic of China.'}, {'lastname': 'Sheen', 'firstname': 'Yi-Jing', 'initials': 'YJ', 'affiliation': None}, {'lastname': 'Kao', 'firstname': 'Chuen-Der', 'initials': 'CD', 'affiliation': None}, {'lastname': 'Chang', 'firstname': 'Chin-An', 'initials': 'CA', 'affiliation': None}, {'lastname': 'Hu', 'firstname': 'Ya-Chun', 'initials': 'YC', 'affiliation': None}, {'lastname': 'Lin', 'firstname': 'Jiann-Liang', 'initials': 'JL', 'affiliation': None}]",,,,,10.1007/s11011-013-9406-2,<Element 'PubmedArticle' at 0x7f05daac03b0>
381,23621305,"Antihypertensives, angiotensin, glucose and Alzheimer's disease.","Evidence supporting a link between vascular disorders such as hypertension and Alzheimer's disease (AD) is increasing. Population studies have suggested an association between hypertension and an increased risk of developing AD. A potential role for antihypertensive medications in the management of cognitive disorders has also been suggested, although findings are mixed. However, it is of interest that evidence is now leaning towards the possibility that some of these antihypertensive medications may improve cognition independent of their blood pressure lowering effects. Many of these drugs cross the blood-brain barrier and may influence neurotransmitters involved in cognition. Increasing knowledge of the actions of antihypertensives in the brain and the vascular system could lead to better treatment and/or prevention options for AD.",[],Expert review of neurotherapeutics,2013-04-30,"[{'lastname': 'Nelson', 'firstname': 'Lucy', 'initials': 'L', 'affiliation': 'Brighton and Sussex Medical School, Brighton, East Sussex, UK.'}, {'lastname': 'Tabet', 'firstname': 'Naji', 'initials': 'N', 'affiliation': None}, {'lastname': 'Richardson', 'firstname': 'Cassie', 'initials': 'C', 'affiliation': None}, {'lastname': 'Gard', 'firstname': 'Paul', 'initials': 'P', 'affiliation': None}]",,,,,10.1586/ern.13.32,<Element 'PubmedArticle' at 0x7f05daad2e50>
382,23465294,Increased systemic oxidatively generated DNA and RNA damage in schizophrenia.,"Schizophrenia is associated with a substantially increased somatic morbidity and mortality, which may partly be caused by accelerated cellular aging. Oxidative stress is an established mediator of aging and a suggested aetiological mechanism in both schizophrenia and age-related medical disorders such as cardiovascular disease, type 2 diabetes and dementia. We determined the urinary excretion of markers of systemic Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) oxidation, 8-oxo-7,8-dihydro-2'-deoxyguanosine and 8-oxo-7,8-dihydroguanosine, respectively, in 40 schizophrenia patients and 40 age- and sex-matched controls, using ultra-performance liquid chromatography with tandem mass spectrometry. Measures of psychopathology, perceived stress and cortisol secretion were collected. Patients were re-examined after four months. We found a 20% increase in the median excretion of both markers in schizophrenia patients vs. healthy controls (P=0.003 and <0.001, respectively). This difference persisted after the adjustment for multiple demographical, lifestyle and metabolic factors. In patients, the marker excretion was not influenced by medication load, and was not driven by symptom severity, perceived stress or cortisol secretion, neither at baseline nor in relation to changes at follow-up. We conclude that schizophrenia is associated with increased systemic nucleic acid damage from oxidation, which could constitute a molecular link between schizophrenia and its associated signs of accelerated aging.","['8-oxoGuo', '8-oxodG', 'Cortisol', 'Oxidative stress', 'Perceived stress', 'Schizophrenia']",Psychiatry research,2013-03-08,"[{'lastname': 'Jorgensen', 'firstname': 'Anders', 'initials': 'A', 'affiliation': 'Psychiatric Centre Copenhagen, University Hospital of Copenhagen, Denmark; Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Denmark. Electronic address: anders.01.joergensen@regionh.dk.'}, {'lastname': 'Broedbaek', 'firstname': 'Kasper', 'initials': 'K', 'affiliation': None}, {'lastname': 'Fink-Jensen', 'firstname': 'Anders', 'initials': 'A', 'affiliation': None}, {'lastname': 'Knorr', 'firstname': 'Ulla', 'initials': 'U', 'affiliation': None}, {'lastname': 'Greisen Soendergaard', 'firstname': 'Mia', 'initials': 'M', 'affiliation': None}, {'lastname': 'Henriksen', 'firstname': 'Trine', 'initials': 'T', 'affiliation': None}, {'lastname': 'Weimann', 'firstname': 'Allan', 'initials': 'A', 'affiliation': None}, {'lastname': 'Jepsen', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Lykkesfeldt', 'firstname': 'Jens', 'initials': 'J', 'affiliation': None}, {'lastname': 'Poulsen', 'firstname': 'Henrik Enghusen', 'initials': 'HE', 'affiliation': None}, {'lastname': 'Balslev Jorgensen', 'firstname': 'Martin', 'initials': 'M', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.psychres.2013.01.033,<Element 'PubmedArticle' at 0x7f05daada630>
383,23396349,Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study.,"Plasma progranulin (PGRN) levels constitute a potentially invaluable biomarker for neurodegenerative diseases including frontotemporal lobar degeneration (FTLD) and, perhaps, Alzheimer's disease (AD). We assessed plasma PGRN levels in 107 AD patients, 36 FTLD patients, and 107 controls. We found that, in female AD patients, there is a positive correlation between PGRN levels and age. Although no significant differences were found between patients and controls, we observed higher levels in females compared to males; in AD patients, a positive correlation between PGRN levels and age was observed in females. In conclusion, our data suggest that PGRN may not be a good biomarker for AD; moreover, gender may influence the plasma PGRN levels of AD patients.",[],Journal of Alzheimer's disease : JAD,2013-02-12,"[{'lastname': 'Piscopo', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.'}, {'lastname': 'Rivabene', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': None}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Crestini', 'firstname': 'Alessio', 'initials': 'A', 'affiliation': None}, {'lastname': 'Talarico', 'firstname': 'Giuseppina', 'initials': 'G', 'affiliation': None}, {'lastname': 'Vanacore', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}, {'lastname': 'Bruno', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Confaloni', 'firstname': 'Annamaria', 'initials': 'A', 'affiliation': None}]",,,,,10.3233/JAD-121606,<Element 'PubmedArticle' at 0x7f05daa66c20>
384,23384944,Cognitive impairment in heart failure: results from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) randomized trial.,"Up to 50% of patients with heart failure (HF) may suffer from severe cognitive impairment (SCI), but longitudinal studies are sparse, and effects of changes in HF severity on cognitive function are unknown. Therefore, we assessed the prevalence of SCI in HF patients, its relationship with HF severity, its effects on morbidity and mortality, and the relationship between changes in HF severity and cognitive function.
We included 611 patients from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) and assessed cognitive function [Hodkinson Abbreviated Mental Test (AMT)] in relation to severity of HF (NYHA class, NT-proBNP) at baseline and 18 months (n = 382) and effects on hospitalization-free survival and mortality. SCI (i.e. AMT score ≤ 7) was present in 9.2% of patients at baseline, but only 20% of them had a diagnosis of dementia. Prevalence of SCI remained stable during follow-up. SCI was present at baseline more often in NYHA IV patients compared with NYHA II [odds ratio 2.94; 95% confidence interval (CI) 1.15-7.51, P = 0.025], but it was not related to NT-proBNP levels. SCI was related to higher mortality (hazard ratio 1.53, 95% CI 1.02-2.30, P = 0.04), but not hospitalization-free survival. Changes in HF severity were not significantly related to changes in cognitive function.
SCI is a frequent, but often unrecognized finding in HF patients, but the influence of HF severity and its changes on cognitive function were less than hypothesized. Trial registration ISRCTN43596477.","['Cognitive impairment', 'Heart failure', 'Left ventricular ejection fraction', 'NYHA class', 'Natriuretic peptides']",European journal of heart failure,2013-02-07,"[{'lastname': 'Huijts', 'firstname': 'Marjolein', 'initials': 'M', 'affiliation': 'Department of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'lastname': 'van Oostenbrugge', 'firstname': 'Robert J', 'initials': 'RJ', 'affiliation': None}, {'lastname': 'Duits', 'firstname': 'Annelien', 'initials': 'A', 'affiliation': None}, {'lastname': 'Burkard', 'firstname': 'Thilo', 'initials': 'T', 'affiliation': None}, {'lastname': 'Muzzarelli', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': None}, {'lastname': 'Maeder', 'firstname': 'Micha T', 'initials': 'MT', 'affiliation': None}, {'lastname': 'Schindler', 'firstname': 'Ruth', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pfisterer', 'firstname': 'Matthias E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Brunner-La Rocca', 'firstname': 'Hans-Peter', 'initials': 'HP', 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,"SCI is a frequent, but often unrecognized finding in HF patients, but the influence of HF severity and its changes on cognitive function were less than hypothesized. Trial registration ISRCTN43596477.",,,10.1093/eurjhf/hft020,<Element 'PubmedArticle' at 0x7f05daa72220>
385,"23276673
9547246
21075087
11978836
17149751
22654716
9786341
453543
7204652
2203093
14988386
21769724
17419049
22407616
21320576
21854273
17720235
22281237
7852993
18353559
22676718
11860494
10221449
10725383
12928058
11687663
11163887
15518235
11296734
17765713
1380440
18493023
12384689
14681930
16919611
10385931
16099088
16785596
8735351
15120494
8878481
10635036
20030415
15522833
12671646
16411893
20356829
12543217
20186709
1827923
9065491
21056867
20030625
9813325
10501474
18807247
16239296
15601941
22412021
1375039
1193012
16897719
10213189
10479701
22120143
8627351
19104150
11435417
18621582
21945235
21308466
21826442
22138012
16579833
9390517
10036289
20360602
8891944
9417837
20670676
12209854
21508625
22854676
10794855
16455144
18782600
2329377
19828787
2313342
11459850
11976383
11745614
20460150
21890593
16472198
9344402
10869836
17026970
9579954
12904263
22845879
14694190
22701110
18541362
11520916
12676795
22681685
1170518
2054188
18596169
17765714
19665523
15669092
17805308
16055761
7886457
18191832
12147321
9202291
17948030
10323674
11295570
12650715
17765738
15575490
11296093
11452016
7649227
21068160
8901619
9704996
19828812
20674095
15175384
9048584
21367572
16807663
16362629
9921852
21045864
17913902
19193892
11729324
12787574
19783454
7644540
16376315
16062169
573635
17942328
18923034
12654337
17850456
16503703
11057516
12404074
9058401
16141956
6163211
19632051
8377221
11162928
10598213
18195084
11416193
15548669
22787630
16122717
22865367
21972199
9425220
16127691
11116225
19927149
18055067
20506473
10066260
19909788
10713570
20683841
19198615
21358740
16198490
6260298
11879813
2090365
7609632
22075082
8617910
20843342
15486301
9407016
8663990
11090653
9492041
1742020
16324798
12699330
573332
22546227
22787590
16939974
16707719
6714163
2501818
22787613
14603320
9365212
15219759
15527861
16344155
19293383
12231258
9307136
11922662
17970745
15667930
16981857
18700946
14684866
20848610
8603699
11413547
1557190
15837123
12121312
15723615
15723163
11444439
7720680
22367796
21123560
17512983
10472516
7479947
11412902
11923430
10817843
22133892
18078984
12468763
22558255
17389368
16330218
9096132
18708092
11169630
15930396
20186707
14704852
8461137
18497100
10328986
11718882
1308182
7842058
16242668
12359832
53165
17537977
12198740
15464121
17650531
18342348
19577647
7353517
9388019
7349961
16025106
2269895
1613547
19804754
10995833
15183502
10725923
12011108
9145800
19451278
19136973
20186705
7828562
16251447
12971897
16856873
11435923
8997515
16179807
15485500
17379385
19498435",Brain-derived neurotrophic factor-estrogen interactions in the hippocampal mossy fiber pathway: implications for normal brain function and disease.,"The neurotrophin brain-derived neurotrophic factor (BDNF) and the steroid hormone estrogen exhibit potent effects on hippocampal neurons during development and in adulthood. BDNF and estrogen have also been implicated in the etiology of diverse types of neurological disorders or psychiatric illnesses, or have been discussed as potentially important in treatment. Although both are typically studied independently, it has been suggested that BDNF mediates several of the effects of estrogen in the hippocampus, and that these interactions play a role in the normal brain as well as disease. Here we focus on the mossy fiber (MF) pathway of the hippocampus, a critical pathway in normal hippocampal function, and a prime example of a location where numerous studies support an interaction between BDNF and estrogen in the rodent brain. We first review the temporal and spatially regulated expression of BDNF and estrogen in the MFs, as well as their receptors. Then we consider the results of studies that suggest that 17β-estradiol alters hippocampal function by its influence on BDNF expression in the MF pathway. We also address the hypothesis that estrogen influences the hippocampus by mechanisms related not only to the mature form of BDNF, acting at trkB receptors, but also by regulating the precursor, proBDNF, acting at p75NTR. We suggest that the interactions between BDNF and 17β-estradiol in the MFs are potentially important in the normal function of the hippocampus, and have implications for sex differences in functions that depend on the MFs and in diseases where MF plasticity has been suggested to play an important role, Alzheimer's disease, epilepsy and addiction.",[],Neuroscience,2013-01-02,"[{'lastname': 'Harte-Hargrove', 'firstname': 'L C', 'initials': 'LC', 'affiliation': 'Nathan Kline Institute for Psychiatric Research, Center of Dementia Research, 140 Old Orangeburg Road, Building 35, Orangeburg, NY 10962, USA.'}, {'lastname': 'Maclusky', 'firstname': 'N J', 'initials': 'NJ', 'affiliation': None}, {'lastname': 'Scharfman', 'firstname': 'H E', 'initials': 'HE', 'affiliation': None}]",,,,Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2012.12.029,<Element 'PubmedArticle' at 0x7f05daa7e220>
386,23228129,The calcium-sensing receptor as a regulator of cellular fate in normal and pathological conditions.,"The calcium-sensing receptor (CaSR) belongs to the evolutionarily conserved family of plasma membrane G protein-coupled receptors (GPCRs). Early studies identified an essential role for the CaSR in systemic calcium homeostasis through its ability to sense small changes in circulating calcium concentration and to couple this information to intracellular signaling pathways that influence parathyroid hormone secretion. However, the presence of CaSR protein in tissues is not directly involved in regulating mineral ion homeostasis points to a role for the CaSR in other cellular functions including the control of cellular proliferation, differentiation and apoptosis. This position at the crossroads of cellular fate designates the CaSR as an interesting study subject is likely to be involved in a variety of previously unconsidered human pathologies, including cancer, atherosclerosis and Alzheimer's disease. Here, we will review the recent discoveries regarding the relevance of CaSR signaling in development and disease. Furthermore, we will discuss the rational for developing and using CaSR-based therapeutics.",[],Current molecular medicine,2012-12-12,"[{'lastname': 'Diez-Fraile', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Basic Medical Sciences, Ghent University, Faculty of Medicine and Health Sciences, Belgium.'}, {'lastname': 'Lammens', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Benoit', 'firstname': 'Y', 'initials': 'Y', 'affiliation': None}, {'lastname': ""D'Herde"", 'firstname': 'K G M A', 'initials': 'KG', 'affiliation': None}]",,,,,10.2174/156652413804810763,<Element 'PubmedArticle' at 0x7f05da9f9f40>
387,23182497,Positive correlation of paraoxonase 1 (PON1) activity with serum insulin level and HOMA-IR in dementia. A possible advantageous role of PON1 in dementia development.,"Paraoxonase 1 (PON1) activity and metabolic syndrome traits were evaluated in 169 demented patients (81 recognized as AD, 32 as VaD, 56 as MD) and in 64 control individuals. Paraoxonase activity was determined spectrophotometrically using phenyloacetate as substrate. Metabolic syndrome was recognized according to AHA/NHLBI criteria. In the whole group with dementia significant positive correlation between PON1 activity/HDL cholesterol ratio (i.e. HDL corrected PON1 activity) and insulin level as well as HOMA IR index, was observed. The multivariate analysis showed that the PON1/HDL-C ratio was also significantly positively associated with the presence of metabolic syndrome (with insulin resistance as a major underlying trait) both in dementia and in control group. High insulin level and HOMA-IR are considered to be the traits of insulin resistance. It has however to be taken into account that they both could also depend on insulin production and release which, as was recently stated in cell experiments, are enhanced by PON1. The observed positive correlation suggests an advantageous role of the enzyme in metabolic syndrome influence on dementia development.",[],Journal of the neurological sciences,2012-11-28,"[{'lastname': 'Bednarska-Makaruk', 'firstname': 'Małgorzata', 'initials': 'M', 'affiliation': 'Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland. makaruk@ipin.edu.pl'}, {'lastname': 'Graban', 'firstname': 'Ałła', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lipczyńska-Łojkowska', 'firstname': 'Wanda', 'initials': 'W', 'affiliation': None}, {'lastname': 'Bochyńska', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Rodo', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Krzywkowski', 'firstname': 'Tomasz', 'initials': 'T', 'affiliation': None}, {'lastname': 'Ryglewicz', 'firstname': 'Danuta', 'initials': 'D', 'affiliation': None}, {'lastname': 'Wehr', 'firstname': 'Hanna', 'initials': 'H', 'affiliation': None}]",,,,Copyright © 2012 Elsevier B.V. All rights reserved.,10.1016/j.jns.2012.11.003,<Element 'PubmedArticle' at 0x7f05daa06450>
388,"23089633
14745075
8276977
14622134
15219659
11113976
20844010
18838102
15383512
15184600
11756600
11335065
8572669
10655508
10718932
974609
20472326
14871891
18560131
10523014
19346482
16503402
16368754
11325319
14523358
21208994
18401021
21985789
7724603
17047326
17928318
7566000
11305852
14745052
12391612
17182789
10634455
11560301
17502554
15582279
10200730
14624021
11449190
12883005
17468195
19470201
19428144
19363264
11689174
11099831","Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.","Testosterone and gonadotropins have been associated with cognitive decline in men and the modulation of β amyloid (Aβ) metabolism. The relatively few studies that have investigated whether changes in one or a combination of these hormones influence Aβ levels have focused primarily on plasma Aβ(1-40) and not on the more pathogenic Aβ(1-42). Currently, no study has investigated whether these hormones are associated with an increase in brain amyloid deposition, ante mortem. Through the highly characterised Australian imaging, biomarkers and lifestyle study, we have determined the impact of these hormones on plasma Aβ levels and brain amyloid burden (Pittsburgh compound B (PiB) retention). Spearman's rank correlation and linear regression analysis was carried out across the cohort and within subclassifications. Luteinizing hormone (LH) was the only variable shown, in the total cohort, to have a significant impact on plasma Aβ(1-40) and Aβ(1-42) levels (beta=0.163, P<0.001; beta=0.446, P<0.001). This held in subjective memory complainers (SMC) (Aβ(1-40); beta=0.208, P=0.017; Aβ(1-42); beta=0.215, P=0.017) but was absent in mild cognitive impairment (MCI) and Alzheimer's disease (AD) groups. In SMC, increased frequency of the APOE-ɛ4 allele (beta=0.536, P<0.001) and increasing serum LH levels (beta=0.421, P=0.004) had a significant impact on PiB retention. Whereas in MCI, PiB retention was associated with increased APOE-ɛ4 allele copy number (beta=0.674, P<0.001) and decreasing calculated free testosterone (beta=-0.303, P=0.043). These findings suggest a potential progressive involvement of LH and testosterone in the early preclinical stages of AD. Furthermore, these hormones should be considered while attempting to predict AD at these earliest stages of the disease.",[],Molecular psychiatry,2012-10-24,"[{'lastname': 'Verdile', 'firstname': 'G', 'initials': 'G', 'affiliation': ""1] Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia [2] Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia.""}, {'lastname': 'Laws', 'firstname': 'S M', 'initials': 'SM', 'affiliation': ""1] Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia [2] Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia [3] Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com.""}, {'lastname': 'Henley', 'firstname': 'D', 'initials': 'D', 'affiliation': '1] Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia [2] School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia.'}, {'lastname': 'Ames', 'firstname': 'D', 'initials': 'D', 'affiliation': ""1] Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, St Vincent's Aged Psychiatry Service, St George's Hospital, Melbourne, Victoria, Australia [2] National Ageing Research Institute, Parkville, Victoria, Australia.""}, {'lastname': 'Bush', 'firstname': 'A I', 'initials': 'AI', 'affiliation': '1] Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com [2] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [3] Centre for Neuroscience, The University of Melbourne, Parkville, Victoria, Australia.'}, {'lastname': 'Ellis', 'firstname': 'K A', 'initials': 'KA', 'affiliation': ""1] Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, St Vincent's Aged Psychiatry Service, St George's Hospital, Melbourne, Victoria, Australia [2] National Ageing Research Institute, Parkville, Victoria, Australia [3] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia.""}, {'lastname': 'Faux', 'firstname': 'N G', 'initials': 'NG', 'affiliation': '1] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [2] Centre for Neuroscience, The University of Melbourne, Parkville, Victoria, Australia.'}, {'lastname': 'Gupta', 'firstname': 'V B', 'initials': 'VB', 'affiliation': ""1] Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia [2] Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia.""}, {'lastname': 'Li', 'firstname': 'Q-X', 'initials': 'QX', 'affiliation': '1] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [2] Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.'}, {'lastname': 'Masters', 'firstname': 'C L', 'initials': 'CL', 'affiliation': '1] Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com [2] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [3] Centre for Neuroscience, The University of Melbourne, Parkville, Victoria, Australia.'}, {'lastname': 'Pike', 'firstname': 'K E', 'initials': 'KE', 'affiliation': '1] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [2] Centre for Neuroscience, The University of Melbourne, Parkville, Victoria, Australia [3] Department of Nuclear Medicine & Centre for PET, Austin Health, Heidelberg, Victoria, Australia [4] School of Psychological Science, La Trobe University, Bundoora, Victoria Australia.'}, {'lastname': 'Rowe', 'firstname': 'C C', 'initials': 'CC', 'affiliation': 'Department of Nuclear Medicine & Centre for PET, Austin Health, Heidelberg, Victoria, Australia.'}, {'lastname': 'Szoeke', 'firstname': 'C', 'initials': 'C', 'affiliation': '1] National Ageing Research Institute, Parkville, Victoria, Australia [2] CSIRO, Parkville, Victoria, Australia.'}, {'lastname': 'Taddei', 'firstname': 'K', 'initials': 'K', 'affiliation': ""1] Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia [2] Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia [3] Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com.""}, {'lastname': 'Villemagne', 'firstname': 'V L', 'initials': 'VL', 'affiliation': '1] Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia [2] Department of Nuclear Medicine & Centre for PET, Austin Health, Heidelberg, Victoria, Australia.'}, {'lastname': 'Martins', 'firstname': 'R N', 'initials': 'RN', 'affiliation': ""1] Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia [2] Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia [3] Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com.""}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.1038/mp.2012.147,<Element 'PubmedArticle' at 0x7f05daa12400>
389,22948764,Positive effect of daylight exposure on nocturnal urinary melatonin excretion in the elderly: a cross-sectional analysis of the HEIJO-KYO study.,"Melatonin is involved in a variety of diseases, including cancer, insomnia, depression, dementia, hypertension, and diabetes; its secretion is influenced by environmental light. Although daylight exposure increases nocturnal melatonin secretion in a controlled laboratory setting, whether it increases nocturnal melatonin secretion in an uncontrolled daily life setting remains unclear.
We aimed to determine the association between daylight exposure in an uncontrolled daily life setting and urinary 6-sulfatoxymelatonin excretion.
A cross-sectional study was conducted in 192 elderly individuals (mean age, 69.9 yr).
We measured ambulatory daylight exposure using a wrist light meter in two 48-h sessions; furthermore, we measured overnight urinary 6-sulfatoxymelatonin excretion, an index of melatonin secretion, on the second night of each session.
The median duration of daylight exposure of at least 1000 lux was 72 min (interquartile range, 37-124). Univariate linear regression analysis showed marginal to significant associations between log-transformed urinary 6-sulfatoxymelatonin excretion and age, current smoking status, benzodiazepine use, day length, log-transformed duration of daylight exposure of at least 1000 lux, and daytime physical activity. In a multivariate model, log-transformed duration of daylight exposure of at least 1000 lux was significantly associated with log-transformed urinary 6-sulfatoxymelatonin excretion (regression coefficient, 0.101; 95% confidence interval, 0.003-0.199; P = 0.043). Furthermore, an increase in the duration of daylight exposure of at least 1000 lux from 37 to 124 min (25th to 75th percentiles) was associated with a 13.0% increase in urinary 6-sulfatoxymelatonin excretion (6.8 to 7.7 μg).
Daylight exposure in an uncontrolled daily life setting is positively associated with urinary 6-sulfatoxymelatonin excretion in the elderly.",[],The Journal of clinical endocrinology and metabolism,2012-09-06,"[{'lastname': 'Obayashi', 'firstname': 'Kenji', 'initials': 'K', 'affiliation': 'Department of Indoor Environmental Medicine, Nara Medical University School of Medicine, 840 Shijocho, Kashiharashi, Nara 634-8521, Japan. obayashi@naramed-u.ac.jp'}, {'lastname': 'Saeki', 'firstname': 'Keigo', 'initials': 'K', 'affiliation': None}, {'lastname': 'Iwamoto', 'firstname': 'Junko', 'initials': 'J', 'affiliation': None}, {'lastname': 'Okamoto', 'firstname': 'Nozomi', 'initials': 'N', 'affiliation': None}, {'lastname': 'Tomioka', 'firstname': 'Kimiko', 'initials': 'K', 'affiliation': None}, {'lastname': 'Nezu', 'firstname': 'Satoko', 'initials': 'S', 'affiliation': None}, {'lastname': 'Ikada', 'firstname': 'Yoshito', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Kurumatani', 'firstname': 'Norio', 'initials': 'N', 'affiliation': None}]",,,"The median duration of daylight exposure of at least 1000 lux was 72 min (interquartile range, 37-124). Univariate linear regression analysis showed marginal to significant associations between log-transformed urinary 6-sulfatoxymelatonin excretion and age, current smoking status, benzodiazepine use, day length, log-transformed duration of daylight exposure of at least 1000 lux, and daytime physical activity. In a multivariate model, log-transformed duration of daylight exposure of at least 1000 lux was significantly associated with log-transformed urinary 6-sulfatoxymelatonin excretion (regression coefficient, 0.101; 95% confidence interval, 0.003-0.199; P = 0.043). Furthermore, an increase in the duration of daylight exposure of at least 1000 lux from 37 to 124 min (25th to 75th percentiles) was associated with a 13.0% increase in urinary 6-sulfatoxymelatonin excretion (6.8 to 7.7 μg).",,10.1210/jc.2012-1873,<Element 'PubmedArticle' at 0x7f05da9af540>
390,"22891244
14986688
17138893
10531053
11937492
11301036
11268214
10652477
19094054
17368826
9425102
19853579
16473372
12906797
16799564
17629417
10882063
10882062
8643690
12548545
12094208
12848929
15925590
12025816
20160459
18172499
20923768
10206644
10993067
12297508
12198112
17071095
16626651
19494151
17828287
16570100
16402900
20347808
14675734
19321773
12493564
11742222
17222950
8543157
16837553
12011466
22122663
20691161
20224929
21045140
20530696
21768095
11483961
20333303
15190179
22537429
15220476
10653284
19699201
21541768
15922461
15078543
15728830","The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats.","Aberrant Notch signaling has recently emerged as a possible mechanism for the altered neurogenesis, cognitive impairment, and learning and memory deficits associated with Alzheimer disease (AD). Recently, targeting the endocannabinoid system in models of AD has emerged as a potential approach to slow the progression of the disease process. Although studies have identified neuroprotective roles for endocannabinoids, there is a paucity of information on modulation of the pro-survival Notch pathway by endocannabinoids. In this study the influence of the endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol, on the Notch-1 pathway and on its endogenous regulators were investigated in an in vitro model of AD. We report that AEA up-regulates Notch-1 signaling in cultured neurons. We also provide evidence that although Aβ(1-42) increases expression of the endogenous inhibitor of Notch-1, numb (Nb), this can be prevented by AEA and 2-arachidonoylglycerol. Interestingly, AEA up-regulated Nct expression, a component of γ-secretase, and this was found to play a crucial role in the enhanced Notch-1 signaling mediated by AEA. The stimulatory effects of AEA on Notch-1 signaling persisted in the presence of Aβ(1-42). AEA was found to induce a preferential processing of Notch-1 over amyloid precursor protein to generate Aβ(1-40). Aging, a natural process of neurodegeneration, was associated with a reduction in Notch-1 signaling in rat cortex and hippocampus, and this was restored with chronic treatment with URB 597. In summary, AEA has the proclivity to enhance Notch-1 signaling in an in vitro model of AD, which may have relevance for restoring neurogenesis and cognition in AD.",[],The Journal of biological chemistry,2012-08-15,"[{'lastname': 'Tanveer', 'firstname': 'Riffat', 'initials': 'R', 'affiliation': 'Department of Physiology, School of Medicine and Trinity College Institute of Neuroscience, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.'}, {'lastname': 'Gowran', 'firstname': 'Aoife', 'initials': 'A', 'affiliation': None}, {'lastname': 'Noonan', 'firstname': 'Janis', 'initials': 'J', 'affiliation': None}, {'lastname': 'Keating', 'firstname': 'Sinead E', 'initials': 'SE', 'affiliation': None}, {'lastname': 'Bowie', 'firstname': 'Andrew G', 'initials': 'AG', 'affiliation': None}, {'lastname': 'Campbell', 'firstname': 'Veronica A', 'initials': 'VA', 'affiliation': None}]",,,,,10.1074/jbc.M112.350678,<Element 'PubmedArticle' at 0x7f05da9b86d0>
391,"22797721
17878930
18768919
9855500
19625741
20061636
17559965
18723524
11846609
17334365
19446372
17974952
19683260
21944779
18413467
21891865
2423876
21558644
16424787
11708987
21944778
21157029
21739720
21709374
21258152
14627790",Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration.,"Mutations in progranulin gene (GRN) are the most common cause of autosomal dominant familial frontotemporal lobar degeneration (FTLD). In addition, GRN variability influences the risk to develop the disease in non-carriers (sporadic FTLD). We evaluated progranulin gene (GRN) promoter methylation levels in peripheral blood mononuclear cells isolated from 38 patients with sporadic FTLD compared with 38 controls, and correlate them with GRN mRNA expression rate. The percentage of methylation of the GRN promoter was increased in patients with FTLD compared with controls (61.5 vs. 46.3 %, P < 0.001). A trend towards decreased GRN relative expression was observed in patients compared with controls (threefold decrease over controls, P > 0.05), together with a negative correlation between the degree of GRN promoter methylation and mRNA GRN levels (ρ = -0.1, P > 0.05). GRN promoter methylation was not correlated with age. In conclusion, the degree of methylation of the GRN promoter is increased in patients with FTLD as compared with controls, likely leading to a decreased expression of GRN.",[],Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,2012-07-17,"[{'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico, Milan, Italy. daniela.galimberti@unimi.it'}, {'lastname': ""D'Addario"", 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': ""Dell'osso"", 'firstname': 'Bernardo', 'initials': 'B', 'affiliation': None}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Marcone', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Cerami', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cappa', 'firstname': 'Stefano F', 'initials': 'SF', 'affiliation': None}, {'lastname': 'Palazzo', 'firstname': 'M Carlotta', 'initials': 'MC', 'affiliation': None}, {'lastname': 'Arosio', 'firstname': 'Beatrice', 'initials': 'B', 'affiliation': None}, {'lastname': 'Mari', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Maccarrone', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bresolin', 'firstname': 'Nereo', 'initials': 'N', 'affiliation': None}, {'lastname': 'Altamura', 'firstname': 'A Carlo', 'initials': 'AC', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}]",,,,,10.1007/s10072-012-1151-5,<Element 'PubmedArticle' at 0x7f05da9e0b80>
392,"22796872
16360788
19703213
20182021
12793519
15590663
19656855
16177050
21305046
18562609
17442823
21324907
15788759
16765602
21383850
15339646
21103342
22045486
21524430
12895417
19476738
17030655
10790869
16942758
20677372
18358666
8592548
7916431
14688411
17123871
11425920
20847408
7777133
16882019
7088155
17005052
15748844
18486110
17112576
19442751
20074654
18045930
20934413
20846376",Broad-based nutritional supplementation in 3xTg mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's disease intervention.,"Nutrition has been highlighted as a potential factor in Alzheimer's disease (AD) risk and decline and has been investigated as a therapeutic target. Broad-based combination diet therapies have the potential to simultaneously effect numerous protective and corrective processes, both directly (e.g., neuroprotection) and indirectly (e.g., improved vascular health). Here we administered either normal mouse chow with a broad-based nutritional supplement or mouse chow alone to aged male and female 3xTg mice and wildtype (WT) controls. After approximately 4 months of feeding, mice were given a battery of cognitive tasks and then injected with a radiolabeled glucose analog. Brains were assessed for differences in regional glucose uptake and mitochondrial cytochrome oxidase activity, AD pathology, and inflammatory markers. Supplementation induced behavioral changes in the 3xTg, but not WT, mice, and the mode of these changes was influenced by sex. Subsequent analyses indicated that differential response to supplementation by male and female 3xTg mice highlighted brain regional strategies for the preservation of function. Several regions involved have been shown to mediate responses to steroid hormones, indicating a mechanism for sex-based vulnerability. Thus, these findings may have broad implications for the human response to future therapeutics.",[],Journal of Alzheimer's disease : JAD,2012-07-17,"[{'lastname': 'Wolf', 'firstname': 'Andrew B', 'initials': 'AB', 'affiliation': ""Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.""}, {'lastname': 'Braden', 'firstname': 'B Blair', 'initials': 'BB', 'affiliation': None}, {'lastname': 'Bimonte-Nelson', 'firstname': 'Heather', 'initials': 'H', 'affiliation': None}, {'lastname': 'Kusne', 'firstname': 'Yael', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Young', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': None}, {'lastname': 'Engler-Chiurazzi', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}, {'lastname': 'Garcia', 'firstname': 'Alexandra N', 'initials': 'AN', 'affiliation': None}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Moses', 'firstname': 'Guna S D', 'initials': 'GS', 'affiliation': None}, {'lastname': 'Tran', 'firstname': 'Hung', 'initials': 'H', 'affiliation': None}, {'lastname': 'LaFerla', 'firstname': 'Frank', 'initials': 'F', 'affiliation': None}, {'lastname': 'Lue', 'firstname': 'LihFen', 'initials': 'L', 'affiliation': None}, {'lastname': 'Emerson Lombardo', 'firstname': 'Nancy', 'initials': 'N', 'affiliation': None}, {'lastname': 'Valla', 'firstname': 'Jon', 'initials': 'J', 'affiliation': None}]",,,,,10.3233/JAD-2012-120478,<Element 'PubmedArticle' at 0x7f05da973900>
393,"22760557
20444578
15525658
16925587
10196370
19174491
20713132
1660734
16613897
18675469
21257974
19008301
12022960
18980809
14733887
17161193
8388035
18617609
22087024
962488
6291080
8909334
19499418
16924259
21907139
19022343
8252624
8021233
21083631
16857744
11223190
12399952
14708030
16458268
15987954
19074532
7129257
15786456
17435662
17433700
21988129
16190907
20588235
18841471
8898202
19956633
15220929
9287218",Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-adrenal axis in a model of Huntington's disease.,"Huntington's disease (HD) has long been regarded as a disease of the central nervous system, partly due to typical disease symptoms that include loss of motor control, cognitive deficits and neuropsychiatric disturbances. However, the huntingtin gene is ubiquitously expressed throughout the body. We had previously reported a female-specific depression-related behavioural phenotype in the R6/1 transgenic mouse model of HD. One hypothesis suggests that pathology of the hypothalamic-pituitary-adrenal (HPA) axis, the key physiological stress-response system that links central and peripheral organs, is a cause of depression. There is evidence of HPA axis pathology in HD, but whether it contributes to the female R6/1 behavioural phenotype is unclear. We have examined HPA axis response of R6/1 mice following acute stress and found evidence of a female-specific dysregulation of the HPA axis in R6/1 mice, which we further isolated to a hyper-response of adrenal cortical cells to stimulation by adrenocorticotrophin hormone. Interestingly, the adrenal pathophysiology was not detected in mice that had been housed in environmentally enriching conditions, an effect of enrichment that was also reproduced in vitro. This constitutes the first evidence that environmental enrichment can in fact exert a lasting influence on peripheral organ function. Cognitive stimulation may therefore not only have benefits for mental function, but also for overall physiological wellbeing.",[],Translational psychiatry,2012-07-05,"[{'lastname': 'Du', 'firstname': 'X', 'initials': 'X', 'affiliation': 'Neural Plasticity Laboratory, Behavioural Neuroscience Division, Florey Neuroscience Institutes, University of Melbourne, Parkville, VIC, Australia.'}, {'lastname': 'Leang', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Mustafa', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Renoir', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Pang', 'firstname': 'T Y', 'initials': 'TY', 'affiliation': None}, {'lastname': 'Hannan', 'firstname': 'A J', 'initials': 'AJ', 'affiliation': None}]",,,,,10.1038/tp.2012.58,<Element 'PubmedArticle' at 0x7f05da99a400>
394,25436686,Steroids and their metabolites in CSF from shunt as potential predictors of further disease progression in patients with hydrocephalus and the importance of 11β-hydroxysteroid dehydrogenase.,"Abstract Hydrocephalus is the result of an imbalance between the formation and drainage of cerebrospinal fluid (CSF), characterized by an elevation of the CSF pressure within the brain. A primary method of its treatment is the surgical insertion of a shunt. The patient's condition is usually improved and he or she attends the hospital for periodic controls, at which CSF can be easily and repeatedly collected. Unfortunately, the effect of the operation is not durable and the number of patients in which the improvement of the clinical stage is recorded sinks considerably, and many of them develop dementia. Various biochemical markers in CSF have been searched to assess the response to surgical treatment and the further prognosis. They include classic clinical biochemistry parameters, some proteins occurring in excess in patients with Alzheimer's disease, other biomarkers generally reflecting the overall neuronal injury, and hormones, including steroids. The existing as well as the potential biomarkers enabling to predict the patient's fate after shunt operation are critically reviewed here. Special attention is paid to corticosteroids with respect to their role in influencing electrolyte balance in choroidal cells and consequently CSF and water flow among the ventricles. The importance of the local activity of steroid 11β-hydroxysteroid dehydrogenase (11β-HSD) of both types for regulation of the actual corticosteroid concentration is emphasized, and an original method for determination of cortisol/cortisone concentration in CSF is described. Preliminary results showing the changes of 11β-HSD activity in ten patients with hydrocephalus immediately after shunt introduction and after 1 month are provided.",[],Hormone molecular biology and clinical investigation,2012-06-01,"[{'lastname': 'Sosvorová', 'firstname': 'Lucie', 'initials': 'L', 'affiliation': None}, {'lastname': 'Bičíková', 'firstname': 'Marie', 'initials': 'M', 'affiliation': None}, {'lastname': 'Mohapl', 'firstname': 'Milan', 'initials': 'M', 'affiliation': None}, {'lastname': 'Hampl', 'firstname': 'Richard', 'initials': 'R', 'affiliation': None}]",,,,,10.1515/hmbci-2012-0002,<Element 'PubmedArticle' at 0x7f05da931e00>
395,"22648398
11978836
17901235
11545012
11351342
20493928
21420980
10366703
12650718
12414126
11292650
9482884
19932751
21277368
16434614
16872778
10970861
10997581
2790487
10927618
12711016
10817919
10762694
10419996
10999823
8175728
13957617
15813954
11739260
20171784
10624800
9733072
15531092
12682286
20595940
12753077
16181121
10368772
11717247
12017552
18195084
12670715
16122717
11116225
19462258
8769313
10697060
9226633
12581835
3427426
9526077
11061547
7896011
16645038
21761133
17261778
2902739
7802415
9153163
12700177
9388012
10662537
10974424
15213206
2324335
12588759
14623515
10087060
12388160
7529755
16566279
12351713
19420261
16420966
8994066
18083219
3865204
11850023
7696260",Aging and substitutive hormonal therapy influence in regional and subcellular distribution of ERα in female rat brain.,"Estrogens are not only critical for sexual differentiation it is well-known for the role of 17β-estradiol (E2) in the adult brain modulating memory, learning, mood and acts as a neuroprotector. E2 exerts its actions through two classical receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). The distribution of both receptors changes from one brain area to another, E2 being able to modulate their expression. Among the classical features of aging in humans, we find cognitive impairment, dementia, memory loss, etc. As estrogen levels change with age, especially in females, it is important to know the effects of low E2 levels on ERα distribution; results from previous studies are controversial regarding this issue. In the present work, we have studied the effects of long-term E2 depletion as well as the ones of E2 treatment on ERα brain distribution of ovariectomized rats along aging in the diencephalon and in the telencephalon. We have found that ovariectomy causes downregulation and affects subcellular localization of ERα expression during aging, meanwhile prolonged estrogen treatment produces upregulation and overexpression of the receptor levels. Our results support the idea of the region-specific neuroprotection mechanisms mediated by estradiol.",[],"Age (Dordrecht, Netherlands)",2012-06-01,"[{'lastname': 'Navarro', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Morphology, Cellular Biology Instituto de Neurociencias del Principado de Asturias (INEUROPA), University of Oviedo, Oviedo, Spain.'}, {'lastname': 'Del Valle', 'firstname': 'Eva', 'initials': 'E', 'affiliation': None}, {'lastname': 'Ordóñez', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': None}, {'lastname': 'Martínez', 'firstname': 'Eva', 'initials': 'E', 'affiliation': None}, {'lastname': 'Pérez', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': None}, {'lastname': 'Alonso', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'González', 'firstname': 'Celestino', 'initials': 'C', 'affiliation': None}, {'lastname': 'Tolivia', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': None}]",,,,,"10.1007/s11357-012-9415-9
10.1210/en.2007-0627
10.1016/S0079-6123(01)32096-4
10.1002/neu.1038
10.1016/j.neuroscience.2010.05.031
10.1016/j.lfs.2011.03.010
10.1016/S0165-3806(99)00050-4
10.1016/S0960-0760(02)00261-3
10.1016/S0169-328X(02)00449-7
10.1096/fj.00-0398com
10.1073/pnas.95.5.2325
10.1016/j.jsbmb.2009.11.007
10.1016/j.bbi.2011.01.013
10.1124/mol.105.018671
10.1016/j.exger.2006.06.032
10.1093/emboj/19.17.4688
10.1016/S0168-0102(00)00150-4
10.1016/0006-8993(89)91113-X
10.1677/joe.0.1660283
10.1016/S0960-0760(03)00043-8
10.1016/S0736-5748(00)00017-4
10.1016/S0006-8993(99)02475-0
10.1111/j.1460-9568.2005.03953.x
10.1093/cercor/12.2.116
10.1016/j.psyneuen.2010.01.014
10.1016/S0304-3940(99)00815-0
10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V
10.1016/j.neulet.2004.09.017
10.1073/pnas.0831079100
10.1046/j.1471-4159.2003.01767.x
10.2174/156720205774322629
10.1210/rp.57.1.357
10.1152/physrev.00010.2007
10.1016/S0169-328X(03)00088-3
10.1016/j.brainres.2005.06.073
10.1002/1096-9861(20010115)429:3<355::AID-CNE1>3.0.CO;2-#
10.1007/s11357-009-9095-2
10.1016/0014-5793(96)00782-X
10.1016/S0047-6374(97)00052-3
10.1016/S0304-3940(02)01416-7
10.1016/0006-8993(87)90483-5
10.1016/S0169-328X(97)00351-3
10.1210/me.2005-0525
10.1196/annals.1386.035
10.1016/0736-5748(87)90054-2
10.1111/j.1749-6632.1994.tb55794.x
10.1212/WNL.48.5_Suppl_7.21S
10.1210/er.2001-0016
10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
10.1006/frne.1999.0190
10.1016/S0306-4522(00)00242-6
10.1001/jama.291.24.2947
10.1002/cne.902940107
10.1161/01.ATV.0000053846.71621.93
10.1016/S0960-0760(03)00360-1
10.1007/BF00269013
10.1523/JNEUROSCI.0774-09.2009
10.1016/j.neuint.2005.11.011
10.1016/j.yfrne.2007.08.003
10.1073/pnas.82.23.7889
10.1016/S0047-6374(01)00406-7
10.1021/bi00012a013",<Element 'PubmedArticle' at 0x7f05da936e00>
396,"22612612
12117397
15082697
17975326
10854354
15068977
9921852
21425187
12374497
8290098
7854529
8709781
8885820
10851365
12413371
11113299
11255426
20943809
16421627
17035515
8844880
8649552
9191757
10668686
10697060
9492970
12771112
15213206
20473134
16631882
19139363
19139364
17434074
19729392
17030472
12413378
15608005
21280086
16310963
9663404
15800139
16279282
16522699
19850684
12459399
7733843
15955933
16831962
15695976
16298249
17341247
3067252
1484915
19468050
16735938
17893293
19590458
11309635
19918203
11238542
16292319
19770382
20136553
15213207
19139364
16024751","Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.","Principal findings on dementia from the Women's Health Initiative Memory Study (WHIMS) showed that conjugated equine estrogens plus medroxyprogesterone acetate (CEE/MPA) increase dementia risk in women aged 65 years and above, but not risk of mild cognitive impairment. The dementia finding was unexpected, given consistent observational evidence that associates use of estrogen-containing hormone therapy with reduced risk of Alzheimer's disease. It remains controversial whether hormone use by younger postmenopausal women near the time of menopause reduces dementia risk or whether WHIMS findings should be generalized to younger women. Given the challenges of conducting a primary prevention trial to address that question, it is helpful to consider the impact of hormone therapy on cognitive test performance, particularly verbal memory, for its own sake and as a proxy for dementia risk. The WHI Study of Cognitive Aging (WHISCA) showed that CEE/MPA worsened verbal memory, whereas CEE alone had no influence on cognition. These findings have been replicated in several randomized, clinical trials. The apparent negative effect of CEE/MPA on verbal memory does not appear to be age-dependent. Additional investigations are needed to understand the impact of other hormonally active compounds on dementia and cognitive outcomes.",[],Climacteric : the journal of the International Menopause Society,2012-05-23,"[{'lastname': 'Maki', 'firstname': 'P M', 'initials': 'PM', 'affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.'}, {'lastname': 'Henderson', 'firstname': 'V W', 'initials': 'VW', 'affiliation': None}]",,,,,10.3109/13697137.2012.660613,<Element 'PubmedArticle' at 0x7f05da8e7cc0>
397,22596080,Male sex hormones and systemic inflammation in Alzheimer disease.,"Several studies have shown that the levels of sex hormones in men with Alzheimer disease (AD) differ from men without AD. Therefore, male sex hormones have been postulated as risk modifiers in AD, possibly through immunomodulatory effects on known inflammatory AD risk factors, such as tumor necrosis factor α (TNF-α). We conducted a cross-sectional study of sex hormones and TNF-α levels in 94 community-dwelling men with AD. Comparisons were made with normal values derived from the literature. Men with AD had lower free testosterone levels than non-AD men (1-sample t test: age <80, P=0.0002; age ≥80, P<0.0001), and higher luteinizing hormone (LH) levels (Wilcoxon signed rank test: age <80, P=0.001; age ≥80, P<0.0001). Within the cohort of men with AD, there was a positive correlation between LH and TNF-α (Spearman r=0.25, P=0.019), and this remained significant after correcting for age (partial r=0.21, P=0.05). These data support the hypothesis that sex hormones and the immune system influence each other in AD. Furthermore, modulatory effects between LH and TNF-α may provide a mechanism for an effect of male sex hormones on AD risk.",[],Alzheimer disease and associated disorders,2012-05-19,"[{'lastname': 'Butchart', 'firstname': 'Joe', 'initials': 'J', 'affiliation': 'Memory Assessment and Research Centre, Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton, UK. j.w.butchart@soton.ac.uk'}, {'lastname': 'Birch', 'firstname': 'Brian', 'initials': 'B', 'affiliation': None}, {'lastname': 'Bassily', 'firstname': 'Ramy', 'initials': 'R', 'affiliation': None}, {'lastname': 'Wolfe', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Holmes', 'firstname': 'Clive', 'initials': 'C', 'affiliation': None}]",,,,,10.1097/WAD.0b013e318258cd63,<Element 'PubmedArticle' at 0x7f05da90cf40>
398,22575905,"Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin.","AD, sleep and circadian rhythm physiology display an intricate relationship. On the one hand, AD pathology leads to sleep and circadian disturbances, with a clear negative influence on quality of life. On the other hand, there is increasing evidence that both sleep and circadian regulating systems exert an influence on AD pathology. In this review we describe the impairments of both sleep regulating systems and circadian rhythms in AD and their link to clinical symptoms, as this may increase knowledge on appropriate diagnosis and adequate treatment of sleep problems in AD. Furthermore we discuss how sleep regulating systems, and especially neurotransmitters such as melatonin and hypocretin, may affect AD pathophysiology, as this may provide a role for lack of sleep and circadian rhythm deterioration in the onset of AD.",[],Ageing research reviews,2012-05-12,"[{'lastname': 'Slats', 'firstname': 'Diane', 'initials': 'D', 'affiliation': 'Radboud University Nijmegen Medical Centre, Department of Geriatric Medicine, The Netherlands. Dianeslats@gmail.com'}, {'lastname': 'Claassen', 'firstname': 'Jurgen A H R', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Verbeek', 'firstname': 'Marcel M', 'initials': 'MM', 'affiliation': None}, {'lastname': 'Overeem', 'firstname': 'Sebastiaan', 'initials': 'S', 'affiliation': None}]",,,,Copyright © 2012 Elsevier B.V. All rights reserved.,10.1016/j.arr.2012.04.003,<Element 'PubmedArticle' at 0x7f05da918090>
399,"22571978
20413862
19273747
21263438
17430239
11306609
15590928
12507914
12634421
10786709
8385036
20164784
19365105
21172030
11986895
18448847
11425934
10794848
21555680
19358976
21810068
19056613
21514249
11735772
20008648
8591825
15326238
18421217
20197703
21115952
15277613
21745183
16598526
10461029
16446752
10818510
18401020
12433261
16418406
8054493
6610841
2771064
9777473
16120536
16120535
18609337
17135809
2341813
18384771
19029150
20393152
19455303
18612998
18261857
17846409
21745566
20847404
19901172
15752921
21466618
3285822
8978879
9514414
16829342",Insulin and sex interactions in older adults with mild cognitive impairment.,"Alzheimer's disease (AD) and other dementias are likely preceded by a protracted preclinical state. Thus, identification of biomarkers that signal potential points of intervention during this prodromal phase (during which patients are largely able to compensate for their cognitive deficits) is of paramount importance. Insulin is a pancreatic hormone with potent central nervous system effects, and insulin dysregulation has been implicated in the pathogenesis of both AD and vascular dementia. The aim of the current study was to determine whether circulating insulin differs as a function of mild cognitive impairment (MCI) diagnosis, and whether this relationship is mediated by sex and apolipoprotein E (APOE) genotype. A sample of 549 nondemented participants aged 65 and over from the Adult Changes in Thought community-based cohort underwent cognitive testing and blood draw to determine fasting levels of plasma insulin. Subjects were categorized as having normal cognitive functioning, amnestic MCI, or nonamnestic MCI. Results showed that the relationship between insulin and diagnostic category is moderated by sex, such that men with nonamnestic or amnestic MCI have higher fasting plasma insulin than cognitively normal men, while women with amnestic MCI have lower fasting plasma insulin than cognitively normal women. Exploratory analyses suggest that APOE ε4 genotype may further influence the relationship between sex and insulin. Future research will help determine whether insulin dysregulation results in differential effects on vascular function and AD pathology as a function of sex and/or APOE genotype.",[],Journal of Alzheimer's disease : JAD,2012-05-11,"[{'lastname': 'Cholerton', 'firstname': 'Brenna', 'initials': 'B', 'affiliation': 'Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98493, USA. bchol@u.washington.edu'}, {'lastname': 'Baker', 'firstname': 'Laura D', 'initials': 'LD', 'affiliation': None}, {'lastname': 'Trittschuh', 'firstname': 'Emily H', 'initials': 'EH', 'affiliation': None}, {'lastname': 'Crane', 'firstname': 'Paul K', 'initials': 'PK', 'affiliation': None}, {'lastname': 'Larson', 'firstname': 'Eric B', 'initials': 'EB', 'affiliation': None}, {'lastname': 'Arbuckle', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': None}, {'lastname': 'Saucedo', 'firstname': 'Hector Hernandez', 'initials': 'HH', 'affiliation': None}, {'lastname': 'McCurry', 'firstname': 'Susan M', 'initials': 'SM', 'affiliation': None}, {'lastname': 'Bowen', 'firstname': 'James D', 'initials': 'JD', 'affiliation': None}, {'lastname': 'McCormick', 'firstname': 'Wayne C', 'initials': 'WC', 'affiliation': None}, {'lastname': 'Craft', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': None}]",,,,,10.3233/JAD-2012-120202,<Element 'PubmedArticle' at 0x7f05da920310>
400,22543853,Adiposity and cognitive decline: underlying mechanisms.,"Level of adiposity is linked to manifest dementia and Alzheimer's disease in epidemiological studies. Overweight and obesity in mid- and late-life may increase risk for dementia, whereas decline in body weight or body mass index and underweight in years preceding and at the time of a dementia diagnosis may also relate to dementia. The role of adiposity during the period of cognitive decline is, as yet, not understood; however, some hypotheses relating adipose tissue to brain can be drawn. This review focuses on potential, varied mechanisms whereby adipose tissue may influence or interact with the brain and/or dementia risk during the dynamic period of life characterized by both body weight and cognitive decline. These mechanisms relate to: a) adipose tissue location and cell types, b) body composition, c) endocrine adipose, and d) the interplay among adipose, brain structure and function, and genes. This review will illustrate that adipose tissue is a quintessential, multifunctional tissue of the human body.",[],Journal of Alzheimer's disease : JAD,2012-05-01,"[{'lastname': 'Gustafson', 'firstname': 'Deborah R', 'initials': 'DR', 'affiliation': 'Section for Psychiatry and Neurochemistry, Neuropsychiatric Epidemiology Unit at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. deborah.gustafson@neuro.gu.se'}]",,,,,10.3233/JAD-2012-120487,<Element 'PubmedArticle' at 0x7f05da8c1770>
401,"22535332
8550619
21298369
6252591
19808775
9272622
9809647
18702730
8971933
9142880
18823656
10399674
18194430
17971014
17900701
19870942
6380316
3252173
1276933
1504842
19948301
17990104
20086056
11352837
19040556
656950
7737728
18160199
11181791
16075377
12676175
15093864
2317275
2054657
12591177
17329311
12433674
7735275
11824873
11390024
9030406
17493693
18609298
15312180
11814638
7843246
4330904
12580855
19654035
19436679
19090987
19769454
18835699
19776283
12871575
21777652
17148957
2407490
17012333
9110385
11428524
20524096
15142685
17169335
20305987
16678218
17684103
20502352
17587312
17145750
2669838
17600375
14351894
9468212
20028326
14996614
22129598
16861928
20059281
15983321
21859930
2720433
7039765
11029614
12649370
12826267
9674690
2579749
4332505
8804084
21147255
17033088
6093165
17504262
16533956
19861346
1425957
11282364
15194488
14699876
7559527
7983006
15063004
18793332
4325462
20182022
13463253
16343778
18607732
12140731
19902810
13523777
12406499
17230549
2836110
21719467
187587
15831814
16771832
15526242
19127486
11120758
4322723
18834074
16352434
19071192
8221142
3551809
28095220
16182260
234776
12584663
1618166
19817870
17045647
11881124
2178480
17965777
19158421
11054586
1361394
4296696
17900533
9370053
6340533
11744165
1558208
2185850
16250855
16995204
19713966
20963849
10565848
11704344
16713498
20595663
15837534
11641136
1438983
10800878
18288214
19233301
8738217
9521751
7122274
4025541
9990655
10373220
13421689
21538707
19747525
18385968
18188697
9886781
12676163
10805970
6142952
10234025
16555051
19686774
10432384
11249971
20302552
16690090
12483279
1166302
16123155
15229174
12966217
8516370
7503230
21143280
21477268
18359517
1337911
20346964
19782074
18716029
21143282
21945916
2604011
7915326
17460286
10977869
10882779
16919623
12884908
20102971
4061676
15187413
20739604
14980384
17094054
11514021
19757839
20370487
8828586
19907343
18650791
19090988
12609768
15302130
8800566
4009600
19660563
16464240
10386186
9741479
8876246
11707427
4353653
12428219
3511737
7411436
15607934
12225947
13307344
17094048
15389834
17923692
17559064
11906704
19635982
19120129
15117826
8621739
12584670
21333703
9538898
17224059
18556208
15607326
21126393
18511928
7523429
21470200
19727113
8738247
16505200
7593643
2243344
11389728
18398343
981282
11207430
17978557
15549173
15906313
16816138
11730987
16476066
15549174
15687842
16386204
10064822
9879741
15450362
14748477
2991265
21763394
19853606
20028450
20369075
2831750
21457753",The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.,"The classic renin-angiotensin system (RAS) was initially described as a hormone system designed to mediate cardiovascular and body water regulation, with angiotensin II as its major effector. The discovery of an independent local brain RAS composed of the necessary functional components (angiotensinogen, peptidases, angiotensins, and specific receptor proteins) significantly expanded the possible physiological and pharmacological functions of this system. This review first describes the enzymatic pathways resulting in active angiotensin ligands and their interaction with AT(1), AT(2), and AT(4) receptor subtypes. Next, we discuss the classic physiologies and behaviors controlled by the RAS including cardiovascular, thirst, and sodium appetite. A final section summarizes non-classic functions and clinical conditions mediated by the brain RAS with focus on memory and Alzheimer's disease. There is no doubt that the brain RAS is an important component in the development of dementia. It also appears to play a role in normal memory consolidation and retrieval. The presently available anti-dementia drugs are proving to be reasonably ineffective, thus alternative treatment approaches must be developed. At the same time, presently available drugs must be tested for their efficacy to treat newly identified syndromes and diseases connected with the RAS. The list of non-classic physiologies and behaviors is ever increasing in both number and scope, attesting to the multidimensional influences of the RAS. Such diversity in function presents a dilemma for both researchers and clinicians. Namely, the blunting of RAS subsystems in the hopes of combating one constellation of underlying causes and disease symptoms may be counter-balanced by unanticipated and unwanted consequences to another RAS subsystem. For example, the use of angiotensin-converting enzyme inhibitors and AT(1) and/or AT(2) receptor blockers have shown great promise in the treatment of cardiovascular related pathologies; however, their use could negate the cerebroprotective benefits offered by this system.",[],Pflugers Archiv : European journal of physiology,2012-04-27,"[{'lastname': 'Wright', 'firstname': 'John W', 'initials': 'JW', 'affiliation': 'Department of Psychology, Washington State University, Pullman, WA 99164-4820, USA. wrightjw@wsu.edu'}, {'lastname': 'Harding', 'firstname': 'Joseph W', 'initials': 'JW', 'affiliation': None}]",,,,,10.1007/s00424-012-1102-2,<Element 'PubmedArticle' at 0x7f05da8cc540>
402,"22503992
21516511
22451468
22421704
22491965
22466316
16024298
20863877
21807098
20186710
22016359
21357188
19933749
20418350
10924684
18329176
20211265
20302918
20374424
22192242
7566338
16289476
21440628
9403139
12143403
15374672
21647399
15190254
20336135
15581395
14624191
17848918
20146700
8631738
10657302
11691998
11753414
15475946
16793874
17553942
19164740
19255244
8421494
4727084
21334194
16931756
16931766
7675078
16261180
22284181
7537406
12080341
18275283
14682362
15642626
17972919
14585998
7923379
7916482
18799741
9252190
21425351
7945346
7891174
11640918
16763567
11778053
2465615
2506642
9593663
10571231
18945891
7902212
15601943
8606805
11056535
9856955
16571754
8876242
12417653
14766180
14529723
11691980
6502226
3401749
11069960
20881117
12832506
5715484
7249999
16621325
18787050
8817729
9618751
15694115
17560153
16707911
10022403
11441649
11134107
9215295
12714114
15737671
21256932
8633830
11297574
9758223
10737685
18086533
19815586
11336996
14984790
15718052
21524689
3771541
2458916
3422422
2015788
7718235
8386530
12574418
18367086
12815703
21496647
8402901
12483226
18959478
10080384
11739399
15217342
7791877
7559614
11242035
11823420
14983047
17192432
19680447
1625766
18342310
8757251
17553951
11356894
20130200
10704784
18720514
11241388
11197531
21633715
22269040
11978832
17957480
20926648
20486800
15548666
17640868
16464236
10774732
10774731
17988632
15985695
9292730
10066247
10939336
21955917
18184559
18184568
18184569
16949624
17335809
20427666
17470753
12743238
19406747
19188609
16286438
16515786
20709114
16902091
20005808
21115535
12670422
16364896
18400162
11099491
15590928
19825975
12415260
21750148
19690465
20466029","Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1.","Insulin-like growth factor (IGF)-1 is an important neurotrophic hormone. Deficiency of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. Nevertheless, there are studies indicating that cognitive function can be maintained into old age even in the absence of circulating IGF-1 and studies that link IGF-1 to an acceleration of neurological diseases. Although IGF-1 has a complex role in brain function, synaptic effects appear to be central to the IGF-1-induced improvement in learning and memory. In this review, synaptic mechanisms of learning and memory and the effects of IGF-1 on synaptic communication are discussed. The emerging data indicate that synaptic function decreases with age and that IGF-1 contributes to information processing in the brain. Further studies that detail the specific actions of this important neurotrophic hormone will likely lead to therapies that result in improved cognitive function for the elderly patients.",[],"The journals of gerontology. Series A, Biological sciences and medical sciences",2012-04-17,"[{'lastname': 'Deak', 'firstname': 'Ferenc', 'initials': 'F', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.'}, {'lastname': 'Sonntag', 'firstname': 'William E', 'initials': 'WE', 'affiliation': None}]",,,,,10.1093/gerona/gls118,<Element 'PubmedArticle' at 0x7f05da89c0e0>
403,22502998,Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia.,"A hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) gene has recently been described as a cause of familial and sporadic frontotemporal lobar degeneration. The aim of this study was to assess whether plasma progranulin (GRN) levels could be modulated by the presence of this repeat expansion. Sixty-five patients diagnosed with frontotemporal dementia and 10 family members with familial aggregation of disease were screened for the presence of the hexanucleotide repeat expansion in C9ORF72 gene, using a repeat-primed polymerase chain reaction method. Plasma GRN levels were measured in all subjects through enzyme-linked immunosorbent assay. Seven individuals with the repeat expansion were identified. No differences were found between C9ORF72 repeat expansion carriers and noncarriers (116.4 ± 21 ng/mL and 131.7 ± 36 ng/mL, respectively, p = 0.3). Analysis of family members did not disclose any difference in plasma GRN levels between carriers and noncarriers. In conclusion, plasma GRN levels are not influenced by the hexanucleotide repeat expansion in C9ORF72 gene, and therefore, cannot be used as a reliable biomarker to detect mutation carriers.",[],Neurobiology of aging,2012-04-17,"[{'lastname': 'Dols-Icardo', 'firstname': 'Oriol', 'initials': 'O', 'affiliation': 'Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.'}, {'lastname': 'Suárez-Calvet', 'firstname': 'Marc', 'initials': 'M', 'affiliation': None}, {'lastname': 'Hernández', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': None}, {'lastname': 'Amer', 'firstname': 'Guillermo', 'initials': 'G', 'affiliation': None}, {'lastname': 'Antón-Aguirre', 'firstname': 'Sofía', 'initials': 'S', 'affiliation': None}, {'lastname': 'Alcolea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Fortea', 'firstname': 'Juan', 'initials': 'J', 'affiliation': None}, {'lastname': 'Boada', 'firstname': 'Mercè', 'initials': 'M', 'affiliation': None}, {'lastname': 'Tárraga', 'firstname': 'Lluís', 'initials': 'L', 'affiliation': None}, {'lastname': 'Blesa', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': None}, {'lastname': 'Lleó', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Clarimón', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2012.03.005,<Element 'PubmedArticle' at 0x7f05da7f0130>
404,"22491866
16862116
16862115
11844889
20479359
17949857
20142524
18245784
21178100
7790950
17210807",Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin.,"To report the phenotypic characterization of monozygotic twins with mutations encoding progranulin (PGRN).
We studied a twin pair with an exon 4 gene deletion in the PGRN gene. Both twins had clinical and neuropsychological examinations as well as structural MRI and fluorodeoxyglucose PET (FDG-PET) scans. PGRN gene sequencing was performed followed by progranulin ELISA in plasma.
Both twins manifested symptoms within 3 years of each other, with early behavioral, language, dysexecutive, and memory problems. MRI and FDG-PET imaging demonstrated a strikingly similar topography of findings with clear left hemisphere predominance. Serum progranulin levels in both were well below those from a normal population sample.
Compared with the heterogeneity seen in many families with PGRN mutations, these monozygotic twins demonstrated strong clinical, neuroimaging, and serum progranulin level similarities, demonstrating the importance of shared genetic profiles beyond environmental influences in the symptomatic expression of the disease.",[],Neurology,2012-04-12,"[{'lastname': 'McDade', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Department of Neurology, Mayo Clinic, Rochester, MN, USA.'}, {'lastname': 'Boeve', 'firstname': 'B F', 'initials': 'BF', 'affiliation': None}, {'lastname': 'Burrus', 'firstname': 'T M', 'initials': 'TM', 'affiliation': None}, {'lastname': 'Boot', 'firstname': 'B P', 'initials': 'BP', 'affiliation': None}, {'lastname': 'Kantarci', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Fields', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Lowe', 'firstname': 'V J', 'initials': 'VJ', 'affiliation': None}, {'lastname': 'Peller', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Knopman', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Baker', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Finch', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Petersen', 'firstname': 'R', 'initials': 'R', 'affiliation': None}]",,,"Both twins manifested symptoms within 3 years of each other, with early behavioral, language, dysexecutive, and memory problems. MRI and FDG-PET imaging demonstrated a strikingly similar topography of findings with clear left hemisphere predominance. Serum progranulin levels in both were well below those from a normal population sample.",,10.1212/WNL.0b013e318251594c,<Element 'PubmedArticle' at 0x7f05da7fd630>
405,22427467,[Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe?].,"Throughout the natural progression of Alzheimer's disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect through increasing energy consumption in the hypothalamus. The goal of our study was to examine donepezil - an acetylcholinesterase inhibitor (AChEI) currently used in AD therapy -, and to what degree it influences the serum adipokine levels and metabolic parameters of AD patients. During the self-evaluation of 26 clinically diagnosed mild to moderate AD patients, therapy with 10 mg/day donepezil was started according to current protocols. We measured serum adiponectin, leptin, LDL, HDL, trigliceride levels, and BMI and ApoE polymorphism at the beginning of our study, and at 3 and 6-months intervals respectively. All data were analyzed with SPSS 17. In comparison with pre-donepezil therapy values, at the third month interval serum adiponectin levels showed an increasing and leptin levels a decreasing tendency. At the six month interval, adiponectin levels significantly increased (p=0.007), leptin levels decreased (p=0.013), BMI (p=0.001) and abdominal circumference (p=0.017) was significantly lower at 6 months as compared to control values. We did not observe any changes in the lipid profile, and ApoE4 allele carrying showed no association with the parameters. To our knowledge, we are the first to publish that AChEI therapy with donepezil alters lipokine levels, which positively influences the currently known pathomechanism and numerous risk factors of AD. The AChEI treatment-induced weight loss should be considered in the long-term therapy of AD patients.",[],Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology,2012-03-20,"[{'lastname': 'Kovacs', 'firstname': 'Janos', 'initials': 'J', 'affiliation': 'Pszichiátriai Klinika, Szegedi Tudományegyetem, Szeged, Hungary. kovacs.janos@med.u-szeged.hu'}, {'lastname': 'Pakaski', 'firstname': 'Magdolna', 'initials': 'M', 'affiliation': None}, {'lastname': 'Juhasz', 'firstname': 'Anna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Feher', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': None}, {'lastname': 'Drotos', 'firstname': 'Gergely', 'initials': 'G', 'affiliation': None}, {'lastname': 'Fazekas', 'firstname': 'Csilla Orsike', 'initials': 'CO', 'affiliation': None}, {'lastname': 'Horvath', 'firstname': 'Tamas Laszlo', 'initials': 'TL', 'affiliation': None}, {'lastname': 'Janka', 'firstname': 'Zoltan', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Kalman', 'firstname': 'Janos', 'initials': 'J', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05da80f630>
406,22398564,Apolipoprotein E ε4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease.,"Studies on the associations between sex hormones and multiple neuropsychiatric symptoms of Alzheimer's disease (AD) are lacking. Apolipoprotein E (APOE) ε4 status may modify the effects of sex hormones on neuropsychiatric symptoms.
A total of 86 male and 87 female AD patients participated in the present study. The adjusted associations between symptoms on the Neuropsychiatric Inventory and serum levels of estradiol (total, bioavailable) and testosterone (total, bioavailable) were analyzed.
Agitation/aggression was negatively associated with quartiles of bioavailable estradiol among male patients, and positively associated with testosterone levels among female patients. The modifying effects of APOE genotype only existed in female patients. Those females with higher levels of estradiol and the ε4 allele had higher odds of agitation/aggression. Furthermore, the testosterone × APOE ε4 status interaction was positively associated with hallucinations in female patients.
There were sex-specific effects of sex hormones on agitation/aggression in AD. Sex hormones and APOE ε4 status synergistically influence some neuropsychiatric symptoms among female but not male AD patients.",[],Dementia and geriatric cognitive disorders,2012-03-09,"[{'lastname': 'Xing', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'Department of Neurology, Xuan Wu Hospital of the Capital Medical University, Beijing, PR China.'}, {'lastname': 'Qin', 'firstname': 'Wei', 'initials': 'W', 'affiliation': None}, {'lastname': 'Li', 'firstname': 'Fang', 'initials': 'F', 'affiliation': None}, {'lastname': 'Jia', 'firstname': 'Xiang-Fei', 'initials': 'XF', 'affiliation': None}, {'lastname': 'Jia', 'firstname': 'Jianping', 'initials': 'J', 'affiliation': None}]",,There were sex-specific effects of sex hormones on agitation/aggression in AD. Sex hormones and APOE ε4 status synergistically influence some neuropsychiatric symptoms among female but not male AD patients.,"Agitation/aggression was negatively associated with quartiles of bioavailable estradiol among male patients, and positively associated with testosterone levels among female patients. The modifying effects of APOE genotype only existed in female patients. Those females with higher levels of estradiol and the ε4 allele had higher odds of agitation/aggression. Furthermore, the testosterone × APOE ε4 status interaction was positively associated with hallucinations in female patients.","Copyright © 2012 S. Karger AG, Basel.",10.1159/000336600,<Element 'PubmedArticle' at 0x7f05da81f4a0>
407,22385117,Subclinical hypothyroidism and cognitive dysfunction in the elderly.,"While overt hypothyroidism is associated with reversible dementia in the elderly, the relationship of subclinical hypothyroidism with cognition remains a controversial issue. Our aim was to investigate the correlation between subclinical hypothyroidism and cognition in the elderly, with particular reference to long term memory and selective attention. We selected 337 outpatients (177 men and 160 women), mean age 74.3 years, excluding the subjects with thyroid dysfunction and those treated with drugs influencing thyroid function. The score of Mini Mental State Examination (MMSE) was significantly lower in the group of patients with subclinical hypothyroidism than in euthyroid subjects (p<0.03). It was observed that patients with subclinical hypothyroidism had a probability about 2 times greater (RR = 2.028, p<0.05) of developing cognitive impairment. Prose Memory Test (PMT) score resulted significantly lower in subjects with subclinical hypothyroidism (p<0.04). Considering the Matrix Test (MT) score, the performance was slightly reduced in subclinical hypothyroidism (NS). Furthermore, TSH was negatively correlated with MMSE (p<0.04), PMT (p<0.05) and MT score (NS). No correlation was found between FT4 and FT3 and MMSE, PMT and MT score. In the elderly, subclinical hypothyroidism is associated with cognitive impairment, and its impact on specific aspects of cognition (long term memory and selective attention) is less evident.",[],"Endocrine, metabolic & immune disorders drug targets",2012-03-06,"[{'lastname': 'Resta', 'firstname': 'F', 'initials': 'F', 'affiliation': 'Department of Geriatrics and Rare Diseases Center, University of Bari Aldo Moro, Bari, Italy. f.resta@geriatria.uniba.it'}, {'lastname': 'Triggiani', 'firstname': 'V', 'initials': 'V', 'affiliation': None}, {'lastname': 'Barile', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Benigno', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Suppressa', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Giagulli', 'firstname': 'V A', 'initials': 'VA', 'affiliation': None}, {'lastname': 'Guastamacchia', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Sabbà', 'firstname': 'C', 'initials': 'C', 'affiliation': None}]",,,,,10.2174/187153012802002875,<Element 'PubmedArticle' at 0x7f05da7a8f90>
408,"22222439
19584431
15996533
20231476
8602739
12719624
16574280
16005567
7659281
4747772
19339973
1759558
5432063
20160453
21170538
17698731
21613497
16779670
15615638
19625739
12377295
17289030
7817900
7812792
3088567
17567816
7620309
5453288
12633144",Tau protein phosphorylation in diverse brain areas of normal and CRH deficient mice: up-regulation by stress.,"Tau protein misfolding is a pathological mechanism, which plays a critical role in the etiopathogenesis of neurodegeneration. However, it is not entirely known what kind of stimuli can induce the misfolding. It is believed that physical and emotional stresses belong to such risk factors. Although the influence of stress on the onset and progression of Alzheimer's disease (AD) has already been proposed, the molecular links between stresses and AD are still unknown. We have therefore focused our attention on determination of the influence of acute immobilization stress (IMO) in normal mice and mice deficient in corticotropin-releasing hormone (CRH). Specifically, we have analyzed levels of hyperphosphorylated tau proteins, bearing the AD-specific phospho-epitopes (AT-8, pT181, and PHF-1), which are implicated in the pathogenesis of AD. We found that IMO induces transient hyperphosphorylation of tau proteins regardless of continuation of the stimulus. Concerning tau modifications, detailed analysis of the mouse brain revealed that neurons in different brain regions including frontal cortex, temporal cortex, hippocampal C1 and CA3 regions, dentate gyrus as well as nucleus basalis Meynert, and several brainstem nuclei such as locus coeruleus but also raphe nucleus and substantia nigra respond similarly to IMO. The strongest tau protein phosphorylation was observed after 30 min of IMO stress. Stress lasting for 120 min led either to the disappearance of tau hyperphosphorylation or to the induction of a second wave of hyperphosphorylation. Noteworthy is the magnitude of pathological phosphorylation of tau protein in CRH and glucocorticoids deficient mice, being much lower in comparison to that observed in wild-type animals, which suggests a critical role of CRH in the pathogenesis of AD. Thus, our results indicate that hyperphosphorylation of tau protein induced by stress may represent the pathogenic event upstream of tau protein misfolding, which leads to progression or eventually initiation of neurodegeneration. The data show that CRH plays an important role in stress induced hyperphosphorylation of tau protein, which might be either a direct effect of CRH innervations in the brain or an effect mediated via the hypothalamo-pituitary-adrenal axis.",[],Cellular and molecular neurobiology,2012-01-10,"[{'lastname': 'Filipcik', 'firstname': 'Peter', 'initials': 'P', 'affiliation': 'Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.'}, {'lastname': 'Novak', 'firstname': 'Petr', 'initials': 'P', 'affiliation': None}, {'lastname': 'Mravec', 'firstname': 'Boris', 'initials': 'B', 'affiliation': None}, {'lastname': 'Ondicova', 'firstname': 'Katarina', 'initials': 'K', 'affiliation': None}, {'lastname': 'Krajciova', 'firstname': 'Gabriela', 'initials': 'G', 'affiliation': None}, {'lastname': 'Novak', 'firstname': 'Michal', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kvetnansky', 'firstname': 'Richard', 'initials': 'R', 'affiliation': None}]",,,,,10.1007/s10571-011-9788-9,<Element 'PubmedArticle' at 0x7f05da7b4680>
409,22204803,The central histamine level in rat model of vascular dementia.,"The histaminergic system plays an important role in memory and learning. Deficient histaminergic transmission in the human brain in vascular dementia (VD) has been suggested. To get a better insight into the problem, a rat model of VD based on permanent bilateral occlusion of the common carotid arteries (BCCAO) leading to chronic cerebral hypoperfusion was used. Prior to the BCCAO, male Wistar rats underwent 7 days training and only those animals that positively passed the holeboard memory test were chosen for the study. The rats which were operated on were injected i.p. daily for 6 days with either a monoamine oxidase B inhibitor - PF9601N (40 mg/kg), an acetycholinesterase inhibitor - tacrine (3 mg/kg), a histamine H(3) receptor blocker - DL76 (6 mg/kg) or saline. The first retest (R1) was performed one week after the surgery while each subsequent test was 5-7 days apart. The rats were euthanized 2 or 4 weeks following the operation. The concentration of brain histamine (HA) and the activity of histamine metabolising enzymes were measured using current procedures. The BCCAO drastically increased latency and run time (p<0.001) 54 ± 30 vs. 3.4 ± 1.2 and 268 ± 18 vs. 74 ± 9, respectively, and affected working memory rather than reference memory as measured by the 1(st) retest (R1). Treatment with either PF9601N or tacrine seems to exert a positive effect on working memory. This tendency disappeared after the drug treatment stopped. Latency and run time, although they improved in R2-R4, never attained the preoperative values. The brain tissues from rats treated with PF9601N showed only 15% and 50% of untreated rat MAO B and MAO A activity, respectively, despite the drug administration having been discontinued for 3 weeks. Other drugs examined did not influence MAO enzymes. Neither did histamine N-methyltransferase activity show changes related to BCCAO nor to the treatments. The hypothalamic HA concentration was significantly reduced after BCCAO: 1.13 ± 0.1 vs. 1.91 ± 0.16. Noteworthy, the rats treated with PF9601N or DL76 had brain HA levels not significantly different from their intact counterparts. The rat vascular dementia model supports deficiency in histaminergic system in VD.",[],Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,2011-12-30,"[{'lastname': 'Stasiak', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Department of Hormone Biochemistry, Medical University of Lodz, Lodz, Poland. anna.stasiak@umed.lodz.pl'}, {'lastname': 'Mussur', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Unzeta', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Lazewska', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Kiec-Kononowicz', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Fogel', 'firstname': 'W A', 'initials': 'WA', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05da7c5270>
410,22107053,Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin.,"Alzheimer's disease (AD) is a highly complex neurodegenerative disorder of the aged that has multiple factors which contribute to its etiology in terms of initiation and progression. This review summarizes these diverse aspects of this form of dementia. Several hypotheses, often with overlapping features, have been formulated to explain this debilitating condition. Perhaps the best-known hypothesis to explain AD is that which involves the role of the accumulation of amyloid-β peptide in the brain. Other theories that have been invoked to explain AD and summarized in this review include the cholinergic hypothesis, the role of neuroinflammation, the calcium hypothesis, the insulin resistance hypothesis, and the association of AD with peroxidation of brain lipids. In addition to summarizing each of the theories that have been used to explain the structural neural changes and the pathophysiology of AD, the potential role of melatonin in influencing each of the theoretical processes involved is discussed. Melatonin is an endogenously produced and multifunctioning molecule that could theoretically intervene at any of a number of sites to abate the changes associated with the development of AD. Production of this indoleamine diminishes with increasing age, coincident with the onset of AD. In addition to its potent antioxidant and anti-inflammatory activities, melatonin has a multitude of other functions that could assist in explaining each of the hypotheses summarized above. The intent of this review is to stimulate interest in melatonin as a potentially useful agent in attenuating and/or delaying AD.",[],Journal of pineal research,2011-11-24,"[{'lastname': 'Rosales-Corral', 'firstname': 'Sergio A', 'initials': 'SA', 'affiliation': 'Centro de Investigación Biomédica de Occidente del Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México. espiral17@gmail.com'}, {'lastname': 'Acuña-Castroviejo', 'firstname': 'Dario', 'initials': 'D', 'affiliation': None}, {'lastname': 'Coto-Montes', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Boga', 'firstname': 'Jose A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Manchester', 'firstname': 'Lucien C', 'initials': 'LC', 'affiliation': None}, {'lastname': 'Fuentes-Broto', 'firstname': 'Lorena', 'initials': 'L', 'affiliation': None}, {'lastname': 'Korkmaz', 'firstname': 'Ahmet', 'initials': 'A', 'affiliation': None}, {'lastname': 'Ma', 'firstname': 'Shuran', 'initials': 'S', 'affiliation': None}, {'lastname': 'Tan', 'firstname': 'Dun-Xian', 'initials': 'DX', 'affiliation': None}, {'lastname': 'Reiter', 'firstname': 'Russel J', 'initials': 'RJ', 'affiliation': None}]",,,,© 2011 John Wiley & Sons A/S.,10.1111/j.1600-079X.2011.00937.x,<Element 'PubmedArticle' at 0x7f05da7cfd60>
411,"22057025
9496988
9670866
11085689
10690972
14749131
14520653
16926067
15374113
14749133
11522943
10680789
17097195
11971659
19022535
12534359
12011802
17010478
16365303
18601693
9535740
9485002
17325027
16949385
10487678
16595226
17589376
10468307
11344237
10861475
11212283
12944421
12584742
15132727
15642171
15591802
16882736
15079018
16020944
18299793
17553421
19879925
19478482
2969441
9161927
9661593
2341813
15297300
8780008
2990988
1316615
7488136
8175728
10881241
9546791
15807883
14641001
15582279
14745075
18956301
2566117",Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome.,"CYP17 and CYP19 are involved in the peripheral synthesis of estrogens, and polymorphisms in CYP17 and CYP19 have been associated with increased risk of estrogen-related disorders. Women with Down syndrome (DS) have early onset and high risk for Alzheimer's disease (AD). We conducted a prospective community-based cohort study to examine the relationship between SNPs in CYP17 and CYP19 and cumulative incidence of AD, hormone levels and sex hormone binding globulin in women with DS. Two hundred and thirty-five women with DS, 31 to 67 years of age and nondemented at initial examination, were assessed for cognitive and functional abilities, behavioral/psychiatric conditions, and health status at 14-20 month intervals over five assessment cycles. We genotyped these individuals for single-nucleotide polymorphisms (SNPs) in CYP17 and CYP19. Four SNPs in CYP17 were associated with a two and one half-fold increased risk of AD, independent of APOE genotype. Four SNPs in CYP19 were associated with a two-fold increased risk of AD, although three were significant only in those without an APOE ε4 allele. Further, carrying high risk alleles in both CYP17 and CYP19 was associated with an almost four-fold increased risk of AD (OR = 3.8, 95% CI, 1.6-9.5) and elevated sex hormone binding globulin in postmenopausal women. The main effect of the CYP17 and CYP19 variants was to decrease the age at onset. These findings suggest that genes contributing to estrogen bioavailability influence risk of AD in women with DS.",[],Journal of Alzheimer's disease : JAD,2011-11-08,"[{'lastname': 'Chace', 'firstname': 'Constance', 'initials': 'C', 'affiliation': ""The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA.""}, {'lastname': 'Pang', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': None}, {'lastname': 'Weng', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Temkin', 'firstname': 'Alexis', 'initials': 'A', 'affiliation': None}, {'lastname': 'Lax', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}, {'lastname': 'Silverman', 'firstname': 'Wayne', 'initials': 'W', 'affiliation': None}, {'lastname': 'Zigman', 'firstname': 'Warren', 'initials': 'W', 'affiliation': None}, {'lastname': 'Ferin', 'firstname': 'Michel', 'initials': 'M', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Joseph H', 'initials': 'JH', 'affiliation': None}, {'lastname': 'Tycko', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': None}, {'lastname': 'Schupf', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': None}]",,,,,10.3233/JAD-2011-110860,<Element 'PubmedArticle' at 0x7f05da7d6950>
412,"22045495
15668449
19193610
17151169
9386855
19077019
14663028
16974109
17499446
9464214
11036168
12476966
3495748
2477071
8834089
7477348
8810256
10195221
15283960
16467370
16943563
17551018
18571864
6603658
18342852
19584430
20164342
17111375
15496472
18337421
11733795
18418360
17567816
19012747
11978854
10758117
18028006
15509759
16918397
12895416
11356984
15514161
18685145
16698938
19895879
15207847
16914869
19850930
21274428
21248787
19012746
16052036
20206287
8637635
17708551
16600515
20615973
20519525
19805389
20037574
16443821
15928715
17507558
15728846
8421494",Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.,"Chronic stress has been suggested to influence the pathogenesis of Alzheimer's disease (AD); however, the mechanism underlying this influence remains unknown. In this study, we created a triple transgenic mouse model that overexpresses corticotrophin-releasing factor (CRF) and human amyloid-β protein precursor (AβPP), to investigate whether increases in the expression of CRF can mimic the effects of stress on amyloid metabolism and the neurodegeneration. Tg2576 mice that overexpresses human AβPP gene were crossbreed with Tetop-CRF (CRF) mice and CaMKII-tTA (tTA) mice to create a novel triple transgenic mouse model that conditioned overexpresses CRF in forebrain and overexpresses human AβPP (called AβPP+/CRF+/tTA+, or TT mice). Then we evaluated serial neuro-anatomical and behavioral phenotypes on TT mice using histological, biochemical, and behavioral assays. TT mice showed a Cushingoid-like phenotype starting at 3 months of age. At 6 months of age, these mice demonstrated increases in tissue-soluble amyloid-β (Aβ) and Aβ plaques in the cortex and hippocampus, as compared to control mice. Moreover, TT mice characterized substantial decreases in dendritic branching and dendritic spine density in pyramidal neurons in layer 4 of the frontal cortex and CA1 of the hippocampus. Finally, TT mice showed significantly impaired working memory and contextual memory, with a modest increase in anxiety-like behavior. Our results suggested genetic increases in the brain of CRF expression mimicked chronic stress on the effects of amyloid deposition, neurodegeneration, and behavioral deficits. The novel transgenic mouse model will provide a unique tool to further investigate the mechanisms between stress and AD.",[],Journal of Alzheimer's disease : JAD,2011-11-03,"[{'lastname': 'Dong', 'firstname': 'Hongxin', 'initials': 'H', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. h-dong@northwestern.edu'}, {'lastname': 'Murphy', 'firstname': 'Keely M', 'initials': 'KM', 'affiliation': None}, {'lastname': 'Meng', 'firstname': 'Liping', 'initials': 'L', 'affiliation': None}, {'lastname': 'Montalvo-Ortiz', 'firstname': 'Janitza', 'initials': 'J', 'affiliation': None}, {'lastname': 'Zeng', 'firstname': 'Ziling', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Kolber', 'firstname': 'Benedict J', 'initials': 'BJ', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Shanshan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Muglia', 'firstname': 'Louis J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Csernansky', 'firstname': 'John G', 'initials': 'JG', 'affiliation': None}]",,,,,10.3233/JAD-2011-111328,<Element 'PubmedArticle' at 0x7f05da77fae0>
413,22045482,Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice.,"The etiology of the more common (sporadic) forms of Alzheimer's disease (AD) remains unknown, although age is the most important risk factor. Nevertheless, interactions between environmental risk factors and genetic background may also influence the onset and progression of sporadic AD. Chronic stress, associated with altered memory and other neurological processes, is thought to influence the pathogenesis of AD. Hence, we evaluated the effect of unpredictable and consecutive chronic mild stressors on the onset of an AD-related pathology in the Tg2576 mouse line that overexpresses the human amyloid-β protein precursor with the Swedish mutation (hAβPP(Swe)). Two months after exposure to chronic mild stress, 4 month-old animals that normally display no pathological features of AD, not only expressed pathological markers but also experienced cognitive dysfunction in the Morris water maze test. These findings suggest that chronic mild stress accelerates the onset of cognitive impairment and produces an increase in hippocampal amyloid-β and phospho-tau levels on a background of AD susceptibility.",[],Journal of Alzheimer's disease : JAD,2011-11-03,"[{'lastname': 'Cuadrado-Tejedor', 'firstname': 'Mar', 'initials': 'M', 'affiliation': 'Division of Neurosciences, CIMA, University of Navarra, Pamplona, Spain. mcuadrado@unav.es'}, {'lastname': 'Ricobaraza', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}, {'lastname': 'Frechilla', 'firstname': 'Diana', 'initials': 'D', 'affiliation': None}, {'lastname': 'Franco', 'firstname': 'Rafael', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pérez-Mediavilla', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Garcia-Osta', 'firstname': 'Ana', 'initials': 'A', 'affiliation': None}]",,,,,10.3233/JAD-2011-110572,<Element 'PubmedArticle' at 0x7f05da72cbd0>
414,"22037597
17682077
17479924
10588579
17151169
16274857
9253318
8182446
19362426
8786810
8622574
10195112
7620309
1759558
7823152
2027050
3527687
8117422
16871536
21059265
16943563
16467370
15324362
19755573
7820622
18854200
19095358
20647348
10204973
12689474
9416776
15522248
15939974
15951357
11324714
15358447
19281812
1334495
19595514
7183759
1009768
6610841
2709039
16401657
19833145
19393639
18583622
16081365
17562829
19187707
17533169
19644122
20157240
20026350
17641528
20129317",The influence of chronic stress on dementia-related diagnostic change in older adults.,"Increased susceptibility of the aging brain to both chronic stress and incipient dementia-related neuropathology may accelerate cognitive decline. We investigated associations between chronic stress and diagnostic change in 62 individuals (mean age, 78.7 y) participating in an Alzheimer disease research center longitudinal study. The subjects, diagnosed at baseline as cognitively normal (CN) or with mild cognitive impairment (MCI), were followed for an average of 2.5 years. Senior neurologists, blind to detailed measures of stress and cognition, assigned diagnoses annually. Logistic regression analyses assessed the accuracy with which measures of stress (event-based ratings, cortisol levels) predicted the conversion to MCI and dementia. Eleven individuals with MCI at baseline received a dementia diagnosis during follow-up. Sixteen converted from cognitively normal to MCI. Prolonged, highly stressful experiences were associated with conversion from MCI to dementia. The cortisol awakening response, with age and education, was associated with a diagnostic change to MCI. Cortisol measures were not associated with the progression from MCI to dementia, and there was no association between stressful experiences and the change to MCI. Mechanisms associated with the transition from normal cognition to MCI may differ from those associated with a diagnostic change to dementia. These findings could facilitate the identification of interventional strategies to reduce the risk of decline at different stages of susceptibility.",[],Alzheimer disease and associated disorders,2011-11-01,"[{'lastname': 'Peavy', 'firstname': 'Guerry M', 'initials': 'GM', 'affiliation': 'Department of Neurosciences, University of California, San Diego, CA, USA. gpeavy@ucsd.edu'}, {'lastname': 'Jacobson', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': None}, {'lastname': 'Salmon', 'firstname': 'David P', 'initials': 'DP', 'affiliation': None}, {'lastname': 'Gamst', 'firstname': 'Anthony C', 'initials': 'AC', 'affiliation': None}, {'lastname': 'Patterson', 'firstname': 'Thomas L', 'initials': 'TL', 'affiliation': None}, {'lastname': 'Goldman', 'firstname': 'Sherry', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mills', 'firstname': 'Paul J', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Khandrika', 'firstname': 'Srikrishna', 'initials': 'S', 'affiliation': None}, {'lastname': 'Galasko', 'firstname': 'Douglas', 'initials': 'D', 'affiliation': None}]",,,,,10.1097/WAD.0b013e3182389a9c,<Element 'PubmedArticle' at 0x7f05da7386d0>
415,"21983493
3472217
16966505
8863508
11852185
14499942
5454590
19864909
17314187
17290105
8863508
10102440
20555148
17596713
8346443
16876668
11746370
10822437
21474934
20029386
20298972
21803501
21455713
18379437
19508444
15174015
8748926
10788705
18562238
20132991
21297645
2492045",Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.,"Neurofilament light (NFL) proteins in cerebrospinal fluid (CSF) are a marker of neuronal damage, especially subcortical axonal injury and white matter disease. Subjects with Alzheimer's disease (AD) have shown elevated levels of CSF NFL as compared to controls. However, the presence of the APOE ε4 allele, an established risk factor for AD, was not found to associate with higher CSF NFL concentrations. We examined whether TOMM40 variants, which have been reported to influence age of onset of AD and are in linkage disequilibrium with APOE, have an effect on CSF NFL levels, in 47 healthy, cognitively intact individuals with or without APOE ε4. Our results show that the presence of APOE ε4 alone does not affect CSF NFL levels significantly; however APOE and TOMM40 appear to interact. Subjects with APOE ε4 have higher CSF NFL levels than non-ε4 carriers, only when they do not carry a short poly-T variant of TOMM40, which is associated with later age of onset of AD, and may act as protective against the dose effect of ε4.",[],Experimental gerontology,2011-10-11,"[{'lastname': 'Bruno', 'firstname': 'Davide', 'initials': 'D', 'affiliation': 'Nathan Kline Institute, Orangeburg, NY 10962, USA. d.bruno@nki.rfmh.org'}, {'lastname': 'Pomara', 'firstname': 'Nunzio', 'initials': 'N', 'affiliation': None}, {'lastname': 'Nierenberg', 'firstname': 'Jay', 'initials': 'J', 'affiliation': None}, {'lastname': 'Ritchie', 'firstname': 'James C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Lutz', 'firstname': 'Michael W', 'initials': 'MW', 'affiliation': None}, {'lastname': 'Zetterberg', 'firstname': 'Henrik', 'initials': 'H', 'affiliation': None}, {'lastname': 'Blennow', 'firstname': 'Kaj', 'initials': 'K', 'affiliation': None}]",,,,Copyright © 2011. Published by Elsevier Inc.,10.1016/j.exger.2011.09.008,<Element 'PubmedArticle' at 0x7f05da758c20>
416,"21983104
17060947
17870207
1759558
19382238
20214944
18434026
12470640
14697239
21219473
19787814
17053024
18541646
12597862
16491079
19595735
20035826
20858966
9379845
18443287
16600402
19352052
10604470
19443690
16112276
17229547
17294832
11880196
15295589
10928290
17560544
20930280
11196643
16723308
12379512
11274343
19828130
19463714
1943736
18267071",Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease.,"Alzheimer's disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by loss of memory and cognitive deficits, strongly influenced by the metabolic status, in which the impairment of neuropeptides/neurotransmitters systems has been previously observed. Ghrelin is a multifunctional hormone produced in a wide variety of tissues, which has been associated with the progression of obesity and metabolic syndrome, but has been also linked to neuromodulation, neuroprotection and memory and learning processes. In addition, ghrelin system also acts in an autocrine/paracrine fashion where the majority of its components [ghrelin variants (native ghrelin, In1-ghrelin), acylation enzyme (GOAT) and receptors (GHS-Rs)] are expressed in the different regions of central nervous system. In spite of all these pieces of information strongly suggesting a close association between ghrelin system and AD, which could be of pathophysiological relevance, few studies have been addressed to clarify this relationship. In this work, the role of ghrelin system in neuroprotection, memory consolidation and learning is reviewed, and its influence in AD, as well as the regulation of its expression in the brain of AD patients, is discussed.",[],Peptides,2011-10-11,"[{'lastname': 'Gahete', 'firstname': 'Manuel D', 'initials': 'MD', 'affiliation': 'Department of Cell Biology, Physiology and Immunology, University of Córdoba, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, and CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.'}, {'lastname': 'Córdoba-Chacón', 'firstname': 'José', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kineman', 'firstname': 'Rhonda D', 'initials': 'RD', 'affiliation': None}, {'lastname': 'Luque', 'firstname': 'Raúl M', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Castaño', 'firstname': 'Justo P', 'initials': 'JP', 'affiliation': None}]",,,,Copyright © 2011 Elsevier Inc. All rights reserved.,10.1016/j.peptides.2011.09.019,<Element 'PubmedArticle' at 0x7f05da6f0900>
417,21967036,"Environmental enrichment compensates for the effects of stress on disease progression in Tg2576 mice, an Alzheimer's disease model.","Various environmental factors are known to influence the onset and progression of Alzheimer's disease (AD). Environmental enrichment was reported to improve cognitive performance in various Alzheimer's transgenic mice via an amyloid-related or unrelated mechanism. However, stress has been found to accelerate amyloid deposition and cognitive deficits in many AD models. The aim of this study was to determine whether environmental enrichment compensates for the effects of stress on disease progression in the Tg2576 mice, an established AD model. We housed Tg2576 mice under environmental enrichment, enrichment plus stress, stress, or control conditions at 3 months of age. In this study, we first report that environmental enrichment counteracts the effects of stress in terms of cognitive deficits, tau phosphorylation, neurogenesis, and neuronal proliferation during AD-like disease progression. These results strongly implicate the importance of environmental factors as a major modulator for the disease progression of AD.",[],Journal of neurochemistry,2011-10-05,"[{'lastname': 'Jeong', 'firstname': 'Yun Ha', 'initials': 'YH', 'affiliation': ""Department of Pharmacology, College of Medicine, National Creative Research Initiative Centre for Alzheimer's Dementia and Neuroscience Research Institute, MRC, Seoul National University, Seoul, Korea.""}, {'lastname': 'Kim', 'firstname': 'Joon Min', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Yoo', 'firstname': 'Jongman', 'initials': 'J', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Sang Hyung', 'initials': 'SH', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Hye-Sun', 'initials': 'HS', 'affiliation': None}, {'lastname': 'Suh', 'firstname': 'Yoo-Hun', 'initials': 'YH', 'affiliation': None}]",,,,© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.,10.1111/j.1471-4159.2011.07514.x,<Element 'PubmedArticle' at 0x7f05da70aea0>
418,21865747,Influence of variation in the follicle-stimulating hormone receptor gene (FSHR) and age at menopause on the development of Alzheimer's disease in women.,"The higher prevalence of sporadic Alzheimer's disease (AD) in women may be explained by their longer life expectancy, but also by biological gender-specific factors such as a woman's past fertility.
We investigated the relationship between fertility and susceptibility to AD in women by studying two polymorphisms at codons 307 and 680 of the follicle-stimulating hormone receptor gene (FSHR) involved in determining human fertility. The role of age at menopause (AM) as a gender-specific AD susceptibility determinant was also examined. The study population comprised 291 AD patients (70.1% women) and 134 controls (63.4% women).
Logistic regression analysis showed that only among the women the FSHR AS/AS genotype was associated with a significantly lower risk of AD (OR = 0.36, 95% CI: 0.15-0.85), suggesting a gender-specific protective role of the FSHR genotype against AD susceptibility. A lower age at natural menopause was observed in the AD patients (49.7 ± 2.53) than in the controls (50.7 ± 2.53, p = 0.02) and on linear regression analysis an association emerged between an earlier AM and an earlier AD onset (p = 0.004).
Genetic and non-genetic gender-specific factors may contribute to the AD pathogenesis in women, although further investigations are required to clarify their actual role.",[],Dementia and geriatric cognitive disorders,2011-08-26,"[{'lastname': 'Corbo', 'firstname': 'Rosa Maria', 'initials': 'RM', 'affiliation': 'Department of Biology and Biotechnology, La Sapienza University, Rome, Italy. rosamaria.corbo @ uniroma1.it'}, {'lastname': 'Gambina', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Broggio', 'firstname': 'Elisabetta', 'initials': 'E', 'affiliation': None}, {'lastname': 'Scacchi', 'firstname': 'Renato', 'initials': 'R', 'affiliation': None}]",,,"Logistic regression analysis showed that only among the women the FSHR AS/AS genotype was associated with a significantly lower risk of AD (OR = 0.36, 95% CI: 0.15-0.85), suggesting a gender-specific protective role of the FSHR genotype against AD susceptibility. A lower age at natural menopause was observed in the AD patients (49.7 ± 2.53) than in the controls (50.7 ± 2.53, p = 0.02) and on linear regression analysis an association emerged between an earlier AM and an earlier AD onset (p = 0.004).","2011 S. Karger AG, Basel.",10.1159/000330472,<Element 'PubmedArticle' at 0x7f05da71d130>
419,"21766035
16648149
11068569
12958002
19219706
2897391
2910973
1739363
1732655
9541379
1955260
12366629
20069607
20649093
20686140
10631588
21481420
15254302
21068014
19219711
8315229
12950477
16434113
15264710
9223710
8708287
19414723
18707942
17203511
17467406
18707945
15313394
10753587
20186710
18500379
18547359
11585617
12359511
8831879
8596223
9114067
15339239
9045866
10782042
15549417
17183314
18590691
7194884
6202444
7955442
8909344
9640414
7519529
9215295
11213280
7539817
2352477
9033509
11549640
12727948
14563498
18931092
14715837
17602136
8857020
10954733
7718235
9618751
8633830
10644927
10022403
10559558
11314741
7133276
7690227
7838905
12415260
19406747
18775495
9391151
10751442
14550766
10668442
12900169
14710348
8682180
9554968
10719076
15232291
7916159
10473933
20471138
15660412
18481319
19269948
21294938
8742417
9722175
10490655
9048647
19834495
20970492
9344566
3467309
3453890
11133160
11600869
14624771
20181121
2458916
1572288
11581107
9316160
8548046
14570891
15738432
9375710
7730546
19247810
2558477
17410470
7915078
1909610
16617154
18312313",Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence.,"Delirium is a frequent complication in medically ill elderly patients that is associated with serious adverse outcomes including increased mortality. Delirium risk is linked to older age, dementia, and illness that involves activation of inflammatory responses. IGF-I is increasingly postulated as a key link between environmental influences on body metabolism with a range of neuronal activities and has been described as the master regulator of the connection between brain and bodily well-being. The relationships between IGF-I and ageing, cognitive impairment and inflammatory illness further support a possible role in delirium pathogenesis. Five studies of IGF-I in delirium were identified by a systematic review. These conflicting findings, with three of the five studies indicating an association between IGF-1 and delirium occurrence, may relate to the considerable methodological differences in these studies. The relevance of IGF-I and related factors to delirium pathogenesis can be clarified by future studies which account for these issues and other confounding factors. Such work can inform therapeutic trials of IGF-I and/or growth hormone administration.",[],Journal of aging research,2011-07-19,"[{'lastname': 'Adamis', 'firstname': 'Dimitrios', 'initials': 'D', 'affiliation': 'Research and Academic Institute of Athens, 27 Themistokleous Street and Akadimias, 10677 Athens, Greece.'}, {'lastname': 'Meagher', 'firstname': 'David', 'initials': 'D', 'affiliation': None}]",,,,,10.4061/2011/951403,<Element 'PubmedArticle' at 0x7f05da6a6270>
420,21762097,Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease.,"Frontotemporal Lobar Degeneration (FTLD) is a genetically and pathologically heterogeneous disorder characterized by behavioral change, executive dysfunction and language impairment associated with frontal and temporal lobe degeneration. Three major clinical subtypes have been identified so far, namely behaviour variant Frontotemporal dementia (bvFTD), Semantic Dementia (SD) and Progressive Non-Fluent Aphasia (PNFA). FTLD might also overlap with atypical parkinsonisms or motor neuron disease. Several pathogenetic mutations have been associated with specific pathological and clinical correlates. FTLD associated with either Microtuble Associated Protein Tau (MAPT) or Progranulin (PGRN) mutations is recognised as the most common form of autosomal dominant inherited disorder. However, monogenic mutations account for only about one third of all FTLD cases. Several studies have evaluated the contribution of genetic background in non-monogenic forms of FTLD, with the attempt to establish its role in increasing disease risk and in modulating clinical phenotypes. Specific MAPT and PGRN polymorphisms have been demonstrated to affect disease onset, clinical features and prognosis of FTLD, and genetic variations within other genes appear to play a role in influencing disease risk and clinical expression of FTLD. The aim of the present review is to discuss the impact and the role of genetic background in non-monogenic forms of FTLD, to highlight new potential pathogenetic and therapeutic targets.",[],Mini reviews in medicinal chemistry,2011-07-19,"[{'lastname': 'Borroni', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Centre for Ageing Brain and Neurodegenerative Disorders, University of Brescia, Italy. bborroni@inwind.it'}, {'lastname': 'Pilotto', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Bianchi', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Gilberti', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Padovani', 'firstname': 'A', 'initials': 'A', 'affiliation': None}]",,,,,10.2174/138955711797068517,<Element 'PubmedArticle' at 0x7f05da6d9900>
421,"21689671
1822725
17970728
10865096
12654969
10573888
8736571
1520089
5815128
17616482
19266016
19465134
7781309
1202204
2082956
19797352
20975559
17293359
19917987
18633132
14991811
17321704
12079762
15496866
11771990
7791999
15582032
12597078
17389003
3816245
19203436
10611129
18766983
19289171
19490081
18330870
17542641
12561084
8413944
20519535
8578071
15917455
20812786
6722512
6610841
2314585
9855500
12902311
20142334
9605389
12441063
15282286
19428428
17376980
15588614
3427396
19766663
19679189
19414722
20407636
12615649
19698727
8186955
20533560
19376066
14714819
15704423
19268594
18694826
3567528
15982678
11784735
18408365
16510269
19657762
6125975
14681117
16644240
17600716
15670682
740510
16136039
3170948",Auditory object cognition in dementia.,"The cognition of nonverbal sounds in dementia has been relatively little explored. Here we undertook a systematic study of nonverbal sound processing in patient groups with canonical dementia syndromes comprising clinically diagnosed typical amnestic Alzheimer's disease (AD; n=21), progressive nonfluent aphasia (PNFA; n=5), logopenic progressive aphasia (LPA; n=7) and aphasia in association with a progranulin gene mutation (GAA; n=1), and in healthy age-matched controls (n=20). Based on a cognitive framework treating complex sounds as 'auditory objects', we designed a novel neuropsychological battery to probe auditory object cognition at early perceptual (sub-object), object representational (apperceptive) and semantic levels. All patients had assessments of peripheral hearing and general neuropsychological functions in addition to the experimental auditory battery. While a number of aspects of auditory object analysis were impaired across patient groups and were influenced by general executive (working memory) capacity, certain auditory deficits had some specificity for particular dementia syndromes. Patients with AD had a disproportionate deficit of auditory apperception but preserved timbre processing. Patients with PNFA had salient deficits of timbre and auditory semantic processing, but intact auditory size and apperceptive processing. Patients with LPA had a generalised auditory deficit that was influenced by working memory function. In contrast, the patient with GAA showed substantial preservation of auditory function, but a mild deficit of pitch direction processing and a more severe deficit of auditory apperception. The findings provide evidence for separable stages of auditory object analysis and separable profiles of impaired auditory object cognition in different dementia syndromes.",[],Neuropsychologia,2011-06-22,"[{'lastname': 'Goll', 'firstname': 'Johanna C', 'initials': 'JC', 'affiliation': 'Dementia Research Centre, Institute of Neurology, University College London, 8-11 Queen Square, London WC1N 3BG, United Kingdom.'}, {'lastname': 'Kim', 'firstname': 'Lois G', 'initials': 'LG', 'affiliation': None}, {'lastname': 'Hailstone', 'firstname': 'Julia C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Lehmann', 'firstname': 'Manja', 'initials': 'M', 'affiliation': None}, {'lastname': 'Buckley', 'firstname': 'Aisling', 'initials': 'A', 'affiliation': None}, {'lastname': 'Crutch', 'firstname': 'Sebastian J', 'initials': 'SJ', 'affiliation': None}, {'lastname': 'Warren', 'firstname': 'Jason D', 'initials': 'JD', 'affiliation': None}]",,,,Copyright © 2011 Elsevier Ltd. All rights reserved.,10.1016/j.neuropsychologia.2011.06.004,<Element 'PubmedArticle' at 0x7f05da662590>
422,"21645364
12928786
17953663
12526812
18568075
14500739
17291356
16862116
16862115
18392865
18771956
15562429
16401871
15258209
20026663
21184660
9855500
11708987
17506892
20522652
20667979
21238488
9353794
19546559",Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients.,"The progranulin gene (PGRN) encodes a pleiotropic molecule with anti-inflammatory actions and neuronal protective effects. Accordingly, PGRN-deficient mice have been demonstrated to develop enhanced inflammation and progressive neurodegeneration. Loss of function mutations of the PGRN gene have been also reported to cause frontotemporal lobar degeneration (FTLD), a neurodegenerative disease leading to dementia generally in the presenium. Since neurodegeneration might be negatively impacted by chronic inflammation, the possible influence of PGRN defects on inflammatory pathways appears to be of great relevance for the understanding of neurodegeneration pathogenic processes in those patients. However, no data about the inflammatory profile of PGRN-defective subjects have been so far provided.In this study, we analyzed serum levels of the pro-inflammatory mediators IL-6, TNF-α and IL-18 in FTLD patients with or without PGRN mutations, at both pre-symptomatic and symptomatic stages. We provide evidence that circulating IL-6 is increased in PGRN-mutated FTLD patients, as compared to both PGRN non-mutated FTLD patients and controls. In contrast, levels of IL-6 were not altered in asymptomatic subjects carrying the PGRN mutations. Finally, TNF-α and IL-18 serum levels did not differ among all groups of included subjects.We conclude that the profile of circulating pro-inflammatory cytokines is altered in PGRN-related symptomatic FTLD. Thus, our findings point to IL-6 as a possible specific mediator and a potential therapeutic target in this monogenic disease, suggesting that an enhanced inflammatory response might be indeed involved in its progression.",[],Journal of neuroinflammation,2011-06-08,"[{'lastname': 'Bossù', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'IRCCS Santa Lucia Foundation, Rome, Italy. p.bossu@hsantalucia.it'}, {'lastname': 'Salani', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Alberici', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': None}, {'lastname': 'Archetti', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': None}, {'lastname': 'Bellelli', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}, {'lastname': 'Spalletta', 'firstname': 'Gianfranco', 'initials': 'G', 'affiliation': None}, {'lastname': 'Caltagirone', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': None}, {'lastname': 'Padovani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': None}, {'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}]",,,,,"10.1186/1742-2094-8-65
10.1007/s00109-003-0474-3
10.1016/S0092-8674(02)01141-8
10.1124/mol.64.4.833
10.1186/1742-2094-4-7
10.1038/nature05017
10.1007/s10048-008-0127-3
10.1016/S1474-4422(08)70194-7
10.1002/ana.20332
10.1136/jnnp.2003.019422
10.1084/jem.20091568
10.1001/archneur.58.11.1803
10.2353/ajpath.2010.090915
10.1096/fj.10-161471
10.1016/S0149-7634(96)00047-4
10.1159/000225962",<Element 'PubmedArticle' at 0x7f05da68de50>
423,"21613497
11381127
16735465
11837744
17409229
7718249
12025941
17912249
17229084
17360899
20097254
17151169
16125145
18071141
16461860
19837693
16943563
3088567
12756137
15883264
9190286
9263193
20231476
21172610
20655099
16467370
17551018
8835879
18007595
20921222
19321462
17430248
12927759
19401723
16406150
17541419
9629527
1674004
16651510
11959919
17567816
17478722
10090741
18177670
9735171
21289177
18573532
18691381
10799757
8083742
15810904
18458206
9809590
1789684
19307538
7876258
17241267
9386855
14663028
17562829",Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits.,"Stressful life experiences are likely etiological factors in sporadic forms of Alzheimer's disease (AD). Many AD patients hypersecrete glucocorticoids (GCs), and their GC levels correlate with the rate of cognitive impairment and extent of neuronal atrophy. Severity of cognitive deficits in AD correlates strongly with levels of hyperphosphorylated forms of the cytoskeletal protein TAU, an essential mediator of the actions of amyloid β (Aβ), another molecule with a key pathogenic role in AD. Our objective was to investigate the sequential interrelationships between these various pathogenic elements, in particular with respect to the mechanisms through which stress might precipitate cognitive decline. We thus examined whether stress, through the mediation of GCs, influences TAU hyperphosphorylation, a critical and early event in the cascade of processes leading to AD pathology. Results from healthy, wild-type, middle-aged rats show that chronic stress and GC induce abnormal hyperphosphorylation of TAU in the hippocampus and prefrontal cortex (PFC), with contemporaneous impairments of hippocampus- and PFC-dependent behaviors. Exogenous GC potentiated the ability of centrally infused Aβ to induce hyperphosphorylation of TAU epitopes associated with AD and cytoplasmic accumulation of TAU, while previous exposure to stress aggravated the biochemical and behavioral effects of GC in Aβ-infused animals. Thus, lifetime stress/GC exposure may have a cumulative impact on the onset and progress of AD pathology, with TAU hyperphosphorylation serving to transduce the negative effects of stress and GC on cognition.",[],The Journal of neuroscience : the official journal of the Society for Neuroscience,2011-05-27,"[{'lastname': 'Sotiropoulos', 'firstname': 'Ioannis', 'initials': 'I', 'affiliation': 'Max Planck Institute of Psychiatry, 80804 Munich, Germany.'}, {'lastname': 'Catania', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': None}, {'lastname': 'Pinto', 'firstname': 'Lucilia G', 'initials': 'LG', 'affiliation': None}, {'lastname': 'Silva', 'firstname': 'Rui', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pollerberg', 'firstname': 'G Elizabeth', 'initials': 'GE', 'affiliation': None}, {'lastname': 'Takashima', 'firstname': 'Akihiko', 'initials': 'A', 'affiliation': None}, {'lastname': 'Sousa', 'firstname': 'Nuno', 'initials': 'N', 'affiliation': None}, {'lastname': 'Almeida', 'firstname': 'Osborne F X', 'initials': 'OF', 'affiliation': None}]",,,,,10.1523/JNEUROSCI.0730-11.2011,<Element 'PubmedArticle' at 0x7f05da6261d0>
424,21574434,[Melatonin: its role in the system of neurohumoral regulation in man. Part 2].,"Part 2 of this review concerns the application of melatonin (Mt) to the treatment of aged patients with cardiovascular diseases and other pathology with reference to its genoprotective and anticarcinogenic action. Effects of Mt on the cardiovascular system are underlain by its antioxidative, vasodilating, and sedative activities, the ability to regulate the heart rate and inhibit platelet aggregation. Certain authors report negative correlation between Mt production and blood cholesterol level. Mt was shown to protect from cardiac lesions associated with ischemia and reperfusion. Mt inhibits carcinogenesis and is active at systemic, tissue, cellular and subcellular levels. At the systemic level, Mt decreases hormonal production, stimulates immune activity, and prevents the development of metabolic syndrome. It inhibits cell proliferation and promotes apoptosis of tumour cells but suppresses it the nervous tissue. Mt activates telomerase. It decreases expression of oncogens and interferes with the action of mutagens and clastogens at the genetic level. Extensive studies of Mt protective action in nervous diseases are underway with special reference to spinal cord, brain, neuron and glial cell lesions; experimental cerebral stroke, Parkinson's and Alzheimer's diseases. Similar studies concern the role of Mt in the protection against ionizing radiation, the development of renal pathology, and ophthalmology (glaucoma, cataract). Mt is shown to influence practically all organ systems by inhibiting mutagenesis and maintaining correlation between circadian rhythms of different biological processes throughout human evolution.",[],Klinicheskaia meditsina,2011-05-18,"[{'lastname': 'Baksheev', 'firstname': 'V I', 'initials': 'VI', 'affiliation': None}, {'lastname': 'Kolomoets', 'firstname': 'N M', 'initials': 'NM', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05da646d10>
425,21557477,Interactions between a luminescent conjugated oligoelectrolyte and insulin during early phases of amyloid formation.,"Aggregates of misfolded proteins play an important role in diseases such as Alzheimer's. Here it is demonstrated how the anionic oligothiophene p-FTAA interacts with and influences pre-fibrillar protein assemblies during the earlier stages of in vitro fibrillation. Conjugated polythiophenes have previously been demonstrated to detect and discriminate between different types of protein aggregates and also introduce luminescent or conductive properties to these nanoscale fiber structures. Fluorescence spectroscopy, DLS, TEM and FCS are employed to follow the interplay between p-FTAA and insulin during in vitro fibrillation.",[],Macromolecular bioscience,2011-05-11,"[{'lastname': 'Wigenius', 'firstname': 'Jens', 'initials': 'J', 'affiliation': 'Biomolecular and Organic Electronics, Department of Applied Physics, IFM, Linköping University, Linköping, Sweden. jens.wigenius@chalmers.se'}, {'lastname': 'Persson', 'firstname': 'Gustav', 'initials': 'G', 'affiliation': None}, {'lastname': 'Widengren', 'firstname': 'Jerker', 'initials': 'J', 'affiliation': None}, {'lastname': 'Inganäs', 'firstname': 'Olle', 'initials': 'O', 'affiliation': None}]",,,,"Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",10.1002/mabi.201100016,<Element 'PubmedArticle' at 0x7f05da64f720>
426,21514366,"Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis.","Steroid hormones (e.g. estrogens, androgens, progestagens) which are synthesized de novo or metabolized within the CNS are called neurosteroids. There is substantial evidence from animal studies suggesting that these steroids can affect brain function by modulating neurotransmission, and influence neuronal survival, neuronal and glial differentiation and myelination in the CNS by regulating gene expression of neurotrophic factors and anti-inflammatory molecules. Indeed, evidence is emerging that expression of the enzymes responsible for the synthesis of neurosteroids changes in neurodegenerative diseases. Some of these changes may contribute to the pathology, while others, conversely, may represent an attempted rescue program in the diseased brain. Here we review the data on changes in neurosteroid levels and neurosteroid synthesis pathways in the human brain in three neurodegenerative conditions, Alzheimers's (AD) and Parkinson's (PD) diseases and Multiple Sclerosis (MS) and the extent to which these findings may implicate protective or pathological roles for neurosteroids in the course of these diseases.Some neurosteroids can modulate neurotransmitter activity, for example, the pregnane steroids allopregnanolone and 3α5α-tetrahydro-deoxycorticosterone which are potent positive allosteric modulators of ionotropic GABA-A receptors. Therefore, neurosteroid-modulated GABA-A receptor subunit alterations found in AD and PD will also be discussed. These data imply an involvement of neurosteroid changes in the neurodegenerative and neuroinflammatory processes and suggest that they may deserve further investigation as potential therapeutic agents in AD, PD and MS. Finally, suggestions for therapeutic strategies will be included. This article is part of a Special Issue entitled: Neuroactive Steroids: Focus on Human Brain.",[],Neuroscience,2011-04-26,"[{'lastname': 'Luchetti', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Netherlands Institute for Neuroscience (NIN), an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands. s.luchetti@nin.knaw.nl'}, {'lastname': 'Huitinga', 'firstname': 'I', 'initials': 'I', 'affiliation': None}, {'lastname': 'Swaab', 'firstname': 'D F', 'initials': 'DF', 'affiliation': None}]",,,,Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2011.04.010,<Element 'PubmedArticle' at 0x7f05da659c70>
427,"21474148
17776927
8593865
1393072
8098802
9524584
18194282
14671395
7895709
8080506
18579535
17956155
15322528
17875490
11375910
8725969
17074984
10438656
11106860
11882475
12834785
15929892
16765025
10188190
16199348
17568585
17683900
18613034
17768031
16690810
16949715
16675520
12060837
15811589
15933200
18252044
17389367
19015723
16079079
16079047
19919614
8340446
18826544
19748073
19375452
15471731
19822263
20049216
12426145
15374672
12843274
16510735
9585224
9809557
11252770
15003168
15082323
17350099
2269895
1613547
15884004
15593136
12629162
15660505
11982672
15099540
16387720
16386941
15582279
16488544
12413371
16310965
15213207
15213206
16607096
15929888
18768812
19059903
17589594
18799442
20525905
16688123",Endocrine disruptors as a threat to neurological function.,"Endocrine disruption is a concept and principle whose origins can be traced to the beginnings of the environmental movement in the 1960s. It began with puzzlement about and the flaring of research on the decline of wildlife, particularly avian species. The proposed causes accented pesticides, especially persistent organochlorines such as DDT. Its scope gradually widened beyond pesticides, and, as endocrine disruption offered an explanation for the wildlife phenomena, it seemed to explain, as well, changes in fertility and disorders of male reproduction such as testicular cancer. Once disturbed gonadal hormone function became the most likely explanation, it provoked other questions. The most challenging arose because of how critical gonadal hormones are to brain function, especially as determinants of brain sexual differentiation. Pursuit of such connections has generated a robust literature embracing a broad swath of chemical classes. How endocrine disrupting chemicals influence the adult and aging brain is a question, so far mostly ignored because of the emphasis on early development, that warrants vigorous investigation. Gonadal hormones are crucial to optimal brain function during maturity and even senescence. They are pivotal to the processes of neurogenesis. They exert protective actions against neurodegenerative disorders such as dementia and support smoothly functioning cognitive activities. The limited research conducted so far on endocrine disruptors, aging, and neurogenesis argues that they should be overlooked no longer.",[],Journal of the neurological sciences,2011-04-09,"[{'lastname': 'Weiss', 'firstname': 'Bernard', 'initials': 'B', 'affiliation': 'Department of Environmental Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA. bernard_weiss@urmc.rochester.edu'}]",,,,Copyright © 2011 Elsevier B.V. All rights reserved.,10.1016/j.jns.2011.03.014,<Element 'PubmedArticle' at 0x7f05da5e1900>
428,21417189,Biological basis for sleep disturbance and behavioral symptoms in dementia: a biobehavioral model.,"Behavioral symptoms and sleep disturbance occur in more than 56% of older adults with mild to moderate dementia and are challenging and costly. This article proposes a biobehavioral causal model to explain sleep disturbances and behavioral symptoms in dementia (BSD) based on an integrative science perspective using the life cycle model of stress (chronic stress) integrating genetic, neuroendocrine, and personality factors. The model proposes that: (a) BSD are an outcome of sleep disturbance; (b) hypothalamic-pituitary-adrenal (HPA) axis dysregulation is key to sleep disturbances and BSD; (c) genotype influences response to stress hormones; (d) HPA is influenced by genotype; (e) trait anxiety moderates the relationship between HPA axis and BSD and/or sleep disturbances; and (f) trait anxiety is influenced by genotype. Examining these relationships simultaneously will advance our theoretical understanding of BSD and sleep disturbances, potentially providing a basis for the design of targeted interventions and prevention strategies with an understanding of risk.",[],Research in gerontological nursing,2011-03-23,"[{'lastname': 'Woods', 'firstname': 'Diana Lynn', 'initials': 'DL', 'affiliation': 'University of California, Los Angeles, CA, USA. lwoods@sonnet.ucla.edu'}, {'lastname': 'Phillips', 'firstname': 'Linda R', 'initials': 'LR', 'affiliation': None}, {'lastname': 'Martin', 'firstname': 'Jennifer L', 'initials': 'JL', 'affiliation': None}]",,,,"Copyright 2011, SLACK Incorporated.",10.3928/19404921-20110302-01,<Element 'PubmedArticle' at 0x7f05da606d10>
429,"21398043
1759558
19595937
18686744
16306154
19671904
18768414
16418406
15383515
15781953
15623693
20101014
15858047
19524672
18813861
19219917
18258444
17698211
16177036
19309034
19360903
20127037
18400101
16806094
15548201
8836544
19923361
19828787
10504200
10022581
17562829
16974109
17544378
20079936
17151169
10195112
1308198
17524488
7729802
15283960
18849021
16467370
19896484
19170443
18571864
19012747
18282566
12603278
9882536
19584431
19948164
11173088
15689544
11675510
16531997
20406350
9618016
20182020
20303880
19221412
18369648
10217662
19443808
18322369
19275634
19002474
19319544
16357086
11448080
15265270
17711428
17068287
18025297
20663268
16139378
12624277
18772322
19246701
8948008
11804992
18609305
15692095
17121741
11020101
20048193
15716413
18202172
18256340
19559404
18564425
19542618
19945109
17765329
15046975
15501922
11801260
18468686
18474414
15100718
16306271
10465438
12661673
20211699
17374720
19589885
12951572
14656329
12086642
14702101
20231468
19576269","Stress, exercise, and Alzheimer's disease: a neurovascular pathway.","Genetic factors are known to play a role in Alzheimer's disease (AD) vulnerability, yet less than 1% of incident AD cases are directly linked to genetic causes, suggesting that environmental variables likely play a role in the majority of cases. Several recent human and animal studies have examined the effects of behavioral factors, specifically psychological stress and exercise, on AD vulnerability. Numerous animal studies have found that, while stress exacerbates neuropathological changes associated with AD, exercise reduces these changes. Some human studies suggest that psychological stress can increase the risk of developing AD, while other studies suggest that exercise can significantly reduce AD risk. Most animal studies investigating the mechanisms responsible for the effects of these behavioral factors have focused on neuronal processes, including the effects of stress hormones and neurotrophic factors on the neuropathological hallmarks of AD, namely amyloid-beta (Aβ) deposition and tau-phosphorylation. However, cumulative evidence indicates that, in humans, AD is associated with the presence of cerebrovascular disease, and cardiovascular risk factors are associated with increased risk of developing AD. There is an extensive literature demonstrating that behavioral factors, particularly stress and exercise, can powerfully modulate the pathophysiology of vascular disease. Thus, the following model proposes that the influence of stress and exercise on AD risk may be partially due to the effects of these behavioral factors on vascular homeostasis and pathology. These effects are likely due to both indirect modification of AD risk through alterations in vascular risk factors, such as hypertension, diabetes, and aortic stiffening, as well as direct influence on the cerebrovasculature, including changes in cerebral blood flow, angiogenesis, and vascular disease. Future studies examining the effects of behavioral factors on AD risk should incorporate measures of both peripheral and cerebral vascular function to further our understanding of the mechanisms by which behavior can modify AD susceptibility. Greater knowledge of the molecular mechanisms behind these behavioral effects would further our understanding of the disease and lead to innovative treatment and preventive approaches.",[],Medical hypotheses,2011-03-15,"[{'lastname': 'Nation', 'firstname': 'Daniel A', 'initials': 'DA', 'affiliation': 'University of California San Diego, School of Medicine, Department of Psychiatry, San Diego, CA, USA. dnation@ucsd.edu'}, {'lastname': 'Hong', 'firstname': 'Suzi', 'initials': 'S', 'affiliation': None}, {'lastname': 'Jak', 'firstname': 'Amy J', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Delano-Wood', 'firstname': 'Lisa', 'initials': 'L', 'affiliation': None}, {'lastname': 'Mills', 'firstname': 'Paul J', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Bondi', 'firstname': 'Mark W', 'initials': 'MW', 'affiliation': None}, {'lastname': 'Dimsdale', 'firstname': 'Joel E', 'initials': 'JE', 'affiliation': None}]",,,,Copyright © 2011 Elsevier Ltd. All rights reserved.,10.1016/j.mehy.2011.02.034,<Element 'PubmedArticle' at 0x7f05da6105e0>
430,"21318332
15044253
6253241
17072330
15837534
10235609
12788798
19763608
15748537
15122352
11795524
18692159
16960103
12709417
15051314
18474827
16513650
15284284
17147916
16784934
19059306
17072321
15853700
17556883
12424381
16221213
19864304
18548143
12470896
20187708
20431987
20211236
17878513
5432063
11348997
19627202
16200195
12631096
16870827
19395552
10642297
10864918
16280370
20689271
18583377
12215489
15834285
1438983
12663375
11200499
16910760
15653325
18073321
12411725
12028439
16497363
11931769
8361127",Mechanism of Ang II involvement in activation of NF-κB through phosphorylation of p65 during aging.,"Angiotensin II (Ang II), a major effector of the renin-angiotensin system, is now recognized as a pro-inflammatory mediator. This Ang II signaling, which causes transcription of pro-inflammatory genes, is regulated through nuclear factor-κB (NF-κB). At present, the molecular mechanisms underlying the effect of aging on Ang II signaling and NF-κB activation are not fully understood. The purpose of this study was to document altered molecular events involved in age-related changes in Ang II signaling and NF-κB activation. Experimentations were carried out using kidney tissues from Fischer 344 rats at 6, 12, 18, and 24 months of age, and the rat endothelial cell line, YPEN-1 for the detailed molecular work. Results show that increases in Ang II and Ang II type 1 receptor during aging were accompanied by the generation of reactive species. Increased Ang II activated NF-κB by phosphorylating IκBα and p65. Increased phosphorylation of p65 at Ser 536 was mediated by the enhanced phosphorylation of IκB kinase αβ, while phosphorylation site Ser 276 of p65 was mediated by upregulated mitogen-activated and stress-activated protein kinase-1. These altered molecular events in aged animals were partly verified by experiments using YPEN-1 cells. Collectively, our findings provide molecular insights into the pro-inflammatory actions of Ang II, actions that influence the phosphorylation of p65-mediated NF-κB activation during aging. Our study demonstrates the age-related pleiotropic nature of the physiologically important Ang II can change into a deleterious culprit that contributes to an increased incidence of many chronic diseases such as atherosclerosis, diabetes, and dementia.",[],"Age (Dordrecht, Netherlands)",2011-02-15,"[{'lastname': 'Kim', 'firstname': 'Ji Min', 'initials': 'JM', 'affiliation': 'Molecular Inflammation Research Center for Aging Intervention, Pusan National University, San 30, Jangjun-dong, Gumjung-gu, Busan, 609-735, South Korea.'}, {'lastname': 'Heo', 'firstname': 'Hyoung-Sam', 'initials': 'HS', 'affiliation': None}, {'lastname': 'Ha', 'firstname': 'Young Mi', 'initials': 'YM', 'affiliation': None}, {'lastname': 'Ye', 'firstname': 'Byeong Hyeok', 'initials': 'BH', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Eun Kyeong', 'initials': 'EK', 'affiliation': None}, {'lastname': 'Choi', 'firstname': 'Yeon Ja', 'initials': 'YJ', 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'Byung Pal', 'initials': 'BP', 'affiliation': None}, {'lastname': 'Chung', 'firstname': 'Hae Young', 'initials': 'HY', 'affiliation': None}]",,,,,"10.1007/s11357-011-9207-7
10.1182/blood-2003-08-2974
10.3109/10641968009037127
10.1038/sj.onc.1209942
10.1016/j.regpep.2004.12.027
10.1210/er.2003-0001
10.1007/s00424-009-0725-4
10.1007/s11906-005-0086-0
10.1038/nrm1368
10.1111/j.1749-6632.2001.tb05662.x
10.1016/j.arr.2008.07.002
10.1161/01.RES.0000244015.10655.3f
10.1016/j.mam.2004.02.006
10.1161/HYPERTENSIONAHA.107.108985
10.1074/jbc.M512815200
10.1097/01.ASN.0000132474.50966.DA
10.1007/s11906-006-0050-7
10.1016/j.amjcard.2006.01.059
10.1016/j.mce.2008.11.003
10.1038/sj.onc.1209954
10.2174/1568016053544363
10.1097/HCO.0b013e3281532b53
10.1126/science.1071914
10.1111/j.1523-1755.2005.00670.x
10.1152/ajprenal.00248.2009
10.1016/S0828-282X(08)70620-2
10.1016/S0047-6374(02)00094-5
10.1007/s11357-009-9124-1
10.1016/j.exger.2010.03.005
10.1124/pr.59.3.3
10.1161/hh0901.090299
10.1089/jmf.2008.1073
10.1172/JCI26322
10.1046/j.1523-1755.2003.00838.x
10.1152/ajpheart.00300.2009
10.1093/ndt/gfi265
10.1159/000318607
10.1152/japplphysiol.90553.2008
10.1161/01.RES.0000033523.08033.16
10.1097/01.hjh.0000166840.63312.12
10.1161/01.ATV.0000069236.27911.68
10.1089/ars.2006.8.1121
10.1016/j.tibs.2004.11.009
10.1159/000066656
10.1046/j.1523-1755.2002.00365.x
10.1016/j.mad.2006.01.023
10.1016/S1097-2765(02)00477-X",<Element 'PubmedArticle' at 0x7f05da5c3e50>
431,21232819,Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia.,"Frontotemporal lobar degeneration with neuronal inclusions containing TAR DNA binding protein 43 (TDP-43) is associated in most cases with null-mutations in the progranulin gene (PGRN). While the mechanisms by which PGRN haploinsufficiency leads to neurodegeneration remained speculative, increasing evidence support the hypothesis that cell cycle reentry of postmitotic neurons precedes many instances of neuronal death. Based in the mitogenic and neurotrophic activities of PGRN, we hypothesized that PGRN deficit may induce cell cycle disturbances and alterations in neuronal vulnerability. Because cell cycle dysfunction is not restricted to neurons, we studied the influence of PGRN haploinsufficiency, on cell cycle control in peripheral cells from patients suffering from frontotemporal dementia, bearing the PGRN mutation c.709-1G>A. Here we show that progranulin deficit increased cell cycle activity in immortalized lymphocytes. This effect was associated with increased levels of cyclin-dependent kinase 6 (CDK6) and phosphorylation of retinoblastoma protein (pRb), resulting in a G(1)/S regulatory failure. A loss of function of TDP-43 repressing CDK6 expression may result from altered subcellular TDP-43 distribution. The distinct functional features of lymphoblastoid cells from c.709-1 G>A carriers offer an invaluable, noninvasive tool to investigate the etiopathogenesis of frontotemporal lobar degeneration.",[],Neurobiology of aging,2011-01-15,"[{'lastname': 'Alquezar', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain.'}, {'lastname': 'Esteras', 'firstname': 'Noemí', 'initials': 'N', 'affiliation': None}, {'lastname': 'Bartolomé', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': None}, {'lastname': 'Merino', 'firstname': 'José J', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Alzualde', 'firstname': 'Ainhoa', 'initials': 'A', 'affiliation': None}, {'lastname': 'López de Munain', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': None}, {'lastname': 'Martín-Requero', 'firstname': 'Ángeles', 'initials': 'Á', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2010.11.020,<Element 'PubmedArticle' at 0x7f05da56e770>
432,"21220649
20460622
19734902
19734903
20070850
20154673
20065792
17334266
16950801
16983685
19012866
19683260
19224898
19158106
8232972
2011243
12074169
17982457
11308071
9697696
10831398
15534888
10815136
17826340
15297300
16845085
18183624
14726484
20354512
19288468
18768919
12891668
20634593
18541914
18813964
20862329
19548255",Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.,"To test whether rs1990622 (TMEM106B) is associated with age at onset (AAO) in granulin (GRN) mutation carriers and with plasma GRN levels in mutation carriers and healthy, elderly individuals. Rs1990622 (TMEM106B) was identified as a risk factor for frontotemporal lobar degeneration with TAR DNA-binding protein inclusions (FTLD-TDP) in a recent genome-wide association.
Rs1990622 was genotyped in GRN mutation carriers and tested for association with AAO using the Kaplan-Meier method and a Cox proportional hazards model.
Alzheimer's Disease Research Center. Subjects  We analyzed 50 affected and unaffected GRN mutation carriers from 4 previously reported FTLD-TDP families (HDDD1, FD1, HDDD2, and the Karolinska family). The GRN plasma levels were also measured in 73 healthy, elderly individuals.
Age at onset and GRN plasma levels.
The risk allele of rs1990622 was associated with a mean decrease of the AAO of 13 years (P = 9.9 × 10(-7)) and with lower plasma GRN levels in both healthy older adults (P = 4 × 10(-4)) and GRN mutation carriers (P = .0027). Analysis of the HapMap database identified a nonsynonymous single-nucleotide polymorphism rs3173615 (T185S) in perfect linkage disequilibrium with rs1990622.
The association of rs1990622 with AAO explains, in part, the wide range in the AAO of disease among GRN mutation carriers. We hypothesize that rs1990622 or another variant in linkage disequilibrium could act in a manner similar to APOE in Alzheimer disease, increasing risk for disease in the general population and modifying AAO in mutation carriers. Our results also suggest that genetic variation in TMEM106B may influence risk for FTLD-TDP by modulating secreted levels of GRN.",[],Archives of neurology,2011-01-12,"[{'lastname': 'Cruchaga', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Department of Psychiatry, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA.'}, {'lastname': 'Graff', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': None}, {'lastname': 'Chiang', 'firstname': 'Huei-Hsin', 'initials': 'HH', 'affiliation': None}, {'lastname': 'Wang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hinrichs', 'firstname': 'Anthony L', 'initials': 'AL', 'affiliation': None}, {'lastname': 'Spiegel', 'firstname': 'Noah', 'initials': 'N', 'affiliation': None}, {'lastname': 'Bertelsen', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mayo', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': None}, {'lastname': 'Norton', 'firstname': 'Joanne B', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Morris', 'firstname': 'John C', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Goate', 'firstname': 'Alison', 'initials': 'A', 'affiliation': None}]",,,The risk allele of rs1990622 was associated with a mean decrease of the AAO of 13 years (P = 9.9 × 10(-7)) and with lower plasma GRN levels in both healthy older adults (P = 4 × 10(-4)) and GRN mutation carriers (P = .0027). Analysis of the HapMap database identified a nonsynonymous single-nucleotide polymorphism rs3173615 (T185S) in perfect linkage disequilibrium with rs1990622.,,10.1001/archneurol.2010.350,<Element 'PubmedArticle' at 0x7f05da579d10>
433,21196374,Inflammation and oxidative damage in Alzheimer's disease: friend or foe?,"The two major neuropathologic hallmarks of AD are extracellular Amyloid beta plaques and intracellular neurofibrillary tangles. A number of additional pathogenic mechanisms have been described, including inflammation and oxidative damage. Regarding inflammation, several cytokines and chemokines have been detected both immunohistochemically and in Cerebrospinal Fluid from patients. Some of them, including Tumor Necrosis Factor-alpha, Interferon-gamma-inducible Protein-10, Monocyte Chemotactic Protein-1 and Interleukin-8, are increased in AD and in Mild Cognitive Impairment, considered the prodromal stage of AD, suggesting that these modifications occur very early during the development of the disease, possibly explaining the failure of trials with anti-inflammatory agents in patients with severe AD. Further evidence suggests that cytokines and chemokines could play a role in other neurodegenerative disorders. These disorders are considered multifactorial diseases, and genetic factors influence pathological events and contribute to change the disease phenotype from patient to patient. Gene polymorphisms in crucial molecules, including cytokines, chemokines and molecules related to oxidative stress, may act as susceptibility factors, or may operate as regulatory factors, modulating the severity of pathogenic processes.",[],Frontiers in bioscience (Scholar edition),2011-01-05,"[{'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Department of Neurological Sciences, Dino Ferrari Center, University of Milan, Fondazione Ca' Granda, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy. daniela.galimberti@unimi.it""}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}]",,,,,10.2741/s149,<Element 'PubmedArticle' at 0x7f05da597c20>
434,"21115952
16361024
10599761
17132977
19029150
18384771
19273747
18198237
19728115
5026763
3899825
10857969
9521184
1202204
996204
3790869
6610841
17623828
11368702
17726040
17320789
7549807
15223696
7635118
20393152
15277613
18401020
19455303
15326238
15477536
9366728
17101823
10818510
15964100
11916953
15477535
17192484",Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study.,"Diabetes mellitus has been associated with an increased risk of Alzheimer disease (AD), but how it exerts its effect remains controversial. Possible pathophysiologic mechanisms are glucose toxicity and a direct effect of insulin on amyloid metabolism. Most studies had short follow-up, and longer-term effects of diabetes on AD risk are unknown. We investigated whether fasting glucose and insulin levels and insulin resistance are associated with the risk of AD and whether this risk is constant over time.
The study was based on 3,139 participants of the Rotterdam Study, a population-based cohort study. All subjects were free from dementia, did not have a history of diabetes, and had fasting levels of glucose and insulin measured at baseline. Insulin resistance was estimated with the homeostasis model assessment. We investigated how fasting glucose, insulin, and insulin resistance are related to the risk of AD in 3 different strata according to time-to-event, using Cox proportional hazards models.
During follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD.
Our findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years.",[],Neurology,2010-12-01,"[{'lastname': 'Schrijvers', 'firstname': 'E M C', 'initials': 'EM', 'affiliation': 'Department of Epidemiology, Erasmus MC University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.'}, {'lastname': 'Witteman', 'firstname': 'J C M', 'initials': 'JC', 'affiliation': None}, {'lastname': 'Sijbrands', 'firstname': 'E J G', 'initials': 'EJ', 'affiliation': None}, {'lastname': 'Hofman', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Koudstaal', 'firstname': 'P J', 'initials': 'PJ', 'affiliation': None}, {'lastname': 'Breteler', 'firstname': 'M M B', 'initials': 'MM', 'affiliation': None}]",,,"During follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD.",,10.1212/WNL.0b013e3181ffe4f6,<Element 'PubmedArticle' at 0x7f05da524180>
435,21053258,Study of the interaction between the amyloid beta peptide (1-40) and antioxidant compounds by nuclear magnetic resonance spectroscopy.,"Amyloid beta peptide (Abeta) aggregation leads to the senile plaque formation, a process that is strongly influenced by oxidative stress and is considered as the molecular basis of various neurodegenerative diseases, such as Alzheimer's disease (AD). Endogenous antioxidants or dietary derived compounds may down-regulate this process. In this study, the interaction of two antioxidants, oleuropein (OE) and melatonin (M), with Abeta is monitored through nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. The concerted application of these two analytical techniques provides new experimental evidence and residue-specific insights into the interacting Abeta peptide amino acids that are implicated in this process. Both antioxidant compounds interact in a similar way with the peptide and cause chemical shift variations. The most pronounced resonance changes have been observed for the 1H-15N signals of N-terminal region and Leu17-Phe20 residues, as monitored by NMR titration studies.",[],Biopolymers,2010-11-06,"[{'lastname': 'Galanakis', 'firstname': 'Petros A', 'initials': 'PA', 'affiliation': 'Department ofPharmacy, University ofPatras, Panepistimioupoli, Rion, GR 26504, Greece.'}, {'lastname': 'Bazoti', 'firstname': 'Fotini N', 'initials': 'FN', 'affiliation': None}, {'lastname': 'Bergquist', 'firstname': 'Jonas', 'initials': 'J', 'affiliation': None}, {'lastname': 'Markides', 'firstname': 'Karin', 'initials': 'K', 'affiliation': None}, {'lastname': 'Spyroulias', 'firstname': 'Georgios A', 'initials': 'GA', 'affiliation': None}, {'lastname': 'Tsarbopoulos', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': None}]",,,,,10.1002/bip.21558,<Element 'PubmedArticle' at 0x7f05da53c590>
436,"21047645
20026663
12928786
18359860
10858277
16862115
16862116
19288468
18768919
19158106
18723524
19847305
19446372
18565828
19625741
6610841
9855500
10190820
11735772
15817019
18184915
18551524
18989115
17949857
18797253
19683260
17291356
19056610",rs5848 polymorphism and serum progranulin level.,"To assess the influence of rs5848 polymorphism in serum progranulin (PGRN) level in a cohort of subjects with Alzheimer and related dementias from a tertiary referral clinic.
Mutations in the GRN gene cause autosomal dominant frontotemporal dementia (FTD) with TDP-43 pathology (FTLD-TDP) through haploinsufficiency. It has recently been shown that homozygous carriers of the T allele of rs5848 have an elevated risk of developing FTD, and this polymorphism may play a role in the pathogenesis of other dementia by modifying progranulin level. We hypothesize that genotype of rs5848 may influence serum PGRN level in AD, FTD, and other dementias.
Blood samples were obtained from patients with cognitive impairment and dementia referred to a tertiary dementia clinic, as well as samples from a cohort of healthy controls. Serum PGRN level was measured using an ELISA assay, and rs5848 genotype was determined by a TaqMan assay.
We found that rs5848 SNP significantly influenced serum PGRN level, with TT genotype having the lowest levels, and CC as the highest. This relationship is observed in each of the subgroups. We also confirmed that GRN mutation carriers had significantly lower serum PGRN levels than all other groups.
The rs5848 polymorphism significantly influences serum PGRN with TT carriers having a lower level of serum PGRN then CT and CC carriers. This is consistent with the finding that miR-659 binding to the high risk T allele of rs5848 may augment translational inhibition of GRN and alter risk of FTD and possibly other dementias.",[],Journal of the neurological sciences,2010-11-05,"[{'lastname': 'Hsiung', 'firstname': 'Ging-Yuek R', 'initials': 'GY', 'affiliation': 'Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada. hsiung@interchange.ubc.ca'}, {'lastname': 'Fok', 'firstname': 'Alice', 'initials': 'A', 'affiliation': None}, {'lastname': 'Feldman', 'firstname': 'Howard H', 'initials': 'HH', 'affiliation': None}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': None}, {'lastname': 'Mackenzie', 'firstname': 'Ian R A', 'initials': 'IR', 'affiliation': None}]",,,"We found that rs5848 SNP significantly influenced serum PGRN level, with TT genotype having the lowest levels, and CC as the highest. This relationship is observed in each of the subgroups. We also confirmed that GRN mutation carriers had significantly lower serum PGRN levels than all other groups.",Copyright © 2010 Elsevier B.V. All rights reserved.,10.1016/j.jns.2010.10.009,<Element 'PubmedArticle' at 0x7f05da5458b0>
437,21039205,The improvement of cognitive functions in patients with bronchial asthma after therapy.,"The severity of asthma in older people is frequently underestimated because of underdiagnosis and undertreatment. There are a number of reasons for this. In elderly patients, chronic diseases can be related to declining cognitive function. This situation could influence diagnosis and treatment. The objective of this study was to evaluate the influence of appropriate asthma therapy on cognitive function.
A total of 359 participants diagnosed with bronchial asthma, 219 women and 140 men with a mean age of 69 ± 4.03 years, were included in this study. Cognitive function was assessed with the Mini-Mental State Examination (MMSE) at the beginning of this study and after 1 year. Patients were divided into three subgroups based on their initial MMSE scores dementia, mild cognitive impairment (MCI), and good cognition.
At the beginning of this study, 31.2% of patients presented uncontrolled asthma, 46.2% exhibited partly controlled asthma, and 25.1% had well-controlled asthma. A significant improvement in control over the patients' asthma was observed over the course of this study. After 1 year of treatment, the mean MMSE score significantly increased in initially demented patients, from 18.2 ± 3.1 (mean ± SD) to 21.9 ± 2.1 (p < .01); in subjects with MCI, from 25.4 ± 0.9 to 27.2 ± 1.2; and in patients with good cognition, from 27.4 ± 0.7 to 29.7 ± 0.4 (chi-square test, p < .01).
Proper control of asthma in patients with cognitive impairments can improve some cognitive functions.",[],The Journal of asthma : official journal of the Association for the Care of Asthma,2010-11-03,"[{'lastname': 'Bozek', 'firstname': 'Andrzej', 'initials': 'A', 'affiliation': 'Clinical Department of Internal Medicine, Dermatology and Allergology, Silesian University School of Medicine, Zabrze, Poland. andrzejbozek@o2.pl'}, {'lastname': 'Krajewska', 'firstname': 'Jolanta', 'initials': 'J', 'affiliation': None}, {'lastname': 'Jarzab', 'firstname': 'Jerzy', 'initials': 'J', 'affiliation': None}]",,Proper control of asthma in patients with cognitive impairments can improve some cognitive functions.,"At the beginning of this study, 31.2% of patients presented uncontrolled asthma, 46.2% exhibited partly controlled asthma, and 25.1% had well-controlled asthma. A significant improvement in control over the patients' asthma was observed over the course of this study. After 1 year of treatment, the mean MMSE score significantly increased in initially demented patients, from 18.2 ± 3.1 (mean ± SD) to 21.9 ± 2.1 (p < .01); in subjects with MCI, from 25.4 ± 0.9 to 27.2 ± 1.2; and in patients with good cognition, from 27.4 ± 0.7 to 29.7 ± 0.4 (chi-square test, p < .01).",,10.3109/02770903.2010.513077,<Element 'PubmedArticle' at 0x7f05da55b810>
438,20888079,Hormone levels and cognitive function in postmenopausal midlife women.,"Gonadal hormones may influence cognitive function. Postmenopausal midlife women in the population-based Melbourne Women's Midlife Health Project cohort were administered a comprehensive battery of neuropsychological tests on two occasions 2 years apart. Participants (n = 148, mean age 60 years) had undergone natural menopause and were not using hormone therapy. Estrone, total and free estradiol, and total and free testosterone levels were measured at time of the first testing. Principal-component analysis identified four cognitive factors. In multiple linear regression analyses, better semantic memory performance was associated with higher total (p = 0.02) and free (p = 0.03) estradiol levels and a lower ratio of testosterone to estradiol (p = 0.007). There were trends for associations between better verbal episodic memory and lower total testosterone (p = 0.08) and lower testosterone/estradiol ratio (p = 0.06). Lower free testosterone levels were associated with greater 2-year improvement on verbal episodic memory (p = 0.04); higher testosterone/estradiol predicted greater semantic memory improvement (p = 0.03). In postmenopausal midlife women, endogenous estradiol and testosterone levels and the testosterone/estradiol ratio are associated with semantic memory and verbal episodic memory abilities.",[],Neurobiology of aging,2010-10-05,"[{'lastname': 'Ryan', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Department of Psychiatry and National Ageing Research Institute, The University of Melbourne, Parkville 3010, Victoria, Australia; INSERM, U888, Montpellier, F-34093, France; University Montpellier 1, Montpellier, F-34000, France.'}, {'lastname': 'Stanczyk', 'firstname': 'Frank Z', 'initials': 'FZ', 'affiliation': None}, {'lastname': 'Dennerstein', 'firstname': 'Lorraine', 'initials': 'L', 'affiliation': None}, {'lastname': 'Mack', 'firstname': 'Wendy J', 'initials': 'WJ', 'affiliation': None}, {'lastname': 'Clark', 'firstname': 'Margaret S', 'initials': 'MS', 'affiliation': None}, {'lastname': 'Szoeke', 'firstname': 'Cassandra', 'initials': 'C', 'affiliation': None}, {'lastname': 'Kildea', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Henderson', 'firstname': 'Victor W', 'initials': 'VW', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2010.07.014,<Element 'PubmedArticle' at 0x7f05da4e5cc0>
439,20858966,Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients.,"Ghrelin and neurotensin (NTS) are neuroendocrine peptides that exert opposite effects on food intake and energy homeostasis, but share comparable actions in improving memory and learning. Ghrelin and NTS mediate their effects via receptors with high evolutionary identity: two ghrelin G-protein coupled receptors (GPCRs; GHS-R1a/1b) and three NTS-receptors, two GPCRs (NTSR1/2) and one non-GPCR (NTSR3). Because ghrelin and NTS systems are tightly linked to energy balance regulation and cognitive processes, they have been proposed to be altered in Alzheimer's disease (AD), a dementia syndrome markedly influenced by the metabolic status. Although it has been demonstrated that ghrelin and NTS can attenuate AD-related cognitive impairment, a comprehensive analysis of these systems in AD has not been conducted. Here, we used quantitative real time-RT-PCR to analyze expression of the ghrelin/NTS axis in one of the cortical regions most affected in AD, the temporal gyrus. Results unveiled a striking reduction of mRNA levels for ghrelin, and its newly discovered In2-ghrelin variant, as well as for the enzyme responsible for ghrelin acylation, ghrelin-O-acyltransferase and GHS-R1a, while expression of GHS-R1b was markedly increased. In addition, expression levels of NTSR1 and NTSR2 were profoundly decreased in AD, whereas mRNA levels of NTS only declined slightly, and those of NTSR3 (which is involved in neuronal apoptosis) did not vary. Taken together, our results provide the first quantitative evidence showing that ghrelin/NTS systems are markedly altered in the brain of AD patients, thereby suggesting that these systems may contribute to the severe cognitive deficit observed in this pathology.",[],Journal of Alzheimer's disease : JAD,2010-09-23,"[{'lastname': 'Gahete', 'firstname': 'Manuel D', 'initials': 'MD', 'affiliation': 'Department of Cell Biology, Physiology and Immunology, University of Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba, and CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.'}, {'lastname': 'Rubio', 'firstname': 'Alicia', 'initials': 'A', 'affiliation': None}, {'lastname': 'Córdoba-Chacón', 'firstname': 'José', 'initials': 'J', 'affiliation': None}, {'lastname': 'Gracia-Navarro', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': None}, {'lastname': 'Kineman', 'firstname': 'Rhonda D', 'initials': 'RD', 'affiliation': None}, {'lastname': 'Avila', 'firstname': 'Jesús', 'initials': 'J', 'affiliation': None}, {'lastname': 'Luque', 'firstname': 'Raúl M', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Castaño', 'firstname': 'Justo P', 'initials': 'JP', 'affiliation': None}]",,,,,10.3233/JAD-2010-100873,<Element 'PubmedArticle' at 0x7f05da4f3950>
440,20804113,Sleep in older adults with Alzheimer's disease.,"Sleep in older adults with Alzheimer's disease can often be extremely fragmented, thus disturbing normal sleep-wake rhythms. This poor-quality sleep is challenging for caregivers and frequently results in admitting older adults to long-term care institutions. Many variables, such as genes, medications, depression, and environmental factors, influence sleep in persons with Alzheimer's disease. Interventions, such as exposure to light, melatonin therapy, sleep hygiene, and physical activity, are commonly used to treat or to prevent sleep problems. Neuroscience nurses can play an important role in assessing sleep characteristics and related factors, educating caregivers and staff, providing family members with emotional support, and conducting research.",[],The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses,2010-09-02,"[{'lastname': 'Song', 'firstname': 'Yeonsu', 'initials': 'Y', 'affiliation': 'San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA. song.yeonsu@gmail.com'}, {'lastname': 'Dowling', 'firstname': 'Glenna A', 'initials': 'GA', 'affiliation': None}, {'lastname': 'Wallhagen', 'firstname': 'Margaret I', 'initials': 'MI', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Kathryn A', 'initials': 'KA', 'affiliation': None}, {'lastname': 'Strawbridge', 'firstname': 'William J', 'initials': 'WJ', 'affiliation': None}]",,,,,10.1097/jnn.0b013e3181e26b1d,<Element 'PubmedArticle' at 0x7f05da4ff3b0>
441,"20711061
16950801
17826340
19101631
18234697
17950702
19858458
16904828
10072441
12183028
18657254",Prion protein codon 129 polymorphism modifies age at onset of frontotemporal dementia with the C.709-1G>A progranulin mutation.,"Frontotemporal lobar degeneration because of mutations in the progranulin (PGRN) gene presents a high variability both in the clinical phenotype and age of onset of disease. Factors that influence this variability remain largely unknown. The aim of our study was to determine whether selected genetic variables modify age at onset of disease in our series of 21 patients with a single splicing mutation (c.709-1G>A) in the PGRN gene, all of whom were of Basque descent. In our analysis, we included the following genetic variables: PGRN rs5848 and rs9897526 polymorphisms, APOE and microtubule-associated protein tau genotypes, and PRNP codon 129 polymorphism. We found no association between PGRN polymorphisms, APOE and microtubule-associated protein tau genotypes, and age at onset of the disease; whereas we report evidence for an association between PRNP codon 129 polymorphism and age at onset of disease in frontotemporal dementia-PGRN(+) patients. MM homozygous carriers presented onset of disease on average 8.5 years earlier than patients who carried at least 1 valine on their PRNP codon 129 (MV or VV). The biological justification for this association remains speculative.",[],Alzheimer disease and associated disorders,2010-08-17,"[{'lastname': 'Moreno', 'firstname': 'Fermín', 'initials': 'F', 'affiliation': 'Department of Neurology, Hospital Donostia, San Sebastian, Gipuzkoa, Spain. FERMIN.MORENOIZCO@osakidetza.net'}, {'lastname': 'Alzualde', 'firstname': 'Ainhoa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Camblor', 'firstname': 'Pablo Martínez', 'initials': 'PM', 'affiliation': None}, {'lastname': 'Barandiaran', 'firstname': 'Myriam', 'initials': 'M', 'affiliation': None}, {'lastname': 'Van Deerlin', 'firstname': 'Vivianna M', 'initials': 'VM', 'affiliation': None}, {'lastname': 'Gabilondo', 'firstname': 'Alazne', 'initials': 'A', 'affiliation': None}, {'lastname': 'Martí Massó', 'firstname': 'José F', 'initials': 'JF', 'affiliation': None}, {'lastname': 'López de Munain', 'firstname': 'Adolfo', 'initials': 'A', 'affiliation': None}, {'lastname': 'Indakoetxea', 'firstname': 'Begoña', 'initials': 'B', 'affiliation': None}]",,,,Copyright © 2011 by Lippincott Williams & Wilkins,10.1097/WAD.0b013e3181eff695,<Element 'PubmedArticle' at 0x7f05da5094f0>
442,20600638,Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.,"Early loss of CB1 receptors is a hallmark of human Huntington's disease. Data from rodent studies suggest that preservation and activation of CB1 receptors may be protective against disease progression. R6/1 transgenic mice are considered to be a model of early pathogenic changes in Huntington's disease. We have shown previously that levels of CB1 in R6/1 mice prior to the onset of motor symptoms (12 weeks of age) remain high enough to justify commencement of cannabinoid drug treatment. Eight weeks of daily treatment with the cannabinoid agonists HU210 (0.01 mg/kg) and Delta(9)-tetrahydrocannabinol (THC, 10.00 mg/kg), or the inhibitor of endocannabinoid metabolism URB597 (0.30 mg/kg), did not alter the progressive deterioration of performance observed in motor behavioural testing. HU210-treated R6/1 mice experienced a significant increase in seizure events suggesting that this therapy may lower the seizure threshold and cautioning against highly efficacious agonists as potential therapy in this disease. Molecular characterisation of brains at the end of the study showed that there were no significant effects of HU210 or THC treatment on the ligand binding of cannabinoid CB1, dopamine D1, D2, serotonin 5HT2A or GABA(A) receptors, nor CB1 or fatty acid amide hydrolase (FAAH) mRNA expression in R6/1 mice. Intriguingly, a significant increase in the number of ubiquitinated aggregates was observed in the striatum with HU210 treatment, indicating an influence of CB1 on the disease process. Chronic URB597 treatment preserved CB1 receptors in the R6/1 striatum, suggesting that the manipulation of endocannabinoid levels warrants further exploration.",[],Neuroscience,2010-07-06,"[{'lastname': 'Dowie', 'firstname': 'M J', 'initials': 'MJ', 'affiliation': 'Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.'}, {'lastname': 'Howard', 'firstname': 'M L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Nicholson', 'firstname': 'L F B', 'initials': 'LF', 'affiliation': None}, {'lastname': 'Faull', 'firstname': 'R L M', 'initials': 'RL', 'affiliation': None}, {'lastname': 'Hannan', 'firstname': 'A J', 'initials': 'AJ', 'affiliation': None}, {'lastname': 'Glass', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2010.06.056,<Element 'PubmedArticle' at 0x7f05da518040>
443,"20541661
18458645
16298249
15082697
15807660
10399774
11524467
19277902
15668595
9566385
9238846
18322373
8541226
15961189
9344546
18774188
10566644
11879646
18045930
16916950
11292650
19382155
19139363
20110600
10622361
16239296
15827095
17403556
9191757
19464292
12543267
10994014
14741674
12374497
10867777
15213207
16360788
3786638
16198073
9559922
10794855
12460585
19303882
17570500
12459399
19470968
11823458
10525133
12925369
8080389
10668686
12707448
15608005
16310963
17476147
17279058
11730394
12904518
11113299
19160224
18541362
2560521
16023653
17010478
18815440
16735938
15249618
19402886
9191758
16607095
1531302
10802706
9921852
18332434
17439378
2990988
15087549
16607096
10867223
17893293
12486194
8629615
10362825
11445026
10430862
18287270
19142633
10697060
12925744
12604781
18094246
11487050
17374850
8528351
18977091
8885820
10881241
12145368
1484915
10098861
18431813
17975326
17261778
19464786
12771113
15582750
3539000
18253054
12413378
16522699
19850684
10847257
14641005
14631268
16917183
17761551
16793026
12204795
12117397
17405972
12805288
2025419
12809703
17568013
14561431
14520653
18487845
10199429
3067252
8675575
9227446
9832469
10683408
12771112
15213206
19410596
10867781
16918818
7648691
14575940
15593136
8709781
19608332
10891957
17873880
15695976
10851363
19276998
16831962
17651965
15024130
12413371
12732395
11796757
17052857",Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.,"Metabolic derangements and oxidative stress are early events in Alzheimer's disease pathogenesis. Multi-faceted effects of estrogens include improved cerebral metabolic profile and reduced oxidative stress through actions on mitochondria, suggesting that a woman's endogenous and exogenous estrogen exposures during midlife and in the late post-menopause might favourably influence Alzheimer risk and symptoms. This prediction finds partial support in the clinical literature. As expected, early menopause induced by oophorectomy may increase cognitive vulnerability; however, there is no clear link between age at menopause and Alzheimer risk in other settings, or between natural menopause and memory loss. Further, among older post-menopausal women, initiating estrogen-containing hormone therapy increases dementia risk and probably does not improve Alzheimer's disease symptoms. As suggested by the 'critical window' or 'healthy cell' hypothesis, better outcomes might be expected from earlier estrogen exposures. Some observational results imply that effects of hormone therapy on Alzheimer risk are indeed modified by age at initiation, temporal proximity to menopause, or a woman's health. However, potential methodological biases warrant caution in interpreting observational findings. Anticipated results from large, ongoing clinical trials [Early Versus Late Intervention Trial with Estradiol (ELITE), Kronos Early Estrogen Prevention Study (KEEPS)] will help settle whether midlife estrogen therapy improves midlife cognitive skills but not whether midlife estrogen exposures modify late-life Alzheimer risk. Estrogen effects on mitochondria adumbrate the potential relevance of estrogens to Alzheimer's disease. However, laboratory models are inexact embodiments of Alzheimer pathogenesis and progression, making it difficult to surmise net effects of estrogen exposures. Research needs include better predictors of adverse cognitive outcomes, biomarkers for risks associated with hormone therapy, and tools for monitoring brain function and disease progression.",[],Progress in brain research,2010-06-15,"[{'lastname': 'Henderson', 'firstname': 'Victor W', 'initials': 'VW', 'affiliation': 'Department of Health Research & Policy (Epidemiology), Stanford University, Stanford, CA, USA. vhenderson@stanford.edu'}, {'lastname': 'Brinton', 'firstname': 'Roberta Diaz', 'initials': 'RD', 'affiliation': None}]",,,,Copyright 2010 Elsevier B.V. All rights reserved.,10.1016/S0079-6123(10)82003-5,<Element 'PubmedArticle' at 0x7f05da4a2cc0>
444,"20535591
8780008
1316615
2990988
7488136
8175728
10599770
9008508
10720283
9663404
8450993
10851365
7715060
12433261
10366167
9484355
8030628
8709781
11085689
12413371
12413378
16735938
1484915
3067252
16298249
15694110
10451908
17893293
11304940
17341247
16522699
12459399
9875839
12771112
15213206
12925744
25380275
9670866
15963061
14520653
14749131
16926067
12730994
17097195
10810962
19880786
8889006
14644069
11890841
11971659
16301487
19615826
16865684
17145137
16406889
11983727
14728639
10931767
15668427
20004499
11982672
15800139
19770382
10558867
16699281
10362895
10765041
18408366
15944651
11781694
16882736
15079018
19879925
19478482",Hormonal influences on cognition and risk for Alzheimer's disease.,"Research increasingly suggests that changes in estrogen levels during aging may increase the risk of Alzheimer's disease, the most common type of dementia. This update reviews the newest information about estrogen and cognitive aging, including information regarding the role of bioavailable estrogen in older women and men, use of selective estrogen receptor modulators to improve cognition, and studies of genetic risk factors to elucidate the effects of endogenous estrogen on aging and cognition. Future trials are needed to determine whether alternate timing, dosage, formulation, or method of administration of hormone replacement can reduce the risk of dementia.",[],Current neurology and neuroscience reports,2010-06-11,"[{'lastname': 'Janicki', 'firstname': 'Sarah C', 'initials': 'SC', 'affiliation': 'G. H. Sergievsky Center, Columbia University Medical Center, 622 West 168th Street, PH-19, New York, NY 10019, USA. scj2110@columbia.edu'}, {'lastname': 'Schupf', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': None}]",,,,,10.1007/s11910-010-0122-6,<Element 'PubmedArticle' at 0x7f05da469270>
445,20472143,Sex steroids and acetylcholine release in the hippocampus.,"The hippocampus is processing contextual and spatial information in behaving animals. Various environmental stimuli, such as exploration, stress, or learning, increase acetylcholine (ACh) release to activate hippocampal functions. In this chapter, we review the in vivo ACh release property and the physiological function in the hippocampus. By monitoring 24-h ACh release profile in the hippocampus, we found a sex-specific and time-dependent ACh release property, providing a neural basis of sex-specific and time-dependent hippocampal function. In both sexes of rats, gonadectomy, known to impair the hippocampal function, dissociated the appropriate timing of the ACh release and attenuated the release amount. However, testosterone in gonadectomized males or estradiol in gonadectomized females restored the timing and maintained the amount of ACh release. Although the contributing sex hormone was sex-specific, neonatal 17beta-estradiol treatment in female pups successfully masculinized the contributing hormone. Moreover, some rearing conditions affected the sex-specific ACh release, since the influence was sex-specific. These results suggest that (1) estrogen receptor mediates neonatal sexual differentiation of septohippocampal cholinergic system and (2) time of day, circulating sex hormone, and rearing conditions affect the sex-specific ACh release in the hippocampus.",[],Vitamins and hormones,2010-05-18,"[{'lastname': 'Mitsushima', 'firstname': 'Dai', 'initials': 'D', 'affiliation': 'Department of Physiology, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama, Japan.'}]",,,,Copyright 2010 Elsevier Inc. All rights reserved.,10.1016/S0083-6729(10)82014-X,<Element 'PubmedArticle' at 0x7f05da48f810>
446,20398699,Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?,"Melatonin, the darkness hormone, synchronizes several physiological functions to light/dark cycle. Besides the awake/sleep cycle that is intuitively linked to day/night, daily variations in memory acquisition and innate or acquired immune responses are some of the major activities linked to melatonin rhythm. The daily variation of these complex processes is due to changes in specific mechanisms. In the last years we focused on the influence of melatonin on the expression and function of nicotinic acetylcholine receptors (nAChRs). Melatonin, either ""in vivo"" or ""in vitro"", increases, in a selective manner, the efficiency of alpha-bungarotoxin (alpha-BTX)-sensitive nAChRs. Melatonin's effect on receptors located in rat sympathetic nerve terminals, cerebellum, skeletal muscle and chick retina, was tested. We observed that melatonin is essential for the development of alpha-BTX-sensitive nAChRs, and important for receptor maintenance in aging models. Taking into account that both melatonin and alpha-7 nAChRs (one of the subtypes sensitive to alpha-BTX) are involved in the development of Alzheimer's disease, here we discuss the possibility of a therapeutic strategy focused on both melatonin replacement and its potential association with cholinergic drugs.",[],Pharmacology & therapeutics,2010-04-20,"[{'lastname': 'Markus', 'firstname': 'Regina P', 'initials': 'RP', 'affiliation': 'Laboratory of Chronopharmacology, Department of Physiology, Institute of Bioscience, Universidade de São Paulo, Brazil. rpmarkus@usp.br'}, {'lastname': 'Silva', 'firstname': 'Claudia L M', 'initials': 'CL', 'affiliation': None}, {'lastname': 'Franco', 'firstname': 'Daiane Gil', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Barbosa', 'firstname': 'Eduardo Mortani', 'initials': 'EM', 'affiliation': None}, {'lastname': 'Ferreira', 'firstname': 'Zulma S', 'initials': 'ZS', 'affiliation': None}]",,,,Copyright 2010 Elsevier Inc. All rights reserved.,10.1016/j.pharmthera.2010.02.009,<Element 'PubmedArticle' at 0x7f05da494db0>
447,"20392807
9314579
12843281
15749347
19160494
10478843
12796219
12725764
15156148
15458927
15664693
18468808
16771794
18268329
3910535
14693420
6370082
11164773
15599615
11351342
16388309
11087781
16580076
17906620
18562608
17524488
18353559
15939846
16272115
16137570
10593204
19446081
17904621
12042878
11746612
9238064
12689773
17888801
15901789
19410597
11738550
16011489
15142991
17470522
17379265
15139797
16024751
18774188
19299024
16688123
17804523
11902121
11400179
17412603
13513270
15120494
15896953
1693953
8518920
15709959
19559056
15668427
17145137
17886255
3444523
1538563
17514590
17879269
7753342
15251266
15099689
15884004
11113510
17544382
19524584
18279872
15721829
17882683
17184480
11932944
17161546
18420742
18031771
16965297
12544829
15891777
10481183
14670982
16009974
9638962
12388607
19430488
16186484
16488877
2330103
12777705
8263548
8739629
11424955
16122814
11442776
15652377
19447561
7955327
19104049
10414967
12171508
12213134
17680007
16598047
10830414
18259859
12965246
8818400
11534979
19207822
18594506
8883823
9799626
17669502
9316021
11172749
15850667
18601693
11040417
18367504
16865684
12460585
15890350
14635215
6287293
19538962
15251260
15723166
19914282
11920153
19660660
16876167
20071507
17570500
18556135
12575756
14568464
10674483
10817919
18511674
10762694
17098842
17317772
18262185
15635591
11305881
2359813
18067894
19420011
10668686
14984886
9626556
17604108
1359459
19185610
16566897
15555924
16498364
14694190
9067991
12955098
16320305
8124476
11584307
12960049
10999823
18210333
15582747
16310318
9517823
18197357
16425668
16480891
11353728
3361004
8889006
11691980
12850432
18601688
11403979
10593187
14699072
17676034
16949139
12504919
15464412
9861029
9050788
11739260
16942768
18799684
12412138
14528452
15740829
16338079
7729817
14713299
11162939
12372667
9733072
12786965
9365211
10952500
11264469
15312910
12629162
11074158
16421862
15601607
18852023
7554237
19775194
10987824
12554748
17581209
18297067
16736049
10911988
17013926
15338563
2990988
17027008
18513207
17850456
3732148
16452668
19401723
1661809
16503703
12404074
9579298
6163211
7704444
7624480
14977405
15935066
16397539
8521507
12112198
15063099
19615826
18569037
16011483
17164817
17116232
16439449
18195084
12193373
16083951
8313946
9629234
10377379
11717247
10368772
17395265
11484002
11750774
16148238
19493163
15101093
19207809
14675539
19416735
9668673
18579753
12697714
17962346
19321777
19356199
18063054
16337092
18515001
17936613
12699782
15452574
11532737
17367828
16616726
9502814
9037079
12777699
12535954
10657731
9918226
9918227
16803960
12668048
17636222
17391878
18550597
18094246
15582382
10536018
9832446
9037078
11334794
11854469
10987818
11061547
10658612
14993040
11493581
9278514
17412808
16310961
12270042
7561861
9554702
18640866
19071129
10022763
19002191
19422828
15704151
19427328
19826450
9619148
14706792
16324798
17336390
18262661
15028776
18278798
14689453
17952068
3504235
18395206
5568506
12766322
14622134
14622899
20015483
12843274
12707423
18253054
9555076
12667452
8573428
15851067
9213137
10933217
2116937
15886244
12160998
18643794
14499203
16276117
18634599
8518922
8466654
19428144
19401952
12117397
12805288
16344155
12890521
19450619
19341798
2714937
9578823
10227628
12128007
9843162
15729494
14643375
10875828
19211896
18430566
15223360
18568035
18406308
7854416
18279543
12413808
14501023
17980408
15054128
11268214
15530885
8987135
9388012
11413547
9832469
16533144
15213206
18823152
2574404
15721748
2324335
17449457
9492079
11826265
15790530
19275906
10864967
18078984
19123998
10622413
10202604
9072284
11955941
19401209
15717309
15724806
18653758
12829102
19084904
11248594
16835042
19162130
15698888
14704219
18460549
10941275
19207820
12865313
12225877
19268677
10407108
17785421
19442988
19207813
16024756
16598276
12351713
10328986
10881255
9202234
2862232
2906901
18249027
12884966
12777365
18974276
18083219
11706965
3405431
10682713
16934233
17873968
11226319
12515851
7893411
9106666
10823946
9388019
18402507
17662459
16429159
8395854
9454668
16203130
18353557
19966177
3555228
1961837
18408991
17307903
15851820
11141318
19877497
11500252
11256441
9520494
10395567
11369763
9661256
18402929
17490623
7538305
16365303
12062475
16533397
17997703
16269315",Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.,"The classic view of estrogen actions in the brain was confined to regulation of ovulation and reproductive behavior in the female of all mammalian species studied, including humans. Burgeoning evidence now documents profound effects of estrogens on learning, memory, and mood as well as neurodevelopmental and neurodegenerative processes. Most data derive from studies in females, but there is mounting recognition that estrogens play important roles in the male brain, where they can be generated from circulating testosterone by local aromatase enzymes or synthesized de novo by neurons and glia. Estrogen-based therapy therefore holds considerable promise for brain disorders that affect both men and women. However, as investigations are beginning to consider the role of estrogens in the male brain more carefully, it emerges that they have different, even opposite, effects as well as similar effects in male and female brains. This review focuses on these differences, including sex dimorphisms in the ability of estradiol to influence synaptic plasticity, neurotransmission, neurodegeneration, and cognition, which, we argue, are due in a large part to sex differences in the organization of the underlying circuitry. There are notable sex differences in the incidence and manifestations of virtually all central nervous system disorders, including neurodegenerative disease (Parkinson's and Alzheimer's), drug abuse, anxiety, and depression. Understanding the cellular and molecular basis of sex differences in brain physiology and responses to estrogen and estrogen mimics is, therefore, vitally important for understanding the nature and origins of sex-specific pathological conditions and for designing novel hormone-based therapeutic agents that will have optimal effectiveness in men or women.",[],Pharmacological reviews,2010-04-16,"[{'lastname': 'Gillies', 'firstname': 'Glenda E', 'initials': 'GE', 'affiliation': 'Centre for Neuroscience, Department of Medicine, Hammersmith Hospital, Imperial College Faculty of Medicine, DuCane Road, London W12ONN, UK. g.gillies@imperial.ac.uk'}, {'lastname': 'McArthur', 'firstname': 'Simon', 'initials': 'S', 'affiliation': None}]",,,,,"10.1124/pr.109.002071
10.1016/j.neubiorev.2009.11.008
10.1016/j.neurobiolaging.2009.04.008",<Element 'PubmedArticle' at 0x7f05da49ed10>
448,20308394,Short-term spatial memory responses in aged Japanese quail selected for divergent adrenocortical stress responsiveness.,"Stress-induced glucocorticoids can dampen learning and spatial memory via neuronal damage to the hippocampus. Cognition losses can be transient (associated with acute stress episodes) or permanent as in aged individuals who show chronic glucocorticoid-induced accelerated brain aging and neurodegeneration (dementia). Thus, chronic versus acute stress effects on spatial memory responses of quail selected for reduced (low stress, LS) or exaggerated (high stress, HS) plasma corticosterone (B) response to brief restraint were assessed. Aged food-motivated male LS and HS quail were tested for 10 min in a feed-baited 8-arm radial arm maze (RAM) 1) at 255 d of age (quail who had experienced lifelong management stressors but who were otherwise never intentionally stressed; that is, chronically stressed birds), 2) on the next day post-acute stressor treatment (5 min of restraint), and 3) on the next day without treatment (acute stress recovery). The RAM tests used the win-shift procedure in which visited arms were not rebaited. Radial arm maze performance was measured by determination of the total number of arm choices made, the number of correct entries made into baited arms out of the first 8 choices, the time required to make a choice, and the number of pellets eaten. Line effects (P < 0.001 in all cases) were detected for total number of arm choices made (HS < LS), number of correct entries made into baited arms out of the first 8 choices (HS < LS), time required to make a choice (HS > LS), and number of pellets eaten (HS < LS). However, neither the effects of day of RAM testing nor its interaction with line further influenced these variables. Thus, although selection for divergent plasma B responsiveness to an acute stressor was found to be associated with severe impairment of spatial memory in aged male HS compared with LS quail, the observed spatial memory impairments (HS > LS) could not be further altered by acute stressor treatment. Line differences in cognition may reflect lifelong management-induced stress episodes that periodically produce higher plasma B responses in HS than LS quail, which underlie HS quail memory deficits, or other etiologies, or both.",[],Poultry science,2010-03-24,"[{'lastname': 'Suhr', 'firstname': 'C L', 'initials': 'CL', 'affiliation': 'Applied Animal Biotechnology Laboratories, School of Animal Sciences, Louisiana Agricultural Experiment Station, Louisiana State University Agricultural Center, Louisiana State University, Baton Rouge, LA 70803, USA.'}, {'lastname': 'Schmidt', 'firstname': 'J B', 'initials': 'JB', 'affiliation': None}, {'lastname': 'Treese', 'firstname': 'S T', 'initials': 'ST', 'affiliation': None}, {'lastname': 'Satterlee', 'firstname': 'D G', 'initials': 'DG', 'affiliation': None}]",,,,,10.3382/ps.2009-00288,<Element 'PubmedArticle' at 0x7f05da3ddcc0>
449,20153425,Neuroimmunomodulatory steroids in Alzheimer dementia.,"Though pathobiochemical and neurochemical changes and accompanied morphological alterations in Alzheimer dementia are well known, the triggering mechanisms, if any, remain obscure. Important factors influencing the development and progression of Alzheimer disease include hormonal steroids and their metabolites, some of which may serve as therapeutic agents. This review focusses on major biochemical alterations in the brain of Alzheimer patients with respect to the involvement of steroids. It includes their role in impairment of fuel supply and in brain glycoregulation, with especial emphasis on glucocorticoids and their counter-regulatory steroids as dehydroepiandrosterone and its metabolites. Further, the role of steroids in beta-amyloid pathology is reviewed including alterations in tau-protein(s) phosphorylation. The (auto)immune theory of Alzheimer dementia is briefly outlined, pointing to the possible involvement of steroids in brain ageing, immunosenescence and neuronal apoptosis. Some effects of steroids are briefly mentioned on the formation and removal of reactive oxygen species and their effect on calcium flux and cytotoxicity. The recent biochemical research of Alzheimer disease focusses on molecular signalling at which steroids also take part. New findings may be anticipated when the mosaic describing the molecular mechanisms behind these events becomes more complete.",[],The Journal of steroid biochemistry and molecular biology,2010-02-16,"[{'lastname': 'Hampl', 'firstname': 'Richard', 'initials': 'R', 'affiliation': 'Institute of Endocrinology, Prague, Czech Republic. rhampl@endo.cz'}, {'lastname': 'Bicíková', 'firstname': 'Marie', 'initials': 'M', 'affiliation': None}]",,,,2010. Published by Elsevier Ltd.,10.1016/j.jsbmb.2010.02.007,<Element 'PubmedArticle' at 0x7f05da367770>
450,"20097678
19608102
16288298
17041811
11932021
11408619
12881722
10402204
15829505
16571604
2932539
16114270
19627267
18550760
12812983
16076956
18558632
7522547
18835735
2249627
11092756
19845833
7733967
7477379
7647777
7568002
8980018
12969257
18981372
2526577
14962685
17653274
7581375
19319184
132511
132332
140180
155781
155768
6455503
6225034
6229607
6684547
8898202
9949199
11152661
17715336
11062468
11567051
11709539
12165554
12165555
18815258
15888475
12165557
17552550
15242649
16230019
10778856
19667213
15811941
16019264
16095740
17940007
19334076
19240687
17997337
8968738
18799679
14654707
11906693
19664996",Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.,"Levels of full-length huntingtin (FL htt) influence organ and body weight, independent of polyglutamine length. The growth hormone-insulin like growth factor-1 (GH-IGF-1) axis is well established as a regulator of organ growth and body weight. In this study, we investigate the involvement of the IGF-1 pathway in mediating the effect of htt on body weight. IGF-1 expression was examined in transgenic mouse lines expressing different levels of FL wild-type (WT) htt (YAC18 mice), FL mutant htt (YAC128 and BACHD mice) and truncated mutant htt (shortstop mice). We demonstrate that htt influences body weight by modulating the IGF-1 pathway. Plasma IGF-1 levels correlate with body weight and htt levels in the transgenic YAC mice expressing human htt. The effect of htt on IGF-1 expression is independent of CAG size. No effect on body weight is observed in transgenic YAC mice expressing a truncated N-terminal htt fragment (shortstop), indicating that FL htt is required for the modulation of IGF-1 expression. Treatment with 17beta-estradiol (17beta-ED) lowers the levels of circulating IGF-1 in mammals. Treatment of YAC128 with 17beta-ED, but not placebo, reduces plasma IGF-1 levels and decreases the body weight of YAC128 animals to WT levels. Furthermore, given the ubiquitous expression of IGF-1 within the central nervous system, we also examined the impact of FL htt levels on IGF-1 expression in different regions of the brain, including the striatum, cerebellum of YAC18, YAC128 and littermate WT mice. We demonstrate that the levels of FL htt influence IGF-1 expression in striatal tissues. Our data identify a novel function for FL htt in influencing IGF-1 expression.",[],Human molecular genetics,2010-01-26,"[{'lastname': 'Pouladi', 'firstname': 'Mahmoud A', 'initials': 'MA', 'affiliation': 'Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, and Child and Family Research Institute, Vancouver, BC, Canada V5Z 4H4.'}, {'lastname': 'Xie', 'firstname': 'Yuanyun', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Skotte', 'firstname': 'Niels Henning', 'initials': 'NH', 'affiliation': None}, {'lastname': 'Ehrnhoefer', 'firstname': 'Dagmar E', 'initials': 'DE', 'affiliation': None}, {'lastname': 'Graham', 'firstname': 'Rona K', 'initials': 'RK', 'affiliation': None}, {'lastname': 'Kim', 'firstname': 'Jeong Eun', 'initials': 'JE', 'affiliation': None}, {'lastname': 'Bissada', 'firstname': 'Nagat', 'initials': 'N', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'X William', 'initials': 'XW', 'affiliation': None}, {'lastname': 'Paganetti', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': None}, {'lastname': 'Friedlander', 'firstname': 'Robert M', 'initials': 'RM', 'affiliation': None}, {'lastname': 'Leavitt', 'firstname': 'Blair R', 'initials': 'BR', 'affiliation': None}, {'lastname': 'Hayden', 'firstname': 'Michael R', 'initials': 'MR', 'affiliation': None}]",,,,,10.1093/hmg/ddq026,<Element 'PubmedArticle' at 0x7f05da370c20>
451,20056462,The role of environmental light in sleep and health: effects of ocular aging and cataract surgery.,"Environmental illumination profoundly influences human health and well-being. Recently discovered photoreceptive retinal ganglion cells (pRGCs) are primary mediators of numerous circadian, neuroendocrine and neurobehavioral responses. pRGCs provide lighting information to diverse nonvisual (non-image-forming) brain centers including the suprachiasmatic nuclei (SCN) which serve as the body's master biological clock. The SCN exert functional control over circadian aspects of physiology. The timing and strength (amplitude) of SCN rhythmic signals are affected by light exposure. Light deficiency may attenuate SCN function and its control of physiological and hormonal rhythms which in turn can result in a cascade of adverse events. Inadequate pRGC photoreception cannot be perceived consciously, but may aggravate many common age-associated problems including insomnia, depression and impaired cognition. In this review we (1) summarize circadian physiology, emphasizing light's critical role as the most important geophysical timing cue in humans; (2) analyze evidence that typical residential lighting is insufficient for optimal pRGC requirements in youth and even more so with advancing age; (3) show how ocular aging and cataract surgery impact circadian photoreception; and (4) review some of the diverse morbidities associated with chronodisruption in general and those which may be caused by light deficiency in particular.",[],Sleep medicine reviews,2010-01-09,"[{'lastname': 'Turner', 'firstname': 'Patricia L', 'initials': 'PL', 'affiliation': 'Department of Ophthalmology, University of Kansas School of Medicine, 7400 State Line Road, Prairie Village, KS 66208-3444, USA. plturnermd@att.net'}, {'lastname': 'Van Someren', 'firstname': 'Eus J W', 'initials': 'EJ', 'affiliation': None}, {'lastname': 'Mainster', 'firstname': 'Martin A', 'initials': 'MA', 'affiliation': None}]",,,,(c) 2009 Elsevier Ltd. All rights reserved.,10.1016/j.smrv.2009.11.002,<Element 'PubmedArticle' at 0x7f05da398950>
452,"20031276
12796530
16801647
16837880
16440209
16246463
12571363
16266773
19273747
12812866
10591291
10818510
10461029
8136068
9443474
14980532
15324364
12221169
14595538
18723162
12885580
14694215
15911795
1202204
16935478
18631949
10382587
2070776
8591825
9287372
19038898
8225537
9829797
17030472
16361959
18577288
10658955
16024761
10867223
2234506
3899825
18484789
10834428
15980938
11916953
18797261
7014326
14999034
2298111
19328637
11591393
18024186
19371207
9135944
1887067
9540022
17430234",Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.,"Insulin resistance (IR) is the main pathological condition underlying vascular disorders, such as diabetes and cardiovascular disease, which are well established risk factors for cognitive decline and Alzheimer disease (AD). Hippocampal atrophy has been associated with cognitive decline, but little is known about the influence of IR on hippocampus integrity in non-diabetic, cognitively intact individuals. Herein, 50 women ages 50-65, current users of hormone therapy, underwent magnetic resonance imaging, cognitive testing, and homeostatic assessment of insulin resistance (HOMA-IR), as part of a longitudinal study examining brain structure and function in postmenopausal women at risk for AD. Results demonstrated a significant negative relationship between HOMA-IR and right and total hippocampal volume, overall cognitive performance, and selective tests of verbal and non-verbal memory. The main effect of HOMA-IR on brain structure and cognition was not altered by the presence of APOE-ε4 allele or by reproductive history, such as duration of endogenous and exogenous estrogen exposure. These results suggest that IR in middle-aged individuals at risk for AD may be biomarker for dementia risk.",[],Neurobiology of aging,2009-12-25,"[{'lastname': 'Rasgon', 'firstname': 'Natalie L', 'initials': 'NL', 'affiliation': ""Stanford Center for Neuroscience in Women's Health, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stan-ford, CA 94305-5723, USA. nrasgon@stanford.edu""}, {'lastname': 'Kenna', 'firstname': 'Heather A', 'initials': 'HA', 'affiliation': None}, {'lastname': 'Wroolie', 'firstname': 'Tonita E', 'initials': 'TE', 'affiliation': None}, {'lastname': 'Kelley', 'firstname': 'Ryan', 'initials': 'R', 'affiliation': None}, {'lastname': 'Silverman', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': None}, {'lastname': 'Brooks', 'firstname': 'John', 'initials': 'J', 'affiliation': None}, {'lastname': 'Williams', 'firstname': 'Katherine E', 'initials': 'KE', 'affiliation': None}, {'lastname': 'Powers', 'firstname': 'Bevin N', 'initials': 'BN', 'affiliation': None}, {'lastname': 'Hallmayer', 'firstname': 'Joachim', 'initials': 'J', 'affiliation': None}, {'lastname': 'Reiss', 'firstname': 'Allan', 'initials': 'A', 'affiliation': None}]",,,,Copyright © 2009 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2009.12.005,<Element 'PubmedArticle' at 0x7f05da3242c0>
453,20028599,Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment.,"Concord grape juice contains polyphenol compounds, which have antioxidant and anti-inflammatory properties and influence neuronal signalling. Concord grape juice supplementation has been shown to reduce inflammation, blood pressure and vascular pathology in individuals with CVD, and consumption of such flavonoid-containing foods is associated with a reduced risk for dementia. In addition, preliminary animal data have indicated improvement in memory and motor function with grape juice supplementation, suggesting potential for cognitive benefit in ageing humans. In this initial investigation of neurocognitive effects, we enrolled twelve older adults with memory decline but not dementia in a randomised, placebo-controlled, double-blind trial with Concord grape juice supplementation for 12 weeks. We observed significant improvement in a measure of verbal learning and non-significant enhancement of verbal and spatial recall. There was no appreciable effect of the intervention on depressive symptoms and no effect on weight or waist circumference. A small increase in fasting insulin was observed for those consuming grape juice. These preliminary findings suggest that supplementation with Concord grape juice may enhance cognitive function for older adults with early memory decline and establish a basis for more comprehensive investigations to evaluate potential benefit and assess mechanisms of action.",[],The British journal of nutrition,2009-12-24,"[{'lastname': 'Krikorian', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Psychiatry, University of Cincinnati Academic Health Center, Cincinnati, OH, USA. robert.krikorian@uc.edu'}, {'lastname': 'Nash', 'firstname': 'Tiffany A', 'initials': 'TA', 'affiliation': None}, {'lastname': 'Shidler', 'firstname': 'Marcelle D', 'initials': 'MD', 'affiliation': None}, {'lastname': 'Shukitt-Hale', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}, {'lastname': 'Joseph', 'firstname': 'James A', 'initials': 'JA', 'affiliation': None}]",,,,,10.1017/S0007114509992364,<Element 'PubmedArticle' at 0x7f05da346c20>
454,20021365,Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology.,"One of the more fascinating recent discoveries in neuroscience is the widespread influence of hormones on brain regions and functions underlying pathological behaviors. A story is unfolding that points to critical roles played by hypothalamic - pituitary - gonadal (HPG) and hypothalamic - pituitary - adrenal (HPA) axes on a startling array of mental disorders, from depression to dementia. The influence of peptides and steroids does not end with hormones released from the two axes, however. It is now clear that the brain has adapted, ""highjacked"" is more descriptive, HPG and HPA hormones for uses unrelated to their original functions in reproduction and responses to stress. Findings of neuromodulatory effects of HPA and HPG hormones on monoamine, GABA, glutamate and opioid pathways and of hormone receptors and enzymes involved in hormone synthesis, particularly of steroids, in the hippocampus, amygdala and other subcortical brain regions provide the brain with multiple evolutionary means to adapt to new functions. The complexity of the metabolic cascade for the steroids also leaves open mechanisms by which endogenous errors and exogenous chemicals could be involved in the etiology of psychopathologies. The planned review will examine the recent literature for evidence of steroidal and peptidergic influences on basic biological functions and on mood disorders, anxiety and PTSD, schizophrenia, substance abuse and dementia. Emphasis will be placed on animal models, although findings with patient populations will be prominently included. Special attention will be paid to novel pathways by which the precursors and metabolites of sex steroids can influence psychopathologies. We also will speculate on promising treatments with hormone modulators that may be useful in mollifying the symptomology of the mental disorders.",[],Central nervous system agents in medicinal chemistry,2009-12-22,"[{'lastname': 'Taylor', 'firstname': 'George Townsend', 'initials': 'GT', 'affiliation': 'University of Missouri St. Louis, 63121, USA. geot@UMSL.edu'}, {'lastname': 'Maloney', 'firstname': 'Susan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Dearborn', 'firstname': 'Joshua', 'initials': 'J', 'affiliation': None}, {'lastname': 'Weiss', 'firstname': 'Juergen', 'initials': 'J', 'affiliation': None}]",,,,,10.2174/187152409789630398,<Element 'PubmedArticle' at 0x7f05da354860>
455,"19996872
12117397
14709575
15229239
18541362
9388012
11116225
16127691
10683408
15709962
15217334
13131095
1580805
10867777
6474172
10190820
3106758
8050041
9707487
17507257
17052857
2269895
2329377
11967893
10407020
2990988
18430566
8466654
17335823
18767068
1484916
18455727
11749982
9926814
12707448
16198073
16607095
17279058
17439378
11445026
10680789
11971659
14644069
17097195
10573435
15703323
12580706
9238064
18060706
18279872
9799627
16735938
11238542
17476147
17893293
3067252
1484915
8417592
15827095
8675575
17761551
9609575
15694110
16298249
15213207
16522699
17405972
17438515
17873880
17389368
15213206
8885820
8709781
9191758
12413371
15608005
16310963
10794855
16239296
12843274
18254016
9344546
12925744
16793026
9492970
11309635
791587
9491878
11304940
15511602
17893293
11306202
12459399
15695976
15748783
16831962","Aging, estrogens, and episodic memory in women.","To review the relation in midlife and beyond between estrogen exposures and episodic memory in women.
Episodic memory performance declines with usual aging, and impairments in episodic memory often portend the development of Alzheimer disease. In the laboratory, estradiol influences hippocampal function and animal learning. However, it is controversial whether estrogens affect memory after a woman's reproductive years.
Focused literature review, including a summary of a systematic search of clinical trials of estrogens in which outcomes included an objective measure of episodic memory.
The natural menopause transition is not associated with the objective changes in episodic memory. Strong clinical trial evidence indicates that initiating estrogen-containing hormone therapy after the age of about 60 years does not benefit episodic memory. Clinical trial findings in middle-aged women before the age of 60 years are limited by smaller sample sizes and shorter treatment durations, but these also do not indicate substantial memory effects. Limited short-term evidence, however, suggests that estrogens may improve verbal memory after surgical menopause. Although hormone therapy initiation in old age increases dementia risk, observational studies raise the question of an early critical window during which midlife estrogen therapy reduces late-life Alzheimer disease. However, almost no data address whether midlife estrogen therapy affects episodic memory in old age.
Episodic memory is not substantially impacted by the natural menopause transition or improved by the use of estrogen-containing hormone therapy after the age of 60 years. Further research is needed to determine whether outcomes differ after surgical menopause or whether episodic memory later in life is modified by midlife estrogenic exposures.",[],Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology,2009-12-10,"[{'lastname': 'Henderson', 'firstname': 'Victor W', 'initials': 'VW', 'affiliation': 'Departments of Health Research and Policy (Epidemiology), and of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305-5405, USA. vhenderson@stanford.edu'}]","Focused literature review, including a summary of a systematic search of clinical trials of estrogens in which outcomes included an objective measure of episodic memory.",,"The natural menopause transition is not associated with the objective changes in episodic memory. Strong clinical trial evidence indicates that initiating estrogen-containing hormone therapy after the age of about 60 years does not benefit episodic memory. Clinical trial findings in middle-aged women before the age of 60 years are limited by smaller sample sizes and shorter treatment durations, but these also do not indicate substantial memory effects. Limited short-term evidence, however, suggests that estrogens may improve verbal memory after surgical menopause. Although hormone therapy initiation in old age increases dementia risk, observational studies raise the question of an early critical window during which midlife estrogen therapy reduces late-life Alzheimer disease. However, almost no data address whether midlife estrogen therapy affects episodic memory in old age.",,10.1097/WNN.0b013e3181a74ce7,<Element 'PubmedArticle' at 0x7f05da3601d0>
456,"19946443
18631956
19595937
15639311
12108606
8759042
15472160
8054494
18204414
7763211
11735772
16966831
11255443
16917193
12226536
8346443
8446617
15172743
15584785
9307589
16306243
8423876
11939702
18796495
16926275
19016932
15883266
18779228
17299455
17430237
16361026
14573579
9330961
3185902
9330965
8606473
16493239
15806897
11159613
12372156
9680492
10668705
7564308
11413873
11416775
15703320
18458216
17535018
10408569
12815504
11673588
9222166
17431012
15557506
14739544
14568809
2353798
8139057
10071096
14718220
9362989
7675231
12719627
9884005
11511701
12541276
15304581
18077796
12297572
16131619
18263600
7969962
7730545
7728017
7824135
18395201
17159087
11425934
12588587
15668425
12160362
16216938
10794848
8608286
11125239
16033691
15791354
14694027
11312234
11779884
10794849
15668423
15159381
14715433
16957545
10983901
16601212
18294116
17339582
11890840
16410024
9549720
11031212
12742802
15148148
10449113
18264008
15911792
2604758
3283935
11673587
9148766
9600988
8626795
12861382
1937129
18457525
16866914
12410906
12114036
12457784
18199831
15699299
15534246
16009757
18663180
18690839
16866913
10102414
17420320
18952836
15557509
18695056
18401020
17130206
15477536
16932542
17764005
12084635
15750214
18855584
12821276
10388978
16286438
16595758
16857578
12860573
15710796
15863436
17430231
18367704
18028342
17881716
16966511
17709705
15642850
15576490
9525362
12111615
8126336
7814211
9513030
18639516
7666229
12876232
10025787
10746604
9290497
11071494
9048710
9883791
15679695
1595677
7898715
15326261
11784357
10599765
10937919
15959838
18979948
11990888
16651510
16461857
10078504
16670246
10883722
16533972
18354253
12900317
10668348
12730309
1635039
16953718
17562829
16974109
18694539
17909133
10403712
15860780
16291928
16319455
12048221
14507930
11756603
19038834
12815502
16239176
18245762
17721898
11255456
15249848
16418406
18511759
15781953
18094335
9744220
18790459
12815136
16467493
12499482
18768414
18585641
14504326
17596582
18004010
12425704
12169801
16019280
17166313
17166314
12786970
9087407
15262214
17714960
2450317
16730391
12414279
15891777
18772473
15576855
18511731
10776744
12646598
15623694
11515736
16260706
16410348
10428732
16632311
16248702
9529263
15277281
16260705
11955468
7652125
16247047
18487267
15304383
18222934
12636463
16185373
12217928
4053968
16162502
14624067
15316040
18414087
9063340
12714116
17573335
17690985
11230877
11255426
12771113
15213207
12771112
12413371
10858586
18509093
18458226
15974901
17460158
18474729
12941571
17636065
12297571
16627007
17640772
3796196
12213959
16507312
9823823
9343463
16375657
18305231
7104545
19017911
18690838
18854539
9322548
17561285
12918012
17210874
16866918
10096843
12076218
14732624
19910881
15128608
12076219
16945610
10959944
18356327
18716168
19005437
18510961
18806104
18400709
15740021
16710090
15136684
12873849
12399342
16256248
18678826
8157129
10964604
17679672
12196314
12099922
16938404
18620014
15380154
15054348
11784412
16256756
11790957
16622828
17435956
11980781
18556609
10170434",Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia.,"The baby boom generation is approaching the age of greatest risk for cognitive impairment and dementia. There is growing interest in strategies to modify the environment in midlife to increase the probability of maintaining cognitive health in late life. Several potentially modifiable risk factors have been studied in relation to cognitive impairment and dementia in late life, but methodological limitations of observational research have resulted in some inconsistencies across studies. The most promising strategies are maintaining cardiovascular health, engagement in mental, physical, and social activities, using alcohol in moderation, abstaining from tobacco use, and following a heart-healthy diet. Other factors that may influence cognitive health are occupational attainment, depression, personality, exposure to general anesthesia, head injury, postmenopausal hormone therapy, non-steroidal anti-inflammatory medications, and nutritional supplements such as antioxidants. Some long-term observational studies initiated in midlife or earlier, and some randomized controlled trials, have examined the effects of specific cognitive health promotion behaviors in midlife on the risk of cognitive impairment in late life. Overall, these studies provide limited support for risk reduction at this time. Recommendations and challenges for developing effective strategies to reduce the burden of cognitive impairment and dementia in the future are discussed.",[],Current psychiatry reviews,2009-12-01,"[{'lastname': 'Hughes', 'firstname': 'Tiffany F', 'initials': 'TF', 'affiliation': 'Departments of Psychiatry (T.F.H., M.G.) and Neurology (M.G.), School of Medicine, and the Department of Epidemiology (M.G.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'lastname': 'Ganguli', 'firstname': 'Mary', 'initials': 'M', 'affiliation': None}]",,,,,10.2174/157340009788167347,<Element 'PubmedArticle' at 0x7f05da30c900>
457,"19943124
19309038
16530419
12752792
12453484
18854182
10037474
9733982
18804330
19387667
9894871
15852400
15605990
11733217
16207868
8247264
15466394
17912249
17360899
9387865
10371714
19273747
17151169
12460689
8597446
19477151
3953862
15677393
10481183
1308198
15283960
18571864
16600515
19477935
19202080
9809557
2812318
19358094
9884123
16720347
17914648
9295187
19046371
12925731
8780008
8070512
9065509
12773581
16943563
19006787
12472904
18295378
19289740
8159737
2795152
10867782
17141742
2118608
18182044
19298551
17979802
16549764
2070776
16467370
14660786
17502912
15734937
9276486
12210782
9287082
15751228
15537891
12354284
11085908
11905999
19012747
18402983
19164583
18504134
19230009
17073656
8627386
9853126
12838272
16998712
8994059
18984744
17256090
11440793
15295589
18709572
15717011
19081372
12000027
17290796
15000414
17224716
3012985
19198615
18801341
4342885
17368447
17467182
19221421
16238459
17185404
11750896
18222612
12392776
12000121
10691302
16515786
17548777
19170443
10913684
11257240
17292975
18218341
2998738
18698410
17923777
11713467
3746406
3527687
17088541
18178006
17470753
16289476
12399581
18359102
18568035
18598755
12900317
8632988
12399578
2704997
15950198
18280601
3212058
7891134
8964797
15652983
18573532
10799757
18849021
19489003
18278039
19070401
19280661
18543119
11079535
19100264
17700021
18457238
15212843
14751768
11036168
17123871
19349082
11875571
16177036
11932745
1308199
6393179
19554673
7916070
10911964
16974109
17244848
15708480
19376098
1705153
17884039
16839619
10215518
9035255
18850490
17070803
11102572","Adverse stress, hippocampal networks, and Alzheimer's disease.","Recent clinical data have implicated chronic adverse stress as a potential risk factor in the development of Alzheimer's disease (AD) and data also suggest that normal, physiological stress responses may be impaired in AD. It is possible that pathology associated with AD causes aberrant responses to chronic stress, due to potential alterations in the hypothalamic-pituitary-adrenal (HPA) axis. Recent study in rodent models of AD suggests that chronic adverse stress exacerbates the cognitive deficits and hippocampal pathology that are present in the AD brain. This review summarizes recent findings obtained in experimental AD models regarding the influence of chronic adverse stress on the underlying cellular and molecular disease processes including the potential role of glucocorticoids. Emerging findings suggest that both AD and chronic adverse stress affect hippocampal neural networks in a similar fashion. We describe alterations in hippocampal plasticity, which occur in both chronic stress and AD including dendritic remodeling, neurogenesis, and long-term potentiation. Finally, we outline potential roles for oxidative stress and neurotrophic factor signaling as the key determinants of the impact of chronic stress on the plasticity of neural networks and AD pathogenesis.",[],Neuromolecular medicine,2009-11-28,"[{'lastname': 'Rothman', 'firstname': 'Sarah M', 'initials': 'SM', 'affiliation': 'Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, Baltimore, MD 21224, USA. sarah.rothman@nih.gov'}, {'lastname': 'Mattson', 'firstname': 'Mark P', 'initials': 'MP', 'affiliation': None}]",,,,,10.1007/s12017-009-8107-9,<Element 'PubmedArticle' at 0x7f05da28e360>
458,"19850684
12771112
15213206
12771113
15213207
16279282
12137675
12763515
16522699
9409335
11156805
9492970
9875839
12117397
15082697
3611032
1484915
11306202
16831962
17341247
16298249
2359813
11749982
19026652
10077001
17316164
14575940
19139364",Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy.,"Different menopausal hormone therapies may have varied effects on specific cognitive functions. We previously reported that conjugated equine estrogens (CEE) with medroxyprogesterone acetate had a negative impact on verbal memory but tended to impact figural memory positively over time in older postmenopausal women.
The objective of the study was to determine the effects of unopposed CEE on changes in domain-specific cognitive function and affect in older postmenopausal women with prior hysterectomy.
This was a randomized, double blind, placebo-controlled clinical trial.
The study was conducted at 14 of 40 Women's Health Initiative (WHI) clinical centers.
Participants were 886 postmenopausal women with prior hysterectomy, aged 65 yr and older (mean 74 yr), free of probable dementia, and enrolled in the WHI and WHI Memory Study (WHIMS) CEE-Alone trial for a mean of 3 yr and followed up for a mean of 2.70 yr.
Intervention was 0.625 mg of CEE daily or placebo.
Annual rates of change in specific cognitive functions and affect, adjusted for time since randomization, were measured.
Compared with placebo, unopposed CEE was associated with lower spatial rotational ability (P < 0.01) at initial assessment (after 3 yr of treatment), a difference that diminished over 2.7 yr of continued treatment. CEE did not significantly influence change in other cognitive functions and affect.
CEE did not improve cognitive functioning in postmenopausal women with prior hysterectomy. CEE was associated with lower spatial rotational performance after an average of 3 yr of treatment. Overall, CEE does not appear to have enduring effects on rates of domain-specific cognitive change in older postmenopausal women.",[],The Journal of clinical endocrinology and metabolism,2009-10-24,"[{'lastname': 'Resnick', 'firstname': 'Susan M', 'initials': 'SM', 'affiliation': 'Laboratory of Personality and Cognition, National Institute on Aging, Biomedical Research Center, Baltimore, Maryland 21224-6825, USA. susan.resnick@nih.gov'}, {'lastname': 'Espeland', 'firstname': 'Mark A', 'initials': 'MA', 'affiliation': None}, {'lastname': 'An', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': None}, {'lastname': 'Maki', 'firstname': 'Pauline M', 'initials': 'PM', 'affiliation': None}, {'lastname': 'Coker', 'firstname': 'Laura H', 'initials': 'LH', 'affiliation': None}, {'lastname': 'Jackson', 'firstname': 'Rebecca', 'initials': 'R', 'affiliation': None}, {'lastname': 'Stefanick', 'firstname': 'Marcia L', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Wallace', 'firstname': 'Robert', 'initials': 'R', 'affiliation': None}, {'lastname': 'Rapp', 'firstname': 'Stephen R', 'initials': 'SR', 'affiliation': None}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,"Compared with placebo, unopposed CEE was associated with lower spatial rotational ability (P < 0.01) at initial assessment (after 3 yr of treatment), a difference that diminished over 2.7 yr of continued treatment. CEE did not significantly influence change in other cognitive functions and affect.",,10.1210/jc.2009-1340,<Element 'PubmedArticle' at 0x7f05da1e1c70>
459,19835274,"[The transcription of the amyloid precursor protein and tryptophan 2,3-dioxygenase genes are increased by aging in the rat brain].","Aging itself is considered as a major risk factor of dementia. The prevalence of the Alzheimer's disease (AD) is increasing exponentially after the age of 65 and doubles every 5 years. The major aim of our present research was to examine the effect of aging on the transcription of certain genes associated with neurodegenerative disorders in the rat brain. The influence of the vasopressin (VP) hormone was also examined in the same experimental paradigm. Age dependent transcriptional changes of the following four genes were examined in the cerebral cortex: the first was the gene of the amyloid precursor protein (APP) which is abnormally cleaved to toxic beta-amyloid fragments. These aggregated peptides are the major components of the senile plaques in the AD brain. The second one was the mitogen-activated protein kinase (MAPK1) gene. The MAPK is involved in the abnormal hyperphosphorylation of the tau-protein which results in aggregated neurofibrillary tangles. The beta-actin gene was the third one. The protein product of this gene is considered to be involved in synaptogenesis, neuronal plasticity and clinical conditions like depression and AD. The last one was the gene of the tryptophan 2,3-dioxygenase (TDO2) enzyme. The activity of this enzyme is considered as a rate limiting factor in the metabolism of the neuro-immune modulator quinolinic acid (QUIN). The transciptional activity of young (2.5 months) and aged (13 months) Brattleboro rats with or without VP expression were compared by means of real time PCR technique. The cortical transciptional activity of the APP and TDO2 genes were increased in the aged animals as compared with the activity of the young ones, and this effect was independent on the presence of the VP. Our results indicate the importance of certain age dependent transcriptional changes might influence the mechanism of AD and other neurodegenerative disorders.",[],Ideggyogyaszati szemle,2009-10-20,"[{'lastname': 'Kálmán', 'firstname': 'Sára', 'initials': 'S', 'affiliation': 'Szegedi Tudományegyetem, Pszichiátriai Klinika, Alzheimer-kór Kutatócsoport, Szeged. ksocy@citromail.hu'}, {'lastname': 'Pákáski', 'firstname': 'Magdolna', 'initials': 'M', 'affiliation': None}, {'lastname': 'Szucs', 'firstname': 'Szabina', 'initials': 'S', 'affiliation': None}, {'lastname': 'Garab', 'firstname': 'Dénes', 'initials': 'D', 'affiliation': None}, {'lastname': 'Domokos', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': None}, {'lastname': 'Zvara', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': None}, {'lastname': 'Puskás', 'firstname': 'László', 'initials': 'L', 'affiliation': None}, {'lastname': 'Bagdy', 'firstname': 'György', 'initials': 'G', 'affiliation': None}, {'lastname': 'Zelena', 'firstname': 'Dóra', 'initials': 'D', 'affiliation': None}, {'lastname': 'Kálmán', 'firstname': 'János', 'initials': 'J', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05da202630>
460,19797897,A prospective study on the development of Alzheimer's disease with regard to thyroid-stimulating hormone and homocysteine.,"The combination of elevated total homocysteine (tHcy) levels and low levels of thyroid-stimulating hormone (TSH) are linked to Alzheimer's disease (AD) in some studies, although the evidence is mixed. Our objective was to prospectively investigate the association between tHcy and TSH and the subsequent development of AD.
A subsample of 200 nondemented subjects was taken from the Kungsholmen Project, a population-based study among people > or =75 years. Information about tHcy and TSH levels were taken from the baseline investigation of the Kungsholmen Project study.
Increased tHcy levels were related to an elevated risk of AD (n = 61) after a mean follow-up time of 6.7 years. People with high tHcy (the 3rd tertile) had more than twice as high a risk of developing AD than those with low tHcy, even after adjusting for age, sex, education, ApoE status, MMSE score and laboratory parameters. tHcy was negatively correlated with TSH (p = 0.02). There was neither an influence of TSH nor an interaction between tHcy and TSH in the development of AD.
These results suggest that homocysteine, but not TSH, is involved in the development of AD. The connection between elevated tHcy and low TSH levels needs to be studied further.",[],Dementia and geriatric cognitive disorders,2009-10-03,"[{'lastname': 'Annerbo', 'firstname': 'Sylvia', 'initials': 'S', 'affiliation': 'Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Kivipelto', 'firstname': 'Miia', 'initials': 'M', 'affiliation': None}, {'lastname': 'Lokk', 'firstname': 'Johan', 'initials': 'J', 'affiliation': None}]",,,"Increased tHcy levels were related to an elevated risk of AD (n = 61) after a mean follow-up time of 6.7 years. People with high tHcy (the 3rd tertile) had more than twice as high a risk of developing AD than those with low tHcy, even after adjusting for age, sex, education, ApoE status, MMSE score and laboratory parameters. tHcy was negatively correlated with TSH (p = 0.02). There was neither an influence of TSH nor an interaction between tHcy and TSH in the development of AD.","Copyright 2009 S. Karger AG, Basel.",10.1159/000242439,<Element 'PubmedArticle' at 0x7f05da20abd0>
461,"19752112
17652657
19110085
18465362
18292129
17652652
9387865
16879779
11916936
17076827
18265477
17720354
18650917
19521513
14704746
18948104
11927139
18707012
19515111
17151862
16362629
17476347
15939120
17325252
19387610
15374669
17130685
10868966
18697873
17690139
18059606
12959703
18525377
18349087
9299565
18718903
8053361
17346289
18923185
17220915
15772055
15383370
19005195
18029463
15677734
19001550
16264856
16239176
19515792
12626436
10078561
11333990
12359832
12843134
11786910
18367704
19209175
18265476
17952830
15910955
16879881",The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk.,"Type 2 diabetes, cardiovascular diseases, colon cancer, breast cancer, dementia and depression constitute a cluster of diseases, which defines 'a diseasome of physical inactivity'. Both physical inactivity and abdominal adiposity, reflecting accumulation of visceral fat mass, are associated with the occurrence of the diseases within the diseasome. Physical inactivity appears to be an independent and strong risk factor for accumulation of visceral fat, which again is a source of systemic inflammation. Chronic inflammation is involved in the pathogenesis of insulin resistance, atherosclerosis, neurodegeneration and tumour growth. Evidence suggests that the protective effect of exercise may to some extent be ascribed to the anti-inflammatory effect of regular exercise, which can be mediated via a reduction in visceral fat mass and/or by induction of an anti-inflammatory environment with each bout of exercise. The finding that muscles produce and release myokines provides a conceptual basis to understand the mechanisms whereby exercise influences metabolism and exerts anti-inflammatory effects. According to our theory, contracting skeletal muscles release myokines, which work in a hormone-like fashion, exerting specific endocrine effects on visceral fat. Other myokines work locally within the muscle via paracrine mechanisms, exerting their effects on signalling pathways involved in fat oxidation.",[],The Journal of physiology,2009-09-16,"[{'lastname': 'Pedersen', 'firstname': 'Bente K', 'initials': 'BK', 'affiliation': 'Centre of Inflammation and Metabolism, Rigshospitalet - Section 7641, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. bkp@rh.dk'}]",,,,,10.1113/jphysiol.2009.179515,<Element 'PubmedArticle' at 0x7f05da214ef0>
462,19702939,Association of plasma sex hormone levels with functional decline in elderly men and women.,"We aimed to determine whether plasma sex hormone levels are associated with activities of daily living (ADL), cognition, depression and vitality in elderly individuals with functional decline.
Two hundred and eight consecutive persons 70 years or older (108 men and 100 women; mean +/- standard deviation, 81 +/- 7 years) with a chronic stable condition, receiving long-term care at a long-term care facilities located in Nagano Prefecture, Japan, were enrolled. Plasma total testosterone, free testosterone (only in men), dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S) and estradiol levels were determined in the morning after an overnight fast. Comprehensive geriatric assessment was performed including basic ADL by Barthel Index, instrumental ADL, cognitive function by Hasegawa Dementia Scale--Revised, mood by Geriatric Depression Scale and ADL-related vitality by Vitality Index.
Simple regression analysis showed that, in men, plasma total and free testosterone levels were associated with basic ADL (R = 0.292 and R = 0.282), instrumental ADL (R = 0.261 and R = 0.408), cognitive function (R = 0.393 and R = 0.553) and vitality (R = 0.246 and R = 0.396), while DHEA(-S) was associated with cognitive function, and estradiol with cognitive function as well as vitality. In women, the only significant correlation was between DHEA(-S) and basic ADL. Adjustment for age and nutritional markers did not influence the associations of plasma sex hormone levels with functional scores except for that of free testosterone with Barthel Index.
These results suggest that sex hormones have sex-specific associations with physical and neuropsychiatric functions in elderly individuals, and that endogenous testosterone is related to global function in elderly men.",[],Geriatrics & gerontology international,2009-08-26,"[{'lastname': 'Fukai', 'firstname': 'Shiho', 'initials': 'S', 'affiliation': 'Department of Geriatric Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.'}, {'lastname': 'Akishita', 'firstname': 'Masahiro', 'initials': 'M', 'affiliation': None}, {'lastname': 'Yamada', 'firstname': 'Shizuru', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hama', 'firstname': 'Tatsuya', 'initials': 'T', 'affiliation': None}, {'lastname': 'Ogawa', 'firstname': 'Sumito', 'initials': 'S', 'affiliation': None}, {'lastname': 'Iijima', 'firstname': 'Katsuya', 'initials': 'K', 'affiliation': None}, {'lastname': 'Eto', 'firstname': 'Masato', 'initials': 'M', 'affiliation': None}, {'lastname': 'Kozaki', 'firstname': 'Koichi', 'initials': 'K', 'affiliation': None}, {'lastname': 'Toba', 'firstname': 'Kenji', 'initials': 'K', 'affiliation': None}, {'lastname': 'Ouchi', 'firstname': 'Yasuyoshi', 'initials': 'Y', 'affiliation': None}]",,"These results suggest that sex hormones have sex-specific associations with physical and neuropsychiatric functions in elderly individuals, and that endogenous testosterone is related to global function in elderly men.","Simple regression analysis showed that, in men, plasma total and free testosterone levels were associated with basic ADL (R = 0.292 and R = 0.282), instrumental ADL (R = 0.261 and R = 0.408), cognitive function (R = 0.393 and R = 0.553) and vitality (R = 0.246 and R = 0.396), while DHEA(-S) was associated with cognitive function, and estradiol with cognitive function as well as vitality. In women, the only significant correlation was between DHEA(-S) and basic ADL. Adjustment for age and nutritional markers did not influence the associations of plasma sex hormone levels with functional scores except for that of free testosterone with Barthel Index.",,10.1111/j.1447-0594.2009.00534.x,<Element 'PubmedArticle' at 0x7f05da1b6720>
463,"19656632
12433001
14993039
10938447
9053781
9113382
11599302
7009200
1912947
11113481
2818831
15959466
15956147
11081851
14718219
9238064
14674857
15301598
10958118
1686744
9295207
14993057
12798975
16842093
9151931
14563073
7706984
17000015
15131017
10218927
4591653
16758493
11998552
10662535
9639289
10716536
16251013
1511342
8047642
7617701
7198905
7478686
10839653
11599304
15467707
9442352
11243495
15936524
12352277
14706945
11744087
11534987
16979750
17379660
11164090
17028418
16324790
10435856
11971664
15251262
15113256
17988898
18342351
15033426
14613726
9832120
9736007
8581984
11599308
9626145
11331087
7037875
15208706
10557352
9807641
12581182
2491857
2223043
15380490
15096691
15096691
10965513
11589143
17531325
12601707
10065332
17556547
1181486
1260208
15814098
8917906
11955475
11113522
10366698
15072555
18266940
17487224
2541695
14611869
16940355
12066445
10091721
17397044
8700112
10902789
1349441
11749982
11790402
16574627
8193545
14667974
8867373
12076726
8027073
8175951
17651807
8111631
17629950
11750861
14609546
12373445
2828079
11602222
11589127
12925744
11751611
9359583
11061547
16338086
18390689
7551184
8946427
7816204
1347506
17869008
17011053
8559360
7645647
16307962
825546
1484916
18473173
3953258
2160838
2120801
1852011
12441021
15538544
11442150
9409335
12467128
10525171
9659856
7925843
12183218
10441302
16632874
9606025
9435325
2980681
3631060
9626129
11392037
16310965
9389534
12771112
14614261
10087060
11444439
16024757
16231167
15219656
9413411
18068517
12578433
9618754
9798080
10451814
11911996
6715808
15100391
8725897
8901628
16249906
9501247
14751405
11078595
19352
10593201
16554740
17613939
16529958
16220340
18220513
17275189
8772579
12414884
11689280
15944068
17406975
15033889
12601167
10854906
14757337","Neurosteroids' effects and mechanisms for social, cognitive, emotional, and physical functions.","Hormones are trophic factors that integrate central and peripheral nervous system functions, and can influence social, cognitive, emotional and physical (SCEP) processes. Greater understanding of behavioral and neurobiological underpinnings of mental, cognitive, and/or physical changes with maturation is becoming increasingly important as the world's population ages. There are individual differences in how people age, but the factors that influence these differences are not well understood. Social supports are one factor that may influence the trajectory of age-related processes. The loss of close relationships, especially among older persons, is one of the greatest risk factors for mental and physical decline. Progesterone, secreted by the ovaries, or produced de novo in the brain, is readily converted centrally to 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP), and can influence SCEP, through rapid, non-classical steroid-mediated actions. Our hypothesis is that 3alpha,5alpha-THP is a key trophic factor in SCEP and development. Our research has demonstrated that 3alpha,5alpha-THP facilitates social and sexual behavior of rodents, which evokes further increases in 3alpha,5alpha-THP in midbrain and hippocampus, brain areas involved in SCEP. The role of 3alpha,5alpha-THP to influence social and/or sexual experience, and thereby SCEP, is discussed in this review. Further understanding of these neurobiological and/or behavioral factors may lead to findings that ultimately can promote health and prevent disease.",[],Psychoneuroendocrinology,2009-08-07,"[{'lastname': 'Frye', 'firstname': 'Cheryl A', 'initials': 'CA', 'affiliation': 'Department of Psychology, The University at Albany-State University of New York, Albany, NY 12222, USA. cafrye@albany.edu'}]",,,,,10.1016/j.psyneuen.2009.07.005,<Element 'PubmedArticle' at 0x7f05da1bec70>
464,"19625741
10600044
16862116
16862115
12526812
17291356
10858277
18551524
17923627
18565828
18752597
6610841
9520006
9073034
16950801
16257118
17266761
11846609
12029063
18723524
15499004
16585533
16417622
18620571
17961233
18793455
16526044
18413474
16401619
9633693
16983685
11571213
17003069
16251468
17984093
18378771
18768919
18184915
17826340",Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease.,"Mutations in the progranulin gene (GRN), causative for Frontotemporal Lobar Degeneration with ubiquitin-immunoreactive neuronal inclusions (FTLD-U), could also be associated with Alzheimer's disease (AD). The influence of GRN genetic variability on susceptibility to AD and on expression levels in a series of neuropathologically-confirmed AD patients as well as in peripheral mononuclear cells (PBMC) and in cells isolated from cerebrospinal fluid (CSF) was investigated. An association study of rs9897526 and rs5848 was carried out in an Italian population and in a replication population of European American patients and controls. None of the variants tested act as unequivocal susceptibility factor in both populations although rs9897526 anticipated the onset of the disease in the Italian population. GRN expression in the parietal lobe of AD cases showed a 0.76-fold decrease compared with controls (1.31 +/- 0.07 versus 1.73 +/- 0.12, P = 0.0025). Patients carrying the rs5848 TT genotype had the lowest GRN expression levels (0.96 +/- 0.12, P = 0.014). Despite no significant differences were found in the relative PBMC and CSF GRN expression in patients compared to controls, stratifying patients according to the presence of rs5848 T allele, a 0.57-fold decrease in GRN mRNA levels over C carriers was found in PBMC (1.22 +/- 0.23 versus 0.70 +/- 0.12, P = 0.04). Similarly to data obtained in brain samples, patients carrying the TT genotype showed the lowest GRN mRNA levels (TT = 0.46 +/- 0.14, CC = 1.22 +/- 0.23; P = 0.013). These data argue against a direct role of GRN as a susceptibility factor for sporadic AD but support a role of GRN as a disease-modifying gene, possibly contributing to the failure of neuronal survival.",[],Journal of Alzheimer's disease : JAD,2009-07-25,"[{'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': 'Department of Neurological Sciences, Dino Ferrari Center, University of Milan, IRCCS Fondazione Ospedale Maggiore Policlinico, Milan, Italy. chiara.fenoglio@unimi.it'}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Cortini', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Kauwe', 'firstname': 'John S K', 'initials': 'JS', 'affiliation': None}, {'lastname': 'Cruchaga', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': None}, {'lastname': 'Venturelli', 'firstname': 'Eliana', 'initials': 'E', 'affiliation': None}, {'lastname': 'Villa', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Serpente', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Scalabrini', 'firstname': 'Diego', 'initials': 'D', 'affiliation': None}, {'lastname': 'Mayo', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': None}, {'lastname': 'Piccio', 'firstname': 'Laura M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Clerici', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Albani', 'firstname': 'Diego', 'initials': 'D', 'affiliation': None}, {'lastname': 'Mariani', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': 'Forloni', 'firstname': 'Gianluigi', 'initials': 'G', 'affiliation': None}, {'lastname': 'Bresolin', 'firstname': 'Nereo', 'initials': 'N', 'affiliation': None}, {'lastname': 'Goate', 'firstname': 'Alison M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}]",,,,,10.3233/JAD-2009-1170,<Element 'PubmedArticle' at 0x7f05da1972c0>
465,"19623253
11371646
12732850
12009529
11717357
14962743
11739234
15678515
12558989
11997711
15128389
14561895
15465011
19386761
16005025
16151632
12562529
10874028
17237715
17003344
16266773
12709405
9813020
16814732
4900611
423789
11479628
12787071
11579100
16581004
15846348
10574411
14558985
17456849
16515786
12410400
18929410
16960089
15070774
17051206
12415260
19470628
16365283",Humanin: a novel central regulator of peripheral insulin action.,"Decline in insulin action is a metabolic feature of aging and is involved in the development of age-related diseases including Type 2 Diabetes Mellitus (T2DM) and Alzheimer's disease (AD). A novel mitochondria-associated peptide, Humanin (HN), has a neuroprotective role against AD-related neurotoxicity. Considering the association between insulin resistance and AD, we investigated if HN influences insulin sensitivity.
Using state of the art clamp technology, we examined the role of central and peripheral HN on insulin action. Continuous infusion of HN intra-cerebro-ventricularly significantly improved overall insulin sensitivity. The central effects of HN on insulin action were associated with activation of hypothalamic STAT-3 signaling; effects that were negated by co-inhibition of hypothalamic STAT-3. Peripheral intravenous infusions of novel and potent HN derivatives reproduced the insulin-sensitizing effects of central HN. Inhibition of hypothalamic STAT-3 completely negated the effects of IV HN analog on liver, suggesting that the hepatic actions of HN are centrally mediated. This is consistent with the lack of a direct effect of HN on primary hepatocytes. Furthermore, single treatment with a highly-potent HN analog significantly lowered blood glucose in Zucker diabetic fatty rats. Based upon the link of HN with two age-related diseases, we examined if there were age associated changes in HN levels. Indeed, the amount of detectable HN in hypothalamus, skeletal muscle, and cortex was decreased with age in rodents, and circulating levels of HN were decreased with age in humans and mice.
We conclude that the decline in HN with age could play a role in the pathogenesis of age-related diseases including AD and T2DM. HN represents a novel link between T2DM and neurodegeneration and along with its analogues offers a potential therapeutic tool to improve insulin action and treat T2DM.",[],PloS one,2009-07-23,"[{'lastname': 'Muzumdar', 'firstname': 'Radhika H', 'initials': 'RH', 'affiliation': ""Department of Pediatrics, Children's Hospital at Montefiore, Institute for Aging Research, Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY, USA.""}, {'lastname': 'Huffman', 'firstname': 'Derek M', 'initials': 'DM', 'affiliation': None}, {'lastname': 'Atzmon', 'firstname': 'Gil', 'initials': 'G', 'affiliation': None}, {'lastname': 'Buettner', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cobb', 'firstname': 'Laura J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Fishman', 'firstname': 'Sigal', 'initials': 'S', 'affiliation': None}, {'lastname': 'Budagov', 'firstname': 'Temuri', 'initials': 'T', 'affiliation': None}, {'lastname': 'Cui', 'firstname': 'Lingguang', 'initials': 'L', 'affiliation': None}, {'lastname': 'Einstein', 'firstname': 'Francine H', 'initials': 'FH', 'affiliation': None}, {'lastname': 'Poduval', 'firstname': 'Aruna', 'initials': 'A', 'affiliation': None}, {'lastname': 'Hwang', 'firstname': 'David', 'initials': 'D', 'affiliation': None}, {'lastname': 'Barzilai', 'firstname': 'Nir', 'initials': 'N', 'affiliation': None}, {'lastname': 'Cohen', 'firstname': 'Pinchas', 'initials': 'P', 'affiliation': None}]",,,,,10.1371/journal.pone.0006334,<Element 'PubmedArticle' at 0x7f05da132400>
466,19602103,Huntington's disease does not appear to increase the risk of diabetes mellitus.,"Huntington's disease (HD) is an autosomal, dominantly inherited, neurodegenerative disorder characterised by neurological, cognitive and psychiatric symptoms. HD has been associated with diabetes mellitus, which is, to some extent, supported by studies in transgenic HD mice. In transgenic mice, the severity of the diabetic phenotype appears to correlate with the length of a polyglutamine expansion in the protein huntingtin. In the present study, we investigated the association between diabetes mellitus and HD by performing an oral glucose-tolerance test (OGTT) to evaluate the glucose-tolerance status and OGTT-related insulin release in 14 HD patients. Furthermore, we expressed N-terminal huntingtin fragments with different polyglutamine lengths in an insulinoma-cell line (INS-1E) to investigate how mutant huntingtin influences glucose-stimulated insulin release in vitro. We found no difference between a group of early- and middle-stage HD patients and a large group of control individuals in any of the assessed variables. However, the glucose-stimulated induction of insulin release was significantly reduced in the insulinoma-cell line expressing highly expanded huntingtin compared to cells expressing huntingtin with modestly elongated polyglutamine stretches. These data indicate that insulin release from beta-cells expressing mutant huntingtin appears to be polyglutamine length-dependent, and that polyglutamine lengths within the range normally found in adult onset HD do not influence insulin release. This challenges the assumption of an increased risk of diabetes among HD patients, although our results do not exclude a changed glucose tolerance in end-stage HD patients or in patients with juvenile onset HD. It also raises the question of which extent transgenic mice models reflect the pathology of human HD in this regard.",[],Journal of neuroendocrinology,2009-07-16,"[{'lastname': 'Boesgaard', 'firstname': 'T W', 'initials': 'TW', 'affiliation': 'Steno Diabetes Center, Gentofte, Denmark.'}, {'lastname': 'Nielsen', 'firstname': 'T T', 'initials': 'TT', 'affiliation': None}, {'lastname': 'Josefsen', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Hansen', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Jørgensen', 'firstname': 'T', 'initials': 'T', 'affiliation': None}, {'lastname': 'Pedersen', 'firstname': 'O', 'initials': 'O', 'affiliation': None}, {'lastname': 'Nørremølle', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Nielsen', 'firstname': 'J E', 'initials': 'JE', 'affiliation': None}, {'lastname': 'Hasholt', 'firstname': 'L', 'initials': 'L', 'affiliation': None}]",,,,,10.1111/j.1365-2826.2009.01898.x,<Element 'PubmedArticle' at 0x7f05da14dbd0>
467,19584452,"Lesion-induced hippocampal plasticity in transgenic Alzheimer's disease mouse models: influences of age, genotype, and estrogen.","We have studied entorhinal cortex lesion-induced sprouting in the hippocampus in young, adult, and aged control and transgenic Alzheimer's disease model mice. The entorhinal cortex was unilaterally, partially lesioned, and four weeks later the subsequent axonal sprouting in dentate gyrus was analyzed. Our data demonstrate that young and adult, control and amyloid-beta protein precursor (AbetaPP)/presenilin 1 (PS1) mice display a significantly increased density of staining for synaptophysin in dentate gyrus, indicative of axonal sprouting. However, whereas young and adult mice demonstrate sprouting, aged mice (control and AbetaPP/PS1) do not show a significant upregulation of synaptophysin staining following the lesions. In contrast, aged mice overexpressing PS1 show an increased regenerative response compared to age-matched control mice and mice overexpressing AbetaPP which do not show sprouting. Further, the data demonstrate that a significant Abeta load in the dentate gyrus does not prevent axonal sprouting. Lastly, only aged mice show significant shrinkage of the molecular layer of dentate gyrus following entorhinal cortex lesions. Further, adult ovariectomized females (control and AbetaPP/PS1) are significantly reduced in their plasticity following lesions. Taken together, the data indicate that amyloid-beta deposits do not negatively impact plasticity in the brain and that overexpression of AbetaPP is not beneficial, but that normal estrogen levels are beneficial for plasticity.",[],Journal of Alzheimer's disease : JAD,2009-07-09,"[{'lastname': 'Kadish', 'firstname': 'Inga', 'initials': 'I', 'affiliation': 'Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ikadisha@uab.edu'}, {'lastname': 'van Groen', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}]",,,,,10.3233/JAD-2009-1157,<Element 'PubmedArticle' at 0x7f05da15aef0>
468,19560872,Action of estrogen on survival of basal forebrain cholinergic neurons: promoting amelioration.,"Extensive studies during the past two decades provide compelling evidence that the gonadal steroid, estrogen, has the potential to affect the viability of basal forebrain cholinergic neurons. These observations reflect a unique ameliorative feature of estrogen as it restores and protects the cholinergic neurons against noxious stimuli or neurodegenerative processes. Hence, we first address the ameliorative function of estrogen on basal forebrain cholinergic neurons such as the actions of estrogen on neuronal plasticity of cholinergic neurons, estrogen-induced memory enhancement and the ameliorative role of estrogen on cholinergic neuron related neurodegenerative processes such as Alzheimer's disease. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of estrogen; influencing the amyloid precursor protein processing, enhancement in neurotrophin receptor signaling and estrogen-induced non-classical actions on second messenger systems. In addition, clinical relevance, pitfalls and future aspects of estrogen therapy on basal forebrain cholinergic neurons will be discussed.",[],Psychoneuroendocrinology,2009-06-30,"[{'lastname': 'Abrahám', 'firstname': 'István M', 'initials': 'IM', 'affiliation': 'Centre for Neuroendocrinology, Department of Physiology, University of Otago, Dunedin, New Zealand. istvan.abraham@otago.ac.nz'}, {'lastname': 'Koszegi', 'firstname': 'Zsombor', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Tolod-Kemp', 'firstname': 'Emeline', 'initials': 'E', 'affiliation': None}, {'lastname': 'Szego', 'firstname': 'Eva M', 'initials': 'EM', 'affiliation': None}]",,,,,10.1016/j.psyneuen.2009.05.024,<Element 'PubmedArticle' at 0x7f05da0e8a90>
469,19552637,Melatonin provides neuroprotection by reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfusion in ovariectomized rats.,"Oxidative stress is believed to contribute to functional and histopathologic disturbances associated with chronic cerebral hypoperfusion (CCH) in rats. Melatonin has protective effects against cerebral ischemia/reperfusion injury. This effect has mainly been attributed to its antioxidant properties. In the present study, we evaluate the effects of melatonin on chronic cerebral hypoperfused rats and examined its possible influence on oxidative stress, superoxide dismutase (SOD) activity, reduced glutathione (GSH) levels, and heat shock protein (HSP) 70 induction. CCH was induced by permanent bilateral common carotid artery occlusion in ovariectomized female rats. Extensive neuronal loss in the hippocampus at day 14 following CCH was observed. The ischemic changes were preceded by increases in malondialdehyde (MDA) concentration and HSP70 induction as well as reductions in GSH and SOD. Melatonin treatment restored the levels of MDA, SOD, GSH, and HSP70 induction as compared to the ischemic group. Histopathologic analysis confirmed the protective effect of melatonin against CCH-induced morphologic alterations. Taken together, our results document that melatonin provides neuroprotective effects in CCH by attenuating oxidative stress and stress protein expression in neurons. This suggests melatonin may be helpful for the treatment of vascular dementia and cerebrovascular insufficiency.",[],Journal of pineal research,2009-06-26,"[{'lastname': 'Ozacmak', 'firstname': 'Veysel H', 'initials': 'VH', 'affiliation': 'Department of Physiology.'}, {'lastname': 'Barut', 'firstname': 'Figen', 'initials': 'F', 'affiliation': 'Department of Pathology, Zonguldak Karaelmas University, Zonguldak, Turkey.'}, {'lastname': 'Ozacmak', 'firstname': 'Hale S', 'initials': 'HS', 'affiliation': 'Department of Physiology.'}]",,,,,10.1111/j.1600-079X.2009.00695.x,<Element 'PubmedArticle' at 0x7f05da0f3310>
470,19519303,The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease.,"In different clinical studies, an association of type 2 diabetes and Alzheimer's disease (AD) has been described. However, the underlying mechanisms are still unclear. One explanation could be that vascular complications of diabetes result in neurodegeneration. Alternatively, the mechanism might be directly related to insulin and insulin-like growth factor(IGF)-1 signaling, leading to the proposal that AD is a ""brain-type diabetes"". Furthermore, postmortem analyses of brains from patients with AD revealed a markedly downregulated expression of insulin receptor (IR), IGF-1 receptor (IGF-1R), insulin receptor substrate (IRS)-1 and IRS-2, and these changes progress with severity of neurodegeneration. These findings raise the question, whether this phenomenon is cause or consequence of neurodegeneration. Recently, Cohen and coworkers have show that knocking down DAF-2 in C. elegans, the homolog of the mammalian IR/IGF-1R, reduces beta-amyloid(Abeta)(1-42) toxicity. Cell based experiments suggest a specific role for the IGF 1/IRS-2 signaling pathway in regulating alpha-/beta-secretase activity. Moreover circulating IGF-1 might influence Abeta clearance from the brain by promoting Abeta transport over the blood brain barrier. Interestingly, brain specific deletion of IRS-2 increases life span, suggesting that long term neuronal IGF-1R signaling might be harmful. Taken together, the data from humans and different model organisms indicate a role of IR/IGF-1R signaling in Abeta metabolism, and clearance as well as longevity. Since more studies are needed to elucidate the impact of insulin and/or IGF-1 treatment in AD, the time to propose these hormones as a potential treatment option for AD has not come yet.",[],Current Alzheimer research,2009-06-13,"[{'lastname': 'Freude', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Department of Internal Medicine II, Center for Molecular Medicine Cologne (CMMC), and Cologne Excellence Cluster on Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Köln, Kerpener Str. 62, 50937 Köln, Germany.'}, {'lastname': 'Schilbach', 'firstname': 'K', 'initials': 'K', 'affiliation': None}, {'lastname': 'Schubert', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,,10.2174/156720509788486527,<Element 'PubmedArticle' at 0x7f05da1053b0>
471,19494437,MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels.,"The distribution of the MCP-1 A-2518G single nucleotide polymorphisms (SNP) was analyzed in a population of 212 patients with frontotemporal lobar degeneration (FTLD) compared with 203 age-matched controls. A significantly decreased allelic frequency of the G allele in patients compared with controls was observed (21.1 versus 29.3%, P = 0.011, OR: 0.59, CI: 0.40-0.87). Stratifying according to gender, the association was maintained in male patients versus male controls (17.8 versus 29.4%, P = 0.016, OR = 0.46, 95% CI: 0.25-0.84), but not in female patients compared with female controls (23.5 versus 29.2%, P > 0.05). The frequency of apolipoprotein E epsilon4 carriers was increased in patients (26.4 versus 13.8%, P = 0.0015, OR: 2.24, 95% CI: 1.37-3.67). Apolipoprotein E status did not influence the distribution of the A-2518G SNP. Monocyte chemotactic protein (MCP)-1 levels were determined in cerebrospinal fluid (CSF) collected from 23 patients and 17 controls. MCP-1 CSF levels were increased in patients compared with controls (449.01 +/- 27.57 versus 364.19 +/- 23.75 pg/ml, P = 0.011). Stratifying patients according to the presence of the polymorphic allele, significantly increased CSF MCP-1 levels were observed in carriers of the G allele compared with non-carriers (502.21 +/- 44.57 versus 395.87 +/- 21.92 pg/ml, P = 0.045). The MCP-1 A-2518G SNP acts as protective factor for sporadic FTLD, possibly by influencing MCP-1 production.",[],Journal of Alzheimer's disease : JAD,2009-06-06,"[{'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Neurological Sciences, ""Dino Ferrari"" Center, University of Milan, IRCCS Fondazione Ospedale Maggiore Policlinico, Milan, Italy. daniela.galimberti@unimi.it'}, {'lastname': 'Venturelli', 'firstname': 'Eliana', 'initials': 'E', 'affiliation': None}, {'lastname': 'Villa', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Fenoglio', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Clerici', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Marcone', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Benussi', 'firstname': 'Luisa', 'initials': 'L', 'affiliation': None}, {'lastname': 'Cortini', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Scalabrini', 'firstname': 'Diego', 'initials': 'D', 'affiliation': None}, {'lastname': 'Perini', 'firstname': 'Luca', 'initials': 'L', 'affiliation': None}, {'lastname': 'Restelli', 'firstname': 'Ilaria', 'initials': 'I', 'affiliation': None}, {'lastname': 'Binetti', 'firstname': 'Giuliano', 'initials': 'G', 'affiliation': None}, {'lastname': 'Cappa', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': None}, {'lastname': 'Mariani', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': 'Bresolin', 'firstname': 'Nereo', 'initials': 'N', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}]",,,,,10.3233/JAD-2009-1019,<Element 'PubmedArticle' at 0x7f05da10f270>
472,19482376,"Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment.","Alzheimer disease (AD) is a common and devastating dementing illness for which there is no effective neuroprotective therapy or cure. The presence of the apolipoprotein E (apoE) ε4 allele is a well-established genetic modifier (risk factor) of sporadic AD. In this review, we provide an update on the implications of apoE for the neurobiology and epidemiology of AD. Moreover, recent evidence is adduced indicating that (i) many AD risk factors are potentially modifiable by adaptive lifestyle changes and pharmacotherapy and (ii) the potency of these modifiable AD determinants and responsiveness to intervention are often significantly impacted by the presence or absence of the ε4 allele. Delineation of the influences of the APOE genotype on modifiable AD risk factors and prevention may spur consideration of APOE testing for presymptomatic individuals seeking to define their personal risk.",[],Neurobiology of aging,2009-06-02,"[{'lastname': 'Schipper', 'firstname': 'Hyman M', 'initials': 'HM', 'affiliation': 'Centre for Neurotranslational Research and Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote St. Catherine Road, McGill University, Montreal, Quebec, Canada H3T 1E2. hyman.schipper@mcgill.ca'}]",,,,Copyright © 2009 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2009.04.021,<Element 'PubmedArticle' at 0x7f05da1191d0>
473,19478482,Genetic variation of CYP19 (aromatase) gene influences age at onset of Alzheimer's disease in women.,"There is evidence for a higher prevalence of Alzheimer's disease (AD) in women, but whether this is due to their longer life expectancy or to biological gender-specific risk factors is unclear. One likely contributing factor is the reduced estrogen neuroprotective action following menopause. In this context, an AD risk gene could be CYP19, encoding aromatase, an enzyme involved in estrogen biosynthesis.
We analyzed the role of 3 CYP19 single-nucleotide polymorphisms (rs12907866, rs17601241, rs4646) in AD development and their possible influence on quantitative traits reflecting disease severity (age at onset and cognitive decline) in 319 patients and 110 controls.
No association was observed between the CYP19 single-nucleotide polymorphisms and AD risk. Yet CYP19 genetic variation did seem to contribute to AD development in women as the rs4646 genotypes carrying the T allele were associated with an earlier onset age (p = 0.01) independently of a similar effect determined by the APOE e*4 allele (p = 0.005). Also, being present only in parous women (p = 0.01), the effect of rs4646 genotypes on onset age appeared to depend on past fertility.
Together with gender-specific factors such as parity, genes controlling estrogen metabolism may play a relevant role in AD susceptibility in women.",[],Dementia and geriatric cognitive disorders,2009-05-30,"[{'lastname': 'Corbo', 'firstname': 'Rosa Maria', 'initials': 'RM', 'affiliation': 'Department of Genetics and Molecular Biology, University La Sapienza, IT-00185 Rome, Italy. rosamaria.corbo@uniroma1.it'}, {'lastname': 'Gambina', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Ulizzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Moretto', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Scacchi', 'firstname': 'Renato', 'initials': 'R', 'affiliation': None}]",,"Together with gender-specific factors such as parity, genes controlling estrogen metabolism may play a relevant role in AD susceptibility in women.","No association was observed between the CYP19 single-nucleotide polymorphisms and AD risk. Yet CYP19 genetic variation did seem to contribute to AD development in women as the rs4646 genotypes carrying the T allele were associated with an earlier onset age (p = 0.01) independently of a similar effect determined by the APOE e*4 allele (p = 0.005). Also, being present only in parous women (p = 0.01), the effect of rs4646 genotypes on onset age appeared to depend on past fertility.",,10.1159/000221832,<Element 'PubmedArticle' at 0x7f05da0a48b0>
474,"19463794
15094083
18157973
17159101
15590460
17510458
15933386
17426095
18319319
1773451
1773694
15983190
3249771
16816092
9258889
12670318
14595538
18276751
18082417
9303923
17334649
15784710
15557505
17536002
15327738
9371913
8586007
15919583
2118608
16216937
17492428
10902785
17003305
18050330
17290035
9054233
17466428
2690106
9152991
18672179
18048471
16545583
11916953
14674838
3249768
11713467
8433101
18726054
18298345
1450290
18024186
18278039
18347963
18223623
17179707
12177370
15111519
16300445",Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus.,"Cognitive deficits and hippocampal atrophy, features that are shared with aging and dementia, have been described in type 2 diabetes mellitus (T2DM). T2DM is associated with obesity, hypertension, dyslipidemia, hypothalamic pituitary adrenocortical (HPA) axis abnormalities and inflammation, all of which have been shown to negatively impact the brain. However, since most reports in T2DM focused on glycemic control, the relative contribution of these modifying factors to the impairments observed in T2DM remains unclear. We contrasted 41 middle-aged dementia-free volunteers with T2DM (on average 7 years since diagnosis) with 47 age-, education-, and gender-matched non-insulin resistant controls on cognition and brain volumes. HPA axis activity and other modifiers that accompany T2DM were assessed to determine their impact on brain and cognition. Individuals with T2DM had specific verbal declarative memory deficits, reduced hippocampal and prefrontal volumes, and impaired HPA axis feedback control. Diminished cortisol suppression after dexamethasone and dyslipidemia were associated with decreased cognitive performance, whereas obesity was negatively related to hippocampal volume. Moreover, prefrontal volume was influenced by worse glycemic control. Thus, obesity and altered cortisol levels may contribute to the impact of T2DM on the hippocampal formation, resulting in decreased verbal declarative memory performance.",[],Brain research,2009-05-26,"[{'lastname': 'Bruehl', 'firstname': 'Hannah', 'initials': 'H', 'affiliation': 'Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA.'}, {'lastname': 'Wolf', 'firstname': 'Oliver T', 'initials': 'OT', 'affiliation': None}, {'lastname': 'Sweat', 'firstname': 'Victoria', 'initials': 'V', 'affiliation': None}, {'lastname': 'Tirsi', 'firstname': 'Aziz', 'initials': 'A', 'affiliation': None}, {'lastname': 'Richardson', 'firstname': 'Stephen', 'initials': 'S', 'affiliation': None}, {'lastname': 'Convit', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': None}]",,,,,10.1016/j.brainres.2009.05.032,<Element 'PubmedArticle' at 0x7f05da0b10e0>
475,19408625,"Influences of twilight on diurnal variation of core temperature, its nadir, and urinary 6-hydroxymelatonin sulfate during nocturnal sleep and morning drowsiness.","This study aimed at elucidating the physiological significance of dusk and dawn in the circadian rhythm of core temperature (T(core)) and urinary 6-hydroxymelatonin sulfate in humans during sleep and the waking sensation just after rising. Seven female and four male students served as participants. Participants retired at 2300 h and rose at 0700 h. They were requested to sit on a chair and spend time as quietly as possible during wakefulness, reading a book or listening to recorded light music. Two lighting conditions were provided for each participant: 1) Light-Dark (LD)-rectangular light change with abrupt decrease from 3,000 lx to 100 lx at 1800 h, abrupt increase from 0 lx to 3,000 lx at 0700 h. 2) LD-twilight light change with gradual decrease from 3,000 lx to 100 lx starting at 1700 h (twilight period about 2 h), with gradual increase from 0 lx to 3,000 lx starting at 0500 h (twilight period about 2 h). The periods of 0 lx at night were from 2300 h to 0700 h on the first day and from 2300 to 0500 h on the second day. Nadir time advanced significantly under the influence of the LD-twilight condition. The amount of 6-hydroxymelatonin sulfate in urine collected at 0200 h was significantly higher under LD-twilight in comparison with LD-rectangular light. Morning drowsiness tended to be lower under LD-twilight. Our results suggest that in architectural design of indoor illumination it is important to provide LD-twilight in the evening and early morning for sleep promotion in healthy normal people and/or light treatment in elderly patients with advanced dementia.",[],Collegium antropologicum,2009-05-05,"[{'lastname': 'Kondo', 'firstname': 'Masayuki', 'initials': 'M', 'affiliation': 'Heart-ful Living R&D Institute, Comprehensive Housing R&D Institute, Sekisui House Ltd., Kyoto, Japan. kondo@gz.sekisuihouse.co.jp'}, {'lastname': 'Tokura', 'firstname': 'Hiromi', 'initials': 'H', 'affiliation': None}, {'lastname': 'Wakamura', 'firstname': 'Tomoko', 'initials': 'T', 'affiliation': None}, {'lastname': 'Hyun', 'firstname': 'Ki-Ja', 'initials': 'KJ', 'affiliation': None}, {'lastname': 'Tamotsu', 'firstname': 'Satoshi', 'initials': 'S', 'affiliation': None}, {'lastname': 'Morita', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Oishi', 'firstname': 'Tadashi', 'initials': 'T', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05da0d7180>
476,"19374686
17114822
8367470
15364416
9600988
11296263
11030795
15911792
15534246
11264981
7830084
12757020
11090130
11149950
15749000
16730733
11113612
15729734
16517099
11450851
1202204
11011111
2341813
12928047
15290652
15185400
15297300
9772023
9600988
12490529
8928008
17151262
9374499
8790411
12202492
17339582
11027840
11171976
15883313
11408727
16730122
17341859
15776446",RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism.,"Cholesterol metabolism is altered in Alzheimer's disease (AD). The nuclear hormone receptor Retinoic X Receptor a (RXRa) is a member of the nuclear ligand-activated transcription factor family. RXRs are key regulators of cholesterol synthesis and thus cholesterol metabolism. We performed a systematic screen for gene variants in the RXRA gene. The effect of these gene variants on the risk of AD was investigated in 405 AD patients (mean age: 74.27 +/- 9.37 years; female 78.6%) and 347 controls (mean age: 73.26 +/- 8.37 years; female 57.2%). Furthermore, the influence of RXRA gene variants on CSF and plasma levels of cholesterol, lathosterol and 24S-hydroxycholesterol were evaluated. One of the identified seven SNPs in RXRA influenced AD risk in our single marker analysis (rs3132293: P= 0.006). Haplotype analysis identified a three-marker haplotype (TGC) consisting of rs3118570, rs1536475 and rs3132293, which decreased the risk of AD (P= 0.009). The single marker rs3132293 (P= 0.026) and the TGC haplotype (P= 0.026) influenced CSF lathosterol levels in non-demented controls, and cholesterol levels in the combined sample comprising AD patients and controls (Rs3132293: P= 0.050; TGC haplotype: P= 0.035). 24S-Hydroxycholesterol CSF and plasma levels were also influenced by rs3132293 (CSF: P= 0.004; plasma: P= 0.001) and the TGC haplotype (CSF: P= 0.004; plasma: P= 0.002); this effect was most pronounced in AD patients (rs3132293: CSF: P= 0.009, plasma: P= 0.002; TGC haplotype: CSF: P= 0.019, plasma: P= 0.005). Our results suggest that RXRA gene variants might act as risk factor for AD via an influence on cerebral cholesterol metabolism.",[],Journal of cellular and molecular medicine,2009-04-21,"[{'lastname': 'Kölsch', 'firstname': 'Heike', 'initials': 'H', 'affiliation': 'Department of Psychiatry, University of Bonn, Bonn, Germany. heike.koelsch@ukb.uni-bonn.de'}, {'lastname': 'Lütjohann', 'firstname': 'Dieter', 'initials': 'D', 'affiliation': None}, {'lastname': 'Jessen', 'firstname': 'Frank', 'initials': 'F', 'affiliation': None}, {'lastname': 'Popp', 'firstname': 'Julius', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hentschel', 'firstname': 'Frank', 'initials': 'F', 'affiliation': None}, {'lastname': 'Kelemen', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Friedrichs', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': None}, {'lastname': 'Maier', 'firstname': 'T A Wolfgang', 'initials': 'TA', 'affiliation': None}, {'lastname': 'Heun', 'firstname': 'Reinhard', 'initials': 'R', 'affiliation': None}]",,,,,10.1111/j.1582-4934.2009.00383.x,<Element 'PubmedArticle' at 0x7f05da0dcb80>
477,"19356123
3520605
3529128
10839332
9843121
15866202
11301030
11301031
11279497
12498988
3352594
2848184
10570211
9931142
11080195
11408610
18084639
1992016
7689702
7724569
17105950
16224028
18286196
12015198
10617691
12084633
8129747
7935333
11106782
1327374
1315042
11677265
8609900
12037135
10525114
12843414
18562289
7867785
8526880
8781236
11468287
7990962
9006968
9831287
9930723
11113634
12679143
10204543
1470919
7605349
7575630
11259648
12023533
12060783
10817598
11277920
9231721
9262477
11106786
9822713
11408519
11118429
12655057
10785540
12244105
12023517
10814517
17346227
11353795
7947736
17222464
16751706
14595399
15894565
10420166
10631784
11279117
16452678
14570037
12182964
17525344
16357196
15465283
11319244
16787257
16212495
15657046
12578907
14610053
9671590
9466436
9183820
9472392
1376455
10462073
6245418
7906890
3531903
2446111
7663970
8800663
9757010
472762
8615904
9804618
9365016
7775459
18261715
18473254
11950549
12181101
12446537
12446534
14754822
15369572
15582916
12888772
12199828
16185213
15231440
11993290
15866551
12432948
11707102
11717385
10341254
16723519
10678533
9382942
12019305
11516401
11976437
18796007
11976704
12741992
12152079
12060781
12925278
16301180
10837502
9285589
15950248
18638556
10891614
10828533
14667455
14529364
11447320
16533591
11842443
15217349
16280684
15310460
12684448
16571781
15204022
16183560
7970006
16183555
16323214
16647138
16512913
12813001
10594923
8840127
10877836
14511339
12177188
11860478
15852389
16412990
11383976
11311783
10208314
15354183
16199010
12969514
12214082
15734686
17978019
15030397
12384227
15728830
10436037
11522331
16406322
12023519
14683467
16732431
14522360
17140265
9309469
8751435
9872309
12399252
14770190
16787229
17017918
19135149
16503766
17098084
16973696
17208644
16448676
17692039
15182777
15836887
11156943
12052039
12154273
12052043
16482090",Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.,"The endocannabinoid system, including endogenous ligands ('endocannabinoids' ECs), their receptors, synthesizing and degrading enzymes, as well as transporter molecules, has been detected from the earliest stages of embryonic development and throughout pre- and postnatal development. ECs are bioactive lipids, which comprise amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) are the best studied ECs, and act as agonists of cannabinoid receptors. Thus, AEA and 2-AG mimic several pharmacological effects of the exogenous cannabinoid delta9-tetrahydrocannabinol (Delta(9)-THC), the psychoactive principle of cannabis sativa preparations like hashish and marijuana. Recently, however, several lines of evidence have suggested that the EC system may play an important role in early neuronal development as well as a widespread role in neurodegeneration disorders. Many of the effects of cannabinoids and ECs are mediated by two G protein-coupled receptors (GPCRs), CB1 and CB2, although additional receptors may be implicated. Both CB1 and CB2 couple primarily to inhibitory G proteins and are subject to the same pharmacological influences as other GPCRs. This new system is briefly presented in this review, in order to put in a better perspective the role of the EC pathway from neurodevelopment to neurodegenerative disorders, like Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. In addition, the potential exploitation of antagonists of CB1 receptors, or of inhibitors of EC metabolism, as next-generation therapeutics is discussed.",[],Mini reviews in medicinal chemistry,2009-04-10,"[{'lastname': 'Basavarajappa', 'firstname': 'Balapal S', 'initials': 'BS', 'affiliation': 'Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA. Basavaraj@nki.rfmh.org'}, {'lastname': 'Nixon', 'firstname': 'Ralph A', 'initials': 'RA', 'affiliation': None}, {'lastname': 'Arancio', 'firstname': 'Ottavio', 'initials': 'O', 'affiliation': None}]",,,,,10.2174/138955709787847921,<Element 'PubmedArticle' at 0x7f05da078900>
478,19267087,[Changes of some elements in rat's tissues except nerve centre with both ovariectomy and chronic aluminum toxication and the effects of estrogen supplement].,"To reveal the influence of ovariectomy and chronic Aluminum toxication in combination on the distribution in tissues except nerve centre and excretion in urine of somel elements. The study will supply the basis for study of Alzheimers disease.
Forty 6-month-old female S-D rats were divided randomly into 4 groups: group OVX, group OVX + Al and group OVX + Al + E2. After 3 months, urine of 24 h were collected by metabolic cages; liver, kidney, heart, bone, tibia and skeletal muscle, were got from the rats. The content of the elements in these tissues and urine was detected by ICP-AES.
Compared of group OVX with group sham, the content of Zn decreased (P < 0.001). Compared of group OVX + Al + E2 with group sham, the content of Al, Cd, Si and Se in heart increased (P < 0.05, P < 0.01, P < 0.01, P < 0.001). The content of Se and Cd in tibia increased (P < 0.01, P < 0.001). The content of Al in kidney increased (P < 0.05). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001) in skeletal muscle. The content of Al, Se and Ca in spinal cord decreased (P < 0.05, P < 0.01, P < 0.05). The content of Mn, Zn and Si in liver increased (P < 0.01, P < 0.05, P < 0.05). The content of Cd, Mg, Se, Al and Ca in urine increased (P < 0.05, P < 0.05, P < 0.01, P < 0.001, P < 0.001). Compared of group OVX + Al + E2 with group OVX + Al, the content of Cd, Mn and Se in heart increased (P < 0.05, P < 0.05, P < 0.01). The content of Al, Mg, Se, Cd and Mn in tibia increased (P < 0.05, P < 0.01, P < 0.001, P < 0.001, P < 0.001). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001), in skeletal muscle. The content of Se in spinal cord decreased (P < 0.05). The content of Al and Ca decreased (P < 0.05, P < 0.01), the content of Cu, Si, Fe, Mg, Mn and Zn incraesed(P <0.05, P < 0.05, P <0.01, P < 0.01, P < 0.001, P < 0.001), in liver. The content of Se, Al, Cd, Mg, Si and Ca in urine increased (P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.01).
Zn in heart can transfer to other tissues after a long time ovariectomy. Heart, skeletal muscle and liver, are mainly affected tissues except nerve centre by ovariectomy and chronic aluminum toxication in combination; and mainly affected elements are Zn, Si, Cu and Se. Chronic aluminum toxication make Si transfer to heart of ovariectomized rats, and facilitate Zn in heart transfer to other tissues. Supply estrogen can promote aluminum excretion in urine. distribution in tissues except nerve centre and excretion in urine of somel elements. The study will supply the basis for study of Alzheimers disease.
Forty 6-month-old female S-D rats were divided randomly into 4 groups: group OVX, group OVX + Al and group OVX + Al + E2. After 3 months, urine of 24h were collected by metabolic cages; Liver, kidney, heart, bone, tibia and skeletal muscle, were got from the rats. The content of the elements in these tissues and urine was detected by ICP-AES.
Compared of group OVX with group sham, the content of Zn decreased (P < 0.001). Compared of group OVX + Al + E2 with group sham, the content of Al, Cd, Si and Se in heart increased (P < 0.05, P < 0.01, P < 0.01, P < 0.001). The content of Se and Cd in tibia increased (P < 0.01, P < 0.001). The content of Al in kidney increased (P < 0.05). The content of Mn and Cu increased (P < 0.05, P < 0.001),Se decreased (P < 0.001) in skeletal muscle. The content of Al, Se and Ca in spinal cord decreased (P < 0.05, P < 0.01, P < 0.05). The content of Mn, Zn and Si in liver increased (P < 0.01, P < 0.05, P < 0.05). The content of Cd, Mg, Se, Al and Ca in urine increased (P < 0.05, P < 0.05, P < 0.01, P < 0.001, P < 0.001). Compared of group OVX + Al + E2 with group OVX + Al, the content of Cd, Mn and Se in heart increased (P < 0.05, P < 0.05, P < 0.01). The content of Al, Mg, Se, Cd and Mn in tibia increased (P < 0.05, P < 0.01, P < 0.001, P < 0.001, P < 0.001). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001), in skeletal muscle. The content of Se in spinal cord decreased (P < 0.05). The content of Al and Ca decreased (P < 0.05, P < 0.01), the content of Cu, Si, Fe, Mg, Mn and Zn incraesed(P <0.05, P < 0.05, P <0.01, P < 0.01, P < 0.001, P < 0.001), in liver. The content of Se, Al, Cd, Mg, Si and Ca in urine increased (P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.01).
Zn in heart can transfer to other tissues after a long time ovariectomy. Heart, skeletal muscle and liver, are mainly affected tissues except nerve centre by ovariectomy and chronic aluminum toxication in combination; and mainly affected elements are Zn, Si, Cu and Se. Chronic aluminum toxication make Si transfer to heart of ovariectomized rats, and facilitate Zn in heart transfer to other tissues. Supply estrogen can promote aluminum excretion in urine.",[],Wei sheng yan jiu = Journal of hygiene research,2009-03-10,"[{'lastname': 'Zhao', 'firstname': 'Changan', 'initials': 'C', 'affiliation': 'Department of Biochemistry and Molecular Biology of Xinxiang Medical University, Xinxiang 453003, China. zca_phd@yahoo.com.cn'}, {'lastname': 'Xu', 'firstname': 'Na', 'initials': 'N', 'affiliation': None}, {'lastname': 'Zhang', 'firstname': 'Wen', 'initials': 'W', 'affiliation': None}, {'lastname': 'Zhao', 'firstname': 'Chunpeng', 'initials': 'C', 'affiliation': None}]",,"Zn in heart can transfer to other tissues after a long time ovariectomy. Heart, skeletal muscle and liver, are mainly affected tissues except nerve centre by ovariectomy and chronic aluminum toxication in combination; and mainly affected elements are Zn, Si, Cu and Se. Chronic aluminum toxication make Si transfer to heart of ovariectomized rats, and facilitate Zn in heart transfer to other tissues. Supply estrogen can promote aluminum excretion in urine. distribution in tissues except nerve centre and excretion in urine of somel elements. The study will supply the basis for study of Alzheimers disease.
Zn in heart can transfer to other tissues after a long time ovariectomy. Heart, skeletal muscle and liver, are mainly affected tissues except nerve centre by ovariectomy and chronic aluminum toxication in combination; and mainly affected elements are Zn, Si, Cu and Se. Chronic aluminum toxication make Si transfer to heart of ovariectomized rats, and facilitate Zn in heart transfer to other tissues. Supply estrogen can promote aluminum excretion in urine.","Compared of group OVX with group sham, the content of Zn decreased (P < 0.001). Compared of group OVX + Al + E2 with group sham, the content of Al, Cd, Si and Se in heart increased (P < 0.05, P < 0.01, P < 0.01, P < 0.001). The content of Se and Cd in tibia increased (P < 0.01, P < 0.001). The content of Al in kidney increased (P < 0.05). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001) in skeletal muscle. The content of Al, Se and Ca in spinal cord decreased (P < 0.05, P < 0.01, P < 0.05). The content of Mn, Zn and Si in liver increased (P < 0.01, P < 0.05, P < 0.05). The content of Cd, Mg, Se, Al and Ca in urine increased (P < 0.05, P < 0.05, P < 0.01, P < 0.001, P < 0.001). Compared of group OVX + Al + E2 with group OVX + Al, the content of Cd, Mn and Se in heart increased (P < 0.05, P < 0.05, P < 0.01). The content of Al, Mg, Se, Cd and Mn in tibia increased (P < 0.05, P < 0.01, P < 0.001, P < 0.001, P < 0.001). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001), in skeletal muscle. The content of Se in spinal cord decreased (P < 0.05). The content of Al and Ca decreased (P < 0.05, P < 0.01), the content of Cu, Si, Fe, Mg, Mn and Zn incraesed(P <0.05, P < 0.05, P <0.01, P < 0.01, P < 0.001, P < 0.001), in liver. The content of Se, Al, Cd, Mg, Si and Ca in urine increased (P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.01).
Compared of group OVX with group sham, the content of Zn decreased (P < 0.001). Compared of group OVX + Al + E2 with group sham, the content of Al, Cd, Si and Se in heart increased (P < 0.05, P < 0.01, P < 0.01, P < 0.001). The content of Se and Cd in tibia increased (P < 0.01, P < 0.001). The content of Al in kidney increased (P < 0.05). The content of Mn and Cu increased (P < 0.05, P < 0.001),Se decreased (P < 0.001) in skeletal muscle. The content of Al, Se and Ca in spinal cord decreased (P < 0.05, P < 0.01, P < 0.05). The content of Mn, Zn and Si in liver increased (P < 0.01, P < 0.05, P < 0.05). The content of Cd, Mg, Se, Al and Ca in urine increased (P < 0.05, P < 0.05, P < 0.01, P < 0.001, P < 0.001). Compared of group OVX + Al + E2 with group OVX + Al, the content of Cd, Mn and Se in heart increased (P < 0.05, P < 0.05, P < 0.01). The content of Al, Mg, Se, Cd and Mn in tibia increased (P < 0.05, P < 0.01, P < 0.001, P < 0.001, P < 0.001). The content of Mn and Cu increased (P < 0.05, P < 0.001), Se decreased (P < 0.001), in skeletal muscle. The content of Se in spinal cord decreased (P < 0.05). The content of Al and Ca decreased (P < 0.05, P < 0.01), the content of Cu, Si, Fe, Mg, Mn and Zn incraesed(P <0.05, P < 0.05, P <0.01, P < 0.01, P < 0.001, P < 0.001), in liver. The content of Se, Al, Cd, Mg, Si and Ca in urine increased (P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.05, P < 0.01).",,,<Element 'PubmedArticle' at 0x7f05da04e8b0>
479,19232475,Milk--the promoter of chronic Western diseases.,"Common chronic diseases of Western societies, such as coronary heart disease, diabetes mellitus, cancer, hypertension, obesity, dementia, and allergic diseases are significantly influenced by dietary habits. Cow's milk and dairy products are nutritional staples in most Western societies. Milk and dairy product consumption is recommended by most nutritional societies because of their beneficial effects for calcium uptake and bone mineralization and as a source of valuable protein. However, the adverse long-term effects of milk and milk protein consumption on human health have been neglected. A hypothesis is presented, showing for the first time that milk protein consumption is an essential adverse environmental factor promoting most chronic diseases of Western societies. Milk protein consumption induces postprandial hyperinsulinaemia and shifts the growth hormone/insulin-like growth factor-1 (IGF-1) axis to permanently increased IGF-1 serum levels. Insulin/IGF-1 signalling is involved in the regulation of fetal growth, T-cell maturation in the thymus, linear growth, pathogenesis of acne, atherosclerosis, diabetes mellitus, obesity, cancer and neurodegenerative diseases, thus affecting most chronic diseases of Western societies. Of special concern is the possibility that milk intake during pregnancy adversely affects the early fetal programming of the IGF-1 axis which will influence health risks later in life. An accumulated body of evidence for the adverse effects of cow's milk consumption from fetal life to childhood, adolescence, adulthood and senescence will be provided which strengthens the presented hypothesis.",[],Medical hypotheses,2009-02-24,"[{'lastname': 'Melnik', 'firstname': 'Bodo C', 'initials': 'BC', 'affiliation': 'Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, Sedanstrasse 115, D-49090 Osnabrück, Germany. melnik@t-online.de'}]",,,,,10.1016/j.mehy.2009.01.008,<Element 'PubmedArticle' at 0x7f05da05ca40>
480,19027461,Cognitive effects of hormonal therapy in older adults.,"There is ample preclinical evidence that gonadal steroids (estrogens and androgens) play an important role in central nervous system development and function. The abrupt decline of estrogen levels in women after menopause, and the slower, subtler decline in total and bioavailable testosterone serum levels that occurs in aging men (""andropause,"" ""male menopause,"" partial androgen deficiency in ageing males [PADAM]), have been implicated in the pathogenesis of cognitive dysfunction prevalent in elderly adults. However, the current clinical evidence supporting hormonal replacement as a neuroprotective therapy is at best inconclusive. Anti-estrogen and anti-androgen hormonal therapies are used in the treatment of breast and prostate carcinomas, respectively. Although generally considered less toxic than conventional cytotoxic chemotherapy, these hormonal manipulations have side effects that are not trivial. This review will summarize the available evidence regarding the impact of these hormonal therapies on cognitive function in older adults. Additional clinical research in this field is needed to confirm the existence and severity of such a possible cognitive impact, which may then need to be considered prior to initiating hormonal therapies in the elderly, as many patients may be in the prodromal phase or early stages of a neurodegenerative disorder, such as Alzheimer's disease, and this information may influence treatment decision-making and subsequent management.",[],Seminars in oncology,2008-11-26,"[{'lastname': 'Mitsiades', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.'}, {'lastname': 'Correa', 'firstname': 'Denise', 'initials': 'D', 'affiliation': None}, {'lastname': 'Gross', 'firstname': 'Cary P', 'initials': 'CP', 'affiliation': None}, {'lastname': 'Hurria', 'firstname': 'Arti', 'initials': 'A', 'affiliation': None}, {'lastname': 'Slovin', 'firstname': 'Susan F', 'initials': 'SF', 'affiliation': None}]",,,,,10.1053/j.seminoncol.2008.08.002,<Element 'PubmedArticle' at 0x7f05d9fe4130>
481,19016491,An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population.,"Granulin protein plays an important role in neurite outgrowth and neuronal survival. Recently, it was shown that mutations in granulin (GRN) gene cause tau-negative frontotemporal dementia supporting the idea that granulin is involved in neurodegeneration. Here we have investigated whether genetic variability in the GRN gene influences also the risk of developing Alzheimer's disease (AD). Genotyping of six single nucleotide polymorphisms (SNPs) in the GRN gene among 512 AD patients and 649 control subjects originating from Finland did not show significant association with AD. However, stratification according to gender revealed a significant male-specific allele, genotype and haplotype association between AD and GRN SNPs rs4792939, rs850713, and rs5848. These data suggest that genetic variability in the GRN gene may also increase the risk for developing AD in a gender-specific manner.",[],"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics",2008-11-20,"[{'lastname': 'Viswanathan', 'firstname': 'Jayashree', 'initials': 'J', 'affiliation': 'Department of Neurology, Clinical Research Centre/Mediteknia, University Hospital and University of Kuopio, Finland.'}, {'lastname': 'Mäkinen', 'firstname': 'Petra', 'initials': 'P', 'affiliation': None}, {'lastname': 'Helisalmi', 'firstname': 'Seppo', 'initials': 'S', 'affiliation': None}, {'lastname': 'Haapasalo', 'firstname': 'Annakaisa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Soininen', 'firstname': 'Hilkka', 'initials': 'H', 'affiliation': None}, {'lastname': 'Hiltunen', 'firstname': 'Mikko', 'initials': 'M', 'affiliation': None}]",,,,"2008 Wiley-Liss, Inc.",10.1002/ajmg.b.30889,<Element 'PubmedArticle' at 0x7f05d9feb8b0>
482,18956301,Sex hormone binding globulin and aging.,"New and more active concepts of steroid binding globulin action are emerging from recent research. As a result, examination of steroid levels in aging humans and the role of steroid binding globulins need to be re-visited. This review will discuss the possibility that sex hormone binding globulin (SHBG) plays an active role in the aging process. It will discuss the changes in blood levels of SHBG in aging humans in association with sexual activity, prostate hypertrophy and cancer, uterine leiomyoma, breast cancer, obesity and particularly the relationship between SHBG and HDL-cholesterol, Alzheimer's disease, osteoporosis, and cardiovascular disease. Starting with the idea that SHBG is an active participant in steroid action demands a re-evaluation of data demonstrating a primary change in blood SHBG levels in association with various pathologies. Here we discuss the postulate that SHBG may act at its own receptor at the plasma membrane level to influence other receptors such as scavenger receptors and HDL-cholesterol receptors. We will also suggest that SHBG is a critical marker for mating and thus may be an important physiological molecule in control of aging.",[],Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,2008-10-29,"[{'lastname': 'Caldwell', 'firstname': 'J D', 'initials': 'JD', 'affiliation': 'Lake Erie College of Osteopathic Medicine, Erie, PA 16509, USA. jcaldwell@lecom.edu'}, {'lastname': 'Jirikowski', 'firstname': 'G F', 'initials': 'GF', 'affiliation': None}]",,,,,10.1055/s-0028-1093351,<Element 'PubmedArticle' at 0x7f05d9ff4810>
483,18947934,Life-time estrogen exposure and cognitive functioning in later life.,"While recent studies suggest that exogenous estrogen treatment could help reduce age-related cognitive decline and delay the onset of dementia, this has not been found consistently. Few studies have considered the influence of life-time estrogen exposure which may have an independent effect on cognition and/or modulate treatment response.
The aim of this study was to examine whether factors related to estrogen exposure across the life-time were associated with cognitive function in postmenopausal women.
A battery of cognitive tests were administered at baseline and at 2 and 4 years of follow-up to evaluate cognitive performance among a population-based cohort of 996 French women aged 65 years or older, who were recruited as part of the ESPRIT study. Detailed reproductive histories were also obtained. Logistic regression models, controlling for an extensive range of potential confounding factors, were generated to determine whether hormone-related factors across a woman's lifetime were associated with poor cognitive performance in later life.
Age at first menses was negatively associated with performance on the tasks of visual memory and psychomotor speed, while a longer reproductive period was associated with better verbal fluency. Likewise, women who had their first child at a young age performed significantly worse on each of these tasks, as well as on a measure of global cognitive function. The results also suggest that current hormone therapy may be beneficial for a number of cognitive domains, however, in multivariate analysis, women performed significantly better on the task of visual memory only. In contrast, in analysis adjusted for baseline cognitive performance and a range of other factors, none of the reproductive variables were associated with a decline in cognitive performance or the incidence of dementia during the 4-year follow-up period.
In addition to hormone therapy, certain hormone-related events across the lifetime are also associated with cognitive functioning in later life. They were not observed in this study to modulate dementia risk; however, this should be verified over a longer follow-up period. Further studies will also be required to determine whether lifetime hormonal exposure may modify women's response to hormone therapy after the menopause.",[],Psychoneuroendocrinology,2008-10-25,"[{'lastname': 'Ryan', 'firstname': 'Joanne', 'initials': 'J', 'affiliation': 'Inserm, U888, Montpellier F-34093, France; Univ Montpellier1, Montpellier F-34000, France; Department of Psychiatry, The University of Melbourne, Melboure, Australia. Electronic address: joanne.ryan@inserm.fr.'}, {'lastname': 'Carrière', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Inserm, U888, Montpellier F-34093, France; Univ Montpellier1, Montpellier F-34000, France.'}, {'lastname': 'Scali', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'Inserm, U888, Montpellier F-34093, France; Univ Montpellier1, Montpellier F-34000, France.'}, {'lastname': 'Ritchie', 'firstname': 'Karen', 'initials': 'K', 'affiliation': 'Inserm, U888, Montpellier F-34093, France; Univ Montpellier1, Montpellier F-34000, France.'}, {'lastname': 'Ancelin', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'Inserm, U888, Montpellier F-34093, France; Univ Montpellier1, Montpellier F-34000, France.'}]",,,"Age at first menses was negatively associated with performance on the tasks of visual memory and psychomotor speed, while a longer reproductive period was associated with better verbal fluency. Likewise, women who had their first child at a young age performed significantly worse on each of these tasks, as well as on a measure of global cognitive function. The results also suggest that current hormone therapy may be beneficial for a number of cognitive domains, however, in multivariate analysis, women performed significantly better on the task of visual memory only. In contrast, in analysis adjusted for baseline cognitive performance and a range of other factors, none of the reproductive variables were associated with a decline in cognitive performance or the incidence of dementia during the 4-year follow-up period.",,10.1016/j.psyneuen.2008.09.008,<Element 'PubmedArticle' at 0x7f05d9ffc3b0>
484,18855585,Insulin resistance and Alzheimer's disease: molecular links & clinical implications.,"Hyperinsulinemia as well as type II diabetes mellitus are among the risk factors for Alzheimer's disease (AD). However, the molecular and cellular basis that link insulin resistance disorders and diabetes with AD are far from clear. Here, we discuss the potential molecular mechanisms that may explain the participation of these metabolic disorders in the pathogenesis of AD. The human brain uses glucose as a primary fuel; insulin secreted by the pancreas cross the blood-brain barrier (BBB), reaching neurons and glial cells, and exerts a region-specific effect on glucose metabolism. Glucose homeostasis is critical for energy generation, neuronal maintenance, neurogenesis, neurotransmitter regulation, cell survival and synaptic plasticity. It also plays a key role in cognitive function. In an insulin resistance condition, there is a reduced sensitivity to insulin resulting in hyperinsulinemia; this condition persists for several years before becoming full-blown diabetes. Toxic levels of insulin negatively influence neuronal function and survival, and elevation of peripheral insulin concentration acutely increases its cerebrospinal fluid (CSF) concentration. Peripheral hyperinsulinemia correlates with an abnormal removal of the amyloid beta peptide (Abeta) and an increase of tau hyperphosphorylation as a result of augmented cdk5 and GSK3beta activities. This leads to cellular cascades that trigger a neurodegenerative phenotype and decline in cognitive function. Chronic peripheral hyperinsulinemia results in a reduction of insulin transport across the BBB and a reduced insulin signaling in brain, altering all of insulin's actions, including its anti-apoptotic effect. However, the increase in brain insulin levels resulting from its peripheral administration at optimal doses has shown a cognition-enhancing effect in patient with AD. Some drugs utilized in type II diabetes mellitus reduce cognitive impairment associated with AD. The link between insulin resistance and neurodegeneration and AD, and the possible therapeutic targets in preventing the insulin-resistance disorders are analyzed.",[],Current Alzheimer research,2008-10-16,"[{'lastname': 'Neumann', 'firstname': 'Karen F', 'initials': 'KF', 'affiliation': 'Laboratory of Cellular and Molecular Neurosciences, University of Chile, Iquique, Chile.'}, {'lastname': 'Rojo', 'firstname': 'Leonel', 'initials': 'L', 'affiliation': None}, {'lastname': 'Navarrete', 'firstname': 'Leonardo P', 'initials': 'LP', 'affiliation': None}, {'lastname': 'Farías', 'firstname': 'Gonzalo', 'initials': 'G', 'affiliation': None}, {'lastname': 'Reyes', 'firstname': 'Paula', 'initials': 'P', 'affiliation': None}, {'lastname': 'Maccioni', 'firstname': 'Ricardo B', 'initials': 'RB', 'affiliation': None}]",,,,,10.2174/156720508785908919,<Element 'PubmedArticle' at 0x7f05da005680>
485,"18806919
17210801
12709467
7826280
11844888
3953862
12603286
16943563
16488378
2375247
11578524
1202204
17586559
17036175
10844576
14706948
17222916
16960575
17151169
17715567
17716786
17639447
17704849
17012293
17615094
11824844
17551018
6610841","Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.","Hypercortisolemia and increased levels of hyperphosphorylated tau proteins in cerebrospinal fluid (CSF) are common features with pathogenic relevance in Alzheimer;s disease (AD). Experimental studies point to an influence of cortisol on Abeta and tau pathology in AD. Association of both parameters have not yet been described in a sample of AD patients. In the present study, serum levels of cortisol were determined in 26 patients with mild AD dementia and 20 age-matched healthy elderly controls by ELISA. In addition, we measured in AD patients CSF levels of cortisol, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau 181), tau protein phosphorylated at threonine 231 (P-tau 231) and beta-Amyloid (Abeta) 1-42 and determined T-tau/Abeta 1-42 ratios in CSF. We found in AD patients significantly increased cortisol serum levels (551.4 +/- 146.1 nmol/l; P = 0.002) as compared to healthy controls (435.3 +/- 83.9 nmol/l). In AD patients, cortisol serum levels were significantly inversely correlated with T-tau (r = -0.496; P = 0.01), P-tau 181 (r = -0.558; P = 0.003) and P-tau 231 (-0.500; P = 0.009) protein levels and T-tau/Abeta 1-42 ratios (r = -0.450; P = 0.021) in CSF. In addition, cortisol serum levels showed a trend of positive correlation with Abeta 1-42 CSF levels (r = 0.386; P = 0.052). However, no significant correlations of cortisol serum with CSF levels as well as cortisol CSF levels with CSF biomarkers could be detected in AD patients. In conclusion, our results show that increased cortisol serum but not CSF levels are associated with minor signs of AD pathology in CSF, indicating a putative neuroprotective effect of moderately elevated cortisol serum levels in patients with mild AD dementia.",[],European archives of psychiatry and clinical neuroscience,2008-09-23,"[{'lastname': 'Laske', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Dept. of Psychiatry and Psychotherapy, University of Tuebingen, Osianderstr. 24, 72076, Tuebingen, Germany. christoph.laske@med.uni-tuebingen.de'}, {'lastname': 'Stransky', 'firstname': 'Elke', 'initials': 'E', 'affiliation': None}, {'lastname': 'Fritsche', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': None}, {'lastname': 'Eschweiler', 'firstname': 'Gerhard W', 'initials': 'GW', 'affiliation': None}, {'lastname': 'Leyhe', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}]",,,,,10.1007/s00406-008-0838-3,<Element 'PubmedArticle' at 0x7f05da00d130>
486,18692321,"Music facilitate the neurogenesis, regeneration and repair of neurons.","Experience has shown that therapy using music for therapeutic purposes has certain effects on neuropsychiatric disorders (both functional and organic disorders). However, the mechanisms of action underlying music therapy remain unknown, and scientific clarification has not advanced. While that study disproved the Mozart effect, the effects of music on the human body and mind were not disproved. In fact, more scientific studies on music have been conducted in recent years, mainly in the field of neuroscience, and the level of interest among researchers is increasing. The results of past studies have clarified that music influences and affects cranial nerves in humans from fetus to adult. The effects of music at a cellular level have not been clarified, and the mechanisms of action for the effects of music on the brain have not been elucidated. We propose that listening to music facilitates the neurogenesis, the regeneration and repair of cerebral nerves by adjusting the secretion of steroid hormones, ultimately leading to cerebral plasticity. Music affects levels of such steroids as cortisol (C), testosterone (T) and estrogen (E), and we believe that music also affects the receptor genes related to these substances, and related proteins. In the prevention of Alzheimer's disease and dementia, hormone replacement therapy has been shown to be effective, but at the same time, side effects have been documented, and the clinical application of hormone replacement therapy is facing a serious challenge. Conversely, music is noninvasive, and its existence is universal and mundane. Thus, if music can be used in medical care, the application of such a safe and inexpensive therapeutic option is limitless.",[],Medical hypotheses,2008-08-12,"[{'lastname': 'Fukui', 'firstname': 'Hajime', 'initials': 'H', 'affiliation': 'Department of Education, Nara University of Education, Takabatake, Nara 630 8528, Japan. fukuih@nara-edu.ac.jp'}, {'lastname': 'Toyoshima', 'firstname': 'Kumiko', 'initials': 'K', 'affiliation': None}]",,,,,10.1016/j.mehy.2008.06.019,<Element 'PubmedArticle' at 0x7f05da01ba90>
487,"18677155
10199429
12707448
17279058
16607095
16198073
10914619
1484915
8675575
17476147
17893293
15249618
11756599
12459399
15695976
16298249
16522699
16831962
12771113
15213207
15668595
16607096
9343467
8885820
8709781
9191758
9566385
12413371
15608005
8030629
11113299
11255426
12771112
15213206
16310963
12413378
11524467
10668686
10851363
10697060
12525745
12925744
11309635
15800139
11194452",Cognitive changes after menopause: influence of estrogen.,"The natural menopause is not associated with substantial cognitive change. Limited clinical trial evidence suggests that estrogen-containing hormone therapy has little effect on cognition during midlife, but prompt initiation after surgical menopause may improve aspects of memory. Among older postmenopausal women, strong clinical trial evidence demonstrates that hormone initiation does not improve cognition. More limited clinical trial evidence indicates no improvement in Alzheimer symptoms, and the Women's Health Initiative Memory Study found an increase in dementia risk among older women. Observational findings of reduced Alzheimer risk may reflect early hormone use in younger women, or findings may be biased. Cognitive effects of selective estrogen receptor modulators are not yet well studied.",[],Clinical obstetrics and gynecology,2008-08-05,"[{'lastname': 'Henderson', 'firstname': 'Victor W', 'initials': 'VW', 'affiliation': 'Departmentsof Health Research and Policy (Epidemiology), Stanford University, Stanford, California 94305-5405, USA. vhenderson@stanford.edu'}]",,,,,10.1097/GRF.0b013e318180ba10,<Element 'PubmedArticle' at 0x7f05d9fa5a90>
488,"18639608
11087964
10674993
1738013
15926930
10757641
16204434
17585061
573796
15772666
12161658
12782748
15939974
2343077
10072430
10647887
17018659
15237086
2684874
16582042
10633533
15870836
1656478
16801953
2485862
17521374
15740829
15949896
17091201
18155362
18028991
3950596
11714181
16861373
10454175
10454175
14515012
15867100
16150550
17079708
8552737
9513749
10204973
9626108
9799080
17085855
10605972
8557205
17379387
17091200
12377295
17301585
16014408
7757819
14599289
2007478
12629534
9352132",HPA axis function in male caregivers: effect of the monoamine oxidase-A gene promoter (MAOA-uVNTR).,"Caregiving stress is associated with negative health outcomes. Neuroendocrine functioning may be a mediator of such outcomes. The MAOA gene regulates activity of neurotransmitters involved with neuroendocrine responses to stress. Differences in polymorphisms of this gene have been shown to influence susceptibility to stress. Therefore, we examined allelic variation in MAOA-uVNTR, a functional polymorphism of MAOA, as a moderator of chronic stress effects on urinary cortisol excretion in 74 males enrolled in a case/control study of caregivers for relatives with dementia. Mixed models analysis of variance were used to examine MAOA-uVNTR genotype (3 repeats vs. 3.5/4 repeats) as a moderator of the impact of stress (caregiver vs. non-caregiver) on the urinary excretion pattern (overnight, daytime, evening) of cortisol. Caregivers with MAOA-uVNTR alleles associated with less transcriptional activity (3-repeats) displayed a pattern of cortisol excretion -- a decrease from overnight to daytime -- that was suggestive of HPA axis blunting, as compared to non-caregivers and those caregivers with the more active alleles (3.5/4 repeats) (cortisol p<.043). Individuals with less active MAOA-uVNTR alleles who are under chronic stress may be at increased risk for exhaustion of the HPA response to such stress.",[],Biological psychology,2008-07-22,"[{'lastname': 'Brummett', 'firstname': 'Beverly H', 'initials': 'BH', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA. brummett@duke.edu'}, {'lastname': 'Boyle', 'firstname': 'Stephen H', 'initials': 'SH', 'affiliation': None}, {'lastname': 'Siegler', 'firstname': 'Ilene C', 'initials': 'IC', 'affiliation': None}, {'lastname': 'Kuhn', 'firstname': 'Cynthia M', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Surwit', 'firstname': 'Richard S', 'initials': 'RS', 'affiliation': None}, {'lastname': 'Garrett', 'firstname': 'Melanie E', 'initials': 'ME', 'affiliation': None}, {'lastname': 'Collins', 'firstname': 'Ann', 'initials': 'A', 'affiliation': None}, {'lastname': 'Ashley-Koch', 'firstname': 'Allison', 'initials': 'A', 'affiliation': None}, {'lastname': 'Williams', 'firstname': 'Redford B', 'initials': 'RB', 'affiliation': None}]",,,,,10.1016/j.biopsycho.2008.06.004,<Element 'PubmedArticle' at 0x7f05d9fbf720>
489,"18593777
2723746
9501234
9391142
15901656
11119695
10579633
10195112
16280187
16274857
9253318
16432152
8346443
8350998
15584785
15668424
10891924
16606914
16033781
12003753
15643038
15743278
10404910
17606815
14998746
16971698
12892658
17544378
16360788
16229931
11682116
12384263
10571474
10799757
8780008
9329348
8592548
10869507
16943563
17151169","Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults.","Elevated cortisol indicates stress and may be a risk factor for cognitive decline in aging. Genetic factors may influence individual vulnerability to the adverse effects of stress on cognitive function in aging.
The authors investigated whether the gene-environment interaction between the genotype for the apolipoprotein E gene (APOE) and cortisol predicted cognitive performance in older urban adults. Cross-sectional data were analyzed from a population-based sample of 50-70-year-old men and women. Cognitive performance, salivary cortisol levels, and APOE genotype were assessed in 962 subjects. Scores on 20 standard cognitive tests were combined into seven domain scores (language, processing speed, eye-hand coordination, executive functioning, verbal memory and learning, visual memory and learning, visuoconstruction).
In adjusted models, while a higher cortisol level was associated with worse cognitive scores, the slopes of the adverse relations were steeper in persons with at least one APOE-epsilon4 allele. Effect sizes were large: for example, the effect of having one epsilon4 allele plus a cortisol area under the curve greater than the 75th percentile was equivalent to a decrease in language score expected from an age increase of 8.0 years (95% confidence interval=1.7-14.4), while having two epsilon4 alleles and a cortisol area under the curve greater than the 75th percentile was equivalent to an age increase of 33.4 years (95% CI=14.8-52.0).
These data suggest that APOE genotype modifies cortisol's relations with cognitive functioning and that the epsilon4 allele increases vulnerability of the aging brain to adverse effects of stress.",[],The American journal of psychiatry,2008-07-03,"[{'lastname': 'Lee', 'firstname': 'Brian K', 'initials': 'BK', 'affiliation': 'Division of Occupational and Environmental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.'}, {'lastname': 'Glass', 'firstname': 'Thomas A', 'initials': 'TA', 'affiliation': None}, {'lastname': 'Wand', 'firstname': 'Gary S', 'initials': 'GS', 'affiliation': None}, {'lastname': 'McAtee', 'firstname': 'Matthew J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Bandeen-Roche', 'firstname': 'Karen', 'initials': 'K', 'affiliation': None}, {'lastname': 'Bolla', 'firstname': 'Karen I', 'initials': 'KI', 'affiliation': None}, {'lastname': 'Schwartz', 'firstname': 'Brian S', 'initials': 'BS', 'affiliation': None}]","The authors investigated whether the gene-environment interaction between the genotype for the apolipoprotein E gene (APOE) and cortisol predicted cognitive performance in older urban adults. Cross-sectional data were analyzed from a population-based sample of 50-70-year-old men and women. Cognitive performance, salivary cortisol levels, and APOE genotype were assessed in 962 subjects. Scores on 20 standard cognitive tests were combined into seven domain scores (language, processing speed, eye-hand coordination, executive functioning, verbal memory and learning, visual memory and learning, visuoconstruction).",,"In adjusted models, while a higher cortisol level was associated with worse cognitive scores, the slopes of the adverse relations were steeper in persons with at least one APOE-epsilon4 allele. Effect sizes were large: for example, the effect of having one epsilon4 allele plus a cortisol area under the curve greater than the 75th percentile was equivalent to a decrease in language score expected from an age increase of 8.0 years (95% confidence interval=1.7-14.4), while having two epsilon4 alleles and a cortisol area under the curve greater than the 75th percentile was equivalent to an age increase of 33.4 years (95% CI=14.8-52.0).",,10.1176/appi.ajp.2008.07091532,<Element 'PubmedArticle' at 0x7f05d9f62130>
490,18573532,Stress and glucocorticoid footprints in the brain-the path from depression to Alzheimer's disease.,"Increasingly, stress is recognized as a trigger of depressive episodes and recent evidence suggests a causal role of stress in the onset and progression of Alzheimer's disease (AD) pathology. Besides aging, sex is an important determinant of prevalence rates for both AD and mood disorders. In light of a recent meta-analysis indicating that depressed subjects have a higher likelihood of developing AD, a key message in this article will be that both depression and AD are stress-related disorders and may represent a continuum that should receive more attention in future neurobiological studies. Accordingly, this review considers some of the cellular mechanisms that may be involved in regulating this transition threshold. In addition, it highlights the importance of addressing the question of how aging and sex interplay with stress to influence mood and cognition, with a bias towards consideration of neuroplastic events in particular brain regions, as the basis of AD and depressive disorders.",[],Neuroscience and biobehavioral reviews,2008-06-25,"[{'lastname': 'Sotiropoulos', 'firstname': 'I', 'initials': 'I', 'affiliation': 'Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. john@brain.riken.jp'}, {'lastname': 'Cerqueira', 'firstname': 'J J', 'initials': 'JJ', 'affiliation': None}, {'lastname': 'Catania', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Takashima', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Sousa', 'firstname': 'N', 'initials': 'N', 'affiliation': None}, {'lastname': 'Almeida', 'firstname': 'O F X', 'initials': 'OF', 'affiliation': None}]",,,,,10.1016/j.neubiorev.2008.05.007,<Element 'PubmedArticle' at 0x7f05d9f7d2c0>
491,18546839,Insulin treatment in diabetics 75+ years: experiences and results in outpatient care.,"Diabetes mellitus (DM) has a crucial impact on personal and social health. In the very old age it significantly affects also the social status of the individual. In the elderly 75+ y. DM occurs often in the domain of multi-morbidity and can conduce to incurrence and development of serious disability, which can significantly influence further therapeutic procedures. The study was aimed at analyzing the situation connected with the DM development, duration, insulin therapy period and overall approach in persons 75+ y. at 8 diabetological outpatient clinics of the Brno city. In the study we included 337 older diabetics 75+ y. who were long-term observed in the above mentioned diabetological outpatient clinics. There were 129 men and 208 women of the average age 79,3+/-4,9 y. (range 75-97 y.) out of this number. DM in patients of our set was detected in the age of 59,9+/-12,9 y. Its duration in the time of this study was 18,8+/-12,9 y. and the insulin therapy duration was 8,0+/-7,3 y. Good mobility was present in 303 persons (89,7%); 73 diabetics suffered from serious cognitive impairment - almost as to beginning dementia (22%). 159 seniors altogether had urinary incontinence, i.e. 47%. Within the study we analyzed such questions as: who applies insulin in the elderly; with whom he or she lives (24% of them are totally alone); how many times per day insulin is applied; which kind of insulin is used and whether there are hypoglycemias. We also took into consideration, if the senior owns a portable glucometer and who helps him or her with self-monitoring. Permanent insulin therapy represents in old age the kind of treatment which is very demanding for the old diabetic as well as for the nursing staff and the patient's close environment. A geriatric patient faces a long-term threat of decompensation of his/ her functional status and therefore he/she requires specific modification of the specialist's approach when deciding on the regimen and therapeutic measures.",[],Advances in gerontology = Uspekhi gerontologii,2008-06-13,"[{'lastname': 'Weber', 'firstname': 'P', 'initials': 'P', 'affiliation': 'Department of Internal Medicine, Geriatrics and Practical Medicine, University Hospital, Brno, Czech Republic. p.weber@fnbrno.cz'}, {'lastname': 'Meluzínová', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Kubesová', 'firstname': 'H', 'initials': 'H', 'affiliation': None}, {'lastname': 'Polcarová', 'firstname': 'V', 'initials': 'V', 'affiliation': None}, {'lastname': 'Kocourhová', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Striová', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Fenclová', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Slívová', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Hejlová', 'firstname': 'D', 'initials': 'D', 'affiliation': None}, {'lastname': 'Pisarcíková', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Tomecková', 'firstname': 'T', 'initials': 'T', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05d9f86180>
492,18543312,Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update.,"Mutations in the gene encoding granulin (HUGO gene symbol GRN, also referred to as progranulin, PGRN), located at chromosome 17q21, were recently linked to tau-negative ubiquitin-positive frontotemporal lobar degeneration (FTLDU). Since then, 63 heterozygous mutations were identified in 163 families worldwide, all leading to loss of functional GRN, implicating a haploinsufficiency mechanism. Together, these mutations explained 5 to 10% of FTLD. The high mutation frequency, however, might still be an underestimation because not all patient samples were examined for all types of loss-of-function mutations and because several variants, including missense mutations, have a yet uncertain pathogenic significance. Although the complete phenotypic spectrum associated with GRN mutations is not yet fully characterized, it was shown that it is highly heterogeneous, suggesting the influence of modifying factors. A role of GRN in neuronal survival was suggested but the exact mechanism by which neurodegeneration and deposition of pathologic brain inclusions occur still has to be clarified.",[],Human mutation,2008-06-11,"[{'lastname': 'Gijselinck', 'firstname': 'I', 'initials': 'I', 'affiliation': 'Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, Flanders Institute for Biotechnology (VIB), Antwerpen, Belgium.'}, {'lastname': 'Van Broeckhoven', 'firstname': 'C', 'initials': 'C', 'affiliation': None}, {'lastname': 'Cruts', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,,10.1002/humu.20785,<Element 'PubmedArticle' at 0x7f05d9f8f8b0>
493,"18511731
8749585
7783883
1436513
15623694
12646598
16260706
1558702
12775218
10326046
15576855
12048221
10428732
10776744
16410348
11515736
12145368
1202204
12673608
11992199
16526589
8637951
12766912
8080390
9152121
15829005
16921004
11522804
17365248
16414964
16461859
16772744
2356012
8933010
16945211
10428739
7924632
12108606
16632311
17201192
17666694
15358804
17804831
17538059
11999495","Social network, cognitive function, and dementia incidence among elderly women.","We examined whether social networks had a protective association with incidence of dementia among elderly women.
We prospectively studied 2249 members of a health maintenance organization who were 78 years or older, were classified as free of dementia in 2001, and had completed at least 1 follow-up interview in 2002 through 2005. We used the Telephone Interview for Cognitive Status-modified, the Telephone Dementia Questionnaire, and medical record review to assess cognitive status. We used the Lubben Social Network Scale-6 to assess social network. We estimated hazard ratios for incident dementia with Cox proportional hazards models, adjusting for age at entry, education, hormone use, cognitive status scores, and health conditions.
We identified 268 incident cases of dementia during follow-up. Compared with women with smaller social networks, the adjusted hazard ratio for incident dementia in women with larger social networks was 0.74 (95% confidence interval=0.57, 0.97).
Our findings suggest that larger social networks have a protective influence on cognitive function among elderly women. Future studies should explore which aspects of social networks are associated with dementia risk and maintenance of cognitive health.",[],American journal of public health,2008-05-31,"[{'lastname': 'Crooks', 'firstname': 'Valerie C', 'initials': 'VC', 'affiliation': 'Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA. valerie.c.crooks@kp.org'}, {'lastname': 'Lubben', 'firstname': 'James', 'initials': 'J', 'affiliation': None}, {'lastname': 'Petitti', 'firstname': 'Diana B', 'initials': 'DB', 'affiliation': None}, {'lastname': 'Little', 'firstname': 'Deborah', 'initials': 'D', 'affiliation': None}, {'lastname': 'Chiu', 'firstname': 'Vicki', 'initials': 'V', 'affiliation': None}]",,,"We identified 268 incident cases of dementia during follow-up. Compared with women with smaller social networks, the adjusted hazard ratio for incident dementia in women with larger social networks was 0.74 (95% confidence interval=0.57, 0.97).",,10.2105/AJPH.2007.115923,<Element 'PubmedArticle' at 0x7f05d9f98180>
494,"18392865
15365985
15776446
10219785
17436289
17949857
15034582
17953663
16495329
16862116
16862115
12565146
17506892
16421333
16041373
17179653
11708987
17826340
9855500
10983715
16950801
9636220
17157414
17620546
16495328
14502657
17345602
9641683
11015796
18157829",Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series.,"Frontotemporal lobar degeneration (FTLD) recognises high familial incidence, with up to 50% of patients reported to have a family history of similar dementia. It has been reported that mutations within progranulin (PGRN) gene are a major cause of FTLD in the USA and worldwide, counting for 5-10% of FTLD and for 20-25% of familiar FTLD cases. The aim of the present study was to define the role of PGRN genetic variations in a large sample of consecutive patients with FTLD in Italy. Two-hundred forty-three FTLD patients were investigated. Each subject performed a clinical and neuropsychological evaluation, a functional and structural brain imaging, and the diagnosis was confirmed by at least 1 year follow-up. PGRN sequencing was performed in all FTLD patients and in 121 healthy age-matched controls drawn from the same geographic area. Only one PGRN pathogenetic mutation was found, consisting of a four-base pair deletion in the coding sequence of exon 8 (delCACT). This mutation was recognised in four patients, being the overall frequency of mutations in our clinical series of 1.64%. Considering only patients with a well-known family history for dementia, the frequency of this mutation was 6%. Moreover, four missense mutations within intron regions (g.100474G>A, g.100674G>A, g.101266G>A, g.102070G>A) were found. The frequency of these genetic variations did not differ in patients compared to controls, and they did not influence on clinical FTLD phenotype. In conclusion, this study supports a lower frequency of PGRN mutations amongst FTLD patients in Italy compared to literature data and further underlies the genetic heterogeneity of FTLD.",[],Neurogenetics,2008-04-09,"[{'lastname': 'Borroni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Department of Neurology, University of Brescia, Brescia, Italy. bborroni@inwind.it'}, {'lastname': 'Archetti', 'firstname': 'Silvana', 'initials': 'S', 'affiliation': None}, {'lastname': 'Alberici', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': None}, {'lastname': 'Agosti', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Gennarelli', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bigni', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}, {'lastname': 'Bonvicini', 'firstname': 'Cristian', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ferrari', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bellelli', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Galimberti', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Scarpini', 'firstname': 'Elio', 'initials': 'E', 'affiliation': None}, {'lastname': 'Di Lorenzo', 'firstname': 'Diego', 'initials': 'D', 'affiliation': None}, {'lastname': 'Caimi', 'firstname': 'Luigi', 'initials': 'L', 'affiliation': None}, {'lastname': 'Caltagirone', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': None}, {'lastname': 'Di Luca', 'firstname': 'Monica', 'initials': 'M', 'affiliation': None}, {'lastname': 'Padovani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': None}]",,,,,10.1007/s10048-008-0127-3,<Element 'PubmedArticle' at 0x7f05d9f2ff40>
495,18328591,Loss of progranulin function in frontotemporal lobar degeneration.,"Frontotemporal lobar degeneration (FTLD) represents a collection of neurodegenerative diseases of frontal and temporal brain regions. It has long been associated with mutations in microtubule-associated protein tau (MAPT), and more recently with loss-of-function mutations in progranulin (PGRN). Phenotypes of PGRN and MAPT mutation carriers overlap, although disease onset in PGRN carriers is a decade later. Mutations in PGRN might influence susceptibility to a wider range of neurodegenerative diseases including Alzheimer and Parkinson diseases. The recent demonstration that mutations in PGRN result in FTLD provided a novel entrance point to the molecular mechanisms leading to this disorder. The high variability in onset age and age-dependent penetrance suggests that the PGRN pathway is highly susceptible to modulating factors that might be exploited to delay the disease processes.",[],Trends in genetics : TIG,2008-03-11,"[{'lastname': 'Cruts', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium.'}, {'lastname': 'Van Broeckhoven', 'firstname': 'Christine', 'initials': 'C', 'affiliation': None}]",,,,,10.1016/j.tig.2008.01.004,<Element 'PubmedArticle' at 0x7f05d9f44a90>
496,"18259770
2995377
9949199
14736883
16280682
9536080
7904897
10845064
8523035
2932539
12586550
3156696
16806565
16443761
8898202
12686466
16925587
10025399
9267033
16531753
12137967
17493035
15175861
10078572
4113563
15459747
12589027
10196370
8275091
16613897
15561905
16505167
8458085
15649949
10907112
9302293
16842168
1660734
17595255",Islet beta-cell area and hormone expression are unaltered in Huntington's disease.,"Neurodegenerative disorders are often associated with metabolic alterations. This has received little attention, but might be clinically important because it can contribute to symptoms and influence the course of the disease. Patients with Huntington's disease (HD) exhibit increased incidence of diabetes mellitus (DM). This is replicated in mouse models of HD, e.g., the R6/2 mouse, in which DM is primarily caused by a deficiency of beta-cells with impaired insulin secretion. Pancreatic tissue from HD patients has previously not been studied and, thus, the pathogenesis of DM in HD is unclear. To address this issue, we examined pancreatic tissue sections from HD patients at different disease stages. We found that the pattern of insulin immunostaining, levels of insulin transcripts and islet beta-cell area were similar in HD patients and controls. Further, there was no sign of amyloid deposition in islets from HD patients. Thus, our data show that pancreatic islets in HD patients appear histologically normal. Functional studies of HD patients with respect to insulin secretion and islet function are required to elucidate the pathogenesis of DM in HD. This may lead to a better understanding of HD and provide novel therapeutic targets for symptomatic treatment in HD.",[],Histochemistry and cell biology,2008-02-09,"[{'lastname': 'Bacos', 'firstname': 'Karl', 'initials': 'K', 'affiliation': 'Unit of Molecular Metabolism, Department of Experimental Medical Science, Lund University, CRC 91-11, 205 02 Malmö, Sweden. karl.bacos@med.lu.se'}, {'lastname': 'Björkqvist', 'firstname': 'Maria', 'initials': 'M', 'affiliation': None}, {'lastname': 'Petersén', 'firstname': 'Asa', 'initials': 'A', 'affiliation': None}, {'lastname': 'Luts', 'firstname': 'Lena', 'initials': 'L', 'affiliation': None}, {'lastname': 'Maat-Schieman', 'firstname': 'Marion L C', 'initials': 'ML', 'affiliation': None}, {'lastname': 'Roos', 'firstname': 'Raymund A C', 'initials': 'RA', 'affiliation': None}, {'lastname': 'Sundler', 'firstname': 'Frank', 'initials': 'F', 'affiliation': None}, {'lastname': 'Brundin', 'firstname': 'Patrik', 'initials': 'P', 'affiliation': None}, {'lastname': 'Mulder', 'firstname': 'Hindrik', 'initials': 'H', 'affiliation': None}, {'lastname': 'Wierup', 'firstname': 'Nils', 'initials': 'N', 'affiliation': None}]",,,,,10.1007/s00418-008-0393-z,<Element 'PubmedArticle' at 0x7f05d9f4c720>
497,18023506,Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels.,"Environmental factors (e.g. stress, exercise, enrichment) are thought to play a role in the development of Alzheimer's disease later in life. We investigated the influence of repeated novel cage exposure on the development of early Alzheimer's-like pathology in adult (4 months old) double transgenic mice over-expressing the amyloid precursor protein and presenilin-1 genes (TASTPM mouse line). The procedure involves the repeated placement of the animal into a novel clean cage, a manipulation which induces a stress response and exploratory activity and, as such, can also be seen as a mild form of enrichment. Before and after exposure to the novel cage procedure, separate groups of mice were evaluated for locomotor performance and short-term contextual memory in the fear-conditioning test. Repeated novel cage exposure prevented the onset of a short-term memory deficit that was apparent in 5.5- but not 4-month-old TASTPM mice, without reversing the deficit in extinction already evident at 4 months of age. Brain regional levels of soluble and insoluble amyloid and of endocannabinoids were quantified. Novel cage exposure attenuated soluble and insoluble amyloid accumulation in the hippocampus and frontal cortex, without affecting the age-related increases in regional brain endocannabinoids levels. These beneficial effects are likely to be the consequence of the increase in physical and exploratory activity induced by novel cage exposure and suggest that the impact of environmental factors on Alzheimer's-like changes may be dependent on the degree of activation of stress pathways.",[],Neurobiology of aging,2007-11-21,"[{'lastname': 'Pardon', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': ""University of Nottingham Medical School, Institute of Neuroscience, School of Biomedical Sciences, Queen's Medical Centre, Nottingham, United Kingdom. marie.pardon@nottingham.ac.uk""}, {'lastname': 'Sarmad', 'firstname': 'Sarir', 'initials': 'S', 'affiliation': None}, {'lastname': 'Rattray', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': None}, {'lastname': 'Bates', 'firstname': 'Timothy E', 'initials': 'TE', 'affiliation': None}, {'lastname': 'Scullion', 'firstname': 'Gillian A', 'initials': 'GA', 'affiliation': None}, {'lastname': 'Marsden', 'firstname': 'Charles A', 'initials': 'CA', 'affiliation': None}, {'lastname': 'Barrett', 'firstname': 'David A', 'initials': 'DA', 'affiliation': None}, {'lastname': 'Lowe', 'firstname': 'James', 'initials': 'J', 'affiliation': None}, {'lastname': 'Kendall', 'firstname': 'David A', 'initials': 'DA', 'affiliation': None}]",,,,,10.1016/j.neurobiolaging.2007.10.002,<Element 'PubmedArticle' at 0x7f05d9ee26d0>
498,17997029,Somatostatinergic systems in brain: networks and functions.,"Somatostatin is abundantly expressed in mammalian brain. The peptide binds with high affinity to six somatostatin receptors, sst1, sst2A and B, sst3 to 5, all belonging to the G-protein-coupled receptor family. Recent advances in the neuroanatomy of somatostatin neurons and cellular distribution of sst receptors shed light on their functional roles in the neuronal network. Beside their initially described neuroendocrine role, somatostatin systems subserve neuromodulatory roles in the brain, influencing motor activity, sleep, sensory processes and cognitive functions, and are altered in brain diseases like affective disorders, epilepsia and Alzheimer's disease.",[],Molecular and cellular endocrinology,2007-11-13,"[{'lastname': 'Viollet', 'firstname': 'Cécile', 'initials': 'C', 'affiliation': 'Inserm, UMR 549, Paris, France.'}, {'lastname': 'Lepousez', 'firstname': 'Gabriel', 'initials': 'G', 'affiliation': None}, {'lastname': 'Loudes', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Videau', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Simon', 'firstname': 'Axelle', 'initials': 'A', 'affiliation': None}, {'lastname': 'Epelbaum', 'firstname': 'Jacques', 'initials': 'J', 'affiliation': None}]",,,,,10.1016/j.mce.2007.09.007,<Element 'PubmedArticle' at 0x7f05d9eedb30>
499,17996334,Influence of genetic polymorphisms in the apolipoprotein (APOE) and the butyrylcholinesterase (BCHE) gene on stress markers in older adults: a 3-year study.,"The present study examined the influence of genetic polymorphisms in the apolipoprotein (APOE) and the butyrylcholinesterase (BCHE) gene on GC secretion, cognition and personality in 66 healthy older adults. These particular variables were chosen given that they have been shown to be associated with human stress (i.e.stress markers). Measures included basal serum GC levels and cognitive scores on declarative memory obtained annually over 3 years. Also, self-esteem, neuroticism and depression were evaluated. Results showed that participants with the APOE E4-BCHE K variant (E4-K group) present increased basal levels of GCs and poorer cognitive performance when compared to non-carriers of these variants. In addition, the E4-K group reported lower self-esteem and higher levels of depression. These findings may indicate a genotype effect on markers of stress and cognitive integrity years before symptoms of dementia are apparent.",[],Neurobiology of aging,2007-11-13,"[{'lastname': 'Fiocco', 'firstname': 'A J', 'initials': 'AJ', 'affiliation': 'Douglas Hospital Research Centre, Verdun, Quebec H4H 1R3, Canada.'}, {'lastname': 'Nair', 'firstname': 'N P V', 'initials': 'NP', 'affiliation': None}, {'lastname': 'Schwartz', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Kin', 'firstname': 'F Ng Ying', 'initials': 'FN', 'affiliation': None}, {'lastname': 'Joober', 'firstname': 'R', 'initials': 'R', 'affiliation': None}, {'lastname': 'Poirier', 'firstname': 'J', 'initials': 'J', 'affiliation': None}, {'lastname': 'Lupien', 'firstname': 'S J', 'initials': 'SJ', 'affiliation': None}]",,,,,10.1016/j.neurobiolaging.2007.09.008,<Element 'PubmedArticle' at 0x7f05d9ef83b0>
